doc_id,term,association
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,therapy,0.311885
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,treated,0.349064
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,melanoma,0.31998
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,commented,0.306236
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,RCC,0.307431
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,treatment,0.409306
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,response,0.421849
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,progression,0.421668
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,respond,0.349638
uuid-7ea3e0fa6da4402a8f17ccb1c1171100,TL shared,0.360862
uuid-ce4d8393ac87460a87609562c882a3f9,patients,0.337911
uuid-ce4d8393ac87460a87609562c882a3f9,Opdivo,0.437141
uuid-ce4d8393ac87460a87609562c882a3f9,treated,0.342188
uuid-ce4d8393ac87460a87609562c882a3f9,shared,0.461784
uuid-ce4d8393ac87460a87609562c882a3f9,institution,0.349289
uuid-ce4d8393ac87460a87609562c882a3f9,stated,0.376187
uuid-ce4d8393ac87460a87609562c882a3f9,approval,0.356366
uuid-ce4d8393ac87460a87609562c882a3f9,physicians,0.480092
uuid-ce4d8393ac87460a87609562c882a3f9,clinical trials,0.373542
uuid-ce4d8393ac87460a87609562c882a3f9,HCP,0.318936
uuid-ce4d8393ac87460a87609562c882a3f9,tumor types,0.337923
uuid-ce4d8393ac87460a87609562c882a3f9,oncologist,0.334432
uuid-ce4d8393ac87460a87609562c882a3f9,Regional TL,0.315022
uuid-6305384769e34016978e46f5e14cbffc,BMS,0.361811
uuid-6305384769e34016978e46f5e14cbffc,PDL1,0.335065
uuid-6305384769e34016978e46f5e14cbffc,trial,0.446608
uuid-6305384769e34016978e46f5e14cbffc,efficacy,0.551193
uuid-6305384769e34016978e46f5e14cbffc,chemo,0.303088
uuid-6305384769e34016978e46f5e14cbffc,OS,0.798228
uuid-6305384769e34016978e46f5e14cbffc,data,0.694433
uuid-6305384769e34016978e46f5e14cbffc,PFS,0.748948
uuid-6305384769e34016978e46f5e14cbffc,ORR,0.730211
uuid-6305384769e34016978e46f5e14cbffc,nivo and pembro,0.356448
uuid-6305384769e34016978e46f5e14cbffc,believes,0.380718
uuid-6305384769e34016978e46f5e14cbffc,impressed,0.597345
uuid-6305384769e34016978e46f5e14cbffc,feels,0.527319
uuid-2c4a32d89c224028adbe1a391025e335,TL,0.428959
uuid-2c4a32d89c224028adbe1a391025e335,shared,0.43565
uuid-2c4a32d89c224028adbe1a391025e335,TL stated,0.385614
uuid-2c4a32d89c224028adbe1a391025e335,institution,0.37287
uuid-2c4a32d89c224028adbe1a391025e335,physicians,0.427999
uuid-2c4a32d89c224028adbe1a391025e335,PD-L1 testing,0.49697
uuid-2c4a32d89c224028adbe1a391025e335,testing,0.37099
uuid-2c4a32d89c224028adbe1a391025e335,PDL1 testing,0.43703
uuid-2c4a32d89c224028adbe1a391025e335,NSCLC patients,0.321781
uuid-2c4a32d89c224028adbe1a391025e335,oncology,0.302817
uuid-2c4a32d89c224028adbe1a391025e335,SCCHN,0.363227
uuid-2c4a32d89c224028adbe1a391025e335,oncologist,0.373647
uuid-2c4a32d89c224028adbe1a391025e335,LTL,0.304614
uuid-2c4a32d89c224028adbe1a391025e335,academic,0.372302
uuid-2c4a32d89c224028adbe1a391025e335,Regional TL,0.399598
uuid-2c4a32d89c224028adbe1a391025e335,RTL stated,0.300651
uuid-36b34cc3d07940ff95e128bbdf6172aa,therapy,0.318919
uuid-36b34cc3d07940ff95e128bbdf6172aa,regimen,0.442448
uuid-36b34cc3d07940ff95e128bbdf6172aa,combination,0.5419
uuid-36b34cc3d07940ff95e128bbdf6172aa,chemo,0.374137
uuid-36b34cc3d07940ff95e128bbdf6172aa,pts,0.420115
uuid-36b34cc3d07940ff95e128bbdf6172aa,IO,0.35343
uuid-36b34cc3d07940ff95e128bbdf6172aa,monotherapy,0.397107
uuid-36b34cc3d07940ff95e128bbdf6172aa,treatment,0.331349
uuid-36b34cc3d07940ff95e128bbdf6172aa,response,0.627743
uuid-36b34cc3d07940ff95e128bbdf6172aa,combo,0.493994
uuid-36b34cc3d07940ff95e128bbdf6172aa,PD1,0.545479
uuid-36b34cc3d07940ff95e128bbdf6172aa,progression,0.557256
uuid-36b34cc3d07940ff95e128bbdf6172aa,chemotherapy,0.413355
uuid-36b34cc3d07940ff95e128bbdf6172aa,impressed,0.320943
uuid-36b34cc3d07940ff95e128bbdf6172aa,respond,0.385016
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,Nivo,0.451618
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,patients,0.319239
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,pembro,0.603401
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,nivolumab,0.311386
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,1L,0.680632
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,shared,0.319761
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,RCC,0.495697
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,2L,0.680356
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,pts,0.34725
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,stated,0.353874
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,approval,0.490099
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,atezo,0.501316
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,preferred,0.556566
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,monotherapy,0.545381
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,using nivo,0.709682
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,combo,0.352909
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,clinical trials,0.377801
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,indication,0.304595
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,NSCLC patients,0.311675
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,approved,0.498105
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,SCCHN,0.502845
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,tumor types,0.375217
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,LTL,0.389343
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,SCLC,0.344217
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,feels,0.375195
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,Regional TL,0.312913
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,RTL stated,0.630569
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,TL shared,0.349459
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,option,0.522719
uuid-03cf45f704fd4ad3be7b8dd9b106d2ad,bladder,0.47076
uuid-5b8bce3c1216418c8e9373af1a2b56e5,patients,0.453799
uuid-5b8bce3c1216418c8e9373af1a2b56e5,Opdivo,0.62794
uuid-5b8bce3c1216418c8e9373af1a2b56e5,dose,0.532582
uuid-5b8bce3c1216418c8e9373af1a2b56e5,preferred,0.312761
uuid-5b8bce3c1216418c8e9373af1a2b56e5,drug,0.391552
uuid-5b8bce3c1216418c8e9373af1a2b56e5,Keytruda,0.470398
uuid-5b8bce3c1216418c8e9373af1a2b56e5,flat dosing,0.666491
uuid-bf40d372744343f79d4270ef7383be5f,TL,0.399092
uuid-bf40d372744343f79d4270ef7383be5f,RTL,0.363485
uuid-bf40d372744343f79d4270ef7383be5f,lung,0.429834
uuid-bf40d372744343f79d4270ef7383be5f,1L,0.35826
uuid-bf40d372744343f79d4270ef7383be5f,shared,0.395215
uuid-bf40d372744343f79d4270ef7383be5f,commented,0.336493
uuid-bf40d372744343f79d4270ef7383be5f,RCC,0.538187
uuid-bf40d372744343f79d4270ef7383be5f,TL stated,0.683662
uuid-bf40d372744343f79d4270ef7383be5f,2L,0.317754
uuid-bf40d372744343f79d4270ef7383be5f,institution,0.336636
uuid-bf40d372744343f79d4270ef7383be5f,stated,0.473154
uuid-bf40d372744343f79d4270ef7383be5f,PD-L1,0.477
uuid-bf40d372744343f79d4270ef7383be5f,approval,0.335017
uuid-bf40d372744343f79d4270ef7383be5f,PD-L1 testing,0.517595
uuid-bf40d372744343f79d4270ef7383be5f,testing,0.605866
uuid-bf40d372744343f79d4270ef7383be5f,expressed,0.349457
uuid-bf40d372744343f79d4270ef7383be5f,clinical trials,0.310086
uuid-bf40d372744343f79d4270ef7383be5f,PDL1 testing,0.718915
uuid-bf40d372744343f79d4270ef7383be5f,NSCLC patients,0.54471
uuid-bf40d372744343f79d4270ef7383be5f,SCCHN,0.540787
uuid-bf40d372744343f79d4270ef7383be5f,tumor types,0.510929
uuid-bf40d372744343f79d4270ef7383be5f,LTL,0.371508
uuid-bf40d372744343f79d4270ef7383be5f,TLs,0.457786
uuid-bf40d372744343f79d4270ef7383be5f,academic,0.324158
uuid-bf40d372744343f79d4270ef7383be5f,Regional TL,0.426914
uuid-bf40d372744343f79d4270ef7383be5f,RTL stated,0.478905
uuid-bf40d372744343f79d4270ef7383be5f,TL shared,0.411718
uuid-bf40d372744343f79d4270ef7383be5f,biomarker,0.320335
uuid-bf40d372744343f79d4270ef7383be5f,bladder,0.432808
uuid-b06fbbc4c5cb4a81b947c96e442073ba,BMS,0.418691
uuid-b06fbbc4c5cb4a81b947c96e442073ba,PDL1,0.391438
uuid-b06fbbc4c5cb4a81b947c96e442073ba,discussed,0.329364
uuid-b06fbbc4c5cb4a81b947c96e442073ba,commented,0.514768
uuid-b06fbbc4c5cb4a81b947c96e442073ba,Merck,0.317845
uuid-b06fbbc4c5cb4a81b947c96e442073ba,stated,0.511153
uuid-b06fbbc4c5cb4a81b947c96e442073ba,OS,0.37841
uuid-b06fbbc4c5cb4a81b947c96e442073ba,regards,0.436158
uuid-b06fbbc4c5cb4a81b947c96e442073ba,data,0.724062
uuid-b06fbbc4c5cb4a81b947c96e442073ba,expressed,0.354774
uuid-b06fbbc4c5cb4a81b947c96e442073ba,indication,0.32366
uuid-b06fbbc4c5cb4a81b947c96e442073ba,PFS,0.352307
uuid-b06fbbc4c5cb4a81b947c96e442073ba,ORR,0.355689
uuid-b06fbbc4c5cb4a81b947c96e442073ba,nivo and pembro,0.336932
uuid-b06fbbc4c5cb4a81b947c96e442073ba,impressed,0.484118
uuid-b06fbbc4c5cb4a81b947c96e442073ba,Regional TL,0.35756
uuid-b06fbbc4c5cb4a81b947c96e442073ba,PDL1 expression,0.337783
uuid-b06fbbc4c5cb4a81b947c96e442073ba,NCCN,0.509969
uuid-eea1ad0c6fd94a438c26609621a920ae,1L,0.346915
uuid-eea1ad0c6fd94a438c26609621a920ae,PDL1,0.514631
uuid-eea1ad0c6fd94a438c26609621a920ae,efficacy,0.341787
uuid-eea1ad0c6fd94a438c26609621a920ae,PD-L1,0.306931
uuid-eea1ad0c6fd94a438c26609621a920ae,atezo,0.301032
uuid-eea1ad0c6fd94a438c26609621a920ae,regards,0.391898
uuid-eea1ad0c6fd94a438c26609621a920ae,indication,0.444588
uuid-eea1ad0c6fd94a438c26609621a920ae,approved,0.338467
uuid-eea1ad0c6fd94a438c26609621a920ae,nivo and pembro,0.450333
uuid-eea1ad0c6fd94a438c26609621a920ae,believes,0.440199
uuid-eea1ad0c6fd94a438c26609621a920ae,label,0.355937
uuid-eea1ad0c6fd94a438c26609621a920ae,PDL1 expression,0.605817
uuid-eea1ad0c6fd94a438c26609621a920ae,option,0.332987
uuid-eea1ad0c6fd94a438c26609621a920ae,biomarker,0.465249
uuid-668db17dd1844096861ea195e68628ed,Opdivo,0.520346
uuid-668db17dd1844096861ea195e68628ed,dose,0.640795
uuid-668db17dd1844096861ea195e68628ed,toxicity,0.428314
uuid-668db17dd1844096861ea195e68628ed,regimen,0.39159
uuid-668db17dd1844096861ea195e68628ed,physicians,0.498482
uuid-668db17dd1844096861ea195e68628ed,treatment,0.338164
uuid-668db17dd1844096861ea195e68628ed,Keytruda,0.356374
uuid-668db17dd1844096861ea195e68628ed,flat dosing,0.486783
uuid-e82deeacfeb94e27b3d3f604866a878f,patients,0.573059
uuid-e82deeacfeb94e27b3d3f604866a878f,Opdivo,0.415858
uuid-e82deeacfeb94e27b3d3f604866a878f,therapy,0.489293
uuid-e82deeacfeb94e27b3d3f604866a878f,nivolumab,0.472227
uuid-e82deeacfeb94e27b3d3f604866a878f,treated,0.463163
uuid-e82deeacfeb94e27b3d3f604866a878f,approval,0.369751
uuid-e82deeacfeb94e27b3d3f604866a878f,physicians,0.316085
uuid-e82deeacfeb94e27b3d3f604866a878f,treatment,0.383186
uuid-e82deeacfeb94e27b3d3f604866a878f,using nivo,0.421793
uuid-e82deeacfeb94e27b3d3f604866a878f,mentioned,0.377373
uuid-e82deeacfeb94e27b3d3f604866a878f,cHL,0.565897
uuid-e82deeacfeb94e27b3d3f604866a878f,RTL stated,0.326038
uuid-78338db6dc4f4bad88e1e7f891809fc8,Nivo,0.404858
uuid-78338db6dc4f4bad88e1e7f891809fc8,pembro,0.446317
uuid-78338db6dc4f4bad88e1e7f891809fc8,1L,0.319149
uuid-78338db6dc4f4bad88e1e7f891809fc8,trial,0.561853
uuid-78338db6dc4f4bad88e1e7f891809fc8,regimen,0.316346
uuid-78338db6dc4f4bad88e1e7f891809fc8,combination,0.513952
uuid-78338db6dc4f4bad88e1e7f891809fc8,chemo,0.400549
uuid-78338db6dc4f4bad88e1e7f891809fc8,pts,0.364572
uuid-78338db6dc4f4bad88e1e7f891809fc8,Ipi,0.499646
uuid-78338db6dc4f4bad88e1e7f891809fc8,monotherapy,0.432858
uuid-78338db6dc4f4bad88e1e7f891809fc8,combo,0.564991
uuid-78338db6dc4f4bad88e1e7f891809fc8,clinical trials,0.416011
uuid-78338db6dc4f4bad88e1e7f891809fc8,PD1,0.316737
uuid-78338db6dc4f4bad88e1e7f891809fc8,chemotherapy,0.355899
uuid-78338db6dc4f4bad88e1e7f891809fc8,impressed,0.318374
uuid-78338db6dc4f4bad88e1e7f891809fc8,vs,0.421104
uuid-78338db6dc4f4bad88e1e7f891809fc8,feels,0.410167
uuid-78a6db680a324427b9afae843ec85f4b,pembro,0.334004
uuid-78a6db680a324427b9afae843ec85f4b,trial,0.644004
uuid-78a6db680a324427b9afae843ec85f4b,clinical trials,0.36659
uuid-06d15eb09d5a4d38afe310c12c8440c7,Nivo,0.619491
uuid-06d15eb09d5a4d38afe310c12c8440c7,patients,0.609138
uuid-06d15eb09d5a4d38afe310c12c8440c7,pembro,0.327205
uuid-06d15eb09d5a4d38afe310c12c8440c7,therapy,0.438927
uuid-06d15eb09d5a4d38afe310c12c8440c7,dose,0.368464
uuid-06d15eb09d5a4d38afe310c12c8440c7,nivolumab,0.341595
uuid-06d15eb09d5a4d38afe310c12c8440c7,1L,0.30951
uuid-06d15eb09d5a4d38afe310c12c8440c7,toxicity,0.442256
uuid-06d15eb09d5a4d38afe310c12c8440c7,efficacy,0.335878
uuid-06d15eb09d5a4d38afe310c12c8440c7,regimen,0.65024
uuid-06d15eb09d5a4d38afe310c12c8440c7,combination,0.450085
uuid-06d15eb09d5a4d38afe310c12c8440c7,chemo,0.629482
uuid-06d15eb09d5a4d38afe310c12c8440c7,2L,0.352781
uuid-06d15eb09d5a4d38afe310c12c8440c7,pts,0.542951
uuid-06d15eb09d5a4d38afe310c12c8440c7,Ipi,0.529003
uuid-06d15eb09d5a4d38afe310c12c8440c7,monotherapy,0.62566
uuid-06d15eb09d5a4d38afe310c12c8440c7,treatment,0.462664
uuid-06d15eb09d5a4d38afe310c12c8440c7,using nivo,0.328419
uuid-06d15eb09d5a4d38afe310c12c8440c7,response,0.392142
uuid-06d15eb09d5a4d38afe310c12c8440c7,combo,0.492624
uuid-06d15eb09d5a4d38afe310c12c8440c7,PD1,0.471529
uuid-06d15eb09d5a4d38afe310c12c8440c7,progression,0.549747
uuid-06d15eb09d5a4d38afe310c12c8440c7,believes,0.317462
uuid-06d15eb09d5a4d38afe310c12c8440c7,chemotherapy,0.568509
uuid-06d15eb09d5a4d38afe310c12c8440c7,vs,0.334214
uuid-06d15eb09d5a4d38afe310c12c8440c7,respond,0.42019
uuid-06d15eb09d5a4d38afe310c12c8440c7,feels,0.386136
uuid-06d15eb09d5a4d38afe310c12c8440c7,option,0.478295
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,Nivo,0.312475
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,patients,0.850619
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,Opdivo,0.404304
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,therapy,0.762943
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,nivolumab,0.592856
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,regimen,0.518525
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,treated,0.60689
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,chemo,0.414174
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,pts,0.624303
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,monotherapy,0.433062
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,treatment,0.737823
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,using nivo,0.334877
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,response,0.53888
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,PD1,0.491106
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,cHL,0.49442
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,progression,0.765719
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,chemotherapy,0.510438
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,respond,0.527161
uuid-20ac4f073b2a42d8aa88c08b4f8e45ec,option,0.37696
uuid-7cc8aa13e9844c158d95ed2e4074136a,Nivo,0.518906
uuid-7cc8aa13e9844c158d95ed2e4074136a,patients,0.603314
uuid-7cc8aa13e9844c158d95ed2e4074136a,therapy,0.613093
uuid-7cc8aa13e9844c158d95ed2e4074136a,nivolumab,0.524002
uuid-7cc8aa13e9844c158d95ed2e4074136a,regimen,0.32462
uuid-7cc8aa13e9844c158d95ed2e4074136a,treated,0.355537
uuid-7cc8aa13e9844c158d95ed2e4074136a,combination,0.341742
uuid-7cc8aa13e9844c158d95ed2e4074136a,chemo,0.419675
uuid-7cc8aa13e9844c158d95ed2e4074136a,pts,0.306978
uuid-7cc8aa13e9844c158d95ed2e4074136a,Ipi,0.34344
uuid-7cc8aa13e9844c158d95ed2e4074136a,preferred,0.320369
uuid-7cc8aa13e9844c158d95ed2e4074136a,monotherapy,0.451759
uuid-7cc8aa13e9844c158d95ed2e4074136a,treatment,0.435678
uuid-7cc8aa13e9844c158d95ed2e4074136a,using nivo,0.506816
uuid-7cc8aa13e9844c158d95ed2e4074136a,PD1,0.429823
uuid-7cc8aa13e9844c158d95ed2e4074136a,cHL,0.459035
uuid-7cc8aa13e9844c158d95ed2e4074136a,progression,0.311345
uuid-7cc8aa13e9844c158d95ed2e4074136a,chemotherapy,0.534837
uuid-7cc8aa13e9844c158d95ed2e4074136a,option,0.412203
uuid-cdeb6174ac684592b0e04ecf76d8ffeb,Ipi,0.407461
uuid-cdeb6174ac684592b0e04ecf76d8ffeb,data,0.381166
uuid-cdeb6174ac684592b0e04ecf76d8ffeb,ORR,0.328628
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,Nivo,0.609217
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,pembro,0.779728
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,dose,0.616045
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,1L,0.435211
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,2L,0.596316
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,agents,0.409146
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,Ipi,0.482687
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,approval,0.346593
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,atezo,0.760509
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,preferred,0.613528
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,monotherapy,0.445281
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,using nivo,0.550621
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,combo,0.314182
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,indication,0.320378
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,approved,0.458841
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,nivo and pembro,0.324054
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,vs,0.65384
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,option,0.430719
uuid-bfb93b1f0cf9412ba56aac3ade5808f1,flat dosing,0.467472
uuid-15e7d04c9ddf4d4783c6dd102406cac5,shared,0.534836
uuid-15e7d04c9ddf4d4783c6dd102406cac5,pts,0.40585
uuid-15e7d04c9ddf4d4783c6dd102406cac5,institution,0.360448
uuid-15e7d04c9ddf4d4783c6dd102406cac5,stated,0.352356
uuid-15e7d04c9ddf4d4783c6dd102406cac5,approval,0.372959
uuid-f57da2975d634d0dae9e13f080258987,Nivo,0.303294
uuid-f57da2975d634d0dae9e13f080258987,patients,0.432364
uuid-f57da2975d634d0dae9e13f080258987,therapy,0.330684
uuid-f57da2975d634d0dae9e13f080258987,nivolumab,0.449335
uuid-f57da2975d634d0dae9e13f080258987,toxicity,0.498526
uuid-f57da2975d634d0dae9e13f080258987,regimen,0.613022
uuid-f57da2975d634d0dae9e13f080258987,treated,0.477899
uuid-f57da2975d634d0dae9e13f080258987,combination,0.505234
uuid-f57da2975d634d0dae9e13f080258987,chemo,0.337608
uuid-f57da2975d634d0dae9e13f080258987,pts,0.323576
uuid-f57da2975d634d0dae9e13f080258987,Ipi,0.333666
uuid-f57da2975d634d0dae9e13f080258987,preferred,0.36558
uuid-f57da2975d634d0dae9e13f080258987,monotherapy,0.621135
uuid-f57da2975d634d0dae9e13f080258987,treatment,0.45364
uuid-f57da2975d634d0dae9e13f080258987,using nivo,0.407542
uuid-f57da2975d634d0dae9e13f080258987,combo,0.419023
uuid-f57da2975d634d0dae9e13f080258987,PD1,0.39553
uuid-f57da2975d634d0dae9e13f080258987,HCP,0.356479
uuid-f57da2975d634d0dae9e13f080258987,progression,0.319725
uuid-f57da2975d634d0dae9e13f080258987,chemotherapy,0.39648
uuid-f57da2975d634d0dae9e13f080258987,SCLC,0.3542
uuid-f57da2975d634d0dae9e13f080258987,feels,0.316793
uuid-f57da2975d634d0dae9e13f080258987,RTL stated,0.409694
uuid-f57da2975d634d0dae9e13f080258987,option,0.450978
uuid-dce50e919ea24b8b97a5def285e47d18,Nivo,0.47426
uuid-dce50e919ea24b8b97a5def285e47d18,pembro,0.329013
uuid-dce50e919ea24b8b97a5def285e47d18,RTL,0.470177
uuid-dce50e919ea24b8b97a5def285e47d18,trial,0.390982
uuid-dce50e919ea24b8b97a5def285e47d18,Ipi,0.334055
uuid-dce50e919ea24b8b97a5def285e47d18,OS,0.402004
uuid-dce50e919ea24b8b97a5def285e47d18,using nivo,0.372442
uuid-dce50e919ea24b8b97a5def285e47d18,data,0.329
uuid-dce50e919ea24b8b97a5def285e47d18,mentioned,0.382921
uuid-dce50e919ea24b8b97a5def285e47d18,PFS,0.404453
uuid-dce50e919ea24b8b97a5def285e47d18,ORR,0.373851
uuid-dce50e919ea24b8b97a5def285e47d18,HCP,0.515335
uuid-dce50e919ea24b8b97a5def285e47d18,impressed,0.376872
uuid-dce50e919ea24b8b97a5def285e47d18,LTL,0.339519
uuid-dce50e919ea24b8b97a5def285e47d18,feels,0.348561
uuid-bc918f19b41d4f258e0cef0570726496,patients,0.674458
uuid-bc918f19b41d4f258e0cef0570726496,Opdivo,0.511212
uuid-bc918f19b41d4f258e0cef0570726496,nivolumab,0.325901
uuid-bc918f19b41d4f258e0cef0570726496,treated,0.362054
uuid-bc918f19b41d4f258e0cef0570726496,pts,0.309193
uuid-bc918f19b41d4f258e0cef0570726496,approval,0.469851
uuid-bc918f19b41d4f258e0cef0570726496,treatment,0.348455
uuid-bc918f19b41d4f258e0cef0570726496,using nivo,0.351973
uuid-bc918f19b41d4f258e0cef0570726496,clinical trials,0.33746
uuid-bc918f19b41d4f258e0cef0570726496,approved,0.473588
uuid-bc918f19b41d4f258e0cef0570726496,tumor types,0.311636
uuid-bc918f19b41d4f258e0cef0570726496,label,0.360167
uuid-2e4b1e2702ee420a9e229ec50e24f40a,patients,0.385194
uuid-2e4b1e2702ee420a9e229ec50e24f40a,therapy,0.314007
uuid-2e4b1e2702ee420a9e229ec50e24f40a,1L,0.41751
uuid-2e4b1e2702ee420a9e229ec50e24f40a,regimen,0.403825
uuid-2e4b1e2702ee420a9e229ec50e24f40a,chemo,0.430233
uuid-2e4b1e2702ee420a9e229ec50e24f40a,2L,0.420095
uuid-2e4b1e2702ee420a9e229ec50e24f40a,agents,0.388861
uuid-2e4b1e2702ee420a9e229ec50e24f40a,preferred,0.668331
uuid-2e4b1e2702ee420a9e229ec50e24f40a,monotherapy,0.564577
uuid-2e4b1e2702ee420a9e229ec50e24f40a,treatment,0.346166
uuid-2e4b1e2702ee420a9e229ec50e24f40a,using nivo,0.352641
uuid-2e4b1e2702ee420a9e229ec50e24f40a,chemotherapy,0.436438
uuid-2e4b1e2702ee420a9e229ec50e24f40a,feels,0.327251
uuid-2e4b1e2702ee420a9e229ec50e24f40a,RTL stated,0.381962
uuid-2e4b1e2702ee420a9e229ec50e24f40a,option,0.634472
uuid-31e707eac69444f896b951ac0a44f8c5,Nivo,0.382299
uuid-31e707eac69444f896b951ac0a44f8c5,patients,0.604789
uuid-31e707eac69444f896b951ac0a44f8c5,therapy,0.538275
uuid-31e707eac69444f896b951ac0a44f8c5,nivolumab,0.422825
uuid-31e707eac69444f896b951ac0a44f8c5,1L,0.411929
uuid-31e707eac69444f896b951ac0a44f8c5,regimen,0.533985
uuid-31e707eac69444f896b951ac0a44f8c5,treated,0.377878
uuid-31e707eac69444f896b951ac0a44f8c5,combination,0.354072
uuid-31e707eac69444f896b951ac0a44f8c5,chemo,0.589582
uuid-31e707eac69444f896b951ac0a44f8c5,2L,0.448637
uuid-31e707eac69444f896b951ac0a44f8c5,pts,0.406228
uuid-31e707eac69444f896b951ac0a44f8c5,agents,0.324689
uuid-31e707eac69444f896b951ac0a44f8c5,preferred,0.583272
uuid-31e707eac69444f896b951ac0a44f8c5,monotherapy,0.59506
uuid-31e707eac69444f896b951ac0a44f8c5,treatment,0.503708
uuid-31e707eac69444f896b951ac0a44f8c5,using nivo,0.432438
uuid-31e707eac69444f896b951ac0a44f8c5,PD1,0.337076
uuid-31e707eac69444f896b951ac0a44f8c5,progression,0.357463
uuid-31e707eac69444f896b951ac0a44f8c5,chemotherapy,0.541003
uuid-31e707eac69444f896b951ac0a44f8c5,respond,0.307007
uuid-31e707eac69444f896b951ac0a44f8c5,RTL stated,0.3882
uuid-31e707eac69444f896b951ac0a44f8c5,option,0.611909
uuid-c18a728dc0df453b97ec205bb81a425e,Nivo,0.591116
uuid-c18a728dc0df453b97ec205bb81a425e,pembro,0.369444
uuid-c18a728dc0df453b97ec205bb81a425e,PFS,0.337075
uuid-c18a728dc0df453b97ec205bb81a425e,cHL,0.507121
uuid-c18a728dc0df453b97ec205bb81a425e,nivo and pembro,0.360264
uuid-c18a728dc0df453b97ec205bb81a425e,vs,0.32763
uuid-4aa0211896b3490f9521383380d5b40c,pembro,0.357022
uuid-4aa0211896b3490f9521383380d5b40c,1L,0.331442
uuid-4aa0211896b3490f9521383380d5b40c,PDL1,0.830805
uuid-4aa0211896b3490f9521383380d5b40c,efficacy,0.320127
uuid-4aa0211896b3490f9521383380d5b40c,Merck,0.336704
uuid-4aa0211896b3490f9521383380d5b40c,PD-L1,0.697871
uuid-4aa0211896b3490f9521383380d5b40c,OS,0.309062
uuid-4aa0211896b3490f9521383380d5b40c,atezo,0.342868
uuid-4aa0211896b3490f9521383380d5b40c,PD-L1 testing,0.372749
uuid-4aa0211896b3490f9521383380d5b40c,testing,0.534086
uuid-4aa0211896b3490f9521383380d5b40c,PDL1 testing,0.303285
uuid-4aa0211896b3490f9521383380d5b40c,PFS,0.351935
uuid-4aa0211896b3490f9521383380d5b40c,NSCLC patients,0.370621
uuid-4aa0211896b3490f9521383380d5b40c,ORR,0.320191
uuid-4aa0211896b3490f9521383380d5b40c,nivo and pembro,0.480528
uuid-4aa0211896b3490f9521383380d5b40c,believes,0.364486
uuid-4aa0211896b3490f9521383380d5b40c,assay,0.655047
uuid-4aa0211896b3490f9521383380d5b40c,PDL1 expression,0.680619
uuid-4aa0211896b3490f9521383380d5b40c,biomarker,0.554361
uuid-a69adb53ee34461fa651061ef804f63b,Nivo,0.466988
uuid-a69adb53ee34461fa651061ef804f63b,patients,0.608674
uuid-a69adb53ee34461fa651061ef804f63b,therapy,0.577373
uuid-a69adb53ee34461fa651061ef804f63b,dose,0.310105
uuid-a69adb53ee34461fa651061ef804f63b,nivolumab,0.479399
uuid-a69adb53ee34461fa651061ef804f63b,regimen,0.507252
uuid-a69adb53ee34461fa651061ef804f63b,treated,0.398626
uuid-a69adb53ee34461fa651061ef804f63b,combination,0.52077
uuid-a69adb53ee34461fa651061ef804f63b,chemo,0.509125
uuid-a69adb53ee34461fa651061ef804f63b,pts,0.538184
uuid-a69adb53ee34461fa651061ef804f63b,Ipi,0.497061
uuid-a69adb53ee34461fa651061ef804f63b,monotherapy,0.520423
uuid-a69adb53ee34461fa651061ef804f63b,treatment,0.511916
uuid-a69adb53ee34461fa651061ef804f63b,using nivo,0.377528
uuid-a69adb53ee34461fa651061ef804f63b,response,0.428271
uuid-a69adb53ee34461fa651061ef804f63b,combo,0.435067
uuid-a69adb53ee34461fa651061ef804f63b,PD1,0.518991
uuid-a69adb53ee34461fa651061ef804f63b,progression,0.571248
uuid-a69adb53ee34461fa651061ef804f63b,chemotherapy,0.539108
uuid-a69adb53ee34461fa651061ef804f63b,respond,0.386902
uuid-a69adb53ee34461fa651061ef804f63b,option,0.383788
uuid-cead67c5ce7b43748a22ad62422f579e,patients,0.348435
uuid-cead67c5ce7b43748a22ad62422f579e,toxicity,0.356576
uuid-cead67c5ce7b43748a22ad62422f579e,regimen,0.350673
uuid-cead67c5ce7b43748a22ad62422f579e,treated,0.373274
uuid-cead67c5ce7b43748a22ad62422f579e,treatment,0.322346
uuid-cead67c5ce7b43748a22ad62422f579e,respond,0.316505
uuid-cead67c5ce7b43748a22ad62422f579e,feels,0.302813
uuid-cead67c5ce7b43748a22ad62422f579e,TL shared,0.312253
uuid-dcffa19b6a404bcd86a6b03bfb12f5c8,Ipi,0.338611
uuid-e7c248cc44d24da69bb0104ce252710c,RTL,0.450925
uuid-e7c248cc44d24da69bb0104ce252710c,NTL,0.314964
uuid-e7c248cc44d24da69bb0104ce252710c,using nivo,0.31598
uuid-e7c248cc44d24da69bb0104ce252710c,expressed,0.361567
uuid-e7c248cc44d24da69bb0104ce252710c,mentioned,0.50984
uuid-e7c248cc44d24da69bb0104ce252710c,HCP,0.740614
uuid-e7c248cc44d24da69bb0104ce252710c,LTL,0.35402
uuid-9cb90df1171c45ed8672bc102420d225,RTL,0.55564
uuid-9cb90df1171c45ed8672bc102420d225,NTL,0.442456
uuid-9cb90df1171c45ed8672bc102420d225,using nivo,0.358913
uuid-9cb90df1171c45ed8672bc102420d225,expressed,0.433768
uuid-9cb90df1171c45ed8672bc102420d225,mentioned,0.544277
uuid-9cb90df1171c45ed8672bc102420d225,SCCHN,0.361227
uuid-9cb90df1171c45ed8672bc102420d225,HCP,0.711537
uuid-9cb90df1171c45ed8672bc102420d225,LTL,0.429073
uuid-9cb90df1171c45ed8672bc102420d225,SCLC,0.375874
uuid-9cb90df1171c45ed8672bc102420d225,Regional TL,0.318276
uuid-35e1eb18fd824d26af437f099a5f09cb,mentioned,0.452099
uuid-35e1eb18fd824d26af437f099a5f09cb,HCP,0.698983
uuid-5f38d2a2e0714df88a1bb06e85463e86,therapy,0.422692
uuid-5f38d2a2e0714df88a1bb06e85463e86,nivolumab,0.353491
uuid-5f38d2a2e0714df88a1bb06e85463e86,combination,0.332507
uuid-5f38d2a2e0714df88a1bb06e85463e86,chemo,0.309464
uuid-5f38d2a2e0714df88a1bb06e85463e86,agents,0.364821
uuid-5f38d2a2e0714df88a1bb06e85463e86,treatment,0.35468
uuid-5f38d2a2e0714df88a1bb06e85463e86,response,0.373281
uuid-5f38d2a2e0714df88a1bb06e85463e86,PD1,0.74049
uuid-5f38d2a2e0714df88a1bb06e85463e86,progression,0.413738
uuid-5f38d2a2e0714df88a1bb06e85463e86,chemotherapy,0.325528
uuid-5f38d2a2e0714df88a1bb06e85463e86,immunotherapy,0.486359
uuid-5f38d2a2e0714df88a1bb06e85463e86,PD-1,0.549002
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,RTL,0.484615
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,BMS,0.412413
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,trial,0.701326
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,NTL,0.363936
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,shared,0.432936
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,commented,0.407417
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,Merck,0.316228
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,stated,0.359128
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,data,0.451868
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,expressed,0.338704
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,clinical trials,0.445585
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,ASCO,0.310131
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,impressed,0.522983
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,SCLC,0.328159
uuid-05f18d80c3c1473c8d5aaf39b4db06a9,Regional TL,0.350694
uuid-e78fc1eaefc746ddb1b17f60b0949b02,patients,0.608068
uuid-e78fc1eaefc746ddb1b17f60b0949b02,Opdivo,0.316375
uuid-e78fc1eaefc746ddb1b17f60b0949b02,therapy,0.352499
uuid-e78fc1eaefc746ddb1b17f60b0949b02,nivolumab,0.436788
uuid-e78fc1eaefc746ddb1b17f60b0949b02,regimen,0.513517
uuid-e78fc1eaefc746ddb1b17f60b0949b02,treated,0.469287
uuid-e78fc1eaefc746ddb1b17f60b0949b02,shared,0.4196
uuid-e78fc1eaefc746ddb1b17f60b0949b02,RCC,0.344247
uuid-e78fc1eaefc746ddb1b17f60b0949b02,combination,0.307826
uuid-e78fc1eaefc746ddb1b17f60b0949b02,pts,0.454346
uuid-e78fc1eaefc746ddb1b17f60b0949b02,IO,0.329169
uuid-e78fc1eaefc746ddb1b17f60b0949b02,monotherapy,0.449224
uuid-e78fc1eaefc746ddb1b17f60b0949b02,treatment,0.417255
uuid-e78fc1eaefc746ddb1b17f60b0949b02,using nivo,0.409685
uuid-e78fc1eaefc746ddb1b17f60b0949b02,response,0.302916
uuid-e78fc1eaefc746ddb1b17f60b0949b02,combo,0.36422
uuid-e78fc1eaefc746ddb1b17f60b0949b02,PD1,0.302685
uuid-e78fc1eaefc746ddb1b17f60b0949b02,progression,0.520394
uuid-e78fc1eaefc746ddb1b17f60b0949b02,respond,0.349263
uuid-e78fc1eaefc746ddb1b17f60b0949b02,feels,0.318409
uuid-e78fc1eaefc746ddb1b17f60b0949b02,RTL stated,0.401218
uuid-e78fc1eaefc746ddb1b17f60b0949b02,TL shared,0.355285
uuid-e78fc1eaefc746ddb1b17f60b0949b02,option,0.331943
uuid-e791257b0a4b42898c27aedda6470af9,patients,0.655349
uuid-e791257b0a4b42898c27aedda6470af9,Opdivo,0.36171
uuid-e791257b0a4b42898c27aedda6470af9,therapy,0.464737
uuid-e791257b0a4b42898c27aedda6470af9,nivolumab,0.391654
uuid-e791257b0a4b42898c27aedda6470af9,regimen,0.314779
uuid-e791257b0a4b42898c27aedda6470af9,treated,0.646788
uuid-e791257b0a4b42898c27aedda6470af9,pts,0.47898
uuid-e791257b0a4b42898c27aedda6470af9,treatment,0.553123
uuid-e791257b0a4b42898c27aedda6470af9,cHL,0.396428
uuid-e791257b0a4b42898c27aedda6470af9,progression,0.558474
uuid-e791257b0a4b42898c27aedda6470af9,respond,0.412587
uuid-f7fe2361325c41a496f38258617e07c9,patients,0.536213
uuid-f7fe2361325c41a496f38258617e07c9,Opdivo,0.304998
uuid-f7fe2361325c41a496f38258617e07c9,therapy,0.469692
uuid-f7fe2361325c41a496f38258617e07c9,nivolumab,0.500913
uuid-f7fe2361325c41a496f38258617e07c9,trial,0.303933
uuid-f7fe2361325c41a496f38258617e07c9,treated,0.387835
uuid-f7fe2361325c41a496f38258617e07c9,approval,0.362307
uuid-f7fe2361325c41a496f38258617e07c9,treatment,0.357225
uuid-f7fe2361325c41a496f38258617e07c9,clinical trials,0.318896
uuid-f7fe2361325c41a496f38258617e07c9,cHL,0.520946
uuid-f7fe2361325c41a496f38258617e07c9,chemotherapy,0.378899
uuid-c8da84cf65f945cfa87805d46f526843,patients,0.497568
uuid-c8da84cf65f945cfa87805d46f526843,RTL,0.378899
uuid-c8da84cf65f945cfa87805d46f526843,nivolumab,0.451247
uuid-c8da84cf65f945cfa87805d46f526843,trial,0.489325
uuid-c8da84cf65f945cfa87805d46f526843,regimen,0.374777
uuid-c8da84cf65f945cfa87805d46f526843,treated,0.44322
uuid-c8da84cf65f945cfa87805d46f526843,combination,0.358285
uuid-c8da84cf65f945cfa87805d46f526843,pts,0.374705
uuid-c8da84cf65f945cfa87805d46f526843,Ipi,0.361196
uuid-c8da84cf65f945cfa87805d46f526843,clinical trials,0.377121
uuid-7c4b0c9a7332459a835fb0f0a100928c,RTL,0.725362
uuid-7c4b0c9a7332459a835fb0f0a100928c,nivolumab,0.374209
uuid-7c4b0c9a7332459a835fb0f0a100928c,NTL,0.59674
uuid-7c4b0c9a7332459a835fb0f0a100928c,shared,0.378211
uuid-7c4b0c9a7332459a835fb0f0a100928c,commented,0.422673
uuid-7c4b0c9a7332459a835fb0f0a100928c,stated,0.531511
uuid-7c4b0c9a7332459a835fb0f0a100928c,approval,0.310107
uuid-7c4b0c9a7332459a835fb0f0a100928c,physicians,0.378513
uuid-7c4b0c9a7332459a835fb0f0a100928c,using nivo,0.309422
uuid-7c4b0c9a7332459a835fb0f0a100928c,mentioned,0.453326
uuid-7c4b0c9a7332459a835fb0f0a100928c,SCCHN,0.51529
uuid-7c4b0c9a7332459a835fb0f0a100928c,HCP,0.410581
uuid-7c4b0c9a7332459a835fb0f0a100928c,impressed,0.338714
uuid-7c4b0c9a7332459a835fb0f0a100928c,LTL,0.565249
uuid-7c4b0c9a7332459a835fb0f0a100928c,TLs,0.365508
uuid-7c4b0c9a7332459a835fb0f0a100928c,academic,0.39831
uuid-7c4b0c9a7332459a835fb0f0a100928c,Regional TL,0.652811
uuid-7c4b0c9a7332459a835fb0f0a100928c,RTL stated,0.403027
uuid-eda06709c2554cbc96276ad21db53ee5,patients,0.653122
uuid-eda06709c2554cbc96276ad21db53ee5,Opdivo,0.346819
uuid-eda06709c2554cbc96276ad21db53ee5,therapy,0.410122
uuid-eda06709c2554cbc96276ad21db53ee5,nivolumab,0.466625
uuid-eda06709c2554cbc96276ad21db53ee5,regimen,0.391064
uuid-eda06709c2554cbc96276ad21db53ee5,treated,0.660397
uuid-eda06709c2554cbc96276ad21db53ee5,pts,0.455275
uuid-eda06709c2554cbc96276ad21db53ee5,treatment,0.572897
uuid-eda06709c2554cbc96276ad21db53ee5,response,0.364475
uuid-eda06709c2554cbc96276ad21db53ee5,cHL,0.357024
uuid-eda06709c2554cbc96276ad21db53ee5,progression,0.549717
uuid-eda06709c2554cbc96276ad21db53ee5,respond,0.374449
uuid-876ae72566d94fb9b224ddce1c54c852,RTL,0.422415
uuid-876ae72566d94fb9b224ddce1c54c852,treated,0.340614
uuid-876ae72566d94fb9b224ddce1c54c852,melanoma,0.422638
uuid-876ae72566d94fb9b224ddce1c54c852,shared,0.436162
uuid-876ae72566d94fb9b224ddce1c54c852,RCC,0.499568
uuid-876ae72566d94fb9b224ddce1c54c852,TL stated,0.372381
uuid-876ae72566d94fb9b224ddce1c54c852,2L,0.332284
uuid-876ae72566d94fb9b224ddce1c54c852,preferred,0.406767
uuid-876ae72566d94fb9b224ddce1c54c852,monotherapy,0.341593
uuid-876ae72566d94fb9b224ddce1c54c852,using nivo,0.375093
uuid-876ae72566d94fb9b224ddce1c54c852,clinical trials,0.3416
uuid-876ae72566d94fb9b224ddce1c54c852,PDL1 testing,0.313994
uuid-876ae72566d94fb9b224ddce1c54c852,NSCLC patients,0.336989
uuid-876ae72566d94fb9b224ddce1c54c852,SCCHN,0.544575
uuid-876ae72566d94fb9b224ddce1c54c852,LTL,0.431208
uuid-876ae72566d94fb9b224ddce1c54c852,TLs,0.464679
uuid-876ae72566d94fb9b224ddce1c54c852,academic,0.681926
uuid-876ae72566d94fb9b224ddce1c54c852,Regional TL,0.42378
uuid-876ae72566d94fb9b224ddce1c54c852,RTL stated,0.644551
uuid-876ae72566d94fb9b224ddce1c54c852,TL shared,0.507405
uuid-182db653b8d24f1d8a022e8dc9461f3a,RTL,0.479937
uuid-182db653b8d24f1d8a022e8dc9461f3a,BMS,0.388576
uuid-182db653b8d24f1d8a022e8dc9461f3a,PDL1,0.388298
uuid-182db653b8d24f1d8a022e8dc9461f3a,trial,0.426316
uuid-182db653b8d24f1d8a022e8dc9461f3a,efficacy,0.437898
uuid-182db653b8d24f1d8a022e8dc9461f3a,commented,0.551154
uuid-182db653b8d24f1d8a022e8dc9461f3a,stated,0.405071
uuid-182db653b8d24f1d8a022e8dc9461f3a,OS,0.690598
uuid-182db653b8d24f1d8a022e8dc9461f3a,regards,0.329428
uuid-182db653b8d24f1d8a022e8dc9461f3a,data,0.853562
uuid-182db653b8d24f1d8a022e8dc9461f3a,expressed,0.420437
uuid-182db653b8d24f1d8a022e8dc9461f3a,PFS,0.606784
uuid-182db653b8d24f1d8a022e8dc9461f3a,ORR,0.657414
uuid-182db653b8d24f1d8a022e8dc9461f3a,SCCHN,0.302026
uuid-182db653b8d24f1d8a022e8dc9461f3a,nivo and pembro,0.305054
uuid-182db653b8d24f1d8a022e8dc9461f3a,ASCO,0.440862
uuid-182db653b8d24f1d8a022e8dc9461f3a,impressed,0.779769
uuid-182db653b8d24f1d8a022e8dc9461f3a,LTL,0.337428
uuid-182db653b8d24f1d8a022e8dc9461f3a,TLs,0.430185
uuid-182db653b8d24f1d8a022e8dc9461f3a,Regional TL,0.375725
uuid-182db653b8d24f1d8a022e8dc9461f3a,PDL1 expression,0.353273
uuid-3496a4be5e20440fa61e9b267995361e,Nivo,0.366116
uuid-3496a4be5e20440fa61e9b267995361e,therapy,0.46478
uuid-3496a4be5e20440fa61e9b267995361e,nivolumab,0.439345
uuid-3496a4be5e20440fa61e9b267995361e,combination,0.316623
uuid-3496a4be5e20440fa61e9b267995361e,chemo,0.318225
uuid-3496a4be5e20440fa61e9b267995361e,pts,0.342768
uuid-3496a4be5e20440fa61e9b267995361e,response,0.382564
uuid-3496a4be5e20440fa61e9b267995361e,PD1,0.416005
uuid-3496a4be5e20440fa61e9b267995361e,cHL,0.348352
uuid-3496a4be5e20440fa61e9b267995361e,immunotherapy,0.319893
uuid-73c017775d164dbca6dcaff70dad6d51,Nivo,0.516522
uuid-73c017775d164dbca6dcaff70dad6d51,pembro,0.6341
uuid-73c017775d164dbca6dcaff70dad6d51,RTL,0.339445
uuid-73c017775d164dbca6dcaff70dad6d51,BMS,0.312225
uuid-73c017775d164dbca6dcaff70dad6d51,trial,0.480798
uuid-73c017775d164dbca6dcaff70dad6d51,efficacy,0.301685
uuid-73c017775d164dbca6dcaff70dad6d51,2L,0.397051
uuid-73c017775d164dbca6dcaff70dad6d51,stated,0.301626
uuid-73c017775d164dbca6dcaff70dad6d51,approval,0.33699
uuid-73c017775d164dbca6dcaff70dad6d51,atezo,0.533685
uuid-73c017775d164dbca6dcaff70dad6d51,using nivo,0.434499
uuid-73c017775d164dbca6dcaff70dad6d51,data,0.341797
uuid-73c017775d164dbca6dcaff70dad6d51,clinical trials,0.409535
uuid-73c017775d164dbca6dcaff70dad6d51,indication,0.374814
uuid-73c017775d164dbca6dcaff70dad6d51,approved,0.384592
uuid-73c017775d164dbca6dcaff70dad6d51,nivo and pembro,0.382416
uuid-73c017775d164dbca6dcaff70dad6d51,vs,0.389726
uuid-73c017775d164dbca6dcaff70dad6d51,label,0.39595
uuid-73c017775d164dbca6dcaff70dad6d51,LTL,0.310154
uuid-73c017775d164dbca6dcaff70dad6d51,feels,0.395825
uuid-73c017775d164dbca6dcaff70dad6d51,bladder,0.342058
uuid-506c9dc991624dbc9ffc49865711f312,patients,0.829653
uuid-506c9dc991624dbc9ffc49865711f312,Opdivo,0.667105
uuid-506c9dc991624dbc9ffc49865711f312,therapy,0.559591
uuid-506c9dc991624dbc9ffc49865711f312,nivolumab,0.537702
uuid-506c9dc991624dbc9ffc49865711f312,regimen,0.371175
uuid-506c9dc991624dbc9ffc49865711f312,treated,0.528474
uuid-506c9dc991624dbc9ffc49865711f312,pts,0.456942
uuid-506c9dc991624dbc9ffc49865711f312,approval,0.343379
uuid-506c9dc991624dbc9ffc49865711f312,treatment,0.661361
uuid-506c9dc991624dbc9ffc49865711f312,using nivo,0.373798
uuid-506c9dc991624dbc9ffc49865711f312,cHL,0.484423
uuid-506c9dc991624dbc9ffc49865711f312,progression,0.501573
uuid-506c9dc991624dbc9ffc49865711f312,label,0.302284
uuid-506c9dc991624dbc9ffc49865711f312,respond,0.338036
uuid-506c9dc991624dbc9ffc49865711f312,option,0.338985
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,Nivo,0.44527
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,patients,0.536455
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,therapy,0.738782
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,nivolumab,0.543123
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,treated,0.346247
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,chemo,0.309126
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,monotherapy,0.33971
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,treatment,0.399117
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,using nivo,0.389911
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,PD1,0.366488
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,cHL,0.707984
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,progression,0.35575
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,chemotherapy,0.461326
uuid-0f4fd35369d049ccbd6a1cf6cde8091a,option,0.341623
uuid-96f5b79b2e42455a97eab378f8687bd2,patients,0.818331
uuid-96f5b79b2e42455a97eab378f8687bd2,therapy,0.606964
uuid-96f5b79b2e42455a97eab378f8687bd2,1L,0.304265
uuid-96f5b79b2e42455a97eab378f8687bd2,regimen,0.45254
uuid-96f5b79b2e42455a97eab378f8687bd2,treated,0.392742
uuid-96f5b79b2e42455a97eab378f8687bd2,chemo,0.563758
uuid-96f5b79b2e42455a97eab378f8687bd2,pts,0.645279
uuid-96f5b79b2e42455a97eab378f8687bd2,monotherapy,0.518024
uuid-96f5b79b2e42455a97eab378f8687bd2,treatment,0.64965
uuid-96f5b79b2e42455a97eab378f8687bd2,response,0.503167
uuid-96f5b79b2e42455a97eab378f8687bd2,PD1,0.435207
uuid-96f5b79b2e42455a97eab378f8687bd2,progression,0.654216
uuid-96f5b79b2e42455a97eab378f8687bd2,chemotherapy,0.545412
uuid-96f5b79b2e42455a97eab378f8687bd2,respond,0.598235
uuid-96f5b79b2e42455a97eab378f8687bd2,option,0.526083
uuid-f40fc36fdfc84a939813c28d81a9a3f1,treated,0.423934
uuid-f40fc36fdfc84a939813c28d81a9a3f1,melanoma,0.351783
uuid-f40fc36fdfc84a939813c28d81a9a3f1,treatment,0.387428
uuid-f40fc36fdfc84a939813c28d81a9a3f1,lung cancer,0.433217
uuid-f40fc36fdfc84a939813c28d81a9a3f1,progression,0.467967
uuid-f40fc36fdfc84a939813c28d81a9a3f1,TL shared,0.320973
uuid-580dcede53144131953977b488562293,toxicity,0.385733
uuid-580dcede53144131953977b488562293,melanoma,0.377822
uuid-1b470789b5374a289e6afd31eb953556,patients,0.467092
uuid-1b470789b5374a289e6afd31eb953556,TL,0.300348
uuid-1b470789b5374a289e6afd31eb953556,treated,0.363259
uuid-1b470789b5374a289e6afd31eb953556,TL stated,0.377887
uuid-1b470789b5374a289e6afd31eb953556,tumor,0.496061
uuid-1b470789b5374a289e6afd31eb953556,pts,0.397172
uuid-1b470789b5374a289e6afd31eb953556,PD-L1 testing,0.429055
uuid-1b470789b5374a289e6afd31eb953556,testing,0.444367
uuid-1b470789b5374a289e6afd31eb953556,PDL1 testing,0.394986
uuid-1b470789b5374a289e6afd31eb953556,NSCLC patients,0.42517
uuid-0eaa5f4c7a2b4620af0d520ee74fb81b,trial,0.546193
uuid-0eaa5f4c7a2b4620af0d520ee74fb81b,vs,0.316414
uuid-7acb3788bcc64e97910a7d9706f0ed5e,pembro,0.360251
uuid-7acb3788bcc64e97910a7d9706f0ed5e,PDL1,0.594944
uuid-7acb3788bcc64e97910a7d9706f0ed5e,trial,0.412853
uuid-7acb3788bcc64e97910a7d9706f0ed5e,efficacy,0.723721
uuid-7acb3788bcc64e97910a7d9706f0ed5e,chemo,0.317905
uuid-7acb3788bcc64e97910a7d9706f0ed5e,agents,0.509996
uuid-7acb3788bcc64e97910a7d9706f0ed5e,OS,0.622491
uuid-7acb3788bcc64e97910a7d9706f0ed5e,atezo,0.353336
uuid-7acb3788bcc64e97910a7d9706f0ed5e,data,0.630056
uuid-7acb3788bcc64e97910a7d9706f0ed5e,PFS,0.594331
uuid-7acb3788bcc64e97910a7d9706f0ed5e,PD1,0.323172
uuid-7acb3788bcc64e97910a7d9706f0ed5e,ORR,0.649761
uuid-7acb3788bcc64e97910a7d9706f0ed5e,nivo and pembro,0.653363
uuid-7acb3788bcc64e97910a7d9706f0ed5e,believes,0.4784
uuid-7acb3788bcc64e97910a7d9706f0ed5e,impressed,0.339484
uuid-7acb3788bcc64e97910a7d9706f0ed5e,vs,0.350792
uuid-7acb3788bcc64e97910a7d9706f0ed5e,feels,0.408046
uuid-7acb3788bcc64e97910a7d9706f0ed5e,PDL1 expression,0.504128
uuid-7acb3788bcc64e97910a7d9706f0ed5e,biomarker,0.399609
uuid-56477b997a3a44c79631db7cbfe07dfc,Nivo,0.324645
uuid-56477b997a3a44c79631db7cbfe07dfc,pembro,0.405004
uuid-56477b997a3a44c79631db7cbfe07dfc,RTL,0.372717
uuid-56477b997a3a44c79631db7cbfe07dfc,nivolumab,0.336617
uuid-56477b997a3a44c79631db7cbfe07dfc,1L,0.453077
uuid-56477b997a3a44c79631db7cbfe07dfc,trial,0.392165
uuid-56477b997a3a44c79631db7cbfe07dfc,NTL,0.3083
uuid-56477b997a3a44c79631db7cbfe07dfc,shared,0.341898
uuid-56477b997a3a44c79631db7cbfe07dfc,RCC,0.377824
uuid-56477b997a3a44c79631db7cbfe07dfc,combination,0.388044
uuid-56477b997a3a44c79631db7cbfe07dfc,2L,0.418593
uuid-56477b997a3a44c79631db7cbfe07dfc,approval,0.43451
uuid-56477b997a3a44c79631db7cbfe07dfc,preferred,0.368467
uuid-56477b997a3a44c79631db7cbfe07dfc,monotherapy,0.411991
uuid-56477b997a3a44c79631db7cbfe07dfc,using nivo,0.470167
uuid-56477b997a3a44c79631db7cbfe07dfc,combo,0.404349
uuid-56477b997a3a44c79631db7cbfe07dfc,clinical trials,0.431918
uuid-56477b997a3a44c79631db7cbfe07dfc,approved,0.391454
uuid-56477b997a3a44c79631db7cbfe07dfc,SCCHN,0.44175
uuid-56477b997a3a44c79631db7cbfe07dfc,impressed,0.397624
uuid-56477b997a3a44c79631db7cbfe07dfc,LTL,0.32348
uuid-56477b997a3a44c79631db7cbfe07dfc,SCLC,0.383158
uuid-56477b997a3a44c79631db7cbfe07dfc,feels,0.309978
uuid-56477b997a3a44c79631db7cbfe07dfc,Regional TL,0.346065
uuid-56477b997a3a44c79631db7cbfe07dfc,RTL stated,0.450211
uuid-56477b997a3a44c79631db7cbfe07dfc,TL shared,0.326508
uuid-56477b997a3a44c79631db7cbfe07dfc,option,0.376308
uuid-56477b997a3a44c79631db7cbfe07dfc,bladder,0.376844
uuid-27591045ccb54d0fa158e0c0ec4fa903,Nivo,0.56428
uuid-27591045ccb54d0fa158e0c0ec4fa903,pembro,0.412679
uuid-27591045ccb54d0fa158e0c0ec4fa903,trial,0.550391
uuid-27591045ccb54d0fa158e0c0ec4fa903,efficacy,0.591454
uuid-27591045ccb54d0fa158e0c0ec4fa903,combination,0.382929
uuid-27591045ccb54d0fa158e0c0ec4fa903,chemo,0.398634
uuid-27591045ccb54d0fa158e0c0ec4fa903,agents,0.320766
uuid-27591045ccb54d0fa158e0c0ec4fa903,Ipi,0.429364
uuid-27591045ccb54d0fa158e0c0ec4fa903,OS,0.445433
uuid-27591045ccb54d0fa158e0c0ec4fa903,atezo,0.309853
uuid-27591045ccb54d0fa158e0c0ec4fa903,data,0.504634
uuid-27591045ccb54d0fa158e0c0ec4fa903,combo,0.326544
uuid-27591045ccb54d0fa158e0c0ec4fa903,PFS,0.431742
uuid-27591045ccb54d0fa158e0c0ec4fa903,ORR,0.527402
uuid-27591045ccb54d0fa158e0c0ec4fa903,nivo and pembro,0.420146
uuid-27591045ccb54d0fa158e0c0ec4fa903,chemotherapy,0.357582
uuid-27591045ccb54d0fa158e0c0ec4fa903,impressed,0.322368
uuid-27591045ccb54d0fa158e0c0ec4fa903,vs,0.518493
uuid-27591045ccb54d0fa158e0c0ec4fa903,feels,0.426956
uuid-43079adc5576451381d3a9a8defa7117,therapy,0.450415
uuid-43079adc5576451381d3a9a8defa7117,regimen,0.319277
uuid-43079adc5576451381d3a9a8defa7117,combination,0.548152
uuid-43079adc5576451381d3a9a8defa7117,chemo,0.524353
uuid-43079adc5576451381d3a9a8defa7117,IO,0.388921
uuid-43079adc5576451381d3a9a8defa7117,agents,0.5563
uuid-43079adc5576451381d3a9a8defa7117,preferred,0.305542
uuid-43079adc5576451381d3a9a8defa7117,monotherapy,0.489134
uuid-43079adc5576451381d3a9a8defa7117,treatment,0.415969
uuid-43079adc5576451381d3a9a8defa7117,response,0.332488
uuid-43079adc5576451381d3a9a8defa7117,combo,0.490061
uuid-43079adc5576451381d3a9a8defa7117,PD1,0.501014
uuid-43079adc5576451381d3a9a8defa7117,progression,0.357907
uuid-43079adc5576451381d3a9a8defa7117,believes,0.379501
uuid-43079adc5576451381d3a9a8defa7117,chemotherapy,0.503667
uuid-43079adc5576451381d3a9a8defa7117,respond,0.324294
uuid-43079adc5576451381d3a9a8defa7117,feels,0.32946
uuid-43079adc5576451381d3a9a8defa7117,PD-1,0.423803
uuid-43079adc5576451381d3a9a8defa7117,option,0.517109
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,RTL,0.30342
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,trial,0.44279
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,NTL,0.325745
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,combination,0.377871
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,agents,0.381906
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,stated,0.316382
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,data,0.409088
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,combo,0.308022
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,clinical trials,0.308122
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,PD1,0.312079
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,ORR,0.332578
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,impressed,0.407052
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,feels,0.366058
uuid-2aeb23c923b74a4ea7cc4fa19426df0c,Regional TL,0.335629
uuid-b396de73150c4923845be6f55e9cded6,BMS,0.357305
uuid-b396de73150c4923845be6f55e9cded6,PDL1,0.441773
uuid-b396de73150c4923845be6f55e9cded6,trial,0.529914
uuid-b396de73150c4923845be6f55e9cded6,efficacy,0.571214
uuid-b396de73150c4923845be6f55e9cded6,OS,0.622237
uuid-b396de73150c4923845be6f55e9cded6,data,0.797695
uuid-b396de73150c4923845be6f55e9cded6,PFS,0.625842
uuid-b396de73150c4923845be6f55e9cded6,ORR,0.680012
uuid-b396de73150c4923845be6f55e9cded6,nivo and pembro,0.443756
uuid-b396de73150c4923845be6f55e9cded6,believes,0.328393
uuid-b396de73150c4923845be6f55e9cded6,impressed,0.553096
uuid-b396de73150c4923845be6f55e9cded6,feels,0.43285
uuid-b396de73150c4923845be6f55e9cded6,PDL1 expression,0.419127
uuid-550667d4757443aa934a08a7428e19a5,TL,0.528458
uuid-550667d4757443aa934a08a7428e19a5,lung,0.485869
uuid-550667d4757443aa934a08a7428e19a5,melanoma,0.337294
uuid-550667d4757443aa934a08a7428e19a5,RCC,0.334736
uuid-550667d4757443aa934a08a7428e19a5,TL stated,0.671659
uuid-550667d4757443aa934a08a7428e19a5,PD-L1,0.514835
uuid-550667d4757443aa934a08a7428e19a5,PD-L1 testing,0.641997
uuid-550667d4757443aa934a08a7428e19a5,testing,0.651001
uuid-550667d4757443aa934a08a7428e19a5,PDL1 testing,0.593027
uuid-550667d4757443aa934a08a7428e19a5,NSCLC patients,0.624278
uuid-550667d4757443aa934a08a7428e19a5,assay,0.426368
uuid-550667d4757443aa934a08a7428e19a5,TL shared,0.441799
uuid-d5ad9cc28fc64b68986523a211fb5c70,TL,0.336615
uuid-d5ad9cc28fc64b68986523a211fb5c70,PDL1,0.535882
uuid-d5ad9cc28fc64b68986523a211fb5c70,PD-L1,0.674224
uuid-d5ad9cc28fc64b68986523a211fb5c70,PD-L1 testing,0.612607
uuid-d5ad9cc28fc64b68986523a211fb5c70,testing,0.656505
uuid-d5ad9cc28fc64b68986523a211fb5c70,PDL1 testing,0.473308
uuid-d5ad9cc28fc64b68986523a211fb5c70,NSCLC patients,0.470734
uuid-d5ad9cc28fc64b68986523a211fb5c70,believes,0.31637
uuid-d5ad9cc28fc64b68986523a211fb5c70,assay,0.472308
uuid-d5ad9cc28fc64b68986523a211fb5c70,PDL1 expression,0.302234
uuid-d5ad9cc28fc64b68986523a211fb5c70,biomarker,0.511274
uuid-bacbed4a9c204681824e42838b8991ad,PDL1,0.335275
uuid-bacbed4a9c204681824e42838b8991ad,regards,0.357185
uuid-bacbed4a9c204681824e42838b8991ad,data,0.34757
uuid-bacbed4a9c204681824e42838b8991ad,biomarker,0.332581
uuid-bacbed4a9c204681824e42838b8991ad,NCCN,0.324861
uuid-e2ee1897990a4734b5b34061bb13f98d,TL,0.372084
uuid-e2ee1897990a4734b5b34061bb13f98d,PDL1,0.319741
uuid-e2ee1897990a4734b5b34061bb13f98d,TL stated,0.414373
uuid-e2ee1897990a4734b5b34061bb13f98d,PD-L1,0.604568
uuid-e2ee1897990a4734b5b34061bb13f98d,PD-L1 testing,0.776062
uuid-e2ee1897990a4734b5b34061bb13f98d,testing,0.695479
uuid-e2ee1897990a4734b5b34061bb13f98d,PDL1 testing,0.583883
uuid-e2ee1897990a4734b5b34061bb13f98d,NSCLC patients,0.447679
uuid-e2ee1897990a4734b5b34061bb13f98d,assay,0.48737
uuid-e2ee1897990a4734b5b34061bb13f98d,biomarker,0.378589
uuid-6f14d957b73147e6a1adaa5ccfb009fa,pembro,0.490106
uuid-6f14d957b73147e6a1adaa5ccfb009fa,BMS,0.367544
uuid-6f14d957b73147e6a1adaa5ccfb009fa,1L,0.403867
uuid-6f14d957b73147e6a1adaa5ccfb009fa,PDL1,0.577883
uuid-6f14d957b73147e6a1adaa5ccfb009fa,commented,0.387902
uuid-6f14d957b73147e6a1adaa5ccfb009fa,TL stated,0.415425
uuid-6f14d957b73147e6a1adaa5ccfb009fa,2L,0.337946
uuid-6f14d957b73147e6a1adaa5ccfb009fa,Merck,0.436278
uuid-6f14d957b73147e6a1adaa5ccfb009fa,stated,0.449983
uuid-6f14d957b73147e6a1adaa5ccfb009fa,PD-L1,0.44122
uuid-6f14d957b73147e6a1adaa5ccfb009fa,atezo,0.489682
uuid-6f14d957b73147e6a1adaa5ccfb009fa,testing,0.39585
uuid-6f14d957b73147e6a1adaa5ccfb009fa,data,0.520937
uuid-6f14d957b73147e6a1adaa5ccfb009fa,expressed,0.374638
uuid-6f14d957b73147e6a1adaa5ccfb009fa,PDL1 testing,0.478022
uuid-6f14d957b73147e6a1adaa5ccfb009fa,NSCLC patients,0.356014
uuid-6f14d957b73147e6a1adaa5ccfb009fa,SCCHN,0.358337
uuid-6f14d957b73147e6a1adaa5ccfb009fa,nivo and pembro,0.426871
uuid-6f14d957b73147e6a1adaa5ccfb009fa,believes,0.306883
uuid-6f14d957b73147e6a1adaa5ccfb009fa,impressed,0.409982
uuid-6f14d957b73147e6a1adaa5ccfb009fa,tumor types,0.325423
uuid-6f14d957b73147e6a1adaa5ccfb009fa,LTL,0.318071
uuid-6f14d957b73147e6a1adaa5ccfb009fa,TLs,0.495542
uuid-6f14d957b73147e6a1adaa5ccfb009fa,feels,0.351109
uuid-6f14d957b73147e6a1adaa5ccfb009fa,assay,0.301136
uuid-6f14d957b73147e6a1adaa5ccfb009fa,PDL1 expression,0.457253
uuid-6f14d957b73147e6a1adaa5ccfb009fa,biomarker,0.341574
uuid-6f14d957b73147e6a1adaa5ccfb009fa,bladder,0.343824
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,Nivo,0.444615
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,patients,0.39156
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,pembro,0.433491
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,1L,0.305861
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,toxicity,0.366994
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,trial,0.401718
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,efficacy,0.325566
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,regimen,0.463562
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,combination,0.403338
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,chemo,0.416102
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,pts,0.349564
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,Ipi,0.417769
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,preferred,0.387927
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,monotherapy,0.489424
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,using nivo,0.346562
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,combo,0.378575
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,clinical trials,0.320411
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,chemotherapy,0.410805
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,impressed,0.303746
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,feels,0.47016
uuid-0e136b368f28426f8ffbfc3d06c7a0a1,option,0.39327
uuid-5cfcab6e41c34d43a92107627ffb4de3,TL,0.574448
uuid-5cfcab6e41c34d43a92107627ffb4de3,PDL1,0.389254
uuid-5cfcab6e41c34d43a92107627ffb4de3,TL stated,0.419388
uuid-5cfcab6e41c34d43a92107627ffb4de3,Merck,0.319537
uuid-5cfcab6e41c34d43a92107627ffb4de3,institution,0.358198
uuid-5cfcab6e41c34d43a92107627ffb4de3,PD-L1,0.744924
uuid-5cfcab6e41c34d43a92107627ffb4de3,PD-L1 testing,0.779123
uuid-5cfcab6e41c34d43a92107627ffb4de3,testing,0.785185
uuid-5cfcab6e41c34d43a92107627ffb4de3,PDL1 testing,0.588855
uuid-5cfcab6e41c34d43a92107627ffb4de3,NSCLC patients,0.518169
uuid-5cfcab6e41c34d43a92107627ffb4de3,assay,0.81386
uuid-5cfcab6e41c34d43a92107627ffb4de3,biomarker,0.314645
uuid-236d57de6f234a6d879a7097d99290a4,therapy,0.303337
uuid-236d57de6f234a6d879a7097d99290a4,trial,0.329971
uuid-236d57de6f234a6d879a7097d99290a4,cHL,0.323753
uuid-236d57de6f234a6d879a7097d99290a4,chemotherapy,0.316587
uuid-d283b9af04f54990adbfccc85be215a6,pembro,0.30521
uuid-d283b9af04f54990adbfccc85be215a6,RTL,0.316384
uuid-d283b9af04f54990adbfccc85be215a6,BMS,0.394999
uuid-d283b9af04f54990adbfccc85be215a6,trial,0.615535
uuid-d283b9af04f54990adbfccc85be215a6,combination,0.301233
uuid-d283b9af04f54990adbfccc85be215a6,data,0.357639
uuid-d283b9af04f54990adbfccc85be215a6,clinical trials,0.413724
uuid-d283b9af04f54990adbfccc85be215a6,indication,0.363199
uuid-d283b9af04f54990adbfccc85be215a6,SCCHN,0.372449
uuid-d283b9af04f54990adbfccc85be215a6,impressed,0.374666
uuid-d283b9af04f54990adbfccc85be215a6,feels,0.394847
uuid-b39d054afa654628a84934742cbd337f,therapy,0.451036
uuid-b39d054afa654628a84934742cbd337f,regimen,0.320965
uuid-b39d054afa654628a84934742cbd337f,combination,0.358127
uuid-b39d054afa654628a84934742cbd337f,chemo,0.373306
uuid-b39d054afa654628a84934742cbd337f,treatment,0.463684
uuid-b39d054afa654628a84934742cbd337f,response,0.388198
uuid-b39d054afa654628a84934742cbd337f,PD1,0.341435
uuid-b39d054afa654628a84934742cbd337f,progression,0.483244
uuid-b39d054afa654628a84934742cbd337f,chemotherapy,0.400651
uuid-b39d054afa654628a84934742cbd337f,immunotherapy,0.383547
uuid-31f8d8c4ccd1400ea3864eb59b217d12,Nivo,0.413489
uuid-31f8d8c4ccd1400ea3864eb59b217d12,dose,0.314701
uuid-31f8d8c4ccd1400ea3864eb59b217d12,efficacy,0.646224
uuid-31f8d8c4ccd1400ea3864eb59b217d12,Ipi,0.306336
uuid-31f8d8c4ccd1400ea3864eb59b217d12,believes,0.392504
uuid-31f8d8c4ccd1400ea3864eb59b217d12,vs,0.341109
uuid-31f8d8c4ccd1400ea3864eb59b217d12,feels,0.36087
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,NSCLC,0.508041
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,treated,0.315508
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,tumor,0.483738
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,pts,0.359282
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,IO,0.436343
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,response,0.551114
uuid-3a66f35ff0aa4da58339d2ad5c7bafe9,progression,0.430822
uuid-3409f0a822b94f6d8f19512fab693242,toxicity,0.500371
uuid-3409f0a822b94f6d8f19512fab693242,physicians,0.383079
uuid-3409f0a822b94f6d8f19512fab693242,treatment,0.368787
uuid-d42db623535944bbad0a0d90ef658430,lung,0.349179
uuid-d42db623535944bbad0a0d90ef658430,1L,0.303567
uuid-d42db623535944bbad0a0d90ef658430,NTL,0.301295
uuid-d42db623535944bbad0a0d90ef658430,melanoma,0.447188
uuid-d42db623535944bbad0a0d90ef658430,RCC,0.391688
uuid-d42db623535944bbad0a0d90ef658430,2L,0.302716
uuid-d42db623535944bbad0a0d90ef658430,preferred,0.34365
uuid-d42db623535944bbad0a0d90ef658430,using nivo,0.337293
uuid-d42db623535944bbad0a0d90ef658430,SCCHN,0.642544
uuid-d42db623535944bbad0a0d90ef658430,RTL stated,0.413293
uuid-d42db623535944bbad0a0d90ef658430,TL shared,0.376874
uuid-d42db623535944bbad0a0d90ef658430,NCCN,0.483148
uuid-d42db623535944bbad0a0d90ef658430,bladder,0.419057
uuid-65518704a72b49a488e24ae3049bfc5a,lung,0.300191
uuid-65518704a72b49a488e24ae3049bfc5a,NTL,0.401806
uuid-65518704a72b49a488e24ae3049bfc5a,melanoma,0.422082
uuid-65518704a72b49a488e24ae3049bfc5a,commented,0.30668
uuid-65518704a72b49a488e24ae3049bfc5a,SCCHN,0.396401
uuid-65518704a72b49a488e24ae3049bfc5a,NCCN,0.638066
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,Nivo,0.620222
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,pembro,0.346451
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,therapy,0.409493
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,nivolumab,0.552287
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,1L,0.418527
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,RCC,0.585773
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,2L,0.549854
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,approval,0.419958
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,preferred,0.422007
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,monotherapy,0.444618
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,using nivo,0.751979
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,PD1,0.354567
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,approved,0.380393
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,SCCHN,0.35922
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,cHL,0.48375
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,RTL stated,0.60438
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,TL shared,0.348379
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,option,0.378402
uuid-dfb9f0e3d6ff43cb965e60c7409bb305,bladder,0.339118
uuid-4d7e7191b15f40608eb87c99bb139a67,Nivo,0.508009
uuid-4d7e7191b15f40608eb87c99bb139a67,patients,0.635481
uuid-4d7e7191b15f40608eb87c99bb139a67,therapy,0.740802
uuid-4d7e7191b15f40608eb87c99bb139a67,nivolumab,0.521454
uuid-4d7e7191b15f40608eb87c99bb139a67,1L,0.443282
uuid-4d7e7191b15f40608eb87c99bb139a67,regimen,0.419768
uuid-4d7e7191b15f40608eb87c99bb139a67,treated,0.372475
uuid-4d7e7191b15f40608eb87c99bb139a67,RCC,0.31357
uuid-4d7e7191b15f40608eb87c99bb139a67,combination,0.4463
uuid-4d7e7191b15f40608eb87c99bb139a67,chemo,0.557186
uuid-4d7e7191b15f40608eb87c99bb139a67,2L,0.456385
uuid-4d7e7191b15f40608eb87c99bb139a67,pts,0.50603
uuid-4d7e7191b15f40608eb87c99bb139a67,IO,0.300149
uuid-4d7e7191b15f40608eb87c99bb139a67,agents,0.351134
uuid-4d7e7191b15f40608eb87c99bb139a67,preferred,0.434219
uuid-4d7e7191b15f40608eb87c99bb139a67,monotherapy,0.657229
uuid-4d7e7191b15f40608eb87c99bb139a67,treatment,0.53474
uuid-4d7e7191b15f40608eb87c99bb139a67,using nivo,0.541693
uuid-4d7e7191b15f40608eb87c99bb139a67,response,0.423332
uuid-4d7e7191b15f40608eb87c99bb139a67,combo,0.389046
uuid-4d7e7191b15f40608eb87c99bb139a67,PD1,0.586963
uuid-4d7e7191b15f40608eb87c99bb139a67,cHL,0.375059
uuid-4d7e7191b15f40608eb87c99bb139a67,progression,0.564229
uuid-4d7e7191b15f40608eb87c99bb139a67,chemotherapy,0.587769
uuid-4d7e7191b15f40608eb87c99bb139a67,respond,0.391194
uuid-4d7e7191b15f40608eb87c99bb139a67,RTL stated,0.3564
uuid-4d7e7191b15f40608eb87c99bb139a67,option,0.666882
uuid-c29859d68fee42569acd8f234aa6c006,pts,0.449965
uuid-c29859d68fee42569acd8f234aa6c006,OS,0.350458
uuid-c29859d68fee42569acd8f234aa6c006,response,0.386337
uuid-c29859d68fee42569acd8f234aa6c006,data,0.310625
uuid-c29859d68fee42569acd8f234aa6c006,progression,0.317244
uuid-c29859d68fee42569acd8f234aa6c006,believes,0.409014
uuid-c29859d68fee42569acd8f234aa6c006,impressed,0.33195
uuid-c29859d68fee42569acd8f234aa6c006,respond,0.385646
uuid-c29859d68fee42569acd8f234aa6c006,feels,0.408757
uuid-391f05e90b724c239dc2a89bdedd8cb1,RCC,0.363589
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,Nivo,0.612472
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,efficacy,0.446601
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,regimen,0.309071
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,combination,0.379677
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,chemo,0.478902
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,OS,0.453748
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,monotherapy,0.435145
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,response,0.362092
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,data,0.446508
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,combo,0.391638
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,PFS,0.422524
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,PD1,0.415266
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,ORR,0.484433
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,nivo and pembro,0.312462
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,progression,0.303178
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,believes,0.3228
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,chemotherapy,0.441063
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,impressed,0.433029
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,feels,0.38966
uuid-7353559e60cb4cae9c4b5b1efbf02f0f,option,0.415044
uuid-a373d3ad47be4138a70f3f272240736d,RTL,0.509168
uuid-a373d3ad47be4138a70f3f272240736d,BMS,0.356121
uuid-a373d3ad47be4138a70f3f272240736d,trial,0.471774
uuid-a373d3ad47be4138a70f3f272240736d,NTL,0.499386
uuid-a373d3ad47be4138a70f3f272240736d,discussed,0.308511
uuid-a373d3ad47be4138a70f3f272240736d,commented,0.553659
uuid-a373d3ad47be4138a70f3f272240736d,stated,0.336213
uuid-a373d3ad47be4138a70f3f272240736d,regards,0.414766
uuid-a373d3ad47be4138a70f3f272240736d,data,0.527076
uuid-a373d3ad47be4138a70f3f272240736d,expressed,0.426576
uuid-a373d3ad47be4138a70f3f272240736d,mentioned,0.41505
uuid-a373d3ad47be4138a70f3f272240736d,ASCO,0.473472
uuid-a373d3ad47be4138a70f3f272240736d,impressed,0.561365
uuid-a373d3ad47be4138a70f3f272240736d,LTL,0.320043
uuid-a373d3ad47be4138a70f3f272240736d,TLs,0.349192
uuid-a373d3ad47be4138a70f3f272240736d,Regional TL,0.453335
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,TL,0.319925
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,RTL,0.420785
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,commented,0.301419
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,stated,0.313895
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,approval,0.31499
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,using nivo,0.434561
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,data,0.412114
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,SCCHN,0.445993
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,impressed,0.318145
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,indicated,0.438224
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,LTL,0.426792
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,TLs,0.366856
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,Regional TL,0.472271
uuid-3f8b77f0429b462c86a47e1d6d47c1ae,RTL stated,0.317067
uuid-22d43cd805f84e4db925887759818dc5,Nivo,0.453846
uuid-22d43cd805f84e4db925887759818dc5,pembro,0.457123
uuid-22d43cd805f84e4db925887759818dc5,BMS,0.306131
uuid-22d43cd805f84e4db925887759818dc5,PDL1,0.52798
uuid-22d43cd805f84e4db925887759818dc5,efficacy,0.7902
uuid-22d43cd805f84e4db925887759818dc5,agents,0.350695
uuid-22d43cd805f84e4db925887759818dc5,OS,0.549618
uuid-22d43cd805f84e4db925887759818dc5,atezo,0.478653
uuid-22d43cd805f84e4db925887759818dc5,data,0.667192
uuid-22d43cd805f84e4db925887759818dc5,PFS,0.519255
uuid-22d43cd805f84e4db925887759818dc5,ORR,0.583441
uuid-22d43cd805f84e4db925887759818dc5,nivo and pembro,0.600206
uuid-22d43cd805f84e4db925887759818dc5,believes,0.53335
uuid-22d43cd805f84e4db925887759818dc5,impressed,0.434152
uuid-22d43cd805f84e4db925887759818dc5,vs,0.385131
uuid-22d43cd805f84e4db925887759818dc5,feels,0.440069
uuid-22d43cd805f84e4db925887759818dc5,PDL1 expression,0.508763
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,patients,0.733621
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,Opdivo,0.674645
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,therapy,0.46466
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,nivolumab,0.528734
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,regimen,0.346581
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,treated,0.614791
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,pts,0.380304
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,treatment,0.576788
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,cHL,0.539824
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,progression,0.525129
uuid-1eb2cd21d85d4f74b83d1cc0f4b639f3,respond,0.30581
uuid-03ef7cc34a4844a3b667febb36c19e2a,RTL,0.334193
uuid-03ef7cc34a4844a3b667febb36c19e2a,nivolumab,0.384483
uuid-03ef7cc34a4844a3b667febb36c19e2a,lung,0.342787
uuid-03ef7cc34a4844a3b667febb36c19e2a,1L,0.405954
uuid-03ef7cc34a4844a3b667febb36c19e2a,discussed,0.356877
uuid-03ef7cc34a4844a3b667febb36c19e2a,melanoma,0.377764
uuid-03ef7cc34a4844a3b667febb36c19e2a,shared,0.329147
uuid-03ef7cc34a4844a3b667febb36c19e2a,RCC,0.636869
uuid-03ef7cc34a4844a3b667febb36c19e2a,2L,0.489523
uuid-03ef7cc34a4844a3b667febb36c19e2a,stated,0.342611
uuid-03ef7cc34a4844a3b667febb36c19e2a,approval,0.626792
uuid-03ef7cc34a4844a3b667febb36c19e2a,preferred,0.382417
uuid-03ef7cc34a4844a3b667febb36c19e2a,monotherapy,0.308296
uuid-03ef7cc34a4844a3b667febb36c19e2a,using nivo,0.545119
uuid-03ef7cc34a4844a3b667febb36c19e2a,approved,0.538943
uuid-03ef7cc34a4844a3b667febb36c19e2a,SCCHN,0.579355
uuid-03ef7cc34a4844a3b667febb36c19e2a,LTL,0.314003
uuid-03ef7cc34a4844a3b667febb36c19e2a,TLs,0.307757
uuid-03ef7cc34a4844a3b667febb36c19e2a,academic,0.485556
uuid-03ef7cc34a4844a3b667febb36c19e2a,Regional TL,0.406069
uuid-03ef7cc34a4844a3b667febb36c19e2a,RTL stated,0.613918
uuid-03ef7cc34a4844a3b667febb36c19e2a,TL shared,0.438497
uuid-03ef7cc34a4844a3b667febb36c19e2a,option,0.336128
uuid-03ef7cc34a4844a3b667febb36c19e2a,bladder,0.361443
uuid-4fa9294d5aca40c5ac9c1f279df391df,OS,0.375376
uuid-4fa9294d5aca40c5ac9c1f279df391df,PFS,0.346613
uuid-4fa9294d5aca40c5ac9c1f279df391df,ORR,0.356311
uuid-4fa9294d5aca40c5ac9c1f279df391df,ASCO,0.309895
uuid-14490240170b4b2b8d951d56b58935e6,NSCLC,0.303214
uuid-14490240170b4b2b8d951d56b58935e6,ASCO,0.408512
uuid-4314e926e30d40dc84f6230c83e15019,TL,0.316726
uuid-4314e926e30d40dc84f6230c83e15019,RTL,0.343942
uuid-4314e926e30d40dc84f6230c83e15019,commented,0.418373
uuid-4314e926e30d40dc84f6230c83e15019,stated,0.32754
uuid-4314e926e30d40dc84f6230c83e15019,data,0.396984
uuid-4314e926e30d40dc84f6230c83e15019,expressed,0.325671
uuid-4314e926e30d40dc84f6230c83e15019,SCCHN,0.328778
uuid-4314e926e30d40dc84f6230c83e15019,ASCO,0.344878
uuid-4314e926e30d40dc84f6230c83e15019,impressed,0.540327
uuid-4314e926e30d40dc84f6230c83e15019,Regional TL,0.545581
uuid-0ffd764017bc46bf9c221ded6d2f9208,Nivo,0.456
uuid-0ffd764017bc46bf9c221ded6d2f9208,patients,0.563322
uuid-0ffd764017bc46bf9c221ded6d2f9208,Opdivo,0.372344
uuid-0ffd764017bc46bf9c221ded6d2f9208,therapy,0.411298
uuid-0ffd764017bc46bf9c221ded6d2f9208,dose,0.369093
uuid-0ffd764017bc46bf9c221ded6d2f9208,nivolumab,0.352288
uuid-0ffd764017bc46bf9c221ded6d2f9208,regimen,0.396205
uuid-0ffd764017bc46bf9c221ded6d2f9208,chemo,0.31588
uuid-0ffd764017bc46bf9c221ded6d2f9208,pts,0.361276
uuid-0ffd764017bc46bf9c221ded6d2f9208,treatment,0.453397
uuid-0ffd764017bc46bf9c221ded6d2f9208,progression,0.493024
uuid-0ffd764017bc46bf9c221ded6d2f9208,respond,0.430861
uuid-23b256941aaa4eb4bfd0931c422dc55c,Nivo,0.573855
uuid-23b256941aaa4eb4bfd0931c422dc55c,patients,0.491695
uuid-23b256941aaa4eb4bfd0931c422dc55c,Opdivo,0.379325
uuid-23b256941aaa4eb4bfd0931c422dc55c,pembro,0.427522
uuid-23b256941aaa4eb4bfd0931c422dc55c,dose,0.758362
uuid-23b256941aaa4eb4bfd0931c422dc55c,nivolumab,0.415648
uuid-23b256941aaa4eb4bfd0931c422dc55c,toxicity,0.300449
uuid-23b256941aaa4eb4bfd0931c422dc55c,regimen,0.465364
uuid-23b256941aaa4eb4bfd0931c422dc55c,chemo,0.340045
uuid-23b256941aaa4eb4bfd0931c422dc55c,pts,0.346435
uuid-23b256941aaa4eb4bfd0931c422dc55c,Ipi,0.576503
uuid-23b256941aaa4eb4bfd0931c422dc55c,treatment,0.332389
uuid-23b256941aaa4eb4bfd0931c422dc55c,progression,0.345021
uuid-23b256941aaa4eb4bfd0931c422dc55c,vs,0.560905
uuid-23b256941aaa4eb4bfd0931c422dc55c,respond,0.311722
uuid-23b256941aaa4eb4bfd0931c422dc55c,flat dosing,0.458951
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,Nivo,0.319032
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,patients,0.542516
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,therapy,0.336072
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,chemo,0.416235
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,pts,0.342143
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,response,0.325583
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,NSCLC patients,0.400172
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,progression,0.393182
uuid-ebbb19f542aa4f4c9a4ae8008f0a56bd,respond,0.484771
uuid-07873a55106746298f16265d1bf6a810,patients,0.501459
uuid-07873a55106746298f16265d1bf6a810,Opdivo,0.496773
uuid-07873a55106746298f16265d1bf6a810,dose,0.538806
uuid-07873a55106746298f16265d1bf6a810,treatment,0.342746
uuid-07873a55106746298f16265d1bf6a810,Keytruda,0.308981
uuid-07873a55106746298f16265d1bf6a810,flat dosing,0.366393
uuid-622df010ad464b5d9aab8ce2641a7e78,lung,0.309882
uuid-622df010ad464b5d9aab8ce2641a7e78,PDL1,0.310568
uuid-622df010ad464b5d9aab8ce2641a7e78,discussed,0.463421
uuid-622df010ad464b5d9aab8ce2641a7e78,melanoma,0.3657
uuid-622df010ad464b5d9aab8ce2641a7e78,RCC,0.331655
uuid-622df010ad464b5d9aab8ce2641a7e78,atezo,0.356452
uuid-622df010ad464b5d9aab8ce2641a7e78,data,0.370029
uuid-622df010ad464b5d9aab8ce2641a7e78,SCCHN,0.309814
uuid-622df010ad464b5d9aab8ce2641a7e78,nivo and pembro,0.329282
uuid-622df010ad464b5d9aab8ce2641a7e78,TLs,0.510423
uuid-622df010ad464b5d9aab8ce2641a7e78,academic,0.510997
uuid-622df010ad464b5d9aab8ce2641a7e78,RTL stated,0.330199
uuid-622df010ad464b5d9aab8ce2641a7e78,TL shared,0.364271
uuid-622df010ad464b5d9aab8ce2641a7e78,PDL1 expression,0.320201
uuid-4e9a6634823f4fd88378a909b8f5fcba,patients,0.793804
uuid-4e9a6634823f4fd88378a909b8f5fcba,Opdivo,0.40215
uuid-4e9a6634823f4fd88378a909b8f5fcba,therapy,0.512964
uuid-4e9a6634823f4fd88378a909b8f5fcba,nivolumab,0.505702
uuid-4e9a6634823f4fd88378a909b8f5fcba,regimen,0.436608
uuid-4e9a6634823f4fd88378a909b8f5fcba,treated,0.694086
uuid-4e9a6634823f4fd88378a909b8f5fcba,pts,0.489765
uuid-4e9a6634823f4fd88378a909b8f5fcba,treatment,0.609193
uuid-4e9a6634823f4fd88378a909b8f5fcba,using nivo,0.307341
uuid-4e9a6634823f4fd88378a909b8f5fcba,response,0.329103
uuid-4e9a6634823f4fd88378a909b8f5fcba,cHL,0.416363
uuid-4e9a6634823f4fd88378a909b8f5fcba,progression,0.605332
uuid-4e9a6634823f4fd88378a909b8f5fcba,chemotherapy,0.302761
uuid-4e9a6634823f4fd88378a909b8f5fcba,respond,0.359266
uuid-b10baa271fe24f1ba01e831d449b1d3a,RTL,0.48302
uuid-b10baa271fe24f1ba01e831d449b1d3a,nivolumab,0.392075
uuid-b10baa271fe24f1ba01e831d449b1d3a,trial,0.395391
uuid-b10baa271fe24f1ba01e831d449b1d3a,commented,0.454457
uuid-b10baa271fe24f1ba01e831d449b1d3a,RCC,0.306061
uuid-b10baa271fe24f1ba01e831d449b1d3a,stated,0.498331
uuid-b10baa271fe24f1ba01e831d449b1d3a,approval,0.385156
uuid-b10baa271fe24f1ba01e831d449b1d3a,using nivo,0.34479
uuid-b10baa271fe24f1ba01e831d449b1d3a,data,0.518078
uuid-b10baa271fe24f1ba01e831d449b1d3a,clinical trials,0.408239
uuid-b10baa271fe24f1ba01e831d449b1d3a,approved,0.315521
uuid-b10baa271fe24f1ba01e831d449b1d3a,SCCHN,0.44698
uuid-b10baa271fe24f1ba01e831d449b1d3a,ASCO,0.31273
uuid-b10baa271fe24f1ba01e831d449b1d3a,impressed,0.636588
uuid-b10baa271fe24f1ba01e831d449b1d3a,LTL,0.430498
uuid-b10baa271fe24f1ba01e831d449b1d3a,TLs,0.36863
uuid-b10baa271fe24f1ba01e831d449b1d3a,SCLC,0.405889
uuid-b10baa271fe24f1ba01e831d449b1d3a,feels,0.367965
uuid-b10baa271fe24f1ba01e831d449b1d3a,Regional TL,0.506535
uuid-b10baa271fe24f1ba01e831d449b1d3a,RTL stated,0.335058
uuid-b10baa271fe24f1ba01e831d449b1d3a,bladder,0.356198
uuid-37691460c35343b1abbd6e9431f6d580,pembro,0.329735
uuid-37691460c35343b1abbd6e9431f6d580,BMS,0.410689
uuid-37691460c35343b1abbd6e9431f6d580,PDL1,0.336942
uuid-37691460c35343b1abbd6e9431f6d580,trial,0.588244
uuid-37691460c35343b1abbd6e9431f6d580,efficacy,0.43022
uuid-37691460c35343b1abbd6e9431f6d580,discussed,0.342744
uuid-37691460c35343b1abbd6e9431f6d580,commented,0.438319
uuid-37691460c35343b1abbd6e9431f6d580,Merck,0.335528
uuid-37691460c35343b1abbd6e9431f6d580,OS,0.584566
uuid-37691460c35343b1abbd6e9431f6d580,regards,0.424996
uuid-37691460c35343b1abbd6e9431f6d580,data,0.807333
uuid-37691460c35343b1abbd6e9431f6d580,expressed,0.346878
uuid-37691460c35343b1abbd6e9431f6d580,PFS,0.58408
uuid-37691460c35343b1abbd6e9431f6d580,ORR,0.621614
uuid-37691460c35343b1abbd6e9431f6d580,nivo and pembro,0.538252
uuid-37691460c35343b1abbd6e9431f6d580,ASCO,0.419318
uuid-37691460c35343b1abbd6e9431f6d580,impressed,0.59856
uuid-37691460c35343b1abbd6e9431f6d580,TLs,0.388721
uuid-37691460c35343b1abbd6e9431f6d580,SCLC,0.306972
uuid-37691460c35343b1abbd6e9431f6d580,PDL1 expression,0.340716
uuid-2e44a65eb4d24d03b8044fe7205ffb99,Nivo,0.708056
uuid-2e44a65eb4d24d03b8044fe7205ffb99,pembro,0.537415
uuid-2e44a65eb4d24d03b8044fe7205ffb99,1L,0.354641
uuid-2e44a65eb4d24d03b8044fe7205ffb99,PDL1,0.427251
uuid-2e44a65eb4d24d03b8044fe7205ffb99,trial,0.380858
uuid-2e44a65eb4d24d03b8044fe7205ffb99,efficacy,0.640329
uuid-2e44a65eb4d24d03b8044fe7205ffb99,chemo,0.477622
uuid-2e44a65eb4d24d03b8044fe7205ffb99,2L,0.311035
uuid-2e44a65eb4d24d03b8044fe7205ffb99,Ipi,0.319753
uuid-2e44a65eb4d24d03b8044fe7205ffb99,OS,0.605822
uuid-2e44a65eb4d24d03b8044fe7205ffb99,atezo,0.437102
uuid-2e44a65eb4d24d03b8044fe7205ffb99,monotherapy,0.369262
uuid-2e44a65eb4d24d03b8044fe7205ffb99,data,0.472897
uuid-2e44a65eb4d24d03b8044fe7205ffb99,PFS,0.674677
uuid-2e44a65eb4d24d03b8044fe7205ffb99,ORR,0.61119
uuid-2e44a65eb4d24d03b8044fe7205ffb99,nivo and pembro,0.611078
uuid-2e44a65eb4d24d03b8044fe7205ffb99,believes,0.428713
uuid-2e44a65eb4d24d03b8044fe7205ffb99,chemotherapy,0.405108
uuid-2e44a65eb4d24d03b8044fe7205ffb99,impressed,0.341593
uuid-2e44a65eb4d24d03b8044fe7205ffb99,vs,0.399488
uuid-2e44a65eb4d24d03b8044fe7205ffb99,feels,0.465715
uuid-2e44a65eb4d24d03b8044fe7205ffb99,PDL1 expression,0.435347
uuid-2e44a65eb4d24d03b8044fe7205ffb99,option,0.364956
uuid-48a8332be3244bb190475612c42e895b,patients,0.316777
uuid-48a8332be3244bb190475612c42e895b,TL,0.590553
uuid-48a8332be3244bb190475612c42e895b,lung,0.367526
uuid-48a8332be3244bb190475612c42e895b,TL stated,0.522223
uuid-48a8332be3244bb190475612c42e895b,PD-L1,0.540362
uuid-48a8332be3244bb190475612c42e895b,PD-L1 testing,0.66286
uuid-48a8332be3244bb190475612c42e895b,testing,0.638613
uuid-48a8332be3244bb190475612c42e895b,PDL1 testing,0.53393
uuid-48a8332be3244bb190475612c42e895b,NSCLC patients,0.568256
uuid-48a8332be3244bb190475612c42e895b,assay,0.463082
uuid-48a8332be3244bb190475612c42e895b,TL shared,0.362591
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,Opdivo,0.382286
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,TL,0.307767
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,TL stated,0.454761
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,PD-L1,0.473939
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,approval,0.452476
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,PD-L1 testing,0.511417
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,testing,0.594294
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,PDL1 testing,0.569913
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,NSCLC patients,0.575017
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,approved,0.32965
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,SCCHN,0.309139
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,tumor types,0.33908
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,label,0.3012
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,Keytruda,0.302287
uuid-b7fc6499d0184e1f923d6f2ae29b02e0,assay,0.303001
uuid-91b1048c41394f52900eec07e97382b4,patients,0.331629
uuid-91b1048c41394f52900eec07e97382b4,pembro,0.340435
uuid-91b1048c41394f52900eec07e97382b4,1L,0.437992
uuid-91b1048c41394f52900eec07e97382b4,PDL1,0.464599
uuid-91b1048c41394f52900eec07e97382b4,chemo,0.42656
uuid-91b1048c41394f52900eec07e97382b4,pts,0.333205
uuid-91b1048c41394f52900eec07e97382b4,nivo and pembro,0.425109
uuid-91b1048c41394f52900eec07e97382b4,believes,0.360859
uuid-91b1048c41394f52900eec07e97382b4,chemotherapy,0.352012
uuid-91b1048c41394f52900eec07e97382b4,respond,0.332675
uuid-91b1048c41394f52900eec07e97382b4,feels,0.326725
uuid-91b1048c41394f52900eec07e97382b4,PDL1 expression,0.423278
uuid-91b1048c41394f52900eec07e97382b4,option,0.416316
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,TL,0.687366
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,PDL1,0.319045
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,TL stated,0.347742
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,Merck,0.362658
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,institution,0.395432
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,PD-L1,0.761231
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,PD-L1 testing,0.881896
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,testing,0.851795
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,PDL1 testing,0.59728
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,NSCLC patients,0.520791
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,assay,0.80477
uuid-ea71a0aab0d74bdea9eb17b9322bf3d2,biomarker,0.387669
uuid-dde32f0fbf3542a08b3d0e3eeffbff55,toxicity,0.365011
uuid-dde32f0fbf3542a08b3d0e3eeffbff55,efficacy,0.318993
uuid-dde32f0fbf3542a08b3d0e3eeffbff55,indication,0.307545
uuid-dde32f0fbf3542a08b3d0e3eeffbff55,Keytruda,0.40139
uuid-dde32f0fbf3542a08b3d0e3eeffbff55,flat dosing,0.316294
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,Nivo,0.401377
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,patients,0.375397
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,Opdivo,0.501317
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,therapy,0.369632
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,nivolumab,0.410921
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,mentioned,0.325772
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,cHL,0.636658
uuid-960ac1bb9ffb4bfbb85954c3c06f1ace,impressed,0.303256
uuid-8a238e8468e14c378e2e8b8fb3019e62,Opdivo,0.62708
uuid-8a238e8468e14c378e2e8b8fb3019e62,stated,0.334838
uuid-8a238e8468e14c378e2e8b8fb3019e62,physicians,0.515688
uuid-8a238e8468e14c378e2e8b8fb3019e62,mentioned,0.394503
uuid-8a238e8468e14c378e2e8b8fb3019e62,HCP,0.414087
uuid-8a238e8468e14c378e2e8b8fb3019e62,cHL,0.417503
uuid-8a238e8468e14c378e2e8b8fb3019e62,impressed,0.311747
uuid-8a238e8468e14c378e2e8b8fb3019e62,LTL,0.304082
uuid-77c9f82ae9e64fe9962215974167c9e9,Nivo,0.418575
uuid-77c9f82ae9e64fe9962215974167c9e9,trial,0.416746
uuid-77c9f82ae9e64fe9962215974167c9e9,efficacy,0.32651
uuid-77c9f82ae9e64fe9962215974167c9e9,combination,0.587633
uuid-77c9f82ae9e64fe9962215974167c9e9,chemo,0.468619
uuid-77c9f82ae9e64fe9962215974167c9e9,tumor,0.390461
uuid-77c9f82ae9e64fe9962215974167c9e9,agents,0.354121
uuid-77c9f82ae9e64fe9962215974167c9e9,combo,0.405471
uuid-77c9f82ae9e64fe9962215974167c9e9,PD1,0.346546
uuid-77c9f82ae9e64fe9962215974167c9e9,chemotherapy,0.414283
uuid-77c9f82ae9e64fe9962215974167c9e9,feels,0.419597
uuid-a75d04bca99647f0974bc026d57e384c,trial,0.410845
uuid-6ff7edd460114470b1c4b5e3a876e7b8,Nivo,0.619124
uuid-6ff7edd460114470b1c4b5e3a876e7b8,patients,0.581723
uuid-6ff7edd460114470b1c4b5e3a876e7b8,pembro,0.306051
uuid-6ff7edd460114470b1c4b5e3a876e7b8,therapy,0.547068
uuid-6ff7edd460114470b1c4b5e3a876e7b8,nivolumab,0.594092
uuid-6ff7edd460114470b1c4b5e3a876e7b8,1L,0.335465
uuid-6ff7edd460114470b1c4b5e3a876e7b8,regimen,0.499684
uuid-6ff7edd460114470b1c4b5e3a876e7b8,treated,0.360063
uuid-6ff7edd460114470b1c4b5e3a876e7b8,RCC,0.308369
uuid-6ff7edd460114470b1c4b5e3a876e7b8,combination,0.546526
uuid-6ff7edd460114470b1c4b5e3a876e7b8,chemo,0.485751
uuid-6ff7edd460114470b1c4b5e3a876e7b8,2L,0.399081
uuid-6ff7edd460114470b1c4b5e3a876e7b8,pts,0.558689
uuid-6ff7edd460114470b1c4b5e3a876e7b8,Ipi,0.586691
uuid-6ff7edd460114470b1c4b5e3a876e7b8,approval,0.36362
uuid-6ff7edd460114470b1c4b5e3a876e7b8,preferred,0.321247
uuid-6ff7edd460114470b1c4b5e3a876e7b8,monotherapy,0.570225
uuid-6ff7edd460114470b1c4b5e3a876e7b8,treatment,0.454811
uuid-6ff7edd460114470b1c4b5e3a876e7b8,using nivo,0.489775
uuid-6ff7edd460114470b1c4b5e3a876e7b8,response,0.407865
uuid-6ff7edd460114470b1c4b5e3a876e7b8,combo,0.472925
uuid-6ff7edd460114470b1c4b5e3a876e7b8,PD1,0.480222
uuid-6ff7edd460114470b1c4b5e3a876e7b8,approved,0.371338
uuid-6ff7edd460114470b1c4b5e3a876e7b8,progression,0.496221
uuid-6ff7edd460114470b1c4b5e3a876e7b8,chemotherapy,0.469617
uuid-6ff7edd460114470b1c4b5e3a876e7b8,respond,0.339881
uuid-6ff7edd460114470b1c4b5e3a876e7b8,SCLC,0.314594
uuid-6ff7edd460114470b1c4b5e3a876e7b8,RTL stated,0.344027
uuid-6ff7edd460114470b1c4b5e3a876e7b8,option,0.46282
uuid-a36c747d2d8347c78b397e55224c90be,tumor,0.483226
uuid-a36c747d2d8347c78b397e55224c90be,response,0.449425
uuid-a36c747d2d8347c78b397e55224c90be,progression,0.31419
uuid-a36c747d2d8347c78b397e55224c90be,clinical,0.358041
uuid-a36c747d2d8347c78b397e55224c90be,immunotherapy,0.373386
uuid-5971829dac2e49ef81ab75d37b20f086,RTL,0.429162
uuid-5971829dac2e49ef81ab75d37b20f086,nivolumab,0.335535
uuid-5971829dac2e49ef81ab75d37b20f086,trial,0.442781
uuid-5971829dac2e49ef81ab75d37b20f086,NTL,0.369303
uuid-5971829dac2e49ef81ab75d37b20f086,shared,0.353583
uuid-5971829dac2e49ef81ab75d37b20f086,commented,0.308219
uuid-5971829dac2e49ef81ab75d37b20f086,RCC,0.422848
uuid-5971829dac2e49ef81ab75d37b20f086,combination,0.45069
uuid-5971829dac2e49ef81ab75d37b20f086,stated,0.398165
uuid-5971829dac2e49ef81ab75d37b20f086,monotherapy,0.313887
uuid-5971829dac2e49ef81ab75d37b20f086,data,0.500307
uuid-5971829dac2e49ef81ab75d37b20f086,combo,0.409737
uuid-5971829dac2e49ef81ab75d37b20f086,clinical trials,0.416183
uuid-5971829dac2e49ef81ab75d37b20f086,PD1,0.398162
uuid-5971829dac2e49ef81ab75d37b20f086,SCCHN,0.351208
uuid-5971829dac2e49ef81ab75d37b20f086,ASCO,0.305228
uuid-5971829dac2e49ef81ab75d37b20f086,impressed,0.4478
uuid-5971829dac2e49ef81ab75d37b20f086,LTL,0.345365
uuid-5971829dac2e49ef81ab75d37b20f086,SCLC,0.36051
uuid-5971829dac2e49ef81ab75d37b20f086,Regional TL,0.41302
uuid-5971829dac2e49ef81ab75d37b20f086,RTL stated,0.386494
uuid-5971829dac2e49ef81ab75d37b20f086,bladder,0.371448
uuid-9ab2f5b6738d452b8b80ba56ab980903,pembro,0.408184
uuid-9ab2f5b6738d452b8b80ba56ab980903,BMS,0.617856
uuid-9ab2f5b6738d452b8b80ba56ab980903,PDL1,0.340019
uuid-9ab2f5b6738d452b8b80ba56ab980903,trial,0.72042
uuid-9ab2f5b6738d452b8b80ba56ab980903,efficacy,0.385818
uuid-9ab2f5b6738d452b8b80ba56ab980903,commented,0.369101
uuid-9ab2f5b6738d452b8b80ba56ab980903,Merck,0.542477
uuid-9ab2f5b6738d452b8b80ba56ab980903,stated,0.374295
uuid-9ab2f5b6738d452b8b80ba56ab980903,approval,0.333953
uuid-9ab2f5b6738d452b8b80ba56ab980903,OS,0.448531
uuid-9ab2f5b6738d452b8b80ba56ab980903,regards,0.300155
uuid-9ab2f5b6738d452b8b80ba56ab980903,data,0.80224
uuid-9ab2f5b6738d452b8b80ba56ab980903,expressed,0.308343
uuid-9ab2f5b6738d452b8b80ba56ab980903,clinical trials,0.412229
uuid-9ab2f5b6738d452b8b80ba56ab980903,indication,0.38236
uuid-9ab2f5b6738d452b8b80ba56ab980903,PFS,0.446078
uuid-9ab2f5b6738d452b8b80ba56ab980903,ORR,0.516279
uuid-9ab2f5b6738d452b8b80ba56ab980903,approved,0.308594
uuid-9ab2f5b6738d452b8b80ba56ab980903,nivo and pembro,0.385772
uuid-9ab2f5b6738d452b8b80ba56ab980903,impressed,0.550052
uuid-9ab2f5b6738d452b8b80ba56ab980903,PDL1 expression,0.398878
uuid-cba7bf4aae8d47dda7c518c6cae459bf,patients,0.600861
uuid-cba7bf4aae8d47dda7c518c6cae459bf,Opdivo,0.334894
uuid-cba7bf4aae8d47dda7c518c6cae459bf,nivolumab,0.378559
uuid-cba7bf4aae8d47dda7c518c6cae459bf,toxicity,0.410238
uuid-cba7bf4aae8d47dda7c518c6cae459bf,regimen,0.581952
uuid-cba7bf4aae8d47dda7c518c6cae459bf,treated,0.548241
uuid-cba7bf4aae8d47dda7c518c6cae459bf,RCC,0.368857
uuid-cba7bf4aae8d47dda7c518c6cae459bf,pts,0.394622
uuid-cba7bf4aae8d47dda7c518c6cae459bf,treatment,0.567692
uuid-cba7bf4aae8d47dda7c518c6cae459bf,using nivo,0.371157
uuid-cba7bf4aae8d47dda7c518c6cae459bf,progression,0.374146
uuid-cba7bf4aae8d47dda7c518c6cae459bf,respond,0.469431
uuid-cba7bf4aae8d47dda7c518c6cae459bf,RTL stated,0.355698
uuid-cba7bf4aae8d47dda7c518c6cae459bf,TL shared,0.417728
uuid-72c490445ffd461b828038c848cd4014,Nivo,0.571366
uuid-72c490445ffd461b828038c848cd4014,patients,0.369232
uuid-72c490445ffd461b828038c848cd4014,pembro,0.579495
uuid-72c490445ffd461b828038c848cd4014,therapy,0.388504
uuid-72c490445ffd461b828038c848cd4014,dose,0.366716
uuid-72c490445ffd461b828038c848cd4014,nivolumab,0.369916
uuid-72c490445ffd461b828038c848cd4014,1L,0.522515
uuid-72c490445ffd461b828038c848cd4014,regimen,0.455426
uuid-72c490445ffd461b828038c848cd4014,combination,0.492528
uuid-72c490445ffd461b828038c848cd4014,chemo,0.483405
uuid-72c490445ffd461b828038c848cd4014,2L,0.614739
uuid-72c490445ffd461b828038c848cd4014,pts,0.336821
uuid-72c490445ffd461b828038c848cd4014,agents,0.526666
uuid-72c490445ffd461b828038c848cd4014,Ipi,0.402193
uuid-72c490445ffd461b828038c848cd4014,atezo,0.557108
uuid-72c490445ffd461b828038c848cd4014,preferred,0.645081
uuid-72c490445ffd461b828038c848cd4014,monotherapy,0.718574
uuid-72c490445ffd461b828038c848cd4014,treatment,0.318623
uuid-72c490445ffd461b828038c848cd4014,using nivo,0.502755
uuid-72c490445ffd461b828038c848cd4014,combo,0.468787
uuid-72c490445ffd461b828038c848cd4014,PD1,0.414156
uuid-72c490445ffd461b828038c848cd4014,approved,0.342733
uuid-72c490445ffd461b828038c848cd4014,believes,0.320904
uuid-72c490445ffd461b828038c848cd4014,chemotherapy,0.421394
uuid-72c490445ffd461b828038c848cd4014,vs,0.316883
uuid-72c490445ffd461b828038c848cd4014,feels,0.342454
uuid-72c490445ffd461b828038c848cd4014,RTL stated,0.397901
uuid-72c490445ffd461b828038c848cd4014,option,0.625311
uuid-c8490768f5884c9998a591de8ae241ea,Nivo,0.597649
uuid-c8490768f5884c9998a591de8ae241ea,pembro,0.615922
uuid-c8490768f5884c9998a591de8ae241ea,1L,0.342273
uuid-c8490768f5884c9998a591de8ae241ea,trial,0.400746
uuid-c8490768f5884c9998a591de8ae241ea,efficacy,0.516686
uuid-c8490768f5884c9998a591de8ae241ea,combination,0.42374
uuid-c8490768f5884c9998a591de8ae241ea,2L,0.404723
uuid-c8490768f5884c9998a591de8ae241ea,agents,0.399402
uuid-c8490768f5884c9998a591de8ae241ea,Ipi,0.524854
uuid-c8490768f5884c9998a591de8ae241ea,atezo,0.571338
uuid-c8490768f5884c9998a591de8ae241ea,preferred,0.37867
uuid-c8490768f5884c9998a591de8ae241ea,monotherapy,0.385425
uuid-c8490768f5884c9998a591de8ae241ea,using nivo,0.399139
uuid-c8490768f5884c9998a591de8ae241ea,data,0.494448
uuid-c8490768f5884c9998a591de8ae241ea,combo,0.451646
uuid-c8490768f5884c9998a591de8ae241ea,indication,0.414651
uuid-c8490768f5884c9998a591de8ae241ea,approved,0.408563
uuid-c8490768f5884c9998a591de8ae241ea,nivo and pembro,0.459006
uuid-c8490768f5884c9998a591de8ae241ea,believes,0.319661
uuid-c8490768f5884c9998a591de8ae241ea,impressed,0.408902
uuid-c8490768f5884c9998a591de8ae241ea,vs,0.453494
uuid-c8490768f5884c9998a591de8ae241ea,feels,0.429766
uuid-c8490768f5884c9998a591de8ae241ea,option,0.320379
uuid-0653cd5537104718943caf15f88b01b8,Nivo,0.484623
uuid-0653cd5537104718943caf15f88b01b8,patients,0.304453
uuid-0653cd5537104718943caf15f88b01b8,therapy,0.366918
uuid-0653cd5537104718943caf15f88b01b8,regimen,0.31388
uuid-0653cd5537104718943caf15f88b01b8,chemo,0.4289
uuid-0653cd5537104718943caf15f88b01b8,pts,0.436691
uuid-0653cd5537104718943caf15f88b01b8,IO,0.336882
uuid-0653cd5537104718943caf15f88b01b8,OS,0.325526
uuid-0653cd5537104718943caf15f88b01b8,monotherapy,0.394183
uuid-0653cd5537104718943caf15f88b01b8,response,0.616572
uuid-0653cd5537104718943caf15f88b01b8,PD1,0.391864
uuid-0653cd5537104718943caf15f88b01b8,progression,0.533366
uuid-0653cd5537104718943caf15f88b01b8,chemotherapy,0.344079
uuid-0653cd5537104718943caf15f88b01b8,respond,0.362554
uuid-114ddc8d35004a1496d37a60e91c3a2c,pembro,0.329715
uuid-114ddc8d35004a1496d37a60e91c3a2c,PDL1,0.400432
uuid-114ddc8d35004a1496d37a60e91c3a2c,Merck,0.347544
uuid-114ddc8d35004a1496d37a60e91c3a2c,stated,0.381553
uuid-114ddc8d35004a1496d37a60e91c3a2c,approval,0.361757
uuid-114ddc8d35004a1496d37a60e91c3a2c,clinical trials,0.411072
uuid-114ddc8d35004a1496d37a60e91c3a2c,approved,0.346712
uuid-114ddc8d35004a1496d37a60e91c3a2c,tumor types,0.384578
uuid-114ddc8d35004a1496d37a60e91c3a2c,feels,0.315467
uuid-114ddc8d35004a1496d37a60e91c3a2c,PDL1 expression,0.310362
uuid-18d7dd52978b4fe2be3bb0ae7e23d61e,physicians,0.427922
uuid-18d7dd52978b4fe2be3bb0ae7e23d61e,treatment,0.342461
uuid-18d7dd52978b4fe2be3bb0ae7e23d61e,oncologist,0.422761
uuid-2e7622d3229c41a8b6e6de6cc226a6ce,tumor,0.844794
uuid-aee07111f7aa4fb194d143b5f7e12d0a,NSCLC,0.383894
uuid-aee07111f7aa4fb194d143b5f7e12d0a,NTL,0.40624
uuid-aee07111f7aa4fb194d143b5f7e12d0a,stated,0.326321
uuid-aee07111f7aa4fb194d143b5f7e12d0a,ASCO,0.392724
uuid-aee07111f7aa4fb194d143b5f7e12d0a,Regional TL,0.316778
uuid-0eeb296c0e364998ac9f37ca33dee998,pembro,0.528257
uuid-0eeb296c0e364998ac9f37ca33dee998,dose,0.360224
uuid-0eeb296c0e364998ac9f37ca33dee998,BMS,0.372519
uuid-0eeb296c0e364998ac9f37ca33dee998,trial,0.38961
uuid-0eeb296c0e364998ac9f37ca33dee998,efficacy,0.567581
uuid-0eeb296c0e364998ac9f37ca33dee998,Merck,0.428414
uuid-0eeb296c0e364998ac9f37ca33dee998,OS,0.307003
uuid-0eeb296c0e364998ac9f37ca33dee998,atezo,0.43477
uuid-0eeb296c0e364998ac9f37ca33dee998,data,0.566715
uuid-0eeb296c0e364998ac9f37ca33dee998,ORR,0.317334
uuid-0eeb296c0e364998ac9f37ca33dee998,nivo and pembro,0.3762
uuid-0eeb296c0e364998ac9f37ca33dee998,impressed,0.331314
uuid-0eeb296c0e364998ac9f37ca33dee998,vs,0.665523
uuid-0eeb296c0e364998ac9f37ca33dee998,feels,0.329346
uuid-0eeb296c0e364998ac9f37ca33dee998,flat dosing,0.361441
uuid-b744a3688f9f49ea83f7f358d98c7f3f,patients,0.403452
uuid-b744a3688f9f49ea83f7f358d98c7f3f,nivolumab,0.341734
uuid-b744a3688f9f49ea83f7f358d98c7f3f,regimen,0.368077
uuid-b744a3688f9f49ea83f7f358d98c7f3f,treated,0.420006
uuid-b744a3688f9f49ea83f7f358d98c7f3f,treatment,0.31621
uuid-0e6bf5a64b82411c829ffd2f696b1086,TL,0.315055
uuid-0e6bf5a64b82411c829ffd2f696b1086,RTL,0.373529
uuid-0e6bf5a64b82411c829ffd2f696b1086,BMS,0.414566
uuid-0e6bf5a64b82411c829ffd2f696b1086,trial,0.320373
uuid-0e6bf5a64b82411c829ffd2f696b1086,discussed,0.386552
uuid-0e6bf5a64b82411c829ffd2f696b1086,shared,0.300084
uuid-0e6bf5a64b82411c829ffd2f696b1086,commented,0.508352
uuid-0e6bf5a64b82411c829ffd2f696b1086,Merck,0.573447
uuid-0e6bf5a64b82411c829ffd2f696b1086,stated,0.372665
uuid-0e6bf5a64b82411c829ffd2f696b1086,approval,0.302949
uuid-0e6bf5a64b82411c829ffd2f696b1086,data,0.512544
uuid-0e6bf5a64b82411c829ffd2f696b1086,SCCHN,0.311294
uuid-0e6bf5a64b82411c829ffd2f696b1086,ASCO,0.342105
uuid-0e6bf5a64b82411c829ffd2f696b1086,impressed,0.428686
uuid-0e6bf5a64b82411c829ffd2f696b1086,LTL,0.335532
uuid-0e6bf5a64b82411c829ffd2f696b1086,TLs,0.365306
uuid-0e6bf5a64b82411c829ffd2f696b1086,Regional TL,0.424818
uuid-dbef05a0bf924df49435c2aac20f54ee,Opdivo,0.337025
uuid-dbef05a0bf924df49435c2aac20f54ee,dose,0.680994
uuid-dbef05a0bf924df49435c2aac20f54ee,toxicity,0.610034
uuid-dbef05a0bf924df49435c2aac20f54ee,regimen,0.376812
uuid-dbef05a0bf924df49435c2aac20f54ee,physicians,0.393772
uuid-dbef05a0bf924df49435c2aac20f54ee,treatment,0.322391
uuid-dbef05a0bf924df49435c2aac20f54ee,respond,0.30972
uuid-dbef05a0bf924df49435c2aac20f54ee,flat dosing,0.376345
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,patients,0.711725
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,Opdivo,0.449955
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,therapy,0.338879
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,nivolumab,0.365595
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,treated,0.483674
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,pts,0.467123
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,approval,0.420891
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,treatment,0.392684
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,using nivo,0.414343
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,NSCLC patients,0.406109
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,approved,0.302279
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,progression,0.323905
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,label,0.310365
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,RTL stated,0.340856
uuid-fdae4a5eabdc4d1880f9fe9bcf3efc1b,option,0.300848
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,patients,0.481084
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,Opdivo,0.514298
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,pembro,0.323119
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,dose,0.533303
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,nivolumab,0.322657
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,approval,0.3213
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,preferred,0.310239
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,using nivo,0.386736
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,vs,0.329291
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,Keytruda,0.349048
uuid-a6c16f16805d49f4b80f3817d5e3c7ba,flat dosing,0.553555
uuid-852ca19ee0c3468b815c213e75c889d1,Nivo,0.321096
uuid-852ca19ee0c3468b815c213e75c889d1,patients,0.677806
uuid-852ca19ee0c3468b815c213e75c889d1,Opdivo,0.487275
uuid-852ca19ee0c3468b815c213e75c889d1,therapy,0.362808
uuid-852ca19ee0c3468b815c213e75c889d1,dose,0.596924
uuid-852ca19ee0c3468b815c213e75c889d1,nivolumab,0.446112
uuid-852ca19ee0c3468b815c213e75c889d1,toxicity,0.444607
uuid-852ca19ee0c3468b815c213e75c889d1,regimen,0.510818
uuid-852ca19ee0c3468b815c213e75c889d1,treated,0.382915
uuid-852ca19ee0c3468b815c213e75c889d1,pts,0.435475
uuid-852ca19ee0c3468b815c213e75c889d1,Ipi,0.392203
uuid-852ca19ee0c3468b815c213e75c889d1,treatment,0.512624
uuid-852ca19ee0c3468b815c213e75c889d1,response,0.303828
uuid-852ca19ee0c3468b815c213e75c889d1,progression,0.488757
uuid-852ca19ee0c3468b815c213e75c889d1,respond,0.432364
uuid-852ca19ee0c3468b815c213e75c889d1,flat dosing,0.329001
uuid-9508ec9cdae34cc1819dee21df9d0350,Nivo,0.405001
uuid-9508ec9cdae34cc1819dee21df9d0350,patients,0.356767
uuid-9508ec9cdae34cc1819dee21df9d0350,Opdivo,0.363703
uuid-9508ec9cdae34cc1819dee21df9d0350,therapy,0.705251
uuid-9508ec9cdae34cc1819dee21df9d0350,nivolumab,0.447855
uuid-9508ec9cdae34cc1819dee21df9d0350,PD1,0.372319
uuid-9508ec9cdae34cc1819dee21df9d0350,cHL,0.704024
uuid-9508ec9cdae34cc1819dee21df9d0350,chemotherapy,0.410665
uuid-9ec0f225d41748c3bbb6c07946767621,lung,0.328873
uuid-9ec0f225d41748c3bbb6c07946767621,1L,0.370978
uuid-9ec0f225d41748c3bbb6c07946767621,RCC,0.424618
uuid-9ec0f225d41748c3bbb6c07946767621,TL stated,0.435845
uuid-9ec0f225d41748c3bbb6c07946767621,2L,0.424694
uuid-9ec0f225d41748c3bbb6c07946767621,PD-L1,0.366149
uuid-9ec0f225d41748c3bbb6c07946767621,preferred,0.463019
uuid-9ec0f225d41748c3bbb6c07946767621,PD-L1 testing,0.325609
uuid-9ec0f225d41748c3bbb6c07946767621,testing,0.41469
uuid-9ec0f225d41748c3bbb6c07946767621,PDL1 testing,0.470126
uuid-9ec0f225d41748c3bbb6c07946767621,NSCLC patients,0.324889
uuid-9ec0f225d41748c3bbb6c07946767621,assay,0.308681
uuid-9ec0f225d41748c3bbb6c07946767621,RTL stated,0.338271
uuid-9ec0f225d41748c3bbb6c07946767621,TL shared,0.361711
uuid-9ec0f225d41748c3bbb6c07946767621,option,0.384171
uuid-c0a93cf62d46412a806754fbc54500c1,patients,0.330298
uuid-c0a93cf62d46412a806754fbc54500c1,therapy,0.319847
uuid-c0a93cf62d46412a806754fbc54500c1,nivolumab,0.370774
uuid-c0a93cf62d46412a806754fbc54500c1,toxicity,0.702399
uuid-c0a93cf62d46412a806754fbc54500c1,regimen,0.343932
uuid-c0a93cf62d46412a806754fbc54500c1,treated,0.318514
uuid-c0a93cf62d46412a806754fbc54500c1,treatment,0.361911
uuid-c0a93cf62d46412a806754fbc54500c1,cHL,0.419968
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,TL,0.498656
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,PD-L1,0.500594
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,PD-L1 testing,0.602477
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,testing,0.504439
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,PDL1 testing,0.33914
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,NSCLC patients,0.371555
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,indicated,0.363907
uuid-d0e56c8aa6774e3f93b419a3dbb954ee,assay,0.433141
uuid-f965686cd31e4b8d91f3526d750c0f56,TL,0.34352
uuid-f965686cd31e4b8d91f3526d750c0f56,physicians,0.587734
uuid-f965686cd31e4b8d91f3526d750c0f56,oncologist,0.373512
uuid-f965686cd31e4b8d91f3526d750c0f56,indicated,0.498056
uuid-f965686cd31e4b8d91f3526d750c0f56,clinical,0.307128
uuid-f965686cd31e4b8d91f3526d750c0f56,Regional TL,0.372792
uuid-73b3033737fe4553aa440ab1eb292078,RTL,0.375959
uuid-73b3033737fe4553aa440ab1eb292078,BMS,0.42662
uuid-73b3033737fe4553aa440ab1eb292078,lung,0.314427
uuid-73b3033737fe4553aa440ab1eb292078,NTL,0.343336
uuid-73b3033737fe4553aa440ab1eb292078,discussed,0.319633
uuid-73b3033737fe4553aa440ab1eb292078,shared,0.478171
uuid-73b3033737fe4553aa440ab1eb292078,commented,0.403619
uuid-73b3033737fe4553aa440ab1eb292078,TL stated,0.32808
uuid-73b3033737fe4553aa440ab1eb292078,Merck,0.491471
uuid-73b3033737fe4553aa440ab1eb292078,stated,0.591709
uuid-73b3033737fe4553aa440ab1eb292078,physicians,0.380457
uuid-73b3033737fe4553aa440ab1eb292078,expressed,0.317229
uuid-73b3033737fe4553aa440ab1eb292078,SCCHN,0.410298
uuid-73b3033737fe4553aa440ab1eb292078,LTL,0.356549
uuid-73b3033737fe4553aa440ab1eb292078,TLs,0.357467
uuid-73b3033737fe4553aa440ab1eb292078,academic,0.410906
uuid-73b3033737fe4553aa440ab1eb292078,Regional TL,0.499921
uuid-b13eae17d6e54211810582ceb5f94269,pembro,0.333429
uuid-b13eae17d6e54211810582ceb5f94269,RTL,0.304242
uuid-b13eae17d6e54211810582ceb5f94269,BMS,0.451318
uuid-b13eae17d6e54211810582ceb5f94269,trial,0.645769
uuid-b13eae17d6e54211810582ceb5f94269,commented,0.394187
uuid-b13eae17d6e54211810582ceb5f94269,Merck,0.655385
uuid-b13eae17d6e54211810582ceb5f94269,stated,0.305872
uuid-b13eae17d6e54211810582ceb5f94269,data,0.40872
uuid-b13eae17d6e54211810582ceb5f94269,expressed,0.35339
uuid-b13eae17d6e54211810582ceb5f94269,clinical trials,0.327434
uuid-b13eae17d6e54211810582ceb5f94269,ASCO,0.376932
uuid-b13eae17d6e54211810582ceb5f94269,impressed,0.354049
uuid-b13eae17d6e54211810582ceb5f94269,Regional TL,0.335055
uuid-b13eae17d6e54211810582ceb5f94269,bladder,0.411895
uuid-ff4730882556458294f87249425b55e4,Nivo,0.371678
uuid-ff4730882556458294f87249425b55e4,pembro,0.464802
uuid-ff4730882556458294f87249425b55e4,nivolumab,0.304584
uuid-ff4730882556458294f87249425b55e4,1L,0.444971
uuid-ff4730882556458294f87249425b55e4,2L,0.431287
uuid-ff4730882556458294f87249425b55e4,approval,0.520775
uuid-ff4730882556458294f87249425b55e4,atezo,0.39537
uuid-ff4730882556458294f87249425b55e4,preferred,0.438742
uuid-ff4730882556458294f87249425b55e4,monotherapy,0.356859
uuid-ff4730882556458294f87249425b55e4,using nivo,0.473943
uuid-ff4730882556458294f87249425b55e4,data,0.430778
uuid-ff4730882556458294f87249425b55e4,clinical trials,0.313257
uuid-ff4730882556458294f87249425b55e4,indication,0.561123
uuid-ff4730882556458294f87249425b55e4,approved,0.579804
uuid-ff4730882556458294f87249425b55e4,SCCHN,0.392959
uuid-ff4730882556458294f87249425b55e4,nivo and pembro,0.322509
uuid-ff4730882556458294f87249425b55e4,impressed,0.351908
uuid-ff4730882556458294f87249425b55e4,label,0.454936
uuid-ff4730882556458294f87249425b55e4,SCLC,0.563597
uuid-ff4730882556458294f87249425b55e4,RTL stated,0.32417
uuid-ff4730882556458294f87249425b55e4,option,0.522664
uuid-ff4730882556458294f87249425b55e4,bladder,0.346962
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,dose,0.302592
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,BMS,0.386018
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,trial,0.438879
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,commented,0.348345
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,physicians,0.367678
uuid-ce5b754ed66d4f7390ca7c0ffa78a778,regards,0.311978
uuid-e9d44c36b53e48119cab165d9106c024,Nivo,0.445258
uuid-e9d44c36b53e48119cab165d9106c024,patients,0.652158
uuid-e9d44c36b53e48119cab165d9106c024,Opdivo,0.448962
uuid-e9d44c36b53e48119cab165d9106c024,therapy,0.597502
uuid-e9d44c36b53e48119cab165d9106c024,nivolumab,0.60599
uuid-e9d44c36b53e48119cab165d9106c024,regimen,0.302873
uuid-e9d44c36b53e48119cab165d9106c024,treated,0.522218
uuid-e9d44c36b53e48119cab165d9106c024,pts,0.322393
uuid-e9d44c36b53e48119cab165d9106c024,approval,0.306864
uuid-e9d44c36b53e48119cab165d9106c024,treatment,0.525452
uuid-e9d44c36b53e48119cab165d9106c024,using nivo,0.388
uuid-e9d44c36b53e48119cab165d9106c024,cHL,0.71202
uuid-e9d44c36b53e48119cab165d9106c024,progression,0.409984
uuid-dc0f735885c94c56ab577dfeedf183ea,patients,0.659201
uuid-dc0f735885c94c56ab577dfeedf183ea,Opdivo,0.588541
uuid-dc0f735885c94c56ab577dfeedf183ea,RTL,0.346326
uuid-dc0f735885c94c56ab577dfeedf183ea,therapy,0.328186
uuid-dc0f735885c94c56ab577dfeedf183ea,nivolumab,0.519497
uuid-dc0f735885c94c56ab577dfeedf183ea,toxicity,0.313244
uuid-dc0f735885c94c56ab577dfeedf183ea,regimen,0.446951
uuid-dc0f735885c94c56ab577dfeedf183ea,treated,0.530148
uuid-dc0f735885c94c56ab577dfeedf183ea,pts,0.350228
uuid-dc0f735885c94c56ab577dfeedf183ea,treatment,0.493748
uuid-dc0f735885c94c56ab577dfeedf183ea,using nivo,0.413248
uuid-dc0f735885c94c56ab577dfeedf183ea,SCCHN,0.314577
uuid-dc0f735885c94c56ab577dfeedf183ea,HCP,0.456852
uuid-dc0f735885c94c56ab577dfeedf183ea,cHL,0.426305
uuid-dc0f735885c94c56ab577dfeedf183ea,progression,0.354471
uuid-dc0f735885c94c56ab577dfeedf183ea,LTL,0.334613
uuid-dc0f735885c94c56ab577dfeedf183ea,RTL stated,0.355056
uuid-bb35df17ab754ab1b5565e416c5168f8,patients,0.76163
uuid-bb35df17ab754ab1b5565e416c5168f8,Opdivo,0.371861
uuid-bb35df17ab754ab1b5565e416c5168f8,therapy,0.572149
uuid-bb35df17ab754ab1b5565e416c5168f8,nivolumab,0.450882
uuid-bb35df17ab754ab1b5565e416c5168f8,regimen,0.370673
uuid-bb35df17ab754ab1b5565e416c5168f8,treated,0.525996
uuid-bb35df17ab754ab1b5565e416c5168f8,pts,0.464902
uuid-bb35df17ab754ab1b5565e416c5168f8,treatment,0.62674
uuid-bb35df17ab754ab1b5565e416c5168f8,response,0.33219
uuid-bb35df17ab754ab1b5565e416c5168f8,cHL,0.403181
uuid-bb35df17ab754ab1b5565e416c5168f8,progression,0.591404
uuid-bb35df17ab754ab1b5565e416c5168f8,chemotherapy,0.344005
uuid-bb35df17ab754ab1b5565e416c5168f8,respond,0.401627
uuid-4f3df11488c24a4f95460fc25029e301,tumor,0.544306
uuid-4f3df11488c24a4f95460fc25029e301,response,0.314454
uuid-4f3df11488c24a4f95460fc25029e301,assay,0.351007
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,TL,0.610461
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,NSCLC,0.318038
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,NTL,0.355086
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,commented,0.386215
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,TL stated,0.484121
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,Merck,0.327779
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,institution,0.311217
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,PD-L1,0.458786
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,PD-L1 testing,0.659984
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,testing,0.592106
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,expressed,0.313893
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,mentioned,0.397949
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,PDL1 testing,0.61344
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,NSCLC patients,0.338039
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,oncologist,0.323144
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,assay,0.428975
uuid-c7f10ed66b924201bcb7a5ff94fb3bb3,Regional TL,0.389766
uuid-1e59b5fe16804297980dc4a008429335,mentioned,0.409136
uuid-1e59b5fe16804297980dc4a008429335,cHL,0.570378
uuid-04fabbdf8cfc447b861fdef927d96eb6,mentioned,0.344507
uuid-04fabbdf8cfc447b861fdef927d96eb6,AI,0.473683
uuid-04fabbdf8cfc447b861fdef927d96eb6,cHL,0.600423
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,TL,0.566713
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,TL stated,0.512895
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,institution,0.33176
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,stated,0.324145
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,PD-L1,0.543098
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,approval,0.340037
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,PD-L1 testing,0.729524
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,testing,0.719217
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,PDL1 testing,0.716015
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,NSCLC patients,0.608559
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,assay,0.384999
uuid-21a31a0c98a94b4ea32bb53ab8a7f065,RTL stated,0.310144
uuid-5d034707151f492e9342bec4fec7871d,patients,0.337189
uuid-5d034707151f492e9342bec4fec7871d,RTL,0.415509
uuid-5d034707151f492e9342bec4fec7871d,nivolumab,0.486537
uuid-5d034707151f492e9342bec4fec7871d,treated,0.460817
uuid-5d034707151f492e9342bec4fec7871d,melanoma,0.398891
uuid-5d034707151f492e9342bec4fec7871d,shared,0.361643
uuid-5d034707151f492e9342bec4fec7871d,RCC,0.570769
uuid-5d034707151f492e9342bec4fec7871d,TL stated,0.306062
uuid-5d034707151f492e9342bec4fec7871d,stated,0.410881
uuid-5d034707151f492e9342bec4fec7871d,approval,0.434851
uuid-5d034707151f492e9342bec4fec7871d,physicians,0.345413
uuid-5d034707151f492e9342bec4fec7871d,preferred,0.318959
uuid-5d034707151f492e9342bec4fec7871d,using nivo,0.482704
uuid-5d034707151f492e9342bec4fec7871d,clinical trials,0.414182
uuid-5d034707151f492e9342bec4fec7871d,approved,0.336417
uuid-5d034707151f492e9342bec4fec7871d,SCCHN,0.566548
uuid-5d034707151f492e9342bec4fec7871d,LTL,0.368529
uuid-5d034707151f492e9342bec4fec7871d,TLs,0.334814
uuid-5d034707151f492e9342bec4fec7871d,academic,0.35173
uuid-5d034707151f492e9342bec4fec7871d,Regional TL,0.504752
uuid-5d034707151f492e9342bec4fec7871d,RTL stated,0.593103
uuid-5d034707151f492e9342bec4fec7871d,TL shared,0.479829
uuid-5d034707151f492e9342bec4fec7871d,bladder,0.426462
uuid-68296bf4111146b58f0eb80ddf3d5c41,Nivo,0.602019
uuid-68296bf4111146b58f0eb80ddf3d5c41,pembro,0.733227
uuid-68296bf4111146b58f0eb80ddf3d5c41,1L,0.460898
uuid-68296bf4111146b58f0eb80ddf3d5c41,trial,0.339624
uuid-68296bf4111146b58f0eb80ddf3d5c41,efficacy,0.402954
uuid-68296bf4111146b58f0eb80ddf3d5c41,2L,0.54644
uuid-68296bf4111146b58f0eb80ddf3d5c41,agents,0.34127
uuid-68296bf4111146b58f0eb80ddf3d5c41,Ipi,0.432112
uuid-68296bf4111146b58f0eb80ddf3d5c41,approval,0.382371
uuid-68296bf4111146b58f0eb80ddf3d5c41,atezo,0.667496
uuid-68296bf4111146b58f0eb80ddf3d5c41,preferred,0.503253
uuid-68296bf4111146b58f0eb80ddf3d5c41,monotherapy,0.383505
uuid-68296bf4111146b58f0eb80ddf3d5c41,using nivo,0.514581
uuid-68296bf4111146b58f0eb80ddf3d5c41,data,0.311843
uuid-68296bf4111146b58f0eb80ddf3d5c41,combo,0.358628
uuid-68296bf4111146b58f0eb80ddf3d5c41,clinical trials,0.349594
uuid-68296bf4111146b58f0eb80ddf3d5c41,indication,0.414076
uuid-68296bf4111146b58f0eb80ddf3d5c41,approved,0.445512
uuid-68296bf4111146b58f0eb80ddf3d5c41,nivo and pembro,0.38735
uuid-68296bf4111146b58f0eb80ddf3d5c41,impressed,0.350764
uuid-68296bf4111146b58f0eb80ddf3d5c41,vs,0.496032
uuid-68296bf4111146b58f0eb80ddf3d5c41,feels,0.461613
uuid-68296bf4111146b58f0eb80ddf3d5c41,RTL stated,0.345177
uuid-68296bf4111146b58f0eb80ddf3d5c41,option,0.40866
uuid-68296bf4111146b58f0eb80ddf3d5c41,bladder,0.350513
uuid-eddb746f0bae4bf79071bac277b631c1,Nivo,0.324456
uuid-eddb746f0bae4bf79071bac277b631c1,patients,0.352315
uuid-eddb746f0bae4bf79071bac277b631c1,RTL,0.317048
uuid-eddb746f0bae4bf79071bac277b631c1,therapy,0.366833
uuid-eddb746f0bae4bf79071bac277b631c1,nivolumab,0.345551
uuid-eddb746f0bae4bf79071bac277b631c1,treated,0.334225
uuid-eddb746f0bae4bf79071bac277b631c1,stated,0.373568
uuid-eddb746f0bae4bf79071bac277b631c1,using nivo,0.384983
uuid-eddb746f0bae4bf79071bac277b631c1,data,0.405078
uuid-eddb746f0bae4bf79071bac277b631c1,SCCHN,0.36535
uuid-eddb746f0bae4bf79071bac277b631c1,cHL,0.374348
uuid-eddb746f0bae4bf79071bac277b631c1,chemotherapy,0.331065
uuid-eddb746f0bae4bf79071bac277b631c1,impressed,0.436307
uuid-eddb746f0bae4bf79071bac277b631c1,LTL,0.343149
uuid-eddb746f0bae4bf79071bac277b631c1,feels,0.383704
uuid-eddb746f0bae4bf79071bac277b631c1,Regional TL,0.357693
uuid-eddb746f0bae4bf79071bac277b631c1,RTL stated,0.389189
uuid-3da5bcb1936246aaae5ef1b83772225f,patients,0.344915
uuid-3da5bcb1936246aaae5ef1b83772225f,Opdivo,0.384718
uuid-3da5bcb1936246aaae5ef1b83772225f,therapy,0.487343
uuid-3da5bcb1936246aaae5ef1b83772225f,nivolumab,0.35704
uuid-3da5bcb1936246aaae5ef1b83772225f,mentioned,0.364936
uuid-3da5bcb1936246aaae5ef1b83772225f,cHL,0.833816
uuid-e0d1bce8221a482084a9ca3297e450b4,agents,0.350899
uuid-e0d1bce8221a482084a9ca3297e450b4,feels,0.315956
uuid-61579fcc6b9f4686b2a4b712019c0687,TL,0.48096
uuid-61579fcc6b9f4686b2a4b712019c0687,PDL1,0.580709
uuid-61579fcc6b9f4686b2a4b712019c0687,TL stated,0.306651
uuid-61579fcc6b9f4686b2a4b712019c0687,Merck,0.483757
uuid-61579fcc6b9f4686b2a4b712019c0687,PD-L1,0.648991
uuid-61579fcc6b9f4686b2a4b712019c0687,atezo,0.384713
uuid-61579fcc6b9f4686b2a4b712019c0687,PD-L1 testing,0.533987
uuid-61579fcc6b9f4686b2a4b712019c0687,testing,0.621175
uuid-61579fcc6b9f4686b2a4b712019c0687,PDL1 testing,0.469195
uuid-61579fcc6b9f4686b2a4b712019c0687,NSCLC patients,0.326414
uuid-61579fcc6b9f4686b2a4b712019c0687,TLs,0.302166
uuid-61579fcc6b9f4686b2a4b712019c0687,assay,0.706416
uuid-61579fcc6b9f4686b2a4b712019c0687,PDL1 expression,0.494989
uuid-61579fcc6b9f4686b2a4b712019c0687,biomarker,0.426625
uuid-0123d5c3450e4dfe89b1c9226e432554,patients,0.318106
uuid-5318fc8ec1a4443aaf8829ba392f9bef,Nivo,0.33657
uuid-5318fc8ec1a4443aaf8829ba392f9bef,pembro,0.383265
uuid-5318fc8ec1a4443aaf8829ba392f9bef,RTL,0.346835
uuid-5318fc8ec1a4443aaf8829ba392f9bef,trial,0.448582
uuid-5318fc8ec1a4443aaf8829ba392f9bef,efficacy,0.407691
uuid-5318fc8ec1a4443aaf8829ba392f9bef,shared,0.404466
uuid-5318fc8ec1a4443aaf8829ba392f9bef,commented,0.449172
uuid-5318fc8ec1a4443aaf8829ba392f9bef,Ipi,0.405803
uuid-5318fc8ec1a4443aaf8829ba392f9bef,stated,0.339186
uuid-5318fc8ec1a4443aaf8829ba392f9bef,OS,0.366744
uuid-5318fc8ec1a4443aaf8829ba392f9bef,atezo,0.301261
uuid-5318fc8ec1a4443aaf8829ba392f9bef,using nivo,0.313386
uuid-5318fc8ec1a4443aaf8829ba392f9bef,data,0.595135
uuid-5318fc8ec1a4443aaf8829ba392f9bef,expressed,0.367449
uuid-5318fc8ec1a4443aaf8829ba392f9bef,clinical trials,0.331209
uuid-5318fc8ec1a4443aaf8829ba392f9bef,indication,0.308552
uuid-5318fc8ec1a4443aaf8829ba392f9bef,PFS,0.321082
uuid-5318fc8ec1a4443aaf8829ba392f9bef,ORR,0.427613
uuid-5318fc8ec1a4443aaf8829ba392f9bef,SCCHN,0.341732
uuid-5318fc8ec1a4443aaf8829ba392f9bef,nivo and pembro,0.334875
uuid-5318fc8ec1a4443aaf8829ba392f9bef,impressed,0.595757
uuid-5318fc8ec1a4443aaf8829ba392f9bef,LTL,0.315082
uuid-5318fc8ec1a4443aaf8829ba392f9bef,TLs,0.401871
uuid-5318fc8ec1a4443aaf8829ba392f9bef,SCLC,0.545501
uuid-5318fc8ec1a4443aaf8829ba392f9bef,feels,0.30416
uuid-5318fc8ec1a4443aaf8829ba392f9bef,Regional TL,0.328056
uuid-5318fc8ec1a4443aaf8829ba392f9bef,bladder,0.332449
uuid-e5a1a4678ebf41b79b94fb8479035d8a,NTL,0.421484
uuid-e5a1a4678ebf41b79b94fb8479035d8a,discussed,0.593769
uuid-e5a1a4678ebf41b79b94fb8479035d8a,commented,0.363027
uuid-e5a1a4678ebf41b79b94fb8479035d8a,regards,0.44033
uuid-e5a1a4678ebf41b79b94fb8479035d8a,data,0.333203
uuid-e5a1a4678ebf41b79b94fb8479035d8a,mentioned,0.323655
uuid-a11a0cf88a964baa8a99623159ceaf86,BMS,0.55808
uuid-a11a0cf88a964baa8a99623159ceaf86,lung,0.31633
uuid-a11a0cf88a964baa8a99623159ceaf86,trial,0.457747
uuid-a11a0cf88a964baa8a99623159ceaf86,shared,0.331596
uuid-a11a0cf88a964baa8a99623159ceaf86,commented,0.344665
uuid-a11a0cf88a964baa8a99623159ceaf86,Merck,0.480162
uuid-a11a0cf88a964baa8a99623159ceaf86,clinical trials,0.379088
uuid-2912dd61fac04760839ef1b8fdcba082,RTL,0.671021
uuid-2912dd61fac04760839ef1b8fdcba082,trial,0.628959
uuid-2912dd61fac04760839ef1b8fdcba082,NTL,0.508253
uuid-2912dd61fac04760839ef1b8fdcba082,commented,0.310548
uuid-2912dd61fac04760839ef1b8fdcba082,stated,0.422392
uuid-2912dd61fac04760839ef1b8fdcba082,data,0.406821
uuid-2912dd61fac04760839ef1b8fdcba082,expressed,0.338714
uuid-2912dd61fac04760839ef1b8fdcba082,clinical trials,0.53717
uuid-2912dd61fac04760839ef1b8fdcba082,SCCHN,0.556949
uuid-2912dd61fac04760839ef1b8fdcba082,impressed,0.45273
uuid-2912dd61fac04760839ef1b8fdcba082,LTL,0.407344
uuid-2912dd61fac04760839ef1b8fdcba082,TLs,0.321347
uuid-2912dd61fac04760839ef1b8fdcba082,academic,0.401585
uuid-2912dd61fac04760839ef1b8fdcba082,Regional TL,0.482462
uuid-2912dd61fac04760839ef1b8fdcba082,RTL stated,0.441127
uuid-2912dd61fac04760839ef1b8fdcba082,bladder,0.52668
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,patients,0.633563
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,Opdivo,0.523667
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,dose,0.50134
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,nivolumab,0.370952
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,toxicity,0.425914
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,regimen,0.535081
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,treated,0.519318
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,pts,0.37941
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,treatment,0.466831
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,progression,0.426922
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,respond,0.340654
uuid-0c60a5cbd7564d5eabfcea192baaf8d2,flat dosing,0.320036
uuid-f66817e1738d434683d63ceee2190582,Nivo,0.328283
uuid-f66817e1738d434683d63ceee2190582,pembro,0.321067
uuid-f66817e1738d434683d63ceee2190582,RTL,0.363226
uuid-f66817e1738d434683d63ceee2190582,trial,0.665509
uuid-f66817e1738d434683d63ceee2190582,efficacy,0.316537
uuid-f66817e1738d434683d63ceee2190582,approval,0.314601
uuid-f66817e1738d434683d63ceee2190582,data,0.424602
uuid-f66817e1738d434683d63ceee2190582,clinical trials,0.434877
uuid-f66817e1738d434683d63ceee2190582,ORR,0.378024
uuid-f66817e1738d434683d63ceee2190582,impressed,0.361468
uuid-71b6ba0fa1c643bc8254454ab36e3c68,RTL,0.439337
uuid-71b6ba0fa1c643bc8254454ab36e3c68,BMS,0.649895
uuid-71b6ba0fa1c643bc8254454ab36e3c68,trial,0.591588
uuid-71b6ba0fa1c643bc8254454ab36e3c68,NTL,0.334716
uuid-71b6ba0fa1c643bc8254454ab36e3c68,shared,0.38623
uuid-71b6ba0fa1c643bc8254454ab36e3c68,commented,0.497297
uuid-71b6ba0fa1c643bc8254454ab36e3c68,Merck,0.582964
uuid-71b6ba0fa1c643bc8254454ab36e3c68,stated,0.458402
uuid-71b6ba0fa1c643bc8254454ab36e3c68,physicians,0.316753
uuid-71b6ba0fa1c643bc8254454ab36e3c68,data,0.412913
uuid-71b6ba0fa1c643bc8254454ab36e3c68,expressed,0.406282
uuid-71b6ba0fa1c643bc8254454ab36e3c68,mentioned,0.324911
uuid-71b6ba0fa1c643bc8254454ab36e3c68,clinical trials,0.517319
uuid-71b6ba0fa1c643bc8254454ab36e3c68,oncology,0.331966
uuid-71b6ba0fa1c643bc8254454ab36e3c68,impressed,0.387294
uuid-71b6ba0fa1c643bc8254454ab36e3c68,LTL,0.389913
uuid-71b6ba0fa1c643bc8254454ab36e3c68,TLs,0.389881
uuid-71b6ba0fa1c643bc8254454ab36e3c68,Regional TL,0.480107
uuid-e64bdc0e388c4d13843a1045007fa961,Nivo,0.339168
uuid-e64bdc0e388c4d13843a1045007fa961,patients,0.437222
uuid-e64bdc0e388c4d13843a1045007fa961,Opdivo,0.399537
uuid-e64bdc0e388c4d13843a1045007fa961,dose,0.793585
uuid-e64bdc0e388c4d13843a1045007fa961,toxicity,0.36477
uuid-e64bdc0e388c4d13843a1045007fa961,regimen,0.424492
uuid-e64bdc0e388c4d13843a1045007fa961,Ipi,0.460633
uuid-e64bdc0e388c4d13843a1045007fa961,preferred,0.338173
uuid-e64bdc0e388c4d13843a1045007fa961,treatment,0.349442
uuid-e64bdc0e388c4d13843a1045007fa961,vs,0.564056
uuid-e64bdc0e388c4d13843a1045007fa961,flat dosing,0.52199
uuid-42cfa241187b4962925739959777df0d,patients,0.712589
uuid-42cfa241187b4962925739959777df0d,Opdivo,0.389552
uuid-42cfa241187b4962925739959777df0d,therapy,0.504949
uuid-42cfa241187b4962925739959777df0d,nivolumab,0.511136
uuid-42cfa241187b4962925739959777df0d,regimen,0.589436
uuid-42cfa241187b4962925739959777df0d,treated,0.632491
uuid-42cfa241187b4962925739959777df0d,pts,0.451286
uuid-42cfa241187b4962925739959777df0d,monotherapy,0.364555
uuid-42cfa241187b4962925739959777df0d,treatment,0.582667
uuid-42cfa241187b4962925739959777df0d,progression,0.470441
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,BMS,0.343995
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,physicians,0.584055
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,clinical trials,0.334646
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,oncology,0.32917
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,indicated,0.413525
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,clinical,0.32626
uuid-65b4e8b1bd354c3eb4fd33b70a66905e,Regional TL,0.304768
uuid-adc7e5d0496945f59f74031c96637e44,Nivo,0.352246
uuid-adc7e5d0496945f59f74031c96637e44,patients,0.488773
uuid-adc7e5d0496945f59f74031c96637e44,Opdivo,0.318592
uuid-adc7e5d0496945f59f74031c96637e44,therapy,0.588844
uuid-adc7e5d0496945f59f74031c96637e44,nivolumab,0.372759
uuid-adc7e5d0496945f59f74031c96637e44,toxicity,0.315261
uuid-adc7e5d0496945f59f74031c96637e44,treated,0.307864
uuid-adc7e5d0496945f59f74031c96637e44,treatment,0.391058
uuid-adc7e5d0496945f59f74031c96637e44,mentioned,0.325783
uuid-adc7e5d0496945f59f74031c96637e44,cHL,0.63592
uuid-adc7e5d0496945f59f74031c96637e44,chemotherapy,0.375129
uuid-c57d0421d007419eab19935c0e488331,TL,0.465705
uuid-c57d0421d007419eab19935c0e488331,commented,0.424556
uuid-c57d0421d007419eab19935c0e488331,TL stated,0.448094
uuid-c57d0421d007419eab19935c0e488331,stated,0.375086
uuid-c57d0421d007419eab19935c0e488331,physicians,0.603842
uuid-c57d0421d007419eab19935c0e488331,mentioned,0.368997
uuid-c57d0421d007419eab19935c0e488331,PDL1 testing,0.304832
uuid-c57d0421d007419eab19935c0e488331,oncologist,0.334465
uuid-c57d0421d007419eab19935c0e488331,LTL,0.352321
uuid-c57d0421d007419eab19935c0e488331,TLs,0.460674
uuid-c57d0421d007419eab19935c0e488331,Regional TL,0.509518
uuid-f22dff46e785465080797fa406a9e72a,BMS,0.630652
uuid-f22dff46e785465080797fa406a9e72a,PDL1,0.450532
uuid-f22dff46e785465080797fa406a9e72a,trial,0.409301
uuid-f22dff46e785465080797fa406a9e72a,efficacy,0.336762
uuid-f22dff46e785465080797fa406a9e72a,commented,0.462899
uuid-f22dff46e785465080797fa406a9e72a,Merck,0.529366
uuid-f22dff46e785465080797fa406a9e72a,stated,0.304783
uuid-f22dff46e785465080797fa406a9e72a,OS,0.616863
uuid-f22dff46e785465080797fa406a9e72a,regards,0.318393
uuid-f22dff46e785465080797fa406a9e72a,data,0.77279
uuid-f22dff46e785465080797fa406a9e72a,expressed,0.393912
uuid-f22dff46e785465080797fa406a9e72a,PFS,0.546068
uuid-f22dff46e785465080797fa406a9e72a,ORR,0.536952
uuid-f22dff46e785465080797fa406a9e72a,ASCO,0.392194
uuid-f22dff46e785465080797fa406a9e72a,impressed,0.639445
uuid-f22dff46e785465080797fa406a9e72a,PDL1 expression,0.346476
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,Nivo,0.340746
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,patients,0.820412
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,Opdivo,0.408493
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,therapy,0.629564
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,nivolumab,0.517687
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,regimen,0.428661
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,treated,0.4506
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,chemo,0.402009
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,pts,0.435641
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,preferred,0.345456
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,monotherapy,0.457977
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,treatment,0.537273
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,using nivo,0.458471
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,PD1,0.30741
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,cHL,0.490577
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,progression,0.492201
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,chemotherapy,0.445822
uuid-dc6786a3b8b946f9b19b84be7f83b3d3,option,0.487583
uuid-58119cbea90d433bae1f1b90e5e112e8,pembro,0.494139
uuid-58119cbea90d433bae1f1b90e5e112e8,dose,0.360683
uuid-58119cbea90d433bae1f1b90e5e112e8,TL stated,0.467839
uuid-58119cbea90d433bae1f1b90e5e112e8,2L,0.354044
uuid-58119cbea90d433bae1f1b90e5e112e8,Merck,0.374648
uuid-58119cbea90d433bae1f1b90e5e112e8,PD-L1,0.325792
uuid-58119cbea90d433bae1f1b90e5e112e8,atezo,0.518043
uuid-58119cbea90d433bae1f1b90e5e112e8,preferred,0.311389
uuid-58119cbea90d433bae1f1b90e5e112e8,testing,0.303808
uuid-58119cbea90d433bae1f1b90e5e112e8,PDL1 testing,0.359324
uuid-58119cbea90d433bae1f1b90e5e112e8,NSCLC patients,0.336056
uuid-58119cbea90d433bae1f1b90e5e112e8,vs,0.353764
uuid-58119cbea90d433bae1f1b90e5e112e8,Keytruda,0.317924
uuid-58119cbea90d433bae1f1b90e5e112e8,TLs,0.419436
uuid-58119cbea90d433bae1f1b90e5e112e8,bladder,0.317075
uuid-58119cbea90d433bae1f1b90e5e112e8,flat dosing,0.31277
uuid-00c249afc02945c2b13e7d5c514df3f0,physicians,0.418146
uuid-00846a6a9fc94b1999c2d2320454254b,patients,0.531624
uuid-00846a6a9fc94b1999c2d2320454254b,dose,0.530389
uuid-00846a6a9fc94b1999c2d2320454254b,toxicity,0.515682
uuid-00846a6a9fc94b1999c2d2320454254b,regimen,0.420934
uuid-00846a6a9fc94b1999c2d2320454254b,treated,0.313372
uuid-00846a6a9fc94b1999c2d2320454254b,treatment,0.480235
uuid-00846a6a9fc94b1999c2d2320454254b,respond,0.360369
uuid-edde7bbf5e6f43d888b03acdb059ba7d,chemo,0.317382
uuid-edde7bbf5e6f43d888b03acdb059ba7d,response,0.34064
uuid-edde7bbf5e6f43d888b03acdb059ba7d,AI,0.565811
uuid-edde7bbf5e6f43d888b03acdb059ba7d,immunotherapy,0.535541
uuid-165abf9ec49c45d78d9f34fcf5094c4d,efficacy,0.318937
uuid-165abf9ec49c45d78d9f34fcf5094c4d,combination,0.352744
uuid-165abf9ec49c45d78d9f34fcf5094c4d,agents,0.472657
uuid-165abf9ec49c45d78d9f34fcf5094c4d,preferred,0.317172
uuid-165abf9ec49c45d78d9f34fcf5094c4d,monotherapy,0.333265
uuid-165abf9ec49c45d78d9f34fcf5094c4d,combo,0.343733
uuid-165abf9ec49c45d78d9f34fcf5094c4d,believes,0.349988
uuid-165abf9ec49c45d78d9f34fcf5094c4d,drug,0.346472
uuid-165abf9ec49c45d78d9f34fcf5094c4d,feels,0.503065
uuid-165abf9ec49c45d78d9f34fcf5094c4d,option,0.362748
uuid-9b08d47e1dcf446da96211a7f7d8bba7,RTL,0.513778
uuid-9b08d47e1dcf446da96211a7f7d8bba7,BMS,0.342041
uuid-9b08d47e1dcf446da96211a7f7d8bba7,trial,0.741251
uuid-9b08d47e1dcf446da96211a7f7d8bba7,NTL,0.316635
uuid-9b08d47e1dcf446da96211a7f7d8bba7,combination,0.381269
uuid-9b08d47e1dcf446da96211a7f7d8bba7,data,0.499518
uuid-9b08d47e1dcf446da96211a7f7d8bba7,expressed,0.302442
uuid-9b08d47e1dcf446da96211a7f7d8bba7,clinical trials,0.402006
uuid-9b08d47e1dcf446da96211a7f7d8bba7,ORR,0.364589
uuid-9b08d47e1dcf446da96211a7f7d8bba7,impressed,0.516161
uuid-9b08d47e1dcf446da96211a7f7d8bba7,SCLC,0.301397
uuid-9b08d47e1dcf446da96211a7f7d8bba7,Regional TL,0.350411
uuid-c15a5967801643d881f61e47de415ece,efficacy,0.405244
uuid-c15a5967801643d881f61e47de415ece,regimen,0.350998
uuid-c15a5967801643d881f61e47de415ece,commented,0.436942
uuid-c15a5967801643d881f61e47de415ece,OS,0.519097
uuid-c15a5967801643d881f61e47de415ece,data,0.577233
uuid-c15a5967801643d881f61e47de415ece,expressed,0.320824
uuid-c15a5967801643d881f61e47de415ece,PFS,0.447272
uuid-c15a5967801643d881f61e47de415ece,ORR,0.524031
uuid-c15a5967801643d881f61e47de415ece,ASCO,0.469331
uuid-c15a5967801643d881f61e47de415ece,impressed,0.663202
uuid-c15a5967801643d881f61e47de415ece,TLs,0.324453
uuid-c15a5967801643d881f61e47de415ece,SCLC,0.414257
uuid-c15a5967801643d881f61e47de415ece,Regional TL,0.33781
uuid-6c598089e04941649c2566be017313a5,pembro,0.327453
uuid-6c598089e04941649c2566be017313a5,RTL,0.331241
uuid-6c598089e04941649c2566be017313a5,BMS,0.331505
uuid-6c598089e04941649c2566be017313a5,trial,0.761832
uuid-6c598089e04941649c2566be017313a5,combination,0.344927
uuid-6c598089e04941649c2566be017313a5,Ipi,0.440858
uuid-6c598089e04941649c2566be017313a5,combo,0.371367
uuid-6c598089e04941649c2566be017313a5,clinical trials,0.323755
uuid-6c598089e04941649c2566be017313a5,impressed,0.345876
uuid-6c598089e04941649c2566be017313a5,vs,0.334379
uuid-c80befac38fe4170aeed60965c7bf1d0,Opdivo,0.376773
uuid-c80befac38fe4170aeed60965c7bf1d0,dose,0.831854
uuid-c80befac38fe4170aeed60965c7bf1d0,toxicity,0.420487
uuid-c80befac38fe4170aeed60965c7bf1d0,regimen,0.347223
uuid-c80befac38fe4170aeed60965c7bf1d0,Ipi,0.62045
uuid-c80befac38fe4170aeed60965c7bf1d0,vs,0.409233
uuid-c80befac38fe4170aeed60965c7bf1d0,Keytruda,0.304123
uuid-c80befac38fe4170aeed60965c7bf1d0,flat dosing,0.687445
uuid-dfbddadea46b4ed996197e782ebd435e,Nivo,0.308287
uuid-dfbddadea46b4ed996197e782ebd435e,patients,0.486611
uuid-dfbddadea46b4ed996197e782ebd435e,therapy,0.657784
uuid-dfbddadea46b4ed996197e782ebd435e,nivolumab,0.376125
uuid-dfbddadea46b4ed996197e782ebd435e,treatment,0.3955
uuid-dfbddadea46b4ed996197e782ebd435e,cHL,0.656667
uuid-dfbddadea46b4ed996197e782ebd435e,progression,0.385091
uuid-dfbddadea46b4ed996197e782ebd435e,chemotherapy,0.4159
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,Opdivo,0.408685
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,RTL,0.365433
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,nivolumab,0.327746
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,NTL,0.321971
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,shared,0.345689
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,stated,0.306488
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,physicians,0.576877
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,HCP,0.371747
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,oncologist,0.307386
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,indicated,0.3522
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,LTL,0.350253
uuid-620909d81c4a4ef69a93fc6a6b14ec7a,Regional TL,0.328786
uuid-8ad86dc6e2d64d1eb028d0ddac984349,RTL,0.340055
uuid-8ad86dc6e2d64d1eb028d0ddac984349,therapy,0.329149
uuid-8ad86dc6e2d64d1eb028d0ddac984349,trial,0.313344
uuid-8ad86dc6e2d64d1eb028d0ddac984349,mentioned,0.415792
uuid-8ad86dc6e2d64d1eb028d0ddac984349,cHL,0.588021
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,Nivo,0.654696
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,pembro,0.376333
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,therapy,0.338219
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,nivolumab,0.346396
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,using nivo,0.407413
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,mentioned,0.354977
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,cHL,0.645585
uuid-a77c22ff97b64e2fbb3dc9c963bb79c8,vs,0.455709
uuid-ff14359812f04548b21b15827c39e438,BMS,0.439494
uuid-ff14359812f04548b21b15827c39e438,PDL1,0.431857
uuid-ff14359812f04548b21b15827c39e438,trial,0.668958
uuid-ff14359812f04548b21b15827c39e438,efficacy,0.458575
uuid-ff14359812f04548b21b15827c39e438,Merck,0.30259
uuid-ff14359812f04548b21b15827c39e438,OS,0.714428
uuid-ff14359812f04548b21b15827c39e438,data,0.626204
uuid-ff14359812f04548b21b15827c39e438,PFS,0.765329
uuid-ff14359812f04548b21b15827c39e438,ORR,0.704943
uuid-ff14359812f04548b21b15827c39e438,nivo and pembro,0.377038
uuid-ff14359812f04548b21b15827c39e438,believes,0.301114
uuid-ff14359812f04548b21b15827c39e438,impressed,0.525668
uuid-ff14359812f04548b21b15827c39e438,feels,0.461297
uuid-ff14359812f04548b21b15827c39e438,PDL1 expression,0.402699
uuid-da12bfa6215f4656a989882641412f14,Nivo,0.526515
uuid-da12bfa6215f4656a989882641412f14,pembro,0.633199
uuid-da12bfa6215f4656a989882641412f14,dose,0.507978
uuid-da12bfa6215f4656a989882641412f14,1L,0.314955
uuid-da12bfa6215f4656a989882641412f14,efficacy,0.448931
uuid-da12bfa6215f4656a989882641412f14,2L,0.457769
uuid-da12bfa6215f4656a989882641412f14,agents,0.30143
uuid-da12bfa6215f4656a989882641412f14,Ipi,0.356756
uuid-da12bfa6215f4656a989882641412f14,atezo,0.660038
uuid-da12bfa6215f4656a989882641412f14,preferred,0.458017
uuid-da12bfa6215f4656a989882641412f14,using nivo,0.311824
uuid-da12bfa6215f4656a989882641412f14,indication,0.391786
uuid-da12bfa6215f4656a989882641412f14,approved,0.351924
uuid-da12bfa6215f4656a989882641412f14,nivo and pembro,0.355827
uuid-da12bfa6215f4656a989882641412f14,vs,0.607757
uuid-da12bfa6215f4656a989882641412f14,Keytruda,0.320994
uuid-da12bfa6215f4656a989882641412f14,feels,0.348913
uuid-da12bfa6215f4656a989882641412f14,option,0.379399
uuid-da12bfa6215f4656a989882641412f14,flat dosing,0.399057
uuid-d56aa55e59234cb798369a400875f602,pembro,0.308665
uuid-d56aa55e59234cb798369a400875f602,BMS,0.593716
uuid-d56aa55e59234cb798369a400875f602,PDL1,0.333438
uuid-d56aa55e59234cb798369a400875f602,trial,0.491556
uuid-d56aa55e59234cb798369a400875f602,efficacy,0.462335
uuid-d56aa55e59234cb798369a400875f602,discussed,0.343962
uuid-d56aa55e59234cb798369a400875f602,commented,0.437527
uuid-d56aa55e59234cb798369a400875f602,Merck,0.429408
uuid-d56aa55e59234cb798369a400875f602,stated,0.310382
uuid-d56aa55e59234cb798369a400875f602,OS,0.42368
uuid-d56aa55e59234cb798369a400875f602,regards,0.349534
uuid-d56aa55e59234cb798369a400875f602,data,0.758902
uuid-d56aa55e59234cb798369a400875f602,expressed,0.353427
uuid-d56aa55e59234cb798369a400875f602,clinical trials,0.318189
uuid-d56aa55e59234cb798369a400875f602,PFS,0.393587
uuid-d56aa55e59234cb798369a400875f602,ORR,0.462211
uuid-d56aa55e59234cb798369a400875f602,nivo and pembro,0.356653
uuid-d56aa55e59234cb798369a400875f602,impressed,0.589142
uuid-d56aa55e59234cb798369a400875f602,LTL,0.36826
uuid-d56aa55e59234cb798369a400875f602,feels,0.332127
uuid-d56aa55e59234cb798369a400875f602,PDL1 expression,0.319411
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,TL,0.323127
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,PDL1,0.464806
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,tumor,0.487114
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,PD-L1,0.735381
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,PD-L1 testing,0.559237
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,testing,0.669426
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,PDL1 testing,0.408631
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,NSCLC patients,0.494673
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,assay,0.623319
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,PDL1 expression,0.413204
uuid-22ccbf60ade74e759bf13ab9e1aa3d2e,biomarker,0.444714
uuid-7622b4e667b641d09eae9440c52153b0,pembro,0.311639
uuid-7622b4e667b641d09eae9440c52153b0,RTL,0.47273
uuid-7622b4e667b641d09eae9440c52153b0,1L,0.390813
uuid-7622b4e667b641d09eae9440c52153b0,trial,0.323919
uuid-7622b4e667b641d09eae9440c52153b0,commented,0.335769
uuid-7622b4e667b641d09eae9440c52153b0,RCC,0.339879
uuid-7622b4e667b641d09eae9440c52153b0,2L,0.330311
uuid-7622b4e667b641d09eae9440c52153b0,stated,0.428001
uuid-7622b4e667b641d09eae9440c52153b0,monotherapy,0.335484
uuid-7622b4e667b641d09eae9440c52153b0,using nivo,0.372347
uuid-7622b4e667b641d09eae9440c52153b0,data,0.567407
uuid-7622b4e667b641d09eae9440c52153b0,clinical trials,0.397706
uuid-7622b4e667b641d09eae9440c52153b0,ORR,0.315525
uuid-7622b4e667b641d09eae9440c52153b0,SCCHN,0.556267
uuid-7622b4e667b641d09eae9440c52153b0,impressed,0.639119
uuid-7622b4e667b641d09eae9440c52153b0,LTL,0.373281
uuid-7622b4e667b641d09eae9440c52153b0,SCLC,0.357049
uuid-7622b4e667b641d09eae9440c52153b0,feels,0.550662
uuid-7622b4e667b641d09eae9440c52153b0,Regional TL,0.425259
uuid-7622b4e667b641d09eae9440c52153b0,RTL stated,0.488908
uuid-7622b4e667b641d09eae9440c52153b0,option,0.304299
uuid-7622b4e667b641d09eae9440c52153b0,bladder,0.341586
uuid-318927cb87334d619647ba1b94f847bd,TL,0.549905
uuid-318927cb87334d619647ba1b94f847bd,PDL1,0.355153
uuid-318927cb87334d619647ba1b94f847bd,TL stated,0.497891
uuid-318927cb87334d619647ba1b94f847bd,institution,0.477048
uuid-318927cb87334d619647ba1b94f847bd,PD-L1,0.763355
uuid-318927cb87334d619647ba1b94f847bd,approval,0.337892
uuid-318927cb87334d619647ba1b94f847bd,PD-L1 testing,0.84486
uuid-318927cb87334d619647ba1b94f847bd,testing,0.887703
uuid-318927cb87334d619647ba1b94f847bd,PDL1 testing,0.767394
uuid-318927cb87334d619647ba1b94f847bd,NSCLC patients,0.746606
uuid-318927cb87334d619647ba1b94f847bd,assay,0.595834
uuid-318927cb87334d619647ba1b94f847bd,biomarker,0.360546
uuid-3013a0a40a9b49478709147f1bba68bd,Nivo,0.437002
uuid-3013a0a40a9b49478709147f1bba68bd,patients,0.570129
uuid-3013a0a40a9b49478709147f1bba68bd,Opdivo,0.57528
uuid-3013a0a40a9b49478709147f1bba68bd,pembro,0.349157
uuid-3013a0a40a9b49478709147f1bba68bd,dose,0.60203
uuid-3013a0a40a9b49478709147f1bba68bd,toxicity,0.39849
uuid-3013a0a40a9b49478709147f1bba68bd,regimen,0.410883
uuid-3013a0a40a9b49478709147f1bba68bd,Ipi,0.34655
uuid-3013a0a40a9b49478709147f1bba68bd,preferred,0.346749
uuid-3013a0a40a9b49478709147f1bba68bd,monotherapy,0.35668
uuid-3013a0a40a9b49478709147f1bba68bd,indication,0.314235
uuid-3013a0a40a9b49478709147f1bba68bd,vs,0.375463
uuid-3013a0a40a9b49478709147f1bba68bd,Keytruda,0.42529
uuid-3013a0a40a9b49478709147f1bba68bd,option,0.343206
uuid-3013a0a40a9b49478709147f1bba68bd,flat dosing,0.502605
uuid-47ad29e8363745d7af394b629cd6d16e,BMS,0.329696
uuid-47ad29e8363745d7af394b629cd6d16e,PDL1,0.471999
uuid-47ad29e8363745d7af394b629cd6d16e,trial,0.388734
uuid-47ad29e8363745d7af394b629cd6d16e,efficacy,0.816509
uuid-47ad29e8363745d7af394b629cd6d16e,OS,0.845256
uuid-47ad29e8363745d7af394b629cd6d16e,regards,0.398539
uuid-47ad29e8363745d7af394b629cd6d16e,data,0.745531
uuid-47ad29e8363745d7af394b629cd6d16e,PFS,0.817376
uuid-47ad29e8363745d7af394b629cd6d16e,ORR,0.820453
uuid-47ad29e8363745d7af394b629cd6d16e,nivo and pembro,0.548635
uuid-47ad29e8363745d7af394b629cd6d16e,believes,0.385141
uuid-47ad29e8363745d7af394b629cd6d16e,impressed,0.504253
uuid-47ad29e8363745d7af394b629cd6d16e,feels,0.341713
uuid-47ad29e8363745d7af394b629cd6d16e,PDL1 expression,0.470212
uuid-1150e1fd09594ef8b712db3152bfb69d,patients,0.365362
uuid-1150e1fd09594ef8b712db3152bfb69d,regimen,0.424172
uuid-1150e1fd09594ef8b712db3152bfb69d,treated,0.508012
uuid-1150e1fd09594ef8b712db3152bfb69d,melanoma,0.334962
uuid-1150e1fd09594ef8b712db3152bfb69d,physicians,0.494573
uuid-1150e1fd09594ef8b712db3152bfb69d,treatment,0.416658
uuid-1150e1fd09594ef8b712db3152bfb69d,progression,0.439543
uuid-1150e1fd09594ef8b712db3152bfb69d,oncologist,0.307095
uuid-1150e1fd09594ef8b712db3152bfb69d,respond,0.347065
uuid-1150e1fd09594ef8b712db3152bfb69d,TL shared,0.361651
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,Nivo,0.397263
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,pembro,0.345394
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,RTL,0.317162
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,1L,0.348798
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,trial,0.334621
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,2L,0.303326
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,pts,0.408902
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,stated,0.366501
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,OS,0.374023
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,monotherapy,0.386844
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,using nivo,0.340347
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,data,0.389804
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,combo,0.300783
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,PFS,0.314463
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,ORR,0.364288
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,SCCHN,0.319673
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,impressed,0.519322
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,SCLC,0.321776
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,feels,0.455767
uuid-d086eb01297a4ccb9fe4230ffa0dca7a,RTL stated,0.34338
uuid-c42dfb7842c440b99e76ef4acb491cc0,patients,0.321737
uuid-c42dfb7842c440b99e76ef4acb491cc0,preferred,0.542183
uuid-c42dfb7842c440b99e76ef4acb491cc0,monotherapy,0.322125
uuid-c42dfb7842c440b99e76ef4acb491cc0,SCCHN,0.36022
uuid-c42dfb7842c440b99e76ef4acb491cc0,RTL stated,0.380333
uuid-c42dfb7842c440b99e76ef4acb491cc0,option,0.446811
uuid-2fdd3b924b964bb6bc58c262ec6334dc,BMS,0.318882
uuid-2fdd3b924b964bb6bc58c262ec6334dc,combination,0.364186
uuid-2fdd3b924b964bb6bc58c262ec6334dc,tumor,0.348136
uuid-2fdd3b924b964bb6bc58c262ec6334dc,clinical trials,0.300645
uuid-2fdd3b924b964bb6bc58c262ec6334dc,clinical,0.366485
uuid-b59f90cf409844cea32ef3d216c58a18,RTL,0.320727
uuid-b59f90cf409844cea32ef3d216c58a18,PDL1,0.406379
uuid-b59f90cf409844cea32ef3d216c58a18,trial,0.309053
uuid-b59f90cf409844cea32ef3d216c58a18,efficacy,0.380895
uuid-b59f90cf409844cea32ef3d216c58a18,commented,0.454565
uuid-b59f90cf409844cea32ef3d216c58a18,stated,0.375913
uuid-b59f90cf409844cea32ef3d216c58a18,OS,0.514174
uuid-b59f90cf409844cea32ef3d216c58a18,data,0.782835
uuid-b59f90cf409844cea32ef3d216c58a18,expressed,0.341917
uuid-b59f90cf409844cea32ef3d216c58a18,PFS,0.470114
uuid-b59f90cf409844cea32ef3d216c58a18,ORR,0.549014
uuid-b59f90cf409844cea32ef3d216c58a18,ASCO,0.378655
uuid-b59f90cf409844cea32ef3d216c58a18,impressed,0.677638
uuid-b59f90cf409844cea32ef3d216c58a18,TLs,0.310627
uuid-b59f90cf409844cea32ef3d216c58a18,feels,0.362342
uuid-b59f90cf409844cea32ef3d216c58a18,Regional TL,0.315323
uuid-b59f90cf409844cea32ef3d216c58a18,PDL1 expression,0.310541
uuid-12f00d07d2914d1db7c9327c75347fd7,trial,0.363965
uuid-12f00d07d2914d1db7c9327c75347fd7,efficacy,0.603986
uuid-12f00d07d2914d1db7c9327c75347fd7,commented,0.322683
uuid-12f00d07d2914d1db7c9327c75347fd7,Ipi,0.372295
uuid-12f00d07d2914d1db7c9327c75347fd7,OS,0.690621
uuid-12f00d07d2914d1db7c9327c75347fd7,data,0.704517
uuid-12f00d07d2914d1db7c9327c75347fd7,combo,0.393096
uuid-12f00d07d2914d1db7c9327c75347fd7,PFS,0.602362
uuid-12f00d07d2914d1db7c9327c75347fd7,ORR,0.692505
uuid-12f00d07d2914d1db7c9327c75347fd7,nivo and pembro,0.322919
uuid-12f00d07d2914d1db7c9327c75347fd7,ASCO,0.330931
uuid-12f00d07d2914d1db7c9327c75347fd7,believes,0.350459
uuid-12f00d07d2914d1db7c9327c75347fd7,impressed,0.719936
uuid-12f00d07d2914d1db7c9327c75347fd7,feels,0.421079
uuid-ddb0b127323546ba87c162275718f620,pembro,0.316252
uuid-ddb0b127323546ba87c162275718f620,BMS,0.649366
uuid-ddb0b127323546ba87c162275718f620,PDL1,0.698821
uuid-ddb0b127323546ba87c162275718f620,trial,0.466955
uuid-ddb0b127323546ba87c162275718f620,efficacy,0.35654
uuid-ddb0b127323546ba87c162275718f620,Merck,0.722499
uuid-ddb0b127323546ba87c162275718f620,PD-L1,0.349463
uuid-ddb0b127323546ba87c162275718f620,OS,0.421354
uuid-ddb0b127323546ba87c162275718f620,regards,0.317592
uuid-ddb0b127323546ba87c162275718f620,data,0.624891
uuid-ddb0b127323546ba87c162275718f620,PFS,0.440351
uuid-ddb0b127323546ba87c162275718f620,ORR,0.429848
uuid-ddb0b127323546ba87c162275718f620,nivo and pembro,0.444204
uuid-ddb0b127323546ba87c162275718f620,impressed,0.344697
uuid-ddb0b127323546ba87c162275718f620,assay,0.422867
uuid-ddb0b127323546ba87c162275718f620,PDL1 expression,0.616609
uuid-ddb0b127323546ba87c162275718f620,biomarker,0.512916
uuid-b66c73a6b1124c5685617e042deaa900,patients,0.501248
uuid-b66c73a6b1124c5685617e042deaa900,Opdivo,0.475919
uuid-b66c73a6b1124c5685617e042deaa900,nivolumab,0.355981
uuid-b66c73a6b1124c5685617e042deaa900,regimen,0.390334
uuid-b66c73a6b1124c5685617e042deaa900,treated,0.476501
uuid-b66c73a6b1124c5685617e042deaa900,RCC,0.332334
uuid-b66c73a6b1124c5685617e042deaa900,TL stated,0.353576
uuid-b66c73a6b1124c5685617e042deaa900,pts,0.350087
uuid-b66c73a6b1124c5685617e042deaa900,treatment,0.35476
uuid-b66c73a6b1124c5685617e042deaa900,RTL stated,0.338402
uuid-b66c73a6b1124c5685617e042deaa900,TL shared,0.346431
uuid-f229736821954f63b7842e4e45828e78,efficacy,0.320531
uuid-f229736821954f63b7842e4e45828e78,combination,0.409076
uuid-f229736821954f63b7842e4e45828e78,chemo,0.32312
uuid-f229736821954f63b7842e4e45828e78,Ipi,0.478203
uuid-f229736821954f63b7842e4e45828e78,data,0.301453
uuid-f229736821954f63b7842e4e45828e78,combo,0.49172
uuid-f229736821954f63b7842e4e45828e78,PD1,0.339085
uuid-f229736821954f63b7842e4e45828e78,ORR,0.327409
uuid-f229736821954f63b7842e4e45828e78,chemotherapy,0.304755
uuid-d0168ebad48049ed8958952c835a2d9d,1L,0.471972
uuid-d0168ebad48049ed8958952c835a2d9d,PDL1,0.393056
uuid-d0168ebad48049ed8958952c835a2d9d,TL stated,0.433165
uuid-d0168ebad48049ed8958952c835a2d9d,2L,0.399202
uuid-d0168ebad48049ed8958952c835a2d9d,PD-L1,0.757583
uuid-d0168ebad48049ed8958952c835a2d9d,approval,0.300351
uuid-d0168ebad48049ed8958952c835a2d9d,preferred,0.391492
uuid-d0168ebad48049ed8958952c835a2d9d,PD-L1 testing,0.622899
uuid-d0168ebad48049ed8958952c835a2d9d,testing,0.828172
uuid-d0168ebad48049ed8958952c835a2d9d,PDL1 testing,0.769228
uuid-d0168ebad48049ed8958952c835a2d9d,NSCLC patients,0.838079
uuid-d0168ebad48049ed8958952c835a2d9d,tumor types,0.469657
uuid-d0168ebad48049ed8958952c835a2d9d,assay,0.394256
uuid-d0168ebad48049ed8958952c835a2d9d,PD-1,0.345579
uuid-d0168ebad48049ed8958952c835a2d9d,biomarker,0.406175
uuid-2fa9ad729e924a3cb4012ab3ef496a43,patients,0.66929
uuid-2fa9ad729e924a3cb4012ab3ef496a43,Opdivo,0.393976
uuid-2fa9ad729e924a3cb4012ab3ef496a43,therapy,0.493158
uuid-2fa9ad729e924a3cb4012ab3ef496a43,nivolumab,0.621885
uuid-2fa9ad729e924a3cb4012ab3ef496a43,regimen,0.30781
uuid-2fa9ad729e924a3cb4012ab3ef496a43,treated,0.591916
uuid-2fa9ad729e924a3cb4012ab3ef496a43,pts,0.317514
uuid-2fa9ad729e924a3cb4012ab3ef496a43,treatment,0.561448
uuid-2fa9ad729e924a3cb4012ab3ef496a43,using nivo,0.38914
uuid-2fa9ad729e924a3cb4012ab3ef496a43,cHL,0.402074
uuid-2fa9ad729e924a3cb4012ab3ef496a43,progression,0.431747
uuid-2fa9ad729e924a3cb4012ab3ef496a43,chemotherapy,0.362751
uuid-2fa9ad729e924a3cb4012ab3ef496a43,RTL stated,0.379204
uuid-2fa9ad729e924a3cb4012ab3ef496a43,TL shared,0.311935
uuid-08634ed2e52940879b30e42d783488b0,patients,0.412919
uuid-08634ed2e52940879b30e42d783488b0,regimen,0.348821
uuid-08634ed2e52940879b30e42d783488b0,pts,0.347583
uuid-08634ed2e52940879b30e42d783488b0,monotherapy,0.429148
uuid-08634ed2e52940879b30e42d783488b0,combo,0.421431
uuid-08634ed2e52940879b30e42d783488b0,clinical trials,0.308329
uuid-08634ed2e52940879b30e42d783488b0,chemotherapy,0.307657
uuid-08634ed2e52940879b30e42d783488b0,feels,0.360115
uuid-08634ed2e52940879b30e42d783488b0,option,0.383178
uuid-57201294fe7c4f718c5a3a298a43a8c4,patients,0.401124
uuid-57201294fe7c4f718c5a3a298a43a8c4,shared,0.326996
uuid-57201294fe7c4f718c5a3a298a43a8c4,approval,0.333871
uuid-57201294fe7c4f718c5a3a298a43a8c4,approved,0.33189
uuid-57201294fe7c4f718c5a3a298a43a8c4,RTL stated,0.301451
uuid-6d019f1d2964423fa319f06e6659eb3f,treated,0.458608
uuid-6d019f1d2964423fa319f06e6659eb3f,treatment,0.326759
uuid-6d019f1d2964423fa319f06e6659eb3f,ASCO,0.466543
uuid-c4356396e6934cf8a70b28e11b5084b8,TL stated,0.308852
uuid-c4356396e6934cf8a70b28e11b5084b8,Keytruda,0.36783
uuid-bfb36b6df4f94b258f6594d55b18773b,patients,0.396877
uuid-bfb36b6df4f94b258f6594d55b18773b,regimen,0.409239
uuid-bfb36b6df4f94b258f6594d55b18773b,treated,0.402168
uuid-bfb36b6df4f94b258f6594d55b18773b,pts,0.32197
uuid-bfb36b6df4f94b258f6594d55b18773b,physicians,0.406094
uuid-bfb36b6df4f94b258f6594d55b18773b,treatment,0.468669
uuid-bfb36b6df4f94b258f6594d55b18773b,response,0.441736
uuid-bfb36b6df4f94b258f6594d55b18773b,progression,0.564801
uuid-bfb36b6df4f94b258f6594d55b18773b,respond,0.499201
uuid-bfb36b6df4f94b258f6594d55b18773b,feels,0.369974
uuid-e7823058a1ea46ee8d77357f4fda5b01,lung,0.687848
uuid-e7823058a1ea46ee8d77357f4fda5b01,NSCLC,0.332115
uuid-e7823058a1ea46ee8d77357f4fda5b01,PDL1,0.314687
uuid-e7823058a1ea46ee8d77357f4fda5b01,melanoma,0.494302
uuid-e7823058a1ea46ee8d77357f4fda5b01,RCC,0.313156
uuid-e7823058a1ea46ee8d77357f4fda5b01,TL stated,0.350303
uuid-e7823058a1ea46ee8d77357f4fda5b01,tumor,0.307681
uuid-e7823058a1ea46ee8d77357f4fda5b01,PDL1 testing,0.36181
uuid-e7823058a1ea46ee8d77357f4fda5b01,AI,0.662357
uuid-e7823058a1ea46ee8d77357f4fda5b01,TL shared,0.382599
uuid-e7823058a1ea46ee8d77357f4fda5b01,biomarker,0.441746
uuid-e7823058a1ea46ee8d77357f4fda5b01,NCCN,0.384364
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,Nivo,0.625516
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,patients,0.587207
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,Opdivo,0.346503
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,therapy,0.432432
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,dose,0.412047
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,nivolumab,0.444847
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,toxicity,0.500532
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,regimen,0.596447
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,treated,0.317822
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,combination,0.487661
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,chemo,0.510573
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,2L,0.40912
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,pts,0.512431
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,Ipi,0.437484
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,preferred,0.424927
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,monotherapy,0.586316
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,treatment,0.477373
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,using nivo,0.403127
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,response,0.398155
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,combo,0.450555
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,PD1,0.397426
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,progression,0.486663
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,chemotherapy,0.407823
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,respond,0.449352
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,feels,0.33242
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,RTL stated,0.30238
uuid-f6d76ab8cddb4a6d837cea0bdaee2dac,option,0.541688
uuid-2843ec5033464788921f1eb874db22e2,patients,0.406342
uuid-2843ec5033464788921f1eb874db22e2,tumor,0.503142
uuid-2843ec5033464788921f1eb874db22e2,pts,0.311766
uuid-2843ec5033464788921f1eb874db22e2,PD-L1,0.309273
uuid-2843ec5033464788921f1eb874db22e2,approval,0.418362
uuid-2843ec5033464788921f1eb874db22e2,testing,0.396987
uuid-2843ec5033464788921f1eb874db22e2,NSCLC patients,0.441636
uuid-2843ec5033464788921f1eb874db22e2,approved,0.32318
uuid-2843ec5033464788921f1eb874db22e2,tumor types,0.456023
uuid-2843ec5033464788921f1eb874db22e2,bladder,0.422122
uuid-840be439f54948d5b811291775566175,therapy,0.347189
uuid-840be439f54948d5b811291775566175,PD1,0.302596
uuid-840be439f54948d5b811291775566175,cHL,0.307268
uuid-840be439f54948d5b811291775566175,immunotherapy,0.328762
uuid-03170cb0f35644b1b2aaa9ca55da856b,response,0.377195
uuid-641329b1a1e8490bbae2e60dfc6227d1,patients,0.7001
uuid-641329b1a1e8490bbae2e60dfc6227d1,Opdivo,0.567731
uuid-641329b1a1e8490bbae2e60dfc6227d1,therapy,0.571014
uuid-641329b1a1e8490bbae2e60dfc6227d1,nivolumab,0.439566
uuid-641329b1a1e8490bbae2e60dfc6227d1,treated,0.410339
uuid-641329b1a1e8490bbae2e60dfc6227d1,treatment,0.52226
uuid-641329b1a1e8490bbae2e60dfc6227d1,cHL,0.587733
uuid-641329b1a1e8490bbae2e60dfc6227d1,progression,0.474086
uuid-641329b1a1e8490bbae2e60dfc6227d1,respond,0.38822
uuid-cbe7fd2a91244a208888d87dcd24630d,patients,0.476866
uuid-cbe7fd2a91244a208888d87dcd24630d,Opdivo,0.518776
uuid-cbe7fd2a91244a208888d87dcd24630d,therapy,0.39583
uuid-cbe7fd2a91244a208888d87dcd24630d,nivolumab,0.392306
uuid-cbe7fd2a91244a208888d87dcd24630d,treated,0.332067
uuid-cbe7fd2a91244a208888d87dcd24630d,treatment,0.417141
uuid-cbe7fd2a91244a208888d87dcd24630d,cHL,0.469014
uuid-cbe7fd2a91244a208888d87dcd24630d,progression,0.425097
uuid-c0b692327da64ffaaf83cdeb5e89b7e5,NTL,0.570553
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,pembro,0.493812
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,1L,0.550481
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,2L,0.64323
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,agents,0.534114
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,atezo,0.608709
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,preferred,0.545163
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,monotherapy,0.444256
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,using nivo,0.316101
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,combo,0.405767
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,approved,0.394097
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,nivo and pembro,0.365034
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,believes,0.418689
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,tumor types,0.303307
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,feels,0.434359
uuid-9ad4a346a3c54923ba9dbb6b4eb144b9,option,0.50787
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,Nivo,0.487556
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,pembro,0.511544
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,1L,0.673547
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,PDL1,0.306424
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,efficacy,0.352712
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,combination,0.440531
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,chemo,0.457212
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,2L,0.627243
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,IO,0.333805
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,agents,0.616879
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,atezo,0.505259
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,preferred,0.604679
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,monotherapy,0.651861
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,using nivo,0.438677
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,data,0.30312
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,combo,0.456633
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,indication,0.325151
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,PD1,0.39403
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,approved,0.473418
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,nivo and pembro,0.430017
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,believes,0.474982
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,chemotherapy,0.401155
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,feels,0.521489
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,RTL stated,0.321933
uuid-bf997e7e42ca4a29bd5e6399a1e9f10b,option,0.696977
uuid-11eed7a6c7654028bb8658cc278c87df,patients,0.3913
uuid-11eed7a6c7654028bb8658cc278c87df,RTL,0.321071
uuid-11eed7a6c7654028bb8658cc278c87df,nivolumab,0.383337
uuid-11eed7a6c7654028bb8658cc278c87df,trial,0.408326
uuid-11eed7a6c7654028bb8658cc278c87df,treated,0.379626
uuid-11eed7a6c7654028bb8658cc278c87df,stated,0.329121
uuid-11eed7a6c7654028bb8658cc278c87df,approval,0.493421
uuid-11eed7a6c7654028bb8658cc278c87df,clinical trials,0.417032
uuid-11eed7a6c7654028bb8658cc278c87df,approved,0.364969
uuid-11eed7a6c7654028bb8658cc278c87df,SCCHN,0.338162
uuid-11eed7a6c7654028bb8658cc278c87df,impressed,0.373238
uuid-11eed7a6c7654028bb8658cc278c87df,Regional TL,0.351277
uuid-11eed7a6c7654028bb8658cc278c87df,RTL stated,0.311053
uuid-b6993d36d3324fd2b7ed556a9e185f08,patients,0.374274
uuid-b6993d36d3324fd2b7ed556a9e185f08,treated,0.334278
uuid-b6993d36d3324fd2b7ed556a9e185f08,pts,0.310519
uuid-b6993d36d3324fd2b7ed556a9e185f08,treatment,0.386396
uuid-b6993d36d3324fd2b7ed556a9e185f08,response,0.386892
uuid-b6993d36d3324fd2b7ed556a9e185f08,lung cancer,0.321513
uuid-b6993d36d3324fd2b7ed556a9e185f08,progression,0.496671
uuid-b6993d36d3324fd2b7ed556a9e185f08,respond,0.339969
uuid-e832b117f2384db89fab9f9a64d4c593,regimen,0.300948
uuid-e832b117f2384db89fab9f9a64d4c593,chemo,0.336421
uuid-e832b117f2384db89fab9f9a64d4c593,monotherapy,0.332009
uuid-e832b117f2384db89fab9f9a64d4c593,chemotherapy,0.440971
uuid-e832b117f2384db89fab9f9a64d4c593,feels,0.334195
uuid-e832b117f2384db89fab9f9a64d4c593,option,0.378878
uuid-2b4f93cadcc443c487acdeeb0eb67951,patients,0.300268
uuid-2b4f93cadcc443c487acdeeb0eb67951,tumor,0.404089
uuid-eb38501c4d6049f0a1185ba5ac469676,TL,0.315767
uuid-eb38501c4d6049f0a1185ba5ac469676,pembro,0.334062
uuid-eb38501c4d6049f0a1185ba5ac469676,1L,0.432326
uuid-eb38501c4d6049f0a1185ba5ac469676,PDL1,0.415823
uuid-eb38501c4d6049f0a1185ba5ac469676,TL stated,0.395711
uuid-eb38501c4d6049f0a1185ba5ac469676,2L,0.388588
uuid-eb38501c4d6049f0a1185ba5ac469676,PD-L1,0.74101
uuid-eb38501c4d6049f0a1185ba5ac469676,approval,0.328143
uuid-eb38501c4d6049f0a1185ba5ac469676,atezo,0.369666
uuid-eb38501c4d6049f0a1185ba5ac469676,preferred,0.333763
uuid-eb38501c4d6049f0a1185ba5ac469676,PD-L1 testing,0.658694
uuid-eb38501c4d6049f0a1185ba5ac469676,testing,0.812887
uuid-eb38501c4d6049f0a1185ba5ac469676,PDL1 testing,0.680295
uuid-eb38501c4d6049f0a1185ba5ac469676,NSCLC patients,0.723604
uuid-eb38501c4d6049f0a1185ba5ac469676,approved,0.323079
uuid-eb38501c4d6049f0a1185ba5ac469676,tumor types,0.384479
uuid-eb38501c4d6049f0a1185ba5ac469676,assay,0.514346
uuid-eb38501c4d6049f0a1185ba5ac469676,PD-1,0.321515
uuid-eb38501c4d6049f0a1185ba5ac469676,option,0.310905
uuid-eb38501c4d6049f0a1185ba5ac469676,biomarker,0.396913
uuid-2f6e06a79b44473b8f54b51f96684686,patients,0.874979
uuid-2f6e06a79b44473b8f54b51f96684686,Opdivo,0.308545
uuid-2f6e06a79b44473b8f54b51f96684686,therapy,0.593886
uuid-2f6e06a79b44473b8f54b51f96684686,nivolumab,0.447285
uuid-2f6e06a79b44473b8f54b51f96684686,regimen,0.486297
uuid-2f6e06a79b44473b8f54b51f96684686,treated,0.538413
uuid-2f6e06a79b44473b8f54b51f96684686,chemo,0.442002
uuid-2f6e06a79b44473b8f54b51f96684686,pts,0.658083
uuid-2f6e06a79b44473b8f54b51f96684686,monotherapy,0.394392
uuid-2f6e06a79b44473b8f54b51f96684686,treatment,0.645664
uuid-2f6e06a79b44473b8f54b51f96684686,using nivo,0.32963
uuid-2f6e06a79b44473b8f54b51f96684686,response,0.458438
uuid-2f6e06a79b44473b8f54b51f96684686,PD1,0.360763
uuid-2f6e06a79b44473b8f54b51f96684686,progression,0.6549
uuid-2f6e06a79b44473b8f54b51f96684686,chemotherapy,0.470373
uuid-2f6e06a79b44473b8f54b51f96684686,respond,0.541993
uuid-2f6e06a79b44473b8f54b51f96684686,option,0.453563
uuid-7e2ca66cacc14befbce5f502d5b38324,BMS,0.348742
uuid-7e2ca66cacc14befbce5f502d5b38324,physicians,0.347882
uuid-7e2ca66cacc14befbce5f502d5b38324,regards,0.338653
uuid-7e2ca66cacc14befbce5f502d5b38324,oncology,0.499631
uuid-7e2ca66cacc14befbce5f502d5b38324,drug,0.309948
uuid-7e2ca66cacc14befbce5f502d5b38324,clinical,0.438308
uuid-0a18e9751446405db311e9539076fe64,TL,0.646605
uuid-0a18e9751446405db311e9539076fe64,RTL,0.319497
uuid-0a18e9751446405db311e9539076fe64,commented,0.337119
uuid-0a18e9751446405db311e9539076fe64,TL stated,0.379777
uuid-0a18e9751446405db311e9539076fe64,Merck,0.328952
uuid-0a18e9751446405db311e9539076fe64,institution,0.314973
uuid-0a18e9751446405db311e9539076fe64,stated,0.391217
uuid-0a18e9751446405db311e9539076fe64,PD-L1,0.523852
uuid-0a18e9751446405db311e9539076fe64,approval,0.328751
uuid-0a18e9751446405db311e9539076fe64,PD-L1 testing,0.685881
uuid-0a18e9751446405db311e9539076fe64,testing,0.54505
uuid-0a18e9751446405db311e9539076fe64,PDL1 testing,0.46859
uuid-0a18e9751446405db311e9539076fe64,NSCLC patients,0.341596
uuid-0a18e9751446405db311e9539076fe64,SCCHN,0.305886
uuid-0a18e9751446405db311e9539076fe64,TLs,0.388943
uuid-0a18e9751446405db311e9539076fe64,assay,0.49295
uuid-0a18e9751446405db311e9539076fe64,Regional TL,0.384833
uuid-0b1381a79652432c880c380c9b99669f,TL,0.628532
uuid-0b1381a79652432c880c380c9b99669f,TL stated,0.439781
uuid-0b1381a79652432c880c380c9b99669f,institution,0.357425
uuid-0b1381a79652432c880c380c9b99669f,PD-L1,0.709135
uuid-0b1381a79652432c880c380c9b99669f,PD-L1 testing,0.91341
uuid-0b1381a79652432c880c380c9b99669f,testing,0.833652
uuid-0b1381a79652432c880c380c9b99669f,PDL1 testing,0.668626
uuid-0b1381a79652432c880c380c9b99669f,NSCLC patients,0.589254
uuid-0b1381a79652432c880c380c9b99669f,assay,0.628609
uuid-ec6e31d84a0b4fc09659ed169589b931,Nivo,0.464986
uuid-ec6e31d84a0b4fc09659ed169589b931,patients,0.554956
uuid-ec6e31d84a0b4fc09659ed169589b931,therapy,0.36449
uuid-ec6e31d84a0b4fc09659ed169589b931,efficacy,0.354993
uuid-ec6e31d84a0b4fc09659ed169589b931,regimen,0.458924
uuid-ec6e31d84a0b4fc09659ed169589b931,chemo,0.564244
uuid-ec6e31d84a0b4fc09659ed169589b931,pts,0.528897
uuid-ec6e31d84a0b4fc09659ed169589b931,OS,0.470139
uuid-ec6e31d84a0b4fc09659ed169589b931,monotherapy,0.422604
uuid-ec6e31d84a0b4fc09659ed169589b931,treatment,0.399053
uuid-ec6e31d84a0b4fc09659ed169589b931,response,0.557343
uuid-ec6e31d84a0b4fc09659ed169589b931,PFS,0.45553
uuid-ec6e31d84a0b4fc09659ed169589b931,PD1,0.350646
uuid-ec6e31d84a0b4fc09659ed169589b931,ORR,0.446183
uuid-ec6e31d84a0b4fc09659ed169589b931,progression,0.569831
uuid-ec6e31d84a0b4fc09659ed169589b931,chemotherapy,0.505067
uuid-ec6e31d84a0b4fc09659ed169589b931,respond,0.486867
uuid-ec6e31d84a0b4fc09659ed169589b931,feels,0.509593
uuid-ec6e31d84a0b4fc09659ed169589b931,option,0.36243
uuid-59dd01638e6144baa2c08a4b94f0f4f4,patients,0.37323
uuid-59dd01638e6144baa2c08a4b94f0f4f4,TL,0.331577
uuid-59dd01638e6144baa2c08a4b94f0f4f4,1L,0.327849
uuid-59dd01638e6144baa2c08a4b94f0f4f4,PDL1,0.319663
uuid-59dd01638e6144baa2c08a4b94f0f4f4,TL stated,0.345906
uuid-59dd01638e6144baa2c08a4b94f0f4f4,pts,0.309515
uuid-59dd01638e6144baa2c08a4b94f0f4f4,PD-L1,0.647409
uuid-59dd01638e6144baa2c08a4b94f0f4f4,approval,0.365188
uuid-59dd01638e6144baa2c08a4b94f0f4f4,PD-L1 testing,0.672064
uuid-59dd01638e6144baa2c08a4b94f0f4f4,testing,0.7921
uuid-59dd01638e6144baa2c08a4b94f0f4f4,PDL1 testing,0.625715
uuid-59dd01638e6144baa2c08a4b94f0f4f4,NSCLC patients,0.771979
uuid-59dd01638e6144baa2c08a4b94f0f4f4,tumor types,0.333928
uuid-59dd01638e6144baa2c08a4b94f0f4f4,assay,0.40151
uuid-59dd01638e6144baa2c08a4b94f0f4f4,biomarker,0.34424
uuid-f344ceabf12449a68332e5c381388a4f,patients,0.513782
uuid-f344ceabf12449a68332e5c381388a4f,toxicity,0.460272
uuid-f344ceabf12449a68332e5c381388a4f,regimen,0.593258
uuid-f344ceabf12449a68332e5c381388a4f,treated,0.491002
uuid-f344ceabf12449a68332e5c381388a4f,physicians,0.389152
uuid-f344ceabf12449a68332e5c381388a4f,treatment,0.491578
uuid-f344ceabf12449a68332e5c381388a4f,combo,0.314387
uuid-f344ceabf12449a68332e5c381388a4f,progression,0.302719
uuid-63e032e246274a638707dbe5a958c3cd,patients,0.440335
uuid-63e032e246274a638707dbe5a958c3cd,Opdivo,0.478654
uuid-63e032e246274a638707dbe5a958c3cd,dose,0.804574
uuid-63e032e246274a638707dbe5a958c3cd,nivolumab,0.340035
uuid-63e032e246274a638707dbe5a958c3cd,toxicity,0.450069
uuid-63e032e246274a638707dbe5a958c3cd,regimen,0.524055
uuid-63e032e246274a638707dbe5a958c3cd,Ipi,0.45082
uuid-63e032e246274a638707dbe5a958c3cd,treatment,0.325244
uuid-63e032e246274a638707dbe5a958c3cd,vs,0.390337
uuid-63e032e246274a638707dbe5a958c3cd,flat dosing,0.578746
uuid-6b5b28febec94f829d6e837f5b40c52b,patients,0.508618
uuid-6b5b28febec94f829d6e837f5b40c52b,therapy,0.669926
uuid-6b5b28febec94f829d6e837f5b40c52b,1L,0.420439
uuid-6b5b28febec94f829d6e837f5b40c52b,regimen,0.393778
uuid-6b5b28febec94f829d6e837f5b40c52b,combination,0.354238
uuid-6b5b28febec94f829d6e837f5b40c52b,chemo,0.578611
uuid-6b5b28febec94f829d6e837f5b40c52b,2L,0.40929
uuid-6b5b28febec94f829d6e837f5b40c52b,pts,0.408355
uuid-6b5b28febec94f829d6e837f5b40c52b,agents,0.43841
uuid-6b5b28febec94f829d6e837f5b40c52b,preferred,0.426144
uuid-6b5b28febec94f829d6e837f5b40c52b,monotherapy,0.615763
uuid-6b5b28febec94f829d6e837f5b40c52b,treatment,0.531143
uuid-6b5b28febec94f829d6e837f5b40c52b,response,0.356205
uuid-6b5b28febec94f829d6e837f5b40c52b,combo,0.309828
uuid-6b5b28febec94f829d6e837f5b40c52b,PD1,0.489988
uuid-6b5b28febec94f829d6e837f5b40c52b,progression,0.509049
uuid-6b5b28febec94f829d6e837f5b40c52b,believes,0.362615
uuid-6b5b28febec94f829d6e837f5b40c52b,chemotherapy,0.614694
uuid-6b5b28febec94f829d6e837f5b40c52b,respond,0.339323
uuid-6b5b28febec94f829d6e837f5b40c52b,PD-1,0.404049
uuid-6b5b28febec94f829d6e837f5b40c52b,option,0.670326
uuid-6b5b28febec94f829d6e837f5b40c52b,biomarker,0.327349
uuid-b2c31df8d87141e4aca29ef8c4bc468a,TL,0.356235
uuid-b2c31df8d87141e4aca29ef8c4bc468a,BMS,0.408758
uuid-b2c31df8d87141e4aca29ef8c4bc468a,PDL1,0.419978
uuid-b2c31df8d87141e4aca29ef8c4bc468a,Merck,0.663513
uuid-b2c31df8d87141e4aca29ef8c4bc468a,PD-L1,0.494357
uuid-b2c31df8d87141e4aca29ef8c4bc468a,PD-L1 testing,0.41204
uuid-b2c31df8d87141e4aca29ef8c4bc468a,testing,0.469392
uuid-b2c31df8d87141e4aca29ef8c4bc468a,assay,0.70085
uuid-b2c31df8d87141e4aca29ef8c4bc468a,PDL1 expression,0.373085
uuid-b2c31df8d87141e4aca29ef8c4bc468a,biomarker,0.416514
uuid-e1c8505060cc4851852998beb0bba34b,Opdivo,0.555133
uuid-e1c8505060cc4851852998beb0bba34b,nivolumab,0.306825
uuid-e1c8505060cc4851852998beb0bba34b,treated,0.430544
uuid-e1c8505060cc4851852998beb0bba34b,shared,0.302917
uuid-e1c8505060cc4851852998beb0bba34b,commented,0.302005
uuid-e1c8505060cc4851852998beb0bba34b,RCC,0.30192
uuid-e1c8505060cc4851852998beb0bba34b,TL stated,0.347606
uuid-e1c8505060cc4851852998beb0bba34b,stated,0.351409
uuid-e1c8505060cc4851852998beb0bba34b,physicians,0.668108
uuid-e1c8505060cc4851852998beb0bba34b,treatment,0.331434
uuid-e1c8505060cc4851852998beb0bba34b,mentioned,0.305837
uuid-e1c8505060cc4851852998beb0bba34b,HCP,0.310877
uuid-e1c8505060cc4851852998beb0bba34b,Regional TL,0.423788
uuid-b245981d884743b98f797c00c59a4b93,BMS,0.361549
uuid-b245981d884743b98f797c00c59a4b93,Merck,0.498634
uuid-b245981d884743b98f797c00c59a4b93,institution,0.305152
uuid-b245981d884743b98f797c00c59a4b93,approval,0.310313
uuid-b245981d884743b98f797c00c59a4b93,PDL1 testing,0.32352
uuid-b245981d884743b98f797c00c59a4b93,indication,0.348214
uuid-b245981d884743b98f797c00c59a4b93,AI,0.310569
uuid-b245981d884743b98f797c00c59a4b93,approved,0.404782
uuid-b245981d884743b98f797c00c59a4b93,label,0.367743
uuid-b245981d884743b98f797c00c59a4b93,drug,0.356406
uuid-b245981d884743b98f797c00c59a4b93,Keytruda,0.342505
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,patients,0.468776
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,Opdivo,0.381885
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,therapy,0.532537
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,nivolumab,0.532922
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,toxicity,0.384538
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,treated,0.459407
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,treatment,0.48688
uuid-1dc4ed4105b943c7bfc6fbdebfd018b8,cHL,0.612209
uuid-f41ffd9c95c04eaab4ec0776823b7062,Nivo,0.612296
uuid-f41ffd9c95c04eaab4ec0776823b7062,patients,0.360304
uuid-f41ffd9c95c04eaab4ec0776823b7062,pembro,0.423257
uuid-f41ffd9c95c04eaab4ec0776823b7062,dose,0.458577
uuid-f41ffd9c95c04eaab4ec0776823b7062,efficacy,0.339872
uuid-f41ffd9c95c04eaab4ec0776823b7062,regimen,0.365603
uuid-f41ffd9c95c04eaab4ec0776823b7062,Ipi,0.498125
uuid-f41ffd9c95c04eaab4ec0776823b7062,atezo,0.353137
uuid-f41ffd9c95c04eaab4ec0776823b7062,monotherapy,0.314994
uuid-f41ffd9c95c04eaab4ec0776823b7062,using nivo,0.376217
uuid-f41ffd9c95c04eaab4ec0776823b7062,vs,0.511517
uuid-f41ffd9c95c04eaab4ec0776823b7062,feels,0.479528
uuid-4c2fdef6c50d4c28b48feabb93932594,patients,0.467248
uuid-4c2fdef6c50d4c28b48feabb93932594,therapy,0.314675
uuid-4c2fdef6c50d4c28b48feabb93932594,toxicity,0.31245
uuid-4c2fdef6c50d4c28b48feabb93932594,efficacy,0.315148
uuid-4c2fdef6c50d4c28b48feabb93932594,regimen,0.361411
uuid-4c2fdef6c50d4c28b48feabb93932594,chemo,0.440478
uuid-4c2fdef6c50d4c28b48feabb93932594,pts,0.438921
uuid-4c2fdef6c50d4c28b48feabb93932594,OS,0.354917
uuid-4c2fdef6c50d4c28b48feabb93932594,treatment,0.38467
uuid-4c2fdef6c50d4c28b48feabb93932594,response,0.60218
uuid-4c2fdef6c50d4c28b48feabb93932594,PFS,0.360269
uuid-4c2fdef6c50d4c28b48feabb93932594,ORR,0.321803
uuid-4c2fdef6c50d4c28b48feabb93932594,progression,0.58585
uuid-4c2fdef6c50d4c28b48feabb93932594,believes,0.325882
uuid-4c2fdef6c50d4c28b48feabb93932594,chemotherapy,0.356377
uuid-4c2fdef6c50d4c28b48feabb93932594,respond,0.640691
uuid-4c2fdef6c50d4c28b48feabb93932594,feels,0.481359
uuid-2fe38a52ae514ef58f741fe1804b3dde,TL,0.350701
uuid-2fe38a52ae514ef58f741fe1804b3dde,1L,0.441709
uuid-2fe38a52ae514ef58f741fe1804b3dde,TL stated,0.452756
uuid-2fe38a52ae514ef58f741fe1804b3dde,2L,0.386641
uuid-2fe38a52ae514ef58f741fe1804b3dde,PD-L1,0.570664
uuid-2fe38a52ae514ef58f741fe1804b3dde,approval,0.396258
uuid-2fe38a52ae514ef58f741fe1804b3dde,preferred,0.417315
uuid-2fe38a52ae514ef58f741fe1804b3dde,PD-L1 testing,0.700052
uuid-2fe38a52ae514ef58f741fe1804b3dde,testing,0.687713
uuid-2fe38a52ae514ef58f741fe1804b3dde,using nivo,0.311125
uuid-2fe38a52ae514ef58f741fe1804b3dde,PDL1 testing,0.681483
uuid-2fe38a52ae514ef58f741fe1804b3dde,NSCLC patients,0.614411
uuid-2fe38a52ae514ef58f741fe1804b3dde,approved,0.363133
uuid-2fe38a52ae514ef58f741fe1804b3dde,SCCHN,0.326571
uuid-2fe38a52ae514ef58f741fe1804b3dde,tumor types,0.313809
uuid-2fe38a52ae514ef58f741fe1804b3dde,assay,0.390586
uuid-2fe38a52ae514ef58f741fe1804b3dde,RTL stated,0.335847
uuid-2fe38a52ae514ef58f741fe1804b3dde,option,0.307404
uuid-e4f0528f1fd2483888f6f925ebc0f79e,TL,0.550036
uuid-e4f0528f1fd2483888f6f925ebc0f79e,pembro,0.466518
uuid-e4f0528f1fd2483888f6f925ebc0f79e,1L,0.420223
uuid-e4f0528f1fd2483888f6f925ebc0f79e,2L,0.42241
uuid-e4f0528f1fd2483888f6f925ebc0f79e,Merck,0.311594
uuid-e4f0528f1fd2483888f6f925ebc0f79e,PD-L1,0.311638
uuid-e4f0528f1fd2483888f6f925ebc0f79e,approval,0.486684
uuid-e4f0528f1fd2483888f6f925ebc0f79e,atezo,0.427796
uuid-e4f0528f1fd2483888f6f925ebc0f79e,preferred,0.374068
uuid-e4f0528f1fd2483888f6f925ebc0f79e,using nivo,0.441042
uuid-e4f0528f1fd2483888f6f925ebc0f79e,approved,0.413815
uuid-e4f0528f1fd2483888f6f925ebc0f79e,SCCHN,0.300735
uuid-e4f0528f1fd2483888f6f925ebc0f79e,assay,0.339282
uuid-e4f0528f1fd2483888f6f925ebc0f79e,RTL stated,0.353241
uuid-e4f0528f1fd2483888f6f925ebc0f79e,bladder,0.305873
uuid-a6fc7364d56449538151090037c40455,RTL,0.36208
uuid-a6fc7364d56449538151090037c40455,NSCLC,0.442007
uuid-a6fc7364d56449538151090037c40455,trial,0.357241
uuid-a6fc7364d56449538151090037c40455,NTL,0.373108
uuid-a6fc7364d56449538151090037c40455,discussed,0.548678
uuid-a6fc7364d56449538151090037c40455,commented,0.504158
uuid-a6fc7364d56449538151090037c40455,OS,0.39303
uuid-a6fc7364d56449538151090037c40455,regards,0.351093
uuid-a6fc7364d56449538151090037c40455,data,0.598647
uuid-a6fc7364d56449538151090037c40455,PFS,0.354205
uuid-a6fc7364d56449538151090037c40455,ORR,0.408861
uuid-a6fc7364d56449538151090037c40455,ASCO,0.541999
uuid-a6fc7364d56449538151090037c40455,impressed,0.52221
uuid-a6fc7364d56449538151090037c40455,TLs,0.422012
uuid-a6fc7364d56449538151090037c40455,academic,0.314526
uuid-a6fc7364d56449538151090037c40455,Regional TL,0.406804
uuid-b8b3e5e546184607937a5bf4472820b4,Opdivo,0.374305
uuid-b8b3e5e546184607937a5bf4472820b4,TL,0.383023
uuid-b8b3e5e546184607937a5bf4472820b4,PDL1,0.316312
uuid-b8b3e5e546184607937a5bf4472820b4,TL stated,0.330993
uuid-b8b3e5e546184607937a5bf4472820b4,Merck,0.337338
uuid-b8b3e5e546184607937a5bf4472820b4,PD-L1,0.623794
uuid-b8b3e5e546184607937a5bf4472820b4,approval,0.332759
uuid-b8b3e5e546184607937a5bf4472820b4,PD-L1 testing,0.547539
uuid-b8b3e5e546184607937a5bf4472820b4,testing,0.633326
uuid-b8b3e5e546184607937a5bf4472820b4,PDL1 testing,0.513929
uuid-b8b3e5e546184607937a5bf4472820b4,NSCLC patients,0.491228
uuid-b8b3e5e546184607937a5bf4472820b4,Keytruda,0.521271
uuid-b8b3e5e546184607937a5bf4472820b4,assay,0.570769
uuid-607b4263b2df4cd59740b803919abc91,RTL,0.377416
uuid-607b4263b2df4cd59740b803919abc91,trial,0.317439
uuid-607b4263b2df4cd59740b803919abc91,efficacy,0.399648
uuid-607b4263b2df4cd59740b803919abc91,commented,0.490033
uuid-607b4263b2df4cd59740b803919abc91,stated,0.311097
uuid-607b4263b2df4cd59740b803919abc91,OS,0.653288
uuid-607b4263b2df4cd59740b803919abc91,data,0.672578
uuid-607b4263b2df4cd59740b803919abc91,expressed,0.30825
uuid-607b4263b2df4cd59740b803919abc91,PFS,0.584743
uuid-607b4263b2df4cd59740b803919abc91,ORR,0.625449
uuid-607b4263b2df4cd59740b803919abc91,ASCO,0.446027
uuid-607b4263b2df4cd59740b803919abc91,impressed,0.664941
uuid-43741483519744b191c95259550f7ba6,patients,0.44682
uuid-43741483519744b191c95259550f7ba6,toxicity,0.367233
uuid-43741483519744b191c95259550f7ba6,regimen,0.338022
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,Nivo,0.320002
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,pembro,0.567248
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,RTL,0.327674
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,dose,0.496193
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,trial,0.400517
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,shared,0.324412
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,Ipi,0.377153
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,approval,0.339326
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,atezo,0.46681
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,preferred,0.314513
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,using nivo,0.393223
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,mentioned,0.34906
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,clinical trials,0.381911
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,indication,0.511465
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,approved,0.343531
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,SCCHN,0.356251
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,HCP,0.320607
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,vs,0.413959
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,label,0.343102
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,LTL,0.354091
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,Keytruda,0.332141
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,TLs,0.378775
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,bladder,0.350984
uuid-3c0be789ff07498eb7d0cb3e1cc5a2b4,flat dosing,0.65349
uuid-d9f78ca245f9421c90f376cc0f29fae7,RTL,0.554404
uuid-d9f78ca245f9421c90f376cc0f29fae7,nivolumab,0.44212
uuid-d9f78ca245f9421c90f376cc0f29fae7,1L,0.321454
uuid-d9f78ca245f9421c90f376cc0f29fae7,treated,0.380846
uuid-d9f78ca245f9421c90f376cc0f29fae7,commented,0.390979
uuid-d9f78ca245f9421c90f376cc0f29fae7,RCC,0.472733
uuid-d9f78ca245f9421c90f376cc0f29fae7,2L,0.333944
uuid-d9f78ca245f9421c90f376cc0f29fae7,stated,0.568952
uuid-d9f78ca245f9421c90f376cc0f29fae7,approval,0.556996
uuid-d9f78ca245f9421c90f376cc0f29fae7,preferred,0.390995
uuid-d9f78ca245f9421c90f376cc0f29fae7,using nivo,0.559349
uuid-d9f78ca245f9421c90f376cc0f29fae7,clinical trials,0.375271
uuid-d9f78ca245f9421c90f376cc0f29fae7,indication,0.417513
uuid-d9f78ca245f9421c90f376cc0f29fae7,approved,0.464802
uuid-d9f78ca245f9421c90f376cc0f29fae7,SCCHN,0.704831
uuid-d9f78ca245f9421c90f376cc0f29fae7,HCP,0.366571
uuid-d9f78ca245f9421c90f376cc0f29fae7,impressed,0.489481
uuid-d9f78ca245f9421c90f376cc0f29fae7,label,0.342598
uuid-d9f78ca245f9421c90f376cc0f29fae7,LTL,0.458238
uuid-d9f78ca245f9421c90f376cc0f29fae7,SCLC,0.391412
uuid-d9f78ca245f9421c90f376cc0f29fae7,Regional TL,0.578643
uuid-d9f78ca245f9421c90f376cc0f29fae7,RTL stated,0.602063
uuid-d9f78ca245f9421c90f376cc0f29fae7,TL shared,0.367795
uuid-d9f78ca245f9421c90f376cc0f29fae7,option,0.328633
uuid-d9f78ca245f9421c90f376cc0f29fae7,bladder,0.461707
uuid-e165abc87e2946f4ab0d98f048e052e3,Nivo,0.421741
uuid-e165abc87e2946f4ab0d98f048e052e3,patients,0.563401
uuid-e165abc87e2946f4ab0d98f048e052e3,Opdivo,0.467157
uuid-e165abc87e2946f4ab0d98f048e052e3,therapy,0.334972
uuid-e165abc87e2946f4ab0d98f048e052e3,dose,0.577609
uuid-e165abc87e2946f4ab0d98f048e052e3,nivolumab,0.462324
uuid-e165abc87e2946f4ab0d98f048e052e3,regimen,0.35997
uuid-e165abc87e2946f4ab0d98f048e052e3,pts,0.395858
uuid-e165abc87e2946f4ab0d98f048e052e3,Ipi,0.33733
uuid-e165abc87e2946f4ab0d98f048e052e3,treatment,0.379244
uuid-e165abc87e2946f4ab0d98f048e052e3,cHL,0.342138
uuid-e165abc87e2946f4ab0d98f048e052e3,vs,0.304596
uuid-e165abc87e2946f4ab0d98f048e052e3,flat dosing,0.382092
uuid-12224806e95d40ba84afa61cf3bd6998,TL,0.350259
uuid-12224806e95d40ba84afa61cf3bd6998,PDL1,0.775665
uuid-12224806e95d40ba84afa61cf3bd6998,Merck,0.343021
uuid-12224806e95d40ba84afa61cf3bd6998,PD-L1,0.797478
uuid-12224806e95d40ba84afa61cf3bd6998,PD-L1 testing,0.549415
uuid-12224806e95d40ba84afa61cf3bd6998,testing,0.686925
uuid-12224806e95d40ba84afa61cf3bd6998,PDL1 testing,0.477574
uuid-12224806e95d40ba84afa61cf3bd6998,NSCLC patients,0.420063
uuid-12224806e95d40ba84afa61cf3bd6998,nivo and pembro,0.354414
uuid-12224806e95d40ba84afa61cf3bd6998,assay,0.676134
uuid-12224806e95d40ba84afa61cf3bd6998,PDL1 expression,0.579892
uuid-12224806e95d40ba84afa61cf3bd6998,biomarker,0.710072
uuid-77743d35356b46d0a27995108a57383e,Nivo,0.308861
uuid-77743d35356b46d0a27995108a57383e,patients,0.513698
uuid-77743d35356b46d0a27995108a57383e,therapy,0.315775
uuid-77743d35356b46d0a27995108a57383e,nivolumab,0.374867
uuid-77743d35356b46d0a27995108a57383e,lung,0.302299
uuid-77743d35356b46d0a27995108a57383e,1L,0.511919
uuid-77743d35356b46d0a27995108a57383e,regimen,0.384517
uuid-77743d35356b46d0a27995108a57383e,treated,0.44644
uuid-77743d35356b46d0a27995108a57383e,melanoma,0.372508
uuid-77743d35356b46d0a27995108a57383e,RCC,0.519893
uuid-77743d35356b46d0a27995108a57383e,2L,0.544078
uuid-77743d35356b46d0a27995108a57383e,pts,0.405959
uuid-77743d35356b46d0a27995108a57383e,approval,0.400171
uuid-77743d35356b46d0a27995108a57383e,preferred,0.483466
uuid-77743d35356b46d0a27995108a57383e,monotherapy,0.426373
uuid-77743d35356b46d0a27995108a57383e,treatment,0.374476
uuid-77743d35356b46d0a27995108a57383e,using nivo,0.549588
uuid-77743d35356b46d0a27995108a57383e,combo,0.373964
uuid-77743d35356b46d0a27995108a57383e,approved,0.379732
uuid-77743d35356b46d0a27995108a57383e,SCCHN,0.437251
uuid-77743d35356b46d0a27995108a57383e,chemotherapy,0.30718
uuid-77743d35356b46d0a27995108a57383e,tumor types,0.317654
uuid-77743d35356b46d0a27995108a57383e,SCLC,0.30908
uuid-77743d35356b46d0a27995108a57383e,RTL stated,0.577607
uuid-77743d35356b46d0a27995108a57383e,TL shared,0.495205
uuid-77743d35356b46d0a27995108a57383e,option,0.449257
uuid-77743d35356b46d0a27995108a57383e,bladder,0.534808
uuid-42257404275c4977a1030cadf965cd3e,RTL,0.471717
uuid-42257404275c4977a1030cadf965cd3e,BMS,0.302632
uuid-42257404275c4977a1030cadf965cd3e,trial,0.360641
uuid-42257404275c4977a1030cadf965cd3e,discussed,0.308032
uuid-42257404275c4977a1030cadf965cd3e,shared,0.526452
uuid-42257404275c4977a1030cadf965cd3e,commented,0.495192
uuid-42257404275c4977a1030cadf965cd3e,stated,0.447265
uuid-42257404275c4977a1030cadf965cd3e,OS,0.304668
uuid-42257404275c4977a1030cadf965cd3e,data,0.657296
uuid-42257404275c4977a1030cadf965cd3e,expressed,0.394085
uuid-42257404275c4977a1030cadf965cd3e,clinical trials,0.317294
uuid-42257404275c4977a1030cadf965cd3e,ORR,0.305527
uuid-42257404275c4977a1030cadf965cd3e,SCCHN,0.388758
uuid-42257404275c4977a1030cadf965cd3e,ASCO,0.357957
uuid-42257404275c4977a1030cadf965cd3e,impressed,0.631681
uuid-42257404275c4977a1030cadf965cd3e,LTL,0.450896
uuid-42257404275c4977a1030cadf965cd3e,TLs,0.371049
uuid-42257404275c4977a1030cadf965cd3e,SCLC,0.312193
uuid-42257404275c4977a1030cadf965cd3e,Regional TL,0.493571
uuid-42257404275c4977a1030cadf965cd3e,RTL stated,0.312431
uuid-25db110c82614d48b01c5993606fdcef,patients,0.869231
uuid-25db110c82614d48b01c5993606fdcef,Opdivo,0.480367
uuid-25db110c82614d48b01c5993606fdcef,therapy,0.53919
uuid-25db110c82614d48b01c5993606fdcef,nivolumab,0.44574
uuid-25db110c82614d48b01c5993606fdcef,toxicity,0.520747
uuid-25db110c82614d48b01c5993606fdcef,regimen,0.691704
uuid-25db110c82614d48b01c5993606fdcef,treated,0.584693
uuid-25db110c82614d48b01c5993606fdcef,chemo,0.307014
uuid-25db110c82614d48b01c5993606fdcef,pts,0.539804
uuid-25db110c82614d48b01c5993606fdcef,monotherapy,0.362739
uuid-25db110c82614d48b01c5993606fdcef,treatment,0.759475
uuid-25db110c82614d48b01c5993606fdcef,response,0.437443
uuid-25db110c82614d48b01c5993606fdcef,progression,0.670433
uuid-25db110c82614d48b01c5993606fdcef,chemotherapy,0.36779
uuid-25db110c82614d48b01c5993606fdcef,respond,0.587701
uuid-1dd24c244a7246178dd7af2bdede700d,TL,0.489471
uuid-1dd24c244a7246178dd7af2bdede700d,TL stated,0.387098
uuid-1dd24c244a7246178dd7af2bdede700d,tumor,0.394074
uuid-1dd24c244a7246178dd7af2bdede700d,PD-L1,0.71487
uuid-1dd24c244a7246178dd7af2bdede700d,PD-L1 testing,0.781153
uuid-1dd24c244a7246178dd7af2bdede700d,testing,0.777501
uuid-1dd24c244a7246178dd7af2bdede700d,PDL1 testing,0.59877
uuid-1dd24c244a7246178dd7af2bdede700d,NSCLC patients,0.579635
uuid-1dd24c244a7246178dd7af2bdede700d,assay,0.585384
uuid-1dd24c244a7246178dd7af2bdede700d,biomarker,0.394181
uuid-f593e7acd48c4310b4231f5ba637a765,toxicity,0.48969
uuid-f593e7acd48c4310b4231f5ba637a765,regimen,0.418488
uuid-f593e7acd48c4310b4231f5ba637a765,combination,0.548786
uuid-f593e7acd48c4310b4231f5ba637a765,chemo,0.370706
uuid-f593e7acd48c4310b4231f5ba637a765,tumor,0.491383
uuid-f593e7acd48c4310b4231f5ba637a765,pts,0.346485
uuid-f593e7acd48c4310b4231f5ba637a765,IO,0.309583
uuid-f593e7acd48c4310b4231f5ba637a765,Ipi,0.327304
uuid-f593e7acd48c4310b4231f5ba637a765,monotherapy,0.315126
uuid-f593e7acd48c4310b4231f5ba637a765,treatment,0.310387
uuid-f593e7acd48c4310b4231f5ba637a765,response,0.43778
uuid-f593e7acd48c4310b4231f5ba637a765,combo,0.45581
uuid-f593e7acd48c4310b4231f5ba637a765,PD1,0.342884
uuid-f593e7acd48c4310b4231f5ba637a765,progression,0.398587
uuid-f593e7acd48c4310b4231f5ba637a765,chemotherapy,0.338834
uuid-f593e7acd48c4310b4231f5ba637a765,immunotherapy,0.34422
uuid-35657a9a0be54c09a07670ddae30e2b1,PDL1,0.344997
uuid-35657a9a0be54c09a07670ddae30e2b1,efficacy,0.435957
uuid-35657a9a0be54c09a07670ddae30e2b1,OS,0.357277
uuid-35657a9a0be54c09a07670ddae30e2b1,data,0.460862
uuid-35657a9a0be54c09a07670ddae30e2b1,PFS,0.323101
uuid-35657a9a0be54c09a07670ddae30e2b1,ORR,0.424264
uuid-35657a9a0be54c09a07670ddae30e2b1,impressed,0.300198
uuid-35657a9a0be54c09a07670ddae30e2b1,PDL1 expression,0.339417
uuid-fc9835d137114d818bd4fa9fe462054e,RTL,0.378245
uuid-fc9835d137114d818bd4fa9fe462054e,BMS,0.606578
uuid-fc9835d137114d818bd4fa9fe462054e,trial,0.645285
uuid-fc9835d137114d818bd4fa9fe462054e,efficacy,0.324964
uuid-fc9835d137114d818bd4fa9fe462054e,shared,0.393331
uuid-fc9835d137114d818bd4fa9fe462054e,commented,0.512702
uuid-fc9835d137114d818bd4fa9fe462054e,Merck,0.55011
uuid-fc9835d137114d818bd4fa9fe462054e,stated,0.415818
uuid-fc9835d137114d818bd4fa9fe462054e,OS,0.340183
uuid-fc9835d137114d818bd4fa9fe462054e,regards,0.305972
uuid-fc9835d137114d818bd4fa9fe462054e,data,0.736092
uuid-fc9835d137114d818bd4fa9fe462054e,expressed,0.499214
uuid-fc9835d137114d818bd4fa9fe462054e,clinical trials,0.419647
uuid-fc9835d137114d818bd4fa9fe462054e,PFS,0.329419
uuid-fc9835d137114d818bd4fa9fe462054e,ORR,0.381199
uuid-fc9835d137114d818bd4fa9fe462054e,ASCO,0.335251
uuid-fc9835d137114d818bd4fa9fe462054e,impressed,0.569487
uuid-fc9835d137114d818bd4fa9fe462054e,LTL,0.330614
uuid-fc9835d137114d818bd4fa9fe462054e,TLs,0.324493
uuid-fc9835d137114d818bd4fa9fe462054e,Regional TL,0.372403
uuid-fc9835d137114d818bd4fa9fe462054e,bladder,0.406011
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,TL,0.590241
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,PDL1,0.318851
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,TL stated,0.490005
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,Merck,0.352527
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,institution,0.443524
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,PD-L1,0.744668
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,PD-L1 testing,0.774431
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,testing,0.831026
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,PDL1 testing,0.706056
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,NSCLC patients,0.571107
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,assay,0.770253
uuid-1dd0f9f4f1c546f1bfe1bfb6a7bbb37c,biomarker,0.362837
uuid-1c603a4d9488412ab3e1a54af260f15f,patients,0.451328
uuid-1c603a4d9488412ab3e1a54af260f15f,RTL,0.489958
uuid-1c603a4d9488412ab3e1a54af260f15f,nivolumab,0.444245
uuid-1c603a4d9488412ab3e1a54af260f15f,treated,0.613645
uuid-1c603a4d9488412ab3e1a54af260f15f,NTL,0.410544
uuid-1c603a4d9488412ab3e1a54af260f15f,melanoma,0.466308
uuid-1c603a4d9488412ab3e1a54af260f15f,shared,0.433191
uuid-1c603a4d9488412ab3e1a54af260f15f,RCC,0.387608
uuid-1c603a4d9488412ab3e1a54af260f15f,pts,0.353927
uuid-1c603a4d9488412ab3e1a54af260f15f,clinical trials,0.451889
uuid-1c603a4d9488412ab3e1a54af260f15f,SCCHN,0.429867
uuid-1c603a4d9488412ab3e1a54af260f15f,academic,0.338959
uuid-1c603a4d9488412ab3e1a54af260f15f,Regional TL,0.405759
uuid-1c603a4d9488412ab3e1a54af260f15f,RTL stated,0.442253
uuid-1c603a4d9488412ab3e1a54af260f15f,TL shared,0.426589
uuid-1c603a4d9488412ab3e1a54af260f15f,bladder,0.31718
uuid-3f65b2900b2c4a379943385b557bcbe5,PDL1,0.344997
uuid-3f65b2900b2c4a379943385b557bcbe5,efficacy,0.435957
uuid-3f65b2900b2c4a379943385b557bcbe5,OS,0.357277
uuid-3f65b2900b2c4a379943385b557bcbe5,data,0.460862
uuid-3f65b2900b2c4a379943385b557bcbe5,PFS,0.323101
uuid-3f65b2900b2c4a379943385b557bcbe5,ORR,0.424264
uuid-3f65b2900b2c4a379943385b557bcbe5,impressed,0.300198
uuid-3f65b2900b2c4a379943385b557bcbe5,PDL1 expression,0.339417
uuid-1bd9152207fa4847a9d24b401fc4545c,TL,0.553434
uuid-1bd9152207fa4847a9d24b401fc4545c,shared,0.348752
uuid-1bd9152207fa4847a9d24b401fc4545c,TL stated,0.507866
uuid-1bd9152207fa4847a9d24b401fc4545c,institution,0.470893
uuid-1bd9152207fa4847a9d24b401fc4545c,PD-L1,0.484766
uuid-1bd9152207fa4847a9d24b401fc4545c,physicians,0.398374
uuid-1bd9152207fa4847a9d24b401fc4545c,PD-L1 testing,0.682713
uuid-1bd9152207fa4847a9d24b401fc4545c,testing,0.619027
uuid-1bd9152207fa4847a9d24b401fc4545c,PDL1 testing,0.617379
uuid-1bd9152207fa4847a9d24b401fc4545c,NSCLC patients,0.460479
uuid-1bd9152207fa4847a9d24b401fc4545c,assay,0.420172
uuid-cda4d4a6e63e49a5ab638ec6b8687278,patients,0.687547
uuid-cda4d4a6e63e49a5ab638ec6b8687278,Opdivo,0.342699
uuid-cda4d4a6e63e49a5ab638ec6b8687278,therapy,0.357634
uuid-cda4d4a6e63e49a5ab638ec6b8687278,nivolumab,0.329647
uuid-cda4d4a6e63e49a5ab638ec6b8687278,toxicity,0.31134
uuid-cda4d4a6e63e49a5ab638ec6b8687278,regimen,0.49995
uuid-cda4d4a6e63e49a5ab638ec6b8687278,treated,0.583391
uuid-cda4d4a6e63e49a5ab638ec6b8687278,pts,0.345628
uuid-cda4d4a6e63e49a5ab638ec6b8687278,treatment,0.706461
uuid-cda4d4a6e63e49a5ab638ec6b8687278,progression,0.416685
uuid-cda4d4a6e63e49a5ab638ec6b8687278,respond,0.404597
uuid-a118850677554bcf97d56b669202e408,Nivo,0.329759
uuid-a118850677554bcf97d56b669202e408,nivolumab,0.417089
uuid-a118850677554bcf97d56b669202e408,toxicity,0.404907
uuid-a118850677554bcf97d56b669202e408,regimen,0.573327
uuid-a118850677554bcf97d56b669202e408,treated,0.327548
uuid-a118850677554bcf97d56b669202e408,shared,0.365184
uuid-a118850677554bcf97d56b669202e408,combination,0.64173
uuid-a118850677554bcf97d56b669202e408,chemo,0.368995
uuid-a118850677554bcf97d56b669202e408,IO,0.30932
uuid-a118850677554bcf97d56b669202e408,agents,0.305048
uuid-a118850677554bcf97d56b669202e408,Ipi,0.436724
uuid-a118850677554bcf97d56b669202e408,monotherapy,0.516933
uuid-a118850677554bcf97d56b669202e408,treatment,0.318391
uuid-a118850677554bcf97d56b669202e408,response,0.328009
uuid-a118850677554bcf97d56b669202e408,combo,0.594605
uuid-a118850677554bcf97d56b669202e408,PD1,0.436025
uuid-a118850677554bcf97d56b669202e408,progression,0.356388
uuid-a118850677554bcf97d56b669202e408,chemotherapy,0.393895
uuid-a118850677554bcf97d56b669202e408,impressed,0.306069
uuid-a118850677554bcf97d56b669202e408,feels,0.452512
uuid-a118850677554bcf97d56b669202e408,option,0.332256
uuid-aac56f5dd5704adcaebae18891e3fa8e,patients,0.355253
uuid-aac56f5dd5704adcaebae18891e3fa8e,BMS,0.376594
uuid-aac56f5dd5704adcaebae18891e3fa8e,shared,0.349037
uuid-aac56f5dd5704adcaebae18891e3fa8e,stated,0.318027
uuid-aac56f5dd5704adcaebae18891e3fa8e,approval,0.371059
uuid-aac56f5dd5704adcaebae18891e3fa8e,physicians,0.32293
uuid-aac56f5dd5704adcaebae18891e3fa8e,clinical trials,0.429129
uuid-aac56f5dd5704adcaebae18891e3fa8e,approved,0.400454
uuid-aac56f5dd5704adcaebae18891e3fa8e,tumor types,0.332334
uuid-4d4277cd879444a1820abbf8fddb7be4,patients,0.725383
uuid-4d4277cd879444a1820abbf8fddb7be4,Opdivo,0.464559
uuid-4d4277cd879444a1820abbf8fddb7be4,therapy,0.555435
uuid-4d4277cd879444a1820abbf8fddb7be4,nivolumab,0.606569
uuid-4d4277cd879444a1820abbf8fddb7be4,regimen,0.308682
uuid-4d4277cd879444a1820abbf8fddb7be4,treated,0.524321
uuid-4d4277cd879444a1820abbf8fddb7be4,pts,0.307436
uuid-4d4277cd879444a1820abbf8fddb7be4,approval,0.340537
uuid-4d4277cd879444a1820abbf8fddb7be4,monotherapy,0.304774
uuid-4d4277cd879444a1820abbf8fddb7be4,treatment,0.544746
uuid-4d4277cd879444a1820abbf8fddb7be4,using nivo,0.412996
uuid-4d4277cd879444a1820abbf8fddb7be4,cHL,0.509828
uuid-4d4277cd879444a1820abbf8fddb7be4,progression,0.39446
uuid-4d4277cd879444a1820abbf8fddb7be4,chemotherapy,0.406325
uuid-4d4277cd879444a1820abbf8fddb7be4,RTL stated,0.332278
uuid-4d4277cd879444a1820abbf8fddb7be4,option,0.357232
uuid-a9fb80b6524f4d5fa29ec131f77cfa87,TL,0.318159
uuid-a9fb80b6524f4d5fa29ec131f77cfa87,PD-L1,0.350914
uuid-a9fb80b6524f4d5fa29ec131f77cfa87,PD-L1 testing,0.309689
uuid-a9fb80b6524f4d5fa29ec131f77cfa87,assay,0.403615
uuid-a9fb80b6524f4d5fa29ec131f77cfa87,biomarker,0.357966
uuid-8791a21caa2a461796c6c4668ff32697,trial,0.386973
uuid-8791a21caa2a461796c6c4668ff32697,efficacy,0.44585
uuid-8791a21caa2a461796c6c4668ff32697,commented,0.304089
uuid-8791a21caa2a461796c6c4668ff32697,OS,0.495189
uuid-8791a21caa2a461796c6c4668ff32697,data,0.573667
uuid-8791a21caa2a461796c6c4668ff32697,PFS,0.433639
uuid-8791a21caa2a461796c6c4668ff32697,ORR,0.524603
uuid-8791a21caa2a461796c6c4668ff32697,ASCO,0.393274
uuid-8791a21caa2a461796c6c4668ff32697,impressed,0.585078
uuid-8791a21caa2a461796c6c4668ff32697,indicated,0.35034
uuid-0fb1a0e623ab44178f22254c1c96f5bf,Nivo,0.419485
uuid-0fb1a0e623ab44178f22254c1c96f5bf,patients,0.395101
uuid-0fb1a0e623ab44178f22254c1c96f5bf,Opdivo,0.311985
uuid-0fb1a0e623ab44178f22254c1c96f5bf,pembro,0.405457
uuid-0fb1a0e623ab44178f22254c1c96f5bf,nivolumab,0.408319
uuid-0fb1a0e623ab44178f22254c1c96f5bf,1L,0.472031
uuid-0fb1a0e623ab44178f22254c1c96f5bf,regimen,0.423754
uuid-0fb1a0e623ab44178f22254c1c96f5bf,combination,0.51749
uuid-0fb1a0e623ab44178f22254c1c96f5bf,chemo,0.357009
uuid-0fb1a0e623ab44178f22254c1c96f5bf,2L,0.509741
uuid-0fb1a0e623ab44178f22254c1c96f5bf,agents,0.39323
uuid-0fb1a0e623ab44178f22254c1c96f5bf,Ipi,0.312597
uuid-0fb1a0e623ab44178f22254c1c96f5bf,approval,0.421869
uuid-0fb1a0e623ab44178f22254c1c96f5bf,atezo,0.305453
uuid-0fb1a0e623ab44178f22254c1c96f5bf,preferred,0.512552
uuid-0fb1a0e623ab44178f22254c1c96f5bf,monotherapy,0.562354
uuid-0fb1a0e623ab44178f22254c1c96f5bf,using nivo,0.483515
uuid-0fb1a0e623ab44178f22254c1c96f5bf,combo,0.55976
uuid-0fb1a0e623ab44178f22254c1c96f5bf,clinical trials,0.337065
uuid-0fb1a0e623ab44178f22254c1c96f5bf,indication,0.342913
uuid-0fb1a0e623ab44178f22254c1c96f5bf,approved,0.62122
uuid-0fb1a0e623ab44178f22254c1c96f5bf,chemotherapy,0.37083
uuid-0fb1a0e623ab44178f22254c1c96f5bf,feels,0.359262
uuid-0fb1a0e623ab44178f22254c1c96f5bf,RTL stated,0.376799
uuid-0fb1a0e623ab44178f22254c1c96f5bf,option,0.571343
uuid-758a19e5cb244c208bdf745037e654cf,regards,0.300307
uuid-4515392d21804330b1e7d1b1593c4b40,Opdivo,0.316464
uuid-4515392d21804330b1e7d1b1593c4b40,RTL,0.386562
uuid-4515392d21804330b1e7d1b1593c4b40,therapy,0.376324
uuid-4515392d21804330b1e7d1b1593c4b40,nivolumab,0.554016
uuid-4515392d21804330b1e7d1b1593c4b40,regimen,0.320788
uuid-4515392d21804330b1e7d1b1593c4b40,NTL,0.367222
uuid-4515392d21804330b1e7d1b1593c4b40,combination,0.588284
uuid-4515392d21804330b1e7d1b1593c4b40,combo,0.342732
uuid-4515392d21804330b1e7d1b1593c4b40,PD1,0.357222
uuid-4515392d21804330b1e7d1b1593c4b40,cHL,0.42882
uuid-4515392d21804330b1e7d1b1593c4b40,chemotherapy,0.395957
uuid-3d55edcaaa354339a50dc7c42da70593,Nivo,0.421113
uuid-3d55edcaaa354339a50dc7c42da70593,trial,0.66674
uuid-3d55edcaaa354339a50dc7c42da70593,efficacy,0.515456
uuid-3d55edcaaa354339a50dc7c42da70593,chemo,0.418834
uuid-3d55edcaaa354339a50dc7c42da70593,Ipi,0.339075
uuid-3d55edcaaa354339a50dc7c42da70593,OS,0.692637
uuid-3d55edcaaa354339a50dc7c42da70593,data,0.435851
uuid-3d55edcaaa354339a50dc7c42da70593,PFS,0.704951
uuid-3d55edcaaa354339a50dc7c42da70593,ORR,0.668875
uuid-3d55edcaaa354339a50dc7c42da70593,nivo and pembro,0.33905
uuid-3d55edcaaa354339a50dc7c42da70593,chemotherapy,0.447277
uuid-3d55edcaaa354339a50dc7c42da70593,impressed,0.38095
uuid-3d55edcaaa354339a50dc7c42da70593,feels,0.330334
uuid-9435c0fb13f94fb99c8daebddbc3425e,OS,0.493183
uuid-9435c0fb13f94fb99c8daebddbc3425e,data,0.634873
uuid-9435c0fb13f94fb99c8daebddbc3425e,PFS,0.446617
uuid-9435c0fb13f94fb99c8daebddbc3425e,ORR,0.458856
uuid-9435c0fb13f94fb99c8daebddbc3425e,impressed,0.526553
uuid-9435c0fb13f94fb99c8daebddbc3425e,feels,0.393908
uuid-5f71b5b243f24ae1b19777811d3339f1,PDL1,0.335028
uuid-5f71b5b243f24ae1b19777811d3339f1,trial,0.462079
uuid-5f71b5b243f24ae1b19777811d3339f1,efficacy,0.479099
uuid-5f71b5b243f24ae1b19777811d3339f1,commented,0.380358
uuid-5f71b5b243f24ae1b19777811d3339f1,OS,0.656712
uuid-5f71b5b243f24ae1b19777811d3339f1,data,0.878612
uuid-5f71b5b243f24ae1b19777811d3339f1,PFS,0.652535
uuid-5f71b5b243f24ae1b19777811d3339f1,ORR,0.694468
uuid-5f71b5b243f24ae1b19777811d3339f1,nivo and pembro,0.365289
uuid-5f71b5b243f24ae1b19777811d3339f1,ASCO,0.446242
uuid-5f71b5b243f24ae1b19777811d3339f1,impressed,0.693035
uuid-5f71b5b243f24ae1b19777811d3339f1,feels,0.322386
uuid-5f71b5b243f24ae1b19777811d3339f1,PDL1 expression,0.350112
uuid-52dcf96223954102905079137e4fed47,Nivo,0.484863
uuid-52dcf96223954102905079137e4fed47,Opdivo,0.366681
uuid-52dcf96223954102905079137e4fed47,therapy,0.40191
uuid-52dcf96223954102905079137e4fed47,nivolumab,0.348046
uuid-52dcf96223954102905079137e4fed47,mentioned,0.315938
uuid-52dcf96223954102905079137e4fed47,cHL,0.622201
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,TL,0.366614
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,pembro,0.417977
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,BMS,0.32291
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,1L,0.350245
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PDL1,0.689697
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,efficacy,0.340101
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,commented,0.311031
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,Merck,0.432692
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,stated,0.331586
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PD-L1,0.564105
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,OS,0.411971
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,atezo,0.408744
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PD-L1 testing,0.344834
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,testing,0.427537
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,data,0.687098
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PDL1 testing,0.377462
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PFS,0.379604
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,NSCLC patients,0.31317
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,ORR,0.432268
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,nivo and pembro,0.45256
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,impressed,0.472518
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,TLs,0.329866
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,assay,0.455673
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,PDL1 expression,0.50702
uuid-dd84afb69f1342a8942f5b25ee0c9ae2,biomarker,0.414894
uuid-9720682bee8a4f928f3ef3e8345dfe7f,Nivo,0.611843
uuid-9720682bee8a4f928f3ef3e8345dfe7f,patients,0.492318
uuid-9720682bee8a4f928f3ef3e8345dfe7f,therapy,0.663567
uuid-9720682bee8a4f928f3ef3e8345dfe7f,nivolumab,0.490881
uuid-9720682bee8a4f928f3ef3e8345dfe7f,combination,0.399926
uuid-9720682bee8a4f928f3ef3e8345dfe7f,chemo,0.408229
uuid-9720682bee8a4f928f3ef3e8345dfe7f,Ipi,0.308651
uuid-9720682bee8a4f928f3ef3e8345dfe7f,monotherapy,0.400351
uuid-9720682bee8a4f928f3ef3e8345dfe7f,treatment,0.351273
uuid-9720682bee8a4f928f3ef3e8345dfe7f,using nivo,0.388601
uuid-9720682bee8a4f928f3ef3e8345dfe7f,PD1,0.432697
uuid-9720682bee8a4f928f3ef3e8345dfe7f,cHL,0.485207
uuid-9720682bee8a4f928f3ef3e8345dfe7f,chemotherapy,0.570804
uuid-9720682bee8a4f928f3ef3e8345dfe7f,option,0.37134
uuid-a135038df63146f6ac50b295acec19a6,patients,0.421433
uuid-a135038df63146f6ac50b295acec19a6,Opdivo,0.398404
uuid-a135038df63146f6ac50b295acec19a6,physicians,0.57764
uuid-a135038df63146f6ac50b295acec19a6,treatment,0.483903
uuid-3cc545ed79654b00ac98c74ceb37d469,Nivo,0.390308
uuid-3cc545ed79654b00ac98c74ceb37d469,patients,0.410501
uuid-3cc545ed79654b00ac98c74ceb37d469,Opdivo,0.380013
uuid-3cc545ed79654b00ac98c74ceb37d469,therapy,0.461135
uuid-3cc545ed79654b00ac98c74ceb37d469,nivolumab,0.391981
uuid-3cc545ed79654b00ac98c74ceb37d469,approval,0.412964
uuid-3cc545ed79654b00ac98c74ceb37d469,mentioned,0.308681
uuid-3cc545ed79654b00ac98c74ceb37d469,cHL,0.708926
uuid-3cc545ed79654b00ac98c74ceb37d469,label,0.331238
uuid-077ef6c1d30b446b9ac809ddf1175062,Nivo,0.300876
uuid-077ef6c1d30b446b9ac809ddf1175062,patients,0.779765
uuid-077ef6c1d30b446b9ac809ddf1175062,therapy,0.797469
uuid-077ef6c1d30b446b9ac809ddf1175062,nivolumab,0.404198
uuid-077ef6c1d30b446b9ac809ddf1175062,1L,0.301907
uuid-077ef6c1d30b446b9ac809ddf1175062,regimen,0.561726
uuid-077ef6c1d30b446b9ac809ddf1175062,treated,0.513348
uuid-077ef6c1d30b446b9ac809ddf1175062,combination,0.322555
uuid-077ef6c1d30b446b9ac809ddf1175062,chemo,0.61135
uuid-077ef6c1d30b446b9ac809ddf1175062,pts,0.654268
uuid-077ef6c1d30b446b9ac809ddf1175062,IO,0.327193
uuid-077ef6c1d30b446b9ac809ddf1175062,monotherapy,0.569178
uuid-077ef6c1d30b446b9ac809ddf1175062,treatment,0.743068
uuid-077ef6c1d30b446b9ac809ddf1175062,response,0.663691
uuid-077ef6c1d30b446b9ac809ddf1175062,PD1,0.581648
uuid-077ef6c1d30b446b9ac809ddf1175062,progression,0.876765
uuid-077ef6c1d30b446b9ac809ddf1175062,chemotherapy,0.57584
uuid-077ef6c1d30b446b9ac809ddf1175062,respond,0.602519
uuid-077ef6c1d30b446b9ac809ddf1175062,option,0.493341
uuid-a9f5165ecd1f4387b302a0dfd981de6d,RTL,0.316337
uuid-a9f5165ecd1f4387b302a0dfd981de6d,BMS,0.321668
uuid-a9f5165ecd1f4387b302a0dfd981de6d,trial,0.307712
uuid-a9f5165ecd1f4387b302a0dfd981de6d,shared,0.35848
uuid-a9f5165ecd1f4387b302a0dfd981de6d,commented,0.455142
uuid-a9f5165ecd1f4387b302a0dfd981de6d,stated,0.350784
uuid-a9f5165ecd1f4387b302a0dfd981de6d,OS,0.339363
uuid-a9f5165ecd1f4387b302a0dfd981de6d,data,0.624554
uuid-a9f5165ecd1f4387b302a0dfd981de6d,expressed,0.401269
uuid-a9f5165ecd1f4387b302a0dfd981de6d,mentioned,0.322536
uuid-a9f5165ecd1f4387b302a0dfd981de6d,indication,0.424921
uuid-a9f5165ecd1f4387b302a0dfd981de6d,SCCHN,0.346938
uuid-a9f5165ecd1f4387b302a0dfd981de6d,impressed,0.546104
uuid-a9f5165ecd1f4387b302a0dfd981de6d,LTL,0.35666
uuid-a9f5165ecd1f4387b302a0dfd981de6d,Regional TL,0.334275
uuid-9da6c0190f5b45a3aa959ded4d457362,combination,0.55247
uuid-9da6c0190f5b45a3aa959ded4d457362,chemo,0.375267
uuid-9da6c0190f5b45a3aa959ded4d457362,tumor,0.348248
uuid-9da6c0190f5b45a3aa959ded4d457362,Ipi,0.304102
uuid-9da6c0190f5b45a3aa959ded4d457362,response,0.57972
uuid-9da6c0190f5b45a3aa959ded4d457362,combo,0.378208
uuid-9da6c0190f5b45a3aa959ded4d457362,PD1,0.332083
uuid-9da6c0190f5b45a3aa959ded4d457362,immunotherapy,0.410505
uuid-ed3b4db622164379bc05ec17f13ed9b3,Nivo,0.612832
uuid-ed3b4db622164379bc05ec17f13ed9b3,therapy,0.508176
uuid-ed3b4db622164379bc05ec17f13ed9b3,nivolumab,0.313604
uuid-ed3b4db622164379bc05ec17f13ed9b3,trial,0.422037
uuid-ed3b4db622164379bc05ec17f13ed9b3,combination,0.576957
uuid-ed3b4db622164379bc05ec17f13ed9b3,chemo,0.566017
uuid-ed3b4db622164379bc05ec17f13ed9b3,agents,0.396207
uuid-ed3b4db622164379bc05ec17f13ed9b3,Ipi,0.38036
uuid-ed3b4db622164379bc05ec17f13ed9b3,monotherapy,0.502101
uuid-ed3b4db622164379bc05ec17f13ed9b3,response,0.350332
uuid-ed3b4db622164379bc05ec17f13ed9b3,combo,0.496008
uuid-ed3b4db622164379bc05ec17f13ed9b3,PD1,0.537784
uuid-ed3b4db622164379bc05ec17f13ed9b3,nivo and pembro,0.32889
uuid-ed3b4db622164379bc05ec17f13ed9b3,believes,0.39255
uuid-ed3b4db622164379bc05ec17f13ed9b3,chemotherapy,0.557732
uuid-ed3b4db622164379bc05ec17f13ed9b3,feels,0.36916
uuid-ed3b4db622164379bc05ec17f13ed9b3,option,0.418323
uuid-b4bee9b0e8974f2cbc9396302c369bb6,Nivo,0.381764
uuid-b4bee9b0e8974f2cbc9396302c369bb6,pembro,0.451
uuid-b4bee9b0e8974f2cbc9396302c369bb6,BMS,0.308969
uuid-b4bee9b0e8974f2cbc9396302c369bb6,1L,0.449152
uuid-b4bee9b0e8974f2cbc9396302c369bb6,trial,0.508537
uuid-b4bee9b0e8974f2cbc9396302c369bb6,efficacy,0.355331
uuid-b4bee9b0e8974f2cbc9396302c369bb6,combination,0.388411
uuid-b4bee9b0e8974f2cbc9396302c369bb6,chemo,0.387292
uuid-b4bee9b0e8974f2cbc9396302c369bb6,2L,0.356098
uuid-b4bee9b0e8974f2cbc9396302c369bb6,agents,0.339629
uuid-b4bee9b0e8974f2cbc9396302c369bb6,Ipi,0.322881
uuid-b4bee9b0e8974f2cbc9396302c369bb6,OS,0.373142
uuid-b4bee9b0e8974f2cbc9396302c369bb6,atezo,0.350184
uuid-b4bee9b0e8974f2cbc9396302c369bb6,monotherapy,0.399417
uuid-b4bee9b0e8974f2cbc9396302c369bb6,data,0.377862
uuid-b4bee9b0e8974f2cbc9396302c369bb6,combo,0.423061
uuid-b4bee9b0e8974f2cbc9396302c369bb6,clinical trials,0.369987
uuid-b4bee9b0e8974f2cbc9396302c369bb6,indication,0.356076
uuid-b4bee9b0e8974f2cbc9396302c369bb6,PFS,0.34671
uuid-b4bee9b0e8974f2cbc9396302c369bb6,ORR,0.345341
uuid-b4bee9b0e8974f2cbc9396302c369bb6,approved,0.443989
uuid-b4bee9b0e8974f2cbc9396302c369bb6,nivo and pembro,0.392815
uuid-b4bee9b0e8974f2cbc9396302c369bb6,believes,0.424398
uuid-b4bee9b0e8974f2cbc9396302c369bb6,chemotherapy,0.341087
uuid-b4bee9b0e8974f2cbc9396302c369bb6,impressed,0.315045
uuid-b4bee9b0e8974f2cbc9396302c369bb6,SCLC,0.3581
uuid-b4bee9b0e8974f2cbc9396302c369bb6,feels,0.490143
uuid-b4bee9b0e8974f2cbc9396302c369bb6,option,0.450738
uuid-129ed77d25b7459080c1ae755abedea7,Nivo,0.369236
uuid-129ed77d25b7459080c1ae755abedea7,pembro,0.339979
uuid-129ed77d25b7459080c1ae755abedea7,lung,0.542481
uuid-129ed77d25b7459080c1ae755abedea7,1L,0.387975
uuid-129ed77d25b7459080c1ae755abedea7,efficacy,0.353923
uuid-129ed77d25b7459080c1ae755abedea7,melanoma,0.425863
uuid-129ed77d25b7459080c1ae755abedea7,RCC,0.356484
uuid-129ed77d25b7459080c1ae755abedea7,2L,0.397363
uuid-129ed77d25b7459080c1ae755abedea7,agents,0.320263
uuid-129ed77d25b7459080c1ae755abedea7,OS,0.316478
uuid-129ed77d25b7459080c1ae755abedea7,atezo,0.372356
uuid-129ed77d25b7459080c1ae755abedea7,regards,0.347487
uuid-129ed77d25b7459080c1ae755abedea7,PFS,0.314722
uuid-129ed77d25b7459080c1ae755abedea7,AI,0.618323
uuid-129ed77d25b7459080c1ae755abedea7,nivo and pembro,0.568821
uuid-129ed77d25b7459080c1ae755abedea7,believes,0.406102
uuid-1d5c20a03d714ddbba572447605f4f4f,patients,0.314165
uuid-1d5c20a03d714ddbba572447605f4f4f,NSCLC,0.371927
uuid-1d5c20a03d714ddbba572447605f4f4f,treated,0.351734
uuid-1d5c20a03d714ddbba572447605f4f4f,melanoma,0.310985
uuid-1d5c20a03d714ddbba572447605f4f4f,tumor,0.541752
uuid-1d5c20a03d714ddbba572447605f4f4f,pts,0.416552
uuid-1d5c20a03d714ddbba572447605f4f4f,IO,0.358093
uuid-1d5c20a03d714ddbba572447605f4f4f,treatment,0.315257
uuid-1d5c20a03d714ddbba572447605f4f4f,response,0.591108
uuid-1d5c20a03d714ddbba572447605f4f4f,progression,0.544885
uuid-1d5c20a03d714ddbba572447605f4f4f,respond,0.34956
uuid-1d5c20a03d714ddbba572447605f4f4f,TL shared,0.334258
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,pembro,0.462931
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,dose,0.60755
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,trial,0.320678
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,efficacy,0.325404
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,Merck,0.359895
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,Ipi,0.335966
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,atezo,0.388425
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,vs,0.636054
uuid-ba5b20e6fa6c420cb9ac31ed9bddc103,flat dosing,0.555286
uuid-b8fca8dcead3486cbaee275669f78327,patients,0.369407
uuid-b8fca8dcead3486cbaee275669f78327,regimen,0.483595
uuid-b8fca8dcead3486cbaee275669f78327,treated,0.373043
uuid-b8fca8dcead3486cbaee275669f78327,OS,0.303305
uuid-b8fca8dcead3486cbaee275669f78327,treatment,0.360256
uuid-b8fca8dcead3486cbaee275669f78327,progression,0.377811
uuid-b8fca8dcead3486cbaee275669f78327,impressed,0.515678
uuid-b8fca8dcead3486cbaee275669f78327,respond,0.38766
uuid-b8fca8dcead3486cbaee275669f78327,feels,0.373461
uuid-fc9772520f724f55ad67e9ab405803a4,PDL1,0.303443
uuid-fc9772520f724f55ad67e9ab405803a4,efficacy,0.443477
uuid-fc9772520f724f55ad67e9ab405803a4,regimen,0.306285
uuid-fc9772520f724f55ad67e9ab405803a4,chemo,0.377205
uuid-fc9772520f724f55ad67e9ab405803a4,OS,0.490676
uuid-fc9772520f724f55ad67e9ab405803a4,regards,0.316651
uuid-fc9772520f724f55ad67e9ab405803a4,response,0.432442
uuid-fc9772520f724f55ad67e9ab405803a4,PFS,0.478438
uuid-fc9772520f724f55ad67e9ab405803a4,ORR,0.53401
uuid-fc9772520f724f55ad67e9ab405803a4,nivo and pembro,0.303304
uuid-fc9772520f724f55ad67e9ab405803a4,believes,0.407517
uuid-fc9772520f724f55ad67e9ab405803a4,impressed,0.329038
uuid-fc9772520f724f55ad67e9ab405803a4,respond,0.383179
uuid-fc9772520f724f55ad67e9ab405803a4,PDL1 expression,0.303798
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,lung,0.609202
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,regimen,0.326149
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,treated,0.50868
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,melanoma,0.635217
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,commented,0.353739
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,RCC,0.576365
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,TL stated,0.465614
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,SCCHN,0.417787
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,progression,0.333225
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,TLs,0.391266
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,Regional TL,0.385796
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,RTL stated,0.421426
uuid-4e3b9cb10bd94a8ba49fb4b8150b4f73,TL shared,0.628447
uuid-b0af0903ba524dfb94917f36950116e4,PDL1,0.326325
uuid-b0af0903ba524dfb94917f36950116e4,trial,0.483452
uuid-b0af0903ba524dfb94917f36950116e4,efficacy,0.309737
uuid-b0af0903ba524dfb94917f36950116e4,OS,0.36033
uuid-b0af0903ba524dfb94917f36950116e4,data,0.498347
uuid-b0af0903ba524dfb94917f36950116e4,PFS,0.346299
uuid-b0af0903ba524dfb94917f36950116e4,ORR,0.403814
uuid-b0af0903ba524dfb94917f36950116e4,impressed,0.416192
uuid-b0af0903ba524dfb94917f36950116e4,feels,0.375401
uuid-5a11bdbfb41e4103809d9459e370c838,lung,0.303406
uuid-5a11bdbfb41e4103809d9459e370c838,efficacy,0.304463
uuid-5a11bdbfb41e4103809d9459e370c838,regimen,0.407483
uuid-5a11bdbfb41e4103809d9459e370c838,melanoma,0.367588
uuid-5a11bdbfb41e4103809d9459e370c838,RCC,0.303546
uuid-5a11bdbfb41e4103809d9459e370c838,combination,0.443518
uuid-5a11bdbfb41e4103809d9459e370c838,chemo,0.372542
uuid-5a11bdbfb41e4103809d9459e370c838,pts,0.327222
uuid-5a11bdbfb41e4103809d9459e370c838,monotherapy,0.379736
uuid-5a11bdbfb41e4103809d9459e370c838,response,0.405493
uuid-5a11bdbfb41e4103809d9459e370c838,combo,0.494858
uuid-5a11bdbfb41e4103809d9459e370c838,PD1,0.422813
uuid-5a11bdbfb41e4103809d9459e370c838,ORR,0.325476
uuid-5a11bdbfb41e4103809d9459e370c838,progression,0.357181
uuid-5a11bdbfb41e4103809d9459e370c838,believes,0.443456
uuid-5a11bdbfb41e4103809d9459e370c838,chemotherapy,0.310111
uuid-5a11bdbfb41e4103809d9459e370c838,SCLC,0.455395
uuid-0bd622e3387d40cc8d02539c51756b3a,patients,0.694129
uuid-0bd622e3387d40cc8d02539c51756b3a,therapy,0.456889
uuid-0bd622e3387d40cc8d02539c51756b3a,nivolumab,0.533147
uuid-0bd622e3387d40cc8d02539c51756b3a,1L,0.383508
uuid-0bd622e3387d40cc8d02539c51756b3a,toxicity,0.361276
uuid-0bd622e3387d40cc8d02539c51756b3a,regimen,0.598584
uuid-0bd622e3387d40cc8d02539c51756b3a,treated,0.488953
uuid-0bd622e3387d40cc8d02539c51756b3a,RCC,0.454226
uuid-0bd622e3387d40cc8d02539c51756b3a,combination,0.43676
uuid-0bd622e3387d40cc8d02539c51756b3a,chemo,0.477818
uuid-0bd622e3387d40cc8d02539c51756b3a,2L,0.384317
uuid-0bd622e3387d40cc8d02539c51756b3a,pts,0.6654
uuid-0bd622e3387d40cc8d02539c51756b3a,IO,0.319285
uuid-0bd622e3387d40cc8d02539c51756b3a,preferred,0.372774
uuid-0bd622e3387d40cc8d02539c51756b3a,monotherapy,0.610363
uuid-0bd622e3387d40cc8d02539c51756b3a,treatment,0.542729
uuid-0bd622e3387d40cc8d02539c51756b3a,using nivo,0.43307
uuid-0bd622e3387d40cc8d02539c51756b3a,response,0.470465
uuid-0bd622e3387d40cc8d02539c51756b3a,combo,0.441431
uuid-0bd622e3387d40cc8d02539c51756b3a,PD1,0.441497
uuid-0bd622e3387d40cc8d02539c51756b3a,progression,0.624277
uuid-0bd622e3387d40cc8d02539c51756b3a,chemotherapy,0.38881
uuid-0bd622e3387d40cc8d02539c51756b3a,respond,0.479409
uuid-0bd622e3387d40cc8d02539c51756b3a,RTL stated,0.478015
uuid-0bd622e3387d40cc8d02539c51756b3a,TL shared,0.395602
uuid-0bd622e3387d40cc8d02539c51756b3a,option,0.524346
uuid-ef89ec621e5f4a4ebbb09685f121784f,RTL,0.316601
uuid-ef89ec621e5f4a4ebbb09685f121784f,BMS,0.339277
uuid-ef89ec621e5f4a4ebbb09685f121784f,trial,0.649283
uuid-ef89ec621e5f4a4ebbb09685f121784f,NTL,0.327291
uuid-ef89ec621e5f4a4ebbb09685f121784f,commented,0.337318
uuid-ef89ec621e5f4a4ebbb09685f121784f,Merck,0.359314
uuid-ef89ec621e5f4a4ebbb09685f121784f,approval,0.377758
uuid-ef89ec621e5f4a4ebbb09685f121784f,data,0.377694
uuid-ef89ec621e5f4a4ebbb09685f121784f,clinical trials,0.506675
uuid-ef89ec621e5f4a4ebbb09685f121784f,impressed,0.414454
uuid-ef89ec621e5f4a4ebbb09685f121784f,Regional TL,0.35381
uuid-ef89ec621e5f4a4ebbb09685f121784f,bladder,0.436212
uuid-8f68b4f4a66f45a99abac9603007ed2b,PDL1,0.304033
uuid-8f68b4f4a66f45a99abac9603007ed2b,efficacy,0.37991
uuid-8f68b4f4a66f45a99abac9603007ed2b,chemo,0.371713
uuid-8f68b4f4a66f45a99abac9603007ed2b,OS,0.598214
uuid-8f68b4f4a66f45a99abac9603007ed2b,response,0.380161
uuid-8f68b4f4a66f45a99abac9603007ed2b,data,0.334277
uuid-8f68b4f4a66f45a99abac9603007ed2b,PFS,0.585738
uuid-8f68b4f4a66f45a99abac9603007ed2b,ORR,0.596097
uuid-8f68b4f4a66f45a99abac9603007ed2b,believes,0.359325
uuid-8f68b4f4a66f45a99abac9603007ed2b,chemotherapy,0.323824
uuid-8f68b4f4a66f45a99abac9603007ed2b,impressed,0.346932
uuid-8f68b4f4a66f45a99abac9603007ed2b,feels,0.337397
uuid-8f68b4f4a66f45a99abac9603007ed2b,PDL1 expression,0.318206
uuid-eb2c0bcc301b4712a18715602af492ab,efficacy,0.410561
uuid-eb2c0bcc301b4712a18715602af492ab,regimen,0.325432
uuid-eb2c0bcc301b4712a18715602af492ab,chemo,0.339849
uuid-eb2c0bcc301b4712a18715602af492ab,pts,0.37693
uuid-eb2c0bcc301b4712a18715602af492ab,OS,0.632414
uuid-eb2c0bcc301b4712a18715602af492ab,response,0.57073
uuid-eb2c0bcc301b4712a18715602af492ab,data,0.40224
uuid-eb2c0bcc301b4712a18715602af492ab,PFS,0.528578
uuid-eb2c0bcc301b4712a18715602af492ab,PD1,0.300609
uuid-eb2c0bcc301b4712a18715602af492ab,ORR,0.577873
uuid-eb2c0bcc301b4712a18715602af492ab,progression,0.519998
uuid-eb2c0bcc301b4712a18715602af492ab,believes,0.302465
uuid-eb2c0bcc301b4712a18715602af492ab,impressed,0.400428
uuid-eb2c0bcc301b4712a18715602af492ab,respond,0.416899
uuid-5732c652769a485e83766b3ab5ff7288,1L,0.310547
uuid-5732c652769a485e83766b3ab5ff7288,efficacy,0.365111
uuid-5732c652769a485e83766b3ab5ff7288,regimen,0.315086
uuid-5732c652769a485e83766b3ab5ff7288,combination,0.549356
uuid-5732c652769a485e83766b3ab5ff7288,chemo,0.513506
uuid-5732c652769a485e83766b3ab5ff7288,IO,0.643228
uuid-5732c652769a485e83766b3ab5ff7288,agents,0.471037
uuid-5732c652769a485e83766b3ab5ff7288,monotherapy,0.470818
uuid-5732c652769a485e83766b3ab5ff7288,response,0.331502
uuid-5732c652769a485e83766b3ab5ff7288,combo,0.559724
uuid-5732c652769a485e83766b3ab5ff7288,PD1,0.355427
uuid-5732c652769a485e83766b3ab5ff7288,believes,0.4613
uuid-5732c652769a485e83766b3ab5ff7288,chemotherapy,0.463125
uuid-5732c652769a485e83766b3ab5ff7288,feels,0.425184
uuid-5732c652769a485e83766b3ab5ff7288,option,0.470236
uuid-2110d4c1da1d4585bc028ec636c63229,1L,0.510253
uuid-2110d4c1da1d4585bc028ec636c63229,RCC,0.388219
uuid-2110d4c1da1d4585bc028ec636c63229,chemo,0.326902
uuid-2110d4c1da1d4585bc028ec636c63229,2L,0.518877
uuid-2110d4c1da1d4585bc028ec636c63229,agents,0.412946
uuid-2110d4c1da1d4585bc028ec636c63229,preferred,0.71401
uuid-2110d4c1da1d4585bc028ec636c63229,monotherapy,0.466814
uuid-2110d4c1da1d4585bc028ec636c63229,using nivo,0.461809
uuid-2110d4c1da1d4585bc028ec636c63229,SCCHN,0.439253
uuid-2110d4c1da1d4585bc028ec636c63229,chemotherapy,0.323767
uuid-2110d4c1da1d4585bc028ec636c63229,feels,0.3304
uuid-2110d4c1da1d4585bc028ec636c63229,RTL stated,0.543939
uuid-2110d4c1da1d4585bc028ec636c63229,TL shared,0.311323
uuid-2110d4c1da1d4585bc028ec636c63229,option,0.600811
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,TL,0.355405
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,RTL,0.504294
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,NTL,0.31149
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,shared,0.303314
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,commented,0.429756
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,Merck,0.335602
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,stated,0.329037
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,approval,0.372343
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,expressed,0.305611
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,mentioned,0.592533
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,indication,0.341339
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,SCCHN,0.387895
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,HCP,0.510482
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,impressed,0.346003
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,label,0.3494
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,LTL,0.49721
uuid-ac0fa7b14c354ecda2b04f58409f4d4f,Regional TL,0.489382
uuid-9420959e5c6b4eec8871934487662e16,Nivo,0.548213
uuid-9420959e5c6b4eec8871934487662e16,pembro,0.522985
uuid-9420959e5c6b4eec8871934487662e16,1L,0.611118
uuid-9420959e5c6b4eec8871934487662e16,efficacy,0.354969
uuid-9420959e5c6b4eec8871934487662e16,combination,0.450154
uuid-9420959e5c6b4eec8871934487662e16,chemo,0.572838
uuid-9420959e5c6b4eec8871934487662e16,2L,0.551466
uuid-9420959e5c6b4eec8871934487662e16,agents,0.466738
uuid-9420959e5c6b4eec8871934487662e16,atezo,0.453375
uuid-9420959e5c6b4eec8871934487662e16,preferred,0.552221
uuid-9420959e5c6b4eec8871934487662e16,monotherapy,0.622472
uuid-9420959e5c6b4eec8871934487662e16,using nivo,0.389346
uuid-9420959e5c6b4eec8871934487662e16,combo,0.473302
uuid-9420959e5c6b4eec8871934487662e16,PD1,0.35331
uuid-9420959e5c6b4eec8871934487662e16,approved,0.376247
uuid-9420959e5c6b4eec8871934487662e16,nivo and pembro,0.344537
uuid-9420959e5c6b4eec8871934487662e16,believes,0.491921
uuid-9420959e5c6b4eec8871934487662e16,chemotherapy,0.458799
uuid-9420959e5c6b4eec8871934487662e16,feels,0.579299
uuid-9420959e5c6b4eec8871934487662e16,option,0.668204
uuid-1e94197c3092476984b2890c4c3e6898,Nivo,0.320812
uuid-1e94197c3092476984b2890c4c3e6898,patients,0.710322
uuid-1e94197c3092476984b2890c4c3e6898,Opdivo,0.341924
uuid-1e94197c3092476984b2890c4c3e6898,therapy,0.521248
uuid-1e94197c3092476984b2890c4c3e6898,nivolumab,0.615318
uuid-1e94197c3092476984b2890c4c3e6898,regimen,0.565471
uuid-1e94197c3092476984b2890c4c3e6898,treated,0.563262
uuid-1e94197c3092476984b2890c4c3e6898,combination,0.311191
uuid-1e94197c3092476984b2890c4c3e6898,chemo,0.401749
uuid-1e94197c3092476984b2890c4c3e6898,pts,0.494723
uuid-1e94197c3092476984b2890c4c3e6898,preferred,0.311163
uuid-1e94197c3092476984b2890c4c3e6898,monotherapy,0.434849
uuid-1e94197c3092476984b2890c4c3e6898,treatment,0.607673
uuid-1e94197c3092476984b2890c4c3e6898,using nivo,0.375606
uuid-1e94197c3092476984b2890c4c3e6898,PD1,0.335182
uuid-1e94197c3092476984b2890c4c3e6898,cHL,0.323524
uuid-1e94197c3092476984b2890c4c3e6898,progression,0.507164
uuid-1e94197c3092476984b2890c4c3e6898,chemotherapy,0.518475
uuid-1e94197c3092476984b2890c4c3e6898,respond,0.334091
uuid-1e94197c3092476984b2890c4c3e6898,RTL stated,0.402771
uuid-1e94197c3092476984b2890c4c3e6898,TL shared,0.315768
uuid-1e94197c3092476984b2890c4c3e6898,option,0.437355
uuid-1ff072cda0f74939bf2442bbeff663d2,RTL,0.452438
uuid-1ff072cda0f74939bf2442bbeff663d2,BMS,0.384552
uuid-1ff072cda0f74939bf2442bbeff663d2,trial,0.486508
uuid-1ff072cda0f74939bf2442bbeff663d2,efficacy,0.429076
uuid-1ff072cda0f74939bf2442bbeff663d2,discussed,0.326299
uuid-1ff072cda0f74939bf2442bbeff663d2,commented,0.549503
uuid-1ff072cda0f74939bf2442bbeff663d2,stated,0.347251
uuid-1ff072cda0f74939bf2442bbeff663d2,OS,0.649261
uuid-1ff072cda0f74939bf2442bbeff663d2,regards,0.391805
uuid-1ff072cda0f74939bf2442bbeff663d2,data,0.776724
uuid-1ff072cda0f74939bf2442bbeff663d2,expressed,0.394221
uuid-1ff072cda0f74939bf2442bbeff663d2,PFS,0.60199
uuid-1ff072cda0f74939bf2442bbeff663d2,ORR,0.675568
uuid-1ff072cda0f74939bf2442bbeff663d2,ASCO,0.512239
uuid-1ff072cda0f74939bf2442bbeff663d2,impressed,0.8739
uuid-1ff072cda0f74939bf2442bbeff663d2,LTL,0.319398
uuid-1ff072cda0f74939bf2442bbeff663d2,TLs,0.414648
uuid-1ff072cda0f74939bf2442bbeff663d2,Regional TL,0.392924
uuid-b01623925c5c4e92b561fcadca4f9666,pembro,0.62226
uuid-b01623925c5c4e92b561fcadca4f9666,1L,0.562788
uuid-b01623925c5c4e92b561fcadca4f9666,PDL1,0.619445
uuid-b01623925c5c4e92b561fcadca4f9666,2L,0.485681
uuid-b01623925c5c4e92b561fcadca4f9666,Merck,0.404726
uuid-b01623925c5c4e92b561fcadca4f9666,PD-L1,0.619753
uuid-b01623925c5c4e92b561fcadca4f9666,approval,0.436082
uuid-b01623925c5c4e92b561fcadca4f9666,atezo,0.643172
uuid-b01623925c5c4e92b561fcadca4f9666,preferred,0.349059
uuid-b01623925c5c4e92b561fcadca4f9666,PD-L1 testing,0.463149
uuid-b01623925c5c4e92b561fcadca4f9666,testing,0.552345
uuid-b01623925c5c4e92b561fcadca4f9666,PDL1 testing,0.514576
uuid-b01623925c5c4e92b561fcadca4f9666,indication,0.342801
uuid-b01623925c5c4e92b561fcadca4f9666,NSCLC patients,0.432651
uuid-b01623925c5c4e92b561fcadca4f9666,approved,0.387543
uuid-b01623925c5c4e92b561fcadca4f9666,nivo and pembro,0.466876
uuid-b01623925c5c4e92b561fcadca4f9666,assay,0.569386
uuid-b01623925c5c4e92b561fcadca4f9666,PDL1 expression,0.541848
uuid-b01623925c5c4e92b561fcadca4f9666,biomarker,0.384145
uuid-b01623925c5c4e92b561fcadca4f9666,bladder,0.304365
uuid-514440da3e2b422882e3e8b3dbfc5fe1,patients,0.527025
uuid-514440da3e2b422882e3e8b3dbfc5fe1,TL stated,0.348529
uuid-514440da3e2b422882e3e8b3dbfc5fe1,pts,0.380488
uuid-514440da3e2b422882e3e8b3dbfc5fe1,PD-L1,0.474313
uuid-514440da3e2b422882e3e8b3dbfc5fe1,PD-L1 testing,0.395809
uuid-514440da3e2b422882e3e8b3dbfc5fe1,testing,0.605992
uuid-514440da3e2b422882e3e8b3dbfc5fe1,PDL1 testing,0.552017
uuid-514440da3e2b422882e3e8b3dbfc5fe1,NSCLC patients,0.782207
uuid-514440da3e2b422882e3e8b3dbfc5fe1,progression,0.302931
uuid-514440da3e2b422882e3e8b3dbfc5fe1,tumor types,0.476327
uuid-1ac47df4966c40a3b9bec757586058ff,therapy,0.305953
uuid-1ac47df4966c40a3b9bec757586058ff,trial,0.456572
uuid-1ac47df4966c40a3b9bec757586058ff,combination,0.389789
uuid-1ac47df4966c40a3b9bec757586058ff,chemo,0.395472
uuid-1ac47df4966c40a3b9bec757586058ff,pts,0.433549
uuid-1ac47df4966c40a3b9bec757586058ff,response,0.371457
uuid-1ac47df4966c40a3b9bec757586058ff,combo,0.382144
uuid-1ac47df4966c40a3b9bec757586058ff,PD1,0.375063
uuid-1ac47df4966c40a3b9bec757586058ff,progression,0.384214
uuid-1ac47df4966c40a3b9bec757586058ff,believes,0.403739
uuid-1ac47df4966c40a3b9bec757586058ff,chemotherapy,0.388811
uuid-1ac47df4966c40a3b9bec757586058ff,respond,0.315566
uuid-1ac47df4966c40a3b9bec757586058ff,feels,0.396469
uuid-c6473042756b4c4499d2a7e8825967de,treatment,0.341246
uuid-c6473042756b4c4499d2a7e8825967de,progression,0.309792
uuid-32d29bb181ae4d729aef4f233e5fc1d4,BMS,0.422516
uuid-32d29bb181ae4d729aef4f233e5fc1d4,trial,0.612576
uuid-32d29bb181ae4d729aef4f233e5fc1d4,efficacy,0.446914
uuid-32d29bb181ae4d729aef4f233e5fc1d4,OS,0.751413
uuid-32d29bb181ae4d729aef4f233e5fc1d4,regards,0.335491
uuid-32d29bb181ae4d729aef4f233e5fc1d4,data,0.634072
uuid-32d29bb181ae4d729aef4f233e5fc1d4,PFS,0.742831
uuid-32d29bb181ae4d729aef4f233e5fc1d4,ORR,0.720843
uuid-32d29bb181ae4d729aef4f233e5fc1d4,ASCO,0.431638
uuid-32d29bb181ae4d729aef4f233e5fc1d4,impressed,0.511193
uuid-32d29bb181ae4d729aef4f233e5fc1d4,PDL1 expression,0.309212
uuid-e51a248a97704e0f8948f9b21ae9c6cf,Nivo,0.3372
uuid-e51a248a97704e0f8948f9b21ae9c6cf,patients,0.894761
uuid-e51a248a97704e0f8948f9b21ae9c6cf,Opdivo,0.48311
uuid-e51a248a97704e0f8948f9b21ae9c6cf,therapy,0.657
uuid-e51a248a97704e0f8948f9b21ae9c6cf,nivolumab,0.584198
uuid-e51a248a97704e0f8948f9b21ae9c6cf,regimen,0.442129
uuid-e51a248a97704e0f8948f9b21ae9c6cf,treated,0.535361
uuid-e51a248a97704e0f8948f9b21ae9c6cf,chemo,0.350713
uuid-e51a248a97704e0f8948f9b21ae9c6cf,2L,0.306587
uuid-e51a248a97704e0f8948f9b21ae9c6cf,pts,0.490727
uuid-e51a248a97704e0f8948f9b21ae9c6cf,approval,0.328849
uuid-e51a248a97704e0f8948f9b21ae9c6cf,preferred,0.383983
uuid-e51a248a97704e0f8948f9b21ae9c6cf,monotherapy,0.435239
uuid-e51a248a97704e0f8948f9b21ae9c6cf,treatment,0.673221
uuid-e51a248a97704e0f8948f9b21ae9c6cf,using nivo,0.479568
uuid-e51a248a97704e0f8948f9b21ae9c6cf,PD1,0.305016
uuid-e51a248a97704e0f8948f9b21ae9c6cf,cHL,0.40762
uuid-e51a248a97704e0f8948f9b21ae9c6cf,progression,0.519517
uuid-e51a248a97704e0f8948f9b21ae9c6cf,chemotherapy,0.432146
uuid-e51a248a97704e0f8948f9b21ae9c6cf,respond,0.383443
uuid-e51a248a97704e0f8948f9b21ae9c6cf,RTL stated,0.342744
uuid-e51a248a97704e0f8948f9b21ae9c6cf,option,0.501952
uuid-54066801faaf4efcbee0d60e90ee8bab,patients,0.517021
uuid-54066801faaf4efcbee0d60e90ee8bab,Opdivo,0.370799
uuid-54066801faaf4efcbee0d60e90ee8bab,therapy,0.574343
uuid-54066801faaf4efcbee0d60e90ee8bab,nivolumab,0.409109
uuid-54066801faaf4efcbee0d60e90ee8bab,treated,0.344953
uuid-54066801faaf4efcbee0d60e90ee8bab,treatment,0.379793
uuid-54066801faaf4efcbee0d60e90ee8bab,cHL,0.738722
uuid-1ea56df6df4942f5aed3b8295352de31,Nivo,0.317195
uuid-1ea56df6df4942f5aed3b8295352de31,patients,0.775783
uuid-1ea56df6df4942f5aed3b8295352de31,Opdivo,0.527211
uuid-1ea56df6df4942f5aed3b8295352de31,therapy,0.591879
uuid-1ea56df6df4942f5aed3b8295352de31,nivolumab,0.469359
uuid-1ea56df6df4942f5aed3b8295352de31,1L,0.309645
uuid-1ea56df6df4942f5aed3b8295352de31,regimen,0.342939
uuid-1ea56df6df4942f5aed3b8295352de31,treated,0.366386
uuid-1ea56df6df4942f5aed3b8295352de31,2L,0.35901
uuid-1ea56df6df4942f5aed3b8295352de31,pts,0.463444
uuid-1ea56df6df4942f5aed3b8295352de31,approval,0.446573
uuid-1ea56df6df4942f5aed3b8295352de31,preferred,0.402693
uuid-1ea56df6df4942f5aed3b8295352de31,monotherapy,0.417188
uuid-1ea56df6df4942f5aed3b8295352de31,treatment,0.533658
uuid-1ea56df6df4942f5aed3b8295352de31,using nivo,0.476258
uuid-1ea56df6df4942f5aed3b8295352de31,approved,0.42957
uuid-1ea56df6df4942f5aed3b8295352de31,cHL,0.355527
uuid-1ea56df6df4942f5aed3b8295352de31,progression,0.436218
uuid-1ea56df6df4942f5aed3b8295352de31,chemotherapy,0.363092
uuid-1ea56df6df4942f5aed3b8295352de31,option,0.546765
uuid-8eaf1e2a30f54c28a53ea8f04a0adc71,physicians,0.445897
uuid-8eaf1e2a30f54c28a53ea8f04a0adc71,ASCO,0.331773
uuid-8eaf1e2a30f54c28a53ea8f04a0adc71,oncologist,0.312213
uuid-8eaf1e2a30f54c28a53ea8f04a0adc71,indicated,0.329753
uuid-8eaf1e2a30f54c28a53ea8f04a0adc71,Regional TL,0.454905
uuid-a5bc9db57a574368ab8130622ba1683e,patients,0.499294
uuid-a5bc9db57a574368ab8130622ba1683e,Opdivo,0.46152
uuid-a5bc9db57a574368ab8130622ba1683e,therapy,0.324324
uuid-a5bc9db57a574368ab8130622ba1683e,physicians,0.388843
uuid-a5bc9db57a574368ab8130622ba1683e,treatment,0.456025
uuid-a5bc9db57a574368ab8130622ba1683e,progression,0.30516
uuid-a5bc9db57a574368ab8130622ba1683e,oncologist,0.329238
uuid-a5bc9db57a574368ab8130622ba1683e,drug,0.420378
uuid-d23cc7eaa384470cac6bf12ae86993f8,patients,0.662164
uuid-d23cc7eaa384470cac6bf12ae86993f8,therapy,0.30885
uuid-d23cc7eaa384470cac6bf12ae86993f8,nivolumab,0.395353
uuid-d23cc7eaa384470cac6bf12ae86993f8,toxicity,0.448728
uuid-d23cc7eaa384470cac6bf12ae86993f8,regimen,0.621063
uuid-d23cc7eaa384470cac6bf12ae86993f8,treated,0.600305
uuid-d23cc7eaa384470cac6bf12ae86993f8,pts,0.551526
uuid-d23cc7eaa384470cac6bf12ae86993f8,monotherapy,0.302845
uuid-d23cc7eaa384470cac6bf12ae86993f8,treatment,0.525133
uuid-d23cc7eaa384470cac6bf12ae86993f8,response,0.483884
uuid-d23cc7eaa384470cac6bf12ae86993f8,progression,0.58076
uuid-d23cc7eaa384470cac6bf12ae86993f8,impressed,0.332976
uuid-d23cc7eaa384470cac6bf12ae86993f8,respond,0.542091
uuid-c7d7995d5a0345a5ade641987fa66cc6,PDL1,0.35493
uuid-c7d7995d5a0345a5ade641987fa66cc6,TL stated,0.363119
uuid-c7d7995d5a0345a5ade641987fa66cc6,PD-L1,0.62728
uuid-c7d7995d5a0345a5ade641987fa66cc6,PD-L1 testing,0.608119
uuid-c7d7995d5a0345a5ade641987fa66cc6,testing,0.791252
uuid-c7d7995d5a0345a5ade641987fa66cc6,PDL1 testing,0.720064
uuid-c7d7995d5a0345a5ade641987fa66cc6,NSCLC patients,0.687796
uuid-c7d7995d5a0345a5ade641987fa66cc6,tumor types,0.320371
uuid-c7d7995d5a0345a5ade641987fa66cc6,assay,0.352176
uuid-c7d7995d5a0345a5ade641987fa66cc6,biomarker,0.515715
uuid-d8c16f1688984c82ba44fcf8f649da88,cHL,0.33516
uuid-fd8182c19c344f9886be43f1450c3450,trial,0.349544
uuid-fd8182c19c344f9886be43f1450c3450,efficacy,0.545393
uuid-fd8182c19c344f9886be43f1450c3450,regimen,0.364696
uuid-fd8182c19c344f9886be43f1450c3450,commented,0.348999
uuid-fd8182c19c344f9886be43f1450c3450,Ipi,0.362453
uuid-fd8182c19c344f9886be43f1450c3450,OS,0.631485
uuid-fd8182c19c344f9886be43f1450c3450,data,0.666196
uuid-fd8182c19c344f9886be43f1450c3450,combo,0.355649
uuid-fd8182c19c344f9886be43f1450c3450,PFS,0.534148
uuid-fd8182c19c344f9886be43f1450c3450,ORR,0.618002
uuid-fd8182c19c344f9886be43f1450c3450,ASCO,0.383768
uuid-fd8182c19c344f9886be43f1450c3450,impressed,0.745388
uuid-fd8182c19c344f9886be43f1450c3450,SCLC,0.324057
uuid-fd8182c19c344f9886be43f1450c3450,feels,0.406778
uuid-f8274093baf64d98a7b57068dc026145,patients,0.897637
uuid-f8274093baf64d98a7b57068dc026145,Opdivo,0.456768
uuid-f8274093baf64d98a7b57068dc026145,therapy,0.611096
uuid-f8274093baf64d98a7b57068dc026145,nivolumab,0.531254
uuid-f8274093baf64d98a7b57068dc026145,regimen,0.614609
uuid-f8274093baf64d98a7b57068dc026145,treated,0.675835
uuid-f8274093baf64d98a7b57068dc026145,chemo,0.384055
uuid-f8274093baf64d98a7b57068dc026145,pts,0.655249
uuid-f8274093baf64d98a7b57068dc026145,monotherapy,0.444254
uuid-f8274093baf64d98a7b57068dc026145,treatment,0.73674
uuid-f8274093baf64d98a7b57068dc026145,response,0.431722
uuid-f8274093baf64d98a7b57068dc026145,PD1,0.387847
uuid-f8274093baf64d98a7b57068dc026145,cHL,0.308346
uuid-f8274093baf64d98a7b57068dc026145,progression,0.729308
uuid-f8274093baf64d98a7b57068dc026145,chemotherapy,0.412054
uuid-f8274093baf64d98a7b57068dc026145,respond,0.561443
uuid-f8274093baf64d98a7b57068dc026145,option,0.387224
uuid-20ab497189204c8db69b3acc574a3b9f,lung,0.40194
uuid-20ab497189204c8db69b3acc574a3b9f,melanoma,0.366666
uuid-20ab497189204c8db69b3acc574a3b9f,shared,0.348737
uuid-20ab497189204c8db69b3acc574a3b9f,RCC,0.377301
uuid-20ab497189204c8db69b3acc574a3b9f,institution,0.39976
uuid-20ab497189204c8db69b3acc574a3b9f,physicians,0.319205
uuid-20ab497189204c8db69b3acc574a3b9f,PDL1 testing,0.312052
uuid-20ab497189204c8db69b3acc574a3b9f,AI,0.449629
uuid-20ab497189204c8db69b3acc574a3b9f,oncology,0.448766
uuid-20ab497189204c8db69b3acc574a3b9f,oncologist,0.446686
uuid-20ab497189204c8db69b3acc574a3b9f,clinical,0.327617
uuid-20ab497189204c8db69b3acc574a3b9f,TL shared,0.309043
uuid-2b3295d8978d4805970650d032800977,physicians,0.416761
uuid-2b3295d8978d4805970650d032800977,oncology,0.37393
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,RTL,0.348886
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,BMS,0.456466
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,1L,0.319168
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,trial,0.356862
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,shared,0.305737
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,RCC,0.468774
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,combination,0.41622
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,2L,0.41379
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,agents,0.391618
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,Merck,0.351582
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,stated,0.474253
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,atezo,0.349254
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,preferred,0.327998
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,using nivo,0.373456
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,combo,0.43597
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,expressed,0.407062
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,clinical trials,0.422519
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,indication,0.313371
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,approved,0.438573
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,SCCHN,0.37401
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,impressed,0.339891
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,tumor types,0.305766
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,LTL,0.362109
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,TLs,0.389648
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,feels,0.330906
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,Regional TL,0.370144
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,RTL stated,0.408807
uuid-66ebc4df58fc48b9ad1fc21ed7ac090a,bladder,0.475082
uuid-1a3cc4cd3bce48049d4c81ac5e351103,Nivo,0.496713
uuid-1a3cc4cd3bce48049d4c81ac5e351103,Opdivo,0.449101
uuid-1a3cc4cd3bce48049d4c81ac5e351103,pembro,0.428561
uuid-1a3cc4cd3bce48049d4c81ac5e351103,dose,0.59158
uuid-1a3cc4cd3bce48049d4c81ac5e351103,Ipi,0.336087
uuid-1a3cc4cd3bce48049d4c81ac5e351103,atezo,0.356971
uuid-1a3cc4cd3bce48049d4c81ac5e351103,indication,0.37389
uuid-1a3cc4cd3bce48049d4c81ac5e351103,vs,0.443034
uuid-1a3cc4cd3bce48049d4c81ac5e351103,label,0.302327
uuid-1a3cc4cd3bce48049d4c81ac5e351103,drug,0.517087
uuid-1a3cc4cd3bce48049d4c81ac5e351103,Keytruda,0.514527
uuid-1a3cc4cd3bce48049d4c81ac5e351103,flat dosing,0.645936
uuid-1a911851340a47b0a526e218fca0bb78,patients,0.535788
uuid-1a911851340a47b0a526e218fca0bb78,therapy,0.56614
uuid-1a911851340a47b0a526e218fca0bb78,1L,0.358832
uuid-1a911851340a47b0a526e218fca0bb78,regimen,0.537468
uuid-1a911851340a47b0a526e218fca0bb78,treated,0.362383
uuid-1a911851340a47b0a526e218fca0bb78,combination,0.468813
uuid-1a911851340a47b0a526e218fca0bb78,chemo,0.665922
uuid-1a911851340a47b0a526e218fca0bb78,pts,0.58248
uuid-1a911851340a47b0a526e218fca0bb78,IO,0.682847
uuid-1a911851340a47b0a526e218fca0bb78,monotherapy,0.617606
uuid-1a911851340a47b0a526e218fca0bb78,treatment,0.548668
uuid-1a911851340a47b0a526e218fca0bb78,response,0.680577
uuid-1a911851340a47b0a526e218fca0bb78,combo,0.46375
uuid-1a911851340a47b0a526e218fca0bb78,PD1,0.52329
uuid-1a911851340a47b0a526e218fca0bb78,progression,0.730545
uuid-1a911851340a47b0a526e218fca0bb78,believes,0.339111
uuid-1a911851340a47b0a526e218fca0bb78,chemotherapy,0.519709
uuid-1a911851340a47b0a526e218fca0bb78,respond,0.544974
uuid-1a911851340a47b0a526e218fca0bb78,option,0.520535
uuid-5b718984a32342b293f7a9196d8124ff,patients,0.487564
uuid-5b718984a32342b293f7a9196d8124ff,Opdivo,0.31058
uuid-5b718984a32342b293f7a9196d8124ff,nivolumab,0.36879
uuid-5b718984a32342b293f7a9196d8124ff,regimen,0.339339
uuid-5b718984a32342b293f7a9196d8124ff,treated,0.351747
uuid-5b718984a32342b293f7a9196d8124ff,RCC,0.386427
uuid-5b718984a32342b293f7a9196d8124ff,pts,0.308755
uuid-5b718984a32342b293f7a9196d8124ff,approval,0.386151
uuid-5b718984a32342b293f7a9196d8124ff,using nivo,0.437056
uuid-5b718984a32342b293f7a9196d8124ff,clinical trials,0.31471
uuid-5b718984a32342b293f7a9196d8124ff,SCCHN,0.370575
uuid-5b718984a32342b293f7a9196d8124ff,impressed,0.453268
uuid-5b718984a32342b293f7a9196d8124ff,Regional TL,0.323907
uuid-5b718984a32342b293f7a9196d8124ff,RTL stated,0.371849
uuid-5b718984a32342b293f7a9196d8124ff,TL shared,0.338774
uuid-5b718984a32342b293f7a9196d8124ff,option,0.305668
uuid-5b718984a32342b293f7a9196d8124ff,bladder,0.38128
uuid-299c338864614406b774701514a27862,TL,0.401758
uuid-299c338864614406b774701514a27862,RTL,0.420655
uuid-299c338864614406b774701514a27862,BMS,0.462305
uuid-299c338864614406b774701514a27862,PDL1,0.344539
uuid-299c338864614406b774701514a27862,discussed,0.324104
uuid-299c338864614406b774701514a27862,commented,0.522895
uuid-299c338864614406b774701514a27862,TL stated,0.34666
uuid-299c338864614406b774701514a27862,Merck,0.518262
uuid-299c338864614406b774701514a27862,stated,0.470759
uuid-299c338864614406b774701514a27862,atezo,0.301965
uuid-299c338864614406b774701514a27862,regards,0.347162
uuid-299c338864614406b774701514a27862,data,0.557996
uuid-299c338864614406b774701514a27862,expressed,0.463878
uuid-299c338864614406b774701514a27862,PDL1 testing,0.307379
uuid-299c338864614406b774701514a27862,SCCHN,0.40908
uuid-299c338864614406b774701514a27862,ASCO,0.304491
uuid-299c338864614406b774701514a27862,impressed,0.49793
uuid-299c338864614406b774701514a27862,LTL,0.337026
uuid-299c338864614406b774701514a27862,TLs,0.614763
uuid-299c338864614406b774701514a27862,academic,0.31815
uuid-299c338864614406b774701514a27862,assay,0.391232
uuid-299c338864614406b774701514a27862,Regional TL,0.424172
uuid-299c338864614406b774701514a27862,PDL1 expression,0.31179
uuid-299c338864614406b774701514a27862,bladder,0.416138
uuid-4dfb5803d40f430e959a2b4625be0398,toxicity,0.47864
uuid-4f753138837e4f80aa8dee4271313577,Nivo,0.366868
uuid-4f753138837e4f80aa8dee4271313577,patients,0.874271
uuid-4f753138837e4f80aa8dee4271313577,Opdivo,0.4608
uuid-4f753138837e4f80aa8dee4271313577,therapy,0.567782
uuid-4f753138837e4f80aa8dee4271313577,nivolumab,0.537059
uuid-4f753138837e4f80aa8dee4271313577,regimen,0.570507
uuid-4f753138837e4f80aa8dee4271313577,treated,0.58641
uuid-4f753138837e4f80aa8dee4271313577,chemo,0.433214
uuid-4f753138837e4f80aa8dee4271313577,pts,0.597267
uuid-4f753138837e4f80aa8dee4271313577,preferred,0.353865
uuid-4f753138837e4f80aa8dee4271313577,monotherapy,0.468351
uuid-4f753138837e4f80aa8dee4271313577,treatment,0.716577
uuid-4f753138837e4f80aa8dee4271313577,using nivo,0.428052
uuid-4f753138837e4f80aa8dee4271313577,response,0.35266
uuid-4f753138837e4f80aa8dee4271313577,PD1,0.328429
uuid-4f753138837e4f80aa8dee4271313577,progression,0.623173
uuid-4f753138837e4f80aa8dee4271313577,chemotherapy,0.439209
uuid-4f753138837e4f80aa8dee4271313577,respond,0.519455
uuid-4f753138837e4f80aa8dee4271313577,RTL stated,0.359312
uuid-4f753138837e4f80aa8dee4271313577,option,0.483259
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,Nivo,0.364272
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,trial,0.472868
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,combination,0.517765
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,chemo,0.493207
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,IO,0.345984
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,monotherapy,0.373064
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,combo,0.518025
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,clinical trials,0.336284
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,PD1,0.338426
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,believes,0.331808
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,chemotherapy,0.492133
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,feels,0.418347
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,RTL stated,0.303632
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,option,0.310206
uuid-d657b1b7b45c4bdf9f6b88f7b62f19ba,bladder,0.365587
uuid-b8fe10fae4964e8395a99eb670a3cba1,RCC,0.327625
uuid-b8fe10fae4964e8395a99eb670a3cba1,preferred,0.484253
uuid-b8fe10fae4964e8395a99eb670a3cba1,SCCHN,0.566172
uuid-b8fe10fae4964e8395a99eb670a3cba1,RTL stated,0.422657
uuid-b8fe10fae4964e8395a99eb670a3cba1,TL shared,0.315227
uuid-b8fe10fae4964e8395a99eb670a3cba1,option,0.349954
uuid-0310d0dfc4bd437f80afbf1027c12098,Nivo,0.473064
uuid-0310d0dfc4bd437f80afbf1027c12098,pembro,0.498575
uuid-0310d0dfc4bd437f80afbf1027c12098,1L,0.607727
uuid-0310d0dfc4bd437f80afbf1027c12098,trial,0.43887
uuid-0310d0dfc4bd437f80afbf1027c12098,RCC,0.375611
uuid-0310d0dfc4bd437f80afbf1027c12098,combination,0.393178
uuid-0310d0dfc4bd437f80afbf1027c12098,chemo,0.363675
uuid-0310d0dfc4bd437f80afbf1027c12098,2L,0.536458
uuid-0310d0dfc4bd437f80afbf1027c12098,pts,0.346369
uuid-0310d0dfc4bd437f80afbf1027c12098,stated,0.348151
uuid-0310d0dfc4bd437f80afbf1027c12098,approval,0.445153
uuid-0310d0dfc4bd437f80afbf1027c12098,atezo,0.357037
uuid-0310d0dfc4bd437f80afbf1027c12098,preferred,0.4601
uuid-0310d0dfc4bd437f80afbf1027c12098,monotherapy,0.520334
uuid-0310d0dfc4bd437f80afbf1027c12098,using nivo,0.504625
uuid-0310d0dfc4bd437f80afbf1027c12098,data,0.326668
uuid-0310d0dfc4bd437f80afbf1027c12098,combo,0.468526
uuid-0310d0dfc4bd437f80afbf1027c12098,clinical trials,0.452911
uuid-0310d0dfc4bd437f80afbf1027c12098,indication,0.345643
uuid-0310d0dfc4bd437f80afbf1027c12098,PD1,0.333994
uuid-0310d0dfc4bd437f80afbf1027c12098,approved,0.509944
uuid-0310d0dfc4bd437f80afbf1027c12098,SCCHN,0.411739
uuid-0310d0dfc4bd437f80afbf1027c12098,chemotherapy,0.380267
uuid-0310d0dfc4bd437f80afbf1027c12098,impressed,0.368051
uuid-0310d0dfc4bd437f80afbf1027c12098,SCLC,0.355951
uuid-0310d0dfc4bd437f80afbf1027c12098,feels,0.42765
uuid-0310d0dfc4bd437f80afbf1027c12098,RTL stated,0.457898
uuid-0310d0dfc4bd437f80afbf1027c12098,option,0.550432
uuid-0310d0dfc4bd437f80afbf1027c12098,bladder,0.399029
uuid-df4ccf41841649438f1b8f56f9820bcd,Nivo,0.360194
uuid-df4ccf41841649438f1b8f56f9820bcd,patients,0.687643
uuid-df4ccf41841649438f1b8f56f9820bcd,Opdivo,0.302853
uuid-df4ccf41841649438f1b8f56f9820bcd,therapy,0.503254
uuid-df4ccf41841649438f1b8f56f9820bcd,nivolumab,0.529538
uuid-df4ccf41841649438f1b8f56f9820bcd,1L,0.32704
uuid-df4ccf41841649438f1b8f56f9820bcd,regimen,0.426936
uuid-df4ccf41841649438f1b8f56f9820bcd,treated,0.430539
uuid-df4ccf41841649438f1b8f56f9820bcd,RCC,0.307642
uuid-df4ccf41841649438f1b8f56f9820bcd,combination,0.367946
uuid-df4ccf41841649438f1b8f56f9820bcd,chemo,0.370872
uuid-df4ccf41841649438f1b8f56f9820bcd,2L,0.362582
uuid-df4ccf41841649438f1b8f56f9820bcd,pts,0.540267
uuid-df4ccf41841649438f1b8f56f9820bcd,approval,0.351974
uuid-df4ccf41841649438f1b8f56f9820bcd,preferred,0.408397
uuid-df4ccf41841649438f1b8f56f9820bcd,monotherapy,0.468858
uuid-df4ccf41841649438f1b8f56f9820bcd,treatment,0.479727
uuid-df4ccf41841649438f1b8f56f9820bcd,using nivo,0.48732
uuid-df4ccf41841649438f1b8f56f9820bcd,combo,0.362654
uuid-df4ccf41841649438f1b8f56f9820bcd,PD1,0.330059
uuid-df4ccf41841649438f1b8f56f9820bcd,approved,0.40201
uuid-df4ccf41841649438f1b8f56f9820bcd,progression,0.483978
uuid-df4ccf41841649438f1b8f56f9820bcd,chemotherapy,0.372302
uuid-df4ccf41841649438f1b8f56f9820bcd,respond,0.324225
uuid-df4ccf41841649438f1b8f56f9820bcd,RTL stated,0.406098
uuid-df4ccf41841649438f1b8f56f9820bcd,option,0.498897
uuid-46da84891e8b4f48a6758ee93c7f0efa,patients,0.416258
uuid-46da84891e8b4f48a6758ee93c7f0efa,therapy,0.397021
uuid-46da84891e8b4f48a6758ee93c7f0efa,regimen,0.436072
uuid-46da84891e8b4f48a6758ee93c7f0efa,treated,0.410784
uuid-46da84891e8b4f48a6758ee93c7f0efa,combination,0.389446
uuid-46da84891e8b4f48a6758ee93c7f0efa,chemo,0.358962
uuid-46da84891e8b4f48a6758ee93c7f0efa,tumor,0.441881
uuid-46da84891e8b4f48a6758ee93c7f0efa,pts,0.496966
uuid-46da84891e8b4f48a6758ee93c7f0efa,IO,0.399305
uuid-46da84891e8b4f48a6758ee93c7f0efa,monotherapy,0.363652
uuid-46da84891e8b4f48a6758ee93c7f0efa,treatment,0.399681
uuid-46da84891e8b4f48a6758ee93c7f0efa,response,0.4677
uuid-46da84891e8b4f48a6758ee93c7f0efa,combo,0.417564
uuid-46da84891e8b4f48a6758ee93c7f0efa,PD1,0.378957
uuid-46da84891e8b4f48a6758ee93c7f0efa,progression,0.60506
uuid-46da84891e8b4f48a6758ee93c7f0efa,chemotherapy,0.327312
uuid-46da84891e8b4f48a6758ee93c7f0efa,respond,0.338471
uuid-845025b4df8c43b58dbe74ab41305030,institution,0.322595
uuid-845025b4df8c43b58dbe74ab41305030,physicians,0.39959
uuid-845025b4df8c43b58dbe74ab41305030,oncology,0.564423
uuid-845025b4df8c43b58dbe74ab41305030,drug,0.670817
uuid-845025b4df8c43b58dbe74ab41305030,clinical,0.354316
uuid-a3b49149bfab44059e56a67fa2d781aa,Nivo,0.312768
uuid-a3b49149bfab44059e56a67fa2d781aa,patients,0.896319
uuid-a3b49149bfab44059e56a67fa2d781aa,Opdivo,0.427792
uuid-a3b49149bfab44059e56a67fa2d781aa,therapy,0.689859
uuid-a3b49149bfab44059e56a67fa2d781aa,nivolumab,0.525926
uuid-a3b49149bfab44059e56a67fa2d781aa,regimen,0.381752
uuid-a3b49149bfab44059e56a67fa2d781aa,treated,0.531116
uuid-a3b49149bfab44059e56a67fa2d781aa,chemo,0.325822
uuid-a3b49149bfab44059e56a67fa2d781aa,pts,0.514817
uuid-a3b49149bfab44059e56a67fa2d781aa,monotherapy,0.354284
uuid-a3b49149bfab44059e56a67fa2d781aa,treatment,0.633433
uuid-a3b49149bfab44059e56a67fa2d781aa,using nivo,0.381452
uuid-a3b49149bfab44059e56a67fa2d781aa,response,0.336517
uuid-a3b49149bfab44059e56a67fa2d781aa,cHL,0.467677
uuid-a3b49149bfab44059e56a67fa2d781aa,progression,0.605285
uuid-a3b49149bfab44059e56a67fa2d781aa,chemotherapy,0.411789
uuid-a3b49149bfab44059e56a67fa2d781aa,respond,0.422981
uuid-a3b49149bfab44059e56a67fa2d781aa,option,0.35061
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,patients,0.332753
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,lung,0.36854
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,treated,0.659526
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,melanoma,0.391902
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,RCC,0.451239
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,TL stated,0.602557
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,PDL1 testing,0.346052
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,NSCLC patients,0.457919
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,SCCHN,0.337845
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,RTL stated,0.428831
uuid-3eaaa77588c14d3c8496e97cd9c38ca5,TL shared,0.601903
uuid-bb8fcf0110f440ebb8169f3993aa2f2f,dose,0.499934
uuid-bb8fcf0110f440ebb8169f3993aa2f2f,toxicity,0.463937
uuid-bb8fcf0110f440ebb8169f3993aa2f2f,Ipi,0.445063
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,Nivo,0.553082
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,pembro,0.562797
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,1L,0.626737
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,PDL1,0.367271
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,efficacy,0.451004
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,regimen,0.346895
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,combination,0.439698
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,chemo,0.555008
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,2L,0.551447
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,pts,0.36757
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,IO,0.30204
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,agents,0.422769
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,Ipi,0.397245
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,atezo,0.507147
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,preferred,0.494012
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,monotherapy,0.66287
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,using nivo,0.363972
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,combo,0.554207
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,PD1,0.40967
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,approved,0.309765
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,nivo and pembro,0.433974
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,believes,0.515778
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,chemotherapy,0.407476
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,vs,0.347009
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,feels,0.450106
uuid-1a1fa8d7d3c34310b13cdfb59b36c383,option,0.583279
uuid-21a5a71040a0470586bc6c20d3f5c204,Opdivo,0.375033
uuid-21a5a71040a0470586bc6c20d3f5c204,dose,0.305531
uuid-21a5a71040a0470586bc6c20d3f5c204,efficacy,0.43658
uuid-21a5a71040a0470586bc6c20d3f5c204,data,0.345268
uuid-21a5a71040a0470586bc6c20d3f5c204,vs,0.337078
uuid-21a5a71040a0470586bc6c20d3f5c204,Keytruda,0.355397
uuid-21a5a71040a0470586bc6c20d3f5c204,flat dosing,0.321255
uuid-313e66c82b2042e7b63aa3767acdbf4f,patients,0.312063
uuid-313e66c82b2042e7b63aa3767acdbf4f,Opdivo,0.305675
uuid-313e66c82b2042e7b63aa3767acdbf4f,toxicity,0.394821
uuid-313e66c82b2042e7b63aa3767acdbf4f,regimen,0.558682
uuid-313e66c82b2042e7b63aa3767acdbf4f,treated,0.375486
uuid-313e66c82b2042e7b63aa3767acdbf4f,melanoma,0.482456
uuid-313e66c82b2042e7b63aa3767acdbf4f,physicians,0.330863
uuid-313e66c82b2042e7b63aa3767acdbf4f,treatment,0.531622
uuid-313e66c82b2042e7b63aa3767acdbf4f,progression,0.371481
uuid-313e66c82b2042e7b63aa3767acdbf4f,TL shared,0.47772
uuid-c2fcca261a304489be9a8407ef975ef7,TL,0.463447
uuid-c2fcca261a304489be9a8407ef975ef7,1L,0.305772
uuid-c2fcca261a304489be9a8407ef975ef7,shared,0.317345
uuid-c2fcca261a304489be9a8407ef975ef7,RCC,0.334387
uuid-c2fcca261a304489be9a8407ef975ef7,TL stated,0.585889
uuid-c2fcca261a304489be9a8407ef975ef7,2L,0.318758
uuid-c2fcca261a304489be9a8407ef975ef7,institution,0.558231
uuid-c2fcca261a304489be9a8407ef975ef7,stated,0.396236
uuid-c2fcca261a304489be9a8407ef975ef7,PD-L1,0.53908
uuid-c2fcca261a304489be9a8407ef975ef7,approval,0.343839
uuid-c2fcca261a304489be9a8407ef975ef7,PD-L1 testing,0.687439
uuid-c2fcca261a304489be9a8407ef975ef7,testing,0.67661
uuid-c2fcca261a304489be9a8407ef975ef7,PDL1 testing,0.741257
uuid-c2fcca261a304489be9a8407ef975ef7,NSCLC patients,0.612192
uuid-c2fcca261a304489be9a8407ef975ef7,SCCHN,0.419309
uuid-c2fcca261a304489be9a8407ef975ef7,tumor types,0.345659
uuid-c2fcca261a304489be9a8407ef975ef7,academic,0.307521
uuid-c2fcca261a304489be9a8407ef975ef7,assay,0.337121
uuid-c2fcca261a304489be9a8407ef975ef7,Regional TL,0.337866
uuid-c2fcca261a304489be9a8407ef975ef7,RTL stated,0.404542
uuid-b06dcd9da207427cb29be1394ba508b4,patients,0.365311
uuid-b06dcd9da207427cb29be1394ba508b4,Opdivo,0.309955
uuid-b06dcd9da207427cb29be1394ba508b4,therapy,0.376131
uuid-b06dcd9da207427cb29be1394ba508b4,nivolumab,0.314502
uuid-b06dcd9da207427cb29be1394ba508b4,toxicity,0.345882
uuid-b06dcd9da207427cb29be1394ba508b4,regimen,0.731369
uuid-b06dcd9da207427cb29be1394ba508b4,treated,0.350717
uuid-b06dcd9da207427cb29be1394ba508b4,RCC,0.312951
uuid-b06dcd9da207427cb29be1394ba508b4,combination,0.444269
uuid-b06dcd9da207427cb29be1394ba508b4,chemo,0.366382
uuid-b06dcd9da207427cb29be1394ba508b4,pts,0.425989
uuid-b06dcd9da207427cb29be1394ba508b4,IO,0.421306
uuid-b06dcd9da207427cb29be1394ba508b4,monotherapy,0.518982
uuid-b06dcd9da207427cb29be1394ba508b4,treatment,0.50205
uuid-b06dcd9da207427cb29be1394ba508b4,response,0.385456
uuid-b06dcd9da207427cb29be1394ba508b4,combo,0.488385
uuid-b06dcd9da207427cb29be1394ba508b4,PD1,0.329707
uuid-b06dcd9da207427cb29be1394ba508b4,progression,0.524592
uuid-b06dcd9da207427cb29be1394ba508b4,chemotherapy,0.336185
uuid-b06dcd9da207427cb29be1394ba508b4,respond,0.383812
uuid-b06dcd9da207427cb29be1394ba508b4,option,0.392883
uuid-4565b2d4136a452aa09cf56996e3a2f1,patients,0.357606
uuid-4565b2d4136a452aa09cf56996e3a2f1,therapy,0.366917
uuid-4565b2d4136a452aa09cf56996e3a2f1,lung,0.332373
uuid-4565b2d4136a452aa09cf56996e3a2f1,1L,0.579043
uuid-4565b2d4136a452aa09cf56996e3a2f1,regimen,0.549811
uuid-4565b2d4136a452aa09cf56996e3a2f1,treated,0.318665
uuid-4565b2d4136a452aa09cf56996e3a2f1,melanoma,0.452603
uuid-4565b2d4136a452aa09cf56996e3a2f1,RCC,0.559724
uuid-4565b2d4136a452aa09cf56996e3a2f1,combination,0.349424
uuid-4565b2d4136a452aa09cf56996e3a2f1,chemo,0.41399
uuid-4565b2d4136a452aa09cf56996e3a2f1,2L,0.534883
uuid-4565b2d4136a452aa09cf56996e3a2f1,pts,0.43735
uuid-4565b2d4136a452aa09cf56996e3a2f1,IO,0.329135
uuid-4565b2d4136a452aa09cf56996e3a2f1,agents,0.30625
uuid-4565b2d4136a452aa09cf56996e3a2f1,preferred,0.47542
uuid-4565b2d4136a452aa09cf56996e3a2f1,monotherapy,0.595772
uuid-4565b2d4136a452aa09cf56996e3a2f1,treatment,0.490774
uuid-4565b2d4136a452aa09cf56996e3a2f1,using nivo,0.368254
uuid-4565b2d4136a452aa09cf56996e3a2f1,combo,0.488967
uuid-4565b2d4136a452aa09cf56996e3a2f1,PD1,0.413062
uuid-4565b2d4136a452aa09cf56996e3a2f1,SCCHN,0.322866
uuid-4565b2d4136a452aa09cf56996e3a2f1,progression,0.460579
uuid-4565b2d4136a452aa09cf56996e3a2f1,believes,0.300276
uuid-4565b2d4136a452aa09cf56996e3a2f1,chemotherapy,0.37875
uuid-4565b2d4136a452aa09cf56996e3a2f1,RTL stated,0.439648
uuid-4565b2d4136a452aa09cf56996e3a2f1,TL shared,0.486029
uuid-4565b2d4136a452aa09cf56996e3a2f1,option,0.634841
uuid-755f36f7c827426ba5a37969e49ca849,Opdivo,0.335262
uuid-755f36f7c827426ba5a37969e49ca849,dose,0.471457
uuid-755f36f7c827426ba5a37969e49ca849,drug,0.525534
uuid-755f36f7c827426ba5a37969e49ca849,Keytruda,0.561538
uuid-755f36f7c827426ba5a37969e49ca849,flat dosing,0.540156
uuid-adfafee8001943d6bbbdb630b4a3fc43,Nivo,0.451948
uuid-adfafee8001943d6bbbdb630b4a3fc43,patients,0.763935
uuid-adfafee8001943d6bbbdb630b4a3fc43,Opdivo,0.352311
uuid-adfafee8001943d6bbbdb630b4a3fc43,therapy,0.784122
uuid-adfafee8001943d6bbbdb630b4a3fc43,nivolumab,0.47341
uuid-adfafee8001943d6bbbdb630b4a3fc43,treated,0.383616
uuid-adfafee8001943d6bbbdb630b4a3fc43,chemo,0.472565
uuid-adfafee8001943d6bbbdb630b4a3fc43,pts,0.408268
uuid-adfafee8001943d6bbbdb630b4a3fc43,monotherapy,0.337343
uuid-adfafee8001943d6bbbdb630b4a3fc43,treatment,0.586431
uuid-adfafee8001943d6bbbdb630b4a3fc43,response,0.378075
uuid-adfafee8001943d6bbbdb630b4a3fc43,PD1,0.454279
uuid-adfafee8001943d6bbbdb630b4a3fc43,cHL,0.591223
uuid-adfafee8001943d6bbbdb630b4a3fc43,progression,0.566436
uuid-adfafee8001943d6bbbdb630b4a3fc43,chemotherapy,0.56041
uuid-adfafee8001943d6bbbdb630b4a3fc43,respond,0.414886
uuid-adfafee8001943d6bbbdb630b4a3fc43,option,0.35964
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,Nivo,0.418373
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,patients,0.495757
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,therapy,0.555142
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,nivolumab,0.39611
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,chemo,0.370018
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,treatment,0.320294
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,response,0.326253
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,PD1,0.328919
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,cHL,0.490332
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,progression,0.350285
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,chemotherapy,0.480341
uuid-a39aaf7c01ea482b9c5b40e6721f65eb,respond,0.319991
uuid-5915d56f63d046e1a9d2a6c801cfd458,BMS,0.447807
uuid-5915d56f63d046e1a9d2a6c801cfd458,NTL,0.356787
uuid-5915d56f63d046e1a9d2a6c801cfd458,discussed,0.396701
uuid-5915d56f63d046e1a9d2a6c801cfd458,commented,0.587928
uuid-5915d56f63d046e1a9d2a6c801cfd458,OS,0.331492
uuid-5915d56f63d046e1a9d2a6c801cfd458,regards,0.469123
uuid-5915d56f63d046e1a9d2a6c801cfd458,data,0.549716
uuid-5915d56f63d046e1a9d2a6c801cfd458,expressed,0.362991
uuid-5915d56f63d046e1a9d2a6c801cfd458,ORR,0.320913
uuid-5915d56f63d046e1a9d2a6c801cfd458,lung cancer,0.480769
uuid-5915d56f63d046e1a9d2a6c801cfd458,ASCO,0.60531
uuid-5915d56f63d046e1a9d2a6c801cfd458,impressed,0.52398
uuid-5915d56f63d046e1a9d2a6c801cfd458,Regional TL,0.328208
uuid-f60ff7c43a124368a669512b46e2d609,dose,0.592892
uuid-f60ff7c43a124368a669512b46e2d609,toxicity,0.411663
uuid-f60ff7c43a124368a669512b46e2d609,regimen,0.311606
uuid-f60ff7c43a124368a669512b46e2d609,combination,0.496769
uuid-f60ff7c43a124368a669512b46e2d609,chemo,0.307884
uuid-f60ff7c43a124368a669512b46e2d609,Ipi,0.613106
uuid-f60ff7c43a124368a669512b46e2d609,combo,0.494222
uuid-f60ff7c43a124368a669512b46e2d609,vs,0.468988
uuid-f60ff7c43a124368a669512b46e2d609,flat dosing,0.319639
uuid-5768a6ecf93d4c12a8887dce7dd22415,patients,0.395541
uuid-5768a6ecf93d4c12a8887dce7dd22415,nivolumab,0.453548
uuid-5768a6ecf93d4c12a8887dce7dd22415,treated,0.593842
uuid-5768a6ecf93d4c12a8887dce7dd22415,treatment,0.351061
uuid-5768a6ecf93d4c12a8887dce7dd22415,SCCHN,0.303002
uuid-5768a6ecf93d4c12a8887dce7dd22415,ASCO,0.367898
uuid-5768a6ecf93d4c12a8887dce7dd22415,Regional TL,0.443103
uuid-5768a6ecf93d4c12a8887dce7dd22415,TL shared,0.322473
uuid-5768a6ecf93d4c12a8887dce7dd22415,bladder,0.34833
uuid-2c78b94bff6b4605a6562555e5ac5611,efficacy,0.314655
uuid-2c78b94bff6b4605a6562555e5ac5611,discussed,0.641661
uuid-2c78b94bff6b4605a6562555e5ac5611,commented,0.476571
uuid-2c78b94bff6b4605a6562555e5ac5611,OS,0.324689
uuid-2c78b94bff6b4605a6562555e5ac5611,data,0.60782
uuid-2c78b94bff6b4605a6562555e5ac5611,ORR,0.34234
uuid-2c78b94bff6b4605a6562555e5ac5611,ASCO,0.711231
uuid-2c78b94bff6b4605a6562555e5ac5611,impressed,0.539181
uuid-2c78b94bff6b4605a6562555e5ac5611,Regional TL,0.314943
uuid-56c58ae26f994932a9ae5c3011b543a5,1L,0.333446
uuid-56c58ae26f994932a9ae5c3011b543a5,2L,0.311245
uuid-56c58ae26f994932a9ae5c3011b543a5,PD-L1,0.304463
uuid-56c58ae26f994932a9ae5c3011b543a5,testing,0.363238
uuid-56c58ae26f994932a9ae5c3011b543a5,PDL1 testing,0.378239
uuid-56c58ae26f994932a9ae5c3011b543a5,NSCLC patients,0.359965
uuid-7c8f0fe441144e04b205aee0e3a27667,patients,0.614717
uuid-7c8f0fe441144e04b205aee0e3a27667,therapy,0.351464
uuid-7c8f0fe441144e04b205aee0e3a27667,nivolumab,0.327748
uuid-7c8f0fe441144e04b205aee0e3a27667,chemo,0.327886
uuid-7c8f0fe441144e04b205aee0e3a27667,pts,0.353068
uuid-7c8f0fe441144e04b205aee0e3a27667,preferred,0.310279
uuid-7c8f0fe441144e04b205aee0e3a27667,monotherapy,0.361148
uuid-7c8f0fe441144e04b205aee0e3a27667,using nivo,0.358502
uuid-7c8f0fe441144e04b205aee0e3a27667,clinical trials,0.327951
uuid-7c8f0fe441144e04b205aee0e3a27667,NSCLC patients,0.328579
uuid-7c8f0fe441144e04b205aee0e3a27667,chemotherapy,0.363627
uuid-7c8f0fe441144e04b205aee0e3a27667,tumor types,0.384839
uuid-7c8f0fe441144e04b205aee0e3a27667,feels,0.334429
uuid-7c8f0fe441144e04b205aee0e3a27667,RTL stated,0.346984
uuid-7c8f0fe441144e04b205aee0e3a27667,option,0.482346
uuid-5c97699640f74ea0887717c02d52f37f,patients,0.343586
uuid-5c97699640f74ea0887717c02d52f37f,toxicity,0.389598
uuid-5c97699640f74ea0887717c02d52f37f,regimen,0.388263
uuid-5c97699640f74ea0887717c02d52f37f,treated,0.349388
uuid-5c97699640f74ea0887717c02d52f37f,physicians,0.420572
uuid-5c97699640f74ea0887717c02d52f37f,treatment,0.536433
uuid-5c97699640f74ea0887717c02d52f37f,progression,0.366299
uuid-5c97699640f74ea0887717c02d52f37f,respond,0.385771
uuid-5c97699640f74ea0887717c02d52f37f,option,0.320273
uuid-6e6d0659bdfc4869be592b4fd9d38b66,AI,0.436007
uuid-6e6d0659bdfc4869be592b4fd9d38b66,oncology,0.375462
uuid-6e6d0659bdfc4869be592b4fd9d38b66,drug,0.537384
uuid-6e6d0659bdfc4869be592b4fd9d38b66,clinical,0.461766
uuid-af386c20ccfa448680466bb01e0a0ab2,2L,0.323739
uuid-af386c20ccfa448680466bb01e0a0ab2,agents,0.57461
uuid-af386c20ccfa448680466bb01e0a0ab2,preferred,0.446099
uuid-af386c20ccfa448680466bb01e0a0ab2,indication,0.453915
uuid-af386c20ccfa448680466bb01e0a0ab2,oncology,0.382727
uuid-af386c20ccfa448680466bb01e0a0ab2,approved,0.328544
uuid-af386c20ccfa448680466bb01e0a0ab2,drug,0.317926
uuid-af386c20ccfa448680466bb01e0a0ab2,clinical,0.499003
uuid-af386c20ccfa448680466bb01e0a0ab2,option,0.358876
uuid-d9133e38180545bc94b3262c93b0a969,patients,0.54581
uuid-d9133e38180545bc94b3262c93b0a969,therapy,0.473608
uuid-d9133e38180545bc94b3262c93b0a969,nivolumab,0.435003
uuid-d9133e38180545bc94b3262c93b0a969,treated,0.47563
uuid-d9133e38180545bc94b3262c93b0a969,stated,0.341267
uuid-d9133e38180545bc94b3262c93b0a969,approval,0.317521
uuid-d9133e38180545bc94b3262c93b0a969,treatment,0.438373
uuid-d9133e38180545bc94b3262c93b0a969,using nivo,0.430375
uuid-d9133e38180545bc94b3262c93b0a969,clinical trials,0.320753
uuid-d9133e38180545bc94b3262c93b0a969,SCCHN,0.393187
uuid-d9133e38180545bc94b3262c93b0a969,cHL,0.434892
uuid-d9133e38180545bc94b3262c93b0a969,RTL stated,0.443095
uuid-d9133e38180545bc94b3262c93b0a969,option,0.315165
uuid-70ec72587f694b3382df0945a7a59099,Nivo,0.526337
uuid-70ec72587f694b3382df0945a7a59099,patients,0.30845
uuid-70ec72587f694b3382df0945a7a59099,pembro,0.338642
uuid-70ec72587f694b3382df0945a7a59099,RTL,0.316027
uuid-70ec72587f694b3382df0945a7a59099,nivolumab,0.373268
uuid-70ec72587f694b3382df0945a7a59099,1L,0.345924
uuid-70ec72587f694b3382df0945a7a59099,trial,0.367078
uuid-70ec72587f694b3382df0945a7a59099,combination,0.385108
uuid-70ec72587f694b3382df0945a7a59099,chemo,0.377114
uuid-70ec72587f694b3382df0945a7a59099,OS,0.344566
uuid-70ec72587f694b3382df0945a7a59099,monotherapy,0.478462
uuid-70ec72587f694b3382df0945a7a59099,using nivo,0.445484
uuid-70ec72587f694b3382df0945a7a59099,data,0.450551
uuid-70ec72587f694b3382df0945a7a59099,combo,0.318434
uuid-70ec72587f694b3382df0945a7a59099,clinical trials,0.353992
uuid-70ec72587f694b3382df0945a7a59099,PFS,0.322525
uuid-70ec72587f694b3382df0945a7a59099,PD1,0.343916
uuid-70ec72587f694b3382df0945a7a59099,ORR,0.364547
uuid-70ec72587f694b3382df0945a7a59099,SCCHN,0.334585
uuid-70ec72587f694b3382df0945a7a59099,chemotherapy,0.429866
uuid-70ec72587f694b3382df0945a7a59099,impressed,0.507794
uuid-70ec72587f694b3382df0945a7a59099,SCLC,0.34919
uuid-70ec72587f694b3382df0945a7a59099,feels,0.433416
uuid-70ec72587f694b3382df0945a7a59099,RTL stated,0.350341
uuid-70ec72587f694b3382df0945a7a59099,option,0.487459
uuid-70ec72587f694b3382df0945a7a59099,bladder,0.316081
uuid-d50ce1b606a944aab631b1edf2e8433a,Nivo,0.519591
uuid-d50ce1b606a944aab631b1edf2e8433a,patients,0.467851
uuid-d50ce1b606a944aab631b1edf2e8433a,pembro,0.389441
uuid-d50ce1b606a944aab631b1edf2e8433a,therapy,0.489805
uuid-d50ce1b606a944aab631b1edf2e8433a,nivolumab,0.383011
uuid-d50ce1b606a944aab631b1edf2e8433a,1L,0.438926
uuid-d50ce1b606a944aab631b1edf2e8433a,trial,0.34711
uuid-d50ce1b606a944aab631b1edf2e8433a,regimen,0.31067
uuid-d50ce1b606a944aab631b1edf2e8433a,combination,0.457291
uuid-d50ce1b606a944aab631b1edf2e8433a,chemo,0.595476
uuid-d50ce1b606a944aab631b1edf2e8433a,2L,0.325645
uuid-d50ce1b606a944aab631b1edf2e8433a,pts,0.644624
uuid-d50ce1b606a944aab631b1edf2e8433a,monotherapy,0.573681
uuid-d50ce1b606a944aab631b1edf2e8433a,using nivo,0.351351
uuid-d50ce1b606a944aab631b1edf2e8433a,response,0.379749
uuid-d50ce1b606a944aab631b1edf2e8433a,combo,0.409816
uuid-d50ce1b606a944aab631b1edf2e8433a,PD1,0.513299
uuid-d50ce1b606a944aab631b1edf2e8433a,progression,0.430146
uuid-d50ce1b606a944aab631b1edf2e8433a,believes,0.301039
uuid-d50ce1b606a944aab631b1edf2e8433a,chemotherapy,0.533017
uuid-d50ce1b606a944aab631b1edf2e8433a,respond,0.324351
uuid-d50ce1b606a944aab631b1edf2e8433a,feels,0.385839
uuid-d50ce1b606a944aab631b1edf2e8433a,option,0.487907
uuid-be7f5c5284394aeba3fc76156d4a1197,TL,0.327645
uuid-be7f5c5284394aeba3fc76156d4a1197,RTL,0.42307
uuid-be7f5c5284394aeba3fc76156d4a1197,NTL,0.34036
uuid-be7f5c5284394aeba3fc76156d4a1197,shared,0.398926
uuid-be7f5c5284394aeba3fc76156d4a1197,institution,0.362423
uuid-be7f5c5284394aeba3fc76156d4a1197,stated,0.356362
uuid-be7f5c5284394aeba3fc76156d4a1197,physicians,0.406754
uuid-be7f5c5284394aeba3fc76156d4a1197,clinical trials,0.311324
uuid-be7f5c5284394aeba3fc76156d4a1197,oncology,0.61301
uuid-be7f5c5284394aeba3fc76156d4a1197,SCCHN,0.332229
uuid-be7f5c5284394aeba3fc76156d4a1197,oncologist,0.40097
uuid-be7f5c5284394aeba3fc76156d4a1197,LTL,0.389849
uuid-be7f5c5284394aeba3fc76156d4a1197,clinical,0.467462
uuid-be7f5c5284394aeba3fc76156d4a1197,academic,0.408129
uuid-be7f5c5284394aeba3fc76156d4a1197,Regional TL,0.516562
uuid-6671d16b84e445459a2ee75cb20df5f7,patients,0.67903
uuid-6671d16b84e445459a2ee75cb20df5f7,therapy,0.515071
uuid-6671d16b84e445459a2ee75cb20df5f7,nivolumab,0.418732
uuid-6671d16b84e445459a2ee75cb20df5f7,1L,0.593872
uuid-6671d16b84e445459a2ee75cb20df5f7,regimen,0.37881
uuid-6671d16b84e445459a2ee75cb20df5f7,treated,0.451507
uuid-6671d16b84e445459a2ee75cb20df5f7,RCC,0.34032
uuid-6671d16b84e445459a2ee75cb20df5f7,chemo,0.493555
uuid-6671d16b84e445459a2ee75cb20df5f7,2L,0.522311
uuid-6671d16b84e445459a2ee75cb20df5f7,pts,0.571883
uuid-6671d16b84e445459a2ee75cb20df5f7,preferred,0.471375
uuid-6671d16b84e445459a2ee75cb20df5f7,testing,0.302738
uuid-6671d16b84e445459a2ee75cb20df5f7,monotherapy,0.630147
uuid-6671d16b84e445459a2ee75cb20df5f7,treatment,0.471897
uuid-6671d16b84e445459a2ee75cb20df5f7,using nivo,0.461319
uuid-6671d16b84e445459a2ee75cb20df5f7,combo,0.314579
uuid-6671d16b84e445459a2ee75cb20df5f7,PDL1 testing,0.331928
uuid-6671d16b84e445459a2ee75cb20df5f7,NSCLC patients,0.52822
uuid-6671d16b84e445459a2ee75cb20df5f7,PD1,0.461561
uuid-6671d16b84e445459a2ee75cb20df5f7,progression,0.484088
uuid-6671d16b84e445459a2ee75cb20df5f7,chemotherapy,0.469117
uuid-6671d16b84e445459a2ee75cb20df5f7,respond,0.3116
uuid-6671d16b84e445459a2ee75cb20df5f7,PD-1,0.322643
uuid-6671d16b84e445459a2ee75cb20df5f7,RTL stated,0.442989
uuid-6671d16b84e445459a2ee75cb20df5f7,option,0.612768
uuid-806f1435c9fd414ea10736249e9e9551,RTL,0.349008
uuid-806f1435c9fd414ea10736249e9e9551,BMS,0.320351
uuid-806f1435c9fd414ea10736249e9e9551,commented,0.324827
uuid-806f1435c9fd414ea10736249e9e9551,institution,0.323799
uuid-806f1435c9fd414ea10736249e9e9551,stated,0.560059
uuid-806f1435c9fd414ea10736249e9e9551,approval,0.358677
uuid-806f1435c9fd414ea10736249e9e9551,data,0.439641
uuid-806f1435c9fd414ea10736249e9e9551,indication,0.327758
uuid-806f1435c9fd414ea10736249e9e9551,approved,0.33931
uuid-806f1435c9fd414ea10736249e9e9551,SCCHN,0.477737
uuid-806f1435c9fd414ea10736249e9e9551,impressed,0.323605
uuid-806f1435c9fd414ea10736249e9e9551,label,0.381641
uuid-806f1435c9fd414ea10736249e9e9551,SCLC,0.314243
uuid-806f1435c9fd414ea10736249e9e9551,Regional TL,0.31087
uuid-806f1435c9fd414ea10736249e9e9551,NCCN,0.513131
uuid-a2a4be4772094049a0e4ccd44dd8b110,patients,0.421545
uuid-a2a4be4772094049a0e4ccd44dd8b110,regimen,0.354185
uuid-a2a4be4772094049a0e4ccd44dd8b110,chemo,0.422237
uuid-a2a4be4772094049a0e4ccd44dd8b110,pts,0.422911
uuid-a2a4be4772094049a0e4ccd44dd8b110,treatment,0.358213
uuid-a2a4be4772094049a0e4ccd44dd8b110,response,0.428873
uuid-a2a4be4772094049a0e4ccd44dd8b110,PD1,0.308145
uuid-a2a4be4772094049a0e4ccd44dd8b110,progression,0.555839
uuid-a2a4be4772094049a0e4ccd44dd8b110,believes,0.35596
uuid-a2a4be4772094049a0e4ccd44dd8b110,respond,0.59507
uuid-a2a4be4772094049a0e4ccd44dd8b110,feels,0.415686
uuid-f3257632107a459fbd23fa27c3c65ad7,patients,0.660676
uuid-f3257632107a459fbd23fa27c3c65ad7,therapy,0.390719
uuid-f3257632107a459fbd23fa27c3c65ad7,regimen,0.364289
uuid-f3257632107a459fbd23fa27c3c65ad7,treated,0.431563
uuid-f3257632107a459fbd23fa27c3c65ad7,pts,0.447523
uuid-f3257632107a459fbd23fa27c3c65ad7,treatment,0.552069
uuid-f3257632107a459fbd23fa27c3c65ad7,response,0.358594
uuid-f3257632107a459fbd23fa27c3c65ad7,progression,0.558783
uuid-f3257632107a459fbd23fa27c3c65ad7,respond,0.484918
uuid-5de02a76bd2647d18e3b52e0b0f830c8,Nivo,0.448491
uuid-5de02a76bd2647d18e3b52e0b0f830c8,RTL,0.499963
uuid-5de02a76bd2647d18e3b52e0b0f830c8,trial,0.36144
uuid-5de02a76bd2647d18e3b52e0b0f830c8,RCC,0.310451
uuid-5de02a76bd2647d18e3b52e0b0f830c8,stated,0.32409
uuid-5de02a76bd2647d18e3b52e0b0f830c8,approval,0.312413
uuid-5de02a76bd2647d18e3b52e0b0f830c8,OS,0.32107
uuid-5de02a76bd2647d18e3b52e0b0f830c8,using nivo,0.385544
uuid-5de02a76bd2647d18e3b52e0b0f830c8,data,0.460442
uuid-5de02a76bd2647d18e3b52e0b0f830c8,ORR,0.336463
uuid-5de02a76bd2647d18e3b52e0b0f830c8,SCCHN,0.360564
uuid-5de02a76bd2647d18e3b52e0b0f830c8,impressed,0.597065
uuid-5de02a76bd2647d18e3b52e0b0f830c8,LTL,0.365513
uuid-5de02a76bd2647d18e3b52e0b0f830c8,SCLC,0.348459
uuid-5de02a76bd2647d18e3b52e0b0f830c8,Regional TL,0.387352
uuid-5de02a76bd2647d18e3b52e0b0f830c8,RTL stated,0.318655
uuid-1114db56baf74815acb89f249338b0ba,pembro,0.393642
uuid-1114db56baf74815acb89f249338b0ba,lung,0.507775
uuid-1114db56baf74815acb89f249338b0ba,1L,0.658074
uuid-1114db56baf74815acb89f249338b0ba,PDL1,0.321875
uuid-1114db56baf74815acb89f249338b0ba,melanoma,0.315641
uuid-1114db56baf74815acb89f249338b0ba,RCC,0.6369
uuid-1114db56baf74815acb89f249338b0ba,TL stated,0.571485
uuid-1114db56baf74815acb89f249338b0ba,2L,0.650992
uuid-1114db56baf74815acb89f249338b0ba,agents,0.378531
uuid-1114db56baf74815acb89f249338b0ba,PD-L1,0.312453
uuid-1114db56baf74815acb89f249338b0ba,approval,0.305408
uuid-1114db56baf74815acb89f249338b0ba,atezo,0.46072
uuid-1114db56baf74815acb89f249338b0ba,preferred,0.604243
uuid-1114db56baf74815acb89f249338b0ba,monotherapy,0.378202
uuid-1114db56baf74815acb89f249338b0ba,using nivo,0.495303
uuid-1114db56baf74815acb89f249338b0ba,expressed,0.321251
uuid-1114db56baf74815acb89f249338b0ba,PDL1 testing,0.535949
uuid-1114db56baf74815acb89f249338b0ba,indication,0.356851
uuid-1114db56baf74815acb89f249338b0ba,NSCLC patients,0.370976
uuid-1114db56baf74815acb89f249338b0ba,approved,0.358989
uuid-1114db56baf74815acb89f249338b0ba,SCCHN,0.554815
uuid-1114db56baf74815acb89f249338b0ba,nivo and pembro,0.324118
uuid-1114db56baf74815acb89f249338b0ba,believes,0.32149
uuid-1114db56baf74815acb89f249338b0ba,tumor types,0.421917
uuid-1114db56baf74815acb89f249338b0ba,TLs,0.422891
uuid-1114db56baf74815acb89f249338b0ba,Regional TL,0.346365
uuid-1114db56baf74815acb89f249338b0ba,RTL stated,0.570059
uuid-1114db56baf74815acb89f249338b0ba,TL shared,0.506048
uuid-1114db56baf74815acb89f249338b0ba,option,0.449752
uuid-1114db56baf74815acb89f249338b0ba,bladder,0.497256
uuid-5183b1e7461c4b2585110333d92fc543,Nivo,0.395825
uuid-5183b1e7461c4b2585110333d92fc543,patients,0.352166
uuid-5183b1e7461c4b2585110333d92fc543,therapy,0.379418
uuid-5183b1e7461c4b2585110333d92fc543,nivolumab,0.358954
uuid-5183b1e7461c4b2585110333d92fc543,1L,0.517793
uuid-5183b1e7461c4b2585110333d92fc543,toxicity,0.325003
uuid-5183b1e7461c4b2585110333d92fc543,regimen,0.487675
uuid-5183b1e7461c4b2585110333d92fc543,RCC,0.365964
uuid-5183b1e7461c4b2585110333d92fc543,combination,0.550466
uuid-5183b1e7461c4b2585110333d92fc543,chemo,0.503362
uuid-5183b1e7461c4b2585110333d92fc543,2L,0.546978
uuid-5183b1e7461c4b2585110333d92fc543,pts,0.372454
uuid-5183b1e7461c4b2585110333d92fc543,IO,0.503275
uuid-5183b1e7461c4b2585110333d92fc543,agents,0.496678
uuid-5183b1e7461c4b2585110333d92fc543,preferred,0.575629
uuid-5183b1e7461c4b2585110333d92fc543,monotherapy,0.686112
uuid-5183b1e7461c4b2585110333d92fc543,treatment,0.356705
uuid-5183b1e7461c4b2585110333d92fc543,using nivo,0.447562
uuid-5183b1e7461c4b2585110333d92fc543,response,0.311945
uuid-5183b1e7461c4b2585110333d92fc543,combo,0.553126
uuid-5183b1e7461c4b2585110333d92fc543,PD1,0.437118
uuid-5183b1e7461c4b2585110333d92fc543,approved,0.448198
uuid-5183b1e7461c4b2585110333d92fc543,progression,0.376051
uuid-5183b1e7461c4b2585110333d92fc543,believes,0.346467
uuid-5183b1e7461c4b2585110333d92fc543,chemotherapy,0.418744
uuid-5183b1e7461c4b2585110333d92fc543,feels,0.396386
uuid-5183b1e7461c4b2585110333d92fc543,RTL stated,0.381981
uuid-5183b1e7461c4b2585110333d92fc543,option,0.676663
uuid-8ecae40de4234323bf73bf77557e2219,lung,0.330351
uuid-8ecae40de4234323bf73bf77557e2219,shared,0.388228
uuid-8ecae40de4234323bf73bf77557e2219,institution,0.409495
uuid-8ecae40de4234323bf73bf77557e2219,physicians,0.347431
uuid-8ecae40de4234323bf73bf77557e2219,AI,0.442362
uuid-8ecae40de4234323bf73bf77557e2219,oncology,0.728122
uuid-8ecae40de4234323bf73bf77557e2219,drug,0.383083
uuid-8ecae40de4234323bf73bf77557e2219,clinical,0.432387
uuid-3ac27bd160394156a102e1c895324bfe,Nivo,0.42559
uuid-3ac27bd160394156a102e1c895324bfe,patients,0.453057
uuid-3ac27bd160394156a102e1c895324bfe,therapy,0.470072
uuid-3ac27bd160394156a102e1c895324bfe,1L,0.315998
uuid-3ac27bd160394156a102e1c895324bfe,regimen,0.449768
uuid-3ac27bd160394156a102e1c895324bfe,chemo,0.646777
uuid-3ac27bd160394156a102e1c895324bfe,pts,0.453376
uuid-3ac27bd160394156a102e1c895324bfe,IO,0.303694
uuid-3ac27bd160394156a102e1c895324bfe,OS,0.551595
uuid-3ac27bd160394156a102e1c895324bfe,monotherapy,0.475103
uuid-3ac27bd160394156a102e1c895324bfe,treatment,0.445192
uuid-3ac27bd160394156a102e1c895324bfe,response,0.515492
uuid-3ac27bd160394156a102e1c895324bfe,PFS,0.502812
uuid-3ac27bd160394156a102e1c895324bfe,PD1,0.397613
uuid-3ac27bd160394156a102e1c895324bfe,ORR,0.394274
uuid-3ac27bd160394156a102e1c895324bfe,progression,0.597504
uuid-3ac27bd160394156a102e1c895324bfe,believes,0.314353
uuid-3ac27bd160394156a102e1c895324bfe,chemotherapy,0.569716
uuid-3ac27bd160394156a102e1c895324bfe,respond,0.466576
uuid-3ac27bd160394156a102e1c895324bfe,feels,0.357871
uuid-3ac27bd160394156a102e1c895324bfe,option,0.402485
uuid-f81d440735b14eee8b5582d057d91229,Nivo,0.506532
uuid-f81d440735b14eee8b5582d057d91229,patients,0.318784
uuid-f81d440735b14eee8b5582d057d91229,pembro,0.670782
uuid-f81d440735b14eee8b5582d057d91229,1L,0.870263
uuid-f81d440735b14eee8b5582d057d91229,RCC,0.40899
uuid-f81d440735b14eee8b5582d057d91229,chemo,0.422514
uuid-f81d440735b14eee8b5582d057d91229,2L,0.872507
uuid-f81d440735b14eee8b5582d057d91229,pts,0.3367
uuid-f81d440735b14eee8b5582d057d91229,agents,0.449008
uuid-f81d440735b14eee8b5582d057d91229,approval,0.409699
uuid-f81d440735b14eee8b5582d057d91229,atezo,0.663428
uuid-f81d440735b14eee8b5582d057d91229,preferred,0.712464
uuid-f81d440735b14eee8b5582d057d91229,testing,0.324843
uuid-f81d440735b14eee8b5582d057d91229,monotherapy,0.611905
uuid-f81d440735b14eee8b5582d057d91229,using nivo,0.635663
uuid-f81d440735b14eee8b5582d057d91229,combo,0.352826
uuid-f81d440735b14eee8b5582d057d91229,PDL1 testing,0.466675
uuid-f81d440735b14eee8b5582d057d91229,NSCLC patients,0.469829
uuid-f81d440735b14eee8b5582d057d91229,PD1,0.311818
uuid-f81d440735b14eee8b5582d057d91229,approved,0.554058
uuid-f81d440735b14eee8b5582d057d91229,nivo and pembro,0.354145
uuid-f81d440735b14eee8b5582d057d91229,believes,0.316509
uuid-f81d440735b14eee8b5582d057d91229,tumor types,0.335988
uuid-f81d440735b14eee8b5582d057d91229,RTL stated,0.469748
uuid-f81d440735b14eee8b5582d057d91229,option,0.661826
uuid-f81d440735b14eee8b5582d057d91229,bladder,0.310715
uuid-3d72e470fb7a444bae7f4df171994085,patients,0.501966
uuid-3d72e470fb7a444bae7f4df171994085,Opdivo,0.682434
uuid-3d72e470fb7a444bae7f4df171994085,nivolumab,0.489793
uuid-3d72e470fb7a444bae7f4df171994085,treated,0.317526
uuid-3d72e470fb7a444bae7f4df171994085,treatment,0.412368
uuid-3d72e470fb7a444bae7f4df171994085,cHL,0.404475
uuid-3d72e470fb7a444bae7f4df171994085,progression,0.30595
uuid-0b13ab6d551f4cfabe9479a4ad461bb4,BMS,0.430079
uuid-0b13ab6d551f4cfabe9479a4ad461bb4,discussed,0.55633
uuid-0b13ab6d551f4cfabe9479a4ad461bb4,physicians,0.370081
uuid-0b13ab6d551f4cfabe9479a4ad461bb4,academic,0.471757
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,patients,0.690399
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,Opdivo,0.559223
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,therapy,0.359773
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,nivolumab,0.44997
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,toxicity,0.313936
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,regimen,0.440665
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,treated,0.440386
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,pts,0.433319
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,treatment,0.462599
uuid-cdcb6e37a21c4dbfa565ecf54e9ea8c6,progression,0.429722
uuid-8d84045f32674279888a2a067353b873,RTL,0.412669
uuid-8d84045f32674279888a2a067353b873,BMS,0.31565
uuid-8d84045f32674279888a2a067353b873,trial,0.413095
uuid-8d84045f32674279888a2a067353b873,commented,0.513589
uuid-8d84045f32674279888a2a067353b873,stated,0.340569
uuid-8d84045f32674279888a2a067353b873,OS,0.553316
uuid-8d84045f32674279888a2a067353b873,data,0.658152
uuid-8d84045f32674279888a2a067353b873,expressed,0.321213
uuid-8d84045f32674279888a2a067353b873,PFS,0.549181
uuid-8d84045f32674279888a2a067353b873,ORR,0.547934
uuid-8d84045f32674279888a2a067353b873,ASCO,0.450179
uuid-8d84045f32674279888a2a067353b873,impressed,0.660995
uuid-8d84045f32674279888a2a067353b873,LTL,0.307488
uuid-8d84045f32674279888a2a067353b873,TLs,0.34917
uuid-8d84045f32674279888a2a067353b873,Regional TL,0.372577
uuid-793bc17e537d4d9796d9116b3a5d7d24,patients,0.366145
uuid-793bc17e537d4d9796d9116b3a5d7d24,toxicity,0.603109
uuid-793bc17e537d4d9796d9116b3a5d7d24,efficacy,0.310985
uuid-793bc17e537d4d9796d9116b3a5d7d24,regimen,0.387806
uuid-793bc17e537d4d9796d9116b3a5d7d24,chemo,0.329952
uuid-793bc17e537d4d9796d9116b3a5d7d24,treatment,0.307293
uuid-793bc17e537d4d9796d9116b3a5d7d24,response,0.480379
uuid-793bc17e537d4d9796d9116b3a5d7d24,progression,0.376165
uuid-793bc17e537d4d9796d9116b3a5d7d24,chemotherapy,0.337379
uuid-793bc17e537d4d9796d9116b3a5d7d24,respond,0.394517
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,patients,0.759355
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,Opdivo,0.507624
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,therapy,0.591323
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,nivolumab,0.434401
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,toxicity,0.325493
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,regimen,0.561658
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,treated,0.542496
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,pts,0.499999
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,treatment,0.797652
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,response,0.313524
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,cHL,0.34975
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,progression,0.673826
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,chemotherapy,0.376151
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,respond,0.483914
uuid-f10e7f03d3fe4ed5a995bee9a0d80349,option,0.320344
uuid-d96359227ef84c3fa112adb5603b5845,oncology,0.364202
uuid-d96359227ef84c3fa112adb5603b5845,drug,0.611902
uuid-f1976a5a231d470b957dd29a821b1d3a,Opdivo,0.334535
uuid-f1976a5a231d470b957dd29a821b1d3a,dose,0.692441
uuid-f1976a5a231d470b957dd29a821b1d3a,indication,0.421418
uuid-f1976a5a231d470b957dd29a821b1d3a,vs,0.405215
uuid-f1976a5a231d470b957dd29a821b1d3a,label,0.328761
uuid-f1976a5a231d470b957dd29a821b1d3a,drug,0.37724
uuid-f1976a5a231d470b957dd29a821b1d3a,Keytruda,0.444874
uuid-f1976a5a231d470b957dd29a821b1d3a,flat dosing,0.874767
uuid-769791de679d4dc49cd983c0890cd03a,pembro,0.604809
uuid-769791de679d4dc49cd983c0890cd03a,1L,0.515078
uuid-769791de679d4dc49cd983c0890cd03a,PDL1,0.580848
uuid-769791de679d4dc49cd983c0890cd03a,2L,0.504811
uuid-769791de679d4dc49cd983c0890cd03a,agents,0.336949
uuid-769791de679d4dc49cd983c0890cd03a,Merck,0.357945
uuid-769791de679d4dc49cd983c0890cd03a,PD-L1,0.550964
uuid-769791de679d4dc49cd983c0890cd03a,atezo,0.643642
uuid-769791de679d4dc49cd983c0890cd03a,preferred,0.407557
uuid-769791de679d4dc49cd983c0890cd03a,PD-L1 testing,0.340077
uuid-769791de679d4dc49cd983c0890cd03a,testing,0.489052
uuid-769791de679d4dc49cd983c0890cd03a,PDL1 testing,0.436966
uuid-769791de679d4dc49cd983c0890cd03a,NSCLC patients,0.365819
uuid-769791de679d4dc49cd983c0890cd03a,approved,0.362853
uuid-769791de679d4dc49cd983c0890cd03a,nivo and pembro,0.466043
uuid-769791de679d4dc49cd983c0890cd03a,believes,0.360934
uuid-769791de679d4dc49cd983c0890cd03a,vs,0.301874
uuid-769791de679d4dc49cd983c0890cd03a,feels,0.360527
uuid-769791de679d4dc49cd983c0890cd03a,assay,0.495338
uuid-769791de679d4dc49cd983c0890cd03a,PDL1 expression,0.408244
uuid-769791de679d4dc49cd983c0890cd03a,biomarker,0.358799
uuid-abfd05db85d84b738a1f75f427cb8599,1L,0.362013
uuid-abfd05db85d84b738a1f75f427cb8599,RCC,0.406269
uuid-abfd05db85d84b738a1f75f427cb8599,TL stated,0.575659
uuid-abfd05db85d84b738a1f75f427cb8599,2L,0.338683
uuid-abfd05db85d84b738a1f75f427cb8599,stated,0.432538
uuid-abfd05db85d84b738a1f75f427cb8599,PD-L1,0.435822
uuid-abfd05db85d84b738a1f75f427cb8599,PD-L1 testing,0.405614
uuid-abfd05db85d84b738a1f75f427cb8599,testing,0.462436
uuid-abfd05db85d84b738a1f75f427cb8599,PDL1 testing,0.638455
uuid-abfd05db85d84b738a1f75f427cb8599,NSCLC patients,0.409762
uuid-abfd05db85d84b738a1f75f427cb8599,SCCHN,0.364318
uuid-abfd05db85d84b738a1f75f427cb8599,tumor types,0.40582
uuid-abfd05db85d84b738a1f75f427cb8599,TLs,0.427936
uuid-abfd05db85d84b738a1f75f427cb8599,Regional TL,0.351472
uuid-abfd05db85d84b738a1f75f427cb8599,biomarker,0.403358
uuid-c0f780d3189747f7a98b7e68e63f5fa9,patients,0.673011
uuid-c0f780d3189747f7a98b7e68e63f5fa9,Opdivo,0.373088
uuid-c0f780d3189747f7a98b7e68e63f5fa9,therapy,0.554435
uuid-c0f780d3189747f7a98b7e68e63f5fa9,nivolumab,0.579437
uuid-c0f780d3189747f7a98b7e68e63f5fa9,regimen,0.605726
uuid-c0f780d3189747f7a98b7e68e63f5fa9,treated,0.688298
uuid-c0f780d3189747f7a98b7e68e63f5fa9,pts,0.442405
uuid-c0f780d3189747f7a98b7e68e63f5fa9,monotherapy,0.381844
uuid-c0f780d3189747f7a98b7e68e63f5fa9,treatment,0.710418
uuid-c0f780d3189747f7a98b7e68e63f5fa9,using nivo,0.35589
uuid-c0f780d3189747f7a98b7e68e63f5fa9,response,0.360686
uuid-c0f780d3189747f7a98b7e68e63f5fa9,PD1,0.33964
uuid-c0f780d3189747f7a98b7e68e63f5fa9,cHL,0.368134
uuid-c0f780d3189747f7a98b7e68e63f5fa9,progression,0.587664
uuid-c0f780d3189747f7a98b7e68e63f5fa9,chemotherapy,0.372838
uuid-c0f780d3189747f7a98b7e68e63f5fa9,respond,0.493211
uuid-c0f780d3189747f7a98b7e68e63f5fa9,RTL stated,0.329139
uuid-c0f780d3189747f7a98b7e68e63f5fa9,TL shared,0.365591
uuid-c0f780d3189747f7a98b7e68e63f5fa9,option,0.331286
uuid-5e6e352d3147410a80f026a1be28ea03,Nivo,0.354021
uuid-5e6e352d3147410a80f026a1be28ea03,patients,0.625178
uuid-5e6e352d3147410a80f026a1be28ea03,Opdivo,0.371333
uuid-5e6e352d3147410a80f026a1be28ea03,therapy,0.315075
uuid-5e6e352d3147410a80f026a1be28ea03,dose,0.496583
uuid-5e6e352d3147410a80f026a1be28ea03,nivolumab,0.433163
uuid-5e6e352d3147410a80f026a1be28ea03,toxicity,0.593853
uuid-5e6e352d3147410a80f026a1be28ea03,regimen,0.736961
uuid-5e6e352d3147410a80f026a1be28ea03,treated,0.492751
uuid-5e6e352d3147410a80f026a1be28ea03,combination,0.422907
uuid-5e6e352d3147410a80f026a1be28ea03,chemo,0.354678
uuid-5e6e352d3147410a80f026a1be28ea03,pts,0.570616
uuid-5e6e352d3147410a80f026a1be28ea03,Ipi,0.490755
uuid-5e6e352d3147410a80f026a1be28ea03,monotherapy,0.427128
uuid-5e6e352d3147410a80f026a1be28ea03,treatment,0.514438
uuid-5e6e352d3147410a80f026a1be28ea03,response,0.430977
uuid-5e6e352d3147410a80f026a1be28ea03,combo,0.390649
uuid-5e6e352d3147410a80f026a1be28ea03,PD1,0.313861
uuid-5e6e352d3147410a80f026a1be28ea03,progression,0.549358
uuid-5e6e352d3147410a80f026a1be28ea03,chemotherapy,0.354592
uuid-5e6e352d3147410a80f026a1be28ea03,respond,0.458752
uuid-965fd986d3224f20af7907619aa9fc34,patients,0.492334
uuid-965fd986d3224f20af7907619aa9fc34,toxicity,0.52946
uuid-965fd986d3224f20af7907619aa9fc34,regimen,0.455535
uuid-965fd986d3224f20af7907619aa9fc34,monotherapy,0.305301
uuid-965fd986d3224f20af7907619aa9fc34,treatment,0.338881
uuid-965fd986d3224f20af7907619aa9fc34,response,0.358564
uuid-965fd986d3224f20af7907619aa9fc34,progression,0.378468
uuid-965fd986d3224f20af7907619aa9fc34,chemotherapy,0.325006
uuid-965fd986d3224f20af7907619aa9fc34,respond,0.35927
uuid-62537a413e954f26a5902c6dce37eb81,1L,0.384574
uuid-62537a413e954f26a5902c6dce37eb81,toxicity,0.369385
uuid-62537a413e954f26a5902c6dce37eb81,regimen,0.379622
uuid-62537a413e954f26a5902c6dce37eb81,RCC,0.395968
uuid-62537a413e954f26a5902c6dce37eb81,combination,0.709156
uuid-62537a413e954f26a5902c6dce37eb81,chemo,0.411307
uuid-62537a413e954f26a5902c6dce37eb81,2L,0.422451
uuid-62537a413e954f26a5902c6dce37eb81,agents,0.533962
uuid-62537a413e954f26a5902c6dce37eb81,Ipi,0.305419
uuid-62537a413e954f26a5902c6dce37eb81,preferred,0.498382
uuid-62537a413e954f26a5902c6dce37eb81,monotherapy,0.589543
uuid-62537a413e954f26a5902c6dce37eb81,combo,0.608445
uuid-62537a413e954f26a5902c6dce37eb81,PD1,0.400556
uuid-62537a413e954f26a5902c6dce37eb81,chemotherapy,0.369353
uuid-62537a413e954f26a5902c6dce37eb81,feels,0.362221
uuid-62537a413e954f26a5902c6dce37eb81,RTL stated,0.43819
uuid-62537a413e954f26a5902c6dce37eb81,option,0.450019
uuid-62537a413e954f26a5902c6dce37eb81,bladder,0.354097
uuid-0cf6f4fab4a94a6283ed5c17af81b114,patients,0.925427
uuid-0cf6f4fab4a94a6283ed5c17af81b114,Opdivo,0.455381
uuid-0cf6f4fab4a94a6283ed5c17af81b114,therapy,0.553576
uuid-0cf6f4fab4a94a6283ed5c17af81b114,nivolumab,0.430013
uuid-0cf6f4fab4a94a6283ed5c17af81b114,regimen,0.372979
uuid-0cf6f4fab4a94a6283ed5c17af81b114,treated,0.55089
uuid-0cf6f4fab4a94a6283ed5c17af81b114,pts,0.517001
uuid-0cf6f4fab4a94a6283ed5c17af81b114,treatment,0.641425
uuid-0cf6f4fab4a94a6283ed5c17af81b114,using nivo,0.310205
uuid-0cf6f4fab4a94a6283ed5c17af81b114,cHL,0.444782
uuid-0cf6f4fab4a94a6283ed5c17af81b114,progression,0.60548
uuid-0cf6f4fab4a94a6283ed5c17af81b114,chemotherapy,0.322155
uuid-0cf6f4fab4a94a6283ed5c17af81b114,respond,0.439039
uuid-0cf6f4fab4a94a6283ed5c17af81b114,option,0.313593
uuid-f4efc96d5fab41e393902db44fbfce0d,RTL,0.316608
uuid-f4efc96d5fab41e393902db44fbfce0d,1L,0.322
uuid-f4efc96d5fab41e393902db44fbfce0d,NTL,0.338552
uuid-f4efc96d5fab41e393902db44fbfce0d,RCC,0.362686
uuid-f4efc96d5fab41e393902db44fbfce0d,pts,0.301248
uuid-f4efc96d5fab41e393902db44fbfce0d,PD-L1,0.450981
uuid-f4efc96d5fab41e393902db44fbfce0d,PD-L1 testing,0.331115
uuid-f4efc96d5fab41e393902db44fbfce0d,testing,0.36377
uuid-f4efc96d5fab41e393902db44fbfce0d,using nivo,0.329222
uuid-f4efc96d5fab41e393902db44fbfce0d,NSCLC patients,0.48382
uuid-f4efc96d5fab41e393902db44fbfce0d,SCCHN,0.358432
uuid-f4efc96d5fab41e393902db44fbfce0d,oncologist,0.385174
uuid-f4efc96d5fab41e393902db44fbfce0d,indicated,0.496585
uuid-f4efc96d5fab41e393902db44fbfce0d,bladder,0.437876
uuid-62807e4ddf7c47e58095434e77d336e9,patients,0.562991
uuid-62807e4ddf7c47e58095434e77d336e9,RTL,0.301169
uuid-62807e4ddf7c47e58095434e77d336e9,nivolumab,0.346376
uuid-62807e4ddf7c47e58095434e77d336e9,1L,0.366807
uuid-62807e4ddf7c47e58095434e77d336e9,treated,0.380926
uuid-62807e4ddf7c47e58095434e77d336e9,RCC,0.433457
uuid-62807e4ddf7c47e58095434e77d336e9,2L,0.368886
uuid-62807e4ddf7c47e58095434e77d336e9,pts,0.368377
uuid-62807e4ddf7c47e58095434e77d336e9,stated,0.388379
uuid-62807e4ddf7c47e58095434e77d336e9,approval,0.432763
uuid-62807e4ddf7c47e58095434e77d336e9,preferred,0.339869
uuid-62807e4ddf7c47e58095434e77d336e9,monotherapy,0.301959
uuid-62807e4ddf7c47e58095434e77d336e9,using nivo,0.556426
uuid-62807e4ddf7c47e58095434e77d336e9,clinical trials,0.306107
uuid-62807e4ddf7c47e58095434e77d336e9,NSCLC patients,0.320244
uuid-62807e4ddf7c47e58095434e77d336e9,approved,0.35248
uuid-62807e4ddf7c47e58095434e77d336e9,SCCHN,0.553549
uuid-62807e4ddf7c47e58095434e77d336e9,HCP,0.347404
uuid-62807e4ddf7c47e58095434e77d336e9,impressed,0.31922
uuid-62807e4ddf7c47e58095434e77d336e9,tumor types,0.378419
uuid-62807e4ddf7c47e58095434e77d336e9,LTL,0.334883
uuid-62807e4ddf7c47e58095434e77d336e9,SCLC,0.32837
uuid-62807e4ddf7c47e58095434e77d336e9,Regional TL,0.417995
uuid-62807e4ddf7c47e58095434e77d336e9,RTL stated,0.525747
uuid-62807e4ddf7c47e58095434e77d336e9,TL shared,0.373971
uuid-62807e4ddf7c47e58095434e77d336e9,option,0.367841
uuid-62807e4ddf7c47e58095434e77d336e9,bladder,0.544034
uuid-39c88c83b5fa4905aeef5928491e6522,Opdivo,0.338506
uuid-39c88c83b5fa4905aeef5928491e6522,dose,0.407493
uuid-39c88c83b5fa4905aeef5928491e6522,efficacy,0.488864
uuid-39c88c83b5fa4905aeef5928491e6522,atezo,0.331288
uuid-39c88c83b5fa4905aeef5928491e6522,regards,0.349327
uuid-39c88c83b5fa4905aeef5928491e6522,data,0.306626
uuid-39c88c83b5fa4905aeef5928491e6522,indication,0.378098
uuid-39c88c83b5fa4905aeef5928491e6522,nivo and pembro,0.351794
uuid-39c88c83b5fa4905aeef5928491e6522,vs,0.414974
uuid-39c88c83b5fa4905aeef5928491e6522,Keytruda,0.591519
uuid-39c88c83b5fa4905aeef5928491e6522,flat dosing,0.479756
uuid-392114e81e8c442ea0f8be06be2a32da,pembro,0.391873
uuid-392114e81e8c442ea0f8be06be2a32da,1L,0.593872
uuid-392114e81e8c442ea0f8be06be2a32da,PDL1,0.373938
uuid-392114e81e8c442ea0f8be06be2a32da,RCC,0.317669
uuid-392114e81e8c442ea0f8be06be2a32da,chemo,0.374786
uuid-392114e81e8c442ea0f8be06be2a32da,2L,0.517558
uuid-392114e81e8c442ea0f8be06be2a32da,agents,0.453983
uuid-392114e81e8c442ea0f8be06be2a32da,atezo,0.380098
uuid-392114e81e8c442ea0f8be06be2a32da,preferred,0.471533
uuid-392114e81e8c442ea0f8be06be2a32da,monotherapy,0.470027
uuid-392114e81e8c442ea0f8be06be2a32da,using nivo,0.35676
uuid-392114e81e8c442ea0f8be06be2a32da,data,0.368587
uuid-392114e81e8c442ea0f8be06be2a32da,clinical trials,0.345868
uuid-392114e81e8c442ea0f8be06be2a32da,indication,0.318947
uuid-392114e81e8c442ea0f8be06be2a32da,PD1,0.3057
uuid-392114e81e8c442ea0f8be06be2a32da,approved,0.427701
uuid-392114e81e8c442ea0f8be06be2a32da,nivo and pembro,0.370004
uuid-392114e81e8c442ea0f8be06be2a32da,believes,0.415201
uuid-392114e81e8c442ea0f8be06be2a32da,chemotherapy,0.317055
uuid-392114e81e8c442ea0f8be06be2a32da,tumor types,0.310343
uuid-392114e81e8c442ea0f8be06be2a32da,feels,0.560477
uuid-392114e81e8c442ea0f8be06be2a32da,PDL1 expression,0.374206
uuid-392114e81e8c442ea0f8be06be2a32da,option,0.566739
uuid-8cd162bd21294f26b7bb5bb06f8fe0bc,patients,0.307568
uuid-8cd162bd21294f26b7bb5bb06f8fe0bc,nivolumab,0.36833
uuid-8cd162bd21294f26b7bb5bb06f8fe0bc,trial,0.403622
uuid-8cd162bd21294f26b7bb5bb06f8fe0bc,NTL,0.369584
uuid-8cd162bd21294f26b7bb5bb06f8fe0bc,chemotherapy,0.355634
uuid-729af8b143c244639b3a7966d420bf45,toxicity,0.361649
uuid-729af8b143c244639b3a7966d420bf45,drug,0.304062
uuid-729af8b143c244639b3a7966d420bf45,Keytruda,0.331435
uuid-729af8b143c244639b3a7966d420bf45,flat dosing,0.335686
uuid-b49ae26d22b04eacae6f470d6f98ac84,institution,0.558261
uuid-b49ae26d22b04eacae6f470d6f98ac84,NCCN,0.51816
uuid-3278855c937b444281f7f48cdeb2febe,lung,0.303337
uuid-3278855c937b444281f7f48cdeb2febe,toxicity,0.398448
uuid-3278855c937b444281f7f48cdeb2febe,regimen,0.44148
uuid-3278855c937b444281f7f48cdeb2febe,melanoma,0.439235
uuid-3278855c937b444281f7f48cdeb2febe,Ipi,0.425108
uuid-3278855c937b444281f7f48cdeb2febe,monotherapy,0.309789
uuid-3278855c937b444281f7f48cdeb2febe,AI,0.468698
uuid-3278855c937b444281f7f48cdeb2febe,SCLC,0.407115
uuid-5c12e66bfa2a43ab8b53d35c39037595,TL,0.577344
uuid-5c12e66bfa2a43ab8b53d35c39037595,pembro,0.335806
uuid-5c12e66bfa2a43ab8b53d35c39037595,1L,0.315528
uuid-5c12e66bfa2a43ab8b53d35c39037595,PDL1,0.475568
uuid-5c12e66bfa2a43ab8b53d35c39037595,TL stated,0.31535
uuid-5c12e66bfa2a43ab8b53d35c39037595,Merck,0.386691
uuid-5c12e66bfa2a43ab8b53d35c39037595,PD-L1,0.715003
uuid-5c12e66bfa2a43ab8b53d35c39037595,approval,0.360324
uuid-5c12e66bfa2a43ab8b53d35c39037595,atezo,0.364999
uuid-5c12e66bfa2a43ab8b53d35c39037595,PD-L1 testing,0.686152
uuid-5c12e66bfa2a43ab8b53d35c39037595,testing,0.680354
uuid-5c12e66bfa2a43ab8b53d35c39037595,PDL1 testing,0.564021
uuid-5c12e66bfa2a43ab8b53d35c39037595,NSCLC patients,0.460977
uuid-5c12e66bfa2a43ab8b53d35c39037595,indicated,0.334084
uuid-5c12e66bfa2a43ab8b53d35c39037595,assay,0.602579
uuid-5c12e66bfa2a43ab8b53d35c39037595,PDL1 expression,0.352047
uuid-5c12e66bfa2a43ab8b53d35c39037595,biomarker,0.381321
uuid-82df6862c42448b68246b4306b947d94,TL,0.327972
uuid-82df6862c42448b68246b4306b947d94,PDL1,0.681659
uuid-82df6862c42448b68246b4306b947d94,Merck,0.319232
uuid-82df6862c42448b68246b4306b947d94,institution,0.325615
uuid-82df6862c42448b68246b4306b947d94,PD-L1,0.790986
uuid-82df6862c42448b68246b4306b947d94,PD-L1 testing,0.686619
uuid-82df6862c42448b68246b4306b947d94,testing,0.788309
uuid-82df6862c42448b68246b4306b947d94,PDL1 testing,0.611042
uuid-82df6862c42448b68246b4306b947d94,NSCLC patients,0.520486
uuid-82df6862c42448b68246b4306b947d94,assay,0.760385
uuid-82df6862c42448b68246b4306b947d94,PDL1 expression,0.557096
uuid-82df6862c42448b68246b4306b947d94,biomarker,0.576292
uuid-b0b7f850483545d18a144be4aac46afe,toxicity,0.40703
uuid-a5e2de2ef8c7462fb61843c730ddab73,pembro,0.369878
uuid-a5e2de2ef8c7462fb61843c730ddab73,trial,0.726369
uuid-a5e2de2ef8c7462fb61843c730ddab73,NTL,0.329009
uuid-a5e2de2ef8c7462fb61843c730ddab73,data,0.422734
uuid-a5e2de2ef8c7462fb61843c730ddab73,ORR,0.40887
uuid-a5e2de2ef8c7462fb61843c730ddab73,impressed,0.326786
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,TL,0.44821
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,TL stated,0.395364
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,institution,0.422944
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,PD-L1,0.531507
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,PD-L1 testing,0.655097
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,testing,0.617492
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,PDL1 testing,0.572347
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,NSCLC patients,0.470928
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,oncology,0.342681
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,oncologist,0.351393
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,clinical,0.393289
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,academic,0.363072
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,assay,0.353732
uuid-5f9d514fb8cd4146a8eefe5c024d4a5d,biomarker,0.320433
uuid-124f538376bd44099ed05e61598d60c5,TL,0.307484
uuid-124f538376bd44099ed05e61598d60c5,pembro,0.381605
uuid-124f538376bd44099ed05e61598d60c5,PDL1,0.506285
uuid-124f538376bd44099ed05e61598d60c5,commented,0.364796
uuid-124f538376bd44099ed05e61598d60c5,Merck,0.440261
uuid-124f538376bd44099ed05e61598d60c5,stated,0.322225
uuid-124f538376bd44099ed05e61598d60c5,PD-L1,0.443398
uuid-124f538376bd44099ed05e61598d60c5,approval,0.303195
uuid-124f538376bd44099ed05e61598d60c5,atezo,0.387935
uuid-124f538376bd44099ed05e61598d60c5,PD-L1 testing,0.42429
uuid-124f538376bd44099ed05e61598d60c5,testing,0.441328
uuid-124f538376bd44099ed05e61598d60c5,data,0.404223
uuid-124f538376bd44099ed05e61598d60c5,PDL1 testing,0.482608
uuid-124f538376bd44099ed05e61598d60c5,indication,0.338087
uuid-124f538376bd44099ed05e61598d60c5,NSCLC patients,0.352753
uuid-124f538376bd44099ed05e61598d60c5,SCCHN,0.306312
uuid-124f538376bd44099ed05e61598d60c5,nivo and pembro,0.354384
uuid-124f538376bd44099ed05e61598d60c5,TLs,0.374567
uuid-124f538376bd44099ed05e61598d60c5,assay,0.364653
uuid-124f538376bd44099ed05e61598d60c5,PDL1 expression,0.40349
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,BMS,0.385539
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,PDL1,0.627812
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,trial,0.454176
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,efficacy,0.56031
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,discussed,0.315715
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,Merck,0.376255
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,OS,0.627931
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,regards,0.376427
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,data,0.659381
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,PFS,0.691919
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,ORR,0.619706
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,nivo and pembro,0.564291
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,believes,0.333662
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,impressed,0.340253
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,assay,0.389972
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,PDL1 expression,0.560752
uuid-41ea73c772fc4fb5b1ba6f5c47cebdc5,biomarker,0.372405
uuid-718bfc201f324671b1622c0d5d163091,pembro,0.31395
uuid-718bfc201f324671b1622c0d5d163091,RTL,0.367252
uuid-718bfc201f324671b1622c0d5d163091,BMS,0.3781
uuid-718bfc201f324671b1622c0d5d163091,trial,0.381635
uuid-718bfc201f324671b1622c0d5d163091,efficacy,0.321585
uuid-718bfc201f324671b1622c0d5d163091,shared,0.341459
uuid-718bfc201f324671b1622c0d5d163091,commented,0.403
uuid-718bfc201f324671b1622c0d5d163091,Merck,0.350804
uuid-718bfc201f324671b1622c0d5d163091,stated,0.399668
uuid-718bfc201f324671b1622c0d5d163091,approval,0.304547
uuid-718bfc201f324671b1622c0d5d163091,data,0.628101
uuid-718bfc201f324671b1622c0d5d163091,expressed,0.477394
uuid-718bfc201f324671b1622c0d5d163091,mentioned,0.332507
uuid-718bfc201f324671b1622c0d5d163091,clinical trials,0.311333
uuid-718bfc201f324671b1622c0d5d163091,indication,0.508375
uuid-718bfc201f324671b1622c0d5d163091,HCP,0.341994
uuid-718bfc201f324671b1622c0d5d163091,ASCO,0.319138
uuid-718bfc201f324671b1622c0d5d163091,impressed,0.521506
uuid-718bfc201f324671b1622c0d5d163091,label,0.323093
uuid-718bfc201f324671b1622c0d5d163091,LTL,0.367438
uuid-718bfc201f324671b1622c0d5d163091,Keytruda,0.32876
uuid-718bfc201f324671b1622c0d5d163091,TLs,0.356388
uuid-718bfc201f324671b1622c0d5d163091,Regional TL,0.31756
uuid-718bfc201f324671b1622c0d5d163091,flat dosing,0.591815
uuid-b3a9f02495c143639350592632adc820,RTL,0.495403
uuid-b3a9f02495c143639350592632adc820,BMS,0.342432
uuid-b3a9f02495c143639350592632adc820,trial,0.493105
uuid-b3a9f02495c143639350592632adc820,efficacy,0.318894
uuid-b3a9f02495c143639350592632adc820,NTL,0.512284
uuid-b3a9f02495c143639350592632adc820,commented,0.471424
uuid-b3a9f02495c143639350592632adc820,stated,0.428502
uuid-b3a9f02495c143639350592632adc820,OS,0.698119
uuid-b3a9f02495c143639350592632adc820,regards,0.313091
uuid-b3a9f02495c143639350592632adc820,data,0.68086
uuid-b3a9f02495c143639350592632adc820,expressed,0.374165
uuid-b3a9f02495c143639350592632adc820,PFS,0.73773
uuid-b3a9f02495c143639350592632adc820,ORR,0.683739
uuid-b3a9f02495c143639350592632adc820,ASCO,0.391998
uuid-b3a9f02495c143639350592632adc820,impressed,0.624142
uuid-b3a9f02495c143639350592632adc820,LTL,0.351161
uuid-b3a9f02495c143639350592632adc820,TLs,0.304664
uuid-b3a9f02495c143639350592632adc820,Regional TL,0.353753
uuid-716114aebb2c418da4b69e9abe0f4aaf,Nivo,0.320942
uuid-716114aebb2c418da4b69e9abe0f4aaf,patients,0.535862
uuid-716114aebb2c418da4b69e9abe0f4aaf,Opdivo,0.414907
uuid-716114aebb2c418da4b69e9abe0f4aaf,pembro,0.312078
uuid-716114aebb2c418da4b69e9abe0f4aaf,therapy,0.323553
uuid-716114aebb2c418da4b69e9abe0f4aaf,dose,0.573122
uuid-716114aebb2c418da4b69e9abe0f4aaf,nivolumab,0.595762
uuid-716114aebb2c418da4b69e9abe0f4aaf,toxicity,0.33299
uuid-716114aebb2c418da4b69e9abe0f4aaf,regimen,0.512745
uuid-716114aebb2c418da4b69e9abe0f4aaf,treated,0.499496
uuid-716114aebb2c418da4b69e9abe0f4aaf,RCC,0.349947
uuid-716114aebb2c418da4b69e9abe0f4aaf,combination,0.39708
uuid-716114aebb2c418da4b69e9abe0f4aaf,2L,0.426912
uuid-716114aebb2c418da4b69e9abe0f4aaf,pts,0.348871
uuid-716114aebb2c418da4b69e9abe0f4aaf,Ipi,0.355394
uuid-716114aebb2c418da4b69e9abe0f4aaf,preferred,0.549947
uuid-716114aebb2c418da4b69e9abe0f4aaf,monotherapy,0.463618
uuid-716114aebb2c418da4b69e9abe0f4aaf,treatment,0.461357
uuid-716114aebb2c418da4b69e9abe0f4aaf,using nivo,0.468648
uuid-716114aebb2c418da4b69e9abe0f4aaf,combo,0.319702
uuid-716114aebb2c418da4b69e9abe0f4aaf,approved,0.358822
uuid-716114aebb2c418da4b69e9abe0f4aaf,RTL stated,0.554891
uuid-716114aebb2c418da4b69e9abe0f4aaf,TL shared,0.338215
uuid-716114aebb2c418da4b69e9abe0f4aaf,option,0.376032
uuid-716114aebb2c418da4b69e9abe0f4aaf,flat dosing,0.382835
uuid-85be526a8f8e4d4da682594905e27d7c,Nivo,0.437401
uuid-85be526a8f8e4d4da682594905e27d7c,pembro,0.604931
uuid-85be526a8f8e4d4da682594905e27d7c,1L,0.751271
uuid-85be526a8f8e4d4da682594905e27d7c,PDL1,0.338877
uuid-85be526a8f8e4d4da682594905e27d7c,efficacy,0.334256
uuid-85be526a8f8e4d4da682594905e27d7c,combination,0.428618
uuid-85be526a8f8e4d4da682594905e27d7c,chemo,0.463941
uuid-85be526a8f8e4d4da682594905e27d7c,2L,0.693386
uuid-85be526a8f8e4d4da682594905e27d7c,pts,0.339474
uuid-85be526a8f8e4d4da682594905e27d7c,agents,0.521262
uuid-85be526a8f8e4d4da682594905e27d7c,approval,0.353746
uuid-85be526a8f8e4d4da682594905e27d7c,atezo,0.573223
uuid-85be526a8f8e4d4da682594905e27d7c,preferred,0.607213
uuid-85be526a8f8e4d4da682594905e27d7c,monotherapy,0.692619
uuid-85be526a8f8e4d4da682594905e27d7c,using nivo,0.484163
uuid-85be526a8f8e4d4da682594905e27d7c,combo,0.506843
uuid-85be526a8f8e4d4da682594905e27d7c,clinical trials,0.316242
uuid-85be526a8f8e4d4da682594905e27d7c,indication,0.366551
uuid-85be526a8f8e4d4da682594905e27d7c,PD1,0.387638
uuid-85be526a8f8e4d4da682594905e27d7c,approved,0.507015
uuid-85be526a8f8e4d4da682594905e27d7c,nivo and pembro,0.41347
uuid-85be526a8f8e4d4da682594905e27d7c,believes,0.474139
uuid-85be526a8f8e4d4da682594905e27d7c,chemotherapy,0.382385
uuid-85be526a8f8e4d4da682594905e27d7c,feels,0.549703
uuid-85be526a8f8e4d4da682594905e27d7c,RTL stated,0.366649
uuid-85be526a8f8e4d4da682594905e27d7c,option,0.688542
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,Nivo,0.48744
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,patients,0.802351
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,Opdivo,0.403443
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,therapy,0.794487
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,nivolumab,0.57606
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,regimen,0.518569
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,treated,0.560917
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,chemo,0.434353
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,pts,0.574548
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,monotherapy,0.436233
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,treatment,0.751458
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,using nivo,0.359684
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,response,0.497104
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,PD1,0.474338
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,cHL,0.561137
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,progression,0.725003
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,chemotherapy,0.523837
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,respond,0.495538
uuid-4286ae9f822c4b34b6fc4f9e71977cd9,option,0.354123
uuid-bc42c4e0722946318fd5d6463c256c3a,Nivo,0.312616
uuid-bc42c4e0722946318fd5d6463c256c3a,patients,0.838532
uuid-bc42c4e0722946318fd5d6463c256c3a,Opdivo,0.403624
uuid-bc42c4e0722946318fd5d6463c256c3a,therapy,0.57722
uuid-bc42c4e0722946318fd5d6463c256c3a,nivolumab,0.431609
uuid-bc42c4e0722946318fd5d6463c256c3a,regimen,0.545228
uuid-bc42c4e0722946318fd5d6463c256c3a,treated,0.444859
uuid-bc42c4e0722946318fd5d6463c256c3a,chemo,0.388814
uuid-bc42c4e0722946318fd5d6463c256c3a,pts,0.486753
uuid-bc42c4e0722946318fd5d6463c256c3a,monotherapy,0.395142
uuid-bc42c4e0722946318fd5d6463c256c3a,treatment,0.568356
uuid-bc42c4e0722946318fd5d6463c256c3a,using nivo,0.310154
uuid-bc42c4e0722946318fd5d6463c256c3a,response,0.333607
uuid-bc42c4e0722946318fd5d6463c256c3a,cHL,0.310893
uuid-bc42c4e0722946318fd5d6463c256c3a,progression,0.545555
uuid-bc42c4e0722946318fd5d6463c256c3a,chemotherapy,0.435484
uuid-bc42c4e0722946318fd5d6463c256c3a,respond,0.418183
uuid-bc42c4e0722946318fd5d6463c256c3a,option,0.366487
uuid-88bdf9b72a3a4c7485c1642674f47df1,patients,0.492334
uuid-88bdf9b72a3a4c7485c1642674f47df1,toxicity,0.52946
uuid-88bdf9b72a3a4c7485c1642674f47df1,regimen,0.455535
uuid-88bdf9b72a3a4c7485c1642674f47df1,monotherapy,0.305301
uuid-88bdf9b72a3a4c7485c1642674f47df1,treatment,0.338881
uuid-88bdf9b72a3a4c7485c1642674f47df1,response,0.358564
uuid-88bdf9b72a3a4c7485c1642674f47df1,progression,0.378468
uuid-88bdf9b72a3a4c7485c1642674f47df1,chemotherapy,0.325006
uuid-88bdf9b72a3a4c7485c1642674f47df1,respond,0.35927
uuid-bbf99841c4c4438383beed0a58118258,Nivo,0.437565
uuid-bbf99841c4c4438383beed0a58118258,patients,0.701083
uuid-bbf99841c4c4438383beed0a58118258,Opdivo,0.393983
uuid-bbf99841c4c4438383beed0a58118258,therapy,0.526131
uuid-bbf99841c4c4438383beed0a58118258,dose,0.422719
uuid-bbf99841c4c4438383beed0a58118258,nivolumab,0.57
uuid-bbf99841c4c4438383beed0a58118258,toxicity,0.378259
uuid-bbf99841c4c4438383beed0a58118258,regimen,0.649575
uuid-bbf99841c4c4438383beed0a58118258,treated,0.461622
uuid-bbf99841c4c4438383beed0a58118258,combination,0.38306
uuid-bbf99841c4c4438383beed0a58118258,chemo,0.450989
uuid-bbf99841c4c4438383beed0a58118258,2L,0.306404
uuid-bbf99841c4c4438383beed0a58118258,pts,0.60024
uuid-bbf99841c4c4438383beed0a58118258,Ipi,0.35906
uuid-bbf99841c4c4438383beed0a58118258,preferred,0.388993
uuid-bbf99841c4c4438383beed0a58118258,monotherapy,0.550017
uuid-bbf99841c4c4438383beed0a58118258,treatment,0.623033
uuid-bbf99841c4c4438383beed0a58118258,using nivo,0.368345
uuid-bbf99841c4c4438383beed0a58118258,response,0.354421
uuid-bbf99841c4c4438383beed0a58118258,combo,0.355378
uuid-bbf99841c4c4438383beed0a58118258,PD1,0.445136
uuid-bbf99841c4c4438383beed0a58118258,progression,0.556797
uuid-bbf99841c4c4438383beed0a58118258,chemotherapy,0.432452
uuid-bbf99841c4c4438383beed0a58118258,respond,0.445005
uuid-bbf99841c4c4438383beed0a58118258,option,0.515361
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,Nivo,0.458327
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,patients,0.546611
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,therapy,0.413527
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,efficacy,0.37848
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,regimen,0.436948
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,chemo,0.564024
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,pts,0.458786
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,OS,0.523943
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,monotherapy,0.42386
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,treatment,0.421477
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,response,0.488936
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,PFS,0.559531
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,PD1,0.344623
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,ORR,0.464467
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,progression,0.547166
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,chemotherapy,0.566193
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,respond,0.476225
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,feels,0.368781
uuid-d41e6aa88d3b4bb5b223eeb069b0d5a2,option,0.445243
uuid-165e17539fb3464a98b2442f9cd5729d,TL,0.522746
uuid-165e17539fb3464a98b2442f9cd5729d,lung,0.318251
uuid-165e17539fb3464a98b2442f9cd5729d,1L,0.369467
uuid-165e17539fb3464a98b2442f9cd5729d,RCC,0.365649
uuid-165e17539fb3464a98b2442f9cd5729d,TL stated,0.537544
uuid-165e17539fb3464a98b2442f9cd5729d,2L,0.336134
uuid-165e17539fb3464a98b2442f9cd5729d,institution,0.363813
uuid-165e17539fb3464a98b2442f9cd5729d,PD-L1,0.700761
uuid-165e17539fb3464a98b2442f9cd5729d,approval,0.396981
uuid-165e17539fb3464a98b2442f9cd5729d,atezo,0.323309
uuid-165e17539fb3464a98b2442f9cd5729d,PD-L1 testing,0.760979
uuid-165e17539fb3464a98b2442f9cd5729d,testing,0.821289
uuid-165e17539fb3464a98b2442f9cd5729d,PDL1 testing,0.742493
uuid-165e17539fb3464a98b2442f9cd5729d,NSCLC patients,0.75946
uuid-165e17539fb3464a98b2442f9cd5729d,SCCHN,0.309583
uuid-165e17539fb3464a98b2442f9cd5729d,assay,0.644435
uuid-165e17539fb3464a98b2442f9cd5729d,RTL stated,0.349455
uuid-165e17539fb3464a98b2442f9cd5729d,TL shared,0.343616
uuid-5a1d1e889dd84758a6c41a103fd83986,Nivo,0.515013
uuid-5a1d1e889dd84758a6c41a103fd83986,patients,0.302128
uuid-5a1d1e889dd84758a6c41a103fd83986,pembro,0.451486
uuid-5a1d1e889dd84758a6c41a103fd83986,therapy,0.327141
uuid-5a1d1e889dd84758a6c41a103fd83986,trial,0.437318
uuid-5a1d1e889dd84758a6c41a103fd83986,efficacy,0.303531
uuid-5a1d1e889dd84758a6c41a103fd83986,combination,0.317707
uuid-5a1d1e889dd84758a6c41a103fd83986,chemo,0.457397
uuid-5a1d1e889dd84758a6c41a103fd83986,Ipi,0.301574
uuid-5a1d1e889dd84758a6c41a103fd83986,preferred,0.323565
uuid-5a1d1e889dd84758a6c41a103fd83986,monotherapy,0.396034
uuid-5a1d1e889dd84758a6c41a103fd83986,indication,0.333836
uuid-5a1d1e889dd84758a6c41a103fd83986,approved,0.330527
uuid-5a1d1e889dd84758a6c41a103fd83986,chemotherapy,0.496618
uuid-5a1d1e889dd84758a6c41a103fd83986,option,0.431725
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,pembro,0.34417
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,BMS,0.308739
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,PDL1,0.469241
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,efficacy,0.518794
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,commented,0.419407
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,stated,0.381247
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,OS,0.477212
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,atezo,0.403188
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,regards,0.333182
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,data,0.666434
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,expressed,0.339509
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,clinical trials,0.306277
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,indication,0.302057
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,PFS,0.440865
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,ORR,0.51056
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,nivo and pembro,0.468984
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,believes,0.340639
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,impressed,0.550547
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,TLs,0.608562
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,feels,0.404864
uuid-4f3ab7fec33f496bbcba5e8d32af5a13,PDL1 expression,0.491597
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,patients,0.325462
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,RTL,0.416842
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,dose,0.345186
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,nivolumab,0.623978
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,treated,0.37648
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,NTL,0.338924
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,SCCHN,0.317545
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,Regional TL,0.359181
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,RTL stated,0.328024
uuid-e7ff0bf5c1cd40c9a677b24a679bdc5a,flat dosing,0.31482
uuid-61aeff2e8395473c89f5f3a1513ae9b2,Nivo,0.370195
uuid-61aeff2e8395473c89f5f3a1513ae9b2,patients,0.442937
uuid-61aeff2e8395473c89f5f3a1513ae9b2,therapy,0.384735
uuid-61aeff2e8395473c89f5f3a1513ae9b2,nivolumab,0.444237
uuid-61aeff2e8395473c89f5f3a1513ae9b2,treated,0.33284
uuid-61aeff2e8395473c89f5f3a1513ae9b2,approval,0.526593
uuid-61aeff2e8395473c89f5f3a1513ae9b2,using nivo,0.338625
uuid-61aeff2e8395473c89f5f3a1513ae9b2,cHL,0.575012
uuid-23e2e9a07e874798ae56adf46cdb8804,Nivo,0.400329
uuid-23e2e9a07e874798ae56adf46cdb8804,patients,0.791291
uuid-23e2e9a07e874798ae56adf46cdb8804,Opdivo,0.402704
uuid-23e2e9a07e874798ae56adf46cdb8804,therapy,0.825956
uuid-23e2e9a07e874798ae56adf46cdb8804,nivolumab,0.645501
uuid-23e2e9a07e874798ae56adf46cdb8804,regimen,0.399502
uuid-23e2e9a07e874798ae56adf46cdb8804,treated,0.575768
uuid-23e2e9a07e874798ae56adf46cdb8804,chemo,0.381879
uuid-23e2e9a07e874798ae56adf46cdb8804,pts,0.472323
uuid-23e2e9a07e874798ae56adf46cdb8804,monotherapy,0.363584
uuid-23e2e9a07e874798ae56adf46cdb8804,treatment,0.702353
uuid-23e2e9a07e874798ae56adf46cdb8804,using nivo,0.38464
uuid-23e2e9a07e874798ae56adf46cdb8804,response,0.416798
uuid-23e2e9a07e874798ae56adf46cdb8804,PD1,0.448369
uuid-23e2e9a07e874798ae56adf46cdb8804,cHL,0.633071
uuid-23e2e9a07e874798ae56adf46cdb8804,progression,0.642612
uuid-23e2e9a07e874798ae56adf46cdb8804,chemotherapy,0.506513
uuid-23e2e9a07e874798ae56adf46cdb8804,respond,0.427059
uuid-23e2e9a07e874798ae56adf46cdb8804,option,0.335636
uuid-b179b95f31e749749f9a4056619861e1,RTL,0.39862
uuid-b179b95f31e749749f9a4056619861e1,therapy,0.341773
uuid-b179b95f31e749749f9a4056619861e1,nivolumab,0.753333
uuid-b179b95f31e749749f9a4056619861e1,regimen,0.462897
uuid-b179b95f31e749749f9a4056619861e1,treated,0.554472
uuid-b179b95f31e749749f9a4056619861e1,melanoma,0.536726
uuid-b179b95f31e749749f9a4056619861e1,shared,0.353357
uuid-b179b95f31e749749f9a4056619861e1,RCC,0.546281
uuid-b179b95f31e749749f9a4056619861e1,combination,0.537374
uuid-b179b95f31e749749f9a4056619861e1,pts,0.33816
uuid-b179b95f31e749749f9a4056619861e1,monotherapy,0.410211
uuid-b179b95f31e749749f9a4056619861e1,treatment,0.326246
uuid-b179b95f31e749749f9a4056619861e1,using nivo,0.409841
uuid-b179b95f31e749749f9a4056619861e1,combo,0.418774
uuid-b179b95f31e749749f9a4056619861e1,PD1,0.392034
uuid-b179b95f31e749749f9a4056619861e1,SCCHN,0.454794
uuid-b179b95f31e749749f9a4056619861e1,SCLC,0.473393
uuid-b179b95f31e749749f9a4056619861e1,Regional TL,0.453249
uuid-b179b95f31e749749f9a4056619861e1,RTL stated,0.585448
uuid-b179b95f31e749749f9a4056619861e1,TL shared,0.51133
uuid-b179b95f31e749749f9a4056619861e1,bladder,0.403908
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,patients,0.76907
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,Opdivo,0.414735
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,therapy,0.443572
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,nivolumab,0.369743
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,treated,0.525901
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,pts,0.529885
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,testing,0.332394
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,treatment,0.482333
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,NSCLC patients,0.453592
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,cHL,0.349361
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,progression,0.469611
uuid-d8d2f2b49abf413fa28bc6c74f0901bc,respond,0.306942
uuid-044e1a9972204303a5600a5684161237,patients,0.321069
uuid-044e1a9972204303a5600a5684161237,therapy,0.329455
uuid-044e1a9972204303a5600a5684161237,treated,0.327503
uuid-044e1a9972204303a5600a5684161237,chemo,0.330958
uuid-044e1a9972204303a5600a5684161237,tumor,0.400901
uuid-044e1a9972204303a5600a5684161237,pts,0.430987
uuid-044e1a9972204303a5600a5684161237,response,0.393736
uuid-044e1a9972204303a5600a5684161237,progression,0.410766
uuid-044e1a9972204303a5600a5684161237,feels,0.486691
uuid-a35f73bd785a4691b04a06a4cf0de07f,Nivo,0.636098
uuid-a35f73bd785a4691b04a06a4cf0de07f,patients,0.396108
uuid-a35f73bd785a4691b04a06a4cf0de07f,pembro,0.400305
uuid-a35f73bd785a4691b04a06a4cf0de07f,nivolumab,0.381697
uuid-a35f73bd785a4691b04a06a4cf0de07f,trial,0.481496
uuid-a35f73bd785a4691b04a06a4cf0de07f,efficacy,0.313257
uuid-a35f73bd785a4691b04a06a4cf0de07f,regimen,0.328134
uuid-a35f73bd785a4691b04a06a4cf0de07f,combination,0.34996
uuid-a35f73bd785a4691b04a06a4cf0de07f,chemo,0.435555
uuid-a35f73bd785a4691b04a06a4cf0de07f,pts,0.32398
uuid-a35f73bd785a4691b04a06a4cf0de07f,Ipi,0.380913
uuid-a35f73bd785a4691b04a06a4cf0de07f,OS,0.33098
uuid-a35f73bd785a4691b04a06a4cf0de07f,monotherapy,0.399985
uuid-a35f73bd785a4691b04a06a4cf0de07f,using nivo,0.306149
uuid-a35f73bd785a4691b04a06a4cf0de07f,data,0.344791
uuid-a35f73bd785a4691b04a06a4cf0de07f,clinical trials,0.304399
uuid-a35f73bd785a4691b04a06a4cf0de07f,PFS,0.303494
uuid-a35f73bd785a4691b04a06a4cf0de07f,ORR,0.392356
uuid-a35f73bd785a4691b04a06a4cf0de07f,chemotherapy,0.428219
uuid-a35f73bd785a4691b04a06a4cf0de07f,impressed,0.475081
uuid-a35f73bd785a4691b04a06a4cf0de07f,feels,0.48168
uuid-a35f73bd785a4691b04a06a4cf0de07f,option,0.309574
uuid-5f1436bc81d545169dea909ec3968c3e,patients,0.785213
uuid-5f1436bc81d545169dea909ec3968c3e,Opdivo,0.431351
uuid-5f1436bc81d545169dea909ec3968c3e,therapy,0.716078
uuid-5f1436bc81d545169dea909ec3968c3e,nivolumab,0.583159
uuid-5f1436bc81d545169dea909ec3968c3e,regimen,0.58192
uuid-5f1436bc81d545169dea909ec3968c3e,treated,0.628834
uuid-5f1436bc81d545169dea909ec3968c3e,chemo,0.391494
uuid-5f1436bc81d545169dea909ec3968c3e,pts,0.499271
uuid-5f1436bc81d545169dea909ec3968c3e,monotherapy,0.416211
uuid-5f1436bc81d545169dea909ec3968c3e,treatment,0.814427
uuid-5f1436bc81d545169dea909ec3968c3e,response,0.470318
uuid-5f1436bc81d545169dea909ec3968c3e,PD1,0.42638
uuid-5f1436bc81d545169dea909ec3968c3e,cHL,0.457605
uuid-5f1436bc81d545169dea909ec3968c3e,progression,0.71681
uuid-5f1436bc81d545169dea909ec3968c3e,chemotherapy,0.486958
uuid-5f1436bc81d545169dea909ec3968c3e,respond,0.527793
uuid-5f1436bc81d545169dea909ec3968c3e,option,0.38507
uuid-903e68f11b914a63b765af5e319520af,Nivo,0.437665
uuid-903e68f11b914a63b765af5e319520af,patients,0.51355
uuid-903e68f11b914a63b765af5e319520af,therapy,0.618743
uuid-903e68f11b914a63b765af5e319520af,nivolumab,0.360577
uuid-903e68f11b914a63b765af5e319520af,treatment,0.335154
uuid-903e68f11b914a63b765af5e319520af,cHL,0.737074
uuid-903e68f11b914a63b765af5e319520af,chemotherapy,0.369944
uuid-90fadb3d2ce54697beddfc06eb37b8d6,Nivo,0.461757
uuid-90fadb3d2ce54697beddfc06eb37b8d6,patients,0.340178
uuid-90fadb3d2ce54697beddfc06eb37b8d6,Opdivo,0.311758
uuid-90fadb3d2ce54697beddfc06eb37b8d6,therapy,0.43114
uuid-90fadb3d2ce54697beddfc06eb37b8d6,nivolumab,0.334794
uuid-90fadb3d2ce54697beddfc06eb37b8d6,using nivo,0.323634
uuid-90fadb3d2ce54697beddfc06eb37b8d6,mentioned,0.371996
uuid-90fadb3d2ce54697beddfc06eb37b8d6,cHL,0.667103
uuid-8866298976ec4572bf93df06bf899b63,Nivo,0.412133
uuid-8866298976ec4572bf93df06bf899b63,patients,0.413195
uuid-8866298976ec4572bf93df06bf899b63,therapy,0.707766
uuid-8866298976ec4572bf93df06bf899b63,nivolumab,0.503159
uuid-8866298976ec4572bf93df06bf899b63,treated,0.318413
uuid-8866298976ec4572bf93df06bf899b63,combination,0.352671
uuid-8866298976ec4572bf93df06bf899b63,chemo,0.37301
uuid-8866298976ec4572bf93df06bf899b63,agents,0.363441
uuid-8866298976ec4572bf93df06bf899b63,monotherapy,0.392728
uuid-8866298976ec4572bf93df06bf899b63,treatment,0.419566
uuid-8866298976ec4572bf93df06bf899b63,using nivo,0.340001
uuid-8866298976ec4572bf93df06bf899b63,PD1,0.425903
uuid-8866298976ec4572bf93df06bf899b63,cHL,0.505429
uuid-8866298976ec4572bf93df06bf899b63,chemotherapy,0.552194
uuid-8866298976ec4572bf93df06bf899b63,PD-1,0.32993
uuid-8866298976ec4572bf93df06bf899b63,option,0.455799
uuid-36432804ebe644449f03951e04f8bb63,Nivo,0.303283
uuid-36432804ebe644449f03951e04f8bb63,BMS,0.309081
uuid-36432804ebe644449f03951e04f8bb63,PDL1,0.308976
uuid-36432804ebe644449f03951e04f8bb63,trial,0.466011
uuid-36432804ebe644449f03951e04f8bb63,efficacy,0.635819
uuid-36432804ebe644449f03951e04f8bb63,commented,0.344955
uuid-36432804ebe644449f03951e04f8bb63,OS,0.714501
uuid-36432804ebe644449f03951e04f8bb63,data,0.804585
uuid-36432804ebe644449f03951e04f8bb63,combo,0.366618
uuid-36432804ebe644449f03951e04f8bb63,PFS,0.66476
uuid-36432804ebe644449f03951e04f8bb63,ORR,0.74699
uuid-36432804ebe644449f03951e04f8bb63,nivo and pembro,0.462185
uuid-36432804ebe644449f03951e04f8bb63,ASCO,0.409288
uuid-36432804ebe644449f03951e04f8bb63,believes,0.353756
uuid-36432804ebe644449f03951e04f8bb63,impressed,0.758164
uuid-36432804ebe644449f03951e04f8bb63,TLs,0.363397
uuid-36432804ebe644449f03951e04f8bb63,SCLC,0.316249
uuid-36432804ebe644449f03951e04f8bb63,feels,0.397725
uuid-8729624460d947a9bf58424d21e08746,1L,0.437999
uuid-8729624460d947a9bf58424d21e08746,PDL1,0.498896
uuid-8729624460d947a9bf58424d21e08746,efficacy,0.47765
uuid-8729624460d947a9bf58424d21e08746,chemo,0.400971
uuid-8729624460d947a9bf58424d21e08746,2L,0.382096
uuid-8729624460d947a9bf58424d21e08746,IO,0.323952
uuid-8729624460d947a9bf58424d21e08746,agents,0.530254
uuid-8729624460d947a9bf58424d21e08746,atezo,0.357345
uuid-8729624460d947a9bf58424d21e08746,preferred,0.403474
uuid-8729624460d947a9bf58424d21e08746,monotherapy,0.442965
uuid-8729624460d947a9bf58424d21e08746,combo,0.330584
uuid-8729624460d947a9bf58424d21e08746,nivo and pembro,0.381214
uuid-8729624460d947a9bf58424d21e08746,believes,0.502786
uuid-8729624460d947a9bf58424d21e08746,chemotherapy,0.320659
uuid-8729624460d947a9bf58424d21e08746,feels,0.539378
uuid-8729624460d947a9bf58424d21e08746,PDL1 expression,0.452088
uuid-8729624460d947a9bf58424d21e08746,option,0.538462
uuid-8729624460d947a9bf58424d21e08746,biomarker,0.460228
uuid-c44ae580ae0b4838975c62849c86e66b,PDL1,0.398039
uuid-c44ae580ae0b4838975c62849c86e66b,PD-L1,0.383903
uuid-c44ae580ae0b4838975c62849c86e66b,testing,0.336673
uuid-c44ae580ae0b4838975c62849c86e66b,regards,0.340568
uuid-c44ae580ae0b4838975c62849c86e66b,PDL1 testing,0.317425
uuid-c44ae580ae0b4838975c62849c86e66b,lung cancer,0.316003
uuid-c44ae580ae0b4838975c62849c86e66b,ASCO,0.319243
uuid-c44ae580ae0b4838975c62849c86e66b,PDL1 expression,0.380484
uuid-c44ae580ae0b4838975c62849c86e66b,biomarker,0.59432
uuid-193a986e4bf24c1b9b873544342f09fb,patients,0.70197
uuid-193a986e4bf24c1b9b873544342f09fb,therapy,0.582276
uuid-193a986e4bf24c1b9b873544342f09fb,nivolumab,0.393619
uuid-193a986e4bf24c1b9b873544342f09fb,regimen,0.58809
uuid-193a986e4bf24c1b9b873544342f09fb,treated,0.500403
uuid-193a986e4bf24c1b9b873544342f09fb,combination,0.455256
uuid-193a986e4bf24c1b9b873544342f09fb,chemo,0.422583
uuid-193a986e4bf24c1b9b873544342f09fb,pts,0.567258
uuid-193a986e4bf24c1b9b873544342f09fb,IO,0.304622
uuid-193a986e4bf24c1b9b873544342f09fb,monotherapy,0.513275
uuid-193a986e4bf24c1b9b873544342f09fb,treatment,0.681203
uuid-193a986e4bf24c1b9b873544342f09fb,response,0.48078
uuid-193a986e4bf24c1b9b873544342f09fb,combo,0.425477
uuid-193a986e4bf24c1b9b873544342f09fb,PD1,0.44222
uuid-193a986e4bf24c1b9b873544342f09fb,progression,0.736036
uuid-193a986e4bf24c1b9b873544342f09fb,chemotherapy,0.478873
uuid-193a986e4bf24c1b9b873544342f09fb,respond,0.46775
uuid-193a986e4bf24c1b9b873544342f09fb,option,0.467102
uuid-6e06b09e4b1048cfb6ff32c940ec78fb,patients,0.435703
uuid-6e06b09e4b1048cfb6ff32c940ec78fb,chemo,0.302548
uuid-6e06b09e4b1048cfb6ff32c940ec78fb,pts,0.341382
uuid-6e06b09e4b1048cfb6ff32c940ec78fb,NSCLC patients,0.314715
uuid-6e06b09e4b1048cfb6ff32c940ec78fb,chemotherapy,0.33344
uuid-9c34bf67b84741ababe9bdedf1a6462e,RTL,0.546599
uuid-9c34bf67b84741ababe9bdedf1a6462e,NSCLC,0.332642
uuid-9c34bf67b84741ababe9bdedf1a6462e,1L,0.397949
uuid-9c34bf67b84741ababe9bdedf1a6462e,trial,0.358374
uuid-9c34bf67b84741ababe9bdedf1a6462e,combination,0.365681
uuid-9c34bf67b84741ababe9bdedf1a6462e,IO,0.327044
uuid-9c34bf67b84741ababe9bdedf1a6462e,preferred,0.313473
uuid-9c34bf67b84741ababe9bdedf1a6462e,monotherapy,0.385775
uuid-9c34bf67b84741ababe9bdedf1a6462e,using nivo,0.314256
uuid-9c34bf67b84741ababe9bdedf1a6462e,data,0.343578
uuid-9c34bf67b84741ababe9bdedf1a6462e,combo,0.396524
uuid-9c34bf67b84741ababe9bdedf1a6462e,SCCHN,0.382611
uuid-9c34bf67b84741ababe9bdedf1a6462e,impressed,0.38428
uuid-9c34bf67b84741ababe9bdedf1a6462e,LTL,0.357783
uuid-9c34bf67b84741ababe9bdedf1a6462e,TLs,0.33108
uuid-9c34bf67b84741ababe9bdedf1a6462e,Regional TL,0.394941
uuid-9c34bf67b84741ababe9bdedf1a6462e,RTL stated,0.372832
uuid-9c34bf67b84741ababe9bdedf1a6462e,option,0.309774
uuid-cc578531544e49cb82bca53c3f0b4ab3,TL,0.378169
uuid-cc578531544e49cb82bca53c3f0b4ab3,TL stated,0.306152
uuid-cc578531544e49cb82bca53c3f0b4ab3,tumor,0.575443
uuid-cc578531544e49cb82bca53c3f0b4ab3,PD-L1,0.335894
uuid-cc578531544e49cb82bca53c3f0b4ab3,PD-L1 testing,0.391876
uuid-cc578531544e49cb82bca53c3f0b4ab3,testing,0.394358
uuid-cc578531544e49cb82bca53c3f0b4ab3,NSCLC patients,0.356744
uuid-26106b6b598342428e7986a2fe96f4fe,patients,0.755183
uuid-26106b6b598342428e7986a2fe96f4fe,therapy,0.328091
uuid-26106b6b598342428e7986a2fe96f4fe,1L,0.495971
uuid-26106b6b598342428e7986a2fe96f4fe,treated,0.353896
uuid-26106b6b598342428e7986a2fe96f4fe,2L,0.434972
uuid-26106b6b598342428e7986a2fe96f4fe,pts,0.503122
uuid-26106b6b598342428e7986a2fe96f4fe,PD-L1,0.358825
uuid-26106b6b598342428e7986a2fe96f4fe,approval,0.400863
uuid-26106b6b598342428e7986a2fe96f4fe,preferred,0.396176
uuid-26106b6b598342428e7986a2fe96f4fe,PD-L1 testing,0.388305
uuid-26106b6b598342428e7986a2fe96f4fe,testing,0.494496
uuid-26106b6b598342428e7986a2fe96f4fe,monotherapy,0.352894
uuid-26106b6b598342428e7986a2fe96f4fe,treatment,0.358013
uuid-26106b6b598342428e7986a2fe96f4fe,using nivo,0.488305
uuid-26106b6b598342428e7986a2fe96f4fe,PDL1 testing,0.484306
uuid-26106b6b598342428e7986a2fe96f4fe,NSCLC patients,0.681
uuid-26106b6b598342428e7986a2fe96f4fe,approved,0.317756
uuid-26106b6b598342428e7986a2fe96f4fe,progression,0.364801
uuid-26106b6b598342428e7986a2fe96f4fe,tumor types,0.342709
uuid-26106b6b598342428e7986a2fe96f4fe,RTL stated,0.403943
uuid-26106b6b598342428e7986a2fe96f4fe,option,0.442648
uuid-e59d237e65db418aaaa57ebab79da1df,pembro,0.378883
uuid-e59d237e65db418aaaa57ebab79da1df,dose,0.781174
uuid-e59d237e65db418aaaa57ebab79da1df,Ipi,0.460044
uuid-e59d237e65db418aaaa57ebab79da1df,atezo,0.448632
uuid-e59d237e65db418aaaa57ebab79da1df,preferred,0.342383
uuid-e59d237e65db418aaaa57ebab79da1df,indication,0.304615
uuid-e59d237e65db418aaaa57ebab79da1df,vs,0.516208
uuid-e59d237e65db418aaaa57ebab79da1df,Keytruda,0.300753
uuid-e59d237e65db418aaaa57ebab79da1df,flat dosing,0.626173
uuid-bddc6492d7f146eea2fcd2dedc73250a,Nivo,0.454493
uuid-bddc6492d7f146eea2fcd2dedc73250a,pembro,0.627242
uuid-bddc6492d7f146eea2fcd2dedc73250a,PDL1,0.556414
uuid-bddc6492d7f146eea2fcd2dedc73250a,trial,0.491832
uuid-bddc6492d7f146eea2fcd2dedc73250a,efficacy,0.738388
uuid-bddc6492d7f146eea2fcd2dedc73250a,Ipi,0.315015
uuid-bddc6492d7f146eea2fcd2dedc73250a,OS,0.566982
uuid-bddc6492d7f146eea2fcd2dedc73250a,atezo,0.575029
uuid-bddc6492d7f146eea2fcd2dedc73250a,regards,0.34923
uuid-bddc6492d7f146eea2fcd2dedc73250a,data,0.642355
uuid-bddc6492d7f146eea2fcd2dedc73250a,PFS,0.579471
uuid-bddc6492d7f146eea2fcd2dedc73250a,ORR,0.621749
uuid-bddc6492d7f146eea2fcd2dedc73250a,nivo and pembro,0.723979
uuid-bddc6492d7f146eea2fcd2dedc73250a,believes,0.378589
uuid-bddc6492d7f146eea2fcd2dedc73250a,impressed,0.400086
uuid-bddc6492d7f146eea2fcd2dedc73250a,vs,0.651945
uuid-bddc6492d7f146eea2fcd2dedc73250a,TLs,0.305983
uuid-bddc6492d7f146eea2fcd2dedc73250a,feels,0.400431
uuid-bddc6492d7f146eea2fcd2dedc73250a,PDL1 expression,0.513742
uuid-00028a204d044c0e8ac8e15e70db1bd3,Nivo,0.602461
uuid-00028a204d044c0e8ac8e15e70db1bd3,patients,0.362555
uuid-00028a204d044c0e8ac8e15e70db1bd3,pembro,0.58233
uuid-00028a204d044c0e8ac8e15e70db1bd3,nivolumab,0.344785
uuid-00028a204d044c0e8ac8e15e70db1bd3,1L,0.460993
uuid-00028a204d044c0e8ac8e15e70db1bd3,2L,0.471541
uuid-00028a204d044c0e8ac8e15e70db1bd3,Ipi,0.320857
uuid-00028a204d044c0e8ac8e15e70db1bd3,approval,0.51014
uuid-00028a204d044c0e8ac8e15e70db1bd3,atezo,0.445837
uuid-00028a204d044c0e8ac8e15e70db1bd3,preferred,0.454031
uuid-00028a204d044c0e8ac8e15e70db1bd3,monotherapy,0.416893
uuid-00028a204d044c0e8ac8e15e70db1bd3,using nivo,0.600544
uuid-00028a204d044c0e8ac8e15e70db1bd3,indication,0.324335
uuid-00028a204d044c0e8ac8e15e70db1bd3,approved,0.473373
uuid-00028a204d044c0e8ac8e15e70db1bd3,SCCHN,0.391037
uuid-00028a204d044c0e8ac8e15e70db1bd3,impressed,0.393265
uuid-00028a204d044c0e8ac8e15e70db1bd3,label,0.301382
uuid-00028a204d044c0e8ac8e15e70db1bd3,SCLC,0.340004
uuid-00028a204d044c0e8ac8e15e70db1bd3,feels,0.350147
uuid-00028a204d044c0e8ac8e15e70db1bd3,RTL stated,0.417359
uuid-00028a204d044c0e8ac8e15e70db1bd3,option,0.481766
uuid-00028a204d044c0e8ac8e15e70db1bd3,bladder,0.300388
uuid-51224a193901486e877335660c220716,Nivo,0.325126
uuid-51224a193901486e877335660c220716,trial,0.556736
uuid-51224a193901486e877335660c220716,efficacy,0.326798
uuid-51224a193901486e877335660c220716,OS,0.627967
uuid-51224a193901486e877335660c220716,data,0.577696
uuid-51224a193901486e877335660c220716,PFS,0.662315
uuid-51224a193901486e877335660c220716,ORR,0.689418
uuid-51224a193901486e877335660c220716,nivo and pembro,0.309238
uuid-51224a193901486e877335660c220716,ASCO,0.322757
uuid-51224a193901486e877335660c220716,impressed,0.459781
uuid-51224a193901486e877335660c220716,PDL1 expression,0.32532
uuid-4638a0356c984b51bce1ea6f69e2e154,Nivo,0.373222
uuid-4638a0356c984b51bce1ea6f69e2e154,pembro,0.324143
uuid-4638a0356c984b51bce1ea6f69e2e154,dose,0.497708
uuid-4638a0356c984b51bce1ea6f69e2e154,Ipi,0.496245
uuid-4638a0356c984b51bce1ea6f69e2e154,vs,0.472094
uuid-4638a0356c984b51bce1ea6f69e2e154,flat dosing,0.396907
uuid-c8897c81c5d8447db47db690910302c8,patients,0.65749
uuid-c8897c81c5d8447db47db690910302c8,RTL,0.461713
uuid-c8897c81c5d8447db47db690910302c8,therapy,0.32273
uuid-c8897c81c5d8447db47db690910302c8,nivolumab,0.462251
uuid-c8897c81c5d8447db47db690910302c8,regimen,0.354002
uuid-c8897c81c5d8447db47db690910302c8,treated,0.535275
uuid-c8897c81c5d8447db47db690910302c8,RCC,0.38207
uuid-c8897c81c5d8447db47db690910302c8,pts,0.464119
uuid-c8897c81c5d8447db47db690910302c8,stated,0.321177
uuid-c8897c81c5d8447db47db690910302c8,approval,0.312673
uuid-c8897c81c5d8447db47db690910302c8,monotherapy,0.340855
uuid-c8897c81c5d8447db47db690910302c8,treatment,0.428883
uuid-c8897c81c5d8447db47db690910302c8,using nivo,0.532764
uuid-c8897c81c5d8447db47db690910302c8,SCCHN,0.528535
uuid-c8897c81c5d8447db47db690910302c8,HCP,0.310654
uuid-c8897c81c5d8447db47db690910302c8,progression,0.391764
uuid-c8897c81c5d8447db47db690910302c8,LTL,0.376326
uuid-c8897c81c5d8447db47db690910302c8,academic,0.436668
uuid-c8897c81c5d8447db47db690910302c8,Regional TL,0.412087
uuid-c8897c81c5d8447db47db690910302c8,RTL stated,0.555981
uuid-c8897c81c5d8447db47db690910302c8,TL shared,0.369877
uuid-c8897c81c5d8447db47db690910302c8,option,0.305594
uuid-b20975d8a8c747dbbf80e4d66de16b07,RTL,0.481372
uuid-b20975d8a8c747dbbf80e4d66de16b07,BMS,0.378099
uuid-b20975d8a8c747dbbf80e4d66de16b07,trial,0.793289
uuid-b20975d8a8c747dbbf80e4d66de16b07,NTL,0.392564
uuid-b20975d8a8c747dbbf80e4d66de16b07,commented,0.333277
uuid-b20975d8a8c747dbbf80e4d66de16b07,Merck,0.372913
uuid-b20975d8a8c747dbbf80e4d66de16b07,data,0.548561
uuid-b20975d8a8c747dbbf80e4d66de16b07,clinical trials,0.47287
uuid-b20975d8a8c747dbbf80e4d66de16b07,ORR,0.383125
uuid-b20975d8a8c747dbbf80e4d66de16b07,ASCO,0.325994
uuid-b20975d8a8c747dbbf80e4d66de16b07,impressed,0.489202
uuid-b20975d8a8c747dbbf80e4d66de16b07,Regional TL,0.337797
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,patients,0.351547
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,Opdivo,0.323451
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,RTL,0.32978
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,therapy,0.338512
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,nivolumab,0.490614
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,treated,0.478854
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,mentioned,0.382554
uuid-2bc6136d13eb45ec9863d4ec1040dc3e,cHL,0.643692
uuid-5f997f99adee44ce8407eef0686cf551,Nivo,0.430202
uuid-5f997f99adee44ce8407eef0686cf551,patients,0.872514
uuid-5f997f99adee44ce8407eef0686cf551,Opdivo,0.393121
uuid-5f997f99adee44ce8407eef0686cf551,therapy,0.515752
uuid-5f997f99adee44ce8407eef0686cf551,nivolumab,0.471121
uuid-5f997f99adee44ce8407eef0686cf551,regimen,0.486132
uuid-5f997f99adee44ce8407eef0686cf551,treated,0.462399
uuid-5f997f99adee44ce8407eef0686cf551,chemo,0.451954
uuid-5f997f99adee44ce8407eef0686cf551,pts,0.628048
uuid-5f997f99adee44ce8407eef0686cf551,monotherapy,0.474967
uuid-5f997f99adee44ce8407eef0686cf551,treatment,0.559112
uuid-5f997f99adee44ce8407eef0686cf551,using nivo,0.401608
uuid-5f997f99adee44ce8407eef0686cf551,response,0.320998
uuid-5f997f99adee44ce8407eef0686cf551,PD1,0.315303
uuid-5f997f99adee44ce8407eef0686cf551,progression,0.590252
uuid-5f997f99adee44ce8407eef0686cf551,chemotherapy,0.441149
uuid-5f997f99adee44ce8407eef0686cf551,respond,0.441709
uuid-5f997f99adee44ce8407eef0686cf551,feels,0.32337
uuid-5f997f99adee44ce8407eef0686cf551,option,0.461625
uuid-0074e4eedefb48b681ad54f406f1e26c,HCP,0.30634
uuid-e6036b15467f46ffa6876821a4eb0345,commented,0.345665
uuid-e6036b15467f46ffa6876821a4eb0345,TL stated,0.308109
uuid-e6036b15467f46ffa6876821a4eb0345,physicians,0.442364
uuid-e6036b15467f46ffa6876821a4eb0345,ASCO,0.397857
uuid-e6036b15467f46ffa6876821a4eb0345,TLs,0.330676
uuid-9a46ee6421f845ad8ded8e803bcadcb9,Nivo,0.444712
uuid-9a46ee6421f845ad8ded8e803bcadcb9,patients,0.809625
uuid-9a46ee6421f845ad8ded8e803bcadcb9,Opdivo,0.423496
uuid-9a46ee6421f845ad8ded8e803bcadcb9,therapy,0.619837
uuid-9a46ee6421f845ad8ded8e803bcadcb9,nivolumab,0.684969
uuid-9a46ee6421f845ad8ded8e803bcadcb9,1L,0.332403
uuid-9a46ee6421f845ad8ded8e803bcadcb9,toxicity,0.351287
uuid-9a46ee6421f845ad8ded8e803bcadcb9,regimen,0.605397
uuid-9a46ee6421f845ad8ded8e803bcadcb9,treated,0.568411
uuid-9a46ee6421f845ad8ded8e803bcadcb9,RCC,0.385883
uuid-9a46ee6421f845ad8ded8e803bcadcb9,combination,0.339091
uuid-9a46ee6421f845ad8ded8e803bcadcb9,chemo,0.452158
uuid-9a46ee6421f845ad8ded8e803bcadcb9,2L,0.409698
uuid-9a46ee6421f845ad8ded8e803bcadcb9,pts,0.588692
uuid-9a46ee6421f845ad8ded8e803bcadcb9,preferred,0.434099
uuid-9a46ee6421f845ad8ded8e803bcadcb9,monotherapy,0.589259
uuid-9a46ee6421f845ad8ded8e803bcadcb9,treatment,0.681771
uuid-9a46ee6421f845ad8ded8e803bcadcb9,using nivo,0.53177
uuid-9a46ee6421f845ad8ded8e803bcadcb9,response,0.352201
uuid-9a46ee6421f845ad8ded8e803bcadcb9,PD1,0.452362
uuid-9a46ee6421f845ad8ded8e803bcadcb9,approved,0.301261
uuid-9a46ee6421f845ad8ded8e803bcadcb9,cHL,0.321897
uuid-9a46ee6421f845ad8ded8e803bcadcb9,progression,0.610056
uuid-9a46ee6421f845ad8ded8e803bcadcb9,chemotherapy,0.447777
uuid-9a46ee6421f845ad8ded8e803bcadcb9,respond,0.420784
uuid-9a46ee6421f845ad8ded8e803bcadcb9,RTL stated,0.484315
uuid-9a46ee6421f845ad8ded8e803bcadcb9,TL shared,0.341034
uuid-9a46ee6421f845ad8ded8e803bcadcb9,option,0.530776
uuid-5f531facdc064067aa2c8c81cc8cf8fe,TL,0.483575
uuid-5f531facdc064067aa2c8c81cc8cf8fe,TL stated,0.337974
uuid-5f531facdc064067aa2c8c81cc8cf8fe,institution,0.443049
uuid-5f531facdc064067aa2c8c81cc8cf8fe,PD-L1,0.748306
uuid-5f531facdc064067aa2c8c81cc8cf8fe,PD-L1 testing,0.833587
uuid-5f531facdc064067aa2c8c81cc8cf8fe,testing,0.858824
uuid-5f531facdc064067aa2c8c81cc8cf8fe,PDL1 testing,0.679928
uuid-5f531facdc064067aa2c8c81cc8cf8fe,NSCLC patients,0.631091
uuid-5f531facdc064067aa2c8c81cc8cf8fe,assay,0.670447
uuid-5f531facdc064067aa2c8c81cc8cf8fe,biomarker,0.43094
uuid-985fb86ace194e4eac4d05d867ede682,patients,0.315727
uuid-985fb86ace194e4eac4d05d867ede682,PDL1,0.386072
uuid-985fb86ace194e4eac4d05d867ede682,PD-L1,0.389244
uuid-985fb86ace194e4eac4d05d867ede682,testing,0.415313
uuid-985fb86ace194e4eac4d05d867ede682,PDL1 testing,0.350582
uuid-985fb86ace194e4eac4d05d867ede682,NSCLC patients,0.55231
uuid-985fb86ace194e4eac4d05d867ede682,PDL1 expression,0.315818
uuid-985fb86ace194e4eac4d05d867ede682,biomarker,0.332086
uuid-0703aef6f72d481196156c40b2a8ca84,Nivo,0.379712
uuid-0703aef6f72d481196156c40b2a8ca84,patients,0.349332
uuid-0703aef6f72d481196156c40b2a8ca84,Opdivo,0.481084
uuid-0703aef6f72d481196156c40b2a8ca84,pembro,0.572177
uuid-0703aef6f72d481196156c40b2a8ca84,nivolumab,0.363239
uuid-0703aef6f72d481196156c40b2a8ca84,1L,0.646819
uuid-0703aef6f72d481196156c40b2a8ca84,RCC,0.527052
uuid-0703aef6f72d481196156c40b2a8ca84,TL stated,0.419846
uuid-0703aef6f72d481196156c40b2a8ca84,2L,0.773173
uuid-0703aef6f72d481196156c40b2a8ca84,agents,0.323865
uuid-0703aef6f72d481196156c40b2a8ca84,approval,0.490317
uuid-0703aef6f72d481196156c40b2a8ca84,atezo,0.563676
uuid-0703aef6f72d481196156c40b2a8ca84,preferred,0.696665
uuid-0703aef6f72d481196156c40b2a8ca84,monotherapy,0.490486
uuid-0703aef6f72d481196156c40b2a8ca84,using nivo,0.673833
uuid-0703aef6f72d481196156c40b2a8ca84,PDL1 testing,0.425436
uuid-0703aef6f72d481196156c40b2a8ca84,indication,0.424026
uuid-0703aef6f72d481196156c40b2a8ca84,NSCLC patients,0.361053
uuid-0703aef6f72d481196156c40b2a8ca84,approved,0.590492
uuid-0703aef6f72d481196156c40b2a8ca84,SCCHN,0.385584
uuid-0703aef6f72d481196156c40b2a8ca84,tumor types,0.326046
uuid-0703aef6f72d481196156c40b2a8ca84,label,0.362207
uuid-0703aef6f72d481196156c40b2a8ca84,Keytruda,0.441471
uuid-0703aef6f72d481196156c40b2a8ca84,RTL stated,0.523303
uuid-0703aef6f72d481196156c40b2a8ca84,TL shared,0.324962
uuid-0703aef6f72d481196156c40b2a8ca84,option,0.523089
uuid-0703aef6f72d481196156c40b2a8ca84,bladder,0.346118
uuid-0703aef6f72d481196156c40b2a8ca84,flat dosing,0.30358
uuid-c1c1b07eab664d3cadd0f9804de99785,Nivo,0.530995
uuid-c1c1b07eab664d3cadd0f9804de99785,pembro,0.548842
uuid-c1c1b07eab664d3cadd0f9804de99785,BMS,0.337156
uuid-c1c1b07eab664d3cadd0f9804de99785,PDL1,0.340397
uuid-c1c1b07eab664d3cadd0f9804de99785,trial,0.507259
uuid-c1c1b07eab664d3cadd0f9804de99785,efficacy,0.616229
uuid-c1c1b07eab664d3cadd0f9804de99785,chemo,0.318514
uuid-c1c1b07eab664d3cadd0f9804de99785,agents,0.362679
uuid-c1c1b07eab664d3cadd0f9804de99785,OS,0.443588
uuid-c1c1b07eab664d3cadd0f9804de99785,atezo,0.449506
uuid-c1c1b07eab664d3cadd0f9804de99785,data,0.582433
uuid-c1c1b07eab664d3cadd0f9804de99785,indication,0.390048
uuid-c1c1b07eab664d3cadd0f9804de99785,PFS,0.465063
uuid-c1c1b07eab664d3cadd0f9804de99785,ORR,0.463918
uuid-c1c1b07eab664d3cadd0f9804de99785,nivo and pembro,0.55192
uuid-c1c1b07eab664d3cadd0f9804de99785,believes,0.405556
uuid-c1c1b07eab664d3cadd0f9804de99785,chemotherapy,0.314463
uuid-c1c1b07eab664d3cadd0f9804de99785,impressed,0.335479
uuid-c1c1b07eab664d3cadd0f9804de99785,vs,0.394034
uuid-c1c1b07eab664d3cadd0f9804de99785,feels,0.514543
uuid-c1c1b07eab664d3cadd0f9804de99785,PDL1 expression,0.357026
uuid-c1c1b07eab664d3cadd0f9804de99785,option,0.348224
uuid-458e66b672ef4a939dfaf9c4dac0e294,RTL,0.350528
uuid-458e66b672ef4a939dfaf9c4dac0e294,discussed,0.615458
uuid-458e66b672ef4a939dfaf9c4dac0e294,commented,0.330834
uuid-458e66b672ef4a939dfaf9c4dac0e294,physicians,0.364875
uuid-458e66b672ef4a939dfaf9c4dac0e294,ASCO,0.332872
uuid-458e66b672ef4a939dfaf9c4dac0e294,academic,0.506866
uuid-458e66b672ef4a939dfaf9c4dac0e294,Regional TL,0.327215
uuid-49a6a0498efe4aafb8a21a9218d58a8d,patients,0.599298
uuid-49a6a0498efe4aafb8a21a9218d58a8d,Opdivo,0.306786
uuid-49a6a0498efe4aafb8a21a9218d58a8d,therapy,0.413973
uuid-49a6a0498efe4aafb8a21a9218d58a8d,regimen,0.336727
uuid-49a6a0498efe4aafb8a21a9218d58a8d,treated,0.400703
uuid-49a6a0498efe4aafb8a21a9218d58a8d,pts,0.419133
uuid-49a6a0498efe4aafb8a21a9218d58a8d,treatment,0.533468
uuid-49a6a0498efe4aafb8a21a9218d58a8d,response,0.462057
uuid-49a6a0498efe4aafb8a21a9218d58a8d,progression,0.612467
uuid-49a6a0498efe4aafb8a21a9218d58a8d,respond,0.42441
uuid-59c10464d2b24ca0917f8b343aba5d59,patients,0.494665
uuid-59c10464d2b24ca0917f8b343aba5d59,Opdivo,0.301025
uuid-59c10464d2b24ca0917f8b343aba5d59,treatment,0.407416
uuid-59c10464d2b24ca0917f8b343aba5d59,progression,0.348783
uuid-59c10464d2b24ca0917f8b343aba5d59,respond,0.328142
uuid-15d7a79f281f48da9ab70edc92ca26cc,patients,0.622512
uuid-15d7a79f281f48da9ab70edc92ca26cc,therapy,0.384092
uuid-15d7a79f281f48da9ab70edc92ca26cc,lung,0.326008
uuid-15d7a79f281f48da9ab70edc92ca26cc,regimen,0.357663
uuid-15d7a79f281f48da9ab70edc92ca26cc,treated,0.476292
uuid-15d7a79f281f48da9ab70edc92ca26cc,melanoma,0.330635
uuid-15d7a79f281f48da9ab70edc92ca26cc,pts,0.42491
uuid-15d7a79f281f48da9ab70edc92ca26cc,treatment,0.554426
uuid-15d7a79f281f48da9ab70edc92ca26cc,response,0.334763
uuid-15d7a79f281f48da9ab70edc92ca26cc,progression,0.620982
uuid-15d7a79f281f48da9ab70edc92ca26cc,respond,0.428051
uuid-15d7a79f281f48da9ab70edc92ca26cc,TL shared,0.40536
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,TL,0.466941
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,1L,0.316273
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,PDL1,0.403735
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,TL stated,0.498866
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,institution,0.30991
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,PD-L1,0.810876
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,PD-L1 testing,0.846838
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,testing,0.891954
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,PDL1 testing,0.764056
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,NSCLC patients,0.747333
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,assay,0.559457
uuid-3c4fe904f2e34d30ba71a2fc6637dd04,biomarker,0.397872
uuid-3ebf4683271848288500a17fb40ee667,therapy,0.320257
uuid-3ebf4683271848288500a17fb40ee667,nivolumab,0.387861
uuid-3ebf4683271848288500a17fb40ee667,trial,0.411097
uuid-3ebf4683271848288500a17fb40ee667,NTL,0.356069
uuid-3ebf4683271848288500a17fb40ee667,combination,0.346486
uuid-3ebf4683271848288500a17fb40ee667,cHL,0.372257
uuid-3ebf4683271848288500a17fb40ee667,chemotherapy,0.325747
uuid-1cf3a539c733448fbd2079481f71ef7a,patients,0.663854
uuid-1cf3a539c733448fbd2079481f71ef7a,therapy,0.440274
uuid-1cf3a539c733448fbd2079481f71ef7a,nivolumab,0.527418
uuid-1cf3a539c733448fbd2079481f71ef7a,toxicity,0.337962
uuid-1cf3a539c733448fbd2079481f71ef7a,regimen,0.595129
uuid-1cf3a539c733448fbd2079481f71ef7a,treated,0.666871
uuid-1cf3a539c733448fbd2079481f71ef7a,melanoma,0.47453
uuid-1cf3a539c733448fbd2079481f71ef7a,RCC,0.4034
uuid-1cf3a539c733448fbd2079481f71ef7a,combination,0.397632
uuid-1cf3a539c733448fbd2079481f71ef7a,chemo,0.304291
uuid-1cf3a539c733448fbd2079481f71ef7a,pts,0.578923
uuid-1cf3a539c733448fbd2079481f71ef7a,Ipi,0.341667
uuid-1cf3a539c733448fbd2079481f71ef7a,monotherapy,0.434133
uuid-1cf3a539c733448fbd2079481f71ef7a,treatment,0.573054
uuid-1cf3a539c733448fbd2079481f71ef7a,using nivo,0.303867
uuid-1cf3a539c733448fbd2079481f71ef7a,response,0.344024
uuid-1cf3a539c733448fbd2079481f71ef7a,combo,0.398679
uuid-1cf3a539c733448fbd2079481f71ef7a,PD1,0.366546
uuid-1cf3a539c733448fbd2079481f71ef7a,progression,0.599773
uuid-1cf3a539c733448fbd2079481f71ef7a,chemotherapy,0.321244
uuid-1cf3a539c733448fbd2079481f71ef7a,respond,0.389997
uuid-1cf3a539c733448fbd2079481f71ef7a,RTL stated,0.372114
uuid-1cf3a539c733448fbd2079481f71ef7a,TL shared,0.475954
uuid-86352ff0769f448e9feae5f1c997afbf,patients,0.719877
uuid-86352ff0769f448e9feae5f1c997afbf,therapy,0.342586
uuid-86352ff0769f448e9feae5f1c997afbf,nivolumab,0.430648
uuid-86352ff0769f448e9feae5f1c997afbf,regimen,0.397708
uuid-86352ff0769f448e9feae5f1c997afbf,treated,0.644569
uuid-86352ff0769f448e9feae5f1c997afbf,pts,0.526323
uuid-86352ff0769f448e9feae5f1c997afbf,approval,0.301714
uuid-86352ff0769f448e9feae5f1c997afbf,monotherapy,0.331936
uuid-86352ff0769f448e9feae5f1c997afbf,treatment,0.467594
uuid-86352ff0769f448e9feae5f1c997afbf,using nivo,0.341994
uuid-86352ff0769f448e9feae5f1c997afbf,progression,0.376389
uuid-86352ff0769f448e9feae5f1c997afbf,RTL stated,0.403779
uuid-86352ff0769f448e9feae5f1c997afbf,TL shared,0.364983
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,dose,0.464845
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,shared,0.406305
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,clinical trials,0.358447
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,LTL,0.317246
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,drug,0.317599
uuid-6b02cc59df4d451f8a4f1fbc2c114cc8,flat dosing,0.723889
uuid-d01b33c8cf1f4120b71255c3f80b2210,Opdivo,0.430252
uuid-d01b33c8cf1f4120b71255c3f80b2210,dose,0.360549
uuid-d01b33c8cf1f4120b71255c3f80b2210,melanoma,0.31606
uuid-d01b33c8cf1f4120b71255c3f80b2210,shared,0.689408
uuid-d01b33c8cf1f4120b71255c3f80b2210,RCC,0.320503
uuid-d01b33c8cf1f4120b71255c3f80b2210,institution,0.558287
uuid-d01b33c8cf1f4120b71255c3f80b2210,stated,0.329414
uuid-d01b33c8cf1f4120b71255c3f80b2210,approval,0.400704
uuid-d01b33c8cf1f4120b71255c3f80b2210,preferred,0.327645
uuid-d01b33c8cf1f4120b71255c3f80b2210,using nivo,0.321839
uuid-d01b33c8cf1f4120b71255c3f80b2210,indication,0.370281
uuid-d01b33c8cf1f4120b71255c3f80b2210,approved,0.410352
uuid-d01b33c8cf1f4120b71255c3f80b2210,SCCHN,0.395995
uuid-d01b33c8cf1f4120b71255c3f80b2210,HCP,0.302138
uuid-d01b33c8cf1f4120b71255c3f80b2210,label,0.346707
uuid-d01b33c8cf1f4120b71255c3f80b2210,LTL,0.358238
uuid-d01b33c8cf1f4120b71255c3f80b2210,Keytruda,0.417553
uuid-d01b33c8cf1f4120b71255c3f80b2210,RTL stated,0.318024
uuid-d01b33c8cf1f4120b71255c3f80b2210,flat dosing,0.669328
uuid-b84be3b64de140b0939e10b94ae6abc0,Nivo,0.369199
uuid-b84be3b64de140b0939e10b94ae6abc0,patients,0.797835
uuid-b84be3b64de140b0939e10b94ae6abc0,Opdivo,0.414874
uuid-b84be3b64de140b0939e10b94ae6abc0,therapy,0.481795
uuid-b84be3b64de140b0939e10b94ae6abc0,dose,0.404272
uuid-b84be3b64de140b0939e10b94ae6abc0,nivolumab,0.529573
uuid-b84be3b64de140b0939e10b94ae6abc0,toxicity,0.354864
uuid-b84be3b64de140b0939e10b94ae6abc0,regimen,0.572265
uuid-b84be3b64de140b0939e10b94ae6abc0,treated,0.500834
uuid-b84be3b64de140b0939e10b94ae6abc0,combination,0.403811
uuid-b84be3b64de140b0939e10b94ae6abc0,chemo,0.399839
uuid-b84be3b64de140b0939e10b94ae6abc0,pts,0.564711
uuid-b84be3b64de140b0939e10b94ae6abc0,Ipi,0.309657
uuid-b84be3b64de140b0939e10b94ae6abc0,preferred,0.322119
uuid-b84be3b64de140b0939e10b94ae6abc0,monotherapy,0.501998
uuid-b84be3b64de140b0939e10b94ae6abc0,treatment,0.54339
uuid-b84be3b64de140b0939e10b94ae6abc0,using nivo,0.333274
uuid-b84be3b64de140b0939e10b94ae6abc0,response,0.36638
uuid-b84be3b64de140b0939e10b94ae6abc0,combo,0.331948
uuid-b84be3b64de140b0939e10b94ae6abc0,PD1,0.332873
uuid-b84be3b64de140b0939e10b94ae6abc0,progression,0.540301
uuid-b84be3b64de140b0939e10b94ae6abc0,chemotherapy,0.488841
uuid-b84be3b64de140b0939e10b94ae6abc0,respond,0.407313
uuid-b84be3b64de140b0939e10b94ae6abc0,option,0.42695
uuid-089f17eff5514e608dbebb4269534763,PDL1,0.32406
uuid-089f17eff5514e608dbebb4269534763,PD1,0.416031
uuid-089f17eff5514e608dbebb4269534763,PD-1,0.417589
uuid-bc7731b37ee24fa5b4dab10bd634a6a5,label,0.402431
uuid-bc7731b37ee24fa5b4dab10bd634a6a5,drug,0.300303
uuid-dcc08dcfeb164fcdaee5bce058887dbc,patients,0.600757
uuid-dcc08dcfeb164fcdaee5bce058887dbc,Opdivo,0.321032
uuid-dcc08dcfeb164fcdaee5bce058887dbc,nivolumab,0.367576
uuid-dcc08dcfeb164fcdaee5bce058887dbc,toxicity,0.420737
uuid-dcc08dcfeb164fcdaee5bce058887dbc,regimen,0.48138
uuid-dcc08dcfeb164fcdaee5bce058887dbc,treated,0.596977
uuid-dcc08dcfeb164fcdaee5bce058887dbc,pts,0.350937
uuid-dcc08dcfeb164fcdaee5bce058887dbc,treatment,0.585558
uuid-dcc08dcfeb164fcdaee5bce058887dbc,progression,0.423339
uuid-dcc08dcfeb164fcdaee5bce058887dbc,respond,0.513392
uuid-dcc08dcfeb164fcdaee5bce058887dbc,TL shared,0.379644
uuid-6a83edd30fb2404193cfabf01c8f7131,patients,0.654559
uuid-6a83edd30fb2404193cfabf01c8f7131,Opdivo,0.384536
uuid-6a83edd30fb2404193cfabf01c8f7131,therapy,0.584898
uuid-6a83edd30fb2404193cfabf01c8f7131,nivolumab,0.379017
uuid-6a83edd30fb2404193cfabf01c8f7131,toxicity,0.320056
uuid-6a83edd30fb2404193cfabf01c8f7131,regimen,0.323407
uuid-6a83edd30fb2404193cfabf01c8f7131,treated,0.402364
uuid-6a83edd30fb2404193cfabf01c8f7131,pts,0.323266
uuid-6a83edd30fb2404193cfabf01c8f7131,treatment,0.506208
uuid-6a83edd30fb2404193cfabf01c8f7131,cHL,0.61273
uuid-6a83edd30fb2404193cfabf01c8f7131,progression,0.43446
uuid-6a83edd30fb2404193cfabf01c8f7131,chemotherapy,0.335181
uuid-6a83edd30fb2404193cfabf01c8f7131,respond,0.351682
uuid-ca726816414043658cc8db6a7732cfcd,PD-L1,0.347494
uuid-ca726816414043658cc8db6a7732cfcd,testing,0.304358
uuid-ca726816414043658cc8db6a7732cfcd,oncologist,0.564283
uuid-ca726816414043658cc8db6a7732cfcd,indicated,0.670116
uuid-038bf20585b142529d488d83431174b9,Nivo,0.54492
uuid-038bf20585b142529d488d83431174b9,patients,0.655097
uuid-038bf20585b142529d488d83431174b9,Opdivo,0.317901
uuid-038bf20585b142529d488d83431174b9,pembro,0.494191
uuid-038bf20585b142529d488d83431174b9,dose,0.400958
uuid-038bf20585b142529d488d83431174b9,nivolumab,0.333066
uuid-038bf20585b142529d488d83431174b9,1L,0.341055
uuid-038bf20585b142529d488d83431174b9,regimen,0.404825
uuid-038bf20585b142529d488d83431174b9,treated,0.312309
uuid-038bf20585b142529d488d83431174b9,chemo,0.373379
uuid-038bf20585b142529d488d83431174b9,2L,0.435028
uuid-038bf20585b142529d488d83431174b9,pts,0.547428
uuid-038bf20585b142529d488d83431174b9,Ipi,0.340891
uuid-038bf20585b142529d488d83431174b9,atezo,0.374883
uuid-038bf20585b142529d488d83431174b9,preferred,0.445618
uuid-038bf20585b142529d488d83431174b9,monotherapy,0.43672
uuid-038bf20585b142529d488d83431174b9,treatment,0.346925
uuid-038bf20585b142529d488d83431174b9,using nivo,0.489223
uuid-038bf20585b142529d488d83431174b9,progression,0.323091
uuid-038bf20585b142529d488d83431174b9,vs,0.315807
uuid-038bf20585b142529d488d83431174b9,respond,0.375538
uuid-038bf20585b142529d488d83431174b9,feels,0.31801
uuid-038bf20585b142529d488d83431174b9,RTL stated,0.319219
uuid-038bf20585b142529d488d83431174b9,option,0.440461
uuid-6b2988627c5441df99f69df4dc0086f8,oncologist,0.561524
uuid-6b2988627c5441df99f69df4dc0086f8,indicated,0.832699
uuid-3822454bd0f14b729861c39bccffa938,PDL1,0.472608
uuid-3822454bd0f14b729861c39bccffa938,trial,0.4242
uuid-3822454bd0f14b729861c39bccffa938,efficacy,0.713336
uuid-3822454bd0f14b729861c39bccffa938,chemo,0.331982
uuid-3822454bd0f14b729861c39bccffa938,OS,0.840673
uuid-3822454bd0f14b729861c39bccffa938,data,0.681605
uuid-3822454bd0f14b729861c39bccffa938,combo,0.306813
uuid-3822454bd0f14b729861c39bccffa938,PFS,0.840388
uuid-3822454bd0f14b729861c39bccffa938,ORR,0.808038
uuid-3822454bd0f14b729861c39bccffa938,nivo and pembro,0.53763
uuid-3822454bd0f14b729861c39bccffa938,believes,0.518171
uuid-3822454bd0f14b729861c39bccffa938,impressed,0.513031
uuid-3822454bd0f14b729861c39bccffa938,feels,0.433328
uuid-3822454bd0f14b729861c39bccffa938,PDL1 expression,0.430734
uuid-4c79ed4c02db4d29989a64814bcde07f,efficacy,0.416315
uuid-4c79ed4c02db4d29989a64814bcde07f,OS,0.568919
uuid-4c79ed4c02db4d29989a64814bcde07f,regards,0.320155
uuid-4c79ed4c02db4d29989a64814bcde07f,data,0.48002
uuid-4c79ed4c02db4d29989a64814bcde07f,PFS,0.612999
uuid-4c79ed4c02db4d29989a64814bcde07f,ORR,0.532505
uuid-4c79ed4c02db4d29989a64814bcde07f,nivo and pembro,0.314107
uuid-4c79ed4c02db4d29989a64814bcde07f,impressed,0.37203
uuid-4c79ed4c02db4d29989a64814bcde07f,indicated,0.574323
uuid-8da062bf60f548269474fcc386b1f0d1,efficacy,0.466449
uuid-8da062bf60f548269474fcc386b1f0d1,OS,0.438547
uuid-8da062bf60f548269474fcc386b1f0d1,regards,0.302897
uuid-8da062bf60f548269474fcc386b1f0d1,data,0.370297
uuid-8da062bf60f548269474fcc386b1f0d1,PFS,0.480388
uuid-8da062bf60f548269474fcc386b1f0d1,ORR,0.491289
uuid-8da062bf60f548269474fcc386b1f0d1,impressed,0.309551
uuid-8da062bf60f548269474fcc386b1f0d1,oncologist,0.360725
uuid-8da062bf60f548269474fcc386b1f0d1,indicated,0.643975
uuid-0a2510a14ed24cc89cbb48dd5e332b86,using nivo,0.304923
uuid-0a2510a14ed24cc89cbb48dd5e332b86,oncologist,0.504301
uuid-0a2510a14ed24cc89cbb48dd5e332b86,indicated,0.782985
uuid-6f19a902b97c477b9deeb563d033d054,oncologist,0.638871
uuid-6f19a902b97c477b9deeb563d033d054,indicated,0.798994
uuid-fb41f2ca692f450a8e1116de94a5762e,using nivo,0.475299
uuid-fb41f2ca692f450a8e1116de94a5762e,oncologist,0.582626
uuid-fb41f2ca692f450a8e1116de94a5762e,indicated,0.685144
uuid-fb41f2ca692f450a8e1116de94a5762e,option,0.33684
uuid-24ef48754f484792ad39f9fb25f42046,oncologist,0.581538
uuid-24ef48754f484792ad39f9fb25f42046,indicated,0.834342
uuid-395d8b12dd1b45309f2715e8e7312cdb,RTL,0.428457
uuid-395d8b12dd1b45309f2715e8e7312cdb,BMS,0.355697
uuid-395d8b12dd1b45309f2715e8e7312cdb,NTL,0.348674
uuid-395d8b12dd1b45309f2715e8e7312cdb,discussed,0.347159
uuid-395d8b12dd1b45309f2715e8e7312cdb,commented,0.577392
uuid-395d8b12dd1b45309f2715e8e7312cdb,stated,0.378754
uuid-395d8b12dd1b45309f2715e8e7312cdb,OS,0.392434
uuid-395d8b12dd1b45309f2715e8e7312cdb,regards,0.385508
uuid-395d8b12dd1b45309f2715e8e7312cdb,data,0.704288
uuid-395d8b12dd1b45309f2715e8e7312cdb,expressed,0.362727
uuid-395d8b12dd1b45309f2715e8e7312cdb,PFS,0.335679
uuid-395d8b12dd1b45309f2715e8e7312cdb,ORR,0.383321
uuid-395d8b12dd1b45309f2715e8e7312cdb,SCCHN,0.463842
uuid-395d8b12dd1b45309f2715e8e7312cdb,ASCO,0.403807
uuid-395d8b12dd1b45309f2715e8e7312cdb,impressed,0.629829
uuid-395d8b12dd1b45309f2715e8e7312cdb,SCLC,0.317169
uuid-395d8b12dd1b45309f2715e8e7312cdb,Regional TL,0.405126
uuid-395d8b12dd1b45309f2715e8e7312cdb,NCCN,0.557754
uuid-1b3c985abc0543f6a76510bf66dd3d14,Nivo,0.393291
uuid-1b3c985abc0543f6a76510bf66dd3d14,patients,0.589755
uuid-1b3c985abc0543f6a76510bf66dd3d14,therapy,0.431275
uuid-1b3c985abc0543f6a76510bf66dd3d14,nivolumab,0.720068
uuid-1b3c985abc0543f6a76510bf66dd3d14,1L,0.311734
uuid-1b3c985abc0543f6a76510bf66dd3d14,trial,0.3549
uuid-1b3c985abc0543f6a76510bf66dd3d14,regimen,0.449369
uuid-1b3c985abc0543f6a76510bf66dd3d14,treated,0.481602
uuid-1b3c985abc0543f6a76510bf66dd3d14,RCC,0.357356
uuid-1b3c985abc0543f6a76510bf66dd3d14,combination,0.572403
uuid-1b3c985abc0543f6a76510bf66dd3d14,chemo,0.392337
uuid-1b3c985abc0543f6a76510bf66dd3d14,2L,0.340122
uuid-1b3c985abc0543f6a76510bf66dd3d14,pts,0.546355
uuid-1b3c985abc0543f6a76510bf66dd3d14,Ipi,0.329697
uuid-1b3c985abc0543f6a76510bf66dd3d14,approval,0.311429
uuid-1b3c985abc0543f6a76510bf66dd3d14,preferred,0.318971
uuid-1b3c985abc0543f6a76510bf66dd3d14,monotherapy,0.505755
uuid-1b3c985abc0543f6a76510bf66dd3d14,treatment,0.380848
uuid-1b3c985abc0543f6a76510bf66dd3d14,using nivo,0.45276
uuid-1b3c985abc0543f6a76510bf66dd3d14,combo,0.499548
uuid-1b3c985abc0543f6a76510bf66dd3d14,clinical trials,0.321282
uuid-1b3c985abc0543f6a76510bf66dd3d14,PD1,0.410891
uuid-1b3c985abc0543f6a76510bf66dd3d14,approved,0.334342
uuid-1b3c985abc0543f6a76510bf66dd3d14,progression,0.379775
uuid-1b3c985abc0543f6a76510bf66dd3d14,chemotherapy,0.436505
uuid-1b3c985abc0543f6a76510bf66dd3d14,SCLC,0.314606
uuid-1b3c985abc0543f6a76510bf66dd3d14,RTL stated,0.447141
uuid-1b3c985abc0543f6a76510bf66dd3d14,option,0.401695
uuid-1b3c985abc0543f6a76510bf66dd3d14,bladder,0.340086
uuid-5dabda219ab54aa68c09a898e06981e6,regimen,0.341767
uuid-5dabda219ab54aa68c09a898e06981e6,melanoma,0.300011
uuid-5dabda219ab54aa68c09a898e06981e6,combination,0.406443
uuid-5dabda219ab54aa68c09a898e06981e6,chemo,0.336531
uuid-5dabda219ab54aa68c09a898e06981e6,IO,0.364189
uuid-5dabda219ab54aa68c09a898e06981e6,monotherapy,0.33389
uuid-5dabda219ab54aa68c09a898e06981e6,treatment,0.32261
uuid-5dabda219ab54aa68c09a898e06981e6,combo,0.30345
uuid-5dabda219ab54aa68c09a898e06981e6,PD1,0.306655
uuid-5dabda219ab54aa68c09a898e06981e6,chemotherapy,0.449497
uuid-5dabda219ab54aa68c09a898e06981e6,immunotherapy,0.312914
uuid-5dabda219ab54aa68c09a898e06981e6,option,0.345353
uuid-7d48860515054942b67838a48f5f4279,nivolumab,0.352649
uuid-7d48860515054942b67838a48f5f4279,treated,0.334634
uuid-7d48860515054942b67838a48f5f4279,NTL,0.34351
uuid-7d48860515054942b67838a48f5f4279,cHL,0.456343
uuid-cf3da958700e433dae2cd1d2e7953940,patients,0.612245
uuid-cf3da958700e433dae2cd1d2e7953940,Opdivo,0.483989
uuid-cf3da958700e433dae2cd1d2e7953940,therapy,0.37314
uuid-cf3da958700e433dae2cd1d2e7953940,nivolumab,0.376057
uuid-cf3da958700e433dae2cd1d2e7953940,regimen,0.360485
uuid-cf3da958700e433dae2cd1d2e7953940,treated,0.500296
uuid-cf3da958700e433dae2cd1d2e7953940,physicians,0.506672
uuid-cf3da958700e433dae2cd1d2e7953940,treatment,0.553048
uuid-cf3da958700e433dae2cd1d2e7953940,oncology,0.378854
uuid-cf3da958700e433dae2cd1d2e7953940,cHL,0.302598
uuid-cf3da958700e433dae2cd1d2e7953940,progression,0.380029
uuid-cf3da958700e433dae2cd1d2e7953940,oncologist,0.392762
uuid-cf3da958700e433dae2cd1d2e7953940,clinical,0.303949
uuid-d1ad593dcde8424da90d04ca4479c0fc,physicians,0.581058
uuid-d1ad593dcde8424da90d04ca4479c0fc,treatment,0.444491
uuid-d1ad593dcde8424da90d04ca4479c0fc,progression,0.311316
uuid-1d6fc246548840998cb9ea0eaf725cc1,Opdivo,0.429608
uuid-1d6fc246548840998cb9ea0eaf725cc1,dose,0.848722
uuid-1d6fc246548840998cb9ea0eaf725cc1,toxicity,0.584842
uuid-1d6fc246548840998cb9ea0eaf725cc1,regimen,0.352729
uuid-1d6fc246548840998cb9ea0eaf725cc1,Ipi,0.520386
uuid-1d6fc246548840998cb9ea0eaf725cc1,vs,0.444433
uuid-1d6fc246548840998cb9ea0eaf725cc1,Keytruda,0.320184
uuid-1d6fc246548840998cb9ea0eaf725cc1,flat dosing,0.751951
uuid-8650ad00d5144292964dc90123d8c874,Nivo,0.303391
uuid-8650ad00d5144292964dc90123d8c874,patients,0.302567
uuid-8650ad00d5144292964dc90123d8c874,pembro,0.328317
uuid-8650ad00d5144292964dc90123d8c874,trial,0.431413
uuid-8650ad00d5144292964dc90123d8c874,chemo,0.339475
uuid-8650ad00d5144292964dc90123d8c874,monotherapy,0.311504
uuid-8650ad00d5144292964dc90123d8c874,combo,0.317069
uuid-8650ad00d5144292964dc90123d8c874,clinical trials,0.407036
uuid-8650ad00d5144292964dc90123d8c874,approved,0.357988
uuid-8650ad00d5144292964dc90123d8c874,believes,0.302007
uuid-8650ad00d5144292964dc90123d8c874,chemotherapy,0.360168
uuid-8650ad00d5144292964dc90123d8c874,feels,0.470244
uuid-8650ad00d5144292964dc90123d8c874,option,0.471867
uuid-f11ba2686d4c40049a1f219117b5d40f,pembro,0.443081
uuid-f11ba2686d4c40049a1f219117b5d40f,RTL,0.447135
uuid-f11ba2686d4c40049a1f219117b5d40f,trial,0.589083
uuid-f11ba2686d4c40049a1f219117b5d40f,shared,0.469544
uuid-f11ba2686d4c40049a1f219117b5d40f,commented,0.305468
uuid-f11ba2686d4c40049a1f219117b5d40f,Ipi,0.353256
uuid-f11ba2686d4c40049a1f219117b5d40f,stated,0.384057
uuid-f11ba2686d4c40049a1f219117b5d40f,approval,0.405177
uuid-f11ba2686d4c40049a1f219117b5d40f,atezo,0.325117
uuid-f11ba2686d4c40049a1f219117b5d40f,combo,0.301022
uuid-f11ba2686d4c40049a1f219117b5d40f,clinical trials,0.543622
uuid-f11ba2686d4c40049a1f219117b5d40f,approved,0.321765
uuid-f11ba2686d4c40049a1f219117b5d40f,SCCHN,0.415618
uuid-f11ba2686d4c40049a1f219117b5d40f,LTL,0.333269
uuid-f11ba2686d4c40049a1f219117b5d40f,TLs,0.373297
uuid-f11ba2686d4c40049a1f219117b5d40f,SCLC,0.307279
uuid-f11ba2686d4c40049a1f219117b5d40f,Regional TL,0.392424
uuid-f11ba2686d4c40049a1f219117b5d40f,RTL stated,0.351995
uuid-f11ba2686d4c40049a1f219117b5d40f,bladder,0.411078
uuid-8d3d9c78350f441db1b477d3fce876d7,pembro,0.404692
uuid-8d3d9c78350f441db1b477d3fce876d7,BMS,0.361121
uuid-8d3d9c78350f441db1b477d3fce876d7,PDL1,0.498275
uuid-8d3d9c78350f441db1b477d3fce876d7,trial,0.460921
uuid-8d3d9c78350f441db1b477d3fce876d7,efficacy,0.703327
uuid-8d3d9c78350f441db1b477d3fce876d7,commented,0.307228
uuid-8d3d9c78350f441db1b477d3fce876d7,OS,0.650686
uuid-8d3d9c78350f441db1b477d3fce876d7,atezo,0.360077
uuid-8d3d9c78350f441db1b477d3fce876d7,regards,0.327039
uuid-8d3d9c78350f441db1b477d3fce876d7,data,0.799998
uuid-8d3d9c78350f441db1b477d3fce876d7,PFS,0.618818
uuid-8d3d9c78350f441db1b477d3fce876d7,ORR,0.688766
uuid-8d3d9c78350f441db1b477d3fce876d7,nivo and pembro,0.545849
uuid-8d3d9c78350f441db1b477d3fce876d7,believes,0.386725
uuid-8d3d9c78350f441db1b477d3fce876d7,impressed,0.595893
uuid-8d3d9c78350f441db1b477d3fce876d7,vs,0.353387
uuid-8d3d9c78350f441db1b477d3fce876d7,TLs,0.374012
uuid-8d3d9c78350f441db1b477d3fce876d7,feels,0.479056
uuid-8d3d9c78350f441db1b477d3fce876d7,PDL1 expression,0.466387
uuid-32c9208840584cffaae41104fb494408,patients,0.482819
uuid-32c9208840584cffaae41104fb494408,nivolumab,0.383177
uuid-32c9208840584cffaae41104fb494408,1L,0.412215
uuid-32c9208840584cffaae41104fb494408,treated,0.447456
uuid-32c9208840584cffaae41104fb494408,RCC,0.535573
uuid-32c9208840584cffaae41104fb494408,TL stated,0.348519
uuid-32c9208840584cffaae41104fb494408,tumor,0.30039
uuid-32c9208840584cffaae41104fb494408,2L,0.440626
uuid-32c9208840584cffaae41104fb494408,pts,0.472923
uuid-32c9208840584cffaae41104fb494408,approval,0.457115
uuid-32c9208840584cffaae41104fb494408,preferred,0.362707
uuid-32c9208840584cffaae41104fb494408,using nivo,0.544602
uuid-32c9208840584cffaae41104fb494408,NSCLC patients,0.410191
uuid-32c9208840584cffaae41104fb494408,approved,0.305464
uuid-32c9208840584cffaae41104fb494408,SCCHN,0.43117
uuid-32c9208840584cffaae41104fb494408,Regional TL,0.30959
uuid-32c9208840584cffaae41104fb494408,RTL stated,0.534245
uuid-32c9208840584cffaae41104fb494408,TL shared,0.358211
uuid-32c9208840584cffaae41104fb494408,option,0.346996
uuid-32c9208840584cffaae41104fb494408,bladder,0.458932
uuid-687435a267fc41f6937540bc36cb1e86,Nivo,0.31006
uuid-687435a267fc41f6937540bc36cb1e86,PDL1,0.377294
uuid-687435a267fc41f6937540bc36cb1e86,trial,0.382077
uuid-687435a267fc41f6937540bc36cb1e86,efficacy,0.495048
uuid-687435a267fc41f6937540bc36cb1e86,combination,0.401216
uuid-687435a267fc41f6937540bc36cb1e86,chemo,0.528327
uuid-687435a267fc41f6937540bc36cb1e86,tumor,0.453753
uuid-687435a267fc41f6937540bc36cb1e86,agents,0.313326
uuid-687435a267fc41f6937540bc36cb1e86,OS,0.35996
uuid-687435a267fc41f6937540bc36cb1e86,response,0.364054
uuid-687435a267fc41f6937540bc36cb1e86,combo,0.387049
uuid-687435a267fc41f6937540bc36cb1e86,PFS,0.353984
uuid-687435a267fc41f6937540bc36cb1e86,PD1,0.332364
uuid-687435a267fc41f6937540bc36cb1e86,ORR,0.398084
uuid-687435a267fc41f6937540bc36cb1e86,nivo and pembro,0.318861
uuid-687435a267fc41f6937540bc36cb1e86,believes,0.480985
uuid-687435a267fc41f6937540bc36cb1e86,chemotherapy,0.354465
uuid-687435a267fc41f6937540bc36cb1e86,feels,0.317987
uuid-687435a267fc41f6937540bc36cb1e86,PDL1 expression,0.376602
uuid-687435a267fc41f6937540bc36cb1e86,biomarker,0.302964
uuid-762dc125e2f848ccb9eb2963b0b6a666,patients,0.359332
uuid-762dc125e2f848ccb9eb2963b0b6a666,Opdivo,0.336132
uuid-762dc125e2f848ccb9eb2963b0b6a666,RTL,0.319653
uuid-762dc125e2f848ccb9eb2963b0b6a666,therapy,0.338149
uuid-762dc125e2f848ccb9eb2963b0b6a666,nivolumab,0.306221
uuid-762dc125e2f848ccb9eb2963b0b6a666,mentioned,0.59075
uuid-762dc125e2f848ccb9eb2963b0b6a666,cHL,0.609443
uuid-27e58cb468cb464197848ba067909eff,dose,0.744032
uuid-27e58cb468cb464197848ba067909eff,toxicity,0.335796
uuid-27e58cb468cb464197848ba067909eff,Ipi,0.373908
uuid-27e58cb468cb464197848ba067909eff,AI,0.310496
uuid-27e58cb468cb464197848ba067909eff,vs,0.382554
uuid-27e58cb468cb464197848ba067909eff,drug,0.514886
uuid-27e58cb468cb464197848ba067909eff,Keytruda,0.300574
uuid-27e58cb468cb464197848ba067909eff,flat dosing,0.606922
uuid-649dbbc63193441f81d791b620a9b821,pembro,0.30637
uuid-649dbbc63193441f81d791b620a9b821,lung,0.389445
uuid-649dbbc63193441f81d791b620a9b821,1L,0.663754
uuid-649dbbc63193441f81d791b620a9b821,melanoma,0.334944
uuid-649dbbc63193441f81d791b620a9b821,RCC,0.736305
uuid-649dbbc63193441f81d791b620a9b821,TL stated,0.627702
uuid-649dbbc63193441f81d791b620a9b821,2L,0.645474
uuid-649dbbc63193441f81d791b620a9b821,pts,0.468833
uuid-649dbbc63193441f81d791b620a9b821,PD-L1,0.556699
uuid-649dbbc63193441f81d791b620a9b821,approval,0.338848
uuid-649dbbc63193441f81d791b620a9b821,atezo,0.362935
uuid-649dbbc63193441f81d791b620a9b821,preferred,0.481086
uuid-649dbbc63193441f81d791b620a9b821,PD-L1 testing,0.456236
uuid-649dbbc63193441f81d791b620a9b821,testing,0.549076
uuid-649dbbc63193441f81d791b620a9b821,monotherapy,0.424079
uuid-649dbbc63193441f81d791b620a9b821,using nivo,0.520516
uuid-649dbbc63193441f81d791b620a9b821,PDL1 testing,0.644455
uuid-649dbbc63193441f81d791b620a9b821,NSCLC patients,0.687311
uuid-649dbbc63193441f81d791b620a9b821,approved,0.373252
uuid-649dbbc63193441f81d791b620a9b821,SCCHN,0.472557
uuid-649dbbc63193441f81d791b620a9b821,tumor types,0.485385
uuid-649dbbc63193441f81d791b620a9b821,PD-1,0.362267
uuid-649dbbc63193441f81d791b620a9b821,RTL stated,0.622797
uuid-649dbbc63193441f81d791b620a9b821,TL shared,0.503482
uuid-649dbbc63193441f81d791b620a9b821,option,0.400023
uuid-649dbbc63193441f81d791b620a9b821,bladder,0.455419
uuid-83e6471c797a4387823bbbdc10c7cd07,shared,0.539883
uuid-83e6471c797a4387823bbbdc10c7cd07,institution,0.75561
uuid-f4036d9a80804753b6b06572e9b0237c,Nivo,0.551379
uuid-f4036d9a80804753b6b06572e9b0237c,pembro,0.59065
uuid-f4036d9a80804753b6b06572e9b0237c,RTL,0.39402
uuid-f4036d9a80804753b6b06572e9b0237c,nivolumab,0.325963
uuid-f4036d9a80804753b6b06572e9b0237c,1L,0.471896
uuid-f4036d9a80804753b6b06572e9b0237c,trial,0.301149
uuid-f4036d9a80804753b6b06572e9b0237c,RCC,0.33678
uuid-f4036d9a80804753b6b06572e9b0237c,combination,0.330973
uuid-f4036d9a80804753b6b06572e9b0237c,2L,0.517859
uuid-f4036d9a80804753b6b06572e9b0237c,Ipi,0.318895
uuid-f4036d9a80804753b6b06572e9b0237c,approval,0.376971
uuid-f4036d9a80804753b6b06572e9b0237c,atezo,0.491518
uuid-f4036d9a80804753b6b06572e9b0237c,preferred,0.582931
uuid-f4036d9a80804753b6b06572e9b0237c,monotherapy,0.457362
uuid-f4036d9a80804753b6b06572e9b0237c,using nivo,0.600764
uuid-f4036d9a80804753b6b06572e9b0237c,combo,0.308097
uuid-f4036d9a80804753b6b06572e9b0237c,clinical trials,0.31146
uuid-f4036d9a80804753b6b06572e9b0237c,indication,0.343838
uuid-f4036d9a80804753b6b06572e9b0237c,approved,0.424438
uuid-f4036d9a80804753b6b06572e9b0237c,SCCHN,0.482256
uuid-f4036d9a80804753b6b06572e9b0237c,impressed,0.345747
uuid-f4036d9a80804753b6b06572e9b0237c,LTL,0.388251
uuid-f4036d9a80804753b6b06572e9b0237c,feels,0.456699
uuid-f4036d9a80804753b6b06572e9b0237c,Regional TL,0.333974
uuid-f4036d9a80804753b6b06572e9b0237c,RTL stated,0.594689
uuid-f4036d9a80804753b6b06572e9b0237c,option,0.452739
uuid-f4036d9a80804753b6b06572e9b0237c,bladder,0.343761
uuid-bfc4c14addeb4c8c893938a5730c1ec7,Nivo,0.568496
uuid-bfc4c14addeb4c8c893938a5730c1ec7,patients,0.633169
uuid-bfc4c14addeb4c8c893938a5730c1ec7,pembro,0.478707
uuid-bfc4c14addeb4c8c893938a5730c1ec7,therapy,0.514463
uuid-bfc4c14addeb4c8c893938a5730c1ec7,nivolumab,0.550907
uuid-bfc4c14addeb4c8c893938a5730c1ec7,1L,0.556181
uuid-bfc4c14addeb4c8c893938a5730c1ec7,regimen,0.348975
uuid-bfc4c14addeb4c8c893938a5730c1ec7,treated,0.358357
uuid-bfc4c14addeb4c8c893938a5730c1ec7,RCC,0.344643
uuid-bfc4c14addeb4c8c893938a5730c1ec7,combination,0.34249
uuid-bfc4c14addeb4c8c893938a5730c1ec7,chemo,0.436865
uuid-bfc4c14addeb4c8c893938a5730c1ec7,2L,0.601459
uuid-bfc4c14addeb4c8c893938a5730c1ec7,pts,0.41331
uuid-bfc4c14addeb4c8c893938a5730c1ec7,approval,0.458559
uuid-bfc4c14addeb4c8c893938a5730c1ec7,atezo,0.33653
uuid-bfc4c14addeb4c8c893938a5730c1ec7,preferred,0.652637
uuid-bfc4c14addeb4c8c893938a5730c1ec7,monotherapy,0.628326
uuid-bfc4c14addeb4c8c893938a5730c1ec7,treatment,0.382762
uuid-bfc4c14addeb4c8c893938a5730c1ec7,using nivo,0.741009
uuid-bfc4c14addeb4c8c893938a5730c1ec7,combo,0.302419
uuid-bfc4c14addeb4c8c893938a5730c1ec7,PD1,0.357948
uuid-bfc4c14addeb4c8c893938a5730c1ec7,approved,0.476882
uuid-bfc4c14addeb4c8c893938a5730c1ec7,SCCHN,0.399453
uuid-bfc4c14addeb4c8c893938a5730c1ec7,cHL,0.300445
uuid-bfc4c14addeb4c8c893938a5730c1ec7,progression,0.310173
uuid-bfc4c14addeb4c8c893938a5730c1ec7,chemotherapy,0.475349
uuid-bfc4c14addeb4c8c893938a5730c1ec7,feels,0.354062
uuid-bfc4c14addeb4c8c893938a5730c1ec7,RTL stated,0.600286
uuid-bfc4c14addeb4c8c893938a5730c1ec7,option,0.708128
uuid-bfc4c14addeb4c8c893938a5730c1ec7,bladder,0.332643
uuid-ea2f391708bb48099783eba8685ea999,Nivo,0.388217
uuid-ea2f391708bb48099783eba8685ea999,dose,0.748826
uuid-ea2f391708bb48099783eba8685ea999,toxicity,0.512982
uuid-ea2f391708bb48099783eba8685ea999,efficacy,0.48696
uuid-ea2f391708bb48099783eba8685ea999,regimen,0.454803
uuid-ea2f391708bb48099783eba8685ea999,combination,0.38643
uuid-ea2f391708bb48099783eba8685ea999,Ipi,0.736545
uuid-ea2f391708bb48099783eba8685ea999,combo,0.405031
uuid-ea2f391708bb48099783eba8685ea999,vs,0.546604
uuid-ea2f391708bb48099783eba8685ea999,flat dosing,0.534253
uuid-c1668090e45c495c99273f9358e168bd,Nivo,0.403596
uuid-c1668090e45c495c99273f9358e168bd,patients,0.40458
uuid-c1668090e45c495c99273f9358e168bd,pembro,0.437574
uuid-c1668090e45c495c99273f9358e168bd,1L,0.379363
uuid-c1668090e45c495c99273f9358e168bd,trial,0.410351
uuid-c1668090e45c495c99273f9358e168bd,efficacy,0.327447
uuid-c1668090e45c495c99273f9358e168bd,regimen,0.363963
uuid-c1668090e45c495c99273f9358e168bd,combination,0.43987
uuid-c1668090e45c495c99273f9358e168bd,chemo,0.462843
uuid-c1668090e45c495c99273f9358e168bd,pts,0.488279
uuid-c1668090e45c495c99273f9358e168bd,Ipi,0.450342
uuid-c1668090e45c495c99273f9358e168bd,monotherapy,0.504611
uuid-c1668090e45c495c99273f9358e168bd,combo,0.54762
uuid-c1668090e45c495c99273f9358e168bd,clinical trials,0.328723
uuid-c1668090e45c495c99273f9358e168bd,PD1,0.370335
uuid-c1668090e45c495c99273f9358e168bd,ORR,0.326977
uuid-c1668090e45c495c99273f9358e168bd,progression,0.328297
uuid-c1668090e45c495c99273f9358e168bd,believes,0.321729
uuid-c1668090e45c495c99273f9358e168bd,chemotherapy,0.3918
uuid-c1668090e45c495c99273f9358e168bd,impressed,0.355965
uuid-c1668090e45c495c99273f9358e168bd,vs,0.303733
uuid-c1668090e45c495c99273f9358e168bd,feels,0.412044
uuid-c1668090e45c495c99273f9358e168bd,option,0.355041
uuid-d727009eae25437fa9fde1c0331328df,PDL1,0.367727
uuid-d727009eae25437fa9fde1c0331328df,trial,0.466505
uuid-d727009eae25437fa9fde1c0331328df,efficacy,0.639028
uuid-d727009eae25437fa9fde1c0331328df,chemo,0.307148
uuid-d727009eae25437fa9fde1c0331328df,OS,0.83774
uuid-d727009eae25437fa9fde1c0331328df,response,0.392314
uuid-d727009eae25437fa9fde1c0331328df,data,0.555615
uuid-d727009eae25437fa9fde1c0331328df,PFS,0.866233
uuid-d727009eae25437fa9fde1c0331328df,ORR,0.86294
uuid-d727009eae25437fa9fde1c0331328df,nivo and pembro,0.356547
uuid-d727009eae25437fa9fde1c0331328df,believes,0.35916
uuid-d727009eae25437fa9fde1c0331328df,impressed,0.497131
uuid-d727009eae25437fa9fde1c0331328df,feels,0.364287
uuid-d727009eae25437fa9fde1c0331328df,PDL1 expression,0.393911
uuid-c191208e2a41411795d734c1ab2fd0f8,Nivo,0.361144
uuid-c191208e2a41411795d734c1ab2fd0f8,patients,0.716407
uuid-c191208e2a41411795d734c1ab2fd0f8,pembro,0.374639
uuid-c191208e2a41411795d734c1ab2fd0f8,therapy,0.315179
uuid-c191208e2a41411795d734c1ab2fd0f8,1L,0.434542
uuid-c191208e2a41411795d734c1ab2fd0f8,PDL1,0.301534
uuid-c191208e2a41411795d734c1ab2fd0f8,chemo,0.347084
uuid-c191208e2a41411795d734c1ab2fd0f8,2L,0.372766
uuid-c191208e2a41411795d734c1ab2fd0f8,pts,0.538777
uuid-c191208e2a41411795d734c1ab2fd0f8,preferred,0.319713
uuid-c191208e2a41411795d734c1ab2fd0f8,monotherapy,0.414597
uuid-c191208e2a41411795d734c1ab2fd0f8,treatment,0.324576
uuid-c191208e2a41411795d734c1ab2fd0f8,using nivo,0.417857
uuid-c191208e2a41411795d734c1ab2fd0f8,NSCLC patients,0.485304
uuid-c191208e2a41411795d734c1ab2fd0f8,progression,0.393129
uuid-c191208e2a41411795d734c1ab2fd0f8,respond,0.419829
uuid-c191208e2a41411795d734c1ab2fd0f8,option,0.460167
uuid-b17bf687ec2f47adb68007a313dfefaf,Nivo,0.374547
uuid-b17bf687ec2f47adb68007a313dfefaf,pembro,0.409607
uuid-b17bf687ec2f47adb68007a313dfefaf,PDL1,0.479107
uuid-b17bf687ec2f47adb68007a313dfefaf,trial,0.560372
uuid-b17bf687ec2f47adb68007a313dfefaf,efficacy,0.658635
uuid-b17bf687ec2f47adb68007a313dfefaf,OS,0.448671
uuid-b17bf687ec2f47adb68007a313dfefaf,atezo,0.315175
uuid-b17bf687ec2f47adb68007a313dfefaf,regards,0.350629
uuid-b17bf687ec2f47adb68007a313dfefaf,data,0.41686
uuid-b17bf687ec2f47adb68007a313dfefaf,PFS,0.514372
uuid-b17bf687ec2f47adb68007a313dfefaf,ORR,0.507487
uuid-b17bf687ec2f47adb68007a313dfefaf,nivo and pembro,0.47798
uuid-b17bf687ec2f47adb68007a313dfefaf,believes,0.323639
uuid-b17bf687ec2f47adb68007a313dfefaf,vs,0.449309
uuid-b17bf687ec2f47adb68007a313dfefaf,feels,0.398362
uuid-b17bf687ec2f47adb68007a313dfefaf,PDL1 expression,0.503031
uuid-7b7de7ba8c314b44baf303645528a66d,patients,0.464427
uuid-7b7de7ba8c314b44baf303645528a66d,pts,0.3547
uuid-7b7de7ba8c314b44baf303645528a66d,response,0.312975
uuid-7b7de7ba8c314b44baf303645528a66d,NSCLC patients,0.416146
uuid-7b7de7ba8c314b44baf303645528a66d,progression,0.406699
uuid-7b7de7ba8c314b44baf303645528a66d,respond,0.479877
uuid-ad6d20ba36414fc489c81526240ce0ba,BMS,0.539878
uuid-ad6d20ba36414fc489c81526240ce0ba,shared,0.305714
uuid-ad6d20ba36414fc489c81526240ce0ba,Merck,0.414105
uuid-ad6d20ba36414fc489c81526240ce0ba,physicians,0.547246
uuid-ad6d20ba36414fc489c81526240ce0ba,regards,0.312462
uuid-ad6d20ba36414fc489c81526240ce0ba,expressed,0.341734
uuid-ad6d20ba36414fc489c81526240ce0ba,clinical,0.357689
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,dose,0.333522
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,toxicity,0.563581
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,regimen,0.43229
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,treated,0.321458
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,physicians,0.360714
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,treatment,0.463617
uuid-01f6d03ce2f649ad9f3c6fcb782ed3ad,respond,0.397079
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,dose,0.744032
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,toxicity,0.335796
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,Ipi,0.373908
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,AI,0.310496
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,vs,0.382554
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,drug,0.514886
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,Keytruda,0.300574
uuid-16d5de90ebe64b3fb5a5c3fca7c4c325,flat dosing,0.606922
uuid-95dccec4f4674b5fb009576b958b5f8d,patients,0.304602
uuid-95dccec4f4674b5fb009576b958b5f8d,Opdivo,0.4811
uuid-95dccec4f4674b5fb009576b958b5f8d,treated,0.384543
uuid-95dccec4f4674b5fb009576b958b5f8d,physicians,0.452085
uuid-95dccec4f4674b5fb009576b958b5f8d,treatment,0.432311
uuid-95dccec4f4674b5fb009576b958b5f8d,progression,0.310993
uuid-95dccec4f4674b5fb009576b958b5f8d,academic,0.372331
uuid-ddd8f8915eca40b1b2b46172c7233897,NSCLC,0.583769
uuid-ddd8f8915eca40b1b2b46172c7233897,trial,0.3271
uuid-ddd8f8915eca40b1b2b46172c7233897,combination,0.302419
uuid-ddd8f8915eca40b1b2b46172c7233897,IO,0.651067
uuid-ddd8f8915eca40b1b2b46172c7233897,OS,0.351678
uuid-ddd8f8915eca40b1b2b46172c7233897,response,0.323382
uuid-ddd8f8915eca40b1b2b46172c7233897,PFS,0.340713
uuid-ddd8f8915eca40b1b2b46172c7233897,ORR,0.390534
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,Nivo,0.356831
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,patients,0.794514
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,Opdivo,0.381733
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,therapy,0.586064
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,nivolumab,0.55121
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,1L,0.332158
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,regimen,0.59591
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,treated,0.520912
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,combination,0.34837
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,chemo,0.422675
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,2L,0.33332
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,pts,0.662786
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,preferred,0.306271
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,monotherapy,0.566114
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,treatment,0.598719
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,using nivo,0.429149
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,response,0.448604
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,combo,0.367788
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,PD1,0.409817
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,progression,0.671138
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,chemotherapy,0.462061
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,respond,0.494231
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,SCLC,0.367918
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,RTL stated,0.308464
uuid-ae1c53a0a2e942179d874bdf3f9aa02c,option,0.53304
uuid-d3f8949c10ae43769d4028e27e69c805,oncologist,0.593849
uuid-d3f8949c10ae43769d4028e27e69c805,indicated,0.850489
uuid-3704d7e99a6b456ba76a86748865ee86,PD-L1,0.590663
uuid-3704d7e99a6b456ba76a86748865ee86,PD-L1 testing,0.583263
uuid-3704d7e99a6b456ba76a86748865ee86,testing,0.583418
uuid-3704d7e99a6b456ba76a86748865ee86,PDL1 testing,0.458395
uuid-3704d7e99a6b456ba76a86748865ee86,NSCLC patients,0.471886
uuid-3704d7e99a6b456ba76a86748865ee86,oncologist,0.573878
uuid-3704d7e99a6b456ba76a86748865ee86,indicated,0.66101
uuid-3704d7e99a6b456ba76a86748865ee86,assay,0.315335
uuid-3704d7e99a6b456ba76a86748865ee86,biomarker,0.310354
uuid-04d6cf22e7c74c549dce12ad0b899d62,therapy,0.310776
uuid-04d6cf22e7c74c549dce12ad0b899d62,using nivo,0.347328
uuid-04d6cf22e7c74c549dce12ad0b899d62,cHL,0.490304
uuid-04d6cf22e7c74c549dce12ad0b899d62,oncologist,0.443193
uuid-04d6cf22e7c74c549dce12ad0b899d62,indicated,0.66253
uuid-04e0711eb585493d96f33528783f78f2,dose,0.32498
uuid-04e0711eb585493d96f33528783f78f2,toxicity,0.53656
uuid-04e0711eb585493d96f33528783f78f2,physicians,0.372749
uuid-04e0711eb585493d96f33528783f78f2,treatment,0.327643
uuid-e37d5405b05c4888a1c68cb43d769a48,patients,0.528365
uuid-e37d5405b05c4888a1c68cb43d769a48,therapy,0.328137
uuid-e37d5405b05c4888a1c68cb43d769a48,treated,0.363775
uuid-e37d5405b05c4888a1c68cb43d769a48,treatment,0.409583
uuid-e37d5405b05c4888a1c68cb43d769a48,response,0.350742
uuid-e37d5405b05c4888a1c68cb43d769a48,progression,0.442019
uuid-e37d5405b05c4888a1c68cb43d769a48,respond,0.351924
uuid-b2c8f636957842fa91a2dfabae255f3e,patients,0.414768
uuid-b2c8f636957842fa91a2dfabae255f3e,therapy,0.413402
uuid-b2c8f636957842fa91a2dfabae255f3e,treatment,0.448586
uuid-b2c8f636957842fa91a2dfabae255f3e,response,0.478291
uuid-b2c8f636957842fa91a2dfabae255f3e,progression,0.520284
uuid-b2c8f636957842fa91a2dfabae255f3e,chemotherapy,0.306837
uuid-b2c8f636957842fa91a2dfabae255f3e,respond,0.48541
uuid-6a5d63df84e7466c9e1ead01fba83488,lung,0.609553
uuid-6a5d63df84e7466c9e1ead01fba83488,melanoma,0.44021
uuid-6a5d63df84e7466c9e1ead01fba83488,regards,0.38465
uuid-6a5d63df84e7466c9e1ead01fba83488,AI,0.758111
uuid-6a5d63df84e7466c9e1ead01fba83488,nivo and pembro,0.331203
uuid-6a5d63df84e7466c9e1ead01fba83488,TL shared,0.328599
uuid-6a5d63df84e7466c9e1ead01fba83488,NCCN,0.328614
uuid-74c4cfd46abb40928b72bf988bbcc38c,patients,0.439154
uuid-74c4cfd46abb40928b72bf988bbcc38c,Opdivo,0.493551
uuid-74c4cfd46abb40928b72bf988bbcc38c,regimen,0.425826
uuid-74c4cfd46abb40928b72bf988bbcc38c,treated,0.447876
uuid-74c4cfd46abb40928b72bf988bbcc38c,shared,0.334008
uuid-74c4cfd46abb40928b72bf988bbcc38c,physicians,0.720201
uuid-74c4cfd46abb40928b72bf988bbcc38c,treatment,0.478576
uuid-e13eef0b96e648c29b06eda9f4b18243,NTL,0.324717
uuid-e13eef0b96e648c29b06eda9f4b18243,mentioned,0.412725
uuid-e13eef0b96e648c29b06eda9f4b18243,cHL,0.563809
uuid-8248594b4d6e4ca49df88faafaabc978,patients,0.722322
uuid-8248594b4d6e4ca49df88faafaabc978,Opdivo,0.462191
uuid-8248594b4d6e4ca49df88faafaabc978,therapy,0.590207
uuid-8248594b4d6e4ca49df88faafaabc978,nivolumab,0.474827
uuid-8248594b4d6e4ca49df88faafaabc978,regimen,0.544032
uuid-8248594b4d6e4ca49df88faafaabc978,treated,0.576524
uuid-8248594b4d6e4ca49df88faafaabc978,melanoma,0.398286
uuid-8248594b4d6e4ca49df88faafaabc978,pts,0.562749
uuid-8248594b4d6e4ca49df88faafaabc978,monotherapy,0.317051
uuid-8248594b4d6e4ca49df88faafaabc978,treatment,0.744227
uuid-8248594b4d6e4ca49df88faafaabc978,response,0.529555
uuid-8248594b4d6e4ca49df88faafaabc978,PD1,0.36692
uuid-8248594b4d6e4ca49df88faafaabc978,cHL,0.421282
uuid-8248594b4d6e4ca49df88faafaabc978,progression,0.756446
uuid-8248594b4d6e4ca49df88faafaabc978,chemotherapy,0.325263
uuid-8248594b4d6e4ca49df88faafaabc978,respond,0.514294
uuid-8248594b4d6e4ca49df88faafaabc978,TL shared,0.374149
uuid-9583c195014048629b58055b2cdb7ba4,Nivo,0.393302
uuid-9583c195014048629b58055b2cdb7ba4,pembro,0.472446
uuid-9583c195014048629b58055b2cdb7ba4,BMS,0.325213
uuid-9583c195014048629b58055b2cdb7ba4,PDL1,0.489546
uuid-9583c195014048629b58055b2cdb7ba4,trial,0.43085
uuid-9583c195014048629b58055b2cdb7ba4,efficacy,0.625441
uuid-9583c195014048629b58055b2cdb7ba4,OS,0.612699
uuid-9583c195014048629b58055b2cdb7ba4,atezo,0.364246
uuid-9583c195014048629b58055b2cdb7ba4,regards,0.318784
uuid-9583c195014048629b58055b2cdb7ba4,data,0.727144
uuid-9583c195014048629b58055b2cdb7ba4,PFS,0.635312
uuid-9583c195014048629b58055b2cdb7ba4,ORR,0.643425
uuid-9583c195014048629b58055b2cdb7ba4,nivo and pembro,0.614728
uuid-9583c195014048629b58055b2cdb7ba4,believes,0.335304
uuid-9583c195014048629b58055b2cdb7ba4,impressed,0.513908
uuid-9583c195014048629b58055b2cdb7ba4,vs,0.438499
uuid-9583c195014048629b58055b2cdb7ba4,feels,0.494662
uuid-9583c195014048629b58055b2cdb7ba4,PDL1 expression,0.445687
uuid-967ff936f8fb4508829280ade7908c72,Opdivo,0.425769
uuid-967ff936f8fb4508829280ade7908c72,dose,0.448936
uuid-967ff936f8fb4508829280ade7908c72,physicians,0.380644
uuid-967ff936f8fb4508829280ade7908c72,oncology,0.460872
uuid-967ff936f8fb4508829280ade7908c72,Keytruda,0.324834
uuid-967ff936f8fb4508829280ade7908c72,flat dosing,0.655221
uuid-631b515084cb4e28ac74992f5e3c902e,TL,0.404294
uuid-631b515084cb4e28ac74992f5e3c902e,RTL,0.445475
uuid-631b515084cb4e28ac74992f5e3c902e,BMS,0.376436
uuid-631b515084cb4e28ac74992f5e3c902e,NTL,0.365395
uuid-631b515084cb4e28ac74992f5e3c902e,shared,0.456056
uuid-631b515084cb4e28ac74992f5e3c902e,commented,0.42284
uuid-631b515084cb4e28ac74992f5e3c902e,Merck,0.367553
uuid-631b515084cb4e28ac74992f5e3c902e,institution,0.35408
uuid-631b515084cb4e28ac74992f5e3c902e,stated,0.51865
uuid-631b515084cb4e28ac74992f5e3c902e,physicians,0.379859
uuid-631b515084cb4e28ac74992f5e3c902e,data,0.327583
uuid-631b515084cb4e28ac74992f5e3c902e,mentioned,0.346141
uuid-631b515084cb4e28ac74992f5e3c902e,ASCO,0.30837
uuid-631b515084cb4e28ac74992f5e3c902e,impressed,0.367588
uuid-631b515084cb4e28ac74992f5e3c902e,LTL,0.413316
uuid-631b515084cb4e28ac74992f5e3c902e,Regional TL,0.535156
uuid-1e69caa487414f98a941419b463872da,pembro,0.409933
uuid-1e69caa487414f98a941419b463872da,BMS,0.570528
uuid-1e69caa487414f98a941419b463872da,trial,0.631971
uuid-1e69caa487414f98a941419b463872da,efficacy,0.507647
uuid-1e69caa487414f98a941419b463872da,Merck,0.390356
uuid-1e69caa487414f98a941419b463872da,OS,0.404459
uuid-1e69caa487414f98a941419b463872da,atezo,0.323291
uuid-1e69caa487414f98a941419b463872da,data,0.585753
uuid-1e69caa487414f98a941419b463872da,clinical trials,0.334497
uuid-1e69caa487414f98a941419b463872da,indication,0.308142
uuid-1e69caa487414f98a941419b463872da,PFS,0.401579
uuid-1e69caa487414f98a941419b463872da,ORR,0.448743
uuid-1e69caa487414f98a941419b463872da,nivo and pembro,0.370714
uuid-1e69caa487414f98a941419b463872da,believes,0.30757
uuid-1e69caa487414f98a941419b463872da,impressed,0.41785
uuid-1e69caa487414f98a941419b463872da,feels,0.542547
uuid-1e69caa487414f98a941419b463872da,PDL1 expression,0.322687
uuid-235d1f06b04548a8ac0dd528e3fa31d1,patients,0.591141
uuid-235d1f06b04548a8ac0dd528e3fa31d1,Opdivo,0.326612
uuid-235d1f06b04548a8ac0dd528e3fa31d1,therapy,0.644611
uuid-235d1f06b04548a8ac0dd528e3fa31d1,nivolumab,0.405464
uuid-235d1f06b04548a8ac0dd528e3fa31d1,regimen,0.523293
uuid-235d1f06b04548a8ac0dd528e3fa31d1,treated,0.661173
uuid-235d1f06b04548a8ac0dd528e3fa31d1,chemo,0.309615
uuid-235d1f06b04548a8ac0dd528e3fa31d1,pts,0.426373
uuid-235d1f06b04548a8ac0dd528e3fa31d1,monotherapy,0.379693
uuid-235d1f06b04548a8ac0dd528e3fa31d1,treatment,0.871797
uuid-235d1f06b04548a8ac0dd528e3fa31d1,response,0.41215
uuid-235d1f06b04548a8ac0dd528e3fa31d1,PD1,0.392083
uuid-235d1f06b04548a8ac0dd528e3fa31d1,progression,0.658194
uuid-235d1f06b04548a8ac0dd528e3fa31d1,chemotherapy,0.393349
uuid-235d1f06b04548a8ac0dd528e3fa31d1,respond,0.508251
uuid-235d1f06b04548a8ac0dd528e3fa31d1,option,0.365117
uuid-e4bdb9a1e26644b499a3351cabb05858,patients,0.388454
uuid-e4bdb9a1e26644b499a3351cabb05858,Opdivo,0.401103
uuid-e4bdb9a1e26644b499a3351cabb05858,pembro,0.366556
uuid-e4bdb9a1e26644b499a3351cabb05858,dose,0.505176
uuid-e4bdb9a1e26644b499a3351cabb05858,regimen,0.440471
uuid-e4bdb9a1e26644b499a3351cabb05858,2L,0.407883
uuid-e4bdb9a1e26644b499a3351cabb05858,Ipi,0.332878
uuid-e4bdb9a1e26644b499a3351cabb05858,approval,0.300118
uuid-e4bdb9a1e26644b499a3351cabb05858,atezo,0.372621
uuid-e4bdb9a1e26644b499a3351cabb05858,physicians,0.309877
uuid-e4bdb9a1e26644b499a3351cabb05858,preferred,0.518309
uuid-e4bdb9a1e26644b499a3351cabb05858,monotherapy,0.331317
uuid-e4bdb9a1e26644b499a3351cabb05858,treatment,0.316814
uuid-e4bdb9a1e26644b499a3351cabb05858,using nivo,0.423464
uuid-e4bdb9a1e26644b499a3351cabb05858,approved,0.352155
uuid-e4bdb9a1e26644b499a3351cabb05858,vs,0.310512
uuid-e4bdb9a1e26644b499a3351cabb05858,option,0.351062
uuid-e4bdb9a1e26644b499a3351cabb05858,flat dosing,0.337249
uuid-155c5cecc8f847aa9360351b2b4a0e8f,patients,0.437382
uuid-155c5cecc8f847aa9360351b2b4a0e8f,Opdivo,0.327481
uuid-155c5cecc8f847aa9360351b2b4a0e8f,regimen,0.304382
uuid-155c5cecc8f847aa9360351b2b4a0e8f,treated,0.308856
uuid-155c5cecc8f847aa9360351b2b4a0e8f,physicians,0.532042
uuid-155c5cecc8f847aa9360351b2b4a0e8f,treatment,0.533969
uuid-155c5cecc8f847aa9360351b2b4a0e8f,progression,0.397654
uuid-155c5cecc8f847aa9360351b2b4a0e8f,respond,0.346319
uuid-f06982bb532d49e58649b44840005283,lung,0.530696
uuid-f06982bb532d49e58649b44840005283,toxicity,0.451723
uuid-f06982bb532d49e58649b44840005283,regimen,0.340629
uuid-f06982bb532d49e58649b44840005283,treated,0.341714
uuid-f06982bb532d49e58649b44840005283,melanoma,0.657666
uuid-f06982bb532d49e58649b44840005283,RCC,0.437873
uuid-f06982bb532d49e58649b44840005283,RTL stated,0.315976
uuid-f06982bb532d49e58649b44840005283,TL shared,0.618121
uuid-f23e45347b5a4674b9edc76b027f54a4,Nivo,0.416996
uuid-f23e45347b5a4674b9edc76b027f54a4,patients,0.716175
uuid-f23e45347b5a4674b9edc76b027f54a4,Opdivo,0.456325
uuid-f23e45347b5a4674b9edc76b027f54a4,pembro,0.335052
uuid-f23e45347b5a4674b9edc76b027f54a4,therapy,0.475547
uuid-f23e45347b5a4674b9edc76b027f54a4,nivolumab,0.64189
uuid-f23e45347b5a4674b9edc76b027f54a4,1L,0.416398
uuid-f23e45347b5a4674b9edc76b027f54a4,regimen,0.447181
uuid-f23e45347b5a4674b9edc76b027f54a4,treated,0.546307
uuid-f23e45347b5a4674b9edc76b027f54a4,RCC,0.385845
uuid-f23e45347b5a4674b9edc76b027f54a4,chemo,0.331932
uuid-f23e45347b5a4674b9edc76b027f54a4,2L,0.525657
uuid-f23e45347b5a4674b9edc76b027f54a4,pts,0.486869
uuid-f23e45347b5a4674b9edc76b027f54a4,approval,0.502898
uuid-f23e45347b5a4674b9edc76b027f54a4,preferred,0.575074
uuid-f23e45347b5a4674b9edc76b027f54a4,monotherapy,0.544678
uuid-f23e45347b5a4674b9edc76b027f54a4,treatment,0.517302
uuid-f23e45347b5a4674b9edc76b027f54a4,using nivo,0.682165
uuid-f23e45347b5a4674b9edc76b027f54a4,PD1,0.344198
uuid-f23e45347b5a4674b9edc76b027f54a4,approved,0.524718
uuid-f23e45347b5a4674b9edc76b027f54a4,SCCHN,0.365768
uuid-f23e45347b5a4674b9edc76b027f54a4,progression,0.416816
uuid-f23e45347b5a4674b9edc76b027f54a4,chemotherapy,0.331704
uuid-f23e45347b5a4674b9edc76b027f54a4,RTL stated,0.522093
uuid-f23e45347b5a4674b9edc76b027f54a4,option,0.567969
uuid-14fdaef7bcda441c8e3a1397b1575fbe,RTL,0.404502
uuid-14fdaef7bcda441c8e3a1397b1575fbe,BMS,0.574092
uuid-14fdaef7bcda441c8e3a1397b1575fbe,trial,0.612645
uuid-14fdaef7bcda441c8e3a1397b1575fbe,NTL,0.358295
uuid-14fdaef7bcda441c8e3a1397b1575fbe,commented,0.304251
uuid-14fdaef7bcda441c8e3a1397b1575fbe,Merck,0.42697
uuid-14fdaef7bcda441c8e3a1397b1575fbe,stated,0.305339
uuid-14fdaef7bcda441c8e3a1397b1575fbe,data,0.383771
uuid-14fdaef7bcda441c8e3a1397b1575fbe,clinical trials,0.388326
uuid-14fdaef7bcda441c8e3a1397b1575fbe,impressed,0.340489
uuid-0f8732148cab4811a6ad7252cc159833,patients,0.38449
uuid-0f8732148cab4811a6ad7252cc159833,regimen,0.380168
uuid-0f8732148cab4811a6ad7252cc159833,treated,0.390718
uuid-0f8732148cab4811a6ad7252cc159833,IO,0.381278
uuid-0f8732148cab4811a6ad7252cc159833,physicians,0.4208
uuid-0f8732148cab4811a6ad7252cc159833,treatment,0.46727
uuid-0f8732148cab4811a6ad7252cc159833,progression,0.376049
uuid-0f8732148cab4811a6ad7252cc159833,oncologist,0.357332
uuid-0f8732148cab4811a6ad7252cc159833,indicated,0.356205
uuid-f7feef0dcd87438c997487b140cb6f30,TL,0.379238
uuid-f7feef0dcd87438c997487b140cb6f30,NSCLC,0.373829
uuid-f7feef0dcd87438c997487b140cb6f30,trial,0.416448
uuid-f7feef0dcd87438c997487b140cb6f30,efficacy,0.348029
uuid-f7feef0dcd87438c997487b140cb6f30,commented,0.338542
uuid-f7feef0dcd87438c997487b140cb6f30,combination,0.340138
uuid-f7feef0dcd87438c997487b140cb6f30,IO,0.399063
uuid-f7feef0dcd87438c997487b140cb6f30,regards,0.309835
uuid-f7feef0dcd87438c997487b140cb6f30,data,0.429784
uuid-f7feef0dcd87438c997487b140cb6f30,combo,0.360626
uuid-f7feef0dcd87438c997487b140cb6f30,expressed,0.318474
uuid-f7feef0dcd87438c997487b140cb6f30,believes,0.309387
uuid-f7feef0dcd87438c997487b140cb6f30,impressed,0.452038
uuid-f7feef0dcd87438c997487b140cb6f30,TLs,0.434408
uuid-f722cef142f04d6a947328f1b802ec48,Nivo,0.302751
uuid-f722cef142f04d6a947328f1b802ec48,patients,0.811156
uuid-f722cef142f04d6a947328f1b802ec48,Opdivo,0.357386
uuid-f722cef142f04d6a947328f1b802ec48,pembro,0.319279
uuid-f722cef142f04d6a947328f1b802ec48,therapy,0.411633
uuid-f722cef142f04d6a947328f1b802ec48,nivolumab,0.350785
uuid-f722cef142f04d6a947328f1b802ec48,1L,0.47903
uuid-f722cef142f04d6a947328f1b802ec48,regimen,0.345303
uuid-f722cef142f04d6a947328f1b802ec48,treated,0.416432
uuid-f722cef142f04d6a947328f1b802ec48,2L,0.508911
uuid-f722cef142f04d6a947328f1b802ec48,pts,0.549344
uuid-f722cef142f04d6a947328f1b802ec48,approval,0.351824
uuid-f722cef142f04d6a947328f1b802ec48,preferred,0.498073
uuid-f722cef142f04d6a947328f1b802ec48,monotherapy,0.456318
uuid-f722cef142f04d6a947328f1b802ec48,treatment,0.525577
uuid-f722cef142f04d6a947328f1b802ec48,using nivo,0.523048
uuid-f722cef142f04d6a947328f1b802ec48,PDL1 testing,0.317073
uuid-f722cef142f04d6a947328f1b802ec48,NSCLC patients,0.498471
uuid-f722cef142f04d6a947328f1b802ec48,approved,0.351752
uuid-f722cef142f04d6a947328f1b802ec48,progression,0.47622
uuid-f722cef142f04d6a947328f1b802ec48,respond,0.37464
uuid-f722cef142f04d6a947328f1b802ec48,RTL stated,0.38025
uuid-f722cef142f04d6a947328f1b802ec48,option,0.524528
uuid-8262e96f3bdc4926b5b5ff20177f7f99,trial,0.394546
uuid-8262e96f3bdc4926b5b5ff20177f7f99,efficacy,0.653307
uuid-8262e96f3bdc4926b5b5ff20177f7f99,combination,0.419817
uuid-8262e96f3bdc4926b5b5ff20177f7f99,chemo,0.404947
uuid-8262e96f3bdc4926b5b5ff20177f7f99,IO,0.325482
uuid-8262e96f3bdc4926b5b5ff20177f7f99,OS,0.567434
uuid-8262e96f3bdc4926b5b5ff20177f7f99,response,0.382019
uuid-8262e96f3bdc4926b5b5ff20177f7f99,data,0.478375
uuid-8262e96f3bdc4926b5b5ff20177f7f99,combo,0.382325
uuid-8262e96f3bdc4926b5b5ff20177f7f99,PFS,0.533518
uuid-8262e96f3bdc4926b5b5ff20177f7f99,ORR,0.589398
uuid-8262e96f3bdc4926b5b5ff20177f7f99,believes,0.434345
uuid-8262e96f3bdc4926b5b5ff20177f7f99,chemotherapy,0.374819
uuid-8262e96f3bdc4926b5b5ff20177f7f99,impressed,0.413886
uuid-8262e96f3bdc4926b5b5ff20177f7f99,feels,0.450838
uuid-46e638716bf8412fbfaab281d66762fb,patients,0.692232
uuid-46e638716bf8412fbfaab281d66762fb,Opdivo,0.530787
uuid-46e638716bf8412fbfaab281d66762fb,therapy,0.443348
uuid-46e638716bf8412fbfaab281d66762fb,nivolumab,0.514483
uuid-46e638716bf8412fbfaab281d66762fb,regimen,0.415636
uuid-46e638716bf8412fbfaab281d66762fb,treated,0.502681
uuid-46e638716bf8412fbfaab281d66762fb,RCC,0.393777
uuid-46e638716bf8412fbfaab281d66762fb,pts,0.506476
uuid-46e638716bf8412fbfaab281d66762fb,approval,0.348509
uuid-46e638716bf8412fbfaab281d66762fb,monotherapy,0.328013
uuid-46e638716bf8412fbfaab281d66762fb,treatment,0.605453
uuid-46e638716bf8412fbfaab281d66762fb,using nivo,0.388454
uuid-46e638716bf8412fbfaab281d66762fb,progression,0.512203
uuid-46e638716bf8412fbfaab281d66762fb,respond,0.306041
uuid-46e638716bf8412fbfaab281d66762fb,RTL stated,0.374812
uuid-46e638716bf8412fbfaab281d66762fb,option,0.333448
uuid-42ed5cf6146244a18d0226cd8a659f77,NSCLC,0.718289
uuid-42ed5cf6146244a18d0226cd8a659f77,combination,0.316189
uuid-42ed5cf6146244a18d0226cd8a659f77,chemo,0.378237
uuid-42ed5cf6146244a18d0226cd8a659f77,IO,0.80193
uuid-42ed5cf6146244a18d0226cd8a659f77,monotherapy,0.351138
uuid-42ed5cf6146244a18d0226cd8a659f77,response,0.381522
uuid-42ed5cf6146244a18d0226cd8a659f77,combo,0.328382
uuid-42ed5cf6146244a18d0226cd8a659f77,chemotherapy,0.309148
uuid-91b827b4da854fc2a19bd78c457a925d,BMS,0.602346
uuid-91b827b4da854fc2a19bd78c457a925d,PDL1,0.331176
uuid-91b827b4da854fc2a19bd78c457a925d,trial,0.729589
uuid-91b827b4da854fc2a19bd78c457a925d,efficacy,0.448158
uuid-91b827b4da854fc2a19bd78c457a925d,commented,0.459068
uuid-91b827b4da854fc2a19bd78c457a925d,Merck,0.43648
uuid-91b827b4da854fc2a19bd78c457a925d,OS,0.585751
uuid-91b827b4da854fc2a19bd78c457a925d,regards,0.424781
uuid-91b827b4da854fc2a19bd78c457a925d,data,0.755307
uuid-91b827b4da854fc2a19bd78c457a925d,expressed,0.342261
uuid-91b827b4da854fc2a19bd78c457a925d,PFS,0.582797
uuid-91b827b4da854fc2a19bd78c457a925d,ORR,0.609965
uuid-91b827b4da854fc2a19bd78c457a925d,nivo and pembro,0.3333
uuid-91b827b4da854fc2a19bd78c457a925d,ASCO,0.31286
uuid-91b827b4da854fc2a19bd78c457a925d,impressed,0.611351
uuid-91b827b4da854fc2a19bd78c457a925d,feels,0.407384
uuid-91b827b4da854fc2a19bd78c457a925d,PDL1 expression,0.324915
uuid-56acbfa51c3e414ba8ed2eb9148add8b,Nivo,0.309006
uuid-56acbfa51c3e414ba8ed2eb9148add8b,therapy,0.488841
uuid-56acbfa51c3e414ba8ed2eb9148add8b,nivolumab,0.335386
uuid-56acbfa51c3e414ba8ed2eb9148add8b,OS,0.347728
uuid-56acbfa51c3e414ba8ed2eb9148add8b,PFS,0.456265
uuid-56acbfa51c3e414ba8ed2eb9148add8b,ORR,0.329393
uuid-56acbfa51c3e414ba8ed2eb9148add8b,cHL,0.644287
uuid-56acbfa51c3e414ba8ed2eb9148add8b,progression,0.301799
uuid-56acbfa51c3e414ba8ed2eb9148add8b,chemotherapy,0.37121
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,Nivo,0.447129
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,Opdivo,0.326362
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,pembro,0.497165
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,dose,0.91085
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,Ipi,0.624778
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,atezo,0.464925
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,vs,0.682526
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,Keytruda,0.401862
uuid-57cdc8a8e9b54d83b55a9cfd5f9dd4fd,flat dosing,0.772192
uuid-25b2764e60654335b2d1054ab18410f8,Nivo,0.48911
uuid-25b2764e60654335b2d1054ab18410f8,pembro,0.477173
uuid-25b2764e60654335b2d1054ab18410f8,dose,0.335563
uuid-25b2764e60654335b2d1054ab18410f8,trial,0.664924
uuid-25b2764e60654335b2d1054ab18410f8,combination,0.335729
uuid-25b2764e60654335b2d1054ab18410f8,chemo,0.317035
uuid-25b2764e60654335b2d1054ab18410f8,Ipi,0.614398
uuid-25b2764e60654335b2d1054ab18410f8,atezo,0.319113
uuid-25b2764e60654335b2d1054ab18410f8,combo,0.31971
uuid-25b2764e60654335b2d1054ab18410f8,chemotherapy,0.345142
uuid-25b2764e60654335b2d1054ab18410f8,vs,0.491269
uuid-ccfea11dfc744d44811f463759ec9a2d,PDL1,0.309762
uuid-ccfea11dfc744d44811f463759ec9a2d,efficacy,0.523311
uuid-ccfea11dfc744d44811f463759ec9a2d,combination,0.326012
uuid-ccfea11dfc744d44811f463759ec9a2d,chemo,0.371584
uuid-ccfea11dfc744d44811f463759ec9a2d,tumor,0.455949
uuid-ccfea11dfc744d44811f463759ec9a2d,OS,0.358382
uuid-ccfea11dfc744d44811f463759ec9a2d,response,0.432133
uuid-ccfea11dfc744d44811f463759ec9a2d,PFS,0.415132
uuid-ccfea11dfc744d44811f463759ec9a2d,PD1,0.325523
uuid-ccfea11dfc744d44811f463759ec9a2d,ORR,0.408522
uuid-ccfea11dfc744d44811f463759ec9a2d,believes,0.430377
uuid-ccfea11dfc744d44811f463759ec9a2d,chemotherapy,0.315593
uuid-ccfea11dfc744d44811f463759ec9a2d,immunotherapy,0.308037
uuid-ccfea11dfc744d44811f463759ec9a2d,PDL1 expression,0.329351
uuid-a67e45f3ebe2464ca9fc8f856fece26d,Nivo,0.519448
uuid-a67e45f3ebe2464ca9fc8f856fece26d,patients,0.63579
uuid-a67e45f3ebe2464ca9fc8f856fece26d,therapy,0.431822
uuid-a67e45f3ebe2464ca9fc8f856fece26d,nivolumab,0.479003
uuid-a67e45f3ebe2464ca9fc8f856fece26d,regimen,0.367198
uuid-a67e45f3ebe2464ca9fc8f856fece26d,treated,0.411165
uuid-a67e45f3ebe2464ca9fc8f856fece26d,chemo,0.348394
uuid-a67e45f3ebe2464ca9fc8f856fece26d,pts,0.469129
uuid-a67e45f3ebe2464ca9fc8f856fece26d,monotherapy,0.356937
uuid-a67e45f3ebe2464ca9fc8f856fece26d,treatment,0.372887
uuid-a67e45f3ebe2464ca9fc8f856fece26d,using nivo,0.383409
uuid-a67e45f3ebe2464ca9fc8f856fece26d,response,0.335736
uuid-a67e45f3ebe2464ca9fc8f856fece26d,PD1,0.318283
uuid-a67e45f3ebe2464ca9fc8f856fece26d,cHL,0.409277
uuid-a67e45f3ebe2464ca9fc8f856fece26d,progression,0.429127
uuid-a67e45f3ebe2464ca9fc8f856fece26d,chemotherapy,0.350697
uuid-a67e45f3ebe2464ca9fc8f856fece26d,respond,0.383212
uuid-ee23c7f522df442ca5430d047b1c5351,Nivo,0.604907
uuid-ee23c7f522df442ca5430d047b1c5351,patients,0.448654
uuid-ee23c7f522df442ca5430d047b1c5351,therapy,0.595177
uuid-ee23c7f522df442ca5430d047b1c5351,nivolumab,0.329161
uuid-ee23c7f522df442ca5430d047b1c5351,chemo,0.321907
uuid-ee23c7f522df442ca5430d047b1c5351,treatment,0.308985
uuid-ee23c7f522df442ca5430d047b1c5351,cHL,0.618477
uuid-ee23c7f522df442ca5430d047b1c5351,chemotherapy,0.398132
uuid-54ac25d5c665436bac6fb5d01a9a76da,Nivo,0.329318
uuid-54ac25d5c665436bac6fb5d01a9a76da,trial,0.479872
uuid-54ac25d5c665436bac6fb5d01a9a76da,efficacy,0.368905
uuid-54ac25d5c665436bac6fb5d01a9a76da,OS,0.626986
uuid-54ac25d5c665436bac6fb5d01a9a76da,data,0.454709
uuid-54ac25d5c665436bac6fb5d01a9a76da,PFS,0.721187
uuid-54ac25d5c665436bac6fb5d01a9a76da,ORR,0.628948
uuid-54ac25d5c665436bac6fb5d01a9a76da,nivo and pembro,0.322845
uuid-54ac25d5c665436bac6fb5d01a9a76da,impressed,0.439208
uuid-73cad2e681384071a019a1973f095ff0,Nivo,0.476979
uuid-73cad2e681384071a019a1973f095ff0,pembro,0.371272
uuid-73cad2e681384071a019a1973f095ff0,dose,0.51495
uuid-73cad2e681384071a019a1973f095ff0,toxicity,0.424905
uuid-73cad2e681384071a019a1973f095ff0,efficacy,0.557061
uuid-73cad2e681384071a019a1973f095ff0,combination,0.362552
uuid-73cad2e681384071a019a1973f095ff0,Ipi,0.730889
uuid-73cad2e681384071a019a1973f095ff0,atezo,0.364582
uuid-73cad2e681384071a019a1973f095ff0,combo,0.427612
uuid-73cad2e681384071a019a1973f095ff0,ORR,0.318694
uuid-73cad2e681384071a019a1973f095ff0,nivo and pembro,0.313902
uuid-73cad2e681384071a019a1973f095ff0,impressed,0.351294
uuid-73cad2e681384071a019a1973f095ff0,vs,0.493524
uuid-73cad2e681384071a019a1973f095ff0,TLs,0.309874
uuid-73cad2e681384071a019a1973f095ff0,flat dosing,0.348593
uuid-49510fe87a454efabed419bc4c2bb5c4,pembro,0.399275
uuid-49510fe87a454efabed419bc4c2bb5c4,BMS,0.379627
uuid-49510fe87a454efabed419bc4c2bb5c4,NSCLC,0.319785
uuid-49510fe87a454efabed419bc4c2bb5c4,PDL1,0.663094
uuid-49510fe87a454efabed419bc4c2bb5c4,trial,0.417076
uuid-49510fe87a454efabed419bc4c2bb5c4,efficacy,0.575442
uuid-49510fe87a454efabed419bc4c2bb5c4,Merck,0.415316
uuid-49510fe87a454efabed419bc4c2bb5c4,PD-L1,0.36582
uuid-49510fe87a454efabed419bc4c2bb5c4,OS,0.393745
uuid-49510fe87a454efabed419bc4c2bb5c4,atezo,0.44993
uuid-49510fe87a454efabed419bc4c2bb5c4,regards,0.312513
uuid-49510fe87a454efabed419bc4c2bb5c4,data,0.451664
uuid-49510fe87a454efabed419bc4c2bb5c4,PFS,0.426378
uuid-49510fe87a454efabed419bc4c2bb5c4,ORR,0.435423
uuid-49510fe87a454efabed419bc4c2bb5c4,nivo and pembro,0.592898
uuid-49510fe87a454efabed419bc4c2bb5c4,believes,0.461428
uuid-49510fe87a454efabed419bc4c2bb5c4,vs,0.421387
uuid-49510fe87a454efabed419bc4c2bb5c4,assay,0.465042
uuid-49510fe87a454efabed419bc4c2bb5c4,PDL1 expression,0.504117
uuid-49510fe87a454efabed419bc4c2bb5c4,biomarker,0.418483
uuid-5af27d78673e4ff8bcf677a04af9fd4c,TL,0.447386
uuid-5af27d78673e4ff8bcf677a04af9fd4c,PDL1,0.345654
uuid-5af27d78673e4ff8bcf677a04af9fd4c,TL stated,0.323285
uuid-5af27d78673e4ff8bcf677a04af9fd4c,institution,0.434478
uuid-5af27d78673e4ff8bcf677a04af9fd4c,PD-L1,0.619526
uuid-5af27d78673e4ff8bcf677a04af9fd4c,PD-L1 testing,0.74244
uuid-5af27d78673e4ff8bcf677a04af9fd4c,testing,0.73615
uuid-5af27d78673e4ff8bcf677a04af9fd4c,PDL1 testing,0.634657
uuid-5af27d78673e4ff8bcf677a04af9fd4c,NSCLC patients,0.479113
uuid-5af27d78673e4ff8bcf677a04af9fd4c,assay,0.585848
uuid-06eb3477c6114391afd417b903ec49fa,Nivo,0.413055
uuid-06eb3477c6114391afd417b903ec49fa,pembro,0.460601
uuid-06eb3477c6114391afd417b903ec49fa,1L,0.350626
uuid-06eb3477c6114391afd417b903ec49fa,PDL1,0.420048
uuid-06eb3477c6114391afd417b903ec49fa,efficacy,0.337648
uuid-06eb3477c6114391afd417b903ec49fa,2L,0.386376
uuid-06eb3477c6114391afd417b903ec49fa,agents,0.324717
uuid-06eb3477c6114391afd417b903ec49fa,atezo,0.488726
uuid-06eb3477c6114391afd417b903ec49fa,data,0.414825
uuid-06eb3477c6114391afd417b903ec49fa,PFS,0.304484
uuid-06eb3477c6114391afd417b903ec49fa,nivo and pembro,0.567016
uuid-06eb3477c6114391afd417b903ec49fa,believes,0.334838
uuid-06eb3477c6114391afd417b903ec49fa,feels,0.329783
uuid-06eb3477c6114391afd417b903ec49fa,PDL1 expression,0.300271
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,Nivo,0.486889
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,pembro,0.505529
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,1L,0.647156
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,PDL1,0.404662
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,efficacy,0.304137
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,RCC,0.395155
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,combination,0.399815
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,chemo,0.504877
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,2L,0.613711
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,agents,0.575014
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,atezo,0.456621
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,preferred,0.499664
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,monotherapy,0.647688
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,using nivo,0.465992
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,data,0.327683
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,combo,0.448158
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,PD1,0.510661
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,approved,0.319722
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,nivo and pembro,0.544092
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,believes,0.451707
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,chemotherapy,0.41405
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,feels,0.431651
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,PD-1,0.304172
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,RTL stated,0.405509
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,PDL1 expression,0.306574
uuid-efd0bc8fa5b64364a8a8a0a59cfaaa9d,option,0.603358
uuid-14a7756e3d964c6a841a78b6d7060746,BMS,0.322525
uuid-14a7756e3d964c6a841a78b6d7060746,trial,0.313424
uuid-14a7756e3d964c6a841a78b6d7060746,commented,0.475689
uuid-14a7756e3d964c6a841a78b6d7060746,tumor,0.333448
uuid-14a7756e3d964c6a841a78b6d7060746,Merck,0.328846
uuid-14a7756e3d964c6a841a78b6d7060746,stated,0.319294
uuid-14a7756e3d964c6a841a78b6d7060746,OS,0.322977
uuid-14a7756e3d964c6a841a78b6d7060746,regards,0.3695
uuid-14a7756e3d964c6a841a78b6d7060746,data,0.620069
uuid-14a7756e3d964c6a841a78b6d7060746,expressed,0.338917
uuid-14a7756e3d964c6a841a78b6d7060746,PFS,0.305232
uuid-14a7756e3d964c6a841a78b6d7060746,ASCO,0.371242
uuid-14a7756e3d964c6a841a78b6d7060746,impressed,0.514822
uuid-14a7756e3d964c6a841a78b6d7060746,feels,0.345789
uuid-14a7756e3d964c6a841a78b6d7060746,Regional TL,0.322306
uuid-5a3d7886ca234685b7e26dc8eb21e292,commented,0.332384
uuid-5a3d7886ca234685b7e26dc8eb21e292,OS,0.332796
uuid-5a3d7886ca234685b7e26dc8eb21e292,PFS,0.329153
uuid-5a3d7886ca234685b7e26dc8eb21e292,Regional TL,0.361475
uuid-67f95a1c9983493b98d2966d076a9cdd,PDL1,0.310788
uuid-67f95a1c9983493b98d2966d076a9cdd,efficacy,0.53512
uuid-67f95a1c9983493b98d2966d076a9cdd,OS,0.515244
uuid-67f95a1c9983493b98d2966d076a9cdd,data,0.395959
uuid-67f95a1c9983493b98d2966d076a9cdd,PFS,0.426468
uuid-67f95a1c9983493b98d2966d076a9cdd,ORR,0.514955
uuid-67f95a1c9983493b98d2966d076a9cdd,nivo and pembro,0.367166
uuid-67f95a1c9983493b98d2966d076a9cdd,believes,0.508766
uuid-67f95a1c9983493b98d2966d076a9cdd,impressed,0.345755
uuid-7fdf3dee56f843f79416e490c5004106,BMS,0.332662
uuid-7fdf3dee56f843f79416e490c5004106,PDL1,0.516023
uuid-7fdf3dee56f843f79416e490c5004106,trial,0.42098
uuid-7fdf3dee56f843f79416e490c5004106,efficacy,0.587661
uuid-7fdf3dee56f843f79416e490c5004106,OS,0.504969
uuid-7fdf3dee56f843f79416e490c5004106,regards,0.468774
uuid-7fdf3dee56f843f79416e490c5004106,data,0.604305
uuid-7fdf3dee56f843f79416e490c5004106,PFS,0.543143
uuid-7fdf3dee56f843f79416e490c5004106,ORR,0.549588
uuid-7fdf3dee56f843f79416e490c5004106,nivo and pembro,0.528962
uuid-7fdf3dee56f843f79416e490c5004106,believes,0.518696
uuid-7fdf3dee56f843f79416e490c5004106,impressed,0.383469
uuid-7fdf3dee56f843f79416e490c5004106,feels,0.322808
uuid-7fdf3dee56f843f79416e490c5004106,PDL1 expression,0.45225
uuid-7fdf3dee56f843f79416e490c5004106,biomarker,0.37357
uuid-f0193535e601462a90770d5d5dec4be7,BMS,0.381038
uuid-f0193535e601462a90770d5d5dec4be7,lung,0.37245
uuid-f0193535e601462a90770d5d5dec4be7,shared,0.341677
uuid-f0193535e601462a90770d5d5dec4be7,commented,0.384007
uuid-f0193535e601462a90770d5d5dec4be7,RCC,0.392355
uuid-f0193535e601462a90770d5d5dec4be7,TL stated,0.305462
uuid-f0193535e601462a90770d5d5dec4be7,2L,0.317868
uuid-f0193535e601462a90770d5d5dec4be7,Merck,0.32794
uuid-f0193535e601462a90770d5d5dec4be7,stated,0.504377
uuid-f0193535e601462a90770d5d5dec4be7,approval,0.499546
uuid-f0193535e601462a90770d5d5dec4be7,using nivo,0.396367
uuid-f0193535e601462a90770d5d5dec4be7,mentioned,0.315113
uuid-f0193535e601462a90770d5d5dec4be7,indication,0.405552
uuid-f0193535e601462a90770d5d5dec4be7,approved,0.433982
uuid-f0193535e601462a90770d5d5dec4be7,SCCHN,0.503697
uuid-f0193535e601462a90770d5d5dec4be7,impressed,0.31362
uuid-f0193535e601462a90770d5d5dec4be7,label,0.316718
uuid-f0193535e601462a90770d5d5dec4be7,LTL,0.30712
uuid-f0193535e601462a90770d5d5dec4be7,TLs,0.34139
uuid-f0193535e601462a90770d5d5dec4be7,Regional TL,0.41674
uuid-f0193535e601462a90770d5d5dec4be7,RTL stated,0.3836
uuid-f0193535e601462a90770d5d5dec4be7,NCCN,0.325218
uuid-f0193535e601462a90770d5d5dec4be7,bladder,0.354369
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,pembro,0.528884
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,RTL,0.377192
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,dose,0.418474
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,shared,0.301252
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,RCC,0.348157
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,TL stated,0.40525
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,2L,0.3446
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,stated,0.39458
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,approval,0.396996
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,atezo,0.51956
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,preferred,0.386562
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,using nivo,0.427862
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,mentioned,0.303066
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,indication,0.487485
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,approved,0.356646
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,SCCHN,0.522688
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,HCP,0.330012
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,vs,0.446948
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,LTL,0.417678
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,TLs,0.549203
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,Regional TL,0.367474
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,RTL stated,0.367019
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,bladder,0.316523
uuid-0f2c83a4c27f4e9fa529f4a2aafd955f,flat dosing,0.589704
uuid-97517aaa7be4482bab95d0b3bcb2af6e,Nivo,0.396051
uuid-97517aaa7be4482bab95d0b3bcb2af6e,patients,0.659404
uuid-97517aaa7be4482bab95d0b3bcb2af6e,Opdivo,0.481985
uuid-97517aaa7be4482bab95d0b3bcb2af6e,pembro,0.449645
uuid-97517aaa7be4482bab95d0b3bcb2af6e,therapy,0.351994
uuid-97517aaa7be4482bab95d0b3bcb2af6e,nivolumab,0.504363
uuid-97517aaa7be4482bab95d0b3bcb2af6e,1L,0.326694
uuid-97517aaa7be4482bab95d0b3bcb2af6e,treated,0.351713
uuid-97517aaa7be4482bab95d0b3bcb2af6e,2L,0.385713
uuid-97517aaa7be4482bab95d0b3bcb2af6e,pts,0.370436
uuid-97517aaa7be4482bab95d0b3bcb2af6e,approval,0.676263
uuid-97517aaa7be4482bab95d0b3bcb2af6e,preferred,0.402289
uuid-97517aaa7be4482bab95d0b3bcb2af6e,treatment,0.377463
uuid-97517aaa7be4482bab95d0b3bcb2af6e,using nivo,0.532214
uuid-97517aaa7be4482bab95d0b3bcb2af6e,indication,0.387762
uuid-97517aaa7be4482bab95d0b3bcb2af6e,approved,0.571317
uuid-97517aaa7be4482bab95d0b3bcb2af6e,SCCHN,0.30297
uuid-97517aaa7be4482bab95d0b3bcb2af6e,label,0.450888
uuid-97517aaa7be4482bab95d0b3bcb2af6e,RTL stated,0.375502
uuid-97517aaa7be4482bab95d0b3bcb2af6e,option,0.37102
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,TL,0.631091
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,TL stated,0.314814
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,institution,0.396468
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,PD-L1,0.743456
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,PD-L1 testing,0.923082
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,testing,0.82178
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,PDL1 testing,0.604547
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,NSCLC patients,0.533161
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,assay,0.659499
uuid-ab2d9ffae1194540a8e0dbbc0dd60d0b,biomarker,0.326055
uuid-bdf80803b3c9417b9d2c5e51c5adf689,patients,0.636327
uuid-bdf80803b3c9417b9d2c5e51c5adf689,Opdivo,0.447813
uuid-bdf80803b3c9417b9d2c5e51c5adf689,therapy,0.463909
uuid-bdf80803b3c9417b9d2c5e51c5adf689,nivolumab,0.585222
uuid-bdf80803b3c9417b9d2c5e51c5adf689,regimen,0.366415
uuid-bdf80803b3c9417b9d2c5e51c5adf689,treated,0.505608
uuid-bdf80803b3c9417b9d2c5e51c5adf689,pts,0.323186
uuid-bdf80803b3c9417b9d2c5e51c5adf689,approval,0.490112
uuid-bdf80803b3c9417b9d2c5e51c5adf689,preferred,0.355068
uuid-bdf80803b3c9417b9d2c5e51c5adf689,treatment,0.524965
uuid-bdf80803b3c9417b9d2c5e51c5adf689,using nivo,0.425674
uuid-bdf80803b3c9417b9d2c5e51c5adf689,approved,0.404164
uuid-bdf80803b3c9417b9d2c5e51c5adf689,HCP,0.330644
uuid-bdf80803b3c9417b9d2c5e51c5adf689,cHL,0.338022
uuid-bdf80803b3c9417b9d2c5e51c5adf689,label,0.421749
uuid-bdf80803b3c9417b9d2c5e51c5adf689,SCLC,0.32505
uuid-bdf80803b3c9417b9d2c5e51c5adf689,RTL stated,0.334579
uuid-bdf80803b3c9417b9d2c5e51c5adf689,option,0.334202
uuid-8b76d36c7cae4481ba3bdac703a063c7,PDL1,0.598378
uuid-8b76d36c7cae4481ba3bdac703a063c7,trial,0.31781
uuid-8b76d36c7cae4481ba3bdac703a063c7,efficacy,0.713835
uuid-8b76d36c7cae4481ba3bdac703a063c7,commented,0.303803
uuid-8b76d36c7cae4481ba3bdac703a063c7,PD-L1,0.305275
uuid-8b76d36c7cae4481ba3bdac703a063c7,OS,0.544249
uuid-8b76d36c7cae4481ba3bdac703a063c7,atezo,0.303532
uuid-8b76d36c7cae4481ba3bdac703a063c7,regards,0.468674
uuid-8b76d36c7cae4481ba3bdac703a063c7,data,0.700677
uuid-8b76d36c7cae4481ba3bdac703a063c7,expressed,0.318927
uuid-8b76d36c7cae4481ba3bdac703a063c7,PFS,0.539889
uuid-8b76d36c7cae4481ba3bdac703a063c7,ORR,0.61226
uuid-8b76d36c7cae4481ba3bdac703a063c7,nivo and pembro,0.53965
uuid-8b76d36c7cae4481ba3bdac703a063c7,believes,0.34954
uuid-8b76d36c7cae4481ba3bdac703a063c7,impressed,0.453355
uuid-8b76d36c7cae4481ba3bdac703a063c7,TLs,0.304445
uuid-8b76d36c7cae4481ba3bdac703a063c7,feels,0.301364
uuid-8b76d36c7cae4481ba3bdac703a063c7,PDL1 expression,0.557642
uuid-8b76d36c7cae4481ba3bdac703a063c7,biomarker,0.474906
uuid-999db3da837f4ab5baff704b051faa38,patients,0.75082
uuid-999db3da837f4ab5baff704b051faa38,Opdivo,0.452912
uuid-999db3da837f4ab5baff704b051faa38,therapy,0.404083
uuid-999db3da837f4ab5baff704b051faa38,nivolumab,0.329197
uuid-999db3da837f4ab5baff704b051faa38,1L,0.394455
uuid-999db3da837f4ab5baff704b051faa38,regimen,0.413162
uuid-999db3da837f4ab5baff704b051faa38,treated,0.5221
uuid-999db3da837f4ab5baff704b051faa38,2L,0.393461
uuid-999db3da837f4ab5baff704b051faa38,pts,0.57045
uuid-999db3da837f4ab5baff704b051faa38,preferred,0.347401
uuid-999db3da837f4ab5baff704b051faa38,testing,0.372949
uuid-999db3da837f4ab5baff704b051faa38,monotherapy,0.438914
uuid-999db3da837f4ab5baff704b051faa38,treatment,0.535205
uuid-999db3da837f4ab5baff704b051faa38,using nivo,0.399275
uuid-999db3da837f4ab5baff704b051faa38,PDL1 testing,0.356322
uuid-999db3da837f4ab5baff704b051faa38,NSCLC patients,0.559055
uuid-999db3da837f4ab5baff704b051faa38,progression,0.565152
uuid-999db3da837f4ab5baff704b051faa38,respond,0.411478
uuid-999db3da837f4ab5baff704b051faa38,RTL stated,0.318631
uuid-999db3da837f4ab5baff704b051faa38,option,0.39589
uuid-1c4f1bdc1d494171b3b4e677b7a3ada6,testing,0.455391
uuid-1c4f1bdc1d494171b3b4e677b7a3ada6,PDL1 testing,0.461478
uuid-1c4f1bdc1d494171b3b4e677b7a3ada6,NSCLC patients,0.597339
uuid-1c4f1bdc1d494171b3b4e677b7a3ada6,tumor types,0.355586
uuid-fce28946c66e4a76b2cc4f026ace54c3,patients,0.675978
uuid-fce28946c66e4a76b2cc4f026ace54c3,Opdivo,0.640657
uuid-fce28946c66e4a76b2cc4f026ace54c3,therapy,0.521838
uuid-fce28946c66e4a76b2cc4f026ace54c3,nivolumab,0.451397
uuid-fce28946c66e4a76b2cc4f026ace54c3,regimen,0.3978
uuid-fce28946c66e4a76b2cc4f026ace54c3,treated,0.579843
uuid-fce28946c66e4a76b2cc4f026ace54c3,pts,0.446322
uuid-fce28946c66e4a76b2cc4f026ace54c3,treatment,0.658842
uuid-fce28946c66e4a76b2cc4f026ace54c3,cHL,0.464314
uuid-fce28946c66e4a76b2cc4f026ace54c3,lung cancer,0.32535
uuid-fce28946c66e4a76b2cc4f026ace54c3,progression,0.594228
uuid-fce28946c66e4a76b2cc4f026ace54c3,respond,0.417021
uuid-46dde13d546f4332a438e2b8b5d3eb3e,patients,0.463774
uuid-46dde13d546f4332a438e2b8b5d3eb3e,treated,0.400651
uuid-46dde13d546f4332a438e2b8b5d3eb3e,approval,0.324292
uuid-46dde13d546f4332a438e2b8b5d3eb3e,preferred,0.300141
uuid-46dde13d546f4332a438e2b8b5d3eb3e,PD-L1 testing,0.333829
uuid-46dde13d546f4332a438e2b8b5d3eb3e,testing,0.333601
uuid-46dde13d546f4332a438e2b8b5d3eb3e,treatment,0.35745
uuid-46dde13d546f4332a438e2b8b5d3eb3e,NSCLC patients,0.354742
uuid-46dde13d546f4332a438e2b8b5d3eb3e,RTL stated,0.30724
uuid-60fbac646a6d4c12966d44e0cf308784,Nivo,0.391994
uuid-60fbac646a6d4c12966d44e0cf308784,patients,0.37267
uuid-60fbac646a6d4c12966d44e0cf308784,therapy,0.34099
uuid-60fbac646a6d4c12966d44e0cf308784,nivolumab,0.530237
uuid-60fbac646a6d4c12966d44e0cf308784,1L,0.313266
uuid-60fbac646a6d4c12966d44e0cf308784,2L,0.420956
uuid-60fbac646a6d4c12966d44e0cf308784,stated,0.314002
uuid-60fbac646a6d4c12966d44e0cf308784,approval,0.476517
uuid-60fbac646a6d4c12966d44e0cf308784,preferred,0.578941
uuid-60fbac646a6d4c12966d44e0cf308784,monotherapy,0.37168
uuid-60fbac646a6d4c12966d44e0cf308784,using nivo,0.580807
uuid-60fbac646a6d4c12966d44e0cf308784,indication,0.406419
uuid-60fbac646a6d4c12966d44e0cf308784,approved,0.518478
uuid-60fbac646a6d4c12966d44e0cf308784,SCCHN,0.45454
uuid-60fbac646a6d4c12966d44e0cf308784,cHL,0.301565
uuid-60fbac646a6d4c12966d44e0cf308784,label,0.313145
uuid-60fbac646a6d4c12966d44e0cf308784,Regional TL,0.323329
uuid-60fbac646a6d4c12966d44e0cf308784,RTL stated,0.471393
uuid-60fbac646a6d4c12966d44e0cf308784,option,0.531856
uuid-36645d6759904b49b90fab01b70bcc2d,physicians,0.375619
uuid-36645d6759904b49b90fab01b70bcc2d,mentioned,0.410105
uuid-36645d6759904b49b90fab01b70bcc2d,oncology,0.402896
uuid-36645d6759904b49b90fab01b70bcc2d,HCP,0.383601
uuid-352cb233726b47879400e88aaf2de73e,toxicity,0.34167
uuid-352cb233726b47879400e88aaf2de73e,combination,0.572303
uuid-352cb233726b47879400e88aaf2de73e,chemo,0.314108
uuid-352cb233726b47879400e88aaf2de73e,IO,0.336211
uuid-352cb233726b47879400e88aaf2de73e,agents,0.351361
uuid-352cb233726b47879400e88aaf2de73e,combo,0.39323
uuid-352cb233726b47879400e88aaf2de73e,believes,0.340527
uuid-352cb233726b47879400e88aaf2de73e,chemotherapy,0.350688
uuid-352cb233726b47879400e88aaf2de73e,immunotherapy,0.363624
uuid-1f768d08f6f34f509b67c809cf39bb3c,physicians,0.30031
uuid-1f768d08f6f34f509b67c809cf39bb3c,oncology,0.495396
uuid-1f768d08f6f34f509b67c809cf39bb3c,drug,0.533708
uuid-1f768d08f6f34f509b67c809cf39bb3c,clinical,0.467897
uuid-1f768d08f6f34f509b67c809cf39bb3c,flat dosing,0.355488
uuid-aaa906249a434e828427c7dca14cf42d,TL,0.518217
uuid-aaa906249a434e828427c7dca14cf42d,TL stated,0.455528
uuid-aaa906249a434e828427c7dca14cf42d,institution,0.502784
uuid-aaa906249a434e828427c7dca14cf42d,PD-L1,0.777074
uuid-aaa906249a434e828427c7dca14cf42d,PD-L1 testing,0.913058
uuid-aaa906249a434e828427c7dca14cf42d,testing,0.894783
uuid-aaa906249a434e828427c7dca14cf42d,PDL1 testing,0.747474
uuid-aaa906249a434e828427c7dca14cf42d,NSCLC patients,0.698558
uuid-aaa906249a434e828427c7dca14cf42d,assay,0.647023
uuid-aaa906249a434e828427c7dca14cf42d,biomarker,0.323454
uuid-b8ebd4939c7d4f0b838984afc73bf157,RTL,0.563417
uuid-b8ebd4939c7d4f0b838984afc73bf157,nivolumab,0.322244
uuid-b8ebd4939c7d4f0b838984afc73bf157,lung,0.433831
uuid-b8ebd4939c7d4f0b838984afc73bf157,1L,0.397283
uuid-b8ebd4939c7d4f0b838984afc73bf157,NTL,0.348091
uuid-b8ebd4939c7d4f0b838984afc73bf157,melanoma,0.448089
uuid-b8ebd4939c7d4f0b838984afc73bf157,shared,0.435942
uuid-b8ebd4939c7d4f0b838984afc73bf157,commented,0.351848
uuid-b8ebd4939c7d4f0b838984afc73bf157,RCC,0.786009
uuid-b8ebd4939c7d4f0b838984afc73bf157,TL stated,0.570373
uuid-b8ebd4939c7d4f0b838984afc73bf157,2L,0.453115
uuid-b8ebd4939c7d4f0b838984afc73bf157,pts,0.348894
uuid-b8ebd4939c7d4f0b838984afc73bf157,stated,0.711433
uuid-b8ebd4939c7d4f0b838984afc73bf157,approval,0.416393
uuid-b8ebd4939c7d4f0b838984afc73bf157,preferred,0.331721
uuid-b8ebd4939c7d4f0b838984afc73bf157,using nivo,0.584433
uuid-b8ebd4939c7d4f0b838984afc73bf157,clinical trials,0.349298
uuid-b8ebd4939c7d4f0b838984afc73bf157,PDL1 testing,0.348308
uuid-b8ebd4939c7d4f0b838984afc73bf157,NSCLC patients,0.310882
uuid-b8ebd4939c7d4f0b838984afc73bf157,approved,0.399909
uuid-b8ebd4939c7d4f0b838984afc73bf157,SCCHN,0.739261
uuid-b8ebd4939c7d4f0b838984afc73bf157,HCP,0.358069
uuid-b8ebd4939c7d4f0b838984afc73bf157,impressed,0.31702
uuid-b8ebd4939c7d4f0b838984afc73bf157,tumor types,0.44421
uuid-b8ebd4939c7d4f0b838984afc73bf157,LTL,0.60374
uuid-b8ebd4939c7d4f0b838984afc73bf157,TLs,0.492658
uuid-b8ebd4939c7d4f0b838984afc73bf157,academic,0.32665
uuid-b8ebd4939c7d4f0b838984afc73bf157,SCLC,0.358483
uuid-b8ebd4939c7d4f0b838984afc73bf157,Regional TL,0.66097
uuid-b8ebd4939c7d4f0b838984afc73bf157,RTL stated,0.697669
uuid-b8ebd4939c7d4f0b838984afc73bf157,TL shared,0.562665
uuid-b8ebd4939c7d4f0b838984afc73bf157,bladder,0.541182
uuid-a48d461818b040a69d1e1a4e0dc18d14,TL,0.489221
uuid-a48d461818b040a69d1e1a4e0dc18d14,TL stated,0.505946
uuid-a48d461818b040a69d1e1a4e0dc18d14,institution,0.486837
uuid-a48d461818b040a69d1e1a4e0dc18d14,PD-L1,0.694519
uuid-a48d461818b040a69d1e1a4e0dc18d14,approval,0.335999
uuid-a48d461818b040a69d1e1a4e0dc18d14,PD-L1 testing,0.857712
uuid-a48d461818b040a69d1e1a4e0dc18d14,testing,0.857847
uuid-a48d461818b040a69d1e1a4e0dc18d14,PDL1 testing,0.754435
uuid-a48d461818b040a69d1e1a4e0dc18d14,NSCLC patients,0.67391
uuid-a48d461818b040a69d1e1a4e0dc18d14,assay,0.553927
uuid-75ae2057066d49bc8448eedb0749eb2b,lung,0.802354
uuid-75ae2057066d49bc8448eedb0749eb2b,1L,0.480747
uuid-75ae2057066d49bc8448eedb0749eb2b,melanoma,0.566412
uuid-75ae2057066d49bc8448eedb0749eb2b,RCC,0.69889
uuid-75ae2057066d49bc8448eedb0749eb2b,TL stated,0.679329
uuid-75ae2057066d49bc8448eedb0749eb2b,2L,0.481193
uuid-75ae2057066d49bc8448eedb0749eb2b,PD-L1,0.318559
uuid-75ae2057066d49bc8448eedb0749eb2b,preferred,0.310839
uuid-75ae2057066d49bc8448eedb0749eb2b,PD-L1 testing,0.347259
uuid-75ae2057066d49bc8448eedb0749eb2b,testing,0.445186
uuid-75ae2057066d49bc8448eedb0749eb2b,using nivo,0.389438
uuid-75ae2057066d49bc8448eedb0749eb2b,PDL1 testing,0.683927
uuid-75ae2057066d49bc8448eedb0749eb2b,AI,0.40278
uuid-75ae2057066d49bc8448eedb0749eb2b,NSCLC patients,0.522132
uuid-75ae2057066d49bc8448eedb0749eb2b,SCCHN,0.547116
uuid-75ae2057066d49bc8448eedb0749eb2b,tumor types,0.646344
uuid-75ae2057066d49bc8448eedb0749eb2b,TLs,0.35493
uuid-75ae2057066d49bc8448eedb0749eb2b,Regional TL,0.353948
uuid-75ae2057066d49bc8448eedb0749eb2b,RTL stated,0.515108
uuid-75ae2057066d49bc8448eedb0749eb2b,TL shared,0.635763
uuid-75ae2057066d49bc8448eedb0749eb2b,NCCN,0.306095
uuid-75ae2057066d49bc8448eedb0749eb2b,bladder,0.500981
uuid-227ce8cef2e34c498245edb589bf95ba,lung,0.523806
uuid-227ce8cef2e34c498245edb589bf95ba,melanoma,0.575706
uuid-227ce8cef2e34c498245edb589bf95ba,shared,0.302294
uuid-227ce8cef2e34c498245edb589bf95ba,commented,0.430967
uuid-227ce8cef2e34c498245edb589bf95ba,RCC,0.375237
uuid-227ce8cef2e34c498245edb589bf95ba,TL stated,0.312281
uuid-227ce8cef2e34c498245edb589bf95ba,regards,0.336824
uuid-227ce8cef2e34c498245edb589bf95ba,AI,0.493467
uuid-227ce8cef2e34c498245edb589bf95ba,SCCHN,0.443269
uuid-227ce8cef2e34c498245edb589bf95ba,SCLC,0.337783
uuid-227ce8cef2e34c498245edb589bf95ba,TL shared,0.407246
uuid-227ce8cef2e34c498245edb589bf95ba,NCCN,0.687612
uuid-b59a7670a7954c4d9da59dd381f9ef18,commented,0.325341
uuid-b59a7670a7954c4d9da59dd381f9ef18,physicians,0.326274
uuid-b59a7670a7954c4d9da59dd381f9ef18,oncology,0.553656
uuid-b59a7670a7954c4d9da59dd381f9ef18,clinical,0.509499
uuid-b59a7670a7954c4d9da59dd381f9ef18,Regional TL,0.348498
uuid-89ea3244a1d7468cb810b8fddd0d22d4,RTL,0.346565
uuid-89ea3244a1d7468cb810b8fddd0d22d4,BMS,0.403428
uuid-89ea3244a1d7468cb810b8fddd0d22d4,discussed,0.301971
uuid-89ea3244a1d7468cb810b8fddd0d22d4,commented,0.428974
uuid-89ea3244a1d7468cb810b8fddd0d22d4,Merck,0.406403
uuid-89ea3244a1d7468cb810b8fddd0d22d4,stated,0.345702
uuid-89ea3244a1d7468cb810b8fddd0d22d4,data,0.481104
uuid-89ea3244a1d7468cb810b8fddd0d22d4,expressed,0.365438
uuid-89ea3244a1d7468cb810b8fddd0d22d4,impressed,0.398602
uuid-c4299175b0f44cc79417a8b2f5ee5184,TL,0.405111
uuid-c4299175b0f44cc79417a8b2f5ee5184,RTL,0.462339
uuid-c4299175b0f44cc79417a8b2f5ee5184,trial,0.331834
uuid-c4299175b0f44cc79417a8b2f5ee5184,NTL,0.492746
uuid-c4299175b0f44cc79417a8b2f5ee5184,commented,0.310167
uuid-c4299175b0f44cc79417a8b2f5ee5184,SCCHN,0.303335
uuid-c4299175b0f44cc79417a8b2f5ee5184,oncologist,0.337895
uuid-c4299175b0f44cc79417a8b2f5ee5184,indicated,0.312858
uuid-c4299175b0f44cc79417a8b2f5ee5184,academic,0.301056
uuid-c4299175b0f44cc79417a8b2f5ee5184,Regional TL,0.500726
uuid-b2312eb072d142bfafe7a0485a886912,trial,0.341119
uuid-f615610a796f407190d1184b724a0b6d,Nivo,0.425044
uuid-f615610a796f407190d1184b724a0b6d,patients,0.839577
uuid-f615610a796f407190d1184b724a0b6d,Opdivo,0.352196
uuid-f615610a796f407190d1184b724a0b6d,therapy,0.599486
uuid-f615610a796f407190d1184b724a0b6d,dose,0.344471
uuid-f615610a796f407190d1184b724a0b6d,nivolumab,0.412871
uuid-f615610a796f407190d1184b724a0b6d,toxicity,0.518352
uuid-f615610a796f407190d1184b724a0b6d,regimen,0.703029
uuid-f615610a796f407190d1184b724a0b6d,treated,0.416455
uuid-f615610a796f407190d1184b724a0b6d,combination,0.380674
uuid-f615610a796f407190d1184b724a0b6d,chemo,0.597278
uuid-f615610a796f407190d1184b724a0b6d,pts,0.61239
uuid-f615610a796f407190d1184b724a0b6d,Ipi,0.321583
uuid-f615610a796f407190d1184b724a0b6d,monotherapy,0.571245
uuid-f615610a796f407190d1184b724a0b6d,treatment,0.685419
uuid-f615610a796f407190d1184b724a0b6d,response,0.529657
uuid-f615610a796f407190d1184b724a0b6d,combo,0.365452
uuid-f615610a796f407190d1184b724a0b6d,PD1,0.444105
uuid-f615610a796f407190d1184b724a0b6d,progression,0.707727
uuid-f615610a796f407190d1184b724a0b6d,chemotherapy,0.571369
uuid-f615610a796f407190d1184b724a0b6d,respond,0.587873
uuid-f615610a796f407190d1184b724a0b6d,option,0.487632
uuid-f22831da45d94f549b847f8987bd4ece,patients,0.739787
uuid-f22831da45d94f549b847f8987bd4ece,Opdivo,0.406343
uuid-f22831da45d94f549b847f8987bd4ece,therapy,0.396942
uuid-f22831da45d94f549b847f8987bd4ece,nivolumab,0.324237
uuid-f22831da45d94f549b847f8987bd4ece,regimen,0.537548
uuid-f22831da45d94f549b847f8987bd4ece,treated,0.514672
uuid-f22831da45d94f549b847f8987bd4ece,pts,0.404915
uuid-f22831da45d94f549b847f8987bd4ece,treatment,0.562496
uuid-f22831da45d94f549b847f8987bd4ece,progression,0.49843
uuid-f22831da45d94f549b847f8987bd4ece,respond,0.342154
uuid-51a05caaac354d9f843e177b4e588223,Nivo,0.393591
uuid-51a05caaac354d9f843e177b4e588223,pembro,0.30053
uuid-51a05caaac354d9f843e177b4e588223,trial,0.395553
uuid-51a05caaac354d9f843e177b4e588223,efficacy,0.488689
uuid-51a05caaac354d9f843e177b4e588223,discussed,0.433499
uuid-51a05caaac354d9f843e177b4e588223,OS,0.519105
uuid-51a05caaac354d9f843e177b4e588223,data,0.679104
uuid-51a05caaac354d9f843e177b4e588223,PFS,0.506222
uuid-51a05caaac354d9f843e177b4e588223,ORR,0.552526
uuid-51a05caaac354d9f843e177b4e588223,nivo and pembro,0.441147
uuid-51a05caaac354d9f843e177b4e588223,believes,0.362243
uuid-51a05caaac354d9f843e177b4e588223,impressed,0.521281
uuid-51a05caaac354d9f843e177b4e588223,feels,0.555259
uuid-569162bb8501485bb4f0d4f705287183,RTL,0.446914
uuid-569162bb8501485bb4f0d4f705287183,trial,0.315202
uuid-569162bb8501485bb4f0d4f705287183,treated,0.309306
uuid-569162bb8501485bb4f0d4f705287183,shared,0.375039
uuid-569162bb8501485bb4f0d4f705287183,combination,0.394932
uuid-569162bb8501485bb4f0d4f705287183,stated,0.333087
uuid-569162bb8501485bb4f0d4f705287183,combo,0.363781
uuid-569162bb8501485bb4f0d4f705287183,clinical trials,0.573819
uuid-569162bb8501485bb4f0d4f705287183,academic,0.368655
uuid-569162bb8501485bb4f0d4f705287183,feels,0.352549
uuid-569162bb8501485bb4f0d4f705287183,Regional TL,0.415489
uuid-569162bb8501485bb4f0d4f705287183,RTL stated,0.362977
uuid-a7022e7d7f7d4ffebe192d70f6e45397,RTL,0.31049
uuid-a7022e7d7f7d4ffebe192d70f6e45397,BMS,0.468603
uuid-a7022e7d7f7d4ffebe192d70f6e45397,lung,0.375828
uuid-a7022e7d7f7d4ffebe192d70f6e45397,trial,0.312475
uuid-a7022e7d7f7d4ffebe192d70f6e45397,NTL,0.346453
uuid-a7022e7d7f7d4ffebe192d70f6e45397,discussed,0.501234
uuid-a7022e7d7f7d4ffebe192d70f6e45397,commented,0.631103
uuid-a7022e7d7f7d4ffebe192d70f6e45397,Merck,0.37854
uuid-a7022e7d7f7d4ffebe192d70f6e45397,stated,0.339035
uuid-a7022e7d7f7d4ffebe192d70f6e45397,OS,0.383635
uuid-a7022e7d7f7d4ffebe192d70f6e45397,regards,0.484848
uuid-a7022e7d7f7d4ffebe192d70f6e45397,data,0.678505
uuid-a7022e7d7f7d4ffebe192d70f6e45397,expressed,0.439439
uuid-a7022e7d7f7d4ffebe192d70f6e45397,PFS,0.381686
uuid-a7022e7d7f7d4ffebe192d70f6e45397,ORR,0.383594
uuid-a7022e7d7f7d4ffebe192d70f6e45397,ASCO,0.443905
uuid-a7022e7d7f7d4ffebe192d70f6e45397,impressed,0.504695
uuid-a7022e7d7f7d4ffebe192d70f6e45397,TLs,0.372038
uuid-a7022e7d7f7d4ffebe192d70f6e45397,Regional TL,0.34537
uuid-54be1a5d653a4699824aec2b3431eaef,pembro,0.496414
uuid-54be1a5d653a4699824aec2b3431eaef,BMS,0.468578
uuid-54be1a5d653a4699824aec2b3431eaef,shared,0.48861
uuid-54be1a5d653a4699824aec2b3431eaef,2L,0.442104
uuid-54be1a5d653a4699824aec2b3431eaef,Merck,0.337598
uuid-54be1a5d653a4699824aec2b3431eaef,atezo,0.578169
uuid-54be1a5d653a4699824aec2b3431eaef,preferred,0.388056
uuid-54be1a5d653a4699824aec2b3431eaef,using nivo,0.355668
uuid-54be1a5d653a4699824aec2b3431eaef,combo,0.30968
uuid-54be1a5d653a4699824aec2b3431eaef,clinical trials,0.318645
uuid-54be1a5d653a4699824aec2b3431eaef,approved,0.36419
uuid-54be1a5d653a4699824aec2b3431eaef,vs,0.334258
uuid-54be1a5d653a4699824aec2b3431eaef,LTL,0.315328
uuid-54be1a5d653a4699824aec2b3431eaef,TLs,0.375264
uuid-54be1a5d653a4699824aec2b3431eaef,feels,0.375821
uuid-54be1a5d653a4699824aec2b3431eaef,flat dosing,0.301983
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,TL,0.351702
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,RTL,0.401199
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,lung,0.343836
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,NTL,0.461091
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,shared,0.478578
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,commented,0.445773
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,TL stated,0.397133
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,Merck,0.37966
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,institution,0.401651
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,stated,0.363687
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,PD-L1,0.340708
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,approval,0.303337
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,PD-L1 testing,0.39236
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,testing,0.423378
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,regards,0.367603
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,expressed,0.425476
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,mentioned,0.306948
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,PDL1 testing,0.507696
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,indication,0.335101
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,SCCHN,0.452265
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,tumor types,0.304334
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,LTL,0.377807
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,TLs,0.38497
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,academic,0.341655
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,assay,0.308636
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,Regional TL,0.399726
uuid-fa2d21e8a75d4b2c9ed493718a9baf9e,bladder,0.321171
uuid-75d886733e1a47f1b1a2c0882400eaac,RTL,0.38918
uuid-75d886733e1a47f1b1a2c0882400eaac,BMS,0.516568
uuid-75d886733e1a47f1b1a2c0882400eaac,trial,0.355288
uuid-75d886733e1a47f1b1a2c0882400eaac,NTL,0.428617
uuid-75d886733e1a47f1b1a2c0882400eaac,discussed,0.306278
uuid-75d886733e1a47f1b1a2c0882400eaac,shared,0.375314
uuid-75d886733e1a47f1b1a2c0882400eaac,commented,0.468319
uuid-75d886733e1a47f1b1a2c0882400eaac,Merck,0.474805
uuid-75d886733e1a47f1b1a2c0882400eaac,stated,0.379191
uuid-75d886733e1a47f1b1a2c0882400eaac,regards,0.301017
uuid-75d886733e1a47f1b1a2c0882400eaac,data,0.60649
uuid-75d886733e1a47f1b1a2c0882400eaac,expressed,0.438918
uuid-75d886733e1a47f1b1a2c0882400eaac,ASCO,0.350488
uuid-75d886733e1a47f1b1a2c0882400eaac,impressed,0.433323
uuid-75d886733e1a47f1b1a2c0882400eaac,LTL,0.314624
uuid-75d886733e1a47f1b1a2c0882400eaac,TLs,0.32015
uuid-75d886733e1a47f1b1a2c0882400eaac,clinical,0.323326
uuid-75d886733e1a47f1b1a2c0882400eaac,Regional TL,0.361069
uuid-374d7bc301f44e098d601c5bfe244ed3,Nivo,0.373143
uuid-374d7bc301f44e098d601c5bfe244ed3,pembro,0.323014
uuid-374d7bc301f44e098d601c5bfe244ed3,PDL1,0.348658
uuid-374d7bc301f44e098d601c5bfe244ed3,trial,0.494636
uuid-374d7bc301f44e098d601c5bfe244ed3,efficacy,0.424106
uuid-374d7bc301f44e098d601c5bfe244ed3,OS,0.707781
uuid-374d7bc301f44e098d601c5bfe244ed3,data,0.669522
uuid-374d7bc301f44e098d601c5bfe244ed3,PFS,0.722799
uuid-374d7bc301f44e098d601c5bfe244ed3,ORR,0.678204
uuid-374d7bc301f44e098d601c5bfe244ed3,nivo and pembro,0.428924
uuid-374d7bc301f44e098d601c5bfe244ed3,impressed,0.570952
uuid-374d7bc301f44e098d601c5bfe244ed3,feels,0.38574
uuid-374d7bc301f44e098d601c5bfe244ed3,PDL1 expression,0.328488
uuid-8d3758b7dda24728b358d962063e1834,physicians,0.325303
uuid-8d3758b7dda24728b358d962063e1834,oncology,0.362255
uuid-8d3758b7dda24728b358d962063e1834,label,0.349249
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,pembro,0.455181
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,BMS,0.429585
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,PDL1,0.440424
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,trial,0.3656
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,efficacy,0.524041
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,commented,0.424749
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,agents,0.323848
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,Merck,0.410827
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,OS,0.3378
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,atezo,0.49795
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,regards,0.422311
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,data,0.715946
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,expressed,0.38396
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,indication,0.443812
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,PFS,0.313884
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,ORR,0.378578
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,nivo and pembro,0.572105
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,believes,0.316843
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,impressed,0.450411
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,TLs,0.446653
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,feels,0.437537
uuid-9e4e628e9c2d4b31b6c2cf4b0808b6c9,PDL1 expression,0.448092
uuid-33e3fb1917504bfa885eae15c57f9819,chemo,0.413516
uuid-33e3fb1917504bfa885eae15c57f9819,OS,0.480391
uuid-33e3fb1917504bfa885eae15c57f9819,PFS,0.484441
uuid-33e3fb1917504bfa885eae15c57f9819,ORR,0.473829
uuid-33e3fb1917504bfa885eae15c57f9819,chemotherapy,0.416279
uuid-33e3fb1917504bfa885eae15c57f9819,impressed,0.315432
uuid-f5c54c02a8fa4069b008054707c5fd60,patients,0.48547
uuid-f5c54c02a8fa4069b008054707c5fd60,Opdivo,0.518491
uuid-f5c54c02a8fa4069b008054707c5fd60,dose,0.554873
uuid-f5c54c02a8fa4069b008054707c5fd60,nivolumab,0.389814
uuid-f5c54c02a8fa4069b008054707c5fd60,treated,0.369343
uuid-f5c54c02a8fa4069b008054707c5fd60,pts,0.303222
uuid-f5c54c02a8fa4069b008054707c5fd60,approval,0.357614
uuid-f5c54c02a8fa4069b008054707c5fd60,treatment,0.343165
uuid-f5c54c02a8fa4069b008054707c5fd60,flat dosing,0.448637
uuid-6c76a4aaa22e4ed78405419146246c69,TL,0.612649
uuid-6c76a4aaa22e4ed78405419146246c69,PDL1,0.499068
uuid-6c76a4aaa22e4ed78405419146246c69,Merck,0.386772
uuid-6c76a4aaa22e4ed78405419146246c69,institution,0.346577
uuid-6c76a4aaa22e4ed78405419146246c69,PD-L1,0.812085
uuid-6c76a4aaa22e4ed78405419146246c69,PD-L1 testing,0.807768
uuid-6c76a4aaa22e4ed78405419146246c69,testing,0.78666
uuid-6c76a4aaa22e4ed78405419146246c69,PDL1 testing,0.491444
uuid-6c76a4aaa22e4ed78405419146246c69,NSCLC patients,0.42724
uuid-6c76a4aaa22e4ed78405419146246c69,assay,0.866844
uuid-6c76a4aaa22e4ed78405419146246c69,PDL1 expression,0.315229
uuid-6c76a4aaa22e4ed78405419146246c69,biomarker,0.476065
uuid-04c336d802644643905181a27237ba78,TL,0.458373
uuid-04c336d802644643905181a27237ba78,1L,0.316771
uuid-04c336d802644643905181a27237ba78,PDL1,0.466265
uuid-04c336d802644643905181a27237ba78,PD-L1,0.813187
uuid-04c336d802644643905181a27237ba78,approval,0.320927
uuid-04c336d802644643905181a27237ba78,PD-L1 testing,0.774962
uuid-04c336d802644643905181a27237ba78,testing,0.84849
uuid-04c336d802644643905181a27237ba78,PDL1 testing,0.627326
uuid-04c336d802644643905181a27237ba78,NSCLC patients,0.624838
uuid-04c336d802644643905181a27237ba78,assay,0.767586
uuid-04c336d802644643905181a27237ba78,biomarker,0.35068
uuid-cfcab9c807d247b29010bb457e4f319f,RTL,0.579521
uuid-cfcab9c807d247b29010bb457e4f319f,nivolumab,0.304715
uuid-cfcab9c807d247b29010bb457e4f319f,NTL,0.445762
uuid-cfcab9c807d247b29010bb457e4f319f,shared,0.317015
uuid-cfcab9c807d247b29010bb457e4f319f,commented,0.336711
uuid-cfcab9c807d247b29010bb457e4f319f,stated,0.417514
uuid-cfcab9c807d247b29010bb457e4f319f,physicians,0.30565
uuid-cfcab9c807d247b29010bb457e4f319f,mentioned,0.425554
uuid-cfcab9c807d247b29010bb457e4f319f,SCCHN,0.315793
uuid-cfcab9c807d247b29010bb457e4f319f,HCP,0.364049
uuid-cfcab9c807d247b29010bb457e4f319f,cHL,0.400639
uuid-cfcab9c807d247b29010bb457e4f319f,impressed,0.359266
uuid-cfcab9c807d247b29010bb457e4f319f,LTL,0.436083
uuid-cfcab9c807d247b29010bb457e4f319f,Regional TL,0.542036
uuid-38a13cbd7ebb41328220c483dcdd4055,TL,0.703909
uuid-38a13cbd7ebb41328220c483dcdd4055,TL stated,0.391184
uuid-38a13cbd7ebb41328220c483dcdd4055,institution,0.404885
uuid-38a13cbd7ebb41328220c483dcdd4055,PD-L1,0.689936
uuid-38a13cbd7ebb41328220c483dcdd4055,PD-L1 testing,0.917446
uuid-38a13cbd7ebb41328220c483dcdd4055,testing,0.811698
uuid-38a13cbd7ebb41328220c483dcdd4055,PDL1 testing,0.643692
uuid-38a13cbd7ebb41328220c483dcdd4055,NSCLC patients,0.557183
uuid-38a13cbd7ebb41328220c483dcdd4055,assay,0.611383
uuid-38a13cbd7ebb41328220c483dcdd4055,biomarker,0.302134
uuid-e6491f56708c445f918b4bf9e8da8126,BMS,0.336219
uuid-e6491f56708c445f918b4bf9e8da8126,lung,0.39259
uuid-e6491f56708c445f918b4bf9e8da8126,institution,0.340235
uuid-e6491f56708c445f918b4bf9e8da8126,regards,0.365043
uuid-e6491f56708c445f918b4bf9e8da8126,data,0.424822
uuid-e6491f56708c445f918b4bf9e8da8126,indication,0.337035
uuid-e6491f56708c445f918b4bf9e8da8126,AI,0.64361
uuid-e6491f56708c445f918b4bf9e8da8126,nivo and pembro,0.339142
uuid-e6491f56708c445f918b4bf9e8da8126,label,0.3104
uuid-e6491f56708c445f918b4bf9e8da8126,SCLC,0.330252
uuid-e6491f56708c445f918b4bf9e8da8126,NCCN,0.600115
uuid-0b732e4d145947c09af1d9e97ba175a5,patients,0.37079
uuid-0b732e4d145947c09af1d9e97ba175a5,Opdivo,0.304605
uuid-0b732e4d145947c09af1d9e97ba175a5,therapy,0.311025
uuid-0b732e4d145947c09af1d9e97ba175a5,nivolumab,0.443519
uuid-0b732e4d145947c09af1d9e97ba175a5,treated,0.553207
uuid-0b732e4d145947c09af1d9e97ba175a5,shared,0.323235
uuid-0b732e4d145947c09af1d9e97ba175a5,RCC,0.320245
uuid-0b732e4d145947c09af1d9e97ba175a5,stated,0.312799
uuid-0b732e4d145947c09af1d9e97ba175a5,approval,0.30924
uuid-0b732e4d145947c09af1d9e97ba175a5,treatment,0.344449
uuid-0b732e4d145947c09af1d9e97ba175a5,using nivo,0.369062
uuid-0b732e4d145947c09af1d9e97ba175a5,Regional TL,0.468055
uuid-0b732e4d145947c09af1d9e97ba175a5,RTL stated,0.410432
uuid-ac69e48fb629403d800c9e5683ac479a,NSCLC,0.618048
uuid-ac69e48fb629403d800c9e5683ac479a,IO,0.62623
uuid-ac69e48fb629403d800c9e5683ac479a,response,0.39245
uuid-228e3828f61444eda240c4cd66200426,NSCLC,0.757653
uuid-228e3828f61444eda240c4cd66200426,IO,0.746856
uuid-228e3828f61444eda240c4cd66200426,response,0.320588
uuid-228e3828f61444eda240c4cd66200426,combo,0.304196
uuid-a531764c7f4246458d2d6f419d564022,NSCLC,0.734263
uuid-a531764c7f4246458d2d6f419d564022,IO,0.704934
uuid-1c6dcf16d230438f8b9389b14d54fd2e,NSCLC,0.76686
uuid-1c6dcf16d230438f8b9389b14d54fd2e,IO,0.718334
uuid-8b657c0f59564305890e392b6f8c2f9a,dose,0.314982
uuid-8b657c0f59564305890e392b6f8c2f9a,NSCLC,0.69452
uuid-8b657c0f59564305890e392b6f8c2f9a,regimen,0.300881
uuid-8b657c0f59564305890e392b6f8c2f9a,IO,0.671106
uuid-8b657c0f59564305890e392b6f8c2f9a,monotherapy,0.311773
uuid-c6cb65591d2b4440ab0a87ed76745c65,RTL,0.361702
uuid-c6cb65591d2b4440ab0a87ed76745c65,BMS,0.36429
uuid-c6cb65591d2b4440ab0a87ed76745c65,trial,0.427738
uuid-c6cb65591d2b4440ab0a87ed76745c65,discussed,0.432592
uuid-c6cb65591d2b4440ab0a87ed76745c65,commented,0.433537
uuid-c6cb65591d2b4440ab0a87ed76745c65,OS,0.494389
uuid-c6cb65591d2b4440ab0a87ed76745c65,regards,0.308916
uuid-c6cb65591d2b4440ab0a87ed76745c65,data,0.798937
uuid-c6cb65591d2b4440ab0a87ed76745c65,mentioned,0.341972
uuid-c6cb65591d2b4440ab0a87ed76745c65,PFS,0.515305
uuid-c6cb65591d2b4440ab0a87ed76745c65,ORR,0.518886
uuid-c6cb65591d2b4440ab0a87ed76745c65,nivo and pembro,0.358872
uuid-c6cb65591d2b4440ab0a87ed76745c65,ASCO,0.419281
uuid-c6cb65591d2b4440ab0a87ed76745c65,impressed,0.576817
uuid-c6cb65591d2b4440ab0a87ed76745c65,LTL,0.31455
uuid-201629aae4f148aa9ce7ea275a9385b1,Nivo,0.306353
uuid-201629aae4f148aa9ce7ea275a9385b1,patients,0.401374
uuid-201629aae4f148aa9ce7ea275a9385b1,therapy,0.355514
uuid-201629aae4f148aa9ce7ea275a9385b1,dose,0.316337
uuid-201629aae4f148aa9ce7ea275a9385b1,nivolumab,0.303124
uuid-201629aae4f148aa9ce7ea275a9385b1,toxicity,0.569544
uuid-201629aae4f148aa9ce7ea275a9385b1,regimen,0.475474
uuid-201629aae4f148aa9ce7ea275a9385b1,treated,0.38996
uuid-201629aae4f148aa9ce7ea275a9385b1,combination,0.396066
uuid-201629aae4f148aa9ce7ea275a9385b1,chemo,0.35616
uuid-201629aae4f148aa9ce7ea275a9385b1,pts,0.356678
uuid-201629aae4f148aa9ce7ea275a9385b1,Ipi,0.564721
uuid-201629aae4f148aa9ce7ea275a9385b1,monotherapy,0.327861
uuid-201629aae4f148aa9ce7ea275a9385b1,treatment,0.323734
uuid-201629aae4f148aa9ce7ea275a9385b1,combo,0.387989
uuid-201629aae4f148aa9ce7ea275a9385b1,PD1,0.304564
uuid-201629aae4f148aa9ce7ea275a9385b1,progression,0.334795
uuid-201629aae4f148aa9ce7ea275a9385b1,chemotherapy,0.321132
uuid-201629aae4f148aa9ce7ea275a9385b1,respond,0.308667
uuid-72e24da57c9c4c848b13264905dd270b,lung,0.360993
uuid-72e24da57c9c4c848b13264905dd270b,melanoma,0.470116
uuid-72e24da57c9c4c848b13264905dd270b,shared,0.504639
uuid-72e24da57c9c4c848b13264905dd270b,institution,0.404179
uuid-72e24da57c9c4c848b13264905dd270b,physicians,0.397809
uuid-72e24da57c9c4c848b13264905dd270b,TL shared,0.318177
uuid-2ab045d4e6f742b4861bfea74fa893c6,pembro,0.48682
uuid-2ab045d4e6f742b4861bfea74fa893c6,RTL,0.411644
uuid-2ab045d4e6f742b4861bfea74fa893c6,shared,0.521117
uuid-2ab045d4e6f742b4861bfea74fa893c6,RCC,0.378358
uuid-2ab045d4e6f742b4861bfea74fa893c6,2L,0.436699
uuid-2ab045d4e6f742b4861bfea74fa893c6,stated,0.385944
uuid-2ab045d4e6f742b4861bfea74fa893c6,approval,0.558518
uuid-2ab045d4e6f742b4861bfea74fa893c6,atezo,0.529061
uuid-2ab045d4e6f742b4861bfea74fa893c6,preferred,0.483731
uuid-2ab045d4e6f742b4861bfea74fa893c6,using nivo,0.486613
uuid-2ab045d4e6f742b4861bfea74fa893c6,clinical trials,0.365371
uuid-2ab045d4e6f742b4861bfea74fa893c6,indication,0.459099
uuid-2ab045d4e6f742b4861bfea74fa893c6,approved,0.505234
uuid-2ab045d4e6f742b4861bfea74fa893c6,SCCHN,0.628315
uuid-2ab045d4e6f742b4861bfea74fa893c6,label,0.363336
uuid-2ab045d4e6f742b4861bfea74fa893c6,LTL,0.42723
uuid-2ab045d4e6f742b4861bfea74fa893c6,TLs,0.344547
uuid-2ab045d4e6f742b4861bfea74fa893c6,academic,0.414764
uuid-2ab045d4e6f742b4861bfea74fa893c6,Regional TL,0.451339
uuid-2ab045d4e6f742b4861bfea74fa893c6,RTL stated,0.545406
uuid-2ab045d4e6f742b4861bfea74fa893c6,bladder,0.38712
uuid-2ab045d4e6f742b4861bfea74fa893c6,flat dosing,0.316324
uuid-32b44a2363a74e33a1290ba1965fffe0,TL,0.728565
uuid-32b44a2363a74e33a1290ba1965fffe0,TL stated,0.325336
uuid-32b44a2363a74e33a1290ba1965fffe0,institution,0.411119
uuid-32b44a2363a74e33a1290ba1965fffe0,PD-L1,0.672161
uuid-32b44a2363a74e33a1290ba1965fffe0,approval,0.329174
uuid-32b44a2363a74e33a1290ba1965fffe0,PD-L1 testing,0.806731
uuid-32b44a2363a74e33a1290ba1965fffe0,testing,0.74368
uuid-32b44a2363a74e33a1290ba1965fffe0,PDL1 testing,0.581538
uuid-32b44a2363a74e33a1290ba1965fffe0,NSCLC patients,0.521304
uuid-32b44a2363a74e33a1290ba1965fffe0,assay,0.718471
uuid-7b75311c5d6c4db5a7839de3e9c23a13,pembro,0.378779
uuid-7b75311c5d6c4db5a7839de3e9c23a13,2L,0.332392
uuid-7b75311c5d6c4db5a7839de3e9c23a13,stated,0.306984
uuid-7b75311c5d6c4db5a7839de3e9c23a13,approval,0.333957
uuid-7b75311c5d6c4db5a7839de3e9c23a13,atezo,0.312558
uuid-7b75311c5d6c4db5a7839de3e9c23a13,preferred,0.518572
uuid-7b75311c5d6c4db5a7839de3e9c23a13,using nivo,0.435752
uuid-7b75311c5d6c4db5a7839de3e9c23a13,indication,0.349032
uuid-7b75311c5d6c4db5a7839de3e9c23a13,SCCHN,0.459375
uuid-7b75311c5d6c4db5a7839de3e9c23a13,impressed,0.307596
uuid-7b75311c5d6c4db5a7839de3e9c23a13,feels,0.461174
uuid-7b75311c5d6c4db5a7839de3e9c23a13,Regional TL,0.306906
uuid-7b75311c5d6c4db5a7839de3e9c23a13,RTL stated,0.44427
uuid-7b75311c5d6c4db5a7839de3e9c23a13,option,0.395223
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,PDL1,0.582694
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,efficacy,0.441375
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,chemo,0.35007
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,OS,0.405392
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,PFS,0.433042
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,ORR,0.381413
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,nivo and pembro,0.449514
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,believes,0.499834
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,vs,0.378268
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,PDL1 expression,0.498611
uuid-79b986ccb3aa4c3c8cfc6c34e0b23e67,biomarker,0.352979
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,BMS,0.524829
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,trial,0.379184
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,commented,0.435249
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,Merck,0.417913
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,regards,0.354239
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,data,0.586293
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,expressed,0.320158
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,PFS,0.302906
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,ORR,0.302688
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,nivo and pembro,0.329642
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,impressed,0.334251
uuid-cdac18682eaa4bdbabb1f80e2d52ad27,feels,0.304401
uuid-8fbb4e6e67434732876ad2c47d3c726c,drug,0.404405
uuid-0f3d247e71854a74bfac1ec6338a6efc,tumor,0.374806
uuid-0f3d247e71854a74bfac1ec6338a6efc,PD-L1,0.343193
uuid-0f3d247e71854a74bfac1ec6338a6efc,testing,0.486595
uuid-0f3d247e71854a74bfac1ec6338a6efc,PDL1 testing,0.427813
uuid-0f3d247e71854a74bfac1ec6338a6efc,NSCLC patients,0.53288
uuid-0f3d247e71854a74bfac1ec6338a6efc,lung cancer,0.321151
uuid-0f3d247e71854a74bfac1ec6338a6efc,tumor types,0.436432
uuid-0f3d247e71854a74bfac1ec6338a6efc,biomarker,0.330456
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,RTL,0.382848
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,lung,0.364027
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,melanoma,0.542045
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,RCC,0.467947
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,TL stated,0.489463
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,pts,0.418128
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,institution,0.303575
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,stated,0.365178
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,PD-L1,0.31279
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,PD-L1 testing,0.451664
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,testing,0.355774
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,PDL1 testing,0.428358
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,NSCLC patients,0.395882
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,SCCHN,0.433036
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,TLs,0.393815
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,academic,0.362663
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,Regional TL,0.354238
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,RTL stated,0.465094
uuid-cd5dea6ca9394fce8c52b0d1fd25980f,TL shared,0.42726
uuid-b82dd3e9b10c47c79794c4efaca853e6,Nivo,0.504162
uuid-b82dd3e9b10c47c79794c4efaca853e6,patients,0.362298
uuid-b82dd3e9b10c47c79794c4efaca853e6,pembro,0.480347
uuid-b82dd3e9b10c47c79794c4efaca853e6,therapy,0.38906
uuid-b82dd3e9b10c47c79794c4efaca853e6,nivolumab,0.502706
uuid-b82dd3e9b10c47c79794c4efaca853e6,1L,0.702328
uuid-b82dd3e9b10c47c79794c4efaca853e6,RCC,0.609358
uuid-b82dd3e9b10c47c79794c4efaca853e6,combination,0.360705
uuid-b82dd3e9b10c47c79794c4efaca853e6,chemo,0.311806
uuid-b82dd3e9b10c47c79794c4efaca853e6,2L,0.78518
uuid-b82dd3e9b10c47c79794c4efaca853e6,pts,0.308321
uuid-b82dd3e9b10c47c79794c4efaca853e6,agents,0.376416
uuid-b82dd3e9b10c47c79794c4efaca853e6,approval,0.482889
uuid-b82dd3e9b10c47c79794c4efaca853e6,atezo,0.440211
uuid-b82dd3e9b10c47c79794c4efaca853e6,preferred,0.734083
uuid-b82dd3e9b10c47c79794c4efaca853e6,monotherapy,0.634446
uuid-b82dd3e9b10c47c79794c4efaca853e6,treatment,0.304768
uuid-b82dd3e9b10c47c79794c4efaca853e6,using nivo,0.831565
uuid-b82dd3e9b10c47c79794c4efaca853e6,combo,0.364104
uuid-b82dd3e9b10c47c79794c4efaca853e6,indication,0.335984
uuid-b82dd3e9b10c47c79794c4efaca853e6,PD1,0.369561
uuid-b82dd3e9b10c47c79794c4efaca853e6,approved,0.556793
uuid-b82dd3e9b10c47c79794c4efaca853e6,SCCHN,0.530671
uuid-b82dd3e9b10c47c79794c4efaca853e6,chemotherapy,0.304057
uuid-b82dd3e9b10c47c79794c4efaca853e6,tumor types,0.315288
uuid-b82dd3e9b10c47c79794c4efaca853e6,label,0.305808
uuid-b82dd3e9b10c47c79794c4efaca853e6,SCLC,0.313191
uuid-b82dd3e9b10c47c79794c4efaca853e6,RTL stated,0.690963
uuid-b82dd3e9b10c47c79794c4efaca853e6,TL shared,0.346382
uuid-b82dd3e9b10c47c79794c4efaca853e6,option,0.685007
uuid-b82dd3e9b10c47c79794c4efaca853e6,bladder,0.410213
uuid-110a926f7e77417995eacc0925a95a1f,TL,0.434668
uuid-110a926f7e77417995eacc0925a95a1f,pembro,0.405079
uuid-110a926f7e77417995eacc0925a95a1f,1L,0.430969
uuid-110a926f7e77417995eacc0925a95a1f,PDL1,0.480058
uuid-110a926f7e77417995eacc0925a95a1f,TL stated,0.433256
uuid-110a926f7e77417995eacc0925a95a1f,2L,0.380452
uuid-110a926f7e77417995eacc0925a95a1f,PD-L1,0.773638
uuid-110a926f7e77417995eacc0925a95a1f,atezo,0.480924
uuid-110a926f7e77417995eacc0925a95a1f,preferred,0.333071
uuid-110a926f7e77417995eacc0925a95a1f,PD-L1 testing,0.738725
uuid-110a926f7e77417995eacc0925a95a1f,testing,0.814413
uuid-110a926f7e77417995eacc0925a95a1f,PDL1 testing,0.728637
uuid-110a926f7e77417995eacc0925a95a1f,NSCLC patients,0.711281
uuid-110a926f7e77417995eacc0925a95a1f,tumor types,0.300239
uuid-110a926f7e77417995eacc0925a95a1f,assay,0.514003
uuid-110a926f7e77417995eacc0925a95a1f,PDL1 expression,0.377982
uuid-110a926f7e77417995eacc0925a95a1f,biomarker,0.409082
uuid-25c7e05855a14eb1af45bd2e6396d0f2,Nivo,0.398311
uuid-25c7e05855a14eb1af45bd2e6396d0f2,patients,0.664259
uuid-25c7e05855a14eb1af45bd2e6396d0f2,Opdivo,0.371959
uuid-25c7e05855a14eb1af45bd2e6396d0f2,therapy,0.630613
uuid-25c7e05855a14eb1af45bd2e6396d0f2,nivolumab,0.443519
uuid-25c7e05855a14eb1af45bd2e6396d0f2,treated,0.40674
uuid-25c7e05855a14eb1af45bd2e6396d0f2,pts,0.448772
uuid-25c7e05855a14eb1af45bd2e6396d0f2,treatment,0.534667
uuid-25c7e05855a14eb1af45bd2e6396d0f2,response,0.331778
uuid-25c7e05855a14eb1af45bd2e6396d0f2,mentioned,0.307629
uuid-25c7e05855a14eb1af45bd2e6396d0f2,cHL,0.607984
uuid-25c7e05855a14eb1af45bd2e6396d0f2,progression,0.49215
uuid-25c7e05855a14eb1af45bd2e6396d0f2,chemotherapy,0.350481
uuid-25c7e05855a14eb1af45bd2e6396d0f2,respond,0.423846
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,RTL,0.301335
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,therapy,0.325106
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,nivolumab,0.310012
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,NTL,0.365719
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,mentioned,0.585593
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,HCP,0.473019
uuid-c26a84d9da2b4ac18987cc58a93d2a4e,cHL,0.487292
uuid-13a21f41aa404a7d9ea26daa94ae79a5,Nivo,0.522459
uuid-13a21f41aa404a7d9ea26daa94ae79a5,patients,0.666483
uuid-13a21f41aa404a7d9ea26daa94ae79a5,Opdivo,0.390886
uuid-13a21f41aa404a7d9ea26daa94ae79a5,therapy,0.482552
uuid-13a21f41aa404a7d9ea26daa94ae79a5,nivolumab,0.594968
uuid-13a21f41aa404a7d9ea26daa94ae79a5,toxicity,0.342328
uuid-13a21f41aa404a7d9ea26daa94ae79a5,regimen,0.578038
uuid-13a21f41aa404a7d9ea26daa94ae79a5,treated,0.516021
uuid-13a21f41aa404a7d9ea26daa94ae79a5,combination,0.492273
uuid-13a21f41aa404a7d9ea26daa94ae79a5,chemo,0.449333
uuid-13a21f41aa404a7d9ea26daa94ae79a5,2L,0.320449
uuid-13a21f41aa404a7d9ea26daa94ae79a5,pts,0.49266
uuid-13a21f41aa404a7d9ea26daa94ae79a5,Ipi,0.338082
uuid-13a21f41aa404a7d9ea26daa94ae79a5,preferred,0.3642
uuid-13a21f41aa404a7d9ea26daa94ae79a5,monotherapy,0.52608
uuid-13a21f41aa404a7d9ea26daa94ae79a5,treatment,0.562624
uuid-13a21f41aa404a7d9ea26daa94ae79a5,using nivo,0.460555
uuid-13a21f41aa404a7d9ea26daa94ae79a5,combo,0.404682
uuid-13a21f41aa404a7d9ea26daa94ae79a5,PD1,0.382462
uuid-13a21f41aa404a7d9ea26daa94ae79a5,approved,0.307787
uuid-13a21f41aa404a7d9ea26daa94ae79a5,progression,0.493222
uuid-13a21f41aa404a7d9ea26daa94ae79a5,chemotherapy,0.472447
uuid-13a21f41aa404a7d9ea26daa94ae79a5,respond,0.369248
uuid-13a21f41aa404a7d9ea26daa94ae79a5,RTL stated,0.435042
uuid-13a21f41aa404a7d9ea26daa94ae79a5,option,0.462289
uuid-2458ead1736a44359bbb11b24c2efb2d,patients,0.38513
uuid-2458ead1736a44359bbb11b24c2efb2d,regimen,0.36435
uuid-2458ead1736a44359bbb11b24c2efb2d,treated,0.341319
uuid-2458ead1736a44359bbb11b24c2efb2d,pts,0.390586
uuid-2458ead1736a44359bbb11b24c2efb2d,IO,0.300366
uuid-2458ead1736a44359bbb11b24c2efb2d,treatment,0.475444
uuid-2458ead1736a44359bbb11b24c2efb2d,response,0.543412
uuid-2458ead1736a44359bbb11b24c2efb2d,PD1,0.314977
uuid-2458ead1736a44359bbb11b24c2efb2d,progression,0.499464
uuid-2458ead1736a44359bbb11b24c2efb2d,respond,0.452514
uuid-b9a82be095734763a8ac1315cb3bd3ba,Nivo,0.482541
uuid-b9a82be095734763a8ac1315cb3bd3ba,pembro,0.602895
uuid-b9a82be095734763a8ac1315cb3bd3ba,BMS,0.33599
uuid-b9a82be095734763a8ac1315cb3bd3ba,PDL1,0.34322
uuid-b9a82be095734763a8ac1315cb3bd3ba,trial,0.47488
uuid-b9a82be095734763a8ac1315cb3bd3ba,efficacy,0.612278
uuid-b9a82be095734763a8ac1315cb3bd3ba,discussed,0.336658
uuid-b9a82be095734763a8ac1315cb3bd3ba,OS,0.469286
uuid-b9a82be095734763a8ac1315cb3bd3ba,atezo,0.523126
uuid-b9a82be095734763a8ac1315cb3bd3ba,data,0.701766
uuid-b9a82be095734763a8ac1315cb3bd3ba,PFS,0.469918
uuid-b9a82be095734763a8ac1315cb3bd3ba,ORR,0.513224
uuid-b9a82be095734763a8ac1315cb3bd3ba,nivo and pembro,0.623463
uuid-b9a82be095734763a8ac1315cb3bd3ba,impressed,0.395443
uuid-b9a82be095734763a8ac1315cb3bd3ba,vs,0.611149
uuid-b9a82be095734763a8ac1315cb3bd3ba,feels,0.389768
uuid-b9a82be095734763a8ac1315cb3bd3ba,PDL1 expression,0.389908
uuid-18fdb2e4608c45f085dfb65eeccb414e,TL,0.506649
uuid-18fdb2e4608c45f085dfb65eeccb414e,1L,0.33264
uuid-18fdb2e4608c45f085dfb65eeccb414e,PDL1,0.48076
uuid-18fdb2e4608c45f085dfb65eeccb414e,TL stated,0.571013
uuid-18fdb2e4608c45f085dfb65eeccb414e,PD-L1,0.786142
uuid-18fdb2e4608c45f085dfb65eeccb414e,PD-L1 testing,0.777921
uuid-18fdb2e4608c45f085dfb65eeccb414e,testing,0.903856
uuid-18fdb2e4608c45f085dfb65eeccb414e,PDL1 testing,0.815766
uuid-18fdb2e4608c45f085dfb65eeccb414e,NSCLC patients,0.783132
uuid-18fdb2e4608c45f085dfb65eeccb414e,tumor types,0.36618
uuid-18fdb2e4608c45f085dfb65eeccb414e,assay,0.555731
uuid-18fdb2e4608c45f085dfb65eeccb414e,PDL1 expression,0.309221
uuid-18fdb2e4608c45f085dfb65eeccb414e,biomarker,0.486879
uuid-75cac775b12540e8a95d4d99e444ee30,RTL,0.330064
uuid-75cac775b12540e8a95d4d99e444ee30,nivolumab,0.317001
uuid-75cac775b12540e8a95d4d99e444ee30,NTL,0.442743
uuid-75cac775b12540e8a95d4d99e444ee30,mentioned,0.499453
uuid-75cac775b12540e8a95d4d99e444ee30,cHL,0.542469
uuid-7641a3a7ace045f3a4f7fe81068fa710,physicians,0.46934
uuid-7641a3a7ace045f3a4f7fe81068fa710,oncology,0.48335
uuid-7641a3a7ace045f3a4f7fe81068fa710,oncologist,0.496984
uuid-7641a3a7ace045f3a4f7fe81068fa710,indicated,0.550173
uuid-7641a3a7ace045f3a4f7fe81068fa710,clinical,0.442365
uuid-8a6dd37f4d584956964ea7ee8552700a,Opdivo,0.390023
uuid-8a6dd37f4d584956964ea7ee8552700a,lung,0.348799
uuid-8a6dd37f4d584956964ea7ee8552700a,1L,0.391746
uuid-8a6dd37f4d584956964ea7ee8552700a,RCC,0.383849
uuid-8a6dd37f4d584956964ea7ee8552700a,TL stated,0.332615
uuid-8a6dd37f4d584956964ea7ee8552700a,2L,0.447182
uuid-8a6dd37f4d584956964ea7ee8552700a,stated,0.31533
uuid-8a6dd37f4d584956964ea7ee8552700a,approval,0.309083
uuid-8a6dd37f4d584956964ea7ee8552700a,preferred,0.380676
uuid-8a6dd37f4d584956964ea7ee8552700a,using nivo,0.336567
uuid-8a6dd37f4d584956964ea7ee8552700a,indication,0.378226
uuid-8a6dd37f4d584956964ea7ee8552700a,approved,0.38336
uuid-8a6dd37f4d584956964ea7ee8552700a,SCCHN,0.397525
uuid-8a6dd37f4d584956964ea7ee8552700a,tumor types,0.335336
uuid-8a6dd37f4d584956964ea7ee8552700a,Keytruda,0.366938
uuid-8a6dd37f4d584956964ea7ee8552700a,RTL stated,0.33548
uuid-8a6dd37f4d584956964ea7ee8552700a,option,0.330326
uuid-8a6dd37f4d584956964ea7ee8552700a,bladder,0.302524
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,efficacy,0.350104
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,agents,0.361955
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,preferred,0.313389
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,indication,0.377496
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,drug,0.461198
uuid-d3c6deb4ad3c4d5da7d0d2d359a84691,Keytruda,0.327001
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,pembro,0.350873
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,1L,0.325154
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,shared,0.360372
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,2L,0.451215
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,institution,0.568506
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,approval,0.440499
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,atezo,0.474297
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,preferred,0.576057
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,using nivo,0.375118
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,PDL1 testing,0.410608
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,indication,0.522544
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,approved,0.478715
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,SCCHN,0.378903
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,label,0.393886
uuid-ade7bd10f696474cbdfd7b24ad5aa67d,Keytruda,0.424343
uuid-08a492bd9b3b4e399e0d5f37ef52e089,combination,0.438922
uuid-08a492bd9b3b4e399e0d5f37ef52e089,chemo,0.397604
uuid-08a492bd9b3b4e399e0d5f37ef52e089,tumor,0.346636
uuid-08a492bd9b3b4e399e0d5f37ef52e089,IO,0.352517
uuid-08a492bd9b3b4e399e0d5f37ef52e089,agents,0.326075
uuid-08a492bd9b3b4e399e0d5f37ef52e089,response,0.420483
uuid-08a492bd9b3b4e399e0d5f37ef52e089,PD1,0.322567
uuid-08a492bd9b3b4e399e0d5f37ef52e089,chemotherapy,0.383624
uuid-08a492bd9b3b4e399e0d5f37ef52e089,feels,0.302655
uuid-08a492bd9b3b4e399e0d5f37ef52e089,immunotherapy,0.383747
uuid-5c32c30a259748dca0d6e40058983c0c,BMS,0.30487
uuid-5c32c30a259748dca0d6e40058983c0c,PDL1,0.63157
uuid-5c32c30a259748dca0d6e40058983c0c,trial,0.373788
uuid-5c32c30a259748dca0d6e40058983c0c,efficacy,0.655621
uuid-5c32c30a259748dca0d6e40058983c0c,OS,0.580414
uuid-5c32c30a259748dca0d6e40058983c0c,regards,0.406381
uuid-5c32c30a259748dca0d6e40058983c0c,data,0.542963
uuid-5c32c30a259748dca0d6e40058983c0c,PFS,0.612555
uuid-5c32c30a259748dca0d6e40058983c0c,AI,0.36506
uuid-5c32c30a259748dca0d6e40058983c0c,ORR,0.626436
uuid-5c32c30a259748dca0d6e40058983c0c,nivo and pembro,0.68514
uuid-5c32c30a259748dca0d6e40058983c0c,believes,0.515542
uuid-5c32c30a259748dca0d6e40058983c0c,PDL1 expression,0.610099
uuid-5c32c30a259748dca0d6e40058983c0c,biomarker,0.412697
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,pembro,0.318808
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,BMS,0.543719
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,PDL1,0.543943
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,trial,0.408296
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,efficacy,0.508101
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,Merck,0.488672
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,OS,0.494281
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,data,0.698471
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,PFS,0.532066
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,ORR,0.532527
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,nivo and pembro,0.448522
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,impressed,0.374444
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,feels,0.332129
uuid-f7c5b856915c4f97a0bcf11e679f0dd5,PDL1 expression,0.585002
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,lung,0.374491
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,melanoma,0.358995
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,combination,0.315299
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,chemo,0.312087
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,combo,0.39096
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,AI,0.680612
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,PD1,0.312224
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,nivo and pembro,0.308437
uuid-2c0b3bc64ffb478b8955de7ed0bb701e,believes,0.323316
uuid-9d076a509093491e889f8990d5e98320,pembro,0.442165
uuid-9d076a509093491e889f8990d5e98320,1L,0.312867
uuid-9d076a509093491e889f8990d5e98320,PDL1,0.519408
uuid-9d076a509093491e889f8990d5e98320,trial,0.436928
uuid-9d076a509093491e889f8990d5e98320,efficacy,0.497551
uuid-9d076a509093491e889f8990d5e98320,OS,0.534397
uuid-9d076a509093491e889f8990d5e98320,atezo,0.35612
uuid-9d076a509093491e889f8990d5e98320,data,0.714618
uuid-9d076a509093491e889f8990d5e98320,PFS,0.530563
uuid-9d076a509093491e889f8990d5e98320,ORR,0.563949
uuid-9d076a509093491e889f8990d5e98320,nivo and pembro,0.498463
uuid-9d076a509093491e889f8990d5e98320,believes,0.373008
uuid-9d076a509093491e889f8990d5e98320,impressed,0.472903
uuid-9d076a509093491e889f8990d5e98320,feels,0.406679
uuid-9d076a509093491e889f8990d5e98320,PDL1 expression,0.532992
uuid-6091d632c68d43dbb38fc47eaa93b3af,BMS,0.381403
uuid-6091d632c68d43dbb38fc47eaa93b3af,trial,0.606104
uuid-6091d632c68d43dbb38fc47eaa93b3af,efficacy,0.30225
uuid-6091d632c68d43dbb38fc47eaa93b3af,NTL,0.335229
uuid-6091d632c68d43dbb38fc47eaa93b3af,Merck,0.350792
uuid-6091d632c68d43dbb38fc47eaa93b3af,OS,0.310985
uuid-6091d632c68d43dbb38fc47eaa93b3af,regards,0.35798
uuid-6091d632c68d43dbb38fc47eaa93b3af,data,0.484431
uuid-6091d632c68d43dbb38fc47eaa93b3af,PFS,0.32234
uuid-6091d632c68d43dbb38fc47eaa93b3af,ORR,0.389323
uuid-6091d632c68d43dbb38fc47eaa93b3af,nivo and pembro,0.331465
uuid-6091d632c68d43dbb38fc47eaa93b3af,believes,0.339886
uuid-6091d632c68d43dbb38fc47eaa93b3af,PDL1 expression,0.311292
uuid-6091d632c68d43dbb38fc47eaa93b3af,biomarker,0.30348
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,Nivo,0.341986
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,patients,0.496208
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,pembro,0.512181
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,nivolumab,0.407549
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,1L,0.353092
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,trial,0.355023
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,treated,0.345271
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,2L,0.402245
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,pts,0.356149
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,approval,0.500241
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,atezo,0.380831
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,preferred,0.346119
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,monotherapy,0.327617
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,using nivo,0.54694
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,clinical trials,0.477699
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,approved,0.402826
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,SCCHN,0.400625
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,tumor types,0.330958
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,SCLC,0.311508
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,RTL stated,0.383044
uuid-d948ba6a3e9b4295a59007a7d8de4bbb,bladder,0.512072
uuid-693a82365dd9471d8d7aced73f9521a3,PDL1,0.500498
uuid-693a82365dd9471d8d7aced73f9521a3,efficacy,0.395777
uuid-693a82365dd9471d8d7aced73f9521a3,PD-L1,0.481265
uuid-693a82365dd9471d8d7aced73f9521a3,atezo,0.333241
uuid-693a82365dd9471d8d7aced73f9521a3,testing,0.302987
uuid-693a82365dd9471d8d7aced73f9521a3,regards,0.316853
uuid-693a82365dd9471d8d7aced73f9521a3,data,0.347277
uuid-693a82365dd9471d8d7aced73f9521a3,indication,0.312246
uuid-693a82365dd9471d8d7aced73f9521a3,PFS,0.341117
uuid-693a82365dd9471d8d7aced73f9521a3,ORR,0.317729
uuid-693a82365dd9471d8d7aced73f9521a3,nivo and pembro,0.438694
uuid-693a82365dd9471d8d7aced73f9521a3,assay,0.365291
uuid-693a82365dd9471d8d7aced73f9521a3,PDL1 expression,0.499372
uuid-693a82365dd9471d8d7aced73f9521a3,biomarker,0.46483
uuid-670fd5446fb74e549f2c2bac737d8241,patients,0.891722
uuid-670fd5446fb74e549f2c2bac737d8241,Opdivo,0.538087
uuid-670fd5446fb74e549f2c2bac737d8241,therapy,0.559496
uuid-670fd5446fb74e549f2c2bac737d8241,nivolumab,0.510656
uuid-670fd5446fb74e549f2c2bac737d8241,regimen,0.493317
uuid-670fd5446fb74e549f2c2bac737d8241,treated,0.56099
uuid-670fd5446fb74e549f2c2bac737d8241,pts,0.520464
uuid-670fd5446fb74e549f2c2bac737d8241,monotherapy,0.324143
uuid-670fd5446fb74e549f2c2bac737d8241,treatment,0.711288
uuid-670fd5446fb74e549f2c2bac737d8241,using nivo,0.383418
uuid-670fd5446fb74e549f2c2bac737d8241,cHL,0.351974
uuid-670fd5446fb74e549f2c2bac737d8241,progression,0.554818
uuid-670fd5446fb74e549f2c2bac737d8241,chemotherapy,0.328081
uuid-670fd5446fb74e549f2c2bac737d8241,respond,0.452549
uuid-670fd5446fb74e549f2c2bac737d8241,option,0.408756
uuid-b8f9e17f28094bdd9b9a6927f113d1d9,toxicity,0.341183
uuid-b8f9e17f28094bdd9b9a6927f113d1d9,physicians,0.558244
uuid-b8f9e17f28094bdd9b9a6927f113d1d9,treatment,0.315179
uuid-4dc4f17f885447718b9c194c3ebd938c,RTL,0.393972
uuid-4dc4f17f885447718b9c194c3ebd938c,dose,0.457827
uuid-4dc4f17f885447718b9c194c3ebd938c,commented,0.36912
uuid-4dc4f17f885447718b9c194c3ebd938c,mentioned,0.555408
uuid-4dc4f17f885447718b9c194c3ebd938c,HCP,0.436024
uuid-4dc4f17f885447718b9c194c3ebd938c,vs,0.355047
uuid-4dc4f17f885447718b9c194c3ebd938c,LTL,0.410811
uuid-4dc4f17f885447718b9c194c3ebd938c,TLs,0.315478
uuid-4dc4f17f885447718b9c194c3ebd938c,Regional TL,0.335577
uuid-4dc4f17f885447718b9c194c3ebd938c,flat dosing,0.429331
uuid-96bf80207e0c4ec48ac69487227e4416,lung,0.324914
uuid-96bf80207e0c4ec48ac69487227e4416,regimen,0.325842
uuid-96bf80207e0c4ec48ac69487227e4416,treated,0.41178
uuid-96bf80207e0c4ec48ac69487227e4416,discussed,0.429272
uuid-96bf80207e0c4ec48ac69487227e4416,melanoma,0.498295
uuid-96bf80207e0c4ec48ac69487227e4416,commented,0.36291
uuid-96bf80207e0c4ec48ac69487227e4416,physicians,0.316168
uuid-96bf80207e0c4ec48ac69487227e4416,treatment,0.423946
uuid-96bf80207e0c4ec48ac69487227e4416,progression,0.316909
uuid-96bf80207e0c4ec48ac69487227e4416,ASCO,0.436253
uuid-96bf80207e0c4ec48ac69487227e4416,academic,0.318368
uuid-96bf80207e0c4ec48ac69487227e4416,TL shared,0.460105
uuid-8abb8e1d115046e9bf5088fb599221cf,Nivo,0.608458
uuid-8abb8e1d115046e9bf5088fb599221cf,patients,0.575169
uuid-8abb8e1d115046e9bf5088fb599221cf,Opdivo,0.332557
uuid-8abb8e1d115046e9bf5088fb599221cf,therapy,0.607717
uuid-8abb8e1d115046e9bf5088fb599221cf,nivolumab,0.368872
uuid-8abb8e1d115046e9bf5088fb599221cf,toxicity,0.460856
uuid-8abb8e1d115046e9bf5088fb599221cf,regimen,0.393083
uuid-8abb8e1d115046e9bf5088fb599221cf,chemo,0.392567
uuid-8abb8e1d115046e9bf5088fb599221cf,pts,0.329436
uuid-8abb8e1d115046e9bf5088fb599221cf,monotherapy,0.314596
uuid-8abb8e1d115046e9bf5088fb599221cf,treatment,0.472794
uuid-8abb8e1d115046e9bf5088fb599221cf,response,0.455643
uuid-8abb8e1d115046e9bf5088fb599221cf,PD1,0.351806
uuid-8abb8e1d115046e9bf5088fb599221cf,cHL,0.518316
uuid-8abb8e1d115046e9bf5088fb599221cf,progression,0.472755
uuid-8abb8e1d115046e9bf5088fb599221cf,chemotherapy,0.425679
uuid-8abb8e1d115046e9bf5088fb599221cf,respond,0.47647
uuid-ed5763fad4614e68a05217449af585eb,Nivo,0.435848
uuid-ed5763fad4614e68a05217449af585eb,patients,0.745263
uuid-ed5763fad4614e68a05217449af585eb,Opdivo,0.39728
uuid-ed5763fad4614e68a05217449af585eb,therapy,0.606253
uuid-ed5763fad4614e68a05217449af585eb,nivolumab,0.636358
uuid-ed5763fad4614e68a05217449af585eb,toxicity,0.507178
uuid-ed5763fad4614e68a05217449af585eb,regimen,0.55493
uuid-ed5763fad4614e68a05217449af585eb,treated,0.466849
uuid-ed5763fad4614e68a05217449af585eb,combination,0.371062
uuid-ed5763fad4614e68a05217449af585eb,chemo,0.461771
uuid-ed5763fad4614e68a05217449af585eb,pts,0.43618
uuid-ed5763fad4614e68a05217449af585eb,preferred,0.321423
uuid-ed5763fad4614e68a05217449af585eb,monotherapy,0.499329
uuid-ed5763fad4614e68a05217449af585eb,treatment,0.603432
uuid-ed5763fad4614e68a05217449af585eb,using nivo,0.331951
uuid-ed5763fad4614e68a05217449af585eb,response,0.347975
uuid-ed5763fad4614e68a05217449af585eb,PD1,0.379804
uuid-ed5763fad4614e68a05217449af585eb,cHL,0.378748
uuid-ed5763fad4614e68a05217449af585eb,progression,0.498225
uuid-ed5763fad4614e68a05217449af585eb,chemotherapy,0.516413
uuid-ed5763fad4614e68a05217449af585eb,respond,0.408625
uuid-ed5763fad4614e68a05217449af585eb,option,0.442791
uuid-3c4ba5299a5242cc83f9f23b66777678,Nivo,0.321372
uuid-3c4ba5299a5242cc83f9f23b66777678,Opdivo,0.472935
uuid-3c4ba5299a5242cc83f9f23b66777678,dose,0.869516
uuid-3c4ba5299a5242cc83f9f23b66777678,toxicity,0.428623
uuid-3c4ba5299a5242cc83f9f23b66777678,efficacy,0.371796
uuid-3c4ba5299a5242cc83f9f23b66777678,regimen,0.318201
uuid-3c4ba5299a5242cc83f9f23b66777678,Ipi,0.444745
uuid-3c4ba5299a5242cc83f9f23b66777678,vs,0.58711
uuid-3c4ba5299a5242cc83f9f23b66777678,drug,0.342844
uuid-3c4ba5299a5242cc83f9f23b66777678,Keytruda,0.395406
uuid-3c4ba5299a5242cc83f9f23b66777678,flat dosing,0.760373
uuid-12371e5c6c90492eb8be1bb3c422764e,tumor,0.350675
uuid-12371e5c6c90492eb8be1bb3c422764e,PDL1 expression,0.415453
uuid-12371e5c6c90492eb8be1bb3c422764e,biomarker,0.407401
uuid-d38e3e0de3c042b593ee5fbc726fe72c,patients,0.356045
uuid-d38e3e0de3c042b593ee5fbc726fe72c,Opdivo,0.375692
uuid-d38e3e0de3c042b593ee5fbc726fe72c,dose,0.710019
uuid-d38e3e0de3c042b593ee5fbc726fe72c,toxicity,0.352881
uuid-d38e3e0de3c042b593ee5fbc726fe72c,regimen,0.336017
uuid-d38e3e0de3c042b593ee5fbc726fe72c,treated,0.318125
uuid-d38e3e0de3c042b593ee5fbc726fe72c,physicians,0.315026
uuid-d38e3e0de3c042b593ee5fbc726fe72c,treatment,0.334687
uuid-d38e3e0de3c042b593ee5fbc726fe72c,vs,0.300548
uuid-d38e3e0de3c042b593ee5fbc726fe72c,flat dosing,0.468511
uuid-dc2efba9082f4822b4e2c88d818d6329,Nivo,0.372658
uuid-dc2efba9082f4822b4e2c88d818d6329,RTL,0.374588
uuid-dc2efba9082f4822b4e2c88d818d6329,trial,0.395416
uuid-dc2efba9082f4822b4e2c88d818d6329,efficacy,0.346111
uuid-dc2efba9082f4822b4e2c88d818d6329,combination,0.327434
uuid-dc2efba9082f4822b4e2c88d818d6329,Ipi,0.436718
uuid-dc2efba9082f4822b4e2c88d818d6329,OS,0.384873
uuid-dc2efba9082f4822b4e2c88d818d6329,data,0.421077
uuid-dc2efba9082f4822b4e2c88d818d6329,combo,0.301938
uuid-dc2efba9082f4822b4e2c88d818d6329,PFS,0.361615
uuid-dc2efba9082f4822b4e2c88d818d6329,ORR,0.474965
uuid-dc2efba9082f4822b4e2c88d818d6329,HCP,0.516934
uuid-dc2efba9082f4822b4e2c88d818d6329,impressed,0.527197
uuid-dc2efba9082f4822b4e2c88d818d6329,SCLC,0.494196
uuid-e4acbd6e14304fb1b676ec133018cb1e,dose,0.362413
uuid-e4acbd6e14304fb1b676ec133018cb1e,toxicity,0.352195
uuid-e4acbd6e14304fb1b676ec133018cb1e,regimen,0.381853
uuid-e4acbd6e14304fb1b676ec133018cb1e,physicians,0.473884
uuid-e4acbd6e14304fb1b676ec133018cb1e,treatment,0.378061
uuid-0616073677a449fa8f2e9445b192bb2a,RTL,0.492514
uuid-0616073677a449fa8f2e9445b192bb2a,commented,0.327023
uuid-0616073677a449fa8f2e9445b192bb2a,using nivo,0.31397
uuid-0616073677a449fa8f2e9445b192bb2a,expressed,0.353921
uuid-0616073677a449fa8f2e9445b192bb2a,mentioned,0.555058
uuid-0616073677a449fa8f2e9445b192bb2a,SCCHN,0.364149
uuid-0616073677a449fa8f2e9445b192bb2a,HCP,0.699628
uuid-0616073677a449fa8f2e9445b192bb2a,impressed,0.355319
uuid-0616073677a449fa8f2e9445b192bb2a,LTL,0.421292
uuid-0616073677a449fa8f2e9445b192bb2a,SCLC,0.34493
uuid-0616073677a449fa8f2e9445b192bb2a,Regional TL,0.319864
uuid-e769270d198b4fd88bf218667450542f,TL,0.312427
uuid-e769270d198b4fd88bf218667450542f,TL stated,0.325161
uuid-e769270d198b4fd88bf218667450542f,PD-L1,0.567797
uuid-e769270d198b4fd88bf218667450542f,approval,0.334838
uuid-e769270d198b4fd88bf218667450542f,PD-L1 testing,0.600672
uuid-e769270d198b4fd88bf218667450542f,testing,0.646801
uuid-e769270d198b4fd88bf218667450542f,using nivo,0.308519
uuid-e769270d198b4fd88bf218667450542f,expressed,0.332304
uuid-e769270d198b4fd88bf218667450542f,mentioned,0.40736
uuid-e769270d198b4fd88bf218667450542f,PDL1 testing,0.566411
uuid-e769270d198b4fd88bf218667450542f,NSCLC patients,0.572948
uuid-e769270d198b4fd88bf218667450542f,HCP,0.591168
uuid-e769270d198b4fd88bf218667450542f,LTL,0.31807
uuid-e769270d198b4fd88bf218667450542f,assay,0.356106
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,PD-L1,0.408675
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,PD-L1 testing,0.483567
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,testing,0.621377
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,PDL1 testing,0.52559
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,NSCLC patients,0.463916
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,lung cancer,0.311589
uuid-8d0e0eec11e948c3a18d763dfb08f6b0,assay,0.303976
uuid-385a3901e4c54357a8606782fd13a0eb,RTL,0.366019
uuid-385a3901e4c54357a8606782fd13a0eb,nivolumab,0.414729
uuid-385a3901e4c54357a8606782fd13a0eb,lung,0.421553
uuid-385a3901e4c54357a8606782fd13a0eb,treated,0.374654
uuid-385a3901e4c54357a8606782fd13a0eb,melanoma,0.388722
uuid-385a3901e4c54357a8606782fd13a0eb,shared,0.354936
uuid-385a3901e4c54357a8606782fd13a0eb,commented,0.312656
uuid-385a3901e4c54357a8606782fd13a0eb,RCC,0.556492
uuid-385a3901e4c54357a8606782fd13a0eb,TL stated,0.389674
uuid-385a3901e4c54357a8606782fd13a0eb,2L,0.352673
uuid-385a3901e4c54357a8606782fd13a0eb,stated,0.402748
uuid-385a3901e4c54357a8606782fd13a0eb,approval,0.416222
uuid-385a3901e4c54357a8606782fd13a0eb,preferred,0.415218
uuid-385a3901e4c54357a8606782fd13a0eb,using nivo,0.528136
uuid-385a3901e4c54357a8606782fd13a0eb,mentioned,0.410802
uuid-385a3901e4c54357a8606782fd13a0eb,clinical trials,0.30295
uuid-385a3901e4c54357a8606782fd13a0eb,approved,0.356696
uuid-385a3901e4c54357a8606782fd13a0eb,SCCHN,0.675208
uuid-385a3901e4c54357a8606782fd13a0eb,HCP,0.33908
uuid-385a3901e4c54357a8606782fd13a0eb,tumor types,0.361078
uuid-385a3901e4c54357a8606782fd13a0eb,LTL,0.399543
uuid-385a3901e4c54357a8606782fd13a0eb,SCLC,0.324166
uuid-385a3901e4c54357a8606782fd13a0eb,Regional TL,0.480939
uuid-385a3901e4c54357a8606782fd13a0eb,RTL stated,0.605841
uuid-385a3901e4c54357a8606782fd13a0eb,TL shared,0.527948
uuid-385a3901e4c54357a8606782fd13a0eb,bladder,0.461052
uuid-6932cefa78aa4d5e8892483770397ea6,Nivo,0.520537
uuid-6932cefa78aa4d5e8892483770397ea6,patients,0.548887
uuid-6932cefa78aa4d5e8892483770397ea6,Opdivo,0.325928
uuid-6932cefa78aa4d5e8892483770397ea6,therapy,0.681259
uuid-6932cefa78aa4d5e8892483770397ea6,nivolumab,0.438012
uuid-6932cefa78aa4d5e8892483770397ea6,toxicity,0.388131
uuid-6932cefa78aa4d5e8892483770397ea6,regimen,0.622843
uuid-6932cefa78aa4d5e8892483770397ea6,treated,0.40308
uuid-6932cefa78aa4d5e8892483770397ea6,combination,0.406623
uuid-6932cefa78aa4d5e8892483770397ea6,chemo,0.493492
uuid-6932cefa78aa4d5e8892483770397ea6,pts,0.323427
uuid-6932cefa78aa4d5e8892483770397ea6,preferred,0.301982
uuid-6932cefa78aa4d5e8892483770397ea6,monotherapy,0.549258
uuid-6932cefa78aa4d5e8892483770397ea6,treatment,0.728123
uuid-6932cefa78aa4d5e8892483770397ea6,response,0.344392
uuid-6932cefa78aa4d5e8892483770397ea6,PD1,0.422648
uuid-6932cefa78aa4d5e8892483770397ea6,cHL,0.378482
uuid-6932cefa78aa4d5e8892483770397ea6,progression,0.49237
uuid-6932cefa78aa4d5e8892483770397ea6,chemotherapy,0.557224
uuid-6932cefa78aa4d5e8892483770397ea6,respond,0.423182
uuid-6932cefa78aa4d5e8892483770397ea6,option,0.502792
uuid-742207f5cea144beb2cf7f4a0f241cbb,Nivo,0.597257
uuid-742207f5cea144beb2cf7f4a0f241cbb,therapy,0.449271
uuid-742207f5cea144beb2cf7f4a0f241cbb,nivolumab,0.487303
uuid-742207f5cea144beb2cf7f4a0f241cbb,trial,0.331682
uuid-742207f5cea144beb2cf7f4a0f241cbb,combination,0.376705
uuid-742207f5cea144beb2cf7f4a0f241cbb,chemo,0.306349
uuid-742207f5cea144beb2cf7f4a0f241cbb,using nivo,0.391198
uuid-742207f5cea144beb2cf7f4a0f241cbb,PD1,0.322514
uuid-742207f5cea144beb2cf7f4a0f241cbb,cHL,0.519102
uuid-742207f5cea144beb2cf7f4a0f241cbb,chemotherapy,0.410579
uuid-c883a76d49fb436c9fbab26fdf632191,patients,0.719888
uuid-c883a76d49fb436c9fbab26fdf632191,Opdivo,0.353494
uuid-c883a76d49fb436c9fbab26fdf632191,therapy,0.504948
uuid-c883a76d49fb436c9fbab26fdf632191,toxicity,0.331879
uuid-c883a76d49fb436c9fbab26fdf632191,regimen,0.521307
uuid-c883a76d49fb436c9fbab26fdf632191,treated,0.581894
uuid-c883a76d49fb436c9fbab26fdf632191,pts,0.448371
uuid-c883a76d49fb436c9fbab26fdf632191,physicians,0.355335
uuid-c883a76d49fb436c9fbab26fdf632191,treatment,0.868718
uuid-c883a76d49fb436c9fbab26fdf632191,response,0.384668
uuid-c883a76d49fb436c9fbab26fdf632191,progression,0.65782
uuid-c883a76d49fb436c9fbab26fdf632191,chemotherapy,0.316998
uuid-c883a76d49fb436c9fbab26fdf632191,respond,0.590388
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,Nivo,0.37794
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,therapy,0.334727
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,toxicity,0.473802
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,treatment,0.337818
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,cHL,0.397718
uuid-0f6caf8c0ea34c5aad505e4f94a534cf,respond,0.328626
uuid-67fe316518ad4137b401d2be0a281a72,Nivo,0.529085
uuid-67fe316518ad4137b401d2be0a281a72,patients,0.369462
uuid-67fe316518ad4137b401d2be0a281a72,therapy,0.500914
uuid-67fe316518ad4137b401d2be0a281a72,1L,0.357731
uuid-67fe316518ad4137b401d2be0a281a72,regimen,0.411834
uuid-67fe316518ad4137b401d2be0a281a72,combination,0.492164
uuid-67fe316518ad4137b401d2be0a281a72,chemo,0.607181
uuid-67fe316518ad4137b401d2be0a281a72,2L,0.398171
uuid-67fe316518ad4137b401d2be0a281a72,pts,0.408157
uuid-67fe316518ad4137b401d2be0a281a72,IO,0.434971
uuid-67fe316518ad4137b401d2be0a281a72,agents,0.464171
uuid-67fe316518ad4137b401d2be0a281a72,Ipi,0.30939
uuid-67fe316518ad4137b401d2be0a281a72,monotherapy,0.56065
uuid-67fe316518ad4137b401d2be0a281a72,treatment,0.398572
uuid-67fe316518ad4137b401d2be0a281a72,response,0.66475
uuid-67fe316518ad4137b401d2be0a281a72,combo,0.451569
uuid-67fe316518ad4137b401d2be0a281a72,PD1,0.542443
uuid-67fe316518ad4137b401d2be0a281a72,progression,0.573317
uuid-67fe316518ad4137b401d2be0a281a72,believes,0.387027
uuid-67fe316518ad4137b401d2be0a281a72,chemotherapy,0.443725
uuid-67fe316518ad4137b401d2be0a281a72,respond,0.510015
uuid-67fe316518ad4137b401d2be0a281a72,option,0.45108
uuid-2854b914f78b4a40b1f5802cb9e7fb64,1L,0.334359
uuid-2854b914f78b4a40b1f5802cb9e7fb64,2L,0.436749
uuid-2854b914f78b4a40b1f5802cb9e7fb64,agents,0.375886
uuid-2854b914f78b4a40b1f5802cb9e7fb64,atezo,0.356811
uuid-2854b914f78b4a40b1f5802cb9e7fb64,preferred,0.605683
uuid-2854b914f78b4a40b1f5802cb9e7fb64,monotherapy,0.327124
uuid-2854b914f78b4a40b1f5802cb9e7fb64,using nivo,0.364021
uuid-2854b914f78b4a40b1f5802cb9e7fb64,PDL1 testing,0.317591
uuid-2854b914f78b4a40b1f5802cb9e7fb64,indication,0.322991
uuid-2854b914f78b4a40b1f5802cb9e7fb64,approved,0.365978
uuid-2854b914f78b4a40b1f5802cb9e7fb64,HCP,0.304804
uuid-2854b914f78b4a40b1f5802cb9e7fb64,RTL stated,0.333339
uuid-2854b914f78b4a40b1f5802cb9e7fb64,option,0.420987
uuid-8581ffd3826244e7a5d3228ce8a9a778,Opdivo,0.308042
uuid-8581ffd3826244e7a5d3228ce8a9a778,therapy,0.56204
uuid-8581ffd3826244e7a5d3228ce8a9a778,treatment,0.379109
uuid-8581ffd3826244e7a5d3228ce8a9a778,cHL,0.524764
uuid-452540e507ad4989bb02e167253a2b56,Nivo,0.620043
uuid-452540e507ad4989bb02e167253a2b56,pembro,0.589102
uuid-452540e507ad4989bb02e167253a2b56,1L,0.393631
uuid-452540e507ad4989bb02e167253a2b56,efficacy,0.497643
uuid-452540e507ad4989bb02e167253a2b56,combination,0.309972
uuid-452540e507ad4989bb02e167253a2b56,chemo,0.382538
uuid-452540e507ad4989bb02e167253a2b56,2L,0.445026
uuid-452540e507ad4989bb02e167253a2b56,agents,0.408276
uuid-452540e507ad4989bb02e167253a2b56,Ipi,0.49396
uuid-452540e507ad4989bb02e167253a2b56,atezo,0.580133
uuid-452540e507ad4989bb02e167253a2b56,preferred,0.414031
uuid-452540e507ad4989bb02e167253a2b56,monotherapy,0.420893
uuid-452540e507ad4989bb02e167253a2b56,using nivo,0.332191
uuid-452540e507ad4989bb02e167253a2b56,combo,0.359371
uuid-452540e507ad4989bb02e167253a2b56,indication,0.310237
uuid-452540e507ad4989bb02e167253a2b56,nivo and pembro,0.512062
uuid-452540e507ad4989bb02e167253a2b56,believes,0.475341
uuid-452540e507ad4989bb02e167253a2b56,vs,0.371932
uuid-452540e507ad4989bb02e167253a2b56,feels,0.443589
uuid-452540e507ad4989bb02e167253a2b56,option,0.413976
uuid-a728f27cf5af446eb89ccea84293b24e,TL,0.331736
uuid-a728f27cf5af446eb89ccea84293b24e,PDL1,0.411953
uuid-a728f27cf5af446eb89ccea84293b24e,TL stated,0.319493
uuid-a728f27cf5af446eb89ccea84293b24e,PD-L1,0.740937
uuid-a728f27cf5af446eb89ccea84293b24e,PD-L1 testing,0.733472
uuid-a728f27cf5af446eb89ccea84293b24e,testing,0.833462
uuid-a728f27cf5af446eb89ccea84293b24e,PDL1 testing,0.659418
uuid-a728f27cf5af446eb89ccea84293b24e,NSCLC patients,0.670218
uuid-a728f27cf5af446eb89ccea84293b24e,assay,0.580792
uuid-a728f27cf5af446eb89ccea84293b24e,biomarker,0.484144
uuid-69e0f7a7825947e98c83ccf54249c0b7,Nivo,0.359442
uuid-69e0f7a7825947e98c83ccf54249c0b7,therapy,0.435727
uuid-69e0f7a7825947e98c83ccf54249c0b7,approval,0.356836
uuid-69e0f7a7825947e98c83ccf54249c0b7,using nivo,0.346157
uuid-69e0f7a7825947e98c83ccf54249c0b7,cHL,0.591128
uuid-9b5b8356ce9b441287185b573f6711e1,agents,0.480928
uuid-9b5b8356ce9b441287185b573f6711e1,Merck,0.302675
uuid-9b5b8356ce9b441287185b573f6711e1,preferred,0.415548
uuid-9b5b8356ce9b441287185b573f6711e1,clinical trials,0.410892
uuid-9b5b8356ce9b441287185b573f6711e1,indication,0.306952
uuid-9b5b8356ce9b441287185b573f6711e1,tumor types,0.311962
uuid-9b5b8356ce9b441287185b573f6711e1,RTL stated,0.315544
uuid-9b5b8356ce9b441287185b573f6711e1,bladder,0.348597
uuid-f2dfa046d109436c853f10574a5722ff,Nivo,0.542227
uuid-f2dfa046d109436c853f10574a5722ff,patients,0.429429
uuid-f2dfa046d109436c853f10574a5722ff,therapy,0.605148
uuid-f2dfa046d109436c853f10574a5722ff,nivolumab,0.488217
uuid-f2dfa046d109436c853f10574a5722ff,1L,0.381843
uuid-f2dfa046d109436c853f10574a5722ff,toxicity,0.422171
uuid-f2dfa046d109436c853f10574a5722ff,regimen,0.667023
uuid-f2dfa046d109436c853f10574a5722ff,treated,0.355892
uuid-f2dfa046d109436c853f10574a5722ff,combination,0.686459
uuid-f2dfa046d109436c853f10574a5722ff,chemo,0.604294
uuid-f2dfa046d109436c853f10574a5722ff,2L,0.455135
uuid-f2dfa046d109436c853f10574a5722ff,pts,0.322129
uuid-f2dfa046d109436c853f10574a5722ff,IO,0.360225
uuid-f2dfa046d109436c853f10574a5722ff,agents,0.584336
uuid-f2dfa046d109436c853f10574a5722ff,Ipi,0.330374
uuid-f2dfa046d109436c853f10574a5722ff,preferred,0.52327
uuid-f2dfa046d109436c853f10574a5722ff,monotherapy,0.755395
uuid-f2dfa046d109436c853f10574a5722ff,treatment,0.611782
uuid-f2dfa046d109436c853f10574a5722ff,using nivo,0.402455
uuid-f2dfa046d109436c853f10574a5722ff,combo,0.537393
uuid-f2dfa046d109436c853f10574a5722ff,PD1,0.559216
uuid-f2dfa046d109436c853f10574a5722ff,progression,0.431373
uuid-f2dfa046d109436c853f10574a5722ff,chemotherapy,0.641771
uuid-f2dfa046d109436c853f10574a5722ff,respond,0.313533
uuid-f2dfa046d109436c853f10574a5722ff,feels,0.313768
uuid-f2dfa046d109436c853f10574a5722ff,RTL stated,0.340285
uuid-f2dfa046d109436c853f10574a5722ff,option,0.628678
uuid-8afad2e86b114364a76656ee0f5aab40,Nivo,0.687043
uuid-8afad2e86b114364a76656ee0f5aab40,pembro,0.62939
uuid-8afad2e86b114364a76656ee0f5aab40,1L,0.384092
uuid-8afad2e86b114364a76656ee0f5aab40,trial,0.331685
uuid-8afad2e86b114364a76656ee0f5aab40,efficacy,0.396832
uuid-8afad2e86b114364a76656ee0f5aab40,chemo,0.395663
uuid-8afad2e86b114364a76656ee0f5aab40,2L,0.407228
uuid-8afad2e86b114364a76656ee0f5aab40,Ipi,0.586179
uuid-8afad2e86b114364a76656ee0f5aab40,atezo,0.567574
uuid-8afad2e86b114364a76656ee0f5aab40,monotherapy,0.345084
uuid-8afad2e86b114364a76656ee0f5aab40,using nivo,0.353172
uuid-8afad2e86b114364a76656ee0f5aab40,combo,0.331858
uuid-8afad2e86b114364a76656ee0f5aab40,nivo and pembro,0.487883
uuid-8afad2e86b114364a76656ee0f5aab40,believes,0.452793
uuid-8afad2e86b114364a76656ee0f5aab40,vs,0.466406
uuid-8afad2e86b114364a76656ee0f5aab40,feels,0.357028
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,Nivo,0.53105
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,patients,0.488226
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,therapy,0.570803
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,nivolumab,0.37595
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,1L,0.452687
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,regimen,0.536554
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,combination,0.582682
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,chemo,0.64679
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,2L,0.463318
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,pts,0.534755
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,IO,0.392923
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,agents,0.44421
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,Ipi,0.452072
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,preferred,0.352221
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,monotherapy,0.679727
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,treatment,0.436911
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,using nivo,0.326942
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,response,0.509878
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,combo,0.596915
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,PD1,0.592832
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,progression,0.566993
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,believes,0.395143
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,chemotherapy,0.523773
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,respond,0.490276
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,PD-1,0.313265
uuid-a9cdf14eeaac4d19b8f23e9aec0cc87b,option,0.575956
uuid-85a9772043674756ab0527aa13544970,patients,0.611031
uuid-85a9772043674756ab0527aa13544970,therapy,0.469152
uuid-85a9772043674756ab0527aa13544970,toxicity,0.305698
uuid-85a9772043674756ab0527aa13544970,regimen,0.381309
uuid-85a9772043674756ab0527aa13544970,treated,0.396646
uuid-85a9772043674756ab0527aa13544970,chemo,0.370307
uuid-85a9772043674756ab0527aa13544970,tumor,0.515333
uuid-85a9772043674756ab0527aa13544970,pts,0.560784
uuid-85a9772043674756ab0527aa13544970,treatment,0.606333
uuid-85a9772043674756ab0527aa13544970,response,0.649746
uuid-85a9772043674756ab0527aa13544970,PD1,0.311827
uuid-85a9772043674756ab0527aa13544970,progression,0.678217
uuid-85a9772043674756ab0527aa13544970,chemotherapy,0.325973
uuid-85a9772043674756ab0527aa13544970,respond,0.562356
uuid-85a9772043674756ab0527aa13544970,immunotherapy,0.327312
uuid-ca37f496156b4af7923b1d17f5503f00,Nivo,0.327839
uuid-ca37f496156b4af7923b1d17f5503f00,pembro,0.365803
uuid-ca37f496156b4af7923b1d17f5503f00,1L,0.373451
uuid-ca37f496156b4af7923b1d17f5503f00,trial,0.300471
uuid-ca37f496156b4af7923b1d17f5503f00,2L,0.3411
uuid-ca37f496156b4af7923b1d17f5503f00,atezo,0.311737
uuid-ca37f496156b4af7923b1d17f5503f00,preferred,0.441677
uuid-ca37f496156b4af7923b1d17f5503f00,feels,0.375364
uuid-ca37f496156b4af7923b1d17f5503f00,option,0.373095
uuid-b8c8846a115546c4943fe2d4178a44e5,Nivo,0.347759
uuid-b8c8846a115546c4943fe2d4178a44e5,pembro,0.611684
uuid-b8c8846a115546c4943fe2d4178a44e5,NSCLC,0.460015
uuid-b8c8846a115546c4943fe2d4178a44e5,1L,0.431059
uuid-b8c8846a115546c4943fe2d4178a44e5,2L,0.516537
uuid-b8c8846a115546c4943fe2d4178a44e5,agents,0.403803
uuid-b8c8846a115546c4943fe2d4178a44e5,approval,0.324117
uuid-b8c8846a115546c4943fe2d4178a44e5,atezo,0.647066
uuid-b8c8846a115546c4943fe2d4178a44e5,preferred,0.564853
uuid-b8c8846a115546c4943fe2d4178a44e5,using nivo,0.439148
uuid-b8c8846a115546c4943fe2d4178a44e5,indication,0.420413
uuid-b8c8846a115546c4943fe2d4178a44e5,approved,0.342407
uuid-b8c8846a115546c4943fe2d4178a44e5,nivo and pembro,0.360812
uuid-b8c8846a115546c4943fe2d4178a44e5,vs,0.378485
uuid-b8c8846a115546c4943fe2d4178a44e5,RTL stated,0.328649
uuid-1befa4cb2ffe49b5a2682d60e9d54899,Nivo,0.358839
uuid-1befa4cb2ffe49b5a2682d60e9d54899,pembro,0.497108
uuid-1befa4cb2ffe49b5a2682d60e9d54899,NSCLC,0.428146
uuid-1befa4cb2ffe49b5a2682d60e9d54899,1L,0.649671
uuid-1befa4cb2ffe49b5a2682d60e9d54899,combination,0.329173
uuid-1befa4cb2ffe49b5a2682d60e9d54899,chemo,0.304428
uuid-1befa4cb2ffe49b5a2682d60e9d54899,2L,0.645033
uuid-1befa4cb2ffe49b5a2682d60e9d54899,IO,0.370253
uuid-1befa4cb2ffe49b5a2682d60e9d54899,agents,0.404202
uuid-1befa4cb2ffe49b5a2682d60e9d54899,Ipi,0.311923
uuid-1befa4cb2ffe49b5a2682d60e9d54899,approval,0.401837
uuid-1befa4cb2ffe49b5a2682d60e9d54899,atezo,0.581276
uuid-1befa4cb2ffe49b5a2682d60e9d54899,preferred,0.553848
uuid-1befa4cb2ffe49b5a2682d60e9d54899,monotherapy,0.524883
uuid-1befa4cb2ffe49b5a2682d60e9d54899,using nivo,0.398186
uuid-1befa4cb2ffe49b5a2682d60e9d54899,combo,0.464802
uuid-1befa4cb2ffe49b5a2682d60e9d54899,indication,0.319291
uuid-1befa4cb2ffe49b5a2682d60e9d54899,approved,0.54371
uuid-1befa4cb2ffe49b5a2682d60e9d54899,RTL stated,0.325524
uuid-1befa4cb2ffe49b5a2682d60e9d54899,option,0.472372
uuid-7368e3c06b6b4cc5a60478a508b40feb,RTL,0.379053
uuid-7368e3c06b6b4cc5a60478a508b40feb,NSCLC,0.300324
uuid-7368e3c06b6b4cc5a60478a508b40feb,efficacy,0.326561
uuid-7368e3c06b6b4cc5a60478a508b40feb,discussed,0.310162
uuid-7368e3c06b6b4cc5a60478a508b40feb,commented,0.547287
uuid-7368e3c06b6b4cc5a60478a508b40feb,OS,0.545137
uuid-7368e3c06b6b4cc5a60478a508b40feb,data,0.660735
uuid-7368e3c06b6b4cc5a60478a508b40feb,PFS,0.450275
uuid-7368e3c06b6b4cc5a60478a508b40feb,ORR,0.546243
uuid-7368e3c06b6b4cc5a60478a508b40feb,ASCO,0.560948
uuid-7368e3c06b6b4cc5a60478a508b40feb,impressed,0.745347
uuid-7368e3c06b6b4cc5a60478a508b40feb,LTL,0.306219
uuid-7368e3c06b6b4cc5a60478a508b40feb,TLs,0.420969
uuid-7368e3c06b6b4cc5a60478a508b40feb,Regional TL,0.40801
uuid-362300dee0b741c495feb8488b7babca,TL,0.303105
uuid-362300dee0b741c495feb8488b7babca,shared,0.308884
uuid-362300dee0b741c495feb8488b7babca,oncology,0.353373
uuid-362300dee0b741c495feb8488b7babca,indicated,0.363841
uuid-362300dee0b741c495feb8488b7babca,flat dosing,0.390257
uuid-2b316b5a95a5440c975878ca6cdd661f,Opdivo,0.558268
uuid-2b316b5a95a5440c975878ca6cdd661f,dose,0.551811
uuid-2b316b5a95a5440c975878ca6cdd661f,shared,0.342046
uuid-2b316b5a95a5440c975878ca6cdd661f,physicians,0.435629
uuid-2b316b5a95a5440c975878ca6cdd661f,oncology,0.309948
uuid-2b316b5a95a5440c975878ca6cdd661f,drug,0.558358
uuid-2b316b5a95a5440c975878ca6cdd661f,Keytruda,0.428087
uuid-2b316b5a95a5440c975878ca6cdd661f,flat dosing,0.685593
uuid-8e0e900affdd4158bfb0451ec2dd38ef,1L,0.317941
uuid-8e0e900affdd4158bfb0451ec2dd38ef,RCC,0.414653
uuid-8e0e900affdd4158bfb0451ec2dd38ef,TL stated,0.355788
uuid-8e0e900affdd4158bfb0451ec2dd38ef,PD-L1,0.363182
uuid-8e0e900affdd4158bfb0451ec2dd38ef,preferred,0.307109
uuid-8e0e900affdd4158bfb0451ec2dd38ef,PD-L1 testing,0.427807
uuid-8e0e900affdd4158bfb0451ec2dd38ef,testing,0.420232
uuid-8e0e900affdd4158bfb0451ec2dd38ef,PDL1 testing,0.458871
uuid-8e0e900affdd4158bfb0451ec2dd38ef,NSCLC patients,0.40203
uuid-8e0e900affdd4158bfb0451ec2dd38ef,SCCHN,0.331638
uuid-8e0e900affdd4158bfb0451ec2dd38ef,RTL stated,0.343663
uuid-a36296ec9d70413da9cb8a1c4a1519be,pembro,0.327987
uuid-a36296ec9d70413da9cb8a1c4a1519be,lung,0.379531
uuid-a36296ec9d70413da9cb8a1c4a1519be,1L,0.556148
uuid-a36296ec9d70413da9cb8a1c4a1519be,RCC,0.77318
uuid-a36296ec9d70413da9cb8a1c4a1519be,TL stated,0.439855
uuid-a36296ec9d70413da9cb8a1c4a1519be,2L,0.621822
uuid-a36296ec9d70413da9cb8a1c4a1519be,stated,0.439028
uuid-a36296ec9d70413da9cb8a1c4a1519be,approval,0.467641
uuid-a36296ec9d70413da9cb8a1c4a1519be,atezo,0.357031
uuid-a36296ec9d70413da9cb8a1c4a1519be,preferred,0.526679
uuid-a36296ec9d70413da9cb8a1c4a1519be,monotherapy,0.306646
uuid-a36296ec9d70413da9cb8a1c4a1519be,using nivo,0.630162
uuid-a36296ec9d70413da9cb8a1c4a1519be,clinical trials,0.336943
uuid-a36296ec9d70413da9cb8a1c4a1519be,PDL1 testing,0.418128
uuid-a36296ec9d70413da9cb8a1c4a1519be,indication,0.340509
uuid-a36296ec9d70413da9cb8a1c4a1519be,NSCLC patients,0.309228
uuid-a36296ec9d70413da9cb8a1c4a1519be,approved,0.507772
uuid-a36296ec9d70413da9cb8a1c4a1519be,SCCHN,0.631902
uuid-a36296ec9d70413da9cb8a1c4a1519be,tumor types,0.473975
uuid-a36296ec9d70413da9cb8a1c4a1519be,LTL,0.312526
uuid-a36296ec9d70413da9cb8a1c4a1519be,TLs,0.359467
uuid-a36296ec9d70413da9cb8a1c4a1519be,Regional TL,0.511613
uuid-a36296ec9d70413da9cb8a1c4a1519be,RTL stated,0.625895
uuid-a36296ec9d70413da9cb8a1c4a1519be,TL shared,0.474362
uuid-a36296ec9d70413da9cb8a1c4a1519be,option,0.390985
uuid-a36296ec9d70413da9cb8a1c4a1519be,bladder,0.513471
uuid-d0f437128079419bb820c963e5e1655c,patients,0.324096
uuid-d0f437128079419bb820c963e5e1655c,RTL,0.324538
uuid-d0f437128079419bb820c963e5e1655c,trial,0.42083
uuid-d0f437128079419bb820c963e5e1655c,commented,0.315757
uuid-d0f437128079419bb820c963e5e1655c,chemo,0.328683
uuid-d0f437128079419bb820c963e5e1655c,pts,0.389144
uuid-d0f437128079419bb820c963e5e1655c,OS,0.322615
uuid-d0f437128079419bb820c963e5e1655c,monotherapy,0.340913
uuid-d0f437128079419bb820c963e5e1655c,response,0.309784
uuid-d0f437128079419bb820c963e5e1655c,data,0.361116
uuid-d0f437128079419bb820c963e5e1655c,clinical trials,0.394334
uuid-d0f437128079419bb820c963e5e1655c,ORR,0.35535
uuid-d0f437128079419bb820c963e5e1655c,chemotherapy,0.324655
uuid-d0f437128079419bb820c963e5e1655c,impressed,0.473613
uuid-d0f437128079419bb820c963e5e1655c,feels,0.451349
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,patients,0.574955
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,therapy,0.302374
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,1L,0.478828
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,treated,0.46481
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,RCC,0.464451
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,TL stated,0.333111
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,2L,0.449473
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,pts,0.519186
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,preferred,0.394334
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,monotherapy,0.439631
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,treatment,0.391087
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,using nivo,0.447823
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,PDL1 testing,0.37418
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,NSCLC patients,0.490387
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,progression,0.388464
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,tumor types,0.301761
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,respond,0.309818
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,RTL stated,0.470942
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,TL shared,0.46335
uuid-b8ca5ab9b1244f6b8d29fcd0d0089231,option,0.445744
uuid-96a3d63118d94706baa76adffdf7b6c6,patients,0.333143
uuid-96a3d63118d94706baa76adffdf7b6c6,Opdivo,0.406922
uuid-96a3d63118d94706baa76adffdf7b6c6,TL,0.31417
uuid-96a3d63118d94706baa76adffdf7b6c6,pembro,0.3689
uuid-96a3d63118d94706baa76adffdf7b6c6,dose,0.738719
uuid-96a3d63118d94706baa76adffdf7b6c6,Ipi,0.38058
uuid-96a3d63118d94706baa76adffdf7b6c6,atezo,0.395919
uuid-96a3d63118d94706baa76adffdf7b6c6,vs,0.42912
uuid-96a3d63118d94706baa76adffdf7b6c6,Keytruda,0.37128
uuid-96a3d63118d94706baa76adffdf7b6c6,flat dosing,0.564446
uuid-5d9c44b349454029b79d93863128903c,RTL,0.81974
uuid-5d9c44b349454029b79d93863128903c,trial,0.380538
uuid-5d9c44b349454029b79d93863128903c,NTL,0.5369
uuid-5d9c44b349454029b79d93863128903c,melanoma,0.301042
uuid-5d9c44b349454029b79d93863128903c,shared,0.498874
uuid-5d9c44b349454029b79d93863128903c,commented,0.403451
uuid-5d9c44b349454029b79d93863128903c,institution,0.373852
uuid-5d9c44b349454029b79d93863128903c,stated,0.499005
uuid-5d9c44b349454029b79d93863128903c,expressed,0.337497
uuid-5d9c44b349454029b79d93863128903c,mentioned,0.387279
uuid-5d9c44b349454029b79d93863128903c,clinical trials,0.458073
uuid-5d9c44b349454029b79d93863128903c,SCCHN,0.571369
uuid-5d9c44b349454029b79d93863128903c,HCP,0.4599
uuid-5d9c44b349454029b79d93863128903c,impressed,0.37155
uuid-5d9c44b349454029b79d93863128903c,LTL,0.580486
uuid-5d9c44b349454029b79d93863128903c,TLs,0.410492
uuid-5d9c44b349454029b79d93863128903c,academic,0.480718
uuid-5d9c44b349454029b79d93863128903c,Regional TL,0.561876
uuid-5d9c44b349454029b79d93863128903c,RTL stated,0.389119
uuid-5d9c44b349454029b79d93863128903c,bladder,0.309683
uuid-d308a77cfaaa4879bd22be3c69185dde,BMS,0.596166
uuid-d308a77cfaaa4879bd22be3c69185dde,lung,0.367744
uuid-d308a77cfaaa4879bd22be3c69185dde,trial,0.342221
uuid-d308a77cfaaa4879bd22be3c69185dde,melanoma,0.333572
uuid-d308a77cfaaa4879bd22be3c69185dde,shared,0.314342
uuid-d308a77cfaaa4879bd22be3c69185dde,commented,0.382628
uuid-d308a77cfaaa4879bd22be3c69185dde,Merck,0.362274
uuid-d308a77cfaaa4879bd22be3c69185dde,regards,0.388337
uuid-d308a77cfaaa4879bd22be3c69185dde,data,0.309662
uuid-d308a77cfaaa4879bd22be3c69185dde,expressed,0.442526
uuid-d308a77cfaaa4879bd22be3c69185dde,AI,0.49175
uuid-d308a77cfaaa4879bd22be3c69185dde,NCCN,0.388068
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,toxicity,0.419226
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,efficacy,0.308826
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,combination,0.444191
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,agents,0.339248
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,combo,0.387667
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,believes,0.444468
uuid-bb35d20dad0d45d0b83bd354e8fd35f7,feels,0.374291
uuid-4da815fd663b462e8f40d3d0dab95737,pembro,0.538597
uuid-4da815fd663b462e8f40d3d0dab95737,lung,0.489998
uuid-4da815fd663b462e8f40d3d0dab95737,1L,0.595852
uuid-4da815fd663b462e8f40d3d0dab95737,trial,0.38504
uuid-4da815fd663b462e8f40d3d0dab95737,melanoma,0.390462
uuid-4da815fd663b462e8f40d3d0dab95737,RCC,0.552996
uuid-4da815fd663b462e8f40d3d0dab95737,TL stated,0.507589
uuid-4da815fd663b462e8f40d3d0dab95737,2L,0.538199
uuid-4da815fd663b462e8f40d3d0dab95737,pts,0.387089
uuid-4da815fd663b462e8f40d3d0dab95737,approval,0.381609
uuid-4da815fd663b462e8f40d3d0dab95737,atezo,0.432224
uuid-4da815fd663b462e8f40d3d0dab95737,preferred,0.358012
uuid-4da815fd663b462e8f40d3d0dab95737,monotherapy,0.333983
uuid-4da815fd663b462e8f40d3d0dab95737,using nivo,0.456244
uuid-4da815fd663b462e8f40d3d0dab95737,combo,0.413444
uuid-4da815fd663b462e8f40d3d0dab95737,PDL1 testing,0.350395
uuid-4da815fd663b462e8f40d3d0dab95737,NSCLC patients,0.342325
uuid-4da815fd663b462e8f40d3d0dab95737,approved,0.355977
uuid-4da815fd663b462e8f40d3d0dab95737,SCCHN,0.415657
uuid-4da815fd663b462e8f40d3d0dab95737,SCLC,0.334656
uuid-4da815fd663b462e8f40d3d0dab95737,RTL stated,0.489721
uuid-4da815fd663b462e8f40d3d0dab95737,TL shared,0.466905
uuid-4da815fd663b462e8f40d3d0dab95737,option,0.303008
uuid-4da815fd663b462e8f40d3d0dab95737,bladder,0.455567
uuid-25906a843c97496a84d1aee2005c90e8,Nivo,0.432639
uuid-25906a843c97496a84d1aee2005c90e8,trial,0.347894
uuid-25906a843c97496a84d1aee2005c90e8,efficacy,0.534696
uuid-25906a843c97496a84d1aee2005c90e8,regimen,0.300515
uuid-25906a843c97496a84d1aee2005c90e8,chemo,0.357625
uuid-25906a843c97496a84d1aee2005c90e8,Ipi,0.40304
uuid-25906a843c97496a84d1aee2005c90e8,OS,0.608383
uuid-25906a843c97496a84d1aee2005c90e8,monotherapy,0.308463
uuid-25906a843c97496a84d1aee2005c90e8,response,0.384868
uuid-25906a843c97496a84d1aee2005c90e8,data,0.508953
uuid-25906a843c97496a84d1aee2005c90e8,combo,0.353529
uuid-25906a843c97496a84d1aee2005c90e8,PFS,0.548076
uuid-25906a843c97496a84d1aee2005c90e8,PD1,0.379649
uuid-25906a843c97496a84d1aee2005c90e8,ORR,0.70795
uuid-25906a843c97496a84d1aee2005c90e8,nivo and pembro,0.318107
uuid-25906a843c97496a84d1aee2005c90e8,ASCO,0.330063
uuid-25906a843c97496a84d1aee2005c90e8,chemotherapy,0.343864
uuid-25906a843c97496a84d1aee2005c90e8,impressed,0.578348
uuid-25906a843c97496a84d1aee2005c90e8,SCLC,0.304693
uuid-25906a843c97496a84d1aee2005c90e8,feels,0.32417
uuid-fc010ccb219148f092ebb8f33a7e361a,patients,0.57801
uuid-fc010ccb219148f092ebb8f33a7e361a,Opdivo,0.768503
uuid-fc010ccb219148f092ebb8f33a7e361a,therapy,0.477142
uuid-fc010ccb219148f092ebb8f33a7e361a,nivolumab,0.475097
uuid-fc010ccb219148f092ebb8f33a7e361a,regimen,0.343018
uuid-fc010ccb219148f092ebb8f33a7e361a,treated,0.475101
uuid-fc010ccb219148f092ebb8f33a7e361a,treatment,0.548611
uuid-fc010ccb219148f092ebb8f33a7e361a,using nivo,0.312361
uuid-fc010ccb219148f092ebb8f33a7e361a,cHL,0.501953
uuid-fc010ccb219148f092ebb8f33a7e361a,progression,0.367716
uuid-fc010ccb219148f092ebb8f33a7e361a,Keytruda,0.319009
uuid-b3e9037b62394eca935a0fb0d915638a,patients,0.472286
uuid-b3e9037b62394eca935a0fb0d915638a,Opdivo,0.701268
uuid-b3e9037b62394eca935a0fb0d915638a,dose,0.388629
uuid-b3e9037b62394eca935a0fb0d915638a,nivolumab,0.312165
uuid-b3e9037b62394eca935a0fb0d915638a,approval,0.401809
uuid-b3e9037b62394eca935a0fb0d915638a,physicians,0.331721
uuid-b3e9037b62394eca935a0fb0d915638a,treatment,0.319858
uuid-b3e9037b62394eca935a0fb0d915638a,indication,0.300398
uuid-b3e9037b62394eca935a0fb0d915638a,approved,0.448434
uuid-b3e9037b62394eca935a0fb0d915638a,label,0.439837
uuid-b3e9037b62394eca935a0fb0d915638a,Keytruda,0.388235
uuid-b3e9037b62394eca935a0fb0d915638a,flat dosing,0.611396
uuid-4318554bad014c83800b286b035570c8,therapy,0.363494
uuid-4318554bad014c83800b286b035570c8,vs,0.365968
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,TL,0.327575
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,1L,0.32393
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PDL1,0.531343
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,TL stated,0.374463
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PD-L1,0.835684
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PD-L1 testing,0.70416
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,testing,0.889224
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PDL1 testing,0.670904
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,NSCLC patients,0.713548
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,assay,0.6142
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PD-1,0.478281
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,PDL1 expression,0.33698
uuid-1e34719530ed4f0fb74d6c53a2f1bc95,biomarker,0.608857
uuid-ca04fbc150bd446aa588b2d057cd5200,TL,0.380483
uuid-ca04fbc150bd446aa588b2d057cd5200,PDL1,0.582471
uuid-ca04fbc150bd446aa588b2d057cd5200,TL stated,0.345654
uuid-ca04fbc150bd446aa588b2d057cd5200,PD-L1,0.854551
uuid-ca04fbc150bd446aa588b2d057cd5200,PD-L1 testing,0.718364
uuid-ca04fbc150bd446aa588b2d057cd5200,testing,0.903456
uuid-ca04fbc150bd446aa588b2d057cd5200,PDL1 testing,0.686895
uuid-ca04fbc150bd446aa588b2d057cd5200,NSCLC patients,0.665774
uuid-ca04fbc150bd446aa588b2d057cd5200,assay,0.689044
uuid-ca04fbc150bd446aa588b2d057cd5200,PD-1,0.457327
uuid-ca04fbc150bd446aa588b2d057cd5200,PDL1 expression,0.418451
uuid-ca04fbc150bd446aa588b2d057cd5200,biomarker,0.676428
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,Opdivo,0.316577
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,therapy,0.350791
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,toxicity,0.455045
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,treated,0.303199
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,treatment,0.338845
uuid-c4d86bfd2b1c4ad1aa5b2dc12bd6a797,cHL,0.483241
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,BMS,0.58308
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,PDL1,0.357192
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,trial,0.350513
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,efficacy,0.334864
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,commented,0.499176
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,Merck,0.483417
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,stated,0.401755
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,OS,0.394497
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,regards,0.400427
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,data,0.76126
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,expressed,0.400349
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,PFS,0.361328
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,ORR,0.407212
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,nivo and pembro,0.339732
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,ASCO,0.367398
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,impressed,0.538599
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,Regional TL,0.32396
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,PDL1 expression,0.315613
uuid-ed0449f7f1cc410d9e9e4b3a56f7c66f,NCCN,0.492235
uuid-f9130ce7a82f4d019eabd85a19641cf5,pembro,0.344826
uuid-f9130ce7a82f4d019eabd85a19641cf5,dose,0.500216
uuid-f9130ce7a82f4d019eabd85a19641cf5,NSCLC,0.318995
uuid-f9130ce7a82f4d019eabd85a19641cf5,trial,0.390148
uuid-f9130ce7a82f4d019eabd85a19641cf5,efficacy,0.304559
uuid-f9130ce7a82f4d019eabd85a19641cf5,Ipi,0.451346
uuid-f9130ce7a82f4d019eabd85a19641cf5,atezo,0.339622
uuid-f9130ce7a82f4d019eabd85a19641cf5,data,0.304147
uuid-f9130ce7a82f4d019eabd85a19641cf5,vs,0.48149
uuid-f9130ce7a82f4d019eabd85a19641cf5,flat dosing,0.446645
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,RTL,0.334911
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,lung,0.407643
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,trial,0.314506
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,NTL,0.423052
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,melanoma,0.478173
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,RCC,0.380099
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,ASCO,0.409947
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,SCLC,0.343491
uuid-4b15574f4e584dd1b6dea0cd0049d6ef,TL shared,0.397837
uuid-16e55b2a074f4941a6f93656b63cc59b,RTL,0.366398
uuid-16e55b2a074f4941a6f93656b63cc59b,BMS,0.636974
uuid-16e55b2a074f4941a6f93656b63cc59b,lung,0.305254
uuid-16e55b2a074f4941a6f93656b63cc59b,trial,0.442473
uuid-16e55b2a074f4941a6f93656b63cc59b,efficacy,0.311228
uuid-16e55b2a074f4941a6f93656b63cc59b,NTL,0.313013
uuid-16e55b2a074f4941a6f93656b63cc59b,discussed,0.355001
uuid-16e55b2a074f4941a6f93656b63cc59b,commented,0.538171
uuid-16e55b2a074f4941a6f93656b63cc59b,Merck,0.400602
uuid-16e55b2a074f4941a6f93656b63cc59b,stated,0.360126
uuid-16e55b2a074f4941a6f93656b63cc59b,OS,0.38233
uuid-16e55b2a074f4941a6f93656b63cc59b,regards,0.542208
uuid-16e55b2a074f4941a6f93656b63cc59b,data,0.568411
uuid-16e55b2a074f4941a6f93656b63cc59b,expressed,0.428295
uuid-16e55b2a074f4941a6f93656b63cc59b,PFS,0.339633
uuid-16e55b2a074f4941a6f93656b63cc59b,ORR,0.379438
uuid-16e55b2a074f4941a6f93656b63cc59b,ASCO,0.349302
uuid-16e55b2a074f4941a6f93656b63cc59b,impressed,0.580464
uuid-16e55b2a074f4941a6f93656b63cc59b,TLs,0.459602
uuid-998a097cc58f4536aecc3eec576393f0,RTL,0.376687
uuid-998a097cc58f4536aecc3eec576393f0,therapy,0.327593
uuid-998a097cc58f4536aecc3eec576393f0,nivolumab,0.57098
uuid-998a097cc58f4536aecc3eec576393f0,treated,0.422768
uuid-998a097cc58f4536aecc3eec576393f0,NTL,0.557413
uuid-998a097cc58f4536aecc3eec576393f0,treatment,0.323173
uuid-998a097cc58f4536aecc3eec576393f0,PD1,0.358739
uuid-998a097cc58f4536aecc3eec576393f0,cHL,0.40597
uuid-998a097cc58f4536aecc3eec576393f0,chemotherapy,0.308876
uuid-edc834f3d715408dac90193707f27291,patients,0.675626
uuid-edc834f3d715408dac90193707f27291,Opdivo,0.399395
uuid-edc834f3d715408dac90193707f27291,therapy,0.486925
uuid-edc834f3d715408dac90193707f27291,nivolumab,0.499291
uuid-edc834f3d715408dac90193707f27291,treated,0.526722
uuid-edc834f3d715408dac90193707f27291,pts,0.308585
uuid-edc834f3d715408dac90193707f27291,treatment,0.553789
uuid-edc834f3d715408dac90193707f27291,cHL,0.505963
uuid-edc834f3d715408dac90193707f27291,progression,0.443394
uuid-edc834f3d715408dac90193707f27291,respond,0.398868
uuid-a781364d05264f93be32cfa2c7236c35,RTL,0.509533
uuid-a781364d05264f93be32cfa2c7236c35,nivolumab,0.461516
uuid-a781364d05264f93be32cfa2c7236c35,trial,0.393837
uuid-a781364d05264f93be32cfa2c7236c35,NTL,0.610762
uuid-a781364d05264f93be32cfa2c7236c35,mentioned,0.431118
uuid-a781364d05264f93be32cfa2c7236c35,cHL,0.420694
uuid-a781364d05264f93be32cfa2c7236c35,indicated,0.312831
uuid-a781364d05264f93be32cfa2c7236c35,LTL,0.330596
uuid-a781364d05264f93be32cfa2c7236c35,Regional TL,0.448824
uuid-7dab0f52bcc8441d84991eb4b0a1c28f,RTL,0.313842
uuid-7dab0f52bcc8441d84991eb4b0a1c28f,NTL,0.528405
uuid-7dab0f52bcc8441d84991eb4b0a1c28f,discussed,0.330906
uuid-7dab0f52bcc8441d84991eb4b0a1c28f,cHL,0.315162
uuid-7dab0f52bcc8441d84991eb4b0a1c28f,indicated,0.403599
uuid-e68f01e689a3443d93dffc7671973f54,Opdivo,0.39212
uuid-e68f01e689a3443d93dffc7671973f54,1L,0.330724
uuid-e68f01e689a3443d93dffc7671973f54,shared,0.384471
uuid-e68f01e689a3443d93dffc7671973f54,2L,0.393557
uuid-e68f01e689a3443d93dffc7671973f54,institution,0.336998
uuid-e68f01e689a3443d93dffc7671973f54,preferred,0.510319
uuid-e68f01e689a3443d93dffc7671973f54,testing,0.313665
uuid-e68f01e689a3443d93dffc7671973f54,PDL1 testing,0.397154
uuid-e68f01e689a3443d93dffc7671973f54,approved,0.394028
uuid-e68f01e689a3443d93dffc7671973f54,Keytruda,0.391942
uuid-e68f01e689a3443d93dffc7671973f54,option,0.380585
uuid-19f584e52d2640cda8740756c78e4dbf,BMS,0.35255
uuid-19f584e52d2640cda8740756c78e4dbf,commented,0.368259
uuid-19f584e52d2640cda8740756c78e4dbf,regards,0.31994
uuid-19f584e52d2640cda8740756c78e4dbf,data,0.457566
uuid-19f584e52d2640cda8740756c78e4dbf,nivo and pembro,0.344314
uuid-19f584e52d2640cda8740756c78e4dbf,believes,0.355906
uuid-19f584e52d2640cda8740756c78e4dbf,feels,0.488735
uuid-a66890854b0a45a2bdcbff259e8f30fa,patients,0.813426
uuid-a66890854b0a45a2bdcbff259e8f30fa,Opdivo,0.458103
uuid-a66890854b0a45a2bdcbff259e8f30fa,therapy,0.605279
uuid-a66890854b0a45a2bdcbff259e8f30fa,nivolumab,0.387473
uuid-a66890854b0a45a2bdcbff259e8f30fa,regimen,0.454977
uuid-a66890854b0a45a2bdcbff259e8f30fa,treated,0.499325
uuid-a66890854b0a45a2bdcbff259e8f30fa,chemo,0.437766
uuid-a66890854b0a45a2bdcbff259e8f30fa,pts,0.584197
uuid-a66890854b0a45a2bdcbff259e8f30fa,monotherapy,0.338476
uuid-a66890854b0a45a2bdcbff259e8f30fa,treatment,0.700811
uuid-a66890854b0a45a2bdcbff259e8f30fa,response,0.381802
uuid-a66890854b0a45a2bdcbff259e8f30fa,PD1,0.317923
uuid-a66890854b0a45a2bdcbff259e8f30fa,progression,0.622572
uuid-a66890854b0a45a2bdcbff259e8f30fa,chemotherapy,0.529736
uuid-a66890854b0a45a2bdcbff259e8f30fa,respond,0.513574
uuid-a66890854b0a45a2bdcbff259e8f30fa,immunotherapy,0.397329
uuid-a66890854b0a45a2bdcbff259e8f30fa,option,0.439183
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,Nivo,0.360103
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,patients,0.874996
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,Opdivo,0.415968
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,therapy,0.712795
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,nivolumab,0.64182
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,regimen,0.487675
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,treated,0.548992
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,combination,0.304525
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,chemo,0.463985
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,pts,0.58571
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,preferred,0.3622
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,monotherapy,0.513639
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,treatment,0.683642
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,using nivo,0.423623
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,response,0.328276
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,PD1,0.430227
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,cHL,0.387669
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,progression,0.594687
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,chemotherapy,0.519808
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,respond,0.442797
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,RTL stated,0.30901
uuid-f9d2fb77f57b4a7b83ec0ee6567f2a09,option,0.556915
uuid-c04652d8e4b8495297f276bc9a301069,patients,0.367838
uuid-c04652d8e4b8495297f276bc9a301069,Opdivo,0.306832
uuid-c04652d8e4b8495297f276bc9a301069,toxicity,0.38612
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,Opdivo,0.431278
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,shared,0.461103
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,physicians,0.595852
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,oncology,0.302212
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,HCP,0.302941
uuid-b92e0ebf1bbd44c7bdfe55dd3b8125a4,Keytruda,0.325734
uuid-61f2c95f2ed84fc5bce41e61b67f3a64,tumor,0.729872
uuid-61f2c95f2ed84fc5bce41e61b67f3a64,response,0.32988
uuid-3182b7505c2f4d0282c085db0406b58e,Nivo,0.361208
uuid-3182b7505c2f4d0282c085db0406b58e,patients,0.378875
uuid-3182b7505c2f4d0282c085db0406b58e,therapy,0.838113
uuid-3182b7505c2f4d0282c085db0406b58e,nivolumab,0.545015
uuid-3182b7505c2f4d0282c085db0406b58e,treated,0.323243
uuid-3182b7505c2f4d0282c085db0406b58e,combination,0.448195
uuid-3182b7505c2f4d0282c085db0406b58e,chemo,0.4939
uuid-3182b7505c2f4d0282c085db0406b58e,monotherapy,0.385827
uuid-3182b7505c2f4d0282c085db0406b58e,treatment,0.467244
uuid-3182b7505c2f4d0282c085db0406b58e,response,0.390209
uuid-3182b7505c2f4d0282c085db0406b58e,PD1,0.505841
uuid-3182b7505c2f4d0282c085db0406b58e,cHL,0.492136
uuid-3182b7505c2f4d0282c085db0406b58e,progression,0.451721
uuid-3182b7505c2f4d0282c085db0406b58e,chemotherapy,0.600703
uuid-3182b7505c2f4d0282c085db0406b58e,PD-1,0.366356
uuid-7a1163b492aa48458ed47ead92df49bf,patients,0.427487
uuid-7a1163b492aa48458ed47ead92df49bf,nivolumab,0.355726
uuid-7a1163b492aa48458ed47ead92df49bf,regimen,0.354126
uuid-7a1163b492aa48458ed47ead92df49bf,treated,0.412812
uuid-7a1163b492aa48458ed47ead92df49bf,shared,0.347136
uuid-7a1163b492aa48458ed47ead92df49bf,RCC,0.32661
uuid-7a1163b492aa48458ed47ead92df49bf,pts,0.321934
uuid-7a1163b492aa48458ed47ead92df49bf,preferred,0.432401
uuid-7a1163b492aa48458ed47ead92df49bf,monotherapy,0.335529
uuid-7a1163b492aa48458ed47ead92df49bf,treatment,0.301437
uuid-7a1163b492aa48458ed47ead92df49bf,using nivo,0.320215
uuid-7a1163b492aa48458ed47ead92df49bf,RTL stated,0.448906
uuid-7a1163b492aa48458ed47ead92df49bf,option,0.377909
uuid-a26584953ec0498bad475731a381eb83,discussed,0.549601
uuid-a26584953ec0498bad475731a381eb83,academic,0.525844
uuid-a26584953ec0498bad475731a381eb83,feels,0.343686
uuid-9fa11d2015a646c5989d88ce514ec20c,BMS,0.475909
uuid-9fa11d2015a646c5989d88ce514ec20c,PDL1,0.422729
uuid-9fa11d2015a646c5989d88ce514ec20c,trial,0.653118
uuid-9fa11d2015a646c5989d88ce514ec20c,efficacy,0.549916
uuid-9fa11d2015a646c5989d88ce514ec20c,chemo,0.319248
uuid-9fa11d2015a646c5989d88ce514ec20c,OS,0.394994
uuid-9fa11d2015a646c5989d88ce514ec20c,data,0.441791
uuid-9fa11d2015a646c5989d88ce514ec20c,PFS,0.438406
uuid-9fa11d2015a646c5989d88ce514ec20c,ORR,0.493898
uuid-9fa11d2015a646c5989d88ce514ec20c,nivo and pembro,0.371861
uuid-9fa11d2015a646c5989d88ce514ec20c,believes,0.387164
uuid-9fa11d2015a646c5989d88ce514ec20c,feels,0.457595
uuid-9fa11d2015a646c5989d88ce514ec20c,PDL1 expression,0.462996
uuid-797648b8e60544eea3fdb9aed974be1e,patients,0.904962
uuid-797648b8e60544eea3fdb9aed974be1e,Opdivo,0.546798
uuid-797648b8e60544eea3fdb9aed974be1e,therapy,0.549813
uuid-797648b8e60544eea3fdb9aed974be1e,nivolumab,0.422335
uuid-797648b8e60544eea3fdb9aed974be1e,regimen,0.585249
uuid-797648b8e60544eea3fdb9aed974be1e,treated,0.584589
uuid-797648b8e60544eea3fdb9aed974be1e,chemo,0.320021
uuid-797648b8e60544eea3fdb9aed974be1e,pts,0.606159
uuid-797648b8e60544eea3fdb9aed974be1e,monotherapy,0.384284
uuid-797648b8e60544eea3fdb9aed974be1e,treatment,0.752498
uuid-797648b8e60544eea3fdb9aed974be1e,using nivo,0.302538
uuid-797648b8e60544eea3fdb9aed974be1e,response,0.385645
uuid-797648b8e60544eea3fdb9aed974be1e,progression,0.747954
uuid-797648b8e60544eea3fdb9aed974be1e,chemotherapy,0.343628
uuid-797648b8e60544eea3fdb9aed974be1e,respond,0.55721
uuid-797648b8e60544eea3fdb9aed974be1e,option,0.37221
uuid-5f5a280ee77c4473bfa15386467e9665,patients,0.743645
uuid-5f5a280ee77c4473bfa15386467e9665,Opdivo,0.625561
uuid-5f5a280ee77c4473bfa15386467e9665,therapy,0.33932
uuid-5f5a280ee77c4473bfa15386467e9665,nivolumab,0.517997
uuid-5f5a280ee77c4473bfa15386467e9665,treated,0.500056
uuid-5f5a280ee77c4473bfa15386467e9665,RCC,0.390225
uuid-5f5a280ee77c4473bfa15386467e9665,2L,0.302626
uuid-5f5a280ee77c4473bfa15386467e9665,pts,0.462409
uuid-5f5a280ee77c4473bfa15386467e9665,approval,0.582105
uuid-5f5a280ee77c4473bfa15386467e9665,preferred,0.308623
uuid-5f5a280ee77c4473bfa15386467e9665,treatment,0.478305
uuid-5f5a280ee77c4473bfa15386467e9665,using nivo,0.54492
uuid-5f5a280ee77c4473bfa15386467e9665,approved,0.435071
uuid-5f5a280ee77c4473bfa15386467e9665,SCCHN,0.480956
uuid-5f5a280ee77c4473bfa15386467e9665,cHL,0.337434
uuid-5f5a280ee77c4473bfa15386467e9665,progression,0.364367
uuid-5f5a280ee77c4473bfa15386467e9665,label,0.322599
uuid-5f5a280ee77c4473bfa15386467e9665,RTL stated,0.434253
uuid-5f5a280ee77c4473bfa15386467e9665,TL shared,0.342084
uuid-5f5a280ee77c4473bfa15386467e9665,option,0.332202
uuid-5f5a280ee77c4473bfa15386467e9665,bladder,0.322776
uuid-f3e47458eef54748974e6fd6e65db13b,TL,0.315267
uuid-f3e47458eef54748974e6fd6e65db13b,PDL1,0.567408
uuid-f3e47458eef54748974e6fd6e65db13b,TL stated,0.43279
uuid-f3e47458eef54748974e6fd6e65db13b,Merck,0.371785
uuid-f3e47458eef54748974e6fd6e65db13b,PD-L1,0.547633
uuid-f3e47458eef54748974e6fd6e65db13b,PD-L1 testing,0.377908
uuid-f3e47458eef54748974e6fd6e65db13b,testing,0.583001
uuid-f3e47458eef54748974e6fd6e65db13b,PDL1 testing,0.545838
uuid-f3e47458eef54748974e6fd6e65db13b,NSCLC patients,0.367306
uuid-f3e47458eef54748974e6fd6e65db13b,believes,0.311759
uuid-f3e47458eef54748974e6fd6e65db13b,tumor types,0.328725
uuid-f3e47458eef54748974e6fd6e65db13b,assay,0.485872
uuid-f3e47458eef54748974e6fd6e65db13b,PDL1 expression,0.341752
uuid-f3e47458eef54748974e6fd6e65db13b,biomarker,0.483858
uuid-904c898cea88477786c1e30c90f6173f,Nivo,0.615789
uuid-904c898cea88477786c1e30c90f6173f,pembro,0.726679
uuid-904c898cea88477786c1e30c90f6173f,BMS,0.36282
uuid-904c898cea88477786c1e30c90f6173f,1L,0.353742
uuid-904c898cea88477786c1e30c90f6173f,trial,0.537433
uuid-904c898cea88477786c1e30c90f6173f,efficacy,0.501977
uuid-904c898cea88477786c1e30c90f6173f,2L,0.380404
uuid-904c898cea88477786c1e30c90f6173f,agents,0.310116
uuid-904c898cea88477786c1e30c90f6173f,Merck,0.332116
uuid-904c898cea88477786c1e30c90f6173f,Ipi,0.305459
uuid-904c898cea88477786c1e30c90f6173f,approval,0.416076
uuid-904c898cea88477786c1e30c90f6173f,OS,0.339869
uuid-904c898cea88477786c1e30c90f6173f,atezo,0.606117
uuid-904c898cea88477786c1e30c90f6173f,preferred,0.340754
uuid-904c898cea88477786c1e30c90f6173f,using nivo,0.427031
uuid-904c898cea88477786c1e30c90f6173f,data,0.640056
uuid-904c898cea88477786c1e30c90f6173f,clinical trials,0.341711
uuid-904c898cea88477786c1e30c90f6173f,indication,0.473372
uuid-904c898cea88477786c1e30c90f6173f,PFS,0.331291
uuid-904c898cea88477786c1e30c90f6173f,ORR,0.386308
uuid-904c898cea88477786c1e30c90f6173f,approved,0.446945
uuid-904c898cea88477786c1e30c90f6173f,nivo and pembro,0.526264
uuid-904c898cea88477786c1e30c90f6173f,impressed,0.47227
uuid-904c898cea88477786c1e30c90f6173f,vs,0.429029
uuid-904c898cea88477786c1e30c90f6173f,label,0.320521
uuid-904c898cea88477786c1e30c90f6173f,feels,0.477152
uuid-904c898cea88477786c1e30c90f6173f,option,0.302351
uuid-763b965fc8654869890da8bf1665e9b4,patients,0.463301
uuid-763b965fc8654869890da8bf1665e9b4,Opdivo,0.457075
uuid-763b965fc8654869890da8bf1665e9b4,dose,0.465815
uuid-763b965fc8654869890da8bf1665e9b4,toxicity,0.437636
uuid-763b965fc8654869890da8bf1665e9b4,regimen,0.524816
uuid-763b965fc8654869890da8bf1665e9b4,treated,0.304206
uuid-763b965fc8654869890da8bf1665e9b4,physicians,0.449316
uuid-763b965fc8654869890da8bf1665e9b4,treatment,0.520572
uuid-763b965fc8654869890da8bf1665e9b4,progression,0.312137
uuid-763b965fc8654869890da8bf1665e9b4,respond,0.335836
uuid-763b965fc8654869890da8bf1665e9b4,drug,0.337925
uuid-d4edf507678a4272a0e5704558cdd7c6,Nivo,0.522569
uuid-d4edf507678a4272a0e5704558cdd7c6,patients,0.597796
uuid-d4edf507678a4272a0e5704558cdd7c6,Opdivo,0.324034
uuid-d4edf507678a4272a0e5704558cdd7c6,pembro,0.432156
uuid-d4edf507678a4272a0e5704558cdd7c6,therapy,0.480417
uuid-d4edf507678a4272a0e5704558cdd7c6,nivolumab,0.49138
uuid-d4edf507678a4272a0e5704558cdd7c6,1L,0.687358
uuid-d4edf507678a4272a0e5704558cdd7c6,regimen,0.451259
uuid-d4edf507678a4272a0e5704558cdd7c6,treated,0.356494
uuid-d4edf507678a4272a0e5704558cdd7c6,RCC,0.476913
uuid-d4edf507678a4272a0e5704558cdd7c6,combination,0.33443
uuid-d4edf507678a4272a0e5704558cdd7c6,chemo,0.42438
uuid-d4edf507678a4272a0e5704558cdd7c6,2L,0.789854
uuid-d4edf507678a4272a0e5704558cdd7c6,pts,0.491332
uuid-d4edf507678a4272a0e5704558cdd7c6,agents,0.38588
uuid-d4edf507678a4272a0e5704558cdd7c6,approval,0.403115
uuid-d4edf507678a4272a0e5704558cdd7c6,atezo,0.410127
uuid-d4edf507678a4272a0e5704558cdd7c6,preferred,0.728992
uuid-d4edf507678a4272a0e5704558cdd7c6,monotherapy,0.695775
uuid-d4edf507678a4272a0e5704558cdd7c6,treatment,0.462334
uuid-d4edf507678a4272a0e5704558cdd7c6,using nivo,0.728096
uuid-d4edf507678a4272a0e5704558cdd7c6,combo,0.369751
uuid-d4edf507678a4272a0e5704558cdd7c6,NSCLC patients,0.328933
uuid-d4edf507678a4272a0e5704558cdd7c6,PD1,0.402466
uuid-d4edf507678a4272a0e5704558cdd7c6,approved,0.526526
uuid-d4edf507678a4272a0e5704558cdd7c6,progression,0.361476
uuid-d4edf507678a4272a0e5704558cdd7c6,chemotherapy,0.346853
uuid-d4edf507678a4272a0e5704558cdd7c6,RTL stated,0.591481
uuid-d4edf507678a4272a0e5704558cdd7c6,option,0.702972
uuid-10c8a79b4b154085b5b04686441cf462,Nivo,0.357372
uuid-10c8a79b4b154085b5b04686441cf462,efficacy,0.642784
uuid-10c8a79b4b154085b5b04686441cf462,regimen,0.503112
uuid-10c8a79b4b154085b5b04686441cf462,combination,0.393255
uuid-10c8a79b4b154085b5b04686441cf462,chemo,0.327517
uuid-10c8a79b4b154085b5b04686441cf462,Ipi,0.368919
uuid-10c8a79b4b154085b5b04686441cf462,OS,0.446271
uuid-10c8a79b4b154085b5b04686441cf462,monotherapy,0.445077
uuid-10c8a79b4b154085b5b04686441cf462,data,0.545517
uuid-10c8a79b4b154085b5b04686441cf462,combo,0.405577
uuid-10c8a79b4b154085b5b04686441cf462,PFS,0.403151
uuid-10c8a79b4b154085b5b04686441cf462,ORR,0.525237
uuid-10c8a79b4b154085b5b04686441cf462,nivo and pembro,0.353679
uuid-10c8a79b4b154085b5b04686441cf462,believes,0.354833
uuid-10c8a79b4b154085b5b04686441cf462,chemotherapy,0.339051
uuid-10c8a79b4b154085b5b04686441cf462,impressed,0.449897
uuid-10c8a79b4b154085b5b04686441cf462,SCLC,0.342636
uuid-10c8a79b4b154085b5b04686441cf462,feels,0.398234
uuid-10c8a79b4b154085b5b04686441cf462,option,0.327967
uuid-e4e09ac4656c43719c746c867b051e7a,Opdivo,0.502695
uuid-e4e09ac4656c43719c746c867b051e7a,shared,0.469549
uuid-e4e09ac4656c43719c746c867b051e7a,commented,0.330434
uuid-e4e09ac4656c43719c746c867b051e7a,physicians,0.584859
uuid-e4e09ac4656c43719c746c867b051e7a,mentioned,0.300116
uuid-e4e09ac4656c43719c746c867b051e7a,oncology,0.381781
uuid-e4e09ac4656c43719c746c867b051e7a,HCP,0.314142
uuid-e4e09ac4656c43719c746c867b051e7a,LTL,0.370049
uuid-e4e09ac4656c43719c746c867b051e7a,drug,0.425848
uuid-e4e09ac4656c43719c746c867b051e7a,Regional TL,0.311184
uuid-e4e09ac4656c43719c746c867b051e7a,flat dosing,0.393817
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,BMS,0.365633
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,PDL1,0.621635
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,trial,0.574219
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,efficacy,0.387049
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,Merck,0.446019
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,PD-L1,0.443597
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,OS,0.499725
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,testing,0.307466
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,data,0.636084
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,PFS,0.494761
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,ORR,0.540753
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,nivo and pembro,0.345533
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,impressed,0.421955
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,assay,0.398927
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,PDL1 expression,0.515852
uuid-c1ec3bdd8f7e45e2be4b3069196afebc,biomarker,0.418939
uuid-acf7e971e5334dedb80778fc099711d5,Nivo,0.438106
uuid-acf7e971e5334dedb80778fc099711d5,patients,0.600439
uuid-acf7e971e5334dedb80778fc099711d5,Opdivo,0.409219
uuid-acf7e971e5334dedb80778fc099711d5,therapy,0.505151
uuid-acf7e971e5334dedb80778fc099711d5,nivolumab,0.503896
uuid-acf7e971e5334dedb80778fc099711d5,1L,0.455987
uuid-acf7e971e5334dedb80778fc099711d5,regimen,0.593286
uuid-acf7e971e5334dedb80778fc099711d5,treated,0.412123
uuid-acf7e971e5334dedb80778fc099711d5,RCC,0.473068
uuid-acf7e971e5334dedb80778fc099711d5,combination,0.322924
uuid-acf7e971e5334dedb80778fc099711d5,chemo,0.412239
uuid-acf7e971e5334dedb80778fc099711d5,2L,0.542731
uuid-acf7e971e5334dedb80778fc099711d5,pts,0.454837
uuid-acf7e971e5334dedb80778fc099711d5,approval,0.323053
uuid-acf7e971e5334dedb80778fc099711d5,preferred,0.502678
uuid-acf7e971e5334dedb80778fc099711d5,monotherapy,0.617219
uuid-acf7e971e5334dedb80778fc099711d5,treatment,0.574591
uuid-acf7e971e5334dedb80778fc099711d5,using nivo,0.542516
uuid-acf7e971e5334dedb80778fc099711d5,combo,0.343815
uuid-acf7e971e5334dedb80778fc099711d5,PD1,0.38481
uuid-acf7e971e5334dedb80778fc099711d5,approved,0.385687
uuid-acf7e971e5334dedb80778fc099711d5,progression,0.507777
uuid-acf7e971e5334dedb80778fc099711d5,chemotherapy,0.427888
uuid-acf7e971e5334dedb80778fc099711d5,respond,0.320643
uuid-acf7e971e5334dedb80778fc099711d5,RTL stated,0.475166
uuid-acf7e971e5334dedb80778fc099711d5,TL shared,0.37835
uuid-acf7e971e5334dedb80778fc099711d5,option,0.537096
uuid-0b60df439ac14031bee03788348591ca,lung,0.490075
uuid-0b60df439ac14031bee03788348591ca,melanoma,0.381237
uuid-0b60df439ac14031bee03788348591ca,RCC,0.353098
uuid-0b60df439ac14031bee03788348591ca,TL stated,0.32879
uuid-0b60df439ac14031bee03788348591ca,SCCHN,0.376287
uuid-0b60df439ac14031bee03788348591ca,TLs,0.398323
uuid-0b60df439ac14031bee03788348591ca,academic,0.40143
uuid-0b60df439ac14031bee03788348591ca,feels,0.414623
uuid-0b60df439ac14031bee03788348591ca,RTL stated,0.34818
uuid-0b60df439ac14031bee03788348591ca,TL shared,0.37741
uuid-05b62176bbb14632a85d4a3f2dc6adae,lung,0.541636
uuid-05b62176bbb14632a85d4a3f2dc6adae,melanoma,0.325736
uuid-05b62176bbb14632a85d4a3f2dc6adae,TL stated,0.522892
uuid-05b62176bbb14632a85d4a3f2dc6adae,PDL1 testing,0.402722
uuid-05b62176bbb14632a85d4a3f2dc6adae,AI,0.377193
uuid-05b62176bbb14632a85d4a3f2dc6adae,TLs,0.305038
uuid-05b62176bbb14632a85d4a3f2dc6adae,PD-1,0.392627
uuid-05b62176bbb14632a85d4a3f2dc6adae,biomarker,0.307287
uuid-cb1edace9e3346b5aaad2be6024fb99a,TL,0.390213
uuid-cb1edace9e3346b5aaad2be6024fb99a,RTL,0.397565
uuid-cb1edace9e3346b5aaad2be6024fb99a,lung,0.465532
uuid-cb1edace9e3346b5aaad2be6024fb99a,NTL,0.500001
uuid-cb1edace9e3346b5aaad2be6024fb99a,melanoma,0.39132
uuid-cb1edace9e3346b5aaad2be6024fb99a,shared,0.368898
uuid-cb1edace9e3346b5aaad2be6024fb99a,commented,0.367568
uuid-cb1edace9e3346b5aaad2be6024fb99a,RCC,0.463511
uuid-cb1edace9e3346b5aaad2be6024fb99a,TL stated,0.315003
uuid-cb1edace9e3346b5aaad2be6024fb99a,oncology,0.301882
uuid-cb1edace9e3346b5aaad2be6024fb99a,SCCHN,0.490606
uuid-cb1edace9e3346b5aaad2be6024fb99a,ASCO,0.40974
uuid-cb1edace9e3346b5aaad2be6024fb99a,oncologist,0.395473
uuid-cb1edace9e3346b5aaad2be6024fb99a,TLs,0.363981
uuid-cb1edace9e3346b5aaad2be6024fb99a,academic,0.362416
uuid-cb1edace9e3346b5aaad2be6024fb99a,Regional TL,0.617964
uuid-cb1edace9e3346b5aaad2be6024fb99a,RTL stated,0.359487
uuid-cb1edace9e3346b5aaad2be6024fb99a,TL shared,0.437916
uuid-cb1edace9e3346b5aaad2be6024fb99a,bladder,0.396946
uuid-9ebada63f4944c81a587d043a998f39c,pembro,0.354428
uuid-9ebada63f4944c81a587d043a998f39c,RTL,0.419144
uuid-9ebada63f4944c81a587d043a998f39c,BMS,0.369242
uuid-9ebada63f4944c81a587d043a998f39c,lung,0.357171
uuid-9ebada63f4944c81a587d043a998f39c,trial,0.690306
uuid-9ebada63f4944c81a587d043a998f39c,efficacy,0.305383
uuid-9ebada63f4944c81a587d043a998f39c,discussed,0.324829
uuid-9ebada63f4944c81a587d043a998f39c,melanoma,0.323052
uuid-9ebada63f4944c81a587d043a998f39c,commented,0.406041
uuid-9ebada63f4944c81a587d043a998f39c,Merck,0.377091
uuid-9ebada63f4944c81a587d043a998f39c,OS,0.366659
uuid-9ebada63f4944c81a587d043a998f39c,regards,0.378578
uuid-9ebada63f4944c81a587d043a998f39c,data,0.493775
uuid-9ebada63f4944c81a587d043a998f39c,expressed,0.350224
uuid-9ebada63f4944c81a587d043a998f39c,clinical trials,0.34484
uuid-9ebada63f4944c81a587d043a998f39c,PFS,0.354137
uuid-9ebada63f4944c81a587d043a998f39c,ORR,0.38258
uuid-9ebada63f4944c81a587d043a998f39c,SCCHN,0.365164
uuid-9ebada63f4944c81a587d043a998f39c,nivo and pembro,0.325664
uuid-9ebada63f4944c81a587d043a998f39c,impressed,0.476379
uuid-9ebada63f4944c81a587d043a998f39c,TLs,0.452258
uuid-9ebada63f4944c81a587d043a998f39c,academic,0.324174
uuid-9ebada63f4944c81a587d043a998f39c,Regional TL,0.314649
uuid-9ebada63f4944c81a587d043a998f39c,bladder,0.319397
uuid-fc99870a4904481281f0a32b07dbacb7,patients,0.833475
uuid-fc99870a4904481281f0a32b07dbacb7,Opdivo,0.394548
uuid-fc99870a4904481281f0a32b07dbacb7,therapy,0.563562
uuid-fc99870a4904481281f0a32b07dbacb7,nivolumab,0.494522
uuid-fc99870a4904481281f0a32b07dbacb7,regimen,0.474826
uuid-fc99870a4904481281f0a32b07dbacb7,treated,0.624891
uuid-fc99870a4904481281f0a32b07dbacb7,pts,0.487825
uuid-fc99870a4904481281f0a32b07dbacb7,treatment,0.621476
uuid-fc99870a4904481281f0a32b07dbacb7,cHL,0.365208
uuid-fc99870a4904481281f0a32b07dbacb7,progression,0.550977
uuid-fc99870a4904481281f0a32b07dbacb7,chemotherapy,0.33403
uuid-fc99870a4904481281f0a32b07dbacb7,respond,0.35262
uuid-6763d65e31974de7a1d03e1ebfa8fb99,Nivo,0.583751
uuid-6763d65e31974de7a1d03e1ebfa8fb99,pembro,0.476487
uuid-6763d65e31974de7a1d03e1ebfa8fb99,therapy,0.320576
uuid-6763d65e31974de7a1d03e1ebfa8fb99,nivolumab,0.332273
uuid-6763d65e31974de7a1d03e1ebfa8fb99,1L,0.69166
uuid-6763d65e31974de7a1d03e1ebfa8fb99,regimen,0.404426
uuid-6763d65e31974de7a1d03e1ebfa8fb99,RCC,0.376947
uuid-6763d65e31974de7a1d03e1ebfa8fb99,combination,0.504742
uuid-6763d65e31974de7a1d03e1ebfa8fb99,chemo,0.565717
uuid-6763d65e31974de7a1d03e1ebfa8fb99,2L,0.780375
uuid-6763d65e31974de7a1d03e1ebfa8fb99,pts,0.352128
uuid-6763d65e31974de7a1d03e1ebfa8fb99,agents,0.579038
uuid-6763d65e31974de7a1d03e1ebfa8fb99,Ipi,0.393594
uuid-6763d65e31974de7a1d03e1ebfa8fb99,atezo,0.540555
uuid-6763d65e31974de7a1d03e1ebfa8fb99,preferred,0.63523
uuid-6763d65e31974de7a1d03e1ebfa8fb99,monotherapy,0.769761
uuid-6763d65e31974de7a1d03e1ebfa8fb99,using nivo,0.555942
uuid-6763d65e31974de7a1d03e1ebfa8fb99,combo,0.61368
uuid-6763d65e31974de7a1d03e1ebfa8fb99,PD1,0.54048
uuid-6763d65e31974de7a1d03e1ebfa8fb99,approved,0.409847
uuid-6763d65e31974de7a1d03e1ebfa8fb99,nivo and pembro,0.354764
uuid-6763d65e31974de7a1d03e1ebfa8fb99,believes,0.484836
uuid-6763d65e31974de7a1d03e1ebfa8fb99,chemotherapy,0.408559
uuid-6763d65e31974de7a1d03e1ebfa8fb99,feels,0.359838
uuid-6763d65e31974de7a1d03e1ebfa8fb99,RTL stated,0.353415
uuid-6763d65e31974de7a1d03e1ebfa8fb99,option,0.658848
uuid-a282f6a2af4847df8136fe4acc31ea91,pembro,0.387667
uuid-a282f6a2af4847df8136fe4acc31ea91,RTL,0.380132
uuid-a282f6a2af4847df8136fe4acc31ea91,lung,0.389718
uuid-a282f6a2af4847df8136fe4acc31ea91,1L,0.436998
uuid-a282f6a2af4847df8136fe4acc31ea91,commented,0.411464
uuid-a282f6a2af4847df8136fe4acc31ea91,RCC,0.584318
uuid-a282f6a2af4847df8136fe4acc31ea91,TL stated,0.404206
uuid-a282f6a2af4847df8136fe4acc31ea91,2L,0.457286
uuid-a282f6a2af4847df8136fe4acc31ea91,stated,0.493493
uuid-a282f6a2af4847df8136fe4acc31ea91,approval,0.405231
uuid-a282f6a2af4847df8136fe4acc31ea91,atezo,0.383577
uuid-a282f6a2af4847df8136fe4acc31ea91,preferred,0.315996
uuid-a282f6a2af4847df8136fe4acc31ea91,using nivo,0.457082
uuid-a282f6a2af4847df8136fe4acc31ea91,data,0.517038
uuid-a282f6a2af4847df8136fe4acc31ea91,expressed,0.321747
uuid-a282f6a2af4847df8136fe4acc31ea91,clinical trials,0.303409
uuid-a282f6a2af4847df8136fe4acc31ea91,indication,0.354057
uuid-a282f6a2af4847df8136fe4acc31ea91,approved,0.428205
uuid-a282f6a2af4847df8136fe4acc31ea91,SCCHN,0.546564
uuid-a282f6a2af4847df8136fe4acc31ea91,nivo and pembro,0.324931
uuid-a282f6a2af4847df8136fe4acc31ea91,impressed,0.500197
uuid-a282f6a2af4847df8136fe4acc31ea91,LTL,0.37165
uuid-a282f6a2af4847df8136fe4acc31ea91,TLs,0.47509
uuid-a282f6a2af4847df8136fe4acc31ea91,SCLC,0.381689
uuid-a282f6a2af4847df8136fe4acc31ea91,Regional TL,0.492662
uuid-a282f6a2af4847df8136fe4acc31ea91,RTL stated,0.483891
uuid-a282f6a2af4847df8136fe4acc31ea91,TL shared,0.348268
uuid-a282f6a2af4847df8136fe4acc31ea91,bladder,0.439099
uuid-77301dd9ea3746d7a74b3d926c0256b3,Nivo,0.45942
uuid-77301dd9ea3746d7a74b3d926c0256b3,PDL1,0.366106
uuid-77301dd9ea3746d7a74b3d926c0256b3,efficacy,0.441057
uuid-77301dd9ea3746d7a74b3d926c0256b3,chemo,0.302385
uuid-77301dd9ea3746d7a74b3d926c0256b3,OS,0.734497
uuid-77301dd9ea3746d7a74b3d926c0256b3,data,0.480358
uuid-77301dd9ea3746d7a74b3d926c0256b3,PFS,0.646213
uuid-77301dd9ea3746d7a74b3d926c0256b3,ORR,0.629592
uuid-77301dd9ea3746d7a74b3d926c0256b3,nivo and pembro,0.431381
uuid-77301dd9ea3746d7a74b3d926c0256b3,impressed,0.473833
uuid-77301dd9ea3746d7a74b3d926c0256b3,PDL1 expression,0.302549
uuid-fc783aea013a4a198f94579881cd0f32,patients,0.561908
uuid-fc783aea013a4a198f94579881cd0f32,lung,0.33128
uuid-fc783aea013a4a198f94579881cd0f32,regimen,0.42016
uuid-fc783aea013a4a198f94579881cd0f32,treated,0.548332
uuid-fc783aea013a4a198f94579881cd0f32,melanoma,0.425681
uuid-fc783aea013a4a198f94579881cd0f32,RCC,0.418661
uuid-fc783aea013a4a198f94579881cd0f32,tumor,0.443878
uuid-fc783aea013a4a198f94579881cd0f32,pts,0.48428
uuid-fc783aea013a4a198f94579881cd0f32,treatment,0.505067
uuid-fc783aea013a4a198f94579881cd0f32,response,0.309156
uuid-fc783aea013a4a198f94579881cd0f32,progression,0.456512
uuid-fc783aea013a4a198f94579881cd0f32,respond,0.31463
uuid-fc783aea013a4a198f94579881cd0f32,TL shared,0.476581
uuid-4791cade8378436598257bcbce888346,Nivo,0.483896
uuid-4791cade8378436598257bcbce888346,pembro,0.544016
uuid-4791cade8378436598257bcbce888346,1L,0.823006
uuid-4791cade8378436598257bcbce888346,RCC,0.53046
uuid-4791cade8378436598257bcbce888346,TL stated,0.300905
uuid-4791cade8378436598257bcbce888346,combination,0.365167
uuid-4791cade8378436598257bcbce888346,chemo,0.435157
uuid-4791cade8378436598257bcbce888346,2L,0.792621
uuid-4791cade8378436598257bcbce888346,pts,0.324649
uuid-4791cade8378436598257bcbce888346,agents,0.472357
uuid-4791cade8378436598257bcbce888346,approval,0.411823
uuid-4791cade8378436598257bcbce888346,atezo,0.524792
uuid-4791cade8378436598257bcbce888346,preferred,0.639343
uuid-4791cade8378436598257bcbce888346,monotherapy,0.689537
uuid-4791cade8378436598257bcbce888346,using nivo,0.631345
uuid-4791cade8378436598257bcbce888346,combo,0.498625
uuid-4791cade8378436598257bcbce888346,PD1,0.395367
uuid-4791cade8378436598257bcbce888346,approved,0.566743
uuid-4791cade8378436598257bcbce888346,SCCHN,0.349473
uuid-4791cade8378436598257bcbce888346,nivo and pembro,0.35657
uuid-4791cade8378436598257bcbce888346,believes,0.414432
uuid-4791cade8378436598257bcbce888346,tumor types,0.309634
uuid-4791cade8378436598257bcbce888346,feels,0.401784
uuid-4791cade8378436598257bcbce888346,RTL stated,0.504191
uuid-4791cade8378436598257bcbce888346,option,0.673514
uuid-4791cade8378436598257bcbce888346,bladder,0.361331
uuid-8d0f3098729643f98b4fe0842d308af5,BMS,0.542028
uuid-8d0f3098729643f98b4fe0842d308af5,trial,0.36457
uuid-8d0f3098729643f98b4fe0842d308af5,NTL,0.426525
uuid-8d0f3098729643f98b4fe0842d308af5,shared,0.314631
uuid-8d0f3098729643f98b4fe0842d308af5,commented,0.344943
uuid-8d0f3098729643f98b4fe0842d308af5,Merck,0.45539
uuid-8d0f3098729643f98b4fe0842d308af5,regards,0.339648
uuid-8d0f3098729643f98b4fe0842d308af5,data,0.323992
uuid-8d0f3098729643f98b4fe0842d308af5,expressed,0.358047
uuid-8d0f3098729643f98b4fe0842d308af5,clinical trials,0.316655
uuid-8d0f3098729643f98b4fe0842d308af5,TLs,0.382649
uuid-cef5c48ec5b0455bb9f9679499515d5e,TL,0.420944
uuid-cef5c48ec5b0455bb9f9679499515d5e,pembro,0.413803
uuid-cef5c48ec5b0455bb9f9679499515d5e,1L,0.454103
uuid-cef5c48ec5b0455bb9f9679499515d5e,PDL1,0.338219
uuid-cef5c48ec5b0455bb9f9679499515d5e,RCC,0.330127
uuid-cef5c48ec5b0455bb9f9679499515d5e,TL stated,0.431241
uuid-cef5c48ec5b0455bb9f9679499515d5e,2L,0.437269
uuid-cef5c48ec5b0455bb9f9679499515d5e,Merck,0.379131
uuid-cef5c48ec5b0455bb9f9679499515d5e,institution,0.398871
uuid-cef5c48ec5b0455bb9f9679499515d5e,PD-L1,0.69448
uuid-cef5c48ec5b0455bb9f9679499515d5e,approval,0.415238
uuid-cef5c48ec5b0455bb9f9679499515d5e,atezo,0.499497
uuid-cef5c48ec5b0455bb9f9679499515d5e,preferred,0.406835
uuid-cef5c48ec5b0455bb9f9679499515d5e,PD-L1 testing,0.652396
uuid-cef5c48ec5b0455bb9f9679499515d5e,testing,0.725013
uuid-cef5c48ec5b0455bb9f9679499515d5e,PDL1 testing,0.677447
uuid-cef5c48ec5b0455bb9f9679499515d5e,NSCLC patients,0.623011
uuid-cef5c48ec5b0455bb9f9679499515d5e,approved,0.346197
uuid-cef5c48ec5b0455bb9f9679499515d5e,assay,0.622379
uuid-cef5c48ec5b0455bb9f9679499515d5e,PD-1,0.306849
uuid-cef5c48ec5b0455bb9f9679499515d5e,RTL stated,0.323855
uuid-0ed6bd8ffe424b189f49884b5d517cd0,TL,0.498949
uuid-0ed6bd8ffe424b189f49884b5d517cd0,lung,0.309779
uuid-0ed6bd8ffe424b189f49884b5d517cd0,NSCLC,0.413086
uuid-0ed6bd8ffe424b189f49884b5d517cd0,shared,0.384051
uuid-0ed6bd8ffe424b189f49884b5d517cd0,RCC,0.302626
uuid-0ed6bd8ffe424b189f49884b5d517cd0,TL stated,0.481482
uuid-0ed6bd8ffe424b189f49884b5d517cd0,Merck,0.319099
uuid-0ed6bd8ffe424b189f49884b5d517cd0,institution,0.561374
uuid-0ed6bd8ffe424b189f49884b5d517cd0,PD-L1,0.563504
uuid-0ed6bd8ffe424b189f49884b5d517cd0,approval,0.371284
uuid-0ed6bd8ffe424b189f49884b5d517cd0,PD-L1 testing,0.696726
uuid-0ed6bd8ffe424b189f49884b5d517cd0,testing,0.68365
uuid-0ed6bd8ffe424b189f49884b5d517cd0,PDL1 testing,0.660802
uuid-0ed6bd8ffe424b189f49884b5d517cd0,NSCLC patients,0.567217
uuid-0ed6bd8ffe424b189f49884b5d517cd0,SCCHN,0.382437
uuid-0ed6bd8ffe424b189f49884b5d517cd0,academic,0.356681
uuid-0ed6bd8ffe424b189f49884b5d517cd0,assay,0.531671
uuid-7a190a328a5b4bf8ba88370f4600a25b,RTL,0.508526
uuid-7a190a328a5b4bf8ba88370f4600a25b,BMS,0.56959
uuid-7a190a328a5b4bf8ba88370f4600a25b,lung,0.360269
uuid-7a190a328a5b4bf8ba88370f4600a25b,trial,0.422586
uuid-7a190a328a5b4bf8ba88370f4600a25b,NTL,0.38175
uuid-7a190a328a5b4bf8ba88370f4600a25b,shared,0.365829
uuid-7a190a328a5b4bf8ba88370f4600a25b,commented,0.593279
uuid-7a190a328a5b4bf8ba88370f4600a25b,TL stated,0.34318
uuid-7a190a328a5b4bf8ba88370f4600a25b,Merck,0.440812
uuid-7a190a328a5b4bf8ba88370f4600a25b,stated,0.596192
uuid-7a190a328a5b4bf8ba88370f4600a25b,OS,0.335087
uuid-7a190a328a5b4bf8ba88370f4600a25b,regards,0.397726
uuid-7a190a328a5b4bf8ba88370f4600a25b,data,0.585811
uuid-7a190a328a5b4bf8ba88370f4600a25b,expressed,0.511441
uuid-7a190a328a5b4bf8ba88370f4600a25b,mentioned,0.302806
uuid-7a190a328a5b4bf8ba88370f4600a25b,ORR,0.30813
uuid-7a190a328a5b4bf8ba88370f4600a25b,SCCHN,0.351783
uuid-7a190a328a5b4bf8ba88370f4600a25b,ASCO,0.345561
uuid-7a190a328a5b4bf8ba88370f4600a25b,impressed,0.60405
uuid-7a190a328a5b4bf8ba88370f4600a25b,LTL,0.44547
uuid-7a190a328a5b4bf8ba88370f4600a25b,TLs,0.487963
uuid-7a190a328a5b4bf8ba88370f4600a25b,Regional TL,0.494381
uuid-7d4122c9e4bc4e8c90fbac92f71de910,Nivo,0.497749
uuid-7d4122c9e4bc4e8c90fbac92f71de910,pembro,0.383285
uuid-7d4122c9e4bc4e8c90fbac92f71de910,BMS,0.318025
uuid-7d4122c9e4bc4e8c90fbac92f71de910,trial,0.453191
uuid-7d4122c9e4bc4e8c90fbac92f71de910,efficacy,0.50281
uuid-7d4122c9e4bc4e8c90fbac92f71de910,combination,0.377144
uuid-7d4122c9e4bc4e8c90fbac92f71de910,chemo,0.322419
uuid-7d4122c9e4bc4e8c90fbac92f71de910,agents,0.33825
uuid-7d4122c9e4bc4e8c90fbac92f71de910,Ipi,0.326752
uuid-7d4122c9e4bc4e8c90fbac92f71de910,OS,0.484898
uuid-7d4122c9e4bc4e8c90fbac92f71de910,atezo,0.331998
uuid-7d4122c9e4bc4e8c90fbac92f71de910,monotherapy,0.323342
uuid-7d4122c9e4bc4e8c90fbac92f71de910,data,0.641528
uuid-7d4122c9e4bc4e8c90fbac92f71de910,combo,0.409478
uuid-7d4122c9e4bc4e8c90fbac92f71de910,PFS,0.42842
uuid-7d4122c9e4bc4e8c90fbac92f71de910,ORR,0.503406
uuid-7d4122c9e4bc4e8c90fbac92f71de910,nivo and pembro,0.472167
uuid-7d4122c9e4bc4e8c90fbac92f71de910,believes,0.43797
uuid-7d4122c9e4bc4e8c90fbac92f71de910,impressed,0.539315
uuid-7d4122c9e4bc4e8c90fbac92f71de910,vs,0.303883
uuid-7d4122c9e4bc4e8c90fbac92f71de910,feels,0.579572
uuid-6b8f89f294f34ecdaba40ef747a37cbb,PDL1,0.387957
uuid-6b8f89f294f34ecdaba40ef747a37cbb,data,0.333914
uuid-6b8f89f294f34ecdaba40ef747a37cbb,biomarker,0.468251
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,patients,0.332161
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,Opdivo,0.565675
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,nivolumab,0.314109
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,1L,0.320772
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,regimen,0.377498
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,treated,0.338155
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,RCC,0.347298
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,2L,0.505389
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,agents,0.31102
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,approval,0.302225
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,physicians,0.39069
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,preferred,0.597479
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,monotherapy,0.407092
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,treatment,0.348925
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,using nivo,0.446152
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,approved,0.460525
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,Keytruda,0.30499
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,RTL stated,0.383898
uuid-7c1999c3389b4cdf9c0ed4a598dfb77c,option,0.435614
uuid-34933137ad4142ceb851d99a8badf68d,OS,0.66286
uuid-34933137ad4142ceb851d99a8badf68d,response,0.359913
uuid-34933137ad4142ceb851d99a8badf68d,PFS,0.641457
uuid-34933137ad4142ceb851d99a8badf68d,ORR,0.517431
uuid-34933137ad4142ceb851d99a8badf68d,progression,0.30894
uuid-34933137ad4142ceb851d99a8badf68d,impressed,0.356587
uuid-83e11ad3474441ff8fe6339d4ead9189,RTL,0.31855
uuid-83e11ad3474441ff8fe6339d4ead9189,BMS,0.519036
uuid-83e11ad3474441ff8fe6339d4ead9189,PDL1,0.428787
uuid-83e11ad3474441ff8fe6339d4ead9189,trial,0.439913
uuid-83e11ad3474441ff8fe6339d4ead9189,commented,0.525877
uuid-83e11ad3474441ff8fe6339d4ead9189,Merck,0.526027
uuid-83e11ad3474441ff8fe6339d4ead9189,stated,0.534425
uuid-83e11ad3474441ff8fe6339d4ead9189,OS,0.362192
uuid-83e11ad3474441ff8fe6339d4ead9189,regards,0.371038
uuid-83e11ad3474441ff8fe6339d4ead9189,data,0.752621
uuid-83e11ad3474441ff8fe6339d4ead9189,expressed,0.430688
uuid-83e11ad3474441ff8fe6339d4ead9189,indication,0.316606
uuid-83e11ad3474441ff8fe6339d4ead9189,PFS,0.324355
uuid-83e11ad3474441ff8fe6339d4ead9189,ORR,0.363303
uuid-83e11ad3474441ff8fe6339d4ead9189,SCCHN,0.352541
uuid-83e11ad3474441ff8fe6339d4ead9189,nivo and pembro,0.331361
uuid-83e11ad3474441ff8fe6339d4ead9189,ASCO,0.335734
uuid-83e11ad3474441ff8fe6339d4ead9189,impressed,0.536756
uuid-83e11ad3474441ff8fe6339d4ead9189,TLs,0.352056
uuid-83e11ad3474441ff8fe6339d4ead9189,Regional TL,0.391219
uuid-83e11ad3474441ff8fe6339d4ead9189,PDL1 expression,0.405313
uuid-83e11ad3474441ff8fe6339d4ead9189,NCCN,0.39041
uuid-83e11ad3474441ff8fe6339d4ead9189,bladder,0.327088
uuid-03520edde9104b52aca6538188716cbe,BMS,0.429266
uuid-03520edde9104b52aca6538188716cbe,commented,0.511033
uuid-03520edde9104b52aca6538188716cbe,tumor,0.334985
uuid-03520edde9104b52aca6538188716cbe,Merck,0.371034
uuid-03520edde9104b52aca6538188716cbe,stated,0.331258
uuid-03520edde9104b52aca6538188716cbe,regards,0.365343
uuid-03520edde9104b52aca6538188716cbe,data,0.344159
uuid-03520edde9104b52aca6538188716cbe,expressed,0.431634
uuid-03520edde9104b52aca6538188716cbe,impressed,0.339964
uuid-03520edde9104b52aca6538188716cbe,Regional TL,0.327773
uuid-03520edde9104b52aca6538188716cbe,biomarker,0.337585
uuid-a90d5474fb5e413bb43a051f4667c6ad,treated,0.320063
uuid-a90d5474fb5e413bb43a051f4667c6ad,clinical trials,0.385529
uuid-a90d5474fb5e413bb43a051f4667c6ad,tumor types,0.393138
uuid-a90d5474fb5e413bb43a051f4667c6ad,feels,0.396661
uuid-0d79fe5ff6034470a3dd9f1517a82234,pembro,0.581318
uuid-0d79fe5ff6034470a3dd9f1517a82234,trial,0.536589
uuid-0d79fe5ff6034470a3dd9f1517a82234,Merck,0.364216
uuid-0d79fe5ff6034470a3dd9f1517a82234,approval,0.38418
uuid-0d79fe5ff6034470a3dd9f1517a82234,atezo,0.550235
uuid-0d79fe5ff6034470a3dd9f1517a82234,PD-L1 testing,0.322953
uuid-0d79fe5ff6034470a3dd9f1517a82234,testing,0.320807
uuid-0d79fe5ff6034470a3dd9f1517a82234,vs,0.376474
uuid-0d79fe5ff6034470a3dd9f1517a82234,assay,0.382277
uuid-0d79fe5ff6034470a3dd9f1517a82234,bladder,0.357161
uuid-1a483fbad8f14edcb608d689d8b858b2,BMS,0.323794
uuid-1a483fbad8f14edcb608d689d8b858b2,PDL1,0.399313
uuid-1a483fbad8f14edcb608d689d8b858b2,trial,0.477691
uuid-1a483fbad8f14edcb608d689d8b858b2,efficacy,0.631878
uuid-1a483fbad8f14edcb608d689d8b858b2,commented,0.305355
uuid-1a483fbad8f14edcb608d689d8b858b2,OS,0.854133
uuid-1a483fbad8f14edcb608d689d8b858b2,regards,0.301049
uuid-1a483fbad8f14edcb608d689d8b858b2,data,0.810512
uuid-1a483fbad8f14edcb608d689d8b858b2,PFS,0.854843
uuid-1a483fbad8f14edcb608d689d8b858b2,ORR,0.815562
uuid-1a483fbad8f14edcb608d689d8b858b2,nivo and pembro,0.433839
uuid-1a483fbad8f14edcb608d689d8b858b2,ASCO,0.376872
uuid-1a483fbad8f14edcb608d689d8b858b2,believes,0.32864
uuid-1a483fbad8f14edcb608d689d8b858b2,impressed,0.647215
uuid-1a483fbad8f14edcb608d689d8b858b2,feels,0.35426
uuid-1a483fbad8f14edcb608d689d8b858b2,PDL1 expression,0.360375
uuid-374c34064014484b84db4d874c2f2352,Nivo,0.30305
uuid-374c34064014484b84db4d874c2f2352,patients,0.371062
uuid-374c34064014484b84db4d874c2f2352,therapy,0.548118
uuid-374c34064014484b84db4d874c2f2352,nivolumab,0.400503
uuid-374c34064014484b84db4d874c2f2352,1L,0.324415
uuid-374c34064014484b84db4d874c2f2352,regimen,0.428319
uuid-374c34064014484b84db4d874c2f2352,treated,0.331679
uuid-374c34064014484b84db4d874c2f2352,combination,0.700525
uuid-374c34064014484b84db4d874c2f2352,chemo,0.524788
uuid-374c34064014484b84db4d874c2f2352,pts,0.428688
uuid-374c34064014484b84db4d874c2f2352,IO,0.456808
uuid-374c34064014484b84db4d874c2f2352,agents,0.387104
uuid-374c34064014484b84db4d874c2f2352,monotherapy,0.585126
uuid-374c34064014484b84db4d874c2f2352,treatment,0.390326
uuid-374c34064014484b84db4d874c2f2352,response,0.370407
uuid-374c34064014484b84db4d874c2f2352,combo,0.600957
uuid-374c34064014484b84db4d874c2f2352,PD1,0.569427
uuid-374c34064014484b84db4d874c2f2352,progression,0.440896
uuid-374c34064014484b84db4d874c2f2352,believes,0.328833
uuid-374c34064014484b84db4d874c2f2352,chemotherapy,0.620119
uuid-374c34064014484b84db4d874c2f2352,feels,0.379602
uuid-374c34064014484b84db4d874c2f2352,option,0.564762
uuid-6d455ab7c2cd45239d801d43bb6c30a3,Nivo,0.311722
uuid-6d455ab7c2cd45239d801d43bb6c30a3,pembro,0.308689
uuid-6d455ab7c2cd45239d801d43bb6c30a3,1L,0.401688
uuid-6d455ab7c2cd45239d801d43bb6c30a3,PDL1,0.531287
uuid-6d455ab7c2cd45239d801d43bb6c30a3,trial,0.388126
uuid-6d455ab7c2cd45239d801d43bb6c30a3,efficacy,0.48569
uuid-6d455ab7c2cd45239d801d43bb6c30a3,chemo,0.347772
uuid-6d455ab7c2cd45239d801d43bb6c30a3,OS,0.747082
uuid-6d455ab7c2cd45239d801d43bb6c30a3,data,0.550307
uuid-6d455ab7c2cd45239d801d43bb6c30a3,PFS,0.713102
uuid-6d455ab7c2cd45239d801d43bb6c30a3,ORR,0.664701
uuid-6d455ab7c2cd45239d801d43bb6c30a3,nivo and pembro,0.469417
uuid-6d455ab7c2cd45239d801d43bb6c30a3,believes,0.445812
uuid-6d455ab7c2cd45239d801d43bb6c30a3,impressed,0.507735
uuid-6d455ab7c2cd45239d801d43bb6c30a3,feels,0.449934
uuid-6d455ab7c2cd45239d801d43bb6c30a3,PDL1 expression,0.45418
uuid-af2f6d39732e400fadb1189c5c7321c3,Nivo,0.499297
uuid-af2f6d39732e400fadb1189c5c7321c3,patients,0.420755
uuid-af2f6d39732e400fadb1189c5c7321c3,pembro,0.531561
uuid-af2f6d39732e400fadb1189c5c7321c3,therapy,0.388651
uuid-af2f6d39732e400fadb1189c5c7321c3,1L,0.414557
uuid-af2f6d39732e400fadb1189c5c7321c3,chemo,0.383488
uuid-af2f6d39732e400fadb1189c5c7321c3,2L,0.333828
uuid-af2f6d39732e400fadb1189c5c7321c3,pts,0.382899
uuid-af2f6d39732e400fadb1189c5c7321c3,approval,0.488715
uuid-af2f6d39732e400fadb1189c5c7321c3,atezo,0.322466
uuid-af2f6d39732e400fadb1189c5c7321c3,monotherapy,0.352217
uuid-af2f6d39732e400fadb1189c5c7321c3,using nivo,0.359288
uuid-af2f6d39732e400fadb1189c5c7321c3,PD1,0.324146
uuid-af2f6d39732e400fadb1189c5c7321c3,approved,0.364767
uuid-af2f6d39732e400fadb1189c5c7321c3,chemotherapy,0.340478
uuid-af2f6d39732e400fadb1189c5c7321c3,option,0.368531
uuid-58ef20bd1fc4429f93f36c626da3f8d5,Nivo,0.487941
uuid-58ef20bd1fc4429f93f36c626da3f8d5,patients,0.723918
uuid-58ef20bd1fc4429f93f36c626da3f8d5,therapy,0.523589
uuid-58ef20bd1fc4429f93f36c626da3f8d5,nivolumab,0.317833
uuid-58ef20bd1fc4429f93f36c626da3f8d5,1L,0.336154
uuid-58ef20bd1fc4429f93f36c626da3f8d5,regimen,0.480709
uuid-58ef20bd1fc4429f93f36c626da3f8d5,treated,0.399266
uuid-58ef20bd1fc4429f93f36c626da3f8d5,chemo,0.658158
uuid-58ef20bd1fc4429f93f36c626da3f8d5,2L,0.306267
uuid-58ef20bd1fc4429f93f36c626da3f8d5,pts,0.526504
uuid-58ef20bd1fc4429f93f36c626da3f8d5,preferred,0.3308
uuid-58ef20bd1fc4429f93f36c626da3f8d5,monotherapy,0.521077
uuid-58ef20bd1fc4429f93f36c626da3f8d5,treatment,0.493814
uuid-58ef20bd1fc4429f93f36c626da3f8d5,using nivo,0.316185
uuid-58ef20bd1fc4429f93f36c626da3f8d5,response,0.334104
uuid-58ef20bd1fc4429f93f36c626da3f8d5,PD1,0.349404
uuid-58ef20bd1fc4429f93f36c626da3f8d5,progression,0.487439
uuid-58ef20bd1fc4429f93f36c626da3f8d5,chemotherapy,0.645722
uuid-58ef20bd1fc4429f93f36c626da3f8d5,respond,0.352442
uuid-58ef20bd1fc4429f93f36c626da3f8d5,option,0.494123
uuid-e00cc24d1b7d49de9021bae4e67346a4,Nivo,0.504589
uuid-e00cc24d1b7d49de9021bae4e67346a4,pembro,0.705327
uuid-e00cc24d1b7d49de9021bae4e67346a4,1L,0.313946
uuid-e00cc24d1b7d49de9021bae4e67346a4,trial,0.42784
uuid-e00cc24d1b7d49de9021bae4e67346a4,2L,0.316851
uuid-e00cc24d1b7d49de9021bae4e67346a4,Ipi,0.30098
uuid-e00cc24d1b7d49de9021bae4e67346a4,PD-L1,0.305159
uuid-e00cc24d1b7d49de9021bae4e67346a4,approval,0.433712
uuid-e00cc24d1b7d49de9021bae4e67346a4,atezo,0.596232
uuid-e00cc24d1b7d49de9021bae4e67346a4,using nivo,0.374813
uuid-e00cc24d1b7d49de9021bae4e67346a4,nivo and pembro,0.371115
uuid-e00cc24d1b7d49de9021bae4e67346a4,vs,0.380187
uuid-e00cc24d1b7d49de9021bae4e67346a4,assay,0.414765
uuid-75efaf51d2214b61b3c9b8e80d072c03,patients,0.708167
uuid-75efaf51d2214b61b3c9b8e80d072c03,Opdivo,0.413091
uuid-75efaf51d2214b61b3c9b8e80d072c03,therapy,0.306333
uuid-75efaf51d2214b61b3c9b8e80d072c03,dose,0.428657
uuid-75efaf51d2214b61b3c9b8e80d072c03,nivolumab,0.310003
uuid-75efaf51d2214b61b3c9b8e80d072c03,toxicity,0.50574
uuid-75efaf51d2214b61b3c9b8e80d072c03,regimen,0.528109
uuid-75efaf51d2214b61b3c9b8e80d072c03,treated,0.523861
uuid-75efaf51d2214b61b3c9b8e80d072c03,pts,0.342457
uuid-75efaf51d2214b61b3c9b8e80d072c03,treatment,0.629971
uuid-75efaf51d2214b61b3c9b8e80d072c03,progression,0.48513
uuid-75efaf51d2214b61b3c9b8e80d072c03,respond,0.49146
uuid-a7aa7b34ea764fa39a6e1297d137336e,patients,0.713819
uuid-a7aa7b34ea764fa39a6e1297d137336e,Opdivo,0.418339
uuid-a7aa7b34ea764fa39a6e1297d137336e,therapy,0.583259
uuid-a7aa7b34ea764fa39a6e1297d137336e,nivolumab,0.380323
uuid-a7aa7b34ea764fa39a6e1297d137336e,regimen,0.608473
uuid-a7aa7b34ea764fa39a6e1297d137336e,treated,0.492872
uuid-a7aa7b34ea764fa39a6e1297d137336e,chemo,0.385018
uuid-a7aa7b34ea764fa39a6e1297d137336e,pts,0.469848
uuid-a7aa7b34ea764fa39a6e1297d137336e,IO,0.333351
uuid-a7aa7b34ea764fa39a6e1297d137336e,monotherapy,0.344083
uuid-a7aa7b34ea764fa39a6e1297d137336e,treatment,0.816936
uuid-a7aa7b34ea764fa39a6e1297d137336e,response,0.574745
uuid-a7aa7b34ea764fa39a6e1297d137336e,PD1,0.335716
uuid-a7aa7b34ea764fa39a6e1297d137336e,progression,0.756605
uuid-a7aa7b34ea764fa39a6e1297d137336e,chemotherapy,0.441919
uuid-a7aa7b34ea764fa39a6e1297d137336e,respond,0.561144
uuid-a7aa7b34ea764fa39a6e1297d137336e,option,0.321131
uuid-c419217c51b54f06ba421dd4ab2675b7,TL,0.55297
uuid-c419217c51b54f06ba421dd4ab2675b7,lung,0.402914
uuid-c419217c51b54f06ba421dd4ab2675b7,PDL1,0.379642
uuid-c419217c51b54f06ba421dd4ab2675b7,TL stated,0.533843
uuid-c419217c51b54f06ba421dd4ab2675b7,Merck,0.307415
uuid-c419217c51b54f06ba421dd4ab2675b7,institution,0.376644
uuid-c419217c51b54f06ba421dd4ab2675b7,PD-L1,0.664001
uuid-c419217c51b54f06ba421dd4ab2675b7,PD-L1 testing,0.714881
uuid-c419217c51b54f06ba421dd4ab2675b7,testing,0.744671
uuid-c419217c51b54f06ba421dd4ab2675b7,PDL1 testing,0.705613
uuid-c419217c51b54f06ba421dd4ab2675b7,NSCLC patients,0.439327
uuid-c419217c51b54f06ba421dd4ab2675b7,assay,0.685129
uuid-c419217c51b54f06ba421dd4ab2675b7,biomarker,0.489094
uuid-701683b884784f96b209e27ce5ac0c64,1L,0.579243
uuid-701683b884784f96b209e27ce5ac0c64,PDL1,0.564112
uuid-701683b884784f96b209e27ce5ac0c64,TL stated,0.367127
uuid-701683b884784f96b209e27ce5ac0c64,2L,0.416707
uuid-701683b884784f96b209e27ce5ac0c64,PD-L1,0.669701
uuid-701683b884784f96b209e27ce5ac0c64,preferred,0.304798
uuid-701683b884784f96b209e27ce5ac0c64,PD-L1 testing,0.555616
uuid-701683b884784f96b209e27ce5ac0c64,testing,0.71066
uuid-701683b884784f96b209e27ce5ac0c64,PDL1 testing,0.678721
uuid-701683b884784f96b209e27ce5ac0c64,NSCLC patients,0.652335
uuid-701683b884784f96b209e27ce5ac0c64,tumor types,0.350061
uuid-701683b884784f96b209e27ce5ac0c64,assay,0.3098
uuid-701683b884784f96b209e27ce5ac0c64,PD-1,0.304677
uuid-701683b884784f96b209e27ce5ac0c64,PDL1 expression,0.36098
uuid-701683b884784f96b209e27ce5ac0c64,option,0.419158
uuid-701683b884784f96b209e27ce5ac0c64,biomarker,0.52056
uuid-2dacf9aec314491da64cbd94417efca0,patients,0.369144
uuid-2dacf9aec314491da64cbd94417efca0,PDL1,0.31089
uuid-2dacf9aec314491da64cbd94417efca0,PD-L1,0.5978
uuid-2dacf9aec314491da64cbd94417efca0,PD-L1 testing,0.676524
uuid-2dacf9aec314491da64cbd94417efca0,testing,0.72999
uuid-2dacf9aec314491da64cbd94417efca0,PDL1 testing,0.631971
uuid-2dacf9aec314491da64cbd94417efca0,NSCLC patients,0.575859
uuid-2dacf9aec314491da64cbd94417efca0,assay,0.335004
uuid-2dacf9aec314491da64cbd94417efca0,biomarker,0.411125
uuid-bb21a93497ce43e1ba7373dcedcab66c,Nivo,0.35138
uuid-bb21a93497ce43e1ba7373dcedcab66c,patients,0.525874
uuid-bb21a93497ce43e1ba7373dcedcab66c,pembro,0.483733
uuid-bb21a93497ce43e1ba7373dcedcab66c,therapy,0.329149
uuid-bb21a93497ce43e1ba7373dcedcab66c,1L,0.603063
uuid-bb21a93497ce43e1ba7373dcedcab66c,PDL1,0.397715
uuid-bb21a93497ce43e1ba7373dcedcab66c,chemo,0.50994
uuid-bb21a93497ce43e1ba7373dcedcab66c,2L,0.473955
uuid-bb21a93497ce43e1ba7373dcedcab66c,pts,0.475102
uuid-bb21a93497ce43e1ba7373dcedcab66c,atezo,0.352885
uuid-bb21a93497ce43e1ba7373dcedcab66c,preferred,0.377983
uuid-bb21a93497ce43e1ba7373dcedcab66c,monotherapy,0.524907
uuid-bb21a93497ce43e1ba7373dcedcab66c,combo,0.353382
uuid-bb21a93497ce43e1ba7373dcedcab66c,clinical trials,0.336042
uuid-bb21a93497ce43e1ba7373dcedcab66c,NSCLC patients,0.383676
uuid-bb21a93497ce43e1ba7373dcedcab66c,PD1,0.313313
uuid-bb21a93497ce43e1ba7373dcedcab66c,approved,0.373773
uuid-bb21a93497ce43e1ba7373dcedcab66c,chemotherapy,0.494402
uuid-bb21a93497ce43e1ba7373dcedcab66c,feels,0.316739
uuid-bb21a93497ce43e1ba7373dcedcab66c,PDL1 expression,0.361345
uuid-bb21a93497ce43e1ba7373dcedcab66c,option,0.586841
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,pembro,0.46488
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,1L,0.43924
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,2L,0.410245
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,agents,0.344137
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,Merck,0.306808
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,approval,0.348325
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,atezo,0.464532
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,preferred,0.457743
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,using nivo,0.338187
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,clinical trials,0.48253
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,indication,0.402005
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,approved,0.529468
uuid-91cd744d3e074ed9b6f86b9e062c0c4f,option,0.328205
uuid-47ebc6ec2c734738a872ddc9c7668243,Nivo,0.350572
uuid-47ebc6ec2c734738a872ddc9c7668243,patients,0.695499
uuid-47ebc6ec2c734738a872ddc9c7668243,therapy,0.612024
uuid-47ebc6ec2c734738a872ddc9c7668243,toxicity,0.304908
uuid-47ebc6ec2c734738a872ddc9c7668243,regimen,0.392417
uuid-47ebc6ec2c734738a872ddc9c7668243,treated,0.304721
uuid-47ebc6ec2c734738a872ddc9c7668243,chemo,0.603787
uuid-47ebc6ec2c734738a872ddc9c7668243,pts,0.524122
uuid-47ebc6ec2c734738a872ddc9c7668243,monotherapy,0.419808
uuid-47ebc6ec2c734738a872ddc9c7668243,treatment,0.566953
uuid-47ebc6ec2c734738a872ddc9c7668243,response,0.437238
uuid-47ebc6ec2c734738a872ddc9c7668243,PD1,0.367831
uuid-47ebc6ec2c734738a872ddc9c7668243,progression,0.566905
uuid-47ebc6ec2c734738a872ddc9c7668243,chemotherapy,0.625055
uuid-47ebc6ec2c734738a872ddc9c7668243,respond,0.477929
uuid-47ebc6ec2c734738a872ddc9c7668243,option,0.436784
uuid-4bf6edcf2c9343a09220b619c3d49b6f,Nivo,0.404816
uuid-4bf6edcf2c9343a09220b619c3d49b6f,pembro,0.490187
uuid-4bf6edcf2c9343a09220b619c3d49b6f,1L,0.345449
uuid-4bf6edcf2c9343a09220b619c3d49b6f,PDL1,0.484366
uuid-4bf6edcf2c9343a09220b619c3d49b6f,trial,0.577792
uuid-4bf6edcf2c9343a09220b619c3d49b6f,efficacy,0.627026
uuid-4bf6edcf2c9343a09220b619c3d49b6f,chemo,0.342984
uuid-4bf6edcf2c9343a09220b619c3d49b6f,OS,0.508345
uuid-4bf6edcf2c9343a09220b619c3d49b6f,atezo,0.401856
uuid-4bf6edcf2c9343a09220b619c3d49b6f,data,0.545855
uuid-4bf6edcf2c9343a09220b619c3d49b6f,indication,0.352855
uuid-4bf6edcf2c9343a09220b619c3d49b6f,PFS,0.507297
uuid-4bf6edcf2c9343a09220b619c3d49b6f,ORR,0.531791
uuid-4bf6edcf2c9343a09220b619c3d49b6f,nivo and pembro,0.486955
uuid-4bf6edcf2c9343a09220b619c3d49b6f,believes,0.421019
uuid-4bf6edcf2c9343a09220b619c3d49b6f,chemotherapy,0.380269
uuid-4bf6edcf2c9343a09220b619c3d49b6f,impressed,0.349186
uuid-4bf6edcf2c9343a09220b619c3d49b6f,vs,0.314325
uuid-4bf6edcf2c9343a09220b619c3d49b6f,feels,0.409509
uuid-4bf6edcf2c9343a09220b619c3d49b6f,PDL1 expression,0.466253
uuid-4bf6edcf2c9343a09220b619c3d49b6f,option,0.324965
uuid-0c64d37b9a1f4f5182fa73050914d3a2,pembro,0.431654
uuid-0c64d37b9a1f4f5182fa73050914d3a2,1L,0.467587
uuid-0c64d37b9a1f4f5182fa73050914d3a2,PDL1,0.665428
uuid-0c64d37b9a1f4f5182fa73050914d3a2,efficacy,0.473076
uuid-0c64d37b9a1f4f5182fa73050914d3a2,2L,0.325056
uuid-0c64d37b9a1f4f5182fa73050914d3a2,PD-L1,0.444138
uuid-0c64d37b9a1f4f5182fa73050914d3a2,OS,0.476424
uuid-0c64d37b9a1f4f5182fa73050914d3a2,atezo,0.427277
uuid-0c64d37b9a1f4f5182fa73050914d3a2,data,0.596135
uuid-0c64d37b9a1f4f5182fa73050914d3a2,indication,0.327637
uuid-0c64d37b9a1f4f5182fa73050914d3a2,PFS,0.464829
uuid-0c64d37b9a1f4f5182fa73050914d3a2,ORR,0.466034
uuid-0c64d37b9a1f4f5182fa73050914d3a2,nivo and pembro,0.555669
uuid-0c64d37b9a1f4f5182fa73050914d3a2,believes,0.486216
uuid-0c64d37b9a1f4f5182fa73050914d3a2,impressed,0.370081
uuid-0c64d37b9a1f4f5182fa73050914d3a2,feels,0.374065
uuid-0c64d37b9a1f4f5182fa73050914d3a2,PDL1 expression,0.602553
uuid-0c64d37b9a1f4f5182fa73050914d3a2,option,0.32284
uuid-0c64d37b9a1f4f5182fa73050914d3a2,biomarker,0.41104
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,Nivo,0.377454
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,pembro,0.508279
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,therapy,0.302139
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,1L,0.610618
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,trial,0.414296
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,combination,0.501913
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,chemo,0.475793
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,2L,0.528717
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,agents,0.584685
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,atezo,0.431356
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,preferred,0.480917
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,monotherapy,0.569564
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,using nivo,0.310721
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,combo,0.489679
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,clinical trials,0.359414
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,indication,0.334535
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,PD1,0.414107
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,approved,0.451023
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,nivo and pembro,0.358199
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,believes,0.388209
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,chemotherapy,0.45035
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,tumor types,0.302055
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,feels,0.332479
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,PD-1,0.40473
uuid-ad3b5bb5d5384070b3d2385cdeca85b6,option,0.545108
uuid-8c0102d04a7b42608471b0b65ee2f64c,TL,0.362502
uuid-8c0102d04a7b42608471b0b65ee2f64c,pembro,0.458771
uuid-8c0102d04a7b42608471b0b65ee2f64c,NSCLC,0.334267
uuid-8c0102d04a7b42608471b0b65ee2f64c,1L,0.478767
uuid-8c0102d04a7b42608471b0b65ee2f64c,RCC,0.320646
uuid-8c0102d04a7b42608471b0b65ee2f64c,TL stated,0.431582
uuid-8c0102d04a7b42608471b0b65ee2f64c,2L,0.580696
uuid-8c0102d04a7b42608471b0b65ee2f64c,agents,0.351898
uuid-8c0102d04a7b42608471b0b65ee2f64c,PD-L1,0.392628
uuid-8c0102d04a7b42608471b0b65ee2f64c,atezo,0.639721
uuid-8c0102d04a7b42608471b0b65ee2f64c,preferred,0.560531
uuid-8c0102d04a7b42608471b0b65ee2f64c,PD-L1 testing,0.424794
uuid-8c0102d04a7b42608471b0b65ee2f64c,testing,0.428401
uuid-8c0102d04a7b42608471b0b65ee2f64c,using nivo,0.374737
uuid-8c0102d04a7b42608471b0b65ee2f64c,PDL1 testing,0.500774
uuid-8c0102d04a7b42608471b0b65ee2f64c,NSCLC patients,0.376501
uuid-8c0102d04a7b42608471b0b65ee2f64c,approved,0.369064
uuid-8c0102d04a7b42608471b0b65ee2f64c,TLs,0.343908
uuid-8c0102d04a7b42608471b0b65ee2f64c,RTL stated,0.31736
uuid-8c0102d04a7b42608471b0b65ee2f64c,bladder,0.329498
uuid-93aa2b1b50904b7fac978811a8e95aeb,Nivo,0.340498
uuid-93aa2b1b50904b7fac978811a8e95aeb,patients,0.693289
uuid-93aa2b1b50904b7fac978811a8e95aeb,therapy,0.736737
uuid-93aa2b1b50904b7fac978811a8e95aeb,nivolumab,0.433904
uuid-93aa2b1b50904b7fac978811a8e95aeb,toxicity,0.304938
uuid-93aa2b1b50904b7fac978811a8e95aeb,regimen,0.455613
uuid-93aa2b1b50904b7fac978811a8e95aeb,treated,0.364517
uuid-93aa2b1b50904b7fac978811a8e95aeb,combination,0.423567
uuid-93aa2b1b50904b7fac978811a8e95aeb,chemo,0.594583
uuid-93aa2b1b50904b7fac978811a8e95aeb,pts,0.565267
uuid-93aa2b1b50904b7fac978811a8e95aeb,IO,0.356755
uuid-93aa2b1b50904b7fac978811a8e95aeb,monotherapy,0.520719
uuid-93aa2b1b50904b7fac978811a8e95aeb,treatment,0.608795
uuid-93aa2b1b50904b7fac978811a8e95aeb,response,0.784146
uuid-93aa2b1b50904b7fac978811a8e95aeb,PD1,0.589974
uuid-93aa2b1b50904b7fac978811a8e95aeb,progression,0.729728
uuid-93aa2b1b50904b7fac978811a8e95aeb,chemotherapy,0.571782
uuid-93aa2b1b50904b7fac978811a8e95aeb,respond,0.592458
uuid-93aa2b1b50904b7fac978811a8e95aeb,immunotherapy,0.317853
uuid-93aa2b1b50904b7fac978811a8e95aeb,PD-1,0.307568
uuid-93aa2b1b50904b7fac978811a8e95aeb,option,0.430382
uuid-97648253f6ca4af8ba42404b08d9df29,BMS,0.379685
uuid-97648253f6ca4af8ba42404b08d9df29,PDL1,0.4303
uuid-97648253f6ca4af8ba42404b08d9df29,trial,0.36851
uuid-97648253f6ca4af8ba42404b08d9df29,efficacy,0.562262
uuid-97648253f6ca4af8ba42404b08d9df29,commented,0.33409
uuid-97648253f6ca4af8ba42404b08d9df29,OS,0.826823
uuid-97648253f6ca4af8ba42404b08d9df29,regards,0.356314
uuid-97648253f6ca4af8ba42404b08d9df29,data,0.779879
uuid-97648253f6ca4af8ba42404b08d9df29,PFS,0.791224
uuid-97648253f6ca4af8ba42404b08d9df29,ORR,0.755949
uuid-97648253f6ca4af8ba42404b08d9df29,nivo and pembro,0.359172
uuid-97648253f6ca4af8ba42404b08d9df29,ASCO,0.35095
uuid-97648253f6ca4af8ba42404b08d9df29,impressed,0.608155
uuid-97648253f6ca4af8ba42404b08d9df29,feels,0.348546
uuid-97648253f6ca4af8ba42404b08d9df29,PDL1 expression,0.376134
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,Nivo,0.392029
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,pembro,0.401091
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,PDL1,0.531152
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,trial,0.470021
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,efficacy,0.691334
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,chemo,0.304683
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,OS,0.600524
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,atezo,0.34129
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,data,0.591498
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,PFS,0.618935
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,ORR,0.688792
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,nivo and pembro,0.576525
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,believes,0.370005
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,impressed,0.348284
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,vs,0.429045
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,feels,0.36025
uuid-b7b2ea6db3174d1eb76b3e0ef265ad90,PDL1 expression,0.587038
uuid-5bde485702fa4b188507949f8701c88c,lung,0.315676
uuid-5bde485702fa4b188507949f8701c88c,NTL,0.383745
uuid-5bde485702fa4b188507949f8701c88c,shared,0.339811
uuid-5bde485702fa4b188507949f8701c88c,commented,0.339717
uuid-5bde485702fa4b188507949f8701c88c,mentioned,0.300332
uuid-5bde485702fa4b188507949f8701c88c,Regional TL,0.334702
uuid-5bde485702fa4b188507949f8701c88c,NCCN,0.421284
uuid-ab0af99061c1406990aefdb94ae25d71,patients,0.775259
uuid-ab0af99061c1406990aefdb94ae25d71,Opdivo,0.545728
uuid-ab0af99061c1406990aefdb94ae25d71,therapy,0.470129
uuid-ab0af99061c1406990aefdb94ae25d71,nivolumab,0.481861
uuid-ab0af99061c1406990aefdb94ae25d71,regimen,0.41551
uuid-ab0af99061c1406990aefdb94ae25d71,treated,0.546724
uuid-ab0af99061c1406990aefdb94ae25d71,pts,0.538466
uuid-ab0af99061c1406990aefdb94ae25d71,treatment,0.558509
uuid-ab0af99061c1406990aefdb94ae25d71,response,0.446572
uuid-ab0af99061c1406990aefdb94ae25d71,cHL,0.324834
uuid-ab0af99061c1406990aefdb94ae25d71,progression,0.619233
uuid-ab0af99061c1406990aefdb94ae25d71,respond,0.448761
uuid-39913ff7de1549429d574c73c8aab0df,NTL,0.382005
uuid-39913ff7de1549429d574c73c8aab0df,lung cancer,0.436077
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,Nivo,0.349154
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,patients,0.347319
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,pembro,0.543229
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,1L,0.612105
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,PDL1,0.4048
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,chemo,0.398752
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,2L,0.560765
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,agents,0.331416
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,PD-L1,0.308774
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,approval,0.316654
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,atezo,0.474713
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,preferred,0.479814
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,monotherapy,0.449985
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,using nivo,0.408422
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,NSCLC patients,0.366895
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,PD1,0.33491
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,approved,0.384859
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,nivo and pembro,0.407117
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,believes,0.435183
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,vs,0.340081
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,feels,0.317
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,PDL1 expression,0.345234
uuid-e1dc662cbbcd4bca9066aa72a9cef2f7,option,0.508169
uuid-51a6fa710be04004b7ed59da91a7dab4,lung,0.462639
uuid-51a6fa710be04004b7ed59da91a7dab4,melanoma,0.350988
uuid-51a6fa710be04004b7ed59da91a7dab4,OS,0.362071
uuid-51a6fa710be04004b7ed59da91a7dab4,regards,0.444378
uuid-51a6fa710be04004b7ed59da91a7dab4,PFS,0.422073
uuid-51a6fa710be04004b7ed59da91a7dab4,AI,0.817301
uuid-51a6fa710be04004b7ed59da91a7dab4,ORR,0.337475
uuid-51a6fa710be04004b7ed59da91a7dab4,nivo and pembro,0.361696
uuid-51a6fa710be04004b7ed59da91a7dab4,believes,0.300926
uuid-51a6fa710be04004b7ed59da91a7dab4,NCCN,0.348866
uuid-04b172aeaf22404a907c835fd45e02ac,Nivo,0.392599
uuid-04b172aeaf22404a907c835fd45e02ac,pembro,0.392875
uuid-04b172aeaf22404a907c835fd45e02ac,RTL,0.3738
uuid-04b172aeaf22404a907c835fd45e02ac,BMS,0.402257
uuid-04b172aeaf22404a907c835fd45e02ac,trial,0.758539
uuid-04b172aeaf22404a907c835fd45e02ac,Merck,0.302706
uuid-04b172aeaf22404a907c835fd45e02ac,OS,0.32244
uuid-04b172aeaf22404a907c835fd45e02ac,data,0.573193
uuid-04b172aeaf22404a907c835fd45e02ac,clinical trials,0.456784
uuid-04b172aeaf22404a907c835fd45e02ac,PFS,0.35683
uuid-04b172aeaf22404a907c835fd45e02ac,ORR,0.430053
uuid-04b172aeaf22404a907c835fd45e02ac,impressed,0.540619
uuid-04b172aeaf22404a907c835fd45e02ac,feels,0.375362
uuid-a06ed4462ec94f5ebde35c98abd027ac,patients,0.546562
uuid-a06ed4462ec94f5ebde35c98abd027ac,therapy,0.328005
uuid-a06ed4462ec94f5ebde35c98abd027ac,nivolumab,0.50368
uuid-a06ed4462ec94f5ebde35c98abd027ac,regimen,0.323738
uuid-a06ed4462ec94f5ebde35c98abd027ac,treated,0.523837
uuid-a06ed4462ec94f5ebde35c98abd027ac,shared,0.387064
uuid-a06ed4462ec94f5ebde35c98abd027ac,RCC,0.383785
uuid-a06ed4462ec94f5ebde35c98abd027ac,combination,0.310884
uuid-a06ed4462ec94f5ebde35c98abd027ac,2L,0.362294
uuid-a06ed4462ec94f5ebde35c98abd027ac,pts,0.437637
uuid-a06ed4462ec94f5ebde35c98abd027ac,stated,0.300595
uuid-a06ed4462ec94f5ebde35c98abd027ac,approval,0.388657
uuid-a06ed4462ec94f5ebde35c98abd027ac,preferred,0.303134
uuid-a06ed4462ec94f5ebde35c98abd027ac,monotherapy,0.396298
uuid-a06ed4462ec94f5ebde35c98abd027ac,treatment,0.331673
uuid-a06ed4462ec94f5ebde35c98abd027ac,using nivo,0.487543
uuid-a06ed4462ec94f5ebde35c98abd027ac,clinical trials,0.391886
uuid-a06ed4462ec94f5ebde35c98abd027ac,approved,0.365792
uuid-a06ed4462ec94f5ebde35c98abd027ac,SCCHN,0.386149
uuid-a06ed4462ec94f5ebde35c98abd027ac,progression,0.30073
uuid-a06ed4462ec94f5ebde35c98abd027ac,chemotherapy,0.345046
uuid-a06ed4462ec94f5ebde35c98abd027ac,tumor types,0.397658
uuid-a06ed4462ec94f5ebde35c98abd027ac,SCLC,0.308013
uuid-a06ed4462ec94f5ebde35c98abd027ac,Regional TL,0.308769
uuid-a06ed4462ec94f5ebde35c98abd027ac,RTL stated,0.428224
uuid-a06ed4462ec94f5ebde35c98abd027ac,option,0.369485
uuid-a06ed4462ec94f5ebde35c98abd027ac,bladder,0.443579
uuid-16bf595706fa4dcebcbc65ac7e940a8c,BMS,0.642003
uuid-16bf595706fa4dcebcbc65ac7e940a8c,PDL1,0.680859
uuid-16bf595706fa4dcebcbc65ac7e940a8c,trial,0.364753
uuid-16bf595706fa4dcebcbc65ac7e940a8c,efficacy,0.412307
uuid-16bf595706fa4dcebcbc65ac7e940a8c,commented,0.353771
uuid-16bf595706fa4dcebcbc65ac7e940a8c,Merck,0.669557
uuid-16bf595706fa4dcebcbc65ac7e940a8c,PD-L1,0.428134
uuid-16bf595706fa4dcebcbc65ac7e940a8c,OS,0.456132
uuid-16bf595706fa4dcebcbc65ac7e940a8c,testing,0.34928
uuid-16bf595706fa4dcebcbc65ac7e940a8c,regards,0.466812
uuid-16bf595706fa4dcebcbc65ac7e940a8c,data,0.657399
uuid-16bf595706fa4dcebcbc65ac7e940a8c,expressed,0.357235
uuid-16bf595706fa4dcebcbc65ac7e940a8c,PFS,0.458682
uuid-16bf595706fa4dcebcbc65ac7e940a8c,ORR,0.431762
uuid-16bf595706fa4dcebcbc65ac7e940a8c,nivo and pembro,0.455631
uuid-16bf595706fa4dcebcbc65ac7e940a8c,impressed,0.374393
uuid-16bf595706fa4dcebcbc65ac7e940a8c,assay,0.48188
uuid-16bf595706fa4dcebcbc65ac7e940a8c,PDL1 expression,0.590015
uuid-16bf595706fa4dcebcbc65ac7e940a8c,biomarker,0.53253
uuid-388f0cfd31f34d45a67d03c9be578e93,BMS,0.399386
uuid-388f0cfd31f34d45a67d03c9be578e93,PDL1,0.427609
uuid-388f0cfd31f34d45a67d03c9be578e93,trial,0.402404
uuid-388f0cfd31f34d45a67d03c9be578e93,efficacy,0.528459
uuid-388f0cfd31f34d45a67d03c9be578e93,discussed,0.306432
uuid-388f0cfd31f34d45a67d03c9be578e93,commented,0.309942
uuid-388f0cfd31f34d45a67d03c9be578e93,OS,0.713196
uuid-388f0cfd31f34d45a67d03c9be578e93,regards,0.391427
uuid-388f0cfd31f34d45a67d03c9be578e93,data,0.773669
uuid-388f0cfd31f34d45a67d03c9be578e93,PFS,0.683201
uuid-388f0cfd31f34d45a67d03c9be578e93,ORR,0.674131
uuid-388f0cfd31f34d45a67d03c9be578e93,nivo and pembro,0.401135
uuid-388f0cfd31f34d45a67d03c9be578e93,ASCO,0.350998
uuid-388f0cfd31f34d45a67d03c9be578e93,impressed,0.505837
uuid-388f0cfd31f34d45a67d03c9be578e93,PDL1 expression,0.560927
uuid-5c7f1a01a6894d4c8b7033b884a6027b,RTL,0.429739
uuid-5c7f1a01a6894d4c8b7033b884a6027b,lung,0.418014
uuid-5c7f1a01a6894d4c8b7033b884a6027b,NTL,0.351616
uuid-5c7f1a01a6894d4c8b7033b884a6027b,melanoma,0.498871
uuid-5c7f1a01a6894d4c8b7033b884a6027b,shared,0.4093
uuid-5c7f1a01a6894d4c8b7033b884a6027b,commented,0.501118
uuid-5c7f1a01a6894d4c8b7033b884a6027b,RCC,0.370769
uuid-5c7f1a01a6894d4c8b7033b884a6027b,Ipi,0.319019
uuid-5c7f1a01a6894d4c8b7033b884a6027b,stated,0.454417
uuid-5c7f1a01a6894d4c8b7033b884a6027b,atezo,0.320143
uuid-5c7f1a01a6894d4c8b7033b884a6027b,regards,0.366815
uuid-5c7f1a01a6894d4c8b7033b884a6027b,data,0.507275
uuid-5c7f1a01a6894d4c8b7033b884a6027b,expressed,0.409311
uuid-5c7f1a01a6894d4c8b7033b884a6027b,indication,0.362132
uuid-5c7f1a01a6894d4c8b7033b884a6027b,SCCHN,0.512781
uuid-5c7f1a01a6894d4c8b7033b884a6027b,ASCO,0.304217
uuid-5c7f1a01a6894d4c8b7033b884a6027b,impressed,0.476598
uuid-5c7f1a01a6894d4c8b7033b884a6027b,TLs,0.471709
uuid-5c7f1a01a6894d4c8b7033b884a6027b,SCLC,0.541764
uuid-5c7f1a01a6894d4c8b7033b884a6027b,Regional TL,0.374421
uuid-5c7f1a01a6894d4c8b7033b884a6027b,NCCN,0.466275
uuid-5c7f1a01a6894d4c8b7033b884a6027b,bladder,0.370232
uuid-04ababbbb9a7442085954d92b8447d17,patients,0.660323
uuid-04ababbbb9a7442085954d92b8447d17,Opdivo,0.311148
uuid-04ababbbb9a7442085954d92b8447d17,toxicity,0.606315
uuid-04ababbbb9a7442085954d92b8447d17,regimen,0.526493
uuid-04ababbbb9a7442085954d92b8447d17,treated,0.363234
uuid-04ababbbb9a7442085954d92b8447d17,chemo,0.320848
uuid-04ababbbb9a7442085954d92b8447d17,pts,0.444643
uuid-04ababbbb9a7442085954d92b8447d17,treatment,0.555987
uuid-04ababbbb9a7442085954d92b8447d17,response,0.35517
uuid-04ababbbb9a7442085954d92b8447d17,progression,0.488298
uuid-04ababbbb9a7442085954d92b8447d17,respond,0.579434
uuid-3dfc68677ae7461db0242e35351cd82e,RTL,0.382458
uuid-3dfc68677ae7461db0242e35351cd82e,1L,0.424773
uuid-3dfc68677ae7461db0242e35351cd82e,melanoma,0.371034
uuid-3dfc68677ae7461db0242e35351cd82e,shared,0.519298
uuid-3dfc68677ae7461db0242e35351cd82e,RCC,0.469864
uuid-3dfc68677ae7461db0242e35351cd82e,combination,0.44267
uuid-3dfc68677ae7461db0242e35351cd82e,2L,0.459924
uuid-3dfc68677ae7461db0242e35351cd82e,agents,0.323374
uuid-3dfc68677ae7461db0242e35351cd82e,stated,0.399338
uuid-3dfc68677ae7461db0242e35351cd82e,preferred,0.489255
uuid-3dfc68677ae7461db0242e35351cd82e,monotherapy,0.45684
uuid-3dfc68677ae7461db0242e35351cd82e,using nivo,0.403513
uuid-3dfc68677ae7461db0242e35351cd82e,combo,0.520059
uuid-3dfc68677ae7461db0242e35351cd82e,expressed,0.303156
uuid-3dfc68677ae7461db0242e35351cd82e,clinical trials,0.413878
uuid-3dfc68677ae7461db0242e35351cd82e,SCCHN,0.471155
uuid-3dfc68677ae7461db0242e35351cd82e,tumor types,0.318654
uuid-3dfc68677ae7461db0242e35351cd82e,LTL,0.427893
uuid-3dfc68677ae7461db0242e35351cd82e,TLs,0.407579
uuid-3dfc68677ae7461db0242e35351cd82e,academic,0.326461
uuid-3dfc68677ae7461db0242e35351cd82e,feels,0.348774
uuid-3dfc68677ae7461db0242e35351cd82e,Regional TL,0.357732
uuid-3dfc68677ae7461db0242e35351cd82e,RTL stated,0.526489
uuid-3dfc68677ae7461db0242e35351cd82e,TL shared,0.358251
uuid-3dfc68677ae7461db0242e35351cd82e,option,0.49039
uuid-3dfc68677ae7461db0242e35351cd82e,bladder,0.391476
uuid-a18f3dc6215c4e4292c81e311339dd32,pembro,0.538206
uuid-a18f3dc6215c4e4292c81e311339dd32,dose,0.342323
uuid-a18f3dc6215c4e4292c81e311339dd32,BMS,0.51391
uuid-a18f3dc6215c4e4292c81e311339dd32,trial,0.388125
uuid-a18f3dc6215c4e4292c81e311339dd32,shared,0.379043
uuid-a18f3dc6215c4e4292c81e311339dd32,commented,0.331232
uuid-a18f3dc6215c4e4292c81e311339dd32,Merck,0.46249
uuid-a18f3dc6215c4e4292c81e311339dd32,stated,0.391561
uuid-a18f3dc6215c4e4292c81e311339dd32,approval,0.528714
uuid-a18f3dc6215c4e4292c81e311339dd32,atezo,0.496722
uuid-a18f3dc6215c4e4292c81e311339dd32,data,0.473442
uuid-a18f3dc6215c4e4292c81e311339dd32,expressed,0.30314
uuid-a18f3dc6215c4e4292c81e311339dd32,clinical trials,0.441488
uuid-a18f3dc6215c4e4292c81e311339dd32,indication,0.603868
uuid-a18f3dc6215c4e4292c81e311339dd32,approved,0.560624
uuid-a18f3dc6215c4e4292c81e311339dd32,SCCHN,0.36871
uuid-a18f3dc6215c4e4292c81e311339dd32,impressed,0.383186
uuid-a18f3dc6215c4e4292c81e311339dd32,vs,0.343097
uuid-a18f3dc6215c4e4292c81e311339dd32,label,0.447927
uuid-a18f3dc6215c4e4292c81e311339dd32,LTL,0.348264
uuid-a18f3dc6215c4e4292c81e311339dd32,Keytruda,0.331854
uuid-a18f3dc6215c4e4292c81e311339dd32,TLs,0.362943
uuid-a18f3dc6215c4e4292c81e311339dd32,bladder,0.339861
uuid-a18f3dc6215c4e4292c81e311339dd32,flat dosing,0.615099
uuid-09b7676321744b62b358c914e13d94db,Nivo,0.378394
uuid-09b7676321744b62b358c914e13d94db,pembro,0.500424
uuid-09b7676321744b62b358c914e13d94db,1L,0.518273
uuid-09b7676321744b62b358c914e13d94db,PDL1,0.456203
uuid-09b7676321744b62b358c914e13d94db,trial,0.40007
uuid-09b7676321744b62b358c914e13d94db,efficacy,0.396519
uuid-09b7676321744b62b358c914e13d94db,chemo,0.406284
uuid-09b7676321744b62b358c914e13d94db,2L,0.404596
uuid-09b7676321744b62b358c914e13d94db,OS,0.405651
uuid-09b7676321744b62b358c914e13d94db,atezo,0.403332
uuid-09b7676321744b62b358c914e13d94db,monotherapy,0.414728
uuid-09b7676321744b62b358c914e13d94db,data,0.462568
uuid-09b7676321744b62b358c914e13d94db,combo,0.36829
uuid-09b7676321744b62b358c914e13d94db,PFS,0.391952
uuid-09b7676321744b62b358c914e13d94db,ORR,0.418368
uuid-09b7676321744b62b358c914e13d94db,nivo and pembro,0.512164
uuid-09b7676321744b62b358c914e13d94db,believes,0.487354
uuid-09b7676321744b62b358c914e13d94db,impressed,0.364415
uuid-09b7676321744b62b358c914e13d94db,feels,0.589309
uuid-09b7676321744b62b358c914e13d94db,PDL1 expression,0.38346
uuid-09b7676321744b62b358c914e13d94db,option,0.410155
uuid-1230bdf7fa6c419785e5ffd4a967082b,1L,0.440517
uuid-1230bdf7fa6c419785e5ffd4a967082b,PDL1,0.705641
uuid-1230bdf7fa6c419785e5ffd4a967082b,efficacy,0.390974
uuid-1230bdf7fa6c419785e5ffd4a967082b,2L,0.370518
uuid-1230bdf7fa6c419785e5ffd4a967082b,agents,0.494136
uuid-1230bdf7fa6c419785e5ffd4a967082b,PD-L1,0.508044
uuid-1230bdf7fa6c419785e5ffd4a967082b,atezo,0.378895
uuid-1230bdf7fa6c419785e5ffd4a967082b,testing,0.370168
uuid-1230bdf7fa6c419785e5ffd4a967082b,data,0.302387
uuid-1230bdf7fa6c419785e5ffd4a967082b,PDL1 testing,0.358139
uuid-1230bdf7fa6c419785e5ffd4a967082b,nivo and pembro,0.512755
uuid-1230bdf7fa6c419785e5ffd4a967082b,believes,0.456055
uuid-1230bdf7fa6c419785e5ffd4a967082b,tumor types,0.307939
uuid-1230bdf7fa6c419785e5ffd4a967082b,assay,0.36688
uuid-1230bdf7fa6c419785e5ffd4a967082b,PD-1,0.427532
uuid-1230bdf7fa6c419785e5ffd4a967082b,PDL1 expression,0.609049
uuid-1230bdf7fa6c419785e5ffd4a967082b,biomarker,0.614712
uuid-f4dcaff2043b432495ede5bf44461b77,Nivo,0.334355
uuid-f4dcaff2043b432495ede5bf44461b77,patients,0.66842
uuid-f4dcaff2043b432495ede5bf44461b77,Opdivo,0.484442
uuid-f4dcaff2043b432495ede5bf44461b77,therapy,0.361903
uuid-f4dcaff2043b432495ede5bf44461b77,dose,0.540519
uuid-f4dcaff2043b432495ede5bf44461b77,nivolumab,0.416132
uuid-f4dcaff2043b432495ede5bf44461b77,toxicity,0.501611
uuid-f4dcaff2043b432495ede5bf44461b77,regimen,0.598606
uuid-f4dcaff2043b432495ede5bf44461b77,treated,0.364831
uuid-f4dcaff2043b432495ede5bf44461b77,combination,0.350956
uuid-f4dcaff2043b432495ede5bf44461b77,chemo,0.370016
uuid-f4dcaff2043b432495ede5bf44461b77,2L,0.316762
uuid-f4dcaff2043b432495ede5bf44461b77,pts,0.492315
uuid-f4dcaff2043b432495ede5bf44461b77,Ipi,0.391592
uuid-f4dcaff2043b432495ede5bf44461b77,preferred,0.394878
uuid-f4dcaff2043b432495ede5bf44461b77,monotherapy,0.463591
uuid-f4dcaff2043b432495ede5bf44461b77,treatment,0.497499
uuid-f4dcaff2043b432495ede5bf44461b77,using nivo,0.335598
uuid-f4dcaff2043b432495ede5bf44461b77,response,0.312155
uuid-f4dcaff2043b432495ede5bf44461b77,combo,0.387704
uuid-f4dcaff2043b432495ede5bf44461b77,progression,0.537391
uuid-f4dcaff2043b432495ede5bf44461b77,chemotherapy,0.306523
uuid-f4dcaff2043b432495ede5bf44461b77,respond,0.406415
uuid-f4dcaff2043b432495ede5bf44461b77,option,0.415916
uuid-f4dcaff2043b432495ede5bf44461b77,flat dosing,0.302897
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,Nivo,0.324798
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,therapy,0.322761
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,nivolumab,0.374882
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,combination,0.318981
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,chemo,0.307143
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,treatment,0.329011
uuid-15dec3b84b324c7c9eeceb69c47bb5e3,chemotherapy,0.314954
uuid-30ac65a09f1d4c14a94fe497cb41c989,patients,0.63739
uuid-30ac65a09f1d4c14a94fe497cb41c989,Opdivo,0.371488
uuid-30ac65a09f1d4c14a94fe497cb41c989,therapy,0.431987
uuid-30ac65a09f1d4c14a94fe497cb41c989,nivolumab,0.373238
uuid-30ac65a09f1d4c14a94fe497cb41c989,toxicity,0.334724
uuid-30ac65a09f1d4c14a94fe497cb41c989,regimen,0.557255
uuid-30ac65a09f1d4c14a94fe497cb41c989,treated,0.553475
uuid-30ac65a09f1d4c14a94fe497cb41c989,pts,0.337687
uuid-30ac65a09f1d4c14a94fe497cb41c989,physicians,0.49611
uuid-30ac65a09f1d4c14a94fe497cb41c989,treatment,0.640578
uuid-30ac65a09f1d4c14a94fe497cb41c989,response,0.47341
uuid-30ac65a09f1d4c14a94fe497cb41c989,progression,0.550112
uuid-30ac65a09f1d4c14a94fe497cb41c989,chemotherapy,0.301171
uuid-30ac65a09f1d4c14a94fe497cb41c989,respond,0.478421
uuid-6891065cd8f24c1bacee8f372bf24cbc,1L,0.502667
uuid-6891065cd8f24c1bacee8f372bf24cbc,PDL1,0.551814
uuid-6891065cd8f24c1bacee8f372bf24cbc,chemo,0.435555
uuid-6891065cd8f24c1bacee8f372bf24cbc,PD-L1,0.411285
uuid-6891065cd8f24c1bacee8f372bf24cbc,testing,0.415261
uuid-6891065cd8f24c1bacee8f372bf24cbc,monotherapy,0.345918
uuid-6891065cd8f24c1bacee8f372bf24cbc,combo,0.328518
uuid-6891065cd8f24c1bacee8f372bf24cbc,NSCLC patients,0.39754
uuid-6891065cd8f24c1bacee8f372bf24cbc,believes,0.451537
uuid-6891065cd8f24c1bacee8f372bf24cbc,chemotherapy,0.33402
uuid-6891065cd8f24c1bacee8f372bf24cbc,PD-1,0.306496
uuid-6891065cd8f24c1bacee8f372bf24cbc,PDL1 expression,0.479991
uuid-6891065cd8f24c1bacee8f372bf24cbc,option,0.441026
uuid-6891065cd8f24c1bacee8f372bf24cbc,biomarker,0.502436
uuid-833111069c654a5b8f88690bdf222950,patients,0.350735
uuid-833111069c654a5b8f88690bdf222950,Opdivo,0.573462
uuid-833111069c654a5b8f88690bdf222950,dose,0.824259
uuid-833111069c654a5b8f88690bdf222950,toxicity,0.35163
uuid-833111069c654a5b8f88690bdf222950,regimen,0.31584
uuid-833111069c654a5b8f88690bdf222950,Ipi,0.421366
uuid-833111069c654a5b8f88690bdf222950,vs,0.369567
uuid-833111069c654a5b8f88690bdf222950,drug,0.306784
uuid-833111069c654a5b8f88690bdf222950,Keytruda,0.350699
uuid-833111069c654a5b8f88690bdf222950,flat dosing,0.756369
uuid-27444a86dad348deaf41f14c145fd335,tumor,0.553307
uuid-27444a86dad348deaf41f14c145fd335,pts,0.333589
uuid-27444a86dad348deaf41f14c145fd335,OS,0.36353
uuid-27444a86dad348deaf41f14c145fd335,response,0.563648
uuid-27444a86dad348deaf41f14c145fd335,PFS,0.340843
uuid-27444a86dad348deaf41f14c145fd335,ORR,0.363528
uuid-27444a86dad348deaf41f14c145fd335,progression,0.345428
uuid-27444a86dad348deaf41f14c145fd335,impressed,0.346327
uuid-3b6dd68783494ee38337c3d8dc019ef2,Nivo,0.345284
uuid-3b6dd68783494ee38337c3d8dc019ef2,Opdivo,0.382736
uuid-3b6dd68783494ee38337c3d8dc019ef2,therapy,0.486958
uuid-3b6dd68783494ee38337c3d8dc019ef2,nivolumab,0.594526
uuid-3b6dd68783494ee38337c3d8dc019ef2,combination,0.312829
uuid-3b6dd68783494ee38337c3d8dc019ef2,treatment,0.357273
uuid-3b6dd68783494ee38337c3d8dc019ef2,cHL,0.62752
uuid-3b6dd68783494ee38337c3d8dc019ef2,chemotherapy,0.35135
uuid-1c3c93f33a914db5a5d16e164f2072e6,Nivo,0.491226
uuid-1c3c93f33a914db5a5d16e164f2072e6,patients,0.385462
uuid-1c3c93f33a914db5a5d16e164f2072e6,therapy,0.538009
uuid-1c3c93f33a914db5a5d16e164f2072e6,cHL,0.56636
uuid-1c3c93f33a914db5a5d16e164f2072e6,chemotherapy,0.341872
uuid-7b3b6aae12db4837bd8945b49a0a68de,patients,0.322261
uuid-7b3b6aae12db4837bd8945b49a0a68de,RTL,0.368851
uuid-7b3b6aae12db4837bd8945b49a0a68de,nivolumab,0.35219
uuid-7b3b6aae12db4837bd8945b49a0a68de,treated,0.342822
uuid-7b3b6aae12db4837bd8945b49a0a68de,NTL,0.364121
uuid-7b3b6aae12db4837bd8945b49a0a68de,RCC,0.318787
uuid-7b3b6aae12db4837bd8945b49a0a68de,approval,0.384015
uuid-7b3b6aae12db4837bd8945b49a0a68de,preferred,0.360332
uuid-7b3b6aae12db4837bd8945b49a0a68de,using nivo,0.595322
uuid-7b3b6aae12db4837bd8945b49a0a68de,mentioned,0.342019
uuid-7b3b6aae12db4837bd8945b49a0a68de,SCCHN,0.51593
uuid-7b3b6aae12db4837bd8945b49a0a68de,HCP,0.348187
uuid-7b3b6aae12db4837bd8945b49a0a68de,cHL,0.300877
uuid-7b3b6aae12db4837bd8945b49a0a68de,oncologist,0.48746
uuid-7b3b6aae12db4837bd8945b49a0a68de,indicated,0.509291
uuid-7b3b6aae12db4837bd8945b49a0a68de,Regional TL,0.397192
uuid-7b3b6aae12db4837bd8945b49a0a68de,RTL stated,0.38655
uuid-7b3b6aae12db4837bd8945b49a0a68de,bladder,0.374037
uuid-18f8f1d1ff71437190a3304a8e18cce4,patients,0.482874
uuid-18f8f1d1ff71437190a3304a8e18cce4,Opdivo,0.466298
uuid-18f8f1d1ff71437190a3304a8e18cce4,dose,0.766319
uuid-18f8f1d1ff71437190a3304a8e18cce4,toxicity,0.636966
uuid-18f8f1d1ff71437190a3304a8e18cce4,regimen,0.49859
uuid-18f8f1d1ff71437190a3304a8e18cce4,treated,0.3382
uuid-18f8f1d1ff71437190a3304a8e18cce4,Ipi,0.344964
uuid-18f8f1d1ff71437190a3304a8e18cce4,treatment,0.417799
uuid-18f8f1d1ff71437190a3304a8e18cce4,vs,0.321034
uuid-18f8f1d1ff71437190a3304a8e18cce4,respond,0.339089
uuid-18f8f1d1ff71437190a3304a8e18cce4,flat dosing,0.45173
uuid-62df86ae5e064f8fab6bcff85e0acc0a,RTL,0.404735
uuid-62df86ae5e064f8fab6bcff85e0acc0a,NSCLC patients,0.39485
uuid-4c6b21667a2b4d429327630695300da8,Nivo,0.377175
uuid-4c6b21667a2b4d429327630695300da8,patients,0.370045
uuid-4c6b21667a2b4d429327630695300da8,pembro,0.431055
uuid-4c6b21667a2b4d429327630695300da8,RTL,0.658176
uuid-4c6b21667a2b4d429327630695300da8,nivolumab,0.502548
uuid-4c6b21667a2b4d429327630695300da8,1L,0.378777
uuid-4c6b21667a2b4d429327630695300da8,treated,0.338639
uuid-4c6b21667a2b4d429327630695300da8,NTL,0.329428
uuid-4c6b21667a2b4d429327630695300da8,RCC,0.45286
uuid-4c6b21667a2b4d429327630695300da8,2L,0.432712
uuid-4c6b21667a2b4d429327630695300da8,pts,0.343075
uuid-4c6b21667a2b4d429327630695300da8,stated,0.424204
uuid-4c6b21667a2b4d429327630695300da8,approval,0.482008
uuid-4c6b21667a2b4d429327630695300da8,preferred,0.3866
uuid-4c6b21667a2b4d429327630695300da8,monotherapy,0.358514
uuid-4c6b21667a2b4d429327630695300da8,using nivo,0.694713
uuid-4c6b21667a2b4d429327630695300da8,clinical trials,0.391382
uuid-4c6b21667a2b4d429327630695300da8,approved,0.362034
uuid-4c6b21667a2b4d429327630695300da8,SCCHN,0.676431
uuid-4c6b21667a2b4d429327630695300da8,HCP,0.425422
uuid-4c6b21667a2b4d429327630695300da8,impressed,0.303448
uuid-4c6b21667a2b4d429327630695300da8,LTL,0.492925
uuid-4c6b21667a2b4d429327630695300da8,academic,0.322579
uuid-4c6b21667a2b4d429327630695300da8,SCLC,0.452329
uuid-4c6b21667a2b4d429327630695300da8,Regional TL,0.525371
uuid-4c6b21667a2b4d429327630695300da8,RTL stated,0.677911
uuid-4c6b21667a2b4d429327630695300da8,TL shared,0.354644
uuid-4c6b21667a2b4d429327630695300da8,bladder,0.459585
uuid-482ac79d164543e4bb9177d0b182173d,Nivo,0.623945
uuid-482ac79d164543e4bb9177d0b182173d,pembro,0.683698
uuid-482ac79d164543e4bb9177d0b182173d,1L,0.673384
uuid-482ac79d164543e4bb9177d0b182173d,PDL1,0.369334
uuid-482ac79d164543e4bb9177d0b182173d,trial,0.329338
uuid-482ac79d164543e4bb9177d0b182173d,efficacy,0.392053
uuid-482ac79d164543e4bb9177d0b182173d,chemo,0.363358
uuid-482ac79d164543e4bb9177d0b182173d,2L,0.65224
uuid-482ac79d164543e4bb9177d0b182173d,agents,0.449323
uuid-482ac79d164543e4bb9177d0b182173d,approval,0.444392
uuid-482ac79d164543e4bb9177d0b182173d,OS,0.305802
uuid-482ac79d164543e4bb9177d0b182173d,atezo,0.630813
uuid-482ac79d164543e4bb9177d0b182173d,preferred,0.439952
uuid-482ac79d164543e4bb9177d0b182173d,monotherapy,0.484907
uuid-482ac79d164543e4bb9177d0b182173d,using nivo,0.49201
uuid-482ac79d164543e4bb9177d0b182173d,data,0.503762
uuid-482ac79d164543e4bb9177d0b182173d,combo,0.354108
uuid-482ac79d164543e4bb9177d0b182173d,indication,0.397143
uuid-482ac79d164543e4bb9177d0b182173d,PD1,0.350983
uuid-482ac79d164543e4bb9177d0b182173d,ORR,0.327346
uuid-482ac79d164543e4bb9177d0b182173d,approved,0.577004
uuid-482ac79d164543e4bb9177d0b182173d,nivo and pembro,0.573353
uuid-482ac79d164543e4bb9177d0b182173d,believes,0.426042
uuid-482ac79d164543e4bb9177d0b182173d,impressed,0.341966
uuid-482ac79d164543e4bb9177d0b182173d,SCLC,0.33881
uuid-482ac79d164543e4bb9177d0b182173d,feels,0.434974
uuid-482ac79d164543e4bb9177d0b182173d,RTL stated,0.32799
uuid-482ac79d164543e4bb9177d0b182173d,PDL1 expression,0.342763
uuid-482ac79d164543e4bb9177d0b182173d,option,0.484998
uuid-482ac79d164543e4bb9177d0b182173d,bladder,0.313105
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,Nivo,0.657223
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,pembro,0.793274
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,dose,0.543304
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,1L,0.474378
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,efficacy,0.446461
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,2L,0.649598
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,agents,0.448011
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,Ipi,0.50219
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,atezo,0.857157
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,preferred,0.547113
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,monotherapy,0.396296
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,using nivo,0.512834
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,combo,0.339961
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,indication,0.360099
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,approved,0.470821
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,nivo and pembro,0.507243
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,believes,0.315775
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,vs,0.681115
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,TLs,0.321296
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,feels,0.319258
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,option,0.348112
uuid-1dfde7faa44644f4ae64be4aaa55b4b5,flat dosing,0.4152
uuid-01e1a829df604f6f927c3d6080ebb869,Nivo,0.727173
uuid-01e1a829df604f6f927c3d6080ebb869,patients,0.309141
uuid-01e1a829df604f6f927c3d6080ebb869,pembro,0.467511
uuid-01e1a829df604f6f927c3d6080ebb869,1L,0.48567
uuid-01e1a829df604f6f927c3d6080ebb869,efficacy,0.458254
uuid-01e1a829df604f6f927c3d6080ebb869,regimen,0.374626
uuid-01e1a829df604f6f927c3d6080ebb869,combination,0.377404
uuid-01e1a829df604f6f927c3d6080ebb869,chemo,0.549959
uuid-01e1a829df604f6f927c3d6080ebb869,2L,0.480666
uuid-01e1a829df604f6f927c3d6080ebb869,pts,0.366265
uuid-01e1a829df604f6f927c3d6080ebb869,agents,0.365619
uuid-01e1a829df604f6f927c3d6080ebb869,Ipi,0.380512
uuid-01e1a829df604f6f927c3d6080ebb869,OS,0.386612
uuid-01e1a829df604f6f927c3d6080ebb869,atezo,0.383394
uuid-01e1a829df604f6f927c3d6080ebb869,preferred,0.346517
uuid-01e1a829df604f6f927c3d6080ebb869,monotherapy,0.609228
uuid-01e1a829df604f6f927c3d6080ebb869,using nivo,0.415491
uuid-01e1a829df604f6f927c3d6080ebb869,response,0.314725
uuid-01e1a829df604f6f927c3d6080ebb869,data,0.328669
uuid-01e1a829df604f6f927c3d6080ebb869,combo,0.452682
uuid-01e1a829df604f6f927c3d6080ebb869,PFS,0.331996
uuid-01e1a829df604f6f927c3d6080ebb869,PD1,0.458085
uuid-01e1a829df604f6f927c3d6080ebb869,ORR,0.412541
uuid-01e1a829df604f6f927c3d6080ebb869,nivo and pembro,0.412453
uuid-01e1a829df604f6f927c3d6080ebb869,progression,0.304341
uuid-01e1a829df604f6f927c3d6080ebb869,believes,0.391758
uuid-01e1a829df604f6f927c3d6080ebb869,chemotherapy,0.44932
uuid-01e1a829df604f6f927c3d6080ebb869,impressed,0.378566
uuid-01e1a829df604f6f927c3d6080ebb869,vs,0.321114
uuid-01e1a829df604f6f927c3d6080ebb869,feels,0.455595
uuid-01e1a829df604f6f927c3d6080ebb869,option,0.541479
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,Nivo,0.596526
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,patients,0.509077
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,therapy,0.414829
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,efficacy,0.32894
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,regimen,0.475316
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,combination,0.362863
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,chemo,0.655526
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,pts,0.53129
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,Ipi,0.351547
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,monotherapy,0.526017
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,treatment,0.369101
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,response,0.51104
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,combo,0.388654
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,PD1,0.463117
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,progression,0.552082
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,believes,0.407058
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,chemotherapy,0.515872
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,respond,0.526965
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,feels,0.473461
uuid-a8d0687b3e7c4d599f7b61e0cf9f296b,option,0.428637
uuid-3f4fc1cf15f84679904a0059c7f5bb37,pembro,0.471992
uuid-3f4fc1cf15f84679904a0059c7f5bb37,lung,0.307387
uuid-3f4fc1cf15f84679904a0059c7f5bb37,1L,0.36422
uuid-3f4fc1cf15f84679904a0059c7f5bb37,shared,0.449444
uuid-3f4fc1cf15f84679904a0059c7f5bb37,RCC,0.349167
uuid-3f4fc1cf15f84679904a0059c7f5bb37,TL stated,0.331608
uuid-3f4fc1cf15f84679904a0059c7f5bb37,2L,0.501167
uuid-3f4fc1cf15f84679904a0059c7f5bb37,institution,0.699342
uuid-3f4fc1cf15f84679904a0059c7f5bb37,approval,0.456573
uuid-3f4fc1cf15f84679904a0059c7f5bb37,atezo,0.616429
uuid-3f4fc1cf15f84679904a0059c7f5bb37,preferred,0.390093
uuid-3f4fc1cf15f84679904a0059c7f5bb37,PD-L1 testing,0.329696
uuid-3f4fc1cf15f84679904a0059c7f5bb37,using nivo,0.438921
uuid-3f4fc1cf15f84679904a0059c7f5bb37,PDL1 testing,0.416732
uuid-3f4fc1cf15f84679904a0059c7f5bb37,indication,0.328345
uuid-3f4fc1cf15f84679904a0059c7f5bb37,approved,0.397169
uuid-3f4fc1cf15f84679904a0059c7f5bb37,SCCHN,0.361177
uuid-3f4fc1cf15f84679904a0059c7f5bb37,RTL stated,0.350579
uuid-3f4fc1cf15f84679904a0059c7f5bb37,bladder,0.461956
uuid-251b61c491e44390907a33bfa89ad36b,patients,0.457845
uuid-251b61c491e44390907a33bfa89ad36b,therapy,0.637238
uuid-251b61c491e44390907a33bfa89ad36b,regimen,0.442996
uuid-251b61c491e44390907a33bfa89ad36b,treated,0.359676
uuid-251b61c491e44390907a33bfa89ad36b,combination,0.422965
uuid-251b61c491e44390907a33bfa89ad36b,chemo,0.553306
uuid-251b61c491e44390907a33bfa89ad36b,pts,0.390552
uuid-251b61c491e44390907a33bfa89ad36b,IO,0.340648
uuid-251b61c491e44390907a33bfa89ad36b,monotherapy,0.430364
uuid-251b61c491e44390907a33bfa89ad36b,treatment,0.564258
uuid-251b61c491e44390907a33bfa89ad36b,response,0.417793
uuid-251b61c491e44390907a33bfa89ad36b,combo,0.393751
uuid-251b61c491e44390907a33bfa89ad36b,PD1,0.462212
uuid-251b61c491e44390907a33bfa89ad36b,progression,0.571912
uuid-251b61c491e44390907a33bfa89ad36b,chemotherapy,0.680085
uuid-251b61c491e44390907a33bfa89ad36b,respond,0.313314
uuid-251b61c491e44390907a33bfa89ad36b,immunotherapy,0.365451
uuid-251b61c491e44390907a33bfa89ad36b,option,0.449126
uuid-a7b5d175b1bf4f70a4edb421816a63b9,BMS,0.480597
uuid-a7b5d175b1bf4f70a4edb421816a63b9,physicians,0.458559
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,Nivo,0.505231
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,pembro,0.47339
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,1L,0.610629
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,regimen,0.400006
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,melanoma,0.357642
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,RCC,0.548699
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,combination,0.448708
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,chemo,0.401307
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,2L,0.693143
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,agents,0.375961
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,Ipi,0.500736
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,atezo,0.524225
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,preferred,0.572544
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,monotherapy,0.591347
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,using nivo,0.595323
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,combo,0.563495
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,PD1,0.330844
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,approved,0.379154
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,SCCHN,0.420322
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,believes,0.34676
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,chemotherapy,0.322968
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,TLs,0.35134
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,SCLC,0.362806
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,RTL stated,0.492901
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,TL shared,0.319512
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,option,0.499047
uuid-c04a91f62f7944faa9e1ce2afa41e7a5,bladder,0.44776
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,commented,0.340125
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,stated,0.348762
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,regards,0.446585
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,data,0.340277
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,indication,0.385612
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,SCCHN,0.351862
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,label,0.403002
uuid-7cb6f1eab5d34b65a6e74f984df60a3d,NCCN,0.677931
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,pembro,0.339855
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,BMS,0.354596
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,PDL1,0.60508
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,trial,0.446883
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,efficacy,0.51274
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,OS,0.556662
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,atezo,0.315529
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,regards,0.433283
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,data,0.530846
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,expressed,0.323916
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,PFS,0.626443
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,AI,0.537526
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,ORR,0.589372
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,nivo and pembro,0.728419
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,believes,0.427881
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,PDL1 expression,0.60524
uuid-4d853a8fa3d546729b7bcbe1eaa0a88a,biomarker,0.371212
uuid-07af4d99dfc941649ad935269d75351a,Nivo,0.31137
uuid-07af4d99dfc941649ad935269d75351a,patients,0.864042
uuid-07af4d99dfc941649ad935269d75351a,Opdivo,0.515457
uuid-07af4d99dfc941649ad935269d75351a,therapy,0.73562
uuid-07af4d99dfc941649ad935269d75351a,nivolumab,0.676318
uuid-07af4d99dfc941649ad935269d75351a,regimen,0.474724
uuid-07af4d99dfc941649ad935269d75351a,treated,0.646567
uuid-07af4d99dfc941649ad935269d75351a,chemo,0.310618
uuid-07af4d99dfc941649ad935269d75351a,pts,0.499367
uuid-07af4d99dfc941649ad935269d75351a,monotherapy,0.351374
uuid-07af4d99dfc941649ad935269d75351a,treatment,0.763965
uuid-07af4d99dfc941649ad935269d75351a,using nivo,0.355483
uuid-07af4d99dfc941649ad935269d75351a,response,0.363223
uuid-07af4d99dfc941649ad935269d75351a,PD1,0.377125
uuid-07af4d99dfc941649ad935269d75351a,cHL,0.622284
uuid-07af4d99dfc941649ad935269d75351a,progression,0.629572
uuid-07af4d99dfc941649ad935269d75351a,chemotherapy,0.445135
uuid-07af4d99dfc941649ad935269d75351a,respond,0.441455
uuid-07af4d99dfc941649ad935269d75351a,option,0.300628
uuid-7b8b9e30c5364453b6dffa4ec3228df4,trial,0.406155
uuid-7b8b9e30c5364453b6dffa4ec3228df4,tumor,0.467689
uuid-eaac29661b9f4bacb2d284c45e0ff92a,PDL1,0.777495
uuid-eaac29661b9f4bacb2d284c45e0ff92a,efficacy,0.424962
uuid-eaac29661b9f4bacb2d284c45e0ff92a,PD-L1,0.435622
uuid-eaac29661b9f4bacb2d284c45e0ff92a,OS,0.477849
uuid-eaac29661b9f4bacb2d284c45e0ff92a,data,0.329088
uuid-eaac29661b9f4bacb2d284c45e0ff92a,PFS,0.489381
uuid-eaac29661b9f4bacb2d284c45e0ff92a,ORR,0.458486
uuid-eaac29661b9f4bacb2d284c45e0ff92a,nivo and pembro,0.513441
uuid-eaac29661b9f4bacb2d284c45e0ff92a,believes,0.524762
uuid-eaac29661b9f4bacb2d284c45e0ff92a,assay,0.392784
uuid-eaac29661b9f4bacb2d284c45e0ff92a,PDL1 expression,0.666228
uuid-eaac29661b9f4bacb2d284c45e0ff92a,biomarker,0.637245
uuid-55a94ca1db094c638125450e44b70389,lung,0.326236
uuid-55a94ca1db094c638125450e44b70389,PDL1,0.570569
uuid-55a94ca1db094c638125450e44b70389,efficacy,0.425115
uuid-55a94ca1db094c638125450e44b70389,OS,0.499309
uuid-55a94ca1db094c638125450e44b70389,regards,0.517339
uuid-55a94ca1db094c638125450e44b70389,data,0.47461
uuid-55a94ca1db094c638125450e44b70389,expressed,0.33134
uuid-55a94ca1db094c638125450e44b70389,PFS,0.582671
uuid-55a94ca1db094c638125450e44b70389,AI,0.672215
uuid-55a94ca1db094c638125450e44b70389,ORR,0.51305
uuid-55a94ca1db094c638125450e44b70389,nivo and pembro,0.640852
uuid-55a94ca1db094c638125450e44b70389,believes,0.303585
uuid-55a94ca1db094c638125450e44b70389,PDL1 expression,0.557307
uuid-55a94ca1db094c638125450e44b70389,biomarker,0.382959
uuid-55a94ca1db094c638125450e44b70389,NCCN,0.487196
uuid-a44232e341924198a910eac2abfb2db0,TL,0.389003
uuid-a44232e341924198a910eac2abfb2db0,PDL1,0.39681
uuid-a44232e341924198a910eac2abfb2db0,tumor,0.37036
uuid-a44232e341924198a910eac2abfb2db0,PD-L1,0.593585
uuid-a44232e341924198a910eac2abfb2db0,PD-L1 testing,0.547791
uuid-a44232e341924198a910eac2abfb2db0,testing,0.600114
uuid-a44232e341924198a910eac2abfb2db0,PDL1 testing,0.349191
uuid-a44232e341924198a910eac2abfb2db0,NSCLC patients,0.426286
uuid-a44232e341924198a910eac2abfb2db0,assay,0.527148
uuid-a44232e341924198a910eac2abfb2db0,biomarker,0.341008
uuid-f787162f35644c3a99a3e94e11b30f24,lung,0.37785
uuid-f787162f35644c3a99a3e94e11b30f24,OS,0.574836
uuid-f787162f35644c3a99a3e94e11b30f24,regards,0.336028
uuid-f787162f35644c3a99a3e94e11b30f24,response,0.424467
uuid-f787162f35644c3a99a3e94e11b30f24,PFS,0.587051
uuid-f787162f35644c3a99a3e94e11b30f24,AI,0.491564
uuid-f787162f35644c3a99a3e94e11b30f24,ORR,0.499758
uuid-f787162f35644c3a99a3e94e11b30f24,nivo and pembro,0.354839
uuid-f787162f35644c3a99a3e94e11b30f24,believes,0.411693
uuid-b4478b93ed04468d99a8c0be324c05f0,pembro,0.398153
uuid-b4478b93ed04468d99a8c0be324c05f0,nivolumab,0.377972
uuid-b4478b93ed04468d99a8c0be324c05f0,1L,0.480938
uuid-b4478b93ed04468d99a8c0be324c05f0,RCC,0.571871
uuid-b4478b93ed04468d99a8c0be324c05f0,TL stated,0.314737
uuid-b4478b93ed04468d99a8c0be324c05f0,combination,0.518351
uuid-b4478b93ed04468d99a8c0be324c05f0,2L,0.586459
uuid-b4478b93ed04468d99a8c0be324c05f0,agents,0.448437
uuid-b4478b93ed04468d99a8c0be324c05f0,Ipi,0.308453
uuid-b4478b93ed04468d99a8c0be324c05f0,approval,0.330645
uuid-b4478b93ed04468d99a8c0be324c05f0,atezo,0.454846
uuid-b4478b93ed04468d99a8c0be324c05f0,preferred,0.600547
uuid-b4478b93ed04468d99a8c0be324c05f0,monotherapy,0.496365
uuid-b4478b93ed04468d99a8c0be324c05f0,using nivo,0.491199
uuid-b4478b93ed04468d99a8c0be324c05f0,combo,0.54643
uuid-b4478b93ed04468d99a8c0be324c05f0,clinical trials,0.352407
uuid-b4478b93ed04468d99a8c0be324c05f0,approved,0.468458
uuid-b4478b93ed04468d99a8c0be324c05f0,SCCHN,0.389297
uuid-b4478b93ed04468d99a8c0be324c05f0,RTL stated,0.560538
uuid-b4478b93ed04468d99a8c0be324c05f0,TL shared,0.370406
uuid-b4478b93ed04468d99a8c0be324c05f0,option,0.4436
uuid-b4478b93ed04468d99a8c0be324c05f0,bladder,0.517306
uuid-7eee9b97efe446d783ed725f9a975e18,patients,0.350206
uuid-14281317f7da4933ba5f489d10e9c08e,patients,0.488776
uuid-14281317f7da4933ba5f489d10e9c08e,RTL,0.606499
uuid-14281317f7da4933ba5f489d10e9c08e,nivolumab,0.566092
uuid-14281317f7da4933ba5f489d10e9c08e,treated,0.477303
uuid-14281317f7da4933ba5f489d10e9c08e,NTL,0.352003
uuid-14281317f7da4933ba5f489d10e9c08e,RCC,0.403544
uuid-14281317f7da4933ba5f489d10e9c08e,pts,0.406114
uuid-14281317f7da4933ba5f489d10e9c08e,stated,0.318742
uuid-14281317f7da4933ba5f489d10e9c08e,approval,0.358985
uuid-14281317f7da4933ba5f489d10e9c08e,using nivo,0.546133
uuid-14281317f7da4933ba5f489d10e9c08e,mentioned,0.359579
uuid-14281317f7da4933ba5f489d10e9c08e,clinical trials,0.330909
uuid-14281317f7da4933ba5f489d10e9c08e,SCCHN,0.537176
uuid-14281317f7da4933ba5f489d10e9c08e,HCP,0.418133
uuid-14281317f7da4933ba5f489d10e9c08e,cHL,0.400469
uuid-14281317f7da4933ba5f489d10e9c08e,LTL,0.426243
uuid-14281317f7da4933ba5f489d10e9c08e,SCLC,0.508814
uuid-14281317f7da4933ba5f489d10e9c08e,Regional TL,0.458073
uuid-14281317f7da4933ba5f489d10e9c08e,RTL stated,0.538265
uuid-14281317f7da4933ba5f489d10e9c08e,TL shared,0.346603
uuid-14281317f7da4933ba5f489d10e9c08e,bladder,0.39141
uuid-90455846edfb4f0faa39e1fc665d6e05,Nivo,0.328563
uuid-90455846edfb4f0faa39e1fc665d6e05,patients,0.741873
uuid-90455846edfb4f0faa39e1fc665d6e05,therapy,0.432827
uuid-90455846edfb4f0faa39e1fc665d6e05,nivolumab,0.419357
uuid-90455846edfb4f0faa39e1fc665d6e05,toxicity,0.508187
uuid-90455846edfb4f0faa39e1fc665d6e05,regimen,0.653186
uuid-90455846edfb4f0faa39e1fc665d6e05,treated,0.526249
uuid-90455846edfb4f0faa39e1fc665d6e05,combination,0.35346
uuid-90455846edfb4f0faa39e1fc665d6e05,chemo,0.429569
uuid-90455846edfb4f0faa39e1fc665d6e05,pts,0.605763
uuid-90455846edfb4f0faa39e1fc665d6e05,Ipi,0.344741
uuid-90455846edfb4f0faa39e1fc665d6e05,monotherapy,0.474188
uuid-90455846edfb4f0faa39e1fc665d6e05,treatment,0.562383
uuid-90455846edfb4f0faa39e1fc665d6e05,response,0.473386
uuid-90455846edfb4f0faa39e1fc665d6e05,PD1,0.332343
uuid-90455846edfb4f0faa39e1fc665d6e05,progression,0.581459
uuid-90455846edfb4f0faa39e1fc665d6e05,chemotherapy,0.40451
uuid-90455846edfb4f0faa39e1fc665d6e05,respond,0.505446
uuid-90455846edfb4f0faa39e1fc665d6e05,option,0.319591
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,patients,0.709281
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,RTL,0.454359
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,therapy,0.350555
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,nivolumab,0.5751
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,regimen,0.417349
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,treated,0.567962
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,pts,0.513731
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,monotherapy,0.322107
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,treatment,0.450452
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,using nivo,0.468296
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,SCCHN,0.385783
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,HCP,0.380872
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,cHL,0.356961
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,progression,0.429431
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,chemotherapy,0.320275
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,LTL,0.312702
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,SCLC,0.300982
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,Regional TL,0.300979
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,RTL stated,0.419706
uuid-50ddc3fc37ec4d3f8ab44b5266450cff,bladder,0.354774
uuid-3fd15de17aa44a6183a7d7eb137fdc01,patients,0.71485
uuid-3fd15de17aa44a6183a7d7eb137fdc01,Opdivo,0.396366
uuid-3fd15de17aa44a6183a7d7eb137fdc01,therapy,0.50525
uuid-3fd15de17aa44a6183a7d7eb137fdc01,nivolumab,0.452313
uuid-3fd15de17aa44a6183a7d7eb137fdc01,toxicity,0.38853
uuid-3fd15de17aa44a6183a7d7eb137fdc01,regimen,0.481387
uuid-3fd15de17aa44a6183a7d7eb137fdc01,treated,0.505476
uuid-3fd15de17aa44a6183a7d7eb137fdc01,pts,0.379748
uuid-3fd15de17aa44a6183a7d7eb137fdc01,treatment,0.567305
uuid-3fd15de17aa44a6183a7d7eb137fdc01,using nivo,0.310864
uuid-3fd15de17aa44a6183a7d7eb137fdc01,progression,0.449616
uuid-3fd15de17aa44a6183a7d7eb137fdc01,chemotherapy,0.384073
uuid-3fd15de17aa44a6183a7d7eb137fdc01,respond,0.351242
uuid-e8de6abdf026435fb02b1dfe171ab084,patients,0.464877
uuid-e8de6abdf026435fb02b1dfe171ab084,Opdivo,0.517809
uuid-e8de6abdf026435fb02b1dfe171ab084,dose,0.469875
uuid-e8de6abdf026435fb02b1dfe171ab084,flat dosing,0.535433
uuid-90ec05cd59224615bb5fc59ff64fd963,commented,0.48357
uuid-90ec05cd59224615bb5fc59ff64fd963,OS,0.628295
uuid-90ec05cd59224615bb5fc59ff64fd963,regards,0.338364
uuid-90ec05cd59224615bb5fc59ff64fd963,data,0.537027
uuid-90ec05cd59224615bb5fc59ff64fd963,PFS,0.559418
uuid-90ec05cd59224615bb5fc59ff64fd963,ORR,0.522271
uuid-90ec05cd59224615bb5fc59ff64fd963,ASCO,0.429934
uuid-90ec05cd59224615bb5fc59ff64fd963,impressed,0.523175
uuid-90ec05cd59224615bb5fc59ff64fd963,NCCN,0.377261
uuid-fa71acaa1f9043a7af297710aa58870d,regimen,0.324504
uuid-fa71acaa1f9043a7af297710aa58870d,chemo,0.318957
uuid-fa71acaa1f9043a7af297710aa58870d,OS,0.31448
uuid-fa71acaa1f9043a7af297710aa58870d,response,0.513801
uuid-fa71acaa1f9043a7af297710aa58870d,progression,0.474682
uuid-fa71acaa1f9043a7af297710aa58870d,respond,0.413039
uuid-d703ec863afd4f3f9521d3f3914006b6,RTL,0.478043
uuid-d703ec863afd4f3f9521d3f3914006b6,lung,0.510394
uuid-d703ec863afd4f3f9521d3f3914006b6,melanoma,0.399264
uuid-d703ec863afd4f3f9521d3f3914006b6,shared,0.340823
uuid-d703ec863afd4f3f9521d3f3914006b6,commented,0.419321
uuid-d703ec863afd4f3f9521d3f3914006b6,RCC,0.544259
uuid-d703ec863afd4f3f9521d3f3914006b6,TL stated,0.636643
uuid-d703ec863afd4f3f9521d3f3914006b6,stated,0.518829
uuid-d703ec863afd4f3f9521d3f3914006b6,testing,0.354564
uuid-d703ec863afd4f3f9521d3f3914006b6,PDL1 testing,0.573833
uuid-d703ec863afd4f3f9521d3f3914006b6,NSCLC patients,0.533251
uuid-d703ec863afd4f3f9521d3f3914006b6,SCCHN,0.566853
uuid-d703ec863afd4f3f9521d3f3914006b6,impressed,0.309411
uuid-d703ec863afd4f3f9521d3f3914006b6,tumor types,0.491666
uuid-d703ec863afd4f3f9521d3f3914006b6,LTL,0.367361
uuid-d703ec863afd4f3f9521d3f3914006b6,TLs,0.453592
uuid-d703ec863afd4f3f9521d3f3914006b6,academic,0.399511
uuid-d703ec863afd4f3f9521d3f3914006b6,Regional TL,0.509253
uuid-d703ec863afd4f3f9521d3f3914006b6,RTL stated,0.498886
uuid-d703ec863afd4f3f9521d3f3914006b6,TL shared,0.494597
uuid-d703ec863afd4f3f9521d3f3914006b6,bladder,0.367465
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,patients,0.361351
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,therapy,0.371806
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,toxicity,0.309542
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,regimen,0.347275
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,combination,0.343307
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,chemo,0.380872
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,2L,0.319516
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,pts,0.312443
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,monotherapy,0.413833
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,response,0.301456
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,combo,0.39043
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,PD1,0.431783
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,progression,0.352139
uuid-cf7eaaa713ee4f458f12fbb4b9b3493c,option,0.390215
uuid-cb62131e5acc486eaca931b13cfaa635,patients,0.321572
uuid-cb62131e5acc486eaca931b13cfaa635,therapy,0.57129
uuid-cb62131e5acc486eaca931b13cfaa635,nivolumab,0.503358
uuid-cb62131e5acc486eaca931b13cfaa635,treated,0.468752
uuid-cb62131e5acc486eaca931b13cfaa635,tumor,0.436514
uuid-cb62131e5acc486eaca931b13cfaa635,pts,0.314231
uuid-cb62131e5acc486eaca931b13cfaa635,treatment,0.384226
uuid-cb62131e5acc486eaca931b13cfaa635,response,0.524631
uuid-cb62131e5acc486eaca931b13cfaa635,PD1,0.430544
uuid-cb62131e5acc486eaca931b13cfaa635,cHL,0.555659
uuid-cb62131e5acc486eaca931b13cfaa635,progression,0.449449
uuid-cb62131e5acc486eaca931b13cfaa635,immunotherapy,0.394559
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,Nivo,0.562412
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,pembro,0.468487
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,trial,0.550957
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,efficacy,0.347127
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,combination,0.386937
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,chemo,0.459575
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,Ipi,0.489965
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,atezo,0.307462
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,monotherapy,0.314502
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,combo,0.386166
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,clinical trials,0.357077
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,chemotherapy,0.383116
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,vs,0.513351
uuid-5d33c3f54b6443a6a7f94f12cf17dd90,feels,0.579344
uuid-20897a35d0f646548268e9a5578a9297,RTL,0.370635
uuid-20897a35d0f646548268e9a5578a9297,lung,0.301555
uuid-20897a35d0f646548268e9a5578a9297,NTL,0.315697
uuid-20897a35d0f646548268e9a5578a9297,shared,0.313621
uuid-20897a35d0f646548268e9a5578a9297,commented,0.517417
uuid-20897a35d0f646548268e9a5578a9297,RCC,0.319869
uuid-20897a35d0f646548268e9a5578a9297,TL stated,0.305601
uuid-20897a35d0f646548268e9a5578a9297,stated,0.334607
uuid-20897a35d0f646548268e9a5578a9297,physicians,0.313065
uuid-20897a35d0f646548268e9a5578a9297,SCCHN,0.426589
uuid-20897a35d0f646548268e9a5578a9297,ASCO,0.586094
uuid-20897a35d0f646548268e9a5578a9297,impressed,0.4996
uuid-20897a35d0f646548268e9a5578a9297,TLs,0.307346
uuid-20897a35d0f646548268e9a5578a9297,Regional TL,0.536414
uuid-20897a35d0f646548268e9a5578a9297,TL shared,0.343527
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,pembro,0.468858
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,dose,0.784684
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,toxicity,0.427162
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,Ipi,0.397859
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,atezo,0.372915
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,vs,0.650818
uuid-a2b5a68ae5ee4e5a93836a8eccfa5f4c,flat dosing,0.51851
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,RTL,0.38107
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,trial,0.315034
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,treated,0.30638
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,RCC,0.411073
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,stated,0.329878
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,preferred,0.41299
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,using nivo,0.394329
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,clinical trials,0.32728
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,SCCHN,0.570229
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,Regional TL,0.411852
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,RTL stated,0.529506
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,TL shared,0.452641
uuid-c1851f0f010e4106a23ecdb4dc71dbf1,bladder,0.379477
uuid-a3098252bbfe46b080ab79fecfac19e6,patients,0.68364
uuid-a3098252bbfe46b080ab79fecfac19e6,Opdivo,0.347419
uuid-a3098252bbfe46b080ab79fecfac19e6,therapy,0.486541
uuid-a3098252bbfe46b080ab79fecfac19e6,nivolumab,0.566837
uuid-a3098252bbfe46b080ab79fecfac19e6,regimen,0.407625
uuid-a3098252bbfe46b080ab79fecfac19e6,treated,0.772135
uuid-a3098252bbfe46b080ab79fecfac19e6,pts,0.355922
uuid-a3098252bbfe46b080ab79fecfac19e6,treatment,0.582146
uuid-a3098252bbfe46b080ab79fecfac19e6,response,0.304876
uuid-a3098252bbfe46b080ab79fecfac19e6,cHL,0.401611
uuid-a3098252bbfe46b080ab79fecfac19e6,progression,0.471721
uuid-a3098252bbfe46b080ab79fecfac19e6,respond,0.335628
uuid-a3098252bbfe46b080ab79fecfac19e6,RTL stated,0.338174
uuid-a3098252bbfe46b080ab79fecfac19e6,TL shared,0.333169
uuid-936eab9305744416b1d27e4706a46f46,RTL,0.375982
uuid-936eab9305744416b1d27e4706a46f46,BMS,0.549705
uuid-936eab9305744416b1d27e4706a46f46,trial,0.399664
uuid-936eab9305744416b1d27e4706a46f46,commented,0.637614
uuid-936eab9305744416b1d27e4706a46f46,Merck,0.425376
uuid-936eab9305744416b1d27e4706a46f46,stated,0.491975
uuid-936eab9305744416b1d27e4706a46f46,OS,0.476347
uuid-936eab9305744416b1d27e4706a46f46,regards,0.42943
uuid-936eab9305744416b1d27e4706a46f46,data,0.788854
uuid-936eab9305744416b1d27e4706a46f46,expressed,0.452713
uuid-936eab9305744416b1d27e4706a46f46,PFS,0.417648
uuid-936eab9305744416b1d27e4706a46f46,ORR,0.454753
uuid-936eab9305744416b1d27e4706a46f46,SCCHN,0.362276
uuid-936eab9305744416b1d27e4706a46f46,nivo and pembro,0.354962
uuid-936eab9305744416b1d27e4706a46f46,ASCO,0.439254
uuid-936eab9305744416b1d27e4706a46f46,impressed,0.635618
uuid-936eab9305744416b1d27e4706a46f46,LTL,0.312384
uuid-936eab9305744416b1d27e4706a46f46,TLs,0.462183
uuid-936eab9305744416b1d27e4706a46f46,Regional TL,0.428605
uuid-936eab9305744416b1d27e4706a46f46,NCCN,0.352055
uuid-920cc6a6fa444e3f98b8a34e1d77107d,patients,0.542125
uuid-920cc6a6fa444e3f98b8a34e1d77107d,chemo,0.409498
uuid-920cc6a6fa444e3f98b8a34e1d77107d,pts,0.499703
uuid-920cc6a6fa444e3f98b8a34e1d77107d,response,0.459538
uuid-920cc6a6fa444e3f98b8a34e1d77107d,NSCLC patients,0.520593
uuid-920cc6a6fa444e3f98b8a34e1d77107d,progression,0.439858
uuid-920cc6a6fa444e3f98b8a34e1d77107d,respond,0.515268
uuid-bcd717d2853d4942993c64389a4514ea,toxicity,0.393909
uuid-bcd717d2853d4942993c64389a4514ea,efficacy,0.304813
uuid-bcd717d2853d4942993c64389a4514ea,chemo,0.330763
uuid-bcd717d2853d4942993c64389a4514ea,chemotherapy,0.359211
uuid-bcd717d2853d4942993c64389a4514ea,feels,0.353546
uuid-4409b7cb66f0471ba577eee1dae8d301,RTL,0.483185
uuid-4409b7cb66f0471ba577eee1dae8d301,nivolumab,0.453247
uuid-4409b7cb66f0471ba577eee1dae8d301,lung,0.339635
uuid-4409b7cb66f0471ba577eee1dae8d301,trial,0.376406
uuid-4409b7cb66f0471ba577eee1dae8d301,NTL,0.60303
uuid-4409b7cb66f0471ba577eee1dae8d301,melanoma,0.309394
uuid-4409b7cb66f0471ba577eee1dae8d301,stated,0.311144
uuid-4409b7cb66f0471ba577eee1dae8d301,mentioned,0.365169
uuid-4409b7cb66f0471ba577eee1dae8d301,cHL,0.321792
uuid-4409b7cb66f0471ba577eee1dae8d301,Regional TL,0.461572
uuid-4409b7cb66f0471ba577eee1dae8d301,bladder,0.303086
uuid-6317b99f9eb647e2a257e34a65900db1,lung,0.535269
uuid-6317b99f9eb647e2a257e34a65900db1,melanoma,0.322277
uuid-6317b99f9eb647e2a257e34a65900db1,institution,0.321128
uuid-6317b99f9eb647e2a257e34a65900db1,regards,0.408519
uuid-6317b99f9eb647e2a257e34a65900db1,AI,0.941087
uuid-6317b99f9eb647e2a257e34a65900db1,oncology,0.391327
uuid-6317b99f9eb647e2a257e34a65900db1,nivo and pembro,0.342464
uuid-6317b99f9eb647e2a257e34a65900db1,NCCN,0.549678
uuid-ee28c9b238e943d3be0510bcef304854,Nivo,0.429808
uuid-ee28c9b238e943d3be0510bcef304854,patients,0.641622
uuid-ee28c9b238e943d3be0510bcef304854,therapy,0.415277
uuid-ee28c9b238e943d3be0510bcef304854,toxicity,0.491391
uuid-ee28c9b238e943d3be0510bcef304854,regimen,0.471648
uuid-ee28c9b238e943d3be0510bcef304854,treated,0.322259
uuid-ee28c9b238e943d3be0510bcef304854,chemo,0.49021
uuid-ee28c9b238e943d3be0510bcef304854,pts,0.483064
uuid-ee28c9b238e943d3be0510bcef304854,monotherapy,0.326737
uuid-ee28c9b238e943d3be0510bcef304854,treatment,0.483997
uuid-ee28c9b238e943d3be0510bcef304854,response,0.500184
uuid-ee28c9b238e943d3be0510bcef304854,progression,0.520173
uuid-ee28c9b238e943d3be0510bcef304854,chemotherapy,0.445104
uuid-ee28c9b238e943d3be0510bcef304854,respond,0.511157
uuid-d8fd41ce1ecc4ce78450fe2a3a907b2d,lung,0.421209
uuid-d8fd41ce1ecc4ce78450fe2a3a907b2d,toxicity,0.368436
uuid-d8fd41ce1ecc4ce78450fe2a3a907b2d,regimen,0.447456
uuid-d8fd41ce1ecc4ce78450fe2a3a907b2d,melanoma,0.490269
uuid-d8fd41ce1ecc4ce78450fe2a3a907b2d,AI,0.69466
uuid-23a22d3267cc4c6f9f269a431f956209,Opdivo,0.313067
uuid-23a22d3267cc4c6f9f269a431f956209,shared,0.367285
uuid-23a22d3267cc4c6f9f269a431f956209,commented,0.357084
uuid-23a22d3267cc4c6f9f269a431f956209,stated,0.314352
uuid-23a22d3267cc4c6f9f269a431f956209,approval,0.35529
uuid-23a22d3267cc4c6f9f269a431f956209,indication,0.379714
uuid-23a22d3267cc4c6f9f269a431f956209,oncology,0.390818
uuid-23a22d3267cc4c6f9f269a431f956209,approved,0.335124
uuid-23a22d3267cc4c6f9f269a431f956209,SCCHN,0.348874
uuid-23a22d3267cc4c6f9f269a431f956209,label,0.391518
uuid-23a22d3267cc4c6f9f269a431f956209,oncologist,0.306416
uuid-23a22d3267cc4c6f9f269a431f956209,indicated,0.375453
uuid-23a22d3267cc4c6f9f269a431f956209,clinical,0.306785
uuid-23a22d3267cc4c6f9f269a431f956209,Regional TL,0.351981
uuid-23a22d3267cc4c6f9f269a431f956209,NCCN,0.360529
uuid-23a22d3267cc4c6f9f269a431f956209,flat dosing,0.441036
uuid-3523f2cc5f014274b98a1944ac4cbfb8,patients,0.660672
uuid-3523f2cc5f014274b98a1944ac4cbfb8,therapy,0.596819
uuid-3523f2cc5f014274b98a1944ac4cbfb8,nivolumab,0.359768
uuid-3523f2cc5f014274b98a1944ac4cbfb8,toxicity,0.348539
uuid-3523f2cc5f014274b98a1944ac4cbfb8,regimen,0.571339
uuid-3523f2cc5f014274b98a1944ac4cbfb8,treated,0.425886
uuid-3523f2cc5f014274b98a1944ac4cbfb8,combination,0.452655
uuid-3523f2cc5f014274b98a1944ac4cbfb8,chemo,0.617394
uuid-3523f2cc5f014274b98a1944ac4cbfb8,pts,0.528014
uuid-3523f2cc5f014274b98a1944ac4cbfb8,IO,0.388347
uuid-3523f2cc5f014274b98a1944ac4cbfb8,monotherapy,0.518906
uuid-3523f2cc5f014274b98a1944ac4cbfb8,treatment,0.668446
uuid-3523f2cc5f014274b98a1944ac4cbfb8,response,0.615217
uuid-3523f2cc5f014274b98a1944ac4cbfb8,combo,0.37553
uuid-3523f2cc5f014274b98a1944ac4cbfb8,PD1,0.547593
uuid-3523f2cc5f014274b98a1944ac4cbfb8,progression,0.752785
uuid-3523f2cc5f014274b98a1944ac4cbfb8,chemotherapy,0.608226
uuid-3523f2cc5f014274b98a1944ac4cbfb8,respond,0.554711
uuid-3523f2cc5f014274b98a1944ac4cbfb8,feels,0.367322
uuid-3523f2cc5f014274b98a1944ac4cbfb8,option,0.457842
uuid-fe5877c817e042dc8eae9872d9b17dab,patients,0.457658
uuid-128b67783d934e74b55b0caf6644d978,RTL,0.443287
uuid-128b67783d934e74b55b0caf6644d978,lung,0.315964
uuid-128b67783d934e74b55b0caf6644d978,toxicity,0.358608
uuid-128b67783d934e74b55b0caf6644d978,regimen,0.417613
uuid-128b67783d934e74b55b0caf6644d978,treated,0.396793
uuid-128b67783d934e74b55b0caf6644d978,melanoma,0.528087
uuid-128b67783d934e74b55b0caf6644d978,shared,0.364815
uuid-128b67783d934e74b55b0caf6644d978,commented,0.300166
uuid-128b67783d934e74b55b0caf6644d978,RCC,0.372155
uuid-128b67783d934e74b55b0caf6644d978,stated,0.427792
uuid-128b67783d934e74b55b0caf6644d978,SCCHN,0.451835
uuid-128b67783d934e74b55b0caf6644d978,LTL,0.379883
uuid-128b67783d934e74b55b0caf6644d978,academic,0.340129
uuid-128b67783d934e74b55b0caf6644d978,SCLC,0.379631
uuid-128b67783d934e74b55b0caf6644d978,Regional TL,0.407865
uuid-128b67783d934e74b55b0caf6644d978,RTL stated,0.362982
uuid-128b67783d934e74b55b0caf6644d978,TL shared,0.423561
uuid-fb6984e7c7f54a51870b28f56b154426,TL,0.464336
uuid-fb6984e7c7f54a51870b28f56b154426,1L,0.315652
uuid-fb6984e7c7f54a51870b28f56b154426,PDL1,0.405188
uuid-fb6984e7c7f54a51870b28f56b154426,TL stated,0.502702
uuid-fb6984e7c7f54a51870b28f56b154426,PD-L1,0.810368
uuid-fb6984e7c7f54a51870b28f56b154426,PD-L1 testing,0.801233
uuid-fb6984e7c7f54a51870b28f56b154426,testing,0.85929
uuid-fb6984e7c7f54a51870b28f56b154426,PDL1 testing,0.738596
uuid-fb6984e7c7f54a51870b28f56b154426,NSCLC patients,0.715206
uuid-fb6984e7c7f54a51870b28f56b154426,tumor types,0.328978
uuid-fb6984e7c7f54a51870b28f56b154426,assay,0.594051
uuid-fb6984e7c7f54a51870b28f56b154426,biomarker,0.449718
uuid-af75dba7de334fdeb339b9abb5b25462,patients,0.436288
uuid-af75dba7de334fdeb339b9abb5b25462,regimen,0.314726
uuid-af75dba7de334fdeb339b9abb5b25462,pts,0.487619
uuid-af75dba7de334fdeb339b9abb5b25462,IO,0.324854
uuid-af75dba7de334fdeb339b9abb5b25462,monotherapy,0.329011
uuid-af75dba7de334fdeb339b9abb5b25462,response,0.370329
uuid-af75dba7de334fdeb339b9abb5b25462,combo,0.303284
uuid-af75dba7de334fdeb339b9abb5b25462,NSCLC patients,0.338319
uuid-af75dba7de334fdeb339b9abb5b25462,progression,0.446304
uuid-af75dba7de334fdeb339b9abb5b25462,respond,0.341679
uuid-af75dba7de334fdeb339b9abb5b25462,TL shared,0.31315
uuid-92b6abea9cb64a3885240573b094aed3,Nivo,0.311838
uuid-92b6abea9cb64a3885240573b094aed3,pembro,0.359971
uuid-92b6abea9cb64a3885240573b094aed3,efficacy,0.501077
uuid-92b6abea9cb64a3885240573b094aed3,agents,0.327636
uuid-92b6abea9cb64a3885240573b094aed3,atezo,0.340774
uuid-92b6abea9cb64a3885240573b094aed3,ORR,0.352058
uuid-92b6abea9cb64a3885240573b094aed3,nivo and pembro,0.557374
uuid-92b6abea9cb64a3885240573b094aed3,believes,0.316307
uuid-92b6abea9cb64a3885240573b094aed3,vs,0.4859
uuid-92b6abea9cb64a3885240573b094aed3,feels,0.453233
uuid-22acf7e6039d42db9e26cec1010f7b46,pembro,0.344233
uuid-22acf7e6039d42db9e26cec1010f7b46,BMS,0.36278
uuid-22acf7e6039d42db9e26cec1010f7b46,PDL1,0.659307
uuid-22acf7e6039d42db9e26cec1010f7b46,trial,0.568518
uuid-22acf7e6039d42db9e26cec1010f7b46,efficacy,0.570019
uuid-22acf7e6039d42db9e26cec1010f7b46,OS,0.61352
uuid-22acf7e6039d42db9e26cec1010f7b46,data,0.637146
uuid-22acf7e6039d42db9e26cec1010f7b46,PFS,0.678782
uuid-22acf7e6039d42db9e26cec1010f7b46,ORR,0.688956
uuid-22acf7e6039d42db9e26cec1010f7b46,nivo and pembro,0.60552
uuid-22acf7e6039d42db9e26cec1010f7b46,believes,0.422462
uuid-22acf7e6039d42db9e26cec1010f7b46,impressed,0.436641
uuid-22acf7e6039d42db9e26cec1010f7b46,feels,0.571573
uuid-22acf7e6039d42db9e26cec1010f7b46,PDL1 expression,0.627962
uuid-22acf7e6039d42db9e26cec1010f7b46,biomarker,0.329754
uuid-b41b02cdbcf245d7862abd8765f3225d,pembro,0.453745
uuid-b41b02cdbcf245d7862abd8765f3225d,dose,0.330358
uuid-b41b02cdbcf245d7862abd8765f3225d,Merck,0.44875
uuid-b41b02cdbcf245d7862abd8765f3225d,atezo,0.397026
uuid-b41b02cdbcf245d7862abd8765f3225d,data,0.358036
uuid-b41b02cdbcf245d7862abd8765f3225d,vs,0.450352
uuid-b41b02cdbcf245d7862abd8765f3225d,flat dosing,0.368371
uuid-78b5c3f041644f959e10513975441237,1L,0.327543
uuid-78b5c3f041644f959e10513975441237,toxicity,0.397585
uuid-78b5c3f041644f959e10513975441237,regimen,0.323444
uuid-78b5c3f041644f959e10513975441237,combination,0.635081
uuid-78b5c3f041644f959e10513975441237,chemo,0.44719
uuid-78b5c3f041644f959e10513975441237,2L,0.367304
uuid-78b5c3f041644f959e10513975441237,IO,0.447897
uuid-78b5c3f041644f959e10513975441237,agents,0.707019
uuid-78b5c3f041644f959e10513975441237,preferred,0.31903
uuid-78b5c3f041644f959e10513975441237,monotherapy,0.50868
uuid-78b5c3f041644f959e10513975441237,combo,0.666113
uuid-78b5c3f041644f959e10513975441237,PD1,0.459302
uuid-78b5c3f041644f959e10513975441237,believes,0.394534
uuid-78b5c3f041644f959e10513975441237,chemotherapy,0.382312
uuid-78b5c3f041644f959e10513975441237,PD-1,0.385202
uuid-78b5c3f041644f959e10513975441237,option,0.368471
uuid-39001ec45c82481f9b232f92327069b1,TL,0.329105
uuid-39001ec45c82481f9b232f92327069b1,pembro,0.422726
uuid-39001ec45c82481f9b232f92327069b1,BMS,0.358122
uuid-39001ec45c82481f9b232f92327069b1,PDL1,0.604906
uuid-39001ec45c82481f9b232f92327069b1,Merck,0.584301
uuid-39001ec45c82481f9b232f92327069b1,PD-L1,0.695107
uuid-39001ec45c82481f9b232f92327069b1,atezo,0.529162
uuid-39001ec45c82481f9b232f92327069b1,PD-L1 testing,0.516766
uuid-39001ec45c82481f9b232f92327069b1,testing,0.695257
uuid-39001ec45c82481f9b232f92327069b1,PDL1 testing,0.53707
uuid-39001ec45c82481f9b232f92327069b1,NSCLC patients,0.417915
uuid-39001ec45c82481f9b232f92327069b1,nivo and pembro,0.357221
uuid-39001ec45c82481f9b232f92327069b1,assay,0.747507
uuid-39001ec45c82481f9b232f92327069b1,PDL1 expression,0.482089
uuid-39001ec45c82481f9b232f92327069b1,biomarker,0.504142
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,Nivo,0.316682
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,pembro,0.514601
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,dose,0.804098
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,efficacy,0.460852
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,Ipi,0.501278
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,atezo,0.599032
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,preferred,0.346828
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,vs,0.748909
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,TLs,0.409262
uuid-b1d37c5aaf894bf3b752a6fb2998e2d7,flat dosing,0.62251
uuid-1eadb9f1d8a54533a86b98ad21ed160f,patients,0.781477
uuid-1eadb9f1d8a54533a86b98ad21ed160f,Opdivo,0.436624
uuid-1eadb9f1d8a54533a86b98ad21ed160f,therapy,0.385529
uuid-1eadb9f1d8a54533a86b98ad21ed160f,dose,0.343882
uuid-1eadb9f1d8a54533a86b98ad21ed160f,nivolumab,0.436971
uuid-1eadb9f1d8a54533a86b98ad21ed160f,toxicity,0.35153
uuid-1eadb9f1d8a54533a86b98ad21ed160f,regimen,0.495041
uuid-1eadb9f1d8a54533a86b98ad21ed160f,treated,0.620623
uuid-1eadb9f1d8a54533a86b98ad21ed160f,pts,0.403039
uuid-1eadb9f1d8a54533a86b98ad21ed160f,treatment,0.602718
uuid-1eadb9f1d8a54533a86b98ad21ed160f,using nivo,0.319749
uuid-1eadb9f1d8a54533a86b98ad21ed160f,cHL,0.313115
uuid-1eadb9f1d8a54533a86b98ad21ed160f,progression,0.49528
uuid-1eadb9f1d8a54533a86b98ad21ed160f,respond,0.403198
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,patients,0.451919
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,RTL,0.401998
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,treated,0.467963
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,melanoma,0.306307
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,shared,0.346773
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,commented,0.366028
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,RCC,0.40699
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,stated,0.363514
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,approval,0.302866
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,using nivo,0.315137
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,clinical trials,0.410015
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,SCCHN,0.524899
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,Regional TL,0.473842
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,RTL stated,0.484073
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,TL shared,0.44655
uuid-6be4dee0d65e44c1a4be074ccdac7fe6,bladder,0.348154
uuid-299d7f9388484b0fa392ac47c11e834f,lung,0.432445
uuid-299d7f9388484b0fa392ac47c11e834f,1L,0.414741
uuid-299d7f9388484b0fa392ac47c11e834f,melanoma,0.36263
uuid-299d7f9388484b0fa392ac47c11e834f,RCC,0.450958
uuid-299d7f9388484b0fa392ac47c11e834f,TL stated,0.34676
uuid-299d7f9388484b0fa392ac47c11e834f,2L,0.450815
uuid-299d7f9388484b0fa392ac47c11e834f,agents,0.487693
uuid-299d7f9388484b0fa392ac47c11e834f,preferred,0.365417
uuid-299d7f9388484b0fa392ac47c11e834f,monotherapy,0.38128
uuid-299d7f9388484b0fa392ac47c11e834f,using nivo,0.322823
uuid-299d7f9388484b0fa392ac47c11e834f,PD1,0.415323
uuid-299d7f9388484b0fa392ac47c11e834f,PD-1,0.477355
uuid-299d7f9388484b0fa392ac47c11e834f,RTL stated,0.364928
uuid-299d7f9388484b0fa392ac47c11e834f,TL shared,0.335378
uuid-299d7f9388484b0fa392ac47c11e834f,option,0.361004
uuid-cafaaa5c005644cc9a8b0ec06b5be452,lung,0.432445
uuid-cafaaa5c005644cc9a8b0ec06b5be452,1L,0.414741
uuid-cafaaa5c005644cc9a8b0ec06b5be452,melanoma,0.36263
uuid-cafaaa5c005644cc9a8b0ec06b5be452,RCC,0.450958
uuid-cafaaa5c005644cc9a8b0ec06b5be452,TL stated,0.34676
uuid-cafaaa5c005644cc9a8b0ec06b5be452,2L,0.450815
uuid-cafaaa5c005644cc9a8b0ec06b5be452,agents,0.487693
uuid-cafaaa5c005644cc9a8b0ec06b5be452,preferred,0.365417
uuid-cafaaa5c005644cc9a8b0ec06b5be452,monotherapy,0.38128
uuid-cafaaa5c005644cc9a8b0ec06b5be452,using nivo,0.322823
uuid-cafaaa5c005644cc9a8b0ec06b5be452,PD1,0.415323
uuid-cafaaa5c005644cc9a8b0ec06b5be452,PD-1,0.477355
uuid-cafaaa5c005644cc9a8b0ec06b5be452,RTL stated,0.364928
uuid-cafaaa5c005644cc9a8b0ec06b5be452,TL shared,0.335378
uuid-cafaaa5c005644cc9a8b0ec06b5be452,option,0.361004
uuid-2a198f1ba5f849989252bb51a9843b57,Nivo,0.402565
uuid-2a198f1ba5f849989252bb51a9843b57,pembro,0.429759
uuid-2a198f1ba5f849989252bb51a9843b57,dose,0.333789
uuid-2a198f1ba5f849989252bb51a9843b57,trial,0.419865
uuid-2a198f1ba5f849989252bb51a9843b57,efficacy,0.586732
uuid-2a198f1ba5f849989252bb51a9843b57,combination,0.307183
uuid-2a198f1ba5f849989252bb51a9843b57,chemo,0.311392
uuid-2a198f1ba5f849989252bb51a9843b57,agents,0.35953
uuid-2a198f1ba5f849989252bb51a9843b57,Ipi,0.334602
uuid-2a198f1ba5f849989252bb51a9843b57,atezo,0.395585
uuid-2a198f1ba5f849989252bb51a9843b57,combo,0.334896
uuid-2a198f1ba5f849989252bb51a9843b57,nivo and pembro,0.400457
uuid-2a198f1ba5f849989252bb51a9843b57,believes,0.403088
uuid-2a198f1ba5f849989252bb51a9843b57,vs,0.647296
uuid-2a198f1ba5f849989252bb51a9843b57,feels,0.544736
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,patients,0.436288
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,regimen,0.314726
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,pts,0.487619
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,IO,0.324854
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,monotherapy,0.329011
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,response,0.370329
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,combo,0.303284
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,NSCLC patients,0.338319
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,progression,0.446304
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,respond,0.341679
uuid-4bcf01d7cd8e4e76bf247eeaae5b7a74,TL shared,0.31315
uuid-ad5fd8092dfc4639a9e26302756a8edf,Opdivo,0.430018
uuid-ad5fd8092dfc4639a9e26302756a8edf,dose,0.885298
uuid-ad5fd8092dfc4639a9e26302756a8edf,toxicity,0.40225
uuid-ad5fd8092dfc4639a9e26302756a8edf,efficacy,0.325901
uuid-ad5fd8092dfc4639a9e26302756a8edf,Ipi,0.452246
uuid-ad5fd8092dfc4639a9e26302756a8edf,vs,0.545441
uuid-ad5fd8092dfc4639a9e26302756a8edf,drug,0.36785
uuid-ad5fd8092dfc4639a9e26302756a8edf,Keytruda,0.487659
uuid-ad5fd8092dfc4639a9e26302756a8edf,flat dosing,0.832086
uuid-028d6e8d39ff44f598411f3e27031077,Opdivo,0.567015
uuid-028d6e8d39ff44f598411f3e27031077,dose,0.754348
uuid-028d6e8d39ff44f598411f3e27031077,toxicity,0.511359
uuid-028d6e8d39ff44f598411f3e27031077,regimen,0.311253
uuid-028d6e8d39ff44f598411f3e27031077,Ipi,0.352549
uuid-028d6e8d39ff44f598411f3e27031077,vs,0.331206
uuid-028d6e8d39ff44f598411f3e27031077,Keytruda,0.412525
uuid-028d6e8d39ff44f598411f3e27031077,flat dosing,0.668827
uuid-711ebcdbeb8f4944822ff0d5d7ba6ab0,treatment,0.335856
uuid-711ebcdbeb8f4944822ff0d5d7ba6ab0,ASCO,0.513907
uuid-711ebcdbeb8f4944822ff0d5d7ba6ab0,oncologist,0.344854
uuid-711ebcdbeb8f4944822ff0d5d7ba6ab0,immunotherapy,0.42251
uuid-ef6e2a8604154182a0af7818d5ec7641,patients,0.771906
uuid-ef6e2a8604154182a0af7818d5ec7641,Opdivo,0.594371
uuid-ef6e2a8604154182a0af7818d5ec7641,therapy,0.366916
uuid-ef6e2a8604154182a0af7818d5ec7641,nivolumab,0.301383
uuid-ef6e2a8604154182a0af7818d5ec7641,treated,0.386133
uuid-ef6e2a8604154182a0af7818d5ec7641,pts,0.497391
uuid-ef6e2a8604154182a0af7818d5ec7641,approval,0.405027
uuid-ef6e2a8604154182a0af7818d5ec7641,PD-L1 testing,0.412467
uuid-ef6e2a8604154182a0af7818d5ec7641,testing,0.373549
uuid-ef6e2a8604154182a0af7818d5ec7641,treatment,0.461656
uuid-ef6e2a8604154182a0af7818d5ec7641,using nivo,0.324038
uuid-ef6e2a8604154182a0af7818d5ec7641,PDL1 testing,0.302245
uuid-ef6e2a8604154182a0af7818d5ec7641,NSCLC patients,0.472217
uuid-ef6e2a8604154182a0af7818d5ec7641,progression,0.412618
uuid-ef6e2a8604154182a0af7818d5ec7641,respond,0.335086
uuid-ef6e2a8604154182a0af7818d5ec7641,option,0.305503
uuid-e42afd02b4744c5d923817d896b52d77,TL,0.415986
uuid-e42afd02b4744c5d923817d896b52d77,TL stated,0.372153
uuid-e42afd02b4744c5d923817d896b52d77,PD-L1,0.616913
uuid-e42afd02b4744c5d923817d896b52d77,PD-L1 testing,0.755908
uuid-e42afd02b4744c5d923817d896b52d77,testing,0.770254
uuid-e42afd02b4744c5d923817d896b52d77,PDL1 testing,0.692271
uuid-e42afd02b4744c5d923817d896b52d77,NSCLC patients,0.603492
uuid-e42afd02b4744c5d923817d896b52d77,assay,0.410351
uuid-e42afd02b4744c5d923817d896b52d77,biomarker,0.37432
uuid-14f449fbbe68496bb48d796ada8f5ae8,Nivo,0.646327
uuid-14f449fbbe68496bb48d796ada8f5ae8,patients,0.822145
uuid-14f449fbbe68496bb48d796ada8f5ae8,Opdivo,0.397046
uuid-14f449fbbe68496bb48d796ada8f5ae8,therapy,0.733126
uuid-14f449fbbe68496bb48d796ada8f5ae8,nivolumab,0.596106
uuid-14f449fbbe68496bb48d796ada8f5ae8,1L,0.347714
uuid-14f449fbbe68496bb48d796ada8f5ae8,regimen,0.416492
uuid-14f449fbbe68496bb48d796ada8f5ae8,treated,0.449575
uuid-14f449fbbe68496bb48d796ada8f5ae8,chemo,0.497246
uuid-14f449fbbe68496bb48d796ada8f5ae8,2L,0.36899
uuid-14f449fbbe68496bb48d796ada8f5ae8,pts,0.558965
uuid-14f449fbbe68496bb48d796ada8f5ae8,approval,0.388233
uuid-14f449fbbe68496bb48d796ada8f5ae8,preferred,0.321455
uuid-14f449fbbe68496bb48d796ada8f5ae8,monotherapy,0.52558
uuid-14f449fbbe68496bb48d796ada8f5ae8,treatment,0.590307
uuid-14f449fbbe68496bb48d796ada8f5ae8,using nivo,0.545457
uuid-14f449fbbe68496bb48d796ada8f5ae8,response,0.352276
uuid-14f449fbbe68496bb48d796ada8f5ae8,PD1,0.42683
uuid-14f449fbbe68496bb48d796ada8f5ae8,approved,0.346119
uuid-14f449fbbe68496bb48d796ada8f5ae8,cHL,0.503677
uuid-14f449fbbe68496bb48d796ada8f5ae8,progression,0.564954
uuid-14f449fbbe68496bb48d796ada8f5ae8,chemotherapy,0.530476
uuid-14f449fbbe68496bb48d796ada8f5ae8,respond,0.395457
uuid-14f449fbbe68496bb48d796ada8f5ae8,RTL stated,0.342752
uuid-14f449fbbe68496bb48d796ada8f5ae8,option,0.515679
uuid-2fc01f159be64d57a0a3cb870770849e,Nivo,0.310142
uuid-2fc01f159be64d57a0a3cb870770849e,pembro,0.55615
uuid-2fc01f159be64d57a0a3cb870770849e,RTL,0.343147
uuid-2fc01f159be64d57a0a3cb870770849e,1L,0.407885
uuid-2fc01f159be64d57a0a3cb870770849e,trial,0.748991
uuid-2fc01f159be64d57a0a3cb870770849e,shared,0.326691
uuid-2fc01f159be64d57a0a3cb870770849e,RCC,0.302702
uuid-2fc01f159be64d57a0a3cb870770849e,combination,0.48899
uuid-2fc01f159be64d57a0a3cb870770849e,2L,0.383824
uuid-2fc01f159be64d57a0a3cb870770849e,agents,0.323837
uuid-2fc01f159be64d57a0a3cb870770849e,Merck,0.305142
uuid-2fc01f159be64d57a0a3cb870770849e,Ipi,0.382717
uuid-2fc01f159be64d57a0a3cb870770849e,approval,0.331734
uuid-2fc01f159be64d57a0a3cb870770849e,atezo,0.442531
uuid-2fc01f159be64d57a0a3cb870770849e,preferred,0.336065
uuid-2fc01f159be64d57a0a3cb870770849e,monotherapy,0.324126
uuid-2fc01f159be64d57a0a3cb870770849e,using nivo,0.334532
uuid-2fc01f159be64d57a0a3cb870770849e,data,0.332933
uuid-2fc01f159be64d57a0a3cb870770849e,combo,0.494169
uuid-2fc01f159be64d57a0a3cb870770849e,clinical trials,0.498187
uuid-2fc01f159be64d57a0a3cb870770849e,approved,0.364451
uuid-2fc01f159be64d57a0a3cb870770849e,SCCHN,0.321402
uuid-2fc01f159be64d57a0a3cb870770849e,impressed,0.304168
uuid-2fc01f159be64d57a0a3cb870770849e,vs,0.308264
uuid-2fc01f159be64d57a0a3cb870770849e,Regional TL,0.318347
uuid-2fc01f159be64d57a0a3cb870770849e,RTL stated,0.363961
uuid-2fc01f159be64d57a0a3cb870770849e,bladder,0.416544
uuid-d7844fd2330548988a16fd6eb6bf25b7,TL,0.407182
uuid-d7844fd2330548988a16fd6eb6bf25b7,PDL1,0.352887
uuid-d7844fd2330548988a16fd6eb6bf25b7,institution,0.321714
uuid-d7844fd2330548988a16fd6eb6bf25b7,PD-L1,0.660311
uuid-d7844fd2330548988a16fd6eb6bf25b7,PD-L1 testing,0.687408
uuid-d7844fd2330548988a16fd6eb6bf25b7,testing,0.675084
uuid-d7844fd2330548988a16fd6eb6bf25b7,PDL1 testing,0.532225
uuid-d7844fd2330548988a16fd6eb6bf25b7,NSCLC patients,0.428931
uuid-d7844fd2330548988a16fd6eb6bf25b7,assay,0.609457
uuid-d7844fd2330548988a16fd6eb6bf25b7,biomarker,0.41713
uuid-6b4ce05dcaec45ccb267b14a24c83992,Nivo,0.574026
uuid-6b4ce05dcaec45ccb267b14a24c83992,patients,0.484693
uuid-6b4ce05dcaec45ccb267b14a24c83992,pembro,0.444806
uuid-6b4ce05dcaec45ccb267b14a24c83992,therapy,0.387166
uuid-6b4ce05dcaec45ccb267b14a24c83992,nivolumab,0.582872
uuid-6b4ce05dcaec45ccb267b14a24c83992,1L,0.600204
uuid-6b4ce05dcaec45ccb267b14a24c83992,regimen,0.431961
uuid-6b4ce05dcaec45ccb267b14a24c83992,RCC,0.445645
uuid-6b4ce05dcaec45ccb267b14a24c83992,combination,0.399214
uuid-6b4ce05dcaec45ccb267b14a24c83992,chemo,0.423394
uuid-6b4ce05dcaec45ccb267b14a24c83992,2L,0.712743
uuid-6b4ce05dcaec45ccb267b14a24c83992,pts,0.376898
uuid-6b4ce05dcaec45ccb267b14a24c83992,agents,0.39441
uuid-6b4ce05dcaec45ccb267b14a24c83992,approval,0.374623
uuid-6b4ce05dcaec45ccb267b14a24c83992,atezo,0.400001
uuid-6b4ce05dcaec45ccb267b14a24c83992,preferred,0.640354
uuid-6b4ce05dcaec45ccb267b14a24c83992,monotherapy,0.668104
uuid-6b4ce05dcaec45ccb267b14a24c83992,treatment,0.339723
uuid-6b4ce05dcaec45ccb267b14a24c83992,using nivo,0.739147
uuid-6b4ce05dcaec45ccb267b14a24c83992,combo,0.410729
uuid-6b4ce05dcaec45ccb267b14a24c83992,PD1,0.404195
uuid-6b4ce05dcaec45ccb267b14a24c83992,approved,0.501266
uuid-6b4ce05dcaec45ccb267b14a24c83992,SCCHN,0.391212
uuid-6b4ce05dcaec45ccb267b14a24c83992,chemotherapy,0.396153
uuid-6b4ce05dcaec45ccb267b14a24c83992,SCLC,0.314434
uuid-6b4ce05dcaec45ccb267b14a24c83992,feels,0.462932
uuid-6b4ce05dcaec45ccb267b14a24c83992,RTL stated,0.557902
uuid-6b4ce05dcaec45ccb267b14a24c83992,option,0.631021
uuid-6b4ce05dcaec45ccb267b14a24c83992,bladder,0.360811
uuid-ca2c231774cf49e79a676f774d048b77,trial,0.749541
uuid-ca2c231774cf49e79a676f774d048b77,OS,0.468998
uuid-ca2c231774cf49e79a676f774d048b77,data,0.480492
uuid-ca2c231774cf49e79a676f774d048b77,clinical trials,0.319818
uuid-ca2c231774cf49e79a676f774d048b77,PFS,0.48099
uuid-ca2c231774cf49e79a676f774d048b77,ORR,0.565609
uuid-ca2c231774cf49e79a676f774d048b77,impressed,0.427468
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,Nivo,0.362896
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,patients,0.822844
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,Opdivo,0.458553
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,therapy,0.674945
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,nivolumab,0.526786
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,regimen,0.565797
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,treated,0.589123
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,chemo,0.408423
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,pts,0.592645
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,monotherapy,0.402748
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,treatment,0.713138
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,using nivo,0.321514
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,response,0.471194
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,PD1,0.402342
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,cHL,0.389046
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,progression,0.758567
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,chemotherapy,0.422815
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,respond,0.552104
uuid-7cb7b778e19e4aa394c30df72a9fb6c2,option,0.330351
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,pembro,0.313577
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,BMS,0.372569
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,PDL1,0.64215
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,efficacy,0.443022
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,Merck,0.413235
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,OS,0.541631
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,atezo,0.324648
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,regards,0.317919
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,data,0.467299
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,PFS,0.517099
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,ORR,0.430486
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,nivo and pembro,0.537276
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,believes,0.401915
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,Keytruda,0.318501
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,feels,0.327967
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,PDL1 expression,0.486305
uuid-c6bf6e03bd2a48849ac4c61004d8d7d9,biomarker,0.322537
uuid-c568cc00683946089e2f10d6f536b4cc,toxicity,0.301219
uuid-c568cc00683946089e2f10d6f536b4cc,treated,0.378632
uuid-c568cc00683946089e2f10d6f536b4cc,physicians,0.555308
uuid-c568cc00683946089e2f10d6f536b4cc,treatment,0.308075
uuid-c568cc00683946089e2f10d6f536b4cc,oncology,0.393745
uuid-c568cc00683946089e2f10d6f536b4cc,academic,0.316039
uuid-49ead6f7cf44463b89ff7ca53196a589,BMS,0.398822
uuid-49ead6f7cf44463b89ff7ca53196a589,Merck,0.430671
uuid-49ead6f7cf44463b89ff7ca53196a589,approval,0.315718
uuid-49ead6f7cf44463b89ff7ca53196a589,clinical trials,0.327752
uuid-f5794538b53848439b7ee400599dd2ca,PDL1,0.63503
uuid-f5794538b53848439b7ee400599dd2ca,agents,0.338679
uuid-f5794538b53848439b7ee400599dd2ca,PD-L1,0.586901
uuid-f5794538b53848439b7ee400599dd2ca,PD-L1 testing,0.34163
uuid-f5794538b53848439b7ee400599dd2ca,testing,0.543245
uuid-f5794538b53848439b7ee400599dd2ca,PDL1 testing,0.483657
uuid-f5794538b53848439b7ee400599dd2ca,believes,0.413571
uuid-f5794538b53848439b7ee400599dd2ca,assay,0.477764
uuid-f5794538b53848439b7ee400599dd2ca,PDL1 expression,0.510111
uuid-f5794538b53848439b7ee400599dd2ca,biomarker,0.70718
uuid-0d1feee05deb4914938a4dc69cbab412,TL,0.369489
uuid-0d1feee05deb4914938a4dc69cbab412,1L,0.497381
uuid-0d1feee05deb4914938a4dc69cbab412,PDL1,0.417059
uuid-0d1feee05deb4914938a4dc69cbab412,TL stated,0.502605
uuid-0d1feee05deb4914938a4dc69cbab412,2L,0.437634
uuid-0d1feee05deb4914938a4dc69cbab412,PD-L1,0.733486
uuid-0d1feee05deb4914938a4dc69cbab412,approval,0.39473
uuid-0d1feee05deb4914938a4dc69cbab412,atezo,0.327083
uuid-0d1feee05deb4914938a4dc69cbab412,preferred,0.3802
uuid-0d1feee05deb4914938a4dc69cbab412,PD-L1 testing,0.725586
uuid-0d1feee05deb4914938a4dc69cbab412,testing,0.864263
uuid-0d1feee05deb4914938a4dc69cbab412,using nivo,0.302779
uuid-0d1feee05deb4914938a4dc69cbab412,PDL1 testing,0.801852
uuid-0d1feee05deb4914938a4dc69cbab412,NSCLC patients,0.781015
uuid-0d1feee05deb4914938a4dc69cbab412,approved,0.347346
uuid-0d1feee05deb4914938a4dc69cbab412,tumor types,0.451822
uuid-0d1feee05deb4914938a4dc69cbab412,assay,0.523904
uuid-0d1feee05deb4914938a4dc69cbab412,RTL stated,0.344339
uuid-0d1feee05deb4914938a4dc69cbab412,biomarker,0.381351
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,patients,0.423449
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,Opdivo,0.427891
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,dose,0.587541
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,toxicity,0.597686
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,regimen,0.446672
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,treated,0.42586
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,Ipi,0.317997
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,treatment,0.514686
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,respond,0.336926
uuid-2ac9717fe7ef4c2f87eaee8ddbd32371,flat dosing,0.317946
uuid-1bf50278c0ac4765a277fd93003a4c17,patients,0.560401
uuid-1bf50278c0ac4765a277fd93003a4c17,Opdivo,0.354741
uuid-1bf50278c0ac4765a277fd93003a4c17,therapy,0.374355
uuid-1bf50278c0ac4765a277fd93003a4c17,nivolumab,0.56889
uuid-1bf50278c0ac4765a277fd93003a4c17,regimen,0.375128
uuid-1bf50278c0ac4765a277fd93003a4c17,treated,0.471177
uuid-1bf50278c0ac4765a277fd93003a4c17,physicians,0.424294
uuid-1bf50278c0ac4765a277fd93003a4c17,treatment,0.422598
uuid-1bf50278c0ac4765a277fd93003a4c17,using nivo,0.36155
uuid-1bf50278c0ac4765a277fd93003a4c17,cHL,0.330207
uuid-1bf50278c0ac4765a277fd93003a4c17,progression,0.302472
uuid-1bf50278c0ac4765a277fd93003a4c17,oncologist,0.336793
uuid-1bf50278c0ac4765a277fd93003a4c17,Regional TL,0.362638
uuid-88e289edc551409c9ac27f4e8dbfc4c1,RTL,0.391078
uuid-88e289edc551409c9ac27f4e8dbfc4c1,nivolumab,0.392005
uuid-88e289edc551409c9ac27f4e8dbfc4c1,trial,0.385564
uuid-88e289edc551409c9ac27f4e8dbfc4c1,physicians,0.337617
uuid-88e289edc551409c9ac27f4e8dbfc4c1,clinical trials,0.424464
uuid-88e289edc551409c9ac27f4e8dbfc4c1,Regional TL,0.389176
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,lung,0.410175
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,commented,0.317196
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,institution,0.402987
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,stated,0.313624
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,regards,0.322588
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,expressed,0.309664
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,AI,0.605746
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,oncology,0.416786
uuid-2af7d0670dfe4ea4909b67a5e73bbf47,NCCN,0.719096
uuid-351b742adb8d49a3b0c1ccf53f119472,Nivo,0.319162
uuid-351b742adb8d49a3b0c1ccf53f119472,pembro,0.572626
uuid-351b742adb8d49a3b0c1ccf53f119472,dose,0.602781
uuid-351b742adb8d49a3b0c1ccf53f119472,trial,0.324359
uuid-351b742adb8d49a3b0c1ccf53f119472,efficacy,0.449391
uuid-351b742adb8d49a3b0c1ccf53f119472,Ipi,0.370791
uuid-351b742adb8d49a3b0c1ccf53f119472,atezo,0.524224
uuid-351b742adb8d49a3b0c1ccf53f119472,data,0.335988
uuid-351b742adb8d49a3b0c1ccf53f119472,nivo and pembro,0.341584
uuid-351b742adb8d49a3b0c1ccf53f119472,vs,0.75361
uuid-351b742adb8d49a3b0c1ccf53f119472,TLs,0.313217
uuid-351b742adb8d49a3b0c1ccf53f119472,flat dosing,0.517014
uuid-60b7aa57c62d495e8a924a0ada1bc9df,Nivo,0.654756
uuid-60b7aa57c62d495e8a924a0ada1bc9df,patients,0.707539
uuid-60b7aa57c62d495e8a924a0ada1bc9df,Opdivo,0.327881
uuid-60b7aa57c62d495e8a924a0ada1bc9df,therapy,0.696973
uuid-60b7aa57c62d495e8a924a0ada1bc9df,nivolumab,0.536961
uuid-60b7aa57c62d495e8a924a0ada1bc9df,toxicity,0.371318
uuid-60b7aa57c62d495e8a924a0ada1bc9df,regimen,0.506619
uuid-60b7aa57c62d495e8a924a0ada1bc9df,treated,0.360752
uuid-60b7aa57c62d495e8a924a0ada1bc9df,combination,0.404765
uuid-60b7aa57c62d495e8a924a0ada1bc9df,chemo,0.575118
uuid-60b7aa57c62d495e8a924a0ada1bc9df,pts,0.464092
uuid-60b7aa57c62d495e8a924a0ada1bc9df,Ipi,0.35211
uuid-60b7aa57c62d495e8a924a0ada1bc9df,monotherapy,0.533955
uuid-60b7aa57c62d495e8a924a0ada1bc9df,treatment,0.535491
uuid-60b7aa57c62d495e8a924a0ada1bc9df,using nivo,0.363102
uuid-60b7aa57c62d495e8a924a0ada1bc9df,response,0.475434
uuid-60b7aa57c62d495e8a924a0ada1bc9df,PD1,0.512902
uuid-60b7aa57c62d495e8a924a0ada1bc9df,cHL,0.494928
uuid-60b7aa57c62d495e8a924a0ada1bc9df,progression,0.561073
uuid-60b7aa57c62d495e8a924a0ada1bc9df,chemotherapy,0.590214
uuid-60b7aa57c62d495e8a924a0ada1bc9df,respond,0.461559
uuid-60b7aa57c62d495e8a924a0ada1bc9df,feels,0.344762
uuid-60b7aa57c62d495e8a924a0ada1bc9df,option,0.424156
uuid-f7bb12515c3d44099744a9330b1bbd44,patients,0.557362
uuid-f7bb12515c3d44099744a9330b1bbd44,Opdivo,0.464138
uuid-f7bb12515c3d44099744a9330b1bbd44,therapy,0.393286
uuid-f7bb12515c3d44099744a9330b1bbd44,dose,0.348748
uuid-f7bb12515c3d44099744a9330b1bbd44,nivolumab,0.427549
uuid-f7bb12515c3d44099744a9330b1bbd44,regimen,0.469305
uuid-f7bb12515c3d44099744a9330b1bbd44,treated,0.61143
uuid-f7bb12515c3d44099744a9330b1bbd44,physicians,0.446
uuid-f7bb12515c3d44099744a9330b1bbd44,treatment,0.639699
uuid-f7bb12515c3d44099744a9330b1bbd44,progression,0.334929
uuid-3d3830322bcb48a69ef75e2ad992569a,Opdivo,0.442135
uuid-3d3830322bcb48a69ef75e2ad992569a,RTL,0.335782
uuid-3d3830322bcb48a69ef75e2ad992569a,BMS,0.36771
uuid-3d3830322bcb48a69ef75e2ad992569a,shared,0.438993
uuid-3d3830322bcb48a69ef75e2ad992569a,commented,0.359169
uuid-3d3830322bcb48a69ef75e2ad992569a,stated,0.433479
uuid-3d3830322bcb48a69ef75e2ad992569a,physicians,0.607829
uuid-3d3830322bcb48a69ef75e2ad992569a,mentioned,0.416166
uuid-3d3830322bcb48a69ef75e2ad992569a,oncology,0.360485
uuid-3d3830322bcb48a69ef75e2ad992569a,HCP,0.321398
uuid-3d3830322bcb48a69ef75e2ad992569a,LTL,0.395114
uuid-3d3830322bcb48a69ef75e2ad992569a,clinical,0.307264
uuid-3d3830322bcb48a69ef75e2ad992569a,Regional TL,0.391281
uuid-f295693c288548f88785f032b41d62b8,Nivo,0.560076
uuid-f295693c288548f88785f032b41d62b8,patients,0.559815
uuid-f295693c288548f88785f032b41d62b8,Opdivo,0.395685
uuid-f295693c288548f88785f032b41d62b8,therapy,0.682162
uuid-f295693c288548f88785f032b41d62b8,nivolumab,0.53172
uuid-f295693c288548f88785f032b41d62b8,treatment,0.351362
uuid-f295693c288548f88785f032b41d62b8,using nivo,0.459277
uuid-f295693c288548f88785f032b41d62b8,cHL,0.768069
uuid-f295693c288548f88785f032b41d62b8,chemotherapy,0.348062
uuid-d8f12107e9054f6db7e2a8d3ef305731,Nivo,0.563262
uuid-d8f12107e9054f6db7e2a8d3ef305731,patients,0.591093
uuid-d8f12107e9054f6db7e2a8d3ef305731,therapy,0.569319
uuid-d8f12107e9054f6db7e2a8d3ef305731,nivolumab,0.548923
uuid-d8f12107e9054f6db7e2a8d3ef305731,toxicity,0.309478
uuid-d8f12107e9054f6db7e2a8d3ef305731,regimen,0.470038
uuid-d8f12107e9054f6db7e2a8d3ef305731,treated,0.384039
uuid-d8f12107e9054f6db7e2a8d3ef305731,combination,0.579529
uuid-d8f12107e9054f6db7e2a8d3ef305731,chemo,0.662508
uuid-d8f12107e9054f6db7e2a8d3ef305731,pts,0.477048
uuid-d8f12107e9054f6db7e2a8d3ef305731,monotherapy,0.572505
uuid-d8f12107e9054f6db7e2a8d3ef305731,treatment,0.512417
uuid-d8f12107e9054f6db7e2a8d3ef305731,response,0.455564
uuid-d8f12107e9054f6db7e2a8d3ef305731,combo,0.449842
uuid-d8f12107e9054f6db7e2a8d3ef305731,PD1,0.564889
uuid-d8f12107e9054f6db7e2a8d3ef305731,progression,0.537777
uuid-d8f12107e9054f6db7e2a8d3ef305731,chemotherapy,0.649024
uuid-d8f12107e9054f6db7e2a8d3ef305731,respond,0.368485
uuid-d8f12107e9054f6db7e2a8d3ef305731,feels,0.471162
uuid-d8f12107e9054f6db7e2a8d3ef305731,option,0.516513
uuid-6f16a3e64ce14520a4e738d13923afb3,patients,0.457156
uuid-6f16a3e64ce14520a4e738d13923afb3,Opdivo,0.411906
uuid-6f16a3e64ce14520a4e738d13923afb3,treated,0.338219
uuid-6f16a3e64ce14520a4e738d13923afb3,physicians,0.653144
uuid-6f16a3e64ce14520a4e738d13923afb3,treatment,0.371332
uuid-6f16a3e64ce14520a4e738d13923afb3,oncology,0.311117
uuid-6a7603ac401b4150aeeb3411a08020f2,patients,0.678897
uuid-6a7603ac401b4150aeeb3411a08020f2,Opdivo,0.568731
uuid-6a7603ac401b4150aeeb3411a08020f2,therapy,0.319366
uuid-6a7603ac401b4150aeeb3411a08020f2,dose,0.45741
uuid-6a7603ac401b4150aeeb3411a08020f2,toxicity,0.502166
uuid-6a7603ac401b4150aeeb3411a08020f2,regimen,0.511557
uuid-6a7603ac401b4150aeeb3411a08020f2,treated,0.513842
uuid-6a7603ac401b4150aeeb3411a08020f2,pts,0.369206
uuid-6a7603ac401b4150aeeb3411a08020f2,treatment,0.655952
uuid-6a7603ac401b4150aeeb3411a08020f2,response,0.307891
uuid-6a7603ac401b4150aeeb3411a08020f2,progression,0.551278
uuid-6a7603ac401b4150aeeb3411a08020f2,respond,0.518237
uuid-1bfd43469ab341c181fe2a147dcb6e04,Nivo,0.468903
uuid-1bfd43469ab341c181fe2a147dcb6e04,trial,0.313285
uuid-1bfd43469ab341c181fe2a147dcb6e04,efficacy,0.399941
uuid-1bfd43469ab341c181fe2a147dcb6e04,OS,0.644187
uuid-1bfd43469ab341c181fe2a147dcb6e04,data,0.503578
uuid-1bfd43469ab341c181fe2a147dcb6e04,PFS,0.71245
uuid-1bfd43469ab341c181fe2a147dcb6e04,ORR,0.671354
uuid-1bfd43469ab341c181fe2a147dcb6e04,cHL,0.377606
uuid-1bfd43469ab341c181fe2a147dcb6e04,impressed,0.460761
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,Nivo,0.39479
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,patients,0.437831
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,therapy,0.567373
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,nivolumab,0.311847
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,regimen,0.30622
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,treated,0.329132
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,chemo,0.3208
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,pts,0.324656
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,treatment,0.552998
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,response,0.534776
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,PD1,0.381505
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,cHL,0.526654
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,progression,0.563154
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,chemotherapy,0.382167
uuid-914ad7d9e2c84fda80faca8ddc2d36e6,respond,0.48995
uuid-e29fea0614444d87acfabfeb7a77cbf5,BMS,0.328011
uuid-e29fea0614444d87acfabfeb7a77cbf5,PDL1,0.307802
uuid-e29fea0614444d87acfabfeb7a77cbf5,trial,0.331068
uuid-e29fea0614444d87acfabfeb7a77cbf5,discussed,0.405237
uuid-e29fea0614444d87acfabfeb7a77cbf5,commented,0.323255
uuid-e29fea0614444d87acfabfeb7a77cbf5,OS,0.39265
uuid-e29fea0614444d87acfabfeb7a77cbf5,regards,0.498748
uuid-e29fea0614444d87acfabfeb7a77cbf5,data,0.577742
uuid-e29fea0614444d87acfabfeb7a77cbf5,PFS,0.427512
uuid-e29fea0614444d87acfabfeb7a77cbf5,AI,0.435993
uuid-e29fea0614444d87acfabfeb7a77cbf5,ORR,0.388512
uuid-e29fea0614444d87acfabfeb7a77cbf5,nivo and pembro,0.402698
uuid-e29fea0614444d87acfabfeb7a77cbf5,NCCN,0.521965
uuid-dc00eb1db5604b4d932a35b613661f2e,patients,0.304656
uuid-dc00eb1db5604b4d932a35b613661f2e,treated,0.46237
uuid-dc00eb1db5604b4d932a35b613661f2e,RCC,0.304232
uuid-dc00eb1db5604b4d932a35b613661f2e,approval,0.345089
uuid-dc00eb1db5604b4d932a35b613661f2e,SCCHN,0.305595
uuid-dc00eb1db5604b4d932a35b613661f2e,RTL stated,0.338183
uuid-dc00eb1db5604b4d932a35b613661f2e,TL shared,0.3063
uuid-dc00eb1db5604b4d932a35b613661f2e,bladder,0.516099
uuid-af4c099390384b31bf62efa893cd4148,physicians,0.330757
uuid-af4c099390384b31bf62efa893cd4148,oncology,0.615921
uuid-af4c099390384b31bf62efa893cd4148,drug,0.319939
uuid-af4c099390384b31bf62efa893cd4148,clinical,0.694407
uuid-37f6b1005516460894d72303b7413b44,therapy,0.356717
uuid-37f6b1005516460894d72303b7413b44,nivolumab,0.385133
uuid-37f6b1005516460894d72303b7413b44,NTL,0.314515
uuid-37f6b1005516460894d72303b7413b44,mentioned,0.433765
uuid-37f6b1005516460894d72303b7413b44,cHL,0.605139
uuid-5021eb3c77f34879af1f5fad03ce1e88,1L,0.330221
uuid-5021eb3c77f34879af1f5fad03ce1e88,trial,0.397797
uuid-5021eb3c77f34879af1f5fad03ce1e88,combination,0.356337
uuid-5021eb3c77f34879af1f5fad03ce1e88,chemo,0.342421
uuid-5021eb3c77f34879af1f5fad03ce1e88,IO,0.338402
uuid-5021eb3c77f34879af1f5fad03ce1e88,agents,0.333686
uuid-5021eb3c77f34879af1f5fad03ce1e88,monotherapy,0.303074
uuid-5021eb3c77f34879af1f5fad03ce1e88,combo,0.500982
uuid-5021eb3c77f34879af1f5fad03ce1e88,believes,0.412716
uuid-5021eb3c77f34879af1f5fad03ce1e88,feels,0.321405
uuid-5021eb3c77f34879af1f5fad03ce1e88,option,0.326166
uuid-530c1270c0674c7fab0924cafe44e8d8,pembro,0.380011
uuid-530c1270c0674c7fab0924cafe44e8d8,BMS,0.325418
uuid-530c1270c0674c7fab0924cafe44e8d8,trial,0.56913
uuid-530c1270c0674c7fab0924cafe44e8d8,combination,0.333685
uuid-530c1270c0674c7fab0924cafe44e8d8,agents,0.304536
uuid-530c1270c0674c7fab0924cafe44e8d8,Merck,0.471292
uuid-530c1270c0674c7fab0924cafe44e8d8,PD-L1,0.306698
uuid-530c1270c0674c7fab0924cafe44e8d8,atezo,0.306587
uuid-530c1270c0674c7fab0924cafe44e8d8,combo,0.316147
uuid-530c1270c0674c7fab0924cafe44e8d8,clinical trials,0.431216
uuid-530c1270c0674c7fab0924cafe44e8d8,assay,0.305107
uuid-cb2be6e19fc145b3a5576ee161cce716,BMS,0.707447
uuid-cb2be6e19fc145b3a5576ee161cce716,trial,0.332119
uuid-cb2be6e19fc145b3a5576ee161cce716,shared,0.34266
uuid-cb2be6e19fc145b3a5576ee161cce716,commented,0.409699
uuid-cb2be6e19fc145b3a5576ee161cce716,Merck,0.485398
uuid-cb2be6e19fc145b3a5576ee161cce716,stated,0.366201
uuid-cb2be6e19fc145b3a5576ee161cce716,expressed,0.429417
uuid-cb2be6e19fc145b3a5576ee161cce716,clinical trials,0.416828
uuid-cb2be6e19fc145b3a5576ee161cce716,impressed,0.323553
uuid-a05e1ddb352646148f4344b720be35f0,Nivo,0.440225
uuid-a05e1ddb352646148f4344b720be35f0,1L,0.474616
uuid-a05e1ddb352646148f4344b720be35f0,regimen,0.387775
uuid-a05e1ddb352646148f4344b720be35f0,RCC,0.419296
uuid-a05e1ddb352646148f4344b720be35f0,combination,0.424392
uuid-a05e1ddb352646148f4344b720be35f0,chemo,0.467719
uuid-a05e1ddb352646148f4344b720be35f0,2L,0.519168
uuid-a05e1ddb352646148f4344b720be35f0,IO,0.422702
uuid-a05e1ddb352646148f4344b720be35f0,agents,0.475268
uuid-a05e1ddb352646148f4344b720be35f0,preferred,0.440349
uuid-a05e1ddb352646148f4344b720be35f0,monotherapy,0.566305
uuid-a05e1ddb352646148f4344b720be35f0,using nivo,0.36638
uuid-a05e1ddb352646148f4344b720be35f0,combo,0.519334
uuid-a05e1ddb352646148f4344b720be35f0,PD1,0.4562
uuid-a05e1ddb352646148f4344b720be35f0,believes,0.527384
uuid-a05e1ddb352646148f4344b720be35f0,chemotherapy,0.356125
uuid-a05e1ddb352646148f4344b720be35f0,feels,0.304692
uuid-a05e1ddb352646148f4344b720be35f0,RTL stated,0.310711
uuid-a05e1ddb352646148f4344b720be35f0,option,0.498734
uuid-dc66f9c0a0d949948506f8a76061b9f6,patients,0.82377
uuid-dc66f9c0a0d949948506f8a76061b9f6,Opdivo,0.379835
uuid-dc66f9c0a0d949948506f8a76061b9f6,therapy,0.563559
uuid-dc66f9c0a0d949948506f8a76061b9f6,nivolumab,0.416102
uuid-dc66f9c0a0d949948506f8a76061b9f6,regimen,0.414555
uuid-dc66f9c0a0d949948506f8a76061b9f6,treated,0.477951
uuid-dc66f9c0a0d949948506f8a76061b9f6,chemo,0.363064
uuid-dc66f9c0a0d949948506f8a76061b9f6,pts,0.61758
uuid-dc66f9c0a0d949948506f8a76061b9f6,treatment,0.619573
uuid-dc66f9c0a0d949948506f8a76061b9f6,response,0.567388
uuid-dc66f9c0a0d949948506f8a76061b9f6,PD1,0.34663
uuid-dc66f9c0a0d949948506f8a76061b9f6,progression,0.750072
uuid-dc66f9c0a0d949948506f8a76061b9f6,chemotherapy,0.373238
uuid-dc66f9c0a0d949948506f8a76061b9f6,respond,0.574981
uuid-f4506d3854b34255818a242088aa2d12,combination,0.617768
uuid-f4506d3854b34255818a242088aa2d12,chemo,0.403357
uuid-f4506d3854b34255818a242088aa2d12,2L,0.340545
uuid-f4506d3854b34255818a242088aa2d12,IO,0.466645
uuid-f4506d3854b34255818a242088aa2d12,agents,0.568511
uuid-f4506d3854b34255818a242088aa2d12,preferred,0.401795
uuid-f4506d3854b34255818a242088aa2d12,monotherapy,0.523593
uuid-f4506d3854b34255818a242088aa2d12,combo,0.539728
uuid-f4506d3854b34255818a242088aa2d12,PD1,0.41674
uuid-f4506d3854b34255818a242088aa2d12,believes,0.449345
uuid-f4506d3854b34255818a242088aa2d12,chemotherapy,0.345723
uuid-f4506d3854b34255818a242088aa2d12,feels,0.39778
uuid-f4506d3854b34255818a242088aa2d12,PD-1,0.302723
uuid-f4506d3854b34255818a242088aa2d12,option,0.439329
uuid-cc5fe0c4d1474a0ca642c198727e8440,Nivo,0.578618
uuid-cc5fe0c4d1474a0ca642c198727e8440,patients,0.657421
uuid-cc5fe0c4d1474a0ca642c198727e8440,Opdivo,0.62795
uuid-cc5fe0c4d1474a0ca642c198727e8440,therapy,0.534756
uuid-cc5fe0c4d1474a0ca642c198727e8440,dose,0.303949
uuid-cc5fe0c4d1474a0ca642c198727e8440,nivolumab,0.548051
uuid-cc5fe0c4d1474a0ca642c198727e8440,regimen,0.328395
uuid-cc5fe0c4d1474a0ca642c198727e8440,pts,0.348369
uuid-cc5fe0c4d1474a0ca642c198727e8440,approval,0.393478
uuid-cc5fe0c4d1474a0ca642c198727e8440,monotherapy,0.310663
uuid-cc5fe0c4d1474a0ca642c198727e8440,treatment,0.45085
uuid-cc5fe0c4d1474a0ca642c198727e8440,using nivo,0.444839
uuid-cc5fe0c4d1474a0ca642c198727e8440,approved,0.357659
uuid-cc5fe0c4d1474a0ca642c198727e8440,cHL,0.525238
uuid-cc5fe0c4d1474a0ca642c198727e8440,progression,0.399557
uuid-cc5fe0c4d1474a0ca642c198727e8440,chemotherapy,0.324394
uuid-cc5fe0c4d1474a0ca642c198727e8440,respond,0.326932
uuid-cc5fe0c4d1474a0ca642c198727e8440,option,0.338052
uuid-aa6ffb04486745cea40e3b0e7e109751,Opdivo,0.381947
uuid-aa6ffb04486745cea40e3b0e7e109751,BMS,0.403298
uuid-aa6ffb04486745cea40e3b0e7e109751,physicians,0.612709
uuid-aa6ffb04486745cea40e3b0e7e109751,drug,0.371288
uuid-04b8097a413943dcaea43ce74ff619bc,patients,0.596719
uuid-04b8097a413943dcaea43ce74ff619bc,Opdivo,0.537349
uuid-04b8097a413943dcaea43ce74ff619bc,therapy,0.346443
uuid-04b8097a413943dcaea43ce74ff619bc,dose,0.364403
uuid-04b8097a413943dcaea43ce74ff619bc,nivolumab,0.371637
uuid-04b8097a413943dcaea43ce74ff619bc,regimen,0.363356
uuid-04b8097a413943dcaea43ce74ff619bc,treated,0.390753
uuid-04b8097a413943dcaea43ce74ff619bc,physicians,0.462522
uuid-04b8097a413943dcaea43ce74ff619bc,treatment,0.489892
uuid-04b8097a413943dcaea43ce74ff619bc,progression,0.401879
uuid-04b8097a413943dcaea43ce74ff619bc,oncologist,0.304345
uuid-04b8097a413943dcaea43ce74ff619bc,respond,0.334266
uuid-04b8097a413943dcaea43ce74ff619bc,flat dosing,0.320553
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,Nivo,0.321266
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,patients,0.513186
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,therapy,0.3285
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,1L,0.399177
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,PDL1,0.384952
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,regimen,0.328395
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,chemo,0.507648
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,pts,0.587793
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,monotherapy,0.492956
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,treatment,0.300431
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,response,0.552714
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,PD1,0.437386
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,progression,0.52253
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,believes,0.364812
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,chemotherapy,0.368705
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,respond,0.522841
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,feels,0.38306
uuid-fd3edc5155ac4f3b9e62f6a202feaa62,option,0.399183
uuid-349c482ab9114f829bf52b3ef7feed44,RTL,0.568375
uuid-349c482ab9114f829bf52b3ef7feed44,NTL,0.416185
uuid-349c482ab9114f829bf52b3ef7feed44,shared,0.514172
uuid-349c482ab9114f829bf52b3ef7feed44,commented,0.456497
uuid-349c482ab9114f829bf52b3ef7feed44,stated,0.593703
uuid-349c482ab9114f829bf52b3ef7feed44,clinical trials,0.363826
uuid-349c482ab9114f829bf52b3ef7feed44,SCCHN,0.405873
uuid-349c482ab9114f829bf52b3ef7feed44,impressed,0.345227
uuid-349c482ab9114f829bf52b3ef7feed44,LTL,0.399857
uuid-349c482ab9114f829bf52b3ef7feed44,academic,0.331666
uuid-349c482ab9114f829bf52b3ef7feed44,Regional TL,0.628137
uuid-5db10c81e263430bbd3d8ced44af26e7,therapy,0.30224
uuid-5db10c81e263430bbd3d8ced44af26e7,treatment,0.386522
uuid-5db10c81e263430bbd3d8ced44af26e7,NSCLC patients,0.317251
uuid-5db10c81e263430bbd3d8ced44af26e7,SCCHN,0.353163
uuid-5db10c81e263430bbd3d8ced44af26e7,oncologist,0.473002
uuid-5db10c81e263430bbd3d8ced44af26e7,indicated,0.472861
uuid-5db10c81e263430bbd3d8ced44af26e7,option,0.339301
uuid-69592e93724a47e9a0bf48a36c7b1a7f,RTL,0.34458
uuid-69592e93724a47e9a0bf48a36c7b1a7f,PDL1,0.308166
uuid-69592e93724a47e9a0bf48a36c7b1a7f,trial,0.308602
uuid-69592e93724a47e9a0bf48a36c7b1a7f,efficacy,0.345916
uuid-69592e93724a47e9a0bf48a36c7b1a7f,commented,0.360924
uuid-69592e93724a47e9a0bf48a36c7b1a7f,OS,0.536378
uuid-69592e93724a47e9a0bf48a36c7b1a7f,data,0.584969
uuid-69592e93724a47e9a0bf48a36c7b1a7f,expressed,0.354419
uuid-69592e93724a47e9a0bf48a36c7b1a7f,PFS,0.493689
uuid-69592e93724a47e9a0bf48a36c7b1a7f,ORR,0.631515
uuid-69592e93724a47e9a0bf48a36c7b1a7f,ASCO,0.362087
uuid-69592e93724a47e9a0bf48a36c7b1a7f,impressed,0.697597
uuid-69592e93724a47e9a0bf48a36c7b1a7f,PDL1 expression,0.367661
uuid-17da54d258f943ffac7def9ec29d5bb1,patients,0.757288
uuid-17da54d258f943ffac7def9ec29d5bb1,Opdivo,0.302669
uuid-17da54d258f943ffac7def9ec29d5bb1,therapy,0.529414
uuid-17da54d258f943ffac7def9ec29d5bb1,nivolumab,0.533073
uuid-17da54d258f943ffac7def9ec29d5bb1,1L,0.334517
uuid-17da54d258f943ffac7def9ec29d5bb1,toxicity,0.305291
uuid-17da54d258f943ffac7def9ec29d5bb1,regimen,0.655246
uuid-17da54d258f943ffac7def9ec29d5bb1,treated,0.599647
uuid-17da54d258f943ffac7def9ec29d5bb1,combination,0.38211
uuid-17da54d258f943ffac7def9ec29d5bb1,chemo,0.428033
uuid-17da54d258f943ffac7def9ec29d5bb1,2L,0.347753
uuid-17da54d258f943ffac7def9ec29d5bb1,pts,0.507673
uuid-17da54d258f943ffac7def9ec29d5bb1,preferred,0.376639
uuid-17da54d258f943ffac7def9ec29d5bb1,monotherapy,0.574898
uuid-17da54d258f943ffac7def9ec29d5bb1,treatment,0.69205
uuid-17da54d258f943ffac7def9ec29d5bb1,using nivo,0.443141
uuid-17da54d258f943ffac7def9ec29d5bb1,response,0.333686
uuid-17da54d258f943ffac7def9ec29d5bb1,combo,0.349226
uuid-17da54d258f943ffac7def9ec29d5bb1,PD1,0.42033
uuid-17da54d258f943ffac7def9ec29d5bb1,progression,0.572771
uuid-17da54d258f943ffac7def9ec29d5bb1,chemotherapy,0.453345
uuid-17da54d258f943ffac7def9ec29d5bb1,respond,0.48622
uuid-17da54d258f943ffac7def9ec29d5bb1,RTL stated,0.382325
uuid-17da54d258f943ffac7def9ec29d5bb1,option,0.489146
uuid-78fe9e7165604be1bdac9fdea8632c41,pembro,0.385921
uuid-78fe9e7165604be1bdac9fdea8632c41,RTL,0.412467
uuid-78fe9e7165604be1bdac9fdea8632c41,BMS,0.30453
uuid-78fe9e7165604be1bdac9fdea8632c41,trial,0.576462
uuid-78fe9e7165604be1bdac9fdea8632c41,efficacy,0.426097
uuid-78fe9e7165604be1bdac9fdea8632c41,commented,0.4072
uuid-78fe9e7165604be1bdac9fdea8632c41,stated,0.352349
uuid-78fe9e7165604be1bdac9fdea8632c41,OS,0.48972
uuid-78fe9e7165604be1bdac9fdea8632c41,data,0.62291
uuid-78fe9e7165604be1bdac9fdea8632c41,PFS,0.45891
uuid-78fe9e7165604be1bdac9fdea8632c41,ORR,0.497984
uuid-78fe9e7165604be1bdac9fdea8632c41,impressed,0.638243
uuid-78fe9e7165604be1bdac9fdea8632c41,vs,0.342681
uuid-78fe9e7165604be1bdac9fdea8632c41,LTL,0.362568
uuid-78fe9e7165604be1bdac9fdea8632c41,TLs,0.349615
uuid-78fe9e7165604be1bdac9fdea8632c41,feels,0.476496
uuid-78fe9e7165604be1bdac9fdea8632c41,Regional TL,0.307226
uuid-65a225ebf78647a1b37e6f6e17735718,pembro,0.392205
uuid-65a225ebf78647a1b37e6f6e17735718,RTL,0.594432
uuid-65a225ebf78647a1b37e6f6e17735718,trial,0.625999
uuid-65a225ebf78647a1b37e6f6e17735718,NTL,0.337626
uuid-65a225ebf78647a1b37e6f6e17735718,commented,0.470063
uuid-65a225ebf78647a1b37e6f6e17735718,Merck,0.311222
uuid-65a225ebf78647a1b37e6f6e17735718,stated,0.468541
uuid-65a225ebf78647a1b37e6f6e17735718,approval,0.300937
uuid-65a225ebf78647a1b37e6f6e17735718,OS,0.441462
uuid-65a225ebf78647a1b37e6f6e17735718,data,0.68182
uuid-65a225ebf78647a1b37e6f6e17735718,expressed,0.345671
uuid-65a225ebf78647a1b37e6f6e17735718,clinical trials,0.320811
uuid-65a225ebf78647a1b37e6f6e17735718,PFS,0.364045
uuid-65a225ebf78647a1b37e6f6e17735718,ORR,0.421563
uuid-65a225ebf78647a1b37e6f6e17735718,SCCHN,0.468128
uuid-65a225ebf78647a1b37e6f6e17735718,HCP,0.306953
uuid-65a225ebf78647a1b37e6f6e17735718,ASCO,0.338441
uuid-65a225ebf78647a1b37e6f6e17735718,impressed,0.660113
uuid-65a225ebf78647a1b37e6f6e17735718,LTL,0.399325
uuid-65a225ebf78647a1b37e6f6e17735718,TLs,0.326897
uuid-65a225ebf78647a1b37e6f6e17735718,SCLC,0.370426
uuid-65a225ebf78647a1b37e6f6e17735718,Regional TL,0.457867
uuid-65a225ebf78647a1b37e6f6e17735718,bladder,0.347721
uuid-e951f9d2064640cdb46aacceed2929c9,Opdivo,0.383359
uuid-e951f9d2064640cdb46aacceed2929c9,pembro,0.386239
uuid-e951f9d2064640cdb46aacceed2929c9,dose,0.862068
uuid-e951f9d2064640cdb46aacceed2929c9,toxicity,0.333931
uuid-e951f9d2064640cdb46aacceed2929c9,efficacy,0.334233
uuid-e951f9d2064640cdb46aacceed2929c9,Ipi,0.470486
uuid-e951f9d2064640cdb46aacceed2929c9,atezo,0.329613
uuid-e951f9d2064640cdb46aacceed2929c9,indication,0.342905
uuid-e951f9d2064640cdb46aacceed2929c9,vs,0.591724
uuid-e951f9d2064640cdb46aacceed2929c9,Keytruda,0.381412
uuid-e951f9d2064640cdb46aacceed2929c9,flat dosing,0.791528
uuid-fdfa4f598da04aad9797bcd173aae247,Nivo,0.404964
uuid-fdfa4f598da04aad9797bcd173aae247,patients,0.406389
uuid-fdfa4f598da04aad9797bcd173aae247,pembro,0.336691
uuid-fdfa4f598da04aad9797bcd173aae247,therapy,0.369267
uuid-fdfa4f598da04aad9797bcd173aae247,nivolumab,0.565268
uuid-fdfa4f598da04aad9797bcd173aae247,1L,0.615442
uuid-fdfa4f598da04aad9797bcd173aae247,regimen,0.442297
uuid-fdfa4f598da04aad9797bcd173aae247,treated,0.357277
uuid-fdfa4f598da04aad9797bcd173aae247,RCC,0.665298
uuid-fdfa4f598da04aad9797bcd173aae247,combination,0.381692
uuid-fdfa4f598da04aad9797bcd173aae247,chemo,0.3493
uuid-fdfa4f598da04aad9797bcd173aae247,2L,0.733464
uuid-fdfa4f598da04aad9797bcd173aae247,pts,0.361392
uuid-fdfa4f598da04aad9797bcd173aae247,agents,0.444021
uuid-fdfa4f598da04aad9797bcd173aae247,approval,0.472713
uuid-fdfa4f598da04aad9797bcd173aae247,atezo,0.342749
uuid-fdfa4f598da04aad9797bcd173aae247,preferred,0.724474
uuid-fdfa4f598da04aad9797bcd173aae247,monotherapy,0.65715
uuid-fdfa4f598da04aad9797bcd173aae247,treatment,0.397815
uuid-fdfa4f598da04aad9797bcd173aae247,using nivo,0.700151
uuid-fdfa4f598da04aad9797bcd173aae247,combo,0.418996
uuid-fdfa4f598da04aad9797bcd173aae247,PD1,0.425277
uuid-fdfa4f598da04aad9797bcd173aae247,approved,0.595346
uuid-fdfa4f598da04aad9797bcd173aae247,SCCHN,0.402865
uuid-fdfa4f598da04aad9797bcd173aae247,RTL stated,0.620053
uuid-fdfa4f598da04aad9797bcd173aae247,TL shared,0.42407
uuid-fdfa4f598da04aad9797bcd173aae247,option,0.644597
uuid-fdfa4f598da04aad9797bcd173aae247,bladder,0.34852
uuid-34b0b0ad775d40968b7b418ef75a9262,Nivo,0.418625
uuid-34b0b0ad775d40968b7b418ef75a9262,pembro,0.375995
uuid-34b0b0ad775d40968b7b418ef75a9262,PDL1,0.618394
uuid-34b0b0ad775d40968b7b418ef75a9262,efficacy,0.687719
uuid-34b0b0ad775d40968b7b418ef75a9262,chemo,0.451708
uuid-34b0b0ad775d40968b7b418ef75a9262,agents,0.484983
uuid-34b0b0ad775d40968b7b418ef75a9262,OS,0.439944
uuid-34b0b0ad775d40968b7b418ef75a9262,atezo,0.352178
uuid-34b0b0ad775d40968b7b418ef75a9262,monotherapy,0.312688
uuid-34b0b0ad775d40968b7b418ef75a9262,response,0.354308
uuid-34b0b0ad775d40968b7b418ef75a9262,data,0.386835
uuid-34b0b0ad775d40968b7b418ef75a9262,PFS,0.485042
uuid-34b0b0ad775d40968b7b418ef75a9262,PD1,0.386942
uuid-34b0b0ad775d40968b7b418ef75a9262,ORR,0.522894
uuid-34b0b0ad775d40968b7b418ef75a9262,nivo and pembro,0.704861
uuid-34b0b0ad775d40968b7b418ef75a9262,believes,0.52602
uuid-34b0b0ad775d40968b7b418ef75a9262,vs,0.417268
uuid-34b0b0ad775d40968b7b418ef75a9262,feels,0.373045
uuid-34b0b0ad775d40968b7b418ef75a9262,PD-1,0.3043
uuid-34b0b0ad775d40968b7b418ef75a9262,PDL1 expression,0.637561
uuid-34b0b0ad775d40968b7b418ef75a9262,biomarker,0.377866
uuid-f00eb129fe604a71b96f5097ec7c6177,patients,0.552889
uuid-f00eb129fe604a71b96f5097ec7c6177,RTL,0.362636
uuid-f00eb129fe604a71b96f5097ec7c6177,nivolumab,0.510204
uuid-f00eb129fe604a71b96f5097ec7c6177,regimen,0.360965
uuid-f00eb129fe604a71b96f5097ec7c6177,treated,0.503801
uuid-f00eb129fe604a71b96f5097ec7c6177,RCC,0.509555
uuid-f00eb129fe604a71b96f5097ec7c6177,combination,0.347095
uuid-f00eb129fe604a71b96f5097ec7c6177,2L,0.343753
uuid-f00eb129fe604a71b96f5097ec7c6177,pts,0.389073
uuid-f00eb129fe604a71b96f5097ec7c6177,stated,0.390877
uuid-f00eb129fe604a71b96f5097ec7c6177,approval,0.349465
uuid-f00eb129fe604a71b96f5097ec7c6177,preferred,0.386106
uuid-f00eb129fe604a71b96f5097ec7c6177,monotherapy,0.362405
uuid-f00eb129fe604a71b96f5097ec7c6177,treatment,0.403738
uuid-f00eb129fe604a71b96f5097ec7c6177,using nivo,0.490729
uuid-f00eb129fe604a71b96f5097ec7c6177,combo,0.337455
uuid-f00eb129fe604a71b96f5097ec7c6177,clinical trials,0.472187
uuid-f00eb129fe604a71b96f5097ec7c6177,approved,0.367582
uuid-f00eb129fe604a71b96f5097ec7c6177,SCCHN,0.504594
uuid-f00eb129fe604a71b96f5097ec7c6177,chemotherapy,0.305525
uuid-f00eb129fe604a71b96f5097ec7c6177,tumor types,0.35144
uuid-f00eb129fe604a71b96f5097ec7c6177,Regional TL,0.404804
uuid-f00eb129fe604a71b96f5097ec7c6177,RTL stated,0.540807
uuid-f00eb129fe604a71b96f5097ec7c6177,TL shared,0.391919
uuid-f00eb129fe604a71b96f5097ec7c6177,option,0.398782
uuid-f00eb129fe604a71b96f5097ec7c6177,bladder,0.5632
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,patients,0.759909
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,therapy,0.362493
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,nivolumab,0.349313
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,1L,0.420869
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,regimen,0.495985
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,treated,0.431234
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,chemo,0.381831
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,2L,0.418312
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,pts,0.631317
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,preferred,0.427668
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,monotherapy,0.531639
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,treatment,0.46551
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,using nivo,0.450974
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,NSCLC patients,0.420737
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,PD1,0.317998
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,progression,0.514477
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,chemotherapy,0.30283
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,respond,0.435071
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,RTL stated,0.375379
uuid-12e7183ce6c94c6d9b7ac9ebd70f5415,option,0.491117
uuid-5e55ce87068d466b9d163777bfcdd983,lung,0.438717
uuid-5e55ce87068d466b9d163777bfcdd983,melanoma,0.449976
uuid-5e55ce87068d466b9d163777bfcdd983,RCC,0.491499
uuid-5e55ce87068d466b9d163777bfcdd983,TL stated,0.363684
uuid-5e55ce87068d466b9d163777bfcdd983,tumor,0.542765
uuid-5e55ce87068d466b9d163777bfcdd983,tumor types,0.465191
uuid-5e55ce87068d466b9d163777bfcdd983,RTL stated,0.347428
uuid-5e55ce87068d466b9d163777bfcdd983,TL shared,0.472771
uuid-5e55ce87068d466b9d163777bfcdd983,bladder,0.419626
uuid-dba836f795d444ce84b1702c8a82546d,patients,0.427939
uuid-dba836f795d444ce84b1702c8a82546d,Opdivo,0.355043
uuid-dba836f795d444ce84b1702c8a82546d,therapy,0.53414
uuid-dba836f795d444ce84b1702c8a82546d,nivolumab,0.412556
uuid-dba836f795d444ce84b1702c8a82546d,mentioned,0.307024
uuid-dba836f795d444ce84b1702c8a82546d,cHL,0.768113
uuid-dbb36fea0ec944f6af37a896abec71fa,RTL,0.522853
uuid-dbb36fea0ec944f6af37a896abec71fa,trial,0.541928
uuid-dbb36fea0ec944f6af37a896abec71fa,NTL,0.460945
uuid-dbb36fea0ec944f6af37a896abec71fa,commented,0.372472
uuid-dbb36fea0ec944f6af37a896abec71fa,OS,0.329299
uuid-dbb36fea0ec944f6af37a896abec71fa,data,0.529315
uuid-dbb36fea0ec944f6af37a896abec71fa,expressed,0.41166
uuid-dbb36fea0ec944f6af37a896abec71fa,mentioned,0.526171
uuid-dbb36fea0ec944f6af37a896abec71fa,PFS,0.327283
uuid-dbb36fea0ec944f6af37a896abec71fa,ORR,0.432153
uuid-dbb36fea0ec944f6af37a896abec71fa,HCP,0.481257
uuid-dbb36fea0ec944f6af37a896abec71fa,ASCO,0.351523
uuid-dbb36fea0ec944f6af37a896abec71fa,impressed,0.500842
uuid-dbb36fea0ec944f6af37a896abec71fa,LTL,0.374409
uuid-dbb36fea0ec944f6af37a896abec71fa,SCLC,0.394404
uuid-dbb36fea0ec944f6af37a896abec71fa,Regional TL,0.332851
uuid-d4d139d9f9054638aac6e242c9bc1124,Nivo,0.548531
uuid-d4d139d9f9054638aac6e242c9bc1124,patients,0.429828
uuid-d4d139d9f9054638aac6e242c9bc1124,Opdivo,0.450272
uuid-d4d139d9f9054638aac6e242c9bc1124,therapy,0.472921
uuid-d4d139d9f9054638aac6e242c9bc1124,nivolumab,0.522611
uuid-d4d139d9f9054638aac6e242c9bc1124,approval,0.424516
uuid-d4d139d9f9054638aac6e242c9bc1124,monotherapy,0.323383
uuid-d4d139d9f9054638aac6e242c9bc1124,using nivo,0.558325
uuid-d4d139d9f9054638aac6e242c9bc1124,mentioned,0.418248
uuid-d4d139d9f9054638aac6e242c9bc1124,approved,0.335467
uuid-d4d139d9f9054638aac6e242c9bc1124,cHL,0.650913
uuid-d4d139d9f9054638aac6e242c9bc1124,label,0.327197
uuid-d4d139d9f9054638aac6e242c9bc1124,LTL,0.356156
uuid-d4d139d9f9054638aac6e242c9bc1124,RTL stated,0.307774
uuid-d4d139d9f9054638aac6e242c9bc1124,option,0.371652
uuid-d1da8ad0218b4c5ca752da973a9788b1,pembro,0.344454
uuid-d1da8ad0218b4c5ca752da973a9788b1,RTL,0.419051
uuid-d1da8ad0218b4c5ca752da973a9788b1,dose,0.366577
uuid-d1da8ad0218b4c5ca752da973a9788b1,Ipi,0.396059
uuid-d1da8ad0218b4c5ca752da973a9788b1,stated,0.317903
uuid-d1da8ad0218b4c5ca752da973a9788b1,atezo,0.341348
uuid-d1da8ad0218b4c5ca752da973a9788b1,clinical trials,0.356157
uuid-d1da8ad0218b4c5ca752da973a9788b1,indication,0.342358
uuid-d1da8ad0218b4c5ca752da973a9788b1,impressed,0.343171
uuid-d1da8ad0218b4c5ca752da973a9788b1,vs,0.305229
uuid-d1da8ad0218b4c5ca752da973a9788b1,LTL,0.368296
uuid-d1da8ad0218b4c5ca752da973a9788b1,TLs,0.452997
uuid-d1da8ad0218b4c5ca752da973a9788b1,Regional TL,0.324698
uuid-d1da8ad0218b4c5ca752da973a9788b1,flat dosing,0.442221
uuid-a34f9b203f484b4daea9399bdeddf9a6,patients,0.364321
uuid-a34f9b203f484b4daea9399bdeddf9a6,Opdivo,0.354219
uuid-a34f9b203f484b4daea9399bdeddf9a6,therapy,0.391266
uuid-a34f9b203f484b4daea9399bdeddf9a6,nivolumab,0.354345
uuid-a34f9b203f484b4daea9399bdeddf9a6,treated,0.31776
uuid-a34f9b203f484b4daea9399bdeddf9a6,treatment,0.33949
uuid-a34f9b203f484b4daea9399bdeddf9a6,cHL,0.541969
uuid-bacfd9e0335a45638f5ac7c3634acc42,pembro,0.531987
uuid-bacfd9e0335a45638f5ac7c3634acc42,1L,0.436562
uuid-bacfd9e0335a45638f5ac7c3634acc42,2L,0.477176
uuid-bacfd9e0335a45638f5ac7c3634acc42,approval,0.393819
uuid-bacfd9e0335a45638f5ac7c3634acc42,atezo,0.571653
uuid-bacfd9e0335a45638f5ac7c3634acc42,preferred,0.400126
uuid-bacfd9e0335a45638f5ac7c3634acc42,using nivo,0.467672
uuid-bacfd9e0335a45638f5ac7c3634acc42,indication,0.434226
uuid-bacfd9e0335a45638f5ac7c3634acc42,approved,0.420953
uuid-bacfd9e0335a45638f5ac7c3634acc42,SCCHN,0.473557
uuid-bacfd9e0335a45638f5ac7c3634acc42,label,0.426835
uuid-bacfd9e0335a45638f5ac7c3634acc42,NCCN,0.450627
uuid-bacfd9e0335a45638f5ac7c3634acc42,bladder,0.321003
uuid-a276878fc81c45a18a3aa60d023e9b8e,patients,0.423956
uuid-a276878fc81c45a18a3aa60d023e9b8e,RTL,0.427258
uuid-a276878fc81c45a18a3aa60d023e9b8e,nivolumab,0.382841
uuid-a276878fc81c45a18a3aa60d023e9b8e,treated,0.403819
uuid-a276878fc81c45a18a3aa60d023e9b8e,shared,0.486172
uuid-a276878fc81c45a18a3aa60d023e9b8e,RCC,0.460887
uuid-a276878fc81c45a18a3aa60d023e9b8e,stated,0.35542
uuid-a276878fc81c45a18a3aa60d023e9b8e,approval,0.449131
uuid-a276878fc81c45a18a3aa60d023e9b8e,using nivo,0.436743
uuid-a276878fc81c45a18a3aa60d023e9b8e,clinical trials,0.457471
uuid-a276878fc81c45a18a3aa60d023e9b8e,SCCHN,0.483644
uuid-a276878fc81c45a18a3aa60d023e9b8e,LTL,0.326633
uuid-a276878fc81c45a18a3aa60d023e9b8e,Regional TL,0.489926
uuid-a276878fc81c45a18a3aa60d023e9b8e,RTL stated,0.494447
uuid-a276878fc81c45a18a3aa60d023e9b8e,TL shared,0.380518
uuid-a276878fc81c45a18a3aa60d023e9b8e,bladder,0.431344
uuid-8b5bf297fa9c40938e4dd897f872d182,patients,0.361146
uuid-8b5bf297fa9c40938e4dd897f872d182,treated,0.673266
uuid-8b5bf297fa9c40938e4dd897f872d182,tumor,0.405991
uuid-8b5bf297fa9c40938e4dd897f872d182,pts,0.301305
uuid-8b5bf297fa9c40938e4dd897f872d182,treatment,0.414408
uuid-8b5bf297fa9c40938e4dd897f872d182,progression,0.380643
uuid-a171c98f68694b82ab659c454c3a4a1a,therapy,0.362093
uuid-a171c98f68694b82ab659c454c3a4a1a,chemotherapy,0.325348
uuid-a171c98f68694b82ab659c454c3a4a1a,oncologist,0.375998
uuid-66915b4e522440bea7dc24c5b9026802,Nivo,0.465697
uuid-66915b4e522440bea7dc24c5b9026802,patients,0.89568
uuid-66915b4e522440bea7dc24c5b9026802,Opdivo,0.532591
uuid-66915b4e522440bea7dc24c5b9026802,therapy,0.656293
uuid-66915b4e522440bea7dc24c5b9026802,nivolumab,0.503494
uuid-66915b4e522440bea7dc24c5b9026802,toxicity,0.381174
uuid-66915b4e522440bea7dc24c5b9026802,regimen,0.571847
uuid-66915b4e522440bea7dc24c5b9026802,treated,0.473365
uuid-66915b4e522440bea7dc24c5b9026802,chemo,0.446018
uuid-66915b4e522440bea7dc24c5b9026802,pts,0.616211
uuid-66915b4e522440bea7dc24c5b9026802,monotherapy,0.479032
uuid-66915b4e522440bea7dc24c5b9026802,treatment,0.698698
uuid-66915b4e522440bea7dc24c5b9026802,using nivo,0.329251
uuid-66915b4e522440bea7dc24c5b9026802,response,0.469078
uuid-66915b4e522440bea7dc24c5b9026802,PD1,0.413015
uuid-66915b4e522440bea7dc24c5b9026802,cHL,0.398466
uuid-66915b4e522440bea7dc24c5b9026802,progression,0.737511
uuid-66915b4e522440bea7dc24c5b9026802,chemotherapy,0.464098
uuid-66915b4e522440bea7dc24c5b9026802,respond,0.570085
uuid-66915b4e522440bea7dc24c5b9026802,option,0.427908
uuid-cb34278e4d1b42449898cfe20c2b635b,pembro,0.413163
uuid-cb34278e4d1b42449898cfe20c2b635b,BMS,0.497525
uuid-cb34278e4d1b42449898cfe20c2b635b,PDL1,0.443645
uuid-cb34278e4d1b42449898cfe20c2b635b,efficacy,0.499455
uuid-cb34278e4d1b42449898cfe20c2b635b,agents,0.524447
uuid-cb34278e4d1b42449898cfe20c2b635b,Merck,0.479199
uuid-cb34278e4d1b42449898cfe20c2b635b,atezo,0.492959
uuid-cb34278e4d1b42449898cfe20c2b635b,data,0.368613
uuid-cb34278e4d1b42449898cfe20c2b635b,indication,0.345883
uuid-cb34278e4d1b42449898cfe20c2b635b,nivo and pembro,0.464723
uuid-cb34278e4d1b42449898cfe20c2b635b,believes,0.431802
uuid-cb34278e4d1b42449898cfe20c2b635b,feels,0.450442
uuid-cb34278e4d1b42449898cfe20c2b635b,PDL1 expression,0.39979
uuid-cb34278e4d1b42449898cfe20c2b635b,biomarker,0.352356
uuid-2f6b4aa8cef0499a88eb502e63b097b3,1L,0.322734
uuid-2f6b4aa8cef0499a88eb502e63b097b3,combination,0.318652
uuid-2f6b4aa8cef0499a88eb502e63b097b3,chemo,0.301763
uuid-2f6b4aa8cef0499a88eb502e63b097b3,2L,0.313169
uuid-2f6b4aa8cef0499a88eb502e63b097b3,agents,0.408418
uuid-2f6b4aa8cef0499a88eb502e63b097b3,preferred,0.396526
uuid-2f6b4aa8cef0499a88eb502e63b097b3,monotherapy,0.318909
uuid-2f6b4aa8cef0499a88eb502e63b097b3,believes,0.335542
uuid-2f6b4aa8cef0499a88eb502e63b097b3,chemotherapy,0.318515
uuid-2f6b4aa8cef0499a88eb502e63b097b3,tumor types,0.306425
uuid-2f6b4aa8cef0499a88eb502e63b097b3,feels,0.357891
uuid-2f6b4aa8cef0499a88eb502e63b097b3,option,0.508677
uuid-2f6b4aa8cef0499a88eb502e63b097b3,biomarker,0.337574
uuid-f2072974588940f8800c54b1f8c5d067,patients,0.489453
uuid-f2072974588940f8800c54b1f8c5d067,pts,0.318917
uuid-f2072974588940f8800c54b1f8c5d067,PD-L1,0.405886
uuid-f2072974588940f8800c54b1f8c5d067,PD-L1 testing,0.343934
uuid-f2072974588940f8800c54b1f8c5d067,testing,0.463345
uuid-f2072974588940f8800c54b1f8c5d067,PDL1 testing,0.358889
uuid-f2072974588940f8800c54b1f8c5d067,NSCLC patients,0.439755
uuid-f2072974588940f8800c54b1f8c5d067,tumor types,0.324044
uuid-f2072974588940f8800c54b1f8c5d067,option,0.399602
uuid-f2072974588940f8800c54b1f8c5d067,biomarker,0.420026
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,Nivo,0.357155
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,pembro,0.397464
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,dose,0.507839
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,BMS,0.468945
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,trial,0.567827
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,efficacy,0.534901
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,Ipi,0.711889
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,atezo,0.337035
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,data,0.469975
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,ORR,0.376124
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,impressed,0.432013
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,vs,0.529193
uuid-ed36c2ea3fc8440e902ee5e69ce8cf2d,flat dosing,0.468388
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,RTL,0.468057
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,trial,0.391367
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,NTL,0.396466
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,commented,0.435325
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,OS,0.320465
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,data,0.541774
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,expressed,0.337654
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,mentioned,0.615941
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,PFS,0.347066
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,ORR,0.351812
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,HCP,0.450522
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,cHL,0.42491
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,ASCO,0.461923
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,impressed,0.516398
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,LTL,0.386041
uuid-ecebeaddb1b848c48d18ba2189ff0f8d,Regional TL,0.334367
uuid-351cf31ef58c43d59c1618f487775faf,therapy,0.304679
uuid-351cf31ef58c43d59c1618f487775faf,regimen,0.367159
uuid-351cf31ef58c43d59c1618f487775faf,treated,0.557249
uuid-351cf31ef58c43d59c1618f487775faf,treatment,0.309981
uuid-33c19ad68ee04a9490a9046b2fce22fb,Opdivo,0.333331
uuid-33c19ad68ee04a9490a9046b2fce22fb,treated,0.335973
uuid-33c19ad68ee04a9490a9046b2fce22fb,shared,0.356715
uuid-33c19ad68ee04a9490a9046b2fce22fb,physicians,0.81159
uuid-33c19ad68ee04a9490a9046b2fce22fb,oncologist,0.309091
uuid-d2f40292c5c044b286d50449842f3a82,Opdivo,0.306131
uuid-d2f40292c5c044b286d50449842f3a82,shared,0.318032
uuid-d2f40292c5c044b286d50449842f3a82,physicians,0.5991
uuid-d2f40292c5c044b286d50449842f3a82,clinical,0.307286
uuid-6953387c7c30477c9bda8610bb4b8f88,patients,0.498462
uuid-6953387c7c30477c9bda8610bb4b8f88,Opdivo,0.419685
uuid-6953387c7c30477c9bda8610bb4b8f88,therapy,0.301162
uuid-6953387c7c30477c9bda8610bb4b8f88,regimen,0.426626
uuid-6953387c7c30477c9bda8610bb4b8f88,treated,0.516898
uuid-6953387c7c30477c9bda8610bb4b8f88,physicians,0.588575
uuid-6953387c7c30477c9bda8610bb4b8f88,treatment,0.583516
uuid-6953387c7c30477c9bda8610bb4b8f88,response,0.329467
uuid-6953387c7c30477c9bda8610bb4b8f88,progression,0.529502
uuid-6953387c7c30477c9bda8610bb4b8f88,respond,0.38105
uuid-87999f40d0a94831ae3e401d294eafb0,commented,0.312046
uuid-87999f40d0a94831ae3e401d294eafb0,Merck,0.317042
uuid-87999f40d0a94831ae3e401d294eafb0,data,0.418152
uuid-87999f40d0a94831ae3e401d294eafb0,expressed,0.312131
uuid-87999f40d0a94831ae3e401d294eafb0,ASCO,0.412933
uuid-87999f40d0a94831ae3e401d294eafb0,impressed,0.350248
uuid-6383ba75b14c4c34a90bacb360a1b46c,option,0.367237
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,Nivo,0.33242
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,pembro,0.505584
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,dose,0.480349
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,trial,0.309236
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,efficacy,0.679148
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,Ipi,0.422036
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,OS,0.348476
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,atezo,0.558351
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,regards,0.326847
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,data,0.447558
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,ORR,0.378414
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,nivo and pembro,0.477876
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,vs,0.709989
uuid-9d56c3f2193e472eb4aa906e6c56c5b3,flat dosing,0.38906
uuid-3b5f0e843e2f46df946b2e6b6c71c395,RTL,0.317958
uuid-3b5f0e843e2f46df946b2e6b6c71c395,trial,0.39575
uuid-3b5f0e843e2f46df946b2e6b6c71c395,commented,0.4495
uuid-3b5f0e843e2f46df946b2e6b6c71c395,OS,0.303497
uuid-3b5f0e843e2f46df946b2e6b6c71c395,data,0.559673
uuid-3b5f0e843e2f46df946b2e6b6c71c395,expressed,0.301511
uuid-3b5f0e843e2f46df946b2e6b6c71c395,clinical trials,0.410535
uuid-3b5f0e843e2f46df946b2e6b6c71c395,ORR,0.333452
uuid-3b5f0e843e2f46df946b2e6b6c71c395,ASCO,0.461298
uuid-3b5f0e843e2f46df946b2e6b6c71c395,impressed,0.525112
uuid-3b5f0e843e2f46df946b2e6b6c71c395,SCLC,0.449557
uuid-3b5f0e843e2f46df946b2e6b6c71c395,Regional TL,0.441798
uuid-3b5f0e843e2f46df946b2e6b6c71c395,bladder,0.430348
uuid-f63da2da19b346f5894a00a07922833c,patients,0.496531
uuid-f63da2da19b346f5894a00a07922833c,Opdivo,0.506892
uuid-f63da2da19b346f5894a00a07922833c,therapy,0.359633
uuid-f63da2da19b346f5894a00a07922833c,pts,0.402279
uuid-f63da2da19b346f5894a00a07922833c,monotherapy,0.373616
uuid-f63da2da19b346f5894a00a07922833c,treatment,0.361003
uuid-f63da2da19b346f5894a00a07922833c,approved,0.393574
uuid-f63da2da19b346f5894a00a07922833c,progression,0.413069
uuid-f63da2da19b346f5894a00a07922833c,respond,0.332272
uuid-f63da2da19b346f5894a00a07922833c,feels,0.433114
uuid-f63da2da19b346f5894a00a07922833c,option,0.44535
uuid-0c00140ab1d548388eb00a11958029e0,RTL,0.392979
uuid-0c00140ab1d548388eb00a11958029e0,BMS,0.398977
uuid-0c00140ab1d548388eb00a11958029e0,trial,0.698942
uuid-0c00140ab1d548388eb00a11958029e0,NTL,0.412779
uuid-0c00140ab1d548388eb00a11958029e0,commented,0.458063
uuid-0c00140ab1d548388eb00a11958029e0,Merck,0.420317
uuid-0c00140ab1d548388eb00a11958029e0,data,0.337401
uuid-0c00140ab1d548388eb00a11958029e0,expressed,0.311611
uuid-0c00140ab1d548388eb00a11958029e0,clinical trials,0.405271
uuid-0c00140ab1d548388eb00a11958029e0,lung cancer,0.306949
uuid-0c00140ab1d548388eb00a11958029e0,impressed,0.408521
uuid-0c00140ab1d548388eb00a11958029e0,Regional TL,0.366325
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,Nivo,0.384741
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,RTL,0.357834
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,nivolumab,0.326585
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,trial,0.451365
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,approval,0.339496
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,data,0.342771
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,clinical trials,0.344247
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,ASCO,0.308144
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,impressed,0.454754
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,Regional TL,0.315414
uuid-f8e2a3f1f7ad402bbe6d7e01ce10eb9a,bladder,0.518006
uuid-93305a6a8b414e5abe041f4b0a2d0bce,patients,0.888386
uuid-93305a6a8b414e5abe041f4b0a2d0bce,Opdivo,0.629662
uuid-93305a6a8b414e5abe041f4b0a2d0bce,therapy,0.512193
uuid-93305a6a8b414e5abe041f4b0a2d0bce,nivolumab,0.473172
uuid-93305a6a8b414e5abe041f4b0a2d0bce,regimen,0.507639
uuid-93305a6a8b414e5abe041f4b0a2d0bce,treated,0.615092
uuid-93305a6a8b414e5abe041f4b0a2d0bce,pts,0.480993
uuid-93305a6a8b414e5abe041f4b0a2d0bce,treatment,0.766656
uuid-93305a6a8b414e5abe041f4b0a2d0bce,progression,0.596606
uuid-93305a6a8b414e5abe041f4b0a2d0bce,chemotherapy,0.303641
uuid-93305a6a8b414e5abe041f4b0a2d0bce,respond,0.429332
uuid-e7a1ec60f9704a2c83eccefe8b600084,Nivo,0.541926
uuid-e7a1ec60f9704a2c83eccefe8b600084,patients,0.740035
uuid-e7a1ec60f9704a2c83eccefe8b600084,Opdivo,0.535942
uuid-e7a1ec60f9704a2c83eccefe8b600084,therapy,0.667568
uuid-e7a1ec60f9704a2c83eccefe8b600084,nivolumab,0.477513
uuid-e7a1ec60f9704a2c83eccefe8b600084,regimen,0.382248
uuid-e7a1ec60f9704a2c83eccefe8b600084,treated,0.348331
uuid-e7a1ec60f9704a2c83eccefe8b600084,chemo,0.343715
uuid-e7a1ec60f9704a2c83eccefe8b600084,pts,0.363703
uuid-e7a1ec60f9704a2c83eccefe8b600084,monotherapy,0.314427
uuid-e7a1ec60f9704a2c83eccefe8b600084,treatment,0.543334
uuid-e7a1ec60f9704a2c83eccefe8b600084,using nivo,0.313237
uuid-e7a1ec60f9704a2c83eccefe8b600084,response,0.331954
uuid-e7a1ec60f9704a2c83eccefe8b600084,cHL,0.538192
uuid-e7a1ec60f9704a2c83eccefe8b600084,progression,0.524127
uuid-e7a1ec60f9704a2c83eccefe8b600084,chemotherapy,0.424797
uuid-e7a1ec60f9704a2c83eccefe8b600084,respond,0.420596
uuid-645647e0fda844ec9135d21551823b2c,TL,0.635878
uuid-645647e0fda844ec9135d21551823b2c,PDL1,0.478308
uuid-645647e0fda844ec9135d21551823b2c,Merck,0.332603
uuid-645647e0fda844ec9135d21551823b2c,PD-L1,0.774436
uuid-645647e0fda844ec9135d21551823b2c,PD-L1 testing,0.725184
uuid-645647e0fda844ec9135d21551823b2c,testing,0.719512
uuid-645647e0fda844ec9135d21551823b2c,PDL1 testing,0.424546
uuid-645647e0fda844ec9135d21551823b2c,NSCLC patients,0.401716
uuid-645647e0fda844ec9135d21551823b2c,assay,0.907903
uuid-645647e0fda844ec9135d21551823b2c,biomarker,0.368087
uuid-7b2de475c19f437e9c601fd9aba07a78,Nivo,0.425609
uuid-7b2de475c19f437e9c601fd9aba07a78,patients,0.541283
uuid-7b2de475c19f437e9c601fd9aba07a78,Opdivo,0.30113
uuid-7b2de475c19f437e9c601fd9aba07a78,RTL,0.317449
uuid-7b2de475c19f437e9c601fd9aba07a78,therapy,0.578407
uuid-7b2de475c19f437e9c601fd9aba07a78,nivolumab,0.608131
uuid-7b2de475c19f437e9c601fd9aba07a78,treated,0.543749
uuid-7b2de475c19f437e9c601fd9aba07a78,pts,0.312662
uuid-7b2de475c19f437e9c601fd9aba07a78,treatment,0.365441
uuid-7b2de475c19f437e9c601fd9aba07a78,using nivo,0.46834
uuid-7b2de475c19f437e9c601fd9aba07a78,mentioned,0.449284
uuid-7b2de475c19f437e9c601fd9aba07a78,PD1,0.359593
uuid-7b2de475c19f437e9c601fd9aba07a78,cHL,0.716111
uuid-7b2de475c19f437e9c601fd9aba07a78,progression,0.344525
uuid-7b2de475c19f437e9c601fd9aba07a78,chemotherapy,0.331059
uuid-7b2de475c19f437e9c601fd9aba07a78,RTL stated,0.345679
uuid-ff3208642d16403498e9e4393e6358ee,Nivo,0.504302
uuid-ff3208642d16403498e9e4393e6358ee,patients,0.600807
uuid-ff3208642d16403498e9e4393e6358ee,Opdivo,0.353433
uuid-ff3208642d16403498e9e4393e6358ee,therapy,0.499894
uuid-ff3208642d16403498e9e4393e6358ee,nivolumab,0.441614
uuid-ff3208642d16403498e9e4393e6358ee,pts,0.379735
uuid-ff3208642d16403498e9e4393e6358ee,treatment,0.344847
uuid-ff3208642d16403498e9e4393e6358ee,response,0.3456
uuid-ff3208642d16403498e9e4393e6358ee,cHL,0.58629
uuid-ff3208642d16403498e9e4393e6358ee,progression,0.416241
uuid-ff3208642d16403498e9e4393e6358ee,chemotherapy,0.312886
uuid-ff3208642d16403498e9e4393e6358ee,respond,0.313296
uuid-88cf917855994dd1881324f0bbf987f1,Nivo,0.402047
uuid-88cf917855994dd1881324f0bbf987f1,pembro,0.361657
uuid-88cf917855994dd1881324f0bbf987f1,combination,0.300564
uuid-88cf917855994dd1881324f0bbf987f1,2L,0.309696
uuid-88cf917855994dd1881324f0bbf987f1,Ipi,0.308242
uuid-88cf917855994dd1881324f0bbf987f1,atezo,0.345964
uuid-88cf917855994dd1881324f0bbf987f1,preferred,0.398836
uuid-88cf917855994dd1881324f0bbf987f1,monotherapy,0.326267
uuid-88cf917855994dd1881324f0bbf987f1,using nivo,0.39534
uuid-88cf917855994dd1881324f0bbf987f1,mentioned,0.324983
uuid-88cf917855994dd1881324f0bbf987f1,indication,0.308215
uuid-88cf917855994dd1881324f0bbf987f1,approved,0.305925
uuid-88cf917855994dd1881324f0bbf987f1,HCP,0.519352
uuid-88cf917855994dd1881324f0bbf987f1,feels,0.381383
uuid-88cf917855994dd1881324f0bbf987f1,option,0.355246
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,commented,0.336804
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,OS,0.57085
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,regards,0.377518
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,data,0.414452
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,PFS,0.633904
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,ORR,0.493647
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,ASCO,0.385261
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,impressed,0.395443
uuid-5ec26cfe7b8547f4b0393401dbab3fd2,TLs,0.323038
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,toxicity,0.5048
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,regimen,0.511026
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,treated,0.472156
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,physicians,0.466123
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,treatment,0.442504
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,response,0.406972
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,progression,0.302582
uuid-177058e6ff0c4af49f5ef8f0fb45d71c,respond,0.439096
uuid-7c1f36bf1c95436aa43b5cf52294daa9,Opdivo,0.596015
uuid-7c1f36bf1c95436aa43b5cf52294daa9,shared,0.387212
uuid-7c1f36bf1c95436aa43b5cf52294daa9,stated,0.368046
uuid-7c1f36bf1c95436aa43b5cf52294daa9,physicians,0.341674
uuid-7c1f36bf1c95436aa43b5cf52294daa9,drug,0.381889
uuid-7c1f36bf1c95436aa43b5cf52294daa9,Keytruda,0.329732
uuid-ae93b71483e34d3196d67900d37bc8f7,Nivo,0.45544
uuid-ae93b71483e34d3196d67900d37bc8f7,pembro,0.349349
uuid-ae93b71483e34d3196d67900d37bc8f7,1L,0.523076
uuid-ae93b71483e34d3196d67900d37bc8f7,efficacy,0.422581
uuid-ae93b71483e34d3196d67900d37bc8f7,regimen,0.46784
uuid-ae93b71483e34d3196d67900d37bc8f7,combination,0.414248
uuid-ae93b71483e34d3196d67900d37bc8f7,chemo,0.589141
uuid-ae93b71483e34d3196d67900d37bc8f7,2L,0.482235
uuid-ae93b71483e34d3196d67900d37bc8f7,agents,0.433196
uuid-ae93b71483e34d3196d67900d37bc8f7,OS,0.358978
uuid-ae93b71483e34d3196d67900d37bc8f7,atezo,0.31781
uuid-ae93b71483e34d3196d67900d37bc8f7,preferred,0.396775
uuid-ae93b71483e34d3196d67900d37bc8f7,monotherapy,0.591253
uuid-ae93b71483e34d3196d67900d37bc8f7,combo,0.549531
uuid-ae93b71483e34d3196d67900d37bc8f7,PFS,0.350575
uuid-ae93b71483e34d3196d67900d37bc8f7,PD1,0.434934
uuid-ae93b71483e34d3196d67900d37bc8f7,ORR,0.320236
uuid-ae93b71483e34d3196d67900d37bc8f7,nivo and pembro,0.396862
uuid-ae93b71483e34d3196d67900d37bc8f7,progression,0.316894
uuid-ae93b71483e34d3196d67900d37bc8f7,believes,0.443802
uuid-ae93b71483e34d3196d67900d37bc8f7,chemotherapy,0.504927
uuid-ae93b71483e34d3196d67900d37bc8f7,feels,0.545812
uuid-ae93b71483e34d3196d67900d37bc8f7,option,0.562197
uuid-d55842c89f9a425a8560399afeb82ed4,TL,0.313282
uuid-d55842c89f9a425a8560399afeb82ed4,RTL,0.358538
uuid-d55842c89f9a425a8560399afeb82ed4,shared,0.382528
uuid-d55842c89f9a425a8560399afeb82ed4,commented,0.306448
uuid-d55842c89f9a425a8560399afeb82ed4,RCC,0.300887
uuid-d55842c89f9a425a8560399afeb82ed4,TL stated,0.41332
uuid-d55842c89f9a425a8560399afeb82ed4,stated,0.41344
uuid-d55842c89f9a425a8560399afeb82ed4,physicians,0.565109
uuid-d55842c89f9a425a8560399afeb82ed4,preferred,0.359215
uuid-d55842c89f9a425a8560399afeb82ed4,PD-L1 testing,0.303646
uuid-d55842c89f9a425a8560399afeb82ed4,testing,0.300981
uuid-d55842c89f9a425a8560399afeb82ed4,using nivo,0.359392
uuid-d55842c89f9a425a8560399afeb82ed4,mentioned,0.391029
uuid-d55842c89f9a425a8560399afeb82ed4,PDL1 testing,0.463538
uuid-d55842c89f9a425a8560399afeb82ed4,indication,0.325705
uuid-d55842c89f9a425a8560399afeb82ed4,SCCHN,0.496621
uuid-d55842c89f9a425a8560399afeb82ed4,HCP,0.420635
uuid-d55842c89f9a425a8560399afeb82ed4,tumor types,0.371316
uuid-d55842c89f9a425a8560399afeb82ed4,oncologist,0.342558
uuid-d55842c89f9a425a8560399afeb82ed4,LTL,0.477866
uuid-d55842c89f9a425a8560399afeb82ed4,TLs,0.351145
uuid-d55842c89f9a425a8560399afeb82ed4,academic,0.33913
uuid-d55842c89f9a425a8560399afeb82ed4,Regional TL,0.503314
uuid-d55842c89f9a425a8560399afeb82ed4,RTL stated,0.379754
uuid-d55842c89f9a425a8560399afeb82ed4,bladder,0.328418
uuid-38b5bd98180343f18acd7a0ed40dcaad,TL,0.624221
uuid-38b5bd98180343f18acd7a0ed40dcaad,TL stated,0.556151
uuid-38b5bd98180343f18acd7a0ed40dcaad,institution,0.333351
uuid-38b5bd98180343f18acd7a0ed40dcaad,PD-L1,0.694968
uuid-38b5bd98180343f18acd7a0ed40dcaad,PD-L1 testing,0.85628
uuid-38b5bd98180343f18acd7a0ed40dcaad,testing,0.858748
uuid-38b5bd98180343f18acd7a0ed40dcaad,PDL1 testing,0.729793
uuid-38b5bd98180343f18acd7a0ed40dcaad,NSCLC patients,0.693355
uuid-38b5bd98180343f18acd7a0ed40dcaad,assay,0.581469
uuid-00d870a7037842b296983ba9e5497dba,therapy,0.40905
uuid-00d870a7037842b296983ba9e5497dba,mentioned,0.384473
uuid-00d870a7037842b296983ba9e5497dba,cHL,0.640755
uuid-e68c1d5ac1564cd28e208d24662fb40f,Nivo,0.302098
uuid-e68c1d5ac1564cd28e208d24662fb40f,Opdivo,0.386075
uuid-e68c1d5ac1564cd28e208d24662fb40f,therapy,0.457489
uuid-e68c1d5ac1564cd28e208d24662fb40f,nivolumab,0.612139
uuid-e68c1d5ac1564cd28e208d24662fb40f,treated,0.311461
uuid-e68c1d5ac1564cd28e208d24662fb40f,approval,0.477976
uuid-e68c1d5ac1564cd28e208d24662fb40f,using nivo,0.412236
uuid-e68c1d5ac1564cd28e208d24662fb40f,mentioned,0.388375
uuid-e68c1d5ac1564cd28e208d24662fb40f,cHL,0.710435
uuid-e68c1d5ac1564cd28e208d24662fb40f,label,0.400485
uuid-3a8477d117ce4c70b48bd4e412c528ff,toxicity,0.511221
uuid-3a8477d117ce4c70b48bd4e412c528ff,regimen,0.474379
uuid-3a8477d117ce4c70b48bd4e412c528ff,treated,0.398066
uuid-3a8477d117ce4c70b48bd4e412c528ff,treatment,0.354785
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,RTL,0.395841
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,BMS,0.377961
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,NTL,0.36736
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,commented,0.636588
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,stated,0.466638
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,OS,0.373171
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,regards,0.438754
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,data,0.676395
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,expressed,0.563232
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,mentioned,0.373292
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,indication,0.33354
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,PFS,0.33095
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,ORR,0.367798
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,SCCHN,0.357451
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,ASCO,0.466824
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,impressed,0.669892
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,LTL,0.329927
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,SCLC,0.459213
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,Regional TL,0.433032
uuid-ae09f7f5a72a4d6fb429d5148f782ef6,NCCN,0.526521
uuid-b6b4354fe91b48e6906833d50ab99422,TL,0.680442
uuid-b6b4354fe91b48e6906833d50ab99422,TL stated,0.499697
uuid-b6b4354fe91b48e6906833d50ab99422,institution,0.376856
uuid-b6b4354fe91b48e6906833d50ab99422,PD-L1,0.680641
uuid-b6b4354fe91b48e6906833d50ab99422,approval,0.326398
uuid-b6b4354fe91b48e6906833d50ab99422,PD-L1 testing,0.861808
uuid-b6b4354fe91b48e6906833d50ab99422,testing,0.854404
uuid-b6b4354fe91b48e6906833d50ab99422,PDL1 testing,0.685584
uuid-b6b4354fe91b48e6906833d50ab99422,NSCLC patients,0.675051
uuid-b6b4354fe91b48e6906833d50ab99422,assay,0.586504
uuid-e0b526fbfbc7446d8e66c90a31a4a974,TL,0.724328
uuid-e0b526fbfbc7446d8e66c90a31a4a974,PDL1,0.303319
uuid-e0b526fbfbc7446d8e66c90a31a4a974,Merck,0.367265
uuid-e0b526fbfbc7446d8e66c90a31a4a974,PD-L1,0.595319
uuid-e0b526fbfbc7446d8e66c90a31a4a974,PD-L1 testing,0.680221
uuid-e0b526fbfbc7446d8e66c90a31a4a974,testing,0.57244
uuid-e0b526fbfbc7446d8e66c90a31a4a974,PDL1 testing,0.308377
uuid-e0b526fbfbc7446d8e66c90a31a4a974,assay,0.764679
uuid-e399ea06d10240cd831fa02184e0c6c9,TL,0.522734
uuid-e399ea06d10240cd831fa02184e0c6c9,PDL1,0.367979
uuid-e399ea06d10240cd831fa02184e0c6c9,tumor,0.518816
uuid-e399ea06d10240cd831fa02184e0c6c9,PD-L1,0.640654
uuid-e399ea06d10240cd831fa02184e0c6c9,PD-L1 testing,0.601694
uuid-e399ea06d10240cd831fa02184e0c6c9,testing,0.597217
uuid-e399ea06d10240cd831fa02184e0c6c9,PDL1 testing,0.341921
uuid-e399ea06d10240cd831fa02184e0c6c9,assay,0.71201
uuid-e399ea06d10240cd831fa02184e0c6c9,PDL1 expression,0.321966
uuid-e399ea06d10240cd831fa02184e0c6c9,biomarker,0.42047
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,nivolumab,0.377792
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,1L,0.321785
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,regimen,0.398344
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,RCC,0.358255
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,combination,0.495135
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,2L,0.394469
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,IO,0.302295
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,agents,0.419516
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,preferred,0.489958
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,monotherapy,0.551395
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,using nivo,0.387036
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,combo,0.421455
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,clinical trials,0.40933
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,PD1,0.365752
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,SCCHN,0.371961
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,chemotherapy,0.362093
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,academic,0.526252
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,feels,0.410322
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,RTL stated,0.517291
uuid-40a74e5a42ae45bfbdfcfcc8b0b95de0,option,0.459946
uuid-738011656d064894a8b3cddd482cb36e,RTL,0.300843
uuid-738011656d064894a8b3cddd482cb36e,shared,0.317552
uuid-738011656d064894a8b3cddd482cb36e,stated,0.480955
uuid-738011656d064894a8b3cddd482cb36e,approval,0.330832
uuid-738011656d064894a8b3cddd482cb36e,physicians,0.301069
uuid-738011656d064894a8b3cddd482cb36e,oncology,0.345964
uuid-738011656d064894a8b3cddd482cb36e,approved,0.341344
uuid-738011656d064894a8b3cddd482cb36e,SCCHN,0.407797
uuid-738011656d064894a8b3cddd482cb36e,LTL,0.365641
uuid-738011656d064894a8b3cddd482cb36e,Regional TL,0.391338
uuid-738011656d064894a8b3cddd482cb36e,RTL stated,0.306157
uuid-1b019ccd329a4e0399d4c896a00a7449,patients,0.329751
uuid-1b019ccd329a4e0399d4c896a00a7449,RTL,0.54481
uuid-1b019ccd329a4e0399d4c896a00a7449,nivolumab,0.436653
uuid-1b019ccd329a4e0399d4c896a00a7449,treated,0.511106
uuid-1b019ccd329a4e0399d4c896a00a7449,NTL,0.380922
uuid-1b019ccd329a4e0399d4c896a00a7449,melanoma,0.336853
uuid-1b019ccd329a4e0399d4c896a00a7449,shared,0.393967
uuid-1b019ccd329a4e0399d4c896a00a7449,commented,0.335234
uuid-1b019ccd329a4e0399d4c896a00a7449,RCC,0.47618
uuid-1b019ccd329a4e0399d4c896a00a7449,stated,0.38378
uuid-1b019ccd329a4e0399d4c896a00a7449,approval,0.391556
uuid-1b019ccd329a4e0399d4c896a00a7449,using nivo,0.447496
uuid-1b019ccd329a4e0399d4c896a00a7449,clinical trials,0.47925
uuid-1b019ccd329a4e0399d4c896a00a7449,SCCHN,0.616429
uuid-1b019ccd329a4e0399d4c896a00a7449,HCP,0.36399
uuid-1b019ccd329a4e0399d4c896a00a7449,LTL,0.400298
uuid-1b019ccd329a4e0399d4c896a00a7449,SCLC,0.31493
uuid-1b019ccd329a4e0399d4c896a00a7449,Regional TL,0.554125
uuid-1b019ccd329a4e0399d4c896a00a7449,RTL stated,0.551503
uuid-1b019ccd329a4e0399d4c896a00a7449,TL shared,0.425376
uuid-1b019ccd329a4e0399d4c896a00a7449,bladder,0.660851
uuid-74e7c7f040764c578a7f707304be38f1,Nivo,0.390251
uuid-74e7c7f040764c578a7f707304be38f1,pembro,0.532746
uuid-74e7c7f040764c578a7f707304be38f1,1L,0.331137
uuid-74e7c7f040764c578a7f707304be38f1,PDL1,0.518775
uuid-74e7c7f040764c578a7f707304be38f1,trial,0.352163
uuid-74e7c7f040764c578a7f707304be38f1,efficacy,0.653634
uuid-74e7c7f040764c578a7f707304be38f1,chemo,0.309259
uuid-74e7c7f040764c578a7f707304be38f1,agents,0.308982
uuid-74e7c7f040764c578a7f707304be38f1,OS,0.502801
uuid-74e7c7f040764c578a7f707304be38f1,atezo,0.516062
uuid-74e7c7f040764c578a7f707304be38f1,data,0.593723
uuid-74e7c7f040764c578a7f707304be38f1,indication,0.319801
uuid-74e7c7f040764c578a7f707304be38f1,PFS,0.47738
uuid-74e7c7f040764c578a7f707304be38f1,ORR,0.547557
uuid-74e7c7f040764c578a7f707304be38f1,nivo and pembro,0.6059
uuid-74e7c7f040764c578a7f707304be38f1,believes,0.442598
uuid-74e7c7f040764c578a7f707304be38f1,impressed,0.451316
uuid-74e7c7f040764c578a7f707304be38f1,vs,0.421249
uuid-74e7c7f040764c578a7f707304be38f1,feels,0.446658
uuid-74e7c7f040764c578a7f707304be38f1,PDL1 expression,0.530691
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,patients,0.793497
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,Opdivo,0.665737
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,therapy,0.553613
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,nivolumab,0.531992
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,treated,0.45121
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,pts,0.320074
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,approval,0.335531
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,treatment,0.542081
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,using nivo,0.355542
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,cHL,0.568245
uuid-7bbfbee0d0e04be49f07d1ee0ffd6760,progression,0.388288
uuid-f39b5111c3654f668017e52d9c6edf85,Nivo,0.392454
uuid-f39b5111c3654f668017e52d9c6edf85,patients,0.301998
uuid-f39b5111c3654f668017e52d9c6edf85,therapy,0.666939
uuid-f39b5111c3654f668017e52d9c6edf85,1L,0.408295
uuid-f39b5111c3654f668017e52d9c6edf85,regimen,0.327568
uuid-f39b5111c3654f668017e52d9c6edf85,combination,0.470826
uuid-f39b5111c3654f668017e52d9c6edf85,chemo,0.739829
uuid-f39b5111c3654f668017e52d9c6edf85,pts,0.330072
uuid-f39b5111c3654f668017e52d9c6edf85,IO,0.384518
uuid-f39b5111c3654f668017e52d9c6edf85,agents,0.463604
uuid-f39b5111c3654f668017e52d9c6edf85,monotherapy,0.589528
uuid-f39b5111c3654f668017e52d9c6edf85,treatment,0.393446
uuid-f39b5111c3654f668017e52d9c6edf85,response,0.476702
uuid-f39b5111c3654f668017e52d9c6edf85,combo,0.414125
uuid-f39b5111c3654f668017e52d9c6edf85,PD1,0.641232
uuid-f39b5111c3654f668017e52d9c6edf85,progression,0.523511
uuid-f39b5111c3654f668017e52d9c6edf85,believes,0.535554
uuid-f39b5111c3654f668017e52d9c6edf85,chemotherapy,0.700627
uuid-f39b5111c3654f668017e52d9c6edf85,respond,0.349875
uuid-f39b5111c3654f668017e52d9c6edf85,feels,0.471096
uuid-f39b5111c3654f668017e52d9c6edf85,immunotherapy,0.31785
uuid-f39b5111c3654f668017e52d9c6edf85,PD-1,0.330434
uuid-f39b5111c3654f668017e52d9c6edf85,option,0.592769
uuid-09b702e9ad024131a047973eea655cd3,commented,0.436498
uuid-09b702e9ad024131a047973eea655cd3,stated,0.301024
uuid-09b702e9ad024131a047973eea655cd3,physicians,0.574846
uuid-09b702e9ad024131a047973eea655cd3,Regional TL,0.30604
uuid-1afc575e3770425f899eafab44c0b545,patients,0.472861
uuid-1afc575e3770425f899eafab44c0b545,nivolumab,0.451164
uuid-1afc575e3770425f899eafab44c0b545,1L,0.56987
uuid-1afc575e3770425f899eafab44c0b545,regimen,0.472546
uuid-1afc575e3770425f899eafab44c0b545,treated,0.353325
uuid-1afc575e3770425f899eafab44c0b545,RCC,0.50644
uuid-1afc575e3770425f899eafab44c0b545,combination,0.393813
uuid-1afc575e3770425f899eafab44c0b545,chemo,0.428115
uuid-1afc575e3770425f899eafab44c0b545,2L,0.626404
uuid-1afc575e3770425f899eafab44c0b545,pts,0.439809
uuid-1afc575e3770425f899eafab44c0b545,agents,0.339621
uuid-1afc575e3770425f899eafab44c0b545,atezo,0.301825
uuid-1afc575e3770425f899eafab44c0b545,preferred,0.633505
uuid-1afc575e3770425f899eafab44c0b545,monotherapy,0.656034
uuid-1afc575e3770425f899eafab44c0b545,treatment,0.327134
uuid-1afc575e3770425f899eafab44c0b545,using nivo,0.525455
uuid-1afc575e3770425f899eafab44c0b545,combo,0.444686
uuid-1afc575e3770425f899eafab44c0b545,NSCLC patients,0.346012
uuid-1afc575e3770425f899eafab44c0b545,PD1,0.398247
uuid-1afc575e3770425f899eafab44c0b545,approved,0.358649
uuid-1afc575e3770425f899eafab44c0b545,SCCHN,0.375096
uuid-1afc575e3770425f899eafab44c0b545,progression,0.303954
uuid-1afc575e3770425f899eafab44c0b545,chemotherapy,0.382787
uuid-1afc575e3770425f899eafab44c0b545,tumor types,0.373783
uuid-1afc575e3770425f899eafab44c0b545,RTL stated,0.509834
uuid-1afc575e3770425f899eafab44c0b545,TL shared,0.373813
uuid-1afc575e3770425f899eafab44c0b545,option,0.606336
uuid-1afc575e3770425f899eafab44c0b545,bladder,0.379098
uuid-01af79e8155244f8ad8f0715db341204,patients,0.606004
uuid-01af79e8155244f8ad8f0715db341204,therapy,0.382073
uuid-01af79e8155244f8ad8f0715db341204,nivolumab,0.556477
uuid-01af79e8155244f8ad8f0715db341204,1L,0.568787
uuid-01af79e8155244f8ad8f0715db341204,regimen,0.381985
uuid-01af79e8155244f8ad8f0715db341204,treated,0.461349
uuid-01af79e8155244f8ad8f0715db341204,RCC,0.552033
uuid-01af79e8155244f8ad8f0715db341204,TL stated,0.371698
uuid-01af79e8155244f8ad8f0715db341204,2L,0.650244
uuid-01af79e8155244f8ad8f0715db341204,pts,0.402769
uuid-01af79e8155244f8ad8f0715db341204,approval,0.414855
uuid-01af79e8155244f8ad8f0715db341204,preferred,0.732567
uuid-01af79e8155244f8ad8f0715db341204,monotherapy,0.554225
uuid-01af79e8155244f8ad8f0715db341204,treatment,0.414755
uuid-01af79e8155244f8ad8f0715db341204,using nivo,0.6603
uuid-01af79e8155244f8ad8f0715db341204,PDL1 testing,0.315726
uuid-01af79e8155244f8ad8f0715db341204,NSCLC patients,0.393771
uuid-01af79e8155244f8ad8f0715db341204,approved,0.438063
uuid-01af79e8155244f8ad8f0715db341204,SCCHN,0.450301
uuid-01af79e8155244f8ad8f0715db341204,progression,0.33088
uuid-01af79e8155244f8ad8f0715db341204,chemotherapy,0.305286
uuid-01af79e8155244f8ad8f0715db341204,tumor types,0.33646
uuid-01af79e8155244f8ad8f0715db341204,RTL stated,0.633772
uuid-01af79e8155244f8ad8f0715db341204,TL shared,0.41971
uuid-01af79e8155244f8ad8f0715db341204,option,0.599961
uuid-01af79e8155244f8ad8f0715db341204,bladder,0.383367
uuid-0b096ec0d1b247b881a1b5f629cfbfae,tumor,0.503664
uuid-0b096ec0d1b247b881a1b5f629cfbfae,response,0.320506
uuid-0b096ec0d1b247b881a1b5f629cfbfae,immunotherapy,0.553929
uuid-efd26d070a184fe5898b18408d817815,RTL,0.340015
uuid-efd26d070a184fe5898b18408d817815,BMS,0.351351
uuid-efd26d070a184fe5898b18408d817815,trial,0.430368
uuid-efd26d070a184fe5898b18408d817815,efficacy,0.31083
uuid-efd26d070a184fe5898b18408d817815,commented,0.545445
uuid-efd26d070a184fe5898b18408d817815,OS,0.426605
uuid-efd26d070a184fe5898b18408d817815,data,0.742615
uuid-efd26d070a184fe5898b18408d817815,expressed,0.364586
uuid-efd26d070a184fe5898b18408d817815,mentioned,0.315959
uuid-efd26d070a184fe5898b18408d817815,PFS,0.390749
uuid-efd26d070a184fe5898b18408d817815,ORR,0.458623
uuid-efd26d070a184fe5898b18408d817815,ASCO,0.631942
uuid-efd26d070a184fe5898b18408d817815,impressed,0.668521
uuid-efd26d070a184fe5898b18408d817815,LTL,0.313527
uuid-efd26d070a184fe5898b18408d817815,Regional TL,0.311156
uuid-56475843a4074a728bb623d0ec387f91,TL,0.375205
uuid-56475843a4074a728bb623d0ec387f91,pembro,0.363918
uuid-56475843a4074a728bb623d0ec387f91,NSCLC,0.368694
uuid-56475843a4074a728bb623d0ec387f91,1L,0.328948
uuid-56475843a4074a728bb623d0ec387f91,PDL1,0.503185
uuid-56475843a4074a728bb623d0ec387f91,PD-L1,0.647206
uuid-56475843a4074a728bb623d0ec387f91,atezo,0.368799
uuid-56475843a4074a728bb623d0ec387f91,PD-L1 testing,0.471773
uuid-56475843a4074a728bb623d0ec387f91,testing,0.5267
uuid-56475843a4074a728bb623d0ec387f91,NSCLC patients,0.416618
uuid-56475843a4074a728bb623d0ec387f91,nivo and pembro,0.336415
uuid-56475843a4074a728bb623d0ec387f91,assay,0.612461
uuid-56475843a4074a728bb623d0ec387f91,PDL1 expression,0.33062
uuid-56475843a4074a728bb623d0ec387f91,biomarker,0.418635
uuid-56b49b3ed2364ad98e8bb3645db66822,patients,0.668009
uuid-56b49b3ed2364ad98e8bb3645db66822,RTL,0.326998
uuid-56b49b3ed2364ad98e8bb3645db66822,therapy,0.426495
uuid-56b49b3ed2364ad98e8bb3645db66822,nivolumab,0.534202
uuid-56b49b3ed2364ad98e8bb3645db66822,regimen,0.39219
uuid-56b49b3ed2364ad98e8bb3645db66822,treated,0.643204
uuid-56b49b3ed2364ad98e8bb3645db66822,chemo,0.304909
uuid-56b49b3ed2364ad98e8bb3645db66822,pts,0.489631
uuid-56b49b3ed2364ad98e8bb3645db66822,treatment,0.576749
uuid-56b49b3ed2364ad98e8bb3645db66822,response,0.305797
uuid-56b49b3ed2364ad98e8bb3645db66822,progression,0.517747
uuid-56b49b3ed2364ad98e8bb3645db66822,chemotherapy,0.362439
uuid-56b49b3ed2364ad98e8bb3645db66822,respond,0.341846
uuid-5ca4b6091296483eafdad2aa7bf15260,response,0.38557
uuid-5ca4b6091296483eafdad2aa7bf15260,PD1,0.637268
uuid-5ca4b6091296483eafdad2aa7bf15260,immunotherapy,0.458256
uuid-5ca4b6091296483eafdad2aa7bf15260,PD-1,0.525293
uuid-2f4f2b934c7640709937bd431e01f717,patients,0.536559
uuid-2f4f2b934c7640709937bd431e01f717,Opdivo,0.479569
uuid-2f4f2b934c7640709937bd431e01f717,1L,0.325441
uuid-2f4f2b934c7640709937bd431e01f717,treated,0.383127
uuid-2f4f2b934c7640709937bd431e01f717,RCC,0.34789
uuid-2f4f2b934c7640709937bd431e01f717,2L,0.373292
uuid-2f4f2b934c7640709937bd431e01f717,pts,0.311694
uuid-2f4f2b934c7640709937bd431e01f717,stated,0.328188
uuid-2f4f2b934c7640709937bd431e01f717,approval,0.41288
uuid-2f4f2b934c7640709937bd431e01f717,physicians,0.435527
uuid-2f4f2b934c7640709937bd431e01f717,preferred,0.462989
uuid-2f4f2b934c7640709937bd431e01f717,treatment,0.501795
uuid-2f4f2b934c7640709937bd431e01f717,using nivo,0.436429
uuid-2f4f2b934c7640709937bd431e01f717,approved,0.464375
uuid-2f4f2b934c7640709937bd431e01f717,SCCHN,0.375097
uuid-2f4f2b934c7640709937bd431e01f717,tumor types,0.301893
uuid-2f4f2b934c7640709937bd431e01f717,oncologist,0.406422
uuid-2f4f2b934c7640709937bd431e01f717,RTL stated,0.369556
uuid-2f4f2b934c7640709937bd431e01f717,option,0.483858
uuid-4bb81b11df0b4f1caed72559d1ef26cf,1L,0.355339
uuid-4bb81b11df0b4f1caed72559d1ef26cf,2L,0.347192
uuid-4bb81b11df0b4f1caed72559d1ef26cf,agents,0.35045
uuid-4bb81b11df0b4f1caed72559d1ef26cf,preferred,0.621789
uuid-4bb81b11df0b4f1caed72559d1ef26cf,monotherapy,0.414924
uuid-4bb81b11df0b4f1caed72559d1ef26cf,using nivo,0.305698
uuid-4bb81b11df0b4f1caed72559d1ef26cf,indication,0.31293
uuid-4bb81b11df0b4f1caed72559d1ef26cf,SCCHN,0.33513
uuid-4bb81b11df0b4f1caed72559d1ef26cf,chemotherapy,0.360265
uuid-4bb81b11df0b4f1caed72559d1ef26cf,RTL stated,0.379394
uuid-4bb81b11df0b4f1caed72559d1ef26cf,option,0.506157
uuid-5569240cc79e4769a65ccdab0ac5f1b0,pembro,0.351563
uuid-5569240cc79e4769a65ccdab0ac5f1b0,PDL1,0.614006
uuid-5569240cc79e4769a65ccdab0ac5f1b0,trial,0.351899
uuid-5569240cc79e4769a65ccdab0ac5f1b0,efficacy,0.548468
uuid-5569240cc79e4769a65ccdab0ac5f1b0,OS,0.573313
uuid-5569240cc79e4769a65ccdab0ac5f1b0,atezo,0.324686
uuid-5569240cc79e4769a65ccdab0ac5f1b0,data,0.707342
uuid-5569240cc79e4769a65ccdab0ac5f1b0,PFS,0.527935
uuid-5569240cc79e4769a65ccdab0ac5f1b0,ORR,0.569609
uuid-5569240cc79e4769a65ccdab0ac5f1b0,nivo and pembro,0.471259
uuid-5569240cc79e4769a65ccdab0ac5f1b0,believes,0.311496
uuid-5569240cc79e4769a65ccdab0ac5f1b0,impressed,0.477457
uuid-5569240cc79e4769a65ccdab0ac5f1b0,vs,0.33643
uuid-5569240cc79e4769a65ccdab0ac5f1b0,feels,0.4068
uuid-5569240cc79e4769a65ccdab0ac5f1b0,PDL1 expression,0.513885
uuid-5569240cc79e4769a65ccdab0ac5f1b0,biomarker,0.392834
uuid-7eec39f80da549229c2f5dacaa9ac26a,PDL1,0.358073
uuid-7eec39f80da549229c2f5dacaa9ac26a,efficacy,0.386033
uuid-7eec39f80da549229c2f5dacaa9ac26a,chemo,0.341369
uuid-7eec39f80da549229c2f5dacaa9ac26a,response,0.327091
uuid-7eec39f80da549229c2f5dacaa9ac26a,believes,0.484642
uuid-7eec39f80da549229c2f5dacaa9ac26a,feels,0.42705
uuid-7eec39f80da549229c2f5dacaa9ac26a,PDL1 expression,0.336504
uuid-7eec39f80da549229c2f5dacaa9ac26a,option,0.345676
uuid-7eec39f80da549229c2f5dacaa9ac26a,biomarker,0.375166
uuid-a146db6859804ad4be25eeb35779efc9,PD-L1,0.419258
uuid-a146db6859804ad4be25eeb35779efc9,PD-L1 testing,0.328872
uuid-a146db6859804ad4be25eeb35779efc9,testing,0.615984
uuid-a146db6859804ad4be25eeb35779efc9,PDL1 testing,0.590054
uuid-a146db6859804ad4be25eeb35779efc9,NSCLC patients,0.626493
uuid-a146db6859804ad4be25eeb35779efc9,tumor types,0.358358
uuid-a146db6859804ad4be25eeb35779efc9,biomarker,0.421425
uuid-4f8a71fa91cd47aca899959c9138f631,TL,0.517479
uuid-4f8a71fa91cd47aca899959c9138f631,PDL1,0.333437
uuid-4f8a71fa91cd47aca899959c9138f631,TL stated,0.516191
uuid-4f8a71fa91cd47aca899959c9138f631,Merck,0.310089
uuid-4f8a71fa91cd47aca899959c9138f631,institution,0.415104
uuid-4f8a71fa91cd47aca899959c9138f631,PD-L1,0.760714
uuid-4f8a71fa91cd47aca899959c9138f631,PD-L1 testing,0.856445
uuid-4f8a71fa91cd47aca899959c9138f631,testing,0.91855
uuid-4f8a71fa91cd47aca899959c9138f631,PDL1 testing,0.827914
uuid-4f8a71fa91cd47aca899959c9138f631,NSCLC patients,0.710586
uuid-4f8a71fa91cd47aca899959c9138f631,assay,0.608884
uuid-4f8a71fa91cd47aca899959c9138f631,biomarker,0.377827
uuid-81f4cae59dda462f87a58939fa9cb0f9,patients,0.532537
uuid-81f4cae59dda462f87a58939fa9cb0f9,Opdivo,0.485725
uuid-81f4cae59dda462f87a58939fa9cb0f9,therapy,0.518311
uuid-81f4cae59dda462f87a58939fa9cb0f9,nivolumab,0.455137
uuid-81f4cae59dda462f87a58939fa9cb0f9,treated,0.323258
uuid-81f4cae59dda462f87a58939fa9cb0f9,treatment,0.323363
uuid-81f4cae59dda462f87a58939fa9cb0f9,cHL,0.770689
uuid-069b41b6ca5f485f863a51a562ebde58,patients,0.463114
uuid-069b41b6ca5f485f863a51a562ebde58,therapy,0.541531
uuid-069b41b6ca5f485f863a51a562ebde58,nivolumab,0.327796
uuid-069b41b6ca5f485f863a51a562ebde58,toxicity,0.606717
uuid-069b41b6ca5f485f863a51a562ebde58,regimen,0.399285
uuid-069b41b6ca5f485f863a51a562ebde58,combination,0.376692
uuid-069b41b6ca5f485f863a51a562ebde58,chemo,0.328093
uuid-069b41b6ca5f485f863a51a562ebde58,treatment,0.440329
uuid-069b41b6ca5f485f863a51a562ebde58,response,0.365331
uuid-069b41b6ca5f485f863a51a562ebde58,PD1,0.300735
uuid-069b41b6ca5f485f863a51a562ebde58,cHL,0.3714
uuid-069b41b6ca5f485f863a51a562ebde58,progression,0.383347
uuid-069b41b6ca5f485f863a51a562ebde58,chemotherapy,0.459641
uuid-66f06640dcd54b0789a8bfe9de8d9880,stated,0.358055
uuid-66f06640dcd54b0789a8bfe9de8d9880,physicians,0.327406
uuid-66f06640dcd54b0789a8bfe9de8d9880,ASCO,0.326269
uuid-5940b001595c46498c09e1097ba942e8,Nivo,0.315015
uuid-5940b001595c46498c09e1097ba942e8,therapy,0.540104
uuid-5940b001595c46498c09e1097ba942e8,nivolumab,0.343703
uuid-5940b001595c46498c09e1097ba942e8,combination,0.373649
uuid-5940b001595c46498c09e1097ba942e8,PD1,0.391477
uuid-5940b001595c46498c09e1097ba942e8,cHL,0.445209
uuid-5940b001595c46498c09e1097ba942e8,chemotherapy,0.512209
uuid-e2af9ee662d245c4929e75388b8a09b0,Nivo,0.44192
uuid-e2af9ee662d245c4929e75388b8a09b0,patients,0.667575
uuid-e2af9ee662d245c4929e75388b8a09b0,Opdivo,0.448916
uuid-e2af9ee662d245c4929e75388b8a09b0,therapy,0.755798
uuid-e2af9ee662d245c4929e75388b8a09b0,nivolumab,0.523019
uuid-e2af9ee662d245c4929e75388b8a09b0,treated,0.35791
uuid-e2af9ee662d245c4929e75388b8a09b0,treatment,0.477337
uuid-e2af9ee662d245c4929e75388b8a09b0,using nivo,0.356323
uuid-e2af9ee662d245c4929e75388b8a09b0,PD1,0.326133
uuid-e2af9ee662d245c4929e75388b8a09b0,cHL,0.772033
uuid-e2af9ee662d245c4929e75388b8a09b0,progression,0.450962
uuid-e2af9ee662d245c4929e75388b8a09b0,chemotherapy,0.398188
uuid-e2af9ee662d245c4929e75388b8a09b0,respond,0.307435
uuid-a50c5dcebc954de6904e4553eb16c4f6,Nivo,0.574199
uuid-a50c5dcebc954de6904e4553eb16c4f6,patients,0.328036
uuid-a50c5dcebc954de6904e4553eb16c4f6,therapy,0.561691
uuid-a50c5dcebc954de6904e4553eb16c4f6,nivolumab,0.498255
uuid-a50c5dcebc954de6904e4553eb16c4f6,1L,0.358925
uuid-a50c5dcebc954de6904e4553eb16c4f6,regimen,0.38923
uuid-a50c5dcebc954de6904e4553eb16c4f6,combination,0.611893
uuid-a50c5dcebc954de6904e4553eb16c4f6,chemo,0.691985
uuid-a50c5dcebc954de6904e4553eb16c4f6,2L,0.355585
uuid-a50c5dcebc954de6904e4553eb16c4f6,pts,0.37658
uuid-a50c5dcebc954de6904e4553eb16c4f6,IO,0.362877
uuid-a50c5dcebc954de6904e4553eb16c4f6,agents,0.432576
uuid-a50c5dcebc954de6904e4553eb16c4f6,preferred,0.305481
uuid-a50c5dcebc954de6904e4553eb16c4f6,monotherapy,0.613102
uuid-a50c5dcebc954de6904e4553eb16c4f6,treatment,0.322986
uuid-a50c5dcebc954de6904e4553eb16c4f6,using nivo,0.352677
uuid-a50c5dcebc954de6904e4553eb16c4f6,response,0.393228
uuid-a50c5dcebc954de6904e4553eb16c4f6,combo,0.505831
uuid-a50c5dcebc954de6904e4553eb16c4f6,PD1,0.580866
uuid-a50c5dcebc954de6904e4553eb16c4f6,progression,0.41879
uuid-a50c5dcebc954de6904e4553eb16c4f6,believes,0.344948
uuid-a50c5dcebc954de6904e4553eb16c4f6,chemotherapy,0.631579
uuid-a50c5dcebc954de6904e4553eb16c4f6,feels,0.457647
uuid-a50c5dcebc954de6904e4553eb16c4f6,RTL stated,0.362701
uuid-a50c5dcebc954de6904e4553eb16c4f6,option,0.514897
uuid-ce45b16e3dd0492c9df47184c194b082,patients,0.838349
uuid-ce45b16e3dd0492c9df47184c194b082,Opdivo,0.385794
uuid-ce45b16e3dd0492c9df47184c194b082,therapy,0.565777
uuid-ce45b16e3dd0492c9df47184c194b082,regimen,0.457335
uuid-ce45b16e3dd0492c9df47184c194b082,treated,0.445619
uuid-ce45b16e3dd0492c9df47184c194b082,chemo,0.427591
uuid-ce45b16e3dd0492c9df47184c194b082,pts,0.645902
uuid-ce45b16e3dd0492c9df47184c194b082,monotherapy,0.462263
uuid-ce45b16e3dd0492c9df47184c194b082,treatment,0.605552
uuid-ce45b16e3dd0492c9df47184c194b082,response,0.449853
uuid-ce45b16e3dd0492c9df47184c194b082,NSCLC patients,0.356771
uuid-ce45b16e3dd0492c9df47184c194b082,progression,0.674528
uuid-ce45b16e3dd0492c9df47184c194b082,chemotherapy,0.440547
uuid-ce45b16e3dd0492c9df47184c194b082,respond,0.520755
uuid-ce45b16e3dd0492c9df47184c194b082,option,0.491782
uuid-a414e3952c764582a2de8e23c00f0de7,patients,0.778776
uuid-a414e3952c764582a2de8e23c00f0de7,Opdivo,0.410784
uuid-a414e3952c764582a2de8e23c00f0de7,therapy,0.470267
uuid-a414e3952c764582a2de8e23c00f0de7,dose,0.350474
uuid-a414e3952c764582a2de8e23c00f0de7,nivolumab,0.317418
uuid-a414e3952c764582a2de8e23c00f0de7,toxicity,0.529423
uuid-a414e3952c764582a2de8e23c00f0de7,regimen,0.60808
uuid-a414e3952c764582a2de8e23c00f0de7,treated,0.395592
uuid-a414e3952c764582a2de8e23c00f0de7,chemo,0.468297
uuid-a414e3952c764582a2de8e23c00f0de7,pts,0.436637
uuid-a414e3952c764582a2de8e23c00f0de7,monotherapy,0.350147
uuid-a414e3952c764582a2de8e23c00f0de7,treatment,0.652206
uuid-a414e3952c764582a2de8e23c00f0de7,response,0.390557
uuid-a414e3952c764582a2de8e23c00f0de7,progression,0.533013
uuid-a414e3952c764582a2de8e23c00f0de7,chemotherapy,0.419212
uuid-a414e3952c764582a2de8e23c00f0de7,respond,0.54516
uuid-a414e3952c764582a2de8e23c00f0de7,option,0.340236
uuid-5717ffbd78274c46ac28524752197eb1,lung,0.415778
uuid-5717ffbd78274c46ac28524752197eb1,TL stated,0.464038
uuid-5717ffbd78274c46ac28524752197eb1,PD-L1 testing,0.428448
uuid-5717ffbd78274c46ac28524752197eb1,testing,0.400383
uuid-5717ffbd78274c46ac28524752197eb1,PDL1 testing,0.497978
uuid-30e10f18af374372b8b140683d216012,patients,0.762632
uuid-30e10f18af374372b8b140683d216012,Opdivo,0.431234
uuid-30e10f18af374372b8b140683d216012,therapy,0.614671
uuid-30e10f18af374372b8b140683d216012,nivolumab,0.371436
uuid-30e10f18af374372b8b140683d216012,regimen,0.43781
uuid-30e10f18af374372b8b140683d216012,treated,0.526513
uuid-30e10f18af374372b8b140683d216012,pts,0.459172
uuid-30e10f18af374372b8b140683d216012,physicians,0.38207
uuid-30e10f18af374372b8b140683d216012,treatment,0.689838
uuid-30e10f18af374372b8b140683d216012,response,0.385057
uuid-30e10f18af374372b8b140683d216012,PD1,0.314221
uuid-30e10f18af374372b8b140683d216012,cHL,0.305511
uuid-30e10f18af374372b8b140683d216012,progression,0.669231
uuid-30e10f18af374372b8b140683d216012,chemotherapy,0.418479
uuid-30e10f18af374372b8b140683d216012,respond,0.443714
uuid-30e10f18af374372b8b140683d216012,option,0.339181
uuid-ba4622f56c204b33b6e5572f343be2e3,1L,0.400504
uuid-ba4622f56c204b33b6e5572f343be2e3,PDL1,0.336994
uuid-ba4622f56c204b33b6e5572f343be2e3,TL stated,0.387411
uuid-ba4622f56c204b33b6e5572f343be2e3,PD-L1,0.541278
uuid-ba4622f56c204b33b6e5572f343be2e3,PD-L1 testing,0.380281
uuid-ba4622f56c204b33b6e5572f343be2e3,testing,0.698372
uuid-ba4622f56c204b33b6e5572f343be2e3,PDL1 testing,0.715721
uuid-ba4622f56c204b33b6e5572f343be2e3,NSCLC patients,0.769634
uuid-ba4622f56c204b33b6e5572f343be2e3,tumor types,0.451825
uuid-ba4622f56c204b33b6e5572f343be2e3,PD-1,0.422015
uuid-ba4622f56c204b33b6e5572f343be2e3,biomarker,0.4256
uuid-591c6c786d4f4478af9242a5dc5d7d58,Nivo,0.399139
uuid-591c6c786d4f4478af9242a5dc5d7d58,patients,0.867874
uuid-591c6c786d4f4478af9242a5dc5d7d58,Opdivo,0.390358
uuid-591c6c786d4f4478af9242a5dc5d7d58,therapy,0.655129
uuid-591c6c786d4f4478af9242a5dc5d7d58,nivolumab,0.426984
uuid-591c6c786d4f4478af9242a5dc5d7d58,regimen,0.498643
uuid-591c6c786d4f4478af9242a5dc5d7d58,treated,0.458279
uuid-591c6c786d4f4478af9242a5dc5d7d58,chemo,0.471346
uuid-591c6c786d4f4478af9242a5dc5d7d58,pts,0.55036
uuid-591c6c786d4f4478af9242a5dc5d7d58,monotherapy,0.411138
uuid-591c6c786d4f4478af9242a5dc5d7d58,treatment,0.714022
uuid-591c6c786d4f4478af9242a5dc5d7d58,response,0.372904
uuid-591c6c786d4f4478af9242a5dc5d7d58,PD1,0.327915
uuid-591c6c786d4f4478af9242a5dc5d7d58,progression,0.661484
uuid-591c6c786d4f4478af9242a5dc5d7d58,chemotherapy,0.504536
uuid-591c6c786d4f4478af9242a5dc5d7d58,respond,0.52655
uuid-591c6c786d4f4478af9242a5dc5d7d58,option,0.447422
uuid-c330985a76424d21bebf96c581a297bc,Nivo,0.421769
uuid-c330985a76424d21bebf96c581a297bc,PDL1,0.31097
uuid-c330985a76424d21bebf96c581a297bc,trial,0.488071
uuid-c330985a76424d21bebf96c581a297bc,efficacy,0.56975
uuid-c330985a76424d21bebf96c581a297bc,OS,0.720247
uuid-c330985a76424d21bebf96c581a297bc,data,0.820008
uuid-c330985a76424d21bebf96c581a297bc,PFS,0.714635
uuid-c330985a76424d21bebf96c581a297bc,ORR,0.807303
uuid-c330985a76424d21bebf96c581a297bc,nivo and pembro,0.403349
uuid-c330985a76424d21bebf96c581a297bc,ASCO,0.391122
uuid-c330985a76424d21bebf96c581a297bc,impressed,0.692215
uuid-c330985a76424d21bebf96c581a297bc,feels,0.336789
uuid-c330985a76424d21bebf96c581a297bc,PDL1 expression,0.318517
uuid-9bb7abfbffb24a44a51fb692a40bbfa1,Ipi,0.436448
uuid-83731202c1c241d286ac2cf332095776,Nivo,0.404597
uuid-83731202c1c241d286ac2cf332095776,patients,0.438026
uuid-83731202c1c241d286ac2cf332095776,Opdivo,0.309016
uuid-83731202c1c241d286ac2cf332095776,therapy,0.532813
uuid-83731202c1c241d286ac2cf332095776,treatment,0.386945
uuid-83731202c1c241d286ac2cf332095776,cHL,0.661912
uuid-83731202c1c241d286ac2cf332095776,progression,0.329115
uuid-83731202c1c241d286ac2cf332095776,respond,0.345094
uuid-00e037f52cbe4f778b817789d4a1b231,Nivo,0.508157
uuid-00e037f52cbe4f778b817789d4a1b231,patients,0.677055
uuid-00e037f52cbe4f778b817789d4a1b231,Opdivo,0.364968
uuid-00e037f52cbe4f778b817789d4a1b231,therapy,0.765483
uuid-00e037f52cbe4f778b817789d4a1b231,nivolumab,0.547778
uuid-00e037f52cbe4f778b817789d4a1b231,treated,0.410982
uuid-00e037f52cbe4f778b817789d4a1b231,chemo,0.305866
uuid-00e037f52cbe4f778b817789d4a1b231,pts,0.321569
uuid-00e037f52cbe4f778b817789d4a1b231,treatment,0.466509
uuid-00e037f52cbe4f778b817789d4a1b231,using nivo,0.409565
uuid-00e037f52cbe4f778b817789d4a1b231,PD1,0.371586
uuid-00e037f52cbe4f778b817789d4a1b231,cHL,0.772927
uuid-00e037f52cbe4f778b817789d4a1b231,progression,0.425898
uuid-00e037f52cbe4f778b817789d4a1b231,chemotherapy,0.444954
uuid-7418bf079e814aceb7fa7cba0a645903,pembro,0.310847
uuid-7418bf079e814aceb7fa7cba0a645903,BMS,0.432764
uuid-7418bf079e814aceb7fa7cba0a645903,PDL1,0.355465
uuid-7418bf079e814aceb7fa7cba0a645903,trial,0.536611
uuid-7418bf079e814aceb7fa7cba0a645903,efficacy,0.523733
uuid-7418bf079e814aceb7fa7cba0a645903,commented,0.396726
uuid-7418bf079e814aceb7fa7cba0a645903,stated,0.304738
uuid-7418bf079e814aceb7fa7cba0a645903,OS,0.628347
uuid-7418bf079e814aceb7fa7cba0a645903,data,0.877766
uuid-7418bf079e814aceb7fa7cba0a645903,PFS,0.576522
uuid-7418bf079e814aceb7fa7cba0a645903,ORR,0.651568
uuid-7418bf079e814aceb7fa7cba0a645903,nivo and pembro,0.462245
uuid-7418bf079e814aceb7fa7cba0a645903,ASCO,0.369932
uuid-7418bf079e814aceb7fa7cba0a645903,believes,0.300686
uuid-7418bf079e814aceb7fa7cba0a645903,impressed,0.711929
uuid-7418bf079e814aceb7fa7cba0a645903,SCLC,0.301742
uuid-7418bf079e814aceb7fa7cba0a645903,feels,0.48484
uuid-7418bf079e814aceb7fa7cba0a645903,PDL1 expression,0.325113
uuid-8454b348c25d4d0890001ac51491b023,patients,0.374929
uuid-8454b348c25d4d0890001ac51491b023,PDL1,0.605773
uuid-8454b348c25d4d0890001ac51491b023,efficacy,0.398976
uuid-8454b348c25d4d0890001ac51491b023,chemo,0.32533
uuid-8454b348c25d4d0890001ac51491b023,pts,0.335802
uuid-8454b348c25d4d0890001ac51491b023,OS,0.385249
uuid-8454b348c25d4d0890001ac51491b023,response,0.328346
uuid-8454b348c25d4d0890001ac51491b023,PFS,0.417295
uuid-8454b348c25d4d0890001ac51491b023,ORR,0.384085
uuid-8454b348c25d4d0890001ac51491b023,progression,0.325854
uuid-8454b348c25d4d0890001ac51491b023,believes,0.34933
uuid-8454b348c25d4d0890001ac51491b023,respond,0.35546
uuid-8454b348c25d4d0890001ac51491b023,feels,0.365216
uuid-8454b348c25d4d0890001ac51491b023,PDL1 expression,0.475437
uuid-8454b348c25d4d0890001ac51491b023,biomarker,0.356976
uuid-777f923014a940b58c4b821bdb260bbe,Nivo,0.380537
uuid-777f923014a940b58c4b821bdb260bbe,pembro,0.375117
uuid-777f923014a940b58c4b821bdb260bbe,1L,0.556187
uuid-777f923014a940b58c4b821bdb260bbe,RCC,0.46917
uuid-777f923014a940b58c4b821bdb260bbe,combination,0.337698
uuid-777f923014a940b58c4b821bdb260bbe,chemo,0.304052
uuid-777f923014a940b58c4b821bdb260bbe,2L,0.693736
uuid-777f923014a940b58c4b821bdb260bbe,agents,0.496211
uuid-777f923014a940b58c4b821bdb260bbe,atezo,0.529908
uuid-777f923014a940b58c4b821bdb260bbe,preferred,0.634329
uuid-777f923014a940b58c4b821bdb260bbe,monotherapy,0.539923
uuid-777f923014a940b58c4b821bdb260bbe,using nivo,0.491539
uuid-777f923014a940b58c4b821bdb260bbe,combo,0.384781
uuid-777f923014a940b58c4b821bdb260bbe,approved,0.36259
uuid-777f923014a940b58c4b821bdb260bbe,believes,0.360348
uuid-777f923014a940b58c4b821bdb260bbe,RTL stated,0.413993
uuid-777f923014a940b58c4b821bdb260bbe,option,0.512322
uuid-4b7efdd7eb074fdc818c5005cc759ff1,pembro,0.324663
uuid-4b7efdd7eb074fdc818c5005cc759ff1,RTL,0.530245
uuid-4b7efdd7eb074fdc818c5005cc759ff1,BMS,0.338963
uuid-4b7efdd7eb074fdc818c5005cc759ff1,trial,0.425073
uuid-4b7efdd7eb074fdc818c5005cc759ff1,NTL,0.385867
uuid-4b7efdd7eb074fdc818c5005cc759ff1,shared,0.424021
uuid-4b7efdd7eb074fdc818c5005cc759ff1,commented,0.51415
uuid-4b7efdd7eb074fdc818c5005cc759ff1,RCC,0.45235
uuid-4b7efdd7eb074fdc818c5005cc759ff1,TL stated,0.346494
uuid-4b7efdd7eb074fdc818c5005cc759ff1,Merck,0.373424
uuid-4b7efdd7eb074fdc818c5005cc759ff1,stated,0.617442
uuid-4b7efdd7eb074fdc818c5005cc759ff1,approval,0.505619
uuid-4b7efdd7eb074fdc818c5005cc759ff1,atezo,0.310812
uuid-4b7efdd7eb074fdc818c5005cc759ff1,using nivo,0.370469
uuid-4b7efdd7eb074fdc818c5005cc759ff1,data,0.478089
uuid-4b7efdd7eb074fdc818c5005cc759ff1,expressed,0.44042
uuid-4b7efdd7eb074fdc818c5005cc759ff1,mentioned,0.356209
uuid-4b7efdd7eb074fdc818c5005cc759ff1,clinical trials,0.410549
uuid-4b7efdd7eb074fdc818c5005cc759ff1,indication,0.369162
uuid-4b7efdd7eb074fdc818c5005cc759ff1,approved,0.474358
uuid-4b7efdd7eb074fdc818c5005cc759ff1,SCCHN,0.55381
uuid-4b7efdd7eb074fdc818c5005cc759ff1,ASCO,0.434223
uuid-4b7efdd7eb074fdc818c5005cc759ff1,impressed,0.567068
uuid-4b7efdd7eb074fdc818c5005cc759ff1,LTL,0.47502
uuid-4b7efdd7eb074fdc818c5005cc759ff1,TLs,0.456523
uuid-4b7efdd7eb074fdc818c5005cc759ff1,SCLC,0.396006
uuid-4b7efdd7eb074fdc818c5005cc759ff1,Regional TL,0.625481
uuid-4b7efdd7eb074fdc818c5005cc759ff1,RTL stated,0.435208
uuid-4b7efdd7eb074fdc818c5005cc759ff1,bladder,0.599935
uuid-f4cfa15db5234ccba4d5aba2664afe73,lung,0.329154
uuid-f4cfa15db5234ccba4d5aba2664afe73,discussed,0.486789
uuid-f4cfa15db5234ccba4d5aba2664afe73,testing,0.30753
uuid-f4cfa15db5234ccba4d5aba2664afe73,academic,0.397413
uuid-f4cfa15db5234ccba4d5aba2664afe73,biomarker,0.457345
uuid-69fb40a036ed44dba63d3bbc1a14b46a,lung,0.344509
uuid-69fb40a036ed44dba63d3bbc1a14b46a,NSCLC,0.439168
uuid-69fb40a036ed44dba63d3bbc1a14b46a,discussed,0.461905
uuid-69fb40a036ed44dba63d3bbc1a14b46a,melanoma,0.367052
uuid-69fb40a036ed44dba63d3bbc1a14b46a,SCCHN,0.342622
uuid-69fb40a036ed44dba63d3bbc1a14b46a,academic,0.44819
uuid-ff92e8489aca47c8988abecf76a85f56,patients,0.403475
uuid-ff92e8489aca47c8988abecf76a85f56,Opdivo,0.307746
uuid-ff92e8489aca47c8988abecf76a85f56,therapy,0.303875
uuid-ff92e8489aca47c8988abecf76a85f56,nivolumab,0.327863
uuid-ff92e8489aca47c8988abecf76a85f56,regimen,0.316302
uuid-ff92e8489aca47c8988abecf76a85f56,treated,0.495929
uuid-ff92e8489aca47c8988abecf76a85f56,treatment,0.379876
uuid-ff92e8489aca47c8988abecf76a85f56,cHL,0.48867
uuid-ff92e8489aca47c8988abecf76a85f56,respond,0.319182
uuid-fcc4c40b0e50418bbe520100bfdae3a3,RTL,0.331069
uuid-fcc4c40b0e50418bbe520100bfdae3a3,commented,0.37745
uuid-fcc4c40b0e50418bbe520100bfdae3a3,stated,0.311967
uuid-fcc4c40b0e50418bbe520100bfdae3a3,physicians,0.313166
uuid-fcc4c40b0e50418bbe520100bfdae3a3,impressed,0.311984
uuid-fcc4c40b0e50418bbe520100bfdae3a3,LTL,0.324524
uuid-fcc4c40b0e50418bbe520100bfdae3a3,TLs,0.347748
uuid-fcc4c40b0e50418bbe520100bfdae3a3,Regional TL,0.343149
uuid-fcc4c40b0e50418bbe520100bfdae3a3,flat dosing,0.430423
uuid-c78f957d1fb14c2aa516b12507e2cf1d,Nivo,0.685788
uuid-c78f957d1fb14c2aa516b12507e2cf1d,patients,0.368554
uuid-c78f957d1fb14c2aa516b12507e2cf1d,pembro,0.467774
uuid-c78f957d1fb14c2aa516b12507e2cf1d,therapy,0.461959
uuid-c78f957d1fb14c2aa516b12507e2cf1d,nivolumab,0.364249
uuid-c78f957d1fb14c2aa516b12507e2cf1d,1L,0.672365
uuid-c78f957d1fb14c2aa516b12507e2cf1d,regimen,0.448704
uuid-c78f957d1fb14c2aa516b12507e2cf1d,combination,0.525296
uuid-c78f957d1fb14c2aa516b12507e2cf1d,chemo,0.600841
uuid-c78f957d1fb14c2aa516b12507e2cf1d,2L,0.723394
uuid-c78f957d1fb14c2aa516b12507e2cf1d,pts,0.389027
uuid-c78f957d1fb14c2aa516b12507e2cf1d,IO,0.366569
uuid-c78f957d1fb14c2aa516b12507e2cf1d,agents,0.597923
uuid-c78f957d1fb14c2aa516b12507e2cf1d,Ipi,0.326842
uuid-c78f957d1fb14c2aa516b12507e2cf1d,atezo,0.485695
uuid-c78f957d1fb14c2aa516b12507e2cf1d,preferred,0.661931
uuid-c78f957d1fb14c2aa516b12507e2cf1d,monotherapy,0.818609
uuid-c78f957d1fb14c2aa516b12507e2cf1d,treatment,0.306391
uuid-c78f957d1fb14c2aa516b12507e2cf1d,using nivo,0.519508
uuid-c78f957d1fb14c2aa516b12507e2cf1d,combo,0.535398
uuid-c78f957d1fb14c2aa516b12507e2cf1d,PD1,0.523281
uuid-c78f957d1fb14c2aa516b12507e2cf1d,approved,0.440232
uuid-c78f957d1fb14c2aa516b12507e2cf1d,believes,0.38371
uuid-c78f957d1fb14c2aa516b12507e2cf1d,chemotherapy,0.522532
uuid-c78f957d1fb14c2aa516b12507e2cf1d,feels,0.379643
uuid-c78f957d1fb14c2aa516b12507e2cf1d,RTL stated,0.362927
uuid-c78f957d1fb14c2aa516b12507e2cf1d,option,0.763747
uuid-4733f83475c24b2486402d5140e8c785,pembro,0.306926
uuid-4733f83475c24b2486402d5140e8c785,1L,0.360588
uuid-4733f83475c24b2486402d5140e8c785,PDL1,0.566936
uuid-4733f83475c24b2486402d5140e8c785,efficacy,0.469719
uuid-4733f83475c24b2486402d5140e8c785,PD-L1,0.331718
uuid-4733f83475c24b2486402d5140e8c785,OS,0.342122
uuid-4733f83475c24b2486402d5140e8c785,data,0.456462
uuid-4733f83475c24b2486402d5140e8c785,ORR,0.345869
uuid-4733f83475c24b2486402d5140e8c785,nivo and pembro,0.396155
uuid-4733f83475c24b2486402d5140e8c785,believes,0.389602
uuid-4733f83475c24b2486402d5140e8c785,feels,0.313532
uuid-4733f83475c24b2486402d5140e8c785,PDL1 expression,0.456396
uuid-4733f83475c24b2486402d5140e8c785,biomarker,0.458431
uuid-3de40f4e8bf6435a8a39953d969ed150,patients,0.783803
uuid-3de40f4e8bf6435a8a39953d969ed150,Opdivo,0.444826
uuid-3de40f4e8bf6435a8a39953d969ed150,therapy,0.760098
uuid-3de40f4e8bf6435a8a39953d969ed150,nivolumab,0.62078
uuid-3de40f4e8bf6435a8a39953d969ed150,regimen,0.372475
uuid-3de40f4e8bf6435a8a39953d969ed150,treated,0.56576
uuid-3de40f4e8bf6435a8a39953d969ed150,pts,0.441803
uuid-3de40f4e8bf6435a8a39953d969ed150,monotherapy,0.303271
uuid-3de40f4e8bf6435a8a39953d969ed150,treatment,0.67071
uuid-3de40f4e8bf6435a8a39953d969ed150,using nivo,0.339245
uuid-3de40f4e8bf6435a8a39953d969ed150,response,0.367221
uuid-3de40f4e8bf6435a8a39953d969ed150,PD1,0.394736
uuid-3de40f4e8bf6435a8a39953d969ed150,cHL,0.653884
uuid-3de40f4e8bf6435a8a39953d969ed150,progression,0.609789
uuid-3de40f4e8bf6435a8a39953d969ed150,chemotherapy,0.470583
uuid-3de40f4e8bf6435a8a39953d969ed150,respond,0.364114
uuid-209b914edbff400593d68823e7b512ad,Nivo,0.30719
uuid-209b914edbff400593d68823e7b512ad,therapy,0.482947
uuid-209b914edbff400593d68823e7b512ad,nivolumab,0.423622
uuid-209b914edbff400593d68823e7b512ad,trial,0.301355
uuid-209b914edbff400593d68823e7b512ad,PD1,0.34072
uuid-209b914edbff400593d68823e7b512ad,cHL,0.563971
uuid-209b914edbff400593d68823e7b512ad,chemotherapy,0.426676
uuid-2e5254771f5247a38300124effec8295,Nivo,0.646935
uuid-2e5254771f5247a38300124effec8295,patients,0.593891
uuid-2e5254771f5247a38300124effec8295,Opdivo,0.360566
uuid-2e5254771f5247a38300124effec8295,therapy,0.714782
uuid-2e5254771f5247a38300124effec8295,nivolumab,0.577301
uuid-2e5254771f5247a38300124effec8295,regimen,0.340206
uuid-2e5254771f5247a38300124effec8295,treated,0.347415
uuid-2e5254771f5247a38300124effec8295,chemo,0.354893
uuid-2e5254771f5247a38300124effec8295,pts,0.39017
uuid-2e5254771f5247a38300124effec8295,monotherapy,0.336835
uuid-2e5254771f5247a38300124effec8295,treatment,0.515877
uuid-2e5254771f5247a38300124effec8295,using nivo,0.398307
uuid-2e5254771f5247a38300124effec8295,response,0.410647
uuid-2e5254771f5247a38300124effec8295,PD1,0.419145
uuid-2e5254771f5247a38300124effec8295,cHL,0.652674
uuid-2e5254771f5247a38300124effec8295,progression,0.528672
uuid-2e5254771f5247a38300124effec8295,chemotherapy,0.444845
uuid-2e5254771f5247a38300124effec8295,respond,0.371087
uuid-1605e4277d054446b1e807f873fe3778,RTL,0.352906
uuid-1605e4277d054446b1e807f873fe3778,BMS,0.587036
uuid-1605e4277d054446b1e807f873fe3778,trial,0.572572
uuid-1605e4277d054446b1e807f873fe3778,NTL,0.328875
uuid-1605e4277d054446b1e807f873fe3778,shared,0.334943
uuid-1605e4277d054446b1e807f873fe3778,commented,0.325966
uuid-1605e4277d054446b1e807f873fe3778,Merck,0.641245
uuid-1605e4277d054446b1e807f873fe3778,stated,0.375137
uuid-1605e4277d054446b1e807f873fe3778,approval,0.356985
uuid-1605e4277d054446b1e807f873fe3778,expressed,0.35854
uuid-1605e4277d054446b1e807f873fe3778,mentioned,0.48704
uuid-1605e4277d054446b1e807f873fe3778,clinical trials,0.499789
uuid-1605e4277d054446b1e807f873fe3778,indication,0.416585
uuid-1605e4277d054446b1e807f873fe3778,approved,0.378207
uuid-1605e4277d054446b1e807f873fe3778,label,0.363248
uuid-1605e4277d054446b1e807f873fe3778,LTL,0.380822
uuid-1605e4277d054446b1e807f873fe3778,Regional TL,0.343581
uuid-a1d0d1f128b04efbbde11a502845a792,Nivo,0.551713
uuid-a1d0d1f128b04efbbde11a502845a792,pembro,0.374693
uuid-a1d0d1f128b04efbbde11a502845a792,nivolumab,0.356224
uuid-a1d0d1f128b04efbbde11a502845a792,2L,0.306985
uuid-a1d0d1f128b04efbbde11a502845a792,atezo,0.316144
uuid-a1d0d1f128b04efbbde11a502845a792,preferred,0.328118
uuid-a1d0d1f128b04efbbde11a502845a792,using nivo,0.535483
uuid-a1d0d1f128b04efbbde11a502845a792,mentioned,0.569383
uuid-a1d0d1f128b04efbbde11a502845a792,indication,0.334043
uuid-a1d0d1f128b04efbbde11a502845a792,HCP,0.341112
uuid-a1d0d1f128b04efbbde11a502845a792,cHL,0.527566
uuid-a1d0d1f128b04efbbde11a502845a792,LTL,0.437975
uuid-a1d0d1f128b04efbbde11a502845a792,feels,0.339611
uuid-a1d0d1f128b04efbbde11a502845a792,RTL stated,0.357079
uuid-c48bbacaec1a42958eb287eaa3058385,Nivo,0.881086
uuid-c48bbacaec1a42958eb287eaa3058385,patients,0.366295
uuid-c48bbacaec1a42958eb287eaa3058385,pembro,0.52577
uuid-c48bbacaec1a42958eb287eaa3058385,therapy,0.494992
uuid-c48bbacaec1a42958eb287eaa3058385,nivolumab,0.483519
uuid-c48bbacaec1a42958eb287eaa3058385,1L,0.411499
uuid-c48bbacaec1a42958eb287eaa3058385,regimen,0.339501
uuid-c48bbacaec1a42958eb287eaa3058385,combination,0.479124
uuid-c48bbacaec1a42958eb287eaa3058385,chemo,0.505718
uuid-c48bbacaec1a42958eb287eaa3058385,2L,0.474122
uuid-c48bbacaec1a42958eb287eaa3058385,pts,0.32143
uuid-c48bbacaec1a42958eb287eaa3058385,agents,0.307779
uuid-c48bbacaec1a42958eb287eaa3058385,Ipi,0.497891
uuid-c48bbacaec1a42958eb287eaa3058385,atezo,0.400559
uuid-c48bbacaec1a42958eb287eaa3058385,preferred,0.405076
uuid-c48bbacaec1a42958eb287eaa3058385,monotherapy,0.59906
uuid-c48bbacaec1a42958eb287eaa3058385,using nivo,0.582245
uuid-c48bbacaec1a42958eb287eaa3058385,combo,0.413104
uuid-c48bbacaec1a42958eb287eaa3058385,PD1,0.434219
uuid-c48bbacaec1a42958eb287eaa3058385,approved,0.348517
uuid-c48bbacaec1a42958eb287eaa3058385,cHL,0.370388
uuid-c48bbacaec1a42958eb287eaa3058385,chemotherapy,0.490962
uuid-c48bbacaec1a42958eb287eaa3058385,vs,0.34197
uuid-c48bbacaec1a42958eb287eaa3058385,RTL stated,0.351537
uuid-c48bbacaec1a42958eb287eaa3058385,option,0.525464
uuid-096bb3a5e57741d2a7097ba5077b5829,RTL,0.404107
uuid-096bb3a5e57741d2a7097ba5077b5829,PDL1,0.482876
uuid-096bb3a5e57741d2a7097ba5077b5829,trial,0.401353
uuid-096bb3a5e57741d2a7097ba5077b5829,commented,0.326396
uuid-096bb3a5e57741d2a7097ba5077b5829,Merck,0.305492
uuid-096bb3a5e57741d2a7097ba5077b5829,PD-L1,0.397362
uuid-096bb3a5e57741d2a7097ba5077b5829,OS,0.602574
uuid-096bb3a5e57741d2a7097ba5077b5829,PD-L1 testing,0.341216
uuid-096bb3a5e57741d2a7097ba5077b5829,data,0.598336
uuid-096bb3a5e57741d2a7097ba5077b5829,PFS,0.616055
uuid-096bb3a5e57741d2a7097ba5077b5829,ORR,0.551478
uuid-096bb3a5e57741d2a7097ba5077b5829,nivo and pembro,0.300378
uuid-096bb3a5e57741d2a7097ba5077b5829,impressed,0.474151
uuid-096bb3a5e57741d2a7097ba5077b5829,assay,0.33318
uuid-096bb3a5e57741d2a7097ba5077b5829,PDL1 expression,0.453388
uuid-096bb3a5e57741d2a7097ba5077b5829,biomarker,0.361054
uuid-4f4ec4bd446845e28c6197895f92e47d,RTL,0.511987
uuid-4f4ec4bd446845e28c6197895f92e47d,BMS,0.38183
uuid-4f4ec4bd446845e28c6197895f92e47d,PDL1,0.322999
uuid-4f4ec4bd446845e28c6197895f92e47d,trial,0.468022
uuid-4f4ec4bd446845e28c6197895f92e47d,efficacy,0.456314
uuid-4f4ec4bd446845e28c6197895f92e47d,NTL,0.33102
uuid-4f4ec4bd446845e28c6197895f92e47d,commented,0.489697
uuid-4f4ec4bd446845e28c6197895f92e47d,Merck,0.329461
uuid-4f4ec4bd446845e28c6197895f92e47d,OS,0.599938
uuid-4f4ec4bd446845e28c6197895f92e47d,regards,0.36774
uuid-4f4ec4bd446845e28c6197895f92e47d,data,0.77226
uuid-4f4ec4bd446845e28c6197895f92e47d,expressed,0.481007
uuid-4f4ec4bd446845e28c6197895f92e47d,PFS,0.548026
uuid-4f4ec4bd446845e28c6197895f92e47d,ORR,0.598864
uuid-4f4ec4bd446845e28c6197895f92e47d,nivo and pembro,0.309947
uuid-4f4ec4bd446845e28c6197895f92e47d,ASCO,0.433391
uuid-4f4ec4bd446845e28c6197895f92e47d,impressed,0.68404
uuid-4f4ec4bd446845e28c6197895f92e47d,LTL,0.335088
uuid-4f4ec4bd446845e28c6197895f92e47d,TLs,0.427924
uuid-4f4ec4bd446845e28c6197895f92e47d,Regional TL,0.302546
uuid-4f4ec4bd446845e28c6197895f92e47d,PDL1 expression,0.346088
uuid-e964ab610d8548fba456f90da1d8fe31,tumor,0.466145
uuid-b55bd778b32e4e85b00117b8994321e0,oncology,0.300812
uuid-8188e160e2ea4605a0c80981300bd478,Nivo,0.57536
uuid-8188e160e2ea4605a0c80981300bd478,patients,0.736234
uuid-8188e160e2ea4605a0c80981300bd478,Opdivo,0.458912
uuid-8188e160e2ea4605a0c80981300bd478,pembro,0.39841
uuid-8188e160e2ea4605a0c80981300bd478,therapy,0.358812
uuid-8188e160e2ea4605a0c80981300bd478,dose,0.675304
uuid-8188e160e2ea4605a0c80981300bd478,nivolumab,0.417594
uuid-8188e160e2ea4605a0c80981300bd478,toxicity,0.36328
uuid-8188e160e2ea4605a0c80981300bd478,regimen,0.495999
uuid-8188e160e2ea4605a0c80981300bd478,treated,0.309415
uuid-8188e160e2ea4605a0c80981300bd478,chemo,0.349779
uuid-8188e160e2ea4605a0c80981300bd478,2L,0.339092
uuid-8188e160e2ea4605a0c80981300bd478,pts,0.481186
uuid-8188e160e2ea4605a0c80981300bd478,Ipi,0.464443
uuid-8188e160e2ea4605a0c80981300bd478,atezo,0.302766
uuid-8188e160e2ea4605a0c80981300bd478,preferred,0.370047
uuid-8188e160e2ea4605a0c80981300bd478,monotherapy,0.4121
uuid-8188e160e2ea4605a0c80981300bd478,treatment,0.460574
uuid-8188e160e2ea4605a0c80981300bd478,using nivo,0.408591
uuid-8188e160e2ea4605a0c80981300bd478,progression,0.424822
uuid-8188e160e2ea4605a0c80981300bd478,chemotherapy,0.312063
uuid-8188e160e2ea4605a0c80981300bd478,vs,0.477331
uuid-8188e160e2ea4605a0c80981300bd478,respond,0.352086
uuid-8188e160e2ea4605a0c80981300bd478,option,0.376331
uuid-8188e160e2ea4605a0c80981300bd478,flat dosing,0.396481
uuid-ae01463f57ae457aa9b407fb73cb5b1d,Nivo,0.547241
uuid-ae01463f57ae457aa9b407fb73cb5b1d,pembro,0.373233
uuid-ae01463f57ae457aa9b407fb73cb5b1d,nivolumab,0.349078
uuid-ae01463f57ae457aa9b407fb73cb5b1d,1L,0.420097
uuid-ae01463f57ae457aa9b407fb73cb5b1d,regimen,0.32169
uuid-ae01463f57ae457aa9b407fb73cb5b1d,RCC,0.433473
uuid-ae01463f57ae457aa9b407fb73cb5b1d,combination,0.362584
uuid-ae01463f57ae457aa9b407fb73cb5b1d,chemo,0.391413
uuid-ae01463f57ae457aa9b407fb73cb5b1d,2L,0.407592
uuid-ae01463f57ae457aa9b407fb73cb5b1d,pts,0.448849
uuid-ae01463f57ae457aa9b407fb73cb5b1d,monotherapy,0.53204
uuid-ae01463f57ae457aa9b407fb73cb5b1d,using nivo,0.418096
uuid-ae01463f57ae457aa9b407fb73cb5b1d,response,0.311978
uuid-ae01463f57ae457aa9b407fb73cb5b1d,combo,0.34952
uuid-ae01463f57ae457aa9b407fb73cb5b1d,PD1,0.402406
uuid-ae01463f57ae457aa9b407fb73cb5b1d,ORR,0.325605
uuid-ae01463f57ae457aa9b407fb73cb5b1d,nivo and pembro,0.37975
uuid-ae01463f57ae457aa9b407fb73cb5b1d,impressed,0.413208
uuid-ae01463f57ae457aa9b407fb73cb5b1d,SCLC,0.41582
uuid-ae01463f57ae457aa9b407fb73cb5b1d,feels,0.368484
uuid-ae01463f57ae457aa9b407fb73cb5b1d,RTL stated,0.484886
uuid-ae01463f57ae457aa9b407fb73cb5b1d,option,0.323224
uuid-ae01463f57ae457aa9b407fb73cb5b1d,bladder,0.335852
uuid-53c554119f7c4f089eb5518058150ef1,Nivo,0.63979
uuid-53c554119f7c4f089eb5518058150ef1,patients,0.381919
uuid-53c554119f7c4f089eb5518058150ef1,pembro,0.439498
uuid-53c554119f7c4f089eb5518058150ef1,dose,0.641507
uuid-53c554119f7c4f089eb5518058150ef1,nivolumab,0.362009
uuid-53c554119f7c4f089eb5518058150ef1,toxicity,0.461831
uuid-53c554119f7c4f089eb5518058150ef1,efficacy,0.364709
uuid-53c554119f7c4f089eb5518058150ef1,regimen,0.622515
uuid-53c554119f7c4f089eb5518058150ef1,combination,0.494003
uuid-53c554119f7c4f089eb5518058150ef1,chemo,0.502253
uuid-53c554119f7c4f089eb5518058150ef1,2L,0.377744
uuid-53c554119f7c4f089eb5518058150ef1,pts,0.436891
uuid-53c554119f7c4f089eb5518058150ef1,Ipi,0.743994
uuid-53c554119f7c4f089eb5518058150ef1,atezo,0.383666
uuid-53c554119f7c4f089eb5518058150ef1,preferred,0.352141
uuid-53c554119f7c4f089eb5518058150ef1,monotherapy,0.559397
uuid-53c554119f7c4f089eb5518058150ef1,using nivo,0.34391
uuid-53c554119f7c4f089eb5518058150ef1,response,0.369204
uuid-53c554119f7c4f089eb5518058150ef1,combo,0.509338
uuid-53c554119f7c4f089eb5518058150ef1,PD1,0.370205
uuid-53c554119f7c4f089eb5518058150ef1,progression,0.350159
uuid-53c554119f7c4f089eb5518058150ef1,chemotherapy,0.362892
uuid-53c554119f7c4f089eb5518058150ef1,vs,0.490433
uuid-53c554119f7c4f089eb5518058150ef1,respond,0.348365
uuid-53c554119f7c4f089eb5518058150ef1,option,0.336139
uuid-fc9eb56621d64fae901ac8ad86dca365,lung,0.375716
uuid-fc9eb56621d64fae901ac8ad86dca365,NTL,0.400309
uuid-fc9eb56621d64fae901ac8ad86dca365,discussed,0.484768
uuid-fc9eb56621d64fae901ac8ad86dca365,melanoma,0.448596
uuid-fc9eb56621d64fae901ac8ad86dca365,regards,0.405593
uuid-fc9eb56621d64fae901ac8ad86dca365,SCCHN,0.394115
uuid-fc9eb56621d64fae901ac8ad86dca365,lung cancer,0.309101
uuid-fc9eb56621d64fae901ac8ad86dca365,academic,0.427798
uuid-fc9eb56621d64fae901ac8ad86dca365,NCCN,0.480317
uuid-c3c767e969f1461492ba4dbc59166a7c,therapy,0.363594
uuid-c3c767e969f1461492ba4dbc59166a7c,nivolumab,0.411236
uuid-c3c767e969f1461492ba4dbc59166a7c,1L,0.352675
uuid-c3c767e969f1461492ba4dbc59166a7c,toxicity,0.313644
uuid-c3c767e969f1461492ba4dbc59166a7c,regimen,0.353882
uuid-c3c767e969f1461492ba4dbc59166a7c,melanoma,0.386326
uuid-c3c767e969f1461492ba4dbc59166a7c,RCC,0.380524
uuid-c3c767e969f1461492ba4dbc59166a7c,combination,0.482348
uuid-c3c767e969f1461492ba4dbc59166a7c,2L,0.44772
uuid-c3c767e969f1461492ba4dbc59166a7c,agents,0.374902
uuid-c3c767e969f1461492ba4dbc59166a7c,preferred,0.445155
uuid-c3c767e969f1461492ba4dbc59166a7c,monotherapy,0.54689
uuid-c3c767e969f1461492ba4dbc59166a7c,treatment,0.359731
uuid-c3c767e969f1461492ba4dbc59166a7c,using nivo,0.380835
uuid-c3c767e969f1461492ba4dbc59166a7c,combo,0.442832
uuid-c3c767e969f1461492ba4dbc59166a7c,PD1,0.379022
uuid-c3c767e969f1461492ba4dbc59166a7c,approved,0.379366
uuid-c3c767e969f1461492ba4dbc59166a7c,chemotherapy,0.30061
uuid-c3c767e969f1461492ba4dbc59166a7c,RTL stated,0.406289
uuid-c3c767e969f1461492ba4dbc59166a7c,option,0.494412
uuid-86c33d4987054fa3979faa807dc96538,therapy,0.368914
uuid-86c33d4987054fa3979faa807dc96538,combination,0.416299
uuid-86c33d4987054fa3979faa807dc96538,chemo,0.333833
uuid-86c33d4987054fa3979faa807dc96538,treatment,0.333874
uuid-86c33d4987054fa3979faa807dc96538,response,0.407069
uuid-86c33d4987054fa3979faa807dc96538,PD1,0.332566
uuid-86c33d4987054fa3979faa807dc96538,chemotherapy,0.361381
uuid-86c33d4987054fa3979faa807dc96538,immunotherapy,0.538813
uuid-29747dcdd5bf48288f4a223b6fc608cd,physicians,0.314417
uuid-7581c9313ba448829055ae12697eff14,RTL,0.482417
uuid-7581c9313ba448829055ae12697eff14,BMS,0.497669
uuid-7581c9313ba448829055ae12697eff14,trial,0.893739
uuid-7581c9313ba448829055ae12697eff14,NTL,0.314229
uuid-7581c9313ba448829055ae12697eff14,commented,0.375974
uuid-7581c9313ba448829055ae12697eff14,Merck,0.468025
uuid-7581c9313ba448829055ae12697eff14,data,0.441011
uuid-7581c9313ba448829055ae12697eff14,expressed,0.320101
uuid-7581c9313ba448829055ae12697eff14,clinical trials,0.489164
uuid-7581c9313ba448829055ae12697eff14,ORR,0.319131
uuid-7581c9313ba448829055ae12697eff14,impressed,0.42904
uuid-a4af613ba1e848159ea2226a284204fc,patients,0.474935
uuid-a4af613ba1e848159ea2226a284204fc,toxicity,0.407183
uuid-a4af613ba1e848159ea2226a284204fc,regimen,0.339936
uuid-a4af613ba1e848159ea2226a284204fc,progression,0.430011
uuid-a4af613ba1e848159ea2226a284204fc,respond,0.322536
uuid-8eee1a61857c4c46bced9721c8fb0b91,TL,0.523681
uuid-8eee1a61857c4c46bced9721c8fb0b91,TL stated,0.31757
uuid-8eee1a61857c4c46bced9721c8fb0b91,institution,0.419182
uuid-8eee1a61857c4c46bced9721c8fb0b91,PD-L1,0.590959
uuid-8eee1a61857c4c46bced9721c8fb0b91,approval,0.439537
uuid-8eee1a61857c4c46bced9721c8fb0b91,PD-L1 testing,0.774904
uuid-8eee1a61857c4c46bced9721c8fb0b91,testing,0.723715
uuid-8eee1a61857c4c46bced9721c8fb0b91,PDL1 testing,0.588996
uuid-8eee1a61857c4c46bced9721c8fb0b91,NSCLC patients,0.553722
uuid-8eee1a61857c4c46bced9721c8fb0b91,assay,0.501305
uuid-e95ae9663804412eba7ac16576b1fd99,patients,0.561748
uuid-e95ae9663804412eba7ac16576b1fd99,therapy,0.477664
uuid-e95ae9663804412eba7ac16576b1fd99,nivolumab,0.445902
uuid-e95ae9663804412eba7ac16576b1fd99,1L,0.499687
uuid-e95ae9663804412eba7ac16576b1fd99,toxicity,0.355898
uuid-e95ae9663804412eba7ac16576b1fd99,regimen,0.628524
uuid-e95ae9663804412eba7ac16576b1fd99,treated,0.512842
uuid-e95ae9663804412eba7ac16576b1fd99,RCC,0.527229
uuid-e95ae9663804412eba7ac16576b1fd99,combination,0.470039
uuid-e95ae9663804412eba7ac16576b1fd99,chemo,0.478644
uuid-e95ae9663804412eba7ac16576b1fd99,2L,0.553795
uuid-e95ae9663804412eba7ac16576b1fd99,pts,0.489256
uuid-e95ae9663804412eba7ac16576b1fd99,IO,0.308663
uuid-e95ae9663804412eba7ac16576b1fd99,agents,0.392695
uuid-e95ae9663804412eba7ac16576b1fd99,preferred,0.627269
uuid-e95ae9663804412eba7ac16576b1fd99,monotherapy,0.686338
uuid-e95ae9663804412eba7ac16576b1fd99,treatment,0.614233
uuid-e95ae9663804412eba7ac16576b1fd99,using nivo,0.481715
uuid-e95ae9663804412eba7ac16576b1fd99,combo,0.482479
uuid-e95ae9663804412eba7ac16576b1fd99,PD1,0.471603
uuid-e95ae9663804412eba7ac16576b1fd99,approved,0.31151
uuid-e95ae9663804412eba7ac16576b1fd99,progression,0.488838
uuid-e95ae9663804412eba7ac16576b1fd99,chemotherapy,0.429016
uuid-e95ae9663804412eba7ac16576b1fd99,respond,0.383807
uuid-e95ae9663804412eba7ac16576b1fd99,RTL stated,0.556443
uuid-e95ae9663804412eba7ac16576b1fd99,TL shared,0.436016
uuid-e95ae9663804412eba7ac16576b1fd99,option,0.662159
uuid-54baa1e8e3b84004808bd91d7341bf7e,patients,0.828744
uuid-54baa1e8e3b84004808bd91d7341bf7e,Opdivo,0.393024
uuid-54baa1e8e3b84004808bd91d7341bf7e,therapy,0.657003
uuid-54baa1e8e3b84004808bd91d7341bf7e,nivolumab,0.604042
uuid-54baa1e8e3b84004808bd91d7341bf7e,regimen,0.493822
uuid-54baa1e8e3b84004808bd91d7341bf7e,treated,0.689406
uuid-54baa1e8e3b84004808bd91d7341bf7e,RCC,0.380644
uuid-54baa1e8e3b84004808bd91d7341bf7e,chemo,0.344365
uuid-54baa1e8e3b84004808bd91d7341bf7e,2L,0.301796
uuid-54baa1e8e3b84004808bd91d7341bf7e,pts,0.543759
uuid-54baa1e8e3b84004808bd91d7341bf7e,preferred,0.364324
uuid-54baa1e8e3b84004808bd91d7341bf7e,monotherapy,0.445833
uuid-54baa1e8e3b84004808bd91d7341bf7e,treatment,0.690306
uuid-54baa1e8e3b84004808bd91d7341bf7e,using nivo,0.503339
uuid-54baa1e8e3b84004808bd91d7341bf7e,PD1,0.347106
uuid-54baa1e8e3b84004808bd91d7341bf7e,cHL,0.409931
uuid-54baa1e8e3b84004808bd91d7341bf7e,progression,0.600848
uuid-54baa1e8e3b84004808bd91d7341bf7e,chemotherapy,0.435139
uuid-54baa1e8e3b84004808bd91d7341bf7e,respond,0.368346
uuid-54baa1e8e3b84004808bd91d7341bf7e,RTL stated,0.473995
uuid-54baa1e8e3b84004808bd91d7341bf7e,TL shared,0.400652
uuid-54baa1e8e3b84004808bd91d7341bf7e,option,0.439979
uuid-aed1843640324a749518305e2143d7f6,patients,0.661481
uuid-aed1843640324a749518305e2143d7f6,therapy,0.389475
uuid-aed1843640324a749518305e2143d7f6,regimen,0.403732
uuid-aed1843640324a749518305e2143d7f6,treated,0.326014
uuid-aed1843640324a749518305e2143d7f6,chemo,0.480649
uuid-aed1843640324a749518305e2143d7f6,pts,0.52018
uuid-aed1843640324a749518305e2143d7f6,IO,0.329402
uuid-aed1843640324a749518305e2143d7f6,monotherapy,0.403064
uuid-aed1843640324a749518305e2143d7f6,treatment,0.52689
uuid-aed1843640324a749518305e2143d7f6,response,0.426681
uuid-aed1843640324a749518305e2143d7f6,PD1,0.302815
uuid-aed1843640324a749518305e2143d7f6,progression,0.505809
uuid-aed1843640324a749518305e2143d7f6,chemotherapy,0.449065
uuid-aed1843640324a749518305e2143d7f6,respond,0.44822
uuid-aed1843640324a749518305e2143d7f6,feels,0.451425
uuid-aed1843640324a749518305e2143d7f6,option,0.459154
uuid-77aef24e25ef4e09ae387901f2eb28fe,toxicity,0.334291
uuid-77aef24e25ef4e09ae387901f2eb28fe,regimen,0.360107
uuid-77aef24e25ef4e09ae387901f2eb28fe,IO,0.390043
uuid-77aef24e25ef4e09ae387901f2eb28fe,lung cancer,0.526615
uuid-77aef24e25ef4e09ae387901f2eb28fe,chemotherapy,0.312857
uuid-a8c2fce908b34e4db0c27f61f48e8dab,toxicity,0.390367
uuid-a8c2fce908b34e4db0c27f61f48e8dab,tumor,0.673975
uuid-a8c2fce908b34e4db0c27f61f48e8dab,response,0.37511
uuid-a8c2fce908b34e4db0c27f61f48e8dab,respond,0.328621
uuid-356ca145f12a4c3cbc167a49480c7869,TL,0.324198
uuid-356ca145f12a4c3cbc167a49480c7869,RTL,0.300897
uuid-356ca145f12a4c3cbc167a49480c7869,NSCLC,0.319611
uuid-356ca145f12a4c3cbc167a49480c7869,NTL,0.478806
uuid-356ca145f12a4c3cbc167a49480c7869,shared,0.3126
uuid-356ca145f12a4c3cbc167a49480c7869,commented,0.301695
uuid-356ca145f12a4c3cbc167a49480c7869,physicians,0.513472
uuid-356ca145f12a4c3cbc167a49480c7869,oncology,0.4013
uuid-356ca145f12a4c3cbc167a49480c7869,SCCHN,0.316296
uuid-356ca145f12a4c3cbc167a49480c7869,lung cancer,0.491409
uuid-356ca145f12a4c3cbc167a49480c7869,indicated,0.357101
uuid-356ca145f12a4c3cbc167a49480c7869,LTL,0.360377
uuid-356ca145f12a4c3cbc167a49480c7869,TLs,0.403963
uuid-356ca145f12a4c3cbc167a49480c7869,clinical,0.302429
uuid-356ca145f12a4c3cbc167a49480c7869,academic,0.38498
uuid-356ca145f12a4c3cbc167a49480c7869,Regional TL,0.471059
uuid-dc0705c09ee24012b0fa881553bbbd94,patients,0.866227
uuid-dc0705c09ee24012b0fa881553bbbd94,Opdivo,0.506381
uuid-dc0705c09ee24012b0fa881553bbbd94,therapy,0.630205
uuid-dc0705c09ee24012b0fa881553bbbd94,nivolumab,0.52482
uuid-dc0705c09ee24012b0fa881553bbbd94,regimen,0.402406
uuid-dc0705c09ee24012b0fa881553bbbd94,treated,0.619113
uuid-dc0705c09ee24012b0fa881553bbbd94,pts,0.512741
uuid-dc0705c09ee24012b0fa881553bbbd94,treatment,0.676468
uuid-dc0705c09ee24012b0fa881553bbbd94,response,0.314782
uuid-dc0705c09ee24012b0fa881553bbbd94,cHL,0.519091
uuid-dc0705c09ee24012b0fa881553bbbd94,progression,0.626469
uuid-dc0705c09ee24012b0fa881553bbbd94,chemotherapy,0.39103
uuid-dc0705c09ee24012b0fa881553bbbd94,respond,0.433525
uuid-36278cd2e81c4222a4814581876dc669,Nivo,0.438009
uuid-36278cd2e81c4222a4814581876dc669,patients,0.793528
uuid-36278cd2e81c4222a4814581876dc669,Opdivo,0.491356
uuid-36278cd2e81c4222a4814581876dc669,therapy,0.665945
uuid-36278cd2e81c4222a4814581876dc669,nivolumab,0.505301
uuid-36278cd2e81c4222a4814581876dc669,regimen,0.492852
uuid-36278cd2e81c4222a4814581876dc669,treated,0.457834
uuid-36278cd2e81c4222a4814581876dc669,chemo,0.508986
uuid-36278cd2e81c4222a4814581876dc669,pts,0.662701
uuid-36278cd2e81c4222a4814581876dc669,monotherapy,0.475274
uuid-36278cd2e81c4222a4814581876dc669,treatment,0.625566
uuid-36278cd2e81c4222a4814581876dc669,using nivo,0.337072
uuid-36278cd2e81c4222a4814581876dc669,response,0.438343
uuid-36278cd2e81c4222a4814581876dc669,PD1,0.395374
uuid-36278cd2e81c4222a4814581876dc669,cHL,0.349559
uuid-36278cd2e81c4222a4814581876dc669,progression,0.642486
uuid-36278cd2e81c4222a4814581876dc669,chemotherapy,0.507134
uuid-36278cd2e81c4222a4814581876dc669,respond,0.500103
uuid-36278cd2e81c4222a4814581876dc669,option,0.470511
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,Nivo,0.366623
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,patients,0.798565
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,Opdivo,0.492077
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,therapy,0.616969
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,nivolumab,0.686949
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,regimen,0.350853
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,treated,0.589056
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,pts,0.446294
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,approval,0.401272
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,monotherapy,0.344959
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,treatment,0.57163
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,using nivo,0.504383
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,PD1,0.331789
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,cHL,0.560375
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,progression,0.47479
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,chemotherapy,0.393724
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,RTL stated,0.383279
uuid-5ef0dd5fe5fd47d6be12467c11b03e43,option,0.372812
uuid-402c508bf7ee423f92072a2448e37565,Nivo,0.356695
uuid-402c508bf7ee423f92072a2448e37565,patients,0.765785
uuid-402c508bf7ee423f92072a2448e37565,Opdivo,0.481459
uuid-402c508bf7ee423f92072a2448e37565,therapy,0.706757
uuid-402c508bf7ee423f92072a2448e37565,nivolumab,0.66542
uuid-402c508bf7ee423f92072a2448e37565,regimen,0.326095
uuid-402c508bf7ee423f92072a2448e37565,treated,0.5308
uuid-402c508bf7ee423f92072a2448e37565,pts,0.395505
uuid-402c508bf7ee423f92072a2448e37565,treatment,0.575317
uuid-402c508bf7ee423f92072a2448e37565,using nivo,0.35856
uuid-402c508bf7ee423f92072a2448e37565,response,0.325391
uuid-402c508bf7ee423f92072a2448e37565,PD1,0.313321
uuid-402c508bf7ee423f92072a2448e37565,cHL,0.703639
uuid-402c508bf7ee423f92072a2448e37565,progression,0.525165
uuid-402c508bf7ee423f92072a2448e37565,chemotherapy,0.353646
uuid-402c508bf7ee423f92072a2448e37565,respond,0.380657
uuid-ceccb1adc3664e378f1638c82dc80f31,commented,0.374181
uuid-ceccb1adc3664e378f1638c82dc80f31,lung cancer,0.585825
uuid-ceccb1adc3664e378f1638c82dc80f31,ASCO,0.426399
uuid-ceccb1adc3664e378f1638c82dc80f31,Regional TL,0.309368
uuid-4cf1d2cfff0248288d7b72062a657fd1,patients,0.642251
uuid-4cf1d2cfff0248288d7b72062a657fd1,therapy,0.405605
uuid-4cf1d2cfff0248288d7b72062a657fd1,1L,0.457385
uuid-4cf1d2cfff0248288d7b72062a657fd1,regimen,0.428783
uuid-4cf1d2cfff0248288d7b72062a657fd1,treated,0.425112
uuid-4cf1d2cfff0248288d7b72062a657fd1,RCC,0.438749
uuid-4cf1d2cfff0248288d7b72062a657fd1,chemo,0.48167
uuid-4cf1d2cfff0248288d7b72062a657fd1,tumor,0.30364
uuid-4cf1d2cfff0248288d7b72062a657fd1,2L,0.441311
uuid-4cf1d2cfff0248288d7b72062a657fd1,pts,0.593789
uuid-4cf1d2cfff0248288d7b72062a657fd1,IO,0.321893
uuid-4cf1d2cfff0248288d7b72062a657fd1,preferred,0.348163
uuid-4cf1d2cfff0248288d7b72062a657fd1,monotherapy,0.495486
uuid-4cf1d2cfff0248288d7b72062a657fd1,treatment,0.516722
uuid-4cf1d2cfff0248288d7b72062a657fd1,using nivo,0.360237
uuid-4cf1d2cfff0248288d7b72062a657fd1,response,0.388708
uuid-4cf1d2cfff0248288d7b72062a657fd1,combo,0.378628
uuid-4cf1d2cfff0248288d7b72062a657fd1,PD1,0.385583
uuid-4cf1d2cfff0248288d7b72062a657fd1,progression,0.598409
uuid-4cf1d2cfff0248288d7b72062a657fd1,chemotherapy,0.350111
uuid-4cf1d2cfff0248288d7b72062a657fd1,tumor types,0.394398
uuid-4cf1d2cfff0248288d7b72062a657fd1,respond,0.427835
uuid-4cf1d2cfff0248288d7b72062a657fd1,RTL stated,0.356107
uuid-4cf1d2cfff0248288d7b72062a657fd1,TL shared,0.338042
uuid-4cf1d2cfff0248288d7b72062a657fd1,option,0.533467
uuid-544f83f5a774498085b36c4c47c7870d,BMS,0.367669
uuid-544f83f5a774498085b36c4c47c7870d,PDL1,0.492924
uuid-544f83f5a774498085b36c4c47c7870d,trial,0.588423
uuid-544f83f5a774498085b36c4c47c7870d,efficacy,0.534416
uuid-544f83f5a774498085b36c4c47c7870d,OS,0.680239
uuid-544f83f5a774498085b36c4c47c7870d,regards,0.328989
uuid-544f83f5a774498085b36c4c47c7870d,data,0.699177
uuid-544f83f5a774498085b36c4c47c7870d,PFS,0.719412
uuid-544f83f5a774498085b36c4c47c7870d,ORR,0.749415
uuid-544f83f5a774498085b36c4c47c7870d,nivo and pembro,0.434511
uuid-544f83f5a774498085b36c4c47c7870d,believes,0.303561
uuid-544f83f5a774498085b36c4c47c7870d,impressed,0.543656
uuid-544f83f5a774498085b36c4c47c7870d,feels,0.464228
uuid-544f83f5a774498085b36c4c47c7870d,PDL1 expression,0.527391
uuid-365ccb95f8284ab39f5df1f155808bf0,RTL,0.315683
uuid-365ccb95f8284ab39f5df1f155808bf0,efficacy,0.324203
uuid-365ccb95f8284ab39f5df1f155808bf0,NTL,0.327707
uuid-365ccb95f8284ab39f5df1f155808bf0,discussed,0.415207
uuid-365ccb95f8284ab39f5df1f155808bf0,commented,0.573718
uuid-365ccb95f8284ab39f5df1f155808bf0,OS,0.470453
uuid-365ccb95f8284ab39f5df1f155808bf0,regards,0.372078
uuid-365ccb95f8284ab39f5df1f155808bf0,data,0.669839
uuid-365ccb95f8284ab39f5df1f155808bf0,PFS,0.437139
uuid-365ccb95f8284ab39f5df1f155808bf0,ORR,0.448481
uuid-365ccb95f8284ab39f5df1f155808bf0,lung cancer,0.46168
uuid-365ccb95f8284ab39f5df1f155808bf0,ASCO,0.546642
uuid-365ccb95f8284ab39f5df1f155808bf0,impressed,0.577051
uuid-365ccb95f8284ab39f5df1f155808bf0,Regional TL,0.367222
uuid-86d0265875b141d3ac4b0890594e4e33,Nivo,0.311241
uuid-86d0265875b141d3ac4b0890594e4e33,patients,0.509541
uuid-86d0265875b141d3ac4b0890594e4e33,RTL,0.354335
uuid-86d0265875b141d3ac4b0890594e4e33,nivolumab,0.316768
uuid-86d0265875b141d3ac4b0890594e4e33,trial,0.436761
uuid-86d0265875b141d3ac4b0890594e4e33,treated,0.300975
uuid-86d0265875b141d3ac4b0890594e4e33,pts,0.427497
uuid-86d0265875b141d3ac4b0890594e4e33,using nivo,0.303768
uuid-86d0265875b141d3ac4b0890594e4e33,clinical trials,0.459318
uuid-86d0265875b141d3ac4b0890594e4e33,chemotherapy,0.303897
uuid-86d0265875b141d3ac4b0890594e4e33,feels,0.300105
uuid-cca9db1c2851409899b600e174e9f245,Nivo,0.349395
uuid-cca9db1c2851409899b600e174e9f245,pembro,0.462059
uuid-cca9db1c2851409899b600e174e9f245,BMS,0.586103
uuid-cca9db1c2851409899b600e174e9f245,trial,0.464232
uuid-cca9db1c2851409899b600e174e9f245,efficacy,0.360578
uuid-cca9db1c2851409899b600e174e9f245,commented,0.344574
uuid-cca9db1c2851409899b600e174e9f245,2L,0.332214
uuid-cca9db1c2851409899b600e174e9f245,agents,0.315231
uuid-cca9db1c2851409899b600e174e9f245,Merck,0.451898
uuid-cca9db1c2851409899b600e174e9f245,stated,0.368798
uuid-cca9db1c2851409899b600e174e9f245,OS,0.377536
uuid-cca9db1c2851409899b600e174e9f245,atezo,0.459515
uuid-cca9db1c2851409899b600e174e9f245,regards,0.301122
uuid-cca9db1c2851409899b600e174e9f245,data,0.612986
uuid-cca9db1c2851409899b600e174e9f245,indication,0.358804
uuid-cca9db1c2851409899b600e174e9f245,PFS,0.319493
uuid-cca9db1c2851409899b600e174e9f245,ORR,0.32218
uuid-cca9db1c2851409899b600e174e9f245,approved,0.381879
uuid-cca9db1c2851409899b600e174e9f245,nivo and pembro,0.450194
uuid-cca9db1c2851409899b600e174e9f245,impressed,0.478392
uuid-cca9db1c2851409899b600e174e9f245,feels,0.450493
uuid-63c7074a4cae4f3696499ebad70f74bf,physicians,0.355158
uuid-63c7074a4cae4f3696499ebad70f74bf,treatment,0.345723
uuid-bf3ec7ae572c47668a838dba38f0c869,Nivo,0.362382
uuid-bf3ec7ae572c47668a838dba38f0c869,patients,0.847929
uuid-bf3ec7ae572c47668a838dba38f0c869,Opdivo,0.43554
uuid-bf3ec7ae572c47668a838dba38f0c869,therapy,0.783011
uuid-bf3ec7ae572c47668a838dba38f0c869,nivolumab,0.559126
uuid-bf3ec7ae572c47668a838dba38f0c869,regimen,0.422857
uuid-bf3ec7ae572c47668a838dba38f0c869,treated,0.517638
uuid-bf3ec7ae572c47668a838dba38f0c869,chemo,0.367651
uuid-bf3ec7ae572c47668a838dba38f0c869,pts,0.51547
uuid-bf3ec7ae572c47668a838dba38f0c869,monotherapy,0.349846
uuid-bf3ec7ae572c47668a838dba38f0c869,treatment,0.670557
uuid-bf3ec7ae572c47668a838dba38f0c869,response,0.464765
uuid-bf3ec7ae572c47668a838dba38f0c869,PD1,0.424442
uuid-bf3ec7ae572c47668a838dba38f0c869,cHL,0.587103
uuid-bf3ec7ae572c47668a838dba38f0c869,progression,0.650389
uuid-bf3ec7ae572c47668a838dba38f0c869,chemotherapy,0.460433
uuid-bf3ec7ae572c47668a838dba38f0c869,respond,0.462132
uuid-bf3ec7ae572c47668a838dba38f0c869,option,0.331147
uuid-612e1e71583f4338a794f8bb4ecb2ead,Nivo,0.339797
uuid-612e1e71583f4338a794f8bb4ecb2ead,pembro,0.31085
uuid-612e1e71583f4338a794f8bb4ecb2ead,PDL1,0.485956
uuid-612e1e71583f4338a794f8bb4ecb2ead,trial,0.398152
uuid-612e1e71583f4338a794f8bb4ecb2ead,efficacy,0.767041
uuid-612e1e71583f4338a794f8bb4ecb2ead,OS,0.688017
uuid-612e1e71583f4338a794f8bb4ecb2ead,regards,0.349293
uuid-612e1e71583f4338a794f8bb4ecb2ead,data,0.600166
uuid-612e1e71583f4338a794f8bb4ecb2ead,PFS,0.707985
uuid-612e1e71583f4338a794f8bb4ecb2ead,ORR,0.706329
uuid-612e1e71583f4338a794f8bb4ecb2ead,nivo and pembro,0.571845
uuid-612e1e71583f4338a794f8bb4ecb2ead,believes,0.412931
uuid-612e1e71583f4338a794f8bb4ecb2ead,impressed,0.377562
uuid-612e1e71583f4338a794f8bb4ecb2ead,vs,0.406307
uuid-612e1e71583f4338a794f8bb4ecb2ead,feels,0.345891
uuid-612e1e71583f4338a794f8bb4ecb2ead,PDL1 expression,0.498294
uuid-66d259221e0e4deda65607b0685c2e69,1L,0.382067
uuid-66d259221e0e4deda65607b0685c2e69,PDL1,0.444334
uuid-66d259221e0e4deda65607b0685c2e69,2L,0.365716
uuid-66d259221e0e4deda65607b0685c2e69,agents,0.426226
uuid-66d259221e0e4deda65607b0685c2e69,PD-L1,0.496199
uuid-66d259221e0e4deda65607b0685c2e69,atezo,0.367161
uuid-66d259221e0e4deda65607b0685c2e69,preferred,0.398373
uuid-66d259221e0e4deda65607b0685c2e69,PD-L1 testing,0.322132
uuid-66d259221e0e4deda65607b0685c2e69,testing,0.473769
uuid-66d259221e0e4deda65607b0685c2e69,PDL1 testing,0.436383
uuid-66d259221e0e4deda65607b0685c2e69,NSCLC patients,0.301011
uuid-66d259221e0e4deda65607b0685c2e69,believes,0.459331
uuid-66d259221e0e4deda65607b0685c2e69,assay,0.461524
uuid-66d259221e0e4deda65607b0685c2e69,option,0.337272
uuid-66d259221e0e4deda65607b0685c2e69,biomarker,0.366884
uuid-632ec6eeeb164e769169f151b259f29c,TL,0.522692
uuid-632ec6eeeb164e769169f151b259f29c,TL stated,0.402833
uuid-632ec6eeeb164e769169f151b259f29c,institution,0.452034
uuid-632ec6eeeb164e769169f151b259f29c,PD-L1,0.329149
uuid-632ec6eeeb164e769169f151b259f29c,physicians,0.305261
uuid-632ec6eeeb164e769169f151b259f29c,PD-L1 testing,0.660395
uuid-632ec6eeeb164e769169f151b259f29c,testing,0.487572
uuid-632ec6eeeb164e769169f151b259f29c,PDL1 testing,0.512116
uuid-632ec6eeeb164e769169f151b259f29c,NSCLC patients,0.362874
uuid-632ec6eeeb164e769169f151b259f29c,oncology,0.656064
uuid-632ec6eeeb164e769169f151b259f29c,oncologist,0.328827
uuid-632ec6eeeb164e769169f151b259f29c,clinical,0.433998
uuid-632ec6eeeb164e769169f151b259f29c,academic,0.393404
uuid-632ec6eeeb164e769169f151b259f29c,Regional TL,0.373592
uuid-0b30b630f0cd49269bce5e97701e39ed,toxicity,0.430489
uuid-0b30b630f0cd49269bce5e97701e39ed,regimen,0.301341
uuid-0b30b630f0cd49269bce5e97701e39ed,treated,0.435423
uuid-0b30b630f0cd49269bce5e97701e39ed,physicians,0.525787
uuid-0b30b630f0cd49269bce5e97701e39ed,treatment,0.390893
uuid-ba98c8dc77cc491eaf0789e17c3c7232,patients,0.557588
uuid-ba98c8dc77cc491eaf0789e17c3c7232,therapy,0.504849
uuid-ba98c8dc77cc491eaf0789e17c3c7232,toxicity,0.300867
uuid-ba98c8dc77cc491eaf0789e17c3c7232,regimen,0.322199
uuid-ba98c8dc77cc491eaf0789e17c3c7232,treatment,0.481198
uuid-ba98c8dc77cc491eaf0789e17c3c7232,cHL,0.442645
uuid-ba98c8dc77cc491eaf0789e17c3c7232,progression,0.406145
uuid-ba98c8dc77cc491eaf0789e17c3c7232,chemotherapy,0.323529
uuid-ba98c8dc77cc491eaf0789e17c3c7232,respond,0.420953
uuid-5391bfae4f42425eb86e11ac5712b265,patients,0.739661
uuid-5391bfae4f42425eb86e11ac5712b265,therapy,0.411471
uuid-5391bfae4f42425eb86e11ac5712b265,regimen,0.393499
uuid-5391bfae4f42425eb86e11ac5712b265,treated,0.530708
uuid-5391bfae4f42425eb86e11ac5712b265,chemo,0.445041
uuid-5391bfae4f42425eb86e11ac5712b265,tumor,0.560712
uuid-5391bfae4f42425eb86e11ac5712b265,pts,0.649786
uuid-5391bfae4f42425eb86e11ac5712b265,treatment,0.531782
uuid-5391bfae4f42425eb86e11ac5712b265,response,0.530431
uuid-5391bfae4f42425eb86e11ac5712b265,progression,0.610484
uuid-5391bfae4f42425eb86e11ac5712b265,chemotherapy,0.387773
uuid-5391bfae4f42425eb86e11ac5712b265,respond,0.494952
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,patients,0.411424
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,Opdivo,0.322583
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,nivolumab,0.324787
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,regimen,0.303473
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,treated,0.624424
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,RCC,0.330048
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,TL stated,0.327436
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,stated,0.315805
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,physicians,0.462711
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,treatment,0.374443
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,Regional TL,0.412399
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,RTL stated,0.331941
uuid-6b472079b0bd4ccc8b2fed6a99911b2f,TL shared,0.392444
uuid-04bb7485ef5f45018e6badd878857dce,Nivo,0.702649
uuid-04bb7485ef5f45018e6badd878857dce,efficacy,0.328129
uuid-04bb7485ef5f45018e6badd878857dce,data,0.313728
uuid-04bb7485ef5f45018e6badd878857dce,cHL,0.325905
uuid-04bb7485ef5f45018e6badd878857dce,feels,0.319819
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,Nivo,0.395066
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,BMS,0.329943
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,trial,0.536796
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,data,0.481729
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,mentioned,0.340818
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,PFS,0.316804
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,ORR,0.302176
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,cHL,0.36497
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,impressed,0.365093
uuid-b25fb1e3ae034df69d6e4bf1ed398e11,feels,0.442151
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,patients,0.706066
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,Opdivo,0.402342
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,therapy,0.592952
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,nivolumab,0.341612
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,regimen,0.34631
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,treated,0.434897
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,pts,0.360593
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,treatment,0.581086
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,cHL,0.469579
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,progression,0.44373
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,chemotherapy,0.310066
uuid-bcf9645d80b24fd4a27c3abb27b8f8bf,respond,0.337097
uuid-2950e93090374cfca44959abe77233e2,patients,0.409422
uuid-2950e93090374cfca44959abe77233e2,RTL,0.346189
uuid-2950e93090374cfca44959abe77233e2,mentioned,0.53942
uuid-2950e93090374cfca44959abe77233e2,HCP,0.326687
uuid-2950e93090374cfca44959abe77233e2,cHL,0.385518
uuid-2950e93090374cfca44959abe77233e2,LTL,0.394183
uuid-76925ccb85484ef8a42c31ed6afd6eaf,patients,0.485849
uuid-76925ccb85484ef8a42c31ed6afd6eaf,therapy,0.604828
uuid-76925ccb85484ef8a42c31ed6afd6eaf,nivolumab,0.337338
uuid-76925ccb85484ef8a42c31ed6afd6eaf,treated,0.427929
uuid-76925ccb85484ef8a42c31ed6afd6eaf,chemo,0.431523
uuid-76925ccb85484ef8a42c31ed6afd6eaf,pts,0.34927
uuid-76925ccb85484ef8a42c31ed6afd6eaf,treatment,0.482954
uuid-76925ccb85484ef8a42c31ed6afd6eaf,response,0.301069
uuid-76925ccb85484ef8a42c31ed6afd6eaf,cHL,0.312821
uuid-76925ccb85484ef8a42c31ed6afd6eaf,progression,0.468548
uuid-76925ccb85484ef8a42c31ed6afd6eaf,chemotherapy,0.392246
uuid-76925ccb85484ef8a42c31ed6afd6eaf,respond,0.354504
uuid-76925ccb85484ef8a42c31ed6afd6eaf,option,0.325548
uuid-37ebe5a885b443aea51fd51010872719,trial,0.303919
uuid-37ebe5a885b443aea51fd51010872719,OS,0.773935
uuid-37ebe5a885b443aea51fd51010872719,response,0.329772
uuid-37ebe5a885b443aea51fd51010872719,data,0.364347
uuid-37ebe5a885b443aea51fd51010872719,PFS,0.712893
uuid-37ebe5a885b443aea51fd51010872719,ORR,0.642778
uuid-37ebe5a885b443aea51fd51010872719,impressed,0.482012
uuid-205a886584dd49e78784e6c8b11f8dd0,Nivo,0.520632
uuid-205a886584dd49e78784e6c8b11f8dd0,patients,0.387693
uuid-205a886584dd49e78784e6c8b11f8dd0,Opdivo,0.38864
uuid-205a886584dd49e78784e6c8b11f8dd0,therapy,0.552113
uuid-205a886584dd49e78784e6c8b11f8dd0,nivolumab,0.443221
uuid-205a886584dd49e78784e6c8b11f8dd0,using nivo,0.390521
uuid-205a886584dd49e78784e6c8b11f8dd0,mentioned,0.34458
uuid-205a886584dd49e78784e6c8b11f8dd0,cHL,0.774456
uuid-680754ec69884dc684cbe5f308c8a6f2,BMS,0.430028
uuid-680754ec69884dc684cbe5f308c8a6f2,trial,0.407972
uuid-680754ec69884dc684cbe5f308c8a6f2,commented,0.429998
uuid-680754ec69884dc684cbe5f308c8a6f2,Merck,0.390586
uuid-680754ec69884dc684cbe5f308c8a6f2,regards,0.462726
uuid-680754ec69884dc684cbe5f308c8a6f2,data,0.485652
uuid-680754ec69884dc684cbe5f308c8a6f2,expressed,0.362181
uuid-680754ec69884dc684cbe5f308c8a6f2,indication,0.49934
uuid-680754ec69884dc684cbe5f308c8a6f2,AI,0.446169
uuid-680754ec69884dc684cbe5f308c8a6f2,impressed,0.323635
uuid-680754ec69884dc684cbe5f308c8a6f2,label,0.410438
uuid-680754ec69884dc684cbe5f308c8a6f2,SCLC,0.323432
uuid-680754ec69884dc684cbe5f308c8a6f2,NCCN,0.685267
uuid-ca1375074a4f435aae857e88c571a52a,pembro,0.342837
uuid-ca1375074a4f435aae857e88c571a52a,RTL,0.396362
uuid-ca1375074a4f435aae857e88c571a52a,lung,0.343097
uuid-ca1375074a4f435aae857e88c571a52a,1L,0.414871
uuid-ca1375074a4f435aae857e88c571a52a,trial,0.513667
uuid-ca1375074a4f435aae857e88c571a52a,NTL,0.315132
uuid-ca1375074a4f435aae857e88c571a52a,melanoma,0.313882
uuid-ca1375074a4f435aae857e88c571a52a,commented,0.311772
uuid-ca1375074a4f435aae857e88c571a52a,RCC,0.580683
uuid-ca1375074a4f435aae857e88c571a52a,2L,0.36741
uuid-ca1375074a4f435aae857e88c571a52a,stated,0.379125
uuid-ca1375074a4f435aae857e88c571a52a,approval,0.327027
uuid-ca1375074a4f435aae857e88c571a52a,OS,0.325742
uuid-ca1375074a4f435aae857e88c571a52a,using nivo,0.385548
uuid-ca1375074a4f435aae857e88c571a52a,data,0.472251
uuid-ca1375074a4f435aae857e88c571a52a,combo,0.317682
uuid-ca1375074a4f435aae857e88c571a52a,clinical trials,0.312283
uuid-ca1375074a4f435aae857e88c571a52a,ORR,0.351853
uuid-ca1375074a4f435aae857e88c571a52a,approved,0.333622
uuid-ca1375074a4f435aae857e88c571a52a,SCCHN,0.501971
uuid-ca1375074a4f435aae857e88c571a52a,ASCO,0.300521
uuid-ca1375074a4f435aae857e88c571a52a,impressed,0.542871
uuid-ca1375074a4f435aae857e88c571a52a,TLs,0.325096
uuid-ca1375074a4f435aae857e88c571a52a,SCLC,0.415342
uuid-ca1375074a4f435aae857e88c571a52a,Regional TL,0.438648
uuid-ca1375074a4f435aae857e88c571a52a,RTL stated,0.434315
uuid-ca1375074a4f435aae857e88c571a52a,TL shared,0.379932
uuid-ca1375074a4f435aae857e88c571a52a,bladder,0.448131
uuid-5a91d90f318c47e78fe712b20d087a7a,RTL,0.370182
uuid-5a91d90f318c47e78fe712b20d087a7a,shared,0.311833
uuid-5a91d90f318c47e78fe712b20d087a7a,stated,0.492376
uuid-5a91d90f318c47e78fe712b20d087a7a,physicians,0.476908
uuid-5a91d90f318c47e78fe712b20d087a7a,preferred,0.356598
uuid-5a91d90f318c47e78fe712b20d087a7a,using nivo,0.462133
uuid-5a91d90f318c47e78fe712b20d087a7a,mentioned,0.369893
uuid-5a91d90f318c47e78fe712b20d087a7a,SCCHN,0.380236
uuid-5a91d90f318c47e78fe712b20d087a7a,HCP,0.387181
uuid-5a91d90f318c47e78fe712b20d087a7a,LTL,0.533559
uuid-5a91d90f318c47e78fe712b20d087a7a,Regional TL,0.433083
uuid-5a91d90f318c47e78fe712b20d087a7a,RTL stated,0.475439
uuid-034f8c79cef344e99ca68ba40ad91af3,patients,0.380415
uuid-034f8c79cef344e99ca68ba40ad91af3,therapy,0.3173
uuid-034f8c79cef344e99ca68ba40ad91af3,1L,0.472026
uuid-034f8c79cef344e99ca68ba40ad91af3,regimen,0.353602
uuid-034f8c79cef344e99ca68ba40ad91af3,combination,0.422442
uuid-034f8c79cef344e99ca68ba40ad91af3,chemo,0.508042
uuid-034f8c79cef344e99ca68ba40ad91af3,2L,0.404483
uuid-034f8c79cef344e99ca68ba40ad91af3,pts,0.348411
uuid-034f8c79cef344e99ca68ba40ad91af3,agents,0.358018
uuid-034f8c79cef344e99ca68ba40ad91af3,preferred,0.569352
uuid-034f8c79cef344e99ca68ba40ad91af3,monotherapy,0.560255
uuid-034f8c79cef344e99ca68ba40ad91af3,using nivo,0.383967
uuid-034f8c79cef344e99ca68ba40ad91af3,combo,0.387991
uuid-034f8c79cef344e99ca68ba40ad91af3,clinical trials,0.306107
uuid-034f8c79cef344e99ca68ba40ad91af3,PD1,0.329752
uuid-034f8c79cef344e99ca68ba40ad91af3,believes,0.365856
uuid-034f8c79cef344e99ca68ba40ad91af3,chemotherapy,0.506095
uuid-034f8c79cef344e99ca68ba40ad91af3,feels,0.514982
uuid-034f8c79cef344e99ca68ba40ad91af3,RTL stated,0.377928
uuid-034f8c79cef344e99ca68ba40ad91af3,option,0.637177
uuid-bcf38768cc984cdeb6cc4d5570a980e3,trial,0.48299
uuid-bcf38768cc984cdeb6cc4d5570a980e3,efficacy,0.311583
uuid-bcf38768cc984cdeb6cc4d5570a980e3,combination,0.486217
uuid-bcf38768cc984cdeb6cc4d5570a980e3,chemo,0.368557
uuid-bcf38768cc984cdeb6cc4d5570a980e3,response,0.361642
uuid-bcf38768cc984cdeb6cc4d5570a980e3,combo,0.414572
uuid-bcf38768cc984cdeb6cc4d5570a980e3,ORR,0.328186
uuid-bcf38768cc984cdeb6cc4d5570a980e3,believes,0.316607
uuid-bcf38768cc984cdeb6cc4d5570a980e3,chemotherapy,0.316131
uuid-bcf38768cc984cdeb6cc4d5570a980e3,impressed,0.326159
uuid-bcf38768cc984cdeb6cc4d5570a980e3,feels,0.349441
uuid-d80b3cd4420249aab57262fb4ab4b183,RTL,0.416986
uuid-d80b3cd4420249aab57262fb4ab4b183,BMS,0.488588
uuid-d80b3cd4420249aab57262fb4ab4b183,trial,0.634917
uuid-d80b3cd4420249aab57262fb4ab4b183,efficacy,0.338329
uuid-d80b3cd4420249aab57262fb4ab4b183,NTL,0.360957
uuid-d80b3cd4420249aab57262fb4ab4b183,commented,0.547031
uuid-d80b3cd4420249aab57262fb4ab4b183,Merck,0.355038
uuid-d80b3cd4420249aab57262fb4ab4b183,stated,0.434986
uuid-d80b3cd4420249aab57262fb4ab4b183,OS,0.582936
uuid-d80b3cd4420249aab57262fb4ab4b183,regards,0.380198
uuid-d80b3cd4420249aab57262fb4ab4b183,data,0.796747
uuid-d80b3cd4420249aab57262fb4ab4b183,expressed,0.444134
uuid-d80b3cd4420249aab57262fb4ab4b183,mentioned,0.316669
uuid-d80b3cd4420249aab57262fb4ab4b183,PFS,0.585379
uuid-d80b3cd4420249aab57262fb4ab4b183,ORR,0.590112
uuid-d80b3cd4420249aab57262fb4ab4b183,nivo and pembro,0.362302
uuid-d80b3cd4420249aab57262fb4ab4b183,ASCO,0.419402
uuid-d80b3cd4420249aab57262fb4ab4b183,impressed,0.683374
uuid-d80b3cd4420249aab57262fb4ab4b183,TLs,0.321025
uuid-d80b3cd4420249aab57262fb4ab4b183,Regional TL,0.332118
uuid-17df74b2aa464c55b7f6d116ec7b0898,patients,0.317313
uuid-17df74b2aa464c55b7f6d116ec7b0898,1L,0.430005
uuid-17df74b2aa464c55b7f6d116ec7b0898,PDL1,0.470207
uuid-17df74b2aa464c55b7f6d116ec7b0898,TL stated,0.394002
uuid-17df74b2aa464c55b7f6d116ec7b0898,pts,0.343472
uuid-17df74b2aa464c55b7f6d116ec7b0898,PD-L1,0.436636
uuid-17df74b2aa464c55b7f6d116ec7b0898,PD-L1 testing,0.325764
uuid-17df74b2aa464c55b7f6d116ec7b0898,testing,0.463898
uuid-17df74b2aa464c55b7f6d116ec7b0898,PDL1 testing,0.451523
uuid-17df74b2aa464c55b7f6d116ec7b0898,NSCLC patients,0.560221
uuid-17df74b2aa464c55b7f6d116ec7b0898,impressed,0.34748
uuid-17df74b2aa464c55b7f6d116ec7b0898,tumor types,0.32937
uuid-17df74b2aa464c55b7f6d116ec7b0898,feels,0.313423
uuid-17df74b2aa464c55b7f6d116ec7b0898,PDL1 expression,0.333735
uuid-a459aad4c9784952bfb33ad3bcb421fa,commented,0.335716
uuid-a459aad4c9784952bfb33ad3bcb421fa,TL stated,0.342008
uuid-a459aad4c9784952bfb33ad3bcb421fa,lung cancer,0.480554
uuid-a459aad4c9784952bfb33ad3bcb421fa,ASCO,0.411752
uuid-a459aad4c9784952bfb33ad3bcb421fa,Regional TL,0.316653
uuid-c96c7efaedca4d4ab9bb3f047da35c58,RTL,0.419808
uuid-c96c7efaedca4d4ab9bb3f047da35c58,BMS,0.600824
uuid-c96c7efaedca4d4ab9bb3f047da35c58,trial,0.564908
uuid-c96c7efaedca4d4ab9bb3f047da35c58,discussed,0.344142
uuid-c96c7efaedca4d4ab9bb3f047da35c58,commented,0.578155
uuid-c96c7efaedca4d4ab9bb3f047da35c58,Merck,0.559229
uuid-c96c7efaedca4d4ab9bb3f047da35c58,stated,0.473367
uuid-c96c7efaedca4d4ab9bb3f047da35c58,approval,0.302385
uuid-c96c7efaedca4d4ab9bb3f047da35c58,OS,0.465284
uuid-c96c7efaedca4d4ab9bb3f047da35c58,regards,0.344516
uuid-c96c7efaedca4d4ab9bb3f047da35c58,data,0.876821
uuid-c96c7efaedca4d4ab9bb3f047da35c58,expressed,0.397887
uuid-c96c7efaedca4d4ab9bb3f047da35c58,clinical trials,0.327046
uuid-c96c7efaedca4d4ab9bb3f047da35c58,PFS,0.409817
uuid-c96c7efaedca4d4ab9bb3f047da35c58,ORR,0.482836
uuid-c96c7efaedca4d4ab9bb3f047da35c58,SCCHN,0.313626
uuid-c96c7efaedca4d4ab9bb3f047da35c58,ASCO,0.494376
uuid-c96c7efaedca4d4ab9bb3f047da35c58,impressed,0.727487
uuid-c96c7efaedca4d4ab9bb3f047da35c58,LTL,0.339557
uuid-c96c7efaedca4d4ab9bb3f047da35c58,Regional TL,0.394714
uuid-21f8c24261594ddea931b53f6864cf60,BMS,0.310827
uuid-21f8c24261594ddea931b53f6864cf60,PDL1,0.35037
uuid-21f8c24261594ddea931b53f6864cf60,trial,0.338036
uuid-21f8c24261594ddea931b53f6864cf60,efficacy,0.435009
uuid-21f8c24261594ddea931b53f6864cf60,discussed,0.317107
uuid-21f8c24261594ddea931b53f6864cf60,commented,0.322092
uuid-21f8c24261594ddea931b53f6864cf60,OS,0.660292
uuid-21f8c24261594ddea931b53f6864cf60,data,0.707937
uuid-21f8c24261594ddea931b53f6864cf60,PFS,0.59721
uuid-21f8c24261594ddea931b53f6864cf60,ORR,0.637868
uuid-21f8c24261594ddea931b53f6864cf60,ASCO,0.351156
uuid-21f8c24261594ddea931b53f6864cf60,impressed,0.60155
uuid-21f8c24261594ddea931b53f6864cf60,feels,0.389889
uuid-21f8c24261594ddea931b53f6864cf60,PDL1 expression,0.333003
uuid-123c142e3a804e04aa2b95e6f2297368,discussed,0.338397
uuid-123c142e3a804e04aa2b95e6f2297368,commented,0.526651
uuid-123c142e3a804e04aa2b95e6f2297368,regards,0.331596
uuid-123c142e3a804e04aa2b95e6f2297368,data,0.378152
uuid-123c142e3a804e04aa2b95e6f2297368,expressed,0.306347
uuid-123c142e3a804e04aa2b95e6f2297368,lung cancer,0.615006
uuid-123c142e3a804e04aa2b95e6f2297368,ASCO,0.496131
uuid-123c142e3a804e04aa2b95e6f2297368,Regional TL,0.337256
uuid-123c142e3a804e04aa2b95e6f2297368,biomarker,0.377033
uuid-361847f4e2504cd3b78b1dfbb2decdaf,Nivo,0.470665
uuid-361847f4e2504cd3b78b1dfbb2decdaf,pembro,0.548642
uuid-361847f4e2504cd3b78b1dfbb2decdaf,BMS,0.356861
uuid-361847f4e2504cd3b78b1dfbb2decdaf,1L,0.345868
uuid-361847f4e2504cd3b78b1dfbb2decdaf,PDL1,0.479568
uuid-361847f4e2504cd3b78b1dfbb2decdaf,trial,0.61701
uuid-361847f4e2504cd3b78b1dfbb2decdaf,efficacy,0.558581
uuid-361847f4e2504cd3b78b1dfbb2decdaf,chemo,0.311348
uuid-361847f4e2504cd3b78b1dfbb2decdaf,OS,0.589467
uuid-361847f4e2504cd3b78b1dfbb2decdaf,atezo,0.424331
uuid-361847f4e2504cd3b78b1dfbb2decdaf,data,0.762673
uuid-361847f4e2504cd3b78b1dfbb2decdaf,PFS,0.589526
uuid-361847f4e2504cd3b78b1dfbb2decdaf,ORR,0.62899
uuid-361847f4e2504cd3b78b1dfbb2decdaf,nivo and pembro,0.581095
uuid-361847f4e2504cd3b78b1dfbb2decdaf,believes,0.39525
uuid-361847f4e2504cd3b78b1dfbb2decdaf,impressed,0.505608
uuid-361847f4e2504cd3b78b1dfbb2decdaf,vs,0.327835
uuid-361847f4e2504cd3b78b1dfbb2decdaf,feels,0.457487
uuid-361847f4e2504cd3b78b1dfbb2decdaf,PDL1 expression,0.456975
uuid-8a79c44d513f4c99ad72e05c874ef2a0,NSCLC patients,0.358565
uuid-8a79c44d513f4c99ad72e05c874ef2a0,lung cancer,0.492928
uuid-8a79c44d513f4c99ad72e05c874ef2a0,tumor types,0.366489
uuid-36561f3586224308aaf16c194db81c45,Nivo,0.526497
uuid-36561f3586224308aaf16c194db81c45,pembro,0.719438
uuid-36561f3586224308aaf16c194db81c45,dose,0.635034
uuid-36561f3586224308aaf16c194db81c45,1L,0.487012
uuid-36561f3586224308aaf16c194db81c45,2L,0.644764
uuid-36561f3586224308aaf16c194db81c45,agents,0.409297
uuid-36561f3586224308aaf16c194db81c45,Ipi,0.470118
uuid-36561f3586224308aaf16c194db81c45,approval,0.300632
uuid-36561f3586224308aaf16c194db81c45,atezo,0.75256
uuid-36561f3586224308aaf16c194db81c45,preferred,0.64452
uuid-36561f3586224308aaf16c194db81c45,monotherapy,0.448955
uuid-36561f3586224308aaf16c194db81c45,using nivo,0.482018
uuid-36561f3586224308aaf16c194db81c45,combo,0.366256
uuid-36561f3586224308aaf16c194db81c45,indication,0.363433
uuid-36561f3586224308aaf16c194db81c45,approved,0.47662
uuid-36561f3586224308aaf16c194db81c45,vs,0.605009
uuid-36561f3586224308aaf16c194db81c45,Keytruda,0.325585
uuid-36561f3586224308aaf16c194db81c45,option,0.483043
uuid-36561f3586224308aaf16c194db81c45,flat dosing,0.453354
uuid-2906011b992142c1badab0419cb94c34,Nivo,0.469058
uuid-2906011b992142c1badab0419cb94c34,pembro,0.579689
uuid-2906011b992142c1badab0419cb94c34,trial,0.686977
uuid-2906011b992142c1badab0419cb94c34,efficacy,0.487465
uuid-2906011b992142c1badab0419cb94c34,Ipi,0.405628
uuid-2906011b992142c1badab0419cb94c34,OS,0.383645
uuid-2906011b992142c1badab0419cb94c34,atezo,0.423325
uuid-2906011b992142c1badab0419cb94c34,data,0.467133
uuid-2906011b992142c1badab0419cb94c34,clinical trials,0.377574
uuid-2906011b992142c1badab0419cb94c34,PFS,0.394568
uuid-2906011b992142c1badab0419cb94c34,ORR,0.467208
uuid-2906011b992142c1badab0419cb94c34,nivo and pembro,0.404806
uuid-2906011b992142c1badab0419cb94c34,impressed,0.37099
uuid-2906011b992142c1badab0419cb94c34,vs,0.531857
uuid-2906011b992142c1badab0419cb94c34,feels,0.489202
uuid-2906011b992142c1badab0419cb94c34,PDL1 expression,0.307264
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,Nivo,0.390972
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,pembro,0.431274
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,PDL1,0.402353
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,trial,0.565115
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,efficacy,0.443626
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,OS,0.445625
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,data,0.430123
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,clinical trials,0.30445
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,PFS,0.534842
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,ORR,0.532858
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,nivo and pembro,0.552986
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,vs,0.433631
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,feels,0.369788
uuid-cbc50169b07f4afdbcfedd03f1f0b9cf,PDL1 expression,0.476946
uuid-1002b43954f54f21bb4f6d29ef84d557,nivolumab,0.369986
uuid-1002b43954f54f21bb4f6d29ef84d557,RCC,0.37872
uuid-1002b43954f54f21bb4f6d29ef84d557,approval,0.374093
uuid-1002b43954f54f21bb4f6d29ef84d557,approved,0.377169
uuid-1002b43954f54f21bb4f6d29ef84d557,RTL stated,0.32489
uuid-1002b43954f54f21bb4f6d29ef84d557,TL shared,0.319121
uuid-76497b272c57412ebf0ddfc8f1c95fa7,therapy,0.457375
uuid-76497b272c57412ebf0ddfc8f1c95fa7,tumor,0.515072
uuid-76497b272c57412ebf0ddfc8f1c95fa7,pts,0.342055
uuid-76497b272c57412ebf0ddfc8f1c95fa7,response,0.556903
uuid-76497b272c57412ebf0ddfc8f1c95fa7,immunotherapy,0.334732
uuid-c29acfcc328e4ad7861bdb41f6d5c940,Nivo,0.543238
uuid-c29acfcc328e4ad7861bdb41f6d5c940,patients,0.497308
uuid-c29acfcc328e4ad7861bdb41f6d5c940,therapy,0.593559
uuid-c29acfcc328e4ad7861bdb41f6d5c940,nivolumab,0.385469
uuid-c29acfcc328e4ad7861bdb41f6d5c940,regimen,0.496369
uuid-c29acfcc328e4ad7861bdb41f6d5c940,treated,0.398952
uuid-c29acfcc328e4ad7861bdb41f6d5c940,combination,0.478609
uuid-c29acfcc328e4ad7861bdb41f6d5c940,chemo,0.673968
uuid-c29acfcc328e4ad7861bdb41f6d5c940,2L,0.304397
uuid-c29acfcc328e4ad7861bdb41f6d5c940,pts,0.587144
uuid-c29acfcc328e4ad7861bdb41f6d5c940,IO,0.353179
uuid-c29acfcc328e4ad7861bdb41f6d5c940,agents,0.319963
uuid-c29acfcc328e4ad7861bdb41f6d5c940,monotherapy,0.588329
uuid-c29acfcc328e4ad7861bdb41f6d5c940,treatment,0.513654
uuid-c29acfcc328e4ad7861bdb41f6d5c940,using nivo,0.319769
uuid-c29acfcc328e4ad7861bdb41f6d5c940,response,0.707043
uuid-c29acfcc328e4ad7861bdb41f6d5c940,combo,0.365838
uuid-c29acfcc328e4ad7861bdb41f6d5c940,PD1,0.589358
uuid-c29acfcc328e4ad7861bdb41f6d5c940,progression,0.636924
uuid-c29acfcc328e4ad7861bdb41f6d5c940,believes,0.344612
uuid-c29acfcc328e4ad7861bdb41f6d5c940,chemotherapy,0.540769
uuid-c29acfcc328e4ad7861bdb41f6d5c940,respond,0.570236
uuid-c29acfcc328e4ad7861bdb41f6d5c940,feels,0.370778
uuid-c29acfcc328e4ad7861bdb41f6d5c940,option,0.492029
uuid-2fe3365235044636a7b08058249e0e63,commented,0.323908
uuid-2fe3365235044636a7b08058249e0e63,tumor,0.525834
uuid-2fe3365235044636a7b08058249e0e63,data,0.337485
uuid-2fe3365235044636a7b08058249e0e63,clinical trials,0.321263
uuid-2fe3365235044636a7b08058249e0e63,impressed,0.314532
uuid-2fe3365235044636a7b08058249e0e63,tumor types,0.455436
uuid-2fe3365235044636a7b08058249e0e63,bladder,0.341778
uuid-451791aa12fd49f8ad85e442a74fe432,regimen,0.345137
uuid-451791aa12fd49f8ad85e442a74fe432,melanoma,0.410693
uuid-451791aa12fd49f8ad85e442a74fe432,treatment,0.31503
uuid-451791aa12fd49f8ad85e442a74fe432,TL shared,0.313168
uuid-451791aa12fd49f8ad85e442a74fe432,NCCN,0.304569
uuid-af37be5fecd44b06b259a4ea004de675,RTL,0.424095
uuid-af37be5fecd44b06b259a4ea004de675,BMS,0.413247
uuid-af37be5fecd44b06b259a4ea004de675,trial,0.445348
uuid-af37be5fecd44b06b259a4ea004de675,efficacy,0.327974
uuid-af37be5fecd44b06b259a4ea004de675,commented,0.513268
uuid-af37be5fecd44b06b259a4ea004de675,Merck,0.30384
uuid-af37be5fecd44b06b259a4ea004de675,stated,0.365147
uuid-af37be5fecd44b06b259a4ea004de675,OS,0.529209
uuid-af37be5fecd44b06b259a4ea004de675,regards,0.323801
uuid-af37be5fecd44b06b259a4ea004de675,data,0.840185
uuid-af37be5fecd44b06b259a4ea004de675,expressed,0.335686
uuid-af37be5fecd44b06b259a4ea004de675,PFS,0.519126
uuid-af37be5fecd44b06b259a4ea004de675,ORR,0.546312
uuid-af37be5fecd44b06b259a4ea004de675,ASCO,0.560308
uuid-af37be5fecd44b06b259a4ea004de675,impressed,0.718313
uuid-af37be5fecd44b06b259a4ea004de675,LTL,0.312311
uuid-af37be5fecd44b06b259a4ea004de675,Regional TL,0.317008
uuid-fdaa55da549b4344933dc8d45378d958,discussed,0.499517
uuid-fdaa55da549b4344933dc8d45378d958,academic,0.477548
uuid-c541291c4ff84a4a9b19bb868114f018,BMS,0.404942
uuid-c541291c4ff84a4a9b19bb868114f018,trial,0.545004
uuid-c541291c4ff84a4a9b19bb868114f018,combination,0.312924
uuid-c541291c4ff84a4a9b19bb868114f018,IO,0.310046
uuid-c541291c4ff84a4a9b19bb868114f018,OS,0.409849
uuid-c541291c4ff84a4a9b19bb868114f018,data,0.426112
uuid-c541291c4ff84a4a9b19bb868114f018,PFS,0.369853
uuid-c541291c4ff84a4a9b19bb868114f018,ORR,0.370684
uuid-c541291c4ff84a4a9b19bb868114f018,impressed,0.362718
uuid-c541291c4ff84a4a9b19bb868114f018,feels,0.402406
uuid-17062ce82447470dacb4c97ceb547bb2,Nivo,0.312433
uuid-17062ce82447470dacb4c97ceb547bb2,1L,0.427423
uuid-17062ce82447470dacb4c97ceb547bb2,chemo,0.430381
uuid-17062ce82447470dacb4c97ceb547bb2,2L,0.456854
uuid-17062ce82447470dacb4c97ceb547bb2,agents,0.540608
uuid-17062ce82447470dacb4c97ceb547bb2,atezo,0.337207
uuid-17062ce82447470dacb4c97ceb547bb2,preferred,0.428204
uuid-17062ce82447470dacb4c97ceb547bb2,monotherapy,0.369662
uuid-17062ce82447470dacb4c97ceb547bb2,combo,0.335506
uuid-17062ce82447470dacb4c97ceb547bb2,PD1,0.393796
uuid-17062ce82447470dacb4c97ceb547bb2,believes,0.428086
uuid-17062ce82447470dacb4c97ceb547bb2,vs,0.309751
uuid-17062ce82447470dacb4c97ceb547bb2,option,0.462786
uuid-4fb3bb0871fc4d35a8aa46031a6f348e,therapy,0.362032
uuid-4fb3bb0871fc4d35a8aa46031a6f348e,discussed,0.614735
uuid-4fb3bb0871fc4d35a8aa46031a6f348e,cHL,0.395277
uuid-4fb3bb0871fc4d35a8aa46031a6f348e,academic,0.58486
uuid-7c8ca550e43e478c867c8868a4ea724c,efficacy,0.352294
uuid-7c8ca550e43e478c867c8868a4ea724c,physicians,0.335126
uuid-7c8ca550e43e478c867c8868a4ea724c,impressed,0.342283
uuid-9c80d69a03ee4980b71682e89e6455e1,lung,0.319211
uuid-9c80d69a03ee4980b71682e89e6455e1,regimen,0.40149
uuid-9c80d69a03ee4980b71682e89e6455e1,melanoma,0.357393
uuid-9c80d69a03ee4980b71682e89e6455e1,treatment,0.342792
uuid-9c80d69a03ee4980b71682e89e6455e1,AI,0.667091
uuid-9c80d69a03ee4980b71682e89e6455e1,progression,0.303174
uuid-9c80d69a03ee4980b71682e89e6455e1,drug,0.304376
uuid-8b2ecf9a62554858ab60a345f47cfdf7,pembro,0.363344
uuid-8b2ecf9a62554858ab60a345f47cfdf7,BMS,0.402558
uuid-8b2ecf9a62554858ab60a345f47cfdf7,PDL1,0.563802
uuid-8b2ecf9a62554858ab60a345f47cfdf7,trial,0.514935
uuid-8b2ecf9a62554858ab60a345f47cfdf7,efficacy,0.335137
uuid-8b2ecf9a62554858ab60a345f47cfdf7,Merck,0.413276
uuid-8b2ecf9a62554858ab60a345f47cfdf7,OS,0.408289
uuid-8b2ecf9a62554858ab60a345f47cfdf7,atezo,0.316927
uuid-8b2ecf9a62554858ab60a345f47cfdf7,data,0.647857
uuid-8b2ecf9a62554858ab60a345f47cfdf7,PFS,0.4223
uuid-8b2ecf9a62554858ab60a345f47cfdf7,ORR,0.46061
uuid-8b2ecf9a62554858ab60a345f47cfdf7,nivo and pembro,0.464611
uuid-8b2ecf9a62554858ab60a345f47cfdf7,believes,0.306858
uuid-8b2ecf9a62554858ab60a345f47cfdf7,impressed,0.431871
uuid-8b2ecf9a62554858ab60a345f47cfdf7,feels,0.313948
uuid-8b2ecf9a62554858ab60a345f47cfdf7,PDL1 expression,0.523434
uuid-8b2ecf9a62554858ab60a345f47cfdf7,biomarker,0.405827
uuid-8b2ecf9a62554858ab60a345f47cfdf7,bladder,0.306348
uuid-493be146be4643bc9a16acf2ec4d746f,Opdivo,0.52459
uuid-493be146be4643bc9a16acf2ec4d746f,RTL,0.321413
uuid-493be146be4643bc9a16acf2ec4d746f,nivolumab,0.392082
uuid-493be146be4643bc9a16acf2ec4d746f,shared,0.368066
uuid-493be146be4643bc9a16acf2ec4d746f,commented,0.334973
uuid-493be146be4643bc9a16acf2ec4d746f,stated,0.504849
uuid-493be146be4643bc9a16acf2ec4d746f,approval,0.391564
uuid-493be146be4643bc9a16acf2ec4d746f,physicians,0.440268
uuid-493be146be4643bc9a16acf2ec4d746f,using nivo,0.332305
uuid-493be146be4643bc9a16acf2ec4d746f,clinical trials,0.402158
uuid-493be146be4643bc9a16acf2ec4d746f,indication,0.364683
uuid-493be146be4643bc9a16acf2ec4d746f,approved,0.346652
uuid-493be146be4643bc9a16acf2ec4d746f,SCCHN,0.42108
uuid-493be146be4643bc9a16acf2ec4d746f,HCP,0.383834
uuid-493be146be4643bc9a16acf2ec4d746f,impressed,0.375103
uuid-493be146be4643bc9a16acf2ec4d746f,tumor types,0.332482
uuid-493be146be4643bc9a16acf2ec4d746f,LTL,0.445861
uuid-493be146be4643bc9a16acf2ec4d746f,Regional TL,0.486519
uuid-493be146be4643bc9a16acf2ec4d746f,RTL stated,0.307546
uuid-493be146be4643bc9a16acf2ec4d746f,bladder,0.303884
uuid-e8b63189f76e4b369f633bf791d93690,patients,0.443341
uuid-e8b63189f76e4b369f633bf791d93690,Opdivo,0.336259
uuid-e8b63189f76e4b369f633bf791d93690,therapy,0.544608
uuid-e8b63189f76e4b369f633bf791d93690,nivolumab,0.484767
uuid-e8b63189f76e4b369f633bf791d93690,treated,0.340557
uuid-e8b63189f76e4b369f633bf791d93690,approval,0.365084
uuid-e8b63189f76e4b369f633bf791d93690,using nivo,0.379474
uuid-e8b63189f76e4b369f633bf791d93690,mentioned,0.339486
uuid-e8b63189f76e4b369f633bf791d93690,cHL,0.793148
uuid-005dc0da990a4ada94bd61b3c5418b51,patients,0.559267
uuid-005dc0da990a4ada94bd61b3c5418b51,Opdivo,0.404597
uuid-005dc0da990a4ada94bd61b3c5418b51,therapy,0.548723
uuid-005dc0da990a4ada94bd61b3c5418b51,nivolumab,0.45086
uuid-005dc0da990a4ada94bd61b3c5418b51,treated,0.410421
uuid-005dc0da990a4ada94bd61b3c5418b51,approval,0.377828
uuid-005dc0da990a4ada94bd61b3c5418b51,treatment,0.422124
uuid-005dc0da990a4ada94bd61b3c5418b51,cHL,0.616141
uuid-110764a4b930459686e256e4d72a717f,patients,0.381647
uuid-110764a4b930459686e256e4d72a717f,nivolumab,0.549638
uuid-110764a4b930459686e256e4d72a717f,treated,0.465565
uuid-110764a4b930459686e256e4d72a717f,pts,0.353056
uuid-110764a4b930459686e256e4d72a717f,physicians,0.31507
uuid-110764a4b930459686e256e4d72a717f,treatment,0.365094
uuid-110764a4b930459686e256e4d72a717f,PD1,0.374486
uuid-110764a4b930459686e256e4d72a717f,progression,0.355511
uuid-031fe1d4e4cf402bb9da824c6c17762b,patients,0.365084
uuid-031fe1d4e4cf402bb9da824c6c17762b,treatment,0.306819
uuid-3b32234790174747b7a77c1ac7f57e0c,Nivo,0.49333
uuid-3b32234790174747b7a77c1ac7f57e0c,efficacy,0.344271
uuid-3b32234790174747b7a77c1ac7f57e0c,chemo,0.411103
uuid-3b32234790174747b7a77c1ac7f57e0c,pts,0.31048
uuid-3b32234790174747b7a77c1ac7f57e0c,OS,0.553384
uuid-3b32234790174747b7a77c1ac7f57e0c,response,0.423876
uuid-3b32234790174747b7a77c1ac7f57e0c,data,0.405949
uuid-3b32234790174747b7a77c1ac7f57e0c,PFS,0.543536
uuid-3b32234790174747b7a77c1ac7f57e0c,ORR,0.499151
uuid-3b32234790174747b7a77c1ac7f57e0c,progression,0.335022
uuid-3b32234790174747b7a77c1ac7f57e0c,chemotherapy,0.375442
uuid-3b32234790174747b7a77c1ac7f57e0c,impressed,0.42189
uuid-3b32234790174747b7a77c1ac7f57e0c,feels,0.30752
uuid-a8e2742cb7a14f84840c5960f007f928,TL,0.308838
uuid-a8e2742cb7a14f84840c5960f007f928,PDL1,0.666239
uuid-a8e2742cb7a14f84840c5960f007f928,trial,0.341684
uuid-a8e2742cb7a14f84840c5960f007f928,efficacy,0.426216
uuid-a8e2742cb7a14f84840c5960f007f928,Merck,0.441673
uuid-a8e2742cb7a14f84840c5960f007f928,PD-L1,0.538069
uuid-a8e2742cb7a14f84840c5960f007f928,OS,0.371255
uuid-a8e2742cb7a14f84840c5960f007f928,atezo,0.30156
uuid-a8e2742cb7a14f84840c5960f007f928,PD-L1 testing,0.323563
uuid-a8e2742cb7a14f84840c5960f007f928,testing,0.374806
uuid-a8e2742cb7a14f84840c5960f007f928,data,0.413311
uuid-a8e2742cb7a14f84840c5960f007f928,PFS,0.450413
uuid-a8e2742cb7a14f84840c5960f007f928,ORR,0.396119
uuid-a8e2742cb7a14f84840c5960f007f928,nivo and pembro,0.54815
uuid-a8e2742cb7a14f84840c5960f007f928,assay,0.764202
uuid-a8e2742cb7a14f84840c5960f007f928,PDL1 expression,0.542409
uuid-a8e2742cb7a14f84840c5960f007f928,biomarker,0.457243
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,patients,0.507322
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,toxicity,0.572747
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,regimen,0.516371
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,treated,0.451583
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,treatment,0.478156
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,progression,0.35048
uuid-6c03b214fb69402c83f2e4f1fb3c54b9,respond,0.359529
uuid-b5e1930423c9450c8c2a67a3d147b7a7,pembro,0.582225
uuid-b5e1930423c9450c8c2a67a3d147b7a7,1L,0.492358
uuid-b5e1930423c9450c8c2a67a3d147b7a7,PDL1,0.604696
uuid-b5e1930423c9450c8c2a67a3d147b7a7,efficacy,0.370219
uuid-b5e1930423c9450c8c2a67a3d147b7a7,2L,0.49858
uuid-b5e1930423c9450c8c2a67a3d147b7a7,agents,0.449817
uuid-b5e1930423c9450c8c2a67a3d147b7a7,Merck,0.366866
uuid-b5e1930423c9450c8c2a67a3d147b7a7,PD-L1,0.54475
uuid-b5e1930423c9450c8c2a67a3d147b7a7,atezo,0.670717
uuid-b5e1930423c9450c8c2a67a3d147b7a7,preferred,0.524837
uuid-b5e1930423c9450c8c2a67a3d147b7a7,PD-L1 testing,0.300495
uuid-b5e1930423c9450c8c2a67a3d147b7a7,testing,0.457905
uuid-b5e1930423c9450c8c2a67a3d147b7a7,PDL1 testing,0.454139
uuid-b5e1930423c9450c8c2a67a3d147b7a7,indication,0.480428
uuid-b5e1930423c9450c8c2a67a3d147b7a7,NSCLC patients,0.346637
uuid-b5e1930423c9450c8c2a67a3d147b7a7,approved,0.400775
uuid-b5e1930423c9450c8c2a67a3d147b7a7,nivo and pembro,0.493757
uuid-b5e1930423c9450c8c2a67a3d147b7a7,believes,0.326765
uuid-b5e1930423c9450c8c2a67a3d147b7a7,assay,0.405562
uuid-b5e1930423c9450c8c2a67a3d147b7a7,PDL1 expression,0.516273
uuid-b5e1930423c9450c8c2a67a3d147b7a7,option,0.320977
uuid-b5e1930423c9450c8c2a67a3d147b7a7,biomarker,0.437409
uuid-b5e1930423c9450c8c2a67a3d147b7a7,bladder,0.345432
uuid-da7ed358f0d142e1acd954c49a269e60,Nivo,0.322546
uuid-da7ed358f0d142e1acd954c49a269e60,pembro,0.415737
uuid-da7ed358f0d142e1acd954c49a269e60,nivolumab,0.408711
uuid-da7ed358f0d142e1acd954c49a269e60,1L,0.67326
uuid-da7ed358f0d142e1acd954c49a269e60,regimen,0.333585
uuid-da7ed358f0d142e1acd954c49a269e60,RCC,0.703886
uuid-da7ed358f0d142e1acd954c49a269e60,TL stated,0.327225
uuid-da7ed358f0d142e1acd954c49a269e60,combination,0.439175
uuid-da7ed358f0d142e1acd954c49a269e60,chemo,0.302679
uuid-da7ed358f0d142e1acd954c49a269e60,2L,0.807694
uuid-da7ed358f0d142e1acd954c49a269e60,agents,0.63942
uuid-da7ed358f0d142e1acd954c49a269e60,approval,0.337829
uuid-da7ed358f0d142e1acd954c49a269e60,atezo,0.485182
uuid-da7ed358f0d142e1acd954c49a269e60,preferred,0.817794
uuid-da7ed358f0d142e1acd954c49a269e60,monotherapy,0.684648
uuid-da7ed358f0d142e1acd954c49a269e60,using nivo,0.681766
uuid-da7ed358f0d142e1acd954c49a269e60,combo,0.486938
uuid-da7ed358f0d142e1acd954c49a269e60,indication,0.345434
uuid-da7ed358f0d142e1acd954c49a269e60,PD1,0.374794
uuid-da7ed358f0d142e1acd954c49a269e60,approved,0.554667
uuid-da7ed358f0d142e1acd954c49a269e60,SCCHN,0.462606
uuid-da7ed358f0d142e1acd954c49a269e60,tumor types,0.378328
uuid-da7ed358f0d142e1acd954c49a269e60,RTL stated,0.653271
uuid-da7ed358f0d142e1acd954c49a269e60,TL shared,0.42345
uuid-da7ed358f0d142e1acd954c49a269e60,option,0.652216
uuid-da7ed358f0d142e1acd954c49a269e60,bladder,0.402986
uuid-bde57fd6fd674b0e8c3770057829b93e,trial,0.303472
uuid-bde57fd6fd674b0e8c3770057829b93e,combination,0.425702
uuid-bde57fd6fd674b0e8c3770057829b93e,chemo,0.312184
uuid-bde57fd6fd674b0e8c3770057829b93e,tumor,0.517031
uuid-bde57fd6fd674b0e8c3770057829b93e,response,0.345814
uuid-bde57fd6fd674b0e8c3770057829b93e,PD1,0.317885
uuid-bde57fd6fd674b0e8c3770057829b93e,immunotherapy,0.302008
uuid-530fbf1122d445c5be0d01013065204b,patients,0.493047
uuid-530fbf1122d445c5be0d01013065204b,Opdivo,0.373926
uuid-530fbf1122d445c5be0d01013065204b,1L,0.391282
uuid-530fbf1122d445c5be0d01013065204b,treated,0.415005
uuid-530fbf1122d445c5be0d01013065204b,RCC,0.383766
uuid-530fbf1122d445c5be0d01013065204b,TL stated,0.443952
uuid-530fbf1122d445c5be0d01013065204b,2L,0.415888
uuid-530fbf1122d445c5be0d01013065204b,pts,0.422247
uuid-530fbf1122d445c5be0d01013065204b,preferred,0.41963
uuid-530fbf1122d445c5be0d01013065204b,PD-L1 testing,0.324062
uuid-530fbf1122d445c5be0d01013065204b,testing,0.394976
uuid-530fbf1122d445c5be0d01013065204b,monotherapy,0.333289
uuid-530fbf1122d445c5be0d01013065204b,treatment,0.344549
uuid-530fbf1122d445c5be0d01013065204b,using nivo,0.42848
uuid-530fbf1122d445c5be0d01013065204b,PDL1 testing,0.515905
uuid-530fbf1122d445c5be0d01013065204b,NSCLC patients,0.518149
uuid-530fbf1122d445c5be0d01013065204b,SCCHN,0.363999
uuid-530fbf1122d445c5be0d01013065204b,tumor types,0.380915
uuid-530fbf1122d445c5be0d01013065204b,RTL stated,0.453514
uuid-530fbf1122d445c5be0d01013065204b,TL shared,0.354883
uuid-530fbf1122d445c5be0d01013065204b,option,0.37263
uuid-c7387c30a49f45dfa1d3c410c160bb65,patients,0.346007
uuid-c7387c30a49f45dfa1d3c410c160bb65,RTL,0.461842
uuid-c7387c30a49f45dfa1d3c410c160bb65,therapy,0.3796
uuid-c7387c30a49f45dfa1d3c410c160bb65,nivolumab,0.428503
uuid-c7387c30a49f45dfa1d3c410c160bb65,treated,0.330717
uuid-c7387c30a49f45dfa1d3c410c160bb65,NTL,0.397526
uuid-c7387c30a49f45dfa1d3c410c160bb65,mentioned,0.421339
uuid-c7387c30a49f45dfa1d3c410c160bb65,cHL,0.552899
uuid-23d0146d55104725995bc085df74d706,TL,0.624478
uuid-23d0146d55104725995bc085df74d706,PDL1,0.348384
uuid-23d0146d55104725995bc085df74d706,TL stated,0.373098
uuid-23d0146d55104725995bc085df74d706,Merck,0.307304
uuid-23d0146d55104725995bc085df74d706,institution,0.360893
uuid-23d0146d55104725995bc085df74d706,PD-L1,0.783026
uuid-23d0146d55104725995bc085df74d706,PD-L1 testing,0.882403
uuid-23d0146d55104725995bc085df74d706,testing,0.883602
uuid-23d0146d55104725995bc085df74d706,PDL1 testing,0.656711
uuid-23d0146d55104725995bc085df74d706,NSCLC patients,0.577254
uuid-23d0146d55104725995bc085df74d706,assay,0.813228
uuid-23d0146d55104725995bc085df74d706,biomarker,0.406344
uuid-9772d86f1ce6474397685f27d9938530,patients,0.510053
uuid-9772d86f1ce6474397685f27d9938530,therapy,0.392593
uuid-9772d86f1ce6474397685f27d9938530,dose,0.391382
uuid-9772d86f1ce6474397685f27d9938530,toxicity,0.58892
uuid-9772d86f1ce6474397685f27d9938530,regimen,0.625737
uuid-9772d86f1ce6474397685f27d9938530,combination,0.458587
uuid-9772d86f1ce6474397685f27d9938530,chemo,0.515036
uuid-9772d86f1ce6474397685f27d9938530,pts,0.328962
uuid-9772d86f1ce6474397685f27d9938530,IO,0.596783
uuid-9772d86f1ce6474397685f27d9938530,agents,0.326615
uuid-9772d86f1ce6474397685f27d9938530,Ipi,0.301734
uuid-9772d86f1ce6474397685f27d9938530,preferred,0.308822
uuid-9772d86f1ce6474397685f27d9938530,monotherapy,0.578107
uuid-9772d86f1ce6474397685f27d9938530,treatment,0.434261
uuid-9772d86f1ce6474397685f27d9938530,response,0.343394
uuid-9772d86f1ce6474397685f27d9938530,combo,0.452153
uuid-9772d86f1ce6474397685f27d9938530,PD1,0.378517
uuid-9772d86f1ce6474397685f27d9938530,progression,0.469213
uuid-9772d86f1ce6474397685f27d9938530,believes,0.309558
uuid-9772d86f1ce6474397685f27d9938530,chemotherapy,0.459234
uuid-9772d86f1ce6474397685f27d9938530,vs,0.321874
uuid-9772d86f1ce6474397685f27d9938530,respond,0.364205
uuid-9772d86f1ce6474397685f27d9938530,option,0.431401
uuid-07b8258f69614699bc7131ef0548e560,patients,0.475099
uuid-07b8258f69614699bc7131ef0548e560,Opdivo,0.470048
uuid-07b8258f69614699bc7131ef0548e560,nivolumab,0.315907
uuid-07b8258f69614699bc7131ef0548e560,treated,0.338898
uuid-07b8258f69614699bc7131ef0548e560,approval,0.458673
uuid-07b8258f69614699bc7131ef0548e560,physicians,0.361749
uuid-07b8258f69614699bc7131ef0548e560,treatment,0.301163
uuid-07b8258f69614699bc7131ef0548e560,clinical trials,0.345111
uuid-07b8258f69614699bc7131ef0548e560,approved,0.349317
uuid-07b8258f69614699bc7131ef0548e560,cHL,0.317825
uuid-07b8258f69614699bc7131ef0548e560,label,0.305392
uuid-88e9eeba56894a9d82d8132f4ab85334,patients,0.556435
uuid-88e9eeba56894a9d82d8132f4ab85334,Opdivo,0.662555
uuid-88e9eeba56894a9d82d8132f4ab85334,physicians,0.420317
uuid-88e9eeba56894a9d82d8132f4ab85334,treatment,0.445259
uuid-88e9eeba56894a9d82d8132f4ab85334,progression,0.366748
uuid-88e9eeba56894a9d82d8132f4ab85334,respond,0.330314
uuid-88e9eeba56894a9d82d8132f4ab85334,drug,0.510931
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,Nivo,0.333972
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,patients,0.623447
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,Opdivo,0.449669
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,therapy,0.407453
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,dose,0.695659
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,nivolumab,0.36814
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,toxicity,0.63302
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,regimen,0.754259
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,treated,0.346452
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,combination,0.378782
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,chemo,0.418644
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,pts,0.438972
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,Ipi,0.474391
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,monotherapy,0.419985
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,treatment,0.609703
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,response,0.426786
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,combo,0.352216
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,progression,0.59376
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,chemotherapy,0.391351
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,respond,0.483709
uuid-d97d2fe8ccbc4188b6203ecefcaacbac,flat dosing,0.333338
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,Nivo,0.305883
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,trial,0.301592
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,AI,0.382472
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,SCCHN,0.344365
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,SCLC,0.381347
uuid-8b1c618f40e6445ca31d0ca6be76cf6f,NCCN,0.580924
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,patients,0.372289
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,Opdivo,0.619984
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,approval,0.321266
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,physicians,0.50609
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,treatment,0.378044
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,oncology,0.429373
uuid-8b2d53a7996f4d2b9f1927f8f88a8bd0,flat dosing,0.340916
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,patients,0.428916
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,trial,0.38949
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,chemo,0.331542
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,pts,0.361854
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,clinical trials,0.359821
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,ORR,0.315973
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,chemotherapy,0.399775
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,impressed,0.312199
uuid-8d91ccb94f2e49cbaa2c069e68483a4f,feels,0.333643
uuid-a64ac50026d44d57a2079dd9de14820c,trial,0.328284
uuid-a64ac50026d44d57a2079dd9de14820c,efficacy,0.325274
uuid-a64ac50026d44d57a2079dd9de14820c,commented,0.490217
uuid-a64ac50026d44d57a2079dd9de14820c,OS,0.471569
uuid-a64ac50026d44d57a2079dd9de14820c,regards,0.437642
uuid-a64ac50026d44d57a2079dd9de14820c,data,0.746536
uuid-a64ac50026d44d57a2079dd9de14820c,mentioned,0.328451
uuid-a64ac50026d44d57a2079dd9de14820c,PFS,0.464504
uuid-a64ac50026d44d57a2079dd9de14820c,AI,0.304241
uuid-a64ac50026d44d57a2079dd9de14820c,ORR,0.47141
uuid-a64ac50026d44d57a2079dd9de14820c,nivo and pembro,0.459432
uuid-a64ac50026d44d57a2079dd9de14820c,ASCO,0.430631
uuid-a64ac50026d44d57a2079dd9de14820c,impressed,0.520921
uuid-a64ac50026d44d57a2079dd9de14820c,SCLC,0.36661
uuid-a64ac50026d44d57a2079dd9de14820c,NCCN,0.5455
uuid-dc0a5c85f1cf4e2d97f329342c741cd7,patients,0.392557
uuid-dc0a5c85f1cf4e2d97f329342c741cd7,Opdivo,0.411236
uuid-dc0a5c85f1cf4e2d97f329342c741cd7,treated,0.326595
uuid-dc0a5c85f1cf4e2d97f329342c741cd7,physicians,0.571929
uuid-dc0a5c85f1cf4e2d97f329342c741cd7,treatment,0.36056
uuid-e9165e904205431492e45965aec6f7e4,discussed,0.794588
uuid-e9165e904205431492e45965aec6f7e4,academic,0.701154
uuid-cc40a61b2be84688863e9ed09c137fd2,discussed,0.698136
uuid-cc40a61b2be84688863e9ed09c137fd2,cHL,0.301511
uuid-cc40a61b2be84688863e9ed09c137fd2,academic,0.665381
uuid-78968f016c4d4e6c9b01b59b84f8b193,discussed,0.729005
uuid-78968f016c4d4e6c9b01b59b84f8b193,academic,0.699898
uuid-335a741a39414601ae68833a1f04acaf,patients,0.690506
uuid-335a741a39414601ae68833a1f04acaf,Opdivo,0.404522
uuid-335a741a39414601ae68833a1f04acaf,therapy,0.461058
uuid-335a741a39414601ae68833a1f04acaf,nivolumab,0.4321
uuid-335a741a39414601ae68833a1f04acaf,toxicity,0.48821
uuid-335a741a39414601ae68833a1f04acaf,regimen,0.589216
uuid-335a741a39414601ae68833a1f04acaf,treated,0.559467
uuid-335a741a39414601ae68833a1f04acaf,pts,0.415223
uuid-335a741a39414601ae68833a1f04acaf,treatment,0.651326
uuid-335a741a39414601ae68833a1f04acaf,progression,0.584783
uuid-335a741a39414601ae68833a1f04acaf,respond,0.445665
uuid-335a741a39414601ae68833a1f04acaf,TL shared,0.352736
uuid-6082404be929432b80c045998f602efb,patients,0.376586
uuid-6082404be929432b80c045998f602efb,toxicity,0.529406
uuid-6082404be929432b80c045998f602efb,regimen,0.576582
uuid-6082404be929432b80c045998f602efb,treated,0.318076
uuid-6082404be929432b80c045998f602efb,combination,0.458443
uuid-6082404be929432b80c045998f602efb,chemo,0.380657
uuid-6082404be929432b80c045998f602efb,pts,0.31195
uuid-6082404be929432b80c045998f602efb,Ipi,0.451911
uuid-6082404be929432b80c045998f602efb,monotherapy,0.458542
uuid-6082404be929432b80c045998f602efb,treatment,0.363987
uuid-6082404be929432b80c045998f602efb,combo,0.562668
uuid-6082404be929432b80c045998f602efb,PD1,0.305205
uuid-6082404be929432b80c045998f602efb,chemotherapy,0.421612
uuid-6082404be929432b80c045998f602efb,option,0.307042
uuid-04e4264305fa4dea996b3b1232bcf943,Nivo,0.465281
uuid-04e4264305fa4dea996b3b1232bcf943,pembro,0.551017
uuid-04e4264305fa4dea996b3b1232bcf943,1L,0.677055
uuid-04e4264305fa4dea996b3b1232bcf943,RCC,0.609482
uuid-04e4264305fa4dea996b3b1232bcf943,TL stated,0.331758
uuid-04e4264305fa4dea996b3b1232bcf943,combination,0.421035
uuid-04e4264305fa4dea996b3b1232bcf943,chemo,0.331028
uuid-04e4264305fa4dea996b3b1232bcf943,2L,0.709346
uuid-04e4264305fa4dea996b3b1232bcf943,agents,0.416488
uuid-04e4264305fa4dea996b3b1232bcf943,Ipi,0.434627
uuid-04e4264305fa4dea996b3b1232bcf943,stated,0.331449
uuid-04e4264305fa4dea996b3b1232bcf943,approval,0.349955
uuid-04e4264305fa4dea996b3b1232bcf943,atezo,0.545748
uuid-04e4264305fa4dea996b3b1232bcf943,preferred,0.610812
uuid-04e4264305fa4dea996b3b1232bcf943,monotherapy,0.569573
uuid-04e4264305fa4dea996b3b1232bcf943,using nivo,0.589696
uuid-04e4264305fa4dea996b3b1232bcf943,combo,0.557911
uuid-04e4264305fa4dea996b3b1232bcf943,clinical trials,0.31587
uuid-04e4264305fa4dea996b3b1232bcf943,indication,0.322169
uuid-04e4264305fa4dea996b3b1232bcf943,PD1,0.308584
uuid-04e4264305fa4dea996b3b1232bcf943,approved,0.503739
uuid-04e4264305fa4dea996b3b1232bcf943,SCCHN,0.469888
uuid-04e4264305fa4dea996b3b1232bcf943,nivo and pembro,0.30981
uuid-04e4264305fa4dea996b3b1232bcf943,believes,0.369718
uuid-04e4264305fa4dea996b3b1232bcf943,impressed,0.327684
uuid-04e4264305fa4dea996b3b1232bcf943,TLs,0.387872
uuid-04e4264305fa4dea996b3b1232bcf943,SCLC,0.39273
uuid-04e4264305fa4dea996b3b1232bcf943,feels,0.383291
uuid-04e4264305fa4dea996b3b1232bcf943,RTL stated,0.552376
uuid-04e4264305fa4dea996b3b1232bcf943,TL shared,0.327971
uuid-04e4264305fa4dea996b3b1232bcf943,option,0.487336
uuid-04e4264305fa4dea996b3b1232bcf943,bladder,0.421555
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,TL,0.349291
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,pembro,0.389358
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,1L,0.364256
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,PDL1,0.594208
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,TL stated,0.321721
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,2L,0.304145
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,Merck,0.46878
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,PD-L1,0.698767
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,atezo,0.458426
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,preferred,0.327306
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,PD-L1 testing,0.528092
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,testing,0.676042
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,PDL1 testing,0.569084
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,NSCLC patients,0.497441
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,nivo and pembro,0.357056
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,assay,0.640506
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,PDL1 expression,0.429619
uuid-8e11dedd362f47fdae8edd8cda1d5ab4,biomarker,0.461204
uuid-25e4ac53a3c7459ab800bbd65714806e,RTL,0.337791
uuid-25e4ac53a3c7459ab800bbd65714806e,BMS,0.30658
uuid-25e4ac53a3c7459ab800bbd65714806e,shared,0.402602
uuid-25e4ac53a3c7459ab800bbd65714806e,commented,0.400037
uuid-25e4ac53a3c7459ab800bbd65714806e,Merck,0.412915
uuid-25e4ac53a3c7459ab800bbd65714806e,stated,0.426087
uuid-25e4ac53a3c7459ab800bbd65714806e,approval,0.501126
uuid-25e4ac53a3c7459ab800bbd65714806e,PD-L1 testing,0.319693
uuid-25e4ac53a3c7459ab800bbd65714806e,data,0.344865
uuid-25e4ac53a3c7459ab800bbd65714806e,expressed,0.493274
uuid-25e4ac53a3c7459ab800bbd65714806e,clinical trials,0.321523
uuid-25e4ac53a3c7459ab800bbd65714806e,PDL1 testing,0.328666
uuid-25e4ac53a3c7459ab800bbd65714806e,indication,0.46242
uuid-25e4ac53a3c7459ab800bbd65714806e,approved,0.45589
uuid-25e4ac53a3c7459ab800bbd65714806e,SCCHN,0.458086
uuid-25e4ac53a3c7459ab800bbd65714806e,HCP,0.34752
uuid-25e4ac53a3c7459ab800bbd65714806e,impressed,0.355314
uuid-25e4ac53a3c7459ab800bbd65714806e,label,0.380341
uuid-25e4ac53a3c7459ab800bbd65714806e,LTL,0.382282
uuid-25e4ac53a3c7459ab800bbd65714806e,Regional TL,0.377682
uuid-25e4ac53a3c7459ab800bbd65714806e,bladder,0.365641
uuid-3714ebc37f8e4adaa18713b27d55435e,physicians,0.379925
uuid-3714ebc37f8e4adaa18713b27d55435e,oncology,0.324353
uuid-3714ebc37f8e4adaa18713b27d55435e,drug,0.569755
uuid-3714ebc37f8e4adaa18713b27d55435e,clinical,0.34193
uuid-340a744dbcee4c508674d56aebd3f476,Opdivo,0.493721
uuid-340a744dbcee4c508674d56aebd3f476,BMS,0.307077
uuid-340a744dbcee4c508674d56aebd3f476,stated,0.512436
uuid-340a744dbcee4c508674d56aebd3f476,physicians,0.419605
uuid-340a744dbcee4c508674d56aebd3f476,HCP,0.300493
uuid-340a744dbcee4c508674d56aebd3f476,LTL,0.322756
uuid-340a744dbcee4c508674d56aebd3f476,feels,0.359131
uuid-13328094732f425ba74cec00c16d84a7,RTL,0.422655
uuid-13328094732f425ba74cec00c16d84a7,BMS,0.509555
uuid-13328094732f425ba74cec00c16d84a7,trial,0.571107
uuid-13328094732f425ba74cec00c16d84a7,NTL,0.522152
uuid-13328094732f425ba74cec00c16d84a7,commented,0.503229
uuid-13328094732f425ba74cec00c16d84a7,Merck,0.659153
uuid-13328094732f425ba74cec00c16d84a7,stated,0.32092
uuid-13328094732f425ba74cec00c16d84a7,OS,0.31286
uuid-13328094732f425ba74cec00c16d84a7,regards,0.362012
uuid-13328094732f425ba74cec00c16d84a7,data,0.557486
uuid-13328094732f425ba74cec00c16d84a7,expressed,0.395762
uuid-13328094732f425ba74cec00c16d84a7,mentioned,0.35216
uuid-13328094732f425ba74cec00c16d84a7,PFS,0.315346
uuid-13328094732f425ba74cec00c16d84a7,ASCO,0.41656
uuid-13328094732f425ba74cec00c16d84a7,impressed,0.406454
uuid-13328094732f425ba74cec00c16d84a7,Regional TL,0.361236
uuid-95c11706d5634e1ea4c4c056543e70b5,RTL,0.380837
uuid-95c11706d5634e1ea4c4c056543e70b5,BMS,0.321785
uuid-95c11706d5634e1ea4c4c056543e70b5,trial,0.608741
uuid-95c11706d5634e1ea4c4c056543e70b5,efficacy,0.355026
uuid-95c11706d5634e1ea4c4c056543e70b5,NTL,0.310378
uuid-95c11706d5634e1ea4c4c056543e70b5,commented,0.508571
uuid-95c11706d5634e1ea4c4c056543e70b5,OS,0.556639
uuid-95c11706d5634e1ea4c4c056543e70b5,regards,0.392277
uuid-95c11706d5634e1ea4c4c056543e70b5,data,0.703244
uuid-95c11706d5634e1ea4c4c056543e70b5,expressed,0.318343
uuid-95c11706d5634e1ea4c4c056543e70b5,PFS,0.518679
uuid-95c11706d5634e1ea4c4c056543e70b5,ORR,0.600617
uuid-95c11706d5634e1ea4c4c056543e70b5,ASCO,0.479209
uuid-95c11706d5634e1ea4c4c056543e70b5,impressed,0.657168
uuid-95c11706d5634e1ea4c4c056543e70b5,SCLC,0.354531
uuid-95c11706d5634e1ea4c4c056543e70b5,Regional TL,0.301883
uuid-95c11706d5634e1ea4c4c056543e70b5,NCCN,0.312623
uuid-d0a24ab3de51407db1b5be8a4085395a,Nivo,0.347189
uuid-d0a24ab3de51407db1b5be8a4085395a,patients,0.705002
uuid-d0a24ab3de51407db1b5be8a4085395a,Opdivo,0.393563
uuid-d0a24ab3de51407db1b5be8a4085395a,therapy,0.793693
uuid-d0a24ab3de51407db1b5be8a4085395a,nivolumab,0.500781
uuid-d0a24ab3de51407db1b5be8a4085395a,regimen,0.323844
uuid-d0a24ab3de51407db1b5be8a4085395a,treated,0.439936
uuid-d0a24ab3de51407db1b5be8a4085395a,pts,0.437825
uuid-d0a24ab3de51407db1b5be8a4085395a,treatment,0.650578
uuid-d0a24ab3de51407db1b5be8a4085395a,response,0.475313
uuid-d0a24ab3de51407db1b5be8a4085395a,PD1,0.384159
uuid-d0a24ab3de51407db1b5be8a4085395a,cHL,0.628292
uuid-d0a24ab3de51407db1b5be8a4085395a,progression,0.659321
uuid-d0a24ab3de51407db1b5be8a4085395a,chemotherapy,0.426944
uuid-d0a24ab3de51407db1b5be8a4085395a,respond,0.469506
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,patients,0.502266
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,therapy,0.690237
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,nivolumab,0.397165
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,toxicity,0.327895
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,regimen,0.440328
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,treated,0.339575
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,combination,0.503378
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,chemo,0.59219
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,pts,0.438017
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,IO,0.303026
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,agents,0.405307
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,monotherapy,0.502009
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,treatment,0.564227
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,response,0.561901
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,combo,0.397562
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,PD1,0.701938
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,progression,0.630586
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,chemotherapy,0.580815
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,respond,0.501946
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,immunotherapy,0.420028
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,PD-1,0.418692
uuid-94d52e0c3592469f9235a1fb3b1b5c5b,option,0.43978
uuid-638e92eb08344995928ce6b3b32ff2f5,patients,0.773876
uuid-638e92eb08344995928ce6b3b32ff2f5,therapy,0.478258
uuid-638e92eb08344995928ce6b3b32ff2f5,nivolumab,0.425651
uuid-638e92eb08344995928ce6b3b32ff2f5,regimen,0.36495
uuid-638e92eb08344995928ce6b3b32ff2f5,treated,0.545572
uuid-638e92eb08344995928ce6b3b32ff2f5,pts,0.508844
uuid-638e92eb08344995928ce6b3b32ff2f5,treatment,0.535866
uuid-638e92eb08344995928ce6b3b32ff2f5,response,0.358299
uuid-638e92eb08344995928ce6b3b32ff2f5,cHL,0.361358
uuid-638e92eb08344995928ce6b3b32ff2f5,progression,0.615262
uuid-638e92eb08344995928ce6b3b32ff2f5,chemotherapy,0.322974
uuid-638e92eb08344995928ce6b3b32ff2f5,respond,0.39133
uuid-0eb91a278b1746f587e0f9d932d20ef0,Nivo,0.468244
uuid-0eb91a278b1746f587e0f9d932d20ef0,patients,0.481157
uuid-0eb91a278b1746f587e0f9d932d20ef0,therapy,0.379885
uuid-0eb91a278b1746f587e0f9d932d20ef0,trial,0.424503
uuid-0eb91a278b1746f587e0f9d932d20ef0,regimen,0.363322
uuid-0eb91a278b1746f587e0f9d932d20ef0,chemo,0.385346
uuid-0eb91a278b1746f587e0f9d932d20ef0,pts,0.470321
uuid-0eb91a278b1746f587e0f9d932d20ef0,Ipi,0.41229
uuid-0eb91a278b1746f587e0f9d932d20ef0,OS,0.322045
uuid-0eb91a278b1746f587e0f9d932d20ef0,response,0.439933
uuid-0eb91a278b1746f587e0f9d932d20ef0,PFS,0.330694
uuid-0eb91a278b1746f587e0f9d932d20ef0,ORR,0.347964
uuid-0eb91a278b1746f587e0f9d932d20ef0,progression,0.45319
uuid-0eb91a278b1746f587e0f9d932d20ef0,chemotherapy,0.437493
uuid-0eb91a278b1746f587e0f9d932d20ef0,respond,0.424786
uuid-e092e9a68f22441fbcbba5085138a3c0,physicians,0.452381
uuid-e092e9a68f22441fbcbba5085138a3c0,oncology,0.78318
uuid-e092e9a68f22441fbcbba5085138a3c0,oncologist,0.323314
uuid-e092e9a68f22441fbcbba5085138a3c0,clinical,0.609214
uuid-28ea64280245468b8c2d7106c0af1b03,Nivo,0.335503
uuid-28ea64280245468b8c2d7106c0af1b03,pembro,0.430556
uuid-28ea64280245468b8c2d7106c0af1b03,dose,0.446317
uuid-28ea64280245468b8c2d7106c0af1b03,trial,0.327025
uuid-28ea64280245468b8c2d7106c0af1b03,efficacy,0.569817
uuid-28ea64280245468b8c2d7106c0af1b03,Ipi,0.560537
uuid-28ea64280245468b8c2d7106c0af1b03,atezo,0.43948
uuid-28ea64280245468b8c2d7106c0af1b03,data,0.312964
uuid-28ea64280245468b8c2d7106c0af1b03,nivo and pembro,0.508197
uuid-28ea64280245468b8c2d7106c0af1b03,believes,0.393496
uuid-28ea64280245468b8c2d7106c0af1b03,vs,0.539834
uuid-28ea64280245468b8c2d7106c0af1b03,SCLC,0.344626
uuid-28ea64280245468b8c2d7106c0af1b03,feels,0.311555
uuid-c571775dd31a4e8a957c90be2587070e,Nivo,0.470367
uuid-c571775dd31a4e8a957c90be2587070e,pembro,0.650709
uuid-c571775dd31a4e8a957c90be2587070e,BMS,0.322247
uuid-c571775dd31a4e8a957c90be2587070e,1L,0.538585
uuid-c571775dd31a4e8a957c90be2587070e,PDL1,0.597681
uuid-c571775dd31a4e8a957c90be2587070e,trial,0.483355
uuid-c571775dd31a4e8a957c90be2587070e,efficacy,0.563057
uuid-c571775dd31a4e8a957c90be2587070e,chemo,0.303656
uuid-c571775dd31a4e8a957c90be2587070e,2L,0.451243
uuid-c571775dd31a4e8a957c90be2587070e,agents,0.394944
uuid-c571775dd31a4e8a957c90be2587070e,OS,0.524493
uuid-c571775dd31a4e8a957c90be2587070e,atezo,0.585744
uuid-c571775dd31a4e8a957c90be2587070e,monotherapy,0.347244
uuid-c571775dd31a4e8a957c90be2587070e,data,0.643943
uuid-c571775dd31a4e8a957c90be2587070e,combo,0.340657
uuid-c571775dd31a4e8a957c90be2587070e,indication,0.316911
uuid-c571775dd31a4e8a957c90be2587070e,PFS,0.506111
uuid-c571775dd31a4e8a957c90be2587070e,ORR,0.535475
uuid-c571775dd31a4e8a957c90be2587070e,approved,0.326756
uuid-c571775dd31a4e8a957c90be2587070e,nivo and pembro,0.728191
uuid-c571775dd31a4e8a957c90be2587070e,believes,0.504233
uuid-c571775dd31a4e8a957c90be2587070e,impressed,0.388179
uuid-c571775dd31a4e8a957c90be2587070e,vs,0.358671
uuid-c571775dd31a4e8a957c90be2587070e,feels,0.462729
uuid-c571775dd31a4e8a957c90be2587070e,PDL1 expression,0.537416
uuid-c571775dd31a4e8a957c90be2587070e,option,0.352395
uuid-619a4ba613af4bfa91151cee3c899e7c,Nivo,0.390576
uuid-619a4ba613af4bfa91151cee3c899e7c,patients,0.570667
uuid-619a4ba613af4bfa91151cee3c899e7c,Opdivo,0.515218
uuid-619a4ba613af4bfa91151cee3c899e7c,dose,0.732498
uuid-619a4ba613af4bfa91151cee3c899e7c,nivolumab,0.380693
uuid-619a4ba613af4bfa91151cee3c899e7c,toxicity,0.463649
uuid-619a4ba613af4bfa91151cee3c899e7c,regimen,0.546616
uuid-619a4ba613af4bfa91151cee3c899e7c,treated,0.343098
uuid-619a4ba613af4bfa91151cee3c899e7c,2L,0.359804
uuid-619a4ba613af4bfa91151cee3c899e7c,pts,0.33263
uuid-619a4ba613af4bfa91151cee3c899e7c,Ipi,0.435337
uuid-619a4ba613af4bfa91151cee3c899e7c,preferred,0.436229
uuid-619a4ba613af4bfa91151cee3c899e7c,monotherapy,0.370674
uuid-619a4ba613af4bfa91151cee3c899e7c,treatment,0.414022
uuid-619a4ba613af4bfa91151cee3c899e7c,using nivo,0.406652
uuid-619a4ba613af4bfa91151cee3c899e7c,progression,0.305187
uuid-619a4ba613af4bfa91151cee3c899e7c,vs,0.396534
uuid-619a4ba613af4bfa91151cee3c899e7c,RTL stated,0.325331
uuid-619a4ba613af4bfa91151cee3c899e7c,option,0.306182
uuid-619a4ba613af4bfa91151cee3c899e7c,flat dosing,0.514863
uuid-cde06da1d2674348bd24326447193f97,1L,0.340096
uuid-cde06da1d2674348bd24326447193f97,PDL1,0.432315
uuid-cde06da1d2674348bd24326447193f97,2L,0.314644
uuid-cde06da1d2674348bd24326447193f97,PD-L1,0.390969
uuid-cde06da1d2674348bd24326447193f97,preferred,0.306108
uuid-cde06da1d2674348bd24326447193f97,testing,0.384725
uuid-cde06da1d2674348bd24326447193f97,PDL1 testing,0.354507
uuid-cde06da1d2674348bd24326447193f97,NSCLC patients,0.330486
uuid-cde06da1d2674348bd24326447193f97,tumor types,0.316108
uuid-cde06da1d2674348bd24326447193f97,PDL1 expression,0.450925
uuid-cde06da1d2674348bd24326447193f97,option,0.354518
uuid-cde06da1d2674348bd24326447193f97,biomarker,0.438157
uuid-03677bbc1152442c92ae1b10fc43d0ed,BMS,0.500128
uuid-03677bbc1152442c92ae1b10fc43d0ed,PDL1,0.614014
uuid-03677bbc1152442c92ae1b10fc43d0ed,trial,0.527552
uuid-03677bbc1152442c92ae1b10fc43d0ed,efficacy,0.608214
uuid-03677bbc1152442c92ae1b10fc43d0ed,Merck,0.343012
uuid-03677bbc1152442c92ae1b10fc43d0ed,OS,0.6574
uuid-03677bbc1152442c92ae1b10fc43d0ed,regards,0.386147
uuid-03677bbc1152442c92ae1b10fc43d0ed,data,0.652443
uuid-03677bbc1152442c92ae1b10fc43d0ed,PFS,0.671
uuid-03677bbc1152442c92ae1b10fc43d0ed,ORR,0.683032
uuid-03677bbc1152442c92ae1b10fc43d0ed,nivo and pembro,0.568095
uuid-03677bbc1152442c92ae1b10fc43d0ed,believes,0.492914
uuid-03677bbc1152442c92ae1b10fc43d0ed,impressed,0.463614
uuid-03677bbc1152442c92ae1b10fc43d0ed,feels,0.372779
uuid-03677bbc1152442c92ae1b10fc43d0ed,PDL1 expression,0.537914
uuid-03677bbc1152442c92ae1b10fc43d0ed,biomarker,0.377223
uuid-84c1900af4f54d069f79230fabf33ea6,RTL,0.343235
uuid-84c1900af4f54d069f79230fabf33ea6,BMS,0.434488
uuid-84c1900af4f54d069f79230fabf33ea6,trial,0.691464
uuid-84c1900af4f54d069f79230fabf33ea6,commented,0.398469
uuid-84c1900af4f54d069f79230fabf33ea6,combination,0.306752
uuid-84c1900af4f54d069f79230fabf33ea6,Ipi,0.400314
uuid-84c1900af4f54d069f79230fabf33ea6,OS,0.316294
uuid-84c1900af4f54d069f79230fabf33ea6,data,0.489376
uuid-84c1900af4f54d069f79230fabf33ea6,combo,0.326412
uuid-84c1900af4f54d069f79230fabf33ea6,expressed,0.355824
uuid-84c1900af4f54d069f79230fabf33ea6,clinical trials,0.368156
uuid-84c1900af4f54d069f79230fabf33ea6,PFS,0.30537
uuid-84c1900af4f54d069f79230fabf33ea6,ORR,0.390162
uuid-84c1900af4f54d069f79230fabf33ea6,impressed,0.54686
uuid-84c1900af4f54d069f79230fabf33ea6,SCLC,0.467913
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,Nivo,0.614107
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,patients,0.651812
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,therapy,0.552106
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,nivolumab,0.53577
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,regimen,0.505831
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,treated,0.615708
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,combination,0.382374
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,chemo,0.533234
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,pts,0.666817
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,Ipi,0.305521
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,monotherapy,0.512956
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,treatment,0.480238
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,using nivo,0.417161
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,response,0.450737
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,combo,0.319653
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,PD1,0.459546
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,cHL,0.351878
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,progression,0.544831
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,chemotherapy,0.489135
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,respond,0.422109
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,RTL stated,0.357141
uuid-b0793c86ba5242e0b9a2425c9a2e08ad,option,0.369671
uuid-090149488c1442b29659c750cc1680e7,Nivo,0.35483
uuid-090149488c1442b29659c750cc1680e7,patients,0.522045
uuid-090149488c1442b29659c750cc1680e7,Opdivo,0.389248
uuid-090149488c1442b29659c750cc1680e7,therapy,0.68555
uuid-090149488c1442b29659c750cc1680e7,nivolumab,0.551911
uuid-090149488c1442b29659c750cc1680e7,treated,0.403354
uuid-090149488c1442b29659c750cc1680e7,treatment,0.419155
uuid-090149488c1442b29659c750cc1680e7,PD1,0.302395
uuid-090149488c1442b29659c750cc1680e7,cHL,0.833331
uuid-090149488c1442b29659c750cc1680e7,progression,0.31623
uuid-090149488c1442b29659c750cc1680e7,chemotherapy,0.317161
uuid-81483e3613574718959ae4f16ade123f,tumor,0.344405
uuid-81483e3613574718959ae4f16ade123f,progression,0.310318
uuid-81483e3613574718959ae4f16ade123f,TL shared,0.31618
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,Opdivo,0.620199
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,dose,0.43599
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,nivolumab,0.557504
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,regimen,0.308122
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,shared,0.324798
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,stated,0.332738
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,approval,0.437674
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,physicians,0.341821
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,preferred,0.411227
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,using nivo,0.411932
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,indication,0.383708
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,approved,0.534587
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,label,0.411441
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,LTL,0.308357
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,Keytruda,0.35406
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,RTL stated,0.347063
uuid-ee3e081ce7cd4d35a759b5a4d7a8152a,flat dosing,0.617191
uuid-0e9ff712732e484cab57d2ed88cc7415,patients,0.79391
uuid-0e9ff712732e484cab57d2ed88cc7415,Opdivo,0.762011
uuid-0e9ff712732e484cab57d2ed88cc7415,therapy,0.460449
uuid-0e9ff712732e484cab57d2ed88cc7415,nivolumab,0.380778
uuid-0e9ff712732e484cab57d2ed88cc7415,toxicity,0.326762
uuid-0e9ff712732e484cab57d2ed88cc7415,regimen,0.522357
uuid-0e9ff712732e484cab57d2ed88cc7415,treated,0.450664
uuid-0e9ff712732e484cab57d2ed88cc7415,pts,0.513076
uuid-0e9ff712732e484cab57d2ed88cc7415,monotherapy,0.344811
uuid-0e9ff712732e484cab57d2ed88cc7415,treatment,0.681979
uuid-0e9ff712732e484cab57d2ed88cc7415,progression,0.608645
uuid-0e9ff712732e484cab57d2ed88cc7415,respond,0.499169
uuid-0e9ff712732e484cab57d2ed88cc7415,Keytruda,0.32193
uuid-0e9ff712732e484cab57d2ed88cc7415,option,0.331232
uuid-7adda2c029d74ba694071fde4dc85e59,toxicity,0.41758
uuid-7adda2c029d74ba694071fde4dc85e59,physicians,0.44755
uuid-7adda2c029d74ba694071fde4dc85e59,treatment,0.330942
uuid-99f9c80519bf48979b33a4e11d0b367c,RTL,0.384837
uuid-99f9c80519bf48979b33a4e11d0b367c,commented,0.35665
uuid-99f9c80519bf48979b33a4e11d0b367c,stated,0.455183
uuid-99f9c80519bf48979b33a4e11d0b367c,preferred,0.305548
uuid-99f9c80519bf48979b33a4e11d0b367c,using nivo,0.402916
uuid-99f9c80519bf48979b33a4e11d0b367c,data,0.422783
uuid-99f9c80519bf48979b33a4e11d0b367c,expressed,0.330961
uuid-99f9c80519bf48979b33a4e11d0b367c,SCCHN,0.47365
uuid-99f9c80519bf48979b33a4e11d0b367c,impressed,0.390039
uuid-99f9c80519bf48979b33a4e11d0b367c,LTL,0.408259
uuid-99f9c80519bf48979b33a4e11d0b367c,TLs,0.394239
uuid-99f9c80519bf48979b33a4e11d0b367c,feels,0.303576
uuid-99f9c80519bf48979b33a4e11d0b367c,Regional TL,0.563102
uuid-99f9c80519bf48979b33a4e11d0b367c,RTL stated,0.443597
uuid-99f9c80519bf48979b33a4e11d0b367c,bladder,0.4083
uuid-f2aa95480b3a4fe095fd3481030806c5,Nivo,0.432934
uuid-f2aa95480b3a4fe095fd3481030806c5,pembro,0.311347
uuid-f2aa95480b3a4fe095fd3481030806c5,1L,0.434256
uuid-f2aa95480b3a4fe095fd3481030806c5,efficacy,0.327361
uuid-f2aa95480b3a4fe095fd3481030806c5,combination,0.353042
uuid-f2aa95480b3a4fe095fd3481030806c5,chemo,0.562316
uuid-f2aa95480b3a4fe095fd3481030806c5,2L,0.408253
uuid-f2aa95480b3a4fe095fd3481030806c5,agents,0.39525
uuid-f2aa95480b3a4fe095fd3481030806c5,preferred,0.445522
uuid-f2aa95480b3a4fe095fd3481030806c5,monotherapy,0.482426
uuid-f2aa95480b3a4fe095fd3481030806c5,using nivo,0.401141
uuid-f2aa95480b3a4fe095fd3481030806c5,combo,0.330887
uuid-f2aa95480b3a4fe095fd3481030806c5,PD1,0.318527
uuid-f2aa95480b3a4fe095fd3481030806c5,nivo and pembro,0.330297
uuid-f2aa95480b3a4fe095fd3481030806c5,believes,0.434408
uuid-f2aa95480b3a4fe095fd3481030806c5,chemotherapy,0.438094
uuid-f2aa95480b3a4fe095fd3481030806c5,feels,0.520028
uuid-f2aa95480b3a4fe095fd3481030806c5,RTL stated,0.301722
uuid-f2aa95480b3a4fe095fd3481030806c5,option,0.504976
uuid-df15488a076d424e9a356c9fae24346c,Nivo,0.386758
uuid-df15488a076d424e9a356c9fae24346c,patients,0.368631
uuid-df15488a076d424e9a356c9fae24346c,pembro,0.444005
uuid-df15488a076d424e9a356c9fae24346c,nivolumab,0.355926
uuid-df15488a076d424e9a356c9fae24346c,1L,0.741091
uuid-df15488a076d424e9a356c9fae24346c,RCC,0.607432
uuid-df15488a076d424e9a356c9fae24346c,TL stated,0.303351
uuid-df15488a076d424e9a356c9fae24346c,chemo,0.316857
uuid-df15488a076d424e9a356c9fae24346c,2L,0.745398
uuid-df15488a076d424e9a356c9fae24346c,pts,0.42242
uuid-df15488a076d424e9a356c9fae24346c,agents,0.332529
uuid-df15488a076d424e9a356c9fae24346c,approval,0.548075
uuid-df15488a076d424e9a356c9fae24346c,atezo,0.387849
uuid-df15488a076d424e9a356c9fae24346c,preferred,0.602432
uuid-df15488a076d424e9a356c9fae24346c,monotherapy,0.577125
uuid-df15488a076d424e9a356c9fae24346c,using nivo,0.642636
uuid-df15488a076d424e9a356c9fae24346c,combo,0.350503
uuid-df15488a076d424e9a356c9fae24346c,indication,0.307589
uuid-df15488a076d424e9a356c9fae24346c,NSCLC patients,0.347506
uuid-df15488a076d424e9a356c9fae24346c,PD1,0.31097
uuid-df15488a076d424e9a356c9fae24346c,approved,0.721554
uuid-df15488a076d424e9a356c9fae24346c,SCCHN,0.404511
uuid-df15488a076d424e9a356c9fae24346c,tumor types,0.43245
uuid-df15488a076d424e9a356c9fae24346c,label,0.328859
uuid-df15488a076d424e9a356c9fae24346c,SCLC,0.332529
uuid-df15488a076d424e9a356c9fae24346c,RTL stated,0.533429
uuid-df15488a076d424e9a356c9fae24346c,TL shared,0.348156
uuid-df15488a076d424e9a356c9fae24346c,option,0.62433
uuid-df15488a076d424e9a356c9fae24346c,bladder,0.374075
uuid-94ba090e337b403b9e35e6eda40cdc1c,toxicity,0.31599
uuid-94ba090e337b403b9e35e6eda40cdc1c,efficacy,0.513128
uuid-94ba090e337b403b9e35e6eda40cdc1c,regards,0.34586
uuid-94ba090e337b403b9e35e6eda40cdc1c,data,0.438317
uuid-94ba090e337b403b9e35e6eda40cdc1c,ORR,0.310802
uuid-94ba090e337b403b9e35e6eda40cdc1c,nivo and pembro,0.318063
uuid-94ba090e337b403b9e35e6eda40cdc1c,believes,0.332979
uuid-94ba090e337b403b9e35e6eda40cdc1c,impressed,0.385268
uuid-94ba090e337b403b9e35e6eda40cdc1c,TLs,0.382738
uuid-94ba090e337b403b9e35e6eda40cdc1c,feels,0.399939
uuid-96030c62d08f49f290c48520e707c67c,Nivo,0.303374
uuid-96030c62d08f49f290c48520e707c67c,patients,0.334787
uuid-96030c62d08f49f290c48520e707c67c,therapy,0.327732
uuid-96030c62d08f49f290c48520e707c67c,dose,0.542811
uuid-96030c62d08f49f290c48520e707c67c,nivolumab,0.415727
uuid-96030c62d08f49f290c48520e707c67c,toxicity,0.357155
uuid-96030c62d08f49f290c48520e707c67c,regimen,0.406181
uuid-96030c62d08f49f290c48520e707c67c,combination,0.377438
uuid-96030c62d08f49f290c48520e707c67c,chemo,0.368054
uuid-96030c62d08f49f290c48520e707c67c,agents,0.424623
uuid-96030c62d08f49f290c48520e707c67c,Ipi,0.300565
uuid-96030c62d08f49f290c48520e707c67c,preferred,0.408184
uuid-96030c62d08f49f290c48520e707c67c,monotherapy,0.418267
uuid-96030c62d08f49f290c48520e707c67c,treatment,0.329129
uuid-96030c62d08f49f290c48520e707c67c,PD1,0.495246
uuid-96030c62d08f49f290c48520e707c67c,vs,0.337054
uuid-96030c62d08f49f290c48520e707c67c,PD-1,0.413045
uuid-96030c62d08f49f290c48520e707c67c,option,0.349048
uuid-33720312e52145d7ab39522e575e71dc,RTL,0.329121
uuid-33720312e52145d7ab39522e575e71dc,BMS,0.405945
uuid-33720312e52145d7ab39522e575e71dc,trial,0.591856
uuid-33720312e52145d7ab39522e575e71dc,efficacy,0.458205
uuid-33720312e52145d7ab39522e575e71dc,discussed,0.352521
uuid-33720312e52145d7ab39522e575e71dc,commented,0.466585
uuid-33720312e52145d7ab39522e575e71dc,OS,0.640071
uuid-33720312e52145d7ab39522e575e71dc,regards,0.338969
uuid-33720312e52145d7ab39522e575e71dc,data,0.817359
uuid-33720312e52145d7ab39522e575e71dc,expressed,0.352827
uuid-33720312e52145d7ab39522e575e71dc,PFS,0.603882
uuid-33720312e52145d7ab39522e575e71dc,ORR,0.653897
uuid-33720312e52145d7ab39522e575e71dc,nivo and pembro,0.356856
uuid-33720312e52145d7ab39522e575e71dc,ASCO,0.513926
uuid-33720312e52145d7ab39522e575e71dc,believes,0.312537
uuid-33720312e52145d7ab39522e575e71dc,impressed,0.674728
uuid-33720312e52145d7ab39522e575e71dc,TLs,0.303498
uuid-33720312e52145d7ab39522e575e71dc,feels,0.332835
uuid-c327d1f468fa47dcbab61e8dbf02ac50,IO,0.349802
uuid-c327d1f468fa47dcbab61e8dbf02ac50,monotherapy,0.305533
uuid-c327d1f468fa47dcbab61e8dbf02ac50,combo,0.331222
uuid-c327d1f468fa47dcbab61e8dbf02ac50,believes,0.456766
uuid-c327d1f468fa47dcbab61e8dbf02ac50,SCLC,0.58673
uuid-c327d1f468fa47dcbab61e8dbf02ac50,option,0.301157
uuid-e3ec458df2424e72862957efac96dce4,NTL,0.307212
uuid-e3ec458df2424e72862957efac96dce4,Merck,0.319437
uuid-b461a5fa4e1a49de86ba500efd480394,nivolumab,0.380769
uuid-b461a5fa4e1a49de86ba500efd480394,combination,0.570499
uuid-b461a5fa4e1a49de86ba500efd480394,monotherapy,0.33587
uuid-b461a5fa4e1a49de86ba500efd480394,combo,0.385799
uuid-b461a5fa4e1a49de86ba500efd480394,PD1,0.390767
uuid-b461a5fa4e1a49de86ba500efd480394,PD-1,0.371147
uuid-a7caba6ae32b420b9f65a6b798db991e,PDL1,0.357887
uuid-a7caba6ae32b420b9f65a6b798db991e,agents,0.308306
uuid-a7caba6ae32b420b9f65a6b798db991e,PD-L1,0.317642
uuid-a7caba6ae32b420b9f65a6b798db991e,PDL1 expression,0.337282
uuid-a7caba6ae32b420b9f65a6b798db991e,biomarker,0.472024
uuid-dd54beed2b9f43dea4eaba05d2d50c01,patients,0.766482
uuid-dd54beed2b9f43dea4eaba05d2d50c01,Opdivo,0.537222
uuid-dd54beed2b9f43dea4eaba05d2d50c01,dose,0.391059
uuid-dd54beed2b9f43dea4eaba05d2d50c01,nivolumab,0.316858
uuid-dd54beed2b9f43dea4eaba05d2d50c01,regimen,0.431576
uuid-dd54beed2b9f43dea4eaba05d2d50c01,treated,0.447881
uuid-dd54beed2b9f43dea4eaba05d2d50c01,pts,0.488083
uuid-dd54beed2b9f43dea4eaba05d2d50c01,treatment,0.510165
uuid-dd54beed2b9f43dea4eaba05d2d50c01,progression,0.485838
uuid-dd54beed2b9f43dea4eaba05d2d50c01,respond,0.42537
uuid-b65561f4e3144785ac4c57558e4aead7,Nivo,0.384746
uuid-b65561f4e3144785ac4c57558e4aead7,patients,0.404269
uuid-b65561f4e3144785ac4c57558e4aead7,pembro,0.415013
uuid-b65561f4e3144785ac4c57558e4aead7,dose,0.353331
uuid-b65561f4e3144785ac4c57558e4aead7,nivolumab,0.368399
uuid-b65561f4e3144785ac4c57558e4aead7,trial,0.364385
uuid-b65561f4e3144785ac4c57558e4aead7,regimen,0.345526
uuid-b65561f4e3144785ac4c57558e4aead7,combination,0.340982
uuid-b65561f4e3144785ac4c57558e4aead7,pts,0.304985
uuid-b65561f4e3144785ac4c57558e4aead7,Ipi,0.423294
uuid-b65561f4e3144785ac4c57558e4aead7,monotherapy,0.320884
uuid-b65561f4e3144785ac4c57558e4aead7,combo,0.349371
uuid-b65561f4e3144785ac4c57558e4aead7,clinical trials,0.321211
uuid-b65561f4e3144785ac4c57558e4aead7,impressed,0.360733
uuid-b65561f4e3144785ac4c57558e4aead7,vs,0.340973
uuid-b65561f4e3144785ac4c57558e4aead7,feels,0.359779
uuid-5cc90b91d2394a28909af6154f1d0ea5,patients,0.902294
uuid-5cc90b91d2394a28909af6154f1d0ea5,Opdivo,0.520678
uuid-5cc90b91d2394a28909af6154f1d0ea5,therapy,0.568274
uuid-5cc90b91d2394a28909af6154f1d0ea5,nivolumab,0.523665
uuid-5cc90b91d2394a28909af6154f1d0ea5,regimen,0.560424
uuid-5cc90b91d2394a28909af6154f1d0ea5,treated,0.66574
uuid-5cc90b91d2394a28909af6154f1d0ea5,pts,0.603745
uuid-5cc90b91d2394a28909af6154f1d0ea5,monotherapy,0.326422
uuid-5cc90b91d2394a28909af6154f1d0ea5,treatment,0.798477
uuid-5cc90b91d2394a28909af6154f1d0ea5,response,0.3898
uuid-5cc90b91d2394a28909af6154f1d0ea5,cHL,0.315382
uuid-5cc90b91d2394a28909af6154f1d0ea5,progression,0.704726
uuid-5cc90b91d2394a28909af6154f1d0ea5,chemotherapy,0.347481
uuid-5cc90b91d2394a28909af6154f1d0ea5,respond,0.526296
uuid-5cc90b91d2394a28909af6154f1d0ea5,option,0.301144
uuid-b4bd610a59244d4bb44b34501d2bebd4,Nivo,0.472678
uuid-b4bd610a59244d4bb44b34501d2bebd4,pembro,0.592762
uuid-b4bd610a59244d4bb44b34501d2bebd4,dose,0.570651
uuid-b4bd610a59244d4bb44b34501d2bebd4,efficacy,0.594444
uuid-b4bd610a59244d4bb44b34501d2bebd4,2L,0.379337
uuid-b4bd610a59244d4bb44b34501d2bebd4,agents,0.422762
uuid-b4bd610a59244d4bb44b34501d2bebd4,Ipi,0.395912
uuid-b4bd610a59244d4bb44b34501d2bebd4,atezo,0.712708
uuid-b4bd610a59244d4bb44b34501d2bebd4,preferred,0.414075
uuid-b4bd610a59244d4bb44b34501d2bebd4,indication,0.375226
uuid-b4bd610a59244d4bb44b34501d2bebd4,nivo and pembro,0.403628
uuid-b4bd610a59244d4bb44b34501d2bebd4,vs,0.647386
uuid-b4bd610a59244d4bb44b34501d2bebd4,Keytruda,0.393654
uuid-b4bd610a59244d4bb44b34501d2bebd4,flat dosing,0.526936
uuid-5d79fe52fd5d4246805fda3101f3a8b1,RTL,0.310065
uuid-5d79fe52fd5d4246805fda3101f3a8b1,nivolumab,0.333944
uuid-5d79fe52fd5d4246805fda3101f3a8b1,BMS,0.365592
uuid-5d79fe52fd5d4246805fda3101f3a8b1,shared,0.502041
uuid-5d79fe52fd5d4246805fda3101f3a8b1,commented,0.370713
uuid-5d79fe52fd5d4246805fda3101f3a8b1,RCC,0.31696
uuid-5d79fe52fd5d4246805fda3101f3a8b1,stated,0.374174
uuid-5d79fe52fd5d4246805fda3101f3a8b1,approval,0.4561
uuid-5d79fe52fd5d4246805fda3101f3a8b1,expressed,0.334333
uuid-5d79fe52fd5d4246805fda3101f3a8b1,clinical trials,0.491458
uuid-5d79fe52fd5d4246805fda3101f3a8b1,approved,0.405312
uuid-5d79fe52fd5d4246805fda3101f3a8b1,SCCHN,0.333301
uuid-5d79fe52fd5d4246805fda3101f3a8b1,impressed,0.435032
uuid-5d79fe52fd5d4246805fda3101f3a8b1,LTL,0.301496
uuid-5d79fe52fd5d4246805fda3101f3a8b1,Regional TL,0.390759
uuid-5d79fe52fd5d4246805fda3101f3a8b1,bladder,0.325421
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,patients,0.513429
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,Opdivo,0.503911
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,therapy,0.52098
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,nivolumab,0.440718
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,treated,0.428378
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,treatment,0.447705
uuid-4a6ce79ec52e4400a4300c5b5ffd0c4a,cHL,0.614776
uuid-ff26a88088204b83a975cd8dee51888a,Nivo,0.421276
uuid-ff26a88088204b83a975cd8dee51888a,patients,0.503839
uuid-ff26a88088204b83a975cd8dee51888a,therapy,0.352389
uuid-ff26a88088204b83a975cd8dee51888a,toxicity,0.389558
uuid-ff26a88088204b83a975cd8dee51888a,monotherapy,0.310716
uuid-ff26a88088204b83a975cd8dee51888a,progression,0.33717
uuid-ff26a88088204b83a975cd8dee51888a,chemotherapy,0.392456
uuid-677a3a7743994c5b8cf67a7b3b591ff1,TL,0.673403
uuid-677a3a7743994c5b8cf67a7b3b591ff1,TL stated,0.434338
uuid-677a3a7743994c5b8cf67a7b3b591ff1,institution,0.560794
uuid-677a3a7743994c5b8cf67a7b3b591ff1,PD-L1,0.718024
uuid-677a3a7743994c5b8cf67a7b3b591ff1,PD-L1 testing,0.934962
uuid-677a3a7743994c5b8cf67a7b3b591ff1,testing,0.812766
uuid-677a3a7743994c5b8cf67a7b3b591ff1,PDL1 testing,0.666803
uuid-677a3a7743994c5b8cf67a7b3b591ff1,NSCLC patients,0.527462
uuid-677a3a7743994c5b8cf67a7b3b591ff1,assay,0.703371
uuid-8d1c774764294d41aee19f69b6b200d7,Nivo,0.451615
uuid-8d1c774764294d41aee19f69b6b200d7,pembro,0.603283
uuid-8d1c774764294d41aee19f69b6b200d7,dose,0.512246
uuid-8d1c774764294d41aee19f69b6b200d7,1L,0.440792
uuid-8d1c774764294d41aee19f69b6b200d7,efficacy,0.518799
uuid-8d1c774764294d41aee19f69b6b200d7,combination,0.466156
uuid-8d1c774764294d41aee19f69b6b200d7,chemo,0.371414
uuid-8d1c774764294d41aee19f69b6b200d7,2L,0.530587
uuid-8d1c774764294d41aee19f69b6b200d7,IO,0.32578
uuid-8d1c774764294d41aee19f69b6b200d7,agents,0.549442
uuid-8d1c774764294d41aee19f69b6b200d7,Ipi,0.544574
uuid-8d1c774764294d41aee19f69b6b200d7,atezo,0.675025
uuid-8d1c774764294d41aee19f69b6b200d7,preferred,0.454076
uuid-8d1c774764294d41aee19f69b6b200d7,monotherapy,0.470368
uuid-8d1c774764294d41aee19f69b6b200d7,combo,0.592325
uuid-8d1c774764294d41aee19f69b6b200d7,approved,0.312967
uuid-8d1c774764294d41aee19f69b6b200d7,nivo and pembro,0.449963
uuid-8d1c774764294d41aee19f69b6b200d7,believes,0.468034
uuid-8d1c774764294d41aee19f69b6b200d7,vs,0.603069
uuid-8d1c774764294d41aee19f69b6b200d7,feels,0.382017
uuid-8d1c774764294d41aee19f69b6b200d7,option,0.398717
uuid-dbb8b0ecb2914c22abc88f8094ebcd2b,dose,0.602225
uuid-dbb8b0ecb2914c22abc88f8094ebcd2b,trial,0.427244
uuid-dbb8b0ecb2914c22abc88f8094ebcd2b,Ipi,0.620352
uuid-dbb8b0ecb2914c22abc88f8094ebcd2b,vs,0.425433
uuid-dbb8b0ecb2914c22abc88f8094ebcd2b,flat dosing,0.351031
uuid-d4d3ff276857498083ac6079b6e40b6f,TL,0.340804
uuid-d4d3ff276857498083ac6079b6e40b6f,RCC,0.345432
uuid-d4d3ff276857498083ac6079b6e40b6f,approval,0.601705
uuid-d4d3ff276857498083ac6079b6e40b6f,approved,0.355913
uuid-d4d3ff276857498083ac6079b6e40b6f,bladder,0.323615
uuid-ce28aecde04d479bba8cb4c816f20fa1,lung,0.350847
uuid-ce28aecde04d479bba8cb4c816f20fa1,institution,0.327864
uuid-ce28aecde04d479bba8cb4c816f20fa1,regards,0.32633
uuid-ce28aecde04d479bba8cb4c816f20fa1,AI,0.706031
uuid-ce28aecde04d479bba8cb4c816f20fa1,oncology,0.423092
uuid-ce28aecde04d479bba8cb4c816f20fa1,clinical,0.343072
uuid-ce28aecde04d479bba8cb4c816f20fa1,NCCN,0.333331
uuid-274d9fc5e4254c23b5a200c147fde5eb,TL,0.352046
uuid-274d9fc5e4254c23b5a200c147fde5eb,lung,0.649031
uuid-274d9fc5e4254c23b5a200c147fde5eb,1L,0.342144
uuid-274d9fc5e4254c23b5a200c147fde5eb,melanoma,0.418702
uuid-274d9fc5e4254c23b5a200c147fde5eb,RCC,0.568163
uuid-274d9fc5e4254c23b5a200c147fde5eb,TL stated,0.777755
uuid-274d9fc5e4254c23b5a200c147fde5eb,2L,0.332956
uuid-274d9fc5e4254c23b5a200c147fde5eb,institution,0.390631
uuid-274d9fc5e4254c23b5a200c147fde5eb,PD-L1,0.385491
uuid-274d9fc5e4254c23b5a200c147fde5eb,PD-L1 testing,0.552368
uuid-274d9fc5e4254c23b5a200c147fde5eb,testing,0.601726
uuid-274d9fc5e4254c23b5a200c147fde5eb,PDL1 testing,0.844282
uuid-274d9fc5e4254c23b5a200c147fde5eb,NSCLC patients,0.614985
uuid-274d9fc5e4254c23b5a200c147fde5eb,SCCHN,0.491531
uuid-274d9fc5e4254c23b5a200c147fde5eb,tumor types,0.428877
uuid-274d9fc5e4254c23b5a200c147fde5eb,TLs,0.389195
uuid-274d9fc5e4254c23b5a200c147fde5eb,academic,0.382352
uuid-274d9fc5e4254c23b5a200c147fde5eb,Regional TL,0.326578
uuid-274d9fc5e4254c23b5a200c147fde5eb,RTL stated,0.495853
uuid-274d9fc5e4254c23b5a200c147fde5eb,TL shared,0.571971
uuid-274d9fc5e4254c23b5a200c147fde5eb,bladder,0.318035
uuid-242a6e001e024760ab72454cac20074b,Nivo,0.52614
uuid-242a6e001e024760ab72454cac20074b,patients,0.530943
uuid-242a6e001e024760ab72454cac20074b,pembro,0.536828
uuid-242a6e001e024760ab72454cac20074b,therapy,0.346069
uuid-242a6e001e024760ab72454cac20074b,1L,0.602448
uuid-242a6e001e024760ab72454cac20074b,PDL1,0.374228
uuid-242a6e001e024760ab72454cac20074b,chemo,0.542014
uuid-242a6e001e024760ab72454cac20074b,2L,0.53221
uuid-242a6e001e024760ab72454cac20074b,pts,0.483638
uuid-242a6e001e024760ab72454cac20074b,atezo,0.420668
uuid-242a6e001e024760ab72454cac20074b,preferred,0.439574
uuid-242a6e001e024760ab72454cac20074b,monotherapy,0.586932
uuid-242a6e001e024760ab72454cac20074b,using nivo,0.446151
uuid-242a6e001e024760ab72454cac20074b,NSCLC patients,0.358046
uuid-242a6e001e024760ab72454cac20074b,PD1,0.372951
uuid-242a6e001e024760ab72454cac20074b,nivo and pembro,0.366467
uuid-242a6e001e024760ab72454cac20074b,progression,0.325866
uuid-242a6e001e024760ab72454cac20074b,believes,0.348141
uuid-242a6e001e024760ab72454cac20074b,chemotherapy,0.419736
uuid-242a6e001e024760ab72454cac20074b,feels,0.441123
uuid-242a6e001e024760ab72454cac20074b,RTL stated,0.314501
uuid-242a6e001e024760ab72454cac20074b,PDL1 expression,0.306994
uuid-242a6e001e024760ab72454cac20074b,option,0.579512
uuid-42fab81005444c3f87d177d4540079e6,PDL1,0.41484
uuid-42fab81005444c3f87d177d4540079e6,trial,0.426645
uuid-42fab81005444c3f87d177d4540079e6,efficacy,0.537819
uuid-42fab81005444c3f87d177d4540079e6,commented,0.460325
uuid-42fab81005444c3f87d177d4540079e6,Merck,0.313312
uuid-42fab81005444c3f87d177d4540079e6,OS,0.607398
uuid-42fab81005444c3f87d177d4540079e6,regards,0.406
uuid-42fab81005444c3f87d177d4540079e6,data,0.764003
uuid-42fab81005444c3f87d177d4540079e6,expressed,0.357153
uuid-42fab81005444c3f87d177d4540079e6,PFS,0.573137
uuid-42fab81005444c3f87d177d4540079e6,ORR,0.64619
uuid-42fab81005444c3f87d177d4540079e6,nivo and pembro,0.398963
uuid-42fab81005444c3f87d177d4540079e6,ASCO,0.473563
uuid-42fab81005444c3f87d177d4540079e6,impressed,0.644913
uuid-42fab81005444c3f87d177d4540079e6,PDL1 expression,0.368587
uuid-6db3227a884a4cdb824604fc1d3bc21e,TL,0.41921
uuid-6db3227a884a4cdb824604fc1d3bc21e,RTL,0.397329
uuid-6db3227a884a4cdb824604fc1d3bc21e,shared,0.324552
uuid-6db3227a884a4cdb824604fc1d3bc21e,commented,0.341586
uuid-6db3227a884a4cdb824604fc1d3bc21e,TL stated,0.391913
uuid-6db3227a884a4cdb824604fc1d3bc21e,institution,0.308311
uuid-6db3227a884a4cdb824604fc1d3bc21e,stated,0.350004
uuid-6db3227a884a4cdb824604fc1d3bc21e,physicians,0.370163
uuid-6db3227a884a4cdb824604fc1d3bc21e,PD-L1 testing,0.458443
uuid-6db3227a884a4cdb824604fc1d3bc21e,PDL1 testing,0.400797
uuid-6db3227a884a4cdb824604fc1d3bc21e,oncology,0.31943
uuid-6db3227a884a4cdb824604fc1d3bc21e,SCCHN,0.39883
uuid-6db3227a884a4cdb824604fc1d3bc21e,LTL,0.3716
uuid-6db3227a884a4cdb824604fc1d3bc21e,TLs,0.43022
uuid-6db3227a884a4cdb824604fc1d3bc21e,clinical,0.309492
uuid-6db3227a884a4cdb824604fc1d3bc21e,academic,0.485784
uuid-6db3227a884a4cdb824604fc1d3bc21e,Regional TL,0.462693
uuid-c7b989c080de42b2b342a1d83948b45d,Nivo,0.50363
uuid-c7b989c080de42b2b342a1d83948b45d,pembro,0.418159
uuid-c7b989c080de42b2b342a1d83948b45d,trial,0.483326
uuid-c7b989c080de42b2b342a1d83948b45d,efficacy,0.605955
uuid-c7b989c080de42b2b342a1d83948b45d,chemo,0.501772
uuid-c7b989c080de42b2b342a1d83948b45d,Ipi,0.425041
uuid-c7b989c080de42b2b342a1d83948b45d,OS,0.504504
uuid-c7b989c080de42b2b342a1d83948b45d,data,0.41027
uuid-c7b989c080de42b2b342a1d83948b45d,combo,0.317202
uuid-c7b989c080de42b2b342a1d83948b45d,PFS,0.494424
uuid-c7b989c080de42b2b342a1d83948b45d,ORR,0.530433
uuid-c7b989c080de42b2b342a1d83948b45d,nivo and pembro,0.392718
uuid-c7b989c080de42b2b342a1d83948b45d,believes,0.391109
uuid-c7b989c080de42b2b342a1d83948b45d,chemotherapy,0.472534
uuid-c7b989c080de42b2b342a1d83948b45d,impressed,0.30813
uuid-c7b989c080de42b2b342a1d83948b45d,vs,0.511467
uuid-c7b989c080de42b2b342a1d83948b45d,feels,0.527854
uuid-c7b989c080de42b2b342a1d83948b45d,option,0.349096
uuid-673aa564281d43a3b5d6ff61a180f32c,patients,0.476228
uuid-673aa564281d43a3b5d6ff61a180f32c,therapy,0.305694
uuid-673aa564281d43a3b5d6ff61a180f32c,toxicity,0.414682
uuid-673aa564281d43a3b5d6ff61a180f32c,regimen,0.468972
uuid-673aa564281d43a3b5d6ff61a180f32c,treated,0.300731
uuid-673aa564281d43a3b5d6ff61a180f32c,IO,0.548897
uuid-673aa564281d43a3b5d6ff61a180f32c,physicians,0.365644
uuid-673aa564281d43a3b5d6ff61a180f32c,treatment,0.452279
uuid-673aa564281d43a3b5d6ff61a180f32c,response,0.338719
uuid-673aa564281d43a3b5d6ff61a180f32c,progression,0.408383
uuid-673aa564281d43a3b5d6ff61a180f32c,respond,0.300411
uuid-8e8b2975f2de456e9feef0c557765eb5,dose,0.431577
uuid-8e8b2975f2de456e9feef0c557765eb5,toxicity,0.612477
uuid-8e8b2975f2de456e9feef0c557765eb5,regimen,0.359323
uuid-8e8b2975f2de456e9feef0c557765eb5,treatment,0.311545
uuid-1f598046cacf48d6893f5a4209999929,BMS,0.527148
uuid-1f598046cacf48d6893f5a4209999929,trial,0.388858
uuid-1f598046cacf48d6893f5a4209999929,commented,0.316088
uuid-1f598046cacf48d6893f5a4209999929,Merck,0.6821
uuid-a23fe5eb8a6647ed89a20fddbb6460cd,NTL,0.387177
uuid-a23fe5eb8a6647ed89a20fddbb6460cd,melanoma,0.446322
uuid-a23fe5eb8a6647ed89a20fddbb6460cd,RCC,0.318371
uuid-a23fe5eb8a6647ed89a20fddbb6460cd,oncologist,0.410099
uuid-a2e611d0b37047d4bcd55a813ad9d40c,RTL,0.420504
uuid-a2e611d0b37047d4bcd55a813ad9d40c,nivolumab,0.40975
uuid-a2e611d0b37047d4bcd55a813ad9d40c,regimen,0.33967
uuid-a2e611d0b37047d4bcd55a813ad9d40c,treated,0.45736
uuid-a2e611d0b37047d4bcd55a813ad9d40c,melanoma,0.630662
uuid-a2e611d0b37047d4bcd55a813ad9d40c,RCC,0.402045
uuid-a2e611d0b37047d4bcd55a813ad9d40c,combination,0.370922
uuid-a2e611d0b37047d4bcd55a813ad9d40c,pts,0.392386
uuid-a2e611d0b37047d4bcd55a813ad9d40c,monotherapy,0.314721
uuid-a2e611d0b37047d4bcd55a813ad9d40c,response,0.304068
uuid-a2e611d0b37047d4bcd55a813ad9d40c,combo,0.314106
uuid-a2e611d0b37047d4bcd55a813ad9d40c,PD1,0.485126
uuid-a2e611d0b37047d4bcd55a813ad9d40c,progression,0.339244
uuid-a2e611d0b37047d4bcd55a813ad9d40c,academic,0.322873
uuid-a2e611d0b37047d4bcd55a813ad9d40c,PD-1,0.309048
uuid-a2e611d0b37047d4bcd55a813ad9d40c,RTL stated,0.450567
uuid-a2e611d0b37047d4bcd55a813ad9d40c,TL shared,0.426627
uuid-10947786012d4e0f80dd17f6b3c63b5f,trial,0.41075
uuid-10947786012d4e0f80dd17f6b3c63b5f,commented,0.373539
uuid-10947786012d4e0f80dd17f6b3c63b5f,RCC,0.33845
uuid-10947786012d4e0f80dd17f6b3c63b5f,data,0.401432
uuid-10947786012d4e0f80dd17f6b3c63b5f,combo,0.326807
uuid-10947786012d4e0f80dd17f6b3c63b5f,clinical trials,0.32994
uuid-10947786012d4e0f80dd17f6b3c63b5f,SCCHN,0.370826
uuid-10947786012d4e0f80dd17f6b3c63b5f,impressed,0.373997
uuid-10947786012d4e0f80dd17f6b3c63b5f,TLs,0.364907
uuid-10947786012d4e0f80dd17f6b3c63b5f,SCLC,0.310576
uuid-10947786012d4e0f80dd17f6b3c63b5f,bladder,0.480169
uuid-5bdd93ff46494e3f824a0a6d390b88d1,patients,0.309408
uuid-5bdd93ff46494e3f824a0a6d390b88d1,therapy,0.358419
uuid-5bdd93ff46494e3f824a0a6d390b88d1,1L,0.390282
uuid-5bdd93ff46494e3f824a0a6d390b88d1,treated,0.369098
uuid-5bdd93ff46494e3f824a0a6d390b88d1,combination,0.364426
uuid-5bdd93ff46494e3f824a0a6d390b88d1,chemo,0.533781
uuid-5bdd93ff46494e3f824a0a6d390b88d1,tumor,0.551641
uuid-5bdd93ff46494e3f824a0a6d390b88d1,2L,0.377034
uuid-5bdd93ff46494e3f824a0a6d390b88d1,pts,0.479226
uuid-5bdd93ff46494e3f824a0a6d390b88d1,agents,0.340834
uuid-5bdd93ff46494e3f824a0a6d390b88d1,preferred,0.300466
uuid-5bdd93ff46494e3f824a0a6d390b88d1,monotherapy,0.400622
uuid-5bdd93ff46494e3f824a0a6d390b88d1,response,0.477795
uuid-5bdd93ff46494e3f824a0a6d390b88d1,PD1,0.435342
uuid-5bdd93ff46494e3f824a0a6d390b88d1,progression,0.369377
uuid-5bdd93ff46494e3f824a0a6d390b88d1,believes,0.335496
uuid-5bdd93ff46494e3f824a0a6d390b88d1,chemotherapy,0.330104
uuid-5bdd93ff46494e3f824a0a6d390b88d1,respond,0.309697
uuid-5bdd93ff46494e3f824a0a6d390b88d1,PD-1,0.319626
uuid-5bdd93ff46494e3f824a0a6d390b88d1,RTL stated,0.310139
uuid-5bdd93ff46494e3f824a0a6d390b88d1,option,0.405901
uuid-fc9279a9d5094e918203ae5832d3dd18,Nivo,0.341321
uuid-fc9279a9d5094e918203ae5832d3dd18,pembro,0.518869
uuid-fc9279a9d5094e918203ae5832d3dd18,1L,0.777272
uuid-fc9279a9d5094e918203ae5832d3dd18,RCC,0.610289
uuid-fc9279a9d5094e918203ae5832d3dd18,TL stated,0.410382
uuid-fc9279a9d5094e918203ae5832d3dd18,2L,0.777937
uuid-fc9279a9d5094e918203ae5832d3dd18,agents,0.459953
uuid-fc9279a9d5094e918203ae5832d3dd18,stated,0.369367
uuid-fc9279a9d5094e918203ae5832d3dd18,approval,0.438746
uuid-fc9279a9d5094e918203ae5832d3dd18,atezo,0.550882
uuid-fc9279a9d5094e918203ae5832d3dd18,preferred,0.649788
uuid-fc9279a9d5094e918203ae5832d3dd18,monotherapy,0.509932
uuid-fc9279a9d5094e918203ae5832d3dd18,using nivo,0.615866
uuid-fc9279a9d5094e918203ae5832d3dd18,data,0.315057
uuid-fc9279a9d5094e918203ae5832d3dd18,combo,0.406553
uuid-fc9279a9d5094e918203ae5832d3dd18,PDL1 testing,0.321004
uuid-fc9279a9d5094e918203ae5832d3dd18,indication,0.37587
uuid-fc9279a9d5094e918203ae5832d3dd18,approved,0.626512
uuid-fc9279a9d5094e918203ae5832d3dd18,SCCHN,0.51277
uuid-fc9279a9d5094e918203ae5832d3dd18,nivo and pembro,0.335696
uuid-fc9279a9d5094e918203ae5832d3dd18,believes,0.332372
uuid-fc9279a9d5094e918203ae5832d3dd18,impressed,0.356321
uuid-fc9279a9d5094e918203ae5832d3dd18,tumor types,0.401911
uuid-fc9279a9d5094e918203ae5832d3dd18,SCLC,0.405596
uuid-fc9279a9d5094e918203ae5832d3dd18,feels,0.34631
uuid-fc9279a9d5094e918203ae5832d3dd18,Regional TL,0.320065
uuid-fc9279a9d5094e918203ae5832d3dd18,RTL stated,0.55137
uuid-fc9279a9d5094e918203ae5832d3dd18,TL shared,0.30509
uuid-fc9279a9d5094e918203ae5832d3dd18,option,0.558784
uuid-fc9279a9d5094e918203ae5832d3dd18,bladder,0.434822
uuid-9db334caaf0b4b86a499ed3a62829fa7,BMS,0.373054
uuid-9db334caaf0b4b86a499ed3a62829fa7,efficacy,0.335822
uuid-9db334caaf0b4b86a499ed3a62829fa7,discussed,0.333373
uuid-9db334caaf0b4b86a499ed3a62829fa7,commented,0.386753
uuid-9db334caaf0b4b86a499ed3a62829fa7,OS,0.664962
uuid-9db334caaf0b4b86a499ed3a62829fa7,regards,0.48046
uuid-9db334caaf0b4b86a499ed3a62829fa7,data,0.512272
uuid-9db334caaf0b4b86a499ed3a62829fa7,expressed,0.388877
uuid-9db334caaf0b4b86a499ed3a62829fa7,PFS,0.684287
uuid-9db334caaf0b4b86a499ed3a62829fa7,AI,0.491298
uuid-9db334caaf0b4b86a499ed3a62829fa7,ORR,0.552995
uuid-9db334caaf0b4b86a499ed3a62829fa7,ASCO,0.379786
uuid-9db334caaf0b4b86a499ed3a62829fa7,impressed,0.42731
uuid-9db334caaf0b4b86a499ed3a62829fa7,TLs,0.308693
uuid-9db334caaf0b4b86a499ed3a62829fa7,NCCN,0.322974
uuid-de4c103f44eb4fbfae8b55b7a0c13800,Nivo,0.382198
uuid-de4c103f44eb4fbfae8b55b7a0c13800,patients,0.584943
uuid-de4c103f44eb4fbfae8b55b7a0c13800,therapy,0.51186
uuid-de4c103f44eb4fbfae8b55b7a0c13800,nivolumab,0.482839
uuid-de4c103f44eb4fbfae8b55b7a0c13800,1L,0.563669
uuid-de4c103f44eb4fbfae8b55b7a0c13800,regimen,0.316
uuid-de4c103f44eb4fbfae8b55b7a0c13800,treated,0.330057
uuid-de4c103f44eb4fbfae8b55b7a0c13800,RCC,0.438314
uuid-de4c103f44eb4fbfae8b55b7a0c13800,2L,0.585767
uuid-de4c103f44eb4fbfae8b55b7a0c13800,pts,0.365079
uuid-de4c103f44eb4fbfae8b55b7a0c13800,approval,0.532092
uuid-de4c103f44eb4fbfae8b55b7a0c13800,preferred,0.522504
uuid-de4c103f44eb4fbfae8b55b7a0c13800,monotherapy,0.513118
uuid-de4c103f44eb4fbfae8b55b7a0c13800,treatment,0.476008
uuid-de4c103f44eb4fbfae8b55b7a0c13800,using nivo,0.612061
uuid-de4c103f44eb4fbfae8b55b7a0c13800,PD1,0.320187
uuid-de4c103f44eb4fbfae8b55b7a0c13800,approved,0.617356
uuid-de4c103f44eb4fbfae8b55b7a0c13800,progression,0.358005
uuid-de4c103f44eb4fbfae8b55b7a0c13800,chemotherapy,0.301423
uuid-de4c103f44eb4fbfae8b55b7a0c13800,label,0.394547
uuid-de4c103f44eb4fbfae8b55b7a0c13800,RTL stated,0.433212
uuid-de4c103f44eb4fbfae8b55b7a0c13800,option,0.580609
uuid-0538ae1669534525b0915483cb60fa5c,TL,0.386976
uuid-0538ae1669534525b0915483cb60fa5c,1L,0.34453
uuid-0538ae1669534525b0915483cb60fa5c,TL stated,0.561588
uuid-0538ae1669534525b0915483cb60fa5c,institution,0.352587
uuid-0538ae1669534525b0915483cb60fa5c,PD-L1,0.644513
uuid-0538ae1669534525b0915483cb60fa5c,approval,0.32182
uuid-0538ae1669534525b0915483cb60fa5c,PD-L1 testing,0.713541
uuid-0538ae1669534525b0915483cb60fa5c,testing,0.860346
uuid-0538ae1669534525b0915483cb60fa5c,PDL1 testing,0.834393
uuid-0538ae1669534525b0915483cb60fa5c,NSCLC patients,0.836126
uuid-0538ae1669534525b0915483cb60fa5c,tumor types,0.322958
uuid-0538ae1669534525b0915483cb60fa5c,assay,0.420945
uuid-0538ae1669534525b0915483cb60fa5c,biomarker,0.303538
uuid-da06913128fd43a0b683cf8fe6b2da33,pembro,0.631732
uuid-da06913128fd43a0b683cf8fe6b2da33,1L,0.59861
uuid-da06913128fd43a0b683cf8fe6b2da33,PDL1,0.54883
uuid-da06913128fd43a0b683cf8fe6b2da33,TL stated,0.332611
uuid-da06913128fd43a0b683cf8fe6b2da33,2L,0.588101
uuid-da06913128fd43a0b683cf8fe6b2da33,agents,0.485212
uuid-da06913128fd43a0b683cf8fe6b2da33,Merck,0.378602
uuid-da06913128fd43a0b683cf8fe6b2da33,PD-L1,0.526442
uuid-da06913128fd43a0b683cf8fe6b2da33,approval,0.307162
uuid-da06913128fd43a0b683cf8fe6b2da33,atezo,0.697674
uuid-da06913128fd43a0b683cf8fe6b2da33,preferred,0.53563
uuid-da06913128fd43a0b683cf8fe6b2da33,PD-L1 testing,0.330022
uuid-da06913128fd43a0b683cf8fe6b2da33,testing,0.483376
uuid-da06913128fd43a0b683cf8fe6b2da33,using nivo,0.315666
uuid-da06913128fd43a0b683cf8fe6b2da33,PDL1 testing,0.482482
uuid-da06913128fd43a0b683cf8fe6b2da33,indication,0.34304
uuid-da06913128fd43a0b683cf8fe6b2da33,NSCLC patients,0.373808
uuid-da06913128fd43a0b683cf8fe6b2da33,approved,0.444312
uuid-da06913128fd43a0b683cf8fe6b2da33,nivo and pembro,0.46818
uuid-da06913128fd43a0b683cf8fe6b2da33,believes,0.425928
uuid-da06913128fd43a0b683cf8fe6b2da33,feels,0.31536
uuid-da06913128fd43a0b683cf8fe6b2da33,assay,0.469783
uuid-da06913128fd43a0b683cf8fe6b2da33,PDL1 expression,0.380139
uuid-da06913128fd43a0b683cf8fe6b2da33,option,0.390225
uuid-da06913128fd43a0b683cf8fe6b2da33,biomarker,0.323262
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,RTL,0.529171
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,nivolumab,0.30571
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,trial,0.352019
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,NTL,0.435418
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,commented,0.372798
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,stated,0.316591
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,approval,0.304648
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,data,0.48945
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,mentioned,0.436741
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,SCCHN,0.36719
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,HCP,0.345387
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,ASCO,0.432344
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,impressed,0.454314
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,LTL,0.418338
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,SCLC,0.419042
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,Regional TL,0.434891
uuid-aeaf3a497fec4ffb916b2ae2dd55a1f5,RTL stated,0.336685
uuid-1dbd402b7b5946b586a9b64ad188e62c,Nivo,0.439959
uuid-1dbd402b7b5946b586a9b64ad188e62c,pembro,0.67578
uuid-1dbd402b7b5946b586a9b64ad188e62c,1L,0.719522
uuid-1dbd402b7b5946b586a9b64ad188e62c,RCC,0.449791
uuid-1dbd402b7b5946b586a9b64ad188e62c,chemo,0.361008
uuid-1dbd402b7b5946b586a9b64ad188e62c,2L,0.788094
uuid-1dbd402b7b5946b586a9b64ad188e62c,pts,0.369706
uuid-1dbd402b7b5946b586a9b64ad188e62c,agents,0.450385
uuid-1dbd402b7b5946b586a9b64ad188e62c,approval,0.440418
uuid-1dbd402b7b5946b586a9b64ad188e62c,atezo,0.673438
uuid-1dbd402b7b5946b586a9b64ad188e62c,preferred,0.679074
uuid-1dbd402b7b5946b586a9b64ad188e62c,monotherapy,0.589984
uuid-1dbd402b7b5946b586a9b64ad188e62c,using nivo,0.599155
uuid-1dbd402b7b5946b586a9b64ad188e62c,combo,0.418801
uuid-1dbd402b7b5946b586a9b64ad188e62c,clinical trials,0.322977
uuid-1dbd402b7b5946b586a9b64ad188e62c,indication,0.36462
uuid-1dbd402b7b5946b586a9b64ad188e62c,NSCLC patients,0.311651
uuid-1dbd402b7b5946b586a9b64ad188e62c,approved,0.572449
uuid-1dbd402b7b5946b586a9b64ad188e62c,SCCHN,0.35435
uuid-1dbd402b7b5946b586a9b64ad188e62c,nivo and pembro,0.360481
uuid-1dbd402b7b5946b586a9b64ad188e62c,believes,0.340069
uuid-1dbd402b7b5946b586a9b64ad188e62c,tumor types,0.346329
uuid-1dbd402b7b5946b586a9b64ad188e62c,TLs,0.354606
uuid-1dbd402b7b5946b586a9b64ad188e62c,feels,0.392842
uuid-1dbd402b7b5946b586a9b64ad188e62c,RTL stated,0.492143
uuid-1dbd402b7b5946b586a9b64ad188e62c,option,0.567188
uuid-1dbd402b7b5946b586a9b64ad188e62c,bladder,0.403892
uuid-016cabb1351f4114b75769b1a202c9ff,TL,0.350606
uuid-016cabb1351f4114b75769b1a202c9ff,1L,0.383221
uuid-016cabb1351f4114b75769b1a202c9ff,PDL1,0.474028
uuid-016cabb1351f4114b75769b1a202c9ff,TL stated,0.422625
uuid-016cabb1351f4114b75769b1a202c9ff,PD-L1,0.801756
uuid-016cabb1351f4114b75769b1a202c9ff,PD-L1 testing,0.720943
uuid-016cabb1351f4114b75769b1a202c9ff,testing,0.869208
uuid-016cabb1351f4114b75769b1a202c9ff,PDL1 testing,0.747326
uuid-016cabb1351f4114b75769b1a202c9ff,NSCLC patients,0.732988
uuid-016cabb1351f4114b75769b1a202c9ff,tumor types,0.37233
uuid-016cabb1351f4114b75769b1a202c9ff,assay,0.527074
uuid-016cabb1351f4114b75769b1a202c9ff,PDL1 expression,0.375676
uuid-016cabb1351f4114b75769b1a202c9ff,biomarker,0.549684
uuid-7d1c815a8980482d83e451883656e5f8,Nivo,0.46544
uuid-7d1c815a8980482d83e451883656e5f8,pembro,0.459502
uuid-7d1c815a8980482d83e451883656e5f8,1L,0.604039
uuid-7d1c815a8980482d83e451883656e5f8,regimen,0.349583
uuid-7d1c815a8980482d83e451883656e5f8,RCC,0.339284
uuid-7d1c815a8980482d83e451883656e5f8,combination,0.54741
uuid-7d1c815a8980482d83e451883656e5f8,chemo,0.460943
uuid-7d1c815a8980482d83e451883656e5f8,2L,0.602271
uuid-7d1c815a8980482d83e451883656e5f8,pts,0.379792
uuid-7d1c815a8980482d83e451883656e5f8,agents,0.462336
uuid-7d1c815a8980482d83e451883656e5f8,Ipi,0.31501
uuid-7d1c815a8980482d83e451883656e5f8,atezo,0.401247
uuid-7d1c815a8980482d83e451883656e5f8,preferred,0.437831
uuid-7d1c815a8980482d83e451883656e5f8,monotherapy,0.631675
uuid-7d1c815a8980482d83e451883656e5f8,using nivo,0.427824
uuid-7d1c815a8980482d83e451883656e5f8,combo,0.666014
uuid-7d1c815a8980482d83e451883656e5f8,PD1,0.435461
uuid-7d1c815a8980482d83e451883656e5f8,approved,0.431107
uuid-7d1c815a8980482d83e451883656e5f8,nivo and pembro,0.302308
uuid-7d1c815a8980482d83e451883656e5f8,believes,0.433279
uuid-7d1c815a8980482d83e451883656e5f8,chemotherapy,0.366418
uuid-7d1c815a8980482d83e451883656e5f8,feels,0.583201
uuid-7d1c815a8980482d83e451883656e5f8,RTL stated,0.353072
uuid-7d1c815a8980482d83e451883656e5f8,option,0.577781
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,TL,0.541015
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,PDL1,0.572261
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,TL stated,0.340224
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,Merck,0.461659
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,institution,0.338249
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,PD-L1,0.837011
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,PD-L1 testing,0.815582
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,testing,0.890783
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,PDL1 testing,0.671097
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,NSCLC patients,0.57096
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,assay,0.807166
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,PDL1 expression,0.365143
uuid-fe7c06ac3f5c420cb54d1e578bc88f19,biomarker,0.499659
uuid-bfc080a55c474b0b8e4c24507e1cefc6,TL,0.60695
uuid-bfc080a55c474b0b8e4c24507e1cefc6,TL stated,0.378727
uuid-bfc080a55c474b0b8e4c24507e1cefc6,PD-L1,0.566209
uuid-bfc080a55c474b0b8e4c24507e1cefc6,PD-L1 testing,0.797823
uuid-bfc080a55c474b0b8e4c24507e1cefc6,testing,0.746846
uuid-bfc080a55c474b0b8e4c24507e1cefc6,PDL1 testing,0.579408
uuid-bfc080a55c474b0b8e4c24507e1cefc6,NSCLC patients,0.539863
uuid-bfc080a55c474b0b8e4c24507e1cefc6,assay,0.529183
uuid-8ad65ed09538492980ef20b1ceea2626,data,0.303009
uuid-8ad65ed09538492980ef20b1ceea2626,Keytruda,0.39057
uuid-97e6628801b34243a75d1943a72fda26,pembro,0.412177
uuid-97e6628801b34243a75d1943a72fda26,1L,0.305643
uuid-97e6628801b34243a75d1943a72fda26,2L,0.330284
uuid-97e6628801b34243a75d1943a72fda26,atezo,0.343735
uuid-97e6628801b34243a75d1943a72fda26,preferred,0.487438
uuid-97e6628801b34243a75d1943a72fda26,using nivo,0.463723
uuid-97e6628801b34243a75d1943a72fda26,mentioned,0.394366
uuid-97e6628801b34243a75d1943a72fda26,indication,0.301818
uuid-97e6628801b34243a75d1943a72fda26,NSCLC patients,0.371752
uuid-97e6628801b34243a75d1943a72fda26,SCCHN,0.312432
uuid-97e6628801b34243a75d1943a72fda26,HCP,0.486323
uuid-97e6628801b34243a75d1943a72fda26,LTL,0.320564
uuid-97e6628801b34243a75d1943a72fda26,RTL stated,0.374325
uuid-97e6628801b34243a75d1943a72fda26,option,0.351981
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,Nivo,0.536806
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,nivolumab,0.323266
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,toxicity,0.357431
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,efficacy,0.366775
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,regimen,0.497293
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,combination,0.661727
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,chemo,0.461231
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,pts,0.34383
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,Ipi,0.575131
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,monotherapy,0.577486
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,using nivo,0.306442
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,response,0.325168
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,combo,0.567575
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,PD1,0.399755
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,chemotherapy,0.440569
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,SCLC,0.342746
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,feels,0.42277
uuid-83879f9c1b244b7f9a8eee3c7cb50c3b,option,0.403035
uuid-b0c13d08d77c4251b975a497d25b5816,Opdivo,0.384056
uuid-b0c13d08d77c4251b975a497d25b5816,shared,0.430401
uuid-b0c13d08d77c4251b975a497d25b5816,institution,0.574721
uuid-b0c13d08d77c4251b975a497d25b5816,approval,0.535341
uuid-b0c13d08d77c4251b975a497d25b5816,preferred,0.322384
uuid-b0c13d08d77c4251b975a497d25b5816,using nivo,0.471269
uuid-b0c13d08d77c4251b975a497d25b5816,expressed,0.312479
uuid-b0c13d08d77c4251b975a497d25b5816,mentioned,0.542066
uuid-b0c13d08d77c4251b975a497d25b5816,PDL1 testing,0.300413
uuid-b0c13d08d77c4251b975a497d25b5816,indication,0.409261
uuid-b0c13d08d77c4251b975a497d25b5816,approved,0.397601
uuid-b0c13d08d77c4251b975a497d25b5816,SCCHN,0.417389
uuid-b0c13d08d77c4251b975a497d25b5816,HCP,0.545785
uuid-b0c13d08d77c4251b975a497d25b5816,label,0.414666
uuid-b0c13d08d77c4251b975a497d25b5816,LTL,0.406612
uuid-b0c13d08d77c4251b975a497d25b5816,RTL stated,0.336181
uuid-4240577310a6452c84a2ecb1e723196e,Nivo,0.309608
uuid-4240577310a6452c84a2ecb1e723196e,pembro,0.378687
uuid-4240577310a6452c84a2ecb1e723196e,1L,0.604772
uuid-4240577310a6452c84a2ecb1e723196e,combination,0.389312
uuid-4240577310a6452c84a2ecb1e723196e,chemo,0.317616
uuid-4240577310a6452c84a2ecb1e723196e,2L,0.630637
uuid-4240577310a6452c84a2ecb1e723196e,agents,0.60058
uuid-4240577310a6452c84a2ecb1e723196e,atezo,0.401564
uuid-4240577310a6452c84a2ecb1e723196e,preferred,0.663409
uuid-4240577310a6452c84a2ecb1e723196e,monotherapy,0.593472
uuid-4240577310a6452c84a2ecb1e723196e,using nivo,0.445408
uuid-4240577310a6452c84a2ecb1e723196e,combo,0.398196
uuid-4240577310a6452c84a2ecb1e723196e,indication,0.348372
uuid-4240577310a6452c84a2ecb1e723196e,PD1,0.341438
uuid-4240577310a6452c84a2ecb1e723196e,approved,0.456282
uuid-4240577310a6452c84a2ecb1e723196e,believes,0.360819
uuid-4240577310a6452c84a2ecb1e723196e,chemotherapy,0.306191
uuid-4240577310a6452c84a2ecb1e723196e,feels,0.487087
uuid-4240577310a6452c84a2ecb1e723196e,RTL stated,0.397815
uuid-4240577310a6452c84a2ecb1e723196e,option,0.70991
uuid-01fb8dda32464eaca4fecad87f3c5631,therapy,0.33939
uuid-01fb8dda32464eaca4fecad87f3c5631,PDL1,0.337453
uuid-01fb8dda32464eaca4fecad87f3c5631,chemo,0.339451
uuid-01fb8dda32464eaca4fecad87f3c5631,PD-L1,0.449909
uuid-01fb8dda32464eaca4fecad87f3c5631,testing,0.305087
uuid-01fb8dda32464eaca4fecad87f3c5631,monotherapy,0.393068
uuid-01fb8dda32464eaca4fecad87f3c5631,chemotherapy,0.397067
uuid-01fb8dda32464eaca4fecad87f3c5631,Keytruda,0.31506
uuid-01fb8dda32464eaca4fecad87f3c5631,option,0.388016
uuid-85170c3868ea418bbb83370440a172a7,pembro,0.320925
uuid-85170c3868ea418bbb83370440a172a7,dose,0.469915
uuid-85170c3868ea418bbb83370440a172a7,toxicity,0.365969
uuid-85170c3868ea418bbb83370440a172a7,efficacy,0.426828
uuid-85170c3868ea418bbb83370440a172a7,agents,0.34869
uuid-85170c3868ea418bbb83370440a172a7,atezo,0.414932
uuid-85170c3868ea418bbb83370440a172a7,preferred,0.406948
uuid-85170c3868ea418bbb83370440a172a7,monotherapy,0.307216
uuid-85170c3868ea418bbb83370440a172a7,indication,0.306166
uuid-85170c3868ea418bbb83370440a172a7,vs,0.379774
uuid-85170c3868ea418bbb83370440a172a7,drug,0.379265
uuid-85170c3868ea418bbb83370440a172a7,Keytruda,0.475373
uuid-85170c3868ea418bbb83370440a172a7,flat dosing,0.399491
uuid-9520e0743634462ea545c6f9f7c59910,Nivo,0.338616
uuid-9520e0743634462ea545c6f9f7c59910,pembro,0.584825
uuid-9520e0743634462ea545c6f9f7c59910,BMS,0.435121
uuid-9520e0743634462ea545c6f9f7c59910,1L,0.513532
uuid-9520e0743634462ea545c6f9f7c59910,2L,0.603278
uuid-9520e0743634462ea545c6f9f7c59910,agents,0.39432
uuid-9520e0743634462ea545c6f9f7c59910,Merck,0.338104
uuid-9520e0743634462ea545c6f9f7c59910,approval,0.300909
uuid-9520e0743634462ea545c6f9f7c59910,atezo,0.631704
uuid-9520e0743634462ea545c6f9f7c59910,preferred,0.474599
uuid-9520e0743634462ea545c6f9f7c59910,monotherapy,0.315201
uuid-9520e0743634462ea545c6f9f7c59910,using nivo,0.371357
uuid-9520e0743634462ea545c6f9f7c59910,combo,0.443777
uuid-9520e0743634462ea545c6f9f7c59910,clinical trials,0.301591
uuid-9520e0743634462ea545c6f9f7c59910,indication,0.366015
uuid-9520e0743634462ea545c6f9f7c59910,approved,0.50597
uuid-9520e0743634462ea545c6f9f7c59910,nivo and pembro,0.345639
uuid-9520e0743634462ea545c6f9f7c59910,vs,0.314636
uuid-9520e0743634462ea545c6f9f7c59910,feels,0.438561
uuid-9520e0743634462ea545c6f9f7c59910,option,0.37252
uuid-f2c819410b1f428fbdef4373eae75507,RTL,0.52603
uuid-f2c819410b1f428fbdef4373eae75507,trial,0.552948
uuid-f2c819410b1f428fbdef4373eae75507,NTL,0.393961
uuid-f2c819410b1f428fbdef4373eae75507,shared,0.325729
uuid-f2c819410b1f428fbdef4373eae75507,commented,0.414662
uuid-f2c819410b1f428fbdef4373eae75507,tumor,0.319248
uuid-f2c819410b1f428fbdef4373eae75507,stated,0.396561
uuid-f2c819410b1f428fbdef4373eae75507,approval,0.397015
uuid-f2c819410b1f428fbdef4373eae75507,expressed,0.329873
uuid-f2c819410b1f428fbdef4373eae75507,clinical trials,0.418895
uuid-f2c819410b1f428fbdef4373eae75507,SCCHN,0.403104
uuid-f2c819410b1f428fbdef4373eae75507,ASCO,0.303115
uuid-f2c819410b1f428fbdef4373eae75507,impressed,0.369022
uuid-f2c819410b1f428fbdef4373eae75507,Regional TL,0.42148
uuid-f2c819410b1f428fbdef4373eae75507,bladder,0.397737
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,patients,0.78286
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,Opdivo,0.302808
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,therapy,0.503589
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,1L,0.340175
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,regimen,0.313046
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,treated,0.410838
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,chemo,0.366187
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,tumor,0.324453
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,pts,0.573541
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,testing,0.325885
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,monotherapy,0.36028
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,treatment,0.586587
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,response,0.302806
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,NSCLC patients,0.463083
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,progression,0.567711
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,chemotherapy,0.346302
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,respond,0.396537
uuid-d3133732e21b4fa0a6fc0eebb7bfbf3d,option,0.471335
uuid-9fd75988a7f5479283e1fd836bc748ae,TL,0.475702
uuid-9fd75988a7f5479283e1fd836bc748ae,BMS,0.34606
uuid-9fd75988a7f5479283e1fd836bc748ae,NSCLC,0.43309
uuid-9fd75988a7f5479283e1fd836bc748ae,trial,0.382871
uuid-9fd75988a7f5479283e1fd836bc748ae,IO,0.317139
uuid-9fd75988a7f5479283e1fd836bc748ae,Merck,0.401864
uuid-9fd75988a7f5479283e1fd836bc748ae,TLs,0.314599
uuid-bdbb1d08dfa04da49d8bf4a787156e67,pembro,0.361827
uuid-bdbb1d08dfa04da49d8bf4a787156e67,1L,0.428544
uuid-bdbb1d08dfa04da49d8bf4a787156e67,2L,0.46597
uuid-bdbb1d08dfa04da49d8bf4a787156e67,agents,0.316072
uuid-bdbb1d08dfa04da49d8bf4a787156e67,PD-L1,0.338144
uuid-bdbb1d08dfa04da49d8bf4a787156e67,approval,0.37468
uuid-bdbb1d08dfa04da49d8bf4a787156e67,atezo,0.419201
uuid-bdbb1d08dfa04da49d8bf4a787156e67,preferred,0.620631
uuid-bdbb1d08dfa04da49d8bf4a787156e67,PD-L1 testing,0.411783
uuid-bdbb1d08dfa04da49d8bf4a787156e67,testing,0.378769
uuid-bdbb1d08dfa04da49d8bf4a787156e67,monotherapy,0.316512
uuid-bdbb1d08dfa04da49d8bf4a787156e67,using nivo,0.382333
uuid-bdbb1d08dfa04da49d8bf4a787156e67,clinical trials,0.321711
uuid-bdbb1d08dfa04da49d8bf4a787156e67,PDL1 testing,0.425637
uuid-bdbb1d08dfa04da49d8bf4a787156e67,indication,0.388781
uuid-bdbb1d08dfa04da49d8bf4a787156e67,NSCLC patients,0.33609
uuid-bdbb1d08dfa04da49d8bf4a787156e67,approved,0.432927
uuid-bdbb1d08dfa04da49d8bf4a787156e67,SCCHN,0.42107
uuid-bdbb1d08dfa04da49d8bf4a787156e67,RTL stated,0.464184
uuid-bdbb1d08dfa04da49d8bf4a787156e67,option,0.438858
uuid-bdbb1d08dfa04da49d8bf4a787156e67,bladder,0.35226
uuid-f251b31cdcc54616b09dc2f65fbf24e6,dose,0.346526
uuid-f251b31cdcc54616b09dc2f65fbf24e6,nivolumab,0.388729
uuid-f251b31cdcc54616b09dc2f65fbf24e6,toxicity,0.579737
uuid-f251b31cdcc54616b09dc2f65fbf24e6,regimen,0.492258
uuid-f251b31cdcc54616b09dc2f65fbf24e6,combination,0.78292
uuid-f251b31cdcc54616b09dc2f65fbf24e6,chemo,0.393954
uuid-f251b31cdcc54616b09dc2f65fbf24e6,2L,0.319033
uuid-f251b31cdcc54616b09dc2f65fbf24e6,IO,0.385575
uuid-f251b31cdcc54616b09dc2f65fbf24e6,agents,0.433925
uuid-f251b31cdcc54616b09dc2f65fbf24e6,Ipi,0.538872
uuid-f251b31cdcc54616b09dc2f65fbf24e6,preferred,0.419665
uuid-f251b31cdcc54616b09dc2f65fbf24e6,monotherapy,0.596153
uuid-f251b31cdcc54616b09dc2f65fbf24e6,combo,0.653047
uuid-f251b31cdcc54616b09dc2f65fbf24e6,PD1,0.433759
uuid-f251b31cdcc54616b09dc2f65fbf24e6,believes,0.309385
uuid-f251b31cdcc54616b09dc2f65fbf24e6,chemotherapy,0.390693
uuid-f251b31cdcc54616b09dc2f65fbf24e6,SCLC,0.326915
uuid-f251b31cdcc54616b09dc2f65fbf24e6,option,0.447283
uuid-00d8292c44d34deca038de7653a41e8b,patients,0.738069
uuid-00d8292c44d34deca038de7653a41e8b,Opdivo,0.316322
uuid-00d8292c44d34deca038de7653a41e8b,therapy,0.416359
uuid-00d8292c44d34deca038de7653a41e8b,nivolumab,0.323574
uuid-00d8292c44d34deca038de7653a41e8b,regimen,0.381916
uuid-00d8292c44d34deca038de7653a41e8b,treated,0.49931
uuid-00d8292c44d34deca038de7653a41e8b,pts,0.420634
uuid-00d8292c44d34deca038de7653a41e8b,treatment,0.559513
uuid-00d8292c44d34deca038de7653a41e8b,progression,0.43221
uuid-00d8292c44d34deca038de7653a41e8b,respond,0.41242
uuid-89d1541058774f19972e722c4104613b,pembro,0.423228
uuid-89d1541058774f19972e722c4104613b,1L,0.327926
uuid-89d1541058774f19972e722c4104613b,PDL1,0.655234
uuid-89d1541058774f19972e722c4104613b,trial,0.356768
uuid-89d1541058774f19972e722c4104613b,efficacy,0.443731
uuid-89d1541058774f19972e722c4104613b,Merck,0.36392
uuid-89d1541058774f19972e722c4104613b,PD-L1,0.504991
uuid-89d1541058774f19972e722c4104613b,OS,0.516746
uuid-89d1541058774f19972e722c4104613b,atezo,0.384792
uuid-89d1541058774f19972e722c4104613b,testing,0.384252
uuid-89d1541058774f19972e722c4104613b,data,0.686855
uuid-89d1541058774f19972e722c4104613b,PFS,0.457382
uuid-89d1541058774f19972e722c4104613b,NSCLC patients,0.325657
uuid-89d1541058774f19972e722c4104613b,ORR,0.520745
uuid-89d1541058774f19972e722c4104613b,nivo and pembro,0.482056
uuid-89d1541058774f19972e722c4104613b,impressed,0.45106
uuid-89d1541058774f19972e722c4104613b,assay,0.387115
uuid-89d1541058774f19972e722c4104613b,PDL1 expression,0.520146
uuid-89d1541058774f19972e722c4104613b,biomarker,0.431241
uuid-934ea7f70950461c93cc54309afd3c9a,oncologist,0.375955
uuid-934ea7f70950461c93cc54309afd3c9a,indicated,0.393563
uuid-934ea7f70950461c93cc54309afd3c9a,SCLC,0.328769
uuid-934ea7f70950461c93cc54309afd3c9a,Regional TL,0.301854
uuid-934ea7f70950461c93cc54309afd3c9a,TL shared,0.329568
uuid-934ea7f70950461c93cc54309afd3c9a,NCCN,0.502269
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,Nivo,0.390166
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,pembro,0.493323
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,trial,0.688912
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,approval,0.350066
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,atezo,0.316037
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,data,0.449791
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,clinical trials,0.404131
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,indication,0.383102
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,chemotherapy,0.334503
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,impressed,0.386578
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,feels,0.349634
uuid-38fb98ae2dfa4966ae1d0672e9ee0a18,bladder,0.336691
uuid-8a1f7d00ff3d478fa1e7259e300c33e3,tumor,0.345868
uuid-8a1f7d00ff3d478fa1e7259e300c33e3,physicians,0.338873
uuid-137c1ad7ceb04a208e792f8417af168a,patients,0.658255
uuid-137c1ad7ceb04a208e792f8417af168a,Opdivo,0.38348
uuid-137c1ad7ceb04a208e792f8417af168a,therapy,0.534873
uuid-137c1ad7ceb04a208e792f8417af168a,nivolumab,0.573242
uuid-137c1ad7ceb04a208e792f8417af168a,regimen,0.474027
uuid-137c1ad7ceb04a208e792f8417af168a,treated,0.764861
uuid-137c1ad7ceb04a208e792f8417af168a,pts,0.459047
uuid-137c1ad7ceb04a208e792f8417af168a,treatment,0.581647
uuid-137c1ad7ceb04a208e792f8417af168a,cHL,0.449625
uuid-137c1ad7ceb04a208e792f8417af168a,progression,0.476014
uuid-137c1ad7ceb04a208e792f8417af168a,respond,0.32357
uuid-137c1ad7ceb04a208e792f8417af168a,RTL stated,0.31559
uuid-a0e2ad355bbf40b2980de6295aa14129,Nivo,0.392436
uuid-a0e2ad355bbf40b2980de6295aa14129,patients,0.65424
uuid-a0e2ad355bbf40b2980de6295aa14129,Opdivo,0.391945
uuid-a0e2ad355bbf40b2980de6295aa14129,therapy,0.569987
uuid-a0e2ad355bbf40b2980de6295aa14129,nivolumab,0.445113
uuid-a0e2ad355bbf40b2980de6295aa14129,regimen,0.498633
uuid-a0e2ad355bbf40b2980de6295aa14129,treated,0.5289
uuid-a0e2ad355bbf40b2980de6295aa14129,chemo,0.328174
uuid-a0e2ad355bbf40b2980de6295aa14129,pts,0.60689
uuid-a0e2ad355bbf40b2980de6295aa14129,monotherapy,0.302832
uuid-a0e2ad355bbf40b2980de6295aa14129,treatment,0.659247
uuid-a0e2ad355bbf40b2980de6295aa14129,response,0.54751
uuid-a0e2ad355bbf40b2980de6295aa14129,PD1,0.376564
uuid-a0e2ad355bbf40b2980de6295aa14129,cHL,0.432422
uuid-a0e2ad355bbf40b2980de6295aa14129,progression,0.71953
uuid-a0e2ad355bbf40b2980de6295aa14129,chemotherapy,0.353769
uuid-a0e2ad355bbf40b2980de6295aa14129,respond,0.580128
uuid-c4cc82b97d14406280eb290c6cfa26fd,patients,0.638864
uuid-c4cc82b97d14406280eb290c6cfa26fd,therapy,0.576372
uuid-c4cc82b97d14406280eb290c6cfa26fd,nivolumab,0.378752
uuid-c4cc82b97d14406280eb290c6cfa26fd,regimen,0.564197
uuid-c4cc82b97d14406280eb290c6cfa26fd,treated,0.510359
uuid-c4cc82b97d14406280eb290c6cfa26fd,chemo,0.412601
uuid-c4cc82b97d14406280eb290c6cfa26fd,pts,0.676931
uuid-c4cc82b97d14406280eb290c6cfa26fd,monotherapy,0.348043
uuid-c4cc82b97d14406280eb290c6cfa26fd,treatment,0.678445
uuid-c4cc82b97d14406280eb290c6cfa26fd,response,0.673639
uuid-c4cc82b97d14406280eb290c6cfa26fd,PD1,0.422287
uuid-c4cc82b97d14406280eb290c6cfa26fd,progression,0.799416
uuid-c4cc82b97d14406280eb290c6cfa26fd,chemotherapy,0.44141
uuid-c4cc82b97d14406280eb290c6cfa26fd,respond,0.666209
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,Nivo,0.30939
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,patients,0.701186
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,Opdivo,0.447151
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,therapy,0.464971
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,dose,0.572467
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,nivolumab,0.334449
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,toxicity,0.539579
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,regimen,0.663146
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,treated,0.462971
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,chemo,0.397102
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,pts,0.515722
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,Ipi,0.3389
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,monotherapy,0.316475
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,treatment,0.693466
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,response,0.453685
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,progression,0.615996
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,chemotherapy,0.387719
uuid-c6dddbbfcdb347d58a0c8c4536b31e5f,respond,0.594095
uuid-1e84efdb7ed94a73988754a6a007b885,patients,0.380307
uuid-1e84efdb7ed94a73988754a6a007b885,therapy,0.301965
uuid-1e84efdb7ed94a73988754a6a007b885,treated,0.389521
uuid-1e84efdb7ed94a73988754a6a007b885,treatment,0.425862
uuid-1e84efdb7ed94a73988754a6a007b885,chemotherapy,0.393278
uuid-1e84efdb7ed94a73988754a6a007b885,oncologist,0.370836
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,TL,0.433876
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,PDL1,0.326665
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,TL stated,0.476391
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,institution,0.417564
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,PD-L1,0.675979
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,PD-L1 testing,0.721547
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,testing,0.767053
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,PDL1 testing,0.731855
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,NSCLC patients,0.661709
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,SCCHN,0.406122
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,HCP,0.319502
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,tumor types,0.343785
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,assay,0.442333
uuid-350f2e4216b94d9fbd3a8bc2bc23a319,biomarker,0.402461
uuid-83dc77ab62304e00b11014433a7271f5,Nivo,0.411359
uuid-83dc77ab62304e00b11014433a7271f5,pembro,0.333955
uuid-83dc77ab62304e00b11014433a7271f5,1L,0.336723
uuid-83dc77ab62304e00b11014433a7271f5,PDL1,0.435574
uuid-83dc77ab62304e00b11014433a7271f5,trial,0.328098
uuid-83dc77ab62304e00b11014433a7271f5,chemo,0.487808
uuid-83dc77ab62304e00b11014433a7271f5,agents,0.334839
uuid-83dc77ab62304e00b11014433a7271f5,OS,0.304765
uuid-83dc77ab62304e00b11014433a7271f5,monotherapy,0.330668
uuid-83dc77ab62304e00b11014433a7271f5,PFS,0.361011
uuid-83dc77ab62304e00b11014433a7271f5,PD1,0.342238
uuid-83dc77ab62304e00b11014433a7271f5,ORR,0.308322
uuid-83dc77ab62304e00b11014433a7271f5,nivo and pembro,0.550505
uuid-83dc77ab62304e00b11014433a7271f5,believes,0.520871
uuid-83dc77ab62304e00b11014433a7271f5,chemotherapy,0.415974
uuid-83dc77ab62304e00b11014433a7271f5,respond,0.309092
uuid-83dc77ab62304e00b11014433a7271f5,feels,0.448002
uuid-83dc77ab62304e00b11014433a7271f5,PDL1 expression,0.354507
uuid-83dc77ab62304e00b11014433a7271f5,option,0.375604
uuid-8b0abc32d89141b2aadde2cce25c6246,RTL,0.37863
uuid-8b0abc32d89141b2aadde2cce25c6246,lung,0.647295
uuid-8b0abc32d89141b2aadde2cce25c6246,NTL,0.386233
uuid-8b0abc32d89141b2aadde2cce25c6246,discussed,0.389672
uuid-8b0abc32d89141b2aadde2cce25c6246,melanoma,0.496199
uuid-8b0abc32d89141b2aadde2cce25c6246,commented,0.542772
uuid-8b0abc32d89141b2aadde2cce25c6246,RCC,0.446017
uuid-8b0abc32d89141b2aadde2cce25c6246,TL stated,0.426289
uuid-8b0abc32d89141b2aadde2cce25c6246,stated,0.445635
uuid-8b0abc32d89141b2aadde2cce25c6246,regards,0.310565
uuid-8b0abc32d89141b2aadde2cce25c6246,data,0.483761
uuid-8b0abc32d89141b2aadde2cce25c6246,expressed,0.370225
uuid-8b0abc32d89141b2aadde2cce25c6246,AI,0.375894
uuid-8b0abc32d89141b2aadde2cce25c6246,SCCHN,0.438554
uuid-8b0abc32d89141b2aadde2cce25c6246,ASCO,0.478448
uuid-8b0abc32d89141b2aadde2cce25c6246,impressed,0.458007
uuid-8b0abc32d89141b2aadde2cce25c6246,TLs,0.455578
uuid-8b0abc32d89141b2aadde2cce25c6246,SCLC,0.313219
uuid-8b0abc32d89141b2aadde2cce25c6246,Regional TL,0.441175
uuid-8b0abc32d89141b2aadde2cce25c6246,TL shared,0.449214
uuid-8b0abc32d89141b2aadde2cce25c6246,NCCN,0.408608
uuid-5993196780ef4bb7ac08198f1a04ddf3,lung,0.383148
uuid-5993196780ef4bb7ac08198f1a04ddf3,NSCLC,0.315611
uuid-5993196780ef4bb7ac08198f1a04ddf3,NTL,0.379881
uuid-5993196780ef4bb7ac08198f1a04ddf3,discussed,0.434901
uuid-5993196780ef4bb7ac08198f1a04ddf3,melanoma,0.323438
uuid-5993196780ef4bb7ac08198f1a04ddf3,commented,0.411936
uuid-5993196780ef4bb7ac08198f1a04ddf3,regards,0.439557
uuid-5993196780ef4bb7ac08198f1a04ddf3,AI,0.382601
uuid-5993196780ef4bb7ac08198f1a04ddf3,lung cancer,0.365994
uuid-5993196780ef4bb7ac08198f1a04ddf3,NCCN,0.687876
uuid-fbeda5b180384dd784abab5fe4877842,response,0.430403
uuid-fbeda5b180384dd784abab5fe4877842,lung cancer,0.448173
uuid-a173be1f44d045b3b01e8ffaafa18310,PDL1,0.636384
uuid-a173be1f44d045b3b01e8ffaafa18310,tumor,0.348816
uuid-a173be1f44d045b3b01e8ffaafa18310,PD-L1,0.399552
uuid-a173be1f44d045b3b01e8ffaafa18310,nivo and pembro,0.335637
uuid-a173be1f44d045b3b01e8ffaafa18310,believes,0.394825
uuid-a173be1f44d045b3b01e8ffaafa18310,assay,0.333283
uuid-a173be1f44d045b3b01e8ffaafa18310,PDL1 expression,0.587838
uuid-a173be1f44d045b3b01e8ffaafa18310,biomarker,0.604686
uuid-a1a4be9db69046bf9528d6968c2bfcd5,NSCLC,0.574958
uuid-a1a4be9db69046bf9528d6968c2bfcd5,melanoma,0.396638
uuid-a1a4be9db69046bf9528d6968c2bfcd5,RCC,0.33116
uuid-a1a4be9db69046bf9528d6968c2bfcd5,TL stated,0.315023
uuid-a1a4be9db69046bf9528d6968c2bfcd5,combination,0.308155
uuid-a1a4be9db69046bf9528d6968c2bfcd5,IO,0.618394
uuid-a1a4be9db69046bf9528d6968c2bfcd5,response,0.509872
uuid-a1a4be9db69046bf9528d6968c2bfcd5,combo,0.31457
uuid-a1a4be9db69046bf9528d6968c2bfcd5,progression,0.315023
uuid-a1a4be9db69046bf9528d6968c2bfcd5,TLs,0.314886
uuid-a1a4be9db69046bf9528d6968c2bfcd5,TL shared,0.382126
uuid-a658c7f1af9244319020165a252209d8,Nivo,0.340998
uuid-a658c7f1af9244319020165a252209d8,patients,0.495874
uuid-a658c7f1af9244319020165a252209d8,Opdivo,0.316519
uuid-a658c7f1af9244319020165a252209d8,therapy,0.503817
uuid-a658c7f1af9244319020165a252209d8,dose,0.33678
uuid-a658c7f1af9244319020165a252209d8,nivolumab,0.396661
uuid-a658c7f1af9244319020165a252209d8,toxicity,0.424539
uuid-a658c7f1af9244319020165a252209d8,regimen,0.444866
uuid-a658c7f1af9244319020165a252209d8,treated,0.338642
uuid-a658c7f1af9244319020165a252209d8,treatment,0.591733
uuid-a658c7f1af9244319020165a252209d8,cHL,0.300066
uuid-a658c7f1af9244319020165a252209d8,progression,0.360224
uuid-a658c7f1af9244319020165a252209d8,chemotherapy,0.403491
uuid-a658c7f1af9244319020165a252209d8,respond,0.358604
uuid-b2119ac83cd14ef3b946700ed22cccd7,patients,0.448404
uuid-b2119ac83cd14ef3b946700ed22cccd7,toxicity,0.417564
uuid-b2119ac83cd14ef3b946700ed22cccd7,regimen,0.356893
uuid-b2119ac83cd14ef3b946700ed22cccd7,treated,0.392734
uuid-b2119ac83cd14ef3b946700ed22cccd7,tumor,0.436534
uuid-b2119ac83cd14ef3b946700ed22cccd7,pts,0.408306
uuid-b2119ac83cd14ef3b946700ed22cccd7,treatment,0.467477
uuid-b2119ac83cd14ef3b946700ed22cccd7,response,0.475996
uuid-b2119ac83cd14ef3b946700ed22cccd7,progression,0.562378
uuid-b2119ac83cd14ef3b946700ed22cccd7,respond,0.476864
uuid-3f0063bda6a14b138a8b1cd87f310813,TL stated,0.300572
uuid-3f0063bda6a14b138a8b1cd87f310813,PD-L1,0.351279
uuid-3f0063bda6a14b138a8b1cd87f310813,testing,0.522699
uuid-3f0063bda6a14b138a8b1cd87f310813,PDL1 testing,0.530431
uuid-3f0063bda6a14b138a8b1cd87f310813,NSCLC patients,0.611864
uuid-3f0063bda6a14b138a8b1cd87f310813,tumor types,0.357788
uuid-3f0063bda6a14b138a8b1cd87f310813,biomarker,0.336387
uuid-b901ed6ae83147e5abcf37b8731933ee,patients,0.631399
uuid-b901ed6ae83147e5abcf37b8731933ee,Opdivo,0.710649
uuid-b901ed6ae83147e5abcf37b8731933ee,nivolumab,0.37877
uuid-b901ed6ae83147e5abcf37b8731933ee,treated,0.405053
uuid-b901ed6ae83147e5abcf37b8731933ee,shared,0.304539
uuid-b901ed6ae83147e5abcf37b8731933ee,approval,0.432898
uuid-b901ed6ae83147e5abcf37b8731933ee,physicians,0.382901
uuid-b901ed6ae83147e5abcf37b8731933ee,preferred,0.36938
uuid-b901ed6ae83147e5abcf37b8731933ee,treatment,0.446874
uuid-b901ed6ae83147e5abcf37b8731933ee,using nivo,0.394651
uuid-b901ed6ae83147e5abcf37b8731933ee,approved,0.423257
uuid-b901ed6ae83147e5abcf37b8731933ee,HCP,0.319511
uuid-b901ed6ae83147e5abcf37b8731933ee,label,0.344344
uuid-b901ed6ae83147e5abcf37b8731933ee,option,0.306542
uuid-b901ed6ae83147e5abcf37b8731933ee,flat dosing,0.317963
uuid-5f9f5ecd5f494e85a47729892f334022,TL,0.420818
uuid-5f9f5ecd5f494e85a47729892f334022,treated,0.326947
uuid-5f9f5ecd5f494e85a47729892f334022,TL stated,0.513404
uuid-5f9f5ecd5f494e85a47729892f334022,PD-L1,0.437705
uuid-5f9f5ecd5f494e85a47729892f334022,PD-L1 testing,0.682949
uuid-5f9f5ecd5f494e85a47729892f334022,testing,0.602607
uuid-5f9f5ecd5f494e85a47729892f334022,PDL1 testing,0.582669
uuid-5f9f5ecd5f494e85a47729892f334022,NSCLC patients,0.58332
uuid-5f9f5ecd5f494e85a47729892f334022,lung cancer,0.578248
uuid-5f9f5ecd5f494e85a47729892f334022,TL shared,0.368665
uuid-6fed26389c914b28a4b2c6307dea8cad,commented,0.356885
uuid-6fed26389c914b28a4b2c6307dea8cad,physicians,0.672338
uuid-6fed26389c914b28a4b2c6307dea8cad,regards,0.353778
uuid-6fed26389c914b28a4b2c6307dea8cad,oncology,0.604359
uuid-6fed26389c914b28a4b2c6307dea8cad,ASCO,0.300631
uuid-6fed26389c914b28a4b2c6307dea8cad,clinical,0.409101
uuid-5480eb7385c2476b9f6819f11519214f,pembro,0.371199
uuid-5480eb7385c2476b9f6819f11519214f,1L,0.646766
uuid-5480eb7385c2476b9f6819f11519214f,PDL1,0.52759
uuid-5480eb7385c2476b9f6819f11519214f,efficacy,0.356723
uuid-5480eb7385c2476b9f6819f11519214f,regimen,0.326442
uuid-5480eb7385c2476b9f6819f11519214f,combination,0.367003
uuid-5480eb7385c2476b9f6819f11519214f,chemo,0.593879
uuid-5480eb7385c2476b9f6819f11519214f,2L,0.569596
uuid-5480eb7385c2476b9f6819f11519214f,pts,0.372641
uuid-5480eb7385c2476b9f6819f11519214f,IO,0.334098
uuid-5480eb7385c2476b9f6819f11519214f,agents,0.609272
uuid-5480eb7385c2476b9f6819f11519214f,PD-L1,0.318083
uuid-5480eb7385c2476b9f6819f11519214f,atezo,0.398187
uuid-5480eb7385c2476b9f6819f11519214f,preferred,0.500363
uuid-5480eb7385c2476b9f6819f11519214f,monotherapy,0.675753
uuid-5480eb7385c2476b9f6819f11519214f,combo,0.448781
uuid-5480eb7385c2476b9f6819f11519214f,PD1,0.562375
uuid-5480eb7385c2476b9f6819f11519214f,nivo and pembro,0.460983
uuid-5480eb7385c2476b9f6819f11519214f,believes,0.549579
uuid-5480eb7385c2476b9f6819f11519214f,chemotherapy,0.421776
uuid-5480eb7385c2476b9f6819f11519214f,feels,0.46248
uuid-5480eb7385c2476b9f6819f11519214f,PD-1,0.399728
uuid-5480eb7385c2476b9f6819f11519214f,PDL1 expression,0.449762
uuid-5480eb7385c2476b9f6819f11519214f,option,0.621966
uuid-5480eb7385c2476b9f6819f11519214f,biomarker,0.337443
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,pembro,0.425125
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,1L,0.478748
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,2L,0.507291
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,agents,0.348767
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,approval,0.338504
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,atezo,0.402043
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,preferred,0.5181
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,monotherapy,0.375539
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,using nivo,0.365376
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,NSCLC patients,0.333985
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,approved,0.433378
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,feels,0.475374
uuid-f9b6a5d92a3a48f7b24c1a1248d8232c,option,0.489899
uuid-9c94475331984c8d9ba31bce24e9c9be,therapy,0.320774
uuid-9c94475331984c8d9ba31bce24e9c9be,regimen,0.31403
uuid-9c94475331984c8d9ba31bce24e9c9be,chemo,0.351177
uuid-9c94475331984c8d9ba31bce24e9c9be,pts,0.326544
uuid-9c94475331984c8d9ba31bce24e9c9be,OS,0.373591
uuid-9c94475331984c8d9ba31bce24e9c9be,response,0.500939
uuid-9c94475331984c8d9ba31bce24e9c9be,data,0.363097
uuid-9c94475331984c8d9ba31bce24e9c9be,PFS,0.31436
uuid-9c94475331984c8d9ba31bce24e9c9be,PD1,0.361751
uuid-9c94475331984c8d9ba31bce24e9c9be,ORR,0.368701
uuid-9c94475331984c8d9ba31bce24e9c9be,progression,0.493521
uuid-9c94475331984c8d9ba31bce24e9c9be,chemotherapy,0.324165
uuid-9c94475331984c8d9ba31bce24e9c9be,impressed,0.400374
uuid-9c94475331984c8d9ba31bce24e9c9be,respond,0.385248
uuid-9c94475331984c8d9ba31bce24e9c9be,SCLC,0.397345
uuid-b8315dd34a304fe29d79c155450a5331,Nivo,0.332133
uuid-b8315dd34a304fe29d79c155450a5331,therapy,0.375566
uuid-b8315dd34a304fe29d79c155450a5331,nivolumab,0.495231
uuid-b8315dd34a304fe29d79c155450a5331,trial,0.454777
uuid-b8315dd34a304fe29d79c155450a5331,regimen,0.301782
uuid-b8315dd34a304fe29d79c155450a5331,combination,0.684097
uuid-b8315dd34a304fe29d79c155450a5331,chemo,0.457248
uuid-b8315dd34a304fe29d79c155450a5331,pts,0.331076
uuid-b8315dd34a304fe29d79c155450a5331,agents,0.360075
uuid-b8315dd34a304fe29d79c155450a5331,monotherapy,0.52912
uuid-b8315dd34a304fe29d79c155450a5331,combo,0.568086
uuid-b8315dd34a304fe29d79c155450a5331,clinical trials,0.372949
uuid-b8315dd34a304fe29d79c155450a5331,PD1,0.63472
uuid-b8315dd34a304fe29d79c155450a5331,chemotherapy,0.520471
uuid-b8315dd34a304fe29d79c155450a5331,impressed,0.308205
uuid-b8315dd34a304fe29d79c155450a5331,feels,0.467152
uuid-b8315dd34a304fe29d79c155450a5331,option,0.425965
uuid-498ab09be20b4cf1bd82622b4b39d525,pembro,0.65665
uuid-498ab09be20b4cf1bd82622b4b39d525,BMS,0.333325
uuid-498ab09be20b4cf1bd82622b4b39d525,1L,0.612466
uuid-498ab09be20b4cf1bd82622b4b39d525,PDL1,0.632256
uuid-498ab09be20b4cf1bd82622b4b39d525,efficacy,0.321655
uuid-498ab09be20b4cf1bd82622b4b39d525,2L,0.558192
uuid-498ab09be20b4cf1bd82622b4b39d525,agents,0.320402
uuid-498ab09be20b4cf1bd82622b4b39d525,Merck,0.406574
uuid-498ab09be20b4cf1bd82622b4b39d525,PD-L1,0.492055
uuid-498ab09be20b4cf1bd82622b4b39d525,approval,0.39676
uuid-498ab09be20b4cf1bd82622b4b39d525,atezo,0.700016
uuid-498ab09be20b4cf1bd82622b4b39d525,preferred,0.366166
uuid-498ab09be20b4cf1bd82622b4b39d525,testing,0.464379
uuid-498ab09be20b4cf1bd82622b4b39d525,data,0.400476
uuid-498ab09be20b4cf1bd82622b4b39d525,PDL1 testing,0.495421
uuid-498ab09be20b4cf1bd82622b4b39d525,indication,0.374838
uuid-498ab09be20b4cf1bd82622b4b39d525,NSCLC patients,0.382055
uuid-498ab09be20b4cf1bd82622b4b39d525,approved,0.463948
uuid-498ab09be20b4cf1bd82622b4b39d525,nivo and pembro,0.574176
uuid-498ab09be20b4cf1bd82622b4b39d525,believes,0.353391
uuid-498ab09be20b4cf1bd82622b4b39d525,tumor types,0.309762
uuid-498ab09be20b4cf1bd82622b4b39d525,TLs,0.301073
uuid-498ab09be20b4cf1bd82622b4b39d525,feels,0.308621
uuid-498ab09be20b4cf1bd82622b4b39d525,assay,0.381598
uuid-498ab09be20b4cf1bd82622b4b39d525,PDL1 expression,0.530957
uuid-498ab09be20b4cf1bd82622b4b39d525,option,0.300273
uuid-498ab09be20b4cf1bd82622b4b39d525,biomarker,0.390917
uuid-83ee9d2ecfe44189a78381f9a932a039,BMS,0.31823
uuid-83ee9d2ecfe44189a78381f9a932a039,toxicity,0.341271
uuid-83ee9d2ecfe44189a78381f9a932a039,regimen,0.303883
uuid-83ee9d2ecfe44189a78381f9a932a039,physicians,0.586514
uuid-42ba03d0e2b24787ad32d1eb3e4ab10c,Nivo,0.34422
uuid-df77a01049d04877a03fd988912f1f56,Nivo,0.405695
uuid-df77a01049d04877a03fd988912f1f56,pembro,0.608799
uuid-df77a01049d04877a03fd988912f1f56,dose,0.601488
uuid-df77a01049d04877a03fd988912f1f56,efficacy,0.47042
uuid-df77a01049d04877a03fd988912f1f56,Ipi,0.498332
uuid-df77a01049d04877a03fd988912f1f56,atezo,0.670275
uuid-df77a01049d04877a03fd988912f1f56,nivo and pembro,0.36701
uuid-df77a01049d04877a03fd988912f1f56,vs,0.752611
uuid-df77a01049d04877a03fd988912f1f56,TLs,0.339351
uuid-df77a01049d04877a03fd988912f1f56,flat dosing,0.496046
uuid-b2657312f1a84a62a1456f788edde927,Nivo,0.34422
uuid-98f378a2cf2441948ae0960eca8b0ce8,chemo,0.433031
uuid-98f378a2cf2441948ae0960eca8b0ce8,tumor,0.551241
uuid-98f378a2cf2441948ae0960eca8b0ce8,pts,0.316399
uuid-98f378a2cf2441948ae0960eca8b0ce8,response,0.345168
uuid-98f378a2cf2441948ae0960eca8b0ce8,progression,0.301433
uuid-98f378a2cf2441948ae0960eca8b0ce8,chemotherapy,0.311848
uuid-98f378a2cf2441948ae0960eca8b0ce8,immunotherapy,0.367662
uuid-98f378a2cf2441948ae0960eca8b0ce8,biomarker,0.315971
uuid-4f2a8b19bd4a421194b90ea1e2214275,trial,0.320009
uuid-4f2a8b19bd4a421194b90ea1e2214275,regards,0.375451
uuid-0c8fd24f33354e4db18ee9e555478914,patients,0.320199
uuid-0c8fd24f33354e4db18ee9e555478914,progression,0.342391
uuid-dd219e4e832b44ae9ced4f5ca504f287,RTL,0.549726
uuid-dd219e4e832b44ae9ced4f5ca504f287,nivolumab,0.305427
uuid-dd219e4e832b44ae9ced4f5ca504f287,trial,0.412251
uuid-dd219e4e832b44ae9ced4f5ca504f287,NTL,0.384967
uuid-dd219e4e832b44ae9ced4f5ca504f287,commented,0.509812
uuid-dd219e4e832b44ae9ced4f5ca504f287,stated,0.344293
uuid-dd219e4e832b44ae9ced4f5ca504f287,data,0.429492
uuid-dd219e4e832b44ae9ced4f5ca504f287,clinical trials,0.303296
uuid-dd219e4e832b44ae9ced4f5ca504f287,SCCHN,0.338227
uuid-dd219e4e832b44ae9ced4f5ca504f287,HCP,0.321778
uuid-dd219e4e832b44ae9ced4f5ca504f287,ASCO,0.591969
uuid-dd219e4e832b44ae9ced4f5ca504f287,impressed,0.63668
uuid-dd219e4e832b44ae9ced4f5ca504f287,LTL,0.383908
uuid-dd219e4e832b44ae9ced4f5ca504f287,SCLC,0.390137
uuid-dd219e4e832b44ae9ced4f5ca504f287,Regional TL,0.457136
uuid-dd219e4e832b44ae9ced4f5ca504f287,RTL stated,0.30097
uuid-dd219e4e832b44ae9ced4f5ca504f287,bladder,0.304733
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,RTL,0.555915
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,NTL,0.493923
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,discussed,0.316253
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,commented,0.649757
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,stated,0.427275
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,regards,0.354327
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,data,0.404342
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,expressed,0.323462
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,mentioned,0.455173
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,SCCHN,0.431831
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,HCP,0.315627
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,ASCO,0.661049
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,impressed,0.540785
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,LTL,0.405076
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,TLs,0.331489
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,SCLC,0.307088
uuid-8867c2b0ec9a4ab0891ccf8b4a46adf5,Regional TL,0.570531
uuid-42815eeb28644662800b4ae2d06e6405,RTL,0.537651
uuid-42815eeb28644662800b4ae2d06e6405,BMS,0.371987
uuid-42815eeb28644662800b4ae2d06e6405,trial,0.450156
uuid-42815eeb28644662800b4ae2d06e6405,NTL,0.377595
uuid-42815eeb28644662800b4ae2d06e6405,discussed,0.314259
uuid-42815eeb28644662800b4ae2d06e6405,commented,0.6058
uuid-42815eeb28644662800b4ae2d06e6405,Merck,0.361158
uuid-42815eeb28644662800b4ae2d06e6405,stated,0.390418
uuid-42815eeb28644662800b4ae2d06e6405,OS,0.455275
uuid-42815eeb28644662800b4ae2d06e6405,regards,0.373204
uuid-42815eeb28644662800b4ae2d06e6405,data,0.811231
uuid-42815eeb28644662800b4ae2d06e6405,expressed,0.500955
uuid-42815eeb28644662800b4ae2d06e6405,mentioned,0.344041
uuid-42815eeb28644662800b4ae2d06e6405,PFS,0.392109
uuid-42815eeb28644662800b4ae2d06e6405,ORR,0.501645
uuid-42815eeb28644662800b4ae2d06e6405,SCCHN,0.363279
uuid-42815eeb28644662800b4ae2d06e6405,ASCO,0.648502
uuid-42815eeb28644662800b4ae2d06e6405,impressed,0.771634
uuid-42815eeb28644662800b4ae2d06e6405,LTL,0.40679
uuid-42815eeb28644662800b4ae2d06e6405,TLs,0.381493
uuid-42815eeb28644662800b4ae2d06e6405,SCLC,0.395331
uuid-42815eeb28644662800b4ae2d06e6405,Regional TL,0.446917
uuid-ba3d1f96071b40d58a2fca7df8bf7794,patients,0.307157
uuid-ba3d1f96071b40d58a2fca7df8bf7794,toxicity,0.466302
uuid-ba3d1f96071b40d58a2fca7df8bf7794,combination,0.399533
uuid-ba3d1f96071b40d58a2fca7df8bf7794,chemo,0.365308
uuid-ba3d1f96071b40d58a2fca7df8bf7794,tumor,0.374342
uuid-ba3d1f96071b40d58a2fca7df8bf7794,pts,0.31953
uuid-ba3d1f96071b40d58a2fca7df8bf7794,treatment,0.302379
uuid-ba3d1f96071b40d58a2fca7df8bf7794,response,0.597759
uuid-ba3d1f96071b40d58a2fca7df8bf7794,PD1,0.32752
uuid-ba3d1f96071b40d58a2fca7df8bf7794,progression,0.408405
uuid-ba3d1f96071b40d58a2fca7df8bf7794,chemotherapy,0.378117
uuid-ba3d1f96071b40d58a2fca7df8bf7794,respond,0.41211
uuid-b041cab8f12f45d79a6e80de3d5088e1,Nivo,0.359975
uuid-b041cab8f12f45d79a6e80de3d5088e1,pembro,0.33967
uuid-b041cab8f12f45d79a6e80de3d5088e1,trial,0.545678
uuid-b041cab8f12f45d79a6e80de3d5088e1,efficacy,0.392013
uuid-b041cab8f12f45d79a6e80de3d5088e1,combination,0.664266
uuid-b041cab8f12f45d79a6e80de3d5088e1,chemo,0.444303
uuid-b041cab8f12f45d79a6e80de3d5088e1,agents,0.430063
uuid-b041cab8f12f45d79a6e80de3d5088e1,Ipi,0.456801
uuid-b041cab8f12f45d79a6e80de3d5088e1,monotherapy,0.402031
uuid-b041cab8f12f45d79a6e80de3d5088e1,combo,0.650411
uuid-b041cab8f12f45d79a6e80de3d5088e1,PD1,0.507548
uuid-b041cab8f12f45d79a6e80de3d5088e1,nivo and pembro,0.328627
uuid-b041cab8f12f45d79a6e80de3d5088e1,believes,0.344219
uuid-b041cab8f12f45d79a6e80de3d5088e1,chemotherapy,0.399292
uuid-b041cab8f12f45d79a6e80de3d5088e1,vs,0.32089
uuid-b041cab8f12f45d79a6e80de3d5088e1,feels,0.3296
uuid-ff4197837e0a4a1d9346881bae9c04da,BMS,0.494167
uuid-ff4197837e0a4a1d9346881bae9c04da,Merck,0.462666
uuid-79121d1765244ab2a6a834e0dd4ec036,patients,0.318006
uuid-79121d1765244ab2a6a834e0dd4ec036,pembro,0.310116
uuid-79121d1765244ab2a6a834e0dd4ec036,RTL,0.300918
uuid-79121d1765244ab2a6a834e0dd4ec036,nivolumab,0.404701
uuid-79121d1765244ab2a6a834e0dd4ec036,1L,0.370166
uuid-79121d1765244ab2a6a834e0dd4ec036,RCC,0.333285
uuid-79121d1765244ab2a6a834e0dd4ec036,2L,0.364171
uuid-79121d1765244ab2a6a834e0dd4ec036,approval,0.401817
uuid-79121d1765244ab2a6a834e0dd4ec036,preferred,0.60648
uuid-79121d1765244ab2a6a834e0dd4ec036,monotherapy,0.381684
uuid-79121d1765244ab2a6a834e0dd4ec036,using nivo,0.532431
uuid-79121d1765244ab2a6a834e0dd4ec036,indication,0.416343
uuid-79121d1765244ab2a6a834e0dd4ec036,approved,0.331352
uuid-79121d1765244ab2a6a834e0dd4ec036,SCCHN,0.571554
uuid-79121d1765244ab2a6a834e0dd4ec036,chemotherapy,0.33837
uuid-79121d1765244ab2a6a834e0dd4ec036,Regional TL,0.313306
uuid-79121d1765244ab2a6a834e0dd4ec036,RTL stated,0.537003
uuid-79121d1765244ab2a6a834e0dd4ec036,option,0.480868
uuid-79121d1765244ab2a6a834e0dd4ec036,bladder,0.358195
uuid-7139371f7f444065a44d6f156d40a1fa,patients,0.415079
uuid-7139371f7f444065a44d6f156d40a1fa,PDL1,0.461089
uuid-7139371f7f444065a44d6f156d40a1fa,pts,0.340336
uuid-7139371f7f444065a44d6f156d40a1fa,OS,0.306321
uuid-7139371f7f444065a44d6f156d40a1fa,PFS,0.344622
uuid-7139371f7f444065a44d6f156d40a1fa,respond,0.381155
uuid-7139371f7f444065a44d6f156d40a1fa,feels,0.327514
uuid-7139371f7f444065a44d6f156d40a1fa,PDL1 expression,0.30071
uuid-2bdce7e8becb4acbab06311b691b3a1f,pembro,0.401691
uuid-2bdce7e8becb4acbab06311b691b3a1f,lung,0.333932
uuid-2bdce7e8becb4acbab06311b691b3a1f,2L,0.328464
uuid-2bdce7e8becb4acbab06311b691b3a1f,atezo,0.445336
uuid-2bdce7e8becb4acbab06311b691b3a1f,nivo and pembro,0.631133
uuid-2bdce7e8becb4acbab06311b691b3a1f,vs,0.31157
uuid-5ab27583073b4194b6481cd50ab809cb,Nivo,0.375552
uuid-5ab27583073b4194b6481cd50ab809cb,patients,0.750543
uuid-5ab27583073b4194b6481cd50ab809cb,Opdivo,0.348077
uuid-5ab27583073b4194b6481cd50ab809cb,therapy,0.553159
uuid-5ab27583073b4194b6481cd50ab809cb,dose,0.308421
uuid-5ab27583073b4194b6481cd50ab809cb,nivolumab,0.660704
uuid-5ab27583073b4194b6481cd50ab809cb,toxicity,0.313781
uuid-5ab27583073b4194b6481cd50ab809cb,regimen,0.567092
uuid-5ab27583073b4194b6481cd50ab809cb,treated,0.552927
uuid-5ab27583073b4194b6481cd50ab809cb,combination,0.509055
uuid-5ab27583073b4194b6481cd50ab809cb,chemo,0.470375
uuid-5ab27583073b4194b6481cd50ab809cb,pts,0.540753
uuid-5ab27583073b4194b6481cd50ab809cb,Ipi,0.317552
uuid-5ab27583073b4194b6481cd50ab809cb,preferred,0.344716
uuid-5ab27583073b4194b6481cd50ab809cb,monotherapy,0.489468
uuid-5ab27583073b4194b6481cd50ab809cb,treatment,0.610675
uuid-5ab27583073b4194b6481cd50ab809cb,using nivo,0.426345
uuid-5ab27583073b4194b6481cd50ab809cb,combo,0.415328
uuid-5ab27583073b4194b6481cd50ab809cb,PD1,0.375159
uuid-5ab27583073b4194b6481cd50ab809cb,progression,0.51512
uuid-5ab27583073b4194b6481cd50ab809cb,chemotherapy,0.554315
uuid-5ab27583073b4194b6481cd50ab809cb,respond,0.334432
uuid-5ab27583073b4194b6481cd50ab809cb,RTL stated,0.371922
uuid-5ab27583073b4194b6481cd50ab809cb,option,0.446773
uuid-294f4c74442a4aa3b373f43181fb6388,patients,0.564248
uuid-294f4c74442a4aa3b373f43181fb6388,Opdivo,0.315377
uuid-294f4c74442a4aa3b373f43181fb6388,therapy,0.366655
uuid-294f4c74442a4aa3b373f43181fb6388,toxicity,0.35164
uuid-294f4c74442a4aa3b373f43181fb6388,regimen,0.327917
uuid-294f4c74442a4aa3b373f43181fb6388,treated,0.477623
uuid-294f4c74442a4aa3b373f43181fb6388,treatment,0.536018
uuid-294f4c74442a4aa3b373f43181fb6388,cHL,0.321605
uuid-294f4c74442a4aa3b373f43181fb6388,progression,0.395335
uuid-294f4c74442a4aa3b373f43181fb6388,respond,0.403063
uuid-56522f9ac3794d4396cedc637eb588c0,Nivo,0.371048
uuid-56522f9ac3794d4396cedc637eb588c0,Opdivo,0.447425
uuid-56522f9ac3794d4396cedc637eb588c0,pembro,0.32583
uuid-56522f9ac3794d4396cedc637eb588c0,stated,0.397601
uuid-56522f9ac3794d4396cedc637eb588c0,approval,0.305811
uuid-56522f9ac3794d4396cedc637eb588c0,using nivo,0.377368
uuid-56522f9ac3794d4396cedc637eb588c0,data,0.341202
uuid-56522f9ac3794d4396cedc637eb588c0,clinical trials,0.375711
uuid-56522f9ac3794d4396cedc637eb588c0,indication,0.327474
uuid-56522f9ac3794d4396cedc637eb588c0,approved,0.348555
uuid-56522f9ac3794d4396cedc637eb588c0,SCCHN,0.338056
uuid-56522f9ac3794d4396cedc637eb588c0,HCP,0.360552
uuid-56522f9ac3794d4396cedc637eb588c0,impressed,0.435288
uuid-56522f9ac3794d4396cedc637eb588c0,LTL,0.384106
uuid-56522f9ac3794d4396cedc637eb588c0,feels,0.45832
uuid-56522f9ac3794d4396cedc637eb588c0,bladder,0.427015
uuid-d1ec5015df594f7889d8705712f28961,efficacy,0.512527
uuid-d1ec5015df594f7889d8705712f28961,discussed,0.332196
uuid-d1ec5015df594f7889d8705712f28961,IO,0.304374
uuid-d1ec5015df594f7889d8705712f28961,regards,0.321298
uuid-d1ec5015df594f7889d8705712f28961,data,0.375164
uuid-d1ec5015df594f7889d8705712f28961,oncology,0.427823
uuid-d1ec5015df594f7889d8705712f28961,ORR,0.318134
uuid-d1ec5015df594f7889d8705712f28961,TLs,0.39032
uuid-d1ec5015df594f7889d8705712f28961,clinical,0.47693
uuid-45d2ded57511482bb76bdde074b8e615,patients,0.354558
uuid-45d2ded57511482bb76bdde074b8e615,Opdivo,0.388985
uuid-45d2ded57511482bb76bdde074b8e615,RTL,0.428668
uuid-45d2ded57511482bb76bdde074b8e615,nivolumab,0.441749
uuid-45d2ded57511482bb76bdde074b8e615,treated,0.360368
uuid-45d2ded57511482bb76bdde074b8e615,shared,0.302964
uuid-45d2ded57511482bb76bdde074b8e615,stated,0.633889
uuid-45d2ded57511482bb76bdde074b8e615,physicians,0.438196
uuid-45d2ded57511482bb76bdde074b8e615,using nivo,0.310061
uuid-45d2ded57511482bb76bdde074b8e615,mentioned,0.311516
uuid-45d2ded57511482bb76bdde074b8e615,SCCHN,0.311797
uuid-45d2ded57511482bb76bdde074b8e615,HCP,0.321386
uuid-45d2ded57511482bb76bdde074b8e615,LTL,0.471112
uuid-45d2ded57511482bb76bdde074b8e615,Regional TL,0.463464
uuid-45d2ded57511482bb76bdde074b8e615,RTL stated,0.359623
uuid-9acca2706dbb47cea5bac844937eabfb,Nivo,0.42336
uuid-9acca2706dbb47cea5bac844937eabfb,pembro,0.332784
uuid-9acca2706dbb47cea5bac844937eabfb,1L,0.406095
uuid-9acca2706dbb47cea5bac844937eabfb,melanoma,0.319883
uuid-9acca2706dbb47cea5bac844937eabfb,RCC,0.51908
uuid-9acca2706dbb47cea5bac844937eabfb,2L,0.489693
uuid-9acca2706dbb47cea5bac844937eabfb,stated,0.302875
uuid-9acca2706dbb47cea5bac844937eabfb,approval,0.367541
uuid-9acca2706dbb47cea5bac844937eabfb,atezo,0.377505
uuid-9acca2706dbb47cea5bac844937eabfb,preferred,0.398764
uuid-9acca2706dbb47cea5bac844937eabfb,monotherapy,0.332526
uuid-9acca2706dbb47cea5bac844937eabfb,using nivo,0.469198
uuid-9acca2706dbb47cea5bac844937eabfb,data,0.335196
uuid-9acca2706dbb47cea5bac844937eabfb,approved,0.380475
uuid-9acca2706dbb47cea5bac844937eabfb,SCCHN,0.510614
uuid-9acca2706dbb47cea5bac844937eabfb,impressed,0.352332
uuid-9acca2706dbb47cea5bac844937eabfb,TLs,0.373786
uuid-9acca2706dbb47cea5bac844937eabfb,SCLC,0.308334
uuid-9acca2706dbb47cea5bac844937eabfb,Regional TL,0.369095
uuid-9acca2706dbb47cea5bac844937eabfb,RTL stated,0.524321
uuid-9acca2706dbb47cea5bac844937eabfb,TL shared,0.340752
uuid-9acca2706dbb47cea5bac844937eabfb,option,0.388275
uuid-9acca2706dbb47cea5bac844937eabfb,bladder,0.367608
uuid-dc82d9fcfb4742d9965b63738520302b,patients,0.726562
uuid-dc82d9fcfb4742d9965b63738520302b,Opdivo,0.330277
uuid-dc82d9fcfb4742d9965b63738520302b,therapy,0.633761
uuid-dc82d9fcfb4742d9965b63738520302b,nivolumab,0.487683
uuid-dc82d9fcfb4742d9965b63738520302b,treated,0.400339
uuid-dc82d9fcfb4742d9965b63738520302b,chemo,0.329447
uuid-dc82d9fcfb4742d9965b63738520302b,pts,0.435851
uuid-dc82d9fcfb4742d9965b63738520302b,treatment,0.535078
uuid-dc82d9fcfb4742d9965b63738520302b,using nivo,0.31209
uuid-dc82d9fcfb4742d9965b63738520302b,cHL,0.410247
uuid-dc82d9fcfb4742d9965b63738520302b,progression,0.506205
uuid-dc82d9fcfb4742d9965b63738520302b,chemotherapy,0.411416
uuid-dc82d9fcfb4742d9965b63738520302b,respond,0.378813
uuid-dc82d9fcfb4742d9965b63738520302b,option,0.337396
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,patients,0.571826
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,Opdivo,0.456146
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,therapy,0.547549
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,nivolumab,0.500369
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,regimen,0.318223
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,treated,0.425418
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,treatment,0.52858
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,cHL,0.62697
uuid-4f7e1c3c8fab44f6bfc0049251bbe658,progression,0.362852
uuid-55473779c9ff4cba86099f9cd9a36520,toxicity,0.353159
uuid-55473779c9ff4cba86099f9cd9a36520,efficacy,0.348908
uuid-55473779c9ff4cba86099f9cd9a36520,combination,0.324185
uuid-55473779c9ff4cba86099f9cd9a36520,chemo,0.357198
uuid-55473779c9ff4cba86099f9cd9a36520,pts,0.338089
uuid-55473779c9ff4cba86099f9cd9a36520,OS,0.339316
uuid-55473779c9ff4cba86099f9cd9a36520,response,0.696644
uuid-55473779c9ff4cba86099f9cd9a36520,PFS,0.323606
uuid-55473779c9ff4cba86099f9cd9a36520,PD1,0.340859
uuid-55473779c9ff4cba86099f9cd9a36520,ORR,0.371959
uuid-55473779c9ff4cba86099f9cd9a36520,progression,0.390804
uuid-55473779c9ff4cba86099f9cd9a36520,chemotherapy,0.313738
uuid-55473779c9ff4cba86099f9cd9a36520,impressed,0.31526
uuid-55473779c9ff4cba86099f9cd9a36520,respond,0.464959
uuid-55473779c9ff4cba86099f9cd9a36520,feels,0.335413
uuid-55473779c9ff4cba86099f9cd9a36520,immunotherapy,0.301836
uuid-283472941f6b414b9d22ecb3b5794f32,pembro,0.30945
uuid-283472941f6b414b9d22ecb3b5794f32,dose,0.358543
uuid-283472941f6b414b9d22ecb3b5794f32,lung,0.355958
uuid-283472941f6b414b9d22ecb3b5794f32,regimen,0.392461
uuid-283472941f6b414b9d22ecb3b5794f32,melanoma,0.567647
uuid-283472941f6b414b9d22ecb3b5794f32,shared,0.306056
uuid-283472941f6b414b9d22ecb3b5794f32,RCC,0.551423
uuid-283472941f6b414b9d22ecb3b5794f32,combination,0.39528
uuid-283472941f6b414b9d22ecb3b5794f32,2L,0.426445
uuid-283472941f6b414b9d22ecb3b5794f32,Ipi,0.521341
uuid-283472941f6b414b9d22ecb3b5794f32,atezo,0.38605
uuid-283472941f6b414b9d22ecb3b5794f32,preferred,0.366357
uuid-283472941f6b414b9d22ecb3b5794f32,monotherapy,0.344118
uuid-283472941f6b414b9d22ecb3b5794f32,using nivo,0.372977
uuid-283472941f6b414b9d22ecb3b5794f32,combo,0.502598
uuid-283472941f6b414b9d22ecb3b5794f32,clinical trials,0.311658
uuid-283472941f6b414b9d22ecb3b5794f32,SCCHN,0.428574
uuid-283472941f6b414b9d22ecb3b5794f32,TLs,0.529079
uuid-283472941f6b414b9d22ecb3b5794f32,academic,0.31365
uuid-283472941f6b414b9d22ecb3b5794f32,SCLC,0.381539
uuid-283472941f6b414b9d22ecb3b5794f32,RTL stated,0.436007
uuid-283472941f6b414b9d22ecb3b5794f32,TL shared,0.40731
uuid-283472941f6b414b9d22ecb3b5794f32,bladder,0.429441
uuid-1a2e93176a83480386e2d4884ce9effd,patients,0.570596
uuid-1a2e93176a83480386e2d4884ce9effd,Opdivo,0.427271
uuid-1a2e93176a83480386e2d4884ce9effd,therapy,0.474642
uuid-1a2e93176a83480386e2d4884ce9effd,nivolumab,0.572557
uuid-1a2e93176a83480386e2d4884ce9effd,treated,0.43913
uuid-1a2e93176a83480386e2d4884ce9effd,physicians,0.342438
uuid-1a2e93176a83480386e2d4884ce9effd,treatment,0.405455
uuid-1a2e93176a83480386e2d4884ce9effd,cHL,0.557823
uuid-1a2e93176a83480386e2d4884ce9effd,progression,0.310839
uuid-cbafafde2cca492bab059313fd2937bd,Nivo,0.654729
uuid-cbafafde2cca492bab059313fd2937bd,patients,0.459209
uuid-cbafafde2cca492bab059313fd2937bd,pembro,0.440742
uuid-cbafafde2cca492bab059313fd2937bd,therapy,0.310456
uuid-cbafafde2cca492bab059313fd2937bd,1L,0.436101
uuid-cbafafde2cca492bab059313fd2937bd,chemo,0.414689
uuid-cbafafde2cca492bab059313fd2937bd,2L,0.471269
uuid-cbafafde2cca492bab059313fd2937bd,pts,0.399203
uuid-cbafafde2cca492bab059313fd2937bd,approval,0.373377
uuid-cbafafde2cca492bab059313fd2937bd,atezo,0.314678
uuid-cbafafde2cca492bab059313fd2937bd,preferred,0.414524
uuid-cbafafde2cca492bab059313fd2937bd,monotherapy,0.453138
uuid-cbafafde2cca492bab059313fd2937bd,using nivo,0.482277
uuid-cbafafde2cca492bab059313fd2937bd,approved,0.51927
uuid-cbafafde2cca492bab059313fd2937bd,respond,0.343148
uuid-cbafafde2cca492bab059313fd2937bd,feels,0.451438
uuid-cbafafde2cca492bab059313fd2937bd,option,0.576964
uuid-dd31ef70b59942469893a3fbd1e1619f,patients,0.507494
uuid-dd31ef70b59942469893a3fbd1e1619f,therapy,0.507017
uuid-dd31ef70b59942469893a3fbd1e1619f,toxicity,0.316683
uuid-dd31ef70b59942469893a3fbd1e1619f,regimen,0.515297
uuid-dd31ef70b59942469893a3fbd1e1619f,treated,0.317414
uuid-dd31ef70b59942469893a3fbd1e1619f,combination,0.316321
uuid-dd31ef70b59942469893a3fbd1e1619f,chemo,0.466934
uuid-dd31ef70b59942469893a3fbd1e1619f,pts,0.524325
uuid-dd31ef70b59942469893a3fbd1e1619f,IO,0.509733
uuid-dd31ef70b59942469893a3fbd1e1619f,monotherapy,0.410978
uuid-dd31ef70b59942469893a3fbd1e1619f,treatment,0.620208
uuid-dd31ef70b59942469893a3fbd1e1619f,response,0.728071
uuid-dd31ef70b59942469893a3fbd1e1619f,PD1,0.458901
uuid-dd31ef70b59942469893a3fbd1e1619f,progression,0.855586
uuid-dd31ef70b59942469893a3fbd1e1619f,believes,0.301999
uuid-dd31ef70b59942469893a3fbd1e1619f,chemotherapy,0.38793
uuid-dd31ef70b59942469893a3fbd1e1619f,respond,0.626503
uuid-dd31ef70b59942469893a3fbd1e1619f,option,0.342083
uuid-763aeb720fd949f993a43a29388e050d,Nivo,0.340556
uuid-763aeb720fd949f993a43a29388e050d,patients,0.521493
uuid-763aeb720fd949f993a43a29388e050d,therapy,0.456426
uuid-763aeb720fd949f993a43a29388e050d,1L,0.423463
uuid-763aeb720fd949f993a43a29388e050d,regimen,0.388189
uuid-763aeb720fd949f993a43a29388e050d,chemo,0.498563
uuid-763aeb720fd949f993a43a29388e050d,2L,0.383958
uuid-763aeb720fd949f993a43a29388e050d,pts,0.472321
uuid-763aeb720fd949f993a43a29388e050d,preferred,0.372124
uuid-763aeb720fd949f993a43a29388e050d,monotherapy,0.540831
uuid-763aeb720fd949f993a43a29388e050d,treatment,0.46396
uuid-763aeb720fd949f993a43a29388e050d,using nivo,0.352899
uuid-763aeb720fd949f993a43a29388e050d,response,0.376646
uuid-763aeb720fd949f993a43a29388e050d,PD1,0.412832
uuid-763aeb720fd949f993a43a29388e050d,progression,0.523505
uuid-763aeb720fd949f993a43a29388e050d,believes,0.336814
uuid-763aeb720fd949f993a43a29388e050d,chemotherapy,0.410438
uuid-763aeb720fd949f993a43a29388e050d,respond,0.48108
uuid-763aeb720fd949f993a43a29388e050d,feels,0.460853
uuid-763aeb720fd949f993a43a29388e050d,option,0.61451
uuid-fc718a4ebaef4d86a6b691cfe2f92743,pembro,0.48489
uuid-fc718a4ebaef4d86a6b691cfe2f92743,RTL,0.343019
uuid-fc718a4ebaef4d86a6b691cfe2f92743,trial,0.362685
uuid-fc718a4ebaef4d86a6b691cfe2f92743,efficacy,0.308081
uuid-fc718a4ebaef4d86a6b691cfe2f92743,commented,0.33372
uuid-fc718a4ebaef4d86a6b691cfe2f92743,stated,0.361581
uuid-fc718a4ebaef4d86a6b691cfe2f92743,approval,0.483134
uuid-fc718a4ebaef4d86a6b691cfe2f92743,atezo,0.413492
uuid-fc718a4ebaef4d86a6b691cfe2f92743,data,0.610931
uuid-fc718a4ebaef4d86a6b691cfe2f92743,clinical trials,0.365315
uuid-fc718a4ebaef4d86a6b691cfe2f92743,indication,0.49717
uuid-fc718a4ebaef4d86a6b691cfe2f92743,approved,0.439382
uuid-fc718a4ebaef4d86a6b691cfe2f92743,SCCHN,0.350316
uuid-fc718a4ebaef4d86a6b691cfe2f92743,impressed,0.496935
uuid-fc718a4ebaef4d86a6b691cfe2f92743,vs,0.31879
uuid-fc718a4ebaef4d86a6b691cfe2f92743,label,0.415934
uuid-fc718a4ebaef4d86a6b691cfe2f92743,LTL,0.393015
uuid-fc718a4ebaef4d86a6b691cfe2f92743,TLs,0.339555
uuid-fc718a4ebaef4d86a6b691cfe2f92743,Regional TL,0.346753
uuid-fc718a4ebaef4d86a6b691cfe2f92743,flat dosing,0.53401
uuid-65b397e8961e4f67b02144ac5259987f,pembro,0.435583
uuid-65b397e8961e4f67b02144ac5259987f,BMS,0.41014
uuid-65b397e8961e4f67b02144ac5259987f,PDL1,0.468252
uuid-65b397e8961e4f67b02144ac5259987f,trial,0.463973
uuid-65b397e8961e4f67b02144ac5259987f,efficacy,0.687411
uuid-65b397e8961e4f67b02144ac5259987f,Merck,0.309318
uuid-65b397e8961e4f67b02144ac5259987f,Ipi,0.317298
uuid-65b397e8961e4f67b02144ac5259987f,OS,0.563976
uuid-65b397e8961e4f67b02144ac5259987f,atezo,0.426531
uuid-65b397e8961e4f67b02144ac5259987f,regards,0.337886
uuid-65b397e8961e4f67b02144ac5259987f,data,0.740082
uuid-65b397e8961e4f67b02144ac5259987f,PFS,0.541308
uuid-65b397e8961e4f67b02144ac5259987f,ORR,0.600513
uuid-65b397e8961e4f67b02144ac5259987f,nivo and pembro,0.543041
uuid-65b397e8961e4f67b02144ac5259987f,believes,0.324079
uuid-65b397e8961e4f67b02144ac5259987f,impressed,0.40935
uuid-65b397e8961e4f67b02144ac5259987f,vs,0.511348
uuid-65b397e8961e4f67b02144ac5259987f,PDL1 expression,0.434926
uuid-1d65d0b5b2c046adba9c36535699981f,BMS,0.530214
uuid-1d65d0b5b2c046adba9c36535699981f,PDL1,0.620879
uuid-1d65d0b5b2c046adba9c36535699981f,trial,0.420702
uuid-1d65d0b5b2c046adba9c36535699981f,efficacy,0.656781
uuid-1d65d0b5b2c046adba9c36535699981f,Merck,0.399471
uuid-1d65d0b5b2c046adba9c36535699981f,OS,0.710438
uuid-1d65d0b5b2c046adba9c36535699981f,regards,0.349148
uuid-1d65d0b5b2c046adba9c36535699981f,data,0.796815
uuid-1d65d0b5b2c046adba9c36535699981f,PFS,0.667298
uuid-1d65d0b5b2c046adba9c36535699981f,ORR,0.710271
uuid-1d65d0b5b2c046adba9c36535699981f,nivo and pembro,0.561909
uuid-1d65d0b5b2c046adba9c36535699981f,believes,0.376879
uuid-1d65d0b5b2c046adba9c36535699981f,impressed,0.509195
uuid-1d65d0b5b2c046adba9c36535699981f,feels,0.437109
uuid-1d65d0b5b2c046adba9c36535699981f,PDL1 expression,0.574715
uuid-1d65d0b5b2c046adba9c36535699981f,biomarker,0.339467
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,Nivo,0.304851
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,patients,0.591856
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,Opdivo,0.300796
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,therapy,0.396614
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,nivolumab,0.423231
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,regimen,0.529356
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,treated,0.395611
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,combination,0.303412
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,chemo,0.308669
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,pts,0.376185
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,preferred,0.430083
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,monotherapy,0.523948
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,treatment,0.446418
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,using nivo,0.388852
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,progression,0.347831
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,chemotherapy,0.330962
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,feels,0.338791
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,RTL stated,0.34375
uuid-7edc70e4376e4f0ebeb9b675ef47b00b,option,0.495294
uuid-0989f56dbaa64cb39786dbff7d0d890c,Nivo,0.351522
uuid-0989f56dbaa64cb39786dbff7d0d890c,patients,0.531159
uuid-0989f56dbaa64cb39786dbff7d0d890c,therapy,0.357899
uuid-0989f56dbaa64cb39786dbff7d0d890c,nivolumab,0.303417
uuid-0989f56dbaa64cb39786dbff7d0d890c,trial,0.420208
uuid-0989f56dbaa64cb39786dbff7d0d890c,treated,0.324415
uuid-0989f56dbaa64cb39786dbff7d0d890c,combination,0.30739
uuid-0989f56dbaa64cb39786dbff7d0d890c,chemo,0.420553
uuid-0989f56dbaa64cb39786dbff7d0d890c,pts,0.60481
uuid-0989f56dbaa64cb39786dbff7d0d890c,monotherapy,0.319913
uuid-0989f56dbaa64cb39786dbff7d0d890c,treatment,0.314777
uuid-0989f56dbaa64cb39786dbff7d0d890c,combo,0.328117
uuid-0989f56dbaa64cb39786dbff7d0d890c,clinical trials,0.359566
uuid-0989f56dbaa64cb39786dbff7d0d890c,progression,0.325008
uuid-0989f56dbaa64cb39786dbff7d0d890c,chemotherapy,0.480707
uuid-0989f56dbaa64cb39786dbff7d0d890c,option,0.365012
uuid-0989f56dbaa64cb39786dbff7d0d890c,bladder,0.433996
uuid-568a1bb3c6b649a592ca5a6bcfdca4cf,expressed,0.332664
uuid-568a1bb3c6b649a592ca5a6bcfdca4cf,clinical,0.322547
uuid-52f1772c258e4ee8b284de5b8ece8504,patients,0.438904
uuid-52f1772c258e4ee8b284de5b8ece8504,treated,0.384355
uuid-52f1772c258e4ee8b284de5b8ece8504,mentioned,0.398006
uuid-52f1772c258e4ee8b284de5b8ece8504,cHL,0.440668
uuid-b8765d14d8d241518e98ba395f246218,RTL,0.45175
uuid-b8765d14d8d241518e98ba395f246218,physicians,0.340431
uuid-b8765d14d8d241518e98ba395f246218,mentioned,0.452577
uuid-b8765d14d8d241518e98ba395f246218,cHL,0.352337
uuid-b8765d14d8d241518e98ba395f246218,LTL,0.381213
uuid-b8765d14d8d241518e98ba395f246218,Regional TL,0.364609
uuid-0876a2e133f5433dabdec93da182c827,Opdivo,0.491394
uuid-0876a2e133f5433dabdec93da182c827,RTL,0.321655
uuid-0876a2e133f5433dabdec93da182c827,stated,0.316973
uuid-0876a2e133f5433dabdec93da182c827,approval,0.439192
uuid-0876a2e133f5433dabdec93da182c827,using nivo,0.350136
uuid-0876a2e133f5433dabdec93da182c827,mentioned,0.422958
uuid-0876a2e133f5433dabdec93da182c827,indication,0.482253
uuid-0876a2e133f5433dabdec93da182c827,approved,0.415125
uuid-0876a2e133f5433dabdec93da182c827,SCCHN,0.379246
uuid-0876a2e133f5433dabdec93da182c827,HCP,0.320951
uuid-0876a2e133f5433dabdec93da182c827,cHL,0.357095
uuid-0876a2e133f5433dabdec93da182c827,label,0.528732
uuid-0876a2e133f5433dabdec93da182c827,Keytruda,0.518163
uuid-0876a2e133f5433dabdec93da182c827,flat dosing,0.364938
uuid-afd4b67ab30946deac8680158aa81759,Nivo,0.5137
uuid-afd4b67ab30946deac8680158aa81759,patients,0.656081
uuid-afd4b67ab30946deac8680158aa81759,Opdivo,0.471332
uuid-afd4b67ab30946deac8680158aa81759,therapy,0.744841
uuid-afd4b67ab30946deac8680158aa81759,nivolumab,0.541517
uuid-afd4b67ab30946deac8680158aa81759,regimen,0.325141
uuid-afd4b67ab30946deac8680158aa81759,treated,0.410367
uuid-afd4b67ab30946deac8680158aa81759,chemo,0.367031
uuid-afd4b67ab30946deac8680158aa81759,monotherapy,0.355336
uuid-afd4b67ab30946deac8680158aa81759,treatment,0.548176
uuid-afd4b67ab30946deac8680158aa81759,using nivo,0.399841
uuid-afd4b67ab30946deac8680158aa81759,PD1,0.398292
uuid-afd4b67ab30946deac8680158aa81759,cHL,0.659275
uuid-afd4b67ab30946deac8680158aa81759,progression,0.426381
uuid-afd4b67ab30946deac8680158aa81759,chemotherapy,0.500532
uuid-afd4b67ab30946deac8680158aa81759,respond,0.300387
uuid-afd4b67ab30946deac8680158aa81759,option,0.379786
uuid-44f07cbc2c294499a7b234f775ab0857,Nivo,0.342515
uuid-44f07cbc2c294499a7b234f775ab0857,patients,0.350752
uuid-44f07cbc2c294499a7b234f775ab0857,Opdivo,0.556863
uuid-44f07cbc2c294499a7b234f775ab0857,2L,0.398431
uuid-44f07cbc2c294499a7b234f775ab0857,approval,0.393781
uuid-44f07cbc2c294499a7b234f775ab0857,preferred,0.424235
uuid-44f07cbc2c294499a7b234f775ab0857,using nivo,0.422954
uuid-44f07cbc2c294499a7b234f775ab0857,indication,0.450775
uuid-44f07cbc2c294499a7b234f775ab0857,approved,0.607285
uuid-44f07cbc2c294499a7b234f775ab0857,label,0.505745
uuid-44f07cbc2c294499a7b234f775ab0857,drug,0.46981
uuid-44f07cbc2c294499a7b234f775ab0857,Keytruda,0.427874
uuid-44f07cbc2c294499a7b234f775ab0857,option,0.45904
uuid-2cff0908fc2c4d49b57fad1ffc5cc23c,Nivo,0.380919
uuid-2cff0908fc2c4d49b57fad1ffc5cc23c,therapy,0.453482
uuid-2cff0908fc2c4d49b57fad1ffc5cc23c,cHL,0.682789
uuid-ba11f5edf4b04742ae3a51a587497cfb,patients,0.572451
uuid-ba11f5edf4b04742ae3a51a587497cfb,Opdivo,0.393643
uuid-ba11f5edf4b04742ae3a51a587497cfb,therapy,0.550863
uuid-ba11f5edf4b04742ae3a51a587497cfb,nivolumab,0.561516
uuid-ba11f5edf4b04742ae3a51a587497cfb,treated,0.420792
uuid-ba11f5edf4b04742ae3a51a587497cfb,approval,0.377328
uuid-ba11f5edf4b04742ae3a51a587497cfb,treatment,0.3846
uuid-ba11f5edf4b04742ae3a51a587497cfb,using nivo,0.442967
uuid-ba11f5edf4b04742ae3a51a587497cfb,mentioned,0.3132
uuid-ba11f5edf4b04742ae3a51a587497cfb,cHL,0.659024
uuid-7b9dd622586141d3a85ffdc2c4d886c1,Nivo,0.309918
uuid-7b9dd622586141d3a85ffdc2c4d886c1,therapy,0.330671
uuid-7b9dd622586141d3a85ffdc2c4d886c1,mentioned,0.369234
uuid-7b9dd622586141d3a85ffdc2c4d886c1,cHL,0.549337
uuid-805a21e3f6644d05a85b5ad7438c94ca,Opdivo,0.485584
uuid-805a21e3f6644d05a85b5ad7438c94ca,physicians,0.36848
uuid-bc7a2876adbb49c5923ad1de076716d0,BMS,0.33041
uuid-bc7a2876adbb49c5923ad1de076716d0,PDL1,0.301462
uuid-bc7a2876adbb49c5923ad1de076716d0,trial,0.406278
uuid-bc7a2876adbb49c5923ad1de076716d0,commented,0.477828
uuid-bc7a2876adbb49c5923ad1de076716d0,Merck,0.351849
uuid-bc7a2876adbb49c5923ad1de076716d0,stated,0.547773
uuid-bc7a2876adbb49c5923ad1de076716d0,approval,0.368714
uuid-bc7a2876adbb49c5923ad1de076716d0,regards,0.330511
uuid-bc7a2876adbb49c5923ad1de076716d0,data,0.539093
uuid-bc7a2876adbb49c5923ad1de076716d0,expressed,0.348638
uuid-bc7a2876adbb49c5923ad1de076716d0,clinical trials,0.306618
uuid-bc7a2876adbb49c5923ad1de076716d0,indication,0.356633
uuid-bc7a2876adbb49c5923ad1de076716d0,approved,0.336842
uuid-bc7a2876adbb49c5923ad1de076716d0,SCCHN,0.342964
uuid-bc7a2876adbb49c5923ad1de076716d0,impressed,0.441924
uuid-bc7a2876adbb49c5923ad1de076716d0,feels,0.318563
uuid-bc7a2876adbb49c5923ad1de076716d0,Regional TL,0.326027
uuid-6fdabffcf115409fb620d7dffaede548,dose,0.335263
uuid-6fdabffcf115409fb620d7dffaede548,lung,0.440672
uuid-6fdabffcf115409fb620d7dffaede548,melanoma,0.48791
uuid-6fdabffcf115409fb620d7dffaede548,shared,0.421712
uuid-6fdabffcf115409fb620d7dffaede548,RCC,0.383851
uuid-6fdabffcf115409fb620d7dffaede548,preferred,0.411977
uuid-6fdabffcf115409fb620d7dffaede548,indication,0.412876
uuid-6fdabffcf115409fb620d7dffaede548,AI,0.368831
uuid-6fdabffcf115409fb620d7dffaede548,SCCHN,0.377371
uuid-6fdabffcf115409fb620d7dffaede548,label,0.313478
uuid-6fdabffcf115409fb620d7dffaede548,RTL stated,0.341178
uuid-6fdabffcf115409fb620d7dffaede548,TL shared,0.379292
uuid-6fdabffcf115409fb620d7dffaede548,flat dosing,0.390673
uuid-fcca822c4b624f61a4ea4b92e15387eb,Nivo,0.588045
uuid-fcca822c4b624f61a4ea4b92e15387eb,pembro,0.335335
uuid-fcca822c4b624f61a4ea4b92e15387eb,therapy,0.51768
uuid-fcca822c4b624f61a4ea4b92e15387eb,nivolumab,0.360835
uuid-fcca822c4b624f61a4ea4b92e15387eb,1L,0.330382
uuid-fcca822c4b624f61a4ea4b92e15387eb,combination,0.559951
uuid-fcca822c4b624f61a4ea4b92e15387eb,chemo,0.463188
uuid-fcca822c4b624f61a4ea4b92e15387eb,2L,0.38233
uuid-fcca822c4b624f61a4ea4b92e15387eb,agents,0.511259
uuid-fcca822c4b624f61a4ea4b92e15387eb,preferred,0.350743
uuid-fcca822c4b624f61a4ea4b92e15387eb,monotherapy,0.577149
uuid-fcca822c4b624f61a4ea4b92e15387eb,response,0.368433
uuid-fcca822c4b624f61a4ea4b92e15387eb,combo,0.387633
uuid-fcca822c4b624f61a4ea4b92e15387eb,PD1,0.543276
uuid-fcca822c4b624f61a4ea4b92e15387eb,chemotherapy,0.404102
uuid-fcca822c4b624f61a4ea4b92e15387eb,PD-1,0.475579
uuid-fcca822c4b624f61a4ea4b92e15387eb,option,0.476809
uuid-da6f81962c954d3b8b48f981a7aa720c,mentioned,0.630664
uuid-da6f81962c954d3b8b48f981a7aa720c,cHL,0.614067
uuid-afec715ce91344a4b24d9c3893d35cae,patients,0.607189
uuid-afec715ce91344a4b24d9c3893d35cae,Opdivo,0.588188
uuid-afec715ce91344a4b24d9c3893d35cae,therapy,0.355261
uuid-afec715ce91344a4b24d9c3893d35cae,nivolumab,0.317111
uuid-afec715ce91344a4b24d9c3893d35cae,treated,0.41658
uuid-afec715ce91344a4b24d9c3893d35cae,pts,0.333209
uuid-afec715ce91344a4b24d9c3893d35cae,physicians,0.358253
uuid-afec715ce91344a4b24d9c3893d35cae,treatment,0.538194
uuid-afec715ce91344a4b24d9c3893d35cae,progression,0.450548
uuid-afec715ce91344a4b24d9c3893d35cae,respond,0.386714
uuid-66e3ffa26c024343b25f48b0d0d82836,pembro,0.416897
uuid-66e3ffa26c024343b25f48b0d0d82836,PDL1,0.376216
uuid-66e3ffa26c024343b25f48b0d0d82836,trial,0.422554
uuid-66e3ffa26c024343b25f48b0d0d82836,efficacy,0.446819
uuid-66e3ffa26c024343b25f48b0d0d82836,commented,0.358746
uuid-66e3ffa26c024343b25f48b0d0d82836,stated,0.324546
uuid-66e3ffa26c024343b25f48b0d0d82836,OS,0.446474
uuid-66e3ffa26c024343b25f48b0d0d82836,data,0.739074
uuid-66e3ffa26c024343b25f48b0d0d82836,PFS,0.413157
uuid-66e3ffa26c024343b25f48b0d0d82836,ORR,0.472154
uuid-66e3ffa26c024343b25f48b0d0d82836,nivo and pembro,0.340287
uuid-66e3ffa26c024343b25f48b0d0d82836,impressed,0.59307
uuid-66e3ffa26c024343b25f48b0d0d82836,feels,0.448629
uuid-66e3ffa26c024343b25f48b0d0d82836,PDL1 expression,0.301999
uuid-bb8a223443c841c89e1770afb9e49cf3,BMS,0.318121
uuid-bb8a223443c841c89e1770afb9e49cf3,discussed,0.377092
uuid-bb8a223443c841c89e1770afb9e49cf3,shared,0.324075
uuid-bb8a223443c841c89e1770afb9e49cf3,commented,0.33958
uuid-bb8a223443c841c89e1770afb9e49cf3,regards,0.309644
uuid-bb8a223443c841c89e1770afb9e49cf3,data,0.362745
uuid-bb8a223443c841c89e1770afb9e49cf3,indicated,0.4807
uuid-1ab20db4844643318bad6309236b0713,pembro,0.474975
uuid-1ab20db4844643318bad6309236b0713,BMS,0.316161
uuid-1ab20db4844643318bad6309236b0713,PDL1,0.566367
uuid-1ab20db4844643318bad6309236b0713,trial,0.45431
uuid-1ab20db4844643318bad6309236b0713,efficacy,0.643521
uuid-1ab20db4844643318bad6309236b0713,Merck,0.397638
uuid-1ab20db4844643318bad6309236b0713,OS,0.378163
uuid-1ab20db4844643318bad6309236b0713,atezo,0.461405
uuid-1ab20db4844643318bad6309236b0713,regards,0.313495
uuid-1ab20db4844643318bad6309236b0713,data,0.482729
uuid-1ab20db4844643318bad6309236b0713,PFS,0.419751
uuid-1ab20db4844643318bad6309236b0713,ORR,0.432005
uuid-1ab20db4844643318bad6309236b0713,nivo and pembro,0.708195
uuid-1ab20db4844643318bad6309236b0713,believes,0.435177
uuid-1ab20db4844643318bad6309236b0713,vs,0.414745
uuid-1ab20db4844643318bad6309236b0713,feels,0.316295
uuid-1ab20db4844643318bad6309236b0713,assay,0.336832
uuid-1ab20db4844643318bad6309236b0713,PDL1 expression,0.493386
uuid-af1116f5caed4fcf80d84bd2e52eac15,1L,0.406722
uuid-af1116f5caed4fcf80d84bd2e52eac15,PDL1,0.389797
uuid-af1116f5caed4fcf80d84bd2e52eac15,2L,0.329733
uuid-af1116f5caed4fcf80d84bd2e52eac15,PD-L1,0.459482
uuid-af1116f5caed4fcf80d84bd2e52eac15,preferred,0.315241
uuid-af1116f5caed4fcf80d84bd2e52eac15,testing,0.562494
uuid-af1116f5caed4fcf80d84bd2e52eac15,PDL1 testing,0.608228
uuid-af1116f5caed4fcf80d84bd2e52eac15,NSCLC patients,0.685679
uuid-af1116f5caed4fcf80d84bd2e52eac15,tumor types,0.450108
uuid-af1116f5caed4fcf80d84bd2e52eac15,PD-1,0.312611
uuid-af1116f5caed4fcf80d84bd2e52eac15,biomarker,0.382674
uuid-df161451237c4b549f32ae6183ab1ccf,pembro,0.330003
uuid-df161451237c4b549f32ae6183ab1ccf,NSCLC,0.313631
uuid-df161451237c4b549f32ae6183ab1ccf,trial,0.670406
uuid-df161451237c4b549f32ae6183ab1ccf,efficacy,0.359334
uuid-df161451237c4b549f32ae6183ab1ccf,combination,0.50496
uuid-df161451237c4b549f32ae6183ab1ccf,IO,0.363158
uuid-df161451237c4b549f32ae6183ab1ccf,Ipi,0.322143
uuid-df161451237c4b549f32ae6183ab1ccf,OS,0.359764
uuid-df161451237c4b549f32ae6183ab1ccf,monotherapy,0.301617
uuid-df161451237c4b549f32ae6183ab1ccf,data,0.539339
uuid-df161451237c4b549f32ae6183ab1ccf,combo,0.476939
uuid-df161451237c4b549f32ae6183ab1ccf,clinical trials,0.346097
uuid-df161451237c4b549f32ae6183ab1ccf,PFS,0.317262
uuid-df161451237c4b549f32ae6183ab1ccf,ORR,0.459091
uuid-df161451237c4b549f32ae6183ab1ccf,nivo and pembro,0.333113
uuid-df161451237c4b549f32ae6183ab1ccf,believes,0.335703
uuid-df161451237c4b549f32ae6183ab1ccf,impressed,0.523857
uuid-df161451237c4b549f32ae6183ab1ccf,feels,0.415686
uuid-5e04fed7ae8e452996873032cb6344b0,pembro,0.60126
uuid-5e04fed7ae8e452996873032cb6344b0,BMS,0.631219
uuid-5e04fed7ae8e452996873032cb6344b0,PDL1,0.536311
uuid-5e04fed7ae8e452996873032cb6344b0,trial,0.518871
uuid-5e04fed7ae8e452996873032cb6344b0,efficacy,0.582172
uuid-5e04fed7ae8e452996873032cb6344b0,agents,0.309651
uuid-5e04fed7ae8e452996873032cb6344b0,Merck,0.61633
uuid-5e04fed7ae8e452996873032cb6344b0,OS,0.401838
uuid-5e04fed7ae8e452996873032cb6344b0,atezo,0.565562
uuid-5e04fed7ae8e452996873032cb6344b0,data,0.751247
uuid-5e04fed7ae8e452996873032cb6344b0,indication,0.356237
uuid-5e04fed7ae8e452996873032cb6344b0,PFS,0.374629
uuid-5e04fed7ae8e452996873032cb6344b0,ORR,0.432106
uuid-5e04fed7ae8e452996873032cb6344b0,nivo and pembro,0.593023
uuid-5e04fed7ae8e452996873032cb6344b0,believes,0.316188
uuid-5e04fed7ae8e452996873032cb6344b0,impressed,0.413078
uuid-5e04fed7ae8e452996873032cb6344b0,vs,0.364558
uuid-5e04fed7ae8e452996873032cb6344b0,feels,0.412356
uuid-5e04fed7ae8e452996873032cb6344b0,PDL1 expression,0.455516
uuid-37c1d9e1c72d495c961eac3e0016eddb,TL,0.358849
uuid-37c1d9e1c72d495c961eac3e0016eddb,TL stated,0.505302
uuid-37c1d9e1c72d495c961eac3e0016eddb,PD-L1,0.498952
uuid-37c1d9e1c72d495c961eac3e0016eddb,PD-L1 testing,0.424672
uuid-37c1d9e1c72d495c961eac3e0016eddb,testing,0.643951
uuid-37c1d9e1c72d495c961eac3e0016eddb,PDL1 testing,0.608893
uuid-37c1d9e1c72d495c961eac3e0016eddb,NSCLC patients,0.696096
uuid-37c1d9e1c72d495c961eac3e0016eddb,tumor types,0.502412
uuid-37c1d9e1c72d495c961eac3e0016eddb,biomarker,0.341607
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,pembro,0.344485
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,1L,0.304366
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PDL1,0.694145
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,trial,0.358847
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,Merck,0.401079
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PD-L1,0.648953
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,OS,0.302042
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PD-L1 testing,0.45987
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,testing,0.599101
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,data,0.375904
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PDL1 testing,0.381437
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PFS,0.347108
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,NSCLC patients,0.41448
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,ORR,0.320844
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,nivo and pembro,0.40451
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,assay,0.595056
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,PDL1 expression,0.605783
uuid-ddd3fd8c3d8c45efa47f21bf6d8f7c48,biomarker,0.56707
uuid-a9d67be9fff744c59b7af99d776f6179,PDL1,0.624244
uuid-a9d67be9fff744c59b7af99d776f6179,trial,0.342214
uuid-a9d67be9fff744c59b7af99d776f6179,efficacy,0.632165
uuid-a9d67be9fff744c59b7af99d776f6179,chemo,0.313582
uuid-a9d67be9fff744c59b7af99d776f6179,OS,0.583408
uuid-a9d67be9fff744c59b7af99d776f6179,regards,0.346647
uuid-a9d67be9fff744c59b7af99d776f6179,data,0.463999
uuid-a9d67be9fff744c59b7af99d776f6179,PFS,0.656568
uuid-a9d67be9fff744c59b7af99d776f6179,ORR,0.623855
uuid-a9d67be9fff744c59b7af99d776f6179,nivo and pembro,0.629975
uuid-a9d67be9fff744c59b7af99d776f6179,believes,0.530352
uuid-a9d67be9fff744c59b7af99d776f6179,vs,0.308579
uuid-a9d67be9fff744c59b7af99d776f6179,feels,0.418137
uuid-a9d67be9fff744c59b7af99d776f6179,PDL1 expression,0.619805
uuid-a9d67be9fff744c59b7af99d776f6179,biomarker,0.404618
uuid-1878397530884a5093e2cc39a56e98fe,pembro,0.470966
uuid-1878397530884a5093e2cc39a56e98fe,BMS,0.510908
uuid-1878397530884a5093e2cc39a56e98fe,PDL1,0.530304
uuid-1878397530884a5093e2cc39a56e98fe,trial,0.781168
uuid-1878397530884a5093e2cc39a56e98fe,efficacy,0.49241
uuid-1878397530884a5093e2cc39a56e98fe,commented,0.317777
uuid-1878397530884a5093e2cc39a56e98fe,Merck,0.523245
uuid-1878397530884a5093e2cc39a56e98fe,OS,0.527251
uuid-1878397530884a5093e2cc39a56e98fe,atezo,0.356406
uuid-1878397530884a5093e2cc39a56e98fe,regards,0.357751
uuid-1878397530884a5093e2cc39a56e98fe,data,0.723053
uuid-1878397530884a5093e2cc39a56e98fe,expressed,0.303485
uuid-1878397530884a5093e2cc39a56e98fe,clinical trials,0.302404
uuid-1878397530884a5093e2cc39a56e98fe,PFS,0.561617
uuid-1878397530884a5093e2cc39a56e98fe,ORR,0.601425
uuid-1878397530884a5093e2cc39a56e98fe,nivo and pembro,0.57408
uuid-1878397530884a5093e2cc39a56e98fe,impressed,0.433771
uuid-1878397530884a5093e2cc39a56e98fe,vs,0.319533
uuid-1878397530884a5093e2cc39a56e98fe,PDL1 expression,0.543335
uuid-1878397530884a5093e2cc39a56e98fe,biomarker,0.321112
uuid-9d4601cc98394106aad30223ce51a015,pembro,0.311714
uuid-9d4601cc98394106aad30223ce51a015,BMS,0.34019
uuid-9d4601cc98394106aad30223ce51a015,PDL1,0.634966
uuid-9d4601cc98394106aad30223ce51a015,trial,0.330271
uuid-9d4601cc98394106aad30223ce51a015,efficacy,0.538172
uuid-9d4601cc98394106aad30223ce51a015,Merck,0.365192
uuid-9d4601cc98394106aad30223ce51a015,OS,0.388052
uuid-9d4601cc98394106aad30223ce51a015,atezo,0.371686
uuid-9d4601cc98394106aad30223ce51a015,regards,0.483966
uuid-9d4601cc98394106aad30223ce51a015,data,0.506359
uuid-9d4601cc98394106aad30223ce51a015,PFS,0.430669
uuid-9d4601cc98394106aad30223ce51a015,ORR,0.399611
uuid-9d4601cc98394106aad30223ce51a015,nivo and pembro,0.662829
uuid-9d4601cc98394106aad30223ce51a015,believes,0.480079
uuid-9d4601cc98394106aad30223ce51a015,assay,0.394106
uuid-9d4601cc98394106aad30223ce51a015,PDL1 expression,0.537015
uuid-9d4601cc98394106aad30223ce51a015,biomarker,0.404993
uuid-903ad311aa274739b84c76c6f86e8c69,PDL1,0.355161
uuid-903ad311aa274739b84c76c6f86e8c69,TL stated,0.324953
uuid-903ad311aa274739b84c76c6f86e8c69,tumor,0.458325
uuid-903ad311aa274739b84c76c6f86e8c69,PD-L1,0.616083
uuid-903ad311aa274739b84c76c6f86e8c69,PD-L1 testing,0.419416
uuid-903ad311aa274739b84c76c6f86e8c69,testing,0.517327
uuid-903ad311aa274739b84c76c6f86e8c69,PDL1 testing,0.453437
uuid-903ad311aa274739b84c76c6f86e8c69,NSCLC patients,0.401088
uuid-903ad311aa274739b84c76c6f86e8c69,assay,0.383661
uuid-903ad311aa274739b84c76c6f86e8c69,biomarker,0.473115
uuid-80d9a2258b2142129e8069150f5164e6,RTL,0.485991
uuid-80d9a2258b2142129e8069150f5164e6,NSCLC,0.340924
uuid-80d9a2258b2142129e8069150f5164e6,NTL,0.392191
uuid-80d9a2258b2142129e8069150f5164e6,melanoma,0.347304
uuid-80d9a2258b2142129e8069150f5164e6,shared,0.424659
uuid-80d9a2258b2142129e8069150f5164e6,IO,0.3265
uuid-80d9a2258b2142129e8069150f5164e6,stated,0.32113
uuid-80d9a2258b2142129e8069150f5164e6,impressed,0.322099
uuid-80d9a2258b2142129e8069150f5164e6,LTL,0.353834
uuid-80d9a2258b2142129e8069150f5164e6,TLs,0.386788
uuid-80d9a2258b2142129e8069150f5164e6,academic,0.358486
uuid-80d9a2258b2142129e8069150f5164e6,Regional TL,0.353227
uuid-26ec89f7c8ac4beabe0a91c9889e1330,toxicity,0.309241
uuid-26ec89f7c8ac4beabe0a91c9889e1330,regimen,0.390878
uuid-26ec89f7c8ac4beabe0a91c9889e1330,combination,0.41208
uuid-26ec89f7c8ac4beabe0a91c9889e1330,IO,0.446626
uuid-26ec89f7c8ac4beabe0a91c9889e1330,monotherapy,0.316498
uuid-26ec89f7c8ac4beabe0a91c9889e1330,response,0.363301
uuid-26ec89f7c8ac4beabe0a91c9889e1330,combo,0.497191
uuid-26ec89f7c8ac4beabe0a91c9889e1330,progression,0.372358
uuid-26ec89f7c8ac4beabe0a91c9889e1330,feels,0.348245
uuid-a8e77dff132d44de9121468f60b2568e,toxicity,0.329139
uuid-a8e77dff132d44de9121468f60b2568e,treatment,0.378289
uuid-a8e77dff132d44de9121468f60b2568e,progression,0.331057
uuid-a8e77dff132d44de9121468f60b2568e,respond,0.435718
uuid-8de06b7934d74b6d9968bfd261c54a9b,RTL,0.781543
uuid-8de06b7934d74b6d9968bfd261c54a9b,NTL,0.5543
uuid-8de06b7934d74b6d9968bfd261c54a9b,shared,0.493553
uuid-8de06b7934d74b6d9968bfd261c54a9b,commented,0.544074
uuid-8de06b7934d74b6d9968bfd261c54a9b,stated,0.745065
uuid-8de06b7934d74b6d9968bfd261c54a9b,physicians,0.404911
uuid-8de06b7934d74b6d9968bfd261c54a9b,expressed,0.342492
uuid-8de06b7934d74b6d9968bfd261c54a9b,mentioned,0.49515
uuid-8de06b7934d74b6d9968bfd261c54a9b,clinical trials,0.322921
uuid-8de06b7934d74b6d9968bfd261c54a9b,SCCHN,0.539704
uuid-8de06b7934d74b6d9968bfd261c54a9b,HCP,0.468154
uuid-8de06b7934d74b6d9968bfd261c54a9b,impressed,0.357196
uuid-8de06b7934d74b6d9968bfd261c54a9b,LTL,0.667781
uuid-8de06b7934d74b6d9968bfd261c54a9b,TLs,0.469823
uuid-8de06b7934d74b6d9968bfd261c54a9b,academic,0.482645
uuid-8de06b7934d74b6d9968bfd261c54a9b,Regional TL,0.725942
uuid-8de06b7934d74b6d9968bfd261c54a9b,RTL stated,0.337383
uuid-7b20d3263dea486192edaf5d718ded58,Opdivo,0.303965
uuid-7b20d3263dea486192edaf5d718ded58,dose,0.372117
uuid-7b20d3263dea486192edaf5d718ded58,drug,0.684453
uuid-7b20d3263dea486192edaf5d718ded58,Keytruda,0.41724
uuid-7b20d3263dea486192edaf5d718ded58,flat dosing,0.486364
uuid-dd10d023406143f6a66a959136072ce6,patients,0.647166
uuid-dd10d023406143f6a66a959136072ce6,Opdivo,0.324009
uuid-dd10d023406143f6a66a959136072ce6,therapy,0.583045
uuid-dd10d023406143f6a66a959136072ce6,nivolumab,0.522295
uuid-dd10d023406143f6a66a959136072ce6,regimen,0.433433
uuid-dd10d023406143f6a66a959136072ce6,treated,0.406839
uuid-dd10d023406143f6a66a959136072ce6,combination,0.379986
uuid-dd10d023406143f6a66a959136072ce6,chemo,0.388736
uuid-dd10d023406143f6a66a959136072ce6,pts,0.539942
uuid-dd10d023406143f6a66a959136072ce6,IO,0.374196
uuid-dd10d023406143f6a66a959136072ce6,monotherapy,0.376435
uuid-dd10d023406143f6a66a959136072ce6,treatment,0.592159
uuid-dd10d023406143f6a66a959136072ce6,response,0.597232
uuid-dd10d023406143f6a66a959136072ce6,PD1,0.416521
uuid-dd10d023406143f6a66a959136072ce6,progression,0.653084
uuid-dd10d023406143f6a66a959136072ce6,chemotherapy,0.413665
uuid-dd10d023406143f6a66a959136072ce6,respond,0.503214
uuid-dd10d023406143f6a66a959136072ce6,option,0.322185
uuid-326033a22855440c9fd84db6f31008b3,Merck,0.369847
uuid-5fffc7b56a914f5f9598114e2688cf83,BMS,0.384013
uuid-5fffc7b56a914f5f9598114e2688cf83,PDL1,0.464399
uuid-5fffc7b56a914f5f9598114e2688cf83,trial,0.395606
uuid-5fffc7b56a914f5f9598114e2688cf83,efficacy,0.38806
uuid-5fffc7b56a914f5f9598114e2688cf83,OS,0.575652
uuid-5fffc7b56a914f5f9598114e2688cf83,data,0.726215
uuid-5fffc7b56a914f5f9598114e2688cf83,PFS,0.546947
uuid-5fffc7b56a914f5f9598114e2688cf83,ORR,0.547225
uuid-5fffc7b56a914f5f9598114e2688cf83,nivo and pembro,0.551549
uuid-5fffc7b56a914f5f9598114e2688cf83,believes,0.42513
uuid-5fffc7b56a914f5f9598114e2688cf83,impressed,0.492124
uuid-5fffc7b56a914f5f9598114e2688cf83,feels,0.477887
uuid-5fffc7b56a914f5f9598114e2688cf83,PDL1 expression,0.361692
uuid-c2ab5386a87846b989663ad9e7e5ddc6,dose,0.432493
uuid-c2ab5386a87846b989663ad9e7e5ddc6,indication,0.303262
uuid-c2ab5386a87846b989663ad9e7e5ddc6,vs,0.386491
uuid-c2ab5386a87846b989663ad9e7e5ddc6,Keytruda,0.348123
uuid-c2ab5386a87846b989663ad9e7e5ddc6,flat dosing,0.521194
uuid-88da6d8c303f445690189c937a44f44c,patients,0.704579
uuid-88da6d8c303f445690189c937a44f44c,Opdivo,0.322455
uuid-88da6d8c303f445690189c937a44f44c,therapy,0.505891
uuid-88da6d8c303f445690189c937a44f44c,nivolumab,0.406437
uuid-88da6d8c303f445690189c937a44f44c,regimen,0.364481
uuid-88da6d8c303f445690189c937a44f44c,treated,0.517456
uuid-88da6d8c303f445690189c937a44f44c,pts,0.504723
uuid-88da6d8c303f445690189c937a44f44c,treatment,0.550331
uuid-88da6d8c303f445690189c937a44f44c,response,0.336262
uuid-88da6d8c303f445690189c937a44f44c,cHL,0.326296
uuid-88da6d8c303f445690189c937a44f44c,progression,0.653271
uuid-88da6d8c303f445690189c937a44f44c,respond,0.426454
uuid-88da6d8c303f445690189c937a44f44c,TL shared,0.450092
uuid-32bac9b38b114b1bb2ba07012b9cbe18,patients,0.502895
uuid-32bac9b38b114b1bb2ba07012b9cbe18,therapy,0.352682
uuid-32bac9b38b114b1bb2ba07012b9cbe18,nivolumab,0.305413
uuid-32bac9b38b114b1bb2ba07012b9cbe18,toxicity,0.302093
uuid-32bac9b38b114b1bb2ba07012b9cbe18,regimen,0.445455
uuid-32bac9b38b114b1bb2ba07012b9cbe18,treated,0.402998
uuid-32bac9b38b114b1bb2ba07012b9cbe18,chemo,0.331768
uuid-32bac9b38b114b1bb2ba07012b9cbe18,pts,0.5312
uuid-32bac9b38b114b1bb2ba07012b9cbe18,monotherapy,0.357896
uuid-32bac9b38b114b1bb2ba07012b9cbe18,treatment,0.394112
uuid-32bac9b38b114b1bb2ba07012b9cbe18,response,0.522968
uuid-32bac9b38b114b1bb2ba07012b9cbe18,PD1,0.414109
uuid-32bac9b38b114b1bb2ba07012b9cbe18,progression,0.629084
uuid-32bac9b38b114b1bb2ba07012b9cbe18,respond,0.463068
uuid-32bac9b38b114b1bb2ba07012b9cbe18,TL shared,0.440567
uuid-721dcbaf1208491a8a5fbbedd05a78cf,TL,0.45844
uuid-721dcbaf1208491a8a5fbbedd05a78cf,RTL,0.521315
uuid-721dcbaf1208491a8a5fbbedd05a78cf,NTL,0.421874
uuid-721dcbaf1208491a8a5fbbedd05a78cf,shared,0.459243
uuid-721dcbaf1208491a8a5fbbedd05a78cf,commented,0.387136
uuid-721dcbaf1208491a8a5fbbedd05a78cf,TL stated,0.38277
uuid-721dcbaf1208491a8a5fbbedd05a78cf,stated,0.516776
uuid-721dcbaf1208491a8a5fbbedd05a78cf,physicians,0.55314
uuid-721dcbaf1208491a8a5fbbedd05a78cf,PD-L1 testing,0.333202
uuid-721dcbaf1208491a8a5fbbedd05a78cf,oncology,0.451302
uuid-721dcbaf1208491a8a5fbbedd05a78cf,SCCHN,0.437557
uuid-721dcbaf1208491a8a5fbbedd05a78cf,HCP,0.321828
uuid-721dcbaf1208491a8a5fbbedd05a78cf,oncologist,0.415559
uuid-721dcbaf1208491a8a5fbbedd05a78cf,indicated,0.376564
uuid-721dcbaf1208491a8a5fbbedd05a78cf,LTL,0.497518
uuid-721dcbaf1208491a8a5fbbedd05a78cf,TLs,0.521968
uuid-721dcbaf1208491a8a5fbbedd05a78cf,clinical,0.345411
uuid-721dcbaf1208491a8a5fbbedd05a78cf,academic,0.526042
uuid-721dcbaf1208491a8a5fbbedd05a78cf,Regional TL,0.655829
uuid-398be35747904c39a9be0e5b2a1b2292,Nivo,0.319862
uuid-398be35747904c39a9be0e5b2a1b2292,pembro,0.532985
uuid-398be35747904c39a9be0e5b2a1b2292,BMS,0.335623
uuid-398be35747904c39a9be0e5b2a1b2292,1L,0.351163
uuid-398be35747904c39a9be0e5b2a1b2292,PDL1,0.545994
uuid-398be35747904c39a9be0e5b2a1b2292,trial,0.347167
uuid-398be35747904c39a9be0e5b2a1b2292,efficacy,0.347348
uuid-398be35747904c39a9be0e5b2a1b2292,agents,0.303537
uuid-398be35747904c39a9be0e5b2a1b2292,Merck,0.376001
uuid-398be35747904c39a9be0e5b2a1b2292,OS,0.338251
uuid-398be35747904c39a9be0e5b2a1b2292,atezo,0.401902
uuid-398be35747904c39a9be0e5b2a1b2292,data,0.526029
uuid-398be35747904c39a9be0e5b2a1b2292,PFS,0.313132
uuid-398be35747904c39a9be0e5b2a1b2292,ORR,0.335512
uuid-398be35747904c39a9be0e5b2a1b2292,nivo and pembro,0.494323
uuid-398be35747904c39a9be0e5b2a1b2292,believes,0.325812
uuid-398be35747904c39a9be0e5b2a1b2292,feels,0.453581
uuid-398be35747904c39a9be0e5b2a1b2292,PDL1 expression,0.467219
uuid-830d3073e81d4edb9685fe4f4c1a351b,pembro,0.39675
uuid-830d3073e81d4edb9685fe4f4c1a351b,BMS,0.309285
uuid-830d3073e81d4edb9685fe4f4c1a351b,PDL1,0.362763
uuid-830d3073e81d4edb9685fe4f4c1a351b,trial,0.610997
uuid-830d3073e81d4edb9685fe4f4c1a351b,efficacy,0.321413
uuid-830d3073e81d4edb9685fe4f4c1a351b,commented,0.422965
uuid-830d3073e81d4edb9685fe4f4c1a351b,Merck,0.313085
uuid-830d3073e81d4edb9685fe4f4c1a351b,OS,0.5199
uuid-830d3073e81d4edb9685fe4f4c1a351b,data,0.652636
uuid-830d3073e81d4edb9685fe4f4c1a351b,clinical trials,0.316557
uuid-830d3073e81d4edb9685fe4f4c1a351b,PFS,0.513936
uuid-830d3073e81d4edb9685fe4f4c1a351b,ORR,0.600269
uuid-830d3073e81d4edb9685fe4f4c1a351b,nivo and pembro,0.374702
uuid-830d3073e81d4edb9685fe4f4c1a351b,impressed,0.580723
uuid-830d3073e81d4edb9685fe4f4c1a351b,feels,0.336393
uuid-830d3073e81d4edb9685fe4f4c1a351b,PDL1 expression,0.376377
uuid-9fd690adf1b2436691206681cf2b340d,discussed,0.349516
uuid-9fd690adf1b2436691206681cf2b340d,data,0.393678
uuid-9fd690adf1b2436691206681cf2b340d,cHL,0.443108
uuid-5baea51efd0d489a9f282b68e7eefb9d,lung,0.388226
uuid-5baea51efd0d489a9f282b68e7eefb9d,AI,0.470583
uuid-5baea51efd0d489a9f282b68e7eefb9d,oncologist,0.533965
uuid-5baea51efd0d489a9f282b68e7eefb9d,indicated,0.683599
uuid-e5a94fc0626f42b497e8269bc29f319d,patients,0.556405
uuid-e5a94fc0626f42b497e8269bc29f319d,therapy,0.307274
uuid-e5a94fc0626f42b497e8269bc29f319d,nivolumab,0.320784
uuid-e5a94fc0626f42b497e8269bc29f319d,1L,0.425161
uuid-e5a94fc0626f42b497e8269bc29f319d,regimen,0.44876
uuid-e5a94fc0626f42b497e8269bc29f319d,treated,0.333898
uuid-e5a94fc0626f42b497e8269bc29f319d,2L,0.453461
uuid-e5a94fc0626f42b497e8269bc29f319d,pts,0.318711
uuid-e5a94fc0626f42b497e8269bc29f319d,preferred,0.690705
uuid-e5a94fc0626f42b497e8269bc29f319d,monotherapy,0.530433
uuid-e5a94fc0626f42b497e8269bc29f319d,treatment,0.406301
uuid-e5a94fc0626f42b497e8269bc29f319d,using nivo,0.448846
uuid-e5a94fc0626f42b497e8269bc29f319d,indication,0.319929
uuid-e5a94fc0626f42b497e8269bc29f319d,NSCLC patients,0.30375
uuid-e5a94fc0626f42b497e8269bc29f319d,approved,0.307903
uuid-e5a94fc0626f42b497e8269bc29f319d,SCCHN,0.323975
uuid-e5a94fc0626f42b497e8269bc29f319d,chemotherapy,0.343968
uuid-e5a94fc0626f42b497e8269bc29f319d,RTL stated,0.443919
uuid-e5a94fc0626f42b497e8269bc29f319d,option,0.636334
uuid-e8d4708842224987a9099b9afe79917c,lung,0.633209
uuid-e8d4708842224987a9099b9afe79917c,melanoma,0.509467
uuid-e8d4708842224987a9099b9afe79917c,RCC,0.488119
uuid-e8d4708842224987a9099b9afe79917c,using nivo,0.328667
uuid-e8d4708842224987a9099b9afe79917c,AI,0.614587
uuid-e8d4708842224987a9099b9afe79917c,SCCHN,0.306843
uuid-e8d4708842224987a9099b9afe79917c,oncologist,0.583091
uuid-e8d4708842224987a9099b9afe79917c,indicated,0.577336
uuid-e8d4708842224987a9099b9afe79917c,TL shared,0.402551
uuid-e8d4708842224987a9099b9afe79917c,NCCN,0.37977
uuid-9a5079a7ba664334ac486d3aa18dc9a9,melanoma,0.311757
uuid-9a5079a7ba664334ac486d3aa18dc9a9,shared,0.376532
uuid-9a5079a7ba664334ac486d3aa18dc9a9,tumor,0.321093
uuid-9a5079a7ba664334ac486d3aa18dc9a9,institution,0.322904
uuid-9a5079a7ba664334ac486d3aa18dc9a9,physicians,0.507255
uuid-9a5079a7ba664334ac486d3aa18dc9a9,oncologist,0.34238
uuid-9a5079a7ba664334ac486d3aa18dc9a9,clinical,0.307976
uuid-9a5079a7ba664334ac486d3aa18dc9a9,academic,0.457636
uuid-9a5079a7ba664334ac486d3aa18dc9a9,Regional TL,0.301863
uuid-a754a555810c479d928c0edba341c682,TL,0.425518
uuid-a754a555810c479d928c0edba341c682,PDL1,0.477447
uuid-a754a555810c479d928c0edba341c682,TL stated,0.375658
uuid-a754a555810c479d928c0edba341c682,PD-L1,0.793348
uuid-a754a555810c479d928c0edba341c682,PD-L1 testing,0.834214
uuid-a754a555810c479d928c0edba341c682,testing,0.911915
uuid-a754a555810c479d928c0edba341c682,PDL1 testing,0.740276
uuid-a754a555810c479d928c0edba341c682,NSCLC patients,0.672651
uuid-a754a555810c479d928c0edba341c682,assay,0.694814
uuid-a754a555810c479d928c0edba341c682,PDL1 expression,0.310335
uuid-a754a555810c479d928c0edba341c682,biomarker,0.493441
uuid-2845d9ad636e41f0a523091bcf963a1d,regimen,0.411493
uuid-2845d9ad636e41f0a523091bcf963a1d,combination,0.582361
uuid-2845d9ad636e41f0a523091bcf963a1d,chemo,0.453727
uuid-2845d9ad636e41f0a523091bcf963a1d,pts,0.463833
uuid-2845d9ad636e41f0a523091bcf963a1d,IO,0.489713
uuid-2845d9ad636e41f0a523091bcf963a1d,Ipi,0.334726
uuid-2845d9ad636e41f0a523091bcf963a1d,monotherapy,0.411436
uuid-2845d9ad636e41f0a523091bcf963a1d,response,0.567291
uuid-2845d9ad636e41f0a523091bcf963a1d,combo,0.505968
uuid-2845d9ad636e41f0a523091bcf963a1d,PD1,0.407407
uuid-2845d9ad636e41f0a523091bcf963a1d,progression,0.492899
uuid-2845d9ad636e41f0a523091bcf963a1d,chemotherapy,0.399582
uuid-2845d9ad636e41f0a523091bcf963a1d,respond,0.353079
uuid-2845d9ad636e41f0a523091bcf963a1d,feels,0.322711
uuid-963cc1b3e02a47cf9e8bf47b9d818422,Nivo,0.310242
uuid-963cc1b3e02a47cf9e8bf47b9d818422,pembro,0.36232
uuid-963cc1b3e02a47cf9e8bf47b9d818422,lung,0.378001
uuid-963cc1b3e02a47cf9e8bf47b9d818422,PDL1,0.322171
uuid-963cc1b3e02a47cf9e8bf47b9d818422,efficacy,0.447341
uuid-963cc1b3e02a47cf9e8bf47b9d818422,discussed,0.330393
uuid-963cc1b3e02a47cf9e8bf47b9d818422,OS,0.43661
uuid-963cc1b3e02a47cf9e8bf47b9d818422,atezo,0.35615
uuid-963cc1b3e02a47cf9e8bf47b9d818422,regards,0.430771
uuid-963cc1b3e02a47cf9e8bf47b9d818422,data,0.385969
uuid-963cc1b3e02a47cf9e8bf47b9d818422,PFS,0.496843
uuid-963cc1b3e02a47cf9e8bf47b9d818422,AI,0.545168
uuid-963cc1b3e02a47cf9e8bf47b9d818422,ORR,0.426164
uuid-963cc1b3e02a47cf9e8bf47b9d818422,nivo and pembro,0.644807
uuid-963cc1b3e02a47cf9e8bf47b9d818422,believes,0.363493
uuid-963cc1b3e02a47cf9e8bf47b9d818422,vs,0.35635
uuid-963cc1b3e02a47cf9e8bf47b9d818422,TLs,0.313015
uuid-963cc1b3e02a47cf9e8bf47b9d818422,PDL1 expression,0.352906
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,pembro,0.321078
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,BMS,0.394743
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,PDL1,0.406625
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,trial,0.442886
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,efficacy,0.417039
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,discussed,0.31001
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,commented,0.449691
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,Merck,0.330813
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,stated,0.317885
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,OS,0.604122
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,regards,0.307403
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,data,0.893153
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,PFS,0.56499
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,ORR,0.611838
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,nivo and pembro,0.510324
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,ASCO,0.376732
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,impressed,0.620144
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,feels,0.400849
uuid-b5d06b68d79f4081aead8c9ea1a9ef23,PDL1 expression,0.38037
uuid-b421e9ae018e45c880b433ac349f9cea,lung,0.411586
uuid-b421e9ae018e45c880b433ac349f9cea,regimen,0.356556
uuid-b421e9ae018e45c880b433ac349f9cea,melanoma,0.406428
uuid-b421e9ae018e45c880b433ac349f9cea,chemo,0.308375
uuid-b421e9ae018e45c880b433ac349f9cea,Ipi,0.343264
uuid-b421e9ae018e45c880b433ac349f9cea,monotherapy,0.334937
uuid-b421e9ae018e45c880b433ac349f9cea,combo,0.373481
uuid-b421e9ae018e45c880b433ac349f9cea,AI,0.37405
uuid-b421e9ae018e45c880b433ac349f9cea,believes,0.305924
uuid-b421e9ae018e45c880b433ac349f9cea,TL shared,0.309828
uuid-e2f08181803e486f86f3675c80a1a3c7,1L,0.333546
uuid-e2f08181803e486f86f3675c80a1a3c7,RCC,0.351022
uuid-e2f08181803e486f86f3675c80a1a3c7,2L,0.330844
uuid-e2f08181803e486f86f3675c80a1a3c7,agents,0.321566
uuid-e2f08181803e486f86f3675c80a1a3c7,preferred,0.479606
uuid-e2f08181803e486f86f3675c80a1a3c7,using nivo,0.308307
uuid-e2f08181803e486f86f3675c80a1a3c7,data,0.322798
uuid-e2f08181803e486f86f3675c80a1a3c7,indication,0.383377
uuid-e2f08181803e486f86f3675c80a1a3c7,SCCHN,0.471696
uuid-e2f08181803e486f86f3675c80a1a3c7,feels,0.390637
uuid-e2f08181803e486f86f3675c80a1a3c7,Regional TL,0.322678
uuid-e2f08181803e486f86f3675c80a1a3c7,RTL stated,0.379951
uuid-e2f08181803e486f86f3675c80a1a3c7,option,0.33626
uuid-6031597b80044032ad73513c643fed7f,TL,0.410999
uuid-6031597b80044032ad73513c643fed7f,RTL,0.48458
uuid-6031597b80044032ad73513c643fed7f,NTL,0.317025
uuid-6031597b80044032ad73513c643fed7f,melanoma,0.411225
uuid-6031597b80044032ad73513c643fed7f,shared,0.414548
uuid-6031597b80044032ad73513c643fed7f,RCC,0.519281
uuid-6031597b80044032ad73513c643fed7f,TL stated,0.385049
uuid-6031597b80044032ad73513c643fed7f,2L,0.308332
uuid-6031597b80044032ad73513c643fed7f,institution,0.336376
uuid-6031597b80044032ad73513c643fed7f,approval,0.379258
uuid-6031597b80044032ad73513c643fed7f,preferred,0.377934
uuid-6031597b80044032ad73513c643fed7f,PD-L1 testing,0.312212
uuid-6031597b80044032ad73513c643fed7f,using nivo,0.374202
uuid-6031597b80044032ad73513c643fed7f,clinical trials,0.429239
uuid-6031597b80044032ad73513c643fed7f,PDL1 testing,0.343261
uuid-6031597b80044032ad73513c643fed7f,SCCHN,0.570189
uuid-6031597b80044032ad73513c643fed7f,LTL,0.321218
uuid-6031597b80044032ad73513c643fed7f,academic,0.348982
uuid-6031597b80044032ad73513c643fed7f,Regional TL,0.448132
uuid-6031597b80044032ad73513c643fed7f,RTL stated,0.588032
uuid-6031597b80044032ad73513c643fed7f,TL shared,0.436233
uuid-6031597b80044032ad73513c643fed7f,bladder,0.423306
uuid-ec665e7ff59047bca6fe4514a1549091,patients,0.365802
uuid-ec665e7ff59047bca6fe4514a1549091,pembro,0.361664
uuid-ec665e7ff59047bca6fe4514a1549091,1L,0.413815
uuid-ec665e7ff59047bca6fe4514a1549091,RCC,0.312372
uuid-ec665e7ff59047bca6fe4514a1549091,TL stated,0.361237
uuid-ec665e7ff59047bca6fe4514a1549091,2L,0.404524
uuid-ec665e7ff59047bca6fe4514a1549091,Merck,0.361111
uuid-ec665e7ff59047bca6fe4514a1549091,approval,0.41003
uuid-ec665e7ff59047bca6fe4514a1549091,preferred,0.381584
uuid-ec665e7ff59047bca6fe4514a1549091,testing,0.304249
uuid-ec665e7ff59047bca6fe4514a1549091,using nivo,0.415195
uuid-ec665e7ff59047bca6fe4514a1549091,PDL1 testing,0.426721
uuid-ec665e7ff59047bca6fe4514a1549091,NSCLC patients,0.407532
uuid-ec665e7ff59047bca6fe4514a1549091,approved,0.400026
uuid-ec665e7ff59047bca6fe4514a1549091,feels,0.302319
uuid-ec665e7ff59047bca6fe4514a1549091,RTL stated,0.358792
uuid-ec665e7ff59047bca6fe4514a1549091,option,0.300987
uuid-bff3df58a3164394b1270ce9858814e6,tumor,0.567998
uuid-bff3df58a3164394b1270ce9858814e6,lung cancer,0.361027
uuid-bff3df58a3164394b1270ce9858814e6,immunotherapy,0.501526
uuid-7fdedd525c4141eea508a37da7f2604f,Nivo,0.437829
uuid-7fdedd525c4141eea508a37da7f2604f,pembro,0.680194
uuid-7fdedd525c4141eea508a37da7f2604f,dose,0.575138
uuid-7fdedd525c4141eea508a37da7f2604f,1L,0.326597
uuid-7fdedd525c4141eea508a37da7f2604f,efficacy,0.480838
uuid-7fdedd525c4141eea508a37da7f2604f,2L,0.460231
uuid-7fdedd525c4141eea508a37da7f2604f,agents,0.446392
uuid-7fdedd525c4141eea508a37da7f2604f,Ipi,0.426481
uuid-7fdedd525c4141eea508a37da7f2604f,atezo,0.725678
uuid-7fdedd525c4141eea508a37da7f2604f,preferred,0.51708
uuid-7fdedd525c4141eea508a37da7f2604f,combo,0.30819
uuid-7fdedd525c4141eea508a37da7f2604f,indication,0.408707
uuid-7fdedd525c4141eea508a37da7f2604f,approved,0.424325
uuid-7fdedd525c4141eea508a37da7f2604f,nivo and pembro,0.346071
uuid-7fdedd525c4141eea508a37da7f2604f,vs,0.727009
uuid-7fdedd525c4141eea508a37da7f2604f,feels,0.354006
uuid-7fdedd525c4141eea508a37da7f2604f,option,0.328168
uuid-7fdedd525c4141eea508a37da7f2604f,flat dosing,0.476374
uuid-51a71399b7a3406698c92be37afe30fc,PDL1,0.485166
uuid-51a71399b7a3406698c92be37afe30fc,trial,0.414731
uuid-51a71399b7a3406698c92be37afe30fc,efficacy,0.343072
uuid-51a71399b7a3406698c92be37afe30fc,discussed,0.524327
uuid-51a71399b7a3406698c92be37afe30fc,OS,0.477294
uuid-51a71399b7a3406698c92be37afe30fc,regards,0.362738
uuid-51a71399b7a3406698c92be37afe30fc,data,0.485713
uuid-51a71399b7a3406698c92be37afe30fc,PFS,0.537374
uuid-51a71399b7a3406698c92be37afe30fc,ORR,0.50165
uuid-51a71399b7a3406698c92be37afe30fc,nivo and pembro,0.366679
uuid-51a71399b7a3406698c92be37afe30fc,PDL1 expression,0.473521
uuid-51a71399b7a3406698c92be37afe30fc,biomarker,0.319654
uuid-626f93f57bed4f14a36ca57ade093fe9,NSCLC,0.370063
uuid-626f93f57bed4f14a36ca57ade093fe9,efficacy,0.351937
uuid-626f93f57bed4f14a36ca57ade093fe9,discussed,0.694042
uuid-626f93f57bed4f14a36ca57ade093fe9,OS,0.384968
uuid-626f93f57bed4f14a36ca57ade093fe9,regards,0.423724
uuid-626f93f57bed4f14a36ca57ade093fe9,data,0.393534
uuid-626f93f57bed4f14a36ca57ade093fe9,PFS,0.396419
uuid-626f93f57bed4f14a36ca57ade093fe9,AI,0.323607
uuid-626f93f57bed4f14a36ca57ade093fe9,ORR,0.399994
uuid-626f93f57bed4f14a36ca57ade093fe9,academic,0.380629
uuid-d10e4dd6a28443c49250c837760a5744,NSCLC,0.390495
uuid-d10e4dd6a28443c49250c837760a5744,PDL1,0.335281
uuid-d10e4dd6a28443c49250c837760a5744,efficacy,0.445364
uuid-d10e4dd6a28443c49250c837760a5744,discussed,0.547237
uuid-d10e4dd6a28443c49250c837760a5744,IO,0.338744
uuid-d10e4dd6a28443c49250c837760a5744,OS,0.364843
uuid-d10e4dd6a28443c49250c837760a5744,regards,0.302733
uuid-d10e4dd6a28443c49250c837760a5744,data,0.303389
uuid-d10e4dd6a28443c49250c837760a5744,PFS,0.400549
uuid-d10e4dd6a28443c49250c837760a5744,ORR,0.370634
uuid-d10e4dd6a28443c49250c837760a5744,nivo and pembro,0.371914
uuid-d10e4dd6a28443c49250c837760a5744,believes,0.308922
uuid-d10e4dd6a28443c49250c837760a5744,PDL1 expression,0.304363
uuid-099dc209fd7147c8849d0a4d65c84041,Nivo,0.326213
uuid-099dc209fd7147c8849d0a4d65c84041,pembro,0.34111
uuid-099dc209fd7147c8849d0a4d65c84041,lung,0.309893
uuid-099dc209fd7147c8849d0a4d65c84041,NSCLC,0.468199
uuid-099dc209fd7147c8849d0a4d65c84041,1L,0.494322
uuid-099dc209fd7147c8849d0a4d65c84041,discussed,0.337708
uuid-099dc209fd7147c8849d0a4d65c84041,chemo,0.302818
uuid-099dc209fd7147c8849d0a4d65c84041,2L,0.429239
uuid-099dc209fd7147c8849d0a4d65c84041,IO,0.332242
uuid-099dc209fd7147c8849d0a4d65c84041,atezo,0.340254
uuid-099dc209fd7147c8849d0a4d65c84041,preferred,0.333949
uuid-099dc209fd7147c8849d0a4d65c84041,monotherapy,0.389847
uuid-099dc209fd7147c8849d0a4d65c84041,nivo and pembro,0.301403
uuid-099dc209fd7147c8849d0a4d65c84041,option,0.393636
uuid-b82d7d19f7d64addac194bef20583c0e,patients,0.499443
uuid-b82d7d19f7d64addac194bef20583c0e,Opdivo,0.585301
uuid-b82d7d19f7d64addac194bef20583c0e,dose,0.514324
uuid-b82d7d19f7d64addac194bef20583c0e,nivolumab,0.343227
uuid-b82d7d19f7d64addac194bef20583c0e,treated,0.330827
uuid-b82d7d19f7d64addac194bef20583c0e,approval,0.314834
uuid-b82d7d19f7d64addac194bef20583c0e,physicians,0.508167
uuid-b82d7d19f7d64addac194bef20583c0e,HCP,0.327248
uuid-b82d7d19f7d64addac194bef20583c0e,flat dosing,0.563034
uuid-ae9b856735d44504a459afe5f35194d7,Opdivo,0.364788
uuid-ae9b856735d44504a459afe5f35194d7,TL,0.374857
uuid-ae9b856735d44504a459afe5f35194d7,dose,0.403971
uuid-ae9b856735d44504a459afe5f35194d7,shared,0.4612
uuid-ae9b856735d44504a459afe5f35194d7,physicians,0.475102
uuid-ae9b856735d44504a459afe5f35194d7,HCP,0.322421
uuid-ae9b856735d44504a459afe5f35194d7,indicated,0.362837
uuid-ae9b856735d44504a459afe5f35194d7,LTL,0.369028
uuid-ae9b856735d44504a459afe5f35194d7,TLs,0.352606
uuid-ae9b856735d44504a459afe5f35194d7,academic,0.319588
uuid-ae9b856735d44504a459afe5f35194d7,Regional TL,0.349784
uuid-ae9b856735d44504a459afe5f35194d7,flat dosing,0.605917
uuid-2508200545c04c66901234680f6fbbae,Opdivo,0.396174
uuid-2508200545c04c66901234680f6fbbae,dose,0.477185
uuid-2508200545c04c66901234680f6fbbae,toxicity,0.313145
uuid-2508200545c04c66901234680f6fbbae,preferred,0.333239
uuid-2508200545c04c66901234680f6fbbae,indication,0.404709
uuid-2508200545c04c66901234680f6fbbae,drug,0.338604
uuid-2508200545c04c66901234680f6fbbae,Keytruda,0.453727
uuid-2508200545c04c66901234680f6fbbae,flat dosing,0.606921
uuid-a85718430152407e9ccb72aac1452133,BMS,0.520473
uuid-a85718430152407e9ccb72aac1452133,PDL1,0.401887
uuid-a85718430152407e9ccb72aac1452133,efficacy,0.698999
uuid-a85718430152407e9ccb72aac1452133,agents,0.3248
uuid-a85718430152407e9ccb72aac1452133,OS,0.412144
uuid-a85718430152407e9ccb72aac1452133,regards,0.398591
uuid-a85718430152407e9ccb72aac1452133,data,0.469619
uuid-a85718430152407e9ccb72aac1452133,PFS,0.415364
uuid-a85718430152407e9ccb72aac1452133,ORR,0.478874
uuid-a85718430152407e9ccb72aac1452133,nivo and pembro,0.427852
uuid-a85718430152407e9ccb72aac1452133,believes,0.465156
uuid-a85718430152407e9ccb72aac1452133,impressed,0.353499
uuid-a85718430152407e9ccb72aac1452133,feels,0.49319
uuid-a85718430152407e9ccb72aac1452133,PDL1 expression,0.373996
uuid-a85718430152407e9ccb72aac1452133,biomarker,0.341835
uuid-bdfd621e50f84bb69e666649cf53aa55,pembro,0.504871
uuid-bdfd621e50f84bb69e666649cf53aa55,BMS,0.405779
uuid-bdfd621e50f84bb69e666649cf53aa55,1L,0.374247
uuid-bdfd621e50f84bb69e666649cf53aa55,PDL1,0.670316
uuid-bdfd621e50f84bb69e666649cf53aa55,trial,0.365025
uuid-bdfd621e50f84bb69e666649cf53aa55,efficacy,0.374826
uuid-bdfd621e50f84bb69e666649cf53aa55,2L,0.306715
uuid-bdfd621e50f84bb69e666649cf53aa55,Merck,0.491413
uuid-bdfd621e50f84bb69e666649cf53aa55,PD-L1,0.39131
uuid-bdfd621e50f84bb69e666649cf53aa55,OS,0.314834
uuid-bdfd621e50f84bb69e666649cf53aa55,atezo,0.562475
uuid-bdfd621e50f84bb69e666649cf53aa55,data,0.506565
uuid-bdfd621e50f84bb69e666649cf53aa55,indication,0.441878
uuid-bdfd621e50f84bb69e666649cf53aa55,PFS,0.320915
uuid-bdfd621e50f84bb69e666649cf53aa55,ORR,0.320232
uuid-bdfd621e50f84bb69e666649cf53aa55,nivo and pembro,0.506464
uuid-bdfd621e50f84bb69e666649cf53aa55,TLs,0.358125
uuid-bdfd621e50f84bb69e666649cf53aa55,assay,0.354603
uuid-bdfd621e50f84bb69e666649cf53aa55,PDL1 expression,0.666279
uuid-bdfd621e50f84bb69e666649cf53aa55,biomarker,0.491204
uuid-bdfd621e50f84bb69e666649cf53aa55,bladder,0.334434
uuid-512d8485579a48dab344f0e39cd1ad23,TL,0.452369
uuid-512d8485579a48dab344f0e39cd1ad23,1L,0.340048
uuid-512d8485579a48dab344f0e39cd1ad23,PDL1,0.303428
uuid-512d8485579a48dab344f0e39cd1ad23,TL stated,0.402995
uuid-512d8485579a48dab344f0e39cd1ad23,2L,0.301225
uuid-512d8485579a48dab344f0e39cd1ad23,Merck,0.314344
uuid-512d8485579a48dab344f0e39cd1ad23,institution,0.409026
uuid-512d8485579a48dab344f0e39cd1ad23,PD-L1,0.733061
uuid-512d8485579a48dab344f0e39cd1ad23,approval,0.388832
uuid-512d8485579a48dab344f0e39cd1ad23,atezo,0.322846
uuid-512d8485579a48dab344f0e39cd1ad23,preferred,0.319112
uuid-512d8485579a48dab344f0e39cd1ad23,PD-L1 testing,0.798154
uuid-512d8485579a48dab344f0e39cd1ad23,testing,0.880216
uuid-512d8485579a48dab344f0e39cd1ad23,PDL1 testing,0.744787
uuid-512d8485579a48dab344f0e39cd1ad23,NSCLC patients,0.656679
uuid-512d8485579a48dab344f0e39cd1ad23,approved,0.351359
uuid-512d8485579a48dab344f0e39cd1ad23,assay,0.661218
uuid-512d8485579a48dab344f0e39cd1ad23,biomarker,0.324463
uuid-281f7daf61c845dfa34ebf01a5bf34b3,RTL,0.500502
uuid-281f7daf61c845dfa34ebf01a5bf34b3,lung,0.447122
uuid-281f7daf61c845dfa34ebf01a5bf34b3,NTL,0.455321
uuid-281f7daf61c845dfa34ebf01a5bf34b3,melanoma,0.406224
uuid-281f7daf61c845dfa34ebf01a5bf34b3,shared,0.694186
uuid-281f7daf61c845dfa34ebf01a5bf34b3,commented,0.569585
uuid-281f7daf61c845dfa34ebf01a5bf34b3,RCC,0.570908
uuid-281f7daf61c845dfa34ebf01a5bf34b3,TL stated,0.553481
uuid-281f7daf61c845dfa34ebf01a5bf34b3,institution,0.309739
uuid-281f7daf61c845dfa34ebf01a5bf34b3,stated,0.552773
uuid-281f7daf61c845dfa34ebf01a5bf34b3,approval,0.30569
uuid-281f7daf61c845dfa34ebf01a5bf34b3,expressed,0.440987
uuid-281f7daf61c845dfa34ebf01a5bf34b3,PDL1 testing,0.335769
uuid-281f7daf61c845dfa34ebf01a5bf34b3,SCCHN,0.588628
uuid-281f7daf61c845dfa34ebf01a5bf34b3,HCP,0.378419
uuid-281f7daf61c845dfa34ebf01a5bf34b3,impressed,0.385406
uuid-281f7daf61c845dfa34ebf01a5bf34b3,tumor types,0.328118
uuid-281f7daf61c845dfa34ebf01a5bf34b3,LTL,0.491458
uuid-281f7daf61c845dfa34ebf01a5bf34b3,TLs,0.498133
uuid-281f7daf61c845dfa34ebf01a5bf34b3,academic,0.374287
uuid-281f7daf61c845dfa34ebf01a5bf34b3,Regional TL,0.599253
uuid-281f7daf61c845dfa34ebf01a5bf34b3,RTL stated,0.477705
uuid-281f7daf61c845dfa34ebf01a5bf34b3,TL shared,0.482941
uuid-281f7daf61c845dfa34ebf01a5bf34b3,bladder,0.381369
uuid-7700dc1106824597ac391a4b390b0a4c,patients,0.6647
uuid-7700dc1106824597ac391a4b390b0a4c,regimen,0.300245
uuid-7700dc1106824597ac391a4b390b0a4c,treated,0.411135
uuid-7700dc1106824597ac391a4b390b0a4c,pts,0.505577
uuid-7700dc1106824597ac391a4b390b0a4c,monotherapy,0.32572
uuid-7700dc1106824597ac391a4b390b0a4c,treatment,0.366222
uuid-7700dc1106824597ac391a4b390b0a4c,clinical trials,0.301697
uuid-7700dc1106824597ac391a4b390b0a4c,NSCLC patients,0.385296
uuid-7700dc1106824597ac391a4b390b0a4c,progression,0.371907
uuid-7700dc1106824597ac391a4b390b0a4c,tumor types,0.346953
uuid-7700dc1106824597ac391a4b390b0a4c,respond,0.325239
uuid-7700dc1106824597ac391a4b390b0a4c,option,0.336534
uuid-c64b0c2a1ac24420966b6d1118403607,TL,0.445644
uuid-c64b0c2a1ac24420966b6d1118403607,RTL,0.547624
uuid-c64b0c2a1ac24420966b6d1118403607,BMS,0.377507
uuid-c64b0c2a1ac24420966b6d1118403607,NTL,0.416378
uuid-c64b0c2a1ac24420966b6d1118403607,shared,0.554762
uuid-c64b0c2a1ac24420966b6d1118403607,commented,0.574836
uuid-c64b0c2a1ac24420966b6d1118403607,TL stated,0.488374
uuid-c64b0c2a1ac24420966b6d1118403607,Merck,0.496855
uuid-c64b0c2a1ac24420966b6d1118403607,institution,0.335443
uuid-c64b0c2a1ac24420966b6d1118403607,stated,0.547885
uuid-c64b0c2a1ac24420966b6d1118403607,PD-L1,0.303881
uuid-c64b0c2a1ac24420966b6d1118403607,approval,0.310876
uuid-c64b0c2a1ac24420966b6d1118403607,PD-L1 testing,0.408111
uuid-c64b0c2a1ac24420966b6d1118403607,testing,0.405013
uuid-c64b0c2a1ac24420966b6d1118403607,data,0.335529
uuid-c64b0c2a1ac24420966b6d1118403607,expressed,0.488679
uuid-c64b0c2a1ac24420966b6d1118403607,mentioned,0.302187
uuid-c64b0c2a1ac24420966b6d1118403607,clinical trials,0.348015
uuid-c64b0c2a1ac24420966b6d1118403607,PDL1 testing,0.470868
uuid-c64b0c2a1ac24420966b6d1118403607,SCCHN,0.461105
uuid-c64b0c2a1ac24420966b6d1118403607,HCP,0.352116
uuid-c64b0c2a1ac24420966b6d1118403607,ASCO,0.323541
uuid-c64b0c2a1ac24420966b6d1118403607,impressed,0.382082
uuid-c64b0c2a1ac24420966b6d1118403607,LTL,0.451475
uuid-c64b0c2a1ac24420966b6d1118403607,TLs,0.420929
uuid-c64b0c2a1ac24420966b6d1118403607,academic,0.330888
uuid-c64b0c2a1ac24420966b6d1118403607,Regional TL,0.564831
uuid-c64b0c2a1ac24420966b6d1118403607,bladder,0.347087
uuid-0df4438bc8904707a13c60034feac8bd,patients,0.719827
uuid-0df4438bc8904707a13c60034feac8bd,therapy,0.352561
uuid-0df4438bc8904707a13c60034feac8bd,nivolumab,0.343239
uuid-0df4438bc8904707a13c60034feac8bd,regimen,0.389711
uuid-0df4438bc8904707a13c60034feac8bd,treated,0.601811
uuid-0df4438bc8904707a13c60034feac8bd,pts,0.544587
uuid-0df4438bc8904707a13c60034feac8bd,monotherapy,0.347147
uuid-0df4438bc8904707a13c60034feac8bd,treatment,0.476436
uuid-0df4438bc8904707a13c60034feac8bd,NSCLC patients,0.373011
uuid-0df4438bc8904707a13c60034feac8bd,progression,0.442727
uuid-0df4438bc8904707a13c60034feac8bd,tumor types,0.32916
uuid-0df4438bc8904707a13c60034feac8bd,respond,0.36855
uuid-0df4438bc8904707a13c60034feac8bd,RTL stated,0.328441
uuid-0df4438bc8904707a13c60034feac8bd,TL shared,0.31443
uuid-0df4438bc8904707a13c60034feac8bd,option,0.322291
uuid-a2ca41b6aede4d51a2f28b2a56180a38,Nivo,0.378802
uuid-a2ca41b6aede4d51a2f28b2a56180a38,pembro,0.468993
uuid-a2ca41b6aede4d51a2f28b2a56180a38,dose,0.652366
uuid-a2ca41b6aede4d51a2f28b2a56180a38,trial,0.482244
uuid-a2ca41b6aede4d51a2f28b2a56180a38,efficacy,0.424147
uuid-a2ca41b6aede4d51a2f28b2a56180a38,combination,0.417475
uuid-a2ca41b6aede4d51a2f28b2a56180a38,Ipi,0.752742
uuid-a2ca41b6aede4d51a2f28b2a56180a38,atezo,0.413434
uuid-a2ca41b6aede4d51a2f28b2a56180a38,combo,0.452589
uuid-a2ca41b6aede4d51a2f28b2a56180a38,vs,0.560953
uuid-a2ca41b6aede4d51a2f28b2a56180a38,flat dosing,0.469764
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,patients,0.486397
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,Opdivo,0.599566
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,dose,0.792129
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,nivolumab,0.355319
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,toxicity,0.345722
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,regimen,0.359435
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,Ipi,0.361209
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,physicians,0.316963
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,treatment,0.354792
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,vs,0.357368
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,Keytruda,0.330714
uuid-6a867ed1a9ab4b2db067e43cc0e505a1,flat dosing,0.678715
uuid-650198adcb9d42a09d4a983826cedc05,BMS,0.324431
uuid-650198adcb9d42a09d4a983826cedc05,trial,0.476802
uuid-650198adcb9d42a09d4a983826cedc05,efficacy,0.304855
uuid-650198adcb9d42a09d4a983826cedc05,combination,0.323888
uuid-650198adcb9d42a09d4a983826cedc05,OS,0.314882
uuid-650198adcb9d42a09d4a983826cedc05,data,0.505514
uuid-650198adcb9d42a09d4a983826cedc05,expressed,0.320068
uuid-650198adcb9d42a09d4a983826cedc05,ORR,0.377987
uuid-650198adcb9d42a09d4a983826cedc05,nivo and pembro,0.392077
uuid-650198adcb9d42a09d4a983826cedc05,believes,0.312973
uuid-650198adcb9d42a09d4a983826cedc05,impressed,0.406704
uuid-650198adcb9d42a09d4a983826cedc05,SCLC,0.56973
uuid-c0ba8920f6604ca989cac06a17368dab,patients,0.345848
uuid-c0ba8920f6604ca989cac06a17368dab,trial,0.600112
uuid-c0ba8920f6604ca989cac06a17368dab,pts,0.321627
uuid-c0ba8920f6604ca989cac06a17368dab,approval,0.319573
uuid-c0ba8920f6604ca989cac06a17368dab,clinical trials,0.520927
uuid-c0ba8920f6604ca989cac06a17368dab,approved,0.315163
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,Opdivo,0.43863
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,dose,0.777371
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,shared,0.358318
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,Ipi,0.36534
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,vs,0.474309
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,Keytruda,0.328781
uuid-7a02d67a6a414e1db9cbe72c18ec42e1,flat dosing,0.804141
uuid-5459e90153ef4d4ab1784dde8c280ff7,BMS,0.409897
uuid-bc2496880da14e488a18d92a72282a2b,patients,0.352878
uuid-bc2496880da14e488a18d92a72282a2b,institution,0.300204
uuid-bc2496880da14e488a18d92a72282a2b,PD-L1,0.460345
uuid-bc2496880da14e488a18d92a72282a2b,PD-L1 testing,0.70474
uuid-bc2496880da14e488a18d92a72282a2b,testing,0.687621
uuid-bc2496880da14e488a18d92a72282a2b,PDL1 testing,0.569583
uuid-bc2496880da14e488a18d92a72282a2b,NSCLC patients,0.541828
uuid-d5fed2f8300d4bbbbeba162d0248cacc,Nivo,0.453458
uuid-d5fed2f8300d4bbbbeba162d0248cacc,patients,0.340921
uuid-d5fed2f8300d4bbbbeba162d0248cacc,therapy,0.581922
uuid-d5fed2f8300d4bbbbeba162d0248cacc,1L,0.550883
uuid-d5fed2f8300d4bbbbeba162d0248cacc,regimen,0.455883
uuid-d5fed2f8300d4bbbbeba162d0248cacc,combination,0.574682
uuid-d5fed2f8300d4bbbbeba162d0248cacc,chemo,0.738331
uuid-d5fed2f8300d4bbbbeba162d0248cacc,2L,0.469074
uuid-d5fed2f8300d4bbbbeba162d0248cacc,pts,0.395222
uuid-d5fed2f8300d4bbbbeba162d0248cacc,IO,0.65588
uuid-d5fed2f8300d4bbbbeba162d0248cacc,agents,0.52663
uuid-d5fed2f8300d4bbbbeba162d0248cacc,preferred,0.441847
uuid-d5fed2f8300d4bbbbeba162d0248cacc,monotherapy,0.732012
uuid-d5fed2f8300d4bbbbeba162d0248cacc,treatment,0.392541
uuid-d5fed2f8300d4bbbbeba162d0248cacc,response,0.447343
uuid-d5fed2f8300d4bbbbeba162d0248cacc,combo,0.590819
uuid-d5fed2f8300d4bbbbeba162d0248cacc,PD1,0.578153
uuid-d5fed2f8300d4bbbbeba162d0248cacc,progression,0.455716
uuid-d5fed2f8300d4bbbbeba162d0248cacc,believes,0.528665
uuid-d5fed2f8300d4bbbbeba162d0248cacc,chemotherapy,0.648935
uuid-d5fed2f8300d4bbbbeba162d0248cacc,respond,0.317177
uuid-d5fed2f8300d4bbbbeba162d0248cacc,feels,0.366104
uuid-d5fed2f8300d4bbbbeba162d0248cacc,PD-1,0.300604
uuid-d5fed2f8300d4bbbbeba162d0248cacc,option,0.688533
uuid-049b5e78970f4162afefa4e3b3ae0c42,patients,0.68734
uuid-049b5e78970f4162afefa4e3b3ae0c42,therapy,0.510881
uuid-049b5e78970f4162afefa4e3b3ae0c42,regimen,0.35956
uuid-049b5e78970f4162afefa4e3b3ae0c42,treated,0.507986
uuid-049b5e78970f4162afefa4e3b3ae0c42,chemo,0.399702
uuid-049b5e78970f4162afefa4e3b3ae0c42,tumor,0.390446
uuid-049b5e78970f4162afefa4e3b3ae0c42,pts,0.560767
uuid-049b5e78970f4162afefa4e3b3ae0c42,treatment,0.638249
uuid-049b5e78970f4162afefa4e3b3ae0c42,response,0.612241
uuid-049b5e78970f4162afefa4e3b3ae0c42,progression,0.719589
uuid-049b5e78970f4162afefa4e3b3ae0c42,chemotherapy,0.43452
uuid-049b5e78970f4162afefa4e3b3ae0c42,respond,0.546641
uuid-049b5e78970f4162afefa4e3b3ae0c42,immunotherapy,0.310243
uuid-69d3204a006c435e927414d440227416,pembro,0.460518
uuid-69d3204a006c435e927414d440227416,1L,0.474306
uuid-69d3204a006c435e927414d440227416,PDL1,0.693161
uuid-69d3204a006c435e927414d440227416,TL stated,0.314085
uuid-69d3204a006c435e927414d440227416,2L,0.33631
uuid-69d3204a006c435e927414d440227416,Merck,0.385338
uuid-69d3204a006c435e927414d440227416,PD-L1,0.652495
uuid-69d3204a006c435e927414d440227416,approval,0.333584
uuid-69d3204a006c435e927414d440227416,atezo,0.473648
uuid-69d3204a006c435e927414d440227416,PD-L1 testing,0.424042
uuid-69d3204a006c435e927414d440227416,testing,0.583224
uuid-69d3204a006c435e927414d440227416,data,0.508711
uuid-69d3204a006c435e927414d440227416,PDL1 testing,0.531311
uuid-69d3204a006c435e927414d440227416,indication,0.353086
uuid-69d3204a006c435e927414d440227416,NSCLC patients,0.512183
uuid-69d3204a006c435e927414d440227416,approved,0.336332
uuid-69d3204a006c435e927414d440227416,nivo and pembro,0.426939
uuid-69d3204a006c435e927414d440227416,tumor types,0.393753
uuid-69d3204a006c435e927414d440227416,assay,0.462025
uuid-69d3204a006c435e927414d440227416,PDL1 expression,0.659632
uuid-69d3204a006c435e927414d440227416,biomarker,0.51125
uuid-8fdee1bda468444e823a51f560028e46,Nivo,0.397537
uuid-8fdee1bda468444e823a51f560028e46,pembro,0.683445
uuid-8fdee1bda468444e823a51f560028e46,BMS,0.382298
uuid-8fdee1bda468444e823a51f560028e46,1L,0.458266
uuid-8fdee1bda468444e823a51f560028e46,PDL1,0.398355
uuid-8fdee1bda468444e823a51f560028e46,trial,0.440704
uuid-8fdee1bda468444e823a51f560028e46,efficacy,0.345376
uuid-8fdee1bda468444e823a51f560028e46,commented,0.314563
uuid-8fdee1bda468444e823a51f560028e46,2L,0.433294
uuid-8fdee1bda468444e823a51f560028e46,Merck,0.428775
uuid-8fdee1bda468444e823a51f560028e46,stated,0.330243
uuid-8fdee1bda468444e823a51f560028e46,approval,0.478179
uuid-8fdee1bda468444e823a51f560028e46,OS,0.391499
uuid-8fdee1bda468444e823a51f560028e46,atezo,0.606655
uuid-8fdee1bda468444e823a51f560028e46,preferred,0.330817
uuid-8fdee1bda468444e823a51f560028e46,using nivo,0.347444
uuid-8fdee1bda468444e823a51f560028e46,data,0.679922
uuid-8fdee1bda468444e823a51f560028e46,indication,0.534646
uuid-8fdee1bda468444e823a51f560028e46,PFS,0.361046
uuid-8fdee1bda468444e823a51f560028e46,ORR,0.376905
uuid-8fdee1bda468444e823a51f560028e46,approved,0.483346
uuid-8fdee1bda468444e823a51f560028e46,SCCHN,0.346216
uuid-8fdee1bda468444e823a51f560028e46,nivo and pembro,0.608363
uuid-8fdee1bda468444e823a51f560028e46,impressed,0.462394
uuid-8fdee1bda468444e823a51f560028e46,label,0.363757
uuid-8fdee1bda468444e823a51f560028e46,feels,0.340723
uuid-8fdee1bda468444e823a51f560028e46,PDL1 expression,0.385412
uuid-8fdee1bda468444e823a51f560028e46,bladder,0.303597
uuid-a001b3ded28d43c491e17dc45f62ed9d,Nivo,0.302903
uuid-a001b3ded28d43c491e17dc45f62ed9d,patients,0.337273
uuid-a001b3ded28d43c491e17dc45f62ed9d,pembro,0.545624
uuid-a001b3ded28d43c491e17dc45f62ed9d,1L,0.620387
uuid-a001b3ded28d43c491e17dc45f62ed9d,RCC,0.512669
uuid-a001b3ded28d43c491e17dc45f62ed9d,TL stated,0.375678
uuid-a001b3ded28d43c491e17dc45f62ed9d,2L,0.633367
uuid-a001b3ded28d43c491e17dc45f62ed9d,pts,0.336228
uuid-a001b3ded28d43c491e17dc45f62ed9d,stated,0.33788
uuid-a001b3ded28d43c491e17dc45f62ed9d,approval,0.629765
uuid-a001b3ded28d43c491e17dc45f62ed9d,atezo,0.517882
uuid-a001b3ded28d43c491e17dc45f62ed9d,preferred,0.53463
uuid-a001b3ded28d43c491e17dc45f62ed9d,monotherapy,0.354713
uuid-a001b3ded28d43c491e17dc45f62ed9d,using nivo,0.664895
uuid-a001b3ded28d43c491e17dc45f62ed9d,clinical trials,0.315206
uuid-a001b3ded28d43c491e17dc45f62ed9d,PDL1 testing,0.395158
uuid-a001b3ded28d43c491e17dc45f62ed9d,indication,0.323615
uuid-a001b3ded28d43c491e17dc45f62ed9d,NSCLC patients,0.439408
uuid-a001b3ded28d43c491e17dc45f62ed9d,approved,0.590561
uuid-a001b3ded28d43c491e17dc45f62ed9d,SCCHN,0.546878
uuid-a001b3ded28d43c491e17dc45f62ed9d,tumor types,0.361057
uuid-a001b3ded28d43c491e17dc45f62ed9d,label,0.304416
uuid-a001b3ded28d43c491e17dc45f62ed9d,Regional TL,0.382466
uuid-a001b3ded28d43c491e17dc45f62ed9d,RTL stated,0.549202
uuid-a001b3ded28d43c491e17dc45f62ed9d,TL shared,0.320139
uuid-a001b3ded28d43c491e17dc45f62ed9d,option,0.428968
uuid-a001b3ded28d43c491e17dc45f62ed9d,bladder,0.541439
uuid-a4099cd081c7427994ff852e6d8fec5e,patients,0.458814
uuid-a4099cd081c7427994ff852e6d8fec5e,dose,0.651803
uuid-a4099cd081c7427994ff852e6d8fec5e,toxicity,0.444265
uuid-a4099cd081c7427994ff852e6d8fec5e,regimen,0.307793
uuid-a4099cd081c7427994ff852e6d8fec5e,Ipi,0.381313
uuid-a4099cd081c7427994ff852e6d8fec5e,vs,0.388441
uuid-a4099cd081c7427994ff852e6d8fec5e,flat dosing,0.338978
uuid-93243fad6fd94efa98c61908d9815c53,TL,0.346104
uuid-93243fad6fd94efa98c61908d9815c53,TL stated,0.325574
uuid-93243fad6fd94efa98c61908d9815c53,tumor,0.580804
uuid-93243fad6fd94efa98c61908d9815c53,PD-L1,0.451212
uuid-93243fad6fd94efa98c61908d9815c53,PD-L1 testing,0.485519
uuid-93243fad6fd94efa98c61908d9815c53,testing,0.585933
uuid-93243fad6fd94efa98c61908d9815c53,PDL1 testing,0.463993
uuid-93243fad6fd94efa98c61908d9815c53,NSCLC patients,0.421332
uuid-93243fad6fd94efa98c61908d9815c53,assay,0.365204
uuid-93243fad6fd94efa98c61908d9815c53,biomarker,0.330097
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,pembro,0.484955
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,lung,0.461613
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,1L,0.596521
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,RCC,0.458186
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,TL stated,0.3549
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,2L,0.618835
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,PD-L1,0.405629
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,atezo,0.530818
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,preferred,0.515171
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,PD-L1 testing,0.377633
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,testing,0.418986
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,monotherapy,0.322544
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,using nivo,0.563513
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,PDL1 testing,0.490366
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,NSCLC patients,0.52625
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,approved,0.306047
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,SCCHN,0.336176
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,RTL stated,0.399537
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,TL shared,0.318745
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,option,0.386451
uuid-401f6e555d7f4975813d6e2bf7bc1eb6,bladder,0.312028
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,patients,0.606267
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,treated,0.32568
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,pts,0.34908
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,PD-L1,0.398546
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,PD-L1 testing,0.505071
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,testing,0.553633
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,treatment,0.326509
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,PDL1 testing,0.51926
uuid-cf719df0cc2d43798f4cc9e4b555e1cf,NSCLC patients,0.571113
uuid-c9420e52f37f41eaaabff7abb7c77773,Nivo,0.5533
uuid-c9420e52f37f41eaaabff7abb7c77773,pembro,0.38229
uuid-c9420e52f37f41eaaabff7abb7c77773,lung,0.505722
uuid-c9420e52f37f41eaaabff7abb7c77773,1L,0.336599
uuid-c9420e52f37f41eaaabff7abb7c77773,melanoma,0.385464
uuid-c9420e52f37f41eaaabff7abb7c77773,RCC,0.381641
uuid-c9420e52f37f41eaaabff7abb7c77773,2L,0.426225
uuid-c9420e52f37f41eaaabff7abb7c77773,atezo,0.346323
uuid-c9420e52f37f41eaaabff7abb7c77773,using nivo,0.532936
uuid-c9420e52f37f41eaaabff7abb7c77773,AI,0.480334
uuid-c9420e52f37f41eaaabff7abb7c77773,nivo and pembro,0.303335
uuid-c9420e52f37f41eaaabff7abb7c77773,vs,0.327779
uuid-c9420e52f37f41eaaabff7abb7c77773,RTL stated,0.313607
uuid-e0c23d574f22414091d7d611c5f20782,Nivo,0.410776
uuid-e0c23d574f22414091d7d611c5f20782,patients,0.599835
uuid-e0c23d574f22414091d7d611c5f20782,Opdivo,0.717493
uuid-e0c23d574f22414091d7d611c5f20782,pembro,0.372707
uuid-e0c23d574f22414091d7d611c5f20782,therapy,0.309933
uuid-e0c23d574f22414091d7d611c5f20782,nivolumab,0.419558
uuid-e0c23d574f22414091d7d611c5f20782,2L,0.378815
uuid-e0c23d574f22414091d7d611c5f20782,pts,0.320435
uuid-e0c23d574f22414091d7d611c5f20782,approval,0.522141
uuid-e0c23d574f22414091d7d611c5f20782,preferred,0.416504
uuid-e0c23d574f22414091d7d611c5f20782,monotherapy,0.342721
uuid-e0c23d574f22414091d7d611c5f20782,treatment,0.313771
uuid-e0c23d574f22414091d7d611c5f20782,using nivo,0.520966
uuid-e0c23d574f22414091d7d611c5f20782,indication,0.398929
uuid-e0c23d574f22414091d7d611c5f20782,approved,0.588485
uuid-e0c23d574f22414091d7d611c5f20782,label,0.502602
uuid-e0c23d574f22414091d7d611c5f20782,Keytruda,0.466358
uuid-e0c23d574f22414091d7d611c5f20782,option,0.432977
uuid-e0c23d574f22414091d7d611c5f20782,flat dosing,0.320823
uuid-4064894fbf9843709d65cd21555093e5,RTL,0.32474
uuid-4064894fbf9843709d65cd21555093e5,lung,0.629678
uuid-4064894fbf9843709d65cd21555093e5,NTL,0.350544
uuid-4064894fbf9843709d65cd21555093e5,melanoma,0.632334
uuid-4064894fbf9843709d65cd21555093e5,shared,0.340941
uuid-4064894fbf9843709d65cd21555093e5,RCC,0.415384
uuid-4064894fbf9843709d65cd21555093e5,institution,0.438245
uuid-4064894fbf9843709d65cd21555093e5,AI,0.509144
uuid-4064894fbf9843709d65cd21555093e5,SCCHN,0.526317
uuid-4064894fbf9843709d65cd21555093e5,oncologist,0.307859
uuid-4064894fbf9843709d65cd21555093e5,academic,0.443747
uuid-4064894fbf9843709d65cd21555093e5,RTL stated,0.393694
uuid-4064894fbf9843709d65cd21555093e5,TL shared,0.451086
uuid-4064894fbf9843709d65cd21555093e5,NCCN,0.417321
uuid-e66af55c3ac64364bf5c15eedfc40ab9,RTL,0.33332
uuid-e66af55c3ac64364bf5c15eedfc40ab9,BMS,0.337557
uuid-e66af55c3ac64364bf5c15eedfc40ab9,trial,0.680942
uuid-e66af55c3ac64364bf5c15eedfc40ab9,Merck,0.371689
uuid-e66af55c3ac64364bf5c15eedfc40ab9,data,0.349521
uuid-f71ebac39fcd479197ac4a6661723a6f,patients,0.794087
uuid-f71ebac39fcd479197ac4a6661723a6f,Opdivo,0.33417
uuid-f71ebac39fcd479197ac4a6661723a6f,therapy,0.418272
uuid-f71ebac39fcd479197ac4a6661723a6f,nivolumab,0.418779
uuid-f71ebac39fcd479197ac4a6661723a6f,toxicity,0.539264
uuid-f71ebac39fcd479197ac4a6661723a6f,regimen,0.639011
uuid-f71ebac39fcd479197ac4a6661723a6f,treated,0.675153
uuid-f71ebac39fcd479197ac4a6661723a6f,chemo,0.375938
uuid-f71ebac39fcd479197ac4a6661723a6f,pts,0.574192
uuid-f71ebac39fcd479197ac4a6661723a6f,monotherapy,0.432222
uuid-f71ebac39fcd479197ac4a6661723a6f,treatment,0.627599
uuid-f71ebac39fcd479197ac4a6661723a6f,response,0.36024
uuid-f71ebac39fcd479197ac4a6661723a6f,PD1,0.31095
uuid-f71ebac39fcd479197ac4a6661723a6f,progression,0.572924
uuid-f71ebac39fcd479197ac4a6661723a6f,chemotherapy,0.42547
uuid-f71ebac39fcd479197ac4a6661723a6f,respond,0.461116
uuid-f71ebac39fcd479197ac4a6661723a6f,TL shared,0.31167
uuid-f71ebac39fcd479197ac4a6661723a6f,option,0.327466
uuid-be43ca7abd0b4823b58e775266e120aa,RTL,0.355094
uuid-be43ca7abd0b4823b58e775266e120aa,lung,0.35855
uuid-be43ca7abd0b4823b58e775266e120aa,NTL,0.431604
uuid-be43ca7abd0b4823b58e775266e120aa,melanoma,0.375987
uuid-be43ca7abd0b4823b58e775266e120aa,commented,0.402121
uuid-be43ca7abd0b4823b58e775266e120aa,RCC,0.332857
uuid-be43ca7abd0b4823b58e775266e120aa,stated,0.321558
uuid-be43ca7abd0b4823b58e775266e120aa,clinical trials,0.371897
uuid-be43ca7abd0b4823b58e775266e120aa,SCCHN,0.366016
uuid-be43ca7abd0b4823b58e775266e120aa,lung cancer,0.342142
uuid-be43ca7abd0b4823b58e775266e120aa,ASCO,0.394669
uuid-be43ca7abd0b4823b58e775266e120aa,impressed,0.4027
uuid-be43ca7abd0b4823b58e775266e120aa,tumor types,0.317776
uuid-be43ca7abd0b4823b58e775266e120aa,SCLC,0.404901
uuid-be43ca7abd0b4823b58e775266e120aa,Regional TL,0.388119
uuid-be43ca7abd0b4823b58e775266e120aa,TL shared,0.371831
uuid-be43ca7abd0b4823b58e775266e120aa,bladder,0.32733
uuid-8bdb5a40e7804c7189e465dcfaba3879,PD-L1,0.392697
uuid-8bdb5a40e7804c7189e465dcfaba3879,approval,0.330191
uuid-8bdb5a40e7804c7189e465dcfaba3879,preferred,0.302189
uuid-8bdb5a40e7804c7189e465dcfaba3879,PD-L1 testing,0.53794
uuid-8bdb5a40e7804c7189e465dcfaba3879,testing,0.593255
uuid-8bdb5a40e7804c7189e465dcfaba3879,PDL1 testing,0.553896
uuid-8bdb5a40e7804c7189e465dcfaba3879,indication,0.309642
uuid-8bdb5a40e7804c7189e465dcfaba3879,NSCLC patients,0.427288
uuid-8bdb5a40e7804c7189e465dcfaba3879,approved,0.337057
uuid-34fd73a8aac14818a099c2bec52a5da3,patients,0.480809
uuid-34fd73a8aac14818a099c2bec52a5da3,therapy,0.409381
uuid-34fd73a8aac14818a099c2bec52a5da3,nivolumab,0.413889
uuid-34fd73a8aac14818a099c2bec52a5da3,lung,0.311755
uuid-34fd73a8aac14818a099c2bec52a5da3,regimen,0.479538
uuid-34fd73a8aac14818a099c2bec52a5da3,treated,0.573475
uuid-34fd73a8aac14818a099c2bec52a5da3,melanoma,0.649427
uuid-34fd73a8aac14818a099c2bec52a5da3,RCC,0.443892
uuid-34fd73a8aac14818a099c2bec52a5da3,pts,0.360125
uuid-34fd73a8aac14818a099c2bec52a5da3,monotherapy,0.318107
uuid-34fd73a8aac14818a099c2bec52a5da3,treatment,0.589841
uuid-34fd73a8aac14818a099c2bec52a5da3,SCCHN,0.344994
uuid-34fd73a8aac14818a099c2bec52a5da3,progression,0.50345
uuid-34fd73a8aac14818a099c2bec52a5da3,chemotherapy,0.359883
uuid-34fd73a8aac14818a099c2bec52a5da3,oncologist,0.330045
uuid-34fd73a8aac14818a099c2bec52a5da3,academic,0.342758
uuid-34fd73a8aac14818a099c2bec52a5da3,RTL stated,0.42886
uuid-34fd73a8aac14818a099c2bec52a5da3,TL shared,0.51199
uuid-44fe2e5f2ad04461bc591e355e8f975c,toxicity,0.419417
uuid-44fe2e5f2ad04461bc591e355e8f975c,treated,0.366838
uuid-44fe2e5f2ad04461bc591e355e8f975c,physicians,0.326087
uuid-44fe2e5f2ad04461bc591e355e8f975c,treatment,0.414178
uuid-1c226102c1ac4472ab4a76477944c0e2,patients,0.613149
uuid-1c226102c1ac4472ab4a76477944c0e2,therapy,0.582125
uuid-1c226102c1ac4472ab4a76477944c0e2,nivolumab,0.593706
uuid-1c226102c1ac4472ab4a76477944c0e2,1L,0.38475
uuid-1c226102c1ac4472ab4a76477944c0e2,regimen,0.398485
uuid-1c226102c1ac4472ab4a76477944c0e2,treated,0.490411
uuid-1c226102c1ac4472ab4a76477944c0e2,RCC,0.46803
uuid-1c226102c1ac4472ab4a76477944c0e2,chemo,0.356372
uuid-1c226102c1ac4472ab4a76477944c0e2,2L,0.404682
uuid-1c226102c1ac4472ab4a76477944c0e2,pts,0.527063
uuid-1c226102c1ac4472ab4a76477944c0e2,approval,0.376357
uuid-1c226102c1ac4472ab4a76477944c0e2,preferred,0.416826
uuid-1c226102c1ac4472ab4a76477944c0e2,monotherapy,0.498637
uuid-1c226102c1ac4472ab4a76477944c0e2,treatment,0.554697
uuid-1c226102c1ac4472ab4a76477944c0e2,using nivo,0.548785
uuid-1c226102c1ac4472ab4a76477944c0e2,response,0.335573
uuid-1c226102c1ac4472ab4a76477944c0e2,PD1,0.444571
uuid-1c226102c1ac4472ab4a76477944c0e2,approved,0.338036
uuid-1c226102c1ac4472ab4a76477944c0e2,SCCHN,0.383755
uuid-1c226102c1ac4472ab4a76477944c0e2,cHL,0.309321
uuid-1c226102c1ac4472ab4a76477944c0e2,progression,0.547514
uuid-1c226102c1ac4472ab4a76477944c0e2,chemotherapy,0.376589
uuid-1c226102c1ac4472ab4a76477944c0e2,respond,0.349553
uuid-1c226102c1ac4472ab4a76477944c0e2,RTL stated,0.540926
uuid-1c226102c1ac4472ab4a76477944c0e2,TL shared,0.306565
uuid-1c226102c1ac4472ab4a76477944c0e2,option,0.501897
uuid-e149391210bf4c929bf4c39298a553d4,patients,0.464309
uuid-e149391210bf4c929bf4c39298a553d4,Opdivo,0.375705
uuid-e149391210bf4c929bf4c39298a553d4,nivolumab,0.314874
uuid-e149391210bf4c929bf4c39298a553d4,treated,0.30436
uuid-e149391210bf4c929bf4c39298a553d4,RCC,0.31143
uuid-e149391210bf4c929bf4c39298a553d4,stated,0.34383
uuid-e149391210bf4c929bf4c39298a553d4,approval,0.372745
uuid-e149391210bf4c929bf4c39298a553d4,using nivo,0.365479
uuid-e149391210bf4c929bf4c39298a553d4,approved,0.399443
uuid-e149391210bf4c929bf4c39298a553d4,SCCHN,0.325808
uuid-e149391210bf4c929bf4c39298a553d4,tumor types,0.34376
uuid-e149391210bf4c929bf4c39298a553d4,label,0.308988
uuid-e149391210bf4c929bf4c39298a553d4,RTL stated,0.308614
uuid-a26d68cdad4147e887be222641036e6d,TL,0.32359
uuid-a26d68cdad4147e887be222641036e6d,pembro,0.309831
uuid-a26d68cdad4147e887be222641036e6d,1L,0.370154
uuid-a26d68cdad4147e887be222641036e6d,PDL1,0.571687
uuid-a26d68cdad4147e887be222641036e6d,TL stated,0.397802
uuid-a26d68cdad4147e887be222641036e6d,Merck,0.31569
uuid-a26d68cdad4147e887be222641036e6d,PD-L1,0.613567
uuid-a26d68cdad4147e887be222641036e6d,atezo,0.347879
uuid-a26d68cdad4147e887be222641036e6d,PD-L1 testing,0.438054
uuid-a26d68cdad4147e887be222641036e6d,testing,0.495653
uuid-a26d68cdad4147e887be222641036e6d,data,0.437322
uuid-a26d68cdad4147e887be222641036e6d,PDL1 testing,0.458458
uuid-a26d68cdad4147e887be222641036e6d,NSCLC patients,0.418045
uuid-a26d68cdad4147e887be222641036e6d,nivo and pembro,0.385834
uuid-a26d68cdad4147e887be222641036e6d,believes,0.342234
uuid-a26d68cdad4147e887be222641036e6d,impressed,0.319459
uuid-a26d68cdad4147e887be222641036e6d,TLs,0.413424
uuid-a26d68cdad4147e887be222641036e6d,assay,0.426159
uuid-a26d68cdad4147e887be222641036e6d,PDL1 expression,0.493932
uuid-a26d68cdad4147e887be222641036e6d,biomarker,0.441953
uuid-b06dd9fb54ba4b099d47c22bd8240bff,Nivo,0.46913
uuid-b06dd9fb54ba4b099d47c22bd8240bff,patients,0.411771
uuid-b06dd9fb54ba4b099d47c22bd8240bff,pembro,0.384634
uuid-b06dd9fb54ba4b099d47c22bd8240bff,therapy,0.349852
uuid-b06dd9fb54ba4b099d47c22bd8240bff,nivolumab,0.342484
uuid-b06dd9fb54ba4b099d47c22bd8240bff,1L,0.390453
uuid-b06dd9fb54ba4b099d47c22bd8240bff,trial,0.461155
uuid-b06dd9fb54ba4b099d47c22bd8240bff,regimen,0.319538
uuid-b06dd9fb54ba4b099d47c22bd8240bff,combination,0.488991
uuid-b06dd9fb54ba4b099d47c22bd8240bff,chemo,0.587726
uuid-b06dd9fb54ba4b099d47c22bd8240bff,2L,0.302559
uuid-b06dd9fb54ba4b099d47c22bd8240bff,pts,0.399756
uuid-b06dd9fb54ba4b099d47c22bd8240bff,Ipi,0.346589
uuid-b06dd9fb54ba4b099d47c22bd8240bff,preferred,0.366325
uuid-b06dd9fb54ba4b099d47c22bd8240bff,monotherapy,0.535564
uuid-b06dd9fb54ba4b099d47c22bd8240bff,combo,0.448833
uuid-b06dd9fb54ba4b099d47c22bd8240bff,clinical trials,0.33271
uuid-b06dd9fb54ba4b099d47c22bd8240bff,PD1,0.375513
uuid-b06dd9fb54ba4b099d47c22bd8240bff,chemotherapy,0.627506
uuid-b06dd9fb54ba4b099d47c22bd8240bff,feels,0.440488
uuid-b06dd9fb54ba4b099d47c22bd8240bff,option,0.561495
uuid-fcd2aa87da924e14a5df8518c72db04f,Nivo,0.447495
uuid-fcd2aa87da924e14a5df8518c72db04f,pembro,0.46787
uuid-fcd2aa87da924e14a5df8518c72db04f,dose,0.626069
uuid-fcd2aa87da924e14a5df8518c72db04f,Ipi,0.528941
uuid-fcd2aa87da924e14a5df8518c72db04f,atezo,0.459436
uuid-fcd2aa87da924e14a5df8518c72db04f,preferred,0.396299
uuid-fcd2aa87da924e14a5df8518c72db04f,using nivo,0.444391
uuid-fcd2aa87da924e14a5df8518c72db04f,HCP,0.491746
uuid-fcd2aa87da924e14a5df8518c72db04f,vs,0.541956
uuid-fcd2aa87da924e14a5df8518c72db04f,LTL,0.321521
uuid-fcd2aa87da924e14a5df8518c72db04f,feels,0.302229
uuid-fcd2aa87da924e14a5df8518c72db04f,flat dosing,0.48472
uuid-e38797b3accb465ab968814e424c752b,RTL,0.644557
uuid-e38797b3accb465ab968814e424c752b,trial,0.481974
uuid-e38797b3accb465ab968814e424c752b,NTL,0.389704
uuid-e38797b3accb465ab968814e424c752b,data,0.342328
uuid-e38797b3accb465ab968814e424c752b,expressed,0.414748
uuid-e38797b3accb465ab968814e424c752b,mentioned,0.458923
uuid-e38797b3accb465ab968814e424c752b,ORR,0.322812
uuid-e38797b3accb465ab968814e424c752b,HCP,0.607855
uuid-e38797b3accb465ab968814e424c752b,impressed,0.428323
uuid-e38797b3accb465ab968814e424c752b,LTL,0.432033
uuid-e38797b3accb465ab968814e424c752b,SCLC,0.330401
uuid-ab6f3c63675e4e5ea14faf06d144faca,RTL,0.678638
uuid-ab6f3c63675e4e5ea14faf06d144faca,BMS,0.33102
uuid-ab6f3c63675e4e5ea14faf06d144faca,trial,0.543185
uuid-ab6f3c63675e4e5ea14faf06d144faca,NTL,0.487012
uuid-ab6f3c63675e4e5ea14faf06d144faca,commented,0.504108
uuid-ab6f3c63675e4e5ea14faf06d144faca,stated,0.405514
uuid-ab6f3c63675e4e5ea14faf06d144faca,OS,0.350274
uuid-ab6f3c63675e4e5ea14faf06d144faca,data,0.536875
uuid-ab6f3c63675e4e5ea14faf06d144faca,expressed,0.532864
uuid-ab6f3c63675e4e5ea14faf06d144faca,mentioned,0.504509
uuid-ab6f3c63675e4e5ea14faf06d144faca,PFS,0.328692
uuid-ab6f3c63675e4e5ea14faf06d144faca,ORR,0.342805
uuid-ab6f3c63675e4e5ea14faf06d144faca,SCCHN,0.334975
uuid-ab6f3c63675e4e5ea14faf06d144faca,HCP,0.531618
uuid-ab6f3c63675e4e5ea14faf06d144faca,ASCO,0.310999
uuid-ab6f3c63675e4e5ea14faf06d144faca,impressed,0.581673
uuid-ab6f3c63675e4e5ea14faf06d144faca,LTL,0.474952
uuid-ab6f3c63675e4e5ea14faf06d144faca,TLs,0.323609
uuid-ab6f3c63675e4e5ea14faf06d144faca,SCLC,0.321058
uuid-ab6f3c63675e4e5ea14faf06d144faca,Regional TL,0.437511
uuid-513355499c904491bc1424510041ac72,Nivo,0.681945
uuid-513355499c904491bc1424510041ac72,pembro,0.33159
uuid-513355499c904491bc1424510041ac72,RTL,0.407408
uuid-513355499c904491bc1424510041ac72,therapy,0.466249
uuid-513355499c904491bc1424510041ac72,nivolumab,0.527973
uuid-513355499c904491bc1424510041ac72,1L,0.325965
uuid-513355499c904491bc1424510041ac72,trial,0.335588
uuid-513355499c904491bc1424510041ac72,combination,0.512814
uuid-513355499c904491bc1424510041ac72,chemo,0.381404
uuid-513355499c904491bc1424510041ac72,2L,0.378781
uuid-513355499c904491bc1424510041ac72,Ipi,0.320291
uuid-513355499c904491bc1424510041ac72,approval,0.312903
uuid-513355499c904491bc1424510041ac72,preferred,0.327455
uuid-513355499c904491bc1424510041ac72,monotherapy,0.459831
uuid-513355499c904491bc1424510041ac72,using nivo,0.587104
uuid-513355499c904491bc1424510041ac72,combo,0.350987
uuid-513355499c904491bc1424510041ac72,mentioned,0.315843
uuid-513355499c904491bc1424510041ac72,PD1,0.453518
uuid-513355499c904491bc1424510041ac72,approved,0.305026
uuid-513355499c904491bc1424510041ac72,SCCHN,0.346013
uuid-513355499c904491bc1424510041ac72,cHL,0.400098
uuid-513355499c904491bc1424510041ac72,chemotherapy,0.420711
uuid-513355499c904491bc1424510041ac72,SCLC,0.394776
uuid-513355499c904491bc1424510041ac72,RTL stated,0.534237
uuid-513355499c904491bc1424510041ac72,option,0.385505
uuid-513355499c904491bc1424510041ac72,bladder,0.330941
uuid-8ad721f714954f7bbb59754217bf5e51,patients,0.391041
uuid-8ad721f714954f7bbb59754217bf5e51,nivolumab,0.307423
uuid-8ad721f714954f7bbb59754217bf5e51,treated,0.518577
uuid-8ad721f714954f7bbb59754217bf5e51,treatment,0.473972
uuid-8ad721f714954f7bbb59754217bf5e51,TL shared,0.337804
uuid-3b630cac3e89442b8a52dc0cf6b302d8,patients,0.321531
uuid-3b630cac3e89442b8a52dc0cf6b302d8,Opdivo,0.463046
uuid-3b630cac3e89442b8a52dc0cf6b302d8,toxicity,0.300146
uuid-3b630cac3e89442b8a52dc0cf6b302d8,treated,0.340618
uuid-3b630cac3e89442b8a52dc0cf6b302d8,physicians,0.547176
uuid-3b630cac3e89442b8a52dc0cf6b302d8,treatment,0.417936
uuid-3b630cac3e89442b8a52dc0cf6b302d8,feels,0.366515
uuid-ca0fbf8815364909b20c86ada155f5e3,Nivo,0.472228
uuid-ca0fbf8815364909b20c86ada155f5e3,patients,0.533614
uuid-ca0fbf8815364909b20c86ada155f5e3,therapy,0.610899
uuid-ca0fbf8815364909b20c86ada155f5e3,1L,0.325043
uuid-ca0fbf8815364909b20c86ada155f5e3,toxicity,0.42947
uuid-ca0fbf8815364909b20c86ada155f5e3,efficacy,0.305735
uuid-ca0fbf8815364909b20c86ada155f5e3,regimen,0.507776
uuid-ca0fbf8815364909b20c86ada155f5e3,combination,0.495201
uuid-ca0fbf8815364909b20c86ada155f5e3,chemo,0.782765
uuid-ca0fbf8815364909b20c86ada155f5e3,pts,0.491888
uuid-ca0fbf8815364909b20c86ada155f5e3,IO,0.351112
uuid-ca0fbf8815364909b20c86ada155f5e3,agents,0.442142
uuid-ca0fbf8815364909b20c86ada155f5e3,preferred,0.30151
uuid-ca0fbf8815364909b20c86ada155f5e3,monotherapy,0.619769
uuid-ca0fbf8815364909b20c86ada155f5e3,treatment,0.537255
uuid-ca0fbf8815364909b20c86ada155f5e3,response,0.607144
uuid-ca0fbf8815364909b20c86ada155f5e3,combo,0.427388
uuid-ca0fbf8815364909b20c86ada155f5e3,PD1,0.589813
uuid-ca0fbf8815364909b20c86ada155f5e3,progression,0.583079
uuid-ca0fbf8815364909b20c86ada155f5e3,believes,0.38764
uuid-ca0fbf8815364909b20c86ada155f5e3,chemotherapy,0.711215
uuid-ca0fbf8815364909b20c86ada155f5e3,respond,0.510067
uuid-ca0fbf8815364909b20c86ada155f5e3,feels,0.323934
uuid-ca0fbf8815364909b20c86ada155f5e3,immunotherapy,0.378871
uuid-ca0fbf8815364909b20c86ada155f5e3,option,0.586836
uuid-0d04417a588a4927861f36584d461dc4,pembro,0.37228
uuid-0d04417a588a4927861f36584d461dc4,RTL,0.421923
uuid-0d04417a588a4927861f36584d461dc4,BMS,0.624617
uuid-0d04417a588a4927861f36584d461dc4,trial,0.84804
uuid-0d04417a588a4927861f36584d461dc4,NTL,0.308582
uuid-0d04417a588a4927861f36584d461dc4,Merck,0.62007
uuid-0d04417a588a4927861f36584d461dc4,stated,0.317898
uuid-0d04417a588a4927861f36584d461dc4,OS,0.309172
uuid-0d04417a588a4927861f36584d461dc4,data,0.539796
uuid-0d04417a588a4927861f36584d461dc4,expressed,0.334793
uuid-0d04417a588a4927861f36584d461dc4,clinical trials,0.450633
uuid-0d04417a588a4927861f36584d461dc4,PFS,0.352593
uuid-0d04417a588a4927861f36584d461dc4,ORR,0.390728
uuid-0d04417a588a4927861f36584d461dc4,impressed,0.435748
uuid-3977279116a74a929b59b1c693cdd254,Nivo,0.372806
uuid-3977279116a74a929b59b1c693cdd254,patients,0.718956
uuid-3977279116a74a929b59b1c693cdd254,Opdivo,0.595596
uuid-3977279116a74a929b59b1c693cdd254,therapy,0.561081
uuid-3977279116a74a929b59b1c693cdd254,nivolumab,0.540954
uuid-3977279116a74a929b59b1c693cdd254,treated,0.499405
uuid-3977279116a74a929b59b1c693cdd254,pts,0.308793
uuid-3977279116a74a929b59b1c693cdd254,treatment,0.458874
uuid-3977279116a74a929b59b1c693cdd254,using nivo,0.405769
uuid-3977279116a74a929b59b1c693cdd254,cHL,0.666335
uuid-3977279116a74a929b59b1c693cdd254,progression,0.365971
uuid-cf66fb8692464901afb284054dd5e4f6,lung,0.438637
uuid-cf66fb8692464901afb284054dd5e4f6,NTL,0.31846
uuid-cf66fb8692464901afb284054dd5e4f6,melanoma,0.373222
uuid-cf66fb8692464901afb284054dd5e4f6,AI,0.520929
uuid-cf66fb8692464901afb284054dd5e4f6,cHL,0.462217
uuid-cf66fb8692464901afb284054dd5e4f6,NCCN,0.3957
uuid-5516d9fc1b38476b9eba717ef9859fb4,Opdivo,0.394188
uuid-5516d9fc1b38476b9eba717ef9859fb4,shared,0.407209
uuid-5516d9fc1b38476b9eba717ef9859fb4,RCC,0.490754
uuid-5516d9fc1b38476b9eba717ef9859fb4,TL stated,0.392996
uuid-5516d9fc1b38476b9eba717ef9859fb4,2L,0.339721
uuid-5516d9fc1b38476b9eba717ef9859fb4,Merck,0.381298
uuid-5516d9fc1b38476b9eba717ef9859fb4,approval,0.321245
uuid-5516d9fc1b38476b9eba717ef9859fb4,preferred,0.343717
uuid-5516d9fc1b38476b9eba717ef9859fb4,using nivo,0.342629
uuid-5516d9fc1b38476b9eba717ef9859fb4,approved,0.373002
uuid-5516d9fc1b38476b9eba717ef9859fb4,SCCHN,0.377258
uuid-5516d9fc1b38476b9eba717ef9859fb4,Keytruda,0.518924
uuid-5516d9fc1b38476b9eba717ef9859fb4,RTL stated,0.344828
uuid-f5b85427d5684cdfa996143a32c0c1a5,pembro,0.539602
uuid-f5b85427d5684cdfa996143a32c0c1a5,BMS,0.359122
uuid-f5b85427d5684cdfa996143a32c0c1a5,1L,0.394265
uuid-f5b85427d5684cdfa996143a32c0c1a5,PDL1,0.461005
uuid-f5b85427d5684cdfa996143a32c0c1a5,trial,0.446572
uuid-f5b85427d5684cdfa996143a32c0c1a5,efficacy,0.362483
uuid-f5b85427d5684cdfa996143a32c0c1a5,commented,0.325673
uuid-f5b85427d5684cdfa996143a32c0c1a5,2L,0.349776
uuid-f5b85427d5684cdfa996143a32c0c1a5,agents,0.344675
uuid-f5b85427d5684cdfa996143a32c0c1a5,Merck,0.373902
uuid-f5b85427d5684cdfa996143a32c0c1a5,stated,0.337707
uuid-f5b85427d5684cdfa996143a32c0c1a5,atezo,0.527863
uuid-f5b85427d5684cdfa996143a32c0c1a5,preferred,0.345982
uuid-f5b85427d5684cdfa996143a32c0c1a5,data,0.636599
uuid-f5b85427d5684cdfa996143a32c0c1a5,clinical trials,0.394728
uuid-f5b85427d5684cdfa996143a32c0c1a5,indication,0.433148
uuid-f5b85427d5684cdfa996143a32c0c1a5,ORR,0.310375
uuid-f5b85427d5684cdfa996143a32c0c1a5,approved,0.317063
uuid-f5b85427d5684cdfa996143a32c0c1a5,SCCHN,0.36847
uuid-f5b85427d5684cdfa996143a32c0c1a5,nivo and pembro,0.499994
uuid-f5b85427d5684cdfa996143a32c0c1a5,impressed,0.386939
uuid-f5b85427d5684cdfa996143a32c0c1a5,TLs,0.310597
uuid-f5b85427d5684cdfa996143a32c0c1a5,feels,0.439927
uuid-f5b85427d5684cdfa996143a32c0c1a5,PDL1 expression,0.470793
uuid-f5b85427d5684cdfa996143a32c0c1a5,bladder,0.306429
uuid-277fb1fc1527428a9adb147ce16b9235,patients,0.355385
uuid-277fb1fc1527428a9adb147ce16b9235,dose,0.462467
uuid-277fb1fc1527428a9adb147ce16b9235,nivolumab,0.330217
uuid-277fb1fc1527428a9adb147ce16b9235,toxicity,0.544514
uuid-277fb1fc1527428a9adb147ce16b9235,regimen,0.629068
uuid-277fb1fc1527428a9adb147ce16b9235,treated,0.317922
uuid-277fb1fc1527428a9adb147ce16b9235,combination,0.540734
uuid-277fb1fc1527428a9adb147ce16b9235,chemo,0.372503
uuid-277fb1fc1527428a9adb147ce16b9235,pts,0.325676
uuid-277fb1fc1527428a9adb147ce16b9235,Ipi,0.618179
uuid-277fb1fc1527428a9adb147ce16b9235,monotherapy,0.454352
uuid-277fb1fc1527428a9adb147ce16b9235,combo,0.547069
uuid-277fb1fc1527428a9adb147ce16b9235,chemotherapy,0.358928
uuid-277fb1fc1527428a9adb147ce16b9235,SCLC,0.311273
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,lung,0.343791
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,melanoma,0.339342
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,RCC,0.570225
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,TL stated,0.423215
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,institution,0.424978
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,PD-L1,0.304164
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,approval,0.344012
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,preferred,0.319551
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,PD-L1 testing,0.400196
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,testing,0.418548
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,using nivo,0.319352
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,PDL1 testing,0.500944
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,NSCLC patients,0.428711
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,approved,0.34317
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,SCCHN,0.372147
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,tumor types,0.349034
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,oncologist,0.394104
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,RTL stated,0.39691
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,TL shared,0.354135
uuid-4f7e6e0bd7474a3ca5b2564bb9efbfeb,bladder,0.345779
uuid-b287db9f7d3a402f934e3b2a11f99003,Nivo,0.538311
uuid-b287db9f7d3a402f934e3b2a11f99003,pembro,0.565513
uuid-b287db9f7d3a402f934e3b2a11f99003,dose,0.630629
uuid-b287db9f7d3a402f934e3b2a11f99003,trial,0.318647
uuid-b287db9f7d3a402f934e3b2a11f99003,regimen,0.368915
uuid-b287db9f7d3a402f934e3b2a11f99003,2L,0.327112
uuid-b287db9f7d3a402f934e3b2a11f99003,Ipi,0.578609
uuid-b287db9f7d3a402f934e3b2a11f99003,approval,0.309373
uuid-b287db9f7d3a402f934e3b2a11f99003,atezo,0.497496
uuid-b287db9f7d3a402f934e3b2a11f99003,preferred,0.355351
uuid-b287db9f7d3a402f934e3b2a11f99003,using nivo,0.397629
uuid-b287db9f7d3a402f934e3b2a11f99003,indication,0.345825
uuid-b287db9f7d3a402f934e3b2a11f99003,vs,0.483963
uuid-b287db9f7d3a402f934e3b2a11f99003,flat dosing,0.501187
uuid-1757c27b229b4ae3953244389ef4b4e2,TL,0.541566
uuid-1757c27b229b4ae3953244389ef4b4e2,pembro,0.37836
uuid-1757c27b229b4ae3953244389ef4b4e2,1L,0.324893
uuid-1757c27b229b4ae3953244389ef4b4e2,PDL1,0.572109
uuid-1757c27b229b4ae3953244389ef4b4e2,TL stated,0.344018
uuid-1757c27b229b4ae3953244389ef4b4e2,Merck,0.569087
uuid-1757c27b229b4ae3953244389ef4b4e2,PD-L1,0.754389
uuid-1757c27b229b4ae3953244389ef4b4e2,approval,0.311012
uuid-1757c27b229b4ae3953244389ef4b4e2,atezo,0.48054
uuid-1757c27b229b4ae3953244389ef4b4e2,PD-L1 testing,0.667214
uuid-1757c27b229b4ae3953244389ef4b4e2,testing,0.778162
uuid-1757c27b229b4ae3953244389ef4b4e2,PDL1 testing,0.621664
uuid-1757c27b229b4ae3953244389ef4b4e2,NSCLC patients,0.456412
uuid-1757c27b229b4ae3953244389ef4b4e2,nivo and pembro,0.304341
uuid-1757c27b229b4ae3953244389ef4b4e2,assay,0.861636
uuid-1757c27b229b4ae3953244389ef4b4e2,PDL1 expression,0.361272
uuid-1757c27b229b4ae3953244389ef4b4e2,biomarker,0.494898
uuid-186de13b790148fe8d9120794cd0f05a,BMS,0.637373
uuid-186de13b790148fe8d9120794cd0f05a,trial,0.54097
uuid-186de13b790148fe8d9120794cd0f05a,commented,0.409621
uuid-186de13b790148fe8d9120794cd0f05a,Merck,0.53654
uuid-186de13b790148fe8d9120794cd0f05a,stated,0.330089
uuid-186de13b790148fe8d9120794cd0f05a,OS,0.424083
uuid-186de13b790148fe8d9120794cd0f05a,data,0.676102
uuid-186de13b790148fe8d9120794cd0f05a,expressed,0.332616
uuid-186de13b790148fe8d9120794cd0f05a,clinical trials,0.33664
uuid-186de13b790148fe8d9120794cd0f05a,PFS,0.35535
uuid-186de13b790148fe8d9120794cd0f05a,ORR,0.423886
uuid-186de13b790148fe8d9120794cd0f05a,ASCO,0.346488
uuid-186de13b790148fe8d9120794cd0f05a,impressed,0.560929
uuid-186de13b790148fe8d9120794cd0f05a,feels,0.360594
uuid-2dc0bef683b544d889e24c0154d4a9ab,Nivo,0.3128
uuid-2dc0bef683b544d889e24c0154d4a9ab,patients,0.571358
uuid-2dc0bef683b544d889e24c0154d4a9ab,Opdivo,0.310927
uuid-2dc0bef683b544d889e24c0154d4a9ab,pembro,0.350569
uuid-2dc0bef683b544d889e24c0154d4a9ab,therapy,0.326107
uuid-2dc0bef683b544d889e24c0154d4a9ab,nivolumab,0.497464
uuid-2dc0bef683b544d889e24c0154d4a9ab,1L,0.530672
uuid-2dc0bef683b544d889e24c0154d4a9ab,regimen,0.397041
uuid-2dc0bef683b544d889e24c0154d4a9ab,treated,0.444288
uuid-2dc0bef683b544d889e24c0154d4a9ab,RCC,0.449888
uuid-2dc0bef683b544d889e24c0154d4a9ab,2L,0.627894
uuid-2dc0bef683b544d889e24c0154d4a9ab,pts,0.376742
uuid-2dc0bef683b544d889e24c0154d4a9ab,approval,0.429325
uuid-2dc0bef683b544d889e24c0154d4a9ab,atezo,0.30592
uuid-2dc0bef683b544d889e24c0154d4a9ab,preferred,0.722537
uuid-2dc0bef683b544d889e24c0154d4a9ab,monotherapy,0.577028
uuid-2dc0bef683b544d889e24c0154d4a9ab,treatment,0.400924
uuid-2dc0bef683b544d889e24c0154d4a9ab,using nivo,0.685634
uuid-2dc0bef683b544d889e24c0154d4a9ab,NSCLC patients,0.372737
uuid-2dc0bef683b544d889e24c0154d4a9ab,approved,0.444844
uuid-2dc0bef683b544d889e24c0154d4a9ab,SCCHN,0.451336
uuid-2dc0bef683b544d889e24c0154d4a9ab,tumor types,0.310087
uuid-2dc0bef683b544d889e24c0154d4a9ab,RTL stated,0.642495
uuid-2dc0bef683b544d889e24c0154d4a9ab,TL shared,0.367987
uuid-2dc0bef683b544d889e24c0154d4a9ab,option,0.631374
uuid-2dc0bef683b544d889e24c0154d4a9ab,bladder,0.312449
uuid-2f14355602b4484dbccb07e90903bcc3,Nivo,0.416335
uuid-2f14355602b4484dbccb07e90903bcc3,patients,0.871471
uuid-2f14355602b4484dbccb07e90903bcc3,Opdivo,0.388876
uuid-2f14355602b4484dbccb07e90903bcc3,therapy,0.759677
uuid-2f14355602b4484dbccb07e90903bcc3,nivolumab,0.573711
uuid-2f14355602b4484dbccb07e90903bcc3,regimen,0.547918
uuid-2f14355602b4484dbccb07e90903bcc3,treated,0.63078
uuid-2f14355602b4484dbccb07e90903bcc3,chemo,0.475979
uuid-2f14355602b4484dbccb07e90903bcc3,pts,0.606757
uuid-2f14355602b4484dbccb07e90903bcc3,monotherapy,0.460017
uuid-2f14355602b4484dbccb07e90903bcc3,treatment,0.728799
uuid-2f14355602b4484dbccb07e90903bcc3,using nivo,0.37018
uuid-2f14355602b4484dbccb07e90903bcc3,response,0.558944
uuid-2f14355602b4484dbccb07e90903bcc3,PD1,0.446813
uuid-2f14355602b4484dbccb07e90903bcc3,cHL,0.449987
uuid-2f14355602b4484dbccb07e90903bcc3,progression,0.739634
uuid-2f14355602b4484dbccb07e90903bcc3,chemotherapy,0.527645
uuid-2f14355602b4484dbccb07e90903bcc3,respond,0.515729
uuid-2f14355602b4484dbccb07e90903bcc3,option,0.391235
uuid-539358a2d86e4653aba4305fd59ddc6c,patients,0.34009
uuid-539358a2d86e4653aba4305fd59ddc6c,BMS,0.307584
uuid-539358a2d86e4653aba4305fd59ddc6c,trial,0.332664
uuid-539358a2d86e4653aba4305fd59ddc6c,clinical trials,0.388758
uuid-539358a2d86e4653aba4305fd59ddc6c,feels,0.373087
uuid-539358a2d86e4653aba4305fd59ddc6c,bladder,0.420322
uuid-3d2c509bcc7644f2ac54c457f9f443fb,Nivo,0.430524
uuid-3d2c509bcc7644f2ac54c457f9f443fb,pembro,0.637442
uuid-3d2c509bcc7644f2ac54c457f9f443fb,1L,0.682736
uuid-3d2c509bcc7644f2ac54c457f9f443fb,RCC,0.408392
uuid-3d2c509bcc7644f2ac54c457f9f443fb,combination,0.300087
uuid-3d2c509bcc7644f2ac54c457f9f443fb,2L,0.736333
uuid-3d2c509bcc7644f2ac54c457f9f443fb,agents,0.446897
uuid-3d2c509bcc7644f2ac54c457f9f443fb,approval,0.398487
uuid-3d2c509bcc7644f2ac54c457f9f443fb,atezo,0.641414
uuid-3d2c509bcc7644f2ac54c457f9f443fb,preferred,0.701661
uuid-3d2c509bcc7644f2ac54c457f9f443fb,monotherapy,0.576383
uuid-3d2c509bcc7644f2ac54c457f9f443fb,using nivo,0.680507
uuid-3d2c509bcc7644f2ac54c457f9f443fb,combo,0.360917
uuid-3d2c509bcc7644f2ac54c457f9f443fb,indication,0.376219
uuid-3d2c509bcc7644f2ac54c457f9f443fb,approved,0.479029
uuid-3d2c509bcc7644f2ac54c457f9f443fb,SCCHN,0.478522
uuid-3d2c509bcc7644f2ac54c457f9f443fb,nivo and pembro,0.365535
uuid-3d2c509bcc7644f2ac54c457f9f443fb,believes,0.315514
uuid-3d2c509bcc7644f2ac54c457f9f443fb,LTL,0.3178
uuid-3d2c509bcc7644f2ac54c457f9f443fb,feels,0.542586
uuid-3d2c509bcc7644f2ac54c457f9f443fb,RTL stated,0.593325
uuid-3d2c509bcc7644f2ac54c457f9f443fb,option,0.590096
uuid-3d2c509bcc7644f2ac54c457f9f443fb,bladder,0.370398
uuid-6eade3a9715e468ba9217bcc67fcb683,Nivo,0.325244
uuid-6eade3a9715e468ba9217bcc67fcb683,patients,0.335525
uuid-6eade3a9715e468ba9217bcc67fcb683,pembro,0.359122
uuid-6eade3a9715e468ba9217bcc67fcb683,nivolumab,0.301122
uuid-6eade3a9715e468ba9217bcc67fcb683,trial,0.429981
uuid-6eade3a9715e468ba9217bcc67fcb683,approval,0.395338
uuid-6eade3a9715e468ba9217bcc67fcb683,preferred,0.35163
uuid-6eade3a9715e468ba9217bcc67fcb683,using nivo,0.345282
uuid-6eade3a9715e468ba9217bcc67fcb683,clinical trials,0.484578
uuid-6eade3a9715e468ba9217bcc67fcb683,approved,0.389694
uuid-6eade3a9715e468ba9217bcc67fcb683,SCCHN,0.302624
uuid-6eade3a9715e468ba9217bcc67fcb683,feels,0.490603
uuid-6eade3a9715e468ba9217bcc67fcb683,RTL stated,0.324101
uuid-6eade3a9715e468ba9217bcc67fcb683,option,0.377678
uuid-15bc7a0198f2424ba64a6a2fa117ea35,patients,0.393064
uuid-15bc7a0198f2424ba64a6a2fa117ea35,treated,0.391298
uuid-15bc7a0198f2424ba64a6a2fa117ea35,commented,0.330462
uuid-15bc7a0198f2424ba64a6a2fa117ea35,approval,0.507424
uuid-15bc7a0198f2424ba64a6a2fa117ea35,using nivo,0.342767
uuid-15bc7a0198f2424ba64a6a2fa117ea35,NSCLC patients,0.336823
uuid-15bc7a0198f2424ba64a6a2fa117ea35,approved,0.362094
uuid-15bc7a0198f2424ba64a6a2fa117ea35,SCCHN,0.403938
uuid-15bc7a0198f2424ba64a6a2fa117ea35,tumor types,0.396932
uuid-15bc7a0198f2424ba64a6a2fa117ea35,label,0.341626
uuid-15bc7a0198f2424ba64a6a2fa117ea35,Regional TL,0.330848
uuid-15bc7a0198f2424ba64a6a2fa117ea35,RTL stated,0.347331
uuid-15bc7a0198f2424ba64a6a2fa117ea35,bladder,0.371563
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,Nivo,0.574353
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,pembro,0.433287
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,nivolumab,0.381962
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,1L,0.383653
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,trial,0.311227
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,commented,0.301768
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,RCC,0.36027
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,2L,0.414906
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,stated,0.341056
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,approval,0.421398
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,preferred,0.33679
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,monotherapy,0.374129
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,using nivo,0.561243
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,data,0.425273
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,approved,0.377239
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,SCCHN,0.42982
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,impressed,0.449852
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,LTL,0.340102
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,SCLC,0.410945
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,feels,0.383928
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,Regional TL,0.369837
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,RTL stated,0.531532
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,option,0.377377
uuid-1140ffbb6a4945a6bf71d405ec6a6b6e,bladder,0.410655
uuid-e427eb981ca94af4a8b3b2b895e73419,Nivo,0.494072
uuid-e427eb981ca94af4a8b3b2b895e73419,pembro,0.306323
uuid-e427eb981ca94af4a8b3b2b895e73419,therapy,0.324667
uuid-e427eb981ca94af4a8b3b2b895e73419,1L,0.386717
uuid-e427eb981ca94af4a8b3b2b895e73419,efficacy,0.311555
uuid-e427eb981ca94af4a8b3b2b895e73419,regimen,0.359954
uuid-e427eb981ca94af4a8b3b2b895e73419,RCC,0.337476
uuid-e427eb981ca94af4a8b3b2b895e73419,combination,0.440098
uuid-e427eb981ca94af4a8b3b2b895e73419,chemo,0.545816
uuid-e427eb981ca94af4a8b3b2b895e73419,2L,0.385752
uuid-e427eb981ca94af4a8b3b2b895e73419,pts,0.392179
uuid-e427eb981ca94af4a8b3b2b895e73419,agents,0.42383
uuid-e427eb981ca94af4a8b3b2b895e73419,monotherapy,0.581601
uuid-e427eb981ca94af4a8b3b2b895e73419,using nivo,0.391061
uuid-e427eb981ca94af4a8b3b2b895e73419,response,0.328179
uuid-e427eb981ca94af4a8b3b2b895e73419,combo,0.424889
uuid-e427eb981ca94af4a8b3b2b895e73419,PD1,0.574561
uuid-e427eb981ca94af4a8b3b2b895e73419,nivo and pembro,0.459355
uuid-e427eb981ca94af4a8b3b2b895e73419,believes,0.51554
uuid-e427eb981ca94af4a8b3b2b895e73419,chemotherapy,0.424109
uuid-e427eb981ca94af4a8b3b2b895e73419,respond,0.357545
uuid-e427eb981ca94af4a8b3b2b895e73419,feels,0.444515
uuid-e427eb981ca94af4a8b3b2b895e73419,RTL stated,0.314701
uuid-e427eb981ca94af4a8b3b2b895e73419,option,0.422589
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,Nivo,0.402655
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,pembro,0.351204
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,trial,0.395628
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,efficacy,0.428774
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,OS,0.652552
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,data,0.68594
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,PFS,0.571904
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,ORR,0.617189
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,nivo and pembro,0.373373
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,impressed,0.613559
uuid-3dbe0bccdfaf4a1daadf48e1dffaa175,feels,0.447578
uuid-ce9927f456f647069508e16a02ba69fb,NTL,0.355866
uuid-ce9927f456f647069508e16a02ba69fb,commented,0.32079
uuid-ce9927f456f647069508e16a02ba69fb,approval,0.340605
uuid-ce9927f456f647069508e16a02ba69fb,SCCHN,0.346476
uuid-ce9927f456f647069508e16a02ba69fb,NCCN,0.388228
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,Nivo,0.585122
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,pembro,0.399141
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,therapy,0.334604
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,nivolumab,0.449374
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,1L,0.413148
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,toxicity,0.427856
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,regimen,0.429729
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,RCC,0.328734
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,combination,0.617504
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,chemo,0.420652
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,2L,0.534371
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,agents,0.552899
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,Ipi,0.379932
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,atezo,0.358709
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,preferred,0.61491
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,monotherapy,0.639264
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,using nivo,0.530625
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,combo,0.50094
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,PD1,0.41513
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,approved,0.325878
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,chemotherapy,0.406703
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,feels,0.339906
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,RTL stated,0.491055
uuid-bdbe4519e7fa4bcda36ad63fcb7546b3,option,0.540113
uuid-19600df2096f4bb38799437084f43222,Opdivo,0.366501
uuid-19600df2096f4bb38799437084f43222,physicians,0.821156
uuid-19600df2096f4bb38799437084f43222,oncology,0.30858
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,patients,0.651712
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,Opdivo,0.540849
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,dose,0.658386
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,toxicity,0.570367
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,regimen,0.519608
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,treated,0.409109
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,treatment,0.569836
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,progression,0.397599
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,respond,0.413207
uuid-b66e9b9d8bb14b64b9df2806aa10cc4d,flat dosing,0.368528
uuid-f18bf33e2393466fb7213e4b7412300a,1L,0.357059
uuid-f18bf33e2393466fb7213e4b7412300a,efficacy,0.54834
uuid-f18bf33e2393466fb7213e4b7412300a,combination,0.559036
uuid-f18bf33e2393466fb7213e4b7412300a,chemo,0.506553
uuid-f18bf33e2393466fb7213e4b7412300a,2L,0.30282
uuid-f18bf33e2393466fb7213e4b7412300a,IO,0.569958
uuid-f18bf33e2393466fb7213e4b7412300a,agents,0.548791
uuid-f18bf33e2393466fb7213e4b7412300a,OS,0.308146
uuid-f18bf33e2393466fb7213e4b7412300a,monotherapy,0.523215
uuid-f18bf33e2393466fb7213e4b7412300a,response,0.306049
uuid-f18bf33e2393466fb7213e4b7412300a,combo,0.590708
uuid-f18bf33e2393466fb7213e4b7412300a,PD1,0.453023
uuid-f18bf33e2393466fb7213e4b7412300a,ORR,0.366656
uuid-f18bf33e2393466fb7213e4b7412300a,nivo and pembro,0.343616
uuid-f18bf33e2393466fb7213e4b7412300a,believes,0.585549
uuid-f18bf33e2393466fb7213e4b7412300a,chemotherapy,0.427566
uuid-f18bf33e2393466fb7213e4b7412300a,TLs,0.32327
uuid-f18bf33e2393466fb7213e4b7412300a,feels,0.412472
uuid-f18bf33e2393466fb7213e4b7412300a,option,0.388299
uuid-3791a583cbb84a22871f9157ad7b44a1,Opdivo,0.333526
uuid-3791a583cbb84a22871f9157ad7b44a1,RTL,0.32159
uuid-3791a583cbb84a22871f9157ad7b44a1,shared,0.314808
uuid-3791a583cbb84a22871f9157ad7b44a1,stated,0.358647
uuid-3791a583cbb84a22871f9157ad7b44a1,physicians,0.537978
uuid-3791a583cbb84a22871f9157ad7b44a1,oncology,0.620887
uuid-3791a583cbb84a22871f9157ad7b44a1,LTL,0.381723
uuid-3791a583cbb84a22871f9157ad7b44a1,clinical,0.37744
uuid-3791a583cbb84a22871f9157ad7b44a1,academic,0.346875
uuid-3791a583cbb84a22871f9157ad7b44a1,Regional TL,0.414942
uuid-3791a583cbb84a22871f9157ad7b44a1,flat dosing,0.406994
uuid-77544cf807fc44778b16b9749d87c436,pembro,0.53969
uuid-77544cf807fc44778b16b9749d87c436,dose,0.592884
uuid-77544cf807fc44778b16b9749d87c436,BMS,0.381771
uuid-77544cf807fc44778b16b9749d87c436,efficacy,0.515604
uuid-77544cf807fc44778b16b9749d87c436,Merck,0.322905
uuid-77544cf807fc44778b16b9749d87c436,Ipi,0.399733
uuid-77544cf807fc44778b16b9749d87c436,atezo,0.620434
uuid-77544cf807fc44778b16b9749d87c436,regards,0.340011
uuid-77544cf807fc44778b16b9749d87c436,indication,0.512913
uuid-77544cf807fc44778b16b9749d87c436,approved,0.319078
uuid-77544cf807fc44778b16b9749d87c436,nivo and pembro,0.303283
uuid-77544cf807fc44778b16b9749d87c436,vs,0.553933
uuid-77544cf807fc44778b16b9749d87c436,Keytruda,0.365534
uuid-77544cf807fc44778b16b9749d87c436,TLs,0.368645
uuid-77544cf807fc44778b16b9749d87c436,flat dosing,0.614165
uuid-c01975a3847a4751bc5b13f4014e1105,Nivo,0.395853
uuid-c01975a3847a4751bc5b13f4014e1105,patients,0.506771
uuid-c01975a3847a4751bc5b13f4014e1105,therapy,0.310413
uuid-c01975a3847a4751bc5b13f4014e1105,nivolumab,0.494535
uuid-c01975a3847a4751bc5b13f4014e1105,1L,0.319882
uuid-c01975a3847a4751bc5b13f4014e1105,regimen,0.462066
uuid-c01975a3847a4751bc5b13f4014e1105,treated,0.526506
uuid-c01975a3847a4751bc5b13f4014e1105,RCC,0.506739
uuid-c01975a3847a4751bc5b13f4014e1105,chemo,0.333891
uuid-c01975a3847a4751bc5b13f4014e1105,2L,0.393147
uuid-c01975a3847a4751bc5b13f4014e1105,pts,0.416288
uuid-c01975a3847a4751bc5b13f4014e1105,preferred,0.304598
uuid-c01975a3847a4751bc5b13f4014e1105,monotherapy,0.464985
uuid-c01975a3847a4751bc5b13f4014e1105,treatment,0.408203
uuid-c01975a3847a4751bc5b13f4014e1105,using nivo,0.53327
uuid-c01975a3847a4751bc5b13f4014e1105,combo,0.34806
uuid-c01975a3847a4751bc5b13f4014e1105,PD1,0.387879
uuid-c01975a3847a4751bc5b13f4014e1105,SCCHN,0.338597
uuid-c01975a3847a4751bc5b13f4014e1105,progression,0.418904
uuid-c01975a3847a4751bc5b13f4014e1105,impressed,0.313861
uuid-c01975a3847a4751bc5b13f4014e1105,respond,0.327934
uuid-c01975a3847a4751bc5b13f4014e1105,SCLC,0.318396
uuid-c01975a3847a4751bc5b13f4014e1105,feels,0.320095
uuid-c01975a3847a4751bc5b13f4014e1105,RTL stated,0.489431
uuid-c01975a3847a4751bc5b13f4014e1105,TL shared,0.378537
uuid-c01975a3847a4751bc5b13f4014e1105,option,0.380749
uuid-c01975a3847a4751bc5b13f4014e1105,bladder,0.323458
uuid-44a6c823b0a04bb08f5b8c238668eced,Nivo,0.47594
uuid-44a6c823b0a04bb08f5b8c238668eced,patients,0.87037
uuid-44a6c823b0a04bb08f5b8c238668eced,Opdivo,0.512745
uuid-44a6c823b0a04bb08f5b8c238668eced,therapy,0.648819
uuid-44a6c823b0a04bb08f5b8c238668eced,nivolumab,0.511717
uuid-44a6c823b0a04bb08f5b8c238668eced,regimen,0.497215
uuid-44a6c823b0a04bb08f5b8c238668eced,treated,0.514395
uuid-44a6c823b0a04bb08f5b8c238668eced,chemo,0.369285
uuid-44a6c823b0a04bb08f5b8c238668eced,pts,0.58356
uuid-44a6c823b0a04bb08f5b8c238668eced,monotherapy,0.355681
uuid-44a6c823b0a04bb08f5b8c238668eced,treatment,0.6724
uuid-44a6c823b0a04bb08f5b8c238668eced,using nivo,0.3378
uuid-44a6c823b0a04bb08f5b8c238668eced,response,0.427937
uuid-44a6c823b0a04bb08f5b8c238668eced,PD1,0.348268
uuid-44a6c823b0a04bb08f5b8c238668eced,cHL,0.440509
uuid-44a6c823b0a04bb08f5b8c238668eced,progression,0.684628
uuid-44a6c823b0a04bb08f5b8c238668eced,chemotherapy,0.413328
uuid-44a6c823b0a04bb08f5b8c238668eced,respond,0.526412
uuid-44a6c823b0a04bb08f5b8c238668eced,option,0.319589
uuid-94d60a5f45bd40c880c444da03d5b667,OS,0.485571
uuid-94d60a5f45bd40c880c444da03d5b667,data,0.384405
uuid-94d60a5f45bd40c880c444da03d5b667,PFS,0.438158
uuid-94d60a5f45bd40c880c444da03d5b667,ORR,0.406985
uuid-94d60a5f45bd40c880c444da03d5b667,nivo and pembro,0.402848
uuid-94d60a5f45bd40c880c444da03d5b667,believes,0.314567
uuid-94d60a5f45bd40c880c444da03d5b667,impressed,0.337582
uuid-94d60a5f45bd40c880c444da03d5b667,feels,0.460364
uuid-e01f3cc170aa469d95967193d4ad7299,Nivo,0.317466
uuid-e01f3cc170aa469d95967193d4ad7299,pembro,0.33932
uuid-e01f3cc170aa469d95967193d4ad7299,1L,0.544465
uuid-e01f3cc170aa469d95967193d4ad7299,RCC,0.515081
uuid-e01f3cc170aa469d95967193d4ad7299,TL stated,0.314967
uuid-e01f3cc170aa469d95967193d4ad7299,combination,0.338842
uuid-e01f3cc170aa469d95967193d4ad7299,chemo,0.338652
uuid-e01f3cc170aa469d95967193d4ad7299,2L,0.661103
uuid-e01f3cc170aa469d95967193d4ad7299,agents,0.626628
uuid-e01f3cc170aa469d95967193d4ad7299,atezo,0.403911
uuid-e01f3cc170aa469d95967193d4ad7299,preferred,0.651934
uuid-e01f3cc170aa469d95967193d4ad7299,monotherapy,0.541036
uuid-e01f3cc170aa469d95967193d4ad7299,using nivo,0.481839
uuid-e01f3cc170aa469d95967193d4ad7299,combo,0.391597
uuid-e01f3cc170aa469d95967193d4ad7299,PD1,0.340005
uuid-e01f3cc170aa469d95967193d4ad7299,approved,0.344777
uuid-e01f3cc170aa469d95967193d4ad7299,nivo and pembro,0.359716
uuid-e01f3cc170aa469d95967193d4ad7299,believes,0.408764
uuid-e01f3cc170aa469d95967193d4ad7299,feels,0.351345
uuid-e01f3cc170aa469d95967193d4ad7299,RTL stated,0.485963
uuid-e01f3cc170aa469d95967193d4ad7299,option,0.538578
uuid-6404c0759e1244c1aea3fb1101fcd3a5,patients,0.503987
uuid-6404c0759e1244c1aea3fb1101fcd3a5,dose,0.387016
uuid-6404c0759e1244c1aea3fb1101fcd3a5,toxicity,0.622203
uuid-6404c0759e1244c1aea3fb1101fcd3a5,regimen,0.583806
uuid-6404c0759e1244c1aea3fb1101fcd3a5,treated,0.52741
uuid-6404c0759e1244c1aea3fb1101fcd3a5,pts,0.312979
uuid-6404c0759e1244c1aea3fb1101fcd3a5,treatment,0.558138
uuid-6404c0759e1244c1aea3fb1101fcd3a5,progression,0.325682
uuid-6404c0759e1244c1aea3fb1101fcd3a5,respond,0.450239
uuid-6404c0759e1244c1aea3fb1101fcd3a5,TL shared,0.351764
uuid-bb1d4acf21094c19a72c72b96e540452,patients,0.744669
uuid-bb1d4acf21094c19a72c72b96e540452,Opdivo,0.545404
uuid-bb1d4acf21094c19a72c72b96e540452,therapy,0.388522
uuid-bb1d4acf21094c19a72c72b96e540452,nivolumab,0.320245
uuid-bb1d4acf21094c19a72c72b96e540452,regimen,0.427506
uuid-bb1d4acf21094c19a72c72b96e540452,treated,0.515676
uuid-bb1d4acf21094c19a72c72b96e540452,pts,0.429366
uuid-bb1d4acf21094c19a72c72b96e540452,physicians,0.397399
uuid-bb1d4acf21094c19a72c72b96e540452,treatment,0.636785
uuid-bb1d4acf21094c19a72c72b96e540452,NSCLC patients,0.340583
uuid-bb1d4acf21094c19a72c72b96e540452,progression,0.499553
uuid-bb1d4acf21094c19a72c72b96e540452,respond,0.405557
uuid-bb1d4acf21094c19a72c72b96e540452,option,0.319321
uuid-71cf17b7421041a7abda341332282a3d,Nivo,0.414604
uuid-71cf17b7421041a7abda341332282a3d,patients,0.362758
uuid-71cf17b7421041a7abda341332282a3d,pembro,0.451571
uuid-71cf17b7421041a7abda341332282a3d,dose,0.454344
uuid-71cf17b7421041a7abda341332282a3d,1L,0.372412
uuid-71cf17b7421041a7abda341332282a3d,toxicity,0.379307
uuid-71cf17b7421041a7abda341332282a3d,regimen,0.394305
uuid-71cf17b7421041a7abda341332282a3d,chemo,0.349192
uuid-71cf17b7421041a7abda341332282a3d,2L,0.513162
uuid-71cf17b7421041a7abda341332282a3d,agents,0.383662
uuid-71cf17b7421041a7abda341332282a3d,Ipi,0.3084
uuid-71cf17b7421041a7abda341332282a3d,atezo,0.434126
uuid-71cf17b7421041a7abda341332282a3d,preferred,0.585036
uuid-71cf17b7421041a7abda341332282a3d,monotherapy,0.485206
uuid-71cf17b7421041a7abda341332282a3d,using nivo,0.453566
uuid-71cf17b7421041a7abda341332282a3d,vs,0.351637
uuid-71cf17b7421041a7abda341332282a3d,RTL stated,0.332559
uuid-71cf17b7421041a7abda341332282a3d,option,0.472134
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,Nivo,0.339714
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,patients,0.369154
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,pembro,0.358203
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,1L,0.377808
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,regimen,0.323325
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,2L,0.471535
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,atezo,0.335675
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,preferred,0.510178
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,monotherapy,0.395135
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,using nivo,0.460949
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,respond,0.322249
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,RTL stated,0.332134
uuid-1c52069aaec247e9a2c3dc79a74b4cd4,option,0.444899
uuid-3a929b9310274a91aecd21a21eddb3a6,patients,0.610962
uuid-3a929b9310274a91aecd21a21eddb3a6,Opdivo,0.356762
uuid-3a929b9310274a91aecd21a21eddb3a6,therapy,0.618473
uuid-3a929b9310274a91aecd21a21eddb3a6,nivolumab,0.432061
uuid-3a929b9310274a91aecd21a21eddb3a6,treated,0.39756
uuid-3a929b9310274a91aecd21a21eddb3a6,treatment,0.414667
uuid-3a929b9310274a91aecd21a21eddb3a6,cHL,0.69793
uuid-3a929b9310274a91aecd21a21eddb3a6,progression,0.325632
uuid-3361391d9ed34df1aeea3523bda87551,patients,0.406659
uuid-3361391d9ed34df1aeea3523bda87551,therapy,0.421306
uuid-3361391d9ed34df1aeea3523bda87551,mentioned,0.331815
uuid-3361391d9ed34df1aeea3523bda87551,cHL,0.671021
uuid-0ef6ceedd4114001bb4355eb7f6a7985,patients,0.66306
uuid-0ef6ceedd4114001bb4355eb7f6a7985,Opdivo,0.345437
uuid-0ef6ceedd4114001bb4355eb7f6a7985,therapy,0.552814
uuid-0ef6ceedd4114001bb4355eb7f6a7985,nivolumab,0.431295
uuid-0ef6ceedd4114001bb4355eb7f6a7985,treated,0.412831
uuid-0ef6ceedd4114001bb4355eb7f6a7985,treatment,0.431144
uuid-0ef6ceedd4114001bb4355eb7f6a7985,cHL,0.652522
uuid-0ef6ceedd4114001bb4355eb7f6a7985,progression,0.371349
uuid-0ef6ceedd4114001bb4355eb7f6a7985,respond,0.330283
uuid-6726126a869342ea9f578415fa097e4d,Nivo,0.469104
uuid-6726126a869342ea9f578415fa097e4d,patients,0.423749
uuid-6726126a869342ea9f578415fa097e4d,therapy,0.389104
uuid-6726126a869342ea9f578415fa097e4d,nivolumab,0.460565
uuid-6726126a869342ea9f578415fa097e4d,approval,0.59454
uuid-6726126a869342ea9f578415fa097e4d,using nivo,0.600766
uuid-6726126a869342ea9f578415fa097e4d,mentioned,0.320144
uuid-6726126a869342ea9f578415fa097e4d,approved,0.388267
uuid-6726126a869342ea9f578415fa097e4d,cHL,0.615399
uuid-6726126a869342ea9f578415fa097e4d,label,0.382542
uuid-9e58091962c945e98b9de29e36b65f49,Nivo,0.409131
uuid-9e58091962c945e98b9de29e36b65f49,pembro,0.379763
uuid-9e58091962c945e98b9de29e36b65f49,1L,0.470313
uuid-9e58091962c945e98b9de29e36b65f49,RCC,0.324381
uuid-9e58091962c945e98b9de29e36b65f49,chemo,0.382264
uuid-9e58091962c945e98b9de29e36b65f49,2L,0.500416
uuid-9e58091962c945e98b9de29e36b65f49,agents,0.465384
uuid-9e58091962c945e98b9de29e36b65f49,atezo,0.35679
uuid-9e58091962c945e98b9de29e36b65f49,preferred,0.38696
uuid-9e58091962c945e98b9de29e36b65f49,monotherapy,0.443496
uuid-9e58091962c945e98b9de29e36b65f49,using nivo,0.398454
uuid-9e58091962c945e98b9de29e36b65f49,combo,0.321031
uuid-9e58091962c945e98b9de29e36b65f49,PD1,0.359526
uuid-9e58091962c945e98b9de29e36b65f49,nivo and pembro,0.555937
uuid-9e58091962c945e98b9de29e36b65f49,believes,0.533069
uuid-9e58091962c945e98b9de29e36b65f49,feels,0.426038
uuid-9e58091962c945e98b9de29e36b65f49,RTL stated,0.300828
uuid-9e58091962c945e98b9de29e36b65f49,option,0.435938
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,Nivo,0.59486
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,patients,0.624573
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,therapy,0.581419
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,nivolumab,0.383189
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,1L,0.396921
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,toxicity,0.427609
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,regimen,0.589146
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,treated,0.315939
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,combination,0.410742
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,chemo,0.639816
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,2L,0.440716
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,pts,0.524635
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,agents,0.35704
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,Ipi,0.308214
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,preferred,0.410132
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,monotherapy,0.674616
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,treatment,0.573247
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,using nivo,0.417274
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,response,0.448961
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,combo,0.400762
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,PD1,0.514452
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,progression,0.565788
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,believes,0.347198
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,chemotherapy,0.532958
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,respond,0.569179
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,feels,0.35876
uuid-d8bd3b1720a840e2b2ffcc30e866bc10,option,0.601598
uuid-9448337de87d4a259b46cbae45afe0e5,Nivo,0.483691
uuid-9448337de87d4a259b46cbae45afe0e5,pembro,0.529136
uuid-9448337de87d4a259b46cbae45afe0e5,1L,0.447086
uuid-9448337de87d4a259b46cbae45afe0e5,toxicity,0.348796
uuid-9448337de87d4a259b46cbae45afe0e5,regimen,0.310403
uuid-9448337de87d4a259b46cbae45afe0e5,RCC,0.430176
uuid-9448337de87d4a259b46cbae45afe0e5,combination,0.412167
uuid-9448337de87d4a259b46cbae45afe0e5,chemo,0.372673
uuid-9448337de87d4a259b46cbae45afe0e5,2L,0.537082
uuid-9448337de87d4a259b46cbae45afe0e5,agents,0.46257
uuid-9448337de87d4a259b46cbae45afe0e5,Ipi,0.436259
uuid-9448337de87d4a259b46cbae45afe0e5,atezo,0.503098
uuid-9448337de87d4a259b46cbae45afe0e5,preferred,0.619715
uuid-9448337de87d4a259b46cbae45afe0e5,monotherapy,0.519889
uuid-9448337de87d4a259b46cbae45afe0e5,using nivo,0.469915
uuid-9448337de87d4a259b46cbae45afe0e5,combo,0.449364
uuid-9448337de87d4a259b46cbae45afe0e5,nivo and pembro,0.378344
uuid-9448337de87d4a259b46cbae45afe0e5,believes,0.305327
uuid-9448337de87d4a259b46cbae45afe0e5,vs,0.387165
uuid-9448337de87d4a259b46cbae45afe0e5,feels,0.415719
uuid-9448337de87d4a259b46cbae45afe0e5,RTL stated,0.430246
uuid-9448337de87d4a259b46cbae45afe0e5,option,0.435363
uuid-09eb8b879b7d45ea812cd51db5272030,Nivo,0.302048
uuid-09eb8b879b7d45ea812cd51db5272030,patients,0.716314
uuid-09eb8b879b7d45ea812cd51db5272030,Opdivo,0.400561
uuid-09eb8b879b7d45ea812cd51db5272030,therapy,0.400055
uuid-09eb8b879b7d45ea812cd51db5272030,dose,0.399188
uuid-09eb8b879b7d45ea812cd51db5272030,nivolumab,0.419192
uuid-09eb8b879b7d45ea812cd51db5272030,toxicity,0.432676
uuid-09eb8b879b7d45ea812cd51db5272030,regimen,0.552874
uuid-09eb8b879b7d45ea812cd51db5272030,treated,0.560164
uuid-09eb8b879b7d45ea812cd51db5272030,pts,0.476121
uuid-09eb8b879b7d45ea812cd51db5272030,treatment,0.666463
uuid-09eb8b879b7d45ea812cd51db5272030,response,0.32443
uuid-09eb8b879b7d45ea812cd51db5272030,progression,0.531854
uuid-09eb8b879b7d45ea812cd51db5272030,respond,0.564242
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,patients,0.443182
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,Opdivo,0.41737
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,dose,0.436899
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,toxicity,0.526361
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,regimen,0.534345
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,treated,0.411067
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,physicians,0.439137
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,treatment,0.616801
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,progression,0.317116
uuid-c04c766d5d1c4114bbe96831b7f4a3d3,respond,0.398849
uuid-2db1c37ff29e454ea814fbdd8865ae35,patients,0.628401
uuid-2db1c37ff29e454ea814fbdd8865ae35,therapy,0.459591
uuid-2db1c37ff29e454ea814fbdd8865ae35,regimen,0.364352
uuid-2db1c37ff29e454ea814fbdd8865ae35,treated,0.480673
uuid-2db1c37ff29e454ea814fbdd8865ae35,chemo,0.501209
uuid-2db1c37ff29e454ea814fbdd8865ae35,tumor,0.577494
uuid-2db1c37ff29e454ea814fbdd8865ae35,pts,0.61204
uuid-2db1c37ff29e454ea814fbdd8865ae35,treatment,0.426154
uuid-2db1c37ff29e454ea814fbdd8865ae35,response,0.668221
uuid-2db1c37ff29e454ea814fbdd8865ae35,PD1,0.356114
uuid-2db1c37ff29e454ea814fbdd8865ae35,progression,0.573646
uuid-2db1c37ff29e454ea814fbdd8865ae35,chemotherapy,0.399461
uuid-2db1c37ff29e454ea814fbdd8865ae35,respond,0.474748
uuid-b1d3e794a7604815b7845798e34d6349,patients,0.807732
uuid-b1d3e794a7604815b7845798e34d6349,Opdivo,0.3724
uuid-b1d3e794a7604815b7845798e34d6349,therapy,0.508953
uuid-b1d3e794a7604815b7845798e34d6349,nivolumab,0.305933
uuid-b1d3e794a7604815b7845798e34d6349,regimen,0.553353
uuid-b1d3e794a7604815b7845798e34d6349,treated,0.624885
uuid-b1d3e794a7604815b7845798e34d6349,pts,0.528367
uuid-b1d3e794a7604815b7845798e34d6349,treatment,0.75725
uuid-b1d3e794a7604815b7845798e34d6349,response,0.48368
uuid-b1d3e794a7604815b7845798e34d6349,progression,0.745635
uuid-b1d3e794a7604815b7845798e34d6349,respond,0.605006
uuid-cd69201f9f114a7e901e47263bfdc603,patients,0.319271
uuid-cd69201f9f114a7e901e47263bfdc603,Opdivo,0.318346
uuid-cd69201f9f114a7e901e47263bfdc603,dose,0.497802
uuid-cd69201f9f114a7e901e47263bfdc603,academic,0.313157
uuid-cd69201f9f114a7e901e47263bfdc603,flat dosing,0.501373
uuid-2591e95315fc428f943a5fb07e94f6ad,oncology,0.510747
uuid-2591e95315fc428f943a5fb07e94f6ad,ASCO,0.411008
uuid-37e6d5ee91bb425a96b0c6a673960501,RTL,0.333988
uuid-37e6d5ee91bb425a96b0c6a673960501,lung,0.357242
uuid-37e6d5ee91bb425a96b0c6a673960501,NTL,0.370973
uuid-37e6d5ee91bb425a96b0c6a673960501,discussed,0.322406
uuid-37e6d5ee91bb425a96b0c6a673960501,melanoma,0.397777
uuid-37e6d5ee91bb425a96b0c6a673960501,commented,0.367703
uuid-37e6d5ee91bb425a96b0c6a673960501,stated,0.389895
uuid-37e6d5ee91bb425a96b0c6a673960501,SCCHN,0.457551
uuid-37e6d5ee91bb425a96b0c6a673960501,academic,0.31119
uuid-37e6d5ee91bb425a96b0c6a673960501,Regional TL,0.373328
uuid-37e6d5ee91bb425a96b0c6a673960501,NCCN,0.522036
uuid-44fc5043c2894872a687f526c179971a,pembro,0.310363
uuid-44fc5043c2894872a687f526c179971a,RTL,0.577352
uuid-44fc5043c2894872a687f526c179971a,BMS,0.403933
uuid-44fc5043c2894872a687f526c179971a,trial,0.504927
uuid-44fc5043c2894872a687f526c179971a,efficacy,0.357652
uuid-44fc5043c2894872a687f526c179971a,NTL,0.342763
uuid-44fc5043c2894872a687f526c179971a,shared,0.367058
uuid-44fc5043c2894872a687f526c179971a,commented,0.568955
uuid-44fc5043c2894872a687f526c179971a,Merck,0.33049
uuid-44fc5043c2894872a687f526c179971a,stated,0.588701
uuid-44fc5043c2894872a687f526c179971a,OS,0.44896
uuid-44fc5043c2894872a687f526c179971a,data,0.816806
uuid-44fc5043c2894872a687f526c179971a,expressed,0.487722
uuid-44fc5043c2894872a687f526c179971a,clinical trials,0.373784
uuid-44fc5043c2894872a687f526c179971a,PFS,0.417046
uuid-44fc5043c2894872a687f526c179971a,ORR,0.49182
uuid-44fc5043c2894872a687f526c179971a,SCCHN,0.418919
uuid-44fc5043c2894872a687f526c179971a,HCP,0.335256
uuid-44fc5043c2894872a687f526c179971a,nivo and pembro,0.342962
uuid-44fc5043c2894872a687f526c179971a,ASCO,0.385199
uuid-44fc5043c2894872a687f526c179971a,impressed,0.696487
uuid-44fc5043c2894872a687f526c179971a,LTL,0.518672
uuid-44fc5043c2894872a687f526c179971a,TLs,0.474273
uuid-44fc5043c2894872a687f526c179971a,SCLC,0.33385
uuid-44fc5043c2894872a687f526c179971a,feels,0.308637
uuid-44fc5043c2894872a687f526c179971a,Regional TL,0.49087
uuid-1297e3ac867444e8bbc1f98d07f9df22,pembro,0.337377
uuid-1297e3ac867444e8bbc1f98d07f9df22,BMS,0.374845
uuid-1297e3ac867444e8bbc1f98d07f9df22,PDL1,0.485803
uuid-1297e3ac867444e8bbc1f98d07f9df22,trial,0.69695
uuid-1297e3ac867444e8bbc1f98d07f9df22,efficacy,0.399092
uuid-1297e3ac867444e8bbc1f98d07f9df22,OS,0.469955
uuid-1297e3ac867444e8bbc1f98d07f9df22,data,0.535527
uuid-1297e3ac867444e8bbc1f98d07f9df22,clinical trials,0.387324
uuid-1297e3ac867444e8bbc1f98d07f9df22,PFS,0.535723
uuid-1297e3ac867444e8bbc1f98d07f9df22,ORR,0.565296
uuid-1297e3ac867444e8bbc1f98d07f9df22,nivo and pembro,0.395489
uuid-1297e3ac867444e8bbc1f98d07f9df22,impressed,0.38892
uuid-1297e3ac867444e8bbc1f98d07f9df22,feels,0.392185
uuid-1297e3ac867444e8bbc1f98d07f9df22,PDL1 expression,0.519649
uuid-1297e3ac867444e8bbc1f98d07f9df22,biomarker,0.322401
uuid-54ac44f8ae764b2b8516a8b0fe873467,pembro,0.312055
uuid-54ac44f8ae764b2b8516a8b0fe873467,BMS,0.34289
uuid-54ac44f8ae764b2b8516a8b0fe873467,trial,0.454393
uuid-54ac44f8ae764b2b8516a8b0fe873467,efficacy,0.391519
uuid-54ac44f8ae764b2b8516a8b0fe873467,agents,0.361424
uuid-54ac44f8ae764b2b8516a8b0fe873467,Merck,0.39166
uuid-54ac44f8ae764b2b8516a8b0fe873467,atezo,0.312559
uuid-54ac44f8ae764b2b8516a8b0fe873467,nivo and pembro,0.425323
uuid-214e90fbe6da43be97681439fc2c780d,patients,0.498471
uuid-214e90fbe6da43be97681439fc2c780d,Opdivo,0.702415
uuid-214e90fbe6da43be97681439fc2c780d,therapy,0.337967
uuid-214e90fbe6da43be97681439fc2c780d,nivolumab,0.350904
uuid-214e90fbe6da43be97681439fc2c780d,regimen,0.474474
uuid-214e90fbe6da43be97681439fc2c780d,treated,0.339276
uuid-214e90fbe6da43be97681439fc2c780d,physicians,0.504081
uuid-214e90fbe6da43be97681439fc2c780d,treatment,0.578882
uuid-214e90fbe6da43be97681439fc2c780d,approved,0.372017
uuid-214e90fbe6da43be97681439fc2c780d,progression,0.380788
uuid-214e90fbe6da43be97681439fc2c780d,respond,0.324811
uuid-214e90fbe6da43be97681439fc2c780d,Keytruda,0.310197
uuid-214e90fbe6da43be97681439fc2c780d,option,0.367105
uuid-befabe45479e47a7b315fb28bbc88054,Nivo,0.416465
uuid-befabe45479e47a7b315fb28bbc88054,patients,0.344665
uuid-befabe45479e47a7b315fb28bbc88054,therapy,0.380665
uuid-befabe45479e47a7b315fb28bbc88054,chemo,0.421209
uuid-befabe45479e47a7b315fb28bbc88054,treatment,0.30905
uuid-befabe45479e47a7b315fb28bbc88054,response,0.491697
uuid-befabe45479e47a7b315fb28bbc88054,PD1,0.31172
uuid-befabe45479e47a7b315fb28bbc88054,progression,0.41392
uuid-befabe45479e47a7b315fb28bbc88054,chemotherapy,0.338643
uuid-befabe45479e47a7b315fb28bbc88054,respond,0.461399
uuid-befabe45479e47a7b315fb28bbc88054,option,0.309638
uuid-50a4dcbf16d84ecfba935e488745f37b,Nivo,0.588109
uuid-50a4dcbf16d84ecfba935e488745f37b,patients,0.430065
uuid-50a4dcbf16d84ecfba935e488745f37b,pembro,0.320324
uuid-50a4dcbf16d84ecfba935e488745f37b,therapy,0.553605
uuid-50a4dcbf16d84ecfba935e488745f37b,nivolumab,0.449648
uuid-50a4dcbf16d84ecfba935e488745f37b,trial,0.418361
uuid-50a4dcbf16d84ecfba935e488745f37b,combination,0.340765
uuid-50a4dcbf16d84ecfba935e488745f37b,chemo,0.432592
uuid-50a4dcbf16d84ecfba935e488745f37b,monotherapy,0.383293
uuid-50a4dcbf16d84ecfba935e488745f37b,using nivo,0.397804
uuid-50a4dcbf16d84ecfba935e488745f37b,PD1,0.36594
uuid-50a4dcbf16d84ecfba935e488745f37b,cHL,0.439214
uuid-50a4dcbf16d84ecfba935e488745f37b,chemotherapy,0.499869
uuid-50a4dcbf16d84ecfba935e488745f37b,SCLC,0.334553
uuid-50a4dcbf16d84ecfba935e488745f37b,option,0.362373
uuid-800348a065b045c1ab7014de4cf9d2c8,Nivo,0.612112
uuid-800348a065b045c1ab7014de4cf9d2c8,patients,0.700679
uuid-800348a065b045c1ab7014de4cf9d2c8,therapy,0.671058
uuid-800348a065b045c1ab7014de4cf9d2c8,nivolumab,0.517097
uuid-800348a065b045c1ab7014de4cf9d2c8,1L,0.300176
uuid-800348a065b045c1ab7014de4cf9d2c8,regimen,0.473826
uuid-800348a065b045c1ab7014de4cf9d2c8,treated,0.436693
uuid-800348a065b045c1ab7014de4cf9d2c8,combination,0.349824
uuid-800348a065b045c1ab7014de4cf9d2c8,chemo,0.536473
uuid-800348a065b045c1ab7014de4cf9d2c8,2L,0.328882
uuid-800348a065b045c1ab7014de4cf9d2c8,pts,0.567976
uuid-800348a065b045c1ab7014de4cf9d2c8,monotherapy,0.565563
uuid-800348a065b045c1ab7014de4cf9d2c8,treatment,0.56314
uuid-800348a065b045c1ab7014de4cf9d2c8,using nivo,0.477735
uuid-800348a065b045c1ab7014de4cf9d2c8,response,0.576656
uuid-800348a065b045c1ab7014de4cf9d2c8,PD1,0.54936
uuid-800348a065b045c1ab7014de4cf9d2c8,cHL,0.400098
uuid-800348a065b045c1ab7014de4cf9d2c8,progression,0.629247
uuid-800348a065b045c1ab7014de4cf9d2c8,chemotherapy,0.474097
uuid-800348a065b045c1ab7014de4cf9d2c8,respond,0.539944
uuid-800348a065b045c1ab7014de4cf9d2c8,RTL stated,0.310566
uuid-800348a065b045c1ab7014de4cf9d2c8,option,0.480707
uuid-bec78738c3564408a95fc07dae53df0c,Nivo,0.660511
uuid-bec78738c3564408a95fc07dae53df0c,patients,0.659576
uuid-bec78738c3564408a95fc07dae53df0c,therapy,0.589806
uuid-bec78738c3564408a95fc07dae53df0c,nivolumab,0.388803
uuid-bec78738c3564408a95fc07dae53df0c,toxicity,0.382715
uuid-bec78738c3564408a95fc07dae53df0c,regimen,0.532667
uuid-bec78738c3564408a95fc07dae53df0c,treated,0.302126
uuid-bec78738c3564408a95fc07dae53df0c,combination,0.403513
uuid-bec78738c3564408a95fc07dae53df0c,chemo,0.661978
uuid-bec78738c3564408a95fc07dae53df0c,pts,0.587484
uuid-bec78738c3564408a95fc07dae53df0c,Ipi,0.320116
uuid-bec78738c3564408a95fc07dae53df0c,monotherapy,0.594169
uuid-bec78738c3564408a95fc07dae53df0c,treatment,0.516877
uuid-bec78738c3564408a95fc07dae53df0c,using nivo,0.318786
uuid-bec78738c3564408a95fc07dae53df0c,response,0.668845
uuid-bec78738c3564408a95fc07dae53df0c,combo,0.35763
uuid-bec78738c3564408a95fc07dae53df0c,PD1,0.534696
uuid-bec78738c3564408a95fc07dae53df0c,progression,0.640833
uuid-bec78738c3564408a95fc07dae53df0c,chemotherapy,0.55402
uuid-bec78738c3564408a95fc07dae53df0c,respond,0.599887
uuid-bec78738c3564408a95fc07dae53df0c,feels,0.329563
uuid-bec78738c3564408a95fc07dae53df0c,option,0.486491
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,Nivo,0.400045
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,pembro,0.688317
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,1L,0.440955
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,PDL1,0.598961
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,efficacy,0.432037
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,2L,0.427432
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,agents,0.380841
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,PD-L1,0.341938
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,atezo,0.651005
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,preferred,0.34337
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,nivo and pembro,0.680799
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,believes,0.486731
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,vs,0.518714
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,feels,0.385941
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,PDL1 expression,0.486145
uuid-aa8494fb64ac43d0bfbeaa66faec86a2,option,0.302079
uuid-8d5c936073224852ba06da5dcf4fcc69,1L,0.343243
uuid-8d5c936073224852ba06da5dcf4fcc69,RCC,0.310575
uuid-8d5c936073224852ba06da5dcf4fcc69,2L,0.429938
uuid-8d5c936073224852ba06da5dcf4fcc69,agents,0.351901
uuid-8d5c936073224852ba06da5dcf4fcc69,atezo,0.348351
uuid-8d5c936073224852ba06da5dcf4fcc69,preferred,0.37426
uuid-8d5c936073224852ba06da5dcf4fcc69,monotherapy,0.332431
uuid-8d5c936073224852ba06da5dcf4fcc69,nivo and pembro,0.378117
uuid-8d5c936073224852ba06da5dcf4fcc69,believes,0.428656
uuid-8d5c936073224852ba06da5dcf4fcc69,feels,0.311417
uuid-8d5c936073224852ba06da5dcf4fcc69,option,0.302447
uuid-d9d80f348a9e42dcb637997414bf73d5,patients,0.68101
uuid-d9d80f348a9e42dcb637997414bf73d5,Opdivo,0.421108
uuid-d9d80f348a9e42dcb637997414bf73d5,therapy,0.41171
uuid-d9d80f348a9e42dcb637997414bf73d5,nivolumab,0.315256
uuid-d9d80f348a9e42dcb637997414bf73d5,toxicity,0.393733
uuid-d9d80f348a9e42dcb637997414bf73d5,regimen,0.481773
uuid-d9d80f348a9e42dcb637997414bf73d5,treated,0.58739
uuid-d9d80f348a9e42dcb637997414bf73d5,tumor,0.375388
uuid-d9d80f348a9e42dcb637997414bf73d5,pts,0.457048
uuid-d9d80f348a9e42dcb637997414bf73d5,treatment,0.715791
uuid-d9d80f348a9e42dcb637997414bf73d5,response,0.375558
uuid-d9d80f348a9e42dcb637997414bf73d5,progression,0.604148
uuid-d9d80f348a9e42dcb637997414bf73d5,respond,0.542698
uuid-4e920b15463b48c18b9a102a12e76202,therapy,0.387149
uuid-4e920b15463b48c18b9a102a12e76202,trial,0.347974
uuid-4e920b15463b48c18b9a102a12e76202,combination,0.406492
uuid-4e920b15463b48c18b9a102a12e76202,chemo,0.525489
uuid-4e920b15463b48c18b9a102a12e76202,IO,0.341423
uuid-4e920b15463b48c18b9a102a12e76202,OS,0.365125
uuid-4e920b15463b48c18b9a102a12e76202,monotherapy,0.337445
uuid-4e920b15463b48c18b9a102a12e76202,response,0.433337
uuid-4e920b15463b48c18b9a102a12e76202,combo,0.332735
uuid-4e920b15463b48c18b9a102a12e76202,PFS,0.392077
uuid-4e920b15463b48c18b9a102a12e76202,PD1,0.476897
uuid-4e920b15463b48c18b9a102a12e76202,ORR,0.372102
uuid-4e920b15463b48c18b9a102a12e76202,progression,0.414141
uuid-4e920b15463b48c18b9a102a12e76202,believes,0.335981
uuid-4e920b15463b48c18b9a102a12e76202,chemotherapy,0.5714
uuid-4e920b15463b48c18b9a102a12e76202,feels,0.363893
uuid-8fb2921e4801468583bc01ec0a6fa86d,TL,0.717447
uuid-8fb2921e4801468583bc01ec0a6fa86d,PDL1,0.3585
uuid-8fb2921e4801468583bc01ec0a6fa86d,TL stated,0.388471
uuid-8fb2921e4801468583bc01ec0a6fa86d,Merck,0.303417
uuid-8fb2921e4801468583bc01ec0a6fa86d,institution,0.38691
uuid-8fb2921e4801468583bc01ec0a6fa86d,PD-L1,0.819078
uuid-8fb2921e4801468583bc01ec0a6fa86d,PD-L1 testing,0.916534
uuid-8fb2921e4801468583bc01ec0a6fa86d,testing,0.87108
uuid-8fb2921e4801468583bc01ec0a6fa86d,PDL1 testing,0.652688
uuid-8fb2921e4801468583bc01ec0a6fa86d,NSCLC patients,0.594001
uuid-8fb2921e4801468583bc01ec0a6fa86d,assay,0.815198
uuid-8fb2921e4801468583bc01ec0a6fa86d,biomarker,0.331289
uuid-d7f310d720ac4765b7126eded9b72ab5,TL,0.770456
uuid-d7f310d720ac4765b7126eded9b72ab5,TL stated,0.383828
uuid-d7f310d720ac4765b7126eded9b72ab5,institution,0.361015
uuid-d7f310d720ac4765b7126eded9b72ab5,PD-L1,0.755657
uuid-d7f310d720ac4765b7126eded9b72ab5,PD-L1 testing,0.880161
uuid-d7f310d720ac4765b7126eded9b72ab5,testing,0.797359
uuid-d7f310d720ac4765b7126eded9b72ab5,PDL1 testing,0.588254
uuid-d7f310d720ac4765b7126eded9b72ab5,NSCLC patients,0.538799
uuid-d7f310d720ac4765b7126eded9b72ab5,assay,0.765976
uuid-c1b24f680bae4370b2077488aca37780,Nivo,0.565324
uuid-c1b24f680bae4370b2077488aca37780,patients,0.499467
uuid-c1b24f680bae4370b2077488aca37780,Opdivo,0.378131
uuid-c1b24f680bae4370b2077488aca37780,RTL,0.301318
uuid-c1b24f680bae4370b2077488aca37780,therapy,0.473656
uuid-c1b24f680bae4370b2077488aca37780,nivolumab,0.567303
uuid-c1b24f680bae4370b2077488aca37780,regimen,0.316773
uuid-c1b24f680bae4370b2077488aca37780,treated,0.320741
uuid-c1b24f680bae4370b2077488aca37780,treatment,0.31651
uuid-c1b24f680bae4370b2077488aca37780,using nivo,0.403558
uuid-c1b24f680bae4370b2077488aca37780,cHL,0.586885
uuid-c1b24f680bae4370b2077488aca37780,progression,0.326151
uuid-dccb74077ed047138851778b8ad00666,Opdivo,0.534927
uuid-dccb74077ed047138851778b8ad00666,dose,0.446879
uuid-dccb74077ed047138851778b8ad00666,indication,0.301989
uuid-dccb74077ed047138851778b8ad00666,drug,0.599171
uuid-dccb74077ed047138851778b8ad00666,Keytruda,0.72141
uuid-dccb74077ed047138851778b8ad00666,flat dosing,0.642376
uuid-bfd5ebd4199246b398a77b6f6a98da24,Opdivo,0.388691
uuid-bfd5ebd4199246b398a77b6f6a98da24,dose,0.791652
uuid-bfd5ebd4199246b398a77b6f6a98da24,toxicity,0.487024
uuid-bfd5ebd4199246b398a77b6f6a98da24,Ipi,0.375452
uuid-bfd5ebd4199246b398a77b6f6a98da24,vs,0.520867
uuid-bfd5ebd4199246b398a77b6f6a98da24,Keytruda,0.308496
uuid-bfd5ebd4199246b398a77b6f6a98da24,flat dosing,0.685253
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,TL,0.306381
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,BMS,0.525096
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,efficacy,0.42202
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,commented,0.45077
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,Merck,0.433333
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,stated,0.316409
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,atezo,0.330341
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,regards,0.402892
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,data,0.611498
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,expressed,0.37666
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,indication,0.35893
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,impressed,0.49259
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,LTL,0.316386
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,TLs,0.447213
uuid-aa1ac0b34c8442f0a2aaec3dc4cfa422,flat dosing,0.460087
uuid-bf99e43293f8463ba9db435b8468270f,pembro,0.300936
uuid-bf99e43293f8463ba9db435b8468270f,PDL1,0.611595
uuid-bf99e43293f8463ba9db435b8468270f,efficacy,0.559651
uuid-bf99e43293f8463ba9db435b8468270f,Merck,0.373313
uuid-bf99e43293f8463ba9db435b8468270f,PD-L1,0.359713
uuid-bf99e43293f8463ba9db435b8468270f,OS,0.381403
uuid-bf99e43293f8463ba9db435b8468270f,atezo,0.416131
uuid-bf99e43293f8463ba9db435b8468270f,regards,0.43218
uuid-bf99e43293f8463ba9db435b8468270f,data,0.450269
uuid-bf99e43293f8463ba9db435b8468270f,PFS,0.4251
uuid-bf99e43293f8463ba9db435b8468270f,ORR,0.389088
uuid-bf99e43293f8463ba9db435b8468270f,nivo and pembro,0.598658
uuid-bf99e43293f8463ba9db435b8468270f,believes,0.388941
uuid-bf99e43293f8463ba9db435b8468270f,vs,0.311194
uuid-bf99e43293f8463ba9db435b8468270f,TLs,0.410968
uuid-bf99e43293f8463ba9db435b8468270f,assay,0.436882
uuid-bf99e43293f8463ba9db435b8468270f,PDL1 expression,0.535614
uuid-bf99e43293f8463ba9db435b8468270f,biomarker,0.390975
uuid-8538544a9c6a4e00a373ad2f79e20b4a,patients,0.474434
uuid-8538544a9c6a4e00a373ad2f79e20b4a,Opdivo,0.435793
uuid-8538544a9c6a4e00a373ad2f79e20b4a,pembro,0.382623
uuid-8538544a9c6a4e00a373ad2f79e20b4a,dose,0.312897
uuid-8538544a9c6a4e00a373ad2f79e20b4a,nivolumab,0.341475
uuid-8538544a9c6a4e00a373ad2f79e20b4a,1L,0.446722
uuid-8538544a9c6a4e00a373ad2f79e20b4a,regimen,0.325444
uuid-8538544a9c6a4e00a373ad2f79e20b4a,RCC,0.312966
uuid-8538544a9c6a4e00a373ad2f79e20b4a,2L,0.579918
uuid-8538544a9c6a4e00a373ad2f79e20b4a,agents,0.308834
uuid-8538544a9c6a4e00a373ad2f79e20b4a,approval,0.344283
uuid-8538544a9c6a4e00a373ad2f79e20b4a,atezo,0.395179
uuid-8538544a9c6a4e00a373ad2f79e20b4a,preferred,0.800154
uuid-8538544a9c6a4e00a373ad2f79e20b4a,monotherapy,0.496035
uuid-8538544a9c6a4e00a373ad2f79e20b4a,treatment,0.313722
uuid-8538544a9c6a4e00a373ad2f79e20b4a,using nivo,0.571097
uuid-8538544a9c6a4e00a373ad2f79e20b4a,indication,0.363632
uuid-8538544a9c6a4e00a373ad2f79e20b4a,approved,0.465368
uuid-8538544a9c6a4e00a373ad2f79e20b4a,SCCHN,0.346812
uuid-8538544a9c6a4e00a373ad2f79e20b4a,Keytruda,0.336251
uuid-8538544a9c6a4e00a373ad2f79e20b4a,feels,0.309786
uuid-8538544a9c6a4e00a373ad2f79e20b4a,RTL stated,0.49179
uuid-8538544a9c6a4e00a373ad2f79e20b4a,option,0.60604
uuid-94a989dc44b14002ae4ce16b2370badf,TL,0.330811
uuid-94a989dc44b14002ae4ce16b2370badf,pembro,0.360589
uuid-94a989dc44b14002ae4ce16b2370badf,1L,0.309506
uuid-94a989dc44b14002ae4ce16b2370badf,PDL1,0.552479
uuid-94a989dc44b14002ae4ce16b2370badf,Merck,0.443506
uuid-94a989dc44b14002ae4ce16b2370badf,PD-L1,0.703937
uuid-94a989dc44b14002ae4ce16b2370badf,atezo,0.427537
uuid-94a989dc44b14002ae4ce16b2370badf,PD-L1 testing,0.590182
uuid-94a989dc44b14002ae4ce16b2370badf,testing,0.705146
uuid-94a989dc44b14002ae4ce16b2370badf,PDL1 testing,0.555409
uuid-94a989dc44b14002ae4ce16b2370badf,NSCLC patients,0.474296
uuid-94a989dc44b14002ae4ce16b2370badf,assay,0.76627
uuid-94a989dc44b14002ae4ce16b2370badf,PDL1 expression,0.348675
uuid-94a989dc44b14002ae4ce16b2370badf,biomarker,0.418204
uuid-93953f4c12874c158b5bdc892f0e85a7,PDL1,0.332423
uuid-93953f4c12874c158b5bdc892f0e85a7,efficacy,0.367565
uuid-93953f4c12874c158b5bdc892f0e85a7,chemo,0.338681
uuid-93953f4c12874c158b5bdc892f0e85a7,OS,0.34059
uuid-93953f4c12874c158b5bdc892f0e85a7,regards,0.326655
uuid-93953f4c12874c158b5bdc892f0e85a7,PFS,0.377009
uuid-93953f4c12874c158b5bdc892f0e85a7,AI,0.372749
uuid-93953f4c12874c158b5bdc892f0e85a7,ORR,0.335483
uuid-93953f4c12874c158b5bdc892f0e85a7,nivo and pembro,0.418695
uuid-93953f4c12874c158b5bdc892f0e85a7,believes,0.435644
uuid-93953f4c12874c158b5bdc892f0e85a7,respond,0.344078
uuid-93953f4c12874c158b5bdc892f0e85a7,feels,0.359258
uuid-93953f4c12874c158b5bdc892f0e85a7,PDL1 expression,0.322512
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,patients,0.8464
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,Opdivo,0.616739
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,therapy,0.513703
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,nivolumab,0.492016
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,regimen,0.421027
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,treated,0.583872
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,pts,0.470572
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,physicians,0.37877
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,treatment,0.691956
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,cHL,0.330422
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,progression,0.55804
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,respond,0.399639
uuid-eb82c95c4a774a0cad9324a9dcafe8d1,option,0.318263
uuid-6045f033a7a947aab2bca948806f3cc7,Nivo,0.431787
uuid-6045f033a7a947aab2bca948806f3cc7,patients,0.622876
uuid-6045f033a7a947aab2bca948806f3cc7,Opdivo,0.419285
uuid-6045f033a7a947aab2bca948806f3cc7,therapy,0.65226
uuid-6045f033a7a947aab2bca948806f3cc7,nivolumab,0.453547
uuid-6045f033a7a947aab2bca948806f3cc7,regimen,0.421275
uuid-6045f033a7a947aab2bca948806f3cc7,treated,0.429293
uuid-6045f033a7a947aab2bca948806f3cc7,combination,0.327667
uuid-6045f033a7a947aab2bca948806f3cc7,chemo,0.431632
uuid-6045f033a7a947aab2bca948806f3cc7,2L,0.332512
uuid-6045f033a7a947aab2bca948806f3cc7,pts,0.328222
uuid-6045f033a7a947aab2bca948806f3cc7,agents,0.343612
uuid-6045f033a7a947aab2bca948806f3cc7,preferred,0.44452
uuid-6045f033a7a947aab2bca948806f3cc7,monotherapy,0.540508
uuid-6045f033a7a947aab2bca948806f3cc7,treatment,0.644228
uuid-6045f033a7a947aab2bca948806f3cc7,using nivo,0.353721
uuid-6045f033a7a947aab2bca948806f3cc7,PD1,0.391873
uuid-6045f033a7a947aab2bca948806f3cc7,cHL,0.353624
uuid-6045f033a7a947aab2bca948806f3cc7,progression,0.398089
uuid-6045f033a7a947aab2bca948806f3cc7,chemotherapy,0.541047
uuid-6045f033a7a947aab2bca948806f3cc7,respond,0.316583
uuid-6045f033a7a947aab2bca948806f3cc7,option,0.591323
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,patients,0.564445
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,Opdivo,0.379183
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,therapy,0.408438
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,treated,0.383499
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,tumor,0.434529
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,pts,0.386891
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,treatment,0.477614
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,response,0.375086
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,cHL,0.378449
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,progression,0.491249
uuid-d10f54e0476f4a3bad03f8ed4de7cb16,respond,0.34811
uuid-d5a460c974654323893fde354d4c9c57,Nivo,0.325664
uuid-d5a460c974654323893fde354d4c9c57,RTL,0.300537
uuid-d5a460c974654323893fde354d4c9c57,trial,0.467492
uuid-d5a460c974654323893fde354d4c9c57,efficacy,0.367946
uuid-d5a460c974654323893fde354d4c9c57,OS,0.621173
uuid-d5a460c974654323893fde354d4c9c57,data,0.551115
uuid-d5a460c974654323893fde354d4c9c57,PFS,0.628425
uuid-d5a460c974654323893fde354d4c9c57,ORR,0.61889
uuid-d5a460c974654323893fde354d4c9c57,nivo and pembro,0.315681
uuid-d5a460c974654323893fde354d4c9c57,ASCO,0.367824
uuid-d5a460c974654323893fde354d4c9c57,impressed,0.639036
uuid-d5a460c974654323893fde354d4c9c57,SCLC,0.310171
uuid-7514937002924fa98f230a5c891a37bc,RTL,0.348035
uuid-7514937002924fa98f230a5c891a37bc,trial,0.351225
uuid-7514937002924fa98f230a5c891a37bc,NTL,0.411346
uuid-7514937002924fa98f230a5c891a37bc,commented,0.365798
uuid-7514937002924fa98f230a5c891a37bc,regards,0.310645
uuid-7514937002924fa98f230a5c891a37bc,data,0.572629
uuid-7514937002924fa98f230a5c891a37bc,mentioned,0.448239
uuid-7514937002924fa98f230a5c891a37bc,ORR,0.312493
uuid-7514937002924fa98f230a5c891a37bc,cHL,0.353069
uuid-7514937002924fa98f230a5c891a37bc,ASCO,0.375137
uuid-7514937002924fa98f230a5c891a37bc,impressed,0.456005
uuid-7514937002924fa98f230a5c891a37bc,LTL,0.303103
uuid-7d259f3395014372a6b636241fcf9bf3,patients,0.464839
uuid-7d259f3395014372a6b636241fcf9bf3,therapy,0.306903
uuid-7d259f3395014372a6b636241fcf9bf3,nivolumab,0.342615
uuid-7d259f3395014372a6b636241fcf9bf3,1L,0.331545
uuid-7d259f3395014372a6b636241fcf9bf3,regimen,0.412943
uuid-7d259f3395014372a6b636241fcf9bf3,chemo,0.359582
uuid-7d259f3395014372a6b636241fcf9bf3,2L,0.36662
uuid-7d259f3395014372a6b636241fcf9bf3,preferred,0.673074
uuid-7d259f3395014372a6b636241fcf9bf3,monotherapy,0.490854
uuid-7d259f3395014372a6b636241fcf9bf3,treatment,0.34611
uuid-7d259f3395014372a6b636241fcf9bf3,using nivo,0.419877
uuid-7d259f3395014372a6b636241fcf9bf3,indication,0.344934
uuid-7d259f3395014372a6b636241fcf9bf3,SCCHN,0.333608
uuid-7d259f3395014372a6b636241fcf9bf3,chemotherapy,0.429694
uuid-7d259f3395014372a6b636241fcf9bf3,RTL stated,0.388575
uuid-7d259f3395014372a6b636241fcf9bf3,option,0.573473
uuid-74be27dd03924512980f9d41e0b16502,pembro,0.517713
uuid-74be27dd03924512980f9d41e0b16502,1L,0.443597
uuid-74be27dd03924512980f9d41e0b16502,PDL1,0.550181
uuid-74be27dd03924512980f9d41e0b16502,efficacy,0.367625
uuid-74be27dd03924512980f9d41e0b16502,2L,0.343763
uuid-74be27dd03924512980f9d41e0b16502,Merck,0.332882
uuid-74be27dd03924512980f9d41e0b16502,PD-L1,0.352294
uuid-74be27dd03924512980f9d41e0b16502,approval,0.34478
uuid-74be27dd03924512980f9d41e0b16502,atezo,0.443431
uuid-74be27dd03924512980f9d41e0b16502,data,0.41002
uuid-74be27dd03924512980f9d41e0b16502,indication,0.345467
uuid-74be27dd03924512980f9d41e0b16502,PFS,0.302893
uuid-74be27dd03924512980f9d41e0b16502,approved,0.423353
uuid-74be27dd03924512980f9d41e0b16502,nivo and pembro,0.391289
uuid-74be27dd03924512980f9d41e0b16502,feels,0.318322
uuid-74be27dd03924512980f9d41e0b16502,PDL1 expression,0.468589
uuid-74be27dd03924512980f9d41e0b16502,option,0.33683
uuid-649bf99d5a414393aa92a63db05b8212,RTL,0.429677
uuid-649bf99d5a414393aa92a63db05b8212,commented,0.370744
uuid-649bf99d5a414393aa92a63db05b8212,stated,0.385441
uuid-649bf99d5a414393aa92a63db05b8212,approval,0.35081
uuid-649bf99d5a414393aa92a63db05b8212,SCCHN,0.411939
uuid-649bf99d5a414393aa92a63db05b8212,impressed,0.539316
uuid-649bf99d5a414393aa92a63db05b8212,LTL,0.415193
uuid-649bf99d5a414393aa92a63db05b8212,Regional TL,0.463642
uuid-9439fbddc5064a76b3198a629b2c2b1e,BMS,0.455522
uuid-9439fbddc5064a76b3198a629b2c2b1e,trial,0.46126
uuid-9439fbddc5064a76b3198a629b2c2b1e,efficacy,0.444197
uuid-9439fbddc5064a76b3198a629b2c2b1e,discussed,0.40815
uuid-9439fbddc5064a76b3198a629b2c2b1e,commented,0.561324
uuid-9439fbddc5064a76b3198a629b2c2b1e,OS,0.520085
uuid-9439fbddc5064a76b3198a629b2c2b1e,regards,0.460049
uuid-9439fbddc5064a76b3198a629b2c2b1e,data,0.842958
uuid-9439fbddc5064a76b3198a629b2c2b1e,expressed,0.31823
uuid-9439fbddc5064a76b3198a629b2c2b1e,PFS,0.49575
uuid-9439fbddc5064a76b3198a629b2c2b1e,ORR,0.561942
uuid-9439fbddc5064a76b3198a629b2c2b1e,nivo and pembro,0.338439
uuid-9439fbddc5064a76b3198a629b2c2b1e,ASCO,0.486859
uuid-9439fbddc5064a76b3198a629b2c2b1e,impressed,0.611302
uuid-9439fbddc5064a76b3198a629b2c2b1e,SCLC,0.310866
uuid-9439fbddc5064a76b3198a629b2c2b1e,NCCN,0.407567
uuid-45db19f550f741ffb2a302eceb06971e,patients,0.612324
uuid-45db19f550f741ffb2a302eceb06971e,Opdivo,0.506095
uuid-45db19f550f741ffb2a302eceb06971e,therapy,0.429707
uuid-45db19f550f741ffb2a302eceb06971e,toxicity,0.3681
uuid-45db19f550f741ffb2a302eceb06971e,regimen,0.36831
uuid-45db19f550f741ffb2a302eceb06971e,chemo,0.325852
uuid-45db19f550f741ffb2a302eceb06971e,pts,0.389912
uuid-45db19f550f741ffb2a302eceb06971e,monotherapy,0.319775
uuid-45db19f550f741ffb2a302eceb06971e,treatment,0.473382
uuid-45db19f550f741ffb2a302eceb06971e,response,0.347094
uuid-45db19f550f741ffb2a302eceb06971e,progression,0.527174
uuid-45db19f550f741ffb2a302eceb06971e,chemotherapy,0.324695
uuid-45db19f550f741ffb2a302eceb06971e,respond,0.417788
uuid-45db19f550f741ffb2a302eceb06971e,drug,0.327267
uuid-45db19f550f741ffb2a302eceb06971e,Keytruda,0.41245
uuid-45db19f550f741ffb2a302eceb06971e,option,0.359443
uuid-19d9b466a6a64611aef863898a9bda03,1L,0.398515
uuid-19d9b466a6a64611aef863898a9bda03,PDL1,0.662644
uuid-19d9b466a6a64611aef863898a9bda03,efficacy,0.320209
uuid-19d9b466a6a64611aef863898a9bda03,2L,0.333125
uuid-19d9b466a6a64611aef863898a9bda03,agents,0.466006
uuid-19d9b466a6a64611aef863898a9bda03,Merck,0.324217
uuid-19d9b466a6a64611aef863898a9bda03,PD-L1,0.605725
uuid-19d9b466a6a64611aef863898a9bda03,atezo,0.408153
uuid-19d9b466a6a64611aef863898a9bda03,PD-L1 testing,0.350394
uuid-19d9b466a6a64611aef863898a9bda03,testing,0.57213
uuid-19d9b466a6a64611aef863898a9bda03,regards,0.327347
uuid-19d9b466a6a64611aef863898a9bda03,PDL1 testing,0.524374
uuid-19d9b466a6a64611aef863898a9bda03,NSCLC patients,0.346768
uuid-19d9b466a6a64611aef863898a9bda03,nivo and pembro,0.426916
uuid-19d9b466a6a64611aef863898a9bda03,believes,0.523534
uuid-19d9b466a6a64611aef863898a9bda03,assay,0.510791
uuid-19d9b466a6a64611aef863898a9bda03,PD-1,0.402477
uuid-19d9b466a6a64611aef863898a9bda03,PDL1 expression,0.492881
uuid-19d9b466a6a64611aef863898a9bda03,biomarker,0.625231
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,patients,0.66073
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,Opdivo,0.625111
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,therapy,0.313706
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,nivolumab,0.423467
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,treated,0.452388
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,stated,0.302219
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,physicians,0.481599
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,treatment,0.462651
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,using nivo,0.341891
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,HCP,0.31162
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,cHL,0.316524
uuid-dab9de52a6d0475aafd7f1d61c7fc33e,progression,0.325949
uuid-7a5dd91967964a3384319f6cb1e83194,patients,0.541888
uuid-7a5dd91967964a3384319f6cb1e83194,Opdivo,0.498192
uuid-7a5dd91967964a3384319f6cb1e83194,therapy,0.447309
uuid-7a5dd91967964a3384319f6cb1e83194,regimen,0.316011
uuid-7a5dd91967964a3384319f6cb1e83194,treated,0.480181
uuid-7a5dd91967964a3384319f6cb1e83194,physicians,0.397293
uuid-7a5dd91967964a3384319f6cb1e83194,treatment,0.584078
uuid-7a5dd91967964a3384319f6cb1e83194,HCP,0.436397
uuid-7a5dd91967964a3384319f6cb1e83194,cHL,0.321051
uuid-7a5dd91967964a3384319f6cb1e83194,progression,0.461018
uuid-88bc9f7c83094576a24bb5e67a9c9d34,patients,0.451251
uuid-88bc9f7c83094576a24bb5e67a9c9d34,nivolumab,0.402215
uuid-88bc9f7c83094576a24bb5e67a9c9d34,regimen,0.487684
uuid-88bc9f7c83094576a24bb5e67a9c9d34,treated,0.328442
uuid-88bc9f7c83094576a24bb5e67a9c9d34,pts,0.31533
uuid-88bc9f7c83094576a24bb5e67a9c9d34,preferred,0.32648
uuid-88bc9f7c83094576a24bb5e67a9c9d34,monotherapy,0.376178
uuid-88bc9f7c83094576a24bb5e67a9c9d34,using nivo,0.349077
uuid-88bc9f7c83094576a24bb5e67a9c9d34,SCCHN,0.370467
uuid-88bc9f7c83094576a24bb5e67a9c9d34,LTL,0.301178
uuid-88bc9f7c83094576a24bb5e67a9c9d34,feels,0.424199
uuid-88bc9f7c83094576a24bb5e67a9c9d34,RTL stated,0.387441
uuid-88bc9f7c83094576a24bb5e67a9c9d34,option,0.375856
uuid-ce2604ce8a804881b229881c3610f2e0,RTL,0.468259
uuid-ce2604ce8a804881b229881c3610f2e0,nivolumab,0.507707
uuid-ce2604ce8a804881b229881c3610f2e0,treated,0.3396
uuid-ce2604ce8a804881b229881c3610f2e0,NTL,0.30791
uuid-ce2604ce8a804881b229881c3610f2e0,shared,0.393996
uuid-ce2604ce8a804881b229881c3610f2e0,commented,0.436624
uuid-ce2604ce8a804881b229881c3610f2e0,stated,0.398079
uuid-ce2604ce8a804881b229881c3610f2e0,using nivo,0.304694
uuid-ce2604ce8a804881b229881c3610f2e0,data,0.372256
uuid-ce2604ce8a804881b229881c3610f2e0,clinical trials,0.319535
uuid-ce2604ce8a804881b229881c3610f2e0,SCCHN,0.347633
uuid-ce2604ce8a804881b229881c3610f2e0,ASCO,0.308975
uuid-ce2604ce8a804881b229881c3610f2e0,impressed,0.519689
uuid-ce2604ce8a804881b229881c3610f2e0,LTL,0.425306
uuid-ce2604ce8a804881b229881c3610f2e0,feels,0.410007
uuid-ce2604ce8a804881b229881c3610f2e0,Regional TL,0.461267
uuid-ce2604ce8a804881b229881c3610f2e0,RTL stated,0.371929
uuid-393cffa3e61041fcab77bb31357e74cb,Nivo,0.32766
uuid-393cffa3e61041fcab77bb31357e74cb,toxicity,0.427466
uuid-393cffa3e61041fcab77bb31357e74cb,efficacy,0.347798
uuid-393cffa3e61041fcab77bb31357e74cb,regimen,0.307358
uuid-393cffa3e61041fcab77bb31357e74cb,combination,0.378558
uuid-393cffa3e61041fcab77bb31357e74cb,chemo,0.328409
uuid-393cffa3e61041fcab77bb31357e74cb,agents,0.371955
uuid-393cffa3e61041fcab77bb31357e74cb,monotherapy,0.35637
uuid-393cffa3e61041fcab77bb31357e74cb,feels,0.495594
uuid-393cffa3e61041fcab77bb31357e74cb,option,0.34413
uuid-418be5882dae4e6e824c7900280cea78,BMS,0.427101
uuid-418be5882dae4e6e824c7900280cea78,PDL1,0.463058
uuid-418be5882dae4e6e824c7900280cea78,trial,0.394521
uuid-418be5882dae4e6e824c7900280cea78,efficacy,0.602084
uuid-418be5882dae4e6e824c7900280cea78,commented,0.402597
uuid-418be5882dae4e6e824c7900280cea78,stated,0.313505
uuid-418be5882dae4e6e824c7900280cea78,OS,0.595393
uuid-418be5882dae4e6e824c7900280cea78,regards,0.360558
uuid-418be5882dae4e6e824c7900280cea78,data,0.818259
uuid-418be5882dae4e6e824c7900280cea78,expressed,0.401114
uuid-418be5882dae4e6e824c7900280cea78,PFS,0.590866
uuid-418be5882dae4e6e824c7900280cea78,ORR,0.618845
uuid-418be5882dae4e6e824c7900280cea78,nivo and pembro,0.439073
uuid-418be5882dae4e6e824c7900280cea78,ASCO,0.302593
uuid-418be5882dae4e6e824c7900280cea78,impressed,0.629445
uuid-418be5882dae4e6e824c7900280cea78,TLs,0.302039
uuid-418be5882dae4e6e824c7900280cea78,feels,0.409283
uuid-418be5882dae4e6e824c7900280cea78,PDL1 expression,0.45499
uuid-acfbd77f9b824e2f8404dfe68a59c254,patients,0.605344
uuid-acfbd77f9b824e2f8404dfe68a59c254,therapy,0.386191
uuid-acfbd77f9b824e2f8404dfe68a59c254,nivolumab,0.318297
uuid-acfbd77f9b824e2f8404dfe68a59c254,toxicity,0.394025
uuid-acfbd77f9b824e2f8404dfe68a59c254,regimen,0.412399
uuid-acfbd77f9b824e2f8404dfe68a59c254,treated,0.678686
uuid-acfbd77f9b824e2f8404dfe68a59c254,pts,0.327568
uuid-acfbd77f9b824e2f8404dfe68a59c254,physicians,0.308865
uuid-acfbd77f9b824e2f8404dfe68a59c254,treatment,0.623353
uuid-acfbd77f9b824e2f8404dfe68a59c254,response,0.360621
uuid-acfbd77f9b824e2f8404dfe68a59c254,progression,0.446344
uuid-acfbd77f9b824e2f8404dfe68a59c254,respond,0.467756
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,BMS,0.602478
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,shared,0.328713
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,Merck,0.338586
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,physicians,0.554383
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,regards,0.3456
uuid-f3f8671d7257435ab3c4d2bcb080e3b5,drug,0.379392
uuid-70873f7bcd8e4e9293c960c7aa5d343b,Opdivo,0.411487
uuid-70873f7bcd8e4e9293c960c7aa5d343b,physicians,0.415352
uuid-70873f7bcd8e4e9293c960c7aa5d343b,treatment,0.318329
uuid-70873f7bcd8e4e9293c960c7aa5d343b,HCP,0.303312
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,patients,0.645056
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,therapy,0.522838
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,nivolumab,0.451814
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,regimen,0.393276
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,treated,0.484416
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,chemo,0.386875
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,pts,0.487442
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,treatment,0.539364
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,PD1,0.317312
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,progression,0.50254
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,chemotherapy,0.469348
uuid-3e9650ed8b3b4dc497e87a111e19eb6f,respond,0.343678
uuid-712448b5530a4c969a10b451232d7d7a,TL,0.508224
uuid-712448b5530a4c969a10b451232d7d7a,PDL1,0.385435
uuid-712448b5530a4c969a10b451232d7d7a,TL stated,0.421193
uuid-712448b5530a4c969a10b451232d7d7a,institution,0.497336
uuid-712448b5530a4c969a10b451232d7d7a,PD-L1,0.859435
uuid-712448b5530a4c969a10b451232d7d7a,PD-L1 testing,0.834852
uuid-712448b5530a4c969a10b451232d7d7a,testing,0.901418
uuid-712448b5530a4c969a10b451232d7d7a,PDL1 testing,0.719267
uuid-712448b5530a4c969a10b451232d7d7a,NSCLC patients,0.688682
uuid-712448b5530a4c969a10b451232d7d7a,assay,0.767505
uuid-712448b5530a4c969a10b451232d7d7a,biomarker,0.388289
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,pembro,0.535903
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,RTL,0.349542
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,1L,0.499482
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,PDL1,0.316542
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,trial,0.40718
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,commented,0.445054
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,2L,0.442124
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,stated,0.487076
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,approval,0.448971
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,atezo,0.48276
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,preferred,0.337929
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,using nivo,0.395309
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,data,0.653731
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,clinical trials,0.39311
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,indication,0.394775
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,ORR,0.313421
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,approved,0.428179
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,SCCHN,0.4908
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,nivo and pembro,0.389926
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,impressed,0.583555
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,LTL,0.347179
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,TLs,0.353886
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,SCLC,0.346542
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,feels,0.448526
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,Regional TL,0.403902
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,RTL stated,0.403189
uuid-4c072ca05b0b407d8dbd1d8688c85ef7,bladder,0.384942
uuid-e0f409d78bd64d6392db3a45285ea34a,Nivo,0.412347
uuid-e0f409d78bd64d6392db3a45285ea34a,patients,0.670889
uuid-e0f409d78bd64d6392db3a45285ea34a,therapy,0.40549
uuid-e0f409d78bd64d6392db3a45285ea34a,nivolumab,0.371348
uuid-e0f409d78bd64d6392db3a45285ea34a,1L,0.404046
uuid-e0f409d78bd64d6392db3a45285ea34a,regimen,0.405858
uuid-e0f409d78bd64d6392db3a45285ea34a,treated,0.4018
uuid-e0f409d78bd64d6392db3a45285ea34a,chemo,0.427662
uuid-e0f409d78bd64d6392db3a45285ea34a,2L,0.357226
uuid-e0f409d78bd64d6392db3a45285ea34a,pts,0.490367
uuid-e0f409d78bd64d6392db3a45285ea34a,preferred,0.378709
uuid-e0f409d78bd64d6392db3a45285ea34a,monotherapy,0.536056
uuid-e0f409d78bd64d6392db3a45285ea34a,treatment,0.435743
uuid-e0f409d78bd64d6392db3a45285ea34a,using nivo,0.473736
uuid-e0f409d78bd64d6392db3a45285ea34a,PD1,0.348627
uuid-e0f409d78bd64d6392db3a45285ea34a,SCCHN,0.378083
uuid-e0f409d78bd64d6392db3a45285ea34a,progression,0.463218
uuid-e0f409d78bd64d6392db3a45285ea34a,chemotherapy,0.446008
uuid-e0f409d78bd64d6392db3a45285ea34a,respond,0.329843
uuid-e0f409d78bd64d6392db3a45285ea34a,feels,0.365489
uuid-e0f409d78bd64d6392db3a45285ea34a,RTL stated,0.484004
uuid-e0f409d78bd64d6392db3a45285ea34a,option,0.561264
uuid-359d5c937a8d4a7895f33de85ea660b0,patients,0.492903
uuid-359d5c937a8d4a7895f33de85ea660b0,toxicity,0.490953
uuid-359d5c937a8d4a7895f33de85ea660b0,regimen,0.410202
uuid-359d5c937a8d4a7895f33de85ea660b0,treated,0.386174
uuid-359d5c937a8d4a7895f33de85ea660b0,treatment,0.433729
uuid-359d5c937a8d4a7895f33de85ea660b0,progression,0.419235
uuid-359d5c937a8d4a7895f33de85ea660b0,oncologist,0.325868
uuid-359d5c937a8d4a7895f33de85ea660b0,respond,0.567751
uuid-d3806316726d4640911171302ee08b74,RTL,0.515542
uuid-d3806316726d4640911171302ee08b74,1L,0.366419
uuid-d3806316726d4640911171302ee08b74,trial,0.491773
uuid-d3806316726d4640911171302ee08b74,shared,0.365891
uuid-d3806316726d4640911171302ee08b74,commented,0.308109
uuid-d3806316726d4640911171302ee08b74,RCC,0.466443
uuid-d3806316726d4640911171302ee08b74,combination,0.322289
uuid-d3806316726d4640911171302ee08b74,2L,0.330876
uuid-d3806316726d4640911171302ee08b74,stated,0.385078
uuid-d3806316726d4640911171302ee08b74,preferred,0.39129
uuid-d3806316726d4640911171302ee08b74,using nivo,0.33634
uuid-d3806316726d4640911171302ee08b74,combo,0.374232
uuid-d3806316726d4640911171302ee08b74,clinical trials,0.662313
uuid-d3806316726d4640911171302ee08b74,approved,0.303209
uuid-d3806316726d4640911171302ee08b74,SCCHN,0.583397
uuid-d3806316726d4640911171302ee08b74,impressed,0.319358
uuid-d3806316726d4640911171302ee08b74,LTL,0.345067
uuid-d3806316726d4640911171302ee08b74,TLs,0.445929
uuid-d3806316726d4640911171302ee08b74,academic,0.415911
uuid-d3806316726d4640911171302ee08b74,Regional TL,0.481236
uuid-d3806316726d4640911171302ee08b74,RTL stated,0.522728
uuid-d3806316726d4640911171302ee08b74,TL shared,0.339791
uuid-d3806316726d4640911171302ee08b74,bladder,0.440864
uuid-2145936b092e453dae2be2b4599514ef,patients,0.321018
uuid-2145936b092e453dae2be2b4599514ef,therapy,0.36921
uuid-2145936b092e453dae2be2b4599514ef,lung,0.385616
uuid-2145936b092e453dae2be2b4599514ef,regimen,0.438694
uuid-2145936b092e453dae2be2b4599514ef,treated,0.326729
uuid-2145936b092e453dae2be2b4599514ef,melanoma,0.484725
uuid-2145936b092e453dae2be2b4599514ef,treatment,0.481095
uuid-2145936b092e453dae2be2b4599514ef,AI,0.541834
uuid-2145936b092e453dae2be2b4599514ef,cHL,0.336147
uuid-2145936b092e453dae2be2b4599514ef,progression,0.402191
uuid-2145936b092e453dae2be2b4599514ef,respond,0.362768
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,BMS,0.312813
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,PDL1,0.420089
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,efficacy,0.350437
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,OS,0.308353
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,regards,0.488157
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,data,0.496503
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,indication,0.360773
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,nivo and pembro,0.389491
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,believes,0.33378
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,PDL1 expression,0.391073
uuid-d2c5c65d743a41a29acd4a1083b3dd2d,NCCN,0.486984
uuid-7b9fdee8c5214840875640a8b0e5628b,TL,0.483853
uuid-7b9fdee8c5214840875640a8b0e5628b,pembro,0.423404
uuid-7b9fdee8c5214840875640a8b0e5628b,1L,0.401016
uuid-7b9fdee8c5214840875640a8b0e5628b,PDL1,0.367849
uuid-7b9fdee8c5214840875640a8b0e5628b,TL stated,0.432824
uuid-7b9fdee8c5214840875640a8b0e5628b,2L,0.387924
uuid-7b9fdee8c5214840875640a8b0e5628b,institution,0.412467
uuid-7b9fdee8c5214840875640a8b0e5628b,PD-L1,0.692153
uuid-7b9fdee8c5214840875640a8b0e5628b,approval,0.428268
uuid-7b9fdee8c5214840875640a8b0e5628b,atezo,0.431837
uuid-7b9fdee8c5214840875640a8b0e5628b,PD-L1 testing,0.774975
uuid-7b9fdee8c5214840875640a8b0e5628b,testing,0.810769
uuid-7b9fdee8c5214840875640a8b0e5628b,using nivo,0.302173
uuid-7b9fdee8c5214840875640a8b0e5628b,PDL1 testing,0.746254
uuid-7b9fdee8c5214840875640a8b0e5628b,NSCLC patients,0.679585
uuid-7b9fdee8c5214840875640a8b0e5628b,assay,0.573597
uuid-dfbf4a31a8f745dbb2ff830453f50278,Nivo,0.412347
uuid-dfbf4a31a8f745dbb2ff830453f50278,patients,0.670889
uuid-dfbf4a31a8f745dbb2ff830453f50278,therapy,0.40549
uuid-dfbf4a31a8f745dbb2ff830453f50278,nivolumab,0.371348
uuid-dfbf4a31a8f745dbb2ff830453f50278,1L,0.404046
uuid-dfbf4a31a8f745dbb2ff830453f50278,regimen,0.405858
uuid-dfbf4a31a8f745dbb2ff830453f50278,treated,0.4018
uuid-dfbf4a31a8f745dbb2ff830453f50278,chemo,0.427662
uuid-dfbf4a31a8f745dbb2ff830453f50278,2L,0.357226
uuid-dfbf4a31a8f745dbb2ff830453f50278,pts,0.490367
uuid-dfbf4a31a8f745dbb2ff830453f50278,preferred,0.378709
uuid-dfbf4a31a8f745dbb2ff830453f50278,monotherapy,0.536056
uuid-dfbf4a31a8f745dbb2ff830453f50278,treatment,0.435743
uuid-dfbf4a31a8f745dbb2ff830453f50278,using nivo,0.473736
uuid-dfbf4a31a8f745dbb2ff830453f50278,PD1,0.348627
uuid-dfbf4a31a8f745dbb2ff830453f50278,SCCHN,0.378083
uuid-dfbf4a31a8f745dbb2ff830453f50278,progression,0.463218
uuid-dfbf4a31a8f745dbb2ff830453f50278,chemotherapy,0.446008
uuid-dfbf4a31a8f745dbb2ff830453f50278,respond,0.329843
uuid-dfbf4a31a8f745dbb2ff830453f50278,feels,0.365489
uuid-dfbf4a31a8f745dbb2ff830453f50278,RTL stated,0.484004
uuid-dfbf4a31a8f745dbb2ff830453f50278,option,0.561264
uuid-c81bb468b6b5484682f5072451323015,PDL1,0.324511
uuid-c81bb468b6b5484682f5072451323015,efficacy,0.407596
uuid-c81bb468b6b5484682f5072451323015,chemo,0.443522
uuid-c81bb468b6b5484682f5072451323015,OS,0.3829
uuid-c81bb468b6b5484682f5072451323015,monotherapy,0.343789
uuid-c81bb468b6b5484682f5072451323015,combo,0.300875
uuid-c81bb468b6b5484682f5072451323015,PFS,0.377678
uuid-c81bb468b6b5484682f5072451323015,ORR,0.368889
uuid-c81bb468b6b5484682f5072451323015,nivo and pembro,0.376648
uuid-c81bb468b6b5484682f5072451323015,believes,0.590427
uuid-c81bb468b6b5484682f5072451323015,chemotherapy,0.397883
uuid-c81bb468b6b5484682f5072451323015,feels,0.360401
uuid-c81bb468b6b5484682f5072451323015,option,0.353029
uuid-3ad1e4601848435b8a1bb58535237cc1,pembro,0.412446
uuid-3ad1e4601848435b8a1bb58535237cc1,RTL,0.478455
uuid-3ad1e4601848435b8a1bb58535237cc1,BMS,0.311491
uuid-3ad1e4601848435b8a1bb58535237cc1,trial,0.736542
uuid-3ad1e4601848435b8a1bb58535237cc1,NTL,0.399097
uuid-3ad1e4601848435b8a1bb58535237cc1,Merck,0.423462
uuid-3ad1e4601848435b8a1bb58535237cc1,approval,0.31438
uuid-3ad1e4601848435b8a1bb58535237cc1,atezo,0.307327
uuid-3ad1e4601848435b8a1bb58535237cc1,clinical trials,0.386478
uuid-3ad1e4601848435b8a1bb58535237cc1,SCCHN,0.367621
uuid-3ad1e4601848435b8a1bb58535237cc1,Regional TL,0.319377
uuid-3ad1e4601848435b8a1bb58535237cc1,bladder,0.349595
uuid-e64248e9bf044df39327cd5ce55a5683,Opdivo,0.767616
uuid-e64248e9bf044df39327cd5ce55a5683,dose,0.315551
uuid-e64248e9bf044df39327cd5ce55a5683,physicians,0.398733
uuid-e64248e9bf044df39327cd5ce55a5683,approved,0.321777
uuid-e64248e9bf044df39327cd5ce55a5683,drug,0.52845
uuid-e64248e9bf044df39327cd5ce55a5683,Keytruda,0.476063
uuid-e64248e9bf044df39327cd5ce55a5683,flat dosing,0.421879
uuid-e5cb96ffe8804306bfd69c395e6e77a5,physicians,0.566143
uuid-e5cb96ffe8804306bfd69c395e6e77a5,oncology,0.507099
uuid-e5cb96ffe8804306bfd69c395e6e77a5,clinical,0.347087
uuid-ffc6886c307444dba9abb5cd84759edd,1L,0.346802
uuid-ffc6886c307444dba9abb5cd84759edd,PDL1,0.497539
uuid-ffc6886c307444dba9abb5cd84759edd,efficacy,0.348601
uuid-ffc6886c307444dba9abb5cd84759edd,PD-L1,0.35893
uuid-ffc6886c307444dba9abb5cd84759edd,monotherapy,0.313266
uuid-ffc6886c307444dba9abb5cd84759edd,believes,0.36825
uuid-ffc6886c307444dba9abb5cd84759edd,feels,0.351394
uuid-ffc6886c307444dba9abb5cd84759edd,PDL1 expression,0.334277
uuid-ffc6886c307444dba9abb5cd84759edd,option,0.332516
uuid-653e9879604d468fa9a2aab2bb6ab55b,oncology,0.440799
uuid-653e9879604d468fa9a2aab2bb6ab55b,drug,0.519261
uuid-653e9879604d468fa9a2aab2bb6ab55b,Keytruda,0.33398
uuid-653e9879604d468fa9a2aab2bb6ab55b,clinical,0.377836
uuid-653e9879604d468fa9a2aab2bb6ab55b,flat dosing,0.385408
uuid-cd41f77e531a4c8ead24e4e718c4bf19,Nivo,0.442884
uuid-cd41f77e531a4c8ead24e4e718c4bf19,pembro,0.70733
uuid-cd41f77e531a4c8ead24e4e718c4bf19,dose,0.578603
uuid-cd41f77e531a4c8ead24e4e718c4bf19,trial,0.313356
uuid-cd41f77e531a4c8ead24e4e718c4bf19,efficacy,0.498563
uuid-cd41f77e531a4c8ead24e4e718c4bf19,Ipi,0.390045
uuid-cd41f77e531a4c8ead24e4e718c4bf19,atezo,0.665559
uuid-cd41f77e531a4c8ead24e4e718c4bf19,preferred,0.358524
uuid-cd41f77e531a4c8ead24e4e718c4bf19,indication,0.440591
uuid-cd41f77e531a4c8ead24e4e718c4bf19,nivo and pembro,0.374154
uuid-cd41f77e531a4c8ead24e4e718c4bf19,vs,0.730869
uuid-cd41f77e531a4c8ead24e4e718c4bf19,Keytruda,0.414519
uuid-cd41f77e531a4c8ead24e4e718c4bf19,TLs,0.311674
uuid-cd41f77e531a4c8ead24e4e718c4bf19,feels,0.333029
uuid-cd41f77e531a4c8ead24e4e718c4bf19,flat dosing,0.549349
uuid-093e2f9a58e84bfaa8c528e4341d56bc,TL,0.326845
uuid-093e2f9a58e84bfaa8c528e4341d56bc,trial,0.675316
uuid-093e2f9a58e84bfaa8c528e4341d56bc,Merck,0.314961
uuid-093e2f9a58e84bfaa8c528e4341d56bc,clinical trials,0.340872
uuid-dd01ace07fbb456aa9b20be6d1f58b83,trial,0.504532
uuid-dd01ace07fbb456aa9b20be6d1f58b83,shared,0.402479
uuid-dd01ace07fbb456aa9b20be6d1f58b83,combination,0.373811
uuid-dd01ace07fbb456aa9b20be6d1f58b83,combo,0.343935
uuid-fa9f7cc31c0b44d19a5a6e900905d462,Nivo,0.62766
uuid-fa9f7cc31c0b44d19a5a6e900905d462,pembro,0.623474
uuid-fa9f7cc31c0b44d19a5a6e900905d462,dose,0.515867
uuid-fa9f7cc31c0b44d19a5a6e900905d462,1L,0.465307
uuid-fa9f7cc31c0b44d19a5a6e900905d462,toxicity,0.355832
uuid-fa9f7cc31c0b44d19a5a6e900905d462,efficacy,0.502328
uuid-fa9f7cc31c0b44d19a5a6e900905d462,regimen,0.361651
uuid-fa9f7cc31c0b44d19a5a6e900905d462,combination,0.366524
uuid-fa9f7cc31c0b44d19a5a6e900905d462,chemo,0.42564
uuid-fa9f7cc31c0b44d19a5a6e900905d462,2L,0.603441
uuid-fa9f7cc31c0b44d19a5a6e900905d462,agents,0.515772
uuid-fa9f7cc31c0b44d19a5a6e900905d462,Ipi,0.488052
uuid-fa9f7cc31c0b44d19a5a6e900905d462,atezo,0.65974
uuid-fa9f7cc31c0b44d19a5a6e900905d462,preferred,0.575649
uuid-fa9f7cc31c0b44d19a5a6e900905d462,monotherapy,0.535226
uuid-fa9f7cc31c0b44d19a5a6e900905d462,using nivo,0.436995
uuid-fa9f7cc31c0b44d19a5a6e900905d462,combo,0.440656
uuid-fa9f7cc31c0b44d19a5a6e900905d462,indication,0.300113
uuid-fa9f7cc31c0b44d19a5a6e900905d462,approved,0.330182
uuid-fa9f7cc31c0b44d19a5a6e900905d462,nivo and pembro,0.428234
uuid-fa9f7cc31c0b44d19a5a6e900905d462,believes,0.358216
uuid-fa9f7cc31c0b44d19a5a6e900905d462,vs,0.584775
uuid-fa9f7cc31c0b44d19a5a6e900905d462,feels,0.412981
uuid-fa9f7cc31c0b44d19a5a6e900905d462,option,0.486082
uuid-1b70eefc7a0d47fc822740ff3fb64af9,TL,0.368268
uuid-1b70eefc7a0d47fc822740ff3fb64af9,lung,0.662474
uuid-1b70eefc7a0d47fc822740ff3fb64af9,1L,0.304209
uuid-1b70eefc7a0d47fc822740ff3fb64af9,melanoma,0.454639
uuid-1b70eefc7a0d47fc822740ff3fb64af9,RCC,0.636104
uuid-1b70eefc7a0d47fc822740ff3fb64af9,TL stated,0.823963
uuid-1b70eefc7a0d47fc822740ff3fb64af9,2L,0.325997
uuid-1b70eefc7a0d47fc822740ff3fb64af9,institution,0.324688
uuid-1b70eefc7a0d47fc822740ff3fb64af9,stated,0.333773
uuid-1b70eefc7a0d47fc822740ff3fb64af9,PD-L1,0.336433
uuid-1b70eefc7a0d47fc822740ff3fb64af9,PD-L1 testing,0.494651
uuid-1b70eefc7a0d47fc822740ff3fb64af9,testing,0.55087
uuid-1b70eefc7a0d47fc822740ff3fb64af9,PDL1 testing,0.778561
uuid-1b70eefc7a0d47fc822740ff3fb64af9,NSCLC patients,0.530805
uuid-1b70eefc7a0d47fc822740ff3fb64af9,SCCHN,0.49397
uuid-1b70eefc7a0d47fc822740ff3fb64af9,tumor types,0.462866
uuid-1b70eefc7a0d47fc822740ff3fb64af9,TLs,0.396775
uuid-1b70eefc7a0d47fc822740ff3fb64af9,Regional TL,0.366691
uuid-1b70eefc7a0d47fc822740ff3fb64af9,RTL stated,0.476694
uuid-1b70eefc7a0d47fc822740ff3fb64af9,TL shared,0.547266
uuid-1b70eefc7a0d47fc822740ff3fb64af9,bladder,0.409308
uuid-4793ca7912b14992b206158215d54af9,Nivo,0.365224
uuid-4793ca7912b14992b206158215d54af9,pembro,0.485447
uuid-4793ca7912b14992b206158215d54af9,BMS,0.314248
uuid-4793ca7912b14992b206158215d54af9,1L,0.42321
uuid-4793ca7912b14992b206158215d54af9,PDL1,0.471043
uuid-4793ca7912b14992b206158215d54af9,trial,0.432531
uuid-4793ca7912b14992b206158215d54af9,efficacy,0.498809
uuid-4793ca7912b14992b206158215d54af9,2L,0.349564
uuid-4793ca7912b14992b206158215d54af9,stated,0.39869
uuid-4793ca7912b14992b206158215d54af9,OS,0.515673
uuid-4793ca7912b14992b206158215d54af9,atezo,0.439281
uuid-4793ca7912b14992b206158215d54af9,data,0.698959
uuid-4793ca7912b14992b206158215d54af9,clinical trials,0.302275
uuid-4793ca7912b14992b206158215d54af9,PFS,0.509514
uuid-4793ca7912b14992b206158215d54af9,ORR,0.537733
uuid-4793ca7912b14992b206158215d54af9,nivo and pembro,0.551944
uuid-4793ca7912b14992b206158215d54af9,believes,0.413694
uuid-4793ca7912b14992b206158215d54af9,impressed,0.532499
uuid-4793ca7912b14992b206158215d54af9,LTL,0.304144
uuid-4793ca7912b14992b206158215d54af9,TLs,0.321532
uuid-4793ca7912b14992b206158215d54af9,feels,0.547009
uuid-4793ca7912b14992b206158215d54af9,PDL1 expression,0.467286
uuid-657106a7582a45b9bca99a1fb41abc63,Nivo,0.577419
uuid-657106a7582a45b9bca99a1fb41abc63,pembro,0.706605
uuid-657106a7582a45b9bca99a1fb41abc63,1L,0.71949
uuid-657106a7582a45b9bca99a1fb41abc63,RCC,0.512565
uuid-657106a7582a45b9bca99a1fb41abc63,2L,0.776541
uuid-657106a7582a45b9bca99a1fb41abc63,agents,0.373499
uuid-657106a7582a45b9bca99a1fb41abc63,stated,0.334891
uuid-657106a7582a45b9bca99a1fb41abc63,approval,0.567796
uuid-657106a7582a45b9bca99a1fb41abc63,atezo,0.677499
uuid-657106a7582a45b9bca99a1fb41abc63,preferred,0.628356
uuid-657106a7582a45b9bca99a1fb41abc63,monotherapy,0.503395
uuid-657106a7582a45b9bca99a1fb41abc63,using nivo,0.724894
uuid-657106a7582a45b9bca99a1fb41abc63,combo,0.339694
uuid-657106a7582a45b9bca99a1fb41abc63,clinical trials,0.32489
uuid-657106a7582a45b9bca99a1fb41abc63,indication,0.472152
uuid-657106a7582a45b9bca99a1fb41abc63,approved,0.640345
uuid-657106a7582a45b9bca99a1fb41abc63,SCCHN,0.521202
uuid-657106a7582a45b9bca99a1fb41abc63,nivo and pembro,0.347227
uuid-657106a7582a45b9bca99a1fb41abc63,tumor types,0.392353
uuid-657106a7582a45b9bca99a1fb41abc63,label,0.373542
uuid-657106a7582a45b9bca99a1fb41abc63,SCLC,0.368552
uuid-657106a7582a45b9bca99a1fb41abc63,feels,0.335061
uuid-657106a7582a45b9bca99a1fb41abc63,RTL stated,0.613833
uuid-657106a7582a45b9bca99a1fb41abc63,option,0.519585
uuid-657106a7582a45b9bca99a1fb41abc63,bladder,0.514654
uuid-57d0010547f347adab7a90783c371df1,Nivo,0.380158
uuid-57d0010547f347adab7a90783c371df1,pembro,0.547042
uuid-57d0010547f347adab7a90783c371df1,dose,0.517403
uuid-57d0010547f347adab7a90783c371df1,BMS,0.439722
uuid-57d0010547f347adab7a90783c371df1,trial,0.451059
uuid-57d0010547f347adab7a90783c371df1,efficacy,0.528562
uuid-57d0010547f347adab7a90783c371df1,Merck,0.36294
uuid-57d0010547f347adab7a90783c371df1,Ipi,0.419488
uuid-57d0010547f347adab7a90783c371df1,atezo,0.542584
uuid-57d0010547f347adab7a90783c371df1,data,0.388745
uuid-57d0010547f347adab7a90783c371df1,nivo and pembro,0.310632
uuid-57d0010547f347adab7a90783c371df1,vs,0.675592
uuid-57d0010547f347adab7a90783c371df1,flat dosing,0.451295
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,Nivo,0.385677
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,pembro,0.314735
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,nivolumab,0.329128
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,1L,0.606886
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,toxicity,0.340412
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,regimen,0.489545
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,RCC,0.45459
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,combination,0.515684
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,chemo,0.493514
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,2L,0.681783
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,IO,0.337656
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,agents,0.708498
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,atezo,0.383767
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,preferred,0.719423
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,monotherapy,0.741233
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,using nivo,0.525447
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,combo,0.566152
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,PD1,0.488027
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,approved,0.452055
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,believes,0.43786
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,chemotherapy,0.410388
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,feels,0.372122
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,PD-1,0.330935
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,RTL stated,0.381871
uuid-8acb1aab8ac246a9baf2d1ddd4327ebc,option,0.749233
uuid-a8023e3b6e37449e99036cc6d2963a48,patients,0.610211
uuid-a8023e3b6e37449e99036cc6d2963a48,therapy,0.319661
uuid-a8023e3b6e37449e99036cc6d2963a48,regimen,0.351175
uuid-a8023e3b6e37449e99036cc6d2963a48,treated,0.586945
uuid-a8023e3b6e37449e99036cc6d2963a48,chemo,0.312073
uuid-a8023e3b6e37449e99036cc6d2963a48,tumor,0.512165
uuid-a8023e3b6e37449e99036cc6d2963a48,pts,0.490043
uuid-a8023e3b6e37449e99036cc6d2963a48,treatment,0.447157
uuid-a8023e3b6e37449e99036cc6d2963a48,response,0.347226
uuid-a8023e3b6e37449e99036cc6d2963a48,progression,0.483903
uuid-a8023e3b6e37449e99036cc6d2963a48,respond,0.401623
uuid-a59535aac05e4daaa5cf32261f977d63,pembro,0.324155
uuid-a59535aac05e4daaa5cf32261f977d63,PDL1,0.587713
uuid-a59535aac05e4daaa5cf32261f977d63,agents,0.32797
uuid-a59535aac05e4daaa5cf32261f977d63,PD-L1,0.616618
uuid-a59535aac05e4daaa5cf32261f977d63,atezo,0.457776
uuid-a59535aac05e4daaa5cf32261f977d63,PD-L1 testing,0.386912
uuid-a59535aac05e4daaa5cf32261f977d63,testing,0.531268
uuid-a59535aac05e4daaa5cf32261f977d63,PDL1 testing,0.427124
uuid-a59535aac05e4daaa5cf32261f977d63,NSCLC patients,0.318358
uuid-a59535aac05e4daaa5cf32261f977d63,nivo and pembro,0.339226
uuid-a59535aac05e4daaa5cf32261f977d63,believes,0.380665
uuid-a59535aac05e4daaa5cf32261f977d63,assay,0.59433
uuid-a59535aac05e4daaa5cf32261f977d63,PDL1 expression,0.504467
uuid-a59535aac05e4daaa5cf32261f977d63,biomarker,0.499482
uuid-c5cd60b9875b4c50a62e9621a70bf6be,Nivo,0.435321
uuid-c5cd60b9875b4c50a62e9621a70bf6be,patients,0.345004
uuid-c5cd60b9875b4c50a62e9621a70bf6be,pembro,0.559692
uuid-c5cd60b9875b4c50a62e9621a70bf6be,nivolumab,0.324954
uuid-c5cd60b9875b4c50a62e9621a70bf6be,1L,0.596621
uuid-c5cd60b9875b4c50a62e9621a70bf6be,RCC,0.39071
uuid-c5cd60b9875b4c50a62e9621a70bf6be,combination,0.30369
uuid-c5cd60b9875b4c50a62e9621a70bf6be,chemo,0.337999
uuid-c5cd60b9875b4c50a62e9621a70bf6be,2L,0.710933
uuid-c5cd60b9875b4c50a62e9621a70bf6be,agents,0.474177
uuid-c5cd60b9875b4c50a62e9621a70bf6be,approval,0.328031
uuid-c5cd60b9875b4c50a62e9621a70bf6be,atezo,0.587836
uuid-c5cd60b9875b4c50a62e9621a70bf6be,preferred,0.77221
uuid-c5cd60b9875b4c50a62e9621a70bf6be,monotherapy,0.582447
uuid-c5cd60b9875b4c50a62e9621a70bf6be,using nivo,0.585866
uuid-c5cd60b9875b4c50a62e9621a70bf6be,combo,0.382803
uuid-c5cd60b9875b4c50a62e9621a70bf6be,indication,0.346999
uuid-c5cd60b9875b4c50a62e9621a70bf6be,NSCLC patients,0.305345
uuid-c5cd60b9875b4c50a62e9621a70bf6be,PD1,0.339237
uuid-c5cd60b9875b4c50a62e9621a70bf6be,approved,0.444349
uuid-c5cd60b9875b4c50a62e9621a70bf6be,SCCHN,0.300893
uuid-c5cd60b9875b4c50a62e9621a70bf6be,vs,0.36558
uuid-c5cd60b9875b4c50a62e9621a70bf6be,feels,0.318979
uuid-c5cd60b9875b4c50a62e9621a70bf6be,RTL stated,0.453372
uuid-c5cd60b9875b4c50a62e9621a70bf6be,option,0.640502
uuid-c5cd60b9875b4c50a62e9621a70bf6be,bladder,0.31559
uuid-acc3dd2d9c8f43449590f93ce769982d,Nivo,0.669129
uuid-acc3dd2d9c8f43449590f93ce769982d,pembro,0.487281
uuid-acc3dd2d9c8f43449590f93ce769982d,trial,0.593812
uuid-acc3dd2d9c8f43449590f93ce769982d,efficacy,0.579789
uuid-acc3dd2d9c8f43449590f93ce769982d,combination,0.325554
uuid-acc3dd2d9c8f43449590f93ce769982d,chemo,0.381653
uuid-acc3dd2d9c8f43449590f93ce769982d,Ipi,0.469169
uuid-acc3dd2d9c8f43449590f93ce769982d,OS,0.459921
uuid-acc3dd2d9c8f43449590f93ce769982d,atezo,0.315504
uuid-acc3dd2d9c8f43449590f93ce769982d,data,0.449333
uuid-acc3dd2d9c8f43449590f93ce769982d,PFS,0.49766
uuid-acc3dd2d9c8f43449590f93ce769982d,ORR,0.540188
uuid-acc3dd2d9c8f43449590f93ce769982d,nivo and pembro,0.445559
uuid-acc3dd2d9c8f43449590f93ce769982d,believes,0.311689
uuid-acc3dd2d9c8f43449590f93ce769982d,chemotherapy,0.346882
uuid-acc3dd2d9c8f43449590f93ce769982d,impressed,0.407507
uuid-acc3dd2d9c8f43449590f93ce769982d,vs,0.446843
uuid-acc3dd2d9c8f43449590f93ce769982d,feels,0.408865
uuid-0b6d2808f7e040ee905cbf0f2452e48a,RTL,0.346459
uuid-0b6d2808f7e040ee905cbf0f2452e48a,BMS,0.313421
uuid-0b6d2808f7e040ee905cbf0f2452e48a,PDL1,0.373302
uuid-0b6d2808f7e040ee905cbf0f2452e48a,trial,0.448904
uuid-0b6d2808f7e040ee905cbf0f2452e48a,efficacy,0.44481
uuid-0b6d2808f7e040ee905cbf0f2452e48a,NTL,0.349106
uuid-0b6d2808f7e040ee905cbf0f2452e48a,commented,0.34621
uuid-0b6d2808f7e040ee905cbf0f2452e48a,Merck,0.300215
uuid-0b6d2808f7e040ee905cbf0f2452e48a,OS,0.382046
uuid-0b6d2808f7e040ee905cbf0f2452e48a,regards,0.383721
uuid-0b6d2808f7e040ee905cbf0f2452e48a,data,0.556224
uuid-0b6d2808f7e040ee905cbf0f2452e48a,expressed,0.442509
uuid-0b6d2808f7e040ee905cbf0f2452e48a,mentioned,0.497404
uuid-0b6d2808f7e040ee905cbf0f2452e48a,PFS,0.443648
uuid-0b6d2808f7e040ee905cbf0f2452e48a,ORR,0.458685
uuid-0b6d2808f7e040ee905cbf0f2452e48a,nivo and pembro,0.432348
uuid-0b6d2808f7e040ee905cbf0f2452e48a,impressed,0.367233
uuid-0b6d2808f7e040ee905cbf0f2452e48a,TLs,0.38241
uuid-0b6d2808f7e040ee905cbf0f2452e48a,PDL1 expression,0.429233
uuid-44530e68ad9c4f0e824b7555c64be6ba,patients,0.338935
uuid-44530e68ad9c4f0e824b7555c64be6ba,toxicity,0.386668
uuid-44530e68ad9c4f0e824b7555c64be6ba,regimen,0.373615
uuid-44530e68ad9c4f0e824b7555c64be6ba,treatment,0.331939
uuid-44530e68ad9c4f0e824b7555c64be6ba,respond,0.426069
uuid-44530e68ad9c4f0e824b7555c64be6ba,feels,0.401749
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,patients,0.739377
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,Opdivo,0.423835
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,therapy,0.378344
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,regimen,0.352436
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,treated,0.360049
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,pts,0.467316
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,treatment,0.55025
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,progression,0.570781
uuid-6ecfa3199378464e8a9bdf66a27b1d8e,respond,0.423482
uuid-8eb4c3a95bfd4f778088b7708247be7c,pembro,0.567765
uuid-8eb4c3a95bfd4f778088b7708247be7c,1L,0.443786
uuid-8eb4c3a95bfd4f778088b7708247be7c,PDL1,0.39459
uuid-8eb4c3a95bfd4f778088b7708247be7c,2L,0.435346
uuid-8eb4c3a95bfd4f778088b7708247be7c,Merck,0.392371
uuid-8eb4c3a95bfd4f778088b7708247be7c,PD-L1,0.618867
uuid-8eb4c3a95bfd4f778088b7708247be7c,approval,0.497589
uuid-8eb4c3a95bfd4f778088b7708247be7c,atezo,0.56829
uuid-8eb4c3a95bfd4f778088b7708247be7c,preferred,0.41082
uuid-8eb4c3a95bfd4f778088b7708247be7c,PD-L1 testing,0.539557
uuid-8eb4c3a95bfd4f778088b7708247be7c,testing,0.654477
uuid-8eb4c3a95bfd4f778088b7708247be7c,PDL1 testing,0.559505
uuid-8eb4c3a95bfd4f778088b7708247be7c,indication,0.383415
uuid-8eb4c3a95bfd4f778088b7708247be7c,NSCLC patients,0.525916
uuid-8eb4c3a95bfd4f778088b7708247be7c,approved,0.534804
uuid-8eb4c3a95bfd4f778088b7708247be7c,label,0.354771
uuid-8eb4c3a95bfd4f778088b7708247be7c,Keytruda,0.530819
uuid-8eb4c3a95bfd4f778088b7708247be7c,assay,0.48445
uuid-52958eba308a499fabb17070c1976936,Nivo,0.333321
uuid-52958eba308a499fabb17070c1976936,pembro,0.32493
uuid-52958eba308a499fabb17070c1976936,dose,0.346232
uuid-52958eba308a499fabb17070c1976936,BMS,0.340995
uuid-52958eba308a499fabb17070c1976936,trial,0.623857
uuid-52958eba308a499fabb17070c1976936,efficacy,0.55292
uuid-52958eba308a499fabb17070c1976936,Ipi,0.729838
uuid-52958eba308a499fabb17070c1976936,OS,0.439383
uuid-52958eba308a499fabb17070c1976936,data,0.532983
uuid-52958eba308a499fabb17070c1976936,PFS,0.423416
uuid-52958eba308a499fabb17070c1976936,ORR,0.578035
uuid-52958eba308a499fabb17070c1976936,impressed,0.475862
uuid-52958eba308a499fabb17070c1976936,vs,0.45769
uuid-d996da7c9ba240da84a86d46690cd219,toxicity,0.460349
uuid-1cd8a054626a450fb7d93394b08b0256,patients,0.340267
uuid-1cd8a054626a450fb7d93394b08b0256,regimen,0.318167
uuid-1cd8a054626a450fb7d93394b08b0256,chemo,0.310768
uuid-1cd8a054626a450fb7d93394b08b0256,2L,0.321233
uuid-1cd8a054626a450fb7d93394b08b0256,preferred,0.607101
uuid-1cd8a054626a450fb7d93394b08b0256,monotherapy,0.376449
uuid-1cd8a054626a450fb7d93394b08b0256,treatment,0.334885
uuid-1cd8a054626a450fb7d93394b08b0256,using nivo,0.366791
uuid-1cd8a054626a450fb7d93394b08b0256,indication,0.32774
uuid-1cd8a054626a450fb7d93394b08b0256,SCCHN,0.335519
uuid-1cd8a054626a450fb7d93394b08b0256,chemotherapy,0.365508
uuid-1cd8a054626a450fb7d93394b08b0256,RTL stated,0.365949
uuid-1cd8a054626a450fb7d93394b08b0256,TL shared,0.30615
uuid-1cd8a054626a450fb7d93394b08b0256,option,0.510003
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,TL,0.504597
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,NSCLC,0.403568
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,1L,0.37931
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,RCC,0.428615
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,TL stated,0.626698
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,2L,0.310771
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,institution,0.337751
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,PD-L1,0.670419
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,approval,0.351643
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,PD-L1 testing,0.765795
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,testing,0.776726
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,PDL1 testing,0.770602
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,NSCLC patients,0.712738
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,SCCHN,0.429487
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,tumor types,0.34516
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,assay,0.414259
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,Regional TL,0.310381
uuid-9fa358160a3c4fb6bba0b1213eb9cc98,RTL stated,0.405556
uuid-052e878b54244cd3b5626e958d3612f3,BMS,0.390061
uuid-052e878b54244cd3b5626e958d3612f3,PDL1,0.699072
uuid-052e878b54244cd3b5626e958d3612f3,trial,0.339665
uuid-052e878b54244cd3b5626e958d3612f3,efficacy,0.414486
uuid-052e878b54244cd3b5626e958d3612f3,discussed,0.355646
uuid-052e878b54244cd3b5626e958d3612f3,commented,0.395405
uuid-052e878b54244cd3b5626e958d3612f3,Merck,0.437044
uuid-052e878b54244cd3b5626e958d3612f3,PD-L1,0.41947
uuid-052e878b54244cd3b5626e958d3612f3,OS,0.471946
uuid-052e878b54244cd3b5626e958d3612f3,regards,0.450838
uuid-052e878b54244cd3b5626e958d3612f3,data,0.725889
uuid-052e878b54244cd3b5626e958d3612f3,expressed,0.302392
uuid-052e878b54244cd3b5626e958d3612f3,PFS,0.520375
uuid-052e878b54244cd3b5626e958d3612f3,ORR,0.50452
uuid-052e878b54244cd3b5626e958d3612f3,nivo and pembro,0.488195
uuid-052e878b54244cd3b5626e958d3612f3,impressed,0.364505
uuid-052e878b54244cd3b5626e958d3612f3,assay,0.478062
uuid-052e878b54244cd3b5626e958d3612f3,PDL1 expression,0.657054
uuid-052e878b54244cd3b5626e958d3612f3,biomarker,0.575792
uuid-d1d3fe6078844b6aa63e33583ef938ca,patients,0.648116
uuid-d1d3fe6078844b6aa63e33583ef938ca,Opdivo,0.432987
uuid-d1d3fe6078844b6aa63e33583ef938ca,therapy,0.577877
uuid-d1d3fe6078844b6aa63e33583ef938ca,nivolumab,0.505646
uuid-d1d3fe6078844b6aa63e33583ef938ca,toxicity,0.306584
uuid-d1d3fe6078844b6aa63e33583ef938ca,regimen,0.555315
uuid-d1d3fe6078844b6aa63e33583ef938ca,treated,0.451498
uuid-d1d3fe6078844b6aa63e33583ef938ca,RCC,0.339045
uuid-d1d3fe6078844b6aa63e33583ef938ca,combination,0.373273
uuid-d1d3fe6078844b6aa63e33583ef938ca,chemo,0.419995
uuid-d1d3fe6078844b6aa63e33583ef938ca,2L,0.322053
uuid-d1d3fe6078844b6aa63e33583ef938ca,pts,0.55317
uuid-d1d3fe6078844b6aa63e33583ef938ca,IO,0.345959
uuid-d1d3fe6078844b6aa63e33583ef938ca,preferred,0.309455
uuid-d1d3fe6078844b6aa63e33583ef938ca,monotherapy,0.538231
uuid-d1d3fe6078844b6aa63e33583ef938ca,treatment,0.611803
uuid-d1d3fe6078844b6aa63e33583ef938ca,using nivo,0.377012
uuid-d1d3fe6078844b6aa63e33583ef938ca,response,0.571192
uuid-d1d3fe6078844b6aa63e33583ef938ca,combo,0.355569
uuid-d1d3fe6078844b6aa63e33583ef938ca,PD1,0.498516
uuid-d1d3fe6078844b6aa63e33583ef938ca,progression,0.72202
uuid-d1d3fe6078844b6aa63e33583ef938ca,chemotherapy,0.374627
uuid-d1d3fe6078844b6aa63e33583ef938ca,respond,0.518697
uuid-d1d3fe6078844b6aa63e33583ef938ca,option,0.495131
uuid-f6f31af810ec4613ae15063112bf93a3,Nivo,0.408487
uuid-f6f31af810ec4613ae15063112bf93a3,patients,0.671921
uuid-f6f31af810ec4613ae15063112bf93a3,Opdivo,0.45808
uuid-f6f31af810ec4613ae15063112bf93a3,therapy,0.493145
uuid-f6f31af810ec4613ae15063112bf93a3,nivolumab,0.574886
uuid-f6f31af810ec4613ae15063112bf93a3,1L,0.346636
uuid-f6f31af810ec4613ae15063112bf93a3,regimen,0.514554
uuid-f6f31af810ec4613ae15063112bf93a3,treated,0.431957
uuid-f6f31af810ec4613ae15063112bf93a3,2L,0.347591
uuid-f6f31af810ec4613ae15063112bf93a3,pts,0.490182
uuid-f6f31af810ec4613ae15063112bf93a3,approval,0.443608
uuid-f6f31af810ec4613ae15063112bf93a3,preferred,0.344908
uuid-f6f31af810ec4613ae15063112bf93a3,monotherapy,0.573087
uuid-f6f31af810ec4613ae15063112bf93a3,treatment,0.438709
uuid-f6f31af810ec4613ae15063112bf93a3,using nivo,0.555485
uuid-f6f31af810ec4613ae15063112bf93a3,PD1,0.341836
uuid-f6f31af810ec4613ae15063112bf93a3,approved,0.41555
uuid-f6f31af810ec4613ae15063112bf93a3,cHL,0.345469
uuid-f6f31af810ec4613ae15063112bf93a3,progression,0.439439
uuid-f6f31af810ec4613ae15063112bf93a3,chemotherapy,0.357779
uuid-f6f31af810ec4613ae15063112bf93a3,label,0.303465
uuid-f6f31af810ec4613ae15063112bf93a3,respond,0.345531
uuid-f6f31af810ec4613ae15063112bf93a3,SCLC,0.401768
uuid-f6f31af810ec4613ae15063112bf93a3,RTL stated,0.40846
uuid-f6f31af810ec4613ae15063112bf93a3,option,0.522778
uuid-74e7edda472b4940826e33a31fb6df6b,patients,0.349046
uuid-74e7edda472b4940826e33a31fb6df6b,nivolumab,0.307328
uuid-74e7edda472b4940826e33a31fb6df6b,pts,0.340466
uuid-74e7edda472b4940826e33a31fb6df6b,treatment,0.331732
uuid-74e7edda472b4940826e33a31fb6df6b,response,0.312977
uuid-74e7edda472b4940826e33a31fb6df6b,PD1,0.333611
uuid-74e7edda472b4940826e33a31fb6df6b,progression,0.39819
uuid-74e7edda472b4940826e33a31fb6df6b,ASCO,0.313124
uuid-2b80e54a48204c91b5ad3a75b28b0484,efficacy,0.477489
uuid-2b80e54a48204c91b5ad3a75b28b0484,OS,0.723576
uuid-2b80e54a48204c91b5ad3a75b28b0484,data,0.589964
uuid-2b80e54a48204c91b5ad3a75b28b0484,PFS,0.651432
uuid-2b80e54a48204c91b5ad3a75b28b0484,ORR,0.619708
uuid-2b80e54a48204c91b5ad3a75b28b0484,impressed,0.55509
uuid-2b80e54a48204c91b5ad3a75b28b0484,feels,0.321301
uuid-922c35d0c58240cd85021f45361e73a9,dose,0.378005
uuid-922c35d0c58240cd85021f45361e73a9,trial,0.386825
uuid-922c35d0c58240cd85021f45361e73a9,Ipi,0.36827
uuid-7dfd903b7b6d49a199f8c62063c7a855,patients,0.432577
uuid-7dfd903b7b6d49a199f8c62063c7a855,trial,0.304449
uuid-7dfd903b7b6d49a199f8c62063c7a855,regimen,0.344768
uuid-7dfd903b7b6d49a199f8c62063c7a855,treated,0.360264
uuid-7dfd903b7b6d49a199f8c62063c7a855,treatment,0.354594
uuid-7dfd903b7b6d49a199f8c62063c7a855,clinical trials,0.360567
uuid-7dfd903b7b6d49a199f8c62063c7a855,feels,0.332499
uuid-37551967857740188cc0cff23c0c2b36,patients,0.359766
uuid-37551967857740188cc0cff23c0c2b36,therapy,0.413044
uuid-37551967857740188cc0cff23c0c2b36,nivolumab,0.321135
uuid-37551967857740188cc0cff23c0c2b36,1L,0.300097
uuid-37551967857740188cc0cff23c0c2b36,regimen,0.498009
uuid-37551967857740188cc0cff23c0c2b36,treated,0.300637
uuid-37551967857740188cc0cff23c0c2b36,combination,0.362442
uuid-37551967857740188cc0cff23c0c2b36,chemo,0.348279
uuid-37551967857740188cc0cff23c0c2b36,preferred,0.382393
uuid-37551967857740188cc0cff23c0c2b36,monotherapy,0.515195
uuid-37551967857740188cc0cff23c0c2b36,treatment,0.60653
uuid-37551967857740188cc0cff23c0c2b36,using nivo,0.300843
uuid-37551967857740188cc0cff23c0c2b36,combo,0.343768
uuid-37551967857740188cc0cff23c0c2b36,PD1,0.348333
uuid-37551967857740188cc0cff23c0c2b36,progression,0.356361
uuid-37551967857740188cc0cff23c0c2b36,chemotherapy,0.452846
uuid-37551967857740188cc0cff23c0c2b36,feels,0.340137
uuid-37551967857740188cc0cff23c0c2b36,option,0.537374
uuid-129864e37b3c46c290400383c0f32dd9,Nivo,0.378929
uuid-129864e37b3c46c290400383c0f32dd9,pembro,0.310233
uuid-129864e37b3c46c290400383c0f32dd9,RTL,0.309704
uuid-129864e37b3c46c290400383c0f32dd9,dose,0.326655
uuid-129864e37b3c46c290400383c0f32dd9,1L,0.344364
uuid-129864e37b3c46c290400383c0f32dd9,toxicity,0.318771
uuid-129864e37b3c46c290400383c0f32dd9,efficacy,0.309419
uuid-129864e37b3c46c290400383c0f32dd9,regimen,0.445897
uuid-129864e37b3c46c290400383c0f32dd9,melanoma,0.364092
uuid-129864e37b3c46c290400383c0f32dd9,RCC,0.382811
uuid-129864e37b3c46c290400383c0f32dd9,combination,0.535137
uuid-129864e37b3c46c290400383c0f32dd9,chemo,0.35486
uuid-129864e37b3c46c290400383c0f32dd9,2L,0.367978
uuid-129864e37b3c46c290400383c0f32dd9,Ipi,0.651841
uuid-129864e37b3c46c290400383c0f32dd9,preferred,0.312952
uuid-129864e37b3c46c290400383c0f32dd9,monotherapy,0.492164
uuid-129864e37b3c46c290400383c0f32dd9,using nivo,0.349217
uuid-129864e37b3c46c290400383c0f32dd9,combo,0.608416
uuid-129864e37b3c46c290400383c0f32dd9,believes,0.318293
uuid-129864e37b3c46c290400383c0f32dd9,vs,0.310194
uuid-129864e37b3c46c290400383c0f32dd9,TLs,0.35118
uuid-129864e37b3c46c290400383c0f32dd9,SCLC,0.364105
uuid-129864e37b3c46c290400383c0f32dd9,RTL stated,0.352071
uuid-74e2eb989fc94ca88d55cef7feb1885f,patients,0.320458
uuid-74e2eb989fc94ca88d55cef7feb1885f,regimen,0.303099
uuid-74e2eb989fc94ca88d55cef7feb1885f,treated,0.346147
uuid-aa45af2b5ebc40dc9073d62f22ee683b,RTL,0.313976
uuid-aa45af2b5ebc40dc9073d62f22ee683b,trial,0.418531
uuid-aa45af2b5ebc40dc9073d62f22ee683b,combination,0.305361
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,pembro,0.334582
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,lung,0.457122
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,1L,0.474954
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,treated,0.316907
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,melanoma,0.444683
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,RCC,0.680652
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,TL stated,0.650349
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,2L,0.597788
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,atezo,0.407817
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,preferred,0.542545
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,monotherapy,0.311837
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,using nivo,0.54636
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,PDL1 testing,0.504499
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,NSCLC patients,0.505683
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,approved,0.307039
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,SCCHN,0.545852
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,tumor types,0.405183
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,TLs,0.45509
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,academic,0.360639
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,Regional TL,0.342932
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,RTL stated,0.634041
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,TL shared,0.550089
uuid-648a8aaeb6ed444c84e2f3cb52f4e7fa,bladder,0.506416
uuid-97e2b25f38574ea99caaf14ac252d8ad,response,0.357704
uuid-97e2b25f38574ea99caaf14ac252d8ad,PD-1,0.369457
uuid-2eca14a476e941218776baccad5fc5be,1L,0.339993
uuid-2eca14a476e941218776baccad5fc5be,PDL1,0.34434
uuid-2eca14a476e941218776baccad5fc5be,combination,0.315618
uuid-2eca14a476e941218776baccad5fc5be,agents,0.459367
uuid-2eca14a476e941218776baccad5fc5be,PD-L1,0.382349
uuid-2eca14a476e941218776baccad5fc5be,monotherapy,0.374478
uuid-2eca14a476e941218776baccad5fc5be,PD1,0.394549
uuid-2eca14a476e941218776baccad5fc5be,nivo and pembro,0.349377
uuid-2eca14a476e941218776baccad5fc5be,PD-1,0.695263
uuid-2eca14a476e941218776baccad5fc5be,option,0.307889
uuid-6aa587bb155d4f6c9ceba1e56cf30098,lung,0.447582
uuid-6aa587bb155d4f6c9ceba1e56cf30098,regards,0.407562
uuid-6aa587bb155d4f6c9ceba1e56cf30098,expressed,0.391764
uuid-6aa587bb155d4f6c9ceba1e56cf30098,indication,0.365031
uuid-6aa587bb155d4f6c9ceba1e56cf30098,AI,0.705765
uuid-6aa587bb155d4f6c9ceba1e56cf30098,oncology,0.363719
uuid-6aa587bb155d4f6c9ceba1e56cf30098,clinical,0.315216
uuid-6aa587bb155d4f6c9ceba1e56cf30098,NCCN,0.472278
uuid-feae33664c8d40a1817ae8b4f8bcd95d,TL,0.407317
uuid-feae33664c8d40a1817ae8b4f8bcd95d,pembro,0.452506
uuid-feae33664c8d40a1817ae8b4f8bcd95d,BMS,0.368328
uuid-feae33664c8d40a1817ae8b4f8bcd95d,NSCLC,0.302252
uuid-feae33664c8d40a1817ae8b4f8bcd95d,PDL1,0.626958
uuid-feae33664c8d40a1817ae8b4f8bcd95d,Merck,0.607845
uuid-feae33664c8d40a1817ae8b4f8bcd95d,PD-L1,0.622422
uuid-feae33664c8d40a1817ae8b4f8bcd95d,atezo,0.532728
uuid-feae33664c8d40a1817ae8b4f8bcd95d,PD-L1 testing,0.478769
uuid-feae33664c8d40a1817ae8b4f8bcd95d,testing,0.574332
uuid-feae33664c8d40a1817ae8b4f8bcd95d,PDL1 testing,0.456683
uuid-feae33664c8d40a1817ae8b4f8bcd95d,nivo and pembro,0.423975
uuid-feae33664c8d40a1817ae8b4f8bcd95d,assay,0.802387
uuid-feae33664c8d40a1817ae8b4f8bcd95d,PDL1 expression,0.422435
uuid-feae33664c8d40a1817ae8b4f8bcd95d,biomarker,0.436224
uuid-064d2a877b424086b1d69f193b4d8397,Nivo,0.330888
uuid-064d2a877b424086b1d69f193b4d8397,1L,0.321197
uuid-064d2a877b424086b1d69f193b4d8397,PDL1,0.644525
uuid-064d2a877b424086b1d69f193b4d8397,trial,0.331977
uuid-064d2a877b424086b1d69f193b4d8397,efficacy,0.452734
uuid-064d2a877b424086b1d69f193b4d8397,chemo,0.416613
uuid-064d2a877b424086b1d69f193b4d8397,OS,0.641566
uuid-064d2a877b424086b1d69f193b4d8397,data,0.368479
uuid-064d2a877b424086b1d69f193b4d8397,PFS,0.667624
uuid-064d2a877b424086b1d69f193b4d8397,ORR,0.609715
uuid-064d2a877b424086b1d69f193b4d8397,nivo and pembro,0.652178
uuid-064d2a877b424086b1d69f193b4d8397,believes,0.555032
uuid-064d2a877b424086b1d69f193b4d8397,PDL1 expression,0.573531
uuid-064d2a877b424086b1d69f193b4d8397,biomarker,0.420214
uuid-3f14d889119842c29a37352f7a87a15d,Nivo,0.414234
uuid-3f14d889119842c29a37352f7a87a15d,RTL,0.393391
uuid-3f14d889119842c29a37352f7a87a15d,trial,0.422029
uuid-3f14d889119842c29a37352f7a87a15d,OS,0.353994
uuid-3f14d889119842c29a37352f7a87a15d,data,0.386587
uuid-3f14d889119842c29a37352f7a87a15d,mentioned,0.354679
uuid-3f14d889119842c29a37352f7a87a15d,PFS,0.455585
uuid-3f14d889119842c29a37352f7a87a15d,ORR,0.351668
uuid-3f14d889119842c29a37352f7a87a15d,cHL,0.616787
uuid-3f14d889119842c29a37352f7a87a15d,impressed,0.384811
uuid-11190e0592f542f3b680ac400c1ac016,RTL,0.620894
uuid-11190e0592f542f3b680ac400c1ac016,nivolumab,0.3214
uuid-11190e0592f542f3b680ac400c1ac016,trial,0.504193
uuid-11190e0592f542f3b680ac400c1ac016,NTL,0.558912
uuid-11190e0592f542f3b680ac400c1ac016,commented,0.453934
uuid-11190e0592f542f3b680ac400c1ac016,stated,0.555644
uuid-11190e0592f542f3b680ac400c1ac016,data,0.38898
uuid-11190e0592f542f3b680ac400c1ac016,expressed,0.314443
uuid-11190e0592f542f3b680ac400c1ac016,mentioned,0.382557
uuid-11190e0592f542f3b680ac400c1ac016,clinical trials,0.380396
uuid-11190e0592f542f3b680ac400c1ac016,SCCHN,0.450343
uuid-11190e0592f542f3b680ac400c1ac016,HCP,0.310967
uuid-11190e0592f542f3b680ac400c1ac016,cHL,0.321746
uuid-11190e0592f542f3b680ac400c1ac016,ASCO,0.372674
uuid-11190e0592f542f3b680ac400c1ac016,impressed,0.545672
uuid-11190e0592f542f3b680ac400c1ac016,LTL,0.426363
uuid-11190e0592f542f3b680ac400c1ac016,SCLC,0.318653
uuid-11190e0592f542f3b680ac400c1ac016,Regional TL,0.62377
uuid-11190e0592f542f3b680ac400c1ac016,RTL stated,0.300415
uuid-11190e0592f542f3b680ac400c1ac016,bladder,0.332516
uuid-cd69579249544871b4805b62ecac88b6,pembro,0.349908
uuid-cd69579249544871b4805b62ecac88b6,BMS,0.759588
uuid-cd69579249544871b4805b62ecac88b6,PDL1,0.319256
uuid-cd69579249544871b4805b62ecac88b6,trial,0.533509
uuid-cd69579249544871b4805b62ecac88b6,efficacy,0.395414
uuid-cd69579249544871b4805b62ecac88b6,commented,0.36509
uuid-cd69579249544871b4805b62ecac88b6,Merck,0.591192
uuid-cd69579249544871b4805b62ecac88b6,stated,0.328652
uuid-cd69579249544871b4805b62ecac88b6,OS,0.407426
uuid-cd69579249544871b4805b62ecac88b6,regards,0.331902
uuid-cd69579249544871b4805b62ecac88b6,data,0.794722
uuid-cd69579249544871b4805b62ecac88b6,expressed,0.392155
uuid-cd69579249544871b4805b62ecac88b6,clinical trials,0.31843
uuid-cd69579249544871b4805b62ecac88b6,indication,0.338231
uuid-cd69579249544871b4805b62ecac88b6,PFS,0.376772
uuid-cd69579249544871b4805b62ecac88b6,ORR,0.407486
uuid-cd69579249544871b4805b62ecac88b6,nivo and pembro,0.407763
uuid-cd69579249544871b4805b62ecac88b6,impressed,0.528132
uuid-cd69579249544871b4805b62ecac88b6,feels,0.3725
uuid-f749944ff0694afaa8afd0d89d990847,Nivo,0.605664
uuid-f749944ff0694afaa8afd0d89d990847,pembro,0.474297
uuid-f749944ff0694afaa8afd0d89d990847,1L,0.314709
uuid-f749944ff0694afaa8afd0d89d990847,PDL1,0.490122
uuid-f749944ff0694afaa8afd0d89d990847,efficacy,0.58265
uuid-f749944ff0694afaa8afd0d89d990847,chemo,0.355791
uuid-f749944ff0694afaa8afd0d89d990847,agents,0.302856
uuid-f749944ff0694afaa8afd0d89d990847,OS,0.417907
uuid-f749944ff0694afaa8afd0d89d990847,atezo,0.44135
uuid-f749944ff0694afaa8afd0d89d990847,monotherapy,0.309018
uuid-f749944ff0694afaa8afd0d89d990847,data,0.459995
uuid-f749944ff0694afaa8afd0d89d990847,PFS,0.470212
uuid-f749944ff0694afaa8afd0d89d990847,ORR,0.480106
uuid-f749944ff0694afaa8afd0d89d990847,nivo and pembro,0.58258
uuid-f749944ff0694afaa8afd0d89d990847,believes,0.428846
uuid-f749944ff0694afaa8afd0d89d990847,vs,0.431823
uuid-f749944ff0694afaa8afd0d89d990847,feels,0.478233
uuid-f749944ff0694afaa8afd0d89d990847,PDL1 expression,0.47634
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,patients,0.437725
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,PD-L1,0.341574
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,PD-L1 testing,0.492248
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,testing,0.470151
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,PDL1 testing,0.40518
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,NSCLC patients,0.415243
uuid-172aabfbd8514bd1ac52d7f9c59f8af3,lung cancer,0.334862
uuid-bbd78a06c1424941946684de8da7924e,therapy,0.343287
uuid-bbd78a06c1424941946684de8da7924e,treated,0.315935
uuid-bbd78a06c1424941946684de8da7924e,chemo,0.419953
uuid-bbd78a06c1424941946684de8da7924e,pts,0.429609
uuid-bbd78a06c1424941946684de8da7924e,monotherapy,0.350209
uuid-bbd78a06c1424941946684de8da7924e,treatment,0.326267
uuid-bbd78a06c1424941946684de8da7924e,response,0.454857
uuid-bbd78a06c1424941946684de8da7924e,PD1,0.525429
uuid-bbd78a06c1424941946684de8da7924e,progression,0.548992
uuid-bbd78a06c1424941946684de8da7924e,believes,0.42694
uuid-bbd78a06c1424941946684de8da7924e,chemotherapy,0.36084
uuid-bbd78a06c1424941946684de8da7924e,respond,0.380115
uuid-bbd78a06c1424941946684de8da7924e,immunotherapy,0.350029
uuid-8d1082b3700148238ac59703515ff6f1,Nivo,0.693348
uuid-8d1082b3700148238ac59703515ff6f1,pembro,0.394524
uuid-8d1082b3700148238ac59703515ff6f1,trial,0.383214
uuid-8d1082b3700148238ac59703515ff6f1,efficacy,0.592427
uuid-8d1082b3700148238ac59703515ff6f1,chemo,0.602727
uuid-8d1082b3700148238ac59703515ff6f1,Ipi,0.412282
uuid-8d1082b3700148238ac59703515ff6f1,OS,0.555834
uuid-8d1082b3700148238ac59703515ff6f1,monotherapy,0.342396
uuid-8d1082b3700148238ac59703515ff6f1,data,0.355323
uuid-8d1082b3700148238ac59703515ff6f1,PFS,0.607656
uuid-8d1082b3700148238ac59703515ff6f1,PD1,0.311464
uuid-8d1082b3700148238ac59703515ff6f1,ORR,0.5894
uuid-8d1082b3700148238ac59703515ff6f1,nivo and pembro,0.516705
uuid-8d1082b3700148238ac59703515ff6f1,believes,0.399515
uuid-8d1082b3700148238ac59703515ff6f1,chemotherapy,0.493539
uuid-8d1082b3700148238ac59703515ff6f1,vs,0.417124
uuid-8d1082b3700148238ac59703515ff6f1,feels,0.394293
uuid-8d1082b3700148238ac59703515ff6f1,PDL1 expression,0.323481
uuid-7da01e328f9141b4b20fe6b5bb0e9152,TL,0.359572
uuid-7da01e328f9141b4b20fe6b5bb0e9152,RTL,0.325659
uuid-7da01e328f9141b4b20fe6b5bb0e9152,BMS,0.510554
uuid-7da01e328f9141b4b20fe6b5bb0e9152,trial,0.437996
uuid-7da01e328f9141b4b20fe6b5bb0e9152,NTL,0.317643
uuid-7da01e328f9141b4b20fe6b5bb0e9152,discussed,0.316654
uuid-7da01e328f9141b4b20fe6b5bb0e9152,commented,0.55143
uuid-7da01e328f9141b4b20fe6b5bb0e9152,Merck,0.650194
uuid-7da01e328f9141b4b20fe6b5bb0e9152,regards,0.544601
uuid-7da01e328f9141b4b20fe6b5bb0e9152,data,0.495638
uuid-7da01e328f9141b4b20fe6b5bb0e9152,expressed,0.426202
uuid-7da01e328f9141b4b20fe6b5bb0e9152,mentioned,0.478167
uuid-7da01e328f9141b4b20fe6b5bb0e9152,ASCO,0.319219
uuid-7da01e328f9141b4b20fe6b5bb0e9152,impressed,0.369793
uuid-7da01e328f9141b4b20fe6b5bb0e9152,assay,0.379196
uuid-52be1a2bc1674073860fe2753a1fc0a9,Nivo,0.518985
uuid-52be1a2bc1674073860fe2753a1fc0a9,pembro,0.54719
uuid-52be1a2bc1674073860fe2753a1fc0a9,1L,0.418461
uuid-52be1a2bc1674073860fe2753a1fc0a9,PDL1,0.557221
uuid-52be1a2bc1674073860fe2753a1fc0a9,trial,0.394207
uuid-52be1a2bc1674073860fe2753a1fc0a9,efficacy,0.724246
uuid-52be1a2bc1674073860fe2753a1fc0a9,combination,0.36158
uuid-52be1a2bc1674073860fe2753a1fc0a9,chemo,0.431431
uuid-52be1a2bc1674073860fe2753a1fc0a9,2L,0.346737
uuid-52be1a2bc1674073860fe2753a1fc0a9,agents,0.496365
uuid-52be1a2bc1674073860fe2753a1fc0a9,Ipi,0.301858
uuid-52be1a2bc1674073860fe2753a1fc0a9,OS,0.490654
uuid-52be1a2bc1674073860fe2753a1fc0a9,atezo,0.521299
uuid-52be1a2bc1674073860fe2753a1fc0a9,monotherapy,0.437864
uuid-52be1a2bc1674073860fe2753a1fc0a9,data,0.521126
uuid-52be1a2bc1674073860fe2753a1fc0a9,combo,0.413322
uuid-52be1a2bc1674073860fe2753a1fc0a9,PFS,0.483047
uuid-52be1a2bc1674073860fe2753a1fc0a9,PD1,0.483949
uuid-52be1a2bc1674073860fe2753a1fc0a9,ORR,0.550453
uuid-52be1a2bc1674073860fe2753a1fc0a9,nivo and pembro,0.729637
uuid-52be1a2bc1674073860fe2753a1fc0a9,believes,0.574466
uuid-52be1a2bc1674073860fe2753a1fc0a9,vs,0.435035
uuid-52be1a2bc1674073860fe2753a1fc0a9,feels,0.402717
uuid-52be1a2bc1674073860fe2753a1fc0a9,PD-1,0.306694
uuid-52be1a2bc1674073860fe2753a1fc0a9,PDL1 expression,0.44968
uuid-edf996cb78ec429c8cff34492563a954,RTL,0.371293
uuid-edf996cb78ec429c8cff34492563a954,lung,0.302482
uuid-edf996cb78ec429c8cff34492563a954,discussed,0.500124
uuid-edf996cb78ec429c8cff34492563a954,melanoma,0.485356
uuid-edf996cb78ec429c8cff34492563a954,SCCHN,0.403486
uuid-edf996cb78ec429c8cff34492563a954,academic,0.586035
uuid-799f4b0735a14e9a9cfb55b554cf877e,PDL1,0.331091
uuid-799f4b0735a14e9a9cfb55b554cf877e,trial,0.353985
uuid-799f4b0735a14e9a9cfb55b554cf877e,discussed,0.373409
uuid-799f4b0735a14e9a9cfb55b554cf877e,OS,0.36782
uuid-799f4b0735a14e9a9cfb55b554cf877e,data,0.397503
uuid-799f4b0735a14e9a9cfb55b554cf877e,PFS,0.404861
uuid-799f4b0735a14e9a9cfb55b554cf877e,ORR,0.400835
uuid-799f4b0735a14e9a9cfb55b554cf877e,PDL1 expression,0.465854
uuid-799f4b0735a14e9a9cfb55b554cf877e,biomarker,0.416085
uuid-24e515d5560744d0a7f57503e7f3e7b2,pembro,0.373344
uuid-24e515d5560744d0a7f57503e7f3e7b2,BMS,0.498179
uuid-24e515d5560744d0a7f57503e7f3e7b2,PDL1,0.479202
uuid-24e515d5560744d0a7f57503e7f3e7b2,trial,0.450267
uuid-24e515d5560744d0a7f57503e7f3e7b2,efficacy,0.39469
uuid-24e515d5560744d0a7f57503e7f3e7b2,commented,0.311907
uuid-24e515d5560744d0a7f57503e7f3e7b2,Merck,0.360586
uuid-24e515d5560744d0a7f57503e7f3e7b2,OS,0.446545
uuid-24e515d5560744d0a7f57503e7f3e7b2,atezo,0.332812
uuid-24e515d5560744d0a7f57503e7f3e7b2,regards,0.469729
uuid-24e515d5560744d0a7f57503e7f3e7b2,data,0.587857
uuid-24e515d5560744d0a7f57503e7f3e7b2,indication,0.320295
uuid-24e515d5560744d0a7f57503e7f3e7b2,PFS,0.479564
uuid-24e515d5560744d0a7f57503e7f3e7b2,AI,0.310121
uuid-24e515d5560744d0a7f57503e7f3e7b2,ORR,0.451094
uuid-24e515d5560744d0a7f57503e7f3e7b2,nivo and pembro,0.559294
uuid-24e515d5560744d0a7f57503e7f3e7b2,impressed,0.334169
uuid-24e515d5560744d0a7f57503e7f3e7b2,feels,0.309608
uuid-24e515d5560744d0a7f57503e7f3e7b2,PDL1 expression,0.504901
uuid-24e515d5560744d0a7f57503e7f3e7b2,NCCN,0.342302
uuid-f99426aa9aab46508ae848a980cfd9fb,Nivo,0.562643
uuid-f99426aa9aab46508ae848a980cfd9fb,pembro,0.793244
uuid-f99426aa9aab46508ae848a980cfd9fb,1L,0.797036
uuid-f99426aa9aab46508ae848a980cfd9fb,PDL1,0.36396
uuid-f99426aa9aab46508ae848a980cfd9fb,RCC,0.34837
uuid-f99426aa9aab46508ae848a980cfd9fb,chemo,0.301855
uuid-f99426aa9aab46508ae848a980cfd9fb,2L,0.830326
uuid-f99426aa9aab46508ae848a980cfd9fb,agents,0.485978
uuid-f99426aa9aab46508ae848a980cfd9fb,approval,0.455381
uuid-f99426aa9aab46508ae848a980cfd9fb,atezo,0.784117
uuid-f99426aa9aab46508ae848a980cfd9fb,preferred,0.695584
uuid-f99426aa9aab46508ae848a980cfd9fb,monotherapy,0.550706
uuid-f99426aa9aab46508ae848a980cfd9fb,using nivo,0.611987
uuid-f99426aa9aab46508ae848a980cfd9fb,combo,0.341614
uuid-f99426aa9aab46508ae848a980cfd9fb,indication,0.482889
uuid-f99426aa9aab46508ae848a980cfd9fb,approved,0.620528
uuid-f99426aa9aab46508ae848a980cfd9fb,SCCHN,0.358735
uuid-f99426aa9aab46508ae848a980cfd9fb,nivo and pembro,0.494338
uuid-f99426aa9aab46508ae848a980cfd9fb,believes,0.322172
uuid-f99426aa9aab46508ae848a980cfd9fb,tumor types,0.317503
uuid-f99426aa9aab46508ae848a980cfd9fb,vs,0.3252
uuid-f99426aa9aab46508ae848a980cfd9fb,label,0.339892
uuid-f99426aa9aab46508ae848a980cfd9fb,feels,0.426756
uuid-f99426aa9aab46508ae848a980cfd9fb,RTL stated,0.442256
uuid-f99426aa9aab46508ae848a980cfd9fb,PDL1 expression,0.341755
uuid-f99426aa9aab46508ae848a980cfd9fb,option,0.596414
uuid-f99426aa9aab46508ae848a980cfd9fb,bladder,0.387006
uuid-eb8a5195d16a402db8343061e5ee582f,pembro,0.374804
uuid-eb8a5195d16a402db8343061e5ee582f,BMS,0.426756
uuid-eb8a5195d16a402db8343061e5ee582f,PDL1,0.607203
uuid-eb8a5195d16a402db8343061e5ee582f,trial,0.398908
uuid-eb8a5195d16a402db8343061e5ee582f,efficacy,0.702186
uuid-eb8a5195d16a402db8343061e5ee582f,Merck,0.342587
uuid-eb8a5195d16a402db8343061e5ee582f,OS,0.484157
uuid-eb8a5195d16a402db8343061e5ee582f,atezo,0.451528
uuid-eb8a5195d16a402db8343061e5ee582f,regards,0.434448
uuid-eb8a5195d16a402db8343061e5ee582f,data,0.726329
uuid-eb8a5195d16a402db8343061e5ee582f,expressed,0.361449
uuid-eb8a5195d16a402db8343061e5ee582f,PFS,0.496368
uuid-eb8a5195d16a402db8343061e5ee582f,ORR,0.566786
uuid-eb8a5195d16a402db8343061e5ee582f,nivo and pembro,0.661793
uuid-eb8a5195d16a402db8343061e5ee582f,believes,0.378047
uuid-eb8a5195d16a402db8343061e5ee582f,impressed,0.448458
uuid-eb8a5195d16a402db8343061e5ee582f,vs,0.333226
uuid-eb8a5195d16a402db8343061e5ee582f,TLs,0.435915
uuid-eb8a5195d16a402db8343061e5ee582f,feels,0.313333
uuid-eb8a5195d16a402db8343061e5ee582f,PDL1 expression,0.596645
uuid-eb8a5195d16a402db8343061e5ee582f,biomarker,0.424782
uuid-63fa851755ef4583a0c0d19339591ce0,efficacy,0.474655
uuid-63fa851755ef4583a0c0d19339591ce0,combination,0.426281
uuid-63fa851755ef4583a0c0d19339591ce0,agents,0.35091
uuid-63fa851755ef4583a0c0d19339591ce0,Ipi,0.329917
uuid-63fa851755ef4583a0c0d19339591ce0,atezo,0.382306
uuid-63fa851755ef4583a0c0d19339591ce0,combo,0.462101
uuid-63fa851755ef4583a0c0d19339591ce0,clinical trials,0.378673
uuid-63fa851755ef4583a0c0d19339591ce0,nivo and pembro,0.305082
uuid-63fa851755ef4583a0c0d19339591ce0,believes,0.365562
uuid-63fa851755ef4583a0c0d19339591ce0,TLs,0.583983
uuid-63fa851755ef4583a0c0d19339591ce0,feels,0.427242
uuid-6508f824c7514774998cd8fa930b1fc4,Nivo,0.44033
uuid-6508f824c7514774998cd8fa930b1fc4,pembro,0.648324
uuid-6508f824c7514774998cd8fa930b1fc4,1L,0.331471
uuid-6508f824c7514774998cd8fa930b1fc4,PDL1,0.431188
uuid-6508f824c7514774998cd8fa930b1fc4,trial,0.31265
uuid-6508f824c7514774998cd8fa930b1fc4,efficacy,0.720131
uuid-6508f824c7514774998cd8fa930b1fc4,2L,0.398678
uuid-6508f824c7514774998cd8fa930b1fc4,agents,0.418071
uuid-6508f824c7514774998cd8fa930b1fc4,OS,0.31805
uuid-6508f824c7514774998cd8fa930b1fc4,atezo,0.748061
uuid-6508f824c7514774998cd8fa930b1fc4,regards,0.342169
uuid-6508f824c7514774998cd8fa930b1fc4,data,0.551837
uuid-6508f824c7514774998cd8fa930b1fc4,indication,0.436837
uuid-6508f824c7514774998cd8fa930b1fc4,PFS,0.302601
uuid-6508f824c7514774998cd8fa930b1fc4,ORR,0.373067
uuid-6508f824c7514774998cd8fa930b1fc4,nivo and pembro,0.669607
uuid-6508f824c7514774998cd8fa930b1fc4,believes,0.353095
uuid-6508f824c7514774998cd8fa930b1fc4,vs,0.563916
uuid-6508f824c7514774998cd8fa930b1fc4,TLs,0.419835
uuid-6508f824c7514774998cd8fa930b1fc4,feels,0.346809
uuid-6508f824c7514774998cd8fa930b1fc4,PDL1 expression,0.451375
uuid-93c6df21ebba461fbef656025c7bc80a,RTL,0.406404
uuid-93c6df21ebba461fbef656025c7bc80a,NTL,0.341821
uuid-93c6df21ebba461fbef656025c7bc80a,discussed,0.573379
uuid-93c6df21ebba461fbef656025c7bc80a,melanoma,0.454328
uuid-93c6df21ebba461fbef656025c7bc80a,SCCHN,0.360381
uuid-93c6df21ebba461fbef656025c7bc80a,academic,0.575358
uuid-625c378b09f6471a9dd67a917d2c8ea5,TL,0.387222
uuid-625c378b09f6471a9dd67a917d2c8ea5,RTL,0.467288
uuid-625c378b09f6471a9dd67a917d2c8ea5,lung,0.433449
uuid-625c378b09f6471a9dd67a917d2c8ea5,NSCLC,0.564962
uuid-625c378b09f6471a9dd67a917d2c8ea5,1L,0.334148
uuid-625c378b09f6471a9dd67a917d2c8ea5,treated,0.35697
uuid-625c378b09f6471a9dd67a917d2c8ea5,NTL,0.34862
uuid-625c378b09f6471a9dd67a917d2c8ea5,melanoma,0.366809
uuid-625c378b09f6471a9dd67a917d2c8ea5,shared,0.340321
uuid-625c378b09f6471a9dd67a917d2c8ea5,RCC,0.593872
uuid-625c378b09f6471a9dd67a917d2c8ea5,TL stated,0.621966
uuid-625c378b09f6471a9dd67a917d2c8ea5,2L,0.318602
uuid-625c378b09f6471a9dd67a917d2c8ea5,stated,0.468208
uuid-625c378b09f6471a9dd67a917d2c8ea5,approval,0.385553
uuid-625c378b09f6471a9dd67a917d2c8ea5,PD-L1 testing,0.442645
uuid-625c378b09f6471a9dd67a917d2c8ea5,testing,0.425387
uuid-625c378b09f6471a9dd67a917d2c8ea5,using nivo,0.405658
uuid-625c378b09f6471a9dd67a917d2c8ea5,PDL1 testing,0.592538
uuid-625c378b09f6471a9dd67a917d2c8ea5,NSCLC patients,0.516368
uuid-625c378b09f6471a9dd67a917d2c8ea5,SCCHN,0.650693
uuid-625c378b09f6471a9dd67a917d2c8ea5,HCP,0.311299
uuid-625c378b09f6471a9dd67a917d2c8ea5,tumor types,0.406371
uuid-625c378b09f6471a9dd67a917d2c8ea5,LTL,0.384524
uuid-625c378b09f6471a9dd67a917d2c8ea5,TLs,0.406013
uuid-625c378b09f6471a9dd67a917d2c8ea5,academic,0.426834
uuid-625c378b09f6471a9dd67a917d2c8ea5,Regional TL,0.573568
uuid-625c378b09f6471a9dd67a917d2c8ea5,RTL stated,0.623986
uuid-625c378b09f6471a9dd67a917d2c8ea5,TL shared,0.520285
uuid-625c378b09f6471a9dd67a917d2c8ea5,bladder,0.429819
uuid-c64dacf3de2d4ceebb56dce6e61063aa,RTL,0.33031
uuid-c64dacf3de2d4ceebb56dce6e61063aa,RCC,0.346104
uuid-c64dacf3de2d4ceebb56dce6e61063aa,stated,0.375654
uuid-c64dacf3de2d4ceebb56dce6e61063aa,data,0.341397
uuid-c64dacf3de2d4ceebb56dce6e61063aa,SCCHN,0.300457
uuid-c64dacf3de2d4ceebb56dce6e61063aa,impressed,0.468674
uuid-c64dacf3de2d4ceebb56dce6e61063aa,TLs,0.324788
uuid-c64dacf3de2d4ceebb56dce6e61063aa,Regional TL,0.368
uuid-c64dacf3de2d4ceebb56dce6e61063aa,RTL stated,0.343969
uuid-c64dacf3de2d4ceebb56dce6e61063aa,bladder,0.399174
uuid-7ff59f766ebc4cc2a974d9121cdd4e16,RTL,0.31055
uuid-7ff59f766ebc4cc2a974d9121cdd4e16,trial,0.316727
uuid-9727a3d5675b4282a69617e678bf57fc,Nivo,0.310808
uuid-9727a3d5675b4282a69617e678bf57fc,patients,0.33102
uuid-9727a3d5675b4282a69617e678bf57fc,1L,0.428541
uuid-9727a3d5675b4282a69617e678bf57fc,regimen,0.497261
uuid-9727a3d5675b4282a69617e678bf57fc,chemo,0.452544
uuid-9727a3d5675b4282a69617e678bf57fc,2L,0.352866
uuid-9727a3d5675b4282a69617e678bf57fc,pts,0.457366
uuid-9727a3d5675b4282a69617e678bf57fc,OS,0.319942
uuid-9727a3d5675b4282a69617e678bf57fc,monotherapy,0.499502
uuid-9727a3d5675b4282a69617e678bf57fc,response,0.350397
uuid-9727a3d5675b4282a69617e678bf57fc,combo,0.398513
uuid-9727a3d5675b4282a69617e678bf57fc,progression,0.411599
uuid-9727a3d5675b4282a69617e678bf57fc,believes,0.309624
uuid-9727a3d5675b4282a69617e678bf57fc,respond,0.401344
uuid-9727a3d5675b4282a69617e678bf57fc,option,0.386701
uuid-44ce2b4d82ae4b92bf74ada0a7878662,therapy,0.331843
uuid-44ce2b4d82ae4b92bf74ada0a7878662,regimen,0.323906
uuid-44ce2b4d82ae4b92bf74ada0a7878662,treatment,0.502685
uuid-44ce2b4d82ae4b92bf74ada0a7878662,response,0.334779
uuid-44ce2b4d82ae4b92bf74ada0a7878662,PD1,0.339253
uuid-44ce2b4d82ae4b92bf74ada0a7878662,progression,0.40444
uuid-44ce2b4d82ae4b92bf74ada0a7878662,respond,0.34799
uuid-03d07c9b7f1c43dab91f95c0794cf8ca,lung,0.687976
uuid-03d07c9b7f1c43dab91f95c0794cf8ca,melanoma,0.558257
uuid-03d07c9b7f1c43dab91f95c0794cf8ca,AI,0.790916
uuid-03d07c9b7f1c43dab91f95c0794cf8ca,TL shared,0.410572
uuid-03d07c9b7f1c43dab91f95c0794cf8ca,NCCN,0.377942
uuid-7d1aca6c4b72408fb1462d6cf75768ff,PDL1,0.545533
uuid-7d1aca6c4b72408fb1462d6cf75768ff,trial,0.321613
uuid-7d1aca6c4b72408fb1462d6cf75768ff,efficacy,0.422337
uuid-7d1aca6c4b72408fb1462d6cf75768ff,OS,0.594788
uuid-7d1aca6c4b72408fb1462d6cf75768ff,regards,0.411189
uuid-7d1aca6c4b72408fb1462d6cf75768ff,data,0.435668
uuid-7d1aca6c4b72408fb1462d6cf75768ff,PFS,0.634588
uuid-7d1aca6c4b72408fb1462d6cf75768ff,AI,0.455984
uuid-7d1aca6c4b72408fb1462d6cf75768ff,ORR,0.585413
uuid-7d1aca6c4b72408fb1462d6cf75768ff,nivo and pembro,0.603577
uuid-7d1aca6c4b72408fb1462d6cf75768ff,believes,0.47046
uuid-7d1aca6c4b72408fb1462d6cf75768ff,PDL1 expression,0.513476
uuid-7d1aca6c4b72408fb1462d6cf75768ff,biomarker,0.38518
uuid-ff6edcc3124440b3b2f808418d98da5d,BMS,0.435001
uuid-ff6edcc3124440b3b2f808418d98da5d,trial,0.419263
uuid-ff6edcc3124440b3b2f808418d98da5d,efficacy,0.317127
uuid-ff6edcc3124440b3b2f808418d98da5d,combination,0.403552
uuid-ff6edcc3124440b3b2f808418d98da5d,OS,0.360171
uuid-ff6edcc3124440b3b2f808418d98da5d,data,0.542976
uuid-ff6edcc3124440b3b2f808418d98da5d,combo,0.387219
uuid-ff6edcc3124440b3b2f808418d98da5d,PFS,0.346152
uuid-ff6edcc3124440b3b2f808418d98da5d,ORR,0.378115
uuid-ff6edcc3124440b3b2f808418d98da5d,nivo and pembro,0.416883
uuid-ff6edcc3124440b3b2f808418d98da5d,believes,0.327217
uuid-ff6edcc3124440b3b2f808418d98da5d,impressed,0.33087
uuid-ff6edcc3124440b3b2f808418d98da5d,feels,0.508853
uuid-80f0df44db1b4592a412b3bc943651e9,BMS,0.313291
uuid-80f0df44db1b4592a412b3bc943651e9,lung,0.326412
uuid-80f0df44db1b4592a412b3bc943651e9,PDL1,0.496671
uuid-80f0df44db1b4592a412b3bc943651e9,trial,0.436244
uuid-80f0df44db1b4592a412b3bc943651e9,efficacy,0.397662
uuid-80f0df44db1b4592a412b3bc943651e9,OS,0.623518
uuid-80f0df44db1b4592a412b3bc943651e9,regards,0.486797
uuid-80f0df44db1b4592a412b3bc943651e9,data,0.498919
uuid-80f0df44db1b4592a412b3bc943651e9,expressed,0.314064
uuid-80f0df44db1b4592a412b3bc943651e9,PFS,0.704159
uuid-80f0df44db1b4592a412b3bc943651e9,AI,0.568575
uuid-80f0df44db1b4592a412b3bc943651e9,ORR,0.612104
uuid-80f0df44db1b4592a412b3bc943651e9,nivo and pembro,0.564902
uuid-80f0df44db1b4592a412b3bc943651e9,believes,0.31146
uuid-80f0df44db1b4592a412b3bc943651e9,PDL1 expression,0.522525
uuid-80f0df44db1b4592a412b3bc943651e9,biomarker,0.384518
uuid-82357b21c7574c648579037f29dc5aea,TL,0.448848
uuid-82357b21c7574c648579037f29dc5aea,PDL1,0.513185
uuid-82357b21c7574c648579037f29dc5aea,Merck,0.309457
uuid-82357b21c7574c648579037f29dc5aea,PD-L1,0.671414
uuid-82357b21c7574c648579037f29dc5aea,PD-L1 testing,0.746666
uuid-82357b21c7574c648579037f29dc5aea,testing,0.680033
uuid-82357b21c7574c648579037f29dc5aea,PDL1 testing,0.454908
uuid-82357b21c7574c648579037f29dc5aea,NSCLC patients,0.41201
uuid-82357b21c7574c648579037f29dc5aea,assay,0.623519
uuid-82357b21c7574c648579037f29dc5aea,PDL1 expression,0.331144
uuid-82357b21c7574c648579037f29dc5aea,biomarker,0.437919
uuid-c2d010eecc7b45949828a467f4df8987,lung,0.389908
uuid-c2d010eecc7b45949828a467f4df8987,NSCLC,0.358324
uuid-c2d010eecc7b45949828a467f4df8987,PDL1,0.383768
uuid-c2d010eecc7b45949828a467f4df8987,OS,0.483113
uuid-c2d010eecc7b45949828a467f4df8987,regards,0.339401
uuid-c2d010eecc7b45949828a467f4df8987,PFS,0.520464
uuid-c2d010eecc7b45949828a467f4df8987,AI,0.678312
uuid-c2d010eecc7b45949828a467f4df8987,ORR,0.454658
uuid-c2d010eecc7b45949828a467f4df8987,nivo and pembro,0.456438
uuid-c2d010eecc7b45949828a467f4df8987,PDL1 expression,0.327729
uuid-c2d010eecc7b45949828a467f4df8987,NCCN,0.40896
uuid-23bccdef1c9f43f6ac83a377d4933872,TL,0.317301
uuid-23bccdef1c9f43f6ac83a377d4933872,RTL,0.433017
uuid-23bccdef1c9f43f6ac83a377d4933872,BMS,0.304891
uuid-23bccdef1c9f43f6ac83a377d4933872,NTL,0.348289
uuid-23bccdef1c9f43f6ac83a377d4933872,discussed,0.575082
uuid-23bccdef1c9f43f6ac83a377d4933872,shared,0.301067
uuid-23bccdef1c9f43f6ac83a377d4933872,commented,0.513143
uuid-23bccdef1c9f43f6ac83a377d4933872,stated,0.350581
uuid-23bccdef1c9f43f6ac83a377d4933872,physicians,0.319468
uuid-23bccdef1c9f43f6ac83a377d4933872,regards,0.311743
uuid-23bccdef1c9f43f6ac83a377d4933872,data,0.551691
uuid-23bccdef1c9f43f6ac83a377d4933872,ASCO,0.393622
uuid-23bccdef1c9f43f6ac83a377d4933872,impressed,0.449638
uuid-23bccdef1c9f43f6ac83a377d4933872,indicated,0.308628
uuid-23bccdef1c9f43f6ac83a377d4933872,LTL,0.435635
uuid-23bccdef1c9f43f6ac83a377d4933872,TLs,0.524871
uuid-23bccdef1c9f43f6ac83a377d4933872,clinical,0.336349
uuid-23bccdef1c9f43f6ac83a377d4933872,academic,0.427847
uuid-23bccdef1c9f43f6ac83a377d4933872,Regional TL,0.498682
uuid-203243ad09fe4ccbafe05c694fb2801b,Opdivo,0.383874
uuid-203243ad09fe4ccbafe05c694fb2801b,approved,0.408065
uuid-203243ad09fe4ccbafe05c694fb2801b,label,0.3643
uuid-203243ad09fe4ccbafe05c694fb2801b,flat dosing,0.425819
uuid-befcd1e7563149dc838362cdca92b50a,oncology,0.389793
uuid-befcd1e7563149dc838362cdca92b50a,oncologist,0.34992
uuid-befcd1e7563149dc838362cdca92b50a,indicated,0.41867
uuid-befcd1e7563149dc838362cdca92b50a,Regional TL,0.333109
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,RTL,0.345859
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,nivolumab,0.445349
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,NTL,0.404346
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,mentioned,0.345963
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,cHL,0.426992
uuid-a06b1d59ff0c4b9f8cf96a6035f729ad,Regional TL,0.373655
uuid-f0bfaa3ac3a84bd3a48e26b17c310fef,Nivo,0.300513
uuid-f0bfaa3ac3a84bd3a48e26b17c310fef,nivolumab,0.536724
uuid-f0bfaa3ac3a84bd3a48e26b17c310fef,combination,0.35088
uuid-f0bfaa3ac3a84bd3a48e26b17c310fef,cHL,0.357823
uuid-f0bfaa3ac3a84bd3a48e26b17c310fef,chemotherapy,0.366298
uuid-aff27d0752824639a6042eee3750aba2,dose,0.335468
uuid-aff27d0752824639a6042eee3750aba2,toxicity,0.580765
uuid-aff27d0752824639a6042eee3750aba2,response,0.327778
uuid-0549ddc308104d5cac132ded2ab5f8ff,Nivo,0.349613
uuid-0549ddc308104d5cac132ded2ab5f8ff,patients,0.781316
uuid-0549ddc308104d5cac132ded2ab5f8ff,Opdivo,0.393595
uuid-0549ddc308104d5cac132ded2ab5f8ff,therapy,0.754501
uuid-0549ddc308104d5cac132ded2ab5f8ff,nivolumab,0.535405
uuid-0549ddc308104d5cac132ded2ab5f8ff,regimen,0.444394
uuid-0549ddc308104d5cac132ded2ab5f8ff,treated,0.538858
uuid-0549ddc308104d5cac132ded2ab5f8ff,chemo,0.357122
uuid-0549ddc308104d5cac132ded2ab5f8ff,pts,0.533769
uuid-0549ddc308104d5cac132ded2ab5f8ff,monotherapy,0.327182
uuid-0549ddc308104d5cac132ded2ab5f8ff,treatment,0.688689
uuid-0549ddc308104d5cac132ded2ab5f8ff,response,0.592239
uuid-0549ddc308104d5cac132ded2ab5f8ff,PD1,0.441958
uuid-0549ddc308104d5cac132ded2ab5f8ff,cHL,0.564619
uuid-0549ddc308104d5cac132ded2ab5f8ff,progression,0.739083
uuid-0549ddc308104d5cac132ded2ab5f8ff,chemotherapy,0.440013
uuid-0549ddc308104d5cac132ded2ab5f8ff,respond,0.570014
uuid-ec38751dc49848908de3da861f25e8c2,patients,0.524055
uuid-ec38751dc49848908de3da861f25e8c2,therapy,0.365445
uuid-ec38751dc49848908de3da861f25e8c2,toxicity,0.302864
uuid-ec38751dc49848908de3da861f25e8c2,regimen,0.418533
uuid-ec38751dc49848908de3da861f25e8c2,treated,0.534772
uuid-ec38751dc49848908de3da861f25e8c2,chemo,0.327037
uuid-ec38751dc49848908de3da861f25e8c2,pts,0.575764
uuid-ec38751dc49848908de3da861f25e8c2,treatment,0.515223
uuid-ec38751dc49848908de3da861f25e8c2,response,0.718876
uuid-ec38751dc49848908de3da861f25e8c2,PD1,0.381554
uuid-ec38751dc49848908de3da861f25e8c2,progression,0.764643
uuid-ec38751dc49848908de3da861f25e8c2,respond,0.585809
uuid-c3822956e8bf41a9866ce0363545be09,RTL,0.41249
uuid-c3822956e8bf41a9866ce0363545be09,BMS,0.575314
uuid-c3822956e8bf41a9866ce0363545be09,trial,0.604304
uuid-c3822956e8bf41a9866ce0363545be09,efficacy,0.339419
uuid-c3822956e8bf41a9866ce0363545be09,NTL,0.311005
uuid-c3822956e8bf41a9866ce0363545be09,commented,0.453683
uuid-c3822956e8bf41a9866ce0363545be09,Merck,0.411265
uuid-c3822956e8bf41a9866ce0363545be09,OS,0.325311
uuid-c3822956e8bf41a9866ce0363545be09,regards,0.465985
uuid-c3822956e8bf41a9866ce0363545be09,data,0.503317
uuid-c3822956e8bf41a9866ce0363545be09,expressed,0.390952
uuid-c3822956e8bf41a9866ce0363545be09,PFS,0.337418
uuid-c3822956e8bf41a9866ce0363545be09,ORR,0.383493
uuid-c3822956e8bf41a9866ce0363545be09,nivo and pembro,0.316283
uuid-c3822956e8bf41a9866ce0363545be09,impressed,0.453348
uuid-c3822956e8bf41a9866ce0363545be09,LTL,0.303209
uuid-c3822956e8bf41a9866ce0363545be09,TLs,0.425666
uuid-bab9f3844f084be98a62e9862577db1e,RTL,0.400747
uuid-bab9f3844f084be98a62e9862577db1e,lung,0.558395
uuid-bab9f3844f084be98a62e9862577db1e,NTL,0.407327
uuid-bab9f3844f084be98a62e9862577db1e,melanoma,0.425464
uuid-bab9f3844f084be98a62e9862577db1e,commented,0.498574
uuid-bab9f3844f084be98a62e9862577db1e,RCC,0.439037
uuid-bab9f3844f084be98a62e9862577db1e,TL stated,0.33145
uuid-bab9f3844f084be98a62e9862577db1e,stated,0.474884
uuid-bab9f3844f084be98a62e9862577db1e,data,0.314535
uuid-bab9f3844f084be98a62e9862577db1e,expressed,0.348329
uuid-bab9f3844f084be98a62e9862577db1e,AI,0.418222
uuid-bab9f3844f084be98a62e9862577db1e,SCCHN,0.557228
uuid-bab9f3844f084be98a62e9862577db1e,ASCO,0.402232
uuid-bab9f3844f084be98a62e9862577db1e,impressed,0.369265
uuid-bab9f3844f084be98a62e9862577db1e,TLs,0.472423
uuid-bab9f3844f084be98a62e9862577db1e,SCLC,0.327175
uuid-bab9f3844f084be98a62e9862577db1e,Regional TL,0.564848
uuid-bab9f3844f084be98a62e9862577db1e,TL shared,0.366209
uuid-bab9f3844f084be98a62e9862577db1e,NCCN,0.617196
uuid-62862efb5d11456680192a7438353511,Nivo,0.313989
uuid-62862efb5d11456680192a7438353511,patients,0.754757
uuid-62862efb5d11456680192a7438353511,therapy,0.711163
uuid-62862efb5d11456680192a7438353511,toxicity,0.308882
uuid-62862efb5d11456680192a7438353511,regimen,0.536761
uuid-62862efb5d11456680192a7438353511,treated,0.387162
uuid-62862efb5d11456680192a7438353511,chemo,0.591958
uuid-62862efb5d11456680192a7438353511,pts,0.576155
uuid-62862efb5d11456680192a7438353511,monotherapy,0.44219
uuid-62862efb5d11456680192a7438353511,treatment,0.669008
uuid-62862efb5d11456680192a7438353511,response,0.62554
uuid-62862efb5d11456680192a7438353511,PD1,0.467023
uuid-62862efb5d11456680192a7438353511,progression,0.785961
uuid-62862efb5d11456680192a7438353511,chemotherapy,0.597361
uuid-62862efb5d11456680192a7438353511,respond,0.651695
uuid-62862efb5d11456680192a7438353511,option,0.367349
uuid-e766a50a18aa41f69c0eac81dd090672,Nivo,0.35805
uuid-e766a50a18aa41f69c0eac81dd090672,pembro,0.389262
uuid-e766a50a18aa41f69c0eac81dd090672,1L,0.492976
uuid-e766a50a18aa41f69c0eac81dd090672,efficacy,0.415281
uuid-e766a50a18aa41f69c0eac81dd090672,combination,0.459567
uuid-e766a50a18aa41f69c0eac81dd090672,chemo,0.425448
uuid-e766a50a18aa41f69c0eac81dd090672,2L,0.544065
uuid-e766a50a18aa41f69c0eac81dd090672,agents,0.867082
uuid-e766a50a18aa41f69c0eac81dd090672,atezo,0.476107
uuid-e766a50a18aa41f69c0eac81dd090672,preferred,0.581163
uuid-e766a50a18aa41f69c0eac81dd090672,monotherapy,0.557067
uuid-e766a50a18aa41f69c0eac81dd090672,combo,0.435498
uuid-e766a50a18aa41f69c0eac81dd090672,indication,0.352124
uuid-e766a50a18aa41f69c0eac81dd090672,PD1,0.432331
uuid-e766a50a18aa41f69c0eac81dd090672,approved,0.355533
uuid-e766a50a18aa41f69c0eac81dd090672,nivo and pembro,0.506117
uuid-e766a50a18aa41f69c0eac81dd090672,believes,0.506723
uuid-e766a50a18aa41f69c0eac81dd090672,chemotherapy,0.348802
uuid-e766a50a18aa41f69c0eac81dd090672,feels,0.387392
uuid-e766a50a18aa41f69c0eac81dd090672,PD-1,0.46891
uuid-e766a50a18aa41f69c0eac81dd090672,option,0.607323
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,RTL,0.654474
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,trial,0.541255
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,NTL,0.564688
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,shared,0.304338
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,commented,0.49454
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,stated,0.53273
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,data,0.499826
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,expressed,0.421122
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,mentioned,0.404225
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,ORR,0.303386
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,SCCHN,0.364606
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,ASCO,0.437715
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,impressed,0.567577
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,LTL,0.421167
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,TLs,0.316411
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,SCLC,0.307843
uuid-15d80cb50279485eb6bdeaffbe4c3ee3,Regional TL,0.583676
uuid-698a3d8f6ea848df969d28bee559a688,lung,0.403043
uuid-698a3d8f6ea848df969d28bee559a688,discussed,0.33032
uuid-698a3d8f6ea848df969d28bee559a688,melanoma,0.313894
uuid-698a3d8f6ea848df969d28bee559a688,TL stated,0.451632
uuid-698a3d8f6ea848df969d28bee559a688,academic,0.370293
uuid-698a3d8f6ea848df969d28bee559a688,TL shared,0.319704
uuid-01d89961690b44ba8cc113782241c36e,toxicity,0.320083
uuid-01d89961690b44ba8cc113782241c36e,physicians,0.439713
uuid-01d89961690b44ba8cc113782241c36e,ASCO,0.310817
uuid-01d89961690b44ba8cc113782241c36e,respond,0.302211
uuid-6fe76800530c4467bb1d8e26f802eb46,Nivo,0.347784
uuid-6fe76800530c4467bb1d8e26f802eb46,therapy,0.415281
uuid-6fe76800530c4467bb1d8e26f802eb46,nivolumab,0.352244
uuid-6fe76800530c4467bb1d8e26f802eb46,using nivo,0.312014
uuid-6fe76800530c4467bb1d8e26f802eb46,cHL,0.688234
uuid-d91d99da543d4e33818915a26f594e63,Nivo,0.405446
uuid-d91d99da543d4e33818915a26f594e63,patients,0.734439
uuid-d91d99da543d4e33818915a26f594e63,Opdivo,0.477599
uuid-d91d99da543d4e33818915a26f594e63,therapy,0.570805
uuid-d91d99da543d4e33818915a26f594e63,nivolumab,0.481795
uuid-d91d99da543d4e33818915a26f594e63,regimen,0.351981
uuid-d91d99da543d4e33818915a26f594e63,treated,0.427995
uuid-d91d99da543d4e33818915a26f594e63,pts,0.386436
uuid-d91d99da543d4e33818915a26f594e63,treatment,0.520944
uuid-d91d99da543d4e33818915a26f594e63,using nivo,0.352514
uuid-d91d99da543d4e33818915a26f594e63,cHL,0.602659
uuid-d91d99da543d4e33818915a26f594e63,progression,0.475297
uuid-d91d99da543d4e33818915a26f594e63,chemotherapy,0.33535
uuid-d91d99da543d4e33818915a26f594e63,respond,0.315189
uuid-b69d316dbb344a08a1e7f636e98ba45c,patients,0.676958
uuid-b69d316dbb344a08a1e7f636e98ba45c,Opdivo,0.373609
uuid-b69d316dbb344a08a1e7f636e98ba45c,therapy,0.518723
uuid-b69d316dbb344a08a1e7f636e98ba45c,nivolumab,0.416649
uuid-b69d316dbb344a08a1e7f636e98ba45c,1L,0.355165
uuid-b69d316dbb344a08a1e7f636e98ba45c,toxicity,0.319451
uuid-b69d316dbb344a08a1e7f636e98ba45c,regimen,0.579826
uuid-b69d316dbb344a08a1e7f636e98ba45c,treated,0.366942
uuid-b69d316dbb344a08a1e7f636e98ba45c,combination,0.310274
uuid-b69d316dbb344a08a1e7f636e98ba45c,chemo,0.406799
uuid-b69d316dbb344a08a1e7f636e98ba45c,2L,0.373065
uuid-b69d316dbb344a08a1e7f636e98ba45c,pts,0.522983
uuid-b69d316dbb344a08a1e7f636e98ba45c,preferred,0.404282
uuid-b69d316dbb344a08a1e7f636e98ba45c,monotherapy,0.573013
uuid-b69d316dbb344a08a1e7f636e98ba45c,treatment,0.568917
uuid-b69d316dbb344a08a1e7f636e98ba45c,using nivo,0.342832
uuid-b69d316dbb344a08a1e7f636e98ba45c,response,0.360709
uuid-b69d316dbb344a08a1e7f636e98ba45c,combo,0.335707
uuid-b69d316dbb344a08a1e7f636e98ba45c,PD1,0.378307
uuid-b69d316dbb344a08a1e7f636e98ba45c,progression,0.649265
uuid-b69d316dbb344a08a1e7f636e98ba45c,chemotherapy,0.383552
uuid-b69d316dbb344a08a1e7f636e98ba45c,respond,0.516649
uuid-b69d316dbb344a08a1e7f636e98ba45c,feels,0.343122
uuid-b69d316dbb344a08a1e7f636e98ba45c,option,0.569813
uuid-39dc80b7ac9048ed9b56adf31eb843ed,1L,0.420523
uuid-39dc80b7ac9048ed9b56adf31eb843ed,PDL1,0.339212
uuid-39dc80b7ac9048ed9b56adf31eb843ed,chemo,0.386931
uuid-39dc80b7ac9048ed9b56adf31eb843ed,tumor,0.380807
uuid-39dc80b7ac9048ed9b56adf31eb843ed,2L,0.304057
uuid-39dc80b7ac9048ed9b56adf31eb843ed,pts,0.341599
uuid-39dc80b7ac9048ed9b56adf31eb843ed,monotherapy,0.312335
uuid-39dc80b7ac9048ed9b56adf31eb843ed,believes,0.392471
uuid-39dc80b7ac9048ed9b56adf31eb843ed,feels,0.338093
uuid-39dc80b7ac9048ed9b56adf31eb843ed,option,0.434472
uuid-3442d6705ba044f78da55dd1b460590a,TL stated,0.408978
uuid-3442d6705ba044f78da55dd1b460590a,PD-L1,0.526956
uuid-3442d6705ba044f78da55dd1b460590a,PD-L1 testing,0.5354
uuid-3442d6705ba044f78da55dd1b460590a,testing,0.738292
uuid-3442d6705ba044f78da55dd1b460590a,PDL1 testing,0.712368
uuid-3442d6705ba044f78da55dd1b460590a,NSCLC patients,0.71105
uuid-3442d6705ba044f78da55dd1b460590a,tumor types,0.45336
uuid-3442d6705ba044f78da55dd1b460590a,biomarker,0.343366
uuid-36f8f63a75824226b8d86cc849767b91,PDL1,0.362401
uuid-36f8f63a75824226b8d86cc849767b91,PD-L1,0.372045
uuid-36f8f63a75824226b8d86cc849767b91,testing,0.34618
uuid-36f8f63a75824226b8d86cc849767b91,mentioned,0.313555
uuid-36f8f63a75824226b8d86cc849767b91,assay,0.300596
uuid-36f8f63a75824226b8d86cc849767b91,biomarker,0.32934
uuid-c264f964d5084683a62c4aea8f54eb9d,TL,0.616741
uuid-c264f964d5084683a62c4aea8f54eb9d,TL stated,0.375269
uuid-c264f964d5084683a62c4aea8f54eb9d,institution,0.468698
uuid-c264f964d5084683a62c4aea8f54eb9d,PD-L1,0.710782
uuid-c264f964d5084683a62c4aea8f54eb9d,PD-L1 testing,0.945151
uuid-c264f964d5084683a62c4aea8f54eb9d,testing,0.82037
uuid-c264f964d5084683a62c4aea8f54eb9d,PDL1 testing,0.668093
uuid-c264f964d5084683a62c4aea8f54eb9d,NSCLC patients,0.552795
uuid-c264f964d5084683a62c4aea8f54eb9d,assay,0.678671
uuid-c264f964d5084683a62c4aea8f54eb9d,biomarker,0.327869
uuid-66823d03956c4800a63669c2b5a18e4e,toxicity,0.431865
uuid-91653407cf2541c9bd34d62ef7d18bf2,physicians,0.383878
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,toxicity,0.309099
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,efficacy,0.375319
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,regimen,0.403768
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,melanoma,0.318542
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,RCC,0.31367
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,combination,0.627573
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,chemo,0.374691
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,IO,0.353526
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,agents,0.348918
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,monotherapy,0.478225
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,response,0.350105
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,combo,0.630193
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,PD1,0.460268
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,believes,0.435892
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,chemotherapy,0.334082
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,impressed,0.363996
uuid-8e18b3f5fe0b404bad3e00bcdc7a3b1c,SCLC,0.335359
uuid-9522e6b2f4554b54b36c64cb73df8278,NSCLC,0.341095
uuid-9522e6b2f4554b54b36c64cb73df8278,1L,0.392826
uuid-9522e6b2f4554b54b36c64cb73df8278,RCC,0.332813
uuid-9522e6b2f4554b54b36c64cb73df8278,TL stated,0.397059
uuid-9522e6b2f4554b54b36c64cb73df8278,IO,0.363124
uuid-9522e6b2f4554b54b36c64cb73df8278,preferred,0.312435
uuid-9522e6b2f4554b54b36c64cb73df8278,testing,0.301175
uuid-9522e6b2f4554b54b36c64cb73df8278,PDL1 testing,0.503583
uuid-9522e6b2f4554b54b36c64cb73df8278,NSCLC patients,0.493353
uuid-9522e6b2f4554b54b36c64cb73df8278,lung cancer,0.347269
uuid-9522e6b2f4554b54b36c64cb73df8278,tumor types,0.402276
uuid-9522e6b2f4554b54b36c64cb73df8278,PD-1,0.436471
uuid-9522e6b2f4554b54b36c64cb73df8278,RTL stated,0.356294
uuid-e6f5498df05d4cb9920b3078168f9a8d,patients,0.357306
uuid-e6f5498df05d4cb9920b3078168f9a8d,nivolumab,0.403921
uuid-e6f5498df05d4cb9920b3078168f9a8d,treated,0.33237
uuid-e6f5498df05d4cb9920b3078168f9a8d,commented,0.338217
uuid-e6f5498df05d4cb9920b3078168f9a8d,RCC,0.358801
uuid-e6f5498df05d4cb9920b3078168f9a8d,pts,0.360378
uuid-e6f5498df05d4cb9920b3078168f9a8d,using nivo,0.440463
uuid-e6f5498df05d4cb9920b3078168f9a8d,mentioned,0.337448
uuid-e6f5498df05d4cb9920b3078168f9a8d,SCCHN,0.414758
uuid-e6f5498df05d4cb9920b3078168f9a8d,ASCO,0.35034
uuid-e6f5498df05d4cb9920b3078168f9a8d,impressed,0.435527
uuid-e6f5498df05d4cb9920b3078168f9a8d,SCLC,0.764872
uuid-e6f5498df05d4cb9920b3078168f9a8d,Regional TL,0.352484
uuid-e6f5498df05d4cb9920b3078168f9a8d,RTL stated,0.38383
uuid-e6f5498df05d4cb9920b3078168f9a8d,TL shared,0.316316
uuid-e6f5498df05d4cb9920b3078168f9a8d,bladder,0.366228
uuid-603c380c323d43bf8b968f73d8e6eb8e,toxicity,0.627841
uuid-603c380c323d43bf8b968f73d8e6eb8e,regimen,0.46077
uuid-603c380c323d43bf8b968f73d8e6eb8e,combination,0.461625
uuid-603c380c323d43bf8b968f73d8e6eb8e,agents,0.334504
uuid-603c380c323d43bf8b968f73d8e6eb8e,combo,0.393865
uuid-677faeffc23f492c8a833ce21331b988,patients,0.697755
uuid-677faeffc23f492c8a833ce21331b988,Opdivo,0.338748
uuid-677faeffc23f492c8a833ce21331b988,therapy,0.55005
uuid-677faeffc23f492c8a833ce21331b988,nivolumab,0.51205
uuid-677faeffc23f492c8a833ce21331b988,regimen,0.552207
uuid-677faeffc23f492c8a833ce21331b988,treated,0.597
uuid-677faeffc23f492c8a833ce21331b988,melanoma,0.483571
uuid-677faeffc23f492c8a833ce21331b988,RCC,0.379649
uuid-677faeffc23f492c8a833ce21331b988,pts,0.541358
uuid-677faeffc23f492c8a833ce21331b988,monotherapy,0.364435
uuid-677faeffc23f492c8a833ce21331b988,treatment,0.628592
uuid-677faeffc23f492c8a833ce21331b988,using nivo,0.302632
uuid-677faeffc23f492c8a833ce21331b988,response,0.490524
uuid-677faeffc23f492c8a833ce21331b988,PD1,0.390156
uuid-677faeffc23f492c8a833ce21331b988,cHL,0.391466
uuid-677faeffc23f492c8a833ce21331b988,progression,0.680854
uuid-677faeffc23f492c8a833ce21331b988,chemotherapy,0.354025
uuid-677faeffc23f492c8a833ce21331b988,respond,0.459182
uuid-677faeffc23f492c8a833ce21331b988,RTL stated,0.354789
uuid-677faeffc23f492c8a833ce21331b988,TL shared,0.464943
uuid-b7e8cfe4355a4be8a60296e4ed557c04,Nivo,0.372373
uuid-b7e8cfe4355a4be8a60296e4ed557c04,pembro,0.304368
uuid-b7e8cfe4355a4be8a60296e4ed557c04,dose,0.672801
uuid-b7e8cfe4355a4be8a60296e4ed557c04,toxicity,0.503744
uuid-b7e8cfe4355a4be8a60296e4ed557c04,efficacy,0.462516
uuid-b7e8cfe4355a4be8a60296e4ed557c04,regimen,0.422655
uuid-b7e8cfe4355a4be8a60296e4ed557c04,combination,0.373977
uuid-b7e8cfe4355a4be8a60296e4ed557c04,Ipi,0.705479
uuid-b7e8cfe4355a4be8a60296e4ed557c04,combo,0.418936
uuid-b7e8cfe4355a4be8a60296e4ed557c04,vs,0.455539
uuid-b7e8cfe4355a4be8a60296e4ed557c04,flat dosing,0.500428
uuid-b41eb647d365469db17583d06fa85480,patients,0.614118
uuid-b41eb647d365469db17583d06fa85480,toxicity,0.390764
uuid-b41eb647d365469db17583d06fa85480,regimen,0.468544
uuid-b41eb647d365469db17583d06fa85480,treated,0.460998
uuid-b41eb647d365469db17583d06fa85480,melanoma,0.306882
uuid-b41eb647d365469db17583d06fa85480,treatment,0.53511
uuid-b41eb647d365469db17583d06fa85480,progression,0.389186
uuid-b41eb647d365469db17583d06fa85480,TL shared,0.308764
uuid-855b002437ad4de981364e6ceff7b0e9,RTL,0.365165
uuid-855b002437ad4de981364e6ceff7b0e9,trial,0.348764
uuid-855b002437ad4de981364e6ceff7b0e9,NTL,0.38944
uuid-855b002437ad4de981364e6ceff7b0e9,OS,0.364762
uuid-855b002437ad4de981364e6ceff7b0e9,data,0.500295
uuid-855b002437ad4de981364e6ceff7b0e9,mentioned,0.5769
uuid-855b002437ad4de981364e6ceff7b0e9,PFS,0.43437
uuid-855b002437ad4de981364e6ceff7b0e9,ORR,0.327958
uuid-855b002437ad4de981364e6ceff7b0e9,cHL,0.491352
uuid-855b002437ad4de981364e6ceff7b0e9,impressed,0.359732
uuid-855b002437ad4de981364e6ceff7b0e9,LTL,0.345324
uuid-0b0f370bcbe24f08b863d117b3282bf5,Nivo,0.4281
uuid-0b0f370bcbe24f08b863d117b3282bf5,patients,0.582942
uuid-0b0f370bcbe24f08b863d117b3282bf5,Opdivo,0.351826
uuid-0b0f370bcbe24f08b863d117b3282bf5,therapy,0.541168
uuid-0b0f370bcbe24f08b863d117b3282bf5,dose,0.412407
uuid-0b0f370bcbe24f08b863d117b3282bf5,nivolumab,0.447184
uuid-0b0f370bcbe24f08b863d117b3282bf5,regimen,0.457084
uuid-0b0f370bcbe24f08b863d117b3282bf5,combination,0.348115
uuid-0b0f370bcbe24f08b863d117b3282bf5,chemo,0.38255
uuid-0b0f370bcbe24f08b863d117b3282bf5,pts,0.378616
uuid-0b0f370bcbe24f08b863d117b3282bf5,Ipi,0.368363
uuid-0b0f370bcbe24f08b863d117b3282bf5,monotherapy,0.309825
uuid-0b0f370bcbe24f08b863d117b3282bf5,treatment,0.450611
uuid-0b0f370bcbe24f08b863d117b3282bf5,response,0.356587
uuid-0b0f370bcbe24f08b863d117b3282bf5,PD1,0.318448
uuid-0b0f370bcbe24f08b863d117b3282bf5,cHL,0.360243
uuid-0b0f370bcbe24f08b863d117b3282bf5,progression,0.447974
uuid-0b0f370bcbe24f08b863d117b3282bf5,chemotherapy,0.468005
uuid-0b0f370bcbe24f08b863d117b3282bf5,respond,0.308053
uuid-8a77860edeb14b1592cc331a0a62bb59,RTL,0.344667
uuid-8a77860edeb14b1592cc331a0a62bb59,BMS,0.611634
uuid-8a77860edeb14b1592cc331a0a62bb59,trial,0.618805
uuid-8a77860edeb14b1592cc331a0a62bb59,discussed,0.324871
uuid-8a77860edeb14b1592cc331a0a62bb59,commented,0.508243
uuid-8a77860edeb14b1592cc331a0a62bb59,Merck,0.503637
uuid-8a77860edeb14b1592cc331a0a62bb59,stated,0.33301
uuid-8a77860edeb14b1592cc331a0a62bb59,OS,0.443993
uuid-8a77860edeb14b1592cc331a0a62bb59,regards,0.373878
uuid-8a77860edeb14b1592cc331a0a62bb59,data,0.816976
uuid-8a77860edeb14b1592cc331a0a62bb59,expressed,0.342986
uuid-8a77860edeb14b1592cc331a0a62bb59,mentioned,0.365942
uuid-8a77860edeb14b1592cc331a0a62bb59,indication,0.33188
uuid-8a77860edeb14b1592cc331a0a62bb59,PFS,0.418526
uuid-8a77860edeb14b1592cc331a0a62bb59,ORR,0.467072
uuid-8a77860edeb14b1592cc331a0a62bb59,nivo and pembro,0.317879
uuid-8a77860edeb14b1592cc331a0a62bb59,ASCO,0.380755
uuid-8a77860edeb14b1592cc331a0a62bb59,impressed,0.599084
uuid-8a77860edeb14b1592cc331a0a62bb59,LTL,0.311678
uuid-8a77860edeb14b1592cc331a0a62bb59,feels,0.325712
uuid-91b32e791d52439fa5bd62e4019fde16,patients,0.471251
uuid-91b32e791d52439fa5bd62e4019fde16,Opdivo,0.506597
uuid-91b32e791d52439fa5bd62e4019fde16,nivolumab,0.489085
uuid-91b32e791d52439fa5bd62e4019fde16,treated,0.371731
uuid-91b32e791d52439fa5bd62e4019fde16,approval,0.36027
uuid-91b32e791d52439fa5bd62e4019fde16,preferred,0.414299
uuid-91b32e791d52439fa5bd62e4019fde16,treatment,0.377404
uuid-91b32e791d52439fa5bd62e4019fde16,using nivo,0.412504
uuid-91b32e791d52439fa5bd62e4019fde16,approved,0.444539
uuid-91b32e791d52439fa5bd62e4019fde16,HCP,0.310958
uuid-91b32e791d52439fa5bd62e4019fde16,RTL stated,0.307708
uuid-98ae9fddae814b258d8468dfd859932a,pembro,0.327545
uuid-98ae9fddae814b258d8468dfd859932a,BMS,0.310276
uuid-98ae9fddae814b258d8468dfd859932a,PDL1,0.722513
uuid-98ae9fddae814b258d8468dfd859932a,trial,0.316428
uuid-98ae9fddae814b258d8468dfd859932a,Merck,0.523355
uuid-98ae9fddae814b258d8468dfd859932a,PD-L1,0.640529
uuid-98ae9fddae814b258d8468dfd859932a,atezo,0.350339
uuid-98ae9fddae814b258d8468dfd859932a,PD-L1 testing,0.410642
uuid-98ae9fddae814b258d8468dfd859932a,testing,0.56701
uuid-98ae9fddae814b258d8468dfd859932a,data,0.368405
uuid-98ae9fddae814b258d8468dfd859932a,PDL1 testing,0.404337
uuid-98ae9fddae814b258d8468dfd859932a,nivo and pembro,0.452857
uuid-98ae9fddae814b258d8468dfd859932a,assay,0.64651
uuid-98ae9fddae814b258d8468dfd859932a,PDL1 expression,0.658231
uuid-98ae9fddae814b258d8468dfd859932a,biomarker,0.701639
uuid-c36885c03d0a4bd0a0edd8c14dae970e,Nivo,0.602392
uuid-c36885c03d0a4bd0a0edd8c14dae970e,patients,0.72864
uuid-c36885c03d0a4bd0a0edd8c14dae970e,pembro,0.33274
uuid-c36885c03d0a4bd0a0edd8c14dae970e,therapy,0.568074
uuid-c36885c03d0a4bd0a0edd8c14dae970e,nivolumab,0.387783
uuid-c36885c03d0a4bd0a0edd8c14dae970e,1L,0.469598
uuid-c36885c03d0a4bd0a0edd8c14dae970e,regimen,0.419062
uuid-c36885c03d0a4bd0a0edd8c14dae970e,chemo,0.580766
uuid-c36885c03d0a4bd0a0edd8c14dae970e,2L,0.46556
uuid-c36885c03d0a4bd0a0edd8c14dae970e,pts,0.580066
uuid-c36885c03d0a4bd0a0edd8c14dae970e,preferred,0.388285
uuid-c36885c03d0a4bd0a0edd8c14dae970e,monotherapy,0.619897
uuid-c36885c03d0a4bd0a0edd8c14dae970e,treatment,0.446079
uuid-c36885c03d0a4bd0a0edd8c14dae970e,using nivo,0.446937
uuid-c36885c03d0a4bd0a0edd8c14dae970e,response,0.318873
uuid-c36885c03d0a4bd0a0edd8c14dae970e,combo,0.340381
uuid-c36885c03d0a4bd0a0edd8c14dae970e,PD1,0.488513
uuid-c36885c03d0a4bd0a0edd8c14dae970e,progression,0.532981
uuid-c36885c03d0a4bd0a0edd8c14dae970e,believes,0.316407
uuid-c36885c03d0a4bd0a0edd8c14dae970e,chemotherapy,0.505902
uuid-c36885c03d0a4bd0a0edd8c14dae970e,respond,0.453798
uuid-c36885c03d0a4bd0a0edd8c14dae970e,feels,0.39003
uuid-c36885c03d0a4bd0a0edd8c14dae970e,option,0.613842
uuid-3c0ec4c944a4470d93690bb45a74cc0f,patients,0.321178
uuid-3c0ec4c944a4470d93690bb45a74cc0f,therapy,0.460173
uuid-3c0ec4c944a4470d93690bb45a74cc0f,nivolumab,0.313118
uuid-3c0ec4c944a4470d93690bb45a74cc0f,regimen,0.338415
uuid-3c0ec4c944a4470d93690bb45a74cc0f,treated,0.408146
uuid-3c0ec4c944a4470d93690bb45a74cc0f,pts,0.356282
uuid-3c0ec4c944a4470d93690bb45a74cc0f,treatment,0.502696
uuid-3c0ec4c944a4470d93690bb45a74cc0f,response,0.40933
uuid-3c0ec4c944a4470d93690bb45a74cc0f,progression,0.555576
uuid-3c0ec4c944a4470d93690bb45a74cc0f,respond,0.31946
uuid-04276b9a87ff4950abf92eaaa8e00d63,physicians,0.427978
uuid-129b6988187f4f2a96f27aa7eaa10723,Nivo,0.334025
uuid-129b6988187f4f2a96f27aa7eaa10723,pembro,0.337388
uuid-129b6988187f4f2a96f27aa7eaa10723,therapy,0.442668
uuid-129b6988187f4f2a96f27aa7eaa10723,nivolumab,0.416036
uuid-129b6988187f4f2a96f27aa7eaa10723,1L,0.654808
uuid-129b6988187f4f2a96f27aa7eaa10723,regimen,0.306375
uuid-129b6988187f4f2a96f27aa7eaa10723,RCC,0.378162
uuid-129b6988187f4f2a96f27aa7eaa10723,combination,0.496593
uuid-129b6988187f4f2a96f27aa7eaa10723,chemo,0.413301
uuid-129b6988187f4f2a96f27aa7eaa10723,2L,0.752506
uuid-129b6988187f4f2a96f27aa7eaa10723,agents,0.708304
uuid-129b6988187f4f2a96f27aa7eaa10723,atezo,0.414692
uuid-129b6988187f4f2a96f27aa7eaa10723,preferred,0.764996
uuid-129b6988187f4f2a96f27aa7eaa10723,monotherapy,0.698009
uuid-129b6988187f4f2a96f27aa7eaa10723,treatment,0.309896
uuid-129b6988187f4f2a96f27aa7eaa10723,using nivo,0.517411
uuid-129b6988187f4f2a96f27aa7eaa10723,combo,0.46722
uuid-129b6988187f4f2a96f27aa7eaa10723,PD1,0.527598
uuid-129b6988187f4f2a96f27aa7eaa10723,approved,0.484098
uuid-129b6988187f4f2a96f27aa7eaa10723,believes,0.321197
uuid-129b6988187f4f2a96f27aa7eaa10723,chemotherapy,0.362687
uuid-129b6988187f4f2a96f27aa7eaa10723,PD-1,0.499251
uuid-129b6988187f4f2a96f27aa7eaa10723,RTL stated,0.469356
uuid-129b6988187f4f2a96f27aa7eaa10723,option,0.695443
uuid-7177b76dbb304683b809a5a4fa58faec,Nivo,0.383051
uuid-7177b76dbb304683b809a5a4fa58faec,pembro,0.364957
uuid-7177b76dbb304683b809a5a4fa58faec,RTL,0.300608
uuid-7177b76dbb304683b809a5a4fa58faec,1L,0.510887
uuid-7177b76dbb304683b809a5a4fa58faec,RCC,0.55237
uuid-7177b76dbb304683b809a5a4fa58faec,combination,0.344232
uuid-7177b76dbb304683b809a5a4fa58faec,2L,0.587303
uuid-7177b76dbb304683b809a5a4fa58faec,agents,0.414195
uuid-7177b76dbb304683b809a5a4fa58faec,stated,0.366783
uuid-7177b76dbb304683b809a5a4fa58faec,approval,0.317409
uuid-7177b76dbb304683b809a5a4fa58faec,atezo,0.418036
uuid-7177b76dbb304683b809a5a4fa58faec,preferred,0.520909
uuid-7177b76dbb304683b809a5a4fa58faec,monotherapy,0.479882
uuid-7177b76dbb304683b809a5a4fa58faec,using nivo,0.532454
uuid-7177b76dbb304683b809a5a4fa58faec,data,0.385951
uuid-7177b76dbb304683b809a5a4fa58faec,combo,0.438274
uuid-7177b76dbb304683b809a5a4fa58faec,indication,0.333981
uuid-7177b76dbb304683b809a5a4fa58faec,approved,0.488225
uuid-7177b76dbb304683b809a5a4fa58faec,SCCHN,0.467015
uuid-7177b76dbb304683b809a5a4fa58faec,impressed,0.437673
uuid-7177b76dbb304683b809a5a4fa58faec,LTL,0.323698
uuid-7177b76dbb304683b809a5a4fa58faec,TLs,0.389446
uuid-7177b76dbb304683b809a5a4fa58faec,SCLC,0.308069
uuid-7177b76dbb304683b809a5a4fa58faec,feels,0.388474
uuid-7177b76dbb304683b809a5a4fa58faec,Regional TL,0.38077
uuid-7177b76dbb304683b809a5a4fa58faec,RTL stated,0.497159
uuid-7177b76dbb304683b809a5a4fa58faec,option,0.483598
uuid-7177b76dbb304683b809a5a4fa58faec,bladder,0.399108
uuid-6160969f6f8c4e97b6cbc63392f2260f,TL,0.355532
uuid-6160969f6f8c4e97b6cbc63392f2260f,PDL1,0.528044
uuid-6160969f6f8c4e97b6cbc63392f2260f,PD-L1,0.814941
uuid-6160969f6f8c4e97b6cbc63392f2260f,PD-L1 testing,0.704698
uuid-6160969f6f8c4e97b6cbc63392f2260f,testing,0.837659
uuid-6160969f6f8c4e97b6cbc63392f2260f,PDL1 testing,0.575598
uuid-6160969f6f8c4e97b6cbc63392f2260f,NSCLC patients,0.572841
uuid-6160969f6f8c4e97b6cbc63392f2260f,assay,0.679755
uuid-6160969f6f8c4e97b6cbc63392f2260f,PDL1 expression,0.383159
uuid-6160969f6f8c4e97b6cbc63392f2260f,biomarker,0.666869
uuid-be3be07f13f9462f986c795ee5974a71,BMS,0.533753
uuid-be3be07f13f9462f986c795ee5974a71,trial,0.770253
uuid-be3be07f13f9462f986c795ee5974a71,Merck,0.420776
uuid-be3be07f13f9462f986c795ee5974a71,OS,0.36762
uuid-be3be07f13f9462f986c795ee5974a71,data,0.522004
uuid-be3be07f13f9462f986c795ee5974a71,clinical trials,0.305718
uuid-be3be07f13f9462f986c795ee5974a71,PFS,0.379175
uuid-be3be07f13f9462f986c795ee5974a71,ORR,0.410239
uuid-be3be07f13f9462f986c795ee5974a71,impressed,0.413974
uuid-be3be07f13f9462f986c795ee5974a71,feels,0.331283
uuid-dff0b517f8834981b767e7672bec73f6,lung,0.419168
uuid-dff0b517f8834981b767e7672bec73f6,NSCLC,0.594257
uuid-dff0b517f8834981b767e7672bec73f6,1L,0.472775
uuid-dff0b517f8834981b767e7672bec73f6,melanoma,0.553525
uuid-dff0b517f8834981b767e7672bec73f6,RCC,0.504634
uuid-dff0b517f8834981b767e7672bec73f6,TL stated,0.33526
uuid-dff0b517f8834981b767e7672bec73f6,combination,0.314844
uuid-dff0b517f8834981b767e7672bec73f6,2L,0.463305
uuid-dff0b517f8834981b767e7672bec73f6,IO,0.400809
uuid-dff0b517f8834981b767e7672bec73f6,preferred,0.376087
uuid-dff0b517f8834981b767e7672bec73f6,monotherapy,0.457914
uuid-dff0b517f8834981b767e7672bec73f6,combo,0.447293
uuid-dff0b517f8834981b767e7672bec73f6,PD1,0.385573
uuid-dff0b517f8834981b767e7672bec73f6,SCCHN,0.340207
uuid-dff0b517f8834981b767e7672bec73f6,believes,0.347503
uuid-dff0b517f8834981b767e7672bec73f6,academic,0.304533
uuid-dff0b517f8834981b767e7672bec73f6,SCLC,0.318986
uuid-dff0b517f8834981b767e7672bec73f6,RTL stated,0.483368
uuid-dff0b517f8834981b767e7672bec73f6,TL shared,0.441898
uuid-dff0b517f8834981b767e7672bec73f6,option,0.361166
uuid-2e9b8684b647438d8f530e26d8390443,patients,0.643719
uuid-2e9b8684b647438d8f530e26d8390443,Opdivo,0.623591
uuid-2e9b8684b647438d8f530e26d8390443,therapy,0.3674
uuid-2e9b8684b647438d8f530e26d8390443,dose,0.495097
uuid-2e9b8684b647438d8f530e26d8390443,nivolumab,0.301649
uuid-2e9b8684b647438d8f530e26d8390443,toxicity,0.479884
uuid-2e9b8684b647438d8f530e26d8390443,regimen,0.597767
uuid-2e9b8684b647438d8f530e26d8390443,treated,0.371924
uuid-2e9b8684b647438d8f530e26d8390443,pts,0.401618
uuid-2e9b8684b647438d8f530e26d8390443,treatment,0.602185
uuid-2e9b8684b647438d8f530e26d8390443,progression,0.516178
uuid-2e9b8684b647438d8f530e26d8390443,respond,0.534578
uuid-98caa16826ad4e25b0bdb98a87cb80ce,patients,0.601252
uuid-98caa16826ad4e25b0bdb98a87cb80ce,pembro,0.362211
uuid-98caa16826ad4e25b0bdb98a87cb80ce,1L,0.563988
uuid-98caa16826ad4e25b0bdb98a87cb80ce,RCC,0.350747
uuid-98caa16826ad4e25b0bdb98a87cb80ce,TL stated,0.454268
uuid-98caa16826ad4e25b0bdb98a87cb80ce,2L,0.570467
uuid-98caa16826ad4e25b0bdb98a87cb80ce,pts,0.439984
uuid-98caa16826ad4e25b0bdb98a87cb80ce,PD-L1,0.375393
uuid-98caa16826ad4e25b0bdb98a87cb80ce,approval,0.370103
uuid-98caa16826ad4e25b0bdb98a87cb80ce,atezo,0.340568
uuid-98caa16826ad4e25b0bdb98a87cb80ce,preferred,0.542428
uuid-98caa16826ad4e25b0bdb98a87cb80ce,PD-L1 testing,0.382193
uuid-98caa16826ad4e25b0bdb98a87cb80ce,testing,0.533985
uuid-98caa16826ad4e25b0bdb98a87cb80ce,monotherapy,0.391697
uuid-98caa16826ad4e25b0bdb98a87cb80ce,using nivo,0.525577
uuid-98caa16826ad4e25b0bdb98a87cb80ce,PDL1 testing,0.587827
uuid-98caa16826ad4e25b0bdb98a87cb80ce,NSCLC patients,0.716121
uuid-98caa16826ad4e25b0bdb98a87cb80ce,approved,0.381298
uuid-98caa16826ad4e25b0bdb98a87cb80ce,SCCHN,0.304686
uuid-98caa16826ad4e25b0bdb98a87cb80ce,tumor types,0.450416
uuid-98caa16826ad4e25b0bdb98a87cb80ce,RTL stated,0.444335
uuid-98caa16826ad4e25b0bdb98a87cb80ce,option,0.480138
uuid-d99948d0acfb478d91d5a1927da0cd71,Nivo,0.430341
uuid-d99948d0acfb478d91d5a1927da0cd71,patients,0.532586
uuid-d99948d0acfb478d91d5a1927da0cd71,pembro,0.348041
uuid-d99948d0acfb478d91d5a1927da0cd71,therapy,0.454441
uuid-d99948d0acfb478d91d5a1927da0cd71,nivolumab,0.421766
uuid-d99948d0acfb478d91d5a1927da0cd71,1L,0.393543
uuid-d99948d0acfb478d91d5a1927da0cd71,trial,0.431165
uuid-d99948d0acfb478d91d5a1927da0cd71,regimen,0.369872
uuid-d99948d0acfb478d91d5a1927da0cd71,treated,0.304445
uuid-d99948d0acfb478d91d5a1927da0cd71,combination,0.539338
uuid-d99948d0acfb478d91d5a1927da0cd71,chemo,0.498421
uuid-d99948d0acfb478d91d5a1927da0cd71,2L,0.337963
uuid-d99948d0acfb478d91d5a1927da0cd71,pts,0.480199
uuid-d99948d0acfb478d91d5a1927da0cd71,Ipi,0.304058
uuid-d99948d0acfb478d91d5a1927da0cd71,preferred,0.357369
uuid-d99948d0acfb478d91d5a1927da0cd71,monotherapy,0.526052
uuid-d99948d0acfb478d91d5a1927da0cd71,treatment,0.33718
uuid-d99948d0acfb478d91d5a1927da0cd71,using nivo,0.392347
uuid-d99948d0acfb478d91d5a1927da0cd71,combo,0.509431
uuid-d99948d0acfb478d91d5a1927da0cd71,clinical trials,0.399774
uuid-d99948d0acfb478d91d5a1927da0cd71,PD1,0.396782
uuid-d99948d0acfb478d91d5a1927da0cd71,approved,0.364477
uuid-d99948d0acfb478d91d5a1927da0cd71,progression,0.377035
uuid-d99948d0acfb478d91d5a1927da0cd71,chemotherapy,0.515849
uuid-d99948d0acfb478d91d5a1927da0cd71,feels,0.397204
uuid-d99948d0acfb478d91d5a1927da0cd71,option,0.550863
uuid-4b25ea280c4c4d0dbe30b354090b435a,TL,0.555467
uuid-4b25ea280c4c4d0dbe30b354090b435a,PDL1,0.301494
uuid-4b25ea280c4c4d0dbe30b354090b435a,TL stated,0.519446
uuid-4b25ea280c4c4d0dbe30b354090b435a,institution,0.385832
uuid-4b25ea280c4c4d0dbe30b354090b435a,PD-L1,0.767992
uuid-4b25ea280c4c4d0dbe30b354090b435a,PD-L1 testing,0.819068
uuid-4b25ea280c4c4d0dbe30b354090b435a,testing,0.888354
uuid-4b25ea280c4c4d0dbe30b354090b435a,PDL1 testing,0.796517
uuid-4b25ea280c4c4d0dbe30b354090b435a,NSCLC patients,0.73125
uuid-4b25ea280c4c4d0dbe30b354090b435a,tumor types,0.316535
uuid-4b25ea280c4c4d0dbe30b354090b435a,assay,0.601852
uuid-4b25ea280c4c4d0dbe30b354090b435a,biomarker,0.376184
uuid-0195eefd5833467a8ae4a7231f879e70,BMS,0.547513
uuid-0195eefd5833467a8ae4a7231f879e70,PDL1,0.415586
uuid-0195eefd5833467a8ae4a7231f879e70,trial,0.305306
uuid-0195eefd5833467a8ae4a7231f879e70,commented,0.464128
uuid-0195eefd5833467a8ae4a7231f879e70,Merck,0.544574
uuid-0195eefd5833467a8ae4a7231f879e70,stated,0.456703
uuid-0195eefd5833467a8ae4a7231f879e70,regards,0.372802
uuid-0195eefd5833467a8ae4a7231f879e70,data,0.573098
uuid-0195eefd5833467a8ae4a7231f879e70,expressed,0.38095
uuid-0195eefd5833467a8ae4a7231f879e70,indication,0.346804
uuid-0195eefd5833467a8ae4a7231f879e70,SCCHN,0.316522
uuid-0195eefd5833467a8ae4a7231f879e70,nivo and pembro,0.337456
uuid-0195eefd5833467a8ae4a7231f879e70,impressed,0.355572
uuid-0195eefd5833467a8ae4a7231f879e70,label,0.310123
uuid-0195eefd5833467a8ae4a7231f879e70,PDL1 expression,0.347839
uuid-0195eefd5833467a8ae4a7231f879e70,NCCN,0.581663
uuid-ec8c726343854032919d3327830d9456,pembro,0.468025
uuid-ec8c726343854032919d3327830d9456,BMS,0.344635
uuid-ec8c726343854032919d3327830d9456,1L,0.325354
uuid-ec8c726343854032919d3327830d9456,PDL1,0.682542
uuid-ec8c726343854032919d3327830d9456,trial,0.34096
uuid-ec8c726343854032919d3327830d9456,efficacy,0.554776
uuid-ec8c726343854032919d3327830d9456,OS,0.600628
uuid-ec8c726343854032919d3327830d9456,atezo,0.408347
uuid-ec8c726343854032919d3327830d9456,regards,0.315026
uuid-ec8c726343854032919d3327830d9456,data,0.601902
uuid-ec8c726343854032919d3327830d9456,PFS,0.605214
uuid-ec8c726343854032919d3327830d9456,ORR,0.589154
uuid-ec8c726343854032919d3327830d9456,nivo and pembro,0.764016
uuid-ec8c726343854032919d3327830d9456,believes,0.547403
uuid-ec8c726343854032919d3327830d9456,impressed,0.367801
uuid-ec8c726343854032919d3327830d9456,feels,0.52062
uuid-ec8c726343854032919d3327830d9456,PDL1 expression,0.554925
uuid-ec8c726343854032919d3327830d9456,biomarker,0.302204
uuid-e3b94988bce1482b9cf482ca98cf8c65,patients,0.702554
uuid-e3b94988bce1482b9cf482ca98cf8c65,therapy,0.495255
uuid-e3b94988bce1482b9cf482ca98cf8c65,nivolumab,0.342755
uuid-e3b94988bce1482b9cf482ca98cf8c65,1L,0.315724
uuid-e3b94988bce1482b9cf482ca98cf8c65,toxicity,0.422255
uuid-e3b94988bce1482b9cf482ca98cf8c65,regimen,0.642725
uuid-e3b94988bce1482b9cf482ca98cf8c65,treated,0.413118
uuid-e3b94988bce1482b9cf482ca98cf8c65,combination,0.473394
uuid-e3b94988bce1482b9cf482ca98cf8c65,chemo,0.597624
uuid-e3b94988bce1482b9cf482ca98cf8c65,pts,0.674515
uuid-e3b94988bce1482b9cf482ca98cf8c65,IO,0.390224
uuid-e3b94988bce1482b9cf482ca98cf8c65,monotherapy,0.632129
uuid-e3b94988bce1482b9cf482ca98cf8c65,treatment,0.586618
uuid-e3b94988bce1482b9cf482ca98cf8c65,response,0.572943
uuid-e3b94988bce1482b9cf482ca98cf8c65,combo,0.492549
uuid-e3b94988bce1482b9cf482ca98cf8c65,PD1,0.47445
uuid-e3b94988bce1482b9cf482ca98cf8c65,progression,0.6471
uuid-e3b94988bce1482b9cf482ca98cf8c65,chemotherapy,0.533673
uuid-e3b94988bce1482b9cf482ca98cf8c65,respond,0.516183
uuid-e3b94988bce1482b9cf482ca98cf8c65,feels,0.310617
uuid-e3b94988bce1482b9cf482ca98cf8c65,option,0.544477
uuid-405df698b60142a69ec35593fa171000,TL,0.461603
uuid-405df698b60142a69ec35593fa171000,PDL1,0.467873
uuid-405df698b60142a69ec35593fa171000,Merck,0.457919
uuid-405df698b60142a69ec35593fa171000,institution,0.465423
uuid-405df698b60142a69ec35593fa171000,PD-L1,0.654368
uuid-405df698b60142a69ec35593fa171000,PD-L1 testing,0.668532
uuid-405df698b60142a69ec35593fa171000,testing,0.688809
uuid-405df698b60142a69ec35593fa171000,PDL1 testing,0.499568
uuid-405df698b60142a69ec35593fa171000,AI,0.438407
uuid-405df698b60142a69ec35593fa171000,NSCLC patients,0.319199
uuid-405df698b60142a69ec35593fa171000,assay,0.849358
uuid-405df698b60142a69ec35593fa171000,PDL1 expression,0.31173
uuid-405df698b60142a69ec35593fa171000,biomarker,0.417444
uuid-3f28205cae3047949f9eb79b4cf84345,patients,0.592629
uuid-3f28205cae3047949f9eb79b4cf84345,Opdivo,0.331111
uuid-3f28205cae3047949f9eb79b4cf84345,therapy,0.485677
uuid-3f28205cae3047949f9eb79b4cf84345,nivolumab,0.374277
uuid-3f28205cae3047949f9eb79b4cf84345,regimen,0.377232
uuid-3f28205cae3047949f9eb79b4cf84345,treated,0.436813
uuid-3f28205cae3047949f9eb79b4cf84345,chemo,0.306928
uuid-3f28205cae3047949f9eb79b4cf84345,pts,0.41775
uuid-3f28205cae3047949f9eb79b4cf84345,preferred,0.317296
uuid-3f28205cae3047949f9eb79b4cf84345,monotherapy,0.369953
uuid-3f28205cae3047949f9eb79b4cf84345,treatment,0.532275
uuid-3f28205cae3047949f9eb79b4cf84345,using nivo,0.345621
uuid-3f28205cae3047949f9eb79b4cf84345,progression,0.45253
uuid-3f28205cae3047949f9eb79b4cf84345,chemotherapy,0.336829
uuid-3f28205cae3047949f9eb79b4cf84345,respond,0.376293
uuid-3f28205cae3047949f9eb79b4cf84345,RTL stated,0.30755
uuid-3f28205cae3047949f9eb79b4cf84345,option,0.416219
uuid-b9ae901797ca4935a19908ac37c7c57a,patients,0.624756
uuid-b9ae901797ca4935a19908ac37c7c57a,Opdivo,0.386668
uuid-b9ae901797ca4935a19908ac37c7c57a,therapy,0.305189
uuid-b9ae901797ca4935a19908ac37c7c57a,nivolumab,0.415464
uuid-b9ae901797ca4935a19908ac37c7c57a,toxicity,0.309897
uuid-b9ae901797ca4935a19908ac37c7c57a,regimen,0.49756
uuid-b9ae901797ca4935a19908ac37c7c57a,treated,0.616065
uuid-b9ae901797ca4935a19908ac37c7c57a,pts,0.41404
uuid-b9ae901797ca4935a19908ac37c7c57a,physicians,0.330258
uuid-b9ae901797ca4935a19908ac37c7c57a,treatment,0.450513
uuid-b9ae901797ca4935a19908ac37c7c57a,progression,0.438695
uuid-b9ae901797ca4935a19908ac37c7c57a,oncologist,0.327392
uuid-b9ae901797ca4935a19908ac37c7c57a,indicated,0.34546
uuid-b9ae901797ca4935a19908ac37c7c57a,respond,0.385839
uuid-65f5579d62ab4abf81eb8e933dce0719,Opdivo,0.390603
uuid-65f5579d62ab4abf81eb8e933dce0719,pembro,0.300058
uuid-65f5579d62ab4abf81eb8e933dce0719,nivolumab,0.334753
uuid-65f5579d62ab4abf81eb8e933dce0719,shared,0.332223
uuid-65f5579d62ab4abf81eb8e933dce0719,RCC,0.379853
uuid-65f5579d62ab4abf81eb8e933dce0719,2L,0.408702
uuid-65f5579d62ab4abf81eb8e933dce0719,stated,0.39191
uuid-65f5579d62ab4abf81eb8e933dce0719,approval,0.495841
uuid-65f5579d62ab4abf81eb8e933dce0719,atezo,0.384866
uuid-65f5579d62ab4abf81eb8e933dce0719,preferred,0.433588
uuid-65f5579d62ab4abf81eb8e933dce0719,using nivo,0.504615
uuid-65f5579d62ab4abf81eb8e933dce0719,clinical trials,0.371046
uuid-65f5579d62ab4abf81eb8e933dce0719,indication,0.475186
uuid-65f5579d62ab4abf81eb8e933dce0719,approved,0.528573
uuid-65f5579d62ab4abf81eb8e933dce0719,SCCHN,0.484828
uuid-65f5579d62ab4abf81eb8e933dce0719,label,0.425403
uuid-65f5579d62ab4abf81eb8e933dce0719,LTL,0.344875
uuid-65f5579d62ab4abf81eb8e933dce0719,TLs,0.333206
uuid-65f5579d62ab4abf81eb8e933dce0719,Regional TL,0.357291
uuid-65f5579d62ab4abf81eb8e933dce0719,RTL stated,0.521344
uuid-65f5579d62ab4abf81eb8e933dce0719,bladder,0.626253
uuid-65f5579d62ab4abf81eb8e933dce0719,flat dosing,0.355281
uuid-0bd63aac5d114f62b6b1c89bfd247484,patients,0.488469
uuid-0bd63aac5d114f62b6b1c89bfd247484,Opdivo,0.458863
uuid-0bd63aac5d114f62b6b1c89bfd247484,dose,0.564679
uuid-0bd63aac5d114f62b6b1c89bfd247484,toxicity,0.43672
uuid-0bd63aac5d114f62b6b1c89bfd247484,regimen,0.411069
uuid-0bd63aac5d114f62b6b1c89bfd247484,treatment,0.442487
uuid-0bd63aac5d114f62b6b1c89bfd247484,progression,0.402483
uuid-0bd63aac5d114f62b6b1c89bfd247484,respond,0.324051
uuid-0bd63aac5d114f62b6b1c89bfd247484,drug,0.317642
uuid-0bd63aac5d114f62b6b1c89bfd247484,flat dosing,0.383204
uuid-f4202bfbb0844784be273a35e328d041,patients,0.678071
uuid-f4202bfbb0844784be273a35e328d041,Opdivo,0.398569
uuid-f4202bfbb0844784be273a35e328d041,toxicity,0.519825
uuid-f4202bfbb0844784be273a35e328d041,regimen,0.515291
uuid-f4202bfbb0844784be273a35e328d041,treated,0.603264
uuid-f4202bfbb0844784be273a35e328d041,physicians,0.349266
uuid-f4202bfbb0844784be273a35e328d041,treatment,0.651603
uuid-f4202bfbb0844784be273a35e328d041,progression,0.46009
uuid-f4202bfbb0844784be273a35e328d041,respond,0.511064
uuid-0f3b239e620140368619e7fb1d819796,RTL,0.325249
uuid-0f3b239e620140368619e7fb1d819796,lung,0.515707
uuid-0f3b239e620140368619e7fb1d819796,NTL,0.3898
uuid-0f3b239e620140368619e7fb1d819796,melanoma,0.523645
uuid-0f3b239e620140368619e7fb1d819796,shared,0.386174
uuid-0f3b239e620140368619e7fb1d819796,RCC,0.373288
uuid-0f3b239e620140368619e7fb1d819796,TL stated,0.342019
uuid-0f3b239e620140368619e7fb1d819796,institution,0.305455
uuid-0f3b239e620140368619e7fb1d819796,AI,0.320588
uuid-0f3b239e620140368619e7fb1d819796,SCCHN,0.412342
uuid-0f3b239e620140368619e7fb1d819796,Regional TL,0.363632
uuid-0f3b239e620140368619e7fb1d819796,TL shared,0.383708
uuid-0f3b239e620140368619e7fb1d819796,bladder,0.341722
uuid-0f3b239e620140368619e7fb1d819796,flat dosing,0.310694
uuid-ead1755269dc46eca48efa6c876b6ca3,Nivo,0.446628
uuid-ead1755269dc46eca48efa6c876b6ca3,pembro,0.497679
uuid-ead1755269dc46eca48efa6c876b6ca3,1L,0.500084
uuid-ead1755269dc46eca48efa6c876b6ca3,PDL1,0.437758
uuid-ead1755269dc46eca48efa6c876b6ca3,efficacy,0.541837
uuid-ead1755269dc46eca48efa6c876b6ca3,combination,0.353486
uuid-ead1755269dc46eca48efa6c876b6ca3,chemo,0.502936
uuid-ead1755269dc46eca48efa6c876b6ca3,2L,0.440484
uuid-ead1755269dc46eca48efa6c876b6ca3,agents,0.478099
uuid-ead1755269dc46eca48efa6c876b6ca3,Ipi,0.309998
uuid-ead1755269dc46eca48efa6c876b6ca3,OS,0.448046
uuid-ead1755269dc46eca48efa6c876b6ca3,atezo,0.458332
uuid-ead1755269dc46eca48efa6c876b6ca3,preferred,0.306063
uuid-ead1755269dc46eca48efa6c876b6ca3,monotherapy,0.513174
uuid-ead1755269dc46eca48efa6c876b6ca3,data,0.32648
uuid-ead1755269dc46eca48efa6c876b6ca3,combo,0.509759
uuid-ead1755269dc46eca48efa6c876b6ca3,PFS,0.405067
uuid-ead1755269dc46eca48efa6c876b6ca3,PD1,0.367824
uuid-ead1755269dc46eca48efa6c876b6ca3,ORR,0.448256
uuid-ead1755269dc46eca48efa6c876b6ca3,nivo and pembro,0.704912
uuid-ead1755269dc46eca48efa6c876b6ca3,believes,0.607882
uuid-ead1755269dc46eca48efa6c876b6ca3,chemotherapy,0.326742
uuid-ead1755269dc46eca48efa6c876b6ca3,vs,0.336272
uuid-ead1755269dc46eca48efa6c876b6ca3,feels,0.494789
uuid-ead1755269dc46eca48efa6c876b6ca3,PDL1 expression,0.367942
uuid-ead1755269dc46eca48efa6c876b6ca3,option,0.407205
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,BMS,0.462824
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,PDL1,0.359223
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,trial,0.462651
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,efficacy,0.51593
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,OS,0.581662
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,data,0.618243
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,PFS,0.57135
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,ORR,0.56609
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,nivo and pembro,0.330276
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,believes,0.371389
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,impressed,0.454358
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,feels,0.464495
uuid-2d063c3ac85f4dbdac92af88e33a9d1d,PDL1 expression,0.31167
uuid-d22683a37ccd46fea3495c7a2e691fd6,pembro,0.552632
uuid-d22683a37ccd46fea3495c7a2e691fd6,1L,0.591452
uuid-d22683a37ccd46fea3495c7a2e691fd6,PDL1,0.421882
uuid-d22683a37ccd46fea3495c7a2e691fd6,RCC,0.362704
uuid-d22683a37ccd46fea3495c7a2e691fd6,TL stated,0.319282
uuid-d22683a37ccd46fea3495c7a2e691fd6,2L,0.598294
uuid-d22683a37ccd46fea3495c7a2e691fd6,approval,0.35423
uuid-d22683a37ccd46fea3495c7a2e691fd6,atezo,0.509365
uuid-d22683a37ccd46fea3495c7a2e691fd6,preferred,0.488279
uuid-d22683a37ccd46fea3495c7a2e691fd6,monotherapy,0.317513
uuid-d22683a37ccd46fea3495c7a2e691fd6,using nivo,0.464864
uuid-d22683a37ccd46fea3495c7a2e691fd6,PDL1 testing,0.414829
uuid-d22683a37ccd46fea3495c7a2e691fd6,indication,0.437034
uuid-d22683a37ccd46fea3495c7a2e691fd6,NSCLC patients,0.345213
uuid-d22683a37ccd46fea3495c7a2e691fd6,approved,0.454264
uuid-d22683a37ccd46fea3495c7a2e691fd6,nivo and pembro,0.412672
uuid-d22683a37ccd46fea3495c7a2e691fd6,believes,0.303184
uuid-d22683a37ccd46fea3495c7a2e691fd6,tumor types,0.382918
uuid-d22683a37ccd46fea3495c7a2e691fd6,label,0.366364
uuid-d22683a37ccd46fea3495c7a2e691fd6,feels,0.325319
uuid-d22683a37ccd46fea3495c7a2e691fd6,RTL stated,0.341313
uuid-d22683a37ccd46fea3495c7a2e691fd6,PDL1 expression,0.400141
uuid-d22683a37ccd46fea3495c7a2e691fd6,option,0.436544
uuid-d22683a37ccd46fea3495c7a2e691fd6,bladder,0.312432
uuid-f834cc63d9f04f648ec50e3cb2b81432,RTL,0.430145
uuid-f834cc63d9f04f648ec50e3cb2b81432,BMS,0.565987
uuid-f834cc63d9f04f648ec50e3cb2b81432,PDL1,0.415331
uuid-f834cc63d9f04f648ec50e3cb2b81432,trial,0.625657
uuid-f834cc63d9f04f648ec50e3cb2b81432,efficacy,0.409
uuid-f834cc63d9f04f648ec50e3cb2b81432,commented,0.540115
uuid-f834cc63d9f04f648ec50e3cb2b81432,Merck,0.514335
uuid-f834cc63d9f04f648ec50e3cb2b81432,stated,0.389324
uuid-f834cc63d9f04f648ec50e3cb2b81432,OS,0.553884
uuid-f834cc63d9f04f648ec50e3cb2b81432,regards,0.367505
uuid-f834cc63d9f04f648ec50e3cb2b81432,data,0.90617
uuid-f834cc63d9f04f648ec50e3cb2b81432,expressed,0.428675
uuid-f834cc63d9f04f648ec50e3cb2b81432,PFS,0.532941
uuid-f834cc63d9f04f648ec50e3cb2b81432,ORR,0.590197
uuid-f834cc63d9f04f648ec50e3cb2b81432,nivo and pembro,0.382401
uuid-f834cc63d9f04f648ec50e3cb2b81432,ASCO,0.413262
uuid-f834cc63d9f04f648ec50e3cb2b81432,impressed,0.669485
uuid-f834cc63d9f04f648ec50e3cb2b81432,LTL,0.307847
uuid-f834cc63d9f04f648ec50e3cb2b81432,TLs,0.303312
uuid-f834cc63d9f04f648ec50e3cb2b81432,Regional TL,0.324471
uuid-f834cc63d9f04f648ec50e3cb2b81432,PDL1 expression,0.399505
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,RTL,0.353412
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,BMS,0.468346
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,PDL1,0.306642
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,trial,0.690746
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,efficacy,0.363067
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,commented,0.484809
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,Merck,0.430151
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,OS,0.496343
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,regards,0.387589
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,data,0.684509
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,expressed,0.361563
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,clinical trials,0.300734
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,PFS,0.508383
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,ORR,0.55907
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,nivo and pembro,0.361824
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,ASCO,0.319364
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,impressed,0.578216
uuid-b6c3c5adc7f149fc82e422bb0bb4096a,PDL1 expression,0.315939
uuid-83b49d7df9b8455896145324fd46d89e,Nivo,0.453025
uuid-83b49d7df9b8455896145324fd46d89e,pembro,0.604772
uuid-83b49d7df9b8455896145324fd46d89e,RTL,0.525373
uuid-83b49d7df9b8455896145324fd46d89e,NTL,0.336203
uuid-83b49d7df9b8455896145324fd46d89e,2L,0.382066
uuid-83b49d7df9b8455896145324fd46d89e,Ipi,0.445655
uuid-83b49d7df9b8455896145324fd46d89e,approval,0.35547
uuid-83b49d7df9b8455896145324fd46d89e,atezo,0.554405
uuid-83b49d7df9b8455896145324fd46d89e,preferred,0.384161
uuid-83b49d7df9b8455896145324fd46d89e,using nivo,0.644743
uuid-83b49d7df9b8455896145324fd46d89e,mentioned,0.510847
uuid-83b49d7df9b8455896145324fd46d89e,indication,0.322535
uuid-83b49d7df9b8455896145324fd46d89e,SCCHN,0.442698
uuid-83b49d7df9b8455896145324fd46d89e,HCP,0.619414
uuid-83b49d7df9b8455896145324fd46d89e,vs,0.386083
uuid-83b49d7df9b8455896145324fd46d89e,LTL,0.520306
uuid-83b49d7df9b8455896145324fd46d89e,TLs,0.366053
uuid-83b49d7df9b8455896145324fd46d89e,SCLC,0.3691
uuid-83b49d7df9b8455896145324fd46d89e,Regional TL,0.36355
uuid-83b49d7df9b8455896145324fd46d89e,RTL stated,0.393484
uuid-83b49d7df9b8455896145324fd46d89e,bladder,0.361313
uuid-7ed123aec6804c4698b90a8480aceda4,patients,0.773478
uuid-7ed123aec6804c4698b90a8480aceda4,Opdivo,0.378323
uuid-7ed123aec6804c4698b90a8480aceda4,therapy,0.423541
uuid-7ed123aec6804c4698b90a8480aceda4,nivolumab,0.313057
uuid-7ed123aec6804c4698b90a8480aceda4,regimen,0.431239
uuid-7ed123aec6804c4698b90a8480aceda4,treated,0.6434
uuid-7ed123aec6804c4698b90a8480aceda4,pts,0.553723
uuid-7ed123aec6804c4698b90a8480aceda4,treatment,0.706126
uuid-7ed123aec6804c4698b90a8480aceda4,response,0.381733
uuid-7ed123aec6804c4698b90a8480aceda4,progression,0.687661
uuid-7ed123aec6804c4698b90a8480aceda4,respond,0.541796
uuid-0637b85344b3406ebe632cabc111fc52,oncology,0.47017
uuid-0637b85344b3406ebe632cabc111fc52,drug,0.474627
uuid-0637b85344b3406ebe632cabc111fc52,Keytruda,0.322712
uuid-0637b85344b3406ebe632cabc111fc52,clinical,0.453839
uuid-0637b85344b3406ebe632cabc111fc52,flat dosing,0.356706
uuid-5e8b7907b676441396cc5552142401b0,RTL,0.697286
uuid-5e8b7907b676441396cc5552142401b0,BMS,0.316627
uuid-5e8b7907b676441396cc5552142401b0,trial,0.460169
uuid-5e8b7907b676441396cc5552142401b0,NTL,0.551372
uuid-5e8b7907b676441396cc5552142401b0,discussed,0.34022
uuid-5e8b7907b676441396cc5552142401b0,commented,0.59574
uuid-5e8b7907b676441396cc5552142401b0,stated,0.416802
uuid-5e8b7907b676441396cc5552142401b0,OS,0.413227
uuid-5e8b7907b676441396cc5552142401b0,data,0.714731
uuid-5e8b7907b676441396cc5552142401b0,expressed,0.511757
uuid-5e8b7907b676441396cc5552142401b0,mentioned,0.628508
uuid-5e8b7907b676441396cc5552142401b0,PFS,0.379771
uuid-5e8b7907b676441396cc5552142401b0,ORR,0.408329
uuid-5e8b7907b676441396cc5552142401b0,SCCHN,0.368333
uuid-5e8b7907b676441396cc5552142401b0,HCP,0.557244
uuid-5e8b7907b676441396cc5552142401b0,ASCO,0.55348
uuid-5e8b7907b676441396cc5552142401b0,impressed,0.668534
uuid-5e8b7907b676441396cc5552142401b0,LTL,0.536044
uuid-5e8b7907b676441396cc5552142401b0,SCLC,0.368039
uuid-5e8b7907b676441396cc5552142401b0,Regional TL,0.491256
uuid-310bd35eff6349b5bf00e925901c85fc,RTL,0.478932
uuid-310bd35eff6349b5bf00e925901c85fc,BMS,0.397226
uuid-310bd35eff6349b5bf00e925901c85fc,trial,0.660687
uuid-310bd35eff6349b5bf00e925901c85fc,NTL,0.317411
uuid-310bd35eff6349b5bf00e925901c85fc,shared,0.33917
uuid-310bd35eff6349b5bf00e925901c85fc,commented,0.335158
uuid-310bd35eff6349b5bf00e925901c85fc,Merck,0.306002
uuid-310bd35eff6349b5bf00e925901c85fc,stated,0.440442
uuid-310bd35eff6349b5bf00e925901c85fc,clinical trials,0.521842
uuid-310bd35eff6349b5bf00e925901c85fc,impressed,0.345811
uuid-310bd35eff6349b5bf00e925901c85fc,LTL,0.302334
uuid-310bd35eff6349b5bf00e925901c85fc,Regional TL,0.402066
uuid-12c61d1f79b8456883b3386bd6e2811c,lung,0.376875
uuid-12c61d1f79b8456883b3386bd6e2811c,1L,0.365777
uuid-12c61d1f79b8456883b3386bd6e2811c,melanoma,0.324732
uuid-12c61d1f79b8456883b3386bd6e2811c,combination,0.391656
uuid-12c61d1f79b8456883b3386bd6e2811c,chemo,0.307233
uuid-12c61d1f79b8456883b3386bd6e2811c,2L,0.374207
uuid-12c61d1f79b8456883b3386bd6e2811c,agents,0.427352
uuid-12c61d1f79b8456883b3386bd6e2811c,monotherapy,0.373675
uuid-12c61d1f79b8456883b3386bd6e2811c,combo,0.48761
uuid-12c61d1f79b8456883b3386bd6e2811c,AI,0.630491
uuid-12c61d1f79b8456883b3386bd6e2811c,nivo and pembro,0.418443
uuid-12c61d1f79b8456883b3386bd6e2811c,believes,0.413274
uuid-12c61d1f79b8456883b3386bd6e2811c,option,0.318764
uuid-3dd2ec45fc854237b7ff758e885cf504,Nivo,0.322641
uuid-3dd2ec45fc854237b7ff758e885cf504,1L,0.308882
uuid-3dd2ec45fc854237b7ff758e885cf504,efficacy,0.341444
uuid-3dd2ec45fc854237b7ff758e885cf504,regimen,0.324372
uuid-3dd2ec45fc854237b7ff758e885cf504,OS,0.596256
uuid-3dd2ec45fc854237b7ff758e885cf504,monotherapy,0.382846
uuid-3dd2ec45fc854237b7ff758e885cf504,data,0.47925
uuid-3dd2ec45fc854237b7ff758e885cf504,PFS,0.480318
uuid-3dd2ec45fc854237b7ff758e885cf504,ORR,0.46335
uuid-3dd2ec45fc854237b7ff758e885cf504,impressed,0.50968
uuid-3dd2ec45fc854237b7ff758e885cf504,feels,0.397019
uuid-3dd2ec45fc854237b7ff758e885cf504,option,0.346904
uuid-e0ca8707263a4453ac806b16fd278464,patients,0.546356
uuid-e0ca8707263a4453ac806b16fd278464,Opdivo,0.312682
uuid-e0ca8707263a4453ac806b16fd278464,treated,0.529137
uuid-e0ca8707263a4453ac806b16fd278464,pts,0.348705
uuid-e0ca8707263a4453ac806b16fd278464,physicians,0.30124
uuid-e0ca8707263a4453ac806b16fd278464,PD-L1 testing,0.330718
uuid-e0ca8707263a4453ac806b16fd278464,testing,0.310026
uuid-e0ca8707263a4453ac806b16fd278464,treatment,0.394156
uuid-e0ca8707263a4453ac806b16fd278464,PDL1 testing,0.318928
uuid-e0ca8707263a4453ac806b16fd278464,NSCLC patients,0.406632
uuid-e0ca8707263a4453ac806b16fd278464,lung cancer,0.419729
uuid-e0ca8707263a4453ac806b16fd278464,progression,0.355224
uuid-e0ca8707263a4453ac806b16fd278464,respond,0.303336
uuid-beb16af5d2354ca7bed9702b106a13db,patients,0.351409
uuid-beb16af5d2354ca7bed9702b106a13db,therapy,0.41282
uuid-beb16af5d2354ca7bed9702b106a13db,treatment,0.470334
uuid-beb16af5d2354ca7bed9702b106a13db,response,0.313738
uuid-beb16af5d2354ca7bed9702b106a13db,PD1,0.328331
uuid-beb16af5d2354ca7bed9702b106a13db,progression,0.533541
uuid-beb16af5d2354ca7bed9702b106a13db,chemotherapy,0.320829
uuid-beb16af5d2354ca7bed9702b106a13db,respond,0.312052
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,patients,0.459228
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,1L,0.640791
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,PDL1,0.391604
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,RCC,0.392539
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,TL stated,0.492258
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,2L,0.56798
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,pts,0.469464
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,PD-L1,0.440599
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,preferred,0.375885
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,PD-L1 testing,0.330395
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,testing,0.521506
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,monotherapy,0.394294
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,using nivo,0.425178
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,PDL1 testing,0.599786
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,NSCLC patients,0.638389
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,approved,0.321983
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,tumor types,0.510128
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,RTL stated,0.410061
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,TL shared,0.309702
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,option,0.490674
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,biomarker,0.333226
uuid-b2100c1bb91f4f299a26ef8f5b56b92a,bladder,0.311425
uuid-e1b161d3d7224166ad48b50019e33de9,patients,0.322386
uuid-e1b161d3d7224166ad48b50019e33de9,Opdivo,0.533807
uuid-e1b161d3d7224166ad48b50019e33de9,dose,0.659977
uuid-e1b161d3d7224166ad48b50019e33de9,oncology,0.325349
uuid-e1b161d3d7224166ad48b50019e33de9,drug,0.408986
uuid-e1b161d3d7224166ad48b50019e33de9,Keytruda,0.426338
uuid-e1b161d3d7224166ad48b50019e33de9,flat dosing,0.753459
uuid-7cc98ecf172d4873ab7243134ae721f6,Opdivo,0.71545
uuid-7cc98ecf172d4873ab7243134ae721f6,physicians,0.346922
uuid-7cc98ecf172d4873ab7243134ae721f6,Keytruda,0.375043
uuid-5cd227113b4c4c2eb7545a189460c87f,oncology,0.477607
uuid-5cd227113b4c4c2eb7545a189460c87f,label,0.304894
uuid-5cd227113b4c4c2eb7545a189460c87f,flat dosing,0.373177
uuid-2dba2c66f54d4aab8996c67dd306d9a5,patients,0.432953
uuid-2dba2c66f54d4aab8996c67dd306d9a5,therapy,0.306978
uuid-2dba2c66f54d4aab8996c67dd306d9a5,nivolumab,0.319354
uuid-2dba2c66f54d4aab8996c67dd306d9a5,1L,0.418245
uuid-2dba2c66f54d4aab8996c67dd306d9a5,regimen,0.325998
uuid-2dba2c66f54d4aab8996c67dd306d9a5,treated,0.33029
uuid-2dba2c66f54d4aab8996c67dd306d9a5,RCC,0.353348
uuid-2dba2c66f54d4aab8996c67dd306d9a5,2L,0.472987
uuid-2dba2c66f54d4aab8996c67dd306d9a5,agents,0.311633
uuid-2dba2c66f54d4aab8996c67dd306d9a5,preferred,0.728325
uuid-2dba2c66f54d4aab8996c67dd306d9a5,monotherapy,0.474009
uuid-2dba2c66f54d4aab8996c67dd306d9a5,treatment,0.350465
uuid-2dba2c66f54d4aab8996c67dd306d9a5,using nivo,0.507779
uuid-2dba2c66f54d4aab8996c67dd306d9a5,SCCHN,0.43467
uuid-2dba2c66f54d4aab8996c67dd306d9a5,chemotherapy,0.32065
uuid-2dba2c66f54d4aab8996c67dd306d9a5,RTL stated,0.55156
uuid-2dba2c66f54d4aab8996c67dd306d9a5,TL shared,0.365436
uuid-2dba2c66f54d4aab8996c67dd306d9a5,option,0.601443
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,Nivo,0.318096
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,patients,0.688442
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,therapy,0.538649
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,nivolumab,0.327694
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,toxicity,0.500261
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,regimen,0.625511
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,treated,0.489785
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,chemo,0.440514
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,pts,0.480925
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,monotherapy,0.395393
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,treatment,0.724448
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,response,0.464416
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,PD1,0.355429
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,progression,0.63139
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,chemotherapy,0.426657
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,respond,0.652407
uuid-7d4ac2f2fc9c4bc8b44207d86c862dcc,option,0.308748
uuid-736ea07cf74c44b2943a67a16c6c673a,Opdivo,0.423003
uuid-736ea07cf74c44b2943a67a16c6c673a,therapy,0.356878
uuid-736ea07cf74c44b2943a67a16c6c673a,nivolumab,0.459665
uuid-736ea07cf74c44b2943a67a16c6c673a,approval,0.407167
uuid-736ea07cf74c44b2943a67a16c6c673a,physicians,0.322338
uuid-736ea07cf74c44b2943a67a16c6c673a,using nivo,0.30298
uuid-736ea07cf74c44b2943a67a16c6c673a,mentioned,0.481854
uuid-736ea07cf74c44b2943a67a16c6c673a,cHL,0.730958
uuid-736ea07cf74c44b2943a67a16c6c673a,label,0.306157
uuid-736ea07cf74c44b2943a67a16c6c673a,LTL,0.305294
uuid-44c734fc8f574a8398a516320aa68920,TL,0.478068
uuid-44c734fc8f574a8398a516320aa68920,RTL,0.459065
uuid-44c734fc8f574a8398a516320aa68920,lung,0.324735
uuid-44c734fc8f574a8398a516320aa68920,NTL,0.526022
uuid-44c734fc8f574a8398a516320aa68920,melanoma,0.341069
uuid-44c734fc8f574a8398a516320aa68920,shared,0.361968
uuid-44c734fc8f574a8398a516320aa68920,TL stated,0.302414
uuid-44c734fc8f574a8398a516320aa68920,institution,0.363527
uuid-44c734fc8f574a8398a516320aa68920,SCCHN,0.363408
uuid-44c734fc8f574a8398a516320aa68920,academic,0.342745
uuid-44c734fc8f574a8398a516320aa68920,Regional TL,0.410024
uuid-4eff3690a814458d8f745519314256f7,TL,0.329451
uuid-4eff3690a814458d8f745519314256f7,1L,0.440217
uuid-4eff3690a814458d8f745519314256f7,PDL1,0.533248
uuid-4eff3690a814458d8f745519314256f7,TL stated,0.431495
uuid-4eff3690a814458d8f745519314256f7,2L,0.319086
uuid-4eff3690a814458d8f745519314256f7,Merck,0.313588
uuid-4eff3690a814458d8f745519314256f7,PD-L1,0.569251
uuid-4eff3690a814458d8f745519314256f7,PD-L1 testing,0.420795
uuid-4eff3690a814458d8f745519314256f7,testing,0.592909
uuid-4eff3690a814458d8f745519314256f7,PDL1 testing,0.548026
uuid-4eff3690a814458d8f745519314256f7,NSCLC patients,0.494392
uuid-4eff3690a814458d8f745519314256f7,believes,0.386835
uuid-4eff3690a814458d8f745519314256f7,tumor types,0.413173
uuid-4eff3690a814458d8f745519314256f7,feels,0.308571
uuid-4eff3690a814458d8f745519314256f7,assay,0.384368
uuid-4eff3690a814458d8f745519314256f7,PDL1 expression,0.355408
uuid-4eff3690a814458d8f745519314256f7,biomarker,0.522355
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,PDL1,0.38296
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,efficacy,0.315582
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,agents,0.510517
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,PD-L1,0.390907
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,atezo,0.326989
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,PDL1 testing,0.3183
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,nivo and pembro,0.351185
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,believes,0.344205
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,assay,0.307483
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,PD-1,0.435775
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,PDL1 expression,0.31066
uuid-fe33b4537d0d4ec9ba12e1e4c0fbcd2e,biomarker,0.368695
uuid-30ccd9133c2d491da9a51d77ff2fed49,patients,0.598302
uuid-30ccd9133c2d491da9a51d77ff2fed49,Opdivo,0.633649
uuid-30ccd9133c2d491da9a51d77ff2fed49,nivolumab,0.489736
uuid-30ccd9133c2d491da9a51d77ff2fed49,regimen,0.321064
uuid-30ccd9133c2d491da9a51d77ff2fed49,treated,0.472553
uuid-30ccd9133c2d491da9a51d77ff2fed49,RCC,0.3542
uuid-30ccd9133c2d491da9a51d77ff2fed49,pts,0.32465
uuid-30ccd9133c2d491da9a51d77ff2fed49,approval,0.506719
uuid-30ccd9133c2d491da9a51d77ff2fed49,physicians,0.341147
uuid-30ccd9133c2d491da9a51d77ff2fed49,preferred,0.32213
uuid-30ccd9133c2d491da9a51d77ff2fed49,treatment,0.389617
uuid-30ccd9133c2d491da9a51d77ff2fed49,using nivo,0.493971
uuid-30ccd9133c2d491da9a51d77ff2fed49,clinical trials,0.371214
uuid-30ccd9133c2d491da9a51d77ff2fed49,indication,0.32551
uuid-30ccd9133c2d491da9a51d77ff2fed49,approved,0.419405
uuid-30ccd9133c2d491da9a51d77ff2fed49,SCCHN,0.444275
uuid-30ccd9133c2d491da9a51d77ff2fed49,HCP,0.357476
uuid-30ccd9133c2d491da9a51d77ff2fed49,label,0.342754
uuid-30ccd9133c2d491da9a51d77ff2fed49,Regional TL,0.339437
uuid-30ccd9133c2d491da9a51d77ff2fed49,RTL stated,0.405113
uuid-30ccd9133c2d491da9a51d77ff2fed49,bladder,0.469276
uuid-4af54185dc15419a9bb1da0aeac830e8,patients,0.603123
uuid-4af54185dc15419a9bb1da0aeac830e8,therapy,0.385458
uuid-4af54185dc15419a9bb1da0aeac830e8,nivolumab,0.340389
uuid-4af54185dc15419a9bb1da0aeac830e8,1L,0.303114
uuid-4af54185dc15419a9bb1da0aeac830e8,regimen,0.307447
uuid-4af54185dc15419a9bb1da0aeac830e8,treated,0.335363
uuid-4af54185dc15419a9bb1da0aeac830e8,RCC,0.336268
uuid-4af54185dc15419a9bb1da0aeac830e8,2L,0.333464
uuid-4af54185dc15419a9bb1da0aeac830e8,pts,0.406585
uuid-4af54185dc15419a9bb1da0aeac830e8,monotherapy,0.366376
uuid-4af54185dc15419a9bb1da0aeac830e8,treatment,0.44167
uuid-4af54185dc15419a9bb1da0aeac830e8,using nivo,0.366128
uuid-4af54185dc15419a9bb1da0aeac830e8,NSCLC patients,0.344362
uuid-4af54185dc15419a9bb1da0aeac830e8,progression,0.460853
uuid-4af54185dc15419a9bb1da0aeac830e8,respond,0.373133
uuid-4af54185dc15419a9bb1da0aeac830e8,RTL stated,0.344445
uuid-4af54185dc15419a9bb1da0aeac830e8,TL shared,0.362042
uuid-4af54185dc15419a9bb1da0aeac830e8,option,0.408757
uuid-bc3a99817b654fbfb0086a3522df8a5b,therapy,0.333066
uuid-bc3a99817b654fbfb0086a3522df8a5b,nivolumab,0.395468
uuid-bc3a99817b654fbfb0086a3522df8a5b,combination,0.317472
uuid-bc3a99817b654fbfb0086a3522df8a5b,IO,0.45697
uuid-bc3a99817b654fbfb0086a3522df8a5b,physicians,0.352931
uuid-bc3a99817b654fbfb0086a3522df8a5b,preferred,0.387625
uuid-bc3a99817b654fbfb0086a3522df8a5b,monotherapy,0.324353
uuid-bc3a99817b654fbfb0086a3522df8a5b,using nivo,0.312368
uuid-bc3a99817b654fbfb0086a3522df8a5b,option,0.378199
uuid-dad3698db00949409525969e916daa58,preferred,0.333677
uuid-dad3698db00949409525969e916daa58,SCCHN,0.315571
uuid-dad3698db00949409525969e916daa58,feels,0.31289
uuid-dad3698db00949409525969e916daa58,RTL stated,0.375419
uuid-2bec971e52364b71a7fe5e3591ff51ab,Nivo,0.419072
uuid-2bec971e52364b71a7fe5e3591ff51ab,patients,0.789515
uuid-2bec971e52364b71a7fe5e3591ff51ab,therapy,0.588063
uuid-2bec971e52364b71a7fe5e3591ff51ab,nivolumab,0.396487
uuid-2bec971e52364b71a7fe5e3591ff51ab,regimen,0.486428
uuid-2bec971e52364b71a7fe5e3591ff51ab,treated,0.556219
uuid-2bec971e52364b71a7fe5e3591ff51ab,chemo,0.491882
uuid-2bec971e52364b71a7fe5e3591ff51ab,pts,0.586538
uuid-2bec971e52364b71a7fe5e3591ff51ab,monotherapy,0.41855
uuid-2bec971e52364b71a7fe5e3591ff51ab,treatment,0.625501
uuid-2bec971e52364b71a7fe5e3591ff51ab,response,0.433053
uuid-2bec971e52364b71a7fe5e3591ff51ab,PD1,0.391805
uuid-2bec971e52364b71a7fe5e3591ff51ab,cHL,0.310416
uuid-2bec971e52364b71a7fe5e3591ff51ab,progression,0.59431
uuid-2bec971e52364b71a7fe5e3591ff51ab,chemotherapy,0.457529
uuid-2bec971e52364b71a7fe5e3591ff51ab,respond,0.656797
uuid-2bec971e52364b71a7fe5e3591ff51ab,option,0.349001
uuid-c15034d9fb764889a01044cef8680638,patients,0.400649
uuid-c15034d9fb764889a01044cef8680638,Opdivo,0.534034
uuid-c15034d9fb764889a01044cef8680638,RTL,0.371396
uuid-c15034d9fb764889a01044cef8680638,nivolumab,0.383419
uuid-c15034d9fb764889a01044cef8680638,regimen,0.360611
uuid-c15034d9fb764889a01044cef8680638,treated,0.631922
uuid-c15034d9fb764889a01044cef8680638,shared,0.365993
uuid-c15034d9fb764889a01044cef8680638,commented,0.33771
uuid-c15034d9fb764889a01044cef8680638,stated,0.303254
uuid-c15034d9fb764889a01044cef8680638,physicians,0.559072
uuid-c15034d9fb764889a01044cef8680638,treatment,0.370607
uuid-c15034d9fb764889a01044cef8680638,SCCHN,0.368202
uuid-c15034d9fb764889a01044cef8680638,HCP,0.504098
uuid-c15034d9fb764889a01044cef8680638,lung cancer,0.386646
uuid-c15034d9fb764889a01044cef8680638,LTL,0.411099
uuid-c15034d9fb764889a01044cef8680638,academic,0.313921
uuid-c15034d9fb764889a01044cef8680638,Regional TL,0.478624
uuid-c15034d9fb764889a01044cef8680638,RTL stated,0.353944
uuid-c15034d9fb764889a01044cef8680638,TL shared,0.337354
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,Nivo,0.553057
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,patients,0.752538
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,Opdivo,0.525759
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,therapy,0.484793
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,dose,0.522791
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,nivolumab,0.45125
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,toxicity,0.361624
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,regimen,0.386146
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,treated,0.317318
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,pts,0.386344
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,Ipi,0.364417
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,treatment,0.457421
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,using nivo,0.33396
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,cHL,0.422764
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,progression,0.407563
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,chemotherapy,0.31961
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,vs,0.335536
uuid-bc87993f351c4e87bce0d7bbb5cf03a6,respond,0.415954
uuid-6f2d7e8559a4406abc691366af1a2137,oncology,0.558872
uuid-6f2d7e8559a4406abc691366af1a2137,clinical,0.365838
uuid-63e90553458e403f93caea5097a2fd02,institution,0.326608
uuid-63e90553458e403f93caea5097a2fd02,indication,0.347403
uuid-63e90553458e403f93caea5097a2fd02,AI,0.451148
uuid-63e90553458e403f93caea5097a2fd02,oncology,0.356146
uuid-63e90553458e403f93caea5097a2fd02,approved,0.325081
uuid-63e90553458e403f93caea5097a2fd02,label,0.44701
uuid-63e90553458e403f93caea5097a2fd02,drug,0.332202
uuid-63e90553458e403f93caea5097a2fd02,NCCN,0.421155
uuid-63e90553458e403f93caea5097a2fd02,flat dosing,0.395337
uuid-08b543f78b804c8ab3172971ecf22f76,physicians,0.317505
uuid-08b543f78b804c8ab3172971ecf22f76,oncology,0.5053
uuid-08b543f78b804c8ab3172971ecf22f76,drug,0.340838
uuid-08b543f78b804c8ab3172971ecf22f76,clinical,0.353975
uuid-08b543f78b804c8ab3172971ecf22f76,flat dosing,0.318965
uuid-7dba71346af84ecf913a6d161cacacc2,toxicity,0.558799
uuid-7dba71346af84ecf913a6d161cacacc2,regimen,0.431765
uuid-7dba71346af84ecf913a6d161cacacc2,treated,0.355759
uuid-7dba71346af84ecf913a6d161cacacc2,melanoma,0.378258
uuid-7dba71346af84ecf913a6d161cacacc2,RTL stated,0.330477
uuid-7dba71346af84ecf913a6d161cacacc2,TL shared,0.455218
uuid-978ddfedcf19448f81e4cd6e80280e2c,patients,0.328878
uuid-978ddfedcf19448f81e4cd6e80280e2c,Opdivo,0.465131
uuid-978ddfedcf19448f81e4cd6e80280e2c,dose,0.767262
uuid-978ddfedcf19448f81e4cd6e80280e2c,nivolumab,0.317225
uuid-978ddfedcf19448f81e4cd6e80280e2c,toxicity,0.392259
uuid-978ddfedcf19448f81e4cd6e80280e2c,regimen,0.304614
uuid-978ddfedcf19448f81e4cd6e80280e2c,Ipi,0.416665
uuid-978ddfedcf19448f81e4cd6e80280e2c,HCP,0.336319
uuid-978ddfedcf19448f81e4cd6e80280e2c,vs,0.420027
uuid-978ddfedcf19448f81e4cd6e80280e2c,flat dosing,0.752062
uuid-5c1960f019f844e5896b6c064f9b9394,Nivo,0.309043
uuid-5c1960f019f844e5896b6c064f9b9394,patients,0.719835
uuid-5c1960f019f844e5896b6c064f9b9394,Opdivo,0.368263
uuid-5c1960f019f844e5896b6c064f9b9394,therapy,0.596486
uuid-5c1960f019f844e5896b6c064f9b9394,nivolumab,0.543578
uuid-5c1960f019f844e5896b6c064f9b9394,treated,0.598122
uuid-5c1960f019f844e5896b6c064f9b9394,pts,0.367023
uuid-5c1960f019f844e5896b6c064f9b9394,treatment,0.492892
uuid-5c1960f019f844e5896b6c064f9b9394,using nivo,0.47661
uuid-5c1960f019f844e5896b6c064f9b9394,cHL,0.661737
uuid-5c1960f019f844e5896b6c064f9b9394,progression,0.399133
uuid-5c1960f019f844e5896b6c064f9b9394,RTL stated,0.367778
uuid-375ff513a5b24ebe9d38d8326e1e85f0,1L,0.305909
uuid-375ff513a5b24ebe9d38d8326e1e85f0,PDL1,0.636371
uuid-375ff513a5b24ebe9d38d8326e1e85f0,efficacy,0.388409
uuid-375ff513a5b24ebe9d38d8326e1e85f0,combination,0.328718
uuid-375ff513a5b24ebe9d38d8326e1e85f0,chemo,0.30969
uuid-375ff513a5b24ebe9d38d8326e1e85f0,agents,0.513517
uuid-375ff513a5b24ebe9d38d8326e1e85f0,PD-L1,0.457616
uuid-375ff513a5b24ebe9d38d8326e1e85f0,monotherapy,0.357159
uuid-375ff513a5b24ebe9d38d8326e1e85f0,PD1,0.421083
uuid-375ff513a5b24ebe9d38d8326e1e85f0,nivo and pembro,0.460701
uuid-375ff513a5b24ebe9d38d8326e1e85f0,believes,0.460117
uuid-375ff513a5b24ebe9d38d8326e1e85f0,feels,0.308029
uuid-375ff513a5b24ebe9d38d8326e1e85f0,assay,0.359356
uuid-375ff513a5b24ebe9d38d8326e1e85f0,PD-1,0.541075
uuid-375ff513a5b24ebe9d38d8326e1e85f0,PDL1 expression,0.385727
uuid-375ff513a5b24ebe9d38d8326e1e85f0,biomarker,0.474793
uuid-ac1319edfb5a467ea68bf3355e59c353,Nivo,0.53805
uuid-ac1319edfb5a467ea68bf3355e59c353,patients,0.638924
uuid-ac1319edfb5a467ea68bf3355e59c353,therapy,0.522633
uuid-ac1319edfb5a467ea68bf3355e59c353,nivolumab,0.417272
uuid-ac1319edfb5a467ea68bf3355e59c353,toxicity,0.362277
uuid-ac1319edfb5a467ea68bf3355e59c353,regimen,0.516857
uuid-ac1319edfb5a467ea68bf3355e59c353,treated,0.393773
uuid-ac1319edfb5a467ea68bf3355e59c353,chemo,0.52735
uuid-ac1319edfb5a467ea68bf3355e59c353,2L,0.30839
uuid-ac1319edfb5a467ea68bf3355e59c353,pts,0.51382
uuid-ac1319edfb5a467ea68bf3355e59c353,monotherapy,0.490651
uuid-ac1319edfb5a467ea68bf3355e59c353,treatment,0.539465
uuid-ac1319edfb5a467ea68bf3355e59c353,using nivo,0.387805
uuid-ac1319edfb5a467ea68bf3355e59c353,response,0.348921
uuid-ac1319edfb5a467ea68bf3355e59c353,PD1,0.419598
uuid-ac1319edfb5a467ea68bf3355e59c353,progression,0.534477
uuid-ac1319edfb5a467ea68bf3355e59c353,chemotherapy,0.465912
uuid-ac1319edfb5a467ea68bf3355e59c353,respond,0.507147
uuid-ac1319edfb5a467ea68bf3355e59c353,option,0.41305
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,PDL1,0.596992
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,PD-L1,0.493788
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,testing,0.421272
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,data,0.357227
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,PDL1 testing,0.366763
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,PFS,0.307143
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,NSCLC patients,0.362195
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,nivo and pembro,0.343393
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,believes,0.325684
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,feels,0.315675
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,assay,0.305005
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,PDL1 expression,0.51372
uuid-f3ddb990c1b74e5bbaf9efdae7e42e32,biomarker,0.446046
uuid-2d0739f0727d4833a5a0bdd43f44618d,patients,0.37708
uuid-2d0739f0727d4833a5a0bdd43f44618d,Opdivo,0.497816
uuid-2d0739f0727d4833a5a0bdd43f44618d,dose,0.381064
uuid-2d0739f0727d4833a5a0bdd43f44618d,nivolumab,0.339384
uuid-2d0739f0727d4833a5a0bdd43f44618d,toxicity,0.345685
uuid-2d0739f0727d4833a5a0bdd43f44618d,regimen,0.342117
uuid-2d0739f0727d4833a5a0bdd43f44618d,RCC,0.389251
uuid-2d0739f0727d4833a5a0bdd43f44618d,preferred,0.372359
uuid-2d0739f0727d4833a5a0bdd43f44618d,using nivo,0.475262
uuid-2d0739f0727d4833a5a0bdd43f44618d,approved,0.327783
uuid-2d0739f0727d4833a5a0bdd43f44618d,HCP,0.335309
uuid-2d0739f0727d4833a5a0bdd43f44618d,label,0.318456
uuid-2d0739f0727d4833a5a0bdd43f44618d,Keytruda,0.30993
uuid-2d0739f0727d4833a5a0bdd43f44618d,flat dosing,0.393966
uuid-02e3167ffa9a44f49d9b699b899ab9b3,Opdivo,0.426339
uuid-02e3167ffa9a44f49d9b699b899ab9b3,dose,0.471131
uuid-02e3167ffa9a44f49d9b699b899ab9b3,preferred,0.408798
uuid-02e3167ffa9a44f49d9b699b899ab9b3,indication,0.353426
uuid-02e3167ffa9a44f49d9b699b899ab9b3,drug,0.418206
uuid-02e3167ffa9a44f49d9b699b899ab9b3,Keytruda,0.57754
uuid-02e3167ffa9a44f49d9b699b899ab9b3,flat dosing,0.568261
uuid-715c4eff3a1f4b53b106ca91c9303b1f,Nivo,0.353917
uuid-715c4eff3a1f4b53b106ca91c9303b1f,lung,0.379576
uuid-715c4eff3a1f4b53b106ca91c9303b1f,1L,0.370968
uuid-715c4eff3a1f4b53b106ca91c9303b1f,melanoma,0.399659
uuid-715c4eff3a1f4b53b106ca91c9303b1f,chemo,0.32197
uuid-715c4eff3a1f4b53b106ca91c9303b1f,2L,0.374664
uuid-715c4eff3a1f4b53b106ca91c9303b1f,monotherapy,0.335718
uuid-715c4eff3a1f4b53b106ca91c9303b1f,AI,0.393325
uuid-715c4eff3a1f4b53b106ca91c9303b1f,believes,0.316433
uuid-715c4eff3a1f4b53b106ca91c9303b1f,option,0.402351
uuid-6c923dee813545808281c59b98b5ac1f,TL,0.446624
uuid-6c923dee813545808281c59b98b5ac1f,TL stated,0.377625
uuid-6c923dee813545808281c59b98b5ac1f,Merck,0.321622
uuid-6c923dee813545808281c59b98b5ac1f,PD-L1,0.578831
uuid-6c923dee813545808281c59b98b5ac1f,PD-L1 testing,0.58503
uuid-6c923dee813545808281c59b98b5ac1f,testing,0.627703
uuid-6c923dee813545808281c59b98b5ac1f,PDL1 testing,0.521442
uuid-6c923dee813545808281c59b98b5ac1f,NSCLC patients,0.446821
uuid-6c923dee813545808281c59b98b5ac1f,assay,0.578973
uuid-6c4f691483f5481aab73c40b09134abe,regards,0.330587
uuid-6c4f691483f5481aab73c40b09134abe,data,0.311666
uuid-6c4f691483f5481aab73c40b09134abe,cHL,0.316864
uuid-6c4f691483f5481aab73c40b09134abe,NCCN,0.528195
uuid-ac3228706ece48f2a188d55ae316e37a,patients,0.307053
uuid-ac3228706ece48f2a188d55ae316e37a,lung,0.336421
uuid-ac3228706ece48f2a188d55ae316e37a,1L,0.364011
uuid-ac3228706ece48f2a188d55ae316e37a,RCC,0.484203
uuid-ac3228706ece48f2a188d55ae316e37a,TL stated,0.414923
uuid-ac3228706ece48f2a188d55ae316e37a,2L,0.471222
uuid-ac3228706ece48f2a188d55ae316e37a,stated,0.301045
uuid-ac3228706ece48f2a188d55ae316e37a,physicians,0.315153
uuid-ac3228706ece48f2a188d55ae316e37a,preferred,0.536209
uuid-ac3228706ece48f2a188d55ae316e37a,using nivo,0.603095
uuid-ac3228706ece48f2a188d55ae316e37a,SCCHN,0.493184
uuid-ac3228706ece48f2a188d55ae316e37a,oncologist,0.437773
uuid-ac3228706ece48f2a188d55ae316e37a,indicated,0.365491
uuid-ac3228706ece48f2a188d55ae316e37a,LTL,0.341345
uuid-ac3228706ece48f2a188d55ae316e37a,TLs,0.432136
uuid-ac3228706ece48f2a188d55ae316e37a,Regional TL,0.434281
uuid-ac3228706ece48f2a188d55ae316e37a,RTL stated,0.499174
uuid-ac3228706ece48f2a188d55ae316e37a,TL shared,0.358964
uuid-ac3228706ece48f2a188d55ae316e37a,option,0.343037
uuid-ac3228706ece48f2a188d55ae316e37a,bladder,0.340462
uuid-57b0fc2855b64a248fdb91f340e0ab09,RTL,0.309087
uuid-57b0fc2855b64a248fdb91f340e0ab09,nivolumab,0.423169
uuid-57b0fc2855b64a248fdb91f340e0ab09,trial,0.578654
uuid-57b0fc2855b64a248fdb91f340e0ab09,NTL,0.301612
uuid-57b0fc2855b64a248fdb91f340e0ab09,combination,0.424546
uuid-57b0fc2855b64a248fdb91f340e0ab09,combo,0.392812
uuid-57b0fc2855b64a248fdb91f340e0ab09,clinical trials,0.409641
uuid-57b0fc2855b64a248fdb91f340e0ab09,chemotherapy,0.3402
uuid-57b0fc2855b64a248fdb91f340e0ab09,SCLC,0.340612
uuid-57b0fc2855b64a248fdb91f340e0ab09,bladder,0.460701
uuid-6244fef25a3746938b57e84d7ffa78cb,patients,0.512264
uuid-6244fef25a3746938b57e84d7ffa78cb,nivolumab,0.301833
uuid-6244fef25a3746938b57e84d7ffa78cb,treated,0.407513
uuid-6244fef25a3746938b57e84d7ffa78cb,tumor,0.607497
uuid-6244fef25a3746938b57e84d7ffa78cb,pts,0.414072
uuid-6244fef25a3746938b57e84d7ffa78cb,treatment,0.338606
uuid-6244fef25a3746938b57e84d7ffa78cb,response,0.30817
uuid-6244fef25a3746938b57e84d7ffa78cb,progression,0.388377
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,Nivo,0.629328
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,nivolumab,0.337766
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,toxicity,0.424338
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,efficacy,0.340928
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,regimen,0.485985
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,combination,0.497777
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,chemo,0.518535
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,2L,0.361304
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,pts,0.414502
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,agents,0.34202
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,Ipi,0.363313
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,preferred,0.312924
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,monotherapy,0.57136
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,using nivo,0.361625
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,response,0.406027
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,combo,0.461013
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,PD1,0.484166
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,progression,0.358391
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,believes,0.336297
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,chemotherapy,0.432769
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,respond,0.340544
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,feels,0.392215
uuid-7ce0f0195cfe45f0adf27723e4ecd0d2,option,0.434583
uuid-158adf198125457b94376269f6a3942a,RTL,0.56784
uuid-158adf198125457b94376269f6a3942a,BMS,0.472628
uuid-158adf198125457b94376269f6a3942a,NTL,0.356647
uuid-158adf198125457b94376269f6a3942a,shared,0.45675
uuid-158adf198125457b94376269f6a3942a,commented,0.596085
uuid-158adf198125457b94376269f6a3942a,RCC,0.345814
uuid-158adf198125457b94376269f6a3942a,TL stated,0.414654
uuid-158adf198125457b94376269f6a3942a,Merck,0.45356
uuid-158adf198125457b94376269f6a3942a,stated,0.619002
uuid-158adf198125457b94376269f6a3942a,approval,0.37386
uuid-158adf198125457b94376269f6a3942a,data,0.466577
uuid-158adf198125457b94376269f6a3942a,expressed,0.418853
uuid-158adf198125457b94376269f6a3942a,mentioned,0.322156
uuid-158adf198125457b94376269f6a3942a,clinical trials,0.348856
uuid-158adf198125457b94376269f6a3942a,approved,0.305414
uuid-158adf198125457b94376269f6a3942a,SCCHN,0.585261
uuid-158adf198125457b94376269f6a3942a,HCP,0.331374
uuid-158adf198125457b94376269f6a3942a,ASCO,0.306762
uuid-158adf198125457b94376269f6a3942a,impressed,0.545917
uuid-158adf198125457b94376269f6a3942a,LTL,0.462972
uuid-158adf198125457b94376269f6a3942a,TLs,0.425847
uuid-158adf198125457b94376269f6a3942a,academic,0.324528
uuid-158adf198125457b94376269f6a3942a,Regional TL,0.555844
uuid-158adf198125457b94376269f6a3942a,RTL stated,0.344136
uuid-158adf198125457b94376269f6a3942a,bladder,0.346303
uuid-0f51a050538d4d16a2f6978feb449f29,Nivo,0.521355
uuid-0f51a050538d4d16a2f6978feb449f29,patients,0.575302
uuid-0f51a050538d4d16a2f6978feb449f29,Opdivo,0.334416
uuid-0f51a050538d4d16a2f6978feb449f29,pembro,0.322579
uuid-0f51a050538d4d16a2f6978feb449f29,therapy,0.392474
uuid-0f51a050538d4d16a2f6978feb449f29,dose,0.557435
uuid-0f51a050538d4d16a2f6978feb449f29,nivolumab,0.37458
uuid-0f51a050538d4d16a2f6978feb449f29,1L,0.397901
uuid-0f51a050538d4d16a2f6978feb449f29,toxicity,0.520288
uuid-0f51a050538d4d16a2f6978feb449f29,regimen,0.649739
uuid-0f51a050538d4d16a2f6978feb449f29,combination,0.435835
uuid-0f51a050538d4d16a2f6978feb449f29,chemo,0.527195
uuid-0f51a050538d4d16a2f6978feb449f29,2L,0.520655
uuid-0f51a050538d4d16a2f6978feb449f29,pts,0.525889
uuid-0f51a050538d4d16a2f6978feb449f29,agents,0.357278
uuid-0f51a050538d4d16a2f6978feb449f29,Ipi,0.464526
uuid-0f51a050538d4d16a2f6978feb449f29,atezo,0.341309
uuid-0f51a050538d4d16a2f6978feb449f29,preferred,0.547197
uuid-0f51a050538d4d16a2f6978feb449f29,monotherapy,0.614151
uuid-0f51a050538d4d16a2f6978feb449f29,treatment,0.509923
uuid-0f51a050538d4d16a2f6978feb449f29,using nivo,0.383383
uuid-0f51a050538d4d16a2f6978feb449f29,response,0.324147
uuid-0f51a050538d4d16a2f6978feb449f29,combo,0.463076
uuid-0f51a050538d4d16a2f6978feb449f29,PD1,0.374671
uuid-0f51a050538d4d16a2f6978feb449f29,approved,0.325095
uuid-0f51a050538d4d16a2f6978feb449f29,progression,0.498516
uuid-0f51a050538d4d16a2f6978feb449f29,chemotherapy,0.387797
uuid-0f51a050538d4d16a2f6978feb449f29,vs,0.314555
uuid-0f51a050538d4d16a2f6978feb449f29,respond,0.437437
uuid-0f51a050538d4d16a2f6978feb449f29,option,0.544932
uuid-5c4a5a1e40a645b084809734ad4df006,patients,0.320092
uuid-5c4a5a1e40a645b084809734ad4df006,1L,0.382458
uuid-5c4a5a1e40a645b084809734ad4df006,PDL1,0.370599
uuid-5c4a5a1e40a645b084809734ad4df006,TL stated,0.445207
uuid-5c4a5a1e40a645b084809734ad4df006,PD-L1,0.670157
uuid-5c4a5a1e40a645b084809734ad4df006,PD-L1 testing,0.653805
uuid-5c4a5a1e40a645b084809734ad4df006,testing,0.857338
uuid-5c4a5a1e40a645b084809734ad4df006,PDL1 testing,0.79307
uuid-5c4a5a1e40a645b084809734ad4df006,NSCLC patients,0.82306
uuid-5c4a5a1e40a645b084809734ad4df006,tumor types,0.405923
uuid-5c4a5a1e40a645b084809734ad4df006,assay,0.378235
uuid-5c4a5a1e40a645b084809734ad4df006,biomarker,0.410082
uuid-e41caa97d48b49d3bfe0d015b3fdfbbb,tumor,0.39387
uuid-e41caa97d48b49d3bfe0d015b3fdfbbb,biomarker,0.329939
uuid-95d2c1804df24306901f485dc00dac18,PDL1,0.677477
uuid-95d2c1804df24306901f485dc00dac18,trial,0.318177
uuid-95d2c1804df24306901f485dc00dac18,efficacy,0.308402
uuid-95d2c1804df24306901f485dc00dac18,PD-L1,0.391954
uuid-95d2c1804df24306901f485dc00dac18,OS,0.362682
uuid-95d2c1804df24306901f485dc00dac18,data,0.340994
uuid-95d2c1804df24306901f485dc00dac18,PFS,0.406609
uuid-95d2c1804df24306901f485dc00dac18,ORR,0.455582
uuid-95d2c1804df24306901f485dc00dac18,nivo and pembro,0.365096
uuid-95d2c1804df24306901f485dc00dac18,PDL1 expression,0.650145
uuid-95d2c1804df24306901f485dc00dac18,biomarker,0.416681
uuid-f09565f9185642ff92614a6f380df320,patients,0.635772
uuid-f09565f9185642ff92614a6f380df320,therapy,0.3949
uuid-f09565f9185642ff92614a6f380df320,1L,0.522374
uuid-f09565f9185642ff92614a6f380df320,PDL1,0.351884
uuid-f09565f9185642ff92614a6f380df320,chemo,0.447639
uuid-f09565f9185642ff92614a6f380df320,2L,0.402048
uuid-f09565f9185642ff92614a6f380df320,pts,0.530619
uuid-f09565f9185642ff92614a6f380df320,PD-L1,0.391197
uuid-f09565f9185642ff92614a6f380df320,preferred,0.38739
uuid-f09565f9185642ff92614a6f380df320,testing,0.415394
uuid-f09565f9185642ff92614a6f380df320,monotherapy,0.514225
uuid-f09565f9185642ff92614a6f380df320,treatment,0.38286
uuid-f09565f9185642ff92614a6f380df320,PDL1 testing,0.37344
uuid-f09565f9185642ff92614a6f380df320,NSCLC patients,0.586728
uuid-f09565f9185642ff92614a6f380df320,PD1,0.342748
uuid-f09565f9185642ff92614a6f380df320,progression,0.44803
uuid-f09565f9185642ff92614a6f380df320,chemotherapy,0.37334
uuid-f09565f9185642ff92614a6f380df320,tumor types,0.427651
uuid-f09565f9185642ff92614a6f380df320,respond,0.406222
uuid-f09565f9185642ff92614a6f380df320,PD-1,0.329194
uuid-f09565f9185642ff92614a6f380df320,option,0.609675
uuid-29596fa33a7b45e48342e7f32db836b4,RTL,0.337708
uuid-29596fa33a7b45e48342e7f32db836b4,toxicity,0.366944
uuid-29596fa33a7b45e48342e7f32db836b4,regimen,0.364349
uuid-29596fa33a7b45e48342e7f32db836b4,treated,0.518704
uuid-29596fa33a7b45e48342e7f32db836b4,shared,0.378294
uuid-29596fa33a7b45e48342e7f32db836b4,commented,0.326922
uuid-29596fa33a7b45e48342e7f32db836b4,physicians,0.564665
uuid-29596fa33a7b45e48342e7f32db836b4,HCP,0.308928
uuid-29596fa33a7b45e48342e7f32db836b4,LTL,0.320631
uuid-29596fa33a7b45e48342e7f32db836b4,TLs,0.332144
uuid-29596fa33a7b45e48342e7f32db836b4,academic,0.366497
uuid-29596fa33a7b45e48342e7f32db836b4,Regional TL,0.388954
uuid-29596fa33a7b45e48342e7f32db836b4,RTL stated,0.300557
uuid-29596fa33a7b45e48342e7f32db836b4,TL shared,0.317339
uuid-e5f762ed9c57401c9c42de30d16b6324,Merck,0.300138
uuid-e5f762ed9c57401c9c42de30d16b6324,institution,0.370347
uuid-e5f762ed9c57401c9c42de30d16b6324,stated,0.32352
uuid-e5f762ed9c57401c9c42de30d16b6324,PDL1 testing,0.356468
uuid-e5f762ed9c57401c9c42de30d16b6324,NCCN,0.427982
uuid-73bffb260bbb43fbb1afef38f7285fbf,discussed,0.411639
uuid-73bffb260bbb43fbb1afef38f7285fbf,oncology,0.61814
uuid-73bffb260bbb43fbb1afef38f7285fbf,clinical,0.334817
uuid-f85585e55c224aacbf349bec9c875b29,TL,0.371653
uuid-f85585e55c224aacbf349bec9c875b29,pembro,0.373329
uuid-f85585e55c224aacbf349bec9c875b29,PDL1,0.530285
uuid-f85585e55c224aacbf349bec9c875b29,Merck,0.566069
uuid-f85585e55c224aacbf349bec9c875b29,PD-L1,0.698713
uuid-f85585e55c224aacbf349bec9c875b29,approval,0.322041
uuid-f85585e55c224aacbf349bec9c875b29,atezo,0.439614
uuid-f85585e55c224aacbf349bec9c875b29,PD-L1 testing,0.633397
uuid-f85585e55c224aacbf349bec9c875b29,testing,0.778472
uuid-f85585e55c224aacbf349bec9c875b29,PDL1 testing,0.61982
uuid-f85585e55c224aacbf349bec9c875b29,NSCLC patients,0.508276
uuid-f85585e55c224aacbf349bec9c875b29,approved,0.321814
uuid-f85585e55c224aacbf349bec9c875b29,assay,0.669379
uuid-f85585e55c224aacbf349bec9c875b29,PDL1 expression,0.432402
uuid-f85585e55c224aacbf349bec9c875b29,biomarker,0.506079
uuid-7badaa7df0bd49be82fe7c4db7639876,Nivo,0.471276
uuid-7badaa7df0bd49be82fe7c4db7639876,pembro,0.549322
uuid-7badaa7df0bd49be82fe7c4db7639876,dose,0.411458
uuid-7badaa7df0bd49be82fe7c4db7639876,1L,0.37286
uuid-7badaa7df0bd49be82fe7c4db7639876,efficacy,0.559891
uuid-7badaa7df0bd49be82fe7c4db7639876,combination,0.354917
uuid-7badaa7df0bd49be82fe7c4db7639876,2L,0.451384
uuid-7badaa7df0bd49be82fe7c4db7639876,agents,0.490507
uuid-7badaa7df0bd49be82fe7c4db7639876,Ipi,0.384399
uuid-7badaa7df0bd49be82fe7c4db7639876,atezo,0.62752
uuid-7badaa7df0bd49be82fe7c4db7639876,preferred,0.432482
uuid-7badaa7df0bd49be82fe7c4db7639876,monotherapy,0.421766
uuid-7badaa7df0bd49be82fe7c4db7639876,combo,0.438264
uuid-7badaa7df0bd49be82fe7c4db7639876,indication,0.355107
uuid-7badaa7df0bd49be82fe7c4db7639876,approved,0.370813
uuid-7badaa7df0bd49be82fe7c4db7639876,nivo and pembro,0.374152
uuid-7badaa7df0bd49be82fe7c4db7639876,believes,0.403701
uuid-7badaa7df0bd49be82fe7c4db7639876,vs,0.517905
uuid-7badaa7df0bd49be82fe7c4db7639876,Keytruda,0.359709
uuid-7badaa7df0bd49be82fe7c4db7639876,option,0.383661
uuid-7badaa7df0bd49be82fe7c4db7639876,flat dosing,0.395904
uuid-2b1effe446d0475ab353ea2ab5971c30,Nivo,0.306905
uuid-2b1effe446d0475ab353ea2ab5971c30,pembro,0.417151
uuid-2b1effe446d0475ab353ea2ab5971c30,dose,0.534304
uuid-2b1effe446d0475ab353ea2ab5971c30,trial,0.401186
uuid-2b1effe446d0475ab353ea2ab5971c30,efficacy,0.519358
uuid-2b1effe446d0475ab353ea2ab5971c30,Ipi,0.498518
uuid-2b1effe446d0475ab353ea2ab5971c30,atezo,0.430268
uuid-2b1effe446d0475ab353ea2ab5971c30,vs,0.707089
uuid-2b1effe446d0475ab353ea2ab5971c30,TLs,0.329131
uuid-2b1effe446d0475ab353ea2ab5971c30,flat dosing,0.451262
uuid-8c1cc635d8224e05b49c7ce35cc69500,Opdivo,0.490074
uuid-8c1cc635d8224e05b49c7ce35cc69500,dose,0.884526
uuid-8c1cc635d8224e05b49c7ce35cc69500,toxicity,0.552591
uuid-8c1cc635d8224e05b49c7ce35cc69500,regimen,0.37993
uuid-8c1cc635d8224e05b49c7ce35cc69500,Ipi,0.485237
uuid-8c1cc635d8224e05b49c7ce35cc69500,vs,0.460812
uuid-8c1cc635d8224e05b49c7ce35cc69500,drug,0.469757
uuid-8c1cc635d8224e05b49c7ce35cc69500,Keytruda,0.438016
uuid-8c1cc635d8224e05b49c7ce35cc69500,flat dosing,0.725608
uuid-cf61f14dce854c4c86904a18333fd2f4,RTL,0.590159
uuid-cf61f14dce854c4c86904a18333fd2f4,trial,0.562711
uuid-cf61f14dce854c4c86904a18333fd2f4,efficacy,0.334859
uuid-cf61f14dce854c4c86904a18333fd2f4,NTL,0.350606
uuid-cf61f14dce854c4c86904a18333fd2f4,commented,0.458541
uuid-cf61f14dce854c4c86904a18333fd2f4,OS,0.483578
uuid-cf61f14dce854c4c86904a18333fd2f4,data,0.592224
uuid-cf61f14dce854c4c86904a18333fd2f4,combo,0.337414
uuid-cf61f14dce854c4c86904a18333fd2f4,expressed,0.396424
uuid-cf61f14dce854c4c86904a18333fd2f4,mentioned,0.328009
uuid-cf61f14dce854c4c86904a18333fd2f4,PFS,0.442624
uuid-cf61f14dce854c4c86904a18333fd2f4,ORR,0.524651
uuid-cf61f14dce854c4c86904a18333fd2f4,ASCO,0.446053
uuid-cf61f14dce854c4c86904a18333fd2f4,impressed,0.69345
uuid-cf61f14dce854c4c86904a18333fd2f4,LTL,0.398513
uuid-cf61f14dce854c4c86904a18333fd2f4,TLs,0.363389
uuid-cf61f14dce854c4c86904a18333fd2f4,SCLC,0.314464
uuid-cf61f14dce854c4c86904a18333fd2f4,feels,0.318922
uuid-cf61f14dce854c4c86904a18333fd2f4,Regional TL,0.359222
uuid-b4299fa365e34658b75ae06af7391e79,lung,0.407811
uuid-b4299fa365e34658b75ae06af7391e79,NTL,0.42362
uuid-b4299fa365e34658b75ae06af7391e79,melanoma,0.327775
uuid-b4299fa365e34658b75ae06af7391e79,RCC,0.307538
uuid-b4299fa365e34658b75ae06af7391e79,expressed,0.31616
uuid-b4299fa365e34658b75ae06af7391e79,ASCO,0.452716
uuid-b4299fa365e34658b75ae06af7391e79,SCLC,0.338691
uuid-b4299fa365e34658b75ae06af7391e79,Regional TL,0.409618
uuid-406a13b33de84ddc9e7d52dddb027477,Nivo,0.37428
uuid-406a13b33de84ddc9e7d52dddb027477,pembro,0.448912
uuid-406a13b33de84ddc9e7d52dddb027477,1L,0.355024
uuid-406a13b33de84ddc9e7d52dddb027477,PDL1,0.474404
uuid-406a13b33de84ddc9e7d52dddb027477,trial,0.450204
uuid-406a13b33de84ddc9e7d52dddb027477,efficacy,0.520729
uuid-406a13b33de84ddc9e7d52dddb027477,combination,0.313885
uuid-406a13b33de84ddc9e7d52dddb027477,2L,0.300392
uuid-406a13b33de84ddc9e7d52dddb027477,agents,0.308201
uuid-406a13b33de84ddc9e7d52dddb027477,OS,0.428638
uuid-406a13b33de84ddc9e7d52dddb027477,atezo,0.457442
uuid-406a13b33de84ddc9e7d52dddb027477,data,0.54994
uuid-406a13b33de84ddc9e7d52dddb027477,combo,0.31153
uuid-406a13b33de84ddc9e7d52dddb027477,PFS,0.393995
uuid-406a13b33de84ddc9e7d52dddb027477,ORR,0.458664
uuid-406a13b33de84ddc9e7d52dddb027477,nivo and pembro,0.521395
uuid-406a13b33de84ddc9e7d52dddb027477,believes,0.44541
uuid-406a13b33de84ddc9e7d52dddb027477,impressed,0.487831
uuid-406a13b33de84ddc9e7d52dddb027477,feels,0.328487
uuid-406a13b33de84ddc9e7d52dddb027477,PDL1 expression,0.429359
uuid-406a13b33de84ddc9e7d52dddb027477,biomarker,0.315408
uuid-406a13b33de84ddc9e7d52dddb027477,bladder,0.308902
uuid-6e3caa25f8f4470bb39cc769b1a741cb,patients,0.331057
uuid-6e3caa25f8f4470bb39cc769b1a741cb,dose,0.599275
uuid-6e3caa25f8f4470bb39cc769b1a741cb,toxicity,0.670156
uuid-6e3caa25f8f4470bb39cc769b1a741cb,regimen,0.486117
uuid-6e3caa25f8f4470bb39cc769b1a741cb,treated,0.343483
uuid-6e3caa25f8f4470bb39cc769b1a741cb,Ipi,0.337555
uuid-6e3caa25f8f4470bb39cc769b1a741cb,treatment,0.455646
uuid-6e3caa25f8f4470bb39cc769b1a741cb,respond,0.38677
uuid-696fd02c15394e60be44792640bd3c86,Nivo,0.479727
uuid-696fd02c15394e60be44792640bd3c86,pembro,0.428443
uuid-696fd02c15394e60be44792640bd3c86,1L,0.49592
uuid-696fd02c15394e60be44792640bd3c86,efficacy,0.539237
uuid-696fd02c15394e60be44792640bd3c86,combination,0.372976
uuid-696fd02c15394e60be44792640bd3c86,chemo,0.431951
uuid-696fd02c15394e60be44792640bd3c86,2L,0.466515
uuid-696fd02c15394e60be44792640bd3c86,agents,0.464293
uuid-696fd02c15394e60be44792640bd3c86,Ipi,0.309239
uuid-696fd02c15394e60be44792640bd3c86,OS,0.471573
uuid-696fd02c15394e60be44792640bd3c86,atezo,0.42234
uuid-696fd02c15394e60be44792640bd3c86,preferred,0.428868
uuid-696fd02c15394e60be44792640bd3c86,monotherapy,0.485643
uuid-696fd02c15394e60be44792640bd3c86,data,0.371204
uuid-696fd02c15394e60be44792640bd3c86,combo,0.50429
uuid-696fd02c15394e60be44792640bd3c86,indication,0.3192
uuid-696fd02c15394e60be44792640bd3c86,PFS,0.410814
uuid-696fd02c15394e60be44792640bd3c86,ORR,0.412504
uuid-696fd02c15394e60be44792640bd3c86,approved,0.376199
uuid-696fd02c15394e60be44792640bd3c86,nivo and pembro,0.438768
uuid-696fd02c15394e60be44792640bd3c86,believes,0.453582
uuid-696fd02c15394e60be44792640bd3c86,chemotherapy,0.330313
uuid-696fd02c15394e60be44792640bd3c86,impressed,0.34869
uuid-696fd02c15394e60be44792640bd3c86,feels,0.499419
uuid-696fd02c15394e60be44792640bd3c86,option,0.542662
uuid-e9236b6154f142c0a13e9aa4992313ce,patients,0.621858
uuid-e9236b6154f142c0a13e9aa4992313ce,Opdivo,0.319669
uuid-e9236b6154f142c0a13e9aa4992313ce,dose,0.4978
uuid-e9236b6154f142c0a13e9aa4992313ce,toxicity,0.492611
uuid-e9236b6154f142c0a13e9aa4992313ce,regimen,0.443711
uuid-e9236b6154f142c0a13e9aa4992313ce,treated,0.412418
uuid-e9236b6154f142c0a13e9aa4992313ce,pts,0.396039
uuid-e9236b6154f142c0a13e9aa4992313ce,treatment,0.500047
uuid-e9236b6154f142c0a13e9aa4992313ce,progression,0.477695
uuid-e9236b6154f142c0a13e9aa4992313ce,respond,0.429966
uuid-72730ab94c724059b1932bfdd64ca300,patients,0.461662
uuid-72730ab94c724059b1932bfdd64ca300,nivolumab,0.364496
uuid-72730ab94c724059b1932bfdd64ca300,trial,0.486232
uuid-72730ab94c724059b1932bfdd64ca300,combination,0.397909
uuid-72730ab94c724059b1932bfdd64ca300,chemo,0.31162
uuid-72730ab94c724059b1932bfdd64ca300,pts,0.43209
uuid-72730ab94c724059b1932bfdd64ca300,monotherapy,0.31182
uuid-72730ab94c724059b1932bfdd64ca300,combo,0.349614
uuid-72730ab94c724059b1932bfdd64ca300,clinical trials,0.536436
uuid-72730ab94c724059b1932bfdd64ca300,chemotherapy,0.364755
uuid-72730ab94c724059b1932bfdd64ca300,option,0.320614
uuid-30409b09be1d48d084d7e26b42b08b29,Nivo,0.444581
uuid-30409b09be1d48d084d7e26b42b08b29,pembro,0.382477
uuid-30409b09be1d48d084d7e26b42b08b29,therapy,0.396402
uuid-30409b09be1d48d084d7e26b42b08b29,nivolumab,0.355931
uuid-30409b09be1d48d084d7e26b42b08b29,1L,0.682389
uuid-30409b09be1d48d084d7e26b42b08b29,regimen,0.365107
uuid-30409b09be1d48d084d7e26b42b08b29,RCC,0.493847
uuid-30409b09be1d48d084d7e26b42b08b29,combination,0.487817
uuid-30409b09be1d48d084d7e26b42b08b29,chemo,0.443845
uuid-30409b09be1d48d084d7e26b42b08b29,2L,0.71983
uuid-30409b09be1d48d084d7e26b42b08b29,agents,0.630529
uuid-30409b09be1d48d084d7e26b42b08b29,atezo,0.417833
uuid-30409b09be1d48d084d7e26b42b08b29,preferred,0.643888
uuid-30409b09be1d48d084d7e26b42b08b29,monotherapy,0.700749
uuid-30409b09be1d48d084d7e26b42b08b29,treatment,0.358838
uuid-30409b09be1d48d084d7e26b42b08b29,using nivo,0.536575
uuid-30409b09be1d48d084d7e26b42b08b29,combo,0.533134
uuid-30409b09be1d48d084d7e26b42b08b29,PD1,0.494557
uuid-30409b09be1d48d084d7e26b42b08b29,approved,0.517308
uuid-30409b09be1d48d084d7e26b42b08b29,believes,0.371042
uuid-30409b09be1d48d084d7e26b42b08b29,chemotherapy,0.417603
uuid-30409b09be1d48d084d7e26b42b08b29,feels,0.307636
uuid-30409b09be1d48d084d7e26b42b08b29,PD-1,0.365744
uuid-30409b09be1d48d084d7e26b42b08b29,RTL stated,0.481062
uuid-30409b09be1d48d084d7e26b42b08b29,option,0.724999
uuid-114510b51def40d6bce804b59f970b73,tumor,0.636095
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,Nivo,0.40239
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,patients,0.555154
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,therapy,0.350814
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,nivolumab,0.302827
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,regimen,0.339553
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,treated,0.31707
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,combination,0.369371
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,chemo,0.520182
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,tumor,0.410209
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,pts,0.605152
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,monotherapy,0.433845
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,response,0.472534
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,combo,0.33755
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,PD1,0.416966
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,progression,0.519633
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,chemotherapy,0.429434
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,respond,0.312138
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,feels,0.358256
uuid-c907ddd1d0fb4f5cb9beaa1eb28c1665,option,0.361764
uuid-979f946ecb144b5ba64f6c5f7bcbb747,Nivo,0.547638
uuid-979f946ecb144b5ba64f6c5f7bcbb747,pembro,0.479946
uuid-979f946ecb144b5ba64f6c5f7bcbb747,therapy,0.325172
uuid-979f946ecb144b5ba64f6c5f7bcbb747,1L,0.796002
uuid-979f946ecb144b5ba64f6c5f7bcbb747,regimen,0.364288
uuid-979f946ecb144b5ba64f6c5f7bcbb747,RCC,0.442762
uuid-979f946ecb144b5ba64f6c5f7bcbb747,combination,0.368345
uuid-979f946ecb144b5ba64f6c5f7bcbb747,chemo,0.52801
uuid-979f946ecb144b5ba64f6c5f7bcbb747,2L,0.843981
uuid-979f946ecb144b5ba64f6c5f7bcbb747,pts,0.359942
uuid-979f946ecb144b5ba64f6c5f7bcbb747,agents,0.525054
uuid-979f946ecb144b5ba64f6c5f7bcbb747,atezo,0.526194
uuid-979f946ecb144b5ba64f6c5f7bcbb747,preferred,0.728154
uuid-979f946ecb144b5ba64f6c5f7bcbb747,monotherapy,0.747328
uuid-979f946ecb144b5ba64f6c5f7bcbb747,using nivo,0.623065
uuid-979f946ecb144b5ba64f6c5f7bcbb747,combo,0.47302
uuid-979f946ecb144b5ba64f6c5f7bcbb747,PD1,0.447601
uuid-979f946ecb144b5ba64f6c5f7bcbb747,approved,0.511287
uuid-979f946ecb144b5ba64f6c5f7bcbb747,nivo and pembro,0.349919
uuid-979f946ecb144b5ba64f6c5f7bcbb747,believes,0.499996
uuid-979f946ecb144b5ba64f6c5f7bcbb747,chemotherapy,0.394562
uuid-979f946ecb144b5ba64f6c5f7bcbb747,feels,0.416462
uuid-979f946ecb144b5ba64f6c5f7bcbb747,RTL stated,0.446622
uuid-979f946ecb144b5ba64f6c5f7bcbb747,option,0.761564
uuid-1ff994c967134eeaabab9829b0e3ed0a,Nivo,0.45604
uuid-1ff994c967134eeaabab9829b0e3ed0a,pembro,0.548913
uuid-1ff994c967134eeaabab9829b0e3ed0a,BMS,0.36261
uuid-1ff994c967134eeaabab9829b0e3ed0a,PDL1,0.512805
uuid-1ff994c967134eeaabab9829b0e3ed0a,trial,0.459991
uuid-1ff994c967134eeaabab9829b0e3ed0a,efficacy,0.70273
uuid-1ff994c967134eeaabab9829b0e3ed0a,Merck,0.349878
uuid-1ff994c967134eeaabab9829b0e3ed0a,OS,0.667541
uuid-1ff994c967134eeaabab9829b0e3ed0a,atezo,0.431471
uuid-1ff994c967134eeaabab9829b0e3ed0a,data,0.72251
uuid-1ff994c967134eeaabab9829b0e3ed0a,PFS,0.623488
uuid-1ff994c967134eeaabab9829b0e3ed0a,ORR,0.662582
uuid-1ff994c967134eeaabab9829b0e3ed0a,nivo and pembro,0.560068
uuid-1ff994c967134eeaabab9829b0e3ed0a,impressed,0.506816
uuid-1ff994c967134eeaabab9829b0e3ed0a,vs,0.492341
uuid-1ff994c967134eeaabab9829b0e3ed0a,feels,0.409454
uuid-1ff994c967134eeaabab9829b0e3ed0a,PDL1 expression,0.456188
uuid-7905fefe5f984852a777fb20ac7d129d,Nivo,0.470392
uuid-7905fefe5f984852a777fb20ac7d129d,patients,0.791324
uuid-7905fefe5f984852a777fb20ac7d129d,Opdivo,0.449212
uuid-7905fefe5f984852a777fb20ac7d129d,therapy,0.561983
uuid-7905fefe5f984852a777fb20ac7d129d,dose,0.452368
uuid-7905fefe5f984852a777fb20ac7d129d,nivolumab,0.510114
uuid-7905fefe5f984852a777fb20ac7d129d,regimen,0.487853
uuid-7905fefe5f984852a777fb20ac7d129d,treated,0.435659
uuid-7905fefe5f984852a777fb20ac7d129d,chemo,0.446017
uuid-7905fefe5f984852a777fb20ac7d129d,pts,0.526545
uuid-7905fefe5f984852a777fb20ac7d129d,Ipi,0.335871
uuid-7905fefe5f984852a777fb20ac7d129d,monotherapy,0.379022
uuid-7905fefe5f984852a777fb20ac7d129d,treatment,0.642854
uuid-7905fefe5f984852a777fb20ac7d129d,using nivo,0.366203
uuid-7905fefe5f984852a777fb20ac7d129d,response,0.34885
uuid-7905fefe5f984852a777fb20ac7d129d,PD1,0.322065
uuid-7905fefe5f984852a777fb20ac7d129d,progression,0.559603
uuid-7905fefe5f984852a777fb20ac7d129d,chemotherapy,0.474602
uuid-7905fefe5f984852a777fb20ac7d129d,respond,0.407397
uuid-7905fefe5f984852a777fb20ac7d129d,option,0.392158
uuid-aaf06b0ae473440d839476dc49046ec9,efficacy,0.601726
uuid-aaf06b0ae473440d839476dc49046ec9,combination,0.320647
uuid-aaf06b0ae473440d839476dc49046ec9,chemo,0.412952
uuid-aaf06b0ae473440d839476dc49046ec9,IO,0.316565
uuid-aaf06b0ae473440d839476dc49046ec9,OS,0.691333
uuid-aaf06b0ae473440d839476dc49046ec9,response,0.491794
uuid-aaf06b0ae473440d839476dc49046ec9,data,0.385863
uuid-aaf06b0ae473440d839476dc49046ec9,PFS,0.64353
uuid-aaf06b0ae473440d839476dc49046ec9,PD1,0.357567
uuid-aaf06b0ae473440d839476dc49046ec9,ORR,0.657338
uuid-aaf06b0ae473440d839476dc49046ec9,believes,0.432934
uuid-aaf06b0ae473440d839476dc49046ec9,chemotherapy,0.354916
uuid-aaf06b0ae473440d839476dc49046ec9,impressed,0.363821
uuid-aaf06b0ae473440d839476dc49046ec9,feels,0.42065
uuid-f9b65cdfdf5f45f38a484b6e4117b602,Nivo,0.32375
uuid-f9b65cdfdf5f45f38a484b6e4117b602,patients,0.319906
uuid-f9b65cdfdf5f45f38a484b6e4117b602,regimen,0.329787
uuid-f9b65cdfdf5f45f38a484b6e4117b602,chemo,0.331755
uuid-f9b65cdfdf5f45f38a484b6e4117b602,pts,0.399431
uuid-f9b65cdfdf5f45f38a484b6e4117b602,monotherapy,0.342903
uuid-f9b65cdfdf5f45f38a484b6e4117b602,response,0.361619
uuid-f9b65cdfdf5f45f38a484b6e4117b602,PD1,0.304792
uuid-f9b65cdfdf5f45f38a484b6e4117b602,progression,0.373345
uuid-f9b65cdfdf5f45f38a484b6e4117b602,chemotherapy,0.312006
uuid-f793f42e018d4ad187b97fa35fd485f1,Nivo,0.567101
uuid-f793f42e018d4ad187b97fa35fd485f1,pembro,0.316459
uuid-f793f42e018d4ad187b97fa35fd485f1,therapy,0.43692
uuid-f793f42e018d4ad187b97fa35fd485f1,combination,0.336953
uuid-f793f42e018d4ad187b97fa35fd485f1,chemo,0.398924
uuid-f793f42e018d4ad187b97fa35fd485f1,monotherapy,0.382725
uuid-f793f42e018d4ad187b97fa35fd485f1,using nivo,0.402222
uuid-f793f42e018d4ad187b97fa35fd485f1,PD1,0.387163
uuid-f793f42e018d4ad187b97fa35fd485f1,cHL,0.466849
uuid-f793f42e018d4ad187b97fa35fd485f1,chemotherapy,0.415813
uuid-f793f42e018d4ad187b97fa35fd485f1,feels,0.393668
uuid-f793f42e018d4ad187b97fa35fd485f1,option,0.374198
uuid-e35c757145694a9c8d428bc090ec32a0,nivolumab,0.340706
uuid-e35c757145694a9c8d428bc090ec32a0,NTL,0.377933
uuid-e35c757145694a9c8d428bc090ec32a0,discussed,0.37253
uuid-e35c757145694a9c8d428bc090ec32a0,mentioned,0.315405
uuid-e35c757145694a9c8d428bc090ec32a0,cHL,0.520525
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,patients,0.767411
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,Opdivo,0.371714
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,therapy,0.450718
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,nivolumab,0.420217
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,toxicity,0.45791
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,regimen,0.650063
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,treated,0.664236
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,pts,0.474471
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,treatment,0.731877
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,response,0.323806
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,progression,0.556901
uuid-57d2c8b9fa9e4ee39c1390dc28f5f36c,respond,0.579252
uuid-8541603f2f744dcaa40a7775ab94abf5,patients,0.628132
uuid-8541603f2f744dcaa40a7775ab94abf5,Opdivo,0.682043
uuid-8541603f2f744dcaa40a7775ab94abf5,therapy,0.474988
uuid-8541603f2f744dcaa40a7775ab94abf5,nivolumab,0.536273
uuid-8541603f2f744dcaa40a7775ab94abf5,regimen,0.39084
uuid-8541603f2f744dcaa40a7775ab94abf5,treated,0.626966
uuid-8541603f2f744dcaa40a7775ab94abf5,pts,0.300393
uuid-8541603f2f744dcaa40a7775ab94abf5,approval,0.348996
uuid-8541603f2f744dcaa40a7775ab94abf5,treatment,0.536059
uuid-8541603f2f744dcaa40a7775ab94abf5,using nivo,0.403404
uuid-8541603f2f744dcaa40a7775ab94abf5,cHL,0.542292
uuid-8541603f2f744dcaa40a7775ab94abf5,progression,0.397849
uuid-8541603f2f744dcaa40a7775ab94abf5,respond,0.326449
uuid-bc627ed1e5734f5fb3f14faf9ecb477f,drug,0.353602
uuid-bc627ed1e5734f5fb3f14faf9ecb477f,PD-1,0.363907
uuid-06bdd0ca778f41a388c509c11a1c12e8,toxicity,0.643097
uuid-06bdd0ca778f41a388c509c11a1c12e8,regimen,0.458185
uuid-06bdd0ca778f41a388c509c11a1c12e8,treated,0.363076
uuid-06bdd0ca778f41a388c509c11a1c12e8,treatment,0.46918
uuid-06bdd0ca778f41a388c509c11a1c12e8,respond,0.490107
uuid-5cb956a7e62647be9c641fa808fb12fc,patients,0.601564
uuid-5cb956a7e62647be9c641fa808fb12fc,treated,0.34034
uuid-5cb956a7e62647be9c641fa808fb12fc,pts,0.392453
uuid-5cb956a7e62647be9c641fa808fb12fc,PD-L1,0.461588
uuid-5cb956a7e62647be9c641fa808fb12fc,approval,0.39655
uuid-5cb956a7e62647be9c641fa808fb12fc,PD-L1 testing,0.54684
uuid-5cb956a7e62647be9c641fa808fb12fc,testing,0.628792
uuid-5cb956a7e62647be9c641fa808fb12fc,treatment,0.367157
uuid-5cb956a7e62647be9c641fa808fb12fc,PDL1 testing,0.431835
uuid-5cb956a7e62647be9c641fa808fb12fc,NSCLC patients,0.670522
uuid-5cb956a7e62647be9c641fa808fb12fc,progression,0.335667
uuid-5cb956a7e62647be9c641fa808fb12fc,respond,0.304687
uuid-ca97d64b5d854513b8984857e1e2edb6,patients,0.33897
uuid-ca97d64b5d854513b8984857e1e2edb6,RTL,0.626976
uuid-ca97d64b5d854513b8984857e1e2edb6,nivolumab,0.428832
uuid-ca97d64b5d854513b8984857e1e2edb6,regimen,0.334632
uuid-ca97d64b5d854513b8984857e1e2edb6,treated,0.381322
uuid-ca97d64b5d854513b8984857e1e2edb6,NTL,0.32153
uuid-ca97d64b5d854513b8984857e1e2edb6,commented,0.398858
uuid-ca97d64b5d854513b8984857e1e2edb6,stated,0.39354
uuid-ca97d64b5d854513b8984857e1e2edb6,physicians,0.319326
uuid-ca97d64b5d854513b8984857e1e2edb6,mentioned,0.341457
uuid-ca97d64b5d854513b8984857e1e2edb6,clinical trials,0.302314
uuid-ca97d64b5d854513b8984857e1e2edb6,SCCHN,0.383495
uuid-ca97d64b5d854513b8984857e1e2edb6,HCP,0.424394
uuid-ca97d64b5d854513b8984857e1e2edb6,ASCO,0.449488
uuid-ca97d64b5d854513b8984857e1e2edb6,impressed,0.536538
uuid-ca97d64b5d854513b8984857e1e2edb6,LTL,0.47489
uuid-ca97d64b5d854513b8984857e1e2edb6,TLs,0.304379
uuid-ca97d64b5d854513b8984857e1e2edb6,academic,0.302024
uuid-ca97d64b5d854513b8984857e1e2edb6,Regional TL,0.526695
uuid-ca97d64b5d854513b8984857e1e2edb6,RTL stated,0.316261
uuid-366f9eeb81a647bda2f05d9989f7d8b7,BMS,0.324996
uuid-366f9eeb81a647bda2f05d9989f7d8b7,PDL1,0.72803
uuid-366f9eeb81a647bda2f05d9989f7d8b7,efficacy,0.410282
uuid-366f9eeb81a647bda2f05d9989f7d8b7,Merck,0.374897
uuid-366f9eeb81a647bda2f05d9989f7d8b7,PD-L1,0.487215
uuid-366f9eeb81a647bda2f05d9989f7d8b7,OS,0.395073
uuid-366f9eeb81a647bda2f05d9989f7d8b7,testing,0.350114
uuid-366f9eeb81a647bda2f05d9989f7d8b7,regards,0.360374
uuid-366f9eeb81a647bda2f05d9989f7d8b7,data,0.54355
uuid-366f9eeb81a647bda2f05d9989f7d8b7,expressed,0.311613
uuid-366f9eeb81a647bda2f05d9989f7d8b7,PFS,0.421447
uuid-366f9eeb81a647bda2f05d9989f7d8b7,ORR,0.455103
uuid-366f9eeb81a647bda2f05d9989f7d8b7,nivo and pembro,0.448513
uuid-366f9eeb81a647bda2f05d9989f7d8b7,believes,0.324619
uuid-366f9eeb81a647bda2f05d9989f7d8b7,impressed,0.303409
uuid-366f9eeb81a647bda2f05d9989f7d8b7,assay,0.464545
uuid-366f9eeb81a647bda2f05d9989f7d8b7,PDL1 expression,0.667767
uuid-366f9eeb81a647bda2f05d9989f7d8b7,biomarker,0.698268
uuid-1a069fb6b5a34b449cef9745951139d6,Opdivo,0.504191
uuid-1a069fb6b5a34b449cef9745951139d6,dose,0.705633
uuid-1a069fb6b5a34b449cef9745951139d6,Ipi,0.305066
uuid-1a069fb6b5a34b449cef9745951139d6,vs,0.417805
uuid-1a069fb6b5a34b449cef9745951139d6,Keytruda,0.352897
uuid-1a069fb6b5a34b449cef9745951139d6,flat dosing,0.644526
uuid-b9f73375e3614704a60b8243b2ae99b8,Opdivo,0.433643
uuid-b9f73375e3614704a60b8243b2ae99b8,physicians,0.328847
uuid-b9f73375e3614704a60b8243b2ae99b8,approved,0.310568
uuid-b9f73375e3614704a60b8243b2ae99b8,label,0.305711
uuid-b9f73375e3614704a60b8243b2ae99b8,drug,0.358129
uuid-b9f73375e3614704a60b8243b2ae99b8,Keytruda,0.328616
uuid-b9f73375e3614704a60b8243b2ae99b8,flat dosing,0.318907
uuid-0b313a78c9514126b3bc09b66053f486,patients,0.387391
uuid-0b313a78c9514126b3bc09b66053f486,Opdivo,0.304513
uuid-0b313a78c9514126b3bc09b66053f486,therapy,0.328512
uuid-0b313a78c9514126b3bc09b66053f486,dose,0.366535
uuid-0b313a78c9514126b3bc09b66053f486,toxicity,0.467495
uuid-0b313a78c9514126b3bc09b66053f486,regimen,0.507437
uuid-0b313a78c9514126b3bc09b66053f486,physicians,0.31212
uuid-0b313a78c9514126b3bc09b66053f486,treatment,0.533845
uuid-0b313a78c9514126b3bc09b66053f486,drug,0.312245
uuid-0917908b66244e3cba4ef357a7dbfeb4,TL,0.455456
uuid-0917908b66244e3cba4ef357a7dbfeb4,RTL,0.30844
uuid-0917908b66244e3cba4ef357a7dbfeb4,lung,0.359759
uuid-0917908b66244e3cba4ef357a7dbfeb4,treated,0.37845
uuid-0917908b66244e3cba4ef357a7dbfeb4,melanoma,0.342087
uuid-0917908b66244e3cba4ef357a7dbfeb4,shared,0.351041
uuid-0917908b66244e3cba4ef357a7dbfeb4,RCC,0.461559
uuid-0917908b66244e3cba4ef357a7dbfeb4,TL stated,0.568377
uuid-0917908b66244e3cba4ef357a7dbfeb4,institution,0.369555
uuid-0917908b66244e3cba4ef357a7dbfeb4,physicians,0.37605
uuid-0917908b66244e3cba4ef357a7dbfeb4,PD-L1 testing,0.51759
uuid-0917908b66244e3cba4ef357a7dbfeb4,testing,0.339311
uuid-0917908b66244e3cba4ef357a7dbfeb4,PDL1 testing,0.463334
uuid-0917908b66244e3cba4ef357a7dbfeb4,NSCLC patients,0.349521
uuid-0917908b66244e3cba4ef357a7dbfeb4,oncology,0.316073
uuid-0917908b66244e3cba4ef357a7dbfeb4,SCCHN,0.413691
uuid-0917908b66244e3cba4ef357a7dbfeb4,oncologist,0.371824
uuid-0917908b66244e3cba4ef357a7dbfeb4,TLs,0.337432
uuid-0917908b66244e3cba4ef357a7dbfeb4,academic,0.400804
uuid-0917908b66244e3cba4ef357a7dbfeb4,Regional TL,0.465994
uuid-0917908b66244e3cba4ef357a7dbfeb4,RTL stated,0.391756
uuid-0917908b66244e3cba4ef357a7dbfeb4,TL shared,0.404452
uuid-d4002d853ef24b82946e34ede410cd0a,Nivo,0.69868
uuid-d4002d853ef24b82946e34ede410cd0a,patients,0.358689
uuid-d4002d853ef24b82946e34ede410cd0a,Opdivo,0.333937
uuid-d4002d853ef24b82946e34ede410cd0a,therapy,0.617082
uuid-d4002d853ef24b82946e34ede410cd0a,nivolumab,0.601159
uuid-d4002d853ef24b82946e34ede410cd0a,approval,0.441481
uuid-d4002d853ef24b82946e34ede410cd0a,monotherapy,0.319697
uuid-d4002d853ef24b82946e34ede410cd0a,treatment,0.308536
uuid-d4002d853ef24b82946e34ede410cd0a,using nivo,0.545668
uuid-d4002d853ef24b82946e34ede410cd0a,PD1,0.353994
uuid-d4002d853ef24b82946e34ede410cd0a,approved,0.333276
uuid-d4002d853ef24b82946e34ede410cd0a,cHL,0.758952
uuid-d4002d853ef24b82946e34ede410cd0a,chemotherapy,0.337815
uuid-d4002d853ef24b82946e34ede410cd0a,RTL stated,0.339667
uuid-9982ce21d9af477fac027b46d1390cc5,patients,0.354018
uuid-9982ce21d9af477fac027b46d1390cc5,RTL,0.3783
uuid-9982ce21d9af477fac027b46d1390cc5,nivolumab,0.311299
uuid-9982ce21d9af477fac027b46d1390cc5,treated,0.47831
uuid-9982ce21d9af477fac027b46d1390cc5,physicians,0.554223
uuid-9982ce21d9af477fac027b46d1390cc5,treatment,0.323824
uuid-9982ce21d9af477fac027b46d1390cc5,SCCHN,0.396799
uuid-9982ce21d9af477fac027b46d1390cc5,oncologist,0.317066
uuid-9982ce21d9af477fac027b46d1390cc5,LTL,0.325734
uuid-9982ce21d9af477fac027b46d1390cc5,TLs,0.305984
uuid-9982ce21d9af477fac027b46d1390cc5,academic,0.6219
uuid-9982ce21d9af477fac027b46d1390cc5,Regional TL,0.432769
uuid-9982ce21d9af477fac027b46d1390cc5,RTL stated,0.370536
uuid-e995625c7de3467c8e6ea777156274ea,Nivo,0.31463
uuid-e995625c7de3467c8e6ea777156274ea,RTL,0.315462
uuid-e995625c7de3467c8e6ea777156274ea,nivolumab,0.378143
uuid-e995625c7de3467c8e6ea777156274ea,1L,0.329814
uuid-e995625c7de3467c8e6ea777156274ea,regimen,0.393066
uuid-e995625c7de3467c8e6ea777156274ea,treated,0.331937
uuid-e995625c7de3467c8e6ea777156274ea,RCC,0.366829
uuid-e995625c7de3467c8e6ea777156274ea,combination,0.49051
uuid-e995625c7de3467c8e6ea777156274ea,2L,0.325033
uuid-e995625c7de3467c8e6ea777156274ea,Ipi,0.362304
uuid-e995625c7de3467c8e6ea777156274ea,preferred,0.326347
uuid-e995625c7de3467c8e6ea777156274ea,monotherapy,0.473285
uuid-e995625c7de3467c8e6ea777156274ea,using nivo,0.434608
uuid-e995625c7de3467c8e6ea777156274ea,data,0.319987
uuid-e995625c7de3467c8e6ea777156274ea,combo,0.433002
uuid-e995625c7de3467c8e6ea777156274ea,approved,0.356451
uuid-e995625c7de3467c8e6ea777156274ea,SCCHN,0.39772
uuid-e995625c7de3467c8e6ea777156274ea,HCP,0.361889
uuid-e995625c7de3467c8e6ea777156274ea,impressed,0.414183
uuid-e995625c7de3467c8e6ea777156274ea,SCLC,0.717081
uuid-e995625c7de3467c8e6ea777156274ea,RTL stated,0.453094
uuid-e995625c7de3467c8e6ea777156274ea,TL shared,0.319787
uuid-e995625c7de3467c8e6ea777156274ea,option,0.336319
uuid-169abf9f7d6c411099bcf36b7f5b028a,patients,0.752568
uuid-169abf9f7d6c411099bcf36b7f5b028a,Opdivo,0.495316
uuid-169abf9f7d6c411099bcf36b7f5b028a,therapy,0.372254
uuid-169abf9f7d6c411099bcf36b7f5b028a,dose,0.497007
uuid-169abf9f7d6c411099bcf36b7f5b028a,nivolumab,0.369667
uuid-169abf9f7d6c411099bcf36b7f5b028a,toxicity,0.544506
uuid-169abf9f7d6c411099bcf36b7f5b028a,regimen,0.620504
uuid-169abf9f7d6c411099bcf36b7f5b028a,treated,0.581632
uuid-169abf9f7d6c411099bcf36b7f5b028a,pts,0.385155
uuid-169abf9f7d6c411099bcf36b7f5b028a,physicians,0.366285
uuid-169abf9f7d6c411099bcf36b7f5b028a,treatment,0.716312
uuid-169abf9f7d6c411099bcf36b7f5b028a,progression,0.495036
uuid-169abf9f7d6c411099bcf36b7f5b028a,respond,0.518237
uuid-f1ec641d46d84dc8a558dd197e16731b,patients,0.574801
uuid-f1ec641d46d84dc8a558dd197e16731b,Opdivo,0.402924
uuid-f1ec641d46d84dc8a558dd197e16731b,therapy,0.359747
uuid-f1ec641d46d84dc8a558dd197e16731b,nivolumab,0.593243
uuid-f1ec641d46d84dc8a558dd197e16731b,1L,0.303736
uuid-f1ec641d46d84dc8a558dd197e16731b,regimen,0.339385
uuid-f1ec641d46d84dc8a558dd197e16731b,treated,0.441997
uuid-f1ec641d46d84dc8a558dd197e16731b,RCC,0.406622
uuid-f1ec641d46d84dc8a558dd197e16731b,2L,0.340715
uuid-f1ec641d46d84dc8a558dd197e16731b,pts,0.380017
uuid-f1ec641d46d84dc8a558dd197e16731b,approval,0.49002
uuid-f1ec641d46d84dc8a558dd197e16731b,preferred,0.353354
uuid-f1ec641d46d84dc8a558dd197e16731b,monotherapy,0.360261
uuid-f1ec641d46d84dc8a558dd197e16731b,treatment,0.401241
uuid-f1ec641d46d84dc8a558dd197e16731b,using nivo,0.511192
uuid-f1ec641d46d84dc8a558dd197e16731b,approved,0.529575
uuid-f1ec641d46d84dc8a558dd197e16731b,SCCHN,0.335976
uuid-f1ec641d46d84dc8a558dd197e16731b,label,0.325365
uuid-f1ec641d46d84dc8a558dd197e16731b,SCLC,0.460581
uuid-f1ec641d46d84dc8a558dd197e16731b,RTL stated,0.436868
uuid-f1ec641d46d84dc8a558dd197e16731b,TL shared,0.320775
uuid-f1ec641d46d84dc8a558dd197e16731b,option,0.401664
uuid-e970a2666c7e4ee6878fe8e7125a4e68,efficacy,0.349462
uuid-e970a2666c7e4ee6878fe8e7125a4e68,commented,0.551471
uuid-e970a2666c7e4ee6878fe8e7125a4e68,OS,0.488638
uuid-e970a2666c7e4ee6878fe8e7125a4e68,regards,0.373964
uuid-e970a2666c7e4ee6878fe8e7125a4e68,data,0.673619
uuid-e970a2666c7e4ee6878fe8e7125a4e68,PFS,0.428725
uuid-e970a2666c7e4ee6878fe8e7125a4e68,ORR,0.484714
uuid-e970a2666c7e4ee6878fe8e7125a4e68,lung cancer,0.342476
uuid-e970a2666c7e4ee6878fe8e7125a4e68,ASCO,0.606879
uuid-e970a2666c7e4ee6878fe8e7125a4e68,impressed,0.62406
uuid-683228b69b78400a997daf9c26a60439,efficacy,0.349462
uuid-683228b69b78400a997daf9c26a60439,commented,0.551471
uuid-683228b69b78400a997daf9c26a60439,OS,0.488638
uuid-683228b69b78400a997daf9c26a60439,regards,0.373964
uuid-683228b69b78400a997daf9c26a60439,data,0.673619
uuid-683228b69b78400a997daf9c26a60439,PFS,0.428725
uuid-683228b69b78400a997daf9c26a60439,ORR,0.484714
uuid-683228b69b78400a997daf9c26a60439,lung cancer,0.342476
uuid-683228b69b78400a997daf9c26a60439,ASCO,0.606879
uuid-683228b69b78400a997daf9c26a60439,impressed,0.62406
uuid-e6be848d986748e6a113ffae86f65f89,RTL,0.389926
uuid-e6be848d986748e6a113ffae86f65f89,treated,0.397745
uuid-e6be848d986748e6a113ffae86f65f89,commented,0.404996
uuid-e6be848d986748e6a113ffae86f65f89,OS,0.404351
uuid-e6be848d986748e6a113ffae86f65f89,data,0.586217
uuid-e6be848d986748e6a113ffae86f65f89,PFS,0.350783
uuid-e6be848d986748e6a113ffae86f65f89,ORR,0.479309
uuid-e6be848d986748e6a113ffae86f65f89,ASCO,0.448986
uuid-e6be848d986748e6a113ffae86f65f89,impressed,0.631406
uuid-e6be848d986748e6a113ffae86f65f89,LTL,0.300624
uuid-e6be848d986748e6a113ffae86f65f89,Regional TL,0.404997
uuid-6927e7a99dcc4b3aa2a55e88ab0ddf4f,response,0.371967
uuid-6927e7a99dcc4b3aa2a55e88ab0ddf4f,progression,0.329358
uuid-6927e7a99dcc4b3aa2a55e88ab0ddf4f,indicated,0.389685
uuid-6927e7a99dcc4b3aa2a55e88ab0ddf4f,respond,0.317131
uuid-1a99ebb3810844d7b1fc7751ea51c599,TL,0.489625
uuid-1a99ebb3810844d7b1fc7751ea51c599,PDL1,0.531029
uuid-1a99ebb3810844d7b1fc7751ea51c599,TL stated,0.409545
uuid-1a99ebb3810844d7b1fc7751ea51c599,Merck,0.353275
uuid-1a99ebb3810844d7b1fc7751ea51c599,institution,0.319222
uuid-1a99ebb3810844d7b1fc7751ea51c599,PD-L1,0.849547
uuid-1a99ebb3810844d7b1fc7751ea51c599,PD-L1 testing,0.844536
uuid-1a99ebb3810844d7b1fc7751ea51c599,testing,0.927987
uuid-1a99ebb3810844d7b1fc7751ea51c599,PDL1 testing,0.737761
uuid-1a99ebb3810844d7b1fc7751ea51c599,NSCLC patients,0.703276
uuid-1a99ebb3810844d7b1fc7751ea51c599,assay,0.731968
uuid-1a99ebb3810844d7b1fc7751ea51c599,PDL1 expression,0.331941
uuid-1a99ebb3810844d7b1fc7751ea51c599,biomarker,0.468244
uuid-18afac70d9134619b81a73145f5865f3,pembro,0.471052
uuid-18afac70d9134619b81a73145f5865f3,RTL,0.43798
uuid-18afac70d9134619b81a73145f5865f3,BMS,0.469294
uuid-18afac70d9134619b81a73145f5865f3,trial,0.486134
uuid-18afac70d9134619b81a73145f5865f3,shared,0.505841
uuid-18afac70d9134619b81a73145f5865f3,commented,0.475848
uuid-18afac70d9134619b81a73145f5865f3,Merck,0.406606
uuid-18afac70d9134619b81a73145f5865f3,stated,0.577417
uuid-18afac70d9134619b81a73145f5865f3,approval,0.453723
uuid-18afac70d9134619b81a73145f5865f3,atezo,0.399633
uuid-18afac70d9134619b81a73145f5865f3,using nivo,0.318507
uuid-18afac70d9134619b81a73145f5865f3,data,0.68667
uuid-18afac70d9134619b81a73145f5865f3,expressed,0.381889
uuid-18afac70d9134619b81a73145f5865f3,clinical trials,0.464982
uuid-18afac70d9134619b81a73145f5865f3,indication,0.388101
uuid-18afac70d9134619b81a73145f5865f3,approved,0.447111
uuid-18afac70d9134619b81a73145f5865f3,SCCHN,0.481161
uuid-18afac70d9134619b81a73145f5865f3,impressed,0.611719
uuid-18afac70d9134619b81a73145f5865f3,LTL,0.488244
uuid-18afac70d9134619b81a73145f5865f3,TLs,0.399069
uuid-18afac70d9134619b81a73145f5865f3,SCLC,0.374679
uuid-18afac70d9134619b81a73145f5865f3,feels,0.363314
uuid-18afac70d9134619b81a73145f5865f3,Regional TL,0.474431
uuid-18afac70d9134619b81a73145f5865f3,RTL stated,0.314311
uuid-18afac70d9134619b81a73145f5865f3,bladder,0.384379
uuid-0ad4934dc59949fc914bbbb38e33fccd,Nivo,0.556833
uuid-0ad4934dc59949fc914bbbb38e33fccd,patients,0.489308
uuid-0ad4934dc59949fc914bbbb38e33fccd,Opdivo,0.325795
uuid-0ad4934dc59949fc914bbbb38e33fccd,pembro,0.393498
uuid-0ad4934dc59949fc914bbbb38e33fccd,nivolumab,0.483004
uuid-0ad4934dc59949fc914bbbb38e33fccd,regimen,0.34976
uuid-0ad4934dc59949fc914bbbb38e33fccd,2L,0.350958
uuid-0ad4934dc59949fc914bbbb38e33fccd,pts,0.382677
uuid-0ad4934dc59949fc914bbbb38e33fccd,stated,0.308571
uuid-0ad4934dc59949fc914bbbb38e33fccd,approval,0.40287
uuid-0ad4934dc59949fc914bbbb38e33fccd,preferred,0.333549
uuid-0ad4934dc59949fc914bbbb38e33fccd,monotherapy,0.4218
uuid-0ad4934dc59949fc914bbbb38e33fccd,using nivo,0.52988
uuid-0ad4934dc59949fc914bbbb38e33fccd,data,0.311663
uuid-0ad4934dc59949fc914bbbb38e33fccd,clinical trials,0.312251
uuid-0ad4934dc59949fc914bbbb38e33fccd,indication,0.316053
uuid-0ad4934dc59949fc914bbbb38e33fccd,approved,0.404467
uuid-0ad4934dc59949fc914bbbb38e33fccd,SCCHN,0.357858
uuid-0ad4934dc59949fc914bbbb38e33fccd,HCP,0.329755
uuid-0ad4934dc59949fc914bbbb38e33fccd,chemotherapy,0.322566
uuid-0ad4934dc59949fc914bbbb38e33fccd,impressed,0.402027
uuid-0ad4934dc59949fc914bbbb38e33fccd,LTL,0.323396
uuid-0ad4934dc59949fc914bbbb38e33fccd,SCLC,0.369367
uuid-0ad4934dc59949fc914bbbb38e33fccd,feels,0.386651
uuid-0ad4934dc59949fc914bbbb38e33fccd,RTL stated,0.383738
uuid-0ad4934dc59949fc914bbbb38e33fccd,option,0.45851
uuid-0ad4934dc59949fc914bbbb38e33fccd,bladder,0.322585
uuid-80afa25e21fb471a898c98c8777a7d0e,pembro,0.570225
uuid-80afa25e21fb471a898c98c8777a7d0e,RTL,0.479676
uuid-80afa25e21fb471a898c98c8777a7d0e,1L,0.341589
uuid-80afa25e21fb471a898c98c8777a7d0e,PDL1,0.339375
uuid-80afa25e21fb471a898c98c8777a7d0e,trial,0.397337
uuid-80afa25e21fb471a898c98c8777a7d0e,commented,0.378828
uuid-80afa25e21fb471a898c98c8777a7d0e,Merck,0.334479
uuid-80afa25e21fb471a898c98c8777a7d0e,stated,0.417829
uuid-80afa25e21fb471a898c98c8777a7d0e,approval,0.51502
uuid-80afa25e21fb471a898c98c8777a7d0e,atezo,0.488676
uuid-80afa25e21fb471a898c98c8777a7d0e,using nivo,0.371711
uuid-80afa25e21fb471a898c98c8777a7d0e,data,0.541863
uuid-80afa25e21fb471a898c98c8777a7d0e,expressed,0.354344
uuid-80afa25e21fb471a898c98c8777a7d0e,mentioned,0.300491
uuid-80afa25e21fb471a898c98c8777a7d0e,clinical trials,0.385869
uuid-80afa25e21fb471a898c98c8777a7d0e,indication,0.466168
uuid-80afa25e21fb471a898c98c8777a7d0e,approved,0.449749
uuid-80afa25e21fb471a898c98c8777a7d0e,SCCHN,0.506992
uuid-80afa25e21fb471a898c98c8777a7d0e,HCP,0.337691
uuid-80afa25e21fb471a898c98c8777a7d0e,nivo and pembro,0.370639
uuid-80afa25e21fb471a898c98c8777a7d0e,impressed,0.449582
uuid-80afa25e21fb471a898c98c8777a7d0e,label,0.48579
uuid-80afa25e21fb471a898c98c8777a7d0e,LTL,0.391173
uuid-80afa25e21fb471a898c98c8777a7d0e,TLs,0.35153
uuid-80afa25e21fb471a898c98c8777a7d0e,SCLC,0.346542
uuid-80afa25e21fb471a898c98c8777a7d0e,Regional TL,0.347963
uuid-80afa25e21fb471a898c98c8777a7d0e,PDL1 expression,0.417037
uuid-80afa25e21fb471a898c98c8777a7d0e,bladder,0.368323
uuid-b1b99c8e0f3b49ebb8a970d263b19502,patients,0.494421
uuid-b1b99c8e0f3b49ebb8a970d263b19502,pembro,0.349003
uuid-b1b99c8e0f3b49ebb8a970d263b19502,1L,0.318375
uuid-b1b99c8e0f3b49ebb8a970d263b19502,regimen,0.362708
uuid-b1b99c8e0f3b49ebb8a970d263b19502,combination,0.30596
uuid-b1b99c8e0f3b49ebb8a970d263b19502,2L,0.321563
uuid-b1b99c8e0f3b49ebb8a970d263b19502,preferred,0.498993
uuid-b1b99c8e0f3b49ebb8a970d263b19502,monotherapy,0.398437
uuid-b1b99c8e0f3b49ebb8a970d263b19502,treatment,0.316108
uuid-b1b99c8e0f3b49ebb8a970d263b19502,clinical trials,0.451974
uuid-b1b99c8e0f3b49ebb8a970d263b19502,indication,0.406848
uuid-b1b99c8e0f3b49ebb8a970d263b19502,approved,0.351394
uuid-b1b99c8e0f3b49ebb8a970d263b19502,chemotherapy,0.443989
uuid-b1b99c8e0f3b49ebb8a970d263b19502,option,0.52566
uuid-8d879fa5333044a9a2bc1c67769c3fb9,Nivo,0.366105
uuid-8d879fa5333044a9a2bc1c67769c3fb9,patients,0.347081
uuid-8d879fa5333044a9a2bc1c67769c3fb9,Opdivo,0.338072
uuid-8d879fa5333044a9a2bc1c67769c3fb9,pembro,0.508685
uuid-8d879fa5333044a9a2bc1c67769c3fb9,dose,0.461091
uuid-8d879fa5333044a9a2bc1c67769c3fb9,nivolumab,0.312919
uuid-8d879fa5333044a9a2bc1c67769c3fb9,trial,0.466345
uuid-8d879fa5333044a9a2bc1c67769c3fb9,Ipi,0.388983
uuid-8d879fa5333044a9a2bc1c67769c3fb9,approval,0.459009
uuid-8d879fa5333044a9a2bc1c67769c3fb9,atezo,0.329916
uuid-8d879fa5333044a9a2bc1c67769c3fb9,clinical trials,0.463945
uuid-8d879fa5333044a9a2bc1c67769c3fb9,indication,0.380301
uuid-8d879fa5333044a9a2bc1c67769c3fb9,approved,0.456594
uuid-8d879fa5333044a9a2bc1c67769c3fb9,vs,0.396326
uuid-8d879fa5333044a9a2bc1c67769c3fb9,label,0.35241
uuid-8d879fa5333044a9a2bc1c67769c3fb9,feels,0.331287
uuid-8d879fa5333044a9a2bc1c67769c3fb9,flat dosing,0.478856
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,Nivo,0.347898
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,patients,0.311374
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,pembro,0.327074
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,1L,0.474162
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,PDL1,0.368684
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,chemo,0.459019
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,2L,0.383989
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,pts,0.401814
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,preferred,0.318607
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,monotherapy,0.481635
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,using nivo,0.301323
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,PD1,0.313753
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,nivo and pembro,0.437568
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,believes,0.48718
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,chemotherapy,0.352455
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,respond,0.362962
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,feels,0.417875
uuid-3f15f7e8560a462f8111bc5e4ba2bb3e,option,0.491511
uuid-2ee83a183a8f439289ed8ecec41c321a,patients,0.438135
uuid-2ee83a183a8f439289ed8ecec41c321a,TL,0.310736
uuid-2ee83a183a8f439289ed8ecec41c321a,treated,0.302105
uuid-2ee83a183a8f439289ed8ecec41c321a,TL stated,0.376035
uuid-2ee83a183a8f439289ed8ecec41c321a,pts,0.303256
uuid-2ee83a183a8f439289ed8ecec41c321a,PD-L1,0.491026
uuid-2ee83a183a8f439289ed8ecec41c321a,approval,0.365577
uuid-2ee83a183a8f439289ed8ecec41c321a,PD-L1 testing,0.544613
uuid-2ee83a183a8f439289ed8ecec41c321a,testing,0.662194
uuid-2ee83a183a8f439289ed8ecec41c321a,using nivo,0.308787
uuid-2ee83a183a8f439289ed8ecec41c321a,PDL1 testing,0.595962
uuid-2ee83a183a8f439289ed8ecec41c321a,NSCLC patients,0.725697
uuid-2ee83a183a8f439289ed8ecec41c321a,SCCHN,0.35382
uuid-2ee83a183a8f439289ed8ecec41c321a,tumor types,0.438723
uuid-2ee83a183a8f439289ed8ecec41c321a,RTL stated,0.381706
uuid-2ee83a183a8f439289ed8ecec41c321a,bladder,0.335804
uuid-c27ae4916afe442e933a89e8aa1dee87,TL,0.559758
uuid-c27ae4916afe442e933a89e8aa1dee87,RTL,0.582979
uuid-c27ae4916afe442e933a89e8aa1dee87,NTL,0.377128
uuid-c27ae4916afe442e933a89e8aa1dee87,TL stated,0.530504
uuid-c27ae4916afe442e933a89e8aa1dee87,institution,0.314911
uuid-c27ae4916afe442e933a89e8aa1dee87,stated,0.376674
uuid-c27ae4916afe442e933a89e8aa1dee87,PD-L1,0.603317
uuid-c27ae4916afe442e933a89e8aa1dee87,approval,0.311393
uuid-c27ae4916afe442e933a89e8aa1dee87,PD-L1 testing,0.675927
uuid-c27ae4916afe442e933a89e8aa1dee87,testing,0.728259
uuid-c27ae4916afe442e933a89e8aa1dee87,expressed,0.30764
uuid-c27ae4916afe442e933a89e8aa1dee87,PDL1 testing,0.673617
uuid-c27ae4916afe442e933a89e8aa1dee87,NSCLC patients,0.645357
uuid-c27ae4916afe442e933a89e8aa1dee87,SCCHN,0.45654
uuid-c27ae4916afe442e933a89e8aa1dee87,HCP,0.373854
uuid-c27ae4916afe442e933a89e8aa1dee87,LTL,0.429451
uuid-c27ae4916afe442e933a89e8aa1dee87,TLs,0.306149
uuid-c27ae4916afe442e933a89e8aa1dee87,academic,0.313403
uuid-c27ae4916afe442e933a89e8aa1dee87,assay,0.437851
uuid-c27ae4916afe442e933a89e8aa1dee87,Regional TL,0.421563
uuid-c27ae4916afe442e933a89e8aa1dee87,RTL stated,0.341895
uuid-c27ae4916afe442e933a89e8aa1dee87,bladder,0.31157
uuid-68a9f468ed0d477599dadfe163885364,1L,0.317676
uuid-68a9f468ed0d477599dadfe163885364,PDL1,0.707473
uuid-68a9f468ed0d477599dadfe163885364,efficacy,0.359701
uuid-68a9f468ed0d477599dadfe163885364,PD-L1,0.562389
uuid-68a9f468ed0d477599dadfe163885364,testing,0.479047
uuid-68a9f468ed0d477599dadfe163885364,PDL1 testing,0.345433
uuid-68a9f468ed0d477599dadfe163885364,NSCLC patients,0.411453
uuid-68a9f468ed0d477599dadfe163885364,ORR,0.326096
uuid-68a9f468ed0d477599dadfe163885364,nivo and pembro,0.406104
uuid-68a9f468ed0d477599dadfe163885364,believes,0.376936
uuid-68a9f468ed0d477599dadfe163885364,tumor types,0.370802
uuid-68a9f468ed0d477599dadfe163885364,assay,0.352758
uuid-68a9f468ed0d477599dadfe163885364,PDL1 expression,0.604078
uuid-68a9f468ed0d477599dadfe163885364,biomarker,0.651463
uuid-e90e62fa6700403384b94a2f75b06e62,RTL,0.433631
uuid-e90e62fa6700403384b94a2f75b06e62,lung,0.460649
uuid-e90e62fa6700403384b94a2f75b06e62,regimen,0.304287
uuid-e90e62fa6700403384b94a2f75b06e62,treated,0.320423
uuid-e90e62fa6700403384b94a2f75b06e62,NTL,0.342069
uuid-e90e62fa6700403384b94a2f75b06e62,discussed,0.339796
uuid-e90e62fa6700403384b94a2f75b06e62,melanoma,0.694434
uuid-e90e62fa6700403384b94a2f75b06e62,shared,0.456954
uuid-e90e62fa6700403384b94a2f75b06e62,RCC,0.499588
uuid-e90e62fa6700403384b94a2f75b06e62,SCCHN,0.520852
uuid-e90e62fa6700403384b94a2f75b06e62,TLs,0.41283
uuid-e90e62fa6700403384b94a2f75b06e62,academic,0.800191
uuid-e90e62fa6700403384b94a2f75b06e62,Regional TL,0.425324
uuid-e90e62fa6700403384b94a2f75b06e62,RTL stated,0.525261
uuid-e90e62fa6700403384b94a2f75b06e62,TL shared,0.562277
uuid-da28ae68653b48f9bc05f34bcf79f80d,dose,0.539243
uuid-da28ae68653b48f9bc05f34bcf79f80d,toxicity,0.607352
uuid-da28ae68653b48f9bc05f34bcf79f80d,regimen,0.377201
uuid-da28ae68653b48f9bc05f34bcf79f80d,academic,0.312952
uuid-da28ae68653b48f9bc05f34bcf79f80d,flat dosing,0.301041
uuid-2a31975fcc3d48fd817bc16bc3a15a14,NSCLC,0.425623
uuid-2a31975fcc3d48fd817bc16bc3a15a14,data,0.463407
uuid-2a31975fcc3d48fd817bc16bc3a15a14,NCCN,0.473124
uuid-d26a4ea370544041941312277c3ae493,NSCLC,0.460928
uuid-d26a4ea370544041941312277c3ae493,data,0.325525
uuid-d26a4ea370544041941312277c3ae493,NCCN,0.536764
uuid-c451a2eaabf346f3b5afc28bead8feb4,NSCLC,0.438868
uuid-c451a2eaabf346f3b5afc28bead8feb4,data,0.303457
uuid-c451a2eaabf346f3b5afc28bead8feb4,NCCN,0.531073
uuid-96ff701b3d94443f861560489151d78a,Nivo,0.353023
uuid-96ff701b3d94443f861560489151d78a,patients,0.540439
uuid-96ff701b3d94443f861560489151d78a,therapy,0.509242
uuid-96ff701b3d94443f861560489151d78a,1L,0.406672
uuid-96ff701b3d94443f861560489151d78a,chemo,0.436509
uuid-96ff701b3d94443f861560489151d78a,2L,0.335493
uuid-96ff701b3d94443f861560489151d78a,pts,0.442687
uuid-96ff701b3d94443f861560489151d78a,preferred,0.338492
uuid-96ff701b3d94443f861560489151d78a,monotherapy,0.424968
uuid-96ff701b3d94443f861560489151d78a,treatment,0.364883
uuid-96ff701b3d94443f861560489151d78a,using nivo,0.309566
uuid-96ff701b3d94443f861560489151d78a,NSCLC patients,0.320404
uuid-96ff701b3d94443f861560489151d78a,PD1,0.342515
uuid-96ff701b3d94443f861560489151d78a,progression,0.451613
uuid-96ff701b3d94443f861560489151d78a,chemotherapy,0.396743
uuid-96ff701b3d94443f861560489151d78a,respond,0.406221
uuid-96ff701b3d94443f861560489151d78a,option,0.484865
uuid-6551f04d14314583980e164748c8c4d9,BMS,0.314001
uuid-6551f04d14314583980e164748c8c4d9,PDL1,0.518835
uuid-6551f04d14314583980e164748c8c4d9,trial,0.38499
uuid-6551f04d14314583980e164748c8c4d9,efficacy,0.525501
uuid-6551f04d14314583980e164748c8c4d9,discussed,0.374475
uuid-6551f04d14314583980e164748c8c4d9,commented,0.393893
uuid-6551f04d14314583980e164748c8c4d9,OS,0.742442
uuid-6551f04d14314583980e164748c8c4d9,regards,0.395582
uuid-6551f04d14314583980e164748c8c4d9,data,0.791775
uuid-6551f04d14314583980e164748c8c4d9,PFS,0.718155
uuid-6551f04d14314583980e164748c8c4d9,ORR,0.723413
uuid-6551f04d14314583980e164748c8c4d9,nivo and pembro,0.482559
uuid-6551f04d14314583980e164748c8c4d9,ASCO,0.320331
uuid-6551f04d14314583980e164748c8c4d9,believes,0.316204
uuid-6551f04d14314583980e164748c8c4d9,impressed,0.542134
uuid-6551f04d14314583980e164748c8c4d9,feels,0.371526
uuid-6551f04d14314583980e164748c8c4d9,PDL1 expression,0.525855
uuid-ef352c63dd2745e998d8c2bb48e6db8a,RTL,0.423318
uuid-ef352c63dd2745e998d8c2bb48e6db8a,BMS,0.475135
uuid-ef352c63dd2745e998d8c2bb48e6db8a,lung,0.426793
uuid-ef352c63dd2745e998d8c2bb48e6db8a,NTL,0.348833
uuid-ef352c63dd2745e998d8c2bb48e6db8a,discussed,0.329999
uuid-ef352c63dd2745e998d8c2bb48e6db8a,shared,0.401451
uuid-ef352c63dd2745e998d8c2bb48e6db8a,commented,0.551393
uuid-ef352c63dd2745e998d8c2bb48e6db8a,RCC,0.309097
uuid-ef352c63dd2745e998d8c2bb48e6db8a,TL stated,0.407697
uuid-ef352c63dd2745e998d8c2bb48e6db8a,Merck,0.532259
uuid-ef352c63dd2745e998d8c2bb48e6db8a,stated,0.496707
uuid-ef352c63dd2745e998d8c2bb48e6db8a,data,0.494286
uuid-ef352c63dd2745e998d8c2bb48e6db8a,expressed,0.372561
uuid-ef352c63dd2745e998d8c2bb48e6db8a,SCCHN,0.482526
uuid-ef352c63dd2745e998d8c2bb48e6db8a,ASCO,0.324883
uuid-ef352c63dd2745e998d8c2bb48e6db8a,impressed,0.420047
uuid-ef352c63dd2745e998d8c2bb48e6db8a,LTL,0.404278
uuid-ef352c63dd2745e998d8c2bb48e6db8a,TLs,0.43995
uuid-ef352c63dd2745e998d8c2bb48e6db8a,Regional TL,0.462323
uuid-ef352c63dd2745e998d8c2bb48e6db8a,bladder,0.313202
uuid-2192c654b54d48c4aa12624b0b9d50eb,BMS,0.628315
uuid-2192c654b54d48c4aa12624b0b9d50eb,trial,0.463756
uuid-2192c654b54d48c4aa12624b0b9d50eb,commented,0.428579
uuid-2192c654b54d48c4aa12624b0b9d50eb,Merck,0.540214
uuid-2192c654b54d48c4aa12624b0b9d50eb,regards,0.318683
uuid-2192c654b54d48c4aa12624b0b9d50eb,data,0.485592
uuid-2192c654b54d48c4aa12624b0b9d50eb,expressed,0.506671
uuid-2192c654b54d48c4aa12624b0b9d50eb,impressed,0.446178
uuid-ee25ce3782544182a1999cf49c9e0451,TL,0.386412
uuid-ee25ce3782544182a1999cf49c9e0451,pembro,0.486332
uuid-ee25ce3782544182a1999cf49c9e0451,1L,0.511384
uuid-ee25ce3782544182a1999cf49c9e0451,PDL1,0.637004
uuid-ee25ce3782544182a1999cf49c9e0451,TL stated,0.510111
uuid-ee25ce3782544182a1999cf49c9e0451,2L,0.402228
uuid-ee25ce3782544182a1999cf49c9e0451,Merck,0.389552
uuid-ee25ce3782544182a1999cf49c9e0451,PD-L1,0.765047
uuid-ee25ce3782544182a1999cf49c9e0451,approval,0.358888
uuid-ee25ce3782544182a1999cf49c9e0451,atezo,0.489198
uuid-ee25ce3782544182a1999cf49c9e0451,PD-L1 testing,0.627681
uuid-ee25ce3782544182a1999cf49c9e0451,testing,0.803678
uuid-ee25ce3782544182a1999cf49c9e0451,PDL1 testing,0.775664
uuid-ee25ce3782544182a1999cf49c9e0451,NSCLC patients,0.723801
uuid-ee25ce3782544182a1999cf49c9e0451,nivo and pembro,0.362946
uuid-ee25ce3782544182a1999cf49c9e0451,tumor types,0.335484
uuid-ee25ce3782544182a1999cf49c9e0451,assay,0.586852
uuid-ee25ce3782544182a1999cf49c9e0451,PDL1 expression,0.447995
uuid-ee25ce3782544182a1999cf49c9e0451,biomarker,0.460711
uuid-76fc8fe5745745d1877dd140807dbcbd,Nivo,0.521232
uuid-76fc8fe5745745d1877dd140807dbcbd,patients,0.459103
uuid-76fc8fe5745745d1877dd140807dbcbd,pembro,0.459795
uuid-76fc8fe5745745d1877dd140807dbcbd,therapy,0.367133
uuid-76fc8fe5745745d1877dd140807dbcbd,nivolumab,0.429966
uuid-76fc8fe5745745d1877dd140807dbcbd,1L,0.601986
uuid-76fc8fe5745745d1877dd140807dbcbd,regimen,0.3449
uuid-76fc8fe5745745d1877dd140807dbcbd,treated,0.339256
uuid-76fc8fe5745745d1877dd140807dbcbd,RCC,0.495572
uuid-76fc8fe5745745d1877dd140807dbcbd,chemo,0.353547
uuid-76fc8fe5745745d1877dd140807dbcbd,2L,0.700196
uuid-76fc8fe5745745d1877dd140807dbcbd,agents,0.382014
uuid-76fc8fe5745745d1877dd140807dbcbd,approval,0.440596
uuid-76fc8fe5745745d1877dd140807dbcbd,atezo,0.435577
uuid-76fc8fe5745745d1877dd140807dbcbd,preferred,0.741606
uuid-76fc8fe5745745d1877dd140807dbcbd,monotherapy,0.597396
uuid-76fc8fe5745745d1877dd140807dbcbd,treatment,0.384851
uuid-76fc8fe5745745d1877dd140807dbcbd,using nivo,0.719123
uuid-76fc8fe5745745d1877dd140807dbcbd,approved,0.469673
uuid-76fc8fe5745745d1877dd140807dbcbd,SCCHN,0.411039
uuid-76fc8fe5745745d1877dd140807dbcbd,chemotherapy,0.322066
uuid-76fc8fe5745745d1877dd140807dbcbd,RTL stated,0.654868
uuid-76fc8fe5745745d1877dd140807dbcbd,TL shared,0.349999
uuid-76fc8fe5745745d1877dd140807dbcbd,option,0.635684
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,pembro,0.317426
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,BMS,0.390864
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,PDL1,0.55908
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,trial,0.495484
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,efficacy,0.487978
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,Merck,0.304235
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,OS,0.547284
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,regards,0.346592
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,data,0.66576
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,PFS,0.58724
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,ORR,0.558718
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,nivo and pembro,0.614505
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,believes,0.448801
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,impressed,0.35405
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,feels,0.482828
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,PDL1 expression,0.523422
uuid-5a8cc286b72c4d5a897163aa6b5f1dc9,biomarker,0.33308
uuid-74fdb16f85c04742b1c16b3e507c17bc,NSCLC,0.327166
uuid-74fdb16f85c04742b1c16b3e507c17bc,PDL1,0.368705
uuid-74fdb16f85c04742b1c16b3e507c17bc,trial,0.386712
uuid-74fdb16f85c04742b1c16b3e507c17bc,efficacy,0.491806
uuid-74fdb16f85c04742b1c16b3e507c17bc,commented,0.320704
uuid-74fdb16f85c04742b1c16b3e507c17bc,OS,0.652483
uuid-74fdb16f85c04742b1c16b3e507c17bc,regards,0.365449
uuid-74fdb16f85c04742b1c16b3e507c17bc,data,0.66076
uuid-74fdb16f85c04742b1c16b3e507c17bc,PFS,0.672686
uuid-74fdb16f85c04742b1c16b3e507c17bc,ORR,0.672302
uuid-74fdb16f85c04742b1c16b3e507c17bc,nivo and pembro,0.383018
uuid-74fdb16f85c04742b1c16b3e507c17bc,impressed,0.47775
uuid-74fdb16f85c04742b1c16b3e507c17bc,PDL1 expression,0.323658
uuid-74fdb16f85c04742b1c16b3e507c17bc,NCCN,0.338341
uuid-309c137b080c493b97e343dd66f5d732,drug,0.308942
uuid-6486efbc36734bd39173c6dd5d9f863d,toxicity,0.335812
uuid-6486efbc36734bd39173c6dd5d9f863d,efficacy,0.319537
uuid-6486efbc36734bd39173c6dd5d9f863d,regimen,0.444636
uuid-6486efbc36734bd39173c6dd5d9f863d,chemo,0.335143
uuid-6486efbc36734bd39173c6dd5d9f863d,OS,0.41314
uuid-6486efbc36734bd39173c6dd5d9f863d,treatment,0.387227
uuid-6486efbc36734bd39173c6dd5d9f863d,response,0.471364
uuid-6486efbc36734bd39173c6dd5d9f863d,PFS,0.349389
uuid-6486efbc36734bd39173c6dd5d9f863d,ORR,0.360222
uuid-6486efbc36734bd39173c6dd5d9f863d,progression,0.401068
uuid-6486efbc36734bd39173c6dd5d9f863d,believes,0.343105
uuid-6486efbc36734bd39173c6dd5d9f863d,respond,0.484486
uuid-6486efbc36734bd39173c6dd5d9f863d,feels,0.34895
uuid-41df960e01b44bb191ca40dd31cebada,TL,0.446014
uuid-41df960e01b44bb191ca40dd31cebada,lung,0.308493
uuid-41df960e01b44bb191ca40dd31cebada,1L,0.311623
uuid-41df960e01b44bb191ca40dd31cebada,RCC,0.378804
uuid-41df960e01b44bb191ca40dd31cebada,TL stated,0.592308
uuid-41df960e01b44bb191ca40dd31cebada,institution,0.386444
uuid-41df960e01b44bb191ca40dd31cebada,PD-L1,0.66741
uuid-41df960e01b44bb191ca40dd31cebada,PD-L1 testing,0.732639
uuid-41df960e01b44bb191ca40dd31cebada,testing,0.774293
uuid-41df960e01b44bb191ca40dd31cebada,PDL1 testing,0.783208
uuid-41df960e01b44bb191ca40dd31cebada,NSCLC patients,0.654729
uuid-41df960e01b44bb191ca40dd31cebada,tumor types,0.323101
uuid-41df960e01b44bb191ca40dd31cebada,assay,0.513982
uuid-41df960e01b44bb191ca40dd31cebada,biomarker,0.344751
uuid-2e870085ff764e51add8468cc15b623e,Nivo,0.341944
uuid-2e870085ff764e51add8468cc15b623e,pembro,0.50731
uuid-2e870085ff764e51add8468cc15b623e,BMS,0.405586
uuid-2e870085ff764e51add8468cc15b623e,1L,0.440364
uuid-2e870085ff764e51add8468cc15b623e,2L,0.478235
uuid-2e870085ff764e51add8468cc15b623e,agents,0.460538
uuid-2e870085ff764e51add8468cc15b623e,atezo,0.495883
uuid-2e870085ff764e51add8468cc15b623e,preferred,0.427633
uuid-2e870085ff764e51add8468cc15b623e,monotherapy,0.33319
uuid-2e870085ff764e51add8468cc15b623e,using nivo,0.317272
uuid-2e870085ff764e51add8468cc15b623e,combo,0.353478
uuid-2e870085ff764e51add8468cc15b623e,approved,0.407718
uuid-2e870085ff764e51add8468cc15b623e,nivo and pembro,0.346295
uuid-2e870085ff764e51add8468cc15b623e,believes,0.334977
uuid-2e870085ff764e51add8468cc15b623e,feels,0.516361
uuid-2e870085ff764e51add8468cc15b623e,option,0.387845
uuid-60bfdf67bb764449ae6074e37ea0fb33,Nivo,0.465959
uuid-60bfdf67bb764449ae6074e37ea0fb33,pembro,0.670931
uuid-60bfdf67bb764449ae6074e37ea0fb33,1L,0.335012
uuid-60bfdf67bb764449ae6074e37ea0fb33,trial,0.517604
uuid-60bfdf67bb764449ae6074e37ea0fb33,efficacy,0.493408
uuid-60bfdf67bb764449ae6074e37ea0fb33,2L,0.38323
uuid-60bfdf67bb764449ae6074e37ea0fb33,Ipi,0.401501
uuid-60bfdf67bb764449ae6074e37ea0fb33,atezo,0.661357
uuid-60bfdf67bb764449ae6074e37ea0fb33,regards,0.318201
uuid-60bfdf67bb764449ae6074e37ea0fb33,data,0.445994
uuid-60bfdf67bb764449ae6074e37ea0fb33,indication,0.325578
uuid-60bfdf67bb764449ae6074e37ea0fb33,PFS,0.303897
uuid-60bfdf67bb764449ae6074e37ea0fb33,ORR,0.331155
uuid-60bfdf67bb764449ae6074e37ea0fb33,nivo and pembro,0.594773
uuid-60bfdf67bb764449ae6074e37ea0fb33,believes,0.321941
uuid-60bfdf67bb764449ae6074e37ea0fb33,impressed,0.349809
uuid-60bfdf67bb764449ae6074e37ea0fb33,vs,0.535511
uuid-60bfdf67bb764449ae6074e37ea0fb33,TLs,0.445628
uuid-60bfdf67bb764449ae6074e37ea0fb33,feels,0.376601
uuid-2ae53d6d49f74834abc00e2e3405c0cb,Nivo,0.412045
uuid-2ae53d6d49f74834abc00e2e3405c0cb,patients,0.386272
uuid-2ae53d6d49f74834abc00e2e3405c0cb,Opdivo,0.385132
uuid-2ae53d6d49f74834abc00e2e3405c0cb,pembro,0.426086
uuid-2ae53d6d49f74834abc00e2e3405c0cb,dose,0.80615
uuid-2ae53d6d49f74834abc00e2e3405c0cb,toxicity,0.338604
uuid-2ae53d6d49f74834abc00e2e3405c0cb,efficacy,0.331798
uuid-2ae53d6d49f74834abc00e2e3405c0cb,Ipi,0.468614
uuid-2ae53d6d49f74834abc00e2e3405c0cb,atezo,0.450081
uuid-2ae53d6d49f74834abc00e2e3405c0cb,preferred,0.332929
uuid-2ae53d6d49f74834abc00e2e3405c0cb,vs,0.642068
uuid-2ae53d6d49f74834abc00e2e3405c0cb,Keytruda,0.358895
uuid-2ae53d6d49f74834abc00e2e3405c0cb,flat dosing,0.56318
uuid-4047fef118e74308ac36eaf337f6a446,PDL1,0.397156
uuid-4047fef118e74308ac36eaf337f6a446,trial,0.44632
uuid-4047fef118e74308ac36eaf337f6a446,efficacy,0.445152
uuid-4047fef118e74308ac36eaf337f6a446,commented,0.373927
uuid-4047fef118e74308ac36eaf337f6a446,OS,0.710767
uuid-4047fef118e74308ac36eaf337f6a446,data,0.611638
uuid-4047fef118e74308ac36eaf337f6a446,PFS,0.704947
uuid-4047fef118e74308ac36eaf337f6a446,ORR,0.702059
uuid-4047fef118e74308ac36eaf337f6a446,nivo and pembro,0.359701
uuid-4047fef118e74308ac36eaf337f6a446,impressed,0.563171
uuid-4047fef118e74308ac36eaf337f6a446,feels,0.419657
uuid-4047fef118e74308ac36eaf337f6a446,PDL1 expression,0.368862
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,Nivo,0.443093
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,pembro,0.408543
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,dose,0.806813
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,toxicity,0.374758
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,efficacy,0.30092
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,regimen,0.400539
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,Ipi,0.769168
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,atezo,0.354821
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,combo,0.313956
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,indication,0.304331
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,vs,0.505142
uuid-f7d526d3cc414906b1ea23af7a5f7bcb,flat dosing,0.614162
uuid-43a0e7681dac45a68d5469220dbd4776,RTL,0.519157
uuid-43a0e7681dac45a68d5469220dbd4776,NTL,0.319577
uuid-43a0e7681dac45a68d5469220dbd4776,shared,0.412643
uuid-43a0e7681dac45a68d5469220dbd4776,commented,0.528861
uuid-43a0e7681dac45a68d5469220dbd4776,institution,0.3485
uuid-43a0e7681dac45a68d5469220dbd4776,stated,0.529787
uuid-43a0e7681dac45a68d5469220dbd4776,approval,0.362556
uuid-43a0e7681dac45a68d5469220dbd4776,data,0.388963
uuid-43a0e7681dac45a68d5469220dbd4776,expressed,0.376509
uuid-43a0e7681dac45a68d5469220dbd4776,clinical trials,0.384852
uuid-43a0e7681dac45a68d5469220dbd4776,indication,0.362644
uuid-43a0e7681dac45a68d5469220dbd4776,SCCHN,0.585894
uuid-43a0e7681dac45a68d5469220dbd4776,impressed,0.435031
uuid-43a0e7681dac45a68d5469220dbd4776,LTL,0.448138
uuid-43a0e7681dac45a68d5469220dbd4776,TLs,0.546921
uuid-43a0e7681dac45a68d5469220dbd4776,academic,0.401342
uuid-43a0e7681dac45a68d5469220dbd4776,Regional TL,0.569647
uuid-43a0e7681dac45a68d5469220dbd4776,bladder,0.314442
uuid-609602c8a18d43b8a76f96ff603868b0,RTL,0.447253
uuid-609602c8a18d43b8a76f96ff603868b0,BMS,0.530816
uuid-609602c8a18d43b8a76f96ff603868b0,trial,0.618311
uuid-609602c8a18d43b8a76f96ff603868b0,Merck,0.487332
uuid-609602c8a18d43b8a76f96ff603868b0,stated,0.341224
uuid-609602c8a18d43b8a76f96ff603868b0,mentioned,0.410244
uuid-609602c8a18d43b8a76f96ff603868b0,clinical trials,0.418594
uuid-94c0aa89146544a1a8012c217203ded2,patients,0.3356
uuid-94c0aa89146544a1a8012c217203ded2,trial,0.452195
uuid-94c0aa89146544a1a8012c217203ded2,chemo,0.318006
uuid-94c0aa89146544a1a8012c217203ded2,pts,0.332176
uuid-94c0aa89146544a1a8012c217203ded2,response,0.411112
uuid-94c0aa89146544a1a8012c217203ded2,chemotherapy,0.305793
uuid-94c0aa89146544a1a8012c217203ded2,respond,0.32737
uuid-94c0aa89146544a1a8012c217203ded2,feels,0.426334
uuid-e693a44e328b411fb876e9f0adaef367,Nivo,0.409249
uuid-e693a44e328b411fb876e9f0adaef367,pembro,0.498423
uuid-e693a44e328b411fb876e9f0adaef367,1L,0.344587
uuid-e693a44e328b411fb876e9f0adaef367,PDL1,0.592999
uuid-e693a44e328b411fb876e9f0adaef367,trial,0.300572
uuid-e693a44e328b411fb876e9f0adaef367,efficacy,0.575721
uuid-e693a44e328b411fb876e9f0adaef367,2L,0.324133
uuid-e693a44e328b411fb876e9f0adaef367,agents,0.307069
uuid-e693a44e328b411fb876e9f0adaef367,OS,0.426379
uuid-e693a44e328b411fb876e9f0adaef367,atezo,0.552659
uuid-e693a44e328b411fb876e9f0adaef367,regards,0.324863
uuid-e693a44e328b411fb876e9f0adaef367,data,0.403699
uuid-e693a44e328b411fb876e9f0adaef367,PFS,0.465927
uuid-e693a44e328b411fb876e9f0adaef367,AI,0.370683
uuid-e693a44e328b411fb876e9f0adaef367,ORR,0.454505
uuid-e693a44e328b411fb876e9f0adaef367,nivo and pembro,0.758657
uuid-e693a44e328b411fb876e9f0adaef367,believes,0.475567
uuid-e693a44e328b411fb876e9f0adaef367,vs,0.380944
uuid-e693a44e328b411fb876e9f0adaef367,feels,0.354846
uuid-e693a44e328b411fb876e9f0adaef367,PDL1 expression,0.546025
uuid-e693a44e328b411fb876e9f0adaef367,biomarker,0.30286
uuid-d96f9ce2a4924348a58c1455306d3841,patients,0.443052
uuid-d96f9ce2a4924348a58c1455306d3841,Opdivo,0.330998
uuid-d96f9ce2a4924348a58c1455306d3841,dose,0.641541
uuid-d96f9ce2a4924348a58c1455306d3841,Ipi,0.316763
uuid-d96f9ce2a4924348a58c1455306d3841,preferred,0.33749
uuid-d96f9ce2a4924348a58c1455306d3841,using nivo,0.344528
uuid-d96f9ce2a4924348a58c1455306d3841,vs,0.405565
uuid-d96f9ce2a4924348a58c1455306d3841,flat dosing,0.529998
uuid-4e4ca5ad628646fd9c96fd2b166f439d,nivolumab,0.321805
uuid-4e4ca5ad628646fd9c96fd2b166f439d,trial,0.390078
uuid-4e4ca5ad628646fd9c96fd2b166f439d,discussed,0.306298
uuid-4e4ca5ad628646fd9c96fd2b166f439d,data,0.418337
uuid-4e4ca5ad628646fd9c96fd2b166f439d,PFS,0.327409
uuid-4e4ca5ad628646fd9c96fd2b166f439d,ORR,0.309487
uuid-4e4ca5ad628646fd9c96fd2b166f439d,cHL,0.42627
uuid-4e4ca5ad628646fd9c96fd2b166f439d,ASCO,0.394178
uuid-4e4ca5ad628646fd9c96fd2b166f439d,impressed,0.407038
uuid-e7f89e673aac43028e094ad8018cfad9,Nivo,0.597563
uuid-e7f89e673aac43028e094ad8018cfad9,Opdivo,0.317586
uuid-e7f89e673aac43028e094ad8018cfad9,pembro,0.600503
uuid-e7f89e673aac43028e094ad8018cfad9,dose,0.640104
uuid-e7f89e673aac43028e094ad8018cfad9,nivolumab,0.329929
uuid-e7f89e673aac43028e094ad8018cfad9,efficacy,0.308434
uuid-e7f89e673aac43028e094ad8018cfad9,regimen,0.345528
uuid-e7f89e673aac43028e094ad8018cfad9,combination,0.332499
uuid-e7f89e673aac43028e094ad8018cfad9,2L,0.380063
uuid-e7f89e673aac43028e094ad8018cfad9,pts,0.351658
uuid-e7f89e673aac43028e094ad8018cfad9,Ipi,0.578155
uuid-e7f89e673aac43028e094ad8018cfad9,atezo,0.524884
uuid-e7f89e673aac43028e094ad8018cfad9,preferred,0.371657
uuid-e7f89e673aac43028e094ad8018cfad9,monotherapy,0.364194
uuid-e7f89e673aac43028e094ad8018cfad9,using nivo,0.384246
uuid-e7f89e673aac43028e094ad8018cfad9,combo,0.380363
uuid-e7f89e673aac43028e094ad8018cfad9,approved,0.314693
uuid-e7f89e673aac43028e094ad8018cfad9,vs,0.556596
uuid-e7f89e673aac43028e094ad8018cfad9,feels,0.316466
uuid-e7f89e673aac43028e094ad8018cfad9,flat dosing,0.482254
uuid-8430a81aade440ca9e4390d9454ef552,patients,0.651886
uuid-8430a81aade440ca9e4390d9454ef552,therapy,0.605353
uuid-8430a81aade440ca9e4390d9454ef552,nivolumab,0.340028
uuid-8430a81aade440ca9e4390d9454ef552,toxicity,0.338094
uuid-8430a81aade440ca9e4390d9454ef552,regimen,0.456251
uuid-8430a81aade440ca9e4390d9454ef552,treated,0.530367
uuid-8430a81aade440ca9e4390d9454ef552,combination,0.333811
uuid-8430a81aade440ca9e4390d9454ef552,chemo,0.469902
uuid-8430a81aade440ca9e4390d9454ef552,tumor,0.384742
uuid-8430a81aade440ca9e4390d9454ef552,pts,0.591138
uuid-8430a81aade440ca9e4390d9454ef552,monotherapy,0.308086
uuid-8430a81aade440ca9e4390d9454ef552,treatment,0.672317
uuid-8430a81aade440ca9e4390d9454ef552,response,0.752357
uuid-8430a81aade440ca9e4390d9454ef552,PD1,0.45218
uuid-8430a81aade440ca9e4390d9454ef552,progression,0.753179
uuid-8430a81aade440ca9e4390d9454ef552,chemotherapy,0.451688
uuid-8430a81aade440ca9e4390d9454ef552,respond,0.584705
uuid-8430a81aade440ca9e4390d9454ef552,immunotherapy,0.429091
uuid-5d142f15980b4aae8164aa08b3604ced,pembro,0.475896
uuid-5d142f15980b4aae8164aa08b3604ced,1L,0.532877
uuid-5d142f15980b4aae8164aa08b3604ced,PDL1,0.590257
uuid-5d142f15980b4aae8164aa08b3604ced,2L,0.441889
uuid-5d142f15980b4aae8164aa08b3604ced,Merck,0.356678
uuid-5d142f15980b4aae8164aa08b3604ced,PD-L1,0.617996
uuid-5d142f15980b4aae8164aa08b3604ced,approval,0.351387
uuid-5d142f15980b4aae8164aa08b3604ced,atezo,0.46553
uuid-5d142f15980b4aae8164aa08b3604ced,PD-L1 testing,0.431125
uuid-5d142f15980b4aae8164aa08b3604ced,testing,0.60419
uuid-5d142f15980b4aae8164aa08b3604ced,PDL1 testing,0.539177
uuid-5d142f15980b4aae8164aa08b3604ced,NSCLC patients,0.537618
uuid-5d142f15980b4aae8164aa08b3604ced,approved,0.302853
uuid-5d142f15980b4aae8164aa08b3604ced,nivo and pembro,0.424114
uuid-5d142f15980b4aae8164aa08b3604ced,assay,0.469882
uuid-5d142f15980b4aae8164aa08b3604ced,PDL1 expression,0.384822
uuid-5d142f15980b4aae8164aa08b3604ced,biomarker,0.387753
uuid-0f6809807a4446049210c7194bd3d911,RTL,0.335996
uuid-0f6809807a4446049210c7194bd3d911,NTL,0.482761
uuid-0f6809807a4446049210c7194bd3d911,physicians,0.396096
uuid-0f6809807a4446049210c7194bd3d911,mentioned,0.312481
uuid-0f6809807a4446049210c7194bd3d911,oncology,0.380952
uuid-0f6809807a4446049210c7194bd3d911,oncologist,0.395169
uuid-0f6809807a4446049210c7194bd3d911,indicated,0.426542
uuid-0f6809807a4446049210c7194bd3d911,Regional TL,0.373622
uuid-9f327c89fc004d1c9d83be21f71474d5,patients,0.551239
uuid-9f327c89fc004d1c9d83be21f71474d5,Opdivo,0.368006
uuid-9f327c89fc004d1c9d83be21f71474d5,nivolumab,0.394053
uuid-9f327c89fc004d1c9d83be21f71474d5,treated,0.630547
uuid-9f327c89fc004d1c9d83be21f71474d5,shared,0.353306
uuid-9f327c89fc004d1c9d83be21f71474d5,pts,0.302701
uuid-9f327c89fc004d1c9d83be21f71474d5,physicians,0.415871
uuid-9f327c89fc004d1c9d83be21f71474d5,treatment,0.376397
uuid-9f327c89fc004d1c9d83be21f71474d5,academic,0.337264
uuid-9f327c89fc004d1c9d83be21f71474d5,Regional TL,0.335128
uuid-13eb40de16b84eac9b7ac44ad0967319,Nivo,0.301921
uuid-13eb40de16b84eac9b7ac44ad0967319,patients,0.495545
uuid-13eb40de16b84eac9b7ac44ad0967319,therapy,0.376287
uuid-13eb40de16b84eac9b7ac44ad0967319,dose,0.372679
uuid-13eb40de16b84eac9b7ac44ad0967319,toxicity,0.359681
uuid-13eb40de16b84eac9b7ac44ad0967319,treatment,0.377555
uuid-13eb40de16b84eac9b7ac44ad0967319,progression,0.304628
uuid-e6b82f171bc54fcdbdb4cd416be91fc9,NSCLC,0.489043
uuid-e6b82f171bc54fcdbdb4cd416be91fc9,data,0.449483
uuid-e6b82f171bc54fcdbdb4cd416be91fc9,NCCN,0.595453
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,Nivo,0.344224
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,pembro,0.400468
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,1L,0.472732
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,PDL1,0.378244
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,chemo,0.374273
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,2L,0.469475
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,agents,0.374963
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,atezo,0.371497
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,preferred,0.428984
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,testing,0.301965
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,monotherapy,0.390833
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,using nivo,0.30611
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,PDL1 testing,0.344981
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,NSCLC patients,0.345713
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,nivo and pembro,0.415569
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,believes,0.457628
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,feels,0.402195
uuid-b942c0d2e1a440a3b5fa41f42ae4b03d,option,0.477596
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,RTL,0.37295
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,BMS,0.628338
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,trial,0.507038
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,shared,0.303278
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,commented,0.572289
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,Merck,0.524382
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,stated,0.454943
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,OS,0.454694
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,regards,0.369971
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,data,0.851769
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,expressed,0.432135
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,PFS,0.398103
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,ORR,0.460992
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,ASCO,0.474579
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,impressed,0.655678
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,LTL,0.316623
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,TLs,0.360599
uuid-6ba1d7a4b1164e4880e25ff8087c2a13,Regional TL,0.341403
uuid-fc1f29cbbb234af3b9bf44824538bd47,NSCLC,0.498684
uuid-fc1f29cbbb234af3b9bf44824538bd47,PDL1,0.408741
uuid-fc1f29cbbb234af3b9bf44824538bd47,trial,0.331535
uuid-fc1f29cbbb234af3b9bf44824538bd47,data,0.467553
uuid-fc1f29cbbb234af3b9bf44824538bd47,PFS,0.326028
uuid-fc1f29cbbb234af3b9bf44824538bd47,ORR,0.332212
uuid-fc1f29cbbb234af3b9bf44824538bd47,NCCN,0.470756
uuid-4027210eb6984a9da92274a442f4ccfc,NSCLC,0.439016
uuid-4027210eb6984a9da92274a442f4ccfc,NTL,0.336684
uuid-4027210eb6984a9da92274a442f4ccfc,commented,0.353507
uuid-4027210eb6984a9da92274a442f4ccfc,data,0.323419
uuid-4027210eb6984a9da92274a442f4ccfc,oncology,0.308387
uuid-4027210eb6984a9da92274a442f4ccfc,Regional TL,0.38451
uuid-4027210eb6984a9da92274a442f4ccfc,NCCN,0.610492
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,Nivo,0.548232
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,patients,0.455376
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,pembro,0.620589
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,1L,0.464765
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,chemo,0.30864
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,2L,0.473125
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,pts,0.34439
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,approval,0.499321
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,atezo,0.422896
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,preferred,0.385363
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,monotherapy,0.381693
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,using nivo,0.555404
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,clinical trials,0.300577
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,approved,0.474777
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,feels,0.4853
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,RTL stated,0.377585
uuid-f598aa2f9fcc48a4b6dafe3fc2732a9d,option,0.435359
uuid-f4615a31427c4e41a81482220e28f949,pembro,0.392458
uuid-f4615a31427c4e41a81482220e28f949,PDL1,0.64519
uuid-f4615a31427c4e41a81482220e28f949,Merck,0.407995
uuid-f4615a31427c4e41a81482220e28f949,PD-L1,0.618554
uuid-f4615a31427c4e41a81482220e28f949,atezo,0.347283
uuid-f4615a31427c4e41a81482220e28f949,PD-L1 testing,0.475783
uuid-f4615a31427c4e41a81482220e28f949,testing,0.61684
uuid-f4615a31427c4e41a81482220e28f949,PDL1 testing,0.495227
uuid-f4615a31427c4e41a81482220e28f949,NSCLC patients,0.451711
uuid-f4615a31427c4e41a81482220e28f949,nivo and pembro,0.325364
uuid-f4615a31427c4e41a81482220e28f949,assay,0.540232
uuid-f4615a31427c4e41a81482220e28f949,PDL1 expression,0.471832
uuid-f4615a31427c4e41a81482220e28f949,biomarker,0.367889
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,dose,0.360542
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,lung,0.335583
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,toxicity,0.455606
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,regimen,0.389929
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,melanoma,0.306797
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,RCC,0.373016
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,TL stated,0.332196
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,combination,0.470566
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,chemo,0.307781
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,2L,0.394668
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,IO,0.409159
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,agents,0.521526
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,Ipi,0.320665
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,preferred,0.396845
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,monotherapy,0.433075
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,combo,0.586753
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,PD1,0.300718
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,vs,0.306826
uuid-2aed7e564cc540fe8e6ea30f01c6a0be,option,0.30895
uuid-2dd543544e3e40fe966cbbc93a7b0944,lung,0.310565
uuid-2dd543544e3e40fe966cbbc93a7b0944,melanoma,0.304365
uuid-2dd543544e3e40fe966cbbc93a7b0944,RCC,0.401085
uuid-2dd543544e3e40fe966cbbc93a7b0944,2L,0.350814
uuid-2dd543544e3e40fe966cbbc93a7b0944,stated,0.433747
uuid-2dd543544e3e40fe966cbbc93a7b0944,approval,0.571057
uuid-2dd543544e3e40fe966cbbc93a7b0944,preferred,0.361743
uuid-2dd543544e3e40fe966cbbc93a7b0944,using nivo,0.415192
uuid-2dd543544e3e40fe966cbbc93a7b0944,indication,0.533118
uuid-2dd543544e3e40fe966cbbc93a7b0944,AI,0.329658
uuid-2dd543544e3e40fe966cbbc93a7b0944,approved,0.621183
uuid-2dd543544e3e40fe966cbbc93a7b0944,SCCHN,0.486433
uuid-2dd543544e3e40fe966cbbc93a7b0944,tumor types,0.358218
uuid-2dd543544e3e40fe966cbbc93a7b0944,label,0.589088
uuid-2dd543544e3e40fe966cbbc93a7b0944,SCLC,0.392521
uuid-2dd543544e3e40fe966cbbc93a7b0944,Regional TL,0.322841
uuid-2dd543544e3e40fe966cbbc93a7b0944,RTL stated,0.343672
uuid-2dd543544e3e40fe966cbbc93a7b0944,NCCN,0.562459
uuid-2dd543544e3e40fe966cbbc93a7b0944,bladder,0.342312
uuid-2dd543544e3e40fe966cbbc93a7b0944,flat dosing,0.305316
uuid-983d8436323647a6a7fc8c9dfae52a2b,patients,0.551617
uuid-983d8436323647a6a7fc8c9dfae52a2b,pts,0.353305
uuid-983d8436323647a6a7fc8c9dfae52a2b,PD-L1,0.515992
uuid-983d8436323647a6a7fc8c9dfae52a2b,PD-L1 testing,0.590626
uuid-983d8436323647a6a7fc8c9dfae52a2b,testing,0.646014
uuid-983d8436323647a6a7fc8c9dfae52a2b,PDL1 testing,0.561096
uuid-983d8436323647a6a7fc8c9dfae52a2b,NSCLC patients,0.62426
uuid-86ab66d9c30540bf946220047daeb3fa,pembro,0.314816
uuid-86ab66d9c30540bf946220047daeb3fa,dose,0.622191
uuid-86ab66d9c30540bf946220047daeb3fa,BMS,0.447645
uuid-86ab66d9c30540bf946220047daeb3fa,efficacy,0.394862
uuid-86ab66d9c30540bf946220047daeb3fa,Merck,0.303309
uuid-86ab66d9c30540bf946220047daeb3fa,Ipi,0.352675
uuid-86ab66d9c30540bf946220047daeb3fa,atezo,0.348911
uuid-86ab66d9c30540bf946220047daeb3fa,regards,0.319664
uuid-86ab66d9c30540bf946220047daeb3fa,indication,0.322397
uuid-86ab66d9c30540bf946220047daeb3fa,vs,0.509565
uuid-86ab66d9c30540bf946220047daeb3fa,flat dosing,0.579659
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,pembro,0.377921
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,BMS,0.380602
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,trial,0.502334
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,efficacy,0.317218
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,Merck,0.409928
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,atezo,0.389529
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,data,0.401474
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,expressed,0.313172
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,nivo and pembro,0.409874
uuid-f55d40aaabfd4d4b90c8bef28ceae72b,Regional TL,0.339978
uuid-8a521241b1824f8b88d06a19536cf6c8,Nivo,0.669266
uuid-8a521241b1824f8b88d06a19536cf6c8,pembro,0.67836
uuid-8a521241b1824f8b88d06a19536cf6c8,dose,0.483152
uuid-8a521241b1824f8b88d06a19536cf6c8,1L,0.32884
uuid-8a521241b1824f8b88d06a19536cf6c8,2L,0.482059
uuid-8a521241b1824f8b88d06a19536cf6c8,Ipi,0.547147
uuid-8a521241b1824f8b88d06a19536cf6c8,approval,0.427023
uuid-8a521241b1824f8b88d06a19536cf6c8,atezo,0.642524
uuid-8a521241b1824f8b88d06a19536cf6c8,preferred,0.499522
uuid-8a521241b1824f8b88d06a19536cf6c8,monotherapy,0.338687
uuid-8a521241b1824f8b88d06a19536cf6c8,using nivo,0.528701
uuid-8a521241b1824f8b88d06a19536cf6c8,indication,0.423126
uuid-8a521241b1824f8b88d06a19536cf6c8,approved,0.46162
uuid-8a521241b1824f8b88d06a19536cf6c8,vs,0.568117
uuid-8a521241b1824f8b88d06a19536cf6c8,feels,0.34935
uuid-8a521241b1824f8b88d06a19536cf6c8,RTL stated,0.330472
uuid-8a521241b1824f8b88d06a19536cf6c8,option,0.335488
uuid-8a521241b1824f8b88d06a19536cf6c8,flat dosing,0.421936
uuid-49242da2a395406d8f93b92a2ee1c053,lung,0.511032
uuid-49242da2a395406d8f93b92a2ee1c053,regards,0.370681
uuid-49242da2a395406d8f93b92a2ee1c053,AI,0.854251
uuid-49242da2a395406d8f93b92a2ee1c053,nivo and pembro,0.557017
uuid-49242da2a395406d8f93b92a2ee1c053,NCCN,0.396104
uuid-59c8796a7f2140118ff9bb8482b0488c,lung,0.464771
uuid-59c8796a7f2140118ff9bb8482b0488c,melanoma,0.33249
uuid-59c8796a7f2140118ff9bb8482b0488c,regards,0.487072
uuid-59c8796a7f2140118ff9bb8482b0488c,indication,0.388627
uuid-59c8796a7f2140118ff9bb8482b0488c,AI,0.708145
uuid-59c8796a7f2140118ff9bb8482b0488c,nivo and pembro,0.345092
uuid-59c8796a7f2140118ff9bb8482b0488c,label,0.339737
uuid-59c8796a7f2140118ff9bb8482b0488c,SCLC,0.349487
uuid-59c8796a7f2140118ff9bb8482b0488c,NCCN,0.738899
uuid-751ec976a2d84bbb9ec7384a4a90c35b,patients,0.511063
uuid-751ec976a2d84bbb9ec7384a4a90c35b,toxicity,0.347181
uuid-751ec976a2d84bbb9ec7384a4a90c35b,regimen,0.540206
uuid-751ec976a2d84bbb9ec7384a4a90c35b,combination,0.319037
uuid-751ec976a2d84bbb9ec7384a4a90c35b,chemo,0.425039
uuid-751ec976a2d84bbb9ec7384a4a90c35b,2L,0.302217
uuid-751ec976a2d84bbb9ec7384a4a90c35b,preferred,0.590072
uuid-751ec976a2d84bbb9ec7384a4a90c35b,monotherapy,0.504635
uuid-751ec976a2d84bbb9ec7384a4a90c35b,treatment,0.352733
uuid-751ec976a2d84bbb9ec7384a4a90c35b,using nivo,0.350037
uuid-751ec976a2d84bbb9ec7384a4a90c35b,indication,0.318719
uuid-751ec976a2d84bbb9ec7384a4a90c35b,chemotherapy,0.438808
uuid-751ec976a2d84bbb9ec7384a4a90c35b,feels,0.365843
uuid-751ec976a2d84bbb9ec7384a4a90c35b,option,0.557484
uuid-d4edc8e451104967a6cbb2a5c6182850,patients,0.487577
uuid-d4edc8e451104967a6cbb2a5c6182850,Opdivo,0.670606
uuid-d4edc8e451104967a6cbb2a5c6182850,therapy,0.394862
uuid-d4edc8e451104967a6cbb2a5c6182850,nivolumab,0.487735
uuid-d4edc8e451104967a6cbb2a5c6182850,treated,0.453391
uuid-d4edc8e451104967a6cbb2a5c6182850,stated,0.310819
uuid-d4edc8e451104967a6cbb2a5c6182850,approval,0.315156
uuid-d4edc8e451104967a6cbb2a5c6182850,treatment,0.366258
uuid-d4edc8e451104967a6cbb2a5c6182850,using nivo,0.406653
uuid-d4edc8e451104967a6cbb2a5c6182850,mentioned,0.326899
uuid-d4edc8e451104967a6cbb2a5c6182850,cHL,0.625937
uuid-d4edc8e451104967a6cbb2a5c6182850,progression,0.319937
uuid-d4edc8e451104967a6cbb2a5c6182850,LTL,0.3465
uuid-d4edc8e451104967a6cbb2a5c6182850,RTL stated,0.349376
uuid-ff7ddebbd8404c27a74b15b1cdaa630c,patients,0.318529
uuid-ff7ddebbd8404c27a74b15b1cdaa630c,Opdivo,0.541926
uuid-ff7ddebbd8404c27a74b15b1cdaa630c,treated,0.37169
uuid-ff7ddebbd8404c27a74b15b1cdaa630c,stated,0.415627
uuid-ff7ddebbd8404c27a74b15b1cdaa630c,cHL,0.407539
uuid-dc1301c235c74eb0890ce84472ffca6d,Opdivo,0.403689
uuid-dc1301c235c74eb0890ce84472ffca6d,NSCLC,0.319977
uuid-dc1301c235c74eb0890ce84472ffca6d,1L,0.300373
uuid-dc1301c235c74eb0890ce84472ffca6d,shared,0.375564
uuid-dc1301c235c74eb0890ce84472ffca6d,RCC,0.397442
uuid-dc1301c235c74eb0890ce84472ffca6d,TL stated,0.522587
uuid-dc1301c235c74eb0890ce84472ffca6d,2L,0.3277
uuid-dc1301c235c74eb0890ce84472ffca6d,stated,0.561033
uuid-dc1301c235c74eb0890ce84472ffca6d,approval,0.374693
uuid-dc1301c235c74eb0890ce84472ffca6d,physicians,0.341015
uuid-dc1301c235c74eb0890ce84472ffca6d,preferred,0.330382
uuid-dc1301c235c74eb0890ce84472ffca6d,testing,0.324196
uuid-dc1301c235c74eb0890ce84472ffca6d,using nivo,0.346411
uuid-dc1301c235c74eb0890ce84472ffca6d,PDL1 testing,0.532039
uuid-dc1301c235c74eb0890ce84472ffca6d,NSCLC patients,0.382103
uuid-dc1301c235c74eb0890ce84472ffca6d,approved,0.38842
uuid-dc1301c235c74eb0890ce84472ffca6d,SCCHN,0.466993
uuid-dc1301c235c74eb0890ce84472ffca6d,HCP,0.329925
uuid-dc1301c235c74eb0890ce84472ffca6d,tumor types,0.418642
uuid-dc1301c235c74eb0890ce84472ffca6d,LTL,0.378988
uuid-dc1301c235c74eb0890ce84472ffca6d,Keytruda,0.32267
uuid-dc1301c235c74eb0890ce84472ffca6d,TLs,0.345273
uuid-dc1301c235c74eb0890ce84472ffca6d,Regional TL,0.39192
uuid-dc1301c235c74eb0890ce84472ffca6d,RTL stated,0.471371
uuid-307eaf2ce8424e3eb910f16a41c775e6,patients,0.506225
uuid-307eaf2ce8424e3eb910f16a41c775e6,pts,0.340713
uuid-307eaf2ce8424e3eb910f16a41c775e6,stated,0.322399
uuid-307eaf2ce8424e3eb910f16a41c775e6,approval,0.311087
uuid-307eaf2ce8424e3eb910f16a41c775e6,preferred,0.310909
uuid-307eaf2ce8424e3eb910f16a41c775e6,treatment,0.303614
uuid-307eaf2ce8424e3eb910f16a41c775e6,using nivo,0.418404
uuid-307eaf2ce8424e3eb910f16a41c775e6,approved,0.300637
uuid-307eaf2ce8424e3eb910f16a41c775e6,SCCHN,0.427756
uuid-307eaf2ce8424e3eb910f16a41c775e6,impressed,0.323763
uuid-307eaf2ce8424e3eb910f16a41c775e6,feels,0.309941
uuid-307eaf2ce8424e3eb910f16a41c775e6,Regional TL,0.320199
uuid-307eaf2ce8424e3eb910f16a41c775e6,option,0.47368
uuid-7591962f1563469381e5af82ede57260,efficacy,0.3353
uuid-7591962f1563469381e5af82ede57260,regimen,0.31001
uuid-7591962f1563469381e5af82ede57260,combination,0.417678
uuid-7591962f1563469381e5af82ede57260,chemo,0.452935
uuid-7591962f1563469381e5af82ede57260,IO,0.443814
uuid-7591962f1563469381e5af82ede57260,OS,0.558089
uuid-7591962f1563469381e5af82ede57260,monotherapy,0.302497
uuid-7591962f1563469381e5af82ede57260,response,0.53099
uuid-7591962f1563469381e5af82ede57260,combo,0.388947
uuid-7591962f1563469381e5af82ede57260,PFS,0.517688
uuid-7591962f1563469381e5af82ede57260,PD1,0.380023
uuid-7591962f1563469381e5af82ede57260,ORR,0.489302
uuid-7591962f1563469381e5af82ede57260,progression,0.401676
uuid-7591962f1563469381e5af82ede57260,believes,0.327131
uuid-7591962f1563469381e5af82ede57260,chemotherapy,0.508327
uuid-7591962f1563469381e5af82ede57260,feels,0.318352
uuid-b9a46da9915949d8a2384c253a6b7aa4,Nivo,0.301683
uuid-b9a46da9915949d8a2384c253a6b7aa4,patients,0.543232
uuid-b9a46da9915949d8a2384c253a6b7aa4,Opdivo,0.445989
uuid-b9a46da9915949d8a2384c253a6b7aa4,pembro,0.32928
uuid-b9a46da9915949d8a2384c253a6b7aa4,nivolumab,0.442089
uuid-b9a46da9915949d8a2384c253a6b7aa4,1L,0.382438
uuid-b9a46da9915949d8a2384c253a6b7aa4,RCC,0.31224
uuid-b9a46da9915949d8a2384c253a6b7aa4,2L,0.469928
uuid-b9a46da9915949d8a2384c253a6b7aa4,pts,0.357744
uuid-b9a46da9915949d8a2384c253a6b7aa4,stated,0.451776
uuid-b9a46da9915949d8a2384c253a6b7aa4,approval,0.645765
uuid-b9a46da9915949d8a2384c253a6b7aa4,preferred,0.453438
uuid-b9a46da9915949d8a2384c253a6b7aa4,using nivo,0.61226
uuid-b9a46da9915949d8a2384c253a6b7aa4,indication,0.345538
uuid-b9a46da9915949d8a2384c253a6b7aa4,approved,0.682837
uuid-b9a46da9915949d8a2384c253a6b7aa4,SCCHN,0.409892
uuid-b9a46da9915949d8a2384c253a6b7aa4,tumor types,0.35551
uuid-b9a46da9915949d8a2384c253a6b7aa4,label,0.481887
uuid-b9a46da9915949d8a2384c253a6b7aa4,LTL,0.30095
uuid-b9a46da9915949d8a2384c253a6b7aa4,SCLC,0.345854
uuid-b9a46da9915949d8a2384c253a6b7aa4,RTL stated,0.429286
uuid-b9a46da9915949d8a2384c253a6b7aa4,option,0.454372
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,Nivo,0.469221
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,pembro,0.430378
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,1L,0.525743
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,PDL1,0.369821
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,efficacy,0.434043
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,combination,0.300467
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,chemo,0.390617
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,2L,0.449254
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,agents,0.459758
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,OS,0.422196
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,atezo,0.380471
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,preferred,0.402878
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,monotherapy,0.479869
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,using nivo,0.32148
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,data,0.525099
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,combo,0.329735
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,PFS,0.395647
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,PD1,0.309529
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,ORR,0.426049
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,approved,0.303609
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,nivo and pembro,0.491982
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,believes,0.437678
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,chemotherapy,0.33237
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,impressed,0.381318
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,feels,0.569468
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,PDL1 expression,0.320918
uuid-bbe9c0dc8cbc44dab9e11d0a569c8c0c,option,0.510449
uuid-29a1cb32862b4f8e8e127048a9b46886,Nivo,0.654404
uuid-29a1cb32862b4f8e8e127048a9b46886,pembro,0.642632
uuid-29a1cb32862b4f8e8e127048a9b46886,therapy,0.366595
uuid-29a1cb32862b4f8e8e127048a9b46886,nivolumab,0.32108
uuid-29a1cb32862b4f8e8e127048a9b46886,1L,0.532581
uuid-29a1cb32862b4f8e8e127048a9b46886,combination,0.314991
uuid-29a1cb32862b4f8e8e127048a9b46886,chemo,0.378892
uuid-29a1cb32862b4f8e8e127048a9b46886,2L,0.613522
uuid-29a1cb32862b4f8e8e127048a9b46886,agents,0.470844
uuid-29a1cb32862b4f8e8e127048a9b46886,approval,0.412385
uuid-29a1cb32862b4f8e8e127048a9b46886,atezo,0.58069
uuid-29a1cb32862b4f8e8e127048a9b46886,preferred,0.62952
uuid-29a1cb32862b4f8e8e127048a9b46886,monotherapy,0.541431
uuid-29a1cb32862b4f8e8e127048a9b46886,using nivo,0.596873
uuid-29a1cb32862b4f8e8e127048a9b46886,indication,0.49452
uuid-29a1cb32862b4f8e8e127048a9b46886,approved,0.533347
uuid-29a1cb32862b4f8e8e127048a9b46886,nivo and pembro,0.321231
uuid-29a1cb32862b4f8e8e127048a9b46886,chemotherapy,0.361452
uuid-29a1cb32862b4f8e8e127048a9b46886,vs,0.323969
uuid-29a1cb32862b4f8e8e127048a9b46886,label,0.307532
uuid-29a1cb32862b4f8e8e127048a9b46886,feels,0.432178
uuid-29a1cb32862b4f8e8e127048a9b46886,RTL stated,0.332866
uuid-29a1cb32862b4f8e8e127048a9b46886,option,0.637618
uuid-9049818c0bf14ed791b74e4ae1c30bfa,Nivo,0.350349
uuid-9049818c0bf14ed791b74e4ae1c30bfa,pembro,0.509299
uuid-9049818c0bf14ed791b74e4ae1c30bfa,1L,0.434464
uuid-9049818c0bf14ed791b74e4ae1c30bfa,PDL1,0.310224
uuid-9049818c0bf14ed791b74e4ae1c30bfa,2L,0.382035
uuid-9049818c0bf14ed791b74e4ae1c30bfa,approval,0.415646
uuid-9049818c0bf14ed791b74e4ae1c30bfa,atezo,0.395517
uuid-9049818c0bf14ed791b74e4ae1c30bfa,using nivo,0.34364
uuid-9049818c0bf14ed791b74e4ae1c30bfa,data,0.523875
uuid-9049818c0bf14ed791b74e4ae1c30bfa,indication,0.370497
uuid-9049818c0bf14ed791b74e4ae1c30bfa,approved,0.415291
uuid-9049818c0bf14ed791b74e4ae1c30bfa,nivo and pembro,0.340692
uuid-9049818c0bf14ed791b74e4ae1c30bfa,impressed,0.327277
uuid-9049818c0bf14ed791b74e4ae1c30bfa,feels,0.360814
uuid-9049818c0bf14ed791b74e4ae1c30bfa,option,0.365432
uuid-36d43185a0da4f35aa7ed19c922bb2d5,PDL1,0.395678
uuid-36d43185a0da4f35aa7ed19c922bb2d5,efficacy,0.413229
uuid-36d43185a0da4f35aa7ed19c922bb2d5,OS,0.409457
uuid-36d43185a0da4f35aa7ed19c922bb2d5,data,0.385341
uuid-36d43185a0da4f35aa7ed19c922bb2d5,PFS,0.458644
uuid-36d43185a0da4f35aa7ed19c922bb2d5,ORR,0.450869
uuid-36d43185a0da4f35aa7ed19c922bb2d5,feels,0.40514
uuid-36d43185a0da4f35aa7ed19c922bb2d5,PDL1 expression,0.372588
uuid-54e68ceba03b48fabb87e69df3eb13ed,PDL1,0.464243
uuid-54e68ceba03b48fabb87e69df3eb13ed,trial,0.312418
uuid-54e68ceba03b48fabb87e69df3eb13ed,efficacy,0.308931
uuid-54e68ceba03b48fabb87e69df3eb13ed,agents,0.363963
uuid-54e68ceba03b48fabb87e69df3eb13ed,Merck,0.325261
uuid-54e68ceba03b48fabb87e69df3eb13ed,PD-L1,0.435715
uuid-54e68ceba03b48fabb87e69df3eb13ed,data,0.351225
uuid-54e68ceba03b48fabb87e69df3eb13ed,lung cancer,0.389183
uuid-54e68ceba03b48fabb87e69df3eb13ed,nivo and pembro,0.414088
uuid-54e68ceba03b48fabb87e69df3eb13ed,assay,0.315612
uuid-54e68ceba03b48fabb87e69df3eb13ed,PD-1,0.504232
uuid-54e68ceba03b48fabb87e69df3eb13ed,PDL1 expression,0.306753
uuid-54e68ceba03b48fabb87e69df3eb13ed,biomarker,0.347574
uuid-d847510d96034ea1b4d8a2ed7ebaed99,patients,0.50517
uuid-d847510d96034ea1b4d8a2ed7ebaed99,Opdivo,0.301259
uuid-d847510d96034ea1b4d8a2ed7ebaed99,toxicity,0.661938
uuid-d847510d96034ea1b4d8a2ed7ebaed99,regimen,0.611941
uuid-d847510d96034ea1b4d8a2ed7ebaed99,treated,0.435084
uuid-d847510d96034ea1b4d8a2ed7ebaed99,pts,0.305133
uuid-d847510d96034ea1b4d8a2ed7ebaed99,treatment,0.536621
uuid-d847510d96034ea1b4d8a2ed7ebaed99,progression,0.430759
uuid-d847510d96034ea1b4d8a2ed7ebaed99,respond,0.504178
uuid-e826f25995fd404691b407629b7f425f,BMS,0.336201
uuid-e826f25995fd404691b407629b7f425f,PDL1,0.409444
uuid-e826f25995fd404691b407629b7f425f,trial,0.435817
uuid-e826f25995fd404691b407629b7f425f,efficacy,0.601123
uuid-e826f25995fd404691b407629b7f425f,discussed,0.36904
uuid-e826f25995fd404691b407629b7f425f,commented,0.349976
uuid-e826f25995fd404691b407629b7f425f,OS,0.751035
uuid-e826f25995fd404691b407629b7f425f,regards,0.46254
uuid-e826f25995fd404691b407629b7f425f,data,0.726224
uuid-e826f25995fd404691b407629b7f425f,expressed,0.316118
uuid-e826f25995fd404691b407629b7f425f,PFS,0.783033
uuid-e826f25995fd404691b407629b7f425f,ORR,0.736124
uuid-e826f25995fd404691b407629b7f425f,nivo and pembro,0.532768
uuid-e826f25995fd404691b407629b7f425f,ASCO,0.359274
uuid-e826f25995fd404691b407629b7f425f,impressed,0.512171
uuid-e826f25995fd404691b407629b7f425f,PDL1 expression,0.419917
uuid-5236bf27c11c40ed8b10b8e67d86f991,feels,0.326005
uuid-142a23d7f13a48f1bfe984f817e43fd5,toxicity,0.528736
uuid-142a23d7f13a48f1bfe984f817e43fd5,regimen,0.354057
uuid-142a23d7f13a48f1bfe984f817e43fd5,treatment,0.307024
uuid-142a23d7f13a48f1bfe984f817e43fd5,response,0.339828
uuid-142a23d7f13a48f1bfe984f817e43fd5,respond,0.407394
uuid-574b51c6a8b74f859aa1fb723c137a89,TL,0.541832
uuid-574b51c6a8b74f859aa1fb723c137a89,PDL1,0.381849
uuid-574b51c6a8b74f859aa1fb723c137a89,TL stated,0.385123
uuid-574b51c6a8b74f859aa1fb723c137a89,institution,0.309026
uuid-574b51c6a8b74f859aa1fb723c137a89,PD-L1,0.731116
uuid-574b51c6a8b74f859aa1fb723c137a89,PD-L1 testing,0.852384
uuid-574b51c6a8b74f859aa1fb723c137a89,testing,0.807687
uuid-574b51c6a8b74f859aa1fb723c137a89,PDL1 testing,0.615517
uuid-574b51c6a8b74f859aa1fb723c137a89,NSCLC patients,0.545974
uuid-574b51c6a8b74f859aa1fb723c137a89,assay,0.679115
uuid-574b51c6a8b74f859aa1fb723c137a89,biomarker,0.391538
uuid-4434aecd26f64df9b4fd91899b01acde,pembro,0.51422
uuid-4434aecd26f64df9b4fd91899b01acde,BMS,0.472865
uuid-4434aecd26f64df9b4fd91899b01acde,1L,0.408574
uuid-4434aecd26f64df9b4fd91899b01acde,PDL1,0.433203
uuid-4434aecd26f64df9b4fd91899b01acde,trial,0.454611
uuid-4434aecd26f64df9b4fd91899b01acde,efficacy,0.333417
uuid-4434aecd26f64df9b4fd91899b01acde,commented,0.444741
uuid-4434aecd26f64df9b4fd91899b01acde,2L,0.318912
uuid-4434aecd26f64df9b4fd91899b01acde,Merck,0.482845
uuid-4434aecd26f64df9b4fd91899b01acde,stated,0.342368
uuid-4434aecd26f64df9b4fd91899b01acde,OS,0.310339
uuid-4434aecd26f64df9b4fd91899b01acde,atezo,0.474802
uuid-4434aecd26f64df9b4fd91899b01acde,data,0.647981
uuid-4434aecd26f64df9b4fd91899b01acde,expressed,0.386774
uuid-4434aecd26f64df9b4fd91899b01acde,clinical trials,0.312409
uuid-4434aecd26f64df9b4fd91899b01acde,indication,0.334066
uuid-4434aecd26f64df9b4fd91899b01acde,ORR,0.320716
uuid-4434aecd26f64df9b4fd91899b01acde,SCCHN,0.301851
uuid-4434aecd26f64df9b4fd91899b01acde,nivo and pembro,0.441612
uuid-4434aecd26f64df9b4fd91899b01acde,impressed,0.514942
uuid-4434aecd26f64df9b4fd91899b01acde,TLs,0.414152
uuid-4434aecd26f64df9b4fd91899b01acde,feels,0.423579
uuid-4434aecd26f64df9b4fd91899b01acde,PDL1 expression,0.337444
uuid-4434aecd26f64df9b4fd91899b01acde,bladder,0.317454
uuid-24b16037728648c3ae84dfec4dfb2687,patients,0.714123
uuid-24b16037728648c3ae84dfec4dfb2687,therapy,0.420754
uuid-24b16037728648c3ae84dfec4dfb2687,nivolumab,0.422752
uuid-24b16037728648c3ae84dfec4dfb2687,regimen,0.383376
uuid-24b16037728648c3ae84dfec4dfb2687,treated,0.556057
uuid-24b16037728648c3ae84dfec4dfb2687,RCC,0.356911
uuid-24b16037728648c3ae84dfec4dfb2687,chemo,0.307028
uuid-24b16037728648c3ae84dfec4dfb2687,pts,0.459165
uuid-24b16037728648c3ae84dfec4dfb2687,treatment,0.544443
uuid-24b16037728648c3ae84dfec4dfb2687,using nivo,0.404156
uuid-24b16037728648c3ae84dfec4dfb2687,progression,0.463585
uuid-24b16037728648c3ae84dfec4dfb2687,chemotherapy,0.321219
uuid-24b16037728648c3ae84dfec4dfb2687,respond,0.361984
uuid-24b16037728648c3ae84dfec4dfb2687,RTL stated,0.377422
uuid-24b16037728648c3ae84dfec4dfb2687,TL shared,0.362343
uuid-24b16037728648c3ae84dfec4dfb2687,option,0.377362
uuid-776b17e88b0142938c2ca362944dfdd4,Nivo,0.324606
uuid-776b17e88b0142938c2ca362944dfdd4,patients,0.725635
uuid-776b17e88b0142938c2ca362944dfdd4,therapy,0.388997
uuid-776b17e88b0142938c2ca362944dfdd4,1L,0.354703
uuid-776b17e88b0142938c2ca362944dfdd4,regimen,0.307437
uuid-776b17e88b0142938c2ca362944dfdd4,treated,0.359102
uuid-776b17e88b0142938c2ca362944dfdd4,chemo,0.459137
uuid-776b17e88b0142938c2ca362944dfdd4,tumor,0.384356
uuid-776b17e88b0142938c2ca362944dfdd4,2L,0.362489
uuid-776b17e88b0142938c2ca362944dfdd4,pts,0.578075
uuid-776b17e88b0142938c2ca362944dfdd4,preferred,0.396272
uuid-776b17e88b0142938c2ca362944dfdd4,monotherapy,0.406339
uuid-776b17e88b0142938c2ca362944dfdd4,treatment,0.41859
uuid-776b17e88b0142938c2ca362944dfdd4,using nivo,0.389938
uuid-776b17e88b0142938c2ca362944dfdd4,NSCLC patients,0.370604
uuid-776b17e88b0142938c2ca362944dfdd4,progression,0.444749
uuid-776b17e88b0142938c2ca362944dfdd4,chemotherapy,0.364878
uuid-776b17e88b0142938c2ca362944dfdd4,respond,0.373963
uuid-776b17e88b0142938c2ca362944dfdd4,option,0.49452
uuid-6ef653a3aa03417ab0a46310bc1eb05a,Nivo,0.606305
uuid-6ef653a3aa03417ab0a46310bc1eb05a,pembro,0.71857
uuid-6ef653a3aa03417ab0a46310bc1eb05a,dose,0.454563
uuid-6ef653a3aa03417ab0a46310bc1eb05a,1L,0.592268
uuid-6ef653a3aa03417ab0a46310bc1eb05a,combination,0.438776
uuid-6ef653a3aa03417ab0a46310bc1eb05a,chemo,0.315108
uuid-6ef653a3aa03417ab0a46310bc1eb05a,2L,0.712128
uuid-6ef653a3aa03417ab0a46310bc1eb05a,agents,0.441744
uuid-6ef653a3aa03417ab0a46310bc1eb05a,Ipi,0.568045
uuid-6ef653a3aa03417ab0a46310bc1eb05a,approval,0.333217
uuid-6ef653a3aa03417ab0a46310bc1eb05a,atezo,0.73052
uuid-6ef653a3aa03417ab0a46310bc1eb05a,preferred,0.628874
uuid-6ef653a3aa03417ab0a46310bc1eb05a,monotherapy,0.559786
uuid-6ef653a3aa03417ab0a46310bc1eb05a,using nivo,0.551811
uuid-6ef653a3aa03417ab0a46310bc1eb05a,combo,0.580215
uuid-6ef653a3aa03417ab0a46310bc1eb05a,approved,0.486106
uuid-6ef653a3aa03417ab0a46310bc1eb05a,nivo and pembro,0.326892
uuid-6ef653a3aa03417ab0a46310bc1eb05a,vs,0.531446
uuid-6ef653a3aa03417ab0a46310bc1eb05a,feels,0.371781
uuid-6ef653a3aa03417ab0a46310bc1eb05a,RTL stated,0.381776
uuid-6ef653a3aa03417ab0a46310bc1eb05a,option,0.49656
uuid-2a7cd738df94423ba63c3ce12204732e,Nivo,0.337569
uuid-2a7cd738df94423ba63c3ce12204732e,Opdivo,0.304283
uuid-2a7cd738df94423ba63c3ce12204732e,pembro,0.335549
uuid-2a7cd738df94423ba63c3ce12204732e,dose,0.841489
uuid-2a7cd738df94423ba63c3ce12204732e,toxicity,0.345582
uuid-2a7cd738df94423ba63c3ce12204732e,regimen,0.30777
uuid-2a7cd738df94423ba63c3ce12204732e,Ipi,0.582444
uuid-2a7cd738df94423ba63c3ce12204732e,atezo,0.322805
uuid-2a7cd738df94423ba63c3ce12204732e,vs,0.550713
uuid-2a7cd738df94423ba63c3ce12204732e,Keytruda,0.36517
uuid-2a7cd738df94423ba63c3ce12204732e,flat dosing,0.657876
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,BMS,0.36021
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,PDL1,0.682
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,trial,0.423714
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,efficacy,0.437189
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,Merck,0.386829
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,PD-L1,0.454035
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,OS,0.449203
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,data,0.406171
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,PFS,0.50064
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,ORR,0.512656
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,nivo and pembro,0.413252
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,believes,0.342837
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,feels,0.302136
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,assay,0.463349
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,PDL1 expression,0.577072
uuid-c9d19d494c7a4b1dbd04ac5f7e25a9f3,biomarker,0.469418
uuid-1c1425a0f5e34b08bbad76d63a0c0f18,PD-L1,0.305955
uuid-1c1425a0f5e34b08bbad76d63a0c0f18,PD-L1 testing,0.358007
uuid-1c1425a0f5e34b08bbad76d63a0c0f18,testing,0.344653
uuid-1c1425a0f5e34b08bbad76d63a0c0f18,lung cancer,0.659875
uuid-32a77aab074c48b08dc77e6f8b96ea55,lung cancer,0.733044
uuid-325441ed3284439f9771a157a196a0ea,lung cancer,0.585159
uuid-325441ed3284439f9771a157a196a0ea,NCCN,0.304305
uuid-085b48d9b4ee414a9c9a23d14e4986e7,PD-L1,0.340393
uuid-085b48d9b4ee414a9c9a23d14e4986e7,PD-L1 testing,0.328583
uuid-085b48d9b4ee414a9c9a23d14e4986e7,testing,0.349709
uuid-085b48d9b4ee414a9c9a23d14e4986e7,lung cancer,0.745259
uuid-085b48d9b4ee414a9c9a23d14e4986e7,assay,0.348352
uuid-7c71f7f89fae4b728d0e0a9781d79348,Nivo,0.400005
uuid-7c71f7f89fae4b728d0e0a9781d79348,patients,0.663257
uuid-7c71f7f89fae4b728d0e0a9781d79348,therapy,0.690438
uuid-7c71f7f89fae4b728d0e0a9781d79348,1L,0.337168
uuid-7c71f7f89fae4b728d0e0a9781d79348,regimen,0.536848
uuid-7c71f7f89fae4b728d0e0a9781d79348,treated,0.344601
uuid-7c71f7f89fae4b728d0e0a9781d79348,combination,0.342239
uuid-7c71f7f89fae4b728d0e0a9781d79348,chemo,0.603814
uuid-7c71f7f89fae4b728d0e0a9781d79348,2L,0.305868
uuid-7c71f7f89fae4b728d0e0a9781d79348,pts,0.618547
uuid-7c71f7f89fae4b728d0e0a9781d79348,IO,0.346422
uuid-7c71f7f89fae4b728d0e0a9781d79348,monotherapy,0.536618
uuid-7c71f7f89fae4b728d0e0a9781d79348,treatment,0.661355
uuid-7c71f7f89fae4b728d0e0a9781d79348,response,0.620019
uuid-7c71f7f89fae4b728d0e0a9781d79348,combo,0.342934
uuid-7c71f7f89fae4b728d0e0a9781d79348,PD1,0.542326
uuid-7c71f7f89fae4b728d0e0a9781d79348,progression,0.84298
uuid-7c71f7f89fae4b728d0e0a9781d79348,chemotherapy,0.53145
uuid-7c71f7f89fae4b728d0e0a9781d79348,respond,0.593555
uuid-7c71f7f89fae4b728d0e0a9781d79348,option,0.495056
uuid-5f092deee8ef40e0865c4065b7297871,RTL,0.335958
uuid-5f092deee8ef40e0865c4065b7297871,efficacy,0.371932
uuid-5f092deee8ef40e0865c4065b7297871,commented,0.384758
uuid-5f092deee8ef40e0865c4065b7297871,stated,0.407157
uuid-5f092deee8ef40e0865c4065b7297871,OS,0.389505
uuid-5f092deee8ef40e0865c4065b7297871,data,0.683021
uuid-5f092deee8ef40e0865c4065b7297871,clinical trials,0.333579
uuid-5f092deee8ef40e0865c4065b7297871,PFS,0.360063
uuid-5f092deee8ef40e0865c4065b7297871,ORR,0.400436
uuid-5f092deee8ef40e0865c4065b7297871,impressed,0.604021
uuid-5f092deee8ef40e0865c4065b7297871,LTL,0.356215
uuid-5f092deee8ef40e0865c4065b7297871,TLs,0.426681
uuid-5f092deee8ef40e0865c4065b7297871,feels,0.420313
uuid-5f092deee8ef40e0865c4065b7297871,Regional TL,0.326766
uuid-b39198b8be1840b3aeab634247449b98,PDL1,0.518637
uuid-b39198b8be1840b3aeab634247449b98,PD-L1,0.57589
uuid-b39198b8be1840b3aeab634247449b98,PD-L1 testing,0.413135
uuid-b39198b8be1840b3aeab634247449b98,testing,0.644332
uuid-b39198b8be1840b3aeab634247449b98,PDL1 testing,0.483111
uuid-b39198b8be1840b3aeab634247449b98,NSCLC patients,0.514423
uuid-b39198b8be1840b3aeab634247449b98,tumor types,0.346721
uuid-b39198b8be1840b3aeab634247449b98,assay,0.384646
uuid-b39198b8be1840b3aeab634247449b98,PDL1 expression,0.330263
uuid-b39198b8be1840b3aeab634247449b98,biomarker,0.633638
uuid-67724b3a098148bba7fdbed1415d5dea,PDL1,0.424819
uuid-67724b3a098148bba7fdbed1415d5dea,OS,0.361616
uuid-67724b3a098148bba7fdbed1415d5dea,PFS,0.379679
uuid-67724b3a098148bba7fdbed1415d5dea,AI,0.448048
uuid-67724b3a098148bba7fdbed1415d5dea,nivo and pembro,0.328359
uuid-67724b3a098148bba7fdbed1415d5dea,believes,0.367887
uuid-67724b3a098148bba7fdbed1415d5dea,immunotherapy,0.36949
uuid-67724b3a098148bba7fdbed1415d5dea,PDL1 expression,0.430106
uuid-67724b3a098148bba7fdbed1415d5dea,biomarker,0.447487
uuid-f40c1c51ca354b7cb37334176ccc5a1b,TL,0.456271
uuid-f40c1c51ca354b7cb37334176ccc5a1b,RTL,0.461344
uuid-f40c1c51ca354b7cb37334176ccc5a1b,lung,0.333564
uuid-f40c1c51ca354b7cb37334176ccc5a1b,1L,0.310091
uuid-f40c1c51ca354b7cb37334176ccc5a1b,shared,0.392873
uuid-f40c1c51ca354b7cb37334176ccc5a1b,RCC,0.479811
uuid-f40c1c51ca354b7cb37334176ccc5a1b,TL stated,0.650709
uuid-f40c1c51ca354b7cb37334176ccc5a1b,institution,0.410629
uuid-f40c1c51ca354b7cb37334176ccc5a1b,stated,0.352039
uuid-f40c1c51ca354b7cb37334176ccc5a1b,PD-L1,0.587014
uuid-f40c1c51ca354b7cb37334176ccc5a1b,approval,0.301537
uuid-f40c1c51ca354b7cb37334176ccc5a1b,PD-L1 testing,0.642144
uuid-f40c1c51ca354b7cb37334176ccc5a1b,testing,0.690254
uuid-f40c1c51ca354b7cb37334176ccc5a1b,PDL1 testing,0.721294
uuid-f40c1c51ca354b7cb37334176ccc5a1b,NSCLC patients,0.697316
uuid-f40c1c51ca354b7cb37334176ccc5a1b,SCCHN,0.503674
uuid-f40c1c51ca354b7cb37334176ccc5a1b,tumor types,0.414964
uuid-f40c1c51ca354b7cb37334176ccc5a1b,LTL,0.340957
uuid-f40c1c51ca354b7cb37334176ccc5a1b,TLs,0.35639
uuid-f40c1c51ca354b7cb37334176ccc5a1b,academic,0.373121
uuid-f40c1c51ca354b7cb37334176ccc5a1b,assay,0.327405
uuid-f40c1c51ca354b7cb37334176ccc5a1b,Regional TL,0.381118
uuid-f40c1c51ca354b7cb37334176ccc5a1b,RTL stated,0.442625
uuid-f40c1c51ca354b7cb37334176ccc5a1b,TL shared,0.358163
uuid-f40c1c51ca354b7cb37334176ccc5a1b,bladder,0.375526
uuid-d147973a258548e68d25f7bd726f6044,Nivo,0.404106
uuid-d147973a258548e68d25f7bd726f6044,pembro,0.499456
uuid-d147973a258548e68d25f7bd726f6044,1L,0.367775
uuid-d147973a258548e68d25f7bd726f6044,PDL1,0.669749
uuid-d147973a258548e68d25f7bd726f6044,trial,0.403966
uuid-d147973a258548e68d25f7bd726f6044,efficacy,0.664343
uuid-d147973a258548e68d25f7bd726f6044,chemo,0.300732
uuid-d147973a258548e68d25f7bd726f6044,OS,0.610129
uuid-d147973a258548e68d25f7bd726f6044,atezo,0.461942
uuid-d147973a258548e68d25f7bd726f6044,data,0.694356
uuid-d147973a258548e68d25f7bd726f6044,PFS,0.628054
uuid-d147973a258548e68d25f7bd726f6044,ORR,0.634712
uuid-d147973a258548e68d25f7bd726f6044,nivo and pembro,0.667919
uuid-d147973a258548e68d25f7bd726f6044,believes,0.497772
uuid-d147973a258548e68d25f7bd726f6044,impressed,0.4178
uuid-d147973a258548e68d25f7bd726f6044,vs,0.32848
uuid-d147973a258548e68d25f7bd726f6044,feels,0.48094
uuid-d147973a258548e68d25f7bd726f6044,PDL1 expression,0.616411
uuid-d147973a258548e68d25f7bd726f6044,biomarker,0.350865
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,Nivo,0.324189
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,lung,0.386452
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,PDL1,0.427217
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,efficacy,0.397289
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,OS,0.503522
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,regards,0.400674
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,PFS,0.600396
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,AI,0.703056
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,ORR,0.49241
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,nivo and pembro,0.638351
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,believes,0.329222
uuid-ce0d2380a20841e3bf8e8c3b31d99b04,PDL1 expression,0.461419
uuid-879adbc3aaef4b0784a9faafb4b582cd,Nivo,0.42326
uuid-879adbc3aaef4b0784a9faafb4b582cd,therapy,0.321735
uuid-879adbc3aaef4b0784a9faafb4b582cd,lung,0.381008
uuid-879adbc3aaef4b0784a9faafb4b582cd,chemo,0.379578
uuid-879adbc3aaef4b0784a9faafb4b582cd,PFS,0.301518
uuid-879adbc3aaef4b0784a9faafb4b582cd,AI,0.655743
uuid-879adbc3aaef4b0784a9faafb4b582cd,nivo and pembro,0.367482
uuid-879adbc3aaef4b0784a9faafb4b582cd,chemotherapy,0.3283
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,RTL,0.535767
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,trial,0.366736
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,NTL,0.554203
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,data,0.30255
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,expressed,0.516846
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,mentioned,0.513175
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,HCP,0.658559
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,impressed,0.321476
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,LTL,0.369687
uuid-1e2b6e1dbadb40c5a4426061cd62f4e2,SCLC,0.311113
uuid-d5bc079960ea43e5a105f1460b546f25,NSCLC,0.411971
uuid-d5bc079960ea43e5a105f1460b546f25,1L,0.353147
uuid-d5bc079960ea43e5a105f1460b546f25,pts,0.323838
uuid-d5bc079960ea43e5a105f1460b546f25,monotherapy,0.303726
uuid-d5bc079960ea43e5a105f1460b546f25,HCP,0.326933
uuid-d5bc079960ea43e5a105f1460b546f25,chemotherapy,0.314759
uuid-d5bc079960ea43e5a105f1460b546f25,bladder,0.310294
uuid-b283663349e64678b1191cc493a11300,RTL,0.407858
uuid-b283663349e64678b1191cc493a11300,PDL1,0.385182
uuid-b283663349e64678b1191cc493a11300,trial,0.505738
uuid-b283663349e64678b1191cc493a11300,efficacy,0.468152
uuid-b283663349e64678b1191cc493a11300,commented,0.319566
uuid-b283663349e64678b1191cc493a11300,OS,0.823683
uuid-b283663349e64678b1191cc493a11300,data,0.685382
uuid-b283663349e64678b1191cc493a11300,expressed,0.33092
uuid-b283663349e64678b1191cc493a11300,PFS,0.811371
uuid-b283663349e64678b1191cc493a11300,ORR,0.771147
uuid-b283663349e64678b1191cc493a11300,nivo and pembro,0.321263
uuid-b283663349e64678b1191cc493a11300,impressed,0.61596
uuid-b283663349e64678b1191cc493a11300,PDL1 expression,0.389662
uuid-98c7858649654aaaadcde9f5ade29637,Nivo,0.323564
uuid-98c7858649654aaaadcde9f5ade29637,patients,0.552408
uuid-98c7858649654aaaadcde9f5ade29637,pembro,0.460967
uuid-98c7858649654aaaadcde9f5ade29637,nivolumab,0.386074
uuid-98c7858649654aaaadcde9f5ade29637,1L,0.462503
uuid-98c7858649654aaaadcde9f5ade29637,trial,0.322197
uuid-98c7858649654aaaadcde9f5ade29637,treated,0.346887
uuid-98c7858649654aaaadcde9f5ade29637,2L,0.437742
uuid-98c7858649654aaaadcde9f5ade29637,pts,0.473192
uuid-98c7858649654aaaadcde9f5ade29637,approval,0.516697
uuid-98c7858649654aaaadcde9f5ade29637,preferred,0.474509
uuid-98c7858649654aaaadcde9f5ade29637,monotherapy,0.452845
uuid-98c7858649654aaaadcde9f5ade29637,using nivo,0.493355
uuid-98c7858649654aaaadcde9f5ade29637,combo,0.300969
uuid-98c7858649654aaaadcde9f5ade29637,clinical trials,0.422876
uuid-98c7858649654aaaadcde9f5ade29637,NSCLC patients,0.342845
uuid-98c7858649654aaaadcde9f5ade29637,approved,0.485518
uuid-98c7858649654aaaadcde9f5ade29637,SCCHN,0.332402
uuid-98c7858649654aaaadcde9f5ade29637,feels,0.319301
uuid-98c7858649654aaaadcde9f5ade29637,RTL stated,0.44006
uuid-98c7858649654aaaadcde9f5ade29637,option,0.498863
uuid-98c7858649654aaaadcde9f5ade29637,bladder,0.311034
uuid-872dc0cb8e0a4b4a84c42992a496e914,TL,0.382255
uuid-872dc0cb8e0a4b4a84c42992a496e914,mentioned,0.419995
uuid-872dc0cb8e0a4b4a84c42992a496e914,HCP,0.368788
uuid-872dc0cb8e0a4b4a84c42992a496e914,assay,0.388191
uuid-c485f824c75a4309b4d1cdefac0138e4,TL,0.628312
uuid-c485f824c75a4309b4d1cdefac0138e4,PDL1,0.436213
uuid-c485f824c75a4309b4d1cdefac0138e4,Merck,0.386456
uuid-c485f824c75a4309b4d1cdefac0138e4,institution,0.308099
uuid-c485f824c75a4309b4d1cdefac0138e4,PD-L1,0.746919
uuid-c485f824c75a4309b4d1cdefac0138e4,PD-L1 testing,0.767102
uuid-c485f824c75a4309b4d1cdefac0138e4,testing,0.715628
uuid-c485f824c75a4309b4d1cdefac0138e4,PDL1 testing,0.439203
uuid-c485f824c75a4309b4d1cdefac0138e4,NSCLC patients,0.383028
uuid-c485f824c75a4309b4d1cdefac0138e4,assay,0.822272
uuid-c485f824c75a4309b4d1cdefac0138e4,biomarker,0.416778
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,RTL,0.63268
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,NTL,0.466204
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,shared,0.309269
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,commented,0.416603
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,RCC,0.350713
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,stated,0.486106
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,approval,0.375623
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,using nivo,0.467194
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,data,0.395046
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,expressed,0.389134
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,mentioned,0.496922
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,clinical trials,0.347437
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,SCCHN,0.659627
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,HCP,0.596069
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,impressed,0.369359
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,LTL,0.586089
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,academic,0.376188
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,SCLC,0.334155
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,Regional TL,0.533172
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,RTL stated,0.495773
uuid-b3fc84f60a6e4c6981b0b1c28b55cc35,bladder,0.366852
uuid-31fcba96eaea454686608af0a28a0a3a,Nivo,0.332946
uuid-31fcba96eaea454686608af0a28a0a3a,pembro,0.44442
uuid-31fcba96eaea454686608af0a28a0a3a,RTL,0.305806
uuid-31fcba96eaea454686608af0a28a0a3a,BMS,0.348308
uuid-31fcba96eaea454686608af0a28a0a3a,1L,0.300442
uuid-31fcba96eaea454686608af0a28a0a3a,trial,0.387681
uuid-31fcba96eaea454686608af0a28a0a3a,commented,0.409557
uuid-31fcba96eaea454686608af0a28a0a3a,2L,0.314255
uuid-31fcba96eaea454686608af0a28a0a3a,Merck,0.325894
uuid-31fcba96eaea454686608af0a28a0a3a,stated,0.397674
uuid-31fcba96eaea454686608af0a28a0a3a,approval,0.348577
uuid-31fcba96eaea454686608af0a28a0a3a,atezo,0.379208
uuid-31fcba96eaea454686608af0a28a0a3a,preferred,0.300681
uuid-31fcba96eaea454686608af0a28a0a3a,using nivo,0.32689
uuid-31fcba96eaea454686608af0a28a0a3a,data,0.640348
uuid-31fcba96eaea454686608af0a28a0a3a,indication,0.361449
uuid-31fcba96eaea454686608af0a28a0a3a,approved,0.378739
uuid-31fcba96eaea454686608af0a28a0a3a,SCCHN,0.383859
uuid-31fcba96eaea454686608af0a28a0a3a,impressed,0.586391
uuid-31fcba96eaea454686608af0a28a0a3a,LTL,0.392031
uuid-31fcba96eaea454686608af0a28a0a3a,SCLC,0.323521
uuid-31fcba96eaea454686608af0a28a0a3a,feels,0.510762
uuid-31fcba96eaea454686608af0a28a0a3a,Regional TL,0.33664
uuid-31fcba96eaea454686608af0a28a0a3a,RTL stated,0.350329
uuid-31fcba96eaea454686608af0a28a0a3a,bladder,0.303167
uuid-0764b3a9bb43404384b03ee29b3fe0df,RTL,0.49002
uuid-0764b3a9bb43404384b03ee29b3fe0df,BMS,0.497831
uuid-0764b3a9bb43404384b03ee29b3fe0df,trial,0.434148
uuid-0764b3a9bb43404384b03ee29b3fe0df,NTL,0.395947
uuid-0764b3a9bb43404384b03ee29b3fe0df,discussed,0.43325
uuid-0764b3a9bb43404384b03ee29b3fe0df,shared,0.324186
uuid-0764b3a9bb43404384b03ee29b3fe0df,commented,0.713996
uuid-0764b3a9bb43404384b03ee29b3fe0df,Merck,0.437683
uuid-0764b3a9bb43404384b03ee29b3fe0df,stated,0.499952
uuid-0764b3a9bb43404384b03ee29b3fe0df,OS,0.452833
uuid-0764b3a9bb43404384b03ee29b3fe0df,regards,0.429495
uuid-0764b3a9bb43404384b03ee29b3fe0df,data,0.818655
uuid-0764b3a9bb43404384b03ee29b3fe0df,expressed,0.463651
uuid-0764b3a9bb43404384b03ee29b3fe0df,mentioned,0.321647
uuid-0764b3a9bb43404384b03ee29b3fe0df,PFS,0.390482
uuid-0764b3a9bb43404384b03ee29b3fe0df,ORR,0.447571
uuid-0764b3a9bb43404384b03ee29b3fe0df,SCCHN,0.330724
uuid-0764b3a9bb43404384b03ee29b3fe0df,ASCO,0.685109
uuid-0764b3a9bb43404384b03ee29b3fe0df,impressed,0.738685
uuid-0764b3a9bb43404384b03ee29b3fe0df,LTL,0.391365
uuid-0764b3a9bb43404384b03ee29b3fe0df,TLs,0.434799
uuid-0764b3a9bb43404384b03ee29b3fe0df,Regional TL,0.515319
uuid-45982dd49ec04501ae01c93c3541b444,pembro,0.309662
uuid-45982dd49ec04501ae01c93c3541b444,nivolumab,0.316218
uuid-45982dd49ec04501ae01c93c3541b444,1L,0.504886
uuid-45982dd49ec04501ae01c93c3541b444,regimen,0.397232
uuid-45982dd49ec04501ae01c93c3541b444,treated,0.302878
uuid-45982dd49ec04501ae01c93c3541b444,shared,0.32625
uuid-45982dd49ec04501ae01c93c3541b444,RCC,0.417803
uuid-45982dd49ec04501ae01c93c3541b444,combination,0.305006
uuid-45982dd49ec04501ae01c93c3541b444,2L,0.568316
uuid-45982dd49ec04501ae01c93c3541b444,agents,0.34112
uuid-45982dd49ec04501ae01c93c3541b444,atezo,0.324762
uuid-45982dd49ec04501ae01c93c3541b444,preferred,0.727086
uuid-45982dd49ec04501ae01c93c3541b444,monotherapy,0.543291
uuid-45982dd49ec04501ae01c93c3541b444,using nivo,0.565996
uuid-45982dd49ec04501ae01c93c3541b444,combo,0.314123
uuid-45982dd49ec04501ae01c93c3541b444,approved,0.346189
uuid-45982dd49ec04501ae01c93c3541b444,SCCHN,0.447842
uuid-45982dd49ec04501ae01c93c3541b444,tumor types,0.316996
uuid-45982dd49ec04501ae01c93c3541b444,RTL stated,0.576778
uuid-45982dd49ec04501ae01c93c3541b444,TL shared,0.372111
uuid-45982dd49ec04501ae01c93c3541b444,option,0.564071
uuid-45982dd49ec04501ae01c93c3541b444,bladder,0.302344
uuid-0cab74a2a8a642f79721fb289d3982ee,RTL,0.385178
uuid-0cab74a2a8a642f79721fb289d3982ee,BMS,0.329323
uuid-0cab74a2a8a642f79721fb289d3982ee,trial,0.502496
uuid-0cab74a2a8a642f79721fb289d3982ee,commented,0.369902
uuid-0cab74a2a8a642f79721fb289d3982ee,OS,0.402137
uuid-0cab74a2a8a642f79721fb289d3982ee,data,0.64983
uuid-0cab74a2a8a642f79721fb289d3982ee,expressed,0.37886
uuid-0cab74a2a8a642f79721fb289d3982ee,clinical trials,0.344659
uuid-0cab74a2a8a642f79721fb289d3982ee,PFS,0.399492
uuid-0cab74a2a8a642f79721fb289d3982ee,ORR,0.430359
uuid-0cab74a2a8a642f79721fb289d3982ee,SCCHN,0.325093
uuid-0cab74a2a8a642f79721fb289d3982ee,impressed,0.561641
uuid-0cab74a2a8a642f79721fb289d3982ee,feels,0.356335
uuid-0cab74a2a8a642f79721fb289d3982ee,Regional TL,0.313719
uuid-298eff43ba504019a66462c0e40d64ab,trial,0.310527
uuid-07efe1a80c0d4f598edf63a2dcef34ce,NSCLC,0.384818
uuid-07efe1a80c0d4f598edf63a2dcef34ce,trial,0.383949
uuid-07efe1a80c0d4f598edf63a2dcef34ce,shared,0.318209
uuid-07efe1a80c0d4f598edf63a2dcef34ce,approval,0.356098
uuid-07efe1a80c0d4f598edf63a2dcef34ce,preferred,0.312365
uuid-07efe1a80c0d4f598edf63a2dcef34ce,clinical trials,0.452356
uuid-07efe1a80c0d4f598edf63a2dcef34ce,SCCHN,0.395877
uuid-07efe1a80c0d4f598edf63a2dcef34ce,tumor types,0.300231
uuid-07efe1a80c0d4f598edf63a2dcef34ce,RTL stated,0.306838
uuid-07efe1a80c0d4f598edf63a2dcef34ce,bladder,0.488559
uuid-5643a6008e7d4d778730435d7501e182,patients,0.455635
uuid-5643a6008e7d4d778730435d7501e182,therapy,0.353736
uuid-5643a6008e7d4d778730435d7501e182,trial,0.352917
uuid-5643a6008e7d4d778730435d7501e182,clinical trials,0.341563
uuid-5643a6008e7d4d778730435d7501e182,chemotherapy,0.384794
uuid-c1cbcea3be554fa2bb566130fe40a257,Nivo,0.414208
uuid-c1cbcea3be554fa2bb566130fe40a257,pembro,0.686482
uuid-c1cbcea3be554fa2bb566130fe40a257,dose,0.500715
uuid-c1cbcea3be554fa2bb566130fe40a257,1L,0.539887
uuid-c1cbcea3be554fa2bb566130fe40a257,TL stated,0.323412
uuid-c1cbcea3be554fa2bb566130fe40a257,2L,0.701648
uuid-c1cbcea3be554fa2bb566130fe40a257,agents,0.497718
uuid-c1cbcea3be554fa2bb566130fe40a257,Ipi,0.370295
uuid-c1cbcea3be554fa2bb566130fe40a257,atezo,0.812337
uuid-c1cbcea3be554fa2bb566130fe40a257,preferred,0.64933
uuid-c1cbcea3be554fa2bb566130fe40a257,monotherapy,0.369352
uuid-c1cbcea3be554fa2bb566130fe40a257,using nivo,0.430063
uuid-c1cbcea3be554fa2bb566130fe40a257,combo,0.381379
uuid-c1cbcea3be554fa2bb566130fe40a257,PDL1 testing,0.307544
uuid-c1cbcea3be554fa2bb566130fe40a257,indication,0.377757
uuid-c1cbcea3be554fa2bb566130fe40a257,approved,0.458128
uuid-c1cbcea3be554fa2bb566130fe40a257,nivo and pembro,0.41182
uuid-c1cbcea3be554fa2bb566130fe40a257,vs,0.557165
uuid-c1cbcea3be554fa2bb566130fe40a257,TLs,0.351798
uuid-c1cbcea3be554fa2bb566130fe40a257,RTL stated,0.314864
uuid-c1cbcea3be554fa2bb566130fe40a257,option,0.373236
uuid-c1cbcea3be554fa2bb566130fe40a257,flat dosing,0.400747
uuid-2473a06e7dc8464188f50b09a7d10391,BMS,0.485106
uuid-2473a06e7dc8464188f50b09a7d10391,lung,0.33957
uuid-2473a06e7dc8464188f50b09a7d10391,commented,0.320031
uuid-2473a06e7dc8464188f50b09a7d10391,TL stated,0.335117
uuid-2473a06e7dc8464188f50b09a7d10391,Merck,0.442681
uuid-2473a06e7dc8464188f50b09a7d10391,regards,0.36991
uuid-2473a06e7dc8464188f50b09a7d10391,expressed,0.34499
uuid-2473a06e7dc8464188f50b09a7d10391,clinical trials,0.337912
uuid-2473a06e7dc8464188f50b09a7d10391,indication,0.333828
uuid-2473a06e7dc8464188f50b09a7d10391,believes,0.32314
uuid-2473a06e7dc8464188f50b09a7d10391,tumor types,0.303668
uuid-2473a06e7dc8464188f50b09a7d10391,TLs,0.459882
uuid-2473a06e7dc8464188f50b09a7d10391,feels,0.324953
uuid-2473a06e7dc8464188f50b09a7d10391,biomarker,0.343228
uuid-27b1e75759ee43a8af16ef8c8ff4738d,Nivo,0.657897
uuid-27b1e75759ee43a8af16ef8c8ff4738d,pembro,0.478543
uuid-27b1e75759ee43a8af16ef8c8ff4738d,1L,0.511511
uuid-27b1e75759ee43a8af16ef8c8ff4738d,efficacy,0.400052
uuid-27b1e75759ee43a8af16ef8c8ff4738d,regimen,0.317643
uuid-27b1e75759ee43a8af16ef8c8ff4738d,combination,0.36604
uuid-27b1e75759ee43a8af16ef8c8ff4738d,chemo,0.618773
uuid-27b1e75759ee43a8af16ef8c8ff4738d,2L,0.545925
uuid-27b1e75759ee43a8af16ef8c8ff4738d,pts,0.374089
uuid-27b1e75759ee43a8af16ef8c8ff4738d,agents,0.38837
uuid-27b1e75759ee43a8af16ef8c8ff4738d,Ipi,0.38909
uuid-27b1e75759ee43a8af16ef8c8ff4738d,atezo,0.464256
uuid-27b1e75759ee43a8af16ef8c8ff4738d,preferred,0.393897
uuid-27b1e75759ee43a8af16ef8c8ff4738d,monotherapy,0.554152
uuid-27b1e75759ee43a8af16ef8c8ff4738d,using nivo,0.354147
uuid-27b1e75759ee43a8af16ef8c8ff4738d,combo,0.468468
uuid-27b1e75759ee43a8af16ef8c8ff4738d,PD1,0.38493
uuid-27b1e75759ee43a8af16ef8c8ff4738d,nivo and pembro,0.46946
uuid-27b1e75759ee43a8af16ef8c8ff4738d,believes,0.45705
uuid-27b1e75759ee43a8af16ef8c8ff4738d,chemotherapy,0.394057
uuid-27b1e75759ee43a8af16ef8c8ff4738d,vs,0.357091
uuid-27b1e75759ee43a8af16ef8c8ff4738d,feels,0.384762
uuid-27b1e75759ee43a8af16ef8c8ff4738d,PDL1 expression,0.323067
uuid-27b1e75759ee43a8af16ef8c8ff4738d,option,0.454057
uuid-d410aafccf084a72832a23f5d8679d1e,Nivo,0.312218
uuid-d410aafccf084a72832a23f5d8679d1e,pembro,0.397903
uuid-d410aafccf084a72832a23f5d8679d1e,1L,0.329636
uuid-d410aafccf084a72832a23f5d8679d1e,PDL1,0.455503
uuid-d410aafccf084a72832a23f5d8679d1e,trial,0.581779
uuid-d410aafccf084a72832a23f5d8679d1e,efficacy,0.531262
uuid-d410aafccf084a72832a23f5d8679d1e,chemo,0.36211
uuid-d410aafccf084a72832a23f5d8679d1e,OS,0.633591
uuid-d410aafccf084a72832a23f5d8679d1e,monotherapy,0.306638
uuid-d410aafccf084a72832a23f5d8679d1e,data,0.671374
uuid-d410aafccf084a72832a23f5d8679d1e,combo,0.358961
uuid-d410aafccf084a72832a23f5d8679d1e,PFS,0.636935
uuid-d410aafccf084a72832a23f5d8679d1e,ORR,0.659511
uuid-d410aafccf084a72832a23f5d8679d1e,nivo and pembro,0.555077
uuid-d410aafccf084a72832a23f5d8679d1e,believes,0.426589
uuid-d410aafccf084a72832a23f5d8679d1e,impressed,0.558143
uuid-d410aafccf084a72832a23f5d8679d1e,feels,0.493914
uuid-d410aafccf084a72832a23f5d8679d1e,PDL1 expression,0.428281
uuid-4d220ed24f364a44bcfb1c00da4149ed,RTL,0.308884
uuid-4d220ed24f364a44bcfb1c00da4149ed,BMS,0.438795
uuid-4d220ed24f364a44bcfb1c00da4149ed,trial,0.388811
uuid-4d220ed24f364a44bcfb1c00da4149ed,commented,0.625018
uuid-4d220ed24f364a44bcfb1c00da4149ed,stated,0.563688
uuid-4d220ed24f364a44bcfb1c00da4149ed,OS,0.455856
uuid-4d220ed24f364a44bcfb1c00da4149ed,regards,0.43964
uuid-4d220ed24f364a44bcfb1c00da4149ed,data,0.778356
uuid-4d220ed24f364a44bcfb1c00da4149ed,expressed,0.425863
uuid-4d220ed24f364a44bcfb1c00da4149ed,indication,0.313848
uuid-4d220ed24f364a44bcfb1c00da4149ed,PFS,0.40343
uuid-4d220ed24f364a44bcfb1c00da4149ed,ORR,0.458238
uuid-4d220ed24f364a44bcfb1c00da4149ed,SCCHN,0.349374
uuid-4d220ed24f364a44bcfb1c00da4149ed,nivo and pembro,0.30625
uuid-4d220ed24f364a44bcfb1c00da4149ed,ASCO,0.397338
uuid-4d220ed24f364a44bcfb1c00da4149ed,impressed,0.64349
uuid-4d220ed24f364a44bcfb1c00da4149ed,TLs,0.300967
uuid-4d220ed24f364a44bcfb1c00da4149ed,SCLC,0.380824
uuid-4d220ed24f364a44bcfb1c00da4149ed,feels,0.361199
uuid-4d220ed24f364a44bcfb1c00da4149ed,Regional TL,0.372073
uuid-4d220ed24f364a44bcfb1c00da4149ed,NCCN,0.455305
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,RTL,0.377095
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,BMS,0.481415
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,trial,0.556846
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,NTL,0.315428
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,commented,0.477686
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,Merck,0.418962
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,stated,0.410582
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,regards,0.318823
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,data,0.401962
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,expressed,0.42098
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,mentioned,0.308188
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,clinical trials,0.378579
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,SCCHN,0.311632
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,impressed,0.413729
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,TLs,0.300219
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,feels,0.36509
uuid-ca19dd5c613b4bb48cccf06ad22f95bb,Regional TL,0.405334
uuid-115e972945c94ee79df5e7fda7ceb45f,Nivo,0.371443
uuid-115e972945c94ee79df5e7fda7ceb45f,pembro,0.494013
uuid-115e972945c94ee79df5e7fda7ceb45f,dose,0.351228
uuid-115e972945c94ee79df5e7fda7ceb45f,1L,0.415246
uuid-115e972945c94ee79df5e7fda7ceb45f,2L,0.546751
uuid-115e972945c94ee79df5e7fda7ceb45f,agents,0.335177
uuid-115e972945c94ee79df5e7fda7ceb45f,Ipi,0.314765
uuid-115e972945c94ee79df5e7fda7ceb45f,atezo,0.605049
uuid-115e972945c94ee79df5e7fda7ceb45f,preferred,0.553059
uuid-115e972945c94ee79df5e7fda7ceb45f,monotherapy,0.307134
uuid-115e972945c94ee79df5e7fda7ceb45f,using nivo,0.400575
uuid-115e972945c94ee79df5e7fda7ceb45f,indication,0.393824
uuid-115e972945c94ee79df5e7fda7ceb45f,approved,0.357838
uuid-115e972945c94ee79df5e7fda7ceb45f,tumor types,0.301875
uuid-115e972945c94ee79df5e7fda7ceb45f,vs,0.344247
uuid-115e972945c94ee79df5e7fda7ceb45f,TLs,0.312357
uuid-115e972945c94ee79df5e7fda7ceb45f,feels,0.334324
uuid-115e972945c94ee79df5e7fda7ceb45f,RTL stated,0.33097
uuid-115e972945c94ee79df5e7fda7ceb45f,option,0.381997
uuid-3163518e239e4b06901f831363b5a47e,dose,0.317912
uuid-3163518e239e4b06901f831363b5a47e,toxicity,0.681895
uuid-3163518e239e4b06901f831363b5a47e,efficacy,0.4852
uuid-3163518e239e4b06901f831363b5a47e,regimen,0.459062
uuid-3163518e239e4b06901f831363b5a47e,chemo,0.4202
uuid-3163518e239e4b06901f831363b5a47e,Ipi,0.32734
uuid-3163518e239e4b06901f831363b5a47e,believes,0.323629
uuid-3163518e239e4b06901f831363b5a47e,respond,0.39555
uuid-3163518e239e4b06901f831363b5a47e,feels,0.383883
uuid-d8a31d0f303746a5996221ef3af5d1fb,Nivo,0.528386
uuid-d8a31d0f303746a5996221ef3af5d1fb,pembro,0.773765
uuid-d8a31d0f303746a5996221ef3af5d1fb,1L,0.535415
uuid-d8a31d0f303746a5996221ef3af5d1fb,PDL1,0.328377
uuid-d8a31d0f303746a5996221ef3af5d1fb,trial,0.33177
uuid-d8a31d0f303746a5996221ef3af5d1fb,2L,0.577829
uuid-d8a31d0f303746a5996221ef3af5d1fb,agents,0.393104
uuid-d8a31d0f303746a5996221ef3af5d1fb,approval,0.375826
uuid-d8a31d0f303746a5996221ef3af5d1fb,atezo,0.708187
uuid-d8a31d0f303746a5996221ef3af5d1fb,preferred,0.499336
uuid-d8a31d0f303746a5996221ef3af5d1fb,monotherapy,0.34781
uuid-d8a31d0f303746a5996221ef3af5d1fb,using nivo,0.454419
uuid-d8a31d0f303746a5996221ef3af5d1fb,indication,0.356527
uuid-d8a31d0f303746a5996221ef3af5d1fb,approved,0.420364
uuid-d8a31d0f303746a5996221ef3af5d1fb,nivo and pembro,0.675794
uuid-d8a31d0f303746a5996221ef3af5d1fb,vs,0.406325
uuid-d8a31d0f303746a5996221ef3af5d1fb,label,0.315716
uuid-d8a31d0f303746a5996221ef3af5d1fb,feels,0.386529
uuid-d8a31d0f303746a5996221ef3af5d1fb,PDL1 expression,0.325067
uuid-d8a31d0f303746a5996221ef3af5d1fb,option,0.391054
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,toxicity,0.317579
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,efficacy,0.49829
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,regimen,0.440727
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,combination,0.464653
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,chemo,0.377113
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,IO,0.327822
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,agents,0.374204
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,Ipi,0.427913
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,atezo,0.315136
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,preferred,0.325746
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,monotherapy,0.421412
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,combo,0.543573
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,believes,0.403816
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,impressed,0.336312
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,feels,0.492809
uuid-025c7a3d74d84b28a7fc80f2ebe67dcc,option,0.36941
uuid-812558f406e4471784fa18248030ea5a,TL,0.616706
uuid-812558f406e4471784fa18248030ea5a,PDL1,0.437166
uuid-812558f406e4471784fa18248030ea5a,TL stated,0.449382
uuid-812558f406e4471784fa18248030ea5a,institution,0.384617
uuid-812558f406e4471784fa18248030ea5a,PD-L1,0.833039
uuid-812558f406e4471784fa18248030ea5a,PD-L1 testing,0.873749
uuid-812558f406e4471784fa18248030ea5a,testing,0.902917
uuid-812558f406e4471784fa18248030ea5a,PDL1 testing,0.690237
uuid-812558f406e4471784fa18248030ea5a,NSCLC patients,0.600059
uuid-812558f406e4471784fa18248030ea5a,assay,0.814347
uuid-812558f406e4471784fa18248030ea5a,biomarker,0.481061
uuid-e60d7f1534ef42d79b830d19d2a2e64c,pembro,0.668329
uuid-e60d7f1534ef42d79b830d19d2a2e64c,1L,0.666973
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PDL1,0.671028
uuid-e60d7f1534ef42d79b830d19d2a2e64c,2L,0.573797
uuid-e60d7f1534ef42d79b830d19d2a2e64c,agents,0.335568
uuid-e60d7f1534ef42d79b830d19d2a2e64c,Merck,0.330152
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PD-L1,0.666787
uuid-e60d7f1534ef42d79b830d19d2a2e64c,approval,0.378453
uuid-e60d7f1534ef42d79b830d19d2a2e64c,atezo,0.669078
uuid-e60d7f1534ef42d79b830d19d2a2e64c,preferred,0.408994
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PD-L1 testing,0.41746
uuid-e60d7f1534ef42d79b830d19d2a2e64c,testing,0.613064
uuid-e60d7f1534ef42d79b830d19d2a2e64c,monotherapy,0.313106
uuid-e60d7f1534ef42d79b830d19d2a2e64c,using nivo,0.324451
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PDL1 testing,0.502226
uuid-e60d7f1534ef42d79b830d19d2a2e64c,NSCLC patients,0.530378
uuid-e60d7f1534ef42d79b830d19d2a2e64c,approved,0.38434
uuid-e60d7f1534ef42d79b830d19d2a2e64c,nivo and pembro,0.505068
uuid-e60d7f1534ef42d79b830d19d2a2e64c,believes,0.353426
uuid-e60d7f1534ef42d79b830d19d2a2e64c,assay,0.594496
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PD-1,0.305997
uuid-e60d7f1534ef42d79b830d19d2a2e64c,PDL1 expression,0.492256
uuid-e60d7f1534ef42d79b830d19d2a2e64c,option,0.363627
uuid-e60d7f1534ef42d79b830d19d2a2e64c,biomarker,0.408612
uuid-7c8883a48d5346439e0d2a272807d9b1,Nivo,0.659035
uuid-7c8883a48d5346439e0d2a272807d9b1,pembro,0.763922
uuid-7c8883a48d5346439e0d2a272807d9b1,dose,0.550956
uuid-7c8883a48d5346439e0d2a272807d9b1,1L,0.377877
uuid-7c8883a48d5346439e0d2a272807d9b1,efficacy,0.492188
uuid-7c8883a48d5346439e0d2a272807d9b1,2L,0.544041
uuid-7c8883a48d5346439e0d2a272807d9b1,agents,0.33304
uuid-7c8883a48d5346439e0d2a272807d9b1,Ipi,0.462314
uuid-7c8883a48d5346439e0d2a272807d9b1,approval,0.316097
uuid-7c8883a48d5346439e0d2a272807d9b1,atezo,0.826173
uuid-7c8883a48d5346439e0d2a272807d9b1,preferred,0.473658
uuid-7c8883a48d5346439e0d2a272807d9b1,monotherapy,0.330142
uuid-7c8883a48d5346439e0d2a272807d9b1,using nivo,0.470019
uuid-7c8883a48d5346439e0d2a272807d9b1,indication,0.382781
uuid-7c8883a48d5346439e0d2a272807d9b1,approved,0.372283
uuid-7c8883a48d5346439e0d2a272807d9b1,nivo and pembro,0.460585
uuid-7c8883a48d5346439e0d2a272807d9b1,vs,0.695188
uuid-7c8883a48d5346439e0d2a272807d9b1,TLs,0.340228
uuid-7c8883a48d5346439e0d2a272807d9b1,feels,0.317089
uuid-7c8883a48d5346439e0d2a272807d9b1,option,0.312926
uuid-7c8883a48d5346439e0d2a272807d9b1,flat dosing,0.415805
uuid-7f4fc90021cb403cb42270bb945433c0,TL,0.457885
uuid-7f4fc90021cb403cb42270bb945433c0,RTL,0.506618
uuid-7f4fc90021cb403cb42270bb945433c0,NTL,0.44829
uuid-7f4fc90021cb403cb42270bb945433c0,shared,0.359961
uuid-7f4fc90021cb403cb42270bb945433c0,Merck,0.412122
uuid-7f4fc90021cb403cb42270bb945433c0,stated,0.400903
uuid-7f4fc90021cb403cb42270bb945433c0,approval,0.374414
uuid-7f4fc90021cb403cb42270bb945433c0,mentioned,0.371058
uuid-7f4fc90021cb403cb42270bb945433c0,clinical trials,0.378021
uuid-7f4fc90021cb403cb42270bb945433c0,SCCHN,0.344619
uuid-7f4fc90021cb403cb42270bb945433c0,LTL,0.430358
uuid-7f4fc90021cb403cb42270bb945433c0,academic,0.347187
uuid-7f4fc90021cb403cb42270bb945433c0,Regional TL,0.548034
uuid-b703a289ce3640fab34176d62d1cfdf3,RTL,0.370292
uuid-b703a289ce3640fab34176d62d1cfdf3,therapy,0.382931
uuid-b703a289ce3640fab34176d62d1cfdf3,nivolumab,0.416359
uuid-b703a289ce3640fab34176d62d1cfdf3,combination,0.428956
uuid-b703a289ce3640fab34176d62d1cfdf3,preferred,0.310911
uuid-b703a289ce3640fab34176d62d1cfdf3,monotherapy,0.392873
uuid-b703a289ce3640fab34176d62d1cfdf3,using nivo,0.418966
uuid-b703a289ce3640fab34176d62d1cfdf3,mentioned,0.364525
uuid-b703a289ce3640fab34176d62d1cfdf3,PD1,0.300059
uuid-b703a289ce3640fab34176d62d1cfdf3,SCCHN,0.344213
uuid-b703a289ce3640fab34176d62d1cfdf3,HCP,0.365011
uuid-b703a289ce3640fab34176d62d1cfdf3,cHL,0.326144
uuid-b703a289ce3640fab34176d62d1cfdf3,chemotherapy,0.320337
uuid-b703a289ce3640fab34176d62d1cfdf3,LTL,0.310324
uuid-b703a289ce3640fab34176d62d1cfdf3,SCLC,0.311985
uuid-b703a289ce3640fab34176d62d1cfdf3,RTL stated,0.401174
uuid-b703a289ce3640fab34176d62d1cfdf3,option,0.343786
uuid-38f9647526c145ab8c89b79e7fdf203a,Nivo,0.35385
uuid-38f9647526c145ab8c89b79e7fdf203a,patients,0.514582
uuid-38f9647526c145ab8c89b79e7fdf203a,pembro,0.593765
uuid-38f9647526c145ab8c89b79e7fdf203a,1L,0.602481
uuid-38f9647526c145ab8c89b79e7fdf203a,PDL1,0.366936
uuid-38f9647526c145ab8c89b79e7fdf203a,chemo,0.326207
uuid-38f9647526c145ab8c89b79e7fdf203a,2L,0.611497
uuid-38f9647526c145ab8c89b79e7fdf203a,pts,0.389095
uuid-38f9647526c145ab8c89b79e7fdf203a,PD-L1,0.472286
uuid-38f9647526c145ab8c89b79e7fdf203a,approval,0.338069
uuid-38f9647526c145ab8c89b79e7fdf203a,atezo,0.568995
uuid-38f9647526c145ab8c89b79e7fdf203a,preferred,0.526414
uuid-38f9647526c145ab8c89b79e7fdf203a,PD-L1 testing,0.355173
uuid-38f9647526c145ab8c89b79e7fdf203a,testing,0.507338
uuid-38f9647526c145ab8c89b79e7fdf203a,monotherapy,0.43588
uuid-38f9647526c145ab8c89b79e7fdf203a,using nivo,0.433066
uuid-38f9647526c145ab8c89b79e7fdf203a,PDL1 testing,0.465146
uuid-38f9647526c145ab8c89b79e7fdf203a,NSCLC patients,0.596159
uuid-38f9647526c145ab8c89b79e7fdf203a,approved,0.339122
uuid-38f9647526c145ab8c89b79e7fdf203a,vs,0.378917
uuid-38f9647526c145ab8c89b79e7fdf203a,option,0.471857
uuid-6a58c8cb7654443ead88e22b237fa55a,pembro,0.434439
uuid-6a58c8cb7654443ead88e22b237fa55a,trial,0.465804
uuid-6a58c8cb7654443ead88e22b237fa55a,approval,0.45243
uuid-6a58c8cb7654443ead88e22b237fa55a,atezo,0.31837
uuid-6a58c8cb7654443ead88e22b237fa55a,preferred,0.381102
uuid-6a58c8cb7654443ead88e22b237fa55a,clinical trials,0.46288
uuid-6a58c8cb7654443ead88e22b237fa55a,indication,0.375517
uuid-6a58c8cb7654443ead88e22b237fa55a,approved,0.364854
uuid-6a58c8cb7654443ead88e22b237fa55a,SCCHN,0.346321
uuid-6a58c8cb7654443ead88e22b237fa55a,RTL stated,0.321195
uuid-6a58c8cb7654443ead88e22b237fa55a,option,0.32375
uuid-6a58c8cb7654443ead88e22b237fa55a,bladder,0.38906
uuid-4c1fdf0bd69f49c6b025464514c28977,Nivo,0.345601
uuid-4c1fdf0bd69f49c6b025464514c28977,pembro,0.412833
uuid-4c1fdf0bd69f49c6b025464514c28977,lung,0.436031
uuid-4c1fdf0bd69f49c6b025464514c28977,1L,0.529076
uuid-4c1fdf0bd69f49c6b025464514c28977,trial,0.302743
uuid-4c1fdf0bd69f49c6b025464514c28977,melanoma,0.318619
uuid-4c1fdf0bd69f49c6b025464514c28977,RCC,0.495176
uuid-4c1fdf0bd69f49c6b025464514c28977,combination,0.420958
uuid-4c1fdf0bd69f49c6b025464514c28977,2L,0.499945
uuid-4c1fdf0bd69f49c6b025464514c28977,agents,0.414546
uuid-4c1fdf0bd69f49c6b025464514c28977,atezo,0.377313
uuid-4c1fdf0bd69f49c6b025464514c28977,preferred,0.312496
uuid-4c1fdf0bd69f49c6b025464514c28977,monotherapy,0.453508
uuid-4c1fdf0bd69f49c6b025464514c28977,using nivo,0.406878
uuid-4c1fdf0bd69f49c6b025464514c28977,data,0.443899
uuid-4c1fdf0bd69f49c6b025464514c28977,combo,0.50476
uuid-4c1fdf0bd69f49c6b025464514c28977,PD1,0.347411
uuid-4c1fdf0bd69f49c6b025464514c28977,SCCHN,0.369626
uuid-4c1fdf0bd69f49c6b025464514c28977,nivo and pembro,0.455493
uuid-4c1fdf0bd69f49c6b025464514c28977,impressed,0.412777
uuid-4c1fdf0bd69f49c6b025464514c28977,TLs,0.30627
uuid-4c1fdf0bd69f49c6b025464514c28977,SCLC,0.436498
uuid-4c1fdf0bd69f49c6b025464514c28977,feels,0.310977
uuid-4c1fdf0bd69f49c6b025464514c28977,RTL stated,0.433042
uuid-4c1fdf0bd69f49c6b025464514c28977,TL shared,0.3842
uuid-4c1fdf0bd69f49c6b025464514c28977,option,0.347783
uuid-4c1fdf0bd69f49c6b025464514c28977,bladder,0.386524
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,BMS,0.663839
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,PDL1,0.368809
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,trial,0.453996
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,efficacy,0.476797
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,commented,0.302093
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,Merck,0.419559
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,OS,0.444252
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,regards,0.490672
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,data,0.491553
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,PFS,0.477788
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,ORR,0.434247
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,nivo and pembro,0.376115
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,believes,0.351079
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,impressed,0.321718
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,feels,0.453096
uuid-454a3893a20a4fa0a55b09c7f3ff73f5,PDL1 expression,0.335662
uuid-39b6297301314422ada46a66cd8640ca,pembro,0.360159
uuid-39b6297301314422ada46a66cd8640ca,BMS,0.365817
uuid-39b6297301314422ada46a66cd8640ca,PDL1,0.493526
uuid-39b6297301314422ada46a66cd8640ca,trial,0.372373
uuid-39b6297301314422ada46a66cd8640ca,efficacy,0.402202
uuid-39b6297301314422ada46a66cd8640ca,commented,0.394613
uuid-39b6297301314422ada46a66cd8640ca,Merck,0.351625
uuid-39b6297301314422ada46a66cd8640ca,OS,0.403023
uuid-39b6297301314422ada46a66cd8640ca,atezo,0.335399
uuid-39b6297301314422ada46a66cd8640ca,regards,0.366296
uuid-39b6297301314422ada46a66cd8640ca,data,0.756006
uuid-39b6297301314422ada46a66cd8640ca,expressed,0.303547
uuid-39b6297301314422ada46a66cd8640ca,indication,0.322057
uuid-39b6297301314422ada46a66cd8640ca,PFS,0.399628
uuid-39b6297301314422ada46a66cd8640ca,ORR,0.420844
uuid-39b6297301314422ada46a66cd8640ca,nivo and pembro,0.454415
uuid-39b6297301314422ada46a66cd8640ca,impressed,0.478241
uuid-39b6297301314422ada46a66cd8640ca,PDL1 expression,0.451649
uuid-39b6297301314422ada46a66cd8640ca,biomarker,0.319668
uuid-8a48308ad2034cb79bbbb060bde4b86c,regards,0.389365
uuid-8a48308ad2034cb79bbbb060bde4b86c,indicated,0.372563
uuid-8a48308ad2034cb79bbbb060bde4b86c,clinical,0.327303
uuid-8a48308ad2034cb79bbbb060bde4b86c,PDL1 expression,0.42426
uuid-8a48308ad2034cb79bbbb060bde4b86c,biomarker,0.340589
uuid-98229304498043b1ae920f9896674200,physicians,0.580406
uuid-98229304498043b1ae920f9896674200,oncology,0.375755
uuid-98229304498043b1ae920f9896674200,drug,0.348167
uuid-98229304498043b1ae920f9896674200,clinical,0.347898
uuid-2005bbb7dd5844c79918aaa992ffdd5f,lung,0.352145
uuid-2005bbb7dd5844c79918aaa992ffdd5f,AI,0.480478
uuid-2005bbb7dd5844c79918aaa992ffdd5f,lung cancer,0.578834
uuid-7dc365211a5440edb3f2ec1826559178,pembro,0.352204
uuid-7dc365211a5440edb3f2ec1826559178,2L,0.305423
uuid-7dc365211a5440edb3f2ec1826559178,atezo,0.399693
uuid-7dc365211a5440edb3f2ec1826559178,lung cancer,0.586386
uuid-7dc365211a5440edb3f2ec1826559178,nivo and pembro,0.362842
uuid-7864e44af18b4b09955f1ba44b2a2a89,pembro,0.321561
uuid-7864e44af18b4b09955f1ba44b2a2a89,nivolumab,0.303281
uuid-7864e44af18b4b09955f1ba44b2a2a89,1L,0.363615
uuid-7864e44af18b4b09955f1ba44b2a2a89,shared,0.393999
uuid-7864e44af18b4b09955f1ba44b2a2a89,RCC,0.429024
uuid-7864e44af18b4b09955f1ba44b2a2a89,2L,0.427076
uuid-7864e44af18b4b09955f1ba44b2a2a89,stated,0.518696
uuid-7864e44af18b4b09955f1ba44b2a2a89,approval,0.600095
uuid-7864e44af18b4b09955f1ba44b2a2a89,preferred,0.376214
uuid-7864e44af18b4b09955f1ba44b2a2a89,using nivo,0.499391
uuid-7864e44af18b4b09955f1ba44b2a2a89,clinical trials,0.493936
uuid-7864e44af18b4b09955f1ba44b2a2a89,indication,0.385786
uuid-7864e44af18b4b09955f1ba44b2a2a89,approved,0.664308
uuid-7864e44af18b4b09955f1ba44b2a2a89,SCCHN,0.418507
uuid-7864e44af18b4b09955f1ba44b2a2a89,impressed,0.313618
uuid-7864e44af18b4b09955f1ba44b2a2a89,tumor types,0.384538
uuid-7864e44af18b4b09955f1ba44b2a2a89,label,0.437536
uuid-7864e44af18b4b09955f1ba44b2a2a89,SCLC,0.337503
uuid-7864e44af18b4b09955f1ba44b2a2a89,Regional TL,0.343209
uuid-7864e44af18b4b09955f1ba44b2a2a89,RTL stated,0.432603
uuid-7864e44af18b4b09955f1ba44b2a2a89,bladder,0.417618
uuid-fd608e810262422b9fc82429f4545514,patients,0.618621
uuid-fd608e810262422b9fc82429f4545514,therapy,0.440705
uuid-fd608e810262422b9fc82429f4545514,nivolumab,0.469442
uuid-fd608e810262422b9fc82429f4545514,toxicity,0.357619
uuid-fd608e810262422b9fc82429f4545514,regimen,0.502363
uuid-fd608e810262422b9fc82429f4545514,treated,0.668615
uuid-fd608e810262422b9fc82429f4545514,melanoma,0.37877
uuid-fd608e810262422b9fc82429f4545514,pts,0.582808
uuid-fd608e810262422b9fc82429f4545514,treatment,0.631636
uuid-fd608e810262422b9fc82429f4545514,response,0.553242
uuid-fd608e810262422b9fc82429f4545514,PD1,0.328
uuid-fd608e810262422b9fc82429f4545514,progression,0.702986
uuid-fd608e810262422b9fc82429f4545514,respond,0.510438
uuid-fd608e810262422b9fc82429f4545514,TL shared,0.431297
uuid-84587c2df7d74c64b1b44ec0c7b29a67,trial,0.385122
uuid-ab2bd8873abe42e684a593d3bf381645,Nivo,0.350858
uuid-ab2bd8873abe42e684a593d3bf381645,patients,0.561481
uuid-ab2bd8873abe42e684a593d3bf381645,therapy,0.527333
uuid-ab2bd8873abe42e684a593d3bf381645,nivolumab,0.377708
uuid-ab2bd8873abe42e684a593d3bf381645,regimen,0.489197
uuid-ab2bd8873abe42e684a593d3bf381645,treated,0.428052
uuid-ab2bd8873abe42e684a593d3bf381645,combination,0.413849
uuid-ab2bd8873abe42e684a593d3bf381645,chemo,0.54348
uuid-ab2bd8873abe42e684a593d3bf381645,pts,0.625459
uuid-ab2bd8873abe42e684a593d3bf381645,IO,0.371262
uuid-ab2bd8873abe42e684a593d3bf381645,monotherapy,0.500997
uuid-ab2bd8873abe42e684a593d3bf381645,treatment,0.477472
uuid-ab2bd8873abe42e684a593d3bf381645,response,0.793726
uuid-ab2bd8873abe42e684a593d3bf381645,combo,0.366781
uuid-ab2bd8873abe42e684a593d3bf381645,PD1,0.551672
uuid-ab2bd8873abe42e684a593d3bf381645,progression,0.698275
uuid-ab2bd8873abe42e684a593d3bf381645,chemotherapy,0.465982
uuid-ab2bd8873abe42e684a593d3bf381645,respond,0.553568
uuid-ab2bd8873abe42e684a593d3bf381645,option,0.343053
uuid-7523b6e1c425403485e80863e118aaf6,toxicity,0.411566
uuid-7523b6e1c425403485e80863e118aaf6,physicians,0.431846
uuid-7523b6e1c425403485e80863e118aaf6,feels,0.340371
uuid-7173cebede9b47feb38b78c17044087c,Nivo,0.34713
uuid-7173cebede9b47feb38b78c17044087c,pembro,0.49174
uuid-7173cebede9b47feb38b78c17044087c,dose,0.571727
uuid-7173cebede9b47feb38b78c17044087c,trial,0.363329
uuid-7173cebede9b47feb38b78c17044087c,efficacy,0.612429
uuid-7173cebede9b47feb38b78c17044087c,Ipi,0.477464
uuid-7173cebede9b47feb38b78c17044087c,atezo,0.401343
uuid-7173cebede9b47feb38b78c17044087c,data,0.458281
uuid-7173cebede9b47feb38b78c17044087c,ORR,0.320365
uuid-7173cebede9b47feb38b78c17044087c,nivo and pembro,0.341403
uuid-7173cebede9b47feb38b78c17044087c,impressed,0.353749
uuid-7173cebede9b47feb38b78c17044087c,vs,0.721187
uuid-7173cebede9b47feb38b78c17044087c,TLs,0.344476
uuid-7173cebede9b47feb38b78c17044087c,flat dosing,0.506234
uuid-482c0a46afa047b3b4357b5b12d4c7fb,Nivo,0.407858
uuid-482c0a46afa047b3b4357b5b12d4c7fb,pembro,0.459341
uuid-482c0a46afa047b3b4357b5b12d4c7fb,BMS,0.326492
uuid-482c0a46afa047b3b4357b5b12d4c7fb,PDL1,0.341014
uuid-482c0a46afa047b3b4357b5b12d4c7fb,trial,0.354945
uuid-482c0a46afa047b3b4357b5b12d4c7fb,efficacy,0.564018
uuid-482c0a46afa047b3b4357b5b12d4c7fb,agents,0.314547
uuid-482c0a46afa047b3b4357b5b12d4c7fb,Ipi,0.342285
uuid-482c0a46afa047b3b4357b5b12d4c7fb,OS,0.361504
uuid-482c0a46afa047b3b4357b5b12d4c7fb,atezo,0.463671
uuid-482c0a46afa047b3b4357b5b12d4c7fb,regards,0.403526
uuid-482c0a46afa047b3b4357b5b12d4c7fb,data,0.301786
uuid-482c0a46afa047b3b4357b5b12d4c7fb,combo,0.35617
uuid-482c0a46afa047b3b4357b5b12d4c7fb,PFS,0.403733
uuid-482c0a46afa047b3b4357b5b12d4c7fb,AI,0.499926
uuid-482c0a46afa047b3b4357b5b12d4c7fb,ORR,0.379931
uuid-482c0a46afa047b3b4357b5b12d4c7fb,nivo and pembro,0.635334
uuid-482c0a46afa047b3b4357b5b12d4c7fb,believes,0.466925
uuid-482c0a46afa047b3b4357b5b12d4c7fb,vs,0.435008
uuid-482c0a46afa047b3b4357b5b12d4c7fb,PDL1 expression,0.329499
uuid-5476b9e1c7294c7380f12d6c6625beff,Nivo,0.313718
uuid-5476b9e1c7294c7380f12d6c6625beff,PDL1,0.4867
uuid-5476b9e1c7294c7380f12d6c6625beff,efficacy,0.496593
uuid-5476b9e1c7294c7380f12d6c6625beff,chemo,0.337812
uuid-5476b9e1c7294c7380f12d6c6625beff,OS,0.563781
uuid-5476b9e1c7294c7380f12d6c6625beff,regards,0.391352
uuid-5476b9e1c7294c7380f12d6c6625beff,PFS,0.647036
uuid-5476b9e1c7294c7380f12d6c6625beff,AI,0.551162
uuid-5476b9e1c7294c7380f12d6c6625beff,ORR,0.562372
uuid-5476b9e1c7294c7380f12d6c6625beff,nivo and pembro,0.662312
uuid-5476b9e1c7294c7380f12d6c6625beff,believes,0.472546
uuid-5476b9e1c7294c7380f12d6c6625beff,PDL1 expression,0.510622
uuid-5476b9e1c7294c7380f12d6c6625beff,biomarker,0.302445
uuid-997ee04ee8fb4a588efef716321ac609,PDL1,0.509193
uuid-997ee04ee8fb4a588efef716321ac609,efficacy,0.502744
uuid-997ee04ee8fb4a588efef716321ac609,chemo,0.365637
uuid-997ee04ee8fb4a588efef716321ac609,OS,0.562354
uuid-997ee04ee8fb4a588efef716321ac609,regards,0.338308
uuid-997ee04ee8fb4a588efef716321ac609,response,0.302517
uuid-997ee04ee8fb4a588efef716321ac609,PFS,0.606962
uuid-997ee04ee8fb4a588efef716321ac609,AI,0.484347
uuid-997ee04ee8fb4a588efef716321ac609,ORR,0.519376
uuid-997ee04ee8fb4a588efef716321ac609,nivo and pembro,0.505055
uuid-997ee04ee8fb4a588efef716321ac609,believes,0.476241
uuid-997ee04ee8fb4a588efef716321ac609,PDL1 expression,0.44845
uuid-997ee04ee8fb4a588efef716321ac609,biomarker,0.358966
uuid-7fc095434bb24005913f4823209c3b19,therapy,0.348031
uuid-7fc095434bb24005913f4823209c3b19,lung,0.408412
uuid-7fc095434bb24005913f4823209c3b19,regimen,0.376461
uuid-7fc095434bb24005913f4823209c3b19,melanoma,0.392735
uuid-7fc095434bb24005913f4823209c3b19,combination,0.46067
uuid-7fc095434bb24005913f4823209c3b19,chemo,0.405462
uuid-7fc095434bb24005913f4823209c3b19,IO,0.40781
uuid-7fc095434bb24005913f4823209c3b19,monotherapy,0.373936
uuid-7fc095434bb24005913f4823209c3b19,response,0.402653
uuid-7fc095434bb24005913f4823209c3b19,combo,0.469023
uuid-7fc095434bb24005913f4823209c3b19,AI,0.50984
uuid-7fc095434bb24005913f4823209c3b19,PD1,0.464273
uuid-7fc095434bb24005913f4823209c3b19,progression,0.323442
uuid-7fc095434bb24005913f4823209c3b19,chemotherapy,0.356182
uuid-7fc095434bb24005913f4823209c3b19,SCLC,0.481319
uuid-7fc095434bb24005913f4823209c3b19,immunotherapy,0.364514
uuid-7fc095434bb24005913f4823209c3b19,TL shared,0.301883
uuid-170c6f3200ea4990b02e0a44c24c910d,Opdivo,0.314379
uuid-170c6f3200ea4990b02e0a44c24c910d,toxicity,0.386779
uuid-170c6f3200ea4990b02e0a44c24c910d,drug,0.446894
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,Nivo,0.32784
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,patients,0.606499
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,therapy,0.683587
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,nivolumab,0.647865
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,regimen,0.393456
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,treated,0.512542
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,combination,0.440938
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,chemo,0.422474
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,pts,0.37266
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,preferred,0.322135
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,monotherapy,0.492436
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,treatment,0.532616
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,using nivo,0.389812
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,PD1,0.477352
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,cHL,0.393354
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,progression,0.42068
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,chemotherapy,0.566002
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,PD-1,0.30787
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,RTL stated,0.31874
uuid-e9df4a8224b04a8bbe52e8b77dcdcaec,option,0.4392
uuid-7f6ebcad3557462aae1f50366203c89d,Nivo,0.40736
uuid-7f6ebcad3557462aae1f50366203c89d,patients,0.330125
uuid-7f6ebcad3557462aae1f50366203c89d,pembro,0.716057
uuid-7f6ebcad3557462aae1f50366203c89d,1L,0.706579
uuid-7f6ebcad3557462aae1f50366203c89d,RCC,0.325786
uuid-7f6ebcad3557462aae1f50366203c89d,2L,0.726787
uuid-7f6ebcad3557462aae1f50366203c89d,agents,0.369984
uuid-7f6ebcad3557462aae1f50366203c89d,PD-L1,0.371521
uuid-7f6ebcad3557462aae1f50366203c89d,approval,0.60434
uuid-7f6ebcad3557462aae1f50366203c89d,atezo,0.637453
uuid-7f6ebcad3557462aae1f50366203c89d,preferred,0.649568
uuid-7f6ebcad3557462aae1f50366203c89d,testing,0.42185
uuid-7f6ebcad3557462aae1f50366203c89d,monotherapy,0.461024
uuid-7f6ebcad3557462aae1f50366203c89d,using nivo,0.63267
uuid-7f6ebcad3557462aae1f50366203c89d,PDL1 testing,0.455568
uuid-7f6ebcad3557462aae1f50366203c89d,indication,0.423223
uuid-7f6ebcad3557462aae1f50366203c89d,NSCLC patients,0.524086
uuid-7f6ebcad3557462aae1f50366203c89d,approved,0.681181
uuid-7f6ebcad3557462aae1f50366203c89d,nivo and pembro,0.302645
uuid-7f6ebcad3557462aae1f50366203c89d,tumor types,0.361712
uuid-7f6ebcad3557462aae1f50366203c89d,label,0.429377
uuid-7f6ebcad3557462aae1f50366203c89d,RTL stated,0.405186
uuid-7f6ebcad3557462aae1f50366203c89d,option,0.578679
uuid-dab3b1d2d96d48429492724b496ed1e8,Nivo,0.393112
uuid-dab3b1d2d96d48429492724b496ed1e8,patients,0.699274
uuid-dab3b1d2d96d48429492724b496ed1e8,Opdivo,0.303261
uuid-dab3b1d2d96d48429492724b496ed1e8,therapy,0.448174
uuid-dab3b1d2d96d48429492724b496ed1e8,dose,0.427395
uuid-dab3b1d2d96d48429492724b496ed1e8,nivolumab,0.359571
uuid-dab3b1d2d96d48429492724b496ed1e8,toxicity,0.332078
uuid-dab3b1d2d96d48429492724b496ed1e8,regimen,0.459037
uuid-dab3b1d2d96d48429492724b496ed1e8,treated,0.359125
uuid-dab3b1d2d96d48429492724b496ed1e8,chemo,0.45545
uuid-dab3b1d2d96d48429492724b496ed1e8,pts,0.488284
uuid-dab3b1d2d96d48429492724b496ed1e8,Ipi,0.351327
uuid-dab3b1d2d96d48429492724b496ed1e8,monotherapy,0.376029
uuid-dab3b1d2d96d48429492724b496ed1e8,treatment,0.45695
uuid-dab3b1d2d96d48429492724b496ed1e8,response,0.434733
uuid-dab3b1d2d96d48429492724b496ed1e8,PD1,0.361471
uuid-dab3b1d2d96d48429492724b496ed1e8,progression,0.613609
uuid-dab3b1d2d96d48429492724b496ed1e8,chemotherapy,0.350738
uuid-dab3b1d2d96d48429492724b496ed1e8,vs,0.346555
uuid-dab3b1d2d96d48429492724b496ed1e8,respond,0.512042
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,TL,0.389946
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,PDL1,0.419379
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,TL stated,0.473804
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,PD-L1,0.783977
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,PD-L1 testing,0.741893
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,testing,0.89753
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,PDL1 testing,0.773283
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,NSCLC patients,0.773636
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,tumor types,0.368702
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,assay,0.525835
uuid-3ceb7cf97ce5493a86618e7e2c06ec36,biomarker,0.518205
uuid-d801ddb535264deaa507a5704a125897,patients,0.621121
uuid-d801ddb535264deaa507a5704a125897,1L,0.373029
uuid-d801ddb535264deaa507a5704a125897,regimen,0.372331
uuid-d801ddb535264deaa507a5704a125897,treated,0.305986
uuid-d801ddb535264deaa507a5704a125897,chemo,0.456754
uuid-d801ddb535264deaa507a5704a125897,pts,0.532706
uuid-d801ddb535264deaa507a5704a125897,preferred,0.317324
uuid-d801ddb535264deaa507a5704a125897,monotherapy,0.461918
uuid-d801ddb535264deaa507a5704a125897,treatment,0.309065
uuid-d801ddb535264deaa507a5704a125897,NSCLC patients,0.314523
uuid-d801ddb535264deaa507a5704a125897,progression,0.383253
uuid-d801ddb535264deaa507a5704a125897,chemotherapy,0.389433
uuid-d801ddb535264deaa507a5704a125897,respond,0.348228
uuid-d801ddb535264deaa507a5704a125897,feels,0.422068
uuid-d801ddb535264deaa507a5704a125897,option,0.495956
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,Nivo,0.528467
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,patients,0.380624
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,chemo,0.521297
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,Ipi,0.309718
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,monotherapy,0.37313
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,PFS,0.321022
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,chemotherapy,0.456683
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,vs,0.346702
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,feels,0.619466
uuid-a5ab47b65ee14c3bb1829ad7208b6e0d,option,0.348021
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,patients,0.57541
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,regimen,0.347033
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,chemo,0.323667
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,pts,0.437844
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,OS,0.311747
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,treatment,0.390382
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,response,0.433716
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,PFS,0.330833
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,progression,0.581283
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,chemotherapy,0.32038
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,respond,0.470957
uuid-f5ee4abb7c644b2195fb79c0cf9a830a,feels,0.424208
uuid-8c02217377154f7b92f1059464cf17f9,BMS,0.352026
uuid-8c02217377154f7b92f1059464cf17f9,PDL1,0.603741
uuid-8c02217377154f7b92f1059464cf17f9,trial,0.533033
uuid-8c02217377154f7b92f1059464cf17f9,efficacy,0.482116
uuid-8c02217377154f7b92f1059464cf17f9,commented,0.32782
uuid-8c02217377154f7b92f1059464cf17f9,OS,0.678892
uuid-8c02217377154f7b92f1059464cf17f9,data,0.671183
uuid-8c02217377154f7b92f1059464cf17f9,PFS,0.714354
uuid-8c02217377154f7b92f1059464cf17f9,ORR,0.728844
uuid-8c02217377154f7b92f1059464cf17f9,nivo and pembro,0.46755
uuid-8c02217377154f7b92f1059464cf17f9,impressed,0.460566
uuid-8c02217377154f7b92f1059464cf17f9,PDL1 expression,0.619804
uuid-8c02217377154f7b92f1059464cf17f9,biomarker,0.344676
uuid-14d800706ec34b4887e6c12a28518eec,patients,0.459335
uuid-14d800706ec34b4887e6c12a28518eec,1L,0.485875
uuid-14d800706ec34b4887e6c12a28518eec,PDL1,0.315512
uuid-14d800706ec34b4887e6c12a28518eec,TL stated,0.327726
uuid-14d800706ec34b4887e6c12a28518eec,2L,0.414125
uuid-14d800706ec34b4887e6c12a28518eec,PD-L1,0.634459
uuid-14d800706ec34b4887e6c12a28518eec,preferred,0.430664
uuid-14d800706ec34b4887e6c12a28518eec,PD-L1 testing,0.573123
uuid-14d800706ec34b4887e6c12a28518eec,testing,0.717943
uuid-14d800706ec34b4887e6c12a28518eec,using nivo,0.32584
uuid-14d800706ec34b4887e6c12a28518eec,PDL1 testing,0.642098
uuid-14d800706ec34b4887e6c12a28518eec,NSCLC patients,0.733814
uuid-14d800706ec34b4887e6c12a28518eec,approved,0.300467
uuid-14d800706ec34b4887e6c12a28518eec,tumor types,0.384859
uuid-14d800706ec34b4887e6c12a28518eec,option,0.43989
uuid-14d800706ec34b4887e6c12a28518eec,biomarker,0.331441
uuid-876fd18cff004a7d9c565ad101a2f232,TL,0.412822
uuid-876fd18cff004a7d9c565ad101a2f232,RTL,0.310296
uuid-876fd18cff004a7d9c565ad101a2f232,commented,0.313849
uuid-876fd18cff004a7d9c565ad101a2f232,RCC,0.36842
uuid-876fd18cff004a7d9c565ad101a2f232,TL stated,0.520152
uuid-876fd18cff004a7d9c565ad101a2f232,stated,0.457631
uuid-876fd18cff004a7d9c565ad101a2f232,PD-L1,0.529774
uuid-876fd18cff004a7d9c565ad101a2f232,approval,0.370596
uuid-876fd18cff004a7d9c565ad101a2f232,PD-L1 testing,0.52413
uuid-876fd18cff004a7d9c565ad101a2f232,testing,0.593221
uuid-876fd18cff004a7d9c565ad101a2f232,PDL1 testing,0.607709
uuid-876fd18cff004a7d9c565ad101a2f232,NSCLC patients,0.620814
uuid-876fd18cff004a7d9c565ad101a2f232,SCCHN,0.476708
uuid-876fd18cff004a7d9c565ad101a2f232,tumor types,0.420969
uuid-876fd18cff004a7d9c565ad101a2f232,Regional TL,0.472562
uuid-876fd18cff004a7d9c565ad101a2f232,RTL stated,0.382512
uuid-876fd18cff004a7d9c565ad101a2f232,TL shared,0.308352
uuid-876fd18cff004a7d9c565ad101a2f232,bladder,0.316504
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,Nivo,0.408138
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,patients,0.400841
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,pembro,0.571752
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,NSCLC,0.395635
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,1L,0.560974
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,chemo,0.320752
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,2L,0.521299
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,approval,0.355636
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,atezo,0.443194
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,preferred,0.527297
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,monotherapy,0.5155
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,using nivo,0.581745
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,NSCLC patients,0.311009
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,approved,0.35728
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,chemotherapy,0.32231
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,RTL stated,0.383234
uuid-41bb125ba64447beb3e1cd4d0e4dc58a,option,0.554622
uuid-8f66941e381341319e68ca81e21bc812,patients,0.624411
uuid-8f66941e381341319e68ca81e21bc812,therapy,0.37091
uuid-8f66941e381341319e68ca81e21bc812,1L,0.373277
uuid-8f66941e381341319e68ca81e21bc812,regimen,0.409626
uuid-8f66941e381341319e68ca81e21bc812,treated,0.377633
uuid-8f66941e381341319e68ca81e21bc812,RCC,0.414008
uuid-8f66941e381341319e68ca81e21bc812,TL stated,0.311018
uuid-8f66941e381341319e68ca81e21bc812,chemo,0.445255
uuid-8f66941e381341319e68ca81e21bc812,2L,0.355967
uuid-8f66941e381341319e68ca81e21bc812,pts,0.591712
uuid-8f66941e381341319e68ca81e21bc812,monotherapy,0.47268
uuid-8f66941e381341319e68ca81e21bc812,treatment,0.418391
uuid-8f66941e381341319e68ca81e21bc812,using nivo,0.329552
uuid-8f66941e381341319e68ca81e21bc812,response,0.447818
uuid-8f66941e381341319e68ca81e21bc812,PD1,0.334929
uuid-8f66941e381341319e68ca81e21bc812,progression,0.553711
uuid-8f66941e381341319e68ca81e21bc812,chemotherapy,0.380729
uuid-8f66941e381341319e68ca81e21bc812,tumor types,0.365868
uuid-8f66941e381341319e68ca81e21bc812,respond,0.408842
uuid-8f66941e381341319e68ca81e21bc812,RTL stated,0.300358
uuid-8f66941e381341319e68ca81e21bc812,TL shared,0.32526
uuid-8f66941e381341319e68ca81e21bc812,option,0.427085
uuid-ad2332d132c840a38570bf67fb90a5c8,Opdivo,0.465861
uuid-ad2332d132c840a38570bf67fb90a5c8,dose,0.554967
uuid-ad2332d132c840a38570bf67fb90a5c8,approval,0.394845
uuid-ad2332d132c840a38570bf67fb90a5c8,indication,0.346319
uuid-ad2332d132c840a38570bf67fb90a5c8,approved,0.417408
uuid-ad2332d132c840a38570bf67fb90a5c8,label,0.440758
uuid-ad2332d132c840a38570bf67fb90a5c8,drug,0.319079
uuid-ad2332d132c840a38570bf67fb90a5c8,Keytruda,0.314449
uuid-ad2332d132c840a38570bf67fb90a5c8,flat dosing,0.674303
uuid-a702e0a17ee145fe93364ede3dde8215,Nivo,0.560801
uuid-a702e0a17ee145fe93364ede3dde8215,pembro,0.637631
uuid-a702e0a17ee145fe93364ede3dde8215,dose,0.502822
uuid-a702e0a17ee145fe93364ede3dde8215,1L,0.31269
uuid-a702e0a17ee145fe93364ede3dde8215,2L,0.461261
uuid-a702e0a17ee145fe93364ede3dde8215,Ipi,0.401175
uuid-a702e0a17ee145fe93364ede3dde8215,approval,0.353495
uuid-a702e0a17ee145fe93364ede3dde8215,atezo,0.618626
uuid-a702e0a17ee145fe93364ede3dde8215,preferred,0.456688
uuid-a702e0a17ee145fe93364ede3dde8215,monotherapy,0.325565
uuid-a702e0a17ee145fe93364ede3dde8215,using nivo,0.50127
uuid-a702e0a17ee145fe93364ede3dde8215,indication,0.382954
uuid-a702e0a17ee145fe93364ede3dde8215,approved,0.414999
uuid-a702e0a17ee145fe93364ede3dde8215,SCCHN,0.302597
uuid-a702e0a17ee145fe93364ede3dde8215,vs,0.55296
uuid-a702e0a17ee145fe93364ede3dde8215,TLs,0.416307
uuid-a702e0a17ee145fe93364ede3dde8215,feels,0.349153
uuid-a702e0a17ee145fe93364ede3dde8215,RTL stated,0.317238
uuid-a702e0a17ee145fe93364ede3dde8215,option,0.345542
uuid-a702e0a17ee145fe93364ede3dde8215,flat dosing,0.490323
uuid-c41b5351a11c4e1a947761c632a78bb9,pembro,0.308534
uuid-c41b5351a11c4e1a947761c632a78bb9,RTL,0.359819
uuid-c41b5351a11c4e1a947761c632a78bb9,BMS,0.352942
uuid-c41b5351a11c4e1a947761c632a78bb9,PDL1,0.318754
uuid-c41b5351a11c4e1a947761c632a78bb9,trial,0.359714
uuid-c41b5351a11c4e1a947761c632a78bb9,commented,0.483376
uuid-c41b5351a11c4e1a947761c632a78bb9,Merck,0.314148
uuid-c41b5351a11c4e1a947761c632a78bb9,stated,0.484451
uuid-c41b5351a11c4e1a947761c632a78bb9,OS,0.390565
uuid-c41b5351a11c4e1a947761c632a78bb9,atezo,0.301132
uuid-c41b5351a11c4e1a947761c632a78bb9,regards,0.301152
uuid-c41b5351a11c4e1a947761c632a78bb9,data,0.689036
uuid-c41b5351a11c4e1a947761c632a78bb9,expressed,0.36184
uuid-c41b5351a11c4e1a947761c632a78bb9,PFS,0.343857
uuid-c41b5351a11c4e1a947761c632a78bb9,ORR,0.386552
uuid-c41b5351a11c4e1a947761c632a78bb9,SCCHN,0.373883
uuid-c41b5351a11c4e1a947761c632a78bb9,nivo and pembro,0.334162
uuid-c41b5351a11c4e1a947761c632a78bb9,ASCO,0.318626
uuid-c41b5351a11c4e1a947761c632a78bb9,impressed,0.632066
uuid-c41b5351a11c4e1a947761c632a78bb9,LTL,0.367761
uuid-c41b5351a11c4e1a947761c632a78bb9,TLs,0.499223
uuid-c41b5351a11c4e1a947761c632a78bb9,feels,0.387035
uuid-c41b5351a11c4e1a947761c632a78bb9,Regional TL,0.419134
uuid-c41b5351a11c4e1a947761c632a78bb9,bladder,0.337735
uuid-998246b431d64447ad7874ad6f2c602f,patients,0.345588
uuid-998246b431d64447ad7874ad6f2c602f,TL,0.410495
uuid-998246b431d64447ad7874ad6f2c602f,lung,0.344366
uuid-998246b431d64447ad7874ad6f2c602f,treated,0.364698
uuid-998246b431d64447ad7874ad6f2c602f,RCC,0.446676
uuid-998246b431d64447ad7874ad6f2c602f,TL stated,0.604784
uuid-998246b431d64447ad7874ad6f2c602f,stated,0.3108
uuid-998246b431d64447ad7874ad6f2c602f,PD-L1,0.432115
uuid-998246b431d64447ad7874ad6f2c602f,PD-L1 testing,0.482506
uuid-998246b431d64447ad7874ad6f2c602f,testing,0.600167
uuid-998246b431d64447ad7874ad6f2c602f,PDL1 testing,0.641871
uuid-998246b431d64447ad7874ad6f2c602f,NSCLC patients,0.702794
uuid-998246b431d64447ad7874ad6f2c602f,SCCHN,0.455333
uuid-998246b431d64447ad7874ad6f2c602f,tumor types,0.501059
uuid-998246b431d64447ad7874ad6f2c602f,Regional TL,0.379868
uuid-998246b431d64447ad7874ad6f2c602f,RTL stated,0.429358
uuid-998246b431d64447ad7874ad6f2c602f,TL shared,0.441468
uuid-998246b431d64447ad7874ad6f2c602f,bladder,0.396812
uuid-b87bc25e241941fa9e846aa397ccde10,patients,0.568675
uuid-b87bc25e241941fa9e846aa397ccde10,Opdivo,0.567788
uuid-b87bc25e241941fa9e846aa397ccde10,dose,0.302205
uuid-b87bc25e241941fa9e846aa397ccde10,regimen,0.338359
uuid-b87bc25e241941fa9e846aa397ccde10,treated,0.343837
uuid-b87bc25e241941fa9e846aa397ccde10,pts,0.309896
uuid-b87bc25e241941fa9e846aa397ccde10,treatment,0.3271
uuid-b87bc25e241941fa9e846aa397ccde10,progression,0.377862
uuid-b87bc25e241941fa9e846aa397ccde10,Keytruda,0.308737
uuid-b87bc25e241941fa9e846aa397ccde10,flat dosing,0.300077
uuid-19acd896e59347c298617ec6d716a275,patients,0.354485
uuid-19acd896e59347c298617ec6d716a275,Opdivo,0.342939
uuid-19acd896e59347c298617ec6d716a275,therapy,0.476834
uuid-19acd896e59347c298617ec6d716a275,nivolumab,0.452005
uuid-19acd896e59347c298617ec6d716a275,treated,0.307967
uuid-19acd896e59347c298617ec6d716a275,mentioned,0.337734
uuid-19acd896e59347c298617ec6d716a275,cHL,0.732973
uuid-e7fe82cf08b643f9ab294f00d2a8c834,pembro,0.319934
uuid-e7fe82cf08b643f9ab294f00d2a8c834,RTL,0.437932
uuid-e7fe82cf08b643f9ab294f00d2a8c834,BMS,0.444263
uuid-e7fe82cf08b643f9ab294f00d2a8c834,trial,0.694501
uuid-e7fe82cf08b643f9ab294f00d2a8c834,commented,0.467525
uuid-e7fe82cf08b643f9ab294f00d2a8c834,Merck,0.39596
uuid-e7fe82cf08b643f9ab294f00d2a8c834,stated,0.429697
uuid-e7fe82cf08b643f9ab294f00d2a8c834,approval,0.420211
uuid-e7fe82cf08b643f9ab294f00d2a8c834,OS,0.582775
uuid-e7fe82cf08b643f9ab294f00d2a8c834,data,0.750768
uuid-e7fe82cf08b643f9ab294f00d2a8c834,expressed,0.359627
uuid-e7fe82cf08b643f9ab294f00d2a8c834,clinical trials,0.346353
uuid-e7fe82cf08b643f9ab294f00d2a8c834,indication,0.373382
uuid-e7fe82cf08b643f9ab294f00d2a8c834,PFS,0.52244
uuid-e7fe82cf08b643f9ab294f00d2a8c834,ORR,0.564081
uuid-e7fe82cf08b643f9ab294f00d2a8c834,SCCHN,0.384469
uuid-e7fe82cf08b643f9ab294f00d2a8c834,ASCO,0.383988
uuid-e7fe82cf08b643f9ab294f00d2a8c834,impressed,0.659534
uuid-e7fe82cf08b643f9ab294f00d2a8c834,SCLC,0.361013
uuid-e7fe82cf08b643f9ab294f00d2a8c834,Regional TL,0.345428
uuid-e7fe82cf08b643f9ab294f00d2a8c834,bladder,0.318668
uuid-a507e725689940c0b3e0665a97699134,patients,0.61571
uuid-a507e725689940c0b3e0665a97699134,toxicity,0.353599
uuid-a507e725689940c0b3e0665a97699134,regimen,0.415189
uuid-a507e725689940c0b3e0665a97699134,pts,0.433574
uuid-a507e725689940c0b3e0665a97699134,treatment,0.437505
uuid-a507e725689940c0b3e0665a97699134,progression,0.48202
uuid-a507e725689940c0b3e0665a97699134,respond,0.395445
uuid-712f6160c23c47ba8d9f5e2c908dd068,NTL,0.480999
uuid-712f6160c23c47ba8d9f5e2c908dd068,commented,0.453666
uuid-712f6160c23c47ba8d9f5e2c908dd068,Merck,0.344017
uuid-712f6160c23c47ba8d9f5e2c908dd068,stated,0.310741
uuid-712f6160c23c47ba8d9f5e2c908dd068,data,0.478729
uuid-712f6160c23c47ba8d9f5e2c908dd068,expressed,0.342959
uuid-712f6160c23c47ba8d9f5e2c908dd068,indication,0.391021
uuid-712f6160c23c47ba8d9f5e2c908dd068,lung cancer,0.611322
uuid-712f6160c23c47ba8d9f5e2c908dd068,ASCO,0.420787
uuid-712f6160c23c47ba8d9f5e2c908dd068,impressed,0.394749
uuid-712f6160c23c47ba8d9f5e2c908dd068,Regional TL,0.357825
uuid-2c1ebbef118a4978adc9c4789dcf3bde,Nivo,0.42544
uuid-2c1ebbef118a4978adc9c4789dcf3bde,patients,0.810136
uuid-2c1ebbef118a4978adc9c4789dcf3bde,Opdivo,0.371971
uuid-2c1ebbef118a4978adc9c4789dcf3bde,pembro,0.339018
uuid-2c1ebbef118a4978adc9c4789dcf3bde,therapy,0.460374
uuid-2c1ebbef118a4978adc9c4789dcf3bde,nivolumab,0.426425
uuid-2c1ebbef118a4978adc9c4789dcf3bde,1L,0.525926
uuid-2c1ebbef118a4978adc9c4789dcf3bde,regimen,0.379585
uuid-2c1ebbef118a4978adc9c4789dcf3bde,treated,0.40842
uuid-2c1ebbef118a4978adc9c4789dcf3bde,RCC,0.332424
uuid-2c1ebbef118a4978adc9c4789dcf3bde,chemo,0.351951
uuid-2c1ebbef118a4978adc9c4789dcf3bde,2L,0.519098
uuid-2c1ebbef118a4978adc9c4789dcf3bde,pts,0.55156
uuid-2c1ebbef118a4978adc9c4789dcf3bde,approval,0.479405
uuid-2c1ebbef118a4978adc9c4789dcf3bde,preferred,0.491627
uuid-2c1ebbef118a4978adc9c4789dcf3bde,monotherapy,0.523734
uuid-2c1ebbef118a4978adc9c4789dcf3bde,treatment,0.472406
uuid-2c1ebbef118a4978adc9c4789dcf3bde,using nivo,0.583736
uuid-2c1ebbef118a4978adc9c4789dcf3bde,NSCLC patients,0.502121
uuid-2c1ebbef118a4978adc9c4789dcf3bde,approved,0.448048
uuid-2c1ebbef118a4978adc9c4789dcf3bde,progression,0.427584
uuid-2c1ebbef118a4978adc9c4789dcf3bde,chemotherapy,0.338838
uuid-2c1ebbef118a4978adc9c4789dcf3bde,respond,0.390481
uuid-2c1ebbef118a4978adc9c4789dcf3bde,RTL stated,0.441148
uuid-2c1ebbef118a4978adc9c4789dcf3bde,option,0.549936
uuid-7cd2585705f94befab48d0682af8803e,TL,0.355902
uuid-7cd2585705f94befab48d0682af8803e,pembro,0.333232
uuid-7cd2585705f94befab48d0682af8803e,RTL,0.379531
uuid-7cd2585705f94befab48d0682af8803e,trial,0.430606
uuid-7cd2585705f94befab48d0682af8803e,approval,0.471306
uuid-7cd2585705f94befab48d0682af8803e,atezo,0.301055
uuid-7cd2585705f94befab48d0682af8803e,preferred,0.39238
uuid-7cd2585705f94befab48d0682af8803e,using nivo,0.325866
uuid-7cd2585705f94befab48d0682af8803e,clinical trials,0.426015
uuid-7cd2585705f94befab48d0682af8803e,indication,0.345517
uuid-7cd2585705f94befab48d0682af8803e,approved,0.39088
uuid-7cd2585705f94befab48d0682af8803e,SCCHN,0.468454
uuid-7cd2585705f94befab48d0682af8803e,impressed,0.34681
uuid-7cd2585705f94befab48d0682af8803e,LTL,0.32711
uuid-7cd2585705f94befab48d0682af8803e,Regional TL,0.440602
uuid-7cd2585705f94befab48d0682af8803e,RTL stated,0.429173
uuid-7cd2585705f94befab48d0682af8803e,bladder,0.444254
uuid-113c563a04fa41128e8790ffdc74545c,patients,0.445162
uuid-113c563a04fa41128e8790ffdc74545c,pembro,0.41967
uuid-113c563a04fa41128e8790ffdc74545c,1L,0.644841
uuid-113c563a04fa41128e8790ffdc74545c,PDL1,0.334902
uuid-113c563a04fa41128e8790ffdc74545c,treated,0.302319
uuid-113c563a04fa41128e8790ffdc74545c,RCC,0.306964
uuid-113c563a04fa41128e8790ffdc74545c,2L,0.527183
uuid-113c563a04fa41128e8790ffdc74545c,pts,0.425345
uuid-113c563a04fa41128e8790ffdc74545c,PD-L1,0.460655
uuid-113c563a04fa41128e8790ffdc74545c,approval,0.431771
uuid-113c563a04fa41128e8790ffdc74545c,atezo,0.317704
uuid-113c563a04fa41128e8790ffdc74545c,preferred,0.487572
uuid-113c563a04fa41128e8790ffdc74545c,PD-L1 testing,0.347993
uuid-113c563a04fa41128e8790ffdc74545c,testing,0.487221
uuid-113c563a04fa41128e8790ffdc74545c,monotherapy,0.459493
uuid-113c563a04fa41128e8790ffdc74545c,using nivo,0.478786
uuid-113c563a04fa41128e8790ffdc74545c,PDL1 testing,0.441752
uuid-113c563a04fa41128e8790ffdc74545c,NSCLC patients,0.65384
uuid-113c563a04fa41128e8790ffdc74545c,approved,0.381093
uuid-113c563a04fa41128e8790ffdc74545c,SCCHN,0.316745
uuid-113c563a04fa41128e8790ffdc74545c,tumor types,0.338609
uuid-113c563a04fa41128e8790ffdc74545c,RTL stated,0.489556
uuid-113c563a04fa41128e8790ffdc74545c,option,0.526186
uuid-3e2f0c109f60466a9c6a75f70de15ebb,drug,0.303448
uuid-287cf167b5254f0cb66da89edaf75959,Nivo,0.349095
uuid-287cf167b5254f0cb66da89edaf75959,patients,0.303633
uuid-287cf167b5254f0cb66da89edaf75959,pembro,0.416209
uuid-287cf167b5254f0cb66da89edaf75959,nivolumab,0.402784
uuid-287cf167b5254f0cb66da89edaf75959,1L,0.591852
uuid-287cf167b5254f0cb66da89edaf75959,regimen,0.309585
uuid-287cf167b5254f0cb66da89edaf75959,RCC,0.576912
uuid-287cf167b5254f0cb66da89edaf75959,2L,0.690946
uuid-287cf167b5254f0cb66da89edaf75959,agents,0.420886
uuid-287cf167b5254f0cb66da89edaf75959,approval,0.438347
uuid-287cf167b5254f0cb66da89edaf75959,atezo,0.440283
uuid-287cf167b5254f0cb66da89edaf75959,preferred,0.806479
uuid-287cf167b5254f0cb66da89edaf75959,monotherapy,0.568196
uuid-287cf167b5254f0cb66da89edaf75959,using nivo,0.638025
uuid-287cf167b5254f0cb66da89edaf75959,PDL1 testing,0.316151
uuid-287cf167b5254f0cb66da89edaf75959,indication,0.455689
uuid-287cf167b5254f0cb66da89edaf75959,approved,0.577954
uuid-287cf167b5254f0cb66da89edaf75959,SCCHN,0.433168
uuid-287cf167b5254f0cb66da89edaf75959,label,0.332729
uuid-287cf167b5254f0cb66da89edaf75959,RTL stated,0.597081
uuid-287cf167b5254f0cb66da89edaf75959,TL shared,0.391299
uuid-287cf167b5254f0cb66da89edaf75959,option,0.655604
uuid-287cf167b5254f0cb66da89edaf75959,bladder,0.361546
uuid-567f984bdb3c4ac7b42160256b67d950,pembro,0.47995
uuid-567f984bdb3c4ac7b42160256b67d950,1L,0.383042
uuid-567f984bdb3c4ac7b42160256b67d950,trial,0.518551
uuid-567f984bdb3c4ac7b42160256b67d950,2L,0.345254
uuid-567f984bdb3c4ac7b42160256b67d950,approval,0.421912
uuid-567f984bdb3c4ac7b42160256b67d950,atezo,0.338512
uuid-567f984bdb3c4ac7b42160256b67d950,preferred,0.411647
uuid-567f984bdb3c4ac7b42160256b67d950,using nivo,0.370716
uuid-567f984bdb3c4ac7b42160256b67d950,clinical trials,0.55873
uuid-567f984bdb3c4ac7b42160256b67d950,indication,0.315618
uuid-567f984bdb3c4ac7b42160256b67d950,approved,0.437614
uuid-567f984bdb3c4ac7b42160256b67d950,SCCHN,0.319249
uuid-567f984bdb3c4ac7b42160256b67d950,feels,0.346007
uuid-567f984bdb3c4ac7b42160256b67d950,RTL stated,0.342218
uuid-567f984bdb3c4ac7b42160256b67d950,option,0.361633
uuid-567f984bdb3c4ac7b42160256b67d950,bladder,0.344427
uuid-b1cca0d87e864062b2124eee1467d0be,Opdivo,0.353181
uuid-b1cca0d87e864062b2124eee1467d0be,dose,0.692823
uuid-b1cca0d87e864062b2124eee1467d0be,Ipi,0.300963
uuid-b1cca0d87e864062b2124eee1467d0be,vs,0.347342
uuid-b1cca0d87e864062b2124eee1467d0be,drug,0.449511
uuid-b1cca0d87e864062b2124eee1467d0be,Keytruda,0.448834
uuid-b1cca0d87e864062b2124eee1467d0be,flat dosing,0.761794
uuid-eaaa4117bf8349448f49830656c5398c,pembro,0.446699
uuid-eaaa4117bf8349448f49830656c5398c,NSCLC,0.374732
uuid-eaaa4117bf8349448f49830656c5398c,PDL1,0.483716
uuid-eaaa4117bf8349448f49830656c5398c,trial,0.49637
uuid-eaaa4117bf8349448f49830656c5398c,efficacy,0.491095
uuid-eaaa4117bf8349448f49830656c5398c,discussed,0.361789
uuid-eaaa4117bf8349448f49830656c5398c,commented,0.352803
uuid-eaaa4117bf8349448f49830656c5398c,OS,0.505937
uuid-eaaa4117bf8349448f49830656c5398c,atezo,0.399702
uuid-eaaa4117bf8349448f49830656c5398c,data,0.653502
uuid-eaaa4117bf8349448f49830656c5398c,PFS,0.484206
uuid-eaaa4117bf8349448f49830656c5398c,ORR,0.540055
uuid-eaaa4117bf8349448f49830656c5398c,nivo and pembro,0.456697
uuid-eaaa4117bf8349448f49830656c5398c,impressed,0.453701
uuid-eaaa4117bf8349448f49830656c5398c,vs,0.407094
uuid-eaaa4117bf8349448f49830656c5398c,TLs,0.333605
uuid-eaaa4117bf8349448f49830656c5398c,PDL1 expression,0.481898
uuid-eaaa4117bf8349448f49830656c5398c,biomarker,0.318393
uuid-c4e843d5139044debe541ab003cd5311,shared,0.47841
uuid-c4e843d5139044debe541ab003cd5311,preferred,0.366076
uuid-c4e843d5139044debe541ab003cd5311,expressed,0.319969
uuid-c4e843d5139044debe541ab003cd5311,approved,0.341574
uuid-c4e843d5139044debe541ab003cd5311,HCP,0.318209
uuid-c4e843d5139044debe541ab003cd5311,drug,0.444141
uuid-c4e843d5139044debe541ab003cd5311,RTL stated,0.320311
uuid-2d1830f6245b4cbdbc374083881d35d4,patients,0.750341
uuid-2d1830f6245b4cbdbc374083881d35d4,Opdivo,0.31226
uuid-2d1830f6245b4cbdbc374083881d35d4,therapy,0.522239
uuid-2d1830f6245b4cbdbc374083881d35d4,nivolumab,0.351408
uuid-2d1830f6245b4cbdbc374083881d35d4,regimen,0.437757
uuid-2d1830f6245b4cbdbc374083881d35d4,treated,0.590917
uuid-2d1830f6245b4cbdbc374083881d35d4,pts,0.525469
uuid-2d1830f6245b4cbdbc374083881d35d4,treatment,0.672657
uuid-2d1830f6245b4cbdbc374083881d35d4,response,0.444122
uuid-2d1830f6245b4cbdbc374083881d35d4,progression,0.611428
uuid-2d1830f6245b4cbdbc374083881d35d4,chemotherapy,0.36878
uuid-2d1830f6245b4cbdbc374083881d35d4,respond,0.490164
uuid-2c3937f3cbe24e6b851e950809275c6c,patients,0.525348
uuid-2c3937f3cbe24e6b851e950809275c6c,Opdivo,0.324167
uuid-2c3937f3cbe24e6b851e950809275c6c,testing,0.392493
uuid-2c3937f3cbe24e6b851e950809275c6c,treatment,0.459409
uuid-2c3937f3cbe24e6b851e950809275c6c,PDL1 testing,0.376729
uuid-2c3937f3cbe24e6b851e950809275c6c,NSCLC patients,0.39059
uuid-2c3937f3cbe24e6b851e950809275c6c,progression,0.326197
uuid-2c3937f3cbe24e6b851e950809275c6c,option,0.321652
uuid-80a9c3858e9b4077ab341723665234e9,patients,0.424642
uuid-80a9c3858e9b4077ab341723665234e9,therapy,0.433829
uuid-80a9c3858e9b4077ab341723665234e9,treated,0.336814
uuid-80a9c3858e9b4077ab341723665234e9,chemo,0.425363
uuid-80a9c3858e9b4077ab341723665234e9,tumor,0.630149
uuid-80a9c3858e9b4077ab341723665234e9,pts,0.446868
uuid-80a9c3858e9b4077ab341723665234e9,treatment,0.39198
uuid-80a9c3858e9b4077ab341723665234e9,response,0.525044
uuid-80a9c3858e9b4077ab341723665234e9,PD1,0.337085
uuid-80a9c3858e9b4077ab341723665234e9,progression,0.462386
uuid-80a9c3858e9b4077ab341723665234e9,chemotherapy,0.412436
uuid-80a9c3858e9b4077ab341723665234e9,respond,0.364476
uuid-80a9c3858e9b4077ab341723665234e9,immunotherapy,0.401686
uuid-c852a4ef0b884adfaae71706f114f891,discussed,0.310481
uuid-c852a4ef0b884adfaae71706f114f891,shared,0.330294
uuid-c852a4ef0b884adfaae71706f114f891,oncology,0.567326
uuid-c852a4ef0b884adfaae71706f114f891,clinical,0.350553
uuid-a6b3dbaf16304f31b455fec7a316dc95,efficacy,0.331918
uuid-a6b3dbaf16304f31b455fec7a316dc95,shared,0.368547
uuid-a6b3dbaf16304f31b455fec7a316dc95,commented,0.348645
uuid-a6b3dbaf16304f31b455fec7a316dc95,HCP,0.340982
uuid-a6b3dbaf16304f31b455fec7a316dc95,LTL,0.339192
uuid-a6b3dbaf16304f31b455fec7a316dc95,TLs,0.347935
uuid-cce34edac7974f2393e78ab0fd8eb2d4,patients,0.309657
uuid-cce34edac7974f2393e78ab0fd8eb2d4,Opdivo,0.516911
uuid-cce34edac7974f2393e78ab0fd8eb2d4,nivolumab,0.341333
uuid-cce34edac7974f2393e78ab0fd8eb2d4,toxicity,0.304492
uuid-cce34edac7974f2393e78ab0fd8eb2d4,regimen,0.568652
uuid-cce34edac7974f2393e78ab0fd8eb2d4,combination,0.300918
uuid-cce34edac7974f2393e78ab0fd8eb2d4,pts,0.317121
uuid-cce34edac7974f2393e78ab0fd8eb2d4,monotherapy,0.330824
uuid-cce34edac7974f2393e78ab0fd8eb2d4,combo,0.31416
uuid-cce34edac7974f2393e78ab0fd8eb2d4,HCP,0.395362
uuid-cce34edac7974f2393e78ab0fd8eb2d4,impressed,0.300099
uuid-cce34edac7974f2393e78ab0fd8eb2d4,respond,0.316937
uuid-cce34edac7974f2393e78ab0fd8eb2d4,SCLC,0.307103
uuid-cce34edac7974f2393e78ab0fd8eb2d4,feels,0.426246
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,TL,0.416153
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,RCC,0.301998
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,TL stated,0.538464
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,institution,0.399612
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,PD-L1,0.637422
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,PD-L1 testing,0.695456
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,testing,0.798072
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,PDL1 testing,0.773922
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,NSCLC patients,0.676099
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,SCCHN,0.372498
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,tumor types,0.49039
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,assay,0.419703
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,RTL stated,0.31001
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,biomarker,0.395258
uuid-dbebfa11e0b242f7a9ff759c2cdbad95,bladder,0.332632
uuid-06bde65f8f3a4a0398fd0398fbf7f2ef,data,0.314532
uuid-06bde65f8f3a4a0398fd0398fbf7f2ef,impressed,0.303658
uuid-03b5e2aac21240f0b274a8827dffc4bf,Nivo,0.326892
uuid-03b5e2aac21240f0b274a8827dffc4bf,therapy,0.343378
uuid-03b5e2aac21240f0b274a8827dffc4bf,nivolumab,0.514807
uuid-03b5e2aac21240f0b274a8827dffc4bf,trial,0.342704
uuid-03b5e2aac21240f0b274a8827dffc4bf,data,0.302883
uuid-03b5e2aac21240f0b274a8827dffc4bf,PD1,0.30194
uuid-03b5e2aac21240f0b274a8827dffc4bf,cHL,0.534575
uuid-03b5e2aac21240f0b274a8827dffc4bf,chemotherapy,0.342121
uuid-037866d67c4d4bcfa1fca7c3b2408290,patients,0.498196
uuid-037866d67c4d4bcfa1fca7c3b2408290,RTL,0.403596
uuid-037866d67c4d4bcfa1fca7c3b2408290,nivolumab,0.36092
uuid-037866d67c4d4bcfa1fca7c3b2408290,regimen,0.46655
uuid-037866d67c4d4bcfa1fca7c3b2408290,treated,0.536
uuid-037866d67c4d4bcfa1fca7c3b2408290,melanoma,0.311363
uuid-037866d67c4d4bcfa1fca7c3b2408290,RCC,0.414757
uuid-037866d67c4d4bcfa1fca7c3b2408290,pts,0.497306
uuid-037866d67c4d4bcfa1fca7c3b2408290,monotherapy,0.347579
uuid-037866d67c4d4bcfa1fca7c3b2408290,using nivo,0.346752
uuid-037866d67c4d4bcfa1fca7c3b2408290,response,0.324804
uuid-037866d67c4d4bcfa1fca7c3b2408290,SCCHN,0.362952
uuid-037866d67c4d4bcfa1fca7c3b2408290,progression,0.427927
uuid-037866d67c4d4bcfa1fca7c3b2408290,impressed,0.348782
uuid-037866d67c4d4bcfa1fca7c3b2408290,LTL,0.308365
uuid-037866d67c4d4bcfa1fca7c3b2408290,Regional TL,0.370445
uuid-037866d67c4d4bcfa1fca7c3b2408290,RTL stated,0.436626
uuid-037866d67c4d4bcfa1fca7c3b2408290,TL shared,0.397826
uuid-81af7e8568e840c9a77b28a73ded8c18,RTL,0.360699
uuid-81af7e8568e840c9a77b28a73ded8c18,BMS,0.509951
uuid-81af7e8568e840c9a77b28a73ded8c18,trial,0.555377
uuid-81af7e8568e840c9a77b28a73ded8c18,commented,0.342207
uuid-81af7e8568e840c9a77b28a73ded8c18,Merck,0.472946
uuid-81af7e8568e840c9a77b28a73ded8c18,stated,0.371653
uuid-81af7e8568e840c9a77b28a73ded8c18,data,0.371177
uuid-81af7e8568e840c9a77b28a73ded8c18,mentioned,0.301734
uuid-81af7e8568e840c9a77b28a73ded8c18,clinical trials,0.307427
uuid-81af7e8568e840c9a77b28a73ded8c18,impressed,0.432727
uuid-81af7e8568e840c9a77b28a73ded8c18,Regional TL,0.312228
uuid-21588f53805b42ebbdcf11717c3150b2,PDL1,0.329986
uuid-21588f53805b42ebbdcf11717c3150b2,efficacy,0.342034
uuid-21588f53805b42ebbdcf11717c3150b2,agents,0.40801
uuid-21588f53805b42ebbdcf11717c3150b2,data,0.508597
uuid-21588f53805b42ebbdcf11717c3150b2,feels,0.343496
uuid-1db33e15fb6a4ce3adb110931a83212f,TL,0.596482
uuid-1db33e15fb6a4ce3adb110931a83212f,PDL1,0.357387
uuid-1db33e15fb6a4ce3adb110931a83212f,Merck,0.327115
uuid-1db33e15fb6a4ce3adb110931a83212f,institution,0.406763
uuid-1db33e15fb6a4ce3adb110931a83212f,PD-L1,0.764579
uuid-1db33e15fb6a4ce3adb110931a83212f,PD-L1 testing,0.901669
uuid-1db33e15fb6a4ce3adb110931a83212f,testing,0.796441
uuid-1db33e15fb6a4ce3adb110931a83212f,PDL1 testing,0.52971
uuid-1db33e15fb6a4ce3adb110931a83212f,NSCLC patients,0.459868
uuid-1db33e15fb6a4ce3adb110931a83212f,assay,0.78177
uuid-1db33e15fb6a4ce3adb110931a83212f,biomarker,0.358869
uuid-c1cc2c3475434b35a56d8c70d26bb789,TL,0.519226
uuid-c1cc2c3475434b35a56d8c70d26bb789,IO,0.361189
uuid-c1cc2c3475434b35a56d8c70d26bb789,PD-L1,0.478534
uuid-c1cc2c3475434b35a56d8c70d26bb789,PD-L1 testing,0.515116
uuid-c1cc2c3475434b35a56d8c70d26bb789,testing,0.457116
uuid-c1cc2c3475434b35a56d8c70d26bb789,indicated,0.314402
uuid-c1cc2c3475434b35a56d8c70d26bb789,clinical,0.366362
uuid-c1cc2c3475434b35a56d8c70d26bb789,assay,0.421423
uuid-c1cc2c3475434b35a56d8c70d26bb789,biomarker,0.425023
uuid-b7265de8e4af480abdf7de6ccba3441f,TL,0.629602
uuid-b7265de8e4af480abdf7de6ccba3441f,PDL1,0.399632
uuid-b7265de8e4af480abdf7de6ccba3441f,TL stated,0.450779
uuid-b7265de8e4af480abdf7de6ccba3441f,Merck,0.418838
uuid-b7265de8e4af480abdf7de6ccba3441f,PD-L1,0.703727
uuid-b7265de8e4af480abdf7de6ccba3441f,PD-L1 testing,0.731791
uuid-b7265de8e4af480abdf7de6ccba3441f,testing,0.759032
uuid-b7265de8e4af480abdf7de6ccba3441f,PDL1 testing,0.660512
uuid-b7265de8e4af480abdf7de6ccba3441f,NSCLC patients,0.500154
uuid-b7265de8e4af480abdf7de6ccba3441f,assay,0.710485
uuid-b7265de8e4af480abdf7de6ccba3441f,biomarker,0.349544
uuid-0f1477bb61d3435d85a68d0f089d919f,BMS,0.524621
uuid-0f1477bb61d3435d85a68d0f089d919f,trial,0.370974
uuid-0f1477bb61d3435d85a68d0f089d919f,Merck,0.543888
uuid-45d982187db542408e5523575f591cc1,1L,0.342414
uuid-45d982187db542408e5523575f591cc1,PDL1,0.346242
uuid-45d982187db542408e5523575f591cc1,TL stated,0.474105
uuid-45d982187db542408e5523575f591cc1,PD-L1,0.632583
uuid-45d982187db542408e5523575f591cc1,PD-L1 testing,0.569506
uuid-45d982187db542408e5523575f591cc1,testing,0.779949
uuid-45d982187db542408e5523575f591cc1,PDL1 testing,0.712432
uuid-45d982187db542408e5523575f591cc1,NSCLC patients,0.817336
uuid-45d982187db542408e5523575f591cc1,tumor types,0.471469
uuid-45d982187db542408e5523575f591cc1,assay,0.3292
uuid-45d982187db542408e5523575f591cc1,biomarker,0.39411
uuid-f66bfa64500f480598c427fd95281210,RTL,0.632774
uuid-f66bfa64500f480598c427fd95281210,trial,0.319912
uuid-f66bfa64500f480598c427fd95281210,NTL,0.313751
uuid-f66bfa64500f480598c427fd95281210,shared,0.342968
uuid-f66bfa64500f480598c427fd95281210,commented,0.500218
uuid-f66bfa64500f480598c427fd95281210,RCC,0.371293
uuid-f66bfa64500f480598c427fd95281210,stated,0.527769
uuid-f66bfa64500f480598c427fd95281210,data,0.549867
uuid-f66bfa64500f480598c427fd95281210,expressed,0.334193
uuid-f66bfa64500f480598c427fd95281210,clinical trials,0.372563
uuid-f66bfa64500f480598c427fd95281210,SCCHN,0.481772
uuid-f66bfa64500f480598c427fd95281210,HCP,0.347964
uuid-f66bfa64500f480598c427fd95281210,ASCO,0.387014
uuid-f66bfa64500f480598c427fd95281210,impressed,0.694498
uuid-f66bfa64500f480598c427fd95281210,LTL,0.546359
uuid-f66bfa64500f480598c427fd95281210,TLs,0.489596
uuid-f66bfa64500f480598c427fd95281210,academic,0.343594
uuid-f66bfa64500f480598c427fd95281210,feels,0.394241
uuid-f66bfa64500f480598c427fd95281210,Regional TL,0.592253
uuid-f66bfa64500f480598c427fd95281210,RTL stated,0.435314
uuid-f66bfa64500f480598c427fd95281210,bladder,0.37355
uuid-c092d53b038048b7ad9cd623b4c33f4f,Nivo,0.408138
uuid-c092d53b038048b7ad9cd623b4c33f4f,patients,0.400841
uuid-c092d53b038048b7ad9cd623b4c33f4f,pembro,0.571752
uuid-c092d53b038048b7ad9cd623b4c33f4f,NSCLC,0.395635
uuid-c092d53b038048b7ad9cd623b4c33f4f,1L,0.560974
uuid-c092d53b038048b7ad9cd623b4c33f4f,chemo,0.320752
uuid-c092d53b038048b7ad9cd623b4c33f4f,2L,0.521299
uuid-c092d53b038048b7ad9cd623b4c33f4f,approval,0.355636
uuid-c092d53b038048b7ad9cd623b4c33f4f,atezo,0.443194
uuid-c092d53b038048b7ad9cd623b4c33f4f,preferred,0.527297
uuid-c092d53b038048b7ad9cd623b4c33f4f,monotherapy,0.5155
uuid-c092d53b038048b7ad9cd623b4c33f4f,using nivo,0.581745
uuid-c092d53b038048b7ad9cd623b4c33f4f,NSCLC patients,0.311009
uuid-c092d53b038048b7ad9cd623b4c33f4f,approved,0.35728
uuid-c092d53b038048b7ad9cd623b4c33f4f,chemotherapy,0.32231
uuid-c092d53b038048b7ad9cd623b4c33f4f,RTL stated,0.383234
uuid-c092d53b038048b7ad9cd623b4c33f4f,option,0.554622
uuid-fa2ca1cefae046b8acf58b2fb2073d65,Nivo,0.503763
uuid-fa2ca1cefae046b8acf58b2fb2073d65,dose,0.339375
uuid-fa2ca1cefae046b8acf58b2fb2073d65,nivolumab,0.423114
uuid-fa2ca1cefae046b8acf58b2fb2073d65,1L,0.333062
uuid-fa2ca1cefae046b8acf58b2fb2073d65,toxicity,0.337858
uuid-fa2ca1cefae046b8acf58b2fb2073d65,regimen,0.446366
uuid-fa2ca1cefae046b8acf58b2fb2073d65,melanoma,0.313503
uuid-fa2ca1cefae046b8acf58b2fb2073d65,RCC,0.468007
uuid-fa2ca1cefae046b8acf58b2fb2073d65,combination,0.562537
uuid-fa2ca1cefae046b8acf58b2fb2073d65,chemo,0.36314
uuid-fa2ca1cefae046b8acf58b2fb2073d65,2L,0.434038
uuid-fa2ca1cefae046b8acf58b2fb2073d65,agents,0.361575
uuid-fa2ca1cefae046b8acf58b2fb2073d65,Ipi,0.565093
uuid-fa2ca1cefae046b8acf58b2fb2073d65,atezo,0.314986
uuid-fa2ca1cefae046b8acf58b2fb2073d65,preferred,0.438677
uuid-fa2ca1cefae046b8acf58b2fb2073d65,monotherapy,0.500168
uuid-fa2ca1cefae046b8acf58b2fb2073d65,using nivo,0.414639
uuid-fa2ca1cefae046b8acf58b2fb2073d65,combo,0.603923
uuid-fa2ca1cefae046b8acf58b2fb2073d65,approved,0.336256
uuid-fa2ca1cefae046b8acf58b2fb2073d65,chemotherapy,0.306237
uuid-fa2ca1cefae046b8acf58b2fb2073d65,SCLC,0.32605
uuid-fa2ca1cefae046b8acf58b2fb2073d65,RTL stated,0.390026
uuid-fa2ca1cefae046b8acf58b2fb2073d65,TL shared,0.31699
uuid-fa2ca1cefae046b8acf58b2fb2073d65,option,0.36861
uuid-fa2ca1cefae046b8acf58b2fb2073d65,bladder,0.369011
uuid-d0e03110f4154c59b7de77f5bd379bdc,Nivo,0.518549
uuid-d0e03110f4154c59b7de77f5bd379bdc,patients,0.362398
uuid-d0e03110f4154c59b7de77f5bd379bdc,pembro,0.370022
uuid-d0e03110f4154c59b7de77f5bd379bdc,therapy,0.378477
uuid-d0e03110f4154c59b7de77f5bd379bdc,1L,0.393837
uuid-d0e03110f4154c59b7de77f5bd379bdc,efficacy,0.369301
uuid-d0e03110f4154c59b7de77f5bd379bdc,regimen,0.446763
uuid-d0e03110f4154c59b7de77f5bd379bdc,combination,0.38069
uuid-d0e03110f4154c59b7de77f5bd379bdc,chemo,0.567739
uuid-d0e03110f4154c59b7de77f5bd379bdc,2L,0.327294
uuid-d0e03110f4154c59b7de77f5bd379bdc,pts,0.424444
uuid-d0e03110f4154c59b7de77f5bd379bdc,Ipi,0.320869
uuid-d0e03110f4154c59b7de77f5bd379bdc,preferred,0.326929
uuid-d0e03110f4154c59b7de77f5bd379bdc,monotherapy,0.521234
uuid-d0e03110f4154c59b7de77f5bd379bdc,treatment,0.350844
uuid-d0e03110f4154c59b7de77f5bd379bdc,combo,0.406531
uuid-d0e03110f4154c59b7de77f5bd379bdc,PD1,0.362681
uuid-d0e03110f4154c59b7de77f5bd379bdc,progression,0.346277
uuid-d0e03110f4154c59b7de77f5bd379bdc,chemotherapy,0.605624
uuid-d0e03110f4154c59b7de77f5bd379bdc,feels,0.316662
uuid-d0e03110f4154c59b7de77f5bd379bdc,option,0.523051
uuid-3500a46c3198429a9105d229b9c98ab1,Nivo,0.398217
uuid-3500a46c3198429a9105d229b9c98ab1,patients,0.59093
uuid-3500a46c3198429a9105d229b9c98ab1,Opdivo,0.357771
uuid-3500a46c3198429a9105d229b9c98ab1,therapy,0.449816
uuid-3500a46c3198429a9105d229b9c98ab1,nivolumab,0.527642
uuid-3500a46c3198429a9105d229b9c98ab1,1L,0.440716
uuid-3500a46c3198429a9105d229b9c98ab1,regimen,0.567214
uuid-3500a46c3198429a9105d229b9c98ab1,treated,0.451251
uuid-3500a46c3198429a9105d229b9c98ab1,RCC,0.521544
uuid-3500a46c3198429a9105d229b9c98ab1,TL stated,0.30808
uuid-3500a46c3198429a9105d229b9c98ab1,combination,0.364285
uuid-3500a46c3198429a9105d229b9c98ab1,chemo,0.41707
uuid-3500a46c3198429a9105d229b9c98ab1,2L,0.573217
uuid-3500a46c3198429a9105d229b9c98ab1,pts,0.479112
uuid-3500a46c3198429a9105d229b9c98ab1,agents,0.302008
uuid-3500a46c3198429a9105d229b9c98ab1,preferred,0.501691
uuid-3500a46c3198429a9105d229b9c98ab1,monotherapy,0.580622
uuid-3500a46c3198429a9105d229b9c98ab1,treatment,0.574062
uuid-3500a46c3198429a9105d229b9c98ab1,using nivo,0.548117
uuid-3500a46c3198429a9105d229b9c98ab1,combo,0.422242
uuid-3500a46c3198429a9105d229b9c98ab1,PD1,0.407943
uuid-3500a46c3198429a9105d229b9c98ab1,approved,0.307164
uuid-3500a46c3198429a9105d229b9c98ab1,progression,0.498641
uuid-3500a46c3198429a9105d229b9c98ab1,chemotherapy,0.365171
uuid-3500a46c3198429a9105d229b9c98ab1,respond,0.344641
uuid-3500a46c3198429a9105d229b9c98ab1,RTL stated,0.492373
uuid-3500a46c3198429a9105d229b9c98ab1,TL shared,0.411191
uuid-3500a46c3198429a9105d229b9c98ab1,option,0.536911
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,BMS,0.39699
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,PDL1,0.354478
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,trial,0.365756
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,efficacy,0.335131
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,discussed,0.401748
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,commented,0.562931
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,Merck,0.372578
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,stated,0.310382
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,OS,0.508851
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,regards,0.515018
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,data,0.749559
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,expressed,0.438997
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,PFS,0.480519
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,ORR,0.51261
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,nivo and pembro,0.358828
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,ASCO,0.513012
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,impressed,0.597388
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,TLs,0.446764
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,Regional TL,0.334216
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,PDL1 expression,0.329545
uuid-782ddcb384bb4fe2a81a079d8aee5ccc,biomarker,0.302689
uuid-0e11d8c359354d7f9f2bee998cf985f8,Nivo,0.413545
uuid-0e11d8c359354d7f9f2bee998cf985f8,patients,0.722409
uuid-0e11d8c359354d7f9f2bee998cf985f8,Opdivo,0.391898
uuid-0e11d8c359354d7f9f2bee998cf985f8,pembro,0.322131
uuid-0e11d8c359354d7f9f2bee998cf985f8,therapy,0.500645
uuid-0e11d8c359354d7f9f2bee998cf985f8,nivolumab,0.538272
uuid-0e11d8c359354d7f9f2bee998cf985f8,1L,0.385947
uuid-0e11d8c359354d7f9f2bee998cf985f8,regimen,0.372533
uuid-0e11d8c359354d7f9f2bee998cf985f8,treated,0.41644
uuid-0e11d8c359354d7f9f2bee998cf985f8,chemo,0.33068
uuid-0e11d8c359354d7f9f2bee998cf985f8,2L,0.483319
uuid-0e11d8c359354d7f9f2bee998cf985f8,pts,0.40279
uuid-0e11d8c359354d7f9f2bee998cf985f8,approval,0.382743
uuid-0e11d8c359354d7f9f2bee998cf985f8,preferred,0.633199
uuid-0e11d8c359354d7f9f2bee998cf985f8,monotherapy,0.491865
uuid-0e11d8c359354d7f9f2bee998cf985f8,treatment,0.492708
uuid-0e11d8c359354d7f9f2bee998cf985f8,using nivo,0.66464
uuid-0e11d8c359354d7f9f2bee998cf985f8,approved,0.38805
uuid-0e11d8c359354d7f9f2bee998cf985f8,SCCHN,0.317115
uuid-0e11d8c359354d7f9f2bee998cf985f8,cHL,0.309014
uuid-0e11d8c359354d7f9f2bee998cf985f8,progression,0.328838
uuid-0e11d8c359354d7f9f2bee998cf985f8,chemotherapy,0.383985
uuid-0e11d8c359354d7f9f2bee998cf985f8,RTL stated,0.474194
uuid-0e11d8c359354d7f9f2bee998cf985f8,option,0.594389
uuid-86891a222fa54fbbb1b9bcf850a81f4f,patients,0.629908
uuid-86891a222fa54fbbb1b9bcf850a81f4f,therapy,0.414309
uuid-86891a222fa54fbbb1b9bcf850a81f4f,nivolumab,0.448967
uuid-86891a222fa54fbbb1b9bcf850a81f4f,trial,0.318699
uuid-86891a222fa54fbbb1b9bcf850a81f4f,treated,0.466424
uuid-86891a222fa54fbbb1b9bcf850a81f4f,pts,0.477974
uuid-86891a222fa54fbbb1b9bcf850a81f4f,approval,0.30004
uuid-86891a222fa54fbbb1b9bcf850a81f4f,treatment,0.411932
uuid-86891a222fa54fbbb1b9bcf850a81f4f,clinical trials,0.463836
uuid-86891a222fa54fbbb1b9bcf850a81f4f,progression,0.356144
uuid-86891a222fa54fbbb1b9bcf850a81f4f,chemotherapy,0.375139
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,1L,0.326493
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,combination,0.540279
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,chemo,0.366744
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,2L,0.30139
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,IO,0.406541
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,agents,0.677201
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,preferred,0.33429
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,monotherapy,0.40191
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,combo,0.541912
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,PD1,0.406492
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,believes,0.401155
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,chemotherapy,0.355801
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,PD-1,0.512048
uuid-a2abcd1e002c4d70a9b853ec7ed1f2b5,option,0.416239
uuid-82b3f76aa4554fbb97c02f245557f000,Nivo,0.302221
uuid-82b3f76aa4554fbb97c02f245557f000,patients,0.726981
uuid-82b3f76aa4554fbb97c02f245557f000,Opdivo,0.371162
uuid-82b3f76aa4554fbb97c02f245557f000,therapy,0.819401
uuid-82b3f76aa4554fbb97c02f245557f000,nivolumab,0.634329
uuid-82b3f76aa4554fbb97c02f245557f000,regimen,0.450349
uuid-82b3f76aa4554fbb97c02f245557f000,treated,0.606112
uuid-82b3f76aa4554fbb97c02f245557f000,chemo,0.322451
uuid-82b3f76aa4554fbb97c02f245557f000,pts,0.412303
uuid-82b3f76aa4554fbb97c02f245557f000,monotherapy,0.382838
uuid-82b3f76aa4554fbb97c02f245557f000,treatment,0.669167
uuid-82b3f76aa4554fbb97c02f245557f000,using nivo,0.325184
uuid-82b3f76aa4554fbb97c02f245557f000,response,0.465482
uuid-82b3f76aa4554fbb97c02f245557f000,PD1,0.473801
uuid-82b3f76aa4554fbb97c02f245557f000,cHL,0.642597
uuid-82b3f76aa4554fbb97c02f245557f000,progression,0.627883
uuid-82b3f76aa4554fbb97c02f245557f000,chemotherapy,0.466302
uuid-82b3f76aa4554fbb97c02f245557f000,respond,0.433354
uuid-80fabe5190b04abebf33e74e514547df,TL,0.399492
uuid-80fabe5190b04abebf33e74e514547df,1L,0.311982
uuid-80fabe5190b04abebf33e74e514547df,PDL1,0.571422
uuid-80fabe5190b04abebf33e74e514547df,TL stated,0.433577
uuid-80fabe5190b04abebf33e74e514547df,PD-L1,0.801817
uuid-80fabe5190b04abebf33e74e514547df,PD-L1 testing,0.726282
uuid-80fabe5190b04abebf33e74e514547df,testing,0.896312
uuid-80fabe5190b04abebf33e74e514547df,PDL1 testing,0.760118
uuid-80fabe5190b04abebf33e74e514547df,NSCLC patients,0.742842
uuid-80fabe5190b04abebf33e74e514547df,assay,0.602141
uuid-80fabe5190b04abebf33e74e514547df,PDL1 expression,0.378882
uuid-80fabe5190b04abebf33e74e514547df,biomarker,0.505603
uuid-b47150d84adc422fb05624f41d6041fd,pembro,0.300934
uuid-b47150d84adc422fb05624f41d6041fd,RTL,0.524656
uuid-b47150d84adc422fb05624f41d6041fd,trial,0.561389
uuid-b47150d84adc422fb05624f41d6041fd,commented,0.502655
uuid-b47150d84adc422fb05624f41d6041fd,RCC,0.322509
uuid-b47150d84adc422fb05624f41d6041fd,stated,0.442388
uuid-b47150d84adc422fb05624f41d6041fd,OS,0.339195
uuid-b47150d84adc422fb05624f41d6041fd,data,0.643229
uuid-b47150d84adc422fb05624f41d6041fd,combo,0.301427
uuid-b47150d84adc422fb05624f41d6041fd,expressed,0.306946
uuid-b47150d84adc422fb05624f41d6041fd,clinical trials,0.469945
uuid-b47150d84adc422fb05624f41d6041fd,PFS,0.30809
uuid-b47150d84adc422fb05624f41d6041fd,ORR,0.394501
uuid-b47150d84adc422fb05624f41d6041fd,SCCHN,0.474653
uuid-b47150d84adc422fb05624f41d6041fd,ASCO,0.357833
uuid-b47150d84adc422fb05624f41d6041fd,impressed,0.655926
uuid-b47150d84adc422fb05624f41d6041fd,LTL,0.40723
uuid-b47150d84adc422fb05624f41d6041fd,TLs,0.398966
uuid-b47150d84adc422fb05624f41d6041fd,SCLC,0.321051
uuid-b47150d84adc422fb05624f41d6041fd,feels,0.387272
uuid-b47150d84adc422fb05624f41d6041fd,Regional TL,0.494497
uuid-b47150d84adc422fb05624f41d6041fd,RTL stated,0.341067
uuid-b47150d84adc422fb05624f41d6041fd,bladder,0.454443
uuid-d6768df0304342e398c7f86168217b11,RTL,0.385597
uuid-d6768df0304342e398c7f86168217b11,NTL,0.470921
uuid-d6768df0304342e398c7f86168217b11,oncologist,0.339376
uuid-d6768df0304342e398c7f86168217b11,indicated,0.59643
uuid-d6768df0304342e398c7f86168217b11,Regional TL,0.361107
uuid-11ec05d4c9074d1ab510153a335cd16f,RTL,0.587468
uuid-11ec05d4c9074d1ab510153a335cd16f,trial,0.403843
uuid-11ec05d4c9074d1ab510153a335cd16f,NTL,0.656887
uuid-11ec05d4c9074d1ab510153a335cd16f,shared,0.31462
uuid-11ec05d4c9074d1ab510153a335cd16f,commented,0.318735
uuid-11ec05d4c9074d1ab510153a335cd16f,stated,0.306074
uuid-11ec05d4c9074d1ab510153a335cd16f,mentioned,0.4482
uuid-11ec05d4c9074d1ab510153a335cd16f,oncologist,0.343444
uuid-11ec05d4c9074d1ab510153a335cd16f,indicated,0.493642
uuid-11ec05d4c9074d1ab510153a335cd16f,LTL,0.404658
uuid-11ec05d4c9074d1ab510153a335cd16f,TLs,0.347306
uuid-11ec05d4c9074d1ab510153a335cd16f,Regional TL,0.560189
uuid-7ca0a363ff2d4332830be9bcfbd772e1,patients,0.870004
uuid-7ca0a363ff2d4332830be9bcfbd772e1,Opdivo,0.571677
uuid-7ca0a363ff2d4332830be9bcfbd772e1,therapy,0.555168
uuid-7ca0a363ff2d4332830be9bcfbd772e1,nivolumab,0.508681
uuid-7ca0a363ff2d4332830be9bcfbd772e1,regimen,0.381414
uuid-7ca0a363ff2d4332830be9bcfbd772e1,treated,0.584749
uuid-7ca0a363ff2d4332830be9bcfbd772e1,pts,0.522483
uuid-7ca0a363ff2d4332830be9bcfbd772e1,treatment,0.604274
uuid-7ca0a363ff2d4332830be9bcfbd772e1,using nivo,0.379019
uuid-7ca0a363ff2d4332830be9bcfbd772e1,cHL,0.390443
uuid-7ca0a363ff2d4332830be9bcfbd772e1,progression,0.588476
uuid-7ca0a363ff2d4332830be9bcfbd772e1,chemotherapy,0.332598
uuid-7ca0a363ff2d4332830be9bcfbd772e1,respond,0.391702
uuid-d98d2496db4443038755b4dbaf101f1e,TL,0.353961
uuid-d98d2496db4443038755b4dbaf101f1e,pembro,0.413417
uuid-d98d2496db4443038755b4dbaf101f1e,1L,0.377725
uuid-d98d2496db4443038755b4dbaf101f1e,PDL1,0.683183
uuid-d98d2496db4443038755b4dbaf101f1e,2L,0.316527
uuid-d98d2496db4443038755b4dbaf101f1e,Merck,0.310081
uuid-d98d2496db4443038755b4dbaf101f1e,PD-L1,0.610266
uuid-d98d2496db4443038755b4dbaf101f1e,atezo,0.473568
uuid-d98d2496db4443038755b4dbaf101f1e,PD-L1 testing,0.343802
uuid-d98d2496db4443038755b4dbaf101f1e,testing,0.497935
uuid-d98d2496db4443038755b4dbaf101f1e,data,0.345725
uuid-d98d2496db4443038755b4dbaf101f1e,PDL1 testing,0.396708
uuid-d98d2496db4443038755b4dbaf101f1e,NSCLC patients,0.352914
uuid-d98d2496db4443038755b4dbaf101f1e,nivo and pembro,0.387036
uuid-d98d2496db4443038755b4dbaf101f1e,believes,0.38036
uuid-d98d2496db4443038755b4dbaf101f1e,assay,0.494175
uuid-d98d2496db4443038755b4dbaf101f1e,PDL1 expression,0.584394
uuid-d98d2496db4443038755b4dbaf101f1e,biomarker,0.472497
uuid-d98d2496db4443038755b4dbaf101f1e,bladder,0.306137
uuid-4fe51e20326f4e408fd7c76be8184774,patients,0.452577
uuid-4fe51e20326f4e408fd7c76be8184774,nivolumab,0.401015
uuid-4fe51e20326f4e408fd7c76be8184774,1L,0.332629
uuid-4fe51e20326f4e408fd7c76be8184774,toxicity,0.448199
uuid-4fe51e20326f4e408fd7c76be8184774,regimen,0.548908
uuid-4fe51e20326f4e408fd7c76be8184774,treated,0.423275
uuid-4fe51e20326f4e408fd7c76be8184774,melanoma,0.326886
uuid-4fe51e20326f4e408fd7c76be8184774,RCC,0.524446
uuid-4fe51e20326f4e408fd7c76be8184774,TL stated,0.352575
uuid-4fe51e20326f4e408fd7c76be8184774,combination,0.32111
uuid-4fe51e20326f4e408fd7c76be8184774,2L,0.492744
uuid-4fe51e20326f4e408fd7c76be8184774,pts,0.309911
uuid-4fe51e20326f4e408fd7c76be8184774,preferred,0.527869
uuid-4fe51e20326f4e408fd7c76be8184774,monotherapy,0.501997
uuid-4fe51e20326f4e408fd7c76be8184774,treatment,0.345835
uuid-4fe51e20326f4e408fd7c76be8184774,using nivo,0.537615
uuid-4fe51e20326f4e408fd7c76be8184774,combo,0.373109
uuid-4fe51e20326f4e408fd7c76be8184774,SCCHN,0.366344
uuid-4fe51e20326f4e408fd7c76be8184774,RTL stated,0.518969
uuid-4fe51e20326f4e408fd7c76be8184774,TL shared,0.473252
uuid-4fe51e20326f4e408fd7c76be8184774,option,0.388477
uuid-4fe51e20326f4e408fd7c76be8184774,bladder,0.422039
uuid-41745802ee1b45278d1b56abeefd5e2f,TL,0.59004
uuid-41745802ee1b45278d1b56abeefd5e2f,institution,0.498657
uuid-41745802ee1b45278d1b56abeefd5e2f,PD-L1,0.733772
uuid-41745802ee1b45278d1b56abeefd5e2f,approval,0.334655
uuid-41745802ee1b45278d1b56abeefd5e2f,PD-L1 testing,0.884854
uuid-41745802ee1b45278d1b56abeefd5e2f,testing,0.793933
uuid-41745802ee1b45278d1b56abeefd5e2f,PDL1 testing,0.532555
uuid-41745802ee1b45278d1b56abeefd5e2f,NSCLC patients,0.539818
uuid-41745802ee1b45278d1b56abeefd5e2f,assay,0.761131
uuid-9a4850f261af4c7eac12f2b6844c6a5c,RTL,0.394605
uuid-9a4850f261af4c7eac12f2b6844c6a5c,nivolumab,0.306829
uuid-9a4850f261af4c7eac12f2b6844c6a5c,trial,0.498046
uuid-9a4850f261af4c7eac12f2b6844c6a5c,treated,0.461598
uuid-9a4850f261af4c7eac12f2b6844c6a5c,commented,0.325277
uuid-9a4850f261af4c7eac12f2b6844c6a5c,clinical trials,0.492806
uuid-9a4850f261af4c7eac12f2b6844c6a5c,SCCHN,0.346042
uuid-9a4850f261af4c7eac12f2b6844c6a5c,impressed,0.372711
uuid-9a4850f261af4c7eac12f2b6844c6a5c,Regional TL,0.457545
uuid-9a4850f261af4c7eac12f2b6844c6a5c,RTL stated,0.300958
uuid-9a4850f261af4c7eac12f2b6844c6a5c,bladder,0.405688
uuid-6f4f9d8070a94e7d8de2776622333bf1,patients,0.454882
uuid-6f4f9d8070a94e7d8de2776622333bf1,Opdivo,0.382134
uuid-6f4f9d8070a94e7d8de2776622333bf1,nivolumab,0.35668
uuid-6f4f9d8070a94e7d8de2776622333bf1,toxicity,0.369301
uuid-6f4f9d8070a94e7d8de2776622333bf1,regimen,0.409019
uuid-6f4f9d8070a94e7d8de2776622333bf1,treated,0.50846
uuid-6f4f9d8070a94e7d8de2776622333bf1,RCC,0.422285
uuid-6f4f9d8070a94e7d8de2776622333bf1,2L,0.391519
uuid-6f4f9d8070a94e7d8de2776622333bf1,physicians,0.308825
uuid-6f4f9d8070a94e7d8de2776622333bf1,preferred,0.578265
uuid-6f4f9d8070a94e7d8de2776622333bf1,monotherapy,0.366149
uuid-6f4f9d8070a94e7d8de2776622333bf1,treatment,0.46517
uuid-6f4f9d8070a94e7d8de2776622333bf1,using nivo,0.456909
uuid-6f4f9d8070a94e7d8de2776622333bf1,RTL stated,0.48268
uuid-6f4f9d8070a94e7d8de2776622333bf1,TL shared,0.420439
uuid-6f4f9d8070a94e7d8de2776622333bf1,option,0.409422
uuid-bd2579e747f14ba78e093561befa309d,TL stated,0.423181
uuid-bd2579e747f14ba78e093561befa309d,PD-L1,0.523664
uuid-bd2579e747f14ba78e093561befa309d,PD-L1 testing,0.418421
uuid-bd2579e747f14ba78e093561befa309d,testing,0.715666
uuid-bd2579e747f14ba78e093561befa309d,PDL1 testing,0.685327
uuid-bd2579e747f14ba78e093561befa309d,NSCLC patients,0.784329
uuid-bd2579e747f14ba78e093561befa309d,tumor types,0.446615
uuid-bd2579e747f14ba78e093561befa309d,PD-1,0.314757
uuid-bd2579e747f14ba78e093561befa309d,biomarker,0.379195
uuid-49e5b3192c96498aaf0878addae04957,patients,0.853682
uuid-49e5b3192c96498aaf0878addae04957,Opdivo,0.538396
uuid-49e5b3192c96498aaf0878addae04957,therapy,0.453978
uuid-49e5b3192c96498aaf0878addae04957,dose,0.470948
uuid-49e5b3192c96498aaf0878addae04957,nivolumab,0.495302
uuid-49e5b3192c96498aaf0878addae04957,toxicity,0.390616
uuid-49e5b3192c96498aaf0878addae04957,regimen,0.58889
uuid-49e5b3192c96498aaf0878addae04957,treated,0.646181
uuid-49e5b3192c96498aaf0878addae04957,chemo,0.317944
uuid-49e5b3192c96498aaf0878addae04957,pts,0.552571
uuid-49e5b3192c96498aaf0878addae04957,preferred,0.323497
uuid-49e5b3192c96498aaf0878addae04957,monotherapy,0.382675
uuid-49e5b3192c96498aaf0878addae04957,treatment,0.647477
uuid-49e5b3192c96498aaf0878addae04957,using nivo,0.350581
uuid-49e5b3192c96498aaf0878addae04957,progression,0.545731
uuid-49e5b3192c96498aaf0878addae04957,chemotherapy,0.328313
uuid-49e5b3192c96498aaf0878addae04957,respond,0.473236
uuid-49e5b3192c96498aaf0878addae04957,option,0.360649
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,Nivo,0.636957
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,pembro,0.50457
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,dose,0.485233
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,nivolumab,0.402364
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,efficacy,0.318937
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,regimen,0.392289
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,combination,0.42396
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,2L,0.382668
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,Ipi,0.605934
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,atezo,0.417274
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,preferred,0.45765
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,monotherapy,0.43237
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,using nivo,0.501422
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,combo,0.379459
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,indication,0.315885
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,approved,0.329802
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,vs,0.438342
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,SCLC,0.349587
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,RTL stated,0.353698
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,option,0.384031
uuid-a3d65bf515e54c7ca6f97b7eadc4b2e5,flat dosing,0.309923
uuid-b94e552c20bd46ef9ddf1075bb3de418,Nivo,0.48215
uuid-b94e552c20bd46ef9ddf1075bb3de418,pembro,0.551905
uuid-b94e552c20bd46ef9ddf1075bb3de418,dose,0.309512
uuid-b94e552c20bd46ef9ddf1075bb3de418,1L,0.309961
uuid-b94e552c20bd46ef9ddf1075bb3de418,efficacy,0.520252
uuid-b94e552c20bd46ef9ddf1075bb3de418,2L,0.425197
uuid-b94e552c20bd46ef9ddf1075bb3de418,agents,0.360321
uuid-b94e552c20bd46ef9ddf1075bb3de418,Ipi,0.320561
uuid-b94e552c20bd46ef9ddf1075bb3de418,atezo,0.597577
uuid-b94e552c20bd46ef9ddf1075bb3de418,preferred,0.436419
uuid-b94e552c20bd46ef9ddf1075bb3de418,monotherapy,0.313878
uuid-b94e552c20bd46ef9ddf1075bb3de418,using nivo,0.350601
uuid-b94e552c20bd46ef9ddf1075bb3de418,data,0.358031
uuid-b94e552c20bd46ef9ddf1075bb3de418,clinical trials,0.338983
uuid-b94e552c20bd46ef9ddf1075bb3de418,indication,0.451395
uuid-b94e552c20bd46ef9ddf1075bb3de418,approved,0.449857
uuid-b94e552c20bd46ef9ddf1075bb3de418,nivo and pembro,0.341855
uuid-b94e552c20bd46ef9ddf1075bb3de418,impressed,0.30114
uuid-b94e552c20bd46ef9ddf1075bb3de418,vs,0.478279
uuid-b94e552c20bd46ef9ddf1075bb3de418,TLs,0.419609
uuid-b94e552c20bd46ef9ddf1075bb3de418,feels,0.331022
uuid-b94e552c20bd46ef9ddf1075bb3de418,flat dosing,0.393437
uuid-03e6674d40794362be370720958d8850,TL,0.339386
uuid-03e6674d40794362be370720958d8850,lung,0.33117
uuid-03e6674d40794362be370720958d8850,1L,0.399733
uuid-03e6674d40794362be370720958d8850,RCC,0.369277
uuid-03e6674d40794362be370720958d8850,TL stated,0.605066
uuid-03e6674d40794362be370720958d8850,2L,0.376924
uuid-03e6674d40794362be370720958d8850,institution,0.42982
uuid-03e6674d40794362be370720958d8850,PD-L1,0.546193
uuid-03e6674d40794362be370720958d8850,approval,0.370012
uuid-03e6674d40794362be370720958d8850,preferred,0.34173
uuid-03e6674d40794362be370720958d8850,PD-L1 testing,0.645588
uuid-03e6674d40794362be370720958d8850,testing,0.760822
uuid-03e6674d40794362be370720958d8850,using nivo,0.305151
uuid-03e6674d40794362be370720958d8850,PDL1 testing,0.813211
uuid-03e6674d40794362be370720958d8850,NSCLC patients,0.722116
uuid-03e6674d40794362be370720958d8850,SCCHN,0.358869
uuid-03e6674d40794362be370720958d8850,tumor types,0.4151
uuid-03e6674d40794362be370720958d8850,assay,0.35472
uuid-03e6674d40794362be370720958d8850,RTL stated,0.422809
uuid-03e6674d40794362be370720958d8850,TL shared,0.342474
uuid-610afdce51ef43fb889a7134a5ec4d29,pembro,0.364436
uuid-610afdce51ef43fb889a7134a5ec4d29,RTL,0.365963
uuid-610afdce51ef43fb889a7134a5ec4d29,PDL1,0.314508
uuid-610afdce51ef43fb889a7134a5ec4d29,trial,0.540016
uuid-610afdce51ef43fb889a7134a5ec4d29,efficacy,0.364473
uuid-610afdce51ef43fb889a7134a5ec4d29,NTL,0.306318
uuid-610afdce51ef43fb889a7134a5ec4d29,OS,0.355798
uuid-610afdce51ef43fb889a7134a5ec4d29,data,0.389617
uuid-610afdce51ef43fb889a7134a5ec4d29,clinical trials,0.308943
uuid-610afdce51ef43fb889a7134a5ec4d29,PFS,0.367382
uuid-610afdce51ef43fb889a7134a5ec4d29,ORR,0.432113
uuid-610afdce51ef43fb889a7134a5ec4d29,impressed,0.369964
uuid-610afdce51ef43fb889a7134a5ec4d29,feels,0.324802
uuid-610afdce51ef43fb889a7134a5ec4d29,PDL1 expression,0.359995
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,patients,0.44819
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,1L,0.314938
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,treated,0.483149
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,RCC,0.370448
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,TL stated,0.523527
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,2L,0.306155
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,PD-L1,0.349312
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,preferred,0.30954
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,PD-L1 testing,0.508777
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,testing,0.580845
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,treatment,0.324535
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,PDL1 testing,0.671843
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,NSCLC patients,0.673315
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,lung cancer,0.355572
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,tumor types,0.390712
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,oncologist,0.313637
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,RTL stated,0.390355
uuid-7e9561a3d18b48f7b1d15bb64fc6339c,TL shared,0.374228
uuid-5c2ce75dec2241b9908ca0c61a8665ec,PD-L1,0.342406
uuid-5c2ce75dec2241b9908ca0c61a8665ec,testing,0.429714
uuid-5c2ce75dec2241b9908ca0c61a8665ec,PDL1 testing,0.413045
uuid-5c2ce75dec2241b9908ca0c61a8665ec,NSCLC patients,0.642646
uuid-5c2ce75dec2241b9908ca0c61a8665ec,tumor types,0.361256
uuid-5c2ce75dec2241b9908ca0c61a8665ec,PD-1,0.347764
uuid-8a13ee9d556a40f4923a01e85cb678ba,pembro,0.457581
uuid-8a13ee9d556a40f4923a01e85cb678ba,RTL,0.360712
uuid-8a13ee9d556a40f4923a01e85cb678ba,dose,0.664014
uuid-8a13ee9d556a40f4923a01e85cb678ba,NTL,0.344323
uuid-8a13ee9d556a40f4923a01e85cb678ba,shared,0.320066
uuid-8a13ee9d556a40f4923a01e85cb678ba,Ipi,0.43028
uuid-8a13ee9d556a40f4923a01e85cb678ba,approval,0.332314
uuid-8a13ee9d556a40f4923a01e85cb678ba,atezo,0.42945
uuid-8a13ee9d556a40f4923a01e85cb678ba,using nivo,0.317047
uuid-8a13ee9d556a40f4923a01e85cb678ba,mentioned,0.369084
uuid-8a13ee9d556a40f4923a01e85cb678ba,approved,0.30003
uuid-8a13ee9d556a40f4923a01e85cb678ba,SCCHN,0.310943
uuid-8a13ee9d556a40f4923a01e85cb678ba,HCP,0.349824
uuid-8a13ee9d556a40f4923a01e85cb678ba,vs,0.462235
uuid-8a13ee9d556a40f4923a01e85cb678ba,LTL,0.330095
uuid-8a13ee9d556a40f4923a01e85cb678ba,Keytruda,0.307312
uuid-8a13ee9d556a40f4923a01e85cb678ba,TLs,0.317699
uuid-8a13ee9d556a40f4923a01e85cb678ba,flat dosing,0.68617
uuid-792add2500674452a1de873845a8b5e9,Nivo,0.308682
uuid-792add2500674452a1de873845a8b5e9,patients,0.563716
uuid-792add2500674452a1de873845a8b5e9,therapy,0.455219
uuid-792add2500674452a1de873845a8b5e9,1L,0.32214
uuid-792add2500674452a1de873845a8b5e9,regimen,0.406975
uuid-792add2500674452a1de873845a8b5e9,combination,0.327506
uuid-792add2500674452a1de873845a8b5e9,chemo,0.586698
uuid-792add2500674452a1de873845a8b5e9,2L,0.305888
uuid-792add2500674452a1de873845a8b5e9,pts,0.429884
uuid-792add2500674452a1de873845a8b5e9,IO,0.348602
uuid-792add2500674452a1de873845a8b5e9,monotherapy,0.474471
uuid-792add2500674452a1de873845a8b5e9,treatment,0.395912
uuid-792add2500674452a1de873845a8b5e9,response,0.417377
uuid-792add2500674452a1de873845a8b5e9,combo,0.317029
uuid-792add2500674452a1de873845a8b5e9,PD1,0.349264
uuid-792add2500674452a1de873845a8b5e9,progression,0.501769
uuid-792add2500674452a1de873845a8b5e9,believes,0.309182
uuid-792add2500674452a1de873845a8b5e9,chemotherapy,0.530244
uuid-792add2500674452a1de873845a8b5e9,respond,0.409869
uuid-792add2500674452a1de873845a8b5e9,option,0.444055
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,patients,0.304147
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,TL,0.444791
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,lung,0.36891
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,treated,0.358938
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,RCC,0.439003
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,TL stated,0.572748
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,PD-L1,0.36542
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,approval,0.418438
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,PD-L1 testing,0.529187
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,testing,0.519459
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,using nivo,0.326032
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,PDL1 testing,0.540499
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,NSCLC patients,0.581055
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,SCCHN,0.463521
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,tumor types,0.317768
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,oncologist,0.319345
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,Regional TL,0.384902
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,RTL stated,0.382486
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,TL shared,0.427362
uuid-679735fb563f4cc0b5ffe4ab9bcf85ae,bladder,0.346439
uuid-8641483341924c12868d2110cc53856d,Nivo,0.336337
uuid-8641483341924c12868d2110cc53856d,pembro,0.420085
uuid-8641483341924c12868d2110cc53856d,dose,0.419741
uuid-8641483341924c12868d2110cc53856d,1L,0.409171
uuid-8641483341924c12868d2110cc53856d,2L,0.52229
uuid-8641483341924c12868d2110cc53856d,agents,0.430598
uuid-8641483341924c12868d2110cc53856d,atezo,0.559326
uuid-8641483341924c12868d2110cc53856d,preferred,0.600871
uuid-8641483341924c12868d2110cc53856d,monotherapy,0.366797
uuid-8641483341924c12868d2110cc53856d,indication,0.444129
uuid-8641483341924c12868d2110cc53856d,approved,0.448204
uuid-8641483341924c12868d2110cc53856d,vs,0.301413
uuid-8641483341924c12868d2110cc53856d,drug,0.413639
uuid-8641483341924c12868d2110cc53856d,Keytruda,0.52812
uuid-8641483341924c12868d2110cc53856d,option,0.476076
uuid-8641483341924c12868d2110cc53856d,flat dosing,0.425303
uuid-cc7c5988daff4be5b16d8b614b671e7d,Nivo,0.414512
uuid-cc7c5988daff4be5b16d8b614b671e7d,Opdivo,0.347487
uuid-cc7c5988daff4be5b16d8b614b671e7d,pembro,0.500841
uuid-cc7c5988daff4be5b16d8b614b671e7d,dose,0.799573
uuid-cc7c5988daff4be5b16d8b614b671e7d,Ipi,0.537888
uuid-cc7c5988daff4be5b16d8b614b671e7d,atezo,0.516756
uuid-cc7c5988daff4be5b16d8b614b671e7d,vs,0.642551
uuid-cc7c5988daff4be5b16d8b614b671e7d,Keytruda,0.360419
uuid-cc7c5988daff4be5b16d8b614b671e7d,flat dosing,0.693242
uuid-d20d9350e1974deaa934054ab4b9b188,patients,0.605248
uuid-d20d9350e1974deaa934054ab4b9b188,RTL,0.342639
uuid-d20d9350e1974deaa934054ab4b9b188,nivolumab,0.458265
uuid-d20d9350e1974deaa934054ab4b9b188,toxicity,0.435764
uuid-d20d9350e1974deaa934054ab4b9b188,regimen,0.570069
uuid-d20d9350e1974deaa934054ab4b9b188,treated,0.479455
uuid-d20d9350e1974deaa934054ab4b9b188,RCC,0.313098
uuid-d20d9350e1974deaa934054ab4b9b188,combination,0.373664
uuid-d20d9350e1974deaa934054ab4b9b188,pts,0.517739
uuid-d20d9350e1974deaa934054ab4b9b188,monotherapy,0.453288
uuid-d20d9350e1974deaa934054ab4b9b188,treatment,0.394218
uuid-d20d9350e1974deaa934054ab4b9b188,using nivo,0.35726
uuid-d20d9350e1974deaa934054ab4b9b188,combo,0.360355
uuid-d20d9350e1974deaa934054ab4b9b188,SCCHN,0.312038
uuid-d20d9350e1974deaa934054ab4b9b188,progression,0.442898
uuid-d20d9350e1974deaa934054ab4b9b188,respond,0.341544
uuid-d20d9350e1974deaa934054ab4b9b188,SCLC,0.390785
uuid-d20d9350e1974deaa934054ab4b9b188,RTL stated,0.40933
uuid-d20d9350e1974deaa934054ab4b9b188,TL shared,0.352902
uuid-d20d9350e1974deaa934054ab4b9b188,option,0.317289
uuid-7ca82ce27c96408c974f61bf03947059,1L,0.572476
uuid-7ca82ce27c96408c974f61bf03947059,toxicity,0.440663
uuid-7ca82ce27c96408c974f61bf03947059,regimen,0.464201
uuid-7ca82ce27c96408c974f61bf03947059,RCC,0.404564
uuid-7ca82ce27c96408c974f61bf03947059,combination,0.701529
uuid-7ca82ce27c96408c974f61bf03947059,chemo,0.587725
uuid-7ca82ce27c96408c974f61bf03947059,2L,0.556329
uuid-7ca82ce27c96408c974f61bf03947059,IO,0.487661
uuid-7ca82ce27c96408c974f61bf03947059,agents,0.682444
uuid-7ca82ce27c96408c974f61bf03947059,preferred,0.473724
uuid-7ca82ce27c96408c974f61bf03947059,monotherapy,0.73866
uuid-7ca82ce27c96408c974f61bf03947059,combo,0.779858
uuid-7ca82ce27c96408c974f61bf03947059,PD1,0.576825
uuid-7ca82ce27c96408c974f61bf03947059,believes,0.496936
uuid-7ca82ce27c96408c974f61bf03947059,chemotherapy,0.468222
uuid-7ca82ce27c96408c974f61bf03947059,feels,0.367805
uuid-7ca82ce27c96408c974f61bf03947059,PD-1,0.378813
uuid-7ca82ce27c96408c974f61bf03947059,RTL stated,0.343151
uuid-7ca82ce27c96408c974f61bf03947059,option,0.574101
uuid-ddec3562309046f78417113a86d6f8d9,Nivo,0.707914
uuid-ddec3562309046f78417113a86d6f8d9,pembro,0.654646
uuid-ddec3562309046f78417113a86d6f8d9,dose,0.462113
uuid-ddec3562309046f78417113a86d6f8d9,1L,0.410241
uuid-ddec3562309046f78417113a86d6f8d9,efficacy,0.427715
uuid-ddec3562309046f78417113a86d6f8d9,chemo,0.33183
uuid-ddec3562309046f78417113a86d6f8d9,2L,0.527618
uuid-ddec3562309046f78417113a86d6f8d9,agents,0.393435
uuid-ddec3562309046f78417113a86d6f8d9,Ipi,0.441544
uuid-ddec3562309046f78417113a86d6f8d9,atezo,0.596741
uuid-ddec3562309046f78417113a86d6f8d9,preferred,0.549426
uuid-ddec3562309046f78417113a86d6f8d9,monotherapy,0.47176
uuid-ddec3562309046f78417113a86d6f8d9,using nivo,0.495524
uuid-ddec3562309046f78417113a86d6f8d9,combo,0.335888
uuid-ddec3562309046f78417113a86d6f8d9,indication,0.384226
uuid-ddec3562309046f78417113a86d6f8d9,approved,0.443518
uuid-ddec3562309046f78417113a86d6f8d9,nivo and pembro,0.333879
uuid-ddec3562309046f78417113a86d6f8d9,vs,0.578076
uuid-ddec3562309046f78417113a86d6f8d9,feels,0.398791
uuid-ddec3562309046f78417113a86d6f8d9,option,0.573001
uuid-ddec3562309046f78417113a86d6f8d9,flat dosing,0.339929
uuid-91adee72ed8047b8a41c6b056e027e3c,1L,0.354386
uuid-91adee72ed8047b8a41c6b056e027e3c,PDL1,0.535277
uuid-91adee72ed8047b8a41c6b056e027e3c,TL stated,0.477051
uuid-91adee72ed8047b8a41c6b056e027e3c,PD-L1,0.719933
uuid-91adee72ed8047b8a41c6b056e027e3c,PD-L1 testing,0.579529
uuid-91adee72ed8047b8a41c6b056e027e3c,testing,0.830271
uuid-91adee72ed8047b8a41c6b056e027e3c,PDL1 testing,0.780342
uuid-91adee72ed8047b8a41c6b056e027e3c,NSCLC patients,0.797701
uuid-91adee72ed8047b8a41c6b056e027e3c,tumor types,0.369594
uuid-91adee72ed8047b8a41c6b056e027e3c,assay,0.40813
uuid-91adee72ed8047b8a41c6b056e027e3c,PDL1 expression,0.365896
uuid-91adee72ed8047b8a41c6b056e027e3c,biomarker,0.538373
uuid-6bdb1519b90748dca041ca10476c1801,institution,0.341061
uuid-6bdb1519b90748dca041ca10476c1801,regards,0.356112
uuid-6bdb1519b90748dca041ca10476c1801,indication,0.303352
uuid-6bdb1519b90748dca041ca10476c1801,AI,0.533798
uuid-6bdb1519b90748dca041ca10476c1801,oncology,0.379698
uuid-6bdb1519b90748dca041ca10476c1801,drug,0.36133
uuid-6bdb1519b90748dca041ca10476c1801,NCCN,0.484761
uuid-6bdb1519b90748dca041ca10476c1801,flat dosing,0.440294
uuid-b921f8a6bce546a7a9276c14d3d02fbd,RTL,0.440293
uuid-b921f8a6bce546a7a9276c14d3d02fbd,BMS,0.50658
uuid-b921f8a6bce546a7a9276c14d3d02fbd,trial,0.42176
uuid-b921f8a6bce546a7a9276c14d3d02fbd,NTL,0.387306
uuid-b921f8a6bce546a7a9276c14d3d02fbd,shared,0.314923
uuid-b921f8a6bce546a7a9276c14d3d02fbd,commented,0.593421
uuid-b921f8a6bce546a7a9276c14d3d02fbd,Merck,0.406292
uuid-b921f8a6bce546a7a9276c14d3d02fbd,stated,0.600447
uuid-b921f8a6bce546a7a9276c14d3d02fbd,approval,0.385422
uuid-b921f8a6bce546a7a9276c14d3d02fbd,regards,0.408945
uuid-b921f8a6bce546a7a9276c14d3d02fbd,data,0.507604
uuid-b921f8a6bce546a7a9276c14d3d02fbd,expressed,0.368459
uuid-b921f8a6bce546a7a9276c14d3d02fbd,clinical trials,0.413537
uuid-b921f8a6bce546a7a9276c14d3d02fbd,indication,0.338669
uuid-b921f8a6bce546a7a9276c14d3d02fbd,approved,0.308799
uuid-b921f8a6bce546a7a9276c14d3d02fbd,SCCHN,0.472602
uuid-b921f8a6bce546a7a9276c14d3d02fbd,ASCO,0.3414
uuid-b921f8a6bce546a7a9276c14d3d02fbd,impressed,0.461201
uuid-b921f8a6bce546a7a9276c14d3d02fbd,label,0.362444
uuid-b921f8a6bce546a7a9276c14d3d02fbd,SCLC,0.315212
uuid-b921f8a6bce546a7a9276c14d3d02fbd,Regional TL,0.429569
uuid-b921f8a6bce546a7a9276c14d3d02fbd,NCCN,0.431213
uuid-b921f8a6bce546a7a9276c14d3d02fbd,bladder,0.311112
uuid-d31cc260ba544c0fa4c638b233e9a703,Nivo,0.346298
uuid-d31cc260ba544c0fa4c638b233e9a703,pembro,0.379194
uuid-d31cc260ba544c0fa4c638b233e9a703,1L,0.423678
uuid-d31cc260ba544c0fa4c638b233e9a703,PDL1,0.40509
uuid-d31cc260ba544c0fa4c638b233e9a703,trial,0.529903
uuid-d31cc260ba544c0fa4c638b233e9a703,efficacy,0.566393
uuid-d31cc260ba544c0fa4c638b233e9a703,combination,0.479885
uuid-d31cc260ba544c0fa4c638b233e9a703,chemo,0.465134
uuid-d31cc260ba544c0fa4c638b233e9a703,IO,0.367593
uuid-d31cc260ba544c0fa4c638b233e9a703,agents,0.3365
uuid-d31cc260ba544c0fa4c638b233e9a703,Ipi,0.36242
uuid-d31cc260ba544c0fa4c638b233e9a703,OS,0.491242
uuid-d31cc260ba544c0fa4c638b233e9a703,atezo,0.317843
uuid-d31cc260ba544c0fa4c638b233e9a703,monotherapy,0.468218
uuid-d31cc260ba544c0fa4c638b233e9a703,data,0.521717
uuid-d31cc260ba544c0fa4c638b233e9a703,combo,0.583453
uuid-d31cc260ba544c0fa4c638b233e9a703,PFS,0.466562
uuid-d31cc260ba544c0fa4c638b233e9a703,PD1,0.337735
uuid-d31cc260ba544c0fa4c638b233e9a703,ORR,0.550848
uuid-d31cc260ba544c0fa4c638b233e9a703,nivo and pembro,0.477365
uuid-d31cc260ba544c0fa4c638b233e9a703,believes,0.571977
uuid-d31cc260ba544c0fa4c638b233e9a703,chemotherapy,0.375416
uuid-d31cc260ba544c0fa4c638b233e9a703,impressed,0.389147
uuid-d31cc260ba544c0fa4c638b233e9a703,feels,0.472329
uuid-d31cc260ba544c0fa4c638b233e9a703,PDL1 expression,0.367085
uuid-d31cc260ba544c0fa4c638b233e9a703,option,0.329208
uuid-487baddc4e16461092bf2de24a14703e,patients,0.461819
uuid-487baddc4e16461092bf2de24a14703e,toxicity,0.577676
uuid-487baddc4e16461092bf2de24a14703e,regimen,0.509217
uuid-487baddc4e16461092bf2de24a14703e,treated,0.444658
uuid-487baddc4e16461092bf2de24a14703e,combination,0.341616
uuid-487baddc4e16461092bf2de24a14703e,pts,0.33955
uuid-487baddc4e16461092bf2de24a14703e,monotherapy,0.309674
uuid-487baddc4e16461092bf2de24a14703e,treatment,0.385279
uuid-487baddc4e16461092bf2de24a14703e,combo,0.356463
uuid-487baddc4e16461092bf2de24a14703e,progression,0.356125
uuid-7bc43fec9fc94ebe93b6e84542e2213b,agents,0.306864
uuid-7bc43fec9fc94ebe93b6e84542e2213b,preferred,0.377773
uuid-7bc43fec9fc94ebe93b6e84542e2213b,oncology,0.474712
uuid-7bc43fec9fc94ebe93b6e84542e2213b,drug,0.432909
uuid-7bc43fec9fc94ebe93b6e84542e2213b,clinical,0.430583
uuid-54a1f7a203034e4eb78e9d928fb57553,pembro,0.35936
uuid-54a1f7a203034e4eb78e9d928fb57553,BMS,0.570476
uuid-54a1f7a203034e4eb78e9d928fb57553,PDL1,0.457827
uuid-54a1f7a203034e4eb78e9d928fb57553,trial,0.715269
uuid-54a1f7a203034e4eb78e9d928fb57553,efficacy,0.419559
uuid-54a1f7a203034e4eb78e9d928fb57553,commented,0.393137
uuid-54a1f7a203034e4eb78e9d928fb57553,Merck,0.433404
uuid-54a1f7a203034e4eb78e9d928fb57553,stated,0.326811
uuid-54a1f7a203034e4eb78e9d928fb57553,OS,0.607539
uuid-54a1f7a203034e4eb78e9d928fb57553,data,0.814908
uuid-54a1f7a203034e4eb78e9d928fb57553,expressed,0.343766
uuid-54a1f7a203034e4eb78e9d928fb57553,clinical trials,0.334378
uuid-54a1f7a203034e4eb78e9d928fb57553,PFS,0.596861
uuid-54a1f7a203034e4eb78e9d928fb57553,ORR,0.653561
uuid-54a1f7a203034e4eb78e9d928fb57553,nivo and pembro,0.456203
uuid-54a1f7a203034e4eb78e9d928fb57553,impressed,0.621661
uuid-54a1f7a203034e4eb78e9d928fb57553,feels,0.389625
uuid-54a1f7a203034e4eb78e9d928fb57553,PDL1 expression,0.443536
uuid-91f743ef7fa94259954733106d9f451c,PDL1,0.334849
uuid-91f743ef7fa94259954733106d9f451c,efficacy,0.358484
uuid-91f743ef7fa94259954733106d9f451c,tumor,0.336985
uuid-91f743ef7fa94259954733106d9f451c,response,0.303249
uuid-91f743ef7fa94259954733106d9f451c,PDL1 expression,0.386357
uuid-91f743ef7fa94259954733106d9f451c,biomarker,0.412501
uuid-5501ef17b5dd435b974aa62fea4c202f,TL shared,0.32035
uuid-5501ef17b5dd435b974aa62fea4c202f,biomarker,0.355401
uuid-30043d8c55a94dddbc9aa811bab806fa,Nivo,0.593368
uuid-30043d8c55a94dddbc9aa811bab806fa,pembro,0.735768
uuid-30043d8c55a94dddbc9aa811bab806fa,dose,0.476111
uuid-30043d8c55a94dddbc9aa811bab806fa,1L,0.500657
uuid-30043d8c55a94dddbc9aa811bab806fa,efficacy,0.366001
uuid-30043d8c55a94dddbc9aa811bab806fa,combination,0.321219
uuid-30043d8c55a94dddbc9aa811bab806fa,chemo,0.35235
uuid-30043d8c55a94dddbc9aa811bab806fa,2L,0.659885
uuid-30043d8c55a94dddbc9aa811bab806fa,agents,0.518129
uuid-30043d8c55a94dddbc9aa811bab806fa,Ipi,0.40796
uuid-30043d8c55a94dddbc9aa811bab806fa,atezo,0.764914
uuid-30043d8c55a94dddbc9aa811bab806fa,preferred,0.672447
uuid-30043d8c55a94dddbc9aa811bab806fa,monotherapy,0.547253
uuid-30043d8c55a94dddbc9aa811bab806fa,using nivo,0.496366
uuid-30043d8c55a94dddbc9aa811bab806fa,combo,0.36968
uuid-30043d8c55a94dddbc9aa811bab806fa,indication,0.313686
uuid-30043d8c55a94dddbc9aa811bab806fa,approved,0.350889
uuid-30043d8c55a94dddbc9aa811bab806fa,nivo and pembro,0.459677
uuid-30043d8c55a94dddbc9aa811bab806fa,believes,0.330311
uuid-30043d8c55a94dddbc9aa811bab806fa,vs,0.59149
uuid-30043d8c55a94dddbc9aa811bab806fa,feels,0.344593
uuid-30043d8c55a94dddbc9aa811bab806fa,RTL stated,0.377036
uuid-30043d8c55a94dddbc9aa811bab806fa,option,0.49535
uuid-4403a1d80c79405c8c5b49bb66a83293,patients,0.657676
uuid-4403a1d80c79405c8c5b49bb66a83293,therapy,0.503347
uuid-4403a1d80c79405c8c5b49bb66a83293,toxicity,0.301808
uuid-4403a1d80c79405c8c5b49bb66a83293,regimen,0.347992
uuid-4403a1d80c79405c8c5b49bb66a83293,treated,0.363548
uuid-4403a1d80c79405c8c5b49bb66a83293,pts,0.49922
uuid-4403a1d80c79405c8c5b49bb66a83293,treatment,0.592212
uuid-4403a1d80c79405c8c5b49bb66a83293,response,0.508255
uuid-4403a1d80c79405c8c5b49bb66a83293,progression,0.69395
uuid-4403a1d80c79405c8c5b49bb66a83293,respond,0.56169
uuid-e1c65cb0bc354250bba0a9e044b98d00,combination,0.533485
uuid-e1c65cb0bc354250bba0a9e044b98d00,chemo,0.394782
uuid-e1c65cb0bc354250bba0a9e044b98d00,tumor,0.324609
uuid-e1c65cb0bc354250bba0a9e044b98d00,pts,0.347409
uuid-e1c65cb0bc354250bba0a9e044b98d00,IO,0.396238
uuid-e1c65cb0bc354250bba0a9e044b98d00,monotherapy,0.323187
uuid-e1c65cb0bc354250bba0a9e044b98d00,response,0.424033
uuid-e1c65cb0bc354250bba0a9e044b98d00,combo,0.445941
uuid-e1c65cb0bc354250bba0a9e044b98d00,PD1,0.366578
uuid-e1c65cb0bc354250bba0a9e044b98d00,progression,0.310822
uuid-e1c65cb0bc354250bba0a9e044b98d00,believes,0.363787
uuid-e1c65cb0bc354250bba0a9e044b98d00,chemotherapy,0.303849
uuid-e1c65cb0bc354250bba0a9e044b98d00,PD-1,0.33751
uuid-015dcbf5a96b48b18723386d90bab4f1,patients,0.699651
uuid-015dcbf5a96b48b18723386d90bab4f1,Opdivo,0.423733
uuid-015dcbf5a96b48b18723386d90bab4f1,therapy,0.303448
uuid-015dcbf5a96b48b18723386d90bab4f1,dose,0.368729
uuid-015dcbf5a96b48b18723386d90bab4f1,nivolumab,0.47311
uuid-015dcbf5a96b48b18723386d90bab4f1,toxicity,0.376918
uuid-015dcbf5a96b48b18723386d90bab4f1,regimen,0.550207
uuid-015dcbf5a96b48b18723386d90bab4f1,treated,0.620572
uuid-015dcbf5a96b48b18723386d90bab4f1,pts,0.363407
uuid-015dcbf5a96b48b18723386d90bab4f1,physicians,0.368659
uuid-015dcbf5a96b48b18723386d90bab4f1,preferred,0.307138
uuid-015dcbf5a96b48b18723386d90bab4f1,monotherapy,0.313006
uuid-015dcbf5a96b48b18723386d90bab4f1,treatment,0.57287
uuid-015dcbf5a96b48b18723386d90bab4f1,using nivo,0.363299
uuid-015dcbf5a96b48b18723386d90bab4f1,progression,0.398622
uuid-015dcbf5a96b48b18723386d90bab4f1,respond,0.374934
uuid-015dcbf5a96b48b18723386d90bab4f1,RTL stated,0.354389
uuid-eddeb27808b640ab90425d1d0994ba1a,Nivo,0.509121
uuid-eddeb27808b640ab90425d1d0994ba1a,patients,0.754536
uuid-eddeb27808b640ab90425d1d0994ba1a,Opdivo,0.332257
uuid-eddeb27808b640ab90425d1d0994ba1a,therapy,0.611177
uuid-eddeb27808b640ab90425d1d0994ba1a,nivolumab,0.533515
uuid-eddeb27808b640ab90425d1d0994ba1a,regimen,0.432373
uuid-eddeb27808b640ab90425d1d0994ba1a,treated,0.543037
uuid-eddeb27808b640ab90425d1d0994ba1a,chemo,0.467175
uuid-eddeb27808b640ab90425d1d0994ba1a,pts,0.552212
uuid-eddeb27808b640ab90425d1d0994ba1a,monotherapy,0.403056
uuid-eddeb27808b640ab90425d1d0994ba1a,treatment,0.586394
uuid-eddeb27808b640ab90425d1d0994ba1a,using nivo,0.462407
uuid-eddeb27808b640ab90425d1d0994ba1a,response,0.385497
uuid-eddeb27808b640ab90425d1d0994ba1a,PD1,0.380107
uuid-eddeb27808b640ab90425d1d0994ba1a,cHL,0.432745
uuid-eddeb27808b640ab90425d1d0994ba1a,progression,0.53396
uuid-eddeb27808b640ab90425d1d0994ba1a,chemotherapy,0.439647
uuid-eddeb27808b640ab90425d1d0994ba1a,respond,0.50135
uuid-eddeb27808b640ab90425d1d0994ba1a,SCLC,0.328353
uuid-eddeb27808b640ab90425d1d0994ba1a,RTL stated,0.300072
uuid-eddeb27808b640ab90425d1d0994ba1a,option,0.397454
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,Nivo,0.326769
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,patients,0.534243
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,therapy,0.499493
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,toxicity,0.367091
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,regimen,0.47456
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,chemo,0.443555
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,pts,0.445058
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,treatment,0.445048
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,response,0.564211
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,PD1,0.385152
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,progression,0.584742
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,chemotherapy,0.420308
uuid-5e5ab7ee17164fe68f82ad9f5ff657fc,respond,0.548483
uuid-af9587bd71e141baa3aaa62d3fd43b90,Nivo,0.466057
uuid-af9587bd71e141baa3aaa62d3fd43b90,patients,0.854464
uuid-af9587bd71e141baa3aaa62d3fd43b90,Opdivo,0.473102
uuid-af9587bd71e141baa3aaa62d3fd43b90,therapy,0.734136
uuid-af9587bd71e141baa3aaa62d3fd43b90,nivolumab,0.56433
uuid-af9587bd71e141baa3aaa62d3fd43b90,regimen,0.360995
uuid-af9587bd71e141baa3aaa62d3fd43b90,treated,0.486724
uuid-af9587bd71e141baa3aaa62d3fd43b90,chemo,0.360118
uuid-af9587bd71e141baa3aaa62d3fd43b90,pts,0.46016
uuid-af9587bd71e141baa3aaa62d3fd43b90,monotherapy,0.355866
uuid-af9587bd71e141baa3aaa62d3fd43b90,treatment,0.617203
uuid-af9587bd71e141baa3aaa62d3fd43b90,using nivo,0.405224
uuid-af9587bd71e141baa3aaa62d3fd43b90,response,0.339536
uuid-af9587bd71e141baa3aaa62d3fd43b90,PD1,0.362586
uuid-af9587bd71e141baa3aaa62d3fd43b90,cHL,0.615028
uuid-af9587bd71e141baa3aaa62d3fd43b90,progression,0.572948
uuid-af9587bd71e141baa3aaa62d3fd43b90,chemotherapy,0.468142
uuid-af9587bd71e141baa3aaa62d3fd43b90,respond,0.404799
uuid-af9587bd71e141baa3aaa62d3fd43b90,option,0.371443
uuid-02da92a384f740c3b8f0f887fb6a4511,RTL,0.315641
uuid-02da92a384f740c3b8f0f887fb6a4511,BMS,0.574661
uuid-02da92a384f740c3b8f0f887fb6a4511,trial,0.319389
uuid-02da92a384f740c3b8f0f887fb6a4511,efficacy,0.321755
uuid-02da92a384f740c3b8f0f887fb6a4511,commented,0.496394
uuid-02da92a384f740c3b8f0f887fb6a4511,Merck,0.321743
uuid-02da92a384f740c3b8f0f887fb6a4511,stated,0.365707
uuid-02da92a384f740c3b8f0f887fb6a4511,OS,0.508781
uuid-02da92a384f740c3b8f0f887fb6a4511,regards,0.30441
uuid-02da92a384f740c3b8f0f887fb6a4511,data,0.663584
uuid-02da92a384f740c3b8f0f887fb6a4511,expressed,0.369183
uuid-02da92a384f740c3b8f0f887fb6a4511,PFS,0.430736
uuid-02da92a384f740c3b8f0f887fb6a4511,ORR,0.503561
uuid-02da92a384f740c3b8f0f887fb6a4511,ASCO,0.384881
uuid-02da92a384f740c3b8f0f887fb6a4511,impressed,0.713649
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,patients,0.447329
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,regimen,0.349263
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,treated,0.484978
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,melanoma,0.429327
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,RCC,0.318954
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,tumor,0.674405
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,pts,0.436284
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,treatment,0.345414
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,progression,0.375864
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,RTL stated,0.319659
uuid-b30cd4ad15584bb8b6394a6f8c04ae6b,TL shared,0.380319
uuid-29d2176695454359936d2400b52e245a,TL,0.445652
uuid-29d2176695454359936d2400b52e245a,NSCLC,0.364704
uuid-29d2176695454359936d2400b52e245a,1L,0.396157
uuid-29d2176695454359936d2400b52e245a,PDL1,0.367966
uuid-29d2176695454359936d2400b52e245a,RCC,0.346474
uuid-29d2176695454359936d2400b52e245a,TL stated,0.49837
uuid-29d2176695454359936d2400b52e245a,2L,0.302731
uuid-29d2176695454359936d2400b52e245a,PD-L1,0.693321
uuid-29d2176695454359936d2400b52e245a,PD-L1 testing,0.65555
uuid-29d2176695454359936d2400b52e245a,testing,0.700625
uuid-29d2176695454359936d2400b52e245a,PDL1 testing,0.655202
uuid-29d2176695454359936d2400b52e245a,NSCLC patients,0.541066
uuid-29d2176695454359936d2400b52e245a,assay,0.506156
uuid-29d2176695454359936d2400b52e245a,PD-1,0.35619
uuid-29d2176695454359936d2400b52e245a,biomarker,0.670552
uuid-51e5b998da7f47aab605c447b4ee09f6,pembro,0.484298
uuid-51e5b998da7f47aab605c447b4ee09f6,BMS,0.657653
uuid-51e5b998da7f47aab605c447b4ee09f6,PDL1,0.407726
uuid-51e5b998da7f47aab605c447b4ee09f6,trial,0.703588
uuid-51e5b998da7f47aab605c447b4ee09f6,efficacy,0.511432
uuid-51e5b998da7f47aab605c447b4ee09f6,Merck,0.578248
uuid-51e5b998da7f47aab605c447b4ee09f6,OS,0.519262
uuid-51e5b998da7f47aab605c447b4ee09f6,atezo,0.372968
uuid-51e5b998da7f47aab605c447b4ee09f6,data,0.628287
uuid-51e5b998da7f47aab605c447b4ee09f6,expressed,0.305568
uuid-51e5b998da7f47aab605c447b4ee09f6,PFS,0.537634
uuid-51e5b998da7f47aab605c447b4ee09f6,ORR,0.542971
uuid-51e5b998da7f47aab605c447b4ee09f6,nivo and pembro,0.569512
uuid-51e5b998da7f47aab605c447b4ee09f6,impressed,0.401202
uuid-51e5b998da7f47aab605c447b4ee09f6,vs,0.391766
uuid-51e5b998da7f47aab605c447b4ee09f6,feels,0.334996
uuid-51e5b998da7f47aab605c447b4ee09f6,PDL1 expression,0.427607
uuid-40954048fcb446e2a22e9aca05519b5d,oncology,0.410976
uuid-10f9b88757b548139af0f5c5924726df,TL,0.301835
uuid-10f9b88757b548139af0f5c5924726df,lung,0.600233
uuid-10f9b88757b548139af0f5c5924726df,1L,0.39618
uuid-10f9b88757b548139af0f5c5924726df,PDL1,0.318053
uuid-10f9b88757b548139af0f5c5924726df,melanoma,0.334581
uuid-10f9b88757b548139af0f5c5924726df,RCC,0.375981
uuid-10f9b88757b548139af0f5c5924726df,TL stated,0.588425
uuid-10f9b88757b548139af0f5c5924726df,2L,0.33293
uuid-10f9b88757b548139af0f5c5924726df,institution,0.514457
uuid-10f9b88757b548139af0f5c5924726df,PD-L1,0.559979
uuid-10f9b88757b548139af0f5c5924726df,PD-L1 testing,0.633002
uuid-10f9b88757b548139af0f5c5924726df,testing,0.719531
uuid-10f9b88757b548139af0f5c5924726df,PDL1 testing,0.778921
uuid-10f9b88757b548139af0f5c5924726df,AI,0.391336
uuid-10f9b88757b548139af0f5c5924726df,NSCLC patients,0.567913
uuid-10f9b88757b548139af0f5c5924726df,SCCHN,0.307778
uuid-10f9b88757b548139af0f5c5924726df,tumor types,0.425159
uuid-10f9b88757b548139af0f5c5924726df,assay,0.425415
uuid-10f9b88757b548139af0f5c5924726df,TL shared,0.350535
uuid-10f9b88757b548139af0f5c5924726df,biomarker,0.457986
uuid-f8a271fe01aa4ec7b891d520b993fbe1,Nivo,0.376792
uuid-f8a271fe01aa4ec7b891d520b993fbe1,pembro,0.481394
uuid-f8a271fe01aa4ec7b891d520b993fbe1,trial,0.583576
uuid-f8a271fe01aa4ec7b891d520b993fbe1,efficacy,0.565705
uuid-f8a271fe01aa4ec7b891d520b993fbe1,combination,0.384071
uuid-f8a271fe01aa4ec7b891d520b993fbe1,Ipi,0.56755
uuid-f8a271fe01aa4ec7b891d520b993fbe1,OS,0.376885
uuid-f8a271fe01aa4ec7b891d520b993fbe1,atezo,0.409934
uuid-f8a271fe01aa4ec7b891d520b993fbe1,data,0.681538
uuid-f8a271fe01aa4ec7b891d520b993fbe1,combo,0.410041
uuid-f8a271fe01aa4ec7b891d520b993fbe1,indication,0.300466
uuid-f8a271fe01aa4ec7b891d520b993fbe1,PFS,0.305268
uuid-f8a271fe01aa4ec7b891d520b993fbe1,ORR,0.499872
uuid-f8a271fe01aa4ec7b891d520b993fbe1,nivo and pembro,0.377374
uuid-f8a271fe01aa4ec7b891d520b993fbe1,impressed,0.590749
uuid-f8a271fe01aa4ec7b891d520b993fbe1,vs,0.362286
uuid-f8a271fe01aa4ec7b891d520b993fbe1,SCLC,0.462573
uuid-f8a271fe01aa4ec7b891d520b993fbe1,feels,0.310085
uuid-4d4bc926f70b46b282b9c5c16b00ab5a,tumor,0.336138
uuid-f0a5795d9d164b51af147c2b8958ec88,Nivo,0.304975
uuid-f0a5795d9d164b51af147c2b8958ec88,PDL1,0.325775
uuid-f0a5795d9d164b51af147c2b8958ec88,trial,0.345489
uuid-f0a5795d9d164b51af147c2b8958ec88,efficacy,0.519891
uuid-f0a5795d9d164b51af147c2b8958ec88,discussed,0.346615
uuid-f0a5795d9d164b51af147c2b8958ec88,OS,0.605257
uuid-f0a5795d9d164b51af147c2b8958ec88,regards,0.350567
uuid-f0a5795d9d164b51af147c2b8958ec88,data,0.528932
uuid-f0a5795d9d164b51af147c2b8958ec88,PFS,0.607204
uuid-f0a5795d9d164b51af147c2b8958ec88,ORR,0.59391
uuid-f0a5795d9d164b51af147c2b8958ec88,nivo and pembro,0.391159
uuid-f0a5795d9d164b51af147c2b8958ec88,impressed,0.380869
uuid-f0a5795d9d164b51af147c2b8958ec88,PDL1 expression,0.378205
uuid-752b10320aaf42a296375dc6fce28895,TL,0.668531
uuid-752b10320aaf42a296375dc6fce28895,PDL1,0.426815
uuid-752b10320aaf42a296375dc6fce28895,TL stated,0.306956
uuid-752b10320aaf42a296375dc6fce28895,Merck,0.379015
uuid-752b10320aaf42a296375dc6fce28895,institution,0.323736
uuid-752b10320aaf42a296375dc6fce28895,PD-L1,0.79469
uuid-752b10320aaf42a296375dc6fce28895,approval,0.312767
uuid-752b10320aaf42a296375dc6fce28895,atezo,0.342532
uuid-752b10320aaf42a296375dc6fce28895,PD-L1 testing,0.806523
uuid-752b10320aaf42a296375dc6fce28895,testing,0.791393
uuid-752b10320aaf42a296375dc6fce28895,PDL1 testing,0.535318
uuid-752b10320aaf42a296375dc6fce28895,NSCLC patients,0.506016
uuid-752b10320aaf42a296375dc6fce28895,assay,0.880243
uuid-752b10320aaf42a296375dc6fce28895,biomarker,0.304611
uuid-d059dc0547b14459ac76dda9f46bfd9f,Nivo,0.370322
uuid-d059dc0547b14459ac76dda9f46bfd9f,patients,0.648815
uuid-d059dc0547b14459ac76dda9f46bfd9f,nivolumab,0.366088
uuid-d059dc0547b14459ac76dda9f46bfd9f,regimen,0.341299
uuid-d059dc0547b14459ac76dda9f46bfd9f,treated,0.37979
uuid-d059dc0547b14459ac76dda9f46bfd9f,pts,0.489331
uuid-d059dc0547b14459ac76dda9f46bfd9f,monotherapy,0.322199
uuid-d059dc0547b14459ac76dda9f46bfd9f,treatment,0.346544
uuid-d059dc0547b14459ac76dda9f46bfd9f,using nivo,0.419443
uuid-d059dc0547b14459ac76dda9f46bfd9f,progression,0.382966
uuid-d059dc0547b14459ac76dda9f46bfd9f,chemotherapy,0.328788
uuid-d059dc0547b14459ac76dda9f46bfd9f,RTL stated,0.344014
uuid-d059dc0547b14459ac76dda9f46bfd9f,option,0.300267
uuid-d059dc0547b14459ac76dda9f46bfd9f,bladder,0.444453
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,TL,0.425988
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,commented,0.389761
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,TL stated,0.471528
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,PD-L1,0.565642
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,PD-L1 testing,0.642224
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,testing,0.638918
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,PDL1 testing,0.636454
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,NSCLC patients,0.607876
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,SCCHN,0.440936
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,tumor types,0.369883
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,assay,0.365162
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,Regional TL,0.437612
uuid-fa8c753cb3fc4f46b2b0f73bf896cefc,biomarker,0.375837
uuid-3008a1a3cef74848b0551de7fbdf4ab4,Nivo,0.629791
uuid-3008a1a3cef74848b0551de7fbdf4ab4,pembro,0.519784
uuid-3008a1a3cef74848b0551de7fbdf4ab4,dose,0.629032
uuid-3008a1a3cef74848b0551de7fbdf4ab4,toxicity,0.431688
uuid-3008a1a3cef74848b0551de7fbdf4ab4,efficacy,0.418497
uuid-3008a1a3cef74848b0551de7fbdf4ab4,regimen,0.391465
uuid-3008a1a3cef74848b0551de7fbdf4ab4,combination,0.516679
uuid-3008a1a3cef74848b0551de7fbdf4ab4,chemo,0.346779
uuid-3008a1a3cef74848b0551de7fbdf4ab4,2L,0.312239
uuid-3008a1a3cef74848b0551de7fbdf4ab4,Ipi,0.839157
uuid-3008a1a3cef74848b0551de7fbdf4ab4,atezo,0.443441
uuid-3008a1a3cef74848b0551de7fbdf4ab4,preferred,0.350179
uuid-3008a1a3cef74848b0551de7fbdf4ab4,monotherapy,0.447824
uuid-3008a1a3cef74848b0551de7fbdf4ab4,using nivo,0.394141
uuid-3008a1a3cef74848b0551de7fbdf4ab4,combo,0.503538
uuid-3008a1a3cef74848b0551de7fbdf4ab4,vs,0.563209
uuid-3008a1a3cef74848b0551de7fbdf4ab4,SCLC,0.334668
uuid-3008a1a3cef74848b0551de7fbdf4ab4,flat dosing,0.4086
uuid-8dd260859b704202911a449ede8670d3,trial,0.475555
uuid-8dd260859b704202911a449ede8670d3,efficacy,0.343362
uuid-8dd260859b704202911a449ede8670d3,chemo,0.30244
uuid-8dd260859b704202911a449ede8670d3,OS,0.672152
uuid-8dd260859b704202911a449ede8670d3,data,0.478327
uuid-8dd260859b704202911a449ede8670d3,PFS,0.703478
uuid-8dd260859b704202911a449ede8670d3,ORR,0.612867
uuid-8dd260859b704202911a449ede8670d3,chemotherapy,0.360884
uuid-8dd260859b704202911a449ede8670d3,impressed,0.401536
uuid-8dd260859b704202911a449ede8670d3,feels,0.301928
uuid-1a7be3b4c3b042c391092395c50c4d47,RTL,0.628324
uuid-1a7be3b4c3b042c391092395c50c4d47,nivolumab,0.349579
uuid-1a7be3b4c3b042c391092395c50c4d47,BMS,0.431797
uuid-1a7be3b4c3b042c391092395c50c4d47,trial,0.548216
uuid-1a7be3b4c3b042c391092395c50c4d47,NTL,0.420225
uuid-1a7be3b4c3b042c391092395c50c4d47,shared,0.330817
uuid-1a7be3b4c3b042c391092395c50c4d47,commented,0.312722
uuid-1a7be3b4c3b042c391092395c50c4d47,stated,0.518929
uuid-1a7be3b4c3b042c391092395c50c4d47,mentioned,0.309627
uuid-1a7be3b4c3b042c391092395c50c4d47,clinical trials,0.487149
uuid-1a7be3b4c3b042c391092395c50c4d47,SCCHN,0.405289
uuid-1a7be3b4c3b042c391092395c50c4d47,impressed,0.436239
uuid-1a7be3b4c3b042c391092395c50c4d47,LTL,0.403795
uuid-1a7be3b4c3b042c391092395c50c4d47,Regional TL,0.461945
uuid-1a7be3b4c3b042c391092395c50c4d47,RTL stated,0.359519
uuid-1a7be3b4c3b042c391092395c50c4d47,bladder,0.370321
uuid-15fe16c8ac77433991abd8a4401b74a0,RTL,0.307425
uuid-15fe16c8ac77433991abd8a4401b74a0,lung,0.526149
uuid-15fe16c8ac77433991abd8a4401b74a0,NTL,0.342355
uuid-15fe16c8ac77433991abd8a4401b74a0,melanoma,0.418552
uuid-15fe16c8ac77433991abd8a4401b74a0,commented,0.389596
uuid-15fe16c8ac77433991abd8a4401b74a0,RCC,0.465624
uuid-15fe16c8ac77433991abd8a4401b74a0,TL stated,0.436381
uuid-15fe16c8ac77433991abd8a4401b74a0,stated,0.456596
uuid-15fe16c8ac77433991abd8a4401b74a0,SCCHN,0.413081
uuid-15fe16c8ac77433991abd8a4401b74a0,ASCO,0.439165
uuid-15fe16c8ac77433991abd8a4401b74a0,impressed,0.391782
uuid-15fe16c8ac77433991abd8a4401b74a0,TLs,0.35432
uuid-15fe16c8ac77433991abd8a4401b74a0,SCLC,0.338886
uuid-15fe16c8ac77433991abd8a4401b74a0,Regional TL,0.46041
uuid-15fe16c8ac77433991abd8a4401b74a0,TL shared,0.363089
uuid-15fe16c8ac77433991abd8a4401b74a0,bladder,0.43079
uuid-8dc5300226dd4850b2da1d231865f859,therapy,0.302318
uuid-8dc5300226dd4850b2da1d231865f859,treated,0.431949
uuid-8dc5300226dd4850b2da1d231865f859,treatment,0.400555
uuid-8dc5300226dd4850b2da1d231865f859,RTL stated,0.343122
uuid-8dc5300226dd4850b2da1d231865f859,bladder,0.313766
uuid-2dfa29990b33487098b4e3926544b833,pembro,0.384102
uuid-2dfa29990b33487098b4e3926544b833,lung,0.369357
uuid-2dfa29990b33487098b4e3926544b833,1L,0.613909
uuid-2dfa29990b33487098b4e3926544b833,regimen,0.302304
uuid-2dfa29990b33487098b4e3926544b833,RCC,0.52666
uuid-2dfa29990b33487098b4e3926544b833,TL stated,0.467536
uuid-2dfa29990b33487098b4e3926544b833,2L,0.68457
uuid-2dfa29990b33487098b4e3926544b833,agents,0.483532
uuid-2dfa29990b33487098b4e3926544b833,atezo,0.429793
uuid-2dfa29990b33487098b4e3926544b833,preferred,0.696865
uuid-2dfa29990b33487098b4e3926544b833,monotherapy,0.516996
uuid-2dfa29990b33487098b4e3926544b833,using nivo,0.489058
uuid-2dfa29990b33487098b4e3926544b833,combo,0.32609
uuid-2dfa29990b33487098b4e3926544b833,PDL1 testing,0.414441
uuid-2dfa29990b33487098b4e3926544b833,NSCLC patients,0.324055
uuid-2dfa29990b33487098b4e3926544b833,approved,0.399215
uuid-2dfa29990b33487098b4e3926544b833,SCCHN,0.35492
uuid-2dfa29990b33487098b4e3926544b833,tumor types,0.344448
uuid-2dfa29990b33487098b4e3926544b833,RTL stated,0.532703
uuid-2dfa29990b33487098b4e3926544b833,TL shared,0.450435
uuid-2dfa29990b33487098b4e3926544b833,option,0.551796
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,patients,0.441939
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,pembro,0.36506
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,1L,0.587451
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,RCC,0.311585
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,TL stated,0.306874
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,2L,0.569046
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,pts,0.349364
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,agents,0.303476
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,PD-L1,0.451958
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,approval,0.424198
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,atezo,0.347532
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,preferred,0.563617
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,PD-L1 testing,0.346938
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,testing,0.494684
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,monotherapy,0.449834
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,using nivo,0.451033
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,PDL1 testing,0.534883
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,NSCLC patients,0.604579
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,approved,0.49145
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,tumor types,0.382369
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,label,0.324363
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,PD-1,0.33193
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,RTL stated,0.377057
uuid-e9d6b27d515d4f6f9aa4867bb5e00a34,option,0.541436
uuid-666053677ecb41dc806f4deb66ff0c30,lung,0.332524
uuid-666053677ecb41dc806f4deb66ff0c30,NSCLC,0.40375
uuid-666053677ecb41dc806f4deb66ff0c30,1L,0.622218
uuid-666053677ecb41dc806f4deb66ff0c30,regimen,0.411166
uuid-666053677ecb41dc806f4deb66ff0c30,RCC,0.529933
uuid-666053677ecb41dc806f4deb66ff0c30,TL stated,0.413776
uuid-666053677ecb41dc806f4deb66ff0c30,combination,0.569108
uuid-666053677ecb41dc806f4deb66ff0c30,chemo,0.466575
uuid-666053677ecb41dc806f4deb66ff0c30,2L,0.579763
uuid-666053677ecb41dc806f4deb66ff0c30,IO,0.664754
uuid-666053677ecb41dc806f4deb66ff0c30,agents,0.506126
uuid-666053677ecb41dc806f4deb66ff0c30,preferred,0.490722
uuid-666053677ecb41dc806f4deb66ff0c30,monotherapy,0.638328
uuid-666053677ecb41dc806f4deb66ff0c30,using nivo,0.34856
uuid-666053677ecb41dc806f4deb66ff0c30,combo,0.677808
uuid-666053677ecb41dc806f4deb66ff0c30,PD1,0.448814
uuid-666053677ecb41dc806f4deb66ff0c30,believes,0.372671
uuid-666053677ecb41dc806f4deb66ff0c30,chemotherapy,0.34873
uuid-666053677ecb41dc806f4deb66ff0c30,PD-1,0.304648
uuid-666053677ecb41dc806f4deb66ff0c30,RTL stated,0.443563
uuid-666053677ecb41dc806f4deb66ff0c30,TL shared,0.371036
uuid-666053677ecb41dc806f4deb66ff0c30,option,0.500255
uuid-6d1e232dc4e4463c99fce087ac86df72,RTL stated,0.417188
uuid-6d1e232dc4e4463c99fce087ac86df72,bladder,0.379999
uuid-b9c279e12c7e4973baefb120e0b89e29,Nivo,0.481435
uuid-b9c279e12c7e4973baefb120e0b89e29,patients,0.764192
uuid-b9c279e12c7e4973baefb120e0b89e29,Opdivo,0.356282
uuid-b9c279e12c7e4973baefb120e0b89e29,therapy,0.510735
uuid-b9c279e12c7e4973baefb120e0b89e29,nivolumab,0.675778
uuid-b9c279e12c7e4973baefb120e0b89e29,1L,0.30977
uuid-b9c279e12c7e4973baefb120e0b89e29,regimen,0.526914
uuid-b9c279e12c7e4973baefb120e0b89e29,treated,0.641912
uuid-b9c279e12c7e4973baefb120e0b89e29,RCC,0.322077
uuid-b9c279e12c7e4973baefb120e0b89e29,combination,0.455012
uuid-b9c279e12c7e4973baefb120e0b89e29,chemo,0.44854
uuid-b9c279e12c7e4973baefb120e0b89e29,2L,0.386355
uuid-b9c279e12c7e4973baefb120e0b89e29,pts,0.567456
uuid-b9c279e12c7e4973baefb120e0b89e29,approval,0.31216
uuid-b9c279e12c7e4973baefb120e0b89e29,preferred,0.405138
uuid-b9c279e12c7e4973baefb120e0b89e29,monotherapy,0.538986
uuid-b9c279e12c7e4973baefb120e0b89e29,treatment,0.548178
uuid-b9c279e12c7e4973baefb120e0b89e29,using nivo,0.532719
uuid-b9c279e12c7e4973baefb120e0b89e29,combo,0.37295
uuid-b9c279e12c7e4973baefb120e0b89e29,PD1,0.392232
uuid-b9c279e12c7e4973baefb120e0b89e29,approved,0.333695
uuid-b9c279e12c7e4973baefb120e0b89e29,progression,0.500471
uuid-b9c279e12c7e4973baefb120e0b89e29,chemotherapy,0.449912
uuid-b9c279e12c7e4973baefb120e0b89e29,respond,0.370331
uuid-b9c279e12c7e4973baefb120e0b89e29,RTL stated,0.46865
uuid-b9c279e12c7e4973baefb120e0b89e29,option,0.445082
uuid-0b9e393f050e446db6899b8383a2f915,RTL,0.300329
uuid-0b9e393f050e446db6899b8383a2f915,lung,0.323403
uuid-0b9e393f050e446db6899b8383a2f915,NTL,0.301268
uuid-0b9e393f050e446db6899b8383a2f915,commented,0.458596
uuid-0b9e393f050e446db6899b8383a2f915,OS,0.692958
uuid-0b9e393f050e446db6899b8383a2f915,regards,0.313138
uuid-0b9e393f050e446db6899b8383a2f915,data,0.577893
uuid-0b9e393f050e446db6899b8383a2f915,expressed,0.332713
uuid-0b9e393f050e446db6899b8383a2f915,PFS,0.645077
uuid-0b9e393f050e446db6899b8383a2f915,ORR,0.56389
uuid-0b9e393f050e446db6899b8383a2f915,ASCO,0.509803
uuid-0b9e393f050e446db6899b8383a2f915,impressed,0.574778
uuid-5930f56450074a86b94ab4a90119230e,Nivo,0.567486
uuid-5930f56450074a86b94ab4a90119230e,pembro,0.335012
uuid-5930f56450074a86b94ab4a90119230e,toxicity,0.400295
uuid-5930f56450074a86b94ab4a90119230e,efficacy,0.680857
uuid-5930f56450074a86b94ab4a90119230e,regimen,0.455625
uuid-5930f56450074a86b94ab4a90119230e,combination,0.460125
uuid-5930f56450074a86b94ab4a90119230e,chemo,0.664746
uuid-5930f56450074a86b94ab4a90119230e,agents,0.42744
uuid-5930f56450074a86b94ab4a90119230e,Ipi,0.419289
uuid-5930f56450074a86b94ab4a90119230e,OS,0.440714
uuid-5930f56450074a86b94ab4a90119230e,monotherapy,0.516739
uuid-5930f56450074a86b94ab4a90119230e,response,0.300507
uuid-5930f56450074a86b94ab4a90119230e,data,0.33227
uuid-5930f56450074a86b94ab4a90119230e,combo,0.447884
uuid-5930f56450074a86b94ab4a90119230e,PFS,0.435433
uuid-5930f56450074a86b94ab4a90119230e,PD1,0.415687
uuid-5930f56450074a86b94ab4a90119230e,ORR,0.485497
uuid-5930f56450074a86b94ab4a90119230e,nivo and pembro,0.446634
uuid-5930f56450074a86b94ab4a90119230e,believes,0.463502
uuid-5930f56450074a86b94ab4a90119230e,chemotherapy,0.578546
uuid-5930f56450074a86b94ab4a90119230e,impressed,0.306933
uuid-5930f56450074a86b94ab4a90119230e,vs,0.389185
uuid-5930f56450074a86b94ab4a90119230e,feels,0.544967
uuid-5930f56450074a86b94ab4a90119230e,option,0.403887
uuid-a51ec1170f4f46a0bbd20b147b907801,tumor,0.547805
uuid-0409805a0b9f4323bd9065371d678534,chemo,0.311068
uuid-0409805a0b9f4323bd9065371d678534,tumor,0.762841
uuid-0409805a0b9f4323bd9065371d678534,pts,0.341315
uuid-0409805a0b9f4323bd9065371d678534,tumor types,0.324029
uuid-1bff4aeb6557468aba8fe4bb85113f44,patients,0.706127
uuid-1bff4aeb6557468aba8fe4bb85113f44,Opdivo,0.416885
uuid-1bff4aeb6557468aba8fe4bb85113f44,therapy,0.350597
uuid-1bff4aeb6557468aba8fe4bb85113f44,nivolumab,0.357022
uuid-1bff4aeb6557468aba8fe4bb85113f44,treated,0.398674
uuid-1bff4aeb6557468aba8fe4bb85113f44,pts,0.487742
uuid-1bff4aeb6557468aba8fe4bb85113f44,treatment,0.405438
uuid-1bff4aeb6557468aba8fe4bb85113f44,cHL,0.416893
uuid-1bff4aeb6557468aba8fe4bb85113f44,progression,0.505521
uuid-1bff4aeb6557468aba8fe4bb85113f44,respond,0.352381
uuid-9de9b4024ea44f5a87ca954c3abb5905,RTL,0.365527
uuid-9de9b4024ea44f5a87ca954c3abb5905,BMS,0.526439
uuid-9de9b4024ea44f5a87ca954c3abb5905,trial,0.558569
uuid-9de9b4024ea44f5a87ca954c3abb5905,efficacy,0.300085
uuid-9de9b4024ea44f5a87ca954c3abb5905,discussed,0.382358
uuid-9de9b4024ea44f5a87ca954c3abb5905,commented,0.519132
uuid-9de9b4024ea44f5a87ca954c3abb5905,Merck,0.428812
uuid-9de9b4024ea44f5a87ca954c3abb5905,stated,0.432543
uuid-9de9b4024ea44f5a87ca954c3abb5905,OS,0.473817
uuid-9de9b4024ea44f5a87ca954c3abb5905,regards,0.373067
uuid-9de9b4024ea44f5a87ca954c3abb5905,data,0.683313
uuid-9de9b4024ea44f5a87ca954c3abb5905,expressed,0.39771
uuid-9de9b4024ea44f5a87ca954c3abb5905,PFS,0.405932
uuid-9de9b4024ea44f5a87ca954c3abb5905,ORR,0.440663
uuid-9de9b4024ea44f5a87ca954c3abb5905,SCCHN,0.306982
uuid-9de9b4024ea44f5a87ca954c3abb5905,nivo and pembro,0.310274
uuid-9de9b4024ea44f5a87ca954c3abb5905,ASCO,0.390728
uuid-9de9b4024ea44f5a87ca954c3abb5905,impressed,0.609194
uuid-9de9b4024ea44f5a87ca954c3abb5905,TLs,0.324617
uuid-9de9b4024ea44f5a87ca954c3abb5905,feels,0.412316
uuid-9de9b4024ea44f5a87ca954c3abb5905,Regional TL,0.331834
uuid-e4b79fc2cc974b52820ab72cdcc3d274,PDL1,0.338289
uuid-e4b79fc2cc974b52820ab72cdcc3d274,PD-L1,0.324502
uuid-e4b79fc2cc974b52820ab72cdcc3d274,PD-L1 testing,0.361664
uuid-e4b79fc2cc974b52820ab72cdcc3d274,testing,0.398486
uuid-e4b79fc2cc974b52820ab72cdcc3d274,PDL1 testing,0.341561
uuid-f2d89fe6544841f49fd53dcdcbf16dd2,TL,0.318776
uuid-f2d89fe6544841f49fd53dcdcbf16dd2,TL stated,0.382404
uuid-29497b9d7ee6493fb739bd389726a6cc,TL,0.408417
uuid-29497b9d7ee6493fb739bd389726a6cc,PDL1,0.632359
uuid-29497b9d7ee6493fb739bd389726a6cc,commented,0.362896
uuid-29497b9d7ee6493fb739bd389726a6cc,Merck,0.482845
uuid-29497b9d7ee6493fb739bd389726a6cc,PD-L1,0.608377
uuid-29497b9d7ee6493fb739bd389726a6cc,OS,0.375329
uuid-29497b9d7ee6493fb739bd389726a6cc,PD-L1 testing,0.424383
uuid-29497b9d7ee6493fb739bd389726a6cc,testing,0.493489
uuid-29497b9d7ee6493fb739bd389726a6cc,data,0.636566
uuid-29497b9d7ee6493fb739bd389726a6cc,PDL1 testing,0.352056
uuid-29497b9d7ee6493fb739bd389726a6cc,PFS,0.334785
uuid-29497b9d7ee6493fb739bd389726a6cc,NSCLC patients,0.355568
uuid-29497b9d7ee6493fb739bd389726a6cc,ORR,0.353605
uuid-29497b9d7ee6493fb739bd389726a6cc,nivo and pembro,0.300206
uuid-29497b9d7ee6493fb739bd389726a6cc,impressed,0.442956
uuid-29497b9d7ee6493fb739bd389726a6cc,assay,0.543947
uuid-29497b9d7ee6493fb739bd389726a6cc,PDL1 expression,0.474997
uuid-29497b9d7ee6493fb739bd389726a6cc,biomarker,0.449978
uuid-115920ec9a164132a0e7cb47683534ee,patients,0.466511
uuid-115920ec9a164132a0e7cb47683534ee,Opdivo,0.36064
uuid-115920ec9a164132a0e7cb47683534ee,therapy,0.310975
uuid-115920ec9a164132a0e7cb47683534ee,nivolumab,0.456456
uuid-115920ec9a164132a0e7cb47683534ee,treated,0.467113
uuid-115920ec9a164132a0e7cb47683534ee,pts,0.413272
uuid-115920ec9a164132a0e7cb47683534ee,stated,0.352134
uuid-115920ec9a164132a0e7cb47683534ee,treatment,0.345657
uuid-115920ec9a164132a0e7cb47683534ee,response,0.382469
uuid-115920ec9a164132a0e7cb47683534ee,progression,0.414382
uuid-925ebe824f61405cb404135755f68aba,patients,0.407108
uuid-925ebe824f61405cb404135755f68aba,toxicity,0.493415
uuid-925ebe824f61405cb404135755f68aba,regimen,0.378322
uuid-925ebe824f61405cb404135755f68aba,treated,0.512026
uuid-925ebe824f61405cb404135755f68aba,treatment,0.520891
uuid-925ebe824f61405cb404135755f68aba,progression,0.394944
uuid-925ebe824f61405cb404135755f68aba,respond,0.401657
uuid-925ebe824f61405cb404135755f68aba,TL shared,0.305841
uuid-a662a70341584d39a491d2506ca0bd7f,RTL,0.399013
uuid-a662a70341584d39a491d2506ca0bd7f,BMS,0.500507
uuid-a662a70341584d39a491d2506ca0bd7f,trial,0.756061
uuid-a662a70341584d39a491d2506ca0bd7f,NTL,0.340037
uuid-a662a70341584d39a491d2506ca0bd7f,shared,0.380545
uuid-a662a70341584d39a491d2506ca0bd7f,commented,0.330345
uuid-a662a70341584d39a491d2506ca0bd7f,Merck,0.516286
uuid-a662a70341584d39a491d2506ca0bd7f,stated,0.343718
uuid-a662a70341584d39a491d2506ca0bd7f,approval,0.331836
uuid-a662a70341584d39a491d2506ca0bd7f,data,0.310514
uuid-a662a70341584d39a491d2506ca0bd7f,mentioned,0.348031
uuid-a662a70341584d39a491d2506ca0bd7f,clinical trials,0.505778
uuid-a662a70341584d39a491d2506ca0bd7f,impressed,0.311474
uuid-a662a70341584d39a491d2506ca0bd7f,Regional TL,0.330554
uuid-a662a70341584d39a491d2506ca0bd7f,bladder,0.38782
uuid-7a40f5346e7140639abaed8f1f0a4534,Nivo,0.346833
uuid-7a40f5346e7140639abaed8f1f0a4534,patients,0.664381
uuid-7a40f5346e7140639abaed8f1f0a4534,therapy,0.348499
uuid-7a40f5346e7140639abaed8f1f0a4534,regimen,0.386034
uuid-7a40f5346e7140639abaed8f1f0a4534,treated,0.328403
uuid-7a40f5346e7140639abaed8f1f0a4534,chemo,0.427873
uuid-7a40f5346e7140639abaed8f1f0a4534,pts,0.547879
uuid-7a40f5346e7140639abaed8f1f0a4534,monotherapy,0.386095
uuid-7a40f5346e7140639abaed8f1f0a4534,treatment,0.465208
uuid-7a40f5346e7140639abaed8f1f0a4534,response,0.354975
uuid-7a40f5346e7140639abaed8f1f0a4534,progression,0.469313
uuid-7a40f5346e7140639abaed8f1f0a4534,chemotherapy,0.404681
uuid-7a40f5346e7140639abaed8f1f0a4534,respond,0.440469
uuid-7a40f5346e7140639abaed8f1f0a4534,feels,0.426177
uuid-7a40f5346e7140639abaed8f1f0a4534,option,0.466334
uuid-0e812fac73c94b27b75a9debdfd840ec,Nivo,0.373445
uuid-0e812fac73c94b27b75a9debdfd840ec,dose,0.387671
uuid-0e812fac73c94b27b75a9debdfd840ec,regimen,0.375425
uuid-0e812fac73c94b27b75a9debdfd840ec,combination,0.489882
uuid-0e812fac73c94b27b75a9debdfd840ec,chemo,0.430203
uuid-0e812fac73c94b27b75a9debdfd840ec,IO,0.453381
uuid-0e812fac73c94b27b75a9debdfd840ec,agents,0.300433
uuid-0e812fac73c94b27b75a9debdfd840ec,Ipi,0.530005
uuid-0e812fac73c94b27b75a9debdfd840ec,preferred,0.325019
uuid-0e812fac73c94b27b75a9debdfd840ec,monotherapy,0.396906
uuid-0e812fac73c94b27b75a9debdfd840ec,combo,0.489575
uuid-0e812fac73c94b27b75a9debdfd840ec,believes,0.300032
uuid-0e812fac73c94b27b75a9debdfd840ec,chemotherapy,0.394663
uuid-0e812fac73c94b27b75a9debdfd840ec,vs,0.432079
uuid-0e812fac73c94b27b75a9debdfd840ec,feels,0.365468
uuid-0e812fac73c94b27b75a9debdfd840ec,option,0.340637
uuid-c9c0bdbe489145bc8c6c081e42a7e206,patients,0.64548
uuid-c9c0bdbe489145bc8c6c081e42a7e206,Opdivo,0.4778
uuid-c9c0bdbe489145bc8c6c081e42a7e206,therapy,0.453525
uuid-c9c0bdbe489145bc8c6c081e42a7e206,nivolumab,0.54089
uuid-c9c0bdbe489145bc8c6c081e42a7e206,regimen,0.369073
uuid-c9c0bdbe489145bc8c6c081e42a7e206,treated,0.452498
uuid-c9c0bdbe489145bc8c6c081e42a7e206,combination,0.364345
uuid-c9c0bdbe489145bc8c6c081e42a7e206,2L,0.326616
uuid-c9c0bdbe489145bc8c6c081e42a7e206,pts,0.506599
uuid-c9c0bdbe489145bc8c6c081e42a7e206,stated,0.313048
uuid-c9c0bdbe489145bc8c6c081e42a7e206,approval,0.327156
uuid-c9c0bdbe489145bc8c6c081e42a7e206,preferred,0.342498
uuid-c9c0bdbe489145bc8c6c081e42a7e206,monotherapy,0.437159
uuid-c9c0bdbe489145bc8c6c081e42a7e206,treatment,0.470696
uuid-c9c0bdbe489145bc8c6c081e42a7e206,using nivo,0.441043
uuid-c9c0bdbe489145bc8c6c081e42a7e206,combo,0.305097
uuid-c9c0bdbe489145bc8c6c081e42a7e206,PD1,0.313541
uuid-c9c0bdbe489145bc8c6c081e42a7e206,approved,0.355491
uuid-c9c0bdbe489145bc8c6c081e42a7e206,progression,0.495011
uuid-c9c0bdbe489145bc8c6c081e42a7e206,chemotherapy,0.309317
uuid-c9c0bdbe489145bc8c6c081e42a7e206,RTL stated,0.391778
uuid-c9c0bdbe489145bc8c6c081e42a7e206,option,0.485823
uuid-87893c0e6dec49f2bff4f403d243dab6,Nivo,0.421172
uuid-87893c0e6dec49f2bff4f403d243dab6,pembro,0.51774
uuid-87893c0e6dec49f2bff4f403d243dab6,dose,0.822299
uuid-87893c0e6dec49f2bff4f403d243dab6,efficacy,0.402497
uuid-87893c0e6dec49f2bff4f403d243dab6,Ipi,0.536354
uuid-87893c0e6dec49f2bff4f403d243dab6,atezo,0.575673
uuid-87893c0e6dec49f2bff4f403d243dab6,preferred,0.348827
uuid-87893c0e6dec49f2bff4f403d243dab6,vs,0.722363
uuid-87893c0e6dec49f2bff4f403d243dab6,Keytruda,0.351014
uuid-87893c0e6dec49f2bff4f403d243dab6,flat dosing,0.638072
uuid-0df50aa385db43a8a65d8d6d81f92721,BMS,0.362976
uuid-0df50aa385db43a8a65d8d6d81f92721,PDL1,0.365149
uuid-0df50aa385db43a8a65d8d6d81f92721,trial,0.446253
uuid-0df50aa385db43a8a65d8d6d81f92721,efficacy,0.499402
uuid-0df50aa385db43a8a65d8d6d81f92721,commented,0.448957
uuid-0df50aa385db43a8a65d8d6d81f92721,stated,0.383662
uuid-0df50aa385db43a8a65d8d6d81f92721,OS,0.612315
uuid-0df50aa385db43a8a65d8d6d81f92721,data,0.859884
uuid-0df50aa385db43a8a65d8d6d81f92721,PFS,0.56878
uuid-0df50aa385db43a8a65d8d6d81f92721,ORR,0.621223
uuid-0df50aa385db43a8a65d8d6d81f92721,nivo and pembro,0.429346
uuid-0df50aa385db43a8a65d8d6d81f92721,ASCO,0.357363
uuid-0df50aa385db43a8a65d8d6d81f92721,impressed,0.694654
uuid-0df50aa385db43a8a65d8d6d81f92721,feels,0.515914
uuid-0df50aa385db43a8a65d8d6d81f92721,PDL1 expression,0.308177
uuid-2479e9ac81304b2793458f5621b2bf8d,patients,0.632619
uuid-2479e9ac81304b2793458f5621b2bf8d,Opdivo,0.362511
uuid-2479e9ac81304b2793458f5621b2bf8d,toxicity,0.520216
uuid-2479e9ac81304b2793458f5621b2bf8d,regimen,0.454317
uuid-2479e9ac81304b2793458f5621b2bf8d,treated,0.459783
uuid-2479e9ac81304b2793458f5621b2bf8d,pts,0.316502
uuid-2479e9ac81304b2793458f5621b2bf8d,treatment,0.627398
uuid-2479e9ac81304b2793458f5621b2bf8d,progression,0.453372
uuid-2479e9ac81304b2793458f5621b2bf8d,respond,0.449012
uuid-14d509ebfc5148ef9d686c68f643766d,pembro,0.57493
uuid-14d509ebfc5148ef9d686c68f643766d,RTL,0.4688
uuid-14d509ebfc5148ef9d686c68f643766d,trial,0.303007
uuid-14d509ebfc5148ef9d686c68f643766d,shared,0.383146
uuid-14d509ebfc5148ef9d686c68f643766d,commented,0.4649
uuid-14d509ebfc5148ef9d686c68f643766d,RCC,0.36523
uuid-14d509ebfc5148ef9d686c68f643766d,2L,0.357935
uuid-14d509ebfc5148ef9d686c68f643766d,Ipi,0.301526
uuid-14d509ebfc5148ef9d686c68f643766d,stated,0.545373
uuid-14d509ebfc5148ef9d686c68f643766d,approval,0.534616
uuid-14d509ebfc5148ef9d686c68f643766d,atezo,0.545005
uuid-14d509ebfc5148ef9d686c68f643766d,preferred,0.366046
uuid-14d509ebfc5148ef9d686c68f643766d,using nivo,0.490788
uuid-14d509ebfc5148ef9d686c68f643766d,data,0.501041
uuid-14d509ebfc5148ef9d686c68f643766d,expressed,0.318797
uuid-14d509ebfc5148ef9d686c68f643766d,mentioned,0.347623
uuid-14d509ebfc5148ef9d686c68f643766d,clinical trials,0.366785
uuid-14d509ebfc5148ef9d686c68f643766d,indication,0.58427
uuid-14d509ebfc5148ef9d686c68f643766d,approved,0.473204
uuid-14d509ebfc5148ef9d686c68f643766d,SCCHN,0.626132
uuid-14d509ebfc5148ef9d686c68f643766d,HCP,0.374896
uuid-14d509ebfc5148ef9d686c68f643766d,impressed,0.514622
uuid-14d509ebfc5148ef9d686c68f643766d,label,0.38261
uuid-14d509ebfc5148ef9d686c68f643766d,LTL,0.5774
uuid-14d509ebfc5148ef9d686c68f643766d,TLs,0.524812
uuid-14d509ebfc5148ef9d686c68f643766d,SCLC,0.367623
uuid-14d509ebfc5148ef9d686c68f643766d,Regional TL,0.526295
uuid-14d509ebfc5148ef9d686c68f643766d,RTL stated,0.421709
uuid-14d509ebfc5148ef9d686c68f643766d,bladder,0.466183
uuid-14d509ebfc5148ef9d686c68f643766d,flat dosing,0.444309
uuid-acb6e7a388884d8b950fbe57354566ae,feels,0.333984
uuid-acb6e7a388884d8b950fbe57354566ae,PDL1 expression,0.347696
uuid-acb6e7a388884d8b950fbe57354566ae,bladder,0.363472
uuid-9f3361210b50405fac31a0f736f10a78,patients,0.388166
uuid-9f3361210b50405fac31a0f736f10a78,Opdivo,0.460152
uuid-9f3361210b50405fac31a0f736f10a78,therapy,0.330277
uuid-9f3361210b50405fac31a0f736f10a78,nivolumab,0.319861
uuid-9f3361210b50405fac31a0f736f10a78,stated,0.302086
uuid-9f3361210b50405fac31a0f736f10a78,using nivo,0.356295
uuid-9f3361210b50405fac31a0f736f10a78,cHL,0.361659
uuid-9f3361210b50405fac31a0f736f10a78,Keytruda,0.324083
uuid-8423698c185e4f169e6d532f1b188f69,Nivo,0.423631
uuid-8423698c185e4f169e6d532f1b188f69,patients,0.486985
uuid-8423698c185e4f169e6d532f1b188f69,pembro,0.452378
uuid-8423698c185e4f169e6d532f1b188f69,therapy,0.485774
uuid-8423698c185e4f169e6d532f1b188f69,nivolumab,0.385349
uuid-8423698c185e4f169e6d532f1b188f69,1L,0.639637
uuid-8423698c185e4f169e6d532f1b188f69,regimen,0.300781
uuid-8423698c185e4f169e6d532f1b188f69,RCC,0.311829
uuid-8423698c185e4f169e6d532f1b188f69,chemo,0.4647
uuid-8423698c185e4f169e6d532f1b188f69,2L,0.679953
uuid-8423698c185e4f169e6d532f1b188f69,pts,0.358511
uuid-8423698c185e4f169e6d532f1b188f69,agents,0.461969
uuid-8423698c185e4f169e6d532f1b188f69,approval,0.355229
uuid-8423698c185e4f169e6d532f1b188f69,atezo,0.401619
uuid-8423698c185e4f169e6d532f1b188f69,preferred,0.721016
uuid-8423698c185e4f169e6d532f1b188f69,monotherapy,0.641949
uuid-8423698c185e4f169e6d532f1b188f69,treatment,0.376287
uuid-8423698c185e4f169e6d532f1b188f69,using nivo,0.609883
uuid-8423698c185e4f169e6d532f1b188f69,PDL1 testing,0.320508
uuid-8423698c185e4f169e6d532f1b188f69,NSCLC patients,0.386716
uuid-8423698c185e4f169e6d532f1b188f69,PD1,0.407097
uuid-8423698c185e4f169e6d532f1b188f69,approved,0.436006
uuid-8423698c185e4f169e6d532f1b188f69,chemotherapy,0.396806
uuid-8423698c185e4f169e6d532f1b188f69,feels,0.359958
uuid-8423698c185e4f169e6d532f1b188f69,PD-1,0.33401
uuid-8423698c185e4f169e6d532f1b188f69,RTL stated,0.514452
uuid-8423698c185e4f169e6d532f1b188f69,option,0.697215
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,RTL,0.589933
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,BMS,0.350191
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,trial,0.385515
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,NTL,0.557131
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,discussed,0.406756
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,shared,0.345872
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,commented,0.693702
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,stated,0.553803
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,OS,0.385171
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,data,0.698723
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,expressed,0.460035
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,mentioned,0.352491
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,PFS,0.314537
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,ORR,0.395993
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,SCCHN,0.431307
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,ASCO,0.653724
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,impressed,0.766268
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,LTL,0.449987
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,TLs,0.452937
uuid-a846dac2a89548a18fcc8d9fc74f3a0b,Regional TL,0.649663
uuid-765c4da59f40405bbff53b0af8e5a767,Nivo,0.335598
uuid-765c4da59f40405bbff53b0af8e5a767,patients,0.325963
uuid-765c4da59f40405bbff53b0af8e5a767,nivolumab,0.302653
uuid-765c4da59f40405bbff53b0af8e5a767,pts,0.461707
uuid-765c4da59f40405bbff53b0af8e5a767,stated,0.369537
uuid-765c4da59f40405bbff53b0af8e5a767,OS,0.32772
uuid-765c4da59f40405bbff53b0af8e5a767,PFS,0.318992
uuid-765c4da59f40405bbff53b0af8e5a767,ORR,0.403882
uuid-765c4da59f40405bbff53b0af8e5a767,impressed,0.439343
uuid-1f16f3101d63416f86b0985a2c0c9494,Nivo,0.433795
uuid-1f16f3101d63416f86b0985a2c0c9494,patients,0.344864
uuid-1f16f3101d63416f86b0985a2c0c9494,nivolumab,0.325072
uuid-1f16f3101d63416f86b0985a2c0c9494,toxicity,0.321832
uuid-1f16f3101d63416f86b0985a2c0c9494,regimen,0.410333
uuid-1f16f3101d63416f86b0985a2c0c9494,combination,0.460153
uuid-1f16f3101d63416f86b0985a2c0c9494,chemo,0.537299
uuid-1f16f3101d63416f86b0985a2c0c9494,pts,0.34918
uuid-1f16f3101d63416f86b0985a2c0c9494,monotherapy,0.394189
uuid-1f16f3101d63416f86b0985a2c0c9494,response,0.374548
uuid-1f16f3101d63416f86b0985a2c0c9494,combo,0.363316
uuid-1f16f3101d63416f86b0985a2c0c9494,PD1,0.335685
uuid-1f16f3101d63416f86b0985a2c0c9494,chemotherapy,0.538005
uuid-1f16f3101d63416f86b0985a2c0c9494,option,0.301091
uuid-1f16f3101d63416f86b0985a2c0c9494,bladder,0.32145
uuid-857b34e640d842f58c47267246435d1d,pembro,0.506102
uuid-857b34e640d842f58c47267246435d1d,PDL1,0.706247
uuid-857b34e640d842f58c47267246435d1d,trial,0.448752
uuid-857b34e640d842f58c47267246435d1d,efficacy,0.37553
uuid-857b34e640d842f58c47267246435d1d,Merck,0.374898
uuid-857b34e640d842f58c47267246435d1d,PD-L1,0.450695
uuid-857b34e640d842f58c47267246435d1d,OS,0.369432
uuid-857b34e640d842f58c47267246435d1d,atezo,0.412567
uuid-857b34e640d842f58c47267246435d1d,testing,0.346832
uuid-857b34e640d842f58c47267246435d1d,data,0.419695
uuid-857b34e640d842f58c47267246435d1d,PFS,0.399597
uuid-857b34e640d842f58c47267246435d1d,NSCLC patients,0.303161
uuid-857b34e640d842f58c47267246435d1d,ORR,0.396239
uuid-857b34e640d842f58c47267246435d1d,nivo and pembro,0.633818
uuid-857b34e640d842f58c47267246435d1d,believes,0.373231
uuid-857b34e640d842f58c47267246435d1d,vs,0.370563
uuid-857b34e640d842f58c47267246435d1d,assay,0.372711
uuid-857b34e640d842f58c47267246435d1d,PDL1 expression,0.613648
uuid-857b34e640d842f58c47267246435d1d,biomarker,0.383428
uuid-b692bb5035f4443b87cba02cbfb1d463,patients,0.310862
uuid-b692bb5035f4443b87cba02cbfb1d463,Opdivo,0.387741
uuid-b692bb5035f4443b87cba02cbfb1d463,dose,0.783461
uuid-b692bb5035f4443b87cba02cbfb1d463,toxicity,0.610729
uuid-b692bb5035f4443b87cba02cbfb1d463,regimen,0.401997
uuid-b692bb5035f4443b87cba02cbfb1d463,Ipi,0.3436
uuid-b692bb5035f4443b87cba02cbfb1d463,treatment,0.305509
uuid-b692bb5035f4443b87cba02cbfb1d463,flat dosing,0.536583
uuid-7b315611f20944d78109f333d4c35061,oncology,0.369639
uuid-7b315611f20944d78109f333d4c35061,NCCN,0.339938
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,physicians,0.338501
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,preferred,0.404634
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,indication,0.41251
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,oncology,0.31471
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,approved,0.406815
uuid-c02ebc629e5f451f809ecd9f3c0db4f6,option,0.333068
uuid-bacb888afd174724add9612e080b9147,pembro,0.412381
uuid-bacb888afd174724add9612e080b9147,RTL,0.312618
uuid-bacb888afd174724add9612e080b9147,nivolumab,0.428489
uuid-bacb888afd174724add9612e080b9147,1L,0.608378
uuid-bacb888afd174724add9612e080b9147,regimen,0.310957
uuid-bacb888afd174724add9612e080b9147,RCC,0.608577
uuid-bacb888afd174724add9612e080b9147,TL stated,0.366988
uuid-bacb888afd174724add9612e080b9147,combination,0.50156
uuid-bacb888afd174724add9612e080b9147,2L,0.731497
uuid-bacb888afd174724add9612e080b9147,agents,0.484046
uuid-bacb888afd174724add9612e080b9147,approval,0.305766
uuid-bacb888afd174724add9612e080b9147,atezo,0.485046
uuid-bacb888afd174724add9612e080b9147,preferred,0.685552
uuid-bacb888afd174724add9612e080b9147,monotherapy,0.622495
uuid-bacb888afd174724add9612e080b9147,using nivo,0.608314
uuid-bacb888afd174724add9612e080b9147,combo,0.540071
uuid-bacb888afd174724add9612e080b9147,clinical trials,0.320523
uuid-bacb888afd174724add9612e080b9147,PD1,0.334871
uuid-bacb888afd174724add9612e080b9147,approved,0.425011
uuid-bacb888afd174724add9612e080b9147,SCCHN,0.512411
uuid-bacb888afd174724add9612e080b9147,LTL,0.346521
uuid-bacb888afd174724add9612e080b9147,TLs,0.467582
uuid-bacb888afd174724add9612e080b9147,academic,0.44056
uuid-bacb888afd174724add9612e080b9147,Regional TL,0.420866
uuid-bacb888afd174724add9612e080b9147,RTL stated,0.70215
uuid-bacb888afd174724add9612e080b9147,TL shared,0.37961
uuid-bacb888afd174724add9612e080b9147,option,0.491258
uuid-bacb888afd174724add9612e080b9147,bladder,0.416406
uuid-b0835f3e38134756b13fb0c48cedcf9d,Nivo,0.32668
uuid-b0835f3e38134756b13fb0c48cedcf9d,patients,0.550732
uuid-b0835f3e38134756b13fb0c48cedcf9d,Opdivo,0.441497
uuid-b0835f3e38134756b13fb0c48cedcf9d,therapy,0.5701
uuid-b0835f3e38134756b13fb0c48cedcf9d,nivolumab,0.453617
uuid-b0835f3e38134756b13fb0c48cedcf9d,treated,0.322712
uuid-b0835f3e38134756b13fb0c48cedcf9d,treatment,0.315952
uuid-b0835f3e38134756b13fb0c48cedcf9d,using nivo,0.309063
uuid-b0835f3e38134756b13fb0c48cedcf9d,cHL,0.794577
uuid-98f2e9701cc94816b4763bc45058f1e6,shared,0.572782
uuid-98f2e9701cc94816b4763bc45058f1e6,institution,0.681952
uuid-98f2e9701cc94816b4763bc45058f1e6,stated,0.357654
uuid-98f2e9701cc94816b4763bc45058f1e6,clinical,0.313862
uuid-1dcbb6849552435f85c94d9776b9d859,patients,0.327157
uuid-1dcbb6849552435f85c94d9776b9d859,physicians,0.31791
uuid-1dcbb6849552435f85c94d9776b9d859,lung cancer,0.344853
uuid-1dcbb6849552435f85c94d9776b9d859,progression,0.303613
uuid-1dcbb6849552435f85c94d9776b9d859,tumor types,0.369121
uuid-3d9cc20fe1a54897b136a5a676c5d54f,toxicity,0.328909
uuid-3d9cc20fe1a54897b136a5a676c5d54f,regimen,0.454081
uuid-3d9cc20fe1a54897b136a5a676c5d54f,combination,0.308468
uuid-3d9cc20fe1a54897b136a5a676c5d54f,chemo,0.340322
uuid-3d9cc20fe1a54897b136a5a676c5d54f,preferred,0.370237
uuid-3d9cc20fe1a54897b136a5a676c5d54f,monotherapy,0.441309
uuid-3d9cc20fe1a54897b136a5a676c5d54f,treatment,0.317588
uuid-3d9cc20fe1a54897b136a5a676c5d54f,combo,0.376938
uuid-3d9cc20fe1a54897b136a5a676c5d54f,chemotherapy,0.387082
uuid-3d9cc20fe1a54897b136a5a676c5d54f,option,0.497113
uuid-3bba1fc4adb04e8cb61c8eaec706d145,patients,0.626418
uuid-3bba1fc4adb04e8cb61c8eaec706d145,therapy,0.487687
uuid-3bba1fc4adb04e8cb61c8eaec706d145,nivolumab,0.300252
uuid-3bba1fc4adb04e8cb61c8eaec706d145,toxicity,0.362196
uuid-3bba1fc4adb04e8cb61c8eaec706d145,regimen,0.514445
uuid-3bba1fc4adb04e8cb61c8eaec706d145,treated,0.550382
uuid-3bba1fc4adb04e8cb61c8eaec706d145,chemo,0.455339
uuid-3bba1fc4adb04e8cb61c8eaec706d145,pts,0.512932
uuid-3bba1fc4adb04e8cb61c8eaec706d145,IO,0.400524
uuid-3bba1fc4adb04e8cb61c8eaec706d145,monotherapy,0.424118
uuid-3bba1fc4adb04e8cb61c8eaec706d145,treatment,0.651584
uuid-3bba1fc4adb04e8cb61c8eaec706d145,response,0.570578
uuid-3bba1fc4adb04e8cb61c8eaec706d145,PD1,0.39133
uuid-3bba1fc4adb04e8cb61c8eaec706d145,progression,0.641055
uuid-3bba1fc4adb04e8cb61c8eaec706d145,chemotherapy,0.388849
uuid-3bba1fc4adb04e8cb61c8eaec706d145,respond,0.618067
uuid-3bba1fc4adb04e8cb61c8eaec706d145,option,0.370179
uuid-80da3ff344d443f984be572752d209d6,patients,0.870386
uuid-80da3ff344d443f984be572752d209d6,Opdivo,0.589178
uuid-80da3ff344d443f984be572752d209d6,therapy,0.606345
uuid-80da3ff344d443f984be572752d209d6,nivolumab,0.42537
uuid-80da3ff344d443f984be572752d209d6,toxicity,0.355965
uuid-80da3ff344d443f984be572752d209d6,regimen,0.578957
uuid-80da3ff344d443f984be572752d209d6,treated,0.520933
uuid-80da3ff344d443f984be572752d209d6,chemo,0.319161
uuid-80da3ff344d443f984be572752d209d6,pts,0.569556
uuid-80da3ff344d443f984be572752d209d6,monotherapy,0.334323
uuid-80da3ff344d443f984be572752d209d6,treatment,0.809423
uuid-80da3ff344d443f984be572752d209d6,response,0.462205
uuid-80da3ff344d443f984be572752d209d6,PD1,0.306446
uuid-80da3ff344d443f984be572752d209d6,cHL,0.309564
uuid-80da3ff344d443f984be572752d209d6,progression,0.755878
uuid-80da3ff344d443f984be572752d209d6,chemotherapy,0.379891
uuid-80da3ff344d443f984be572752d209d6,respond,0.641486
uuid-80da3ff344d443f984be572752d209d6,option,0.318762
uuid-65be29c40e8a48208003dcc2f030ec7f,RTL,0.308071
uuid-65be29c40e8a48208003dcc2f030ec7f,nivolumab,0.303038
uuid-65be29c40e8a48208003dcc2f030ec7f,1L,0.385863
uuid-65be29c40e8a48208003dcc2f030ec7f,regimen,0.412775
uuid-65be29c40e8a48208003dcc2f030ec7f,RCC,0.336399
uuid-65be29c40e8a48208003dcc2f030ec7f,combination,0.537443
uuid-65be29c40e8a48208003dcc2f030ec7f,2L,0.396742
uuid-65be29c40e8a48208003dcc2f030ec7f,IO,0.425657
uuid-65be29c40e8a48208003dcc2f030ec7f,Ipi,0.373425
uuid-65be29c40e8a48208003dcc2f030ec7f,preferred,0.365646
uuid-65be29c40e8a48208003dcc2f030ec7f,monotherapy,0.527185
uuid-65be29c40e8a48208003dcc2f030ec7f,using nivo,0.438398
uuid-65be29c40e8a48208003dcc2f030ec7f,combo,0.636249
uuid-65be29c40e8a48208003dcc2f030ec7f,PD1,0.325517
uuid-65be29c40e8a48208003dcc2f030ec7f,believes,0.369201
uuid-65be29c40e8a48208003dcc2f030ec7f,TLs,0.464577
uuid-65be29c40e8a48208003dcc2f030ec7f,feels,0.388093
uuid-65be29c40e8a48208003dcc2f030ec7f,Regional TL,0.345404
uuid-65be29c40e8a48208003dcc2f030ec7f,RTL stated,0.34161
uuid-65be29c40e8a48208003dcc2f030ec7f,option,0.358218
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,1L,0.314641
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,2L,0.430715
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,agents,0.420285
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,physicians,0.347393
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,preferred,0.480044
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,monotherapy,0.31799
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,using nivo,0.328566
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,approved,0.372638
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,oncologist,0.395182
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,feels,0.307605
uuid-22f1a3b2715247a1b4f1fd30557cf5c7,option,0.433326
uuid-8ea62ab3f27649038223555482edb2dc,lung,0.302624
uuid-8ea62ab3f27649038223555482edb2dc,NSCLC,0.300348
uuid-8ea62ab3f27649038223555482edb2dc,1L,0.347729
uuid-8ea62ab3f27649038223555482edb2dc,PDL1,0.462464
uuid-8ea62ab3f27649038223555482edb2dc,TL stated,0.340387
uuid-8ea62ab3f27649038223555482edb2dc,stated,0.300034
uuid-8ea62ab3f27649038223555482edb2dc,PDL1 testing,0.389495
uuid-8ea62ab3f27649038223555482edb2dc,nivo and pembro,0.334599
uuid-8ea62ab3f27649038223555482edb2dc,believes,0.398936
uuid-8ea62ab3f27649038223555482edb2dc,feels,0.365036
uuid-8ea62ab3f27649038223555482edb2dc,PDL1 expression,0.306404
uuid-8ea62ab3f27649038223555482edb2dc,biomarker,0.359268
uuid-818b463ebd3245e9848567a0f11b2db1,1L,0.484549
uuid-818b463ebd3245e9848567a0f11b2db1,PDL1,0.4953
uuid-818b463ebd3245e9848567a0f11b2db1,TL stated,0.304988
uuid-818b463ebd3245e9848567a0f11b2db1,2L,0.381351
uuid-818b463ebd3245e9848567a0f11b2db1,PD-L1,0.580844
uuid-818b463ebd3245e9848567a0f11b2db1,preferred,0.321613
uuid-818b463ebd3245e9848567a0f11b2db1,PD-L1 testing,0.47649
uuid-818b463ebd3245e9848567a0f11b2db1,testing,0.62597
uuid-818b463ebd3245e9848567a0f11b2db1,PDL1 testing,0.554088
uuid-818b463ebd3245e9848567a0f11b2db1,NSCLC patients,0.486531
uuid-818b463ebd3245e9848567a0f11b2db1,believes,0.379986
uuid-818b463ebd3245e9848567a0f11b2db1,assay,0.344547
uuid-818b463ebd3245e9848567a0f11b2db1,PD-1,0.317764
uuid-818b463ebd3245e9848567a0f11b2db1,option,0.403194
uuid-818b463ebd3245e9848567a0f11b2db1,biomarker,0.507928
uuid-4403155cca4545b0b8ba2e42e53a2355,PDL1,0.310197
uuid-4403155cca4545b0b8ba2e42e53a2355,efficacy,0.454819
uuid-4403155cca4545b0b8ba2e42e53a2355,OS,0.47877
uuid-4403155cca4545b0b8ba2e42e53a2355,data,0.323396
uuid-4403155cca4545b0b8ba2e42e53a2355,PFS,0.537403
uuid-4403155cca4545b0b8ba2e42e53a2355,ORR,0.500994
uuid-4403155cca4545b0b8ba2e42e53a2355,nivo and pembro,0.375893
uuid-4403155cca4545b0b8ba2e42e53a2355,believes,0.339335
uuid-4403155cca4545b0b8ba2e42e53a2355,immunotherapy,0.363431
uuid-4403155cca4545b0b8ba2e42e53a2355,PDL1 expression,0.315618
uuid-2adf0084e3584f41a9e43efc2bc6b9ba,patients,0.418072
uuid-2adf0084e3584f41a9e43efc2bc6b9ba,Opdivo,0.330351
uuid-2adf0084e3584f41a9e43efc2bc6b9ba,physicians,0.383135
uuid-2adf0084e3584f41a9e43efc2bc6b9ba,clinical trials,0.36851
uuid-2adf0084e3584f41a9e43efc2bc6b9ba,academic,0.314365
uuid-b72f87e739214db2a01d3c0e1914389e,Nivo,0.389909
uuid-b72f87e739214db2a01d3c0e1914389e,patients,0.473374
uuid-b72f87e739214db2a01d3c0e1914389e,Opdivo,0.553409
uuid-b72f87e739214db2a01d3c0e1914389e,dose,0.563712
uuid-b72f87e739214db2a01d3c0e1914389e,nivolumab,0.323505
uuid-b72f87e739214db2a01d3c0e1914389e,regimen,0.407174
uuid-b72f87e739214db2a01d3c0e1914389e,chemo,0.303556
uuid-b72f87e739214db2a01d3c0e1914389e,2L,0.34741
uuid-b72f87e739214db2a01d3c0e1914389e,preferred,0.454717
uuid-b72f87e739214db2a01d3c0e1914389e,monotherapy,0.409432
uuid-b72f87e739214db2a01d3c0e1914389e,treatment,0.350607
uuid-b72f87e739214db2a01d3c0e1914389e,approved,0.333312
uuid-b72f87e739214db2a01d3c0e1914389e,vs,0.360478
uuid-b72f87e739214db2a01d3c0e1914389e,drug,0.329538
uuid-b72f87e739214db2a01d3c0e1914389e,Keytruda,0.396066
uuid-b72f87e739214db2a01d3c0e1914389e,feels,0.307799
uuid-b72f87e739214db2a01d3c0e1914389e,option,0.42189
uuid-b72f87e739214db2a01d3c0e1914389e,flat dosing,0.443966
uuid-3248add23c1344e69fda588e4db4bc5b,pembro,0.306524
uuid-3248add23c1344e69fda588e4db4bc5b,BMS,0.32193
uuid-3248add23c1344e69fda588e4db4bc5b,PDL1,0.317138
uuid-3248add23c1344e69fda588e4db4bc5b,trial,0.645022
uuid-3248add23c1344e69fda588e4db4bc5b,data,0.314801
uuid-3248add23c1344e69fda588e4db4bc5b,combo,0.332107
uuid-3248add23c1344e69fda588e4db4bc5b,clinical trials,0.447143
uuid-3248add23c1344e69fda588e4db4bc5b,ORR,0.318947
uuid-3248add23c1344e69fda588e4db4bc5b,impressed,0.342715
uuid-3248add23c1344e69fda588e4db4bc5b,feels,0.439312
uuid-ba3272ab73c24ed68937f19ae10fc7f4,patients,0.76632
uuid-ba3272ab73c24ed68937f19ae10fc7f4,therapy,0.466205
uuid-ba3272ab73c24ed68937f19ae10fc7f4,nivolumab,0.378642
uuid-ba3272ab73c24ed68937f19ae10fc7f4,regimen,0.535635
uuid-ba3272ab73c24ed68937f19ae10fc7f4,treated,0.418543
uuid-ba3272ab73c24ed68937f19ae10fc7f4,combination,0.370351
uuid-ba3272ab73c24ed68937f19ae10fc7f4,chemo,0.433149
uuid-ba3272ab73c24ed68937f19ae10fc7f4,pts,0.590152
uuid-ba3272ab73c24ed68937f19ae10fc7f4,Ipi,0.39264
uuid-ba3272ab73c24ed68937f19ae10fc7f4,monotherapy,0.448682
uuid-ba3272ab73c24ed68937f19ae10fc7f4,treatment,0.514426
uuid-ba3272ab73c24ed68937f19ae10fc7f4,response,0.381058
uuid-ba3272ab73c24ed68937f19ae10fc7f4,combo,0.442947
uuid-ba3272ab73c24ed68937f19ae10fc7f4,PD1,0.334002
uuid-ba3272ab73c24ed68937f19ae10fc7f4,progression,0.579664
uuid-ba3272ab73c24ed68937f19ae10fc7f4,chemotherapy,0.470999
uuid-ba3272ab73c24ed68937f19ae10fc7f4,respond,0.439656
uuid-ba3272ab73c24ed68937f19ae10fc7f4,option,0.370976
uuid-4d9e710767644e0d87473647482839c7,Nivo,0.364057
uuid-4d9e710767644e0d87473647482839c7,patients,0.631964
uuid-4d9e710767644e0d87473647482839c7,therapy,0.334121
uuid-4d9e710767644e0d87473647482839c7,dose,0.378469
uuid-4d9e710767644e0d87473647482839c7,toxicity,0.382735
uuid-4d9e710767644e0d87473647482839c7,regimen,0.525769
uuid-4d9e710767644e0d87473647482839c7,treated,0.356275
uuid-4d9e710767644e0d87473647482839c7,combination,0.360497
uuid-4d9e710767644e0d87473647482839c7,chemo,0.420279
uuid-4d9e710767644e0d87473647482839c7,pts,0.437594
uuid-4d9e710767644e0d87473647482839c7,Ipi,0.525362
uuid-4d9e710767644e0d87473647482839c7,monotherapy,0.33627
uuid-4d9e710767644e0d87473647482839c7,treatment,0.429168
uuid-4d9e710767644e0d87473647482839c7,combo,0.374985
uuid-4d9e710767644e0d87473647482839c7,progression,0.395713
uuid-4d9e710767644e0d87473647482839c7,chemotherapy,0.478476
uuid-4d9e710767644e0d87473647482839c7,respond,0.363623
uuid-02977e56087b488bb6dc048783e11da0,Nivo,0.465703
uuid-02977e56087b488bb6dc048783e11da0,patients,0.756067
uuid-02977e56087b488bb6dc048783e11da0,Opdivo,0.522747
uuid-02977e56087b488bb6dc048783e11da0,pembro,0.306565
uuid-02977e56087b488bb6dc048783e11da0,therapy,0.569697
uuid-02977e56087b488bb6dc048783e11da0,nivolumab,0.580046
uuid-02977e56087b488bb6dc048783e11da0,treated,0.420376
uuid-02977e56087b488bb6dc048783e11da0,pts,0.415014
uuid-02977e56087b488bb6dc048783e11da0,approval,0.535548
uuid-02977e56087b488bb6dc048783e11da0,preferred,0.306723
uuid-02977e56087b488bb6dc048783e11da0,monotherapy,0.334633
uuid-02977e56087b488bb6dc048783e11da0,treatment,0.436628
uuid-02977e56087b488bb6dc048783e11da0,using nivo,0.500611
uuid-02977e56087b488bb6dc048783e11da0,approved,0.417476
uuid-02977e56087b488bb6dc048783e11da0,cHL,0.543934
uuid-02977e56087b488bb6dc048783e11da0,progression,0.320402
uuid-02977e56087b488bb6dc048783e11da0,chemotherapy,0.358859
uuid-02977e56087b488bb6dc048783e11da0,label,0.435171
uuid-02977e56087b488bb6dc048783e11da0,option,0.396055
uuid-ba9f11683d8041039c2042fd625fe804,pembro,0.539541
uuid-ba9f11683d8041039c2042fd625fe804,1L,0.532213
uuid-ba9f11683d8041039c2042fd625fe804,TL stated,0.379451
uuid-ba9f11683d8041039c2042fd625fe804,2L,0.573628
uuid-ba9f11683d8041039c2042fd625fe804,agents,0.309854
uuid-ba9f11683d8041039c2042fd625fe804,Merck,0.37376
uuid-ba9f11683d8041039c2042fd625fe804,stated,0.357614
uuid-ba9f11683d8041039c2042fd625fe804,PD-L1,0.384139
uuid-ba9f11683d8041039c2042fd625fe804,approval,0.474847
uuid-ba9f11683d8041039c2042fd625fe804,atezo,0.53984
uuid-ba9f11683d8041039c2042fd625fe804,preferred,0.57985
uuid-ba9f11683d8041039c2042fd625fe804,PD-L1 testing,0.328393
uuid-ba9f11683d8041039c2042fd625fe804,testing,0.44566
uuid-ba9f11683d8041039c2042fd625fe804,using nivo,0.463263
uuid-ba9f11683d8041039c2042fd625fe804,PDL1 testing,0.557989
uuid-ba9f11683d8041039c2042fd625fe804,indication,0.391811
uuid-ba9f11683d8041039c2042fd625fe804,NSCLC patients,0.435593
uuid-ba9f11683d8041039c2042fd625fe804,approved,0.52461
uuid-ba9f11683d8041039c2042fd625fe804,SCCHN,0.353683
uuid-ba9f11683d8041039c2042fd625fe804,tumor types,0.381981
uuid-ba9f11683d8041039c2042fd625fe804,feels,0.353916
uuid-ba9f11683d8041039c2042fd625fe804,RTL stated,0.408652
uuid-ba9f11683d8041039c2042fd625fe804,option,0.391111
uuid-c06ae0bd08064f5ebfa4abe62061918a,patients,0.567805
uuid-c06ae0bd08064f5ebfa4abe62061918a,Opdivo,0.398613
uuid-c06ae0bd08064f5ebfa4abe62061918a,therapy,0.353144
uuid-c06ae0bd08064f5ebfa4abe62061918a,nivolumab,0.520902
uuid-c06ae0bd08064f5ebfa4abe62061918a,treated,0.399078
uuid-c06ae0bd08064f5ebfa4abe62061918a,treatment,0.31566
uuid-c06ae0bd08064f5ebfa4abe62061918a,using nivo,0.303191
uuid-c06ae0bd08064f5ebfa4abe62061918a,mentioned,0.318991
uuid-c06ae0bd08064f5ebfa4abe62061918a,cHL,0.469376
uuid-1d191b02452648d59686379bb4b1cf42,PDL1,0.648117
uuid-1d191b02452648d59686379bb4b1cf42,efficacy,0.52855
uuid-1d191b02452648d59686379bb4b1cf42,chemo,0.301165
uuid-1d191b02452648d59686379bb4b1cf42,PD-L1,0.357953
uuid-1d191b02452648d59686379bb4b1cf42,OS,0.360624
uuid-1d191b02452648d59686379bb4b1cf42,data,0.336605
uuid-1d191b02452648d59686379bb4b1cf42,PFS,0.37389
uuid-1d191b02452648d59686379bb4b1cf42,ORR,0.409545
uuid-1d191b02452648d59686379bb4b1cf42,nivo and pembro,0.496999
uuid-1d191b02452648d59686379bb4b1cf42,believes,0.460079
uuid-1d191b02452648d59686379bb4b1cf42,feels,0.522949
uuid-1d191b02452648d59686379bb4b1cf42,PDL1 expression,0.680746
uuid-1d191b02452648d59686379bb4b1cf42,option,0.323876
uuid-1d191b02452648d59686379bb4b1cf42,biomarker,0.426418
uuid-3967714198024235a9dcc55535013757,patients,0.301146
uuid-3967714198024235a9dcc55535013757,dose,0.59175
uuid-3967714198024235a9dcc55535013757,nivolumab,0.31381
uuid-3967714198024235a9dcc55535013757,toxicity,0.404396
uuid-3967714198024235a9dcc55535013757,regimen,0.453435
uuid-3967714198024235a9dcc55535013757,treated,0.439726
uuid-3967714198024235a9dcc55535013757,melanoma,0.46992
uuid-3967714198024235a9dcc55535013757,combination,0.366836
uuid-3967714198024235a9dcc55535013757,Ipi,0.419988
uuid-3967714198024235a9dcc55535013757,treatment,0.341596
uuid-3967714198024235a9dcc55535013757,combo,0.353646
uuid-3967714198024235a9dcc55535013757,TL shared,0.347937
uuid-3967714198024235a9dcc55535013757,flat dosing,0.370603
uuid-ec2aa14c334244b88d6ce273c6f355c6,patients,0.375874
uuid-ec2aa14c334244b88d6ce273c6f355c6,Opdivo,0.429149
uuid-ec2aa14c334244b88d6ce273c6f355c6,dose,0.445113
uuid-ec2aa14c334244b88d6ce273c6f355c6,toxicity,0.495633
uuid-ec2aa14c334244b88d6ce273c6f355c6,regimen,0.541315
uuid-ec2aa14c334244b88d6ce273c6f355c6,treated,0.318245
uuid-ec2aa14c334244b88d6ce273c6f355c6,shared,0.411697
uuid-ec2aa14c334244b88d6ce273c6f355c6,physicians,0.563465
uuid-ec2aa14c334244b88d6ce273c6f355c6,treatment,0.361531
uuid-ec2aa14c334244b88d6ce273c6f355c6,drug,0.327728
uuid-ec2aa14c334244b88d6ce273c6f355c6,flat dosing,0.32274
uuid-86a4c0199def409681527af1cde28e60,Nivo,0.769707
uuid-86a4c0199def409681527af1cde28e60,patients,0.335133
uuid-86a4c0199def409681527af1cde28e60,pembro,0.469938
uuid-86a4c0199def409681527af1cde28e60,therapy,0.348171
uuid-86a4c0199def409681527af1cde28e60,1L,0.35945
uuid-86a4c0199def409681527af1cde28e60,efficacy,0.54455
uuid-86a4c0199def409681527af1cde28e60,chemo,0.650833
uuid-86a4c0199def409681527af1cde28e60,2L,0.312131
uuid-86a4c0199def409681527af1cde28e60,pts,0.313775
uuid-86a4c0199def409681527af1cde28e60,Ipi,0.399427
uuid-86a4c0199def409681527af1cde28e60,OS,0.541842
uuid-86a4c0199def409681527af1cde28e60,atezo,0.319392
uuid-86a4c0199def409681527af1cde28e60,monotherapy,0.498291
uuid-86a4c0199def409681527af1cde28e60,using nivo,0.300196
uuid-86a4c0199def409681527af1cde28e60,response,0.325947
uuid-86a4c0199def409681527af1cde28e60,combo,0.334355
uuid-86a4c0199def409681527af1cde28e60,PFS,0.555288
uuid-86a4c0199def409681527af1cde28e60,PD1,0.397995
uuid-86a4c0199def409681527af1cde28e60,ORR,0.511175
uuid-86a4c0199def409681527af1cde28e60,nivo and pembro,0.455412
uuid-86a4c0199def409681527af1cde28e60,progression,0.319877
uuid-86a4c0199def409681527af1cde28e60,believes,0.393435
uuid-86a4c0199def409681527af1cde28e60,chemotherapy,0.553224
uuid-86a4c0199def409681527af1cde28e60,vs,0.489574
uuid-86a4c0199def409681527af1cde28e60,feels,0.443141
uuid-86a4c0199def409681527af1cde28e60,option,0.443199
uuid-72a84963cbc1435d95ca039b736b7c5b,patients,0.378344
uuid-72a84963cbc1435d95ca039b736b7c5b,Opdivo,0.448535
uuid-72a84963cbc1435d95ca039b736b7c5b,therapy,0.371841
uuid-72a84963cbc1435d95ca039b736b7c5b,nivolumab,0.424839
uuid-72a84963cbc1435d95ca039b736b7c5b,toxicity,0.316553
uuid-72a84963cbc1435d95ca039b736b7c5b,treated,0.345241
uuid-72a84963cbc1435d95ca039b736b7c5b,mentioned,0.326228
uuid-72a84963cbc1435d95ca039b736b7c5b,cHL,0.711586
uuid-3f2d4ca6d91e47158820d67b9e3a2054,Nivo,0.319719
uuid-3f2d4ca6d91e47158820d67b9e3a2054,trial,0.306775
uuid-3f2d4ca6d91e47158820d67b9e3a2054,pts,0.377364
uuid-3f2d4ca6d91e47158820d67b9e3a2054,stated,0.414537
uuid-3f2d4ca6d91e47158820d67b9e3a2054,OS,0.334712
uuid-3f2d4ca6d91e47158820d67b9e3a2054,data,0.339903
uuid-3f2d4ca6d91e47158820d67b9e3a2054,combo,0.323574
uuid-3f2d4ca6d91e47158820d67b9e3a2054,progression,0.308341
uuid-3f2d4ca6d91e47158820d67b9e3a2054,impressed,0.470538
uuid-3f2d4ca6d91e47158820d67b9e3a2054,feels,0.419303
uuid-da8899c08b53401bb1e0c6668ce18129,patients,0.668431
uuid-da8899c08b53401bb1e0c6668ce18129,therapy,0.356915
uuid-da8899c08b53401bb1e0c6668ce18129,toxicity,0.522645
uuid-da8899c08b53401bb1e0c6668ce18129,regimen,0.475164
uuid-da8899c08b53401bb1e0c6668ce18129,treated,0.413219
uuid-da8899c08b53401bb1e0c6668ce18129,pts,0.404005
uuid-da8899c08b53401bb1e0c6668ce18129,treatment,0.587087
uuid-da8899c08b53401bb1e0c6668ce18129,response,0.44946
uuid-da8899c08b53401bb1e0c6668ce18129,progression,0.55489
uuid-da8899c08b53401bb1e0c6668ce18129,respond,0.605939
uuid-00f20b5304084f06932495a132d25508,therapy,0.302008
uuid-00f20b5304084f06932495a132d25508,1L,0.457249
uuid-00f20b5304084f06932495a132d25508,regimen,0.350705
uuid-00f20b5304084f06932495a132d25508,RCC,0.326294
uuid-00f20b5304084f06932495a132d25508,combination,0.500456
uuid-00f20b5304084f06932495a132d25508,chemo,0.31797
uuid-00f20b5304084f06932495a132d25508,2L,0.441759
uuid-00f20b5304084f06932495a132d25508,IO,0.524114
uuid-00f20b5304084f06932495a132d25508,agents,0.415652
uuid-00f20b5304084f06932495a132d25508,preferred,0.483302
uuid-00f20b5304084f06932495a132d25508,monotherapy,0.618259
uuid-00f20b5304084f06932495a132d25508,using nivo,0.307826
uuid-00f20b5304084f06932495a132d25508,combo,0.473378
uuid-00f20b5304084f06932495a132d25508,PD1,0.33654
uuid-00f20b5304084f06932495a132d25508,believes,0.311694
uuid-00f20b5304084f06932495a132d25508,chemotherapy,0.357142
uuid-00f20b5304084f06932495a132d25508,RTL stated,0.451881
uuid-00f20b5304084f06932495a132d25508,option,0.572823
uuid-c6f20b8b4d9d495ab47cd70133947148,patients,0.582731
uuid-c6f20b8b4d9d495ab47cd70133947148,Opdivo,0.437913
uuid-c6f20b8b4d9d495ab47cd70133947148,therapy,0.459894
uuid-c6f20b8b4d9d495ab47cd70133947148,nivolumab,0.351319
uuid-c6f20b8b4d9d495ab47cd70133947148,regimen,0.586696
uuid-c6f20b8b4d9d495ab47cd70133947148,treated,0.475969
uuid-c6f20b8b4d9d495ab47cd70133947148,pts,0.335473
uuid-c6f20b8b4d9d495ab47cd70133947148,physicians,0.401353
uuid-c6f20b8b4d9d495ab47cd70133947148,monotherapy,0.487542
uuid-c6f20b8b4d9d495ab47cd70133947148,treatment,0.675452
uuid-c6f20b8b4d9d495ab47cd70133947148,progression,0.470143
uuid-c6f20b8b4d9d495ab47cd70133947148,chemotherapy,0.328571
uuid-c6f20b8b4d9d495ab47cd70133947148,respond,0.436538
uuid-c6f20b8b4d9d495ab47cd70133947148,feels,0.394939
uuid-c6f20b8b4d9d495ab47cd70133947148,option,0.444621
uuid-0089f0260f9e49a49536166e93dc3342,Opdivo,0.490516
uuid-0089f0260f9e49a49536166e93dc3342,physicians,0.376295
uuid-2a199807c17e4b44aa1d93d1ff1981f2,Nivo,0.522544
uuid-2a199807c17e4b44aa1d93d1ff1981f2,patients,0.468633
uuid-2a199807c17e4b44aa1d93d1ff1981f2,pembro,0.355432
uuid-2a199807c17e4b44aa1d93d1ff1981f2,nivolumab,0.321068
uuid-2a199807c17e4b44aa1d93d1ff1981f2,1L,0.464901
uuid-2a199807c17e4b44aa1d93d1ff1981f2,regimen,0.375979
uuid-2a199807c17e4b44aa1d93d1ff1981f2,combination,0.34427
uuid-2a199807c17e4b44aa1d93d1ff1981f2,chemo,0.474886
uuid-2a199807c17e4b44aa1d93d1ff1981f2,2L,0.406139
uuid-2a199807c17e4b44aa1d93d1ff1981f2,pts,0.524367
uuid-2a199807c17e4b44aa1d93d1ff1981f2,monotherapy,0.530637
uuid-2a199807c17e4b44aa1d93d1ff1981f2,using nivo,0.408152
uuid-2a199807c17e4b44aa1d93d1ff1981f2,response,0.361965
uuid-2a199807c17e4b44aa1d93d1ff1981f2,combo,0.425999
uuid-2a199807c17e4b44aa1d93d1ff1981f2,PD1,0.393529
uuid-2a199807c17e4b44aa1d93d1ff1981f2,approved,0.357584
uuid-2a199807c17e4b44aa1d93d1ff1981f2,progression,0.409179
uuid-2a199807c17e4b44aa1d93d1ff1981f2,believes,0.327617
uuid-2a199807c17e4b44aa1d93d1ff1981f2,chemotherapy,0.344145
uuid-2a199807c17e4b44aa1d93d1ff1981f2,impressed,0.391249
uuid-2a199807c17e4b44aa1d93d1ff1981f2,respond,0.363396
uuid-2a199807c17e4b44aa1d93d1ff1981f2,feels,0.511521
uuid-2a199807c17e4b44aa1d93d1ff1981f2,option,0.495675
uuid-b25ca235525946fa8ecd1b7afdda22b0,patients,0.785289
uuid-b25ca235525946fa8ecd1b7afdda22b0,therapy,0.626429
uuid-b25ca235525946fa8ecd1b7afdda22b0,nivolumab,0.334471
uuid-b25ca235525946fa8ecd1b7afdda22b0,regimen,0.542771
uuid-b25ca235525946fa8ecd1b7afdda22b0,treated,0.477699
uuid-b25ca235525946fa8ecd1b7afdda22b0,chemo,0.62561
uuid-b25ca235525946fa8ecd1b7afdda22b0,pts,0.59795
uuid-b25ca235525946fa8ecd1b7afdda22b0,monotherapy,0.448395
uuid-b25ca235525946fa8ecd1b7afdda22b0,treatment,0.735989
uuid-b25ca235525946fa8ecd1b7afdda22b0,response,0.571326
uuid-b25ca235525946fa8ecd1b7afdda22b0,PD1,0.439071
uuid-b25ca235525946fa8ecd1b7afdda22b0,progression,0.775193
uuid-b25ca235525946fa8ecd1b7afdda22b0,chemotherapy,0.575293
uuid-b25ca235525946fa8ecd1b7afdda22b0,respond,0.556064
uuid-b25ca235525946fa8ecd1b7afdda22b0,option,0.466832
uuid-d05decd3f8774c449d7b04b432dd1afb,patients,0.606943
uuid-d05decd3f8774c449d7b04b432dd1afb,therapy,0.319551
uuid-d05decd3f8774c449d7b04b432dd1afb,toxicity,0.623591
uuid-d05decd3f8774c449d7b04b432dd1afb,regimen,0.488103
uuid-d05decd3f8774c449d7b04b432dd1afb,treated,0.457109
uuid-d05decd3f8774c449d7b04b432dd1afb,pts,0.338511
uuid-d05decd3f8774c449d7b04b432dd1afb,treatment,0.5938
uuid-d05decd3f8774c449d7b04b432dd1afb,progression,0.510079
uuid-d05decd3f8774c449d7b04b432dd1afb,respond,0.398856
uuid-c71f59eace4841038e7e9d20647d3d68,patients,0.542879
uuid-c71f59eace4841038e7e9d20647d3d68,therapy,0.653907
uuid-c71f59eace4841038e7e9d20647d3d68,nivolumab,0.344378
uuid-c71f59eace4841038e7e9d20647d3d68,regimen,0.451219
uuid-c71f59eace4841038e7e9d20647d3d68,treated,0.414995
uuid-c71f59eace4841038e7e9d20647d3d68,combination,0.312137
uuid-c71f59eace4841038e7e9d20647d3d68,chemo,0.470876
uuid-c71f59eace4841038e7e9d20647d3d68,pts,0.471911
uuid-c71f59eace4841038e7e9d20647d3d68,IO,0.30343
uuid-c71f59eace4841038e7e9d20647d3d68,monotherapy,0.411631
uuid-c71f59eace4841038e7e9d20647d3d68,treatment,0.647487
uuid-c71f59eace4841038e7e9d20647d3d68,response,0.576671
uuid-c71f59eace4841038e7e9d20647d3d68,PD1,0.476334
uuid-c71f59eace4841038e7e9d20647d3d68,progression,0.687062
uuid-c71f59eace4841038e7e9d20647d3d68,chemotherapy,0.464986
uuid-c71f59eace4841038e7e9d20647d3d68,respond,0.525964
uuid-c71f59eace4841038e7e9d20647d3d68,option,0.385605
uuid-a8ad747a58ee4ddbbb117d7af725b94a,trial,0.351026
uuid-a8ad747a58ee4ddbbb117d7af725b94a,clinical trials,0.345309
uuid-a8ad747a58ee4ddbbb117d7af725b94a,impressed,0.350241
uuid-a8ad747a58ee4ddbbb117d7af725b94a,respond,0.316893
uuid-a8ad747a58ee4ddbbb117d7af725b94a,feels,0.350424
uuid-02ac24d7642449d99f6e2d83f09c6f76,Nivo,0.339873
uuid-02ac24d7642449d99f6e2d83f09c6f76,Opdivo,0.439463
uuid-02ac24d7642449d99f6e2d83f09c6f76,pembro,0.444969
uuid-02ac24d7642449d99f6e2d83f09c6f76,dose,0.90716
uuid-02ac24d7642449d99f6e2d83f09c6f76,efficacy,0.312518
uuid-02ac24d7642449d99f6e2d83f09c6f76,Ipi,0.55074
uuid-02ac24d7642449d99f6e2d83f09c6f76,atezo,0.451363
uuid-02ac24d7642449d99f6e2d83f09c6f76,vs,0.631994
uuid-02ac24d7642449d99f6e2d83f09c6f76,Keytruda,0.48116
uuid-02ac24d7642449d99f6e2d83f09c6f76,flat dosing,0.796041
uuid-7959c951687f42bc8dea89e769c5212f,commented,0.383306
uuid-7959c951687f42bc8dea89e769c5212f,stated,0.383318
uuid-7959c951687f42bc8dea89e769c5212f,atezo,0.328158
uuid-7959c951687f42bc8dea89e769c5212f,regards,0.428093
uuid-7959c951687f42bc8dea89e769c5212f,data,0.330155
uuid-7959c951687f42bc8dea89e769c5212f,expressed,0.423544
uuid-7959c951687f42bc8dea89e769c5212f,indication,0.520672
uuid-7959c951687f42bc8dea89e769c5212f,approved,0.392948
uuid-7959c951687f42bc8dea89e769c5212f,SCCHN,0.350961
uuid-7959c951687f42bc8dea89e769c5212f,impressed,0.314434
uuid-7959c951687f42bc8dea89e769c5212f,TLs,0.439613
uuid-7959c951687f42bc8dea89e769c5212f,Regional TL,0.333258
uuid-7959c951687f42bc8dea89e769c5212f,NCCN,0.321174
uuid-4bed2fdd0b5445e499c79709fd40a7d5,patients,0.367204
uuid-4bed2fdd0b5445e499c79709fd40a7d5,therapy,0.47875
uuid-4bed2fdd0b5445e499c79709fd40a7d5,nivolumab,0.312779
uuid-4bed2fdd0b5445e499c79709fd40a7d5,toxicity,0.702495
uuid-4bed2fdd0b5445e499c79709fd40a7d5,regimen,0.617646
uuid-4bed2fdd0b5445e499c79709fd40a7d5,treated,0.403805
uuid-4bed2fdd0b5445e499c79709fd40a7d5,combination,0.474589
uuid-4bed2fdd0b5445e499c79709fd40a7d5,chemo,0.453916
uuid-4bed2fdd0b5445e499c79709fd40a7d5,pts,0.30498
uuid-4bed2fdd0b5445e499c79709fd40a7d5,IO,0.311121
uuid-4bed2fdd0b5445e499c79709fd40a7d5,agents,0.32275
uuid-4bed2fdd0b5445e499c79709fd40a7d5,monotherapy,0.463355
uuid-4bed2fdd0b5445e499c79709fd40a7d5,treatment,0.595842
uuid-4bed2fdd0b5445e499c79709fd40a7d5,response,0.425896
uuid-4bed2fdd0b5445e499c79709fd40a7d5,combo,0.385106
uuid-4bed2fdd0b5445e499c79709fd40a7d5,PD1,0.499562
uuid-4bed2fdd0b5445e499c79709fd40a7d5,progression,0.518096
uuid-4bed2fdd0b5445e499c79709fd40a7d5,believes,0.31754
uuid-4bed2fdd0b5445e499c79709fd40a7d5,chemotherapy,0.459565
uuid-4bed2fdd0b5445e499c79709fd40a7d5,respond,0.495572
uuid-cfbb38f4cd65404bbe165519e1033ccb,toxicity,0.454427
uuid-cfbb38f4cd65404bbe165519e1033ccb,physicians,0.316435
uuid-cfbb38f4cd65404bbe165519e1033ccb,oncology,0.300188
uuid-cfbb38f4cd65404bbe165519e1033ccb,drug,0.327791
uuid-cfbb38f4cd65404bbe165519e1033ccb,clinical,0.375012
uuid-16dffb533cd3455fab3d014b8fba30a7,Nivo,0.300614
uuid-16dffb533cd3455fab3d014b8fba30a7,pembro,0.3549
uuid-16dffb533cd3455fab3d014b8fba30a7,RTL,0.389403
uuid-16dffb533cd3455fab3d014b8fba30a7,trial,0.309285
uuid-16dffb533cd3455fab3d014b8fba30a7,using nivo,0.372371
uuid-16dffb533cd3455fab3d014b8fba30a7,mentioned,0.439651
uuid-16dffb533cd3455fab3d014b8fba30a7,HCP,0.678077
uuid-16dffb533cd3455fab3d014b8fba30a7,impressed,0.405997
uuid-16dffb533cd3455fab3d014b8fba30a7,LTL,0.399109
uuid-16dffb533cd3455fab3d014b8fba30a7,feels,0.431812
uuid-fabed750d71543ccb1bdb901fe974951,Nivo,0.401342
uuid-fabed750d71543ccb1bdb901fe974951,patients,0.399462
uuid-fabed750d71543ccb1bdb901fe974951,therapy,0.693068
uuid-fabed750d71543ccb1bdb901fe974951,nivolumab,0.514305
uuid-fabed750d71543ccb1bdb901fe974951,cHL,0.817307
uuid-fabed750d71543ccb1bdb901fe974951,chemotherapy,0.387508
uuid-49428479734b42679023f1635f47a9cb,Opdivo,0.543289
uuid-49428479734b42679023f1635f47a9cb,pembro,0.300056
uuid-49428479734b42679023f1635f47a9cb,dose,0.838204
uuid-49428479734b42679023f1635f47a9cb,toxicity,0.305015
uuid-49428479734b42679023f1635f47a9cb,Ipi,0.432752
uuid-49428479734b42679023f1635f47a9cb,vs,0.436931
uuid-49428479734b42679023f1635f47a9cb,Keytruda,0.529338
uuid-49428479734b42679023f1635f47a9cb,flat dosing,0.804011
uuid-694f335beb3d43cb9e3e883b7931e506,patients,0.363807
uuid-694f335beb3d43cb9e3e883b7931e506,TL,0.358779
uuid-694f335beb3d43cb9e3e883b7931e506,1L,0.419619
uuid-694f335beb3d43cb9e3e883b7931e506,RCC,0.386229
uuid-694f335beb3d43cb9e3e883b7931e506,TL stated,0.605528
uuid-694f335beb3d43cb9e3e883b7931e506,2L,0.335573
uuid-694f335beb3d43cb9e3e883b7931e506,pts,0.309235
uuid-694f335beb3d43cb9e3e883b7931e506,PD-L1,0.659325
uuid-694f335beb3d43cb9e3e883b7931e506,approval,0.321812
uuid-694f335beb3d43cb9e3e883b7931e506,PD-L1 testing,0.657893
uuid-694f335beb3d43cb9e3e883b7931e506,testing,0.788218
uuid-694f335beb3d43cb9e3e883b7931e506,PDL1 testing,0.738301
uuid-694f335beb3d43cb9e3e883b7931e506,NSCLC patients,0.828329
uuid-694f335beb3d43cb9e3e883b7931e506,tumor types,0.453534
uuid-694f335beb3d43cb9e3e883b7931e506,assay,0.383218
uuid-694f335beb3d43cb9e3e883b7931e506,RTL stated,0.34284
uuid-694f335beb3d43cb9e3e883b7931e506,TL shared,0.382173
uuid-694f335beb3d43cb9e3e883b7931e506,biomarker,0.30169
uuid-87e4b20524c6401ea6b1e1bf018669da,Nivo,0.659846
uuid-87e4b20524c6401ea6b1e1bf018669da,pembro,0.767306
uuid-87e4b20524c6401ea6b1e1bf018669da,dose,0.405663
uuid-87e4b20524c6401ea6b1e1bf018669da,1L,0.323134
uuid-87e4b20524c6401ea6b1e1bf018669da,efficacy,0.510338
uuid-87e4b20524c6401ea6b1e1bf018669da,2L,0.445693
uuid-87e4b20524c6401ea6b1e1bf018669da,agents,0.309583
uuid-87e4b20524c6401ea6b1e1bf018669da,Ipi,0.477093
uuid-87e4b20524c6401ea6b1e1bf018669da,atezo,0.737435
uuid-87e4b20524c6401ea6b1e1bf018669da,preferred,0.403699
uuid-87e4b20524c6401ea6b1e1bf018669da,using nivo,0.480269
uuid-87e4b20524c6401ea6b1e1bf018669da,data,0.35195
uuid-87e4b20524c6401ea6b1e1bf018669da,indication,0.394066
uuid-87e4b20524c6401ea6b1e1bf018669da,approved,0.361378
uuid-87e4b20524c6401ea6b1e1bf018669da,HCP,0.342355
uuid-87e4b20524c6401ea6b1e1bf018669da,nivo and pembro,0.504245
uuid-87e4b20524c6401ea6b1e1bf018669da,vs,0.627337
uuid-87e4b20524c6401ea6b1e1bf018669da,feels,0.350016
uuid-87e4b20524c6401ea6b1e1bf018669da,flat dosing,0.347961
uuid-9057c14dcf8e460b86ab257169d97631,Nivo,0.404609
uuid-9057c14dcf8e460b86ab257169d97631,RTL,0.447119
uuid-9057c14dcf8e460b86ab257169d97631,nivolumab,0.337322
uuid-9057c14dcf8e460b86ab257169d97631,trial,0.32848
uuid-9057c14dcf8e460b86ab257169d97631,regimen,0.302094
uuid-9057c14dcf8e460b86ab257169d97631,combination,0.348893
uuid-9057c14dcf8e460b86ab257169d97631,Ipi,0.599258
uuid-9057c14dcf8e460b86ab257169d97631,using nivo,0.406507
uuid-9057c14dcf8e460b86ab257169d97631,combo,0.313549
uuid-9057c14dcf8e460b86ab257169d97631,mentioned,0.359327
uuid-9057c14dcf8e460b86ab257169d97631,HCP,0.472221
uuid-9057c14dcf8e460b86ab257169d97631,SCLC,0.572253
uuid-c1cb734196a34530a67d80e98b289646,Nivo,0.431259
uuid-c1cb734196a34530a67d80e98b289646,patients,0.424201
uuid-c1cb734196a34530a67d80e98b289646,RTL,0.454873
uuid-c1cb734196a34530a67d80e98b289646,nivolumab,0.476577
uuid-c1cb734196a34530a67d80e98b289646,regimen,0.427986
uuid-c1cb734196a34530a67d80e98b289646,combination,0.434965
uuid-c1cb734196a34530a67d80e98b289646,2L,0.303125
uuid-c1cb734196a34530a67d80e98b289646,pts,0.370332
uuid-c1cb734196a34530a67d80e98b289646,Ipi,0.580693
uuid-c1cb734196a34530a67d80e98b289646,preferred,0.342001
uuid-c1cb734196a34530a67d80e98b289646,monotherapy,0.435795
uuid-c1cb734196a34530a67d80e98b289646,using nivo,0.601118
uuid-c1cb734196a34530a67d80e98b289646,combo,0.414635
uuid-c1cb734196a34530a67d80e98b289646,mentioned,0.361433
uuid-c1cb734196a34530a67d80e98b289646,SCCHN,0.324843
uuid-c1cb734196a34530a67d80e98b289646,HCP,0.532116
uuid-c1cb734196a34530a67d80e98b289646,LTL,0.361797
uuid-c1cb734196a34530a67d80e98b289646,SCLC,0.477091
uuid-c1cb734196a34530a67d80e98b289646,RTL stated,0.390912
uuid-c1cb734196a34530a67d80e98b289646,option,0.348393
uuid-204e279b17eb40a2ab2499d2430a8863,TL,0.351307
uuid-204e279b17eb40a2ab2499d2430a8863,PDL1,0.33316
uuid-204e279b17eb40a2ab2499d2430a8863,tumor,0.492974
uuid-204e279b17eb40a2ab2499d2430a8863,PD-L1,0.569259
uuid-204e279b17eb40a2ab2499d2430a8863,PD-L1 testing,0.473601
uuid-204e279b17eb40a2ab2499d2430a8863,testing,0.521951
uuid-204e279b17eb40a2ab2499d2430a8863,PDL1 testing,0.306379
uuid-204e279b17eb40a2ab2499d2430a8863,NSCLC patients,0.408662
uuid-204e279b17eb40a2ab2499d2430a8863,HCP,0.37017
uuid-204e279b17eb40a2ab2499d2430a8863,assay,0.545433
uuid-204e279b17eb40a2ab2499d2430a8863,PDL1 expression,0.31468
uuid-204e279b17eb40a2ab2499d2430a8863,biomarker,0.328827
uuid-859825054a3c467bb169e22dbc64f09b,Nivo,0.373732
uuid-859825054a3c467bb169e22dbc64f09b,patients,0.627879
uuid-859825054a3c467bb169e22dbc64f09b,Opdivo,0.398204
uuid-859825054a3c467bb169e22dbc64f09b,therapy,0.702073
uuid-859825054a3c467bb169e22dbc64f09b,nivolumab,0.51586
uuid-859825054a3c467bb169e22dbc64f09b,treated,0.378863
uuid-859825054a3c467bb169e22dbc64f09b,treatment,0.453162
uuid-859825054a3c467bb169e22dbc64f09b,using nivo,0.30135
uuid-859825054a3c467bb169e22dbc64f09b,cHL,0.796117
uuid-859825054a3c467bb169e22dbc64f09b,progression,0.415319
uuid-859825054a3c467bb169e22dbc64f09b,chemotherapy,0.346169
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,patients,0.464203
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,therapy,0.33378
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,nivolumab,0.331255
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,treated,0.327169
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,treatment,0.415334
uuid-d9df0359f56f4fa7b18cb2b0ed1c52d7,progression,0.446316
uuid-2908769e12b34352b84e4864200b7280,patients,0.592488
uuid-2908769e12b34352b84e4864200b7280,Opdivo,0.305145
uuid-2908769e12b34352b84e4864200b7280,therapy,0.359488
uuid-2908769e12b34352b84e4864200b7280,nivolumab,0.408055
uuid-2908769e12b34352b84e4864200b7280,trial,0.315922
uuid-2908769e12b34352b84e4864200b7280,regimen,0.300576
uuid-2908769e12b34352b84e4864200b7280,treated,0.518764
uuid-2908769e12b34352b84e4864200b7280,pts,0.419539
uuid-2908769e12b34352b84e4864200b7280,treatment,0.386843
uuid-2908769e12b34352b84e4864200b7280,cHL,0.340321
uuid-2908769e12b34352b84e4864200b7280,progression,0.381076
uuid-2908769e12b34352b84e4864200b7280,chemotherapy,0.332955
uuid-2908769e12b34352b84e4864200b7280,respond,0.311723
uuid-65b40143f8b24894af389734f3cafe3e,patients,0.441735
uuid-65b40143f8b24894af389734f3cafe3e,Opdivo,0.543161
uuid-65b40143f8b24894af389734f3cafe3e,dose,0.429432
uuid-65b40143f8b24894af389734f3cafe3e,physicians,0.301684
uuid-65b40143f8b24894af389734f3cafe3e,treatment,0.322699
uuid-65b40143f8b24894af389734f3cafe3e,label,0.335715
uuid-65b40143f8b24894af389734f3cafe3e,flat dosing,0.555761
uuid-df269af55c0f42de947222d36240a08a,preferred,0.388478
uuid-df269af55c0f42de947222d36240a08a,using nivo,0.316662
uuid-df269af55c0f42de947222d36240a08a,feels,0.323202
uuid-df269af55c0f42de947222d36240a08a,RTL stated,0.350587
uuid-65385a09edba4c019ecde6894f86a42d,pembro,0.505592
uuid-65385a09edba4c019ecde6894f86a42d,1L,0.50378
uuid-65385a09edba4c019ecde6894f86a42d,PDL1,0.361494
uuid-65385a09edba4c019ecde6894f86a42d,TL stated,0.376992
uuid-65385a09edba4c019ecde6894f86a42d,2L,0.46953
uuid-65385a09edba4c019ecde6894f86a42d,Merck,0.373015
uuid-65385a09edba4c019ecde6894f86a42d,institution,0.435932
uuid-65385a09edba4c019ecde6894f86a42d,stated,0.442663
uuid-65385a09edba4c019ecde6894f86a42d,PD-L1,0.486976
uuid-65385a09edba4c019ecde6894f86a42d,approval,0.498956
uuid-65385a09edba4c019ecde6894f86a42d,atezo,0.467732
uuid-65385a09edba4c019ecde6894f86a42d,preferred,0.354037
uuid-65385a09edba4c019ecde6894f86a42d,PD-L1 testing,0.52084
uuid-65385a09edba4c019ecde6894f86a42d,testing,0.571793
uuid-65385a09edba4c019ecde6894f86a42d,using nivo,0.443995
uuid-65385a09edba4c019ecde6894f86a42d,PDL1 testing,0.602888
uuid-65385a09edba4c019ecde6894f86a42d,NSCLC patients,0.506328
uuid-65385a09edba4c019ecde6894f86a42d,approved,0.41515
uuid-65385a09edba4c019ecde6894f86a42d,SCCHN,0.413525
uuid-65385a09edba4c019ecde6894f86a42d,tumor types,0.327139
uuid-65385a09edba4c019ecde6894f86a42d,assay,0.346828
uuid-65385a09edba4c019ecde6894f86a42d,RTL stated,0.397243
uuid-65385a09edba4c019ecde6894f86a42d,bladder,0.342374
uuid-8e9ce8d280024954a893099f8098b0d7,drug,0.379219
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,Nivo,0.660007
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,patients,0.333784
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,pembro,0.471402
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,nivolumab,0.333554
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,1L,0.352906
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,2L,0.39389
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,approval,0.554846
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,atezo,0.34191
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,preferred,0.311099
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,using nivo,0.552874
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,approved,0.410967
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,cHL,0.326107
uuid-5b96ada593e6445eb4e2ac1a4cc3937d,RTL stated,0.335378
uuid-fd01567e8b31457d9fef80031de50ecb,RTL,0.586545
uuid-fd01567e8b31457d9fef80031de50ecb,commented,0.394198
uuid-fd01567e8b31457d9fef80031de50ecb,RCC,0.317482
uuid-fd01567e8b31457d9fef80031de50ecb,stated,0.55735
uuid-fd01567e8b31457d9fef80031de50ecb,approval,0.391529
uuid-fd01567e8b31457d9fef80031de50ecb,preferred,0.363808
uuid-fd01567e8b31457d9fef80031de50ecb,using nivo,0.434419
uuid-fd01567e8b31457d9fef80031de50ecb,data,0.528122
uuid-fd01567e8b31457d9fef80031de50ecb,expressed,0.337395
uuid-fd01567e8b31457d9fef80031de50ecb,mentioned,0.320318
uuid-fd01567e8b31457d9fef80031de50ecb,clinical trials,0.381552
uuid-fd01567e8b31457d9fef80031de50ecb,indication,0.40315
uuid-fd01567e8b31457d9fef80031de50ecb,approved,0.337955
uuid-fd01567e8b31457d9fef80031de50ecb,SCCHN,0.66858
uuid-fd01567e8b31457d9fef80031de50ecb,HCP,0.34461
uuid-fd01567e8b31457d9fef80031de50ecb,impressed,0.618442
uuid-fd01567e8b31457d9fef80031de50ecb,LTL,0.542415
uuid-fd01567e8b31457d9fef80031de50ecb,TLs,0.340387
uuid-fd01567e8b31457d9fef80031de50ecb,SCLC,0.306288
uuid-fd01567e8b31457d9fef80031de50ecb,feels,0.338935
uuid-fd01567e8b31457d9fef80031de50ecb,Regional TL,0.549998
uuid-fd01567e8b31457d9fef80031de50ecb,RTL stated,0.530566
uuid-fd01567e8b31457d9fef80031de50ecb,bladder,0.378307
uuid-e56af3b05b8d4ca78acef52a7bc894d0,TL,0.502798
uuid-e56af3b05b8d4ca78acef52a7bc894d0,TL stated,0.378982
uuid-e56af3b05b8d4ca78acef52a7bc894d0,institution,0.354818
uuid-e56af3b05b8d4ca78acef52a7bc894d0,PD-L1,0.574869
uuid-e56af3b05b8d4ca78acef52a7bc894d0,PD-L1 testing,0.820319
uuid-e56af3b05b8d4ca78acef52a7bc894d0,testing,0.718257
uuid-e56af3b05b8d4ca78acef52a7bc894d0,PDL1 testing,0.613275
uuid-e56af3b05b8d4ca78acef52a7bc894d0,NSCLC patients,0.46962
uuid-e56af3b05b8d4ca78acef52a7bc894d0,assay,0.481696
uuid-c7086b2f4e07466397ef9314c5736328,shared,0.519074
uuid-c7086b2f4e07466397ef9314c5736328,RCC,0.328466
uuid-c7086b2f4e07466397ef9314c5736328,TL stated,0.45251
uuid-c7086b2f4e07466397ef9314c5736328,pts,0.309908
uuid-c7086b2f4e07466397ef9314c5736328,institution,0.371183
uuid-c7086b2f4e07466397ef9314c5736328,stated,0.385587
uuid-c7086b2f4e07466397ef9314c5736328,PD-L1 testing,0.406255
uuid-c7086b2f4e07466397ef9314c5736328,testing,0.445033
uuid-c7086b2f4e07466397ef9314c5736328,clinical trials,0.312064
uuid-c7086b2f4e07466397ef9314c5736328,PDL1 testing,0.56917
uuid-c7086b2f4e07466397ef9314c5736328,NSCLC patients,0.457524
uuid-c7086b2f4e07466397ef9314c5736328,SCCHN,0.356488
uuid-c7086b2f4e07466397ef9314c5736328,tumor types,0.398674
uuid-c7086b2f4e07466397ef9314c5736328,RTL stated,0.381757
uuid-ccd5b66249b24988bd761c3e0cb53098,patients,0.472227
uuid-ccd5b66249b24988bd761c3e0cb53098,therapy,0.411749
uuid-ccd5b66249b24988bd761c3e0cb53098,toxicity,0.496293
uuid-ccd5b66249b24988bd761c3e0cb53098,regimen,0.508252
uuid-ccd5b66249b24988bd761c3e0cb53098,treated,0.509721
uuid-ccd5b66249b24988bd761c3e0cb53098,physicians,0.316147
uuid-ccd5b66249b24988bd761c3e0cb53098,treatment,0.70206
uuid-ccd5b66249b24988bd761c3e0cb53098,response,0.404732
uuid-ccd5b66249b24988bd761c3e0cb53098,progression,0.490862
uuid-ccd5b66249b24988bd761c3e0cb53098,chemotherapy,0.338154
uuid-ccd5b66249b24988bd761c3e0cb53098,respond,0.454655
uuid-ccd5b66249b24988bd761c3e0cb53098,immunotherapy,0.419991
uuid-654796ef18b840dc8af34c8a81c8fbcd,patients,0.305679
uuid-654796ef18b840dc8af34c8a81c8fbcd,therapy,0.403796
uuid-654796ef18b840dc8af34c8a81c8fbcd,PDL1,0.344436
uuid-654796ef18b840dc8af34c8a81c8fbcd,response,0.46067
uuid-654796ef18b840dc8af34c8a81c8fbcd,PD1,0.304294
uuid-654796ef18b840dc8af34c8a81c8fbcd,cHL,0.322722
uuid-654796ef18b840dc8af34c8a81c8fbcd,progression,0.335605
uuid-654796ef18b840dc8af34c8a81c8fbcd,biomarker,0.317829
uuid-b805beb420a34279ac160019fb53fc99,NSCLC,0.381893
uuid-b805beb420a34279ac160019fb53fc99,discussed,0.683812
uuid-b805beb420a34279ac160019fb53fc99,IO,0.48771
uuid-b805beb420a34279ac160019fb53fc99,TLs,0.361752
uuid-b805beb420a34279ac160019fb53fc99,academic,0.569732
uuid-b805beb420a34279ac160019fb53fc99,feels,0.314415
uuid-5f2d9e8425704b9f909fc6131a613f03,BMS,0.315161
uuid-5f2d9e8425704b9f909fc6131a613f03,NTL,0.30041
uuid-5f2d9e8425704b9f909fc6131a613f03,discussed,0.830144
uuid-5f2d9e8425704b9f909fc6131a613f03,commented,0.372081
uuid-5f2d9e8425704b9f909fc6131a613f03,OS,0.31949
uuid-5f2d9e8425704b9f909fc6131a613f03,regards,0.342177
uuid-5f2d9e8425704b9f909fc6131a613f03,data,0.486174
uuid-5f2d9e8425704b9f909fc6131a613f03,PFS,0.31675
uuid-5f2d9e8425704b9f909fc6131a613f03,impressed,0.307981
uuid-5f2d9e8425704b9f909fc6131a613f03,TLs,0.398536
uuid-5f2d9e8425704b9f909fc6131a613f03,academic,0.603674
uuid-74f55da6e07d486cae47307628248289,RTL,0.478955
uuid-74f55da6e07d486cae47307628248289,lung,0.333909
uuid-74f55da6e07d486cae47307628248289,1L,0.310244
uuid-74f55da6e07d486cae47307628248289,NTL,0.316722
uuid-74f55da6e07d486cae47307628248289,commented,0.392754
uuid-74f55da6e07d486cae47307628248289,RCC,0.530604
uuid-74f55da6e07d486cae47307628248289,TL stated,0.325941
uuid-74f55da6e07d486cae47307628248289,2L,0.317537
uuid-74f55da6e07d486cae47307628248289,stated,0.45082
uuid-74f55da6e07d486cae47307628248289,using nivo,0.397471
uuid-74f55da6e07d486cae47307628248289,data,0.307831
uuid-74f55da6e07d486cae47307628248289,expressed,0.359266
uuid-74f55da6e07d486cae47307628248289,SCCHN,0.567143
uuid-74f55da6e07d486cae47307628248289,impressed,0.497444
uuid-74f55da6e07d486cae47307628248289,LTL,0.399957
uuid-74f55da6e07d486cae47307628248289,TLs,0.458034
uuid-74f55da6e07d486cae47307628248289,SCLC,0.323318
uuid-74f55da6e07d486cae47307628248289,Regional TL,0.618412
uuid-74f55da6e07d486cae47307628248289,RTL stated,0.50824
uuid-74f55da6e07d486cae47307628248289,TL shared,0.38017
uuid-74f55da6e07d486cae47307628248289,bladder,0.382702
uuid-69719eae228d402596a1cbc39d596761,Nivo,0.329318
uuid-69719eae228d402596a1cbc39d596761,trial,0.479872
uuid-69719eae228d402596a1cbc39d596761,efficacy,0.368905
uuid-69719eae228d402596a1cbc39d596761,OS,0.626986
uuid-69719eae228d402596a1cbc39d596761,data,0.454709
uuid-69719eae228d402596a1cbc39d596761,PFS,0.721187
uuid-69719eae228d402596a1cbc39d596761,ORR,0.628948
uuid-69719eae228d402596a1cbc39d596761,nivo and pembro,0.322845
uuid-69719eae228d402596a1cbc39d596761,impressed,0.439208
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,PDL1,0.463035
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,PD-L1,0.722782
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,PD-L1 testing,0.627041
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,testing,0.785642
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,PDL1 testing,0.648647
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,NSCLC patients,0.534921
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,assay,0.55101
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,PDL1 expression,0.351032
uuid-ab1af06242f34b86a2cf911b7bdfc9aa,biomarker,0.613974
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,Nivo,0.305398
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,patients,0.326642
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,Opdivo,0.428818
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,pembro,0.418625
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,dose,0.368298
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,atezo,0.3287
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,indication,0.390728
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,approved,0.304466
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,vs,0.31606
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,Keytruda,0.417888
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,feels,0.335583
uuid-f8801d9452f64fd5a713b67bc2f3f4ec,flat dosing,0.308609
uuid-cf206207392c4c86b601909978e25a2f,patients,0.59139
uuid-cf206207392c4c86b601909978e25a2f,Opdivo,0.354258
uuid-cf206207392c4c86b601909978e25a2f,therapy,0.401626
uuid-cf206207392c4c86b601909978e25a2f,regimen,0.434691
uuid-cf206207392c4c86b601909978e25a2f,treated,0.430095
uuid-cf206207392c4c86b601909978e25a2f,pts,0.494718
uuid-cf206207392c4c86b601909978e25a2f,treatment,0.621798
uuid-cf206207392c4c86b601909978e25a2f,response,0.546876
uuid-cf206207392c4c86b601909978e25a2f,progression,0.717001
uuid-cf206207392c4c86b601909978e25a2f,respond,0.600319
uuid-a3c10c6e41ad4b7a90addd66ce129785,commented,0.425509
uuid-a3c10c6e41ad4b7a90addd66ce129785,response,0.362603
uuid-a3c10c6e41ad4b7a90addd66ce129785,ASCO,0.332524
uuid-f0dd3c4db8c2495d889eb1b901ee380a,TL,0.482897
uuid-f0dd3c4db8c2495d889eb1b901ee380a,pembro,0.398242
uuid-f0dd3c4db8c2495d889eb1b901ee380a,1L,0.327072
uuid-f0dd3c4db8c2495d889eb1b901ee380a,PDL1,0.703374
uuid-f0dd3c4db8c2495d889eb1b901ee380a,Merck,0.432644
uuid-f0dd3c4db8c2495d889eb1b901ee380a,PD-L1,0.759172
uuid-f0dd3c4db8c2495d889eb1b901ee380a,atezo,0.438769
uuid-f0dd3c4db8c2495d889eb1b901ee380a,PD-L1 testing,0.548326
uuid-f0dd3c4db8c2495d889eb1b901ee380a,testing,0.667824
uuid-f0dd3c4db8c2495d889eb1b901ee380a,PDL1 testing,0.451952
uuid-f0dd3c4db8c2495d889eb1b901ee380a,NSCLC patients,0.480799
uuid-f0dd3c4db8c2495d889eb1b901ee380a,nivo and pembro,0.37579
uuid-f0dd3c4db8c2495d889eb1b901ee380a,assay,0.785507
uuid-f0dd3c4db8c2495d889eb1b901ee380a,PDL1 expression,0.508806
uuid-f0dd3c4db8c2495d889eb1b901ee380a,biomarker,0.4583
uuid-9c867d2094a04d52aca614e9fd2f7c43,Nivo,0.350355
uuid-9c867d2094a04d52aca614e9fd2f7c43,patients,0.582231
uuid-9c867d2094a04d52aca614e9fd2f7c43,therapy,0.400198
uuid-9c867d2094a04d52aca614e9fd2f7c43,nivolumab,0.470943
uuid-9c867d2094a04d52aca614e9fd2f7c43,regimen,0.610058
uuid-9c867d2094a04d52aca614e9fd2f7c43,treated,0.445935
uuid-9c867d2094a04d52aca614e9fd2f7c43,combination,0.555996
uuid-9c867d2094a04d52aca614e9fd2f7c43,chemo,0.397283
uuid-9c867d2094a04d52aca614e9fd2f7c43,pts,0.682258
uuid-9c867d2094a04d52aca614e9fd2f7c43,IO,0.302144
uuid-9c867d2094a04d52aca614e9fd2f7c43,Ipi,0.442495
uuid-9c867d2094a04d52aca614e9fd2f7c43,monotherapy,0.520283
uuid-9c867d2094a04d52aca614e9fd2f7c43,treatment,0.439226
uuid-9c867d2094a04d52aca614e9fd2f7c43,using nivo,0.328977
uuid-9c867d2094a04d52aca614e9fd2f7c43,response,0.424807
uuid-9c867d2094a04d52aca614e9fd2f7c43,combo,0.535644
uuid-9c867d2094a04d52aca614e9fd2f7c43,PD1,0.398072
uuid-9c867d2094a04d52aca614e9fd2f7c43,progression,0.551497
uuid-9c867d2094a04d52aca614e9fd2f7c43,chemotherapy,0.41008
uuid-9c867d2094a04d52aca614e9fd2f7c43,respond,0.437739
uuid-9c867d2094a04d52aca614e9fd2f7c43,SCLC,0.334973
uuid-9c867d2094a04d52aca614e9fd2f7c43,option,0.398254
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,Nivo,0.391981
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,pembro,0.52785
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,BMS,0.315477
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,PDL1,0.530722
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,trial,0.503857
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,efficacy,0.757183
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,Ipi,0.314799
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,OS,0.58139
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,atezo,0.488222
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,data,0.666074
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,PFS,0.576973
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,ORR,0.629407
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,nivo and pembro,0.662783
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,believes,0.464649
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,impressed,0.414504
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,vs,0.574565
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,feels,0.407826
uuid-b9428a54704e4b51aad3b4c8b3a7a73e,PDL1 expression,0.475513
uuid-834a8c46f1cc424883f363b685d98d3f,Nivo,0.375126
uuid-834a8c46f1cc424883f363b685d98d3f,patients,0.351157
uuid-834a8c46f1cc424883f363b685d98d3f,pembro,0.576516
uuid-834a8c46f1cc424883f363b685d98d3f,dose,0.384548
uuid-834a8c46f1cc424883f363b685d98d3f,1L,0.447738
uuid-834a8c46f1cc424883f363b685d98d3f,2L,0.566341
uuid-834a8c46f1cc424883f363b685d98d3f,agents,0.314161
uuid-834a8c46f1cc424883f363b685d98d3f,approval,0.393336
uuid-834a8c46f1cc424883f363b685d98d3f,atezo,0.573074
uuid-834a8c46f1cc424883f363b685d98d3f,preferred,0.763166
uuid-834a8c46f1cc424883f363b685d98d3f,monotherapy,0.423127
uuid-834a8c46f1cc424883f363b685d98d3f,using nivo,0.542577
uuid-834a8c46f1cc424883f363b685d98d3f,indication,0.404214
uuid-834a8c46f1cc424883f363b685d98d3f,NSCLC patients,0.30824
uuid-834a8c46f1cc424883f363b685d98d3f,approved,0.466743
uuid-834a8c46f1cc424883f363b685d98d3f,SCCHN,0.353587
uuid-834a8c46f1cc424883f363b685d98d3f,vs,0.36122
uuid-834a8c46f1cc424883f363b685d98d3f,RTL stated,0.490423
uuid-834a8c46f1cc424883f363b685d98d3f,option,0.536949
uuid-56370ee7b4e6478eb31dfad62abb8e1b,patients,0.342787
uuid-56370ee7b4e6478eb31dfad62abb8e1b,pembro,0.314215
uuid-56370ee7b4e6478eb31dfad62abb8e1b,regimen,0.348865
uuid-56370ee7b4e6478eb31dfad62abb8e1b,treated,0.325061
uuid-56370ee7b4e6478eb31dfad62abb8e1b,pts,0.536036
uuid-56370ee7b4e6478eb31dfad62abb8e1b,monotherapy,0.330208
uuid-56370ee7b4e6478eb31dfad62abb8e1b,feels,0.46428
uuid-ef4a5dc394914edbb24b414e88d91a71,NSCLC,0.339305
uuid-ef4a5dc394914edbb24b414e88d91a71,PDL1,0.522928
uuid-ef4a5dc394914edbb24b414e88d91a71,trial,0.478308
uuid-ef4a5dc394914edbb24b414e88d91a71,efficacy,0.447821
uuid-ef4a5dc394914edbb24b414e88d91a71,IO,0.364737
uuid-ef4a5dc394914edbb24b414e88d91a71,OS,0.482066
uuid-ef4a5dc394914edbb24b414e88d91a71,data,0.5267
uuid-ef4a5dc394914edbb24b414e88d91a71,PFS,0.52367
uuid-ef4a5dc394914edbb24b414e88d91a71,ORR,0.524309
uuid-ef4a5dc394914edbb24b414e88d91a71,nivo and pembro,0.490265
uuid-ef4a5dc394914edbb24b414e88d91a71,believes,0.411922
uuid-ef4a5dc394914edbb24b414e88d91a71,impressed,0.317423
uuid-ef4a5dc394914edbb24b414e88d91a71,feels,0.420986
uuid-ef4a5dc394914edbb24b414e88d91a71,PDL1 expression,0.411528
uuid-a5be2fc1193c4c96a10685c5d1a9d423,dose,0.380382
uuid-a5be2fc1193c4c96a10685c5d1a9d423,toxicity,0.394833
uuid-a5be2fc1193c4c96a10685c5d1a9d423,oncology,0.335775
uuid-a5be2fc1193c4c96a10685c5d1a9d423,drug,0.477566
uuid-a5be2fc1193c4c96a10685c5d1a9d423,clinical,0.334207
uuid-a5be2fc1193c4c96a10685c5d1a9d423,flat dosing,0.486401
uuid-b54bf1886d384e5ea610f1499a5d96b6,RTL,0.320343
uuid-b54bf1886d384e5ea610f1499a5d96b6,NTL,0.318534
uuid-b54bf1886d384e5ea610f1499a5d96b6,melanoma,0.408111
uuid-b54bf1886d384e5ea610f1499a5d96b6,RCC,0.331387
uuid-b54bf1886d384e5ea610f1499a5d96b6,SCCHN,0.32822
uuid-b54bf1886d384e5ea610f1499a5d96b6,lung cancer,0.361946
uuid-b54bf1886d384e5ea610f1499a5d96b6,TL shared,0.402066
uuid-7cf7ba304c65442eb54f21f722736bb9,patients,0.834397
uuid-7cf7ba304c65442eb54f21f722736bb9,Opdivo,0.499662
uuid-7cf7ba304c65442eb54f21f722736bb9,therapy,0.595167
uuid-7cf7ba304c65442eb54f21f722736bb9,nivolumab,0.513868
uuid-7cf7ba304c65442eb54f21f722736bb9,regimen,0.587717
uuid-7cf7ba304c65442eb54f21f722736bb9,treated,0.626125
uuid-7cf7ba304c65442eb54f21f722736bb9,chemo,0.372628
uuid-7cf7ba304c65442eb54f21f722736bb9,pts,0.543761
uuid-7cf7ba304c65442eb54f21f722736bb9,monotherapy,0.390206
uuid-7cf7ba304c65442eb54f21f722736bb9,treatment,0.762328
uuid-7cf7ba304c65442eb54f21f722736bb9,response,0.443977
uuid-7cf7ba304c65442eb54f21f722736bb9,PD1,0.309274
uuid-7cf7ba304c65442eb54f21f722736bb9,progression,0.691795
uuid-7cf7ba304c65442eb54f21f722736bb9,chemotherapy,0.492751
uuid-7cf7ba304c65442eb54f21f722736bb9,respond,0.497192
uuid-7cf7ba304c65442eb54f21f722736bb9,option,0.377589
uuid-84cde3d15aef4a0fb56eeec41647c247,Nivo,0.507822
uuid-84cde3d15aef4a0fb56eeec41647c247,pembro,0.627405
uuid-84cde3d15aef4a0fb56eeec41647c247,dose,0.52485
uuid-84cde3d15aef4a0fb56eeec41647c247,trial,0.620942
uuid-84cde3d15aef4a0fb56eeec41647c247,efficacy,0.351987
uuid-84cde3d15aef4a0fb56eeec41647c247,Ipi,0.53073
uuid-84cde3d15aef4a0fb56eeec41647c247,approval,0.340313
uuid-84cde3d15aef4a0fb56eeec41647c247,atezo,0.528937
uuid-84cde3d15aef4a0fb56eeec41647c247,using nivo,0.302705
uuid-84cde3d15aef4a0fb56eeec41647c247,clinical trials,0.34506
uuid-84cde3d15aef4a0fb56eeec41647c247,indication,0.401726
uuid-84cde3d15aef4a0fb56eeec41647c247,approved,0.35993
uuid-84cde3d15aef4a0fb56eeec41647c247,vs,0.566381
uuid-84cde3d15aef4a0fb56eeec41647c247,Keytruda,0.30096
uuid-84cde3d15aef4a0fb56eeec41647c247,flat dosing,0.521907
uuid-0c9e62106d0d4671a779df9d0f1ec36a,Nivo,0.488503
uuid-0c9e62106d0d4671a779df9d0f1ec36a,pembro,0.559564
uuid-0c9e62106d0d4671a779df9d0f1ec36a,PDL1,0.459611
uuid-0c9e62106d0d4671a779df9d0f1ec36a,trial,0.371313
uuid-0c9e62106d0d4671a779df9d0f1ec36a,efficacy,0.729639
uuid-0c9e62106d0d4671a779df9d0f1ec36a,agents,0.392159
uuid-0c9e62106d0d4671a779df9d0f1ec36a,Ipi,0.324095
uuid-0c9e62106d0d4671a779df9d0f1ec36a,OS,0.400704
uuid-0c9e62106d0d4671a779df9d0f1ec36a,atezo,0.57751
uuid-0c9e62106d0d4671a779df9d0f1ec36a,regards,0.308342
uuid-0c9e62106d0d4671a779df9d0f1ec36a,data,0.460103
uuid-0c9e62106d0d4671a779df9d0f1ec36a,indication,0.330025
uuid-0c9e62106d0d4671a779df9d0f1ec36a,PFS,0.411664
uuid-0c9e62106d0d4671a779df9d0f1ec36a,ORR,0.45341
uuid-0c9e62106d0d4671a779df9d0f1ec36a,nivo and pembro,0.644283
uuid-0c9e62106d0d4671a779df9d0f1ec36a,believes,0.49583
uuid-0c9e62106d0d4671a779df9d0f1ec36a,vs,0.56397
uuid-0c9e62106d0d4671a779df9d0f1ec36a,feels,0.360996
uuid-0c9e62106d0d4671a779df9d0f1ec36a,PDL1 expression,0.450653
uuid-ca7b11ac07b54f4995e4f10932a24bb8,RTL,0.3373
uuid-ca7b11ac07b54f4995e4f10932a24bb8,BMS,0.328142
uuid-ca7b11ac07b54f4995e4f10932a24bb8,trial,0.581764
uuid-ca7b11ac07b54f4995e4f10932a24bb8,efficacy,0.437889
uuid-ca7b11ac07b54f4995e4f10932a24bb8,discussed,0.35551
uuid-ca7b11ac07b54f4995e4f10932a24bb8,commented,0.36174
uuid-ca7b11ac07b54f4995e4f10932a24bb8,OS,0.725856
uuid-ca7b11ac07b54f4995e4f10932a24bb8,regards,0.334232
uuid-ca7b11ac07b54f4995e4f10932a24bb8,data,0.68093
uuid-ca7b11ac07b54f4995e4f10932a24bb8,PFS,0.747337
uuid-ca7b11ac07b54f4995e4f10932a24bb8,ORR,0.706691
uuid-ca7b11ac07b54f4995e4f10932a24bb8,nivo and pembro,0.373697
uuid-ca7b11ac07b54f4995e4f10932a24bb8,ASCO,0.323983
uuid-ca7b11ac07b54f4995e4f10932a24bb8,impressed,0.56231
uuid-ca7b11ac07b54f4995e4f10932a24bb8,feels,0.318016
uuid-ca7b11ac07b54f4995e4f10932a24bb8,PDL1 expression,0.310915
uuid-3ca93c52795341a0b6367d7230d3a682,TL,0.678748
uuid-3ca93c52795341a0b6367d7230d3a682,PDL1,0.34039
uuid-3ca93c52795341a0b6367d7230d3a682,TL stated,0.379121
uuid-3ca93c52795341a0b6367d7230d3a682,institution,0.404142
uuid-3ca93c52795341a0b6367d7230d3a682,PD-L1,0.801336
uuid-3ca93c52795341a0b6367d7230d3a682,PD-L1 testing,0.912645
uuid-3ca93c52795341a0b6367d7230d3a682,testing,0.871234
uuid-3ca93c52795341a0b6367d7230d3a682,PDL1 testing,0.640516
uuid-3ca93c52795341a0b6367d7230d3a682,NSCLC patients,0.601276
uuid-3ca93c52795341a0b6367d7230d3a682,assay,0.785761
uuid-3ca93c52795341a0b6367d7230d3a682,biomarker,0.367363
uuid-1948bea8394c472dba801046a99c262c,pembro,0.315012
uuid-1948bea8394c472dba801046a99c262c,BMS,0.330213
uuid-1948bea8394c472dba801046a99c262c,1L,0.389228
uuid-1948bea8394c472dba801046a99c262c,PDL1,0.335413
uuid-1948bea8394c472dba801046a99c262c,TL stated,0.370974
uuid-1948bea8394c472dba801046a99c262c,2L,0.382807
uuid-1948bea8394c472dba801046a99c262c,Merck,0.369966
uuid-1948bea8394c472dba801046a99c262c,stated,0.505776
uuid-1948bea8394c472dba801046a99c262c,approval,0.417891
uuid-1948bea8394c472dba801046a99c262c,atezo,0.342159
uuid-1948bea8394c472dba801046a99c262c,testing,0.403702
uuid-1948bea8394c472dba801046a99c262c,PDL1 testing,0.522005
uuid-1948bea8394c472dba801046a99c262c,indication,0.313213
uuid-1948bea8394c472dba801046a99c262c,NSCLC patients,0.328182
uuid-1948bea8394c472dba801046a99c262c,approved,0.475531
uuid-1948bea8394c472dba801046a99c262c,tumor types,0.361179
uuid-1948bea8394c472dba801046a99c262c,LTL,0.310493
uuid-a39989dab3064ad9b15a6adbdaa615ae,BMS,0.333348
uuid-a39989dab3064ad9b15a6adbdaa615ae,trial,0.531706
uuid-a39989dab3064ad9b15a6adbdaa615ae,commented,0.320085
uuid-a39989dab3064ad9b15a6adbdaa615ae,clinical trials,0.337382
uuid-c163f4ab5a7b463ebc7526a21125b548,TL,0.36954
uuid-c163f4ab5a7b463ebc7526a21125b548,1L,0.409406
uuid-c163f4ab5a7b463ebc7526a21125b548,PDL1,0.381619
uuid-c163f4ab5a7b463ebc7526a21125b548,RCC,0.350285
uuid-c163f4ab5a7b463ebc7526a21125b548,TL stated,0.525397
uuid-c163f4ab5a7b463ebc7526a21125b548,2L,0.345258
uuid-c163f4ab5a7b463ebc7526a21125b548,stated,0.412869
uuid-c163f4ab5a7b463ebc7526a21125b548,PD-L1,0.530843
uuid-c163f4ab5a7b463ebc7526a21125b548,approval,0.409568
uuid-c163f4ab5a7b463ebc7526a21125b548,PD-L1 testing,0.502372
uuid-c163f4ab5a7b463ebc7526a21125b548,testing,0.612219
uuid-c163f4ab5a7b463ebc7526a21125b548,PDL1 testing,0.661322
uuid-c163f4ab5a7b463ebc7526a21125b548,NSCLC patients,0.576041
uuid-c163f4ab5a7b463ebc7526a21125b548,SCCHN,0.440519
uuid-c163f4ab5a7b463ebc7526a21125b548,tumor types,0.346596
uuid-c163f4ab5a7b463ebc7526a21125b548,assay,0.385916
uuid-c163f4ab5a7b463ebc7526a21125b548,Regional TL,0.430506
uuid-c163f4ab5a7b463ebc7526a21125b548,RTL stated,0.345929
uuid-c163f4ab5a7b463ebc7526a21125b548,bladder,0.327513
uuid-8f71be4d2fe045d19afc48cf3ad61f99,PDL1,0.324304
uuid-8f71be4d2fe045d19afc48cf3ad61f99,efficacy,0.451557
uuid-8f71be4d2fe045d19afc48cf3ad61f99,chemo,0.498442
uuid-8f71be4d2fe045d19afc48cf3ad61f99,IO,0.394635
uuid-8f71be4d2fe045d19afc48cf3ad61f99,OS,0.726731
uuid-8f71be4d2fe045d19afc48cf3ad61f99,monotherapy,0.306006
uuid-8f71be4d2fe045d19afc48cf3ad61f99,response,0.402884
uuid-8f71be4d2fe045d19afc48cf3ad61f99,PFS,0.663002
uuid-8f71be4d2fe045d19afc48cf3ad61f99,ORR,0.549637
uuid-8f71be4d2fe045d19afc48cf3ad61f99,progression,0.370257
uuid-8f71be4d2fe045d19afc48cf3ad61f99,believes,0.444147
uuid-8f71be4d2fe045d19afc48cf3ad61f99,chemotherapy,0.35792
uuid-8f71be4d2fe045d19afc48cf3ad61f99,feels,0.458913
uuid-72841fb4f1654dc08676232446b10c4a,1L,0.522468
uuid-72841fb4f1654dc08676232446b10c4a,RCC,0.371416
uuid-72841fb4f1654dc08676232446b10c4a,TL stated,0.443011
uuid-72841fb4f1654dc08676232446b10c4a,2L,0.396274
uuid-72841fb4f1654dc08676232446b10c4a,stated,0.38208
uuid-72841fb4f1654dc08676232446b10c4a,PD-L1,0.428922
uuid-72841fb4f1654dc08676232446b10c4a,approval,0.324599
uuid-72841fb4f1654dc08676232446b10c4a,preferred,0.410209
uuid-72841fb4f1654dc08676232446b10c4a,PD-L1 testing,0.425186
uuid-72841fb4f1654dc08676232446b10c4a,testing,0.575706
uuid-72841fb4f1654dc08676232446b10c4a,using nivo,0.379574
uuid-72841fb4f1654dc08676232446b10c4a,PDL1 testing,0.640797
uuid-72841fb4f1654dc08676232446b10c4a,NSCLC patients,0.675252
uuid-72841fb4f1654dc08676232446b10c4a,SCCHN,0.472586
uuid-72841fb4f1654dc08676232446b10c4a,tumor types,0.463527
uuid-72841fb4f1654dc08676232446b10c4a,RTL stated,0.535123
uuid-72841fb4f1654dc08676232446b10c4a,TL shared,0.337299
uuid-72841fb4f1654dc08676232446b10c4a,option,0.380759
uuid-2bba51ee04c44370a2459907933e456d,Nivo,0.764858
uuid-2bba51ee04c44370a2459907933e456d,patients,0.383638
uuid-2bba51ee04c44370a2459907933e456d,Opdivo,0.331414
uuid-2bba51ee04c44370a2459907933e456d,pembro,0.75412
uuid-2bba51ee04c44370a2459907933e456d,dose,0.489819
uuid-2bba51ee04c44370a2459907933e456d,nivolumab,0.327268
uuid-2bba51ee04c44370a2459907933e456d,1L,0.474543
uuid-2bba51ee04c44370a2459907933e456d,chemo,0.353278
uuid-2bba51ee04c44370a2459907933e456d,2L,0.599825
uuid-2bba51ee04c44370a2459907933e456d,agents,0.337001
uuid-2bba51ee04c44370a2459907933e456d,Ipi,0.502616
uuid-2bba51ee04c44370a2459907933e456d,approval,0.460521
uuid-2bba51ee04c44370a2459907933e456d,atezo,0.679552
uuid-2bba51ee04c44370a2459907933e456d,preferred,0.562517
uuid-2bba51ee04c44370a2459907933e456d,monotherapy,0.482691
uuid-2bba51ee04c44370a2459907933e456d,using nivo,0.589903
uuid-2bba51ee04c44370a2459907933e456d,indication,0.403774
uuid-2bba51ee04c44370a2459907933e456d,approved,0.53478
uuid-2bba51ee04c44370a2459907933e456d,vs,0.513089
uuid-2bba51ee04c44370a2459907933e456d,label,0.363761
uuid-2bba51ee04c44370a2459907933e456d,Keytruda,0.31279
uuid-2bba51ee04c44370a2459907933e456d,option,0.487127
uuid-2bba51ee04c44370a2459907933e456d,flat dosing,0.348509
uuid-3988c03170e445ccaf1e4180b115599c,Nivo,0.513561
uuid-3988c03170e445ccaf1e4180b115599c,pembro,0.59478
uuid-3988c03170e445ccaf1e4180b115599c,RTL,0.302611
uuid-3988c03170e445ccaf1e4180b115599c,trial,0.479572
uuid-3988c03170e445ccaf1e4180b115599c,2L,0.334599
uuid-3988c03170e445ccaf1e4180b115599c,Ipi,0.334143
uuid-3988c03170e445ccaf1e4180b115599c,stated,0.43245
uuid-3988c03170e445ccaf1e4180b115599c,approval,0.511534
uuid-3988c03170e445ccaf1e4180b115599c,atezo,0.466884
uuid-3988c03170e445ccaf1e4180b115599c,using nivo,0.428876
uuid-3988c03170e445ccaf1e4180b115599c,data,0.458583
uuid-3988c03170e445ccaf1e4180b115599c,clinical trials,0.381554
uuid-3988c03170e445ccaf1e4180b115599c,indication,0.440532
uuid-3988c03170e445ccaf1e4180b115599c,approved,0.524343
uuid-3988c03170e445ccaf1e4180b115599c,SCCHN,0.354892
uuid-3988c03170e445ccaf1e4180b115599c,impressed,0.462494
uuid-3988c03170e445ccaf1e4180b115599c,vs,0.338321
uuid-3988c03170e445ccaf1e4180b115599c,label,0.36056
uuid-3988c03170e445ccaf1e4180b115599c,LTL,0.326125
uuid-3988c03170e445ccaf1e4180b115599c,SCLC,0.350265
uuid-3988c03170e445ccaf1e4180b115599c,feels,0.337708
uuid-3988c03170e445ccaf1e4180b115599c,bladder,0.391928
uuid-3988c03170e445ccaf1e4180b115599c,flat dosing,0.312173
uuid-a1113614292c4030bb27f13703c00d8b,oncology,0.48207
uuid-a1113614292c4030bb27f13703c00d8b,drug,0.320123
uuid-a1113614292c4030bb27f13703c00d8b,clinical,0.447729
uuid-a1113614292c4030bb27f13703c00d8b,biomarker,0.353528
uuid-2751e1857ceb40de9a44bef1cf06f54d,Nivo,0.363382
uuid-2751e1857ceb40de9a44bef1cf06f54d,patients,0.605755
uuid-2751e1857ceb40de9a44bef1cf06f54d,Opdivo,0.583515
uuid-2751e1857ceb40de9a44bef1cf06f54d,therapy,0.649155
uuid-2751e1857ceb40de9a44bef1cf06f54d,nivolumab,0.574643
uuid-2751e1857ceb40de9a44bef1cf06f54d,regimen,0.347426
uuid-2751e1857ceb40de9a44bef1cf06f54d,treated,0.403774
uuid-2751e1857ceb40de9a44bef1cf06f54d,treatment,0.499778
uuid-2751e1857ceb40de9a44bef1cf06f54d,using nivo,0.328359
uuid-2751e1857ceb40de9a44bef1cf06f54d,PD1,0.307967
uuid-2751e1857ceb40de9a44bef1cf06f54d,cHL,0.637248
uuid-2751e1857ceb40de9a44bef1cf06f54d,progression,0.473532
uuid-2751e1857ceb40de9a44bef1cf06f54d,chemotherapy,0.378655
uuid-2751e1857ceb40de9a44bef1cf06f54d,respond,0.306185
uuid-e6c77edd67a045ad96111b7087f811fe,Nivo,0.381557
uuid-e6c77edd67a045ad96111b7087f811fe,pembro,0.598567
uuid-e6c77edd67a045ad96111b7087f811fe,BMS,0.329063
uuid-e6c77edd67a045ad96111b7087f811fe,1L,0.341444
uuid-e6c77edd67a045ad96111b7087f811fe,PDL1,0.530604
uuid-e6c77edd67a045ad96111b7087f811fe,trial,0.458981
uuid-e6c77edd67a045ad96111b7087f811fe,efficacy,0.557223
uuid-e6c77edd67a045ad96111b7087f811fe,Merck,0.32139
uuid-e6c77edd67a045ad96111b7087f811fe,OS,0.484391
uuid-e6c77edd67a045ad96111b7087f811fe,atezo,0.606546
uuid-e6c77edd67a045ad96111b7087f811fe,data,0.813465
uuid-e6c77edd67a045ad96111b7087f811fe,indication,0.309539
uuid-e6c77edd67a045ad96111b7087f811fe,PFS,0.45218
uuid-e6c77edd67a045ad96111b7087f811fe,ORR,0.551643
uuid-e6c77edd67a045ad96111b7087f811fe,nivo and pembro,0.613151
uuid-e6c77edd67a045ad96111b7087f811fe,impressed,0.490665
uuid-e6c77edd67a045ad96111b7087f811fe,vs,0.391882
uuid-e6c77edd67a045ad96111b7087f811fe,TLs,0.373832
uuid-e6c77edd67a045ad96111b7087f811fe,feels,0.325701
uuid-e6c77edd67a045ad96111b7087f811fe,PDL1 expression,0.474814
uuid-d906bb6e7a364afa98a0bfbb67153d9b,lung,0.396248
uuid-d906bb6e7a364afa98a0bfbb67153d9b,PDL1 testing,0.320688
uuid-d906bb6e7a364afa98a0bfbb67153d9b,AI,0.488963
uuid-d906bb6e7a364afa98a0bfbb67153d9b,oncology,0.355498
uuid-d906bb6e7a364afa98a0bfbb67153d9b,SCCHN,0.300201
uuid-d906bb6e7a364afa98a0bfbb67153d9b,label,0.350153
uuid-d906bb6e7a364afa98a0bfbb67153d9b,NCCN,0.475015
uuid-fc4a4ab12526427dba06b5d93c47a9eb,TL,0.639136
uuid-fc4a4ab12526427dba06b5d93c47a9eb,TL stated,0.503719
uuid-fc4a4ab12526427dba06b5d93c47a9eb,PD-L1 testing,0.461677
uuid-fc4a4ab12526427dba06b5d93c47a9eb,testing,0.388268
uuid-fc4a4ab12526427dba06b5d93c47a9eb,PDL1 testing,0.465337
uuid-fc4a4ab12526427dba06b5d93c47a9eb,SCCHN,0.321715
uuid-fc4a4ab12526427dba06b5d93c47a9eb,Regional TL,0.429571
uuid-40ebc0848143402db03287b514a00a8c,RTL,0.649504
uuid-40ebc0848143402db03287b514a00a8c,lung,0.311311
uuid-40ebc0848143402db03287b514a00a8c,trial,0.343774
uuid-40ebc0848143402db03287b514a00a8c,NTL,0.592687
uuid-40ebc0848143402db03287b514a00a8c,shared,0.52862
uuid-40ebc0848143402db03287b514a00a8c,commented,0.5069
uuid-40ebc0848143402db03287b514a00a8c,RCC,0.309576
uuid-40ebc0848143402db03287b514a00a8c,institution,0.305931
uuid-40ebc0848143402db03287b514a00a8c,stated,0.709277
uuid-40ebc0848143402db03287b514a00a8c,approval,0.398477
uuid-40ebc0848143402db03287b514a00a8c,using nivo,0.315312
uuid-40ebc0848143402db03287b514a00a8c,data,0.327417
uuid-40ebc0848143402db03287b514a00a8c,expressed,0.337037
uuid-40ebc0848143402db03287b514a00a8c,mentioned,0.326332
uuid-40ebc0848143402db03287b514a00a8c,clinical trials,0.358853
uuid-40ebc0848143402db03287b514a00a8c,SCCHN,0.558306
uuid-40ebc0848143402db03287b514a00a8c,HCP,0.305702
uuid-40ebc0848143402db03287b514a00a8c,ASCO,0.329364
uuid-40ebc0848143402db03287b514a00a8c,impressed,0.438309
uuid-40ebc0848143402db03287b514a00a8c,LTL,0.532277
uuid-40ebc0848143402db03287b514a00a8c,TLs,0.492544
uuid-40ebc0848143402db03287b514a00a8c,academic,0.360527
uuid-40ebc0848143402db03287b514a00a8c,Regional TL,0.742621
uuid-40ebc0848143402db03287b514a00a8c,RTL stated,0.332011
uuid-40ebc0848143402db03287b514a00a8c,bladder,0.347025
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,pembro,0.424953
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,BMS,0.53501
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,PDL1,0.388501
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,trial,0.54235
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,efficacy,0.425049
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,commented,0.324924
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,Merck,0.468846
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,OS,0.410472
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,atezo,0.417052
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,regards,0.41044
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,data,0.556153
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,PFS,0.410656
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,ORR,0.39885
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,nivo and pembro,0.53445
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,believes,0.406048
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,impressed,0.352264
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,vs,0.418606
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,TLs,0.320016
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,feels,0.446681
uuid-8aee2f03d15e4dd4a81dcc23cb6b0a2d,PDL1 expression,0.319625
uuid-9163784b7a074d32bdce106f25e2c443,Nivo,0.655787
uuid-9163784b7a074d32bdce106f25e2c443,pembro,0.569069
uuid-9163784b7a074d32bdce106f25e2c443,1L,0.535342
uuid-9163784b7a074d32bdce106f25e2c443,trial,0.411709
uuid-9163784b7a074d32bdce106f25e2c443,efficacy,0.396106
uuid-9163784b7a074d32bdce106f25e2c443,RCC,0.332249
uuid-9163784b7a074d32bdce106f25e2c443,combination,0.387882
uuid-9163784b7a074d32bdce106f25e2c443,chemo,0.382593
uuid-9163784b7a074d32bdce106f25e2c443,2L,0.545984
uuid-9163784b7a074d32bdce106f25e2c443,agents,0.387108
uuid-9163784b7a074d32bdce106f25e2c443,Ipi,0.361917
uuid-9163784b7a074d32bdce106f25e2c443,approval,0.377708
uuid-9163784b7a074d32bdce106f25e2c443,atezo,0.524255
uuid-9163784b7a074d32bdce106f25e2c443,preferred,0.333802
uuid-9163784b7a074d32bdce106f25e2c443,monotherapy,0.475026
uuid-9163784b7a074d32bdce106f25e2c443,using nivo,0.458117
uuid-9163784b7a074d32bdce106f25e2c443,data,0.446461
uuid-9163784b7a074d32bdce106f25e2c443,combo,0.473462
uuid-9163784b7a074d32bdce106f25e2c443,PD1,0.381738
uuid-9163784b7a074d32bdce106f25e2c443,ORR,0.358781
uuid-9163784b7a074d32bdce106f25e2c443,approved,0.491535
uuid-9163784b7a074d32bdce106f25e2c443,nivo and pembro,0.479616
uuid-9163784b7a074d32bdce106f25e2c443,believes,0.467406
uuid-9163784b7a074d32bdce106f25e2c443,impressed,0.449079
uuid-9163784b7a074d32bdce106f25e2c443,SCLC,0.342467
uuid-9163784b7a074d32bdce106f25e2c443,feels,0.463401
uuid-9163784b7a074d32bdce106f25e2c443,RTL stated,0.349613
uuid-9163784b7a074d32bdce106f25e2c443,option,0.406545
uuid-9163784b7a074d32bdce106f25e2c443,bladder,0.381859
uuid-77115437621a4dc081113ff6e0927b72,RTL,0.394442
uuid-77115437621a4dc081113ff6e0927b72,lung,0.31357
uuid-77115437621a4dc081113ff6e0927b72,melanoma,0.357496
uuid-77115437621a4dc081113ff6e0927b72,shared,0.556469
uuid-77115437621a4dc081113ff6e0927b72,commented,0.411237
uuid-77115437621a4dc081113ff6e0927b72,RCC,0.364296
uuid-77115437621a4dc081113ff6e0927b72,institution,0.427442
uuid-77115437621a4dc081113ff6e0927b72,stated,0.544856
uuid-77115437621a4dc081113ff6e0927b72,approval,0.354461
uuid-77115437621a4dc081113ff6e0927b72,data,0.383894
uuid-77115437621a4dc081113ff6e0927b72,clinical trials,0.304748
uuid-77115437621a4dc081113ff6e0927b72,SCCHN,0.509157
uuid-77115437621a4dc081113ff6e0927b72,impressed,0.425156
uuid-77115437621a4dc081113ff6e0927b72,LTL,0.350639
uuid-77115437621a4dc081113ff6e0927b72,TLs,0.324812
uuid-77115437621a4dc081113ff6e0927b72,SCLC,0.326167
uuid-77115437621a4dc081113ff6e0927b72,Regional TL,0.457716
uuid-77115437621a4dc081113ff6e0927b72,RTL stated,0.425851
uuid-77115437621a4dc081113ff6e0927b72,TL shared,0.306756
uuid-77115437621a4dc081113ff6e0927b72,NCCN,0.376392
uuid-77115437621a4dc081113ff6e0927b72,bladder,0.337815
uuid-69dccddaf2c441be98d4cb0a17101d8b,NSCLC,0.341404
uuid-69dccddaf2c441be98d4cb0a17101d8b,preferred,0.503936
uuid-69dccddaf2c441be98d4cb0a17101d8b,using nivo,0.31531
uuid-69dccddaf2c441be98d4cb0a17101d8b,feels,0.367285
uuid-69dccddaf2c441be98d4cb0a17101d8b,RTL stated,0.403021
uuid-69dccddaf2c441be98d4cb0a17101d8b,option,0.31773
uuid-5881fb7eee6341a9a7f4b233621b6535,patients,0.442695
uuid-5881fb7eee6341a9a7f4b233621b6535,therapy,0.327322
uuid-5881fb7eee6341a9a7f4b233621b6535,1L,0.354344
uuid-5881fb7eee6341a9a7f4b233621b6535,regimen,0.427384
uuid-5881fb7eee6341a9a7f4b233621b6535,combination,0.333961
uuid-5881fb7eee6341a9a7f4b233621b6535,chemo,0.41044
uuid-5881fb7eee6341a9a7f4b233621b6535,2L,0.385443
uuid-5881fb7eee6341a9a7f4b233621b6535,pts,0.407287
uuid-5881fb7eee6341a9a7f4b233621b6535,IO,0.359374
uuid-5881fb7eee6341a9a7f4b233621b6535,preferred,0.319067
uuid-5881fb7eee6341a9a7f4b233621b6535,monotherapy,0.487749
uuid-5881fb7eee6341a9a7f4b233621b6535,treatment,0.344555
uuid-5881fb7eee6341a9a7f4b233621b6535,combo,0.406629
uuid-5881fb7eee6341a9a7f4b233621b6535,PD1,0.36595
uuid-5881fb7eee6341a9a7f4b233621b6535,progression,0.442052
uuid-5881fb7eee6341a9a7f4b233621b6535,chemotherapy,0.312824
uuid-5881fb7eee6341a9a7f4b233621b6535,respond,0.33483
uuid-5881fb7eee6341a9a7f4b233621b6535,option,0.43845
uuid-05b1753148444df4a2d2139d23be1f33,Nivo,0.517983
uuid-05b1753148444df4a2d2139d23be1f33,patients,0.57443
uuid-05b1753148444df4a2d2139d23be1f33,therapy,0.539126
uuid-05b1753148444df4a2d2139d23be1f33,nivolumab,0.462545
uuid-05b1753148444df4a2d2139d23be1f33,1L,0.680042
uuid-05b1753148444df4a2d2139d23be1f33,regimen,0.539611
uuid-05b1753148444df4a2d2139d23be1f33,treated,0.328902
uuid-05b1753148444df4a2d2139d23be1f33,RCC,0.44413
uuid-05b1753148444df4a2d2139d23be1f33,combination,0.488464
uuid-05b1753148444df4a2d2139d23be1f33,chemo,0.626472
uuid-05b1753148444df4a2d2139d23be1f33,2L,0.699793
uuid-05b1753148444df4a2d2139d23be1f33,pts,0.592188
uuid-05b1753148444df4a2d2139d23be1f33,IO,0.363738
uuid-05b1753148444df4a2d2139d23be1f33,agents,0.480804
uuid-05b1753148444df4a2d2139d23be1f33,preferred,0.593841
uuid-05b1753148444df4a2d2139d23be1f33,monotherapy,0.780753
uuid-05b1753148444df4a2d2139d23be1f33,treatment,0.502035
uuid-05b1753148444df4a2d2139d23be1f33,using nivo,0.554303
uuid-05b1753148444df4a2d2139d23be1f33,response,0.444466
uuid-05b1753148444df4a2d2139d23be1f33,combo,0.521848
uuid-05b1753148444df4a2d2139d23be1f33,PD1,0.589501
uuid-05b1753148444df4a2d2139d23be1f33,approved,0.427801
uuid-05b1753148444df4a2d2139d23be1f33,progression,0.566721
uuid-05b1753148444df4a2d2139d23be1f33,believes,0.329141
uuid-05b1753148444df4a2d2139d23be1f33,chemotherapy,0.480332
uuid-05b1753148444df4a2d2139d23be1f33,respond,0.437938
uuid-05b1753148444df4a2d2139d23be1f33,feels,0.318733
uuid-05b1753148444df4a2d2139d23be1f33,PD-1,0.322361
uuid-05b1753148444df4a2d2139d23be1f33,RTL stated,0.472835
uuid-05b1753148444df4a2d2139d23be1f33,option,0.706249
uuid-7b363d3336004caaa44ed71b4151bdc6,patients,0.302771
uuid-7b363d3336004caaa44ed71b4151bdc6,toxicity,0.322274
uuid-7b363d3336004caaa44ed71b4151bdc6,regimen,0.484657
uuid-7b363d3336004caaa44ed71b4151bdc6,shared,0.349586
uuid-7b363d3336004caaa44ed71b4151bdc6,combination,0.415735
uuid-7b363d3336004caaa44ed71b4151bdc6,chemo,0.300904
uuid-7b363d3336004caaa44ed71b4151bdc6,Ipi,0.428511
uuid-7b363d3336004caaa44ed71b4151bdc6,monotherapy,0.427589
uuid-7b363d3336004caaa44ed71b4151bdc6,combo,0.492051
uuid-7b363d3336004caaa44ed71b4151bdc6,clinical trials,0.351517
uuid-7b363d3336004caaa44ed71b4151bdc6,chemotherapy,0.349144
uuid-7b363d3336004caaa44ed71b4151bdc6,impressed,0.383026
uuid-7b363d3336004caaa44ed71b4151bdc6,feels,0.457387
uuid-7b363d3336004caaa44ed71b4151bdc6,option,0.419831
uuid-e7d7ec6e78de486b9fcb09717492af93,pembro,0.303899
uuid-e7d7ec6e78de486b9fcb09717492af93,RTL,0.335983
uuid-e7d7ec6e78de486b9fcb09717492af93,dose,0.32862
uuid-e7d7ec6e78de486b9fcb09717492af93,BMS,0.350794
uuid-e7d7ec6e78de486b9fcb09717492af93,trial,0.496642
uuid-e7d7ec6e78de486b9fcb09717492af93,efficacy,0.36067
uuid-e7d7ec6e78de486b9fcb09717492af93,shared,0.58494
uuid-e7d7ec6e78de486b9fcb09717492af93,commented,0.373165
uuid-e7d7ec6e78de486b9fcb09717492af93,combination,0.338088
uuid-e7d7ec6e78de486b9fcb09717492af93,Ipi,0.489964
uuid-e7d7ec6e78de486b9fcb09717492af93,data,0.471633
uuid-e7d7ec6e78de486b9fcb09717492af93,combo,0.3611
uuid-e7d7ec6e78de486b9fcb09717492af93,clinical trials,0.326682
uuid-e7d7ec6e78de486b9fcb09717492af93,impressed,0.464085
uuid-e7d7ec6e78de486b9fcb09717492af93,LTL,0.321159
uuid-e7d7ec6e78de486b9fcb09717492af93,TLs,0.313538
uuid-e7d7ec6e78de486b9fcb09717492af93,SCLC,0.320213
uuid-e7d7ec6e78de486b9fcb09717492af93,flat dosing,0.354768
uuid-bf9b8528c8724cf786c2a888823b057b,BMS,0.430434
uuid-bf9b8528c8724cf786c2a888823b057b,PDL1,0.454327
uuid-bf9b8528c8724cf786c2a888823b057b,trial,0.468869
uuid-bf9b8528c8724cf786c2a888823b057b,efficacy,0.534299
uuid-bf9b8528c8724cf786c2a888823b057b,OS,0.684144
uuid-bf9b8528c8724cf786c2a888823b057b,regards,0.524264
uuid-bf9b8528c8724cf786c2a888823b057b,data,0.572636
uuid-bf9b8528c8724cf786c2a888823b057b,expressed,0.372613
uuid-bf9b8528c8724cf786c2a888823b057b,PFS,0.768147
uuid-bf9b8528c8724cf786c2a888823b057b,AI,0.547086
uuid-bf9b8528c8724cf786c2a888823b057b,ORR,0.684995
uuid-bf9b8528c8724cf786c2a888823b057b,nivo and pembro,0.600935
uuid-bf9b8528c8724cf786c2a888823b057b,believes,0.300998
uuid-bf9b8528c8724cf786c2a888823b057b,impressed,0.376307
uuid-bf9b8528c8724cf786c2a888823b057b,PDL1 expression,0.505883
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,Nivo,0.545914
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,patients,0.656293
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,therapy,0.705683
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,nivolumab,0.5868
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,1L,0.397024
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,toxicity,0.4219
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,regimen,0.703049
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,treated,0.425413
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,combination,0.648274
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,chemo,0.640872
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,2L,0.417327
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,pts,0.537574
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,IO,0.351268
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,agents,0.358891
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,Ipi,0.437012
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,preferred,0.404127
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,monotherapy,0.78466
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,treatment,0.603982
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,using nivo,0.475864
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,response,0.423671
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,combo,0.578459
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,PD1,0.639193
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,progression,0.583824
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,chemotherapy,0.656788
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,respond,0.399178
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,RTL stated,0.335659
uuid-1c0ba69a452f49369cb83e1ef1c4bb85,option,0.623026
uuid-a9526ce9d4e74f05bccc9ba824c48082,RTL,0.380875
uuid-a9526ce9d4e74f05bccc9ba824c48082,trial,0.620367
uuid-a9526ce9d4e74f05bccc9ba824c48082,clinical trials,0.324551
uuid-a9526ce9d4e74f05bccc9ba824c48082,Regional TL,0.319035
uuid-58c167e4a1b8479db384e4de20a37864,patients,0.417959
uuid-58c167e4a1b8479db384e4de20a37864,Opdivo,0.321077
uuid-58c167e4a1b8479db384e4de20a37864,therapy,0.355506
uuid-58c167e4a1b8479db384e4de20a37864,nivolumab,0.366651
uuid-58c167e4a1b8479db384e4de20a37864,1L,0.394264
uuid-58c167e4a1b8479db384e4de20a37864,treated,0.300933
uuid-58c167e4a1b8479db384e4de20a37864,RCC,0.446665
uuid-58c167e4a1b8479db384e4de20a37864,2L,0.435625
uuid-58c167e4a1b8479db384e4de20a37864,approval,0.415378
uuid-58c167e4a1b8479db384e4de20a37864,preferred,0.428822
uuid-58c167e4a1b8479db384e4de20a37864,monotherapy,0.413356
uuid-58c167e4a1b8479db384e4de20a37864,treatment,0.305296
uuid-58c167e4a1b8479db384e4de20a37864,using nivo,0.563897
uuid-58c167e4a1b8479db384e4de20a37864,indication,0.390639
uuid-58c167e4a1b8479db384e4de20a37864,approved,0.342471
uuid-58c167e4a1b8479db384e4de20a37864,SCCHN,0.356114
uuid-58c167e4a1b8479db384e4de20a37864,cHL,0.317574
uuid-58c167e4a1b8479db384e4de20a37864,RTL stated,0.420764
uuid-58c167e4a1b8479db384e4de20a37864,TL shared,0.347759
uuid-58c167e4a1b8479db384e4de20a37864,option,0.440894
uuid-58c167e4a1b8479db384e4de20a37864,bladder,0.311548
uuid-39d35fa77c9244c5a0944037fdc2a20c,patients,0.546724
uuid-39d35fa77c9244c5a0944037fdc2a20c,Opdivo,0.622524
uuid-39d35fa77c9244c5a0944037fdc2a20c,treated,0.30535
uuid-39d35fa77c9244c5a0944037fdc2a20c,pts,0.307112
uuid-39d35fa77c9244c5a0944037fdc2a20c,physicians,0.47812
uuid-39d35fa77c9244c5a0944037fdc2a20c,treatment,0.426071
uuid-39d35fa77c9244c5a0944037fdc2a20c,progression,0.417696
uuid-39d35fa77c9244c5a0944037fdc2a20c,respond,0.398133
uuid-39d35fa77c9244c5a0944037fdc2a20c,feels,0.304087
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,Nivo,0.416511
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,pembro,0.326752
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,BMS,0.367812
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,PDL1,0.301906
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,trial,0.570701
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,efficacy,0.490706
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,OS,0.605033
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,data,0.84756
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,PFS,0.577841
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,ORR,0.647816
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,nivo and pembro,0.439662
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,ASCO,0.30934
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,impressed,0.618941
uuid-a6f1e898e2cc4d7a88db12f4e201ec2f,feels,0.405355
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,Nivo,0.403445
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,patients,0.526938
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,therapy,0.793394
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,nivolumab,0.60766
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,treated,0.381839
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,combination,0.368606
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,chemo,0.361985
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,monotherapy,0.395253
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,treatment,0.447657
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,using nivo,0.36812
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,response,0.312809
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,PD1,0.490467
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,cHL,0.6719
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,progression,0.402746
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,chemotherapy,0.503688
uuid-836cf1d6ca0840a39e8d5ba164fd2d7c,option,0.337626
uuid-c3537018186a4fedb8c18ec14bed65af,Nivo,0.309815
uuid-c3537018186a4fedb8c18ec14bed65af,patients,0.37911
uuid-c3537018186a4fedb8c18ec14bed65af,Opdivo,0.372434
uuid-c3537018186a4fedb8c18ec14bed65af,therapy,0.514854
uuid-c3537018186a4fedb8c18ec14bed65af,nivolumab,0.458906
uuid-c3537018186a4fedb8c18ec14bed65af,toxicity,0.406497
uuid-c3537018186a4fedb8c18ec14bed65af,regimen,0.31717
uuid-c3537018186a4fedb8c18ec14bed65af,treatment,0.35513
uuid-c3537018186a4fedb8c18ec14bed65af,PD1,0.344982
uuid-c3537018186a4fedb8c18ec14bed65af,cHL,0.522932
uuid-ad743c98de8b44b79b583a40a2876270,patients,0.557863
uuid-ad743c98de8b44b79b583a40a2876270,therapy,0.395545
uuid-ad743c98de8b44b79b583a40a2876270,1L,0.423735
uuid-ad743c98de8b44b79b583a40a2876270,PDL1,0.327067
uuid-ad743c98de8b44b79b583a40a2876270,treated,0.35001
uuid-ad743c98de8b44b79b583a40a2876270,chemo,0.318289
uuid-ad743c98de8b44b79b583a40a2876270,2L,0.337993
uuid-ad743c98de8b44b79b583a40a2876270,pts,0.499541
uuid-ad743c98de8b44b79b583a40a2876270,PD-L1,0.363946
uuid-ad743c98de8b44b79b583a40a2876270,testing,0.415859
uuid-ad743c98de8b44b79b583a40a2876270,monotherapy,0.4206
uuid-ad743c98de8b44b79b583a40a2876270,treatment,0.452943
uuid-ad743c98de8b44b79b583a40a2876270,response,0.304004
uuid-ad743c98de8b44b79b583a40a2876270,PDL1 testing,0.385675
uuid-ad743c98de8b44b79b583a40a2876270,NSCLC patients,0.539909
uuid-ad743c98de8b44b79b583a40a2876270,PD1,0.38293
uuid-ad743c98de8b44b79b583a40a2876270,progression,0.470622
uuid-ad743c98de8b44b79b583a40a2876270,tumor types,0.310947
uuid-ad743c98de8b44b79b583a40a2876270,respond,0.412232
uuid-ad743c98de8b44b79b583a40a2876270,feels,0.300553
uuid-ad743c98de8b44b79b583a40a2876270,PD-1,0.326243
uuid-ad743c98de8b44b79b583a40a2876270,option,0.445796
uuid-ef4d9eec0533458ca8d148233f0a33cf,Nivo,0.359201
uuid-ef4d9eec0533458ca8d148233f0a33cf,toxicity,0.475051
uuid-ef4d9eec0533458ca8d148233f0a33cf,efficacy,0.684065
uuid-ef4d9eec0533458ca8d148233f0a33cf,regimen,0.496946
uuid-ef4d9eec0533458ca8d148233f0a33cf,chemo,0.436871
uuid-ef4d9eec0533458ca8d148233f0a33cf,Ipi,0.34315
uuid-ef4d9eec0533458ca8d148233f0a33cf,OS,0.555549
uuid-ef4d9eec0533458ca8d148233f0a33cf,monotherapy,0.306301
uuid-ef4d9eec0533458ca8d148233f0a33cf,response,0.460618
uuid-ef4d9eec0533458ca8d148233f0a33cf,PFS,0.538235
uuid-ef4d9eec0533458ca8d148233f0a33cf,ORR,0.60919
uuid-ef4d9eec0533458ca8d148233f0a33cf,progression,0.39099
uuid-ef4d9eec0533458ca8d148233f0a33cf,chemotherapy,0.444227
uuid-ef4d9eec0533458ca8d148233f0a33cf,impressed,0.301949
uuid-ef4d9eec0533458ca8d148233f0a33cf,respond,0.372602
uuid-ef4d9eec0533458ca8d148233f0a33cf,feels,0.363247
uuid-4e34c914f8114c39ab099dc3da72714c,Nivo,0.310112
uuid-4e34c914f8114c39ab099dc3da72714c,dose,0.686937
uuid-4e34c914f8114c39ab099dc3da72714c,toxicity,0.705077
uuid-4e34c914f8114c39ab099dc3da72714c,efficacy,0.498996
uuid-4e34c914f8114c39ab099dc3da72714c,regimen,0.528376
uuid-4e34c914f8114c39ab099dc3da72714c,Ipi,0.564404
uuid-4e34c914f8114c39ab099dc3da72714c,combo,0.306064
uuid-4e34c914f8114c39ab099dc3da72714c,vs,0.417286
uuid-4e34c914f8114c39ab099dc3da72714c,flat dosing,0.430643
uuid-8fb47262fa964fbf8432258d0df5ca7f,Nivo,0.488956
uuid-8fb47262fa964fbf8432258d0df5ca7f,Ipi,0.507822
uuid-8fb47262fa964fbf8432258d0df5ca7f,approval,0.352569
uuid-8fb47262fa964fbf8432258d0df5ca7f,using nivo,0.368432
uuid-8fb47262fa964fbf8432258d0df5ca7f,mentioned,0.368654
uuid-8fb47262fa964fbf8432258d0df5ca7f,indication,0.335431
uuid-8fb47262fa964fbf8432258d0df5ca7f,approved,0.36433
uuid-8fb47262fa964fbf8432258d0df5ca7f,HCP,0.39363
uuid-8fb47262fa964fbf8432258d0df5ca7f,label,0.330879
uuid-8fb47262fa964fbf8432258d0df5ca7f,SCLC,0.628109
uuid-1236e2b4f2dd4b6c8a2357cb3c242fbe,therapy,0.312424
uuid-1236e2b4f2dd4b6c8a2357cb3c242fbe,mentioned,0.358797
uuid-1236e2b4f2dd4b6c8a2357cb3c242fbe,cHL,0.663891
uuid-92edbd09928d4d61b55cff147573b9d2,patients,0.830808
uuid-92edbd09928d4d61b55cff147573b9d2,Opdivo,0.490425
uuid-92edbd09928d4d61b55cff147573b9d2,therapy,0.619865
uuid-92edbd09928d4d61b55cff147573b9d2,nivolumab,0.489593
uuid-92edbd09928d4d61b55cff147573b9d2,regimen,0.57542
uuid-92edbd09928d4d61b55cff147573b9d2,treated,0.670204
uuid-92edbd09928d4d61b55cff147573b9d2,chemo,0.328044
uuid-92edbd09928d4d61b55cff147573b9d2,pts,0.609134
uuid-92edbd09928d4d61b55cff147573b9d2,monotherapy,0.402327
uuid-92edbd09928d4d61b55cff147573b9d2,treatment,0.830043
uuid-92edbd09928d4d61b55cff147573b9d2,using nivo,0.317669
uuid-92edbd09928d4d61b55cff147573b9d2,response,0.440122
uuid-92edbd09928d4d61b55cff147573b9d2,PD1,0.35446
uuid-92edbd09928d4d61b55cff147573b9d2,cHL,0.304392
uuid-92edbd09928d4d61b55cff147573b9d2,progression,0.709935
uuid-92edbd09928d4d61b55cff147573b9d2,chemotherapy,0.368048
uuid-92edbd09928d4d61b55cff147573b9d2,respond,0.609119
uuid-92edbd09928d4d61b55cff147573b9d2,option,0.407756
uuid-3fa34caeca9646fdaba9722409b104d0,Nivo,0.306485
uuid-3fa34caeca9646fdaba9722409b104d0,patients,0.503217
uuid-3fa34caeca9646fdaba9722409b104d0,Opdivo,0.483746
uuid-3fa34caeca9646fdaba9722409b104d0,therapy,0.593448
uuid-3fa34caeca9646fdaba9722409b104d0,nivolumab,0.461391
uuid-3fa34caeca9646fdaba9722409b104d0,treated,0.31063
uuid-3fa34caeca9646fdaba9722409b104d0,treatment,0.339342
uuid-3fa34caeca9646fdaba9722409b104d0,cHL,0.810917
uuid-ed9b2de2f4f142b4b948f03fddf3f686,TL,0.445186
uuid-ed9b2de2f4f142b4b948f03fddf3f686,RTL,0.50495
uuid-ed9b2de2f4f142b4b948f03fddf3f686,NTL,0.504949
uuid-ed9b2de2f4f142b4b948f03fddf3f686,commented,0.366085
uuid-ed9b2de2f4f142b4b948f03fddf3f686,stated,0.375205
uuid-ed9b2de2f4f142b4b948f03fddf3f686,physicians,0.37877
uuid-ed9b2de2f4f142b4b948f03fddf3f686,mentioned,0.373011
uuid-ed9b2de2f4f142b4b948f03fddf3f686,oncology,0.356056
uuid-ed9b2de2f4f142b4b948f03fddf3f686,indicated,0.384484
uuid-ed9b2de2f4f142b4b948f03fddf3f686,LTL,0.40156
uuid-ed9b2de2f4f142b4b948f03fddf3f686,TLs,0.355713
uuid-ed9b2de2f4f142b4b948f03fddf3f686,clinical,0.343059
uuid-ed9b2de2f4f142b4b948f03fddf3f686,academic,0.348838
uuid-ed9b2de2f4f142b4b948f03fddf3f686,Regional TL,0.564722
uuid-8ee7648b89a941f889ae91ab78b6c1a8,lung,0.423431
uuid-8ee7648b89a941f889ae91ab78b6c1a8,PDL1,0.490834
uuid-8ee7648b89a941f889ae91ab78b6c1a8,efficacy,0.345689
uuid-8ee7648b89a941f889ae91ab78b6c1a8,atezo,0.300402
uuid-8ee7648b89a941f889ae91ab78b6c1a8,regards,0.443346
uuid-8ee7648b89a941f889ae91ab78b6c1a8,PFS,0.338924
uuid-8ee7648b89a941f889ae91ab78b6c1a8,AI,0.723892
uuid-8ee7648b89a941f889ae91ab78b6c1a8,nivo and pembro,0.628423
uuid-8ee7648b89a941f889ae91ab78b6c1a8,believes,0.389396
uuid-8ee7648b89a941f889ae91ab78b6c1a8,PDL1 expression,0.437343
uuid-8ee7648b89a941f889ae91ab78b6c1a8,biomarker,0.322332
uuid-8ee7648b89a941f889ae91ab78b6c1a8,NCCN,0.420178
uuid-2b49797697c44085a5824761f8227835,lung,0.429842
uuid-2b49797697c44085a5824761f8227835,trial,0.346449
uuid-2b49797697c44085a5824761f8227835,melanoma,0.428504
uuid-2b49797697c44085a5824761f8227835,OS,0.343317
uuid-2b49797697c44085a5824761f8227835,regards,0.448885
uuid-2b49797697c44085a5824761f8227835,PFS,0.378955
uuid-2b49797697c44085a5824761f8227835,AI,0.758343
uuid-2b49797697c44085a5824761f8227835,ORR,0.34332
uuid-2b49797697c44085a5824761f8227835,nivo and pembro,0.365812
uuid-2b49797697c44085a5824761f8227835,SCLC,0.3478
uuid-2b49797697c44085a5824761f8227835,NCCN,0.509363
uuid-b892dd64b680482e9da5a97670a449d5,lung,0.350847
uuid-b892dd64b680482e9da5a97670a449d5,institution,0.327864
uuid-b892dd64b680482e9da5a97670a449d5,regards,0.32633
uuid-b892dd64b680482e9da5a97670a449d5,AI,0.706031
uuid-b892dd64b680482e9da5a97670a449d5,oncology,0.423092
uuid-b892dd64b680482e9da5a97670a449d5,clinical,0.343072
uuid-b892dd64b680482e9da5a97670a449d5,NCCN,0.333331
uuid-2de8f3403b064e5bb27bb011c78f8fe0,patients,0.340023
uuid-2de8f3403b064e5bb27bb011c78f8fe0,progression,0.357039
uuid-bddbe308161a4a86955a6f48c5722d28,patients,0.445157
uuid-bddbe308161a4a86955a6f48c5722d28,Opdivo,0.335918
uuid-bddbe308161a4a86955a6f48c5722d28,nivolumab,0.359145
uuid-bddbe308161a4a86955a6f48c5722d28,physicians,0.362596
uuid-bddbe308161a4a86955a6f48c5722d28,clinical trials,0.315096
uuid-1c127facc1fb44bb86d4e762d0e85bfa,patients,0.496765
uuid-1c127facc1fb44bb86d4e762d0e85bfa,nivolumab,0.303144
uuid-1c127facc1fb44bb86d4e762d0e85bfa,lung,0.47525
uuid-1c127facc1fb44bb86d4e762d0e85bfa,1L,0.639424
uuid-1c127facc1fb44bb86d4e762d0e85bfa,regimen,0.349902
uuid-1c127facc1fb44bb86d4e762d0e85bfa,treated,0.351666
uuid-1c127facc1fb44bb86d4e762d0e85bfa,melanoma,0.418567
uuid-1c127facc1fb44bb86d4e762d0e85bfa,RCC,0.641533
uuid-1c127facc1fb44bb86d4e762d0e85bfa,TL stated,0.509963
uuid-1c127facc1fb44bb86d4e762d0e85bfa,chemo,0.333383
uuid-1c127facc1fb44bb86d4e762d0e85bfa,2L,0.649178
uuid-1c127facc1fb44bb86d4e762d0e85bfa,pts,0.476205
uuid-1c127facc1fb44bb86d4e762d0e85bfa,preferred,0.511186
uuid-1c127facc1fb44bb86d4e762d0e85bfa,monotherapy,0.532678
uuid-1c127facc1fb44bb86d4e762d0e85bfa,using nivo,0.570902
uuid-1c127facc1fb44bb86d4e762d0e85bfa,combo,0.380706
uuid-1c127facc1fb44bb86d4e762d0e85bfa,PDL1 testing,0.397556
uuid-1c127facc1fb44bb86d4e762d0e85bfa,NSCLC patients,0.418925
uuid-1c127facc1fb44bb86d4e762d0e85bfa,approved,0.352937
uuid-1c127facc1fb44bb86d4e762d0e85bfa,SCCHN,0.442896
uuid-1c127facc1fb44bb86d4e762d0e85bfa,progression,0.33086
uuid-1c127facc1fb44bb86d4e762d0e85bfa,tumor types,0.494826
uuid-1c127facc1fb44bb86d4e762d0e85bfa,RTL stated,0.591673
uuid-1c127facc1fb44bb86d4e762d0e85bfa,TL shared,0.551453
uuid-1c127facc1fb44bb86d4e762d0e85bfa,option,0.546479
uuid-1c127facc1fb44bb86d4e762d0e85bfa,bladder,0.439192
uuid-f2212e94441b4fed86a17515f40c55cc,toxicity,0.51117
uuid-f2212e94441b4fed86a17515f40c55cc,regimen,0.358873
uuid-f2212e94441b4fed86a17515f40c55cc,combination,0.320977
uuid-f2212e94441b4fed86a17515f40c55cc,IO,0.350267
uuid-f2212e94441b4fed86a17515f40c55cc,physicians,0.427042
uuid-f2212e94441b4fed86a17515f40c55cc,combo,0.366627
uuid-f2212e94441b4fed86a17515f40c55cc,oncology,0.357086
uuid-f2212e94441b4fed86a17515f40c55cc,TLs,0.336774
uuid-f2212e94441b4fed86a17515f40c55cc,academic,0.349611
uuid-0908cec50da5440995952e45393c2d38,lung,0.303817
uuid-0908cec50da5440995952e45393c2d38,1L,0.416827
uuid-0908cec50da5440995952e45393c2d38,RCC,0.349001
uuid-0908cec50da5440995952e45393c2d38,2L,0.426206
uuid-0908cec50da5440995952e45393c2d38,stated,0.485622
uuid-0908cec50da5440995952e45393c2d38,approval,0.382926
uuid-0908cec50da5440995952e45393c2d38,preferred,0.39055
uuid-0908cec50da5440995952e45393c2d38,using nivo,0.342737
uuid-0908cec50da5440995952e45393c2d38,expressed,0.309415
uuid-0908cec50da5440995952e45393c2d38,indication,0.452873
uuid-0908cec50da5440995952e45393c2d38,approved,0.483253
uuid-0908cec50da5440995952e45393c2d38,SCCHN,0.399102
uuid-0908cec50da5440995952e45393c2d38,tumor types,0.312962
uuid-0908cec50da5440995952e45393c2d38,label,0.420169
uuid-0908cec50da5440995952e45393c2d38,RTL stated,0.324389
uuid-0908cec50da5440995952e45393c2d38,option,0.331133
uuid-a804b5a718044c41baed7257d212f23c,BMS,0.41435
uuid-a804b5a718044c41baed7257d212f23c,PDL1,0.519711
uuid-a804b5a718044c41baed7257d212f23c,trial,0.574975
uuid-a804b5a718044c41baed7257d212f23c,efficacy,0.529896
uuid-a804b5a718044c41baed7257d212f23c,OS,0.704521
uuid-a804b5a718044c41baed7257d212f23c,regards,0.339319
uuid-a804b5a718044c41baed7257d212f23c,data,0.656596
uuid-a804b5a718044c41baed7257d212f23c,PFS,0.737446
uuid-a804b5a718044c41baed7257d212f23c,ORR,0.684187
uuid-a804b5a718044c41baed7257d212f23c,nivo and pembro,0.621302
uuid-a804b5a718044c41baed7257d212f23c,believes,0.346397
uuid-a804b5a718044c41baed7257d212f23c,impressed,0.43664
uuid-a804b5a718044c41baed7257d212f23c,feels,0.348139
uuid-a804b5a718044c41baed7257d212f23c,PDL1 expression,0.439821
uuid-7eeca9c6841a40c28d96178f2b5f9333,oncology,0.530257
uuid-7eeca9c6841a40c28d96178f2b5f9333,drug,0.61349
uuid-7eeca9c6841a40c28d96178f2b5f9333,clinical,0.435506
uuid-a460ab06c9194ee9ae494d0369445024,Nivo,0.568902
uuid-a460ab06c9194ee9ae494d0369445024,therapy,0.39103
uuid-a460ab06c9194ee9ae494d0369445024,efficacy,0.455894
uuid-a460ab06c9194ee9ae494d0369445024,chemo,0.64162
uuid-a460ab06c9194ee9ae494d0369445024,OS,0.446313
uuid-a460ab06c9194ee9ae494d0369445024,monotherapy,0.345388
uuid-a460ab06c9194ee9ae494d0369445024,response,0.501756
uuid-a460ab06c9194ee9ae494d0369445024,PFS,0.504457
uuid-a460ab06c9194ee9ae494d0369445024,PD1,0.386355
uuid-a460ab06c9194ee9ae494d0369445024,ORR,0.421333
uuid-a460ab06c9194ee9ae494d0369445024,nivo and pembro,0.402946
uuid-a460ab06c9194ee9ae494d0369445024,progression,0.337911
uuid-a460ab06c9194ee9ae494d0369445024,believes,0.457358
uuid-a460ab06c9194ee9ae494d0369445024,chemotherapy,0.504458
uuid-a460ab06c9194ee9ae494d0369445024,respond,0.372472
uuid-a460ab06c9194ee9ae494d0369445024,feels,0.371752
uuid-a460ab06c9194ee9ae494d0369445024,option,0.342691
uuid-a72ad7883f2a4073b9e20e734d65892e,approval,0.332875
uuid-a72ad7883f2a4073b9e20e734d65892e,clinical trials,0.334678
uuid-a72ad7883f2a4073b9e20e734d65892e,indication,0.515523
uuid-a72ad7883f2a4073b9e20e734d65892e,approved,0.54617
uuid-a72ad7883f2a4073b9e20e734d65892e,label,0.507105
uuid-a72ad7883f2a4073b9e20e734d65892e,drug,0.323409
uuid-e99c4b5909ab45d3861f3c985166a4e1,patients,0.529542
uuid-e99c4b5909ab45d3861f3c985166a4e1,pts,0.304502
uuid-e99c4b5909ab45d3861f3c985166a4e1,clinical trials,0.391149
uuid-c71fdeca00e441768f60bbebaf73d7d3,patients,0.488458
uuid-c71fdeca00e441768f60bbebaf73d7d3,Opdivo,0.518754
uuid-c71fdeca00e441768f60bbebaf73d7d3,nivolumab,0.46321
uuid-c71fdeca00e441768f60bbebaf73d7d3,treated,0.356498
uuid-c71fdeca00e441768f60bbebaf73d7d3,pts,0.384749
uuid-c71fdeca00e441768f60bbebaf73d7d3,approval,0.421232
uuid-c71fdeca00e441768f60bbebaf73d7d3,treatment,0.347353
uuid-c71fdeca00e441768f60bbebaf73d7d3,using nivo,0.393946
uuid-c71fdeca00e441768f60bbebaf73d7d3,SCCHN,0.434661
uuid-c71fdeca00e441768f60bbebaf73d7d3,cHL,0.348855
uuid-c71fdeca00e441768f60bbebaf73d7d3,RTL stated,0.333093
uuid-51d1250e26ca4abcba15c5b5fbfa4907,Nivo,0.367042
uuid-51d1250e26ca4abcba15c5b5fbfa4907,patients,0.732865
uuid-51d1250e26ca4abcba15c5b5fbfa4907,Opdivo,0.580366
uuid-51d1250e26ca4abcba15c5b5fbfa4907,therapy,0.435128
uuid-51d1250e26ca4abcba15c5b5fbfa4907,nivolumab,0.551422
uuid-51d1250e26ca4abcba15c5b5fbfa4907,regimen,0.465655
uuid-51d1250e26ca4abcba15c5b5fbfa4907,treated,0.608243
uuid-51d1250e26ca4abcba15c5b5fbfa4907,pts,0.456944
uuid-51d1250e26ca4abcba15c5b5fbfa4907,approval,0.426504
uuid-51d1250e26ca4abcba15c5b5fbfa4907,monotherapy,0.326863
uuid-51d1250e26ca4abcba15c5b5fbfa4907,treatment,0.544716
uuid-51d1250e26ca4abcba15c5b5fbfa4907,using nivo,0.463055
uuid-51d1250e26ca4abcba15c5b5fbfa4907,approved,0.311808
uuid-51d1250e26ca4abcba15c5b5fbfa4907,SCCHN,0.324972
uuid-51d1250e26ca4abcba15c5b5fbfa4907,cHL,0.364311
uuid-51d1250e26ca4abcba15c5b5fbfa4907,progression,0.443816
uuid-51d1250e26ca4abcba15c5b5fbfa4907,respond,0.348484
uuid-51d1250e26ca4abcba15c5b5fbfa4907,RTL stated,0.384853
uuid-51d1250e26ca4abcba15c5b5fbfa4907,option,0.344146
uuid-a2f19525831e4ad88cd230d6d27e314d,Nivo,0.301202
uuid-a2f19525831e4ad88cd230d6d27e314d,Opdivo,0.444715
uuid-a2f19525831e4ad88cd230d6d27e314d,pembro,0.530744
uuid-a2f19525831e4ad88cd230d6d27e314d,dose,0.347934
uuid-a2f19525831e4ad88cd230d6d27e314d,2L,0.412206
uuid-a2f19525831e4ad88cd230d6d27e314d,approval,0.337491
uuid-a2f19525831e4ad88cd230d6d27e314d,atezo,0.517559
uuid-a2f19525831e4ad88cd230d6d27e314d,preferred,0.55308
uuid-a2f19525831e4ad88cd230d6d27e314d,using nivo,0.370148
uuid-a2f19525831e4ad88cd230d6d27e314d,indication,0.503997
uuid-a2f19525831e4ad88cd230d6d27e314d,approved,0.432115
uuid-a2f19525831e4ad88cd230d6d27e314d,vs,0.341802
uuid-a2f19525831e4ad88cd230d6d27e314d,label,0.306533
uuid-a2f19525831e4ad88cd230d6d27e314d,Keytruda,0.501044
uuid-a2f19525831e4ad88cd230d6d27e314d,feels,0.349285
uuid-a2f19525831e4ad88cd230d6d27e314d,option,0.407907
uuid-a2f19525831e4ad88cd230d6d27e314d,flat dosing,0.385623
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,lung,0.393257
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,discussed,0.381907
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,commented,0.44971
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,RCC,0.31357
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,stated,0.357325
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,regards,0.451892
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,data,0.390419
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,expressed,0.386486
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,indication,0.514724
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,approved,0.303088
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,SCCHN,0.447407
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,impressed,0.329482
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,indicated,0.356226
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,LTL,0.301897
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,TLs,0.516329
uuid-1c0c9ec91b7845e3a32be1cd37a183c5,Regional TL,0.360382
uuid-d722dda77a6d471698ccd5cd8ecc1209,BMS,0.34605
uuid-d722dda77a6d471698ccd5cd8ecc1209,efficacy,0.484292
uuid-d722dda77a6d471698ccd5cd8ecc1209,agents,0.532221
uuid-d722dda77a6d471698ccd5cd8ecc1209,atezo,0.329914
uuid-d722dda77a6d471698ccd5cd8ecc1209,regards,0.418951
uuid-d722dda77a6d471698ccd5cd8ecc1209,data,0.358881
uuid-d722dda77a6d471698ccd5cd8ecc1209,expressed,0.328036
uuid-d722dda77a6d471698ccd5cd8ecc1209,indication,0.375644
uuid-d722dda77a6d471698ccd5cd8ecc1209,nivo and pembro,0.394901
uuid-d722dda77a6d471698ccd5cd8ecc1209,believes,0.363175
uuid-d722dda77a6d471698ccd5cd8ecc1209,TLs,0.405734
uuid-d722dda77a6d471698ccd5cd8ecc1209,clinical,0.406818
uuid-d722dda77a6d471698ccd5cd8ecc1209,feels,0.309861
uuid-aa364e89197e4a0192f9bada44bc3c07,pembro,0.507491
uuid-aa364e89197e4a0192f9bada44bc3c07,lung,0.537252
uuid-aa364e89197e4a0192f9bada44bc3c07,1L,0.56377
uuid-aa364e89197e4a0192f9bada44bc3c07,commented,0.336658
uuid-aa364e89197e4a0192f9bada44bc3c07,RCC,0.551338
uuid-aa364e89197e4a0192f9bada44bc3c07,TL stated,0.567375
uuid-aa364e89197e4a0192f9bada44bc3c07,2L,0.619841
uuid-aa364e89197e4a0192f9bada44bc3c07,stated,0.38749
uuid-aa364e89197e4a0192f9bada44bc3c07,approval,0.372698
uuid-aa364e89197e4a0192f9bada44bc3c07,atezo,0.579478
uuid-aa364e89197e4a0192f9bada44bc3c07,preferred,0.420799
uuid-aa364e89197e4a0192f9bada44bc3c07,using nivo,0.514258
uuid-aa364e89197e4a0192f9bada44bc3c07,data,0.325785
uuid-aa364e89197e4a0192f9bada44bc3c07,PDL1 testing,0.463712
uuid-aa364e89197e4a0192f9bada44bc3c07,indication,0.364946
uuid-aa364e89197e4a0192f9bada44bc3c07,approved,0.375637
uuid-aa364e89197e4a0192f9bada44bc3c07,SCCHN,0.54945
uuid-aa364e89197e4a0192f9bada44bc3c07,nivo and pembro,0.361495
uuid-aa364e89197e4a0192f9bada44bc3c07,tumor types,0.315788
uuid-aa364e89197e4a0192f9bada44bc3c07,LTL,0.345095
uuid-aa364e89197e4a0192f9bada44bc3c07,TLs,0.542454
uuid-aa364e89197e4a0192f9bada44bc3c07,Regional TL,0.398
uuid-aa364e89197e4a0192f9bada44bc3c07,RTL stated,0.52726
uuid-aa364e89197e4a0192f9bada44bc3c07,TL shared,0.37381
uuid-aa364e89197e4a0192f9bada44bc3c07,bladder,0.463465
uuid-bffe5bbac8814c5c84fd534b691aaf64,TL,0.367989
uuid-bffe5bbac8814c5c84fd534b691aaf64,RTL,0.391651
uuid-bffe5bbac8814c5c84fd534b691aaf64,shared,0.429917
uuid-bffe5bbac8814c5c84fd534b691aaf64,RCC,0.41223
uuid-bffe5bbac8814c5c84fd534b691aaf64,TL stated,0.489621
uuid-bffe5bbac8814c5c84fd534b691aaf64,institution,0.576436
uuid-bffe5bbac8814c5c84fd534b691aaf64,stated,0.430708
uuid-bffe5bbac8814c5c84fd534b691aaf64,PD-L1,0.508977
uuid-bffe5bbac8814c5c84fd534b691aaf64,approval,0.42467
uuid-bffe5bbac8814c5c84fd534b691aaf64,PD-L1 testing,0.606844
uuid-bffe5bbac8814c5c84fd534b691aaf64,testing,0.605583
uuid-bffe5bbac8814c5c84fd534b691aaf64,PDL1 testing,0.587825
uuid-bffe5bbac8814c5c84fd534b691aaf64,NSCLC patients,0.584499
uuid-bffe5bbac8814c5c84fd534b691aaf64,SCCHN,0.478938
uuid-bffe5bbac8814c5c84fd534b691aaf64,tumor types,0.387764
uuid-bffe5bbac8814c5c84fd534b691aaf64,LTL,0.30978
uuid-bffe5bbac8814c5c84fd534b691aaf64,Regional TL,0.371282
uuid-bffe5bbac8814c5c84fd534b691aaf64,RTL stated,0.38439
uuid-bffe5bbac8814c5c84fd534b691aaf64,bladder,0.311551
uuid-9daec118ac834307a7dec0b14aaea849,NTL,0.430652
uuid-9daec118ac834307a7dec0b14aaea849,discussed,0.318225
uuid-9daec118ac834307a7dec0b14aaea849,commented,0.434419
uuid-9daec118ac834307a7dec0b14aaea849,physicians,0.384807
uuid-9daec118ac834307a7dec0b14aaea849,regards,0.472798
uuid-9daec118ac834307a7dec0b14aaea849,mentioned,0.31601
uuid-9daec118ac834307a7dec0b14aaea849,oncology,0.316183
uuid-9daec118ac834307a7dec0b14aaea849,ASCO,0.318215
uuid-9daec118ac834307a7dec0b14aaea849,clinical,0.404713
uuid-ae0fc98ec12c41bfa936e75d94337a71,Nivo,0.348342
uuid-ae0fc98ec12c41bfa936e75d94337a71,RTL,0.33455
uuid-ae0fc98ec12c41bfa936e75d94337a71,nivolumab,0.344115
uuid-ae0fc98ec12c41bfa936e75d94337a71,trial,0.610862
uuid-ae0fc98ec12c41bfa936e75d94337a71,OS,0.342495
uuid-ae0fc98ec12c41bfa936e75d94337a71,response,0.340988
uuid-ae0fc98ec12c41bfa936e75d94337a71,data,0.370043
uuid-ae0fc98ec12c41bfa936e75d94337a71,PFS,0.382122
uuid-ae0fc98ec12c41bfa936e75d94337a71,ORR,0.435279
uuid-ae0fc98ec12c41bfa936e75d94337a71,chemotherapy,0.337508
uuid-ae0fc98ec12c41bfa936e75d94337a71,impressed,0.440719
uuid-f4478f8be32243c4aeb41a159be9bb49,shared,0.539883
uuid-f4478f8be32243c4aeb41a159be9bb49,institution,0.75561
uuid-9d5eb13cfff84800a4d0efe37f33a831,trial,0.371091
uuid-9d5eb13cfff84800a4d0efe37f33a831,response,0.366656
uuid-9d5eb13cfff84800a4d0efe37f33a831,ORR,0.34055
uuid-45feb04b8c0a41b795c3adf0c86500fd,therapy,0.452003
uuid-45feb04b8c0a41b795c3adf0c86500fd,nivolumab,0.305503
uuid-45feb04b8c0a41b795c3adf0c86500fd,tumor,0.354597
uuid-45feb04b8c0a41b795c3adf0c86500fd,response,0.373741
uuid-45feb04b8c0a41b795c3adf0c86500fd,cHL,0.498177
uuid-45feb04b8c0a41b795c3adf0c86500fd,immunotherapy,0.324973
uuid-95f39fd3619a407b83092a2511c9128d,NSCLC,0.437209
uuid-95f39fd3619a407b83092a2511c9128d,1L,0.495045
uuid-95f39fd3619a407b83092a2511c9128d,RCC,0.316891
uuid-95f39fd3619a407b83092a2511c9128d,TL stated,0.325481
uuid-95f39fd3619a407b83092a2511c9128d,2L,0.398945
uuid-95f39fd3619a407b83092a2511c9128d,pts,0.457618
uuid-95f39fd3619a407b83092a2511c9128d,IO,0.370032
uuid-95f39fd3619a407b83092a2511c9128d,PD-L1,0.405636
uuid-95f39fd3619a407b83092a2511c9128d,preferred,0.431799
uuid-95f39fd3619a407b83092a2511c9128d,PD-L1 testing,0.424108
uuid-95f39fd3619a407b83092a2511c9128d,testing,0.425066
uuid-95f39fd3619a407b83092a2511c9128d,monotherapy,0.423889
uuid-95f39fd3619a407b83092a2511c9128d,combo,0.338101
uuid-95f39fd3619a407b83092a2511c9128d,PDL1 testing,0.41654
uuid-95f39fd3619a407b83092a2511c9128d,NSCLC patients,0.503804
uuid-95f39fd3619a407b83092a2511c9128d,RTL stated,0.379374
uuid-95f39fd3619a407b83092a2511c9128d,option,0.448742
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,Opdivo,0.683488
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,dose,0.536679
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,indication,0.364822
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,approved,0.300591
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,label,0.383651
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,Keytruda,0.552707
uuid-7d0f56b109aa488ea0f15a4c1b5a2d4c,flat dosing,0.756388
uuid-066e8697acfa4a279d45a9082a6f57f4,therapy,0.481213
uuid-066e8697acfa4a279d45a9082a6f57f4,nivolumab,0.534007
uuid-066e8697acfa4a279d45a9082a6f57f4,regimen,0.354913
uuid-066e8697acfa4a279d45a9082a6f57f4,combination,0.707261
uuid-066e8697acfa4a279d45a9082a6f57f4,chemo,0.555144
uuid-066e8697acfa4a279d45a9082a6f57f4,pts,0.424233
uuid-066e8697acfa4a279d45a9082a6f57f4,IO,0.383881
uuid-066e8697acfa4a279d45a9082a6f57f4,agents,0.340317
uuid-066e8697acfa4a279d45a9082a6f57f4,monotherapy,0.547407
uuid-066e8697acfa4a279d45a9082a6f57f4,response,0.562763
uuid-066e8697acfa4a279d45a9082a6f57f4,combo,0.562833
uuid-066e8697acfa4a279d45a9082a6f57f4,PD1,0.75562
uuid-066e8697acfa4a279d45a9082a6f57f4,progression,0.465582
uuid-066e8697acfa4a279d45a9082a6f57f4,believes,0.310302
uuid-066e8697acfa4a279d45a9082a6f57f4,chemotherapy,0.505678
uuid-066e8697acfa4a279d45a9082a6f57f4,immunotherapy,0.317994
uuid-066e8697acfa4a279d45a9082a6f57f4,PD-1,0.447482
uuid-066e8697acfa4a279d45a9082a6f57f4,option,0.334231
uuid-f6deff90e4024fbfba333ca16987eb26,Nivo,0.454428
uuid-f6deff90e4024fbfba333ca16987eb26,pembro,0.602031
uuid-f6deff90e4024fbfba333ca16987eb26,dose,0.625719
uuid-f6deff90e4024fbfba333ca16987eb26,efficacy,0.491888
uuid-f6deff90e4024fbfba333ca16987eb26,Ipi,0.431818
uuid-f6deff90e4024fbfba333ca16987eb26,atezo,0.620942
uuid-f6deff90e4024fbfba333ca16987eb26,preferred,0.336823
uuid-f6deff90e4024fbfba333ca16987eb26,indication,0.378077
uuid-f6deff90e4024fbfba333ca16987eb26,nivo and pembro,0.339948
uuid-f6deff90e4024fbfba333ca16987eb26,vs,0.661453
uuid-f6deff90e4024fbfba333ca16987eb26,Keytruda,0.490633
uuid-f6deff90e4024fbfba333ca16987eb26,flat dosing,0.611955
uuid-a69ee2f7acba4e7f999997387215340d,NSCLC,0.428722
uuid-a69ee2f7acba4e7f999997387215340d,PDL1,0.46847
uuid-a69ee2f7acba4e7f999997387215340d,TL stated,0.388949
uuid-a69ee2f7acba4e7f999997387215340d,PD-L1,0.717816
uuid-a69ee2f7acba4e7f999997387215340d,PD-L1 testing,0.642578
uuid-a69ee2f7acba4e7f999997387215340d,testing,0.720148
uuid-a69ee2f7acba4e7f999997387215340d,PDL1 testing,0.605789
uuid-a69ee2f7acba4e7f999997387215340d,NSCLC patients,0.606997
uuid-a69ee2f7acba4e7f999997387215340d,assay,0.438035
uuid-a69ee2f7acba4e7f999997387215340d,biomarker,0.509643
uuid-c474ed53f86b48b8a886bcd010452acb,pembro,0.587909
uuid-c474ed53f86b48b8a886bcd010452acb,1L,0.538021
uuid-c474ed53f86b48b8a886bcd010452acb,PDL1,0.657681
uuid-c474ed53f86b48b8a886bcd010452acb,TL stated,0.300533
uuid-c474ed53f86b48b8a886bcd010452acb,2L,0.485911
uuid-c474ed53f86b48b8a886bcd010452acb,agents,0.30496
uuid-c474ed53f86b48b8a886bcd010452acb,Merck,0.379409
uuid-c474ed53f86b48b8a886bcd010452acb,PD-L1,0.655528
uuid-c474ed53f86b48b8a886bcd010452acb,approval,0.334076
uuid-c474ed53f86b48b8a886bcd010452acb,atezo,0.600803
uuid-c474ed53f86b48b8a886bcd010452acb,preferred,0.376481
uuid-c474ed53f86b48b8a886bcd010452acb,PD-L1 testing,0.343748
uuid-c474ed53f86b48b8a886bcd010452acb,testing,0.547965
uuid-c474ed53f86b48b8a886bcd010452acb,data,0.31837
uuid-c474ed53f86b48b8a886bcd010452acb,expressed,0.372637
uuid-c474ed53f86b48b8a886bcd010452acb,PDL1 testing,0.505719
uuid-c474ed53f86b48b8a886bcd010452acb,indication,0.384265
uuid-c474ed53f86b48b8a886bcd010452acb,NSCLC patients,0.456271
uuid-c474ed53f86b48b8a886bcd010452acb,approved,0.419635
uuid-c474ed53f86b48b8a886bcd010452acb,nivo and pembro,0.49392
uuid-c474ed53f86b48b8a886bcd010452acb,tumor types,0.397464
uuid-c474ed53f86b48b8a886bcd010452acb,assay,0.461349
uuid-c474ed53f86b48b8a886bcd010452acb,PDL1 expression,0.535985
uuid-c474ed53f86b48b8a886bcd010452acb,biomarker,0.434749
uuid-c474ed53f86b48b8a886bcd010452acb,bladder,0.306938
uuid-e3395ae54e3e4563bea748d886ffc717,PDL1,0.333475
uuid-e3395ae54e3e4563bea748d886ffc717,efficacy,0.31453
uuid-e3395ae54e3e4563bea748d886ffc717,commented,0.32489
uuid-e3395ae54e3e4563bea748d886ffc717,expressed,0.458928
uuid-e3395ae54e3e4563bea748d886ffc717,HCP,0.389089
uuid-e3395ae54e3e4563bea748d886ffc717,lung cancer,0.427371
uuid-e3395ae54e3e4563bea748d886ffc717,TLs,0.310652
uuid-cca80043d7e846fbade1fa39bbf78b72,TL,0.456694
uuid-cca80043d7e846fbade1fa39bbf78b72,TL stated,0.449038
uuid-cca80043d7e846fbade1fa39bbf78b72,PD-L1,0.681578
uuid-cca80043d7e846fbade1fa39bbf78b72,PD-L1 testing,0.67382
uuid-cca80043d7e846fbade1fa39bbf78b72,testing,0.797958
uuid-cca80043d7e846fbade1fa39bbf78b72,PDL1 testing,0.68129
uuid-cca80043d7e846fbade1fa39bbf78b72,NSCLC patients,0.724553
uuid-cca80043d7e846fbade1fa39bbf78b72,tumor types,0.391128
uuid-cca80043d7e846fbade1fa39bbf78b72,assay,0.462557
uuid-cca80043d7e846fbade1fa39bbf78b72,biomarker,0.353604
uuid-0ef233f6880e4bd69b54a56ee3aae2be,TL,0.374914
uuid-0ef233f6880e4bd69b54a56ee3aae2be,lung,0.322476
uuid-0ef233f6880e4bd69b54a56ee3aae2be,RCC,0.318652
uuid-0ef233f6880e4bd69b54a56ee3aae2be,TL stated,0.359971
uuid-0ef233f6880e4bd69b54a56ee3aae2be,PD-L1,0.533354
uuid-0ef233f6880e4bd69b54a56ee3aae2be,PD-L1 testing,0.536891
uuid-0ef233f6880e4bd69b54a56ee3aae2be,testing,0.501291
uuid-0ef233f6880e4bd69b54a56ee3aae2be,PDL1 testing,0.427408
uuid-0ef233f6880e4bd69b54a56ee3aae2be,NSCLC patients,0.479715
uuid-0ef233f6880e4bd69b54a56ee3aae2be,SCCHN,0.318471
uuid-0ef233f6880e4bd69b54a56ee3aae2be,oncologist,0.531037
uuid-0ef233f6880e4bd69b54a56ee3aae2be,indicated,0.68272
uuid-0ef233f6880e4bd69b54a56ee3aae2be,TLs,0.315468
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,TL,0.343313
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,TL stated,0.346913
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,PD-L1,0.366695
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,PD-L1 testing,0.603283
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,testing,0.48784
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,PDL1 testing,0.428778
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,NSCLC patients,0.36684
uuid-0cc98fc0fc124b43bb0b8a358efa3f41,assay,0.346501
uuid-45335d3142304d3ab1b05114c9e628ed,TL,0.70439
uuid-45335d3142304d3ab1b05114c9e628ed,TL stated,0.392972
uuid-45335d3142304d3ab1b05114c9e628ed,institution,0.357633
uuid-45335d3142304d3ab1b05114c9e628ed,PD-L1,0.681402
uuid-45335d3142304d3ab1b05114c9e628ed,PD-L1 testing,0.91114
uuid-45335d3142304d3ab1b05114c9e628ed,testing,0.812567
uuid-45335d3142304d3ab1b05114c9e628ed,PDL1 testing,0.641718
uuid-45335d3142304d3ab1b05114c9e628ed,NSCLC patients,0.525133
uuid-45335d3142304d3ab1b05114c9e628ed,clinical,0.325215
uuid-45335d3142304d3ab1b05114c9e628ed,assay,0.665183
uuid-45335d3142304d3ab1b05114c9e628ed,biomarker,0.306366
uuid-ba5fe652dc9b4526acf69212f7253fa1,Nivo,0.6645
uuid-ba5fe652dc9b4526acf69212f7253fa1,patients,0.332467
uuid-ba5fe652dc9b4526acf69212f7253fa1,therapy,0.576953
uuid-ba5fe652dc9b4526acf69212f7253fa1,nivolumab,0.468538
uuid-ba5fe652dc9b4526acf69212f7253fa1,regimen,0.373136
uuid-ba5fe652dc9b4526acf69212f7253fa1,combination,0.698775
uuid-ba5fe652dc9b4526acf69212f7253fa1,chemo,0.568986
uuid-ba5fe652dc9b4526acf69212f7253fa1,pts,0.314338
uuid-ba5fe652dc9b4526acf69212f7253fa1,IO,0.309858
uuid-ba5fe652dc9b4526acf69212f7253fa1,agents,0.433609
uuid-ba5fe652dc9b4526acf69212f7253fa1,Ipi,0.390842
uuid-ba5fe652dc9b4526acf69212f7253fa1,monotherapy,0.555653
uuid-ba5fe652dc9b4526acf69212f7253fa1,treatment,0.34341
uuid-ba5fe652dc9b4526acf69212f7253fa1,response,0.388479
uuid-ba5fe652dc9b4526acf69212f7253fa1,combo,0.511268
uuid-ba5fe652dc9b4526acf69212f7253fa1,PD1,0.570018
uuid-ba5fe652dc9b4526acf69212f7253fa1,cHL,0.300155
uuid-ba5fe652dc9b4526acf69212f7253fa1,progression,0.368273
uuid-ba5fe652dc9b4526acf69212f7253fa1,chemotherapy,0.578345
uuid-ba5fe652dc9b4526acf69212f7253fa1,feels,0.338006
uuid-ba5fe652dc9b4526acf69212f7253fa1,option,0.42391
uuid-7d828c1486fd42e38d73812a477b81db,pembro,0.302501
uuid-7d828c1486fd42e38d73812a477b81db,BMS,0.323558
uuid-7d828c1486fd42e38d73812a477b81db,trial,0.393875
uuid-7d828c1486fd42e38d73812a477b81db,efficacy,0.505724
uuid-7d828c1486fd42e38d73812a477b81db,commented,0.374832
uuid-7d828c1486fd42e38d73812a477b81db,stated,0.309653
uuid-7d828c1486fd42e38d73812a477b81db,OS,0.548362
uuid-7d828c1486fd42e38d73812a477b81db,data,0.863
uuid-7d828c1486fd42e38d73812a477b81db,indication,0.360791
uuid-7d828c1486fd42e38d73812a477b81db,PFS,0.488032
uuid-7d828c1486fd42e38d73812a477b81db,ORR,0.55956
uuid-7d828c1486fd42e38d73812a477b81db,nivo and pembro,0.307484
uuid-7d828c1486fd42e38d73812a477b81db,ASCO,0.395716
uuid-7d828c1486fd42e38d73812a477b81db,impressed,0.652182
uuid-7d828c1486fd42e38d73812a477b81db,PDL1 expression,0.302783
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,Nivo,0.301441
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,pembro,0.504952
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,1L,0.364032
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,trial,0.32829
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,2L,0.380238
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,agents,0.308237
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,approval,0.313026
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,atezo,0.4096
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,preferred,0.370594
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,monotherapy,0.318334
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,data,0.332217
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,clinical trials,0.310207
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,indication,0.345548
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,approved,0.425939
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,nivo and pembro,0.332746
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,tumor types,0.301601
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,feels,0.315584
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,RTL stated,0.303092
uuid-f92f4ece108c4a5e9a59855d60f1a9bc,option,0.351739
uuid-13b42c8faf3d45279268d531f7d34e8f,Opdivo,0.516688
uuid-13b42c8faf3d45279268d531f7d34e8f,dose,0.563555
uuid-13b42c8faf3d45279268d531f7d34e8f,physicians,0.44449
uuid-13b42c8faf3d45279268d531f7d34e8f,oncology,0.321661
uuid-13b42c8faf3d45279268d531f7d34e8f,indicated,0.32404
uuid-13b42c8faf3d45279268d531f7d34e8f,Keytruda,0.468338
uuid-13b42c8faf3d45279268d531f7d34e8f,flat dosing,0.662901
uuid-fbc3903632eb49dca17d3031490be295,patients,0.791308
uuid-fbc3903632eb49dca17d3031490be295,Opdivo,0.634159
uuid-fbc3903632eb49dca17d3031490be295,therapy,0.654541
uuid-fbc3903632eb49dca17d3031490be295,nivolumab,0.537421
uuid-fbc3903632eb49dca17d3031490be295,regimen,0.520853
uuid-fbc3903632eb49dca17d3031490be295,treated,0.592044
uuid-fbc3903632eb49dca17d3031490be295,pts,0.441871
uuid-fbc3903632eb49dca17d3031490be295,physicians,0.424882
uuid-fbc3903632eb49dca17d3031490be295,treatment,0.74487
uuid-fbc3903632eb49dca17d3031490be295,response,0.307574
uuid-fbc3903632eb49dca17d3031490be295,cHL,0.402927
uuid-fbc3903632eb49dca17d3031490be295,progression,0.636201
uuid-fbc3903632eb49dca17d3031490be295,chemotherapy,0.32784
uuid-fbc3903632eb49dca17d3031490be295,respond,0.425882
uuid-f4184d8369a3400b88e9d9265b163313,Opdivo,0.388826
uuid-f4184d8369a3400b88e9d9265b163313,physicians,0.5205
uuid-f4184d8369a3400b88e9d9265b163313,preferred,0.494209
uuid-f4184d8369a3400b88e9d9265b163313,PDL1 testing,0.323822
uuid-f4184d8369a3400b88e9d9265b163313,indication,0.341605
uuid-f4184d8369a3400b88e9d9265b163313,approved,0.375466
uuid-f4184d8369a3400b88e9d9265b163313,drug,0.316217
uuid-f4184d8369a3400b88e9d9265b163313,Keytruda,0.348376
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,Opdivo,0.345069
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,shared,0.327488
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,physicians,0.699017
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,oncology,0.307081
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,indicated,0.338862
uuid-3fb5d3ea2be544f8bb58f45c4b6d1476,clinical,0.330396
uuid-e35380580d394ef58de523067725b4b2,Opdivo,0.545594
uuid-e35380580d394ef58de523067725b4b2,dose,0.776276
uuid-e35380580d394ef58de523067725b4b2,toxicity,0.32515
uuid-e35380580d394ef58de523067725b4b2,Ipi,0.355543
uuid-e35380580d394ef58de523067725b4b2,vs,0.359497
uuid-e35380580d394ef58de523067725b4b2,drug,0.335533
uuid-e35380580d394ef58de523067725b4b2,Keytruda,0.523067
uuid-e35380580d394ef58de523067725b4b2,flat dosing,0.768037
uuid-eb8ecef8db8144c1bd81613d9deafed4,Nivo,0.401324
uuid-eb8ecef8db8144c1bd81613d9deafed4,pembro,0.311161
uuid-eb8ecef8db8144c1bd81613d9deafed4,trial,0.305119
uuid-eb8ecef8db8144c1bd81613d9deafed4,efficacy,0.452201
uuid-eb8ecef8db8144c1bd81613d9deafed4,Ipi,0.308133
uuid-eb8ecef8db8144c1bd81613d9deafed4,OS,0.527322
uuid-eb8ecef8db8144c1bd81613d9deafed4,data,0.375989
uuid-eb8ecef8db8144c1bd81613d9deafed4,PFS,0.463812
uuid-eb8ecef8db8144c1bd81613d9deafed4,ORR,0.488839
uuid-eb8ecef8db8144c1bd81613d9deafed4,nivo and pembro,0.417396
uuid-eb8ecef8db8144c1bd81613d9deafed4,believes,0.407537
uuid-eb8ecef8db8144c1bd81613d9deafed4,impressed,0.417468
uuid-eb8ecef8db8144c1bd81613d9deafed4,feels,0.417331
uuid-6dc048e34d3849aeb35bb8bf571cf495,patients,0.315178
uuid-6dc048e34d3849aeb35bb8bf571cf495,1L,0.430518
uuid-6dc048e34d3849aeb35bb8bf571cf495,2L,0.370721
uuid-6dc048e34d3849aeb35bb8bf571cf495,preferred,0.403763
uuid-6dc048e34d3849aeb35bb8bf571cf495,monotherapy,0.360434
uuid-6dc048e34d3849aeb35bb8bf571cf495,using nivo,0.323202
uuid-6dc048e34d3849aeb35bb8bf571cf495,NSCLC patients,0.43232
uuid-6dc048e34d3849aeb35bb8bf571cf495,tumor types,0.51403
uuid-6dc048e34d3849aeb35bb8bf571cf495,feels,0.358731
uuid-6dc048e34d3849aeb35bb8bf571cf495,RTL stated,0.407068
uuid-6dc048e34d3849aeb35bb8bf571cf495,option,0.414913
uuid-0322b9deb1574de5a6daf29e0560a70f,discussed,0.337542
uuid-0322b9deb1574de5a6daf29e0560a70f,physicians,0.7395
uuid-0322b9deb1574de5a6daf29e0560a70f,oncologist,0.307814
uuid-0322b9deb1574de5a6daf29e0560a70f,indicated,0.340561
uuid-0322b9deb1574de5a6daf29e0560a70f,clinical,0.346983
uuid-0322b9deb1574de5a6daf29e0560a70f,academic,0.374263
uuid-790ecee980774cc1a1f10a7f7a8caa7b,patients,0.666289
uuid-790ecee980774cc1a1f10a7f7a8caa7b,Opdivo,0.54173
uuid-790ecee980774cc1a1f10a7f7a8caa7b,nivolumab,0.483225
uuid-790ecee980774cc1a1f10a7f7a8caa7b,regimen,0.309265
uuid-790ecee980774cc1a1f10a7f7a8caa7b,treated,0.642797
uuid-790ecee980774cc1a1f10a7f7a8caa7b,pts,0.331822
uuid-790ecee980774cc1a1f10a7f7a8caa7b,approval,0.367164
uuid-790ecee980774cc1a1f10a7f7a8caa7b,physicians,0.304182
uuid-790ecee980774cc1a1f10a7f7a8caa7b,treatment,0.482765
uuid-790ecee980774cc1a1f10a7f7a8caa7b,using nivo,0.332491
uuid-790ecee980774cc1a1f10a7f7a8caa7b,SCCHN,0.309183
uuid-790ecee980774cc1a1f10a7f7a8caa7b,cHL,0.306932
uuid-790ecee980774cc1a1f10a7f7a8caa7b,progression,0.309318
uuid-790ecee980774cc1a1f10a7f7a8caa7b,RTL stated,0.332942
uuid-790ecee980774cc1a1f10a7f7a8caa7b,bladder,0.327132
uuid-8d9b005e0e554b6081acad6e79e61c86,patients,0.37554
uuid-8d9b005e0e554b6081acad6e79e61c86,Opdivo,0.38713
uuid-8d9b005e0e554b6081acad6e79e61c86,dose,0.709308
uuid-8d9b005e0e554b6081acad6e79e61c86,toxicity,0.597238
uuid-8d9b005e0e554b6081acad6e79e61c86,regimen,0.502274
uuid-8d9b005e0e554b6081acad6e79e61c86,treated,0.316632
uuid-8d9b005e0e554b6081acad6e79e61c86,Ipi,0.325389
uuid-8d9b005e0e554b6081acad6e79e61c86,physicians,0.359984
uuid-8d9b005e0e554b6081acad6e79e61c86,treatment,0.457805
uuid-8d9b005e0e554b6081acad6e79e61c86,respond,0.339803
uuid-8d9b005e0e554b6081acad6e79e61c86,flat dosing,0.387131
uuid-f25d7301420947298fabc80303263c49,Nivo,0.373433
uuid-f25d7301420947298fabc80303263c49,patients,0.774932
uuid-f25d7301420947298fabc80303263c49,Opdivo,0.360751
uuid-f25d7301420947298fabc80303263c49,therapy,0.651471
uuid-f25d7301420947298fabc80303263c49,nivolumab,0.538481
uuid-f25d7301420947298fabc80303263c49,1L,0.36779
uuid-f25d7301420947298fabc80303263c49,toxicity,0.409221
uuid-f25d7301420947298fabc80303263c49,regimen,0.732583
uuid-f25d7301420947298fabc80303263c49,treated,0.561866
uuid-f25d7301420947298fabc80303263c49,RCC,0.335604
uuid-f25d7301420947298fabc80303263c49,combination,0.47199
uuid-f25d7301420947298fabc80303263c49,chemo,0.534513
uuid-f25d7301420947298fabc80303263c49,2L,0.406624
uuid-f25d7301420947298fabc80303263c49,pts,0.596425
uuid-f25d7301420947298fabc80303263c49,preferred,0.472534
uuid-f25d7301420947298fabc80303263c49,monotherapy,0.674596
uuid-f25d7301420947298fabc80303263c49,treatment,0.695956
uuid-f25d7301420947298fabc80303263c49,using nivo,0.441854
uuid-f25d7301420947298fabc80303263c49,response,0.355717
uuid-f25d7301420947298fabc80303263c49,combo,0.448445
uuid-f25d7301420947298fabc80303263c49,PD1,0.479731
uuid-f25d7301420947298fabc80303263c49,progression,0.64214
uuid-f25d7301420947298fabc80303263c49,chemotherapy,0.555473
uuid-f25d7301420947298fabc80303263c49,respond,0.475828
uuid-f25d7301420947298fabc80303263c49,RTL stated,0.404719
uuid-f25d7301420947298fabc80303263c49,TL shared,0.356191
uuid-f25d7301420947298fabc80303263c49,option,0.611024
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,pembro,0.456456
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,1L,0.35886
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PDL1,0.769544
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,efficacy,0.393225
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,agents,0.375331
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,Merck,0.381742
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PD-L1,0.804313
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,atezo,0.548099
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PD-L1 testing,0.44781
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,testing,0.615725
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PDL1 testing,0.410424
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,NSCLC patients,0.425299
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,nivo and pembro,0.534575
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,believes,0.35284
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,assay,0.771352
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PD-1,0.337475
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,PDL1 expression,0.586114
uuid-e0cc0d9fb882435abe29eb5fa507e3dd,biomarker,0.540894
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,pembro,0.336418
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,lung,0.51177
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,efficacy,0.337389
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,melanoma,0.313167
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,atezo,0.398318
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,regards,0.421127
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,AI,0.834767
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,nivo and pembro,0.568439
uuid-ced3f80d1ed64b9d9dfbf87d881dae36,NCCN,0.41402
uuid-fcea1cfd281a4a1db96a825ea1e39867,PD-L1,0.331135
uuid-fcea1cfd281a4a1db96a825ea1e39867,testing,0.529359
uuid-fcea1cfd281a4a1db96a825ea1e39867,PDL1 testing,0.509478
uuid-fcea1cfd281a4a1db96a825ea1e39867,NSCLC patients,0.65379
uuid-fcea1cfd281a4a1db96a825ea1e39867,tumor types,0.366402
uuid-d33eb4e2d1384a1cbee5d34d8c951169,RTL,0.303683
uuid-d33eb4e2d1384a1cbee5d34d8c951169,trial,0.656681
uuid-d33eb4e2d1384a1cbee5d34d8c951169,combination,0.535384
uuid-d33eb4e2d1384a1cbee5d34d8c951169,Ipi,0.309823
uuid-d33eb4e2d1384a1cbee5d34d8c951169,data,0.340777
uuid-d33eb4e2d1384a1cbee5d34d8c951169,combo,0.397406
uuid-d33eb4e2d1384a1cbee5d34d8c951169,PD1,0.319524
uuid-d33eb4e2d1384a1cbee5d34d8c951169,ORR,0.342537
uuid-d33eb4e2d1384a1cbee5d34d8c951169,impressed,0.382697
uuid-d33eb4e2d1384a1cbee5d34d8c951169,SCLC,0.410805
uuid-621a98826e58438593598415d4f3077f,patients,0.664629
uuid-621a98826e58438593598415d4f3077f,Opdivo,0.372656
uuid-621a98826e58438593598415d4f3077f,therapy,0.3464
uuid-621a98826e58438593598415d4f3077f,nivolumab,0.391051
uuid-621a98826e58438593598415d4f3077f,toxicity,0.373452
uuid-621a98826e58438593598415d4f3077f,regimen,0.646135
uuid-621a98826e58438593598415d4f3077f,treated,0.486351
uuid-621a98826e58438593598415d4f3077f,pts,0.491706
uuid-621a98826e58438593598415d4f3077f,monotherapy,0.427537
uuid-621a98826e58438593598415d4f3077f,treatment,0.543904
uuid-621a98826e58438593598415d4f3077f,using nivo,0.304522
uuid-621a98826e58438593598415d4f3077f,combo,0.314736
uuid-621a98826e58438593598415d4f3077f,lung cancer,0.359696
uuid-621a98826e58438593598415d4f3077f,progression,0.483432
uuid-621a98826e58438593598415d4f3077f,chemotherapy,0.355439
uuid-621a98826e58438593598415d4f3077f,respond,0.390501
uuid-621a98826e58438593598415d4f3077f,option,0.346041
uuid-ab9225f234894c9f8fdea533a5bad5b9,Nivo,0.301628
uuid-ab9225f234894c9f8fdea533a5bad5b9,nivolumab,0.308748
uuid-ab9225f234894c9f8fdea533a5bad5b9,1L,0.312394
uuid-ab9225f234894c9f8fdea533a5bad5b9,regimen,0.403582
uuid-ab9225f234894c9f8fdea533a5bad5b9,RCC,0.30175
uuid-ab9225f234894c9f8fdea533a5bad5b9,2L,0.357072
uuid-ab9225f234894c9f8fdea533a5bad5b9,Ipi,0.346386
uuid-ab9225f234894c9f8fdea533a5bad5b9,approval,0.453625
uuid-ab9225f234894c9f8fdea533a5bad5b9,monotherapy,0.363936
uuid-ab9225f234894c9f8fdea533a5bad5b9,using nivo,0.429767
uuid-ab9225f234894c9f8fdea533a5bad5b9,combo,0.326813
uuid-ab9225f234894c9f8fdea533a5bad5b9,indication,0.340313
uuid-ab9225f234894c9f8fdea533a5bad5b9,approved,0.487148
uuid-ab9225f234894c9f8fdea533a5bad5b9,impressed,0.301695
uuid-ab9225f234894c9f8fdea533a5bad5b9,label,0.373737
uuid-ab9225f234894c9f8fdea533a5bad5b9,SCLC,0.496584
uuid-ab9225f234894c9f8fdea533a5bad5b9,option,0.345336
uuid-76bb6d9209ef43359fd0fdbeb4b13107,patients,0.607975
uuid-76bb6d9209ef43359fd0fdbeb4b13107,Opdivo,0.42407
uuid-76bb6d9209ef43359fd0fdbeb4b13107,therapy,0.317077
uuid-76bb6d9209ef43359fd0fdbeb4b13107,regimen,0.360721
uuid-76bb6d9209ef43359fd0fdbeb4b13107,treated,0.482734
uuid-76bb6d9209ef43359fd0fdbeb4b13107,physicians,0.539654
uuid-76bb6d9209ef43359fd0fdbeb4b13107,treatment,0.62469
uuid-76bb6d9209ef43359fd0fdbeb4b13107,progression,0.33215
uuid-76bb6d9209ef43359fd0fdbeb4b13107,respond,0.339513
uuid-287057cc0e6d4d7fbaff331cf4750362,Nivo,0.377474
uuid-287057cc0e6d4d7fbaff331cf4750362,pembro,0.575079
uuid-287057cc0e6d4d7fbaff331cf4750362,1L,0.798686
uuid-287057cc0e6d4d7fbaff331cf4750362,PDL1,0.481075
uuid-287057cc0e6d4d7fbaff331cf4750362,chemo,0.40387
uuid-287057cc0e6d4d7fbaff331cf4750362,2L,0.742882
uuid-287057cc0e6d4d7fbaff331cf4750362,agents,0.591443
uuid-287057cc0e6d4d7fbaff331cf4750362,PD-L1,0.395888
uuid-287057cc0e6d4d7fbaff331cf4750362,atezo,0.617994
uuid-287057cc0e6d4d7fbaff331cf4750362,preferred,0.69443
uuid-287057cc0e6d4d7fbaff331cf4750362,monotherapy,0.635323
uuid-287057cc0e6d4d7fbaff331cf4750362,using nivo,0.419062
uuid-287057cc0e6d4d7fbaff331cf4750362,combo,0.37923
uuid-287057cc0e6d4d7fbaff331cf4750362,PDL1 testing,0.349573
uuid-287057cc0e6d4d7fbaff331cf4750362,indication,0.366889
uuid-287057cc0e6d4d7fbaff331cf4750362,NSCLC patients,0.328256
uuid-287057cc0e6d4d7fbaff331cf4750362,approved,0.457905
uuid-287057cc0e6d4d7fbaff331cf4750362,nivo and pembro,0.469773
uuid-287057cc0e6d4d7fbaff331cf4750362,believes,0.468385
uuid-287057cc0e6d4d7fbaff331cf4750362,chemotherapy,0.303903
uuid-287057cc0e6d4d7fbaff331cf4750362,feels,0.398245
uuid-287057cc0e6d4d7fbaff331cf4750362,PD-1,0.329099
uuid-287057cc0e6d4d7fbaff331cf4750362,RTL stated,0.320107
uuid-287057cc0e6d4d7fbaff331cf4750362,PDL1 expression,0.405586
uuid-287057cc0e6d4d7fbaff331cf4750362,option,0.685031
uuid-6cc25c41dca348ddb122a180b92f14af,NSCLC,0.51794
uuid-6cc25c41dca348ddb122a180b92f14af,1L,0.41343
uuid-6cc25c41dca348ddb122a180b92f14af,efficacy,0.372564
uuid-6cc25c41dca348ddb122a180b92f14af,regimen,0.323591
uuid-6cc25c41dca348ddb122a180b92f14af,combination,0.570552
uuid-6cc25c41dca348ddb122a180b92f14af,chemo,0.458374
uuid-6cc25c41dca348ddb122a180b92f14af,2L,0.354058
uuid-6cc25c41dca348ddb122a180b92f14af,IO,0.762889
uuid-6cc25c41dca348ddb122a180b92f14af,agents,0.469662
uuid-6cc25c41dca348ddb122a180b92f14af,preferred,0.336656
uuid-6cc25c41dca348ddb122a180b92f14af,monotherapy,0.582457
uuid-6cc25c41dca348ddb122a180b92f14af,combo,0.655126
uuid-6cc25c41dca348ddb122a180b92f14af,PD1,0.379914
uuid-6cc25c41dca348ddb122a180b92f14af,believes,0.536369
uuid-6cc25c41dca348ddb122a180b92f14af,chemotherapy,0.358041
uuid-6cc25c41dca348ddb122a180b92f14af,vs,0.326011
uuid-6cc25c41dca348ddb122a180b92f14af,feels,0.361311
uuid-6cc25c41dca348ddb122a180b92f14af,option,0.441348
uuid-6e61f02787b34e1687b2ad6825e84a63,TL,0.407792
uuid-6e61f02787b34e1687b2ad6825e84a63,pembro,0.33402
uuid-6e61f02787b34e1687b2ad6825e84a63,1L,0.472641
uuid-6e61f02787b34e1687b2ad6825e84a63,PDL1,0.655646
uuid-6e61f02787b34e1687b2ad6825e84a63,TL stated,0.323839
uuid-6e61f02787b34e1687b2ad6825e84a63,2L,0.35501
uuid-6e61f02787b34e1687b2ad6825e84a63,Merck,0.40537
uuid-6e61f02787b34e1687b2ad6825e84a63,PD-L1,0.713373
uuid-6e61f02787b34e1687b2ad6825e84a63,atezo,0.417512
uuid-6e61f02787b34e1687b2ad6825e84a63,PD-L1 testing,0.564829
uuid-6e61f02787b34e1687b2ad6825e84a63,testing,0.737354
uuid-6e61f02787b34e1687b2ad6825e84a63,PDL1 testing,0.633535
uuid-6e61f02787b34e1687b2ad6825e84a63,NSCLC patients,0.549777
uuid-6e61f02787b34e1687b2ad6825e84a63,nivo and pembro,0.370936
uuid-6e61f02787b34e1687b2ad6825e84a63,believes,0.327427
uuid-6e61f02787b34e1687b2ad6825e84a63,assay,0.593204
uuid-6e61f02787b34e1687b2ad6825e84a63,PDL1 expression,0.485866
uuid-6e61f02787b34e1687b2ad6825e84a63,biomarker,0.5581
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,Nivo,0.370653
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,patients,0.354445
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,pembro,0.459251
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,1L,0.669383
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,regimen,0.341839
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,chemo,0.431029
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,2L,0.696582
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,pts,0.391808
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,IO,0.317877
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,agents,0.390298
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,atezo,0.514547
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,preferred,0.590042
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,monotherapy,0.659411
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,using nivo,0.465536
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,combo,0.404585
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,PD1,0.37238
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,approved,0.35949
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,believes,0.405229
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,feels,0.323697
uuid-04bc8979d32b46ad8e2c5ee1d64fe717,option,0.595782
uuid-d52378f54f8a4cbb9137be65c2e417b6,TL,0.476854
uuid-d52378f54f8a4cbb9137be65c2e417b6,pembro,0.473707
uuid-d52378f54f8a4cbb9137be65c2e417b6,PDL1,0.307509
uuid-d52378f54f8a4cbb9137be65c2e417b6,efficacy,0.355357
uuid-d52378f54f8a4cbb9137be65c2e417b6,PD-L1,0.306563
uuid-d52378f54f8a4cbb9137be65c2e417b6,atezo,0.468439
uuid-d52378f54f8a4cbb9137be65c2e417b6,nivo and pembro,0.425853
uuid-d52378f54f8a4cbb9137be65c2e417b6,vs,0.301042
uuid-d52378f54f8a4cbb9137be65c2e417b6,assay,0.460464
uuid-cc19d2886be241c3affd525a7a57de4f,TL,0.364977
uuid-cc19d2886be241c3affd525a7a57de4f,BMS,0.313687
uuid-cc19d2886be241c3affd525a7a57de4f,trial,0.433441
uuid-cc19d2886be241c3affd525a7a57de4f,efficacy,0.490487
uuid-cc19d2886be241c3affd525a7a57de4f,commented,0.345649
uuid-cc19d2886be241c3affd525a7a57de4f,OS,0.331057
uuid-cc19d2886be241c3affd525a7a57de4f,regards,0.452416
uuid-cc19d2886be241c3affd525a7a57de4f,data,0.519644
uuid-cc19d2886be241c3affd525a7a57de4f,indication,0.372395
uuid-cc19d2886be241c3affd525a7a57de4f,PFS,0.315351
uuid-cc19d2886be241c3affd525a7a57de4f,ORR,0.413379
uuid-cc19d2886be241c3affd525a7a57de4f,impressed,0.441304
uuid-275b6b663af74b6e9061bce97718be3c,BMS,0.57468
uuid-275b6b663af74b6e9061bce97718be3c,trial,0.476567
uuid-275b6b663af74b6e9061bce97718be3c,commented,0.406533
uuid-275b6b663af74b6e9061bce97718be3c,Merck,0.457178
uuid-275b6b663af74b6e9061bce97718be3c,stated,0.31465
uuid-275b6b663af74b6e9061bce97718be3c,data,0.466406
uuid-275b6b663af74b6e9061bce97718be3c,expressed,0.337379
uuid-275b6b663af74b6e9061bce97718be3c,clinical trials,0.372164
uuid-275b6b663af74b6e9061bce97718be3c,impressed,0.454406
uuid-275b6b663af74b6e9061bce97718be3c,feels,0.341445
uuid-8a5cddec04e647f3b220ed035edf450a,Nivo,0.325953
uuid-8a5cddec04e647f3b220ed035edf450a,patients,0.341306
uuid-8a5cddec04e647f3b220ed035edf450a,efficacy,0.317909
uuid-8a5cddec04e647f3b220ed035edf450a,chemo,0.353731
uuid-8a5cddec04e647f3b220ed035edf450a,pts,0.325784
uuid-8a5cddec04e647f3b220ed035edf450a,OS,0.567255
uuid-8a5cddec04e647f3b220ed035edf450a,response,0.439976
uuid-8a5cddec04e647f3b220ed035edf450a,PFS,0.59222
uuid-8a5cddec04e647f3b220ed035edf450a,ORR,0.478805
uuid-8a5cddec04e647f3b220ed035edf450a,progression,0.506413
uuid-8a5cddec04e647f3b220ed035edf450a,chemotherapy,0.343889
uuid-8a5cddec04e647f3b220ed035edf450a,respond,0.306782
uuid-d51598ede9af44a19ffc51fd58b160cc,preferred,0.419105
uuid-d51598ede9af44a19ffc51fd58b160cc,using nivo,0.324202
uuid-d51598ede9af44a19ffc51fd58b160cc,SCCHN,0.331372
uuid-d51598ede9af44a19ffc51fd58b160cc,LTL,0.35666
uuid-d51598ede9af44a19ffc51fd58b160cc,feels,0.434842
uuid-d51598ede9af44a19ffc51fd58b160cc,Regional TL,0.315532
uuid-433c46dcbbe24316b1ca2ac6db29db52,Opdivo,0.420427
uuid-433c46dcbbe24316b1ca2ac6db29db52,Keytruda,0.357671
uuid-433c46dcbbe24316b1ca2ac6db29db52,flat dosing,0.56015
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,Nivo,0.351769
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,patients,0.437928
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,pembro,0.303939
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,therapy,0.345431
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,nivolumab,0.350394
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,1L,0.499267
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,regimen,0.332048
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,RCC,0.342002
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,chemo,0.387891
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,2L,0.555169
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,agents,0.387256
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,preferred,0.821654
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,monotherapy,0.555627
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,treatment,0.313136
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,using nivo,0.550973
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,indication,0.333155
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,approved,0.330666
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,SCCHN,0.384356
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,chemotherapy,0.404131
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,RTL stated,0.520901
uuid-c571ab0f6c8b4221bf008c6895f4b5cf,option,0.683029
uuid-008a8b73a79045989181224f2c5439e4,trial,0.330455
uuid-008a8b73a79045989181224f2c5439e4,efficacy,0.402543
uuid-008a8b73a79045989181224f2c5439e4,commented,0.363613
uuid-008a8b73a79045989181224f2c5439e4,OS,0.601696
uuid-008a8b73a79045989181224f2c5439e4,data,0.642137
uuid-008a8b73a79045989181224f2c5439e4,PFS,0.623906
uuid-008a8b73a79045989181224f2c5439e4,ORR,0.670736
uuid-008a8b73a79045989181224f2c5439e4,ASCO,0.379418
uuid-008a8b73a79045989181224f2c5439e4,impressed,0.560183
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,RTL,0.417529
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,BMS,0.311336
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,trial,0.580219
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,NTL,0.313132
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,Merck,0.358549
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,Ipi,0.305933
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,stated,0.339636
uuid-7c1cf53ee8a14de9b935c5bd49ca3945,clinical trials,0.308684
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,TL,0.525306
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,RTL,0.322306
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,TL stated,0.580265
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,institution,0.412445
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,stated,0.470389
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,PD-L1,0.564628
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,approval,0.350855
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,PD-L1 testing,0.725607
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,testing,0.755087
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,PDL1 testing,0.778123
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,NSCLC patients,0.641396
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,SCCHN,0.468516
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,tumor types,0.367395
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,LTL,0.32033
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,assay,0.374814
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,Regional TL,0.416302
uuid-fd5a77fdd5014e4b8a6785abd8cddc19,RTL stated,0.348474
uuid-53d003ddd45342ed9b4b5da21edb54a7,BMS,0.542182
uuid-53d003ddd45342ed9b4b5da21edb54a7,Merck,0.368029
uuid-53d003ddd45342ed9b4b5da21edb54a7,indication,0.338984
uuid-53d003ddd45342ed9b4b5da21edb54a7,approved,0.403592
uuid-53d003ddd45342ed9b4b5da21edb54a7,drug,0.452324
uuid-53d003ddd45342ed9b4b5da21edb54a7,feels,0.331256
uuid-a58e342ed29c40a9b7b5264847703142,Nivo,0.468397
uuid-a58e342ed29c40a9b7b5264847703142,patients,0.692127
uuid-a58e342ed29c40a9b7b5264847703142,Opdivo,0.313051
uuid-a58e342ed29c40a9b7b5264847703142,therapy,0.426282
uuid-a58e342ed29c40a9b7b5264847703142,nivolumab,0.325224
uuid-a58e342ed29c40a9b7b5264847703142,regimen,0.46659
uuid-a58e342ed29c40a9b7b5264847703142,treated,0.360595
uuid-a58e342ed29c40a9b7b5264847703142,chemo,0.411059
uuid-a58e342ed29c40a9b7b5264847703142,pts,0.541484
uuid-a58e342ed29c40a9b7b5264847703142,monotherapy,0.358785
uuid-a58e342ed29c40a9b7b5264847703142,treatment,0.493261
uuid-a58e342ed29c40a9b7b5264847703142,response,0.485747
uuid-a58e342ed29c40a9b7b5264847703142,PD1,0.339597
uuid-a58e342ed29c40a9b7b5264847703142,progression,0.608389
uuid-a58e342ed29c40a9b7b5264847703142,chemotherapy,0.393184
uuid-a58e342ed29c40a9b7b5264847703142,respond,0.55465
uuid-a58e342ed29c40a9b7b5264847703142,feels,0.40752
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,Nivo,0.466698
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,pembro,0.485161
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,dose,0.655594
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,trial,0.450992
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,efficacy,0.369556
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,combination,0.31907
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,Ipi,0.795591
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,atezo,0.406834
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,combo,0.383852
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,indication,0.333755
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,approved,0.333395
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,vs,0.453402
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,label,0.31855
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,SCLC,0.44525
uuid-4c44fe27fa6e4e8eac4484093b6ad4f5,flat dosing,0.532695
uuid-b119f8b06c024dae81219384e307fdf5,PDL1,0.368541
uuid-b119f8b06c024dae81219384e307fdf5,TL stated,0.361786
uuid-b119f8b06c024dae81219384e307fdf5,PD-L1,0.57569
uuid-b119f8b06c024dae81219384e307fdf5,PD-L1 testing,0.471657
uuid-b119f8b06c024dae81219384e307fdf5,testing,0.743137
uuid-b119f8b06c024dae81219384e307fdf5,PDL1 testing,0.700522
uuid-b119f8b06c024dae81219384e307fdf5,NSCLC patients,0.749329
uuid-b119f8b06c024dae81219384e307fdf5,tumor types,0.358505
uuid-b119f8b06c024dae81219384e307fdf5,biomarker,0.469801
uuid-c29cd78a1cbf410fbf9399112f0783c7,patients,0.499015
uuid-c29cd78a1cbf410fbf9399112f0783c7,Opdivo,0.502149
uuid-c29cd78a1cbf410fbf9399112f0783c7,nivolumab,0.30028
uuid-c29cd78a1cbf410fbf9399112f0783c7,treated,0.377904
uuid-c29cd78a1cbf410fbf9399112f0783c7,shared,0.309693
uuid-c29cd78a1cbf410fbf9399112f0783c7,approval,0.506425
uuid-c29cd78a1cbf410fbf9399112f0783c7,clinical trials,0.312813
uuid-c29cd78a1cbf410fbf9399112f0783c7,approved,0.388627
uuid-c29cd78a1cbf410fbf9399112f0783c7,tumor types,0.318909
uuid-c29cd78a1cbf410fbf9399112f0783c7,label,0.339773
uuid-1bcde1242b2e4f4f848343e47fc75b0b,BMS,0.367888
uuid-1bcde1242b2e4f4f848343e47fc75b0b,PDL1,0.618443
uuid-1bcde1242b2e4f4f848343e47fc75b0b,trial,0.348587
uuid-1bcde1242b2e4f4f848343e47fc75b0b,efficacy,0.368219
uuid-1bcde1242b2e4f4f848343e47fc75b0b,commented,0.338693
uuid-1bcde1242b2e4f4f848343e47fc75b0b,Merck,0.395927
uuid-1bcde1242b2e4f4f848343e47fc75b0b,PD-L1,0.397262
uuid-1bcde1242b2e4f4f848343e47fc75b0b,OS,0.311562
uuid-1bcde1242b2e4f4f848343e47fc75b0b,data,0.574602
uuid-1bcde1242b2e4f4f848343e47fc75b0b,expressed,0.346301
uuid-1bcde1242b2e4f4f848343e47fc75b0b,PFS,0.358618
uuid-1bcde1242b2e4f4f848343e47fc75b0b,ORR,0.390104
uuid-1bcde1242b2e4f4f848343e47fc75b0b,nivo and pembro,0.401632
uuid-1bcde1242b2e4f4f848343e47fc75b0b,impressed,0.413963
uuid-1bcde1242b2e4f4f848343e47fc75b0b,TLs,0.334143
uuid-1bcde1242b2e4f4f848343e47fc75b0b,assay,0.393904
uuid-1bcde1242b2e4f4f848343e47fc75b0b,PDL1 expression,0.56106
uuid-1bcde1242b2e4f4f848343e47fc75b0b,biomarker,0.443803
uuid-c95500a7cad44bd6b460f1450c3e6400,TL,0.45695
uuid-c95500a7cad44bd6b460f1450c3e6400,lung,0.307301
uuid-c95500a7cad44bd6b460f1450c3e6400,1L,0.349505
uuid-c95500a7cad44bd6b460f1450c3e6400,PDL1,0.34578
uuid-c95500a7cad44bd6b460f1450c3e6400,RCC,0.410123
uuid-c95500a7cad44bd6b460f1450c3e6400,TL stated,0.631238
uuid-c95500a7cad44bd6b460f1450c3e6400,tumor,0.353282
uuid-c95500a7cad44bd6b460f1450c3e6400,2L,0.318692
uuid-c95500a7cad44bd6b460f1450c3e6400,stated,0.369699
uuid-c95500a7cad44bd6b460f1450c3e6400,PD-L1,0.641158
uuid-c95500a7cad44bd6b460f1450c3e6400,PD-L1 testing,0.599629
uuid-c95500a7cad44bd6b460f1450c3e6400,testing,0.715132
uuid-c95500a7cad44bd6b460f1450c3e6400,PDL1 testing,0.724065
uuid-c95500a7cad44bd6b460f1450c3e6400,NSCLC patients,0.633088
uuid-c95500a7cad44bd6b460f1450c3e6400,SCCHN,0.390872
uuid-c95500a7cad44bd6b460f1450c3e6400,tumor types,0.487296
uuid-c95500a7cad44bd6b460f1450c3e6400,TLs,0.303782
uuid-c95500a7cad44bd6b460f1450c3e6400,assay,0.449781
uuid-c95500a7cad44bd6b460f1450c3e6400,RTL stated,0.363719
uuid-c95500a7cad44bd6b460f1450c3e6400,biomarker,0.449501
uuid-c95500a7cad44bd6b460f1450c3e6400,bladder,0.45435
uuid-7616f5fe7df2436ba4484ca3a0c504a9,biomarker,0.37149
uuid-dba9ecddae7c4a0d9a66909281b75583,patients,0.556608
uuid-dba9ecddae7c4a0d9a66909281b75583,therapy,0.364182
uuid-dba9ecddae7c4a0d9a66909281b75583,toxicity,0.585209
uuid-dba9ecddae7c4a0d9a66909281b75583,regimen,0.484498
uuid-dba9ecddae7c4a0d9a66909281b75583,treated,0.366721
uuid-dba9ecddae7c4a0d9a66909281b75583,chemo,0.315031
uuid-dba9ecddae7c4a0d9a66909281b75583,pts,0.391542
uuid-dba9ecddae7c4a0d9a66909281b75583,treatment,0.571443
uuid-dba9ecddae7c4a0d9a66909281b75583,response,0.487454
uuid-dba9ecddae7c4a0d9a66909281b75583,progression,0.562267
uuid-dba9ecddae7c4a0d9a66909281b75583,chemotherapy,0.34888
uuid-dba9ecddae7c4a0d9a66909281b75583,respond,0.619819
uuid-ee6076fad77145e5a5701a72197eaddc,TL,0.71412
uuid-ee6076fad77145e5a5701a72197eaddc,PDL1,0.305663
uuid-ee6076fad77145e5a5701a72197eaddc,TL stated,0.404557
uuid-ee6076fad77145e5a5701a72197eaddc,institution,0.415328
uuid-ee6076fad77145e5a5701a72197eaddc,PD-L1,0.771167
uuid-ee6076fad77145e5a5701a72197eaddc,approval,0.320616
uuid-ee6076fad77145e5a5701a72197eaddc,PD-L1 testing,0.894469
uuid-ee6076fad77145e5a5701a72197eaddc,testing,0.85435
uuid-ee6076fad77145e5a5701a72197eaddc,PDL1 testing,0.636004
uuid-ee6076fad77145e5a5701a72197eaddc,NSCLC patients,0.588374
uuid-ee6076fad77145e5a5701a72197eaddc,assay,0.835861
uuid-5328f92281d14f5aa0a91c5df1169414,TL,0.55529
uuid-5328f92281d14f5aa0a91c5df1169414,PDL1,0.451772
uuid-5328f92281d14f5aa0a91c5df1169414,trial,0.311229
uuid-5328f92281d14f5aa0a91c5df1169414,Merck,0.441184
uuid-5328f92281d14f5aa0a91c5df1169414,PD-L1,0.468251
uuid-5328f92281d14f5aa0a91c5df1169414,OS,0.410919
uuid-5328f92281d14f5aa0a91c5df1169414,PD-L1 testing,0.41367
uuid-5328f92281d14f5aa0a91c5df1169414,testing,0.367159
uuid-5328f92281d14f5aa0a91c5df1169414,regards,0.309592
uuid-5328f92281d14f5aa0a91c5df1169414,data,0.564551
uuid-5328f92281d14f5aa0a91c5df1169414,PFS,0.414955
uuid-5328f92281d14f5aa0a91c5df1169414,ORR,0.419439
uuid-5328f92281d14f5aa0a91c5df1169414,nivo and pembro,0.318459
uuid-5328f92281d14f5aa0a91c5df1169414,ASCO,0.30344
uuid-5328f92281d14f5aa0a91c5df1169414,impressed,0.382556
uuid-5328f92281d14f5aa0a91c5df1169414,assay,0.668712
uuid-5328f92281d14f5aa0a91c5df1169414,PDL1 expression,0.314302
uuid-559dc46c7a58416fb5f7827b381814d2,toxicity,0.343855
uuid-559dc46c7a58416fb5f7827b381814d2,physicians,0.630421
uuid-559dc46c7a58416fb5f7827b381814d2,treatment,0.357606
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,pembro,0.412186
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,lung,0.328996
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,1L,0.380679
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,PDL1,0.718216
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,TL stated,0.31137
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,Merck,0.402527
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,PD-L1,0.647386
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,atezo,0.477605
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,PD-L1 testing,0.4423
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,testing,0.612671
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,data,0.304908
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,PDL1 testing,0.568806
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,AI,0.42669
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,NSCLC patients,0.398634
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,nivo and pembro,0.538704
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,assay,0.637924
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,PDL1 expression,0.610208
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,biomarker,0.569304
uuid-cfc2f1855daf4b34884b2b7bbc82a55c,NCCN,0.313055
uuid-414de0b6721245e6b78774c0dc8360e9,Nivo,0.407418
uuid-414de0b6721245e6b78774c0dc8360e9,pembro,0.333387
uuid-414de0b6721245e6b78774c0dc8360e9,1L,0.496338
uuid-414de0b6721245e6b78774c0dc8360e9,PDL1,0.424648
uuid-414de0b6721245e6b78774c0dc8360e9,efficacy,0.525827
uuid-414de0b6721245e6b78774c0dc8360e9,combination,0.344869
uuid-414de0b6721245e6b78774c0dc8360e9,chemo,0.487346
uuid-414de0b6721245e6b78774c0dc8360e9,2L,0.410543
uuid-414de0b6721245e6b78774c0dc8360e9,IO,0.32451
uuid-414de0b6721245e6b78774c0dc8360e9,agents,0.461899
uuid-414de0b6721245e6b78774c0dc8360e9,OS,0.432747
uuid-414de0b6721245e6b78774c0dc8360e9,atezo,0.367852
uuid-414de0b6721245e6b78774c0dc8360e9,monotherapy,0.482918
uuid-414de0b6721245e6b78774c0dc8360e9,combo,0.527114
uuid-414de0b6721245e6b78774c0dc8360e9,PFS,0.440661
uuid-414de0b6721245e6b78774c0dc8360e9,AI,0.445867
uuid-414de0b6721245e6b78774c0dc8360e9,PD1,0.375096
uuid-414de0b6721245e6b78774c0dc8360e9,ORR,0.404541
uuid-414de0b6721245e6b78774c0dc8360e9,nivo and pembro,0.649814
uuid-414de0b6721245e6b78774c0dc8360e9,believes,0.617687
uuid-414de0b6721245e6b78774c0dc8360e9,chemotherapy,0.346426
uuid-414de0b6721245e6b78774c0dc8360e9,PDL1 expression,0.354733
uuid-414de0b6721245e6b78774c0dc8360e9,option,0.407245
uuid-238502d4495747378a63d98dcf0f9864,Nivo,0.327697
uuid-238502d4495747378a63d98dcf0f9864,patients,0.846098
uuid-238502d4495747378a63d98dcf0f9864,Opdivo,0.528235
uuid-238502d4495747378a63d98dcf0f9864,therapy,0.647723
uuid-238502d4495747378a63d98dcf0f9864,nivolumab,0.55116
uuid-238502d4495747378a63d98dcf0f9864,regimen,0.33022
uuid-238502d4495747378a63d98dcf0f9864,treated,0.463068
uuid-238502d4495747378a63d98dcf0f9864,pts,0.470413
uuid-238502d4495747378a63d98dcf0f9864,approval,0.320056
uuid-238502d4495747378a63d98dcf0f9864,treatment,0.597779
uuid-238502d4495747378a63d98dcf0f9864,using nivo,0.330272
uuid-238502d4495747378a63d98dcf0f9864,response,0.355918
uuid-238502d4495747378a63d98dcf0f9864,cHL,0.593011
uuid-238502d4495747378a63d98dcf0f9864,progression,0.601142
uuid-238502d4495747378a63d98dcf0f9864,chemotherapy,0.338832
uuid-238502d4495747378a63d98dcf0f9864,respond,0.433187
uuid-0a3332ab914443fe87c31173c22ee38f,BMS,0.451023
uuid-0a3332ab914443fe87c31173c22ee38f,PDL1,0.533194
uuid-0a3332ab914443fe87c31173c22ee38f,trial,0.520812
uuid-0a3332ab914443fe87c31173c22ee38f,efficacy,0.511868
uuid-0a3332ab914443fe87c31173c22ee38f,commented,0.328748
uuid-0a3332ab914443fe87c31173c22ee38f,Merck,0.422838
uuid-0a3332ab914443fe87c31173c22ee38f,OS,0.624769
uuid-0a3332ab914443fe87c31173c22ee38f,data,0.897545
uuid-0a3332ab914443fe87c31173c22ee38f,PFS,0.614416
uuid-0a3332ab914443fe87c31173c22ee38f,ORR,0.638107
uuid-0a3332ab914443fe87c31173c22ee38f,nivo and pembro,0.495981
uuid-0a3332ab914443fe87c31173c22ee38f,ASCO,0.327419
uuid-0a3332ab914443fe87c31173c22ee38f,impressed,0.495823
uuid-0a3332ab914443fe87c31173c22ee38f,PDL1 expression,0.481784
uuid-0a3332ab914443fe87c31173c22ee38f,biomarker,0.30792
uuid-028df6523eb6429f8fba7f9924d27813,Nivo,0.338125
uuid-028df6523eb6429f8fba7f9924d27813,pembro,0.507519
uuid-028df6523eb6429f8fba7f9924d27813,BMS,0.385242
uuid-028df6523eb6429f8fba7f9924d27813,PDL1,0.466319
uuid-028df6523eb6429f8fba7f9924d27813,trial,0.707571
uuid-028df6523eb6429f8fba7f9924d27813,efficacy,0.563347
uuid-028df6523eb6429f8fba7f9924d27813,agents,0.426727
uuid-028df6523eb6429f8fba7f9924d27813,Merck,0.347437
uuid-028df6523eb6429f8fba7f9924d27813,OS,0.482535
uuid-028df6523eb6429f8fba7f9924d27813,atezo,0.424812
uuid-028df6523eb6429f8fba7f9924d27813,data,0.594755
uuid-028df6523eb6429f8fba7f9924d27813,combo,0.34083
uuid-028df6523eb6429f8fba7f9924d27813,PFS,0.515366
uuid-028df6523eb6429f8fba7f9924d27813,ORR,0.554384
uuid-028df6523eb6429f8fba7f9924d27813,nivo and pembro,0.728526
uuid-028df6523eb6429f8fba7f9924d27813,believes,0.508359
uuid-028df6523eb6429f8fba7f9924d27813,impressed,0.338781
uuid-028df6523eb6429f8fba7f9924d27813,vs,0.383507
uuid-028df6523eb6429f8fba7f9924d27813,feels,0.405886
uuid-028df6523eb6429f8fba7f9924d27813,PDL1 expression,0.424136
uuid-72b183cfe159488e90daf115e8bb0896,Nivo,0.693677
uuid-72b183cfe159488e90daf115e8bb0896,pembro,0.80536
uuid-72b183cfe159488e90daf115e8bb0896,1L,0.594373
uuid-72b183cfe159488e90daf115e8bb0896,efficacy,0.323114
uuid-72b183cfe159488e90daf115e8bb0896,chemo,0.347564
uuid-72b183cfe159488e90daf115e8bb0896,2L,0.657551
uuid-72b183cfe159488e90daf115e8bb0896,agents,0.508458
uuid-72b183cfe159488e90daf115e8bb0896,Ipi,0.312158
uuid-72b183cfe159488e90daf115e8bb0896,approval,0.347393
uuid-72b183cfe159488e90daf115e8bb0896,atezo,0.754552
uuid-72b183cfe159488e90daf115e8bb0896,preferred,0.642806
uuid-72b183cfe159488e90daf115e8bb0896,monotherapy,0.479909
uuid-72b183cfe159488e90daf115e8bb0896,using nivo,0.562195
uuid-72b183cfe159488e90daf115e8bb0896,indication,0.380224
uuid-72b183cfe159488e90daf115e8bb0896,approved,0.418266
uuid-72b183cfe159488e90daf115e8bb0896,nivo and pembro,0.557075
uuid-72b183cfe159488e90daf115e8bb0896,vs,0.498409
uuid-72b183cfe159488e90daf115e8bb0896,feels,0.43714
uuid-72b183cfe159488e90daf115e8bb0896,RTL stated,0.372885
uuid-72b183cfe159488e90daf115e8bb0896,option,0.520324
uuid-4fbbe08b4ca54601b77475503be3f78f,pembro,0.515176
uuid-4fbbe08b4ca54601b77475503be3f78f,1L,0.495012
uuid-4fbbe08b4ca54601b77475503be3f78f,PDL1,0.48576
uuid-4fbbe08b4ca54601b77475503be3f78f,2L,0.47939
uuid-4fbbe08b4ca54601b77475503be3f78f,agents,0.39769
uuid-4fbbe08b4ca54601b77475503be3f78f,PD-L1,0.420531
uuid-4fbbe08b4ca54601b77475503be3f78f,approval,0.315333
uuid-4fbbe08b4ca54601b77475503be3f78f,atezo,0.517562
uuid-4fbbe08b4ca54601b77475503be3f78f,preferred,0.40503
uuid-4fbbe08b4ca54601b77475503be3f78f,testing,0.39228
uuid-4fbbe08b4ca54601b77475503be3f78f,PDL1 testing,0.391279
uuid-4fbbe08b4ca54601b77475503be3f78f,indication,0.378135
uuid-4fbbe08b4ca54601b77475503be3f78f,NSCLC patients,0.305171
uuid-4fbbe08b4ca54601b77475503be3f78f,approved,0.31015
uuid-4fbbe08b4ca54601b77475503be3f78f,nivo and pembro,0.496602
uuid-4fbbe08b4ca54601b77475503be3f78f,believes,0.30666
uuid-4fbbe08b4ca54601b77475503be3f78f,assay,0.393261
uuid-4fbbe08b4ca54601b77475503be3f78f,PDL1 expression,0.379033
uuid-4fbbe08b4ca54601b77475503be3f78f,option,0.332221
uuid-4fbbe08b4ca54601b77475503be3f78f,biomarker,0.313106
uuid-b32b2cb1896b4b078ac34ac3bcf54574,Nivo,0.322929
uuid-b32b2cb1896b4b078ac34ac3bcf54574,pembro,0.404369
uuid-b32b2cb1896b4b078ac34ac3bcf54574,RTL,0.354877
uuid-b32b2cb1896b4b078ac34ac3bcf54574,1L,0.525903
uuid-b32b2cb1896b4b078ac34ac3bcf54574,RCC,0.371205
uuid-b32b2cb1896b4b078ac34ac3bcf54574,chemo,0.313454
uuid-b32b2cb1896b4b078ac34ac3bcf54574,2L,0.427016
uuid-b32b2cb1896b4b078ac34ac3bcf54574,OS,0.395702
uuid-b32b2cb1896b4b078ac34ac3bcf54574,atezo,0.327372
uuid-b32b2cb1896b4b078ac34ac3bcf54574,preferred,0.368928
uuid-b32b2cb1896b4b078ac34ac3bcf54574,monotherapy,0.476067
uuid-b32b2cb1896b4b078ac34ac3bcf54574,using nivo,0.350506
uuid-b32b2cb1896b4b078ac34ac3bcf54574,data,0.407386
uuid-b32b2cb1896b4b078ac34ac3bcf54574,combo,0.395539
uuid-b32b2cb1896b4b078ac34ac3bcf54574,ORR,0.343906
uuid-b32b2cb1896b4b078ac34ac3bcf54574,SCCHN,0.388901
uuid-b32b2cb1896b4b078ac34ac3bcf54574,believes,0.305724
uuid-b32b2cb1896b4b078ac34ac3bcf54574,impressed,0.439603
uuid-b32b2cb1896b4b078ac34ac3bcf54574,feels,0.314586
uuid-b32b2cb1896b4b078ac34ac3bcf54574,RTL stated,0.387425
uuid-b32b2cb1896b4b078ac34ac3bcf54574,option,0.401456
uuid-b32b2cb1896b4b078ac34ac3bcf54574,bladder,0.310611
uuid-0c80290cb83c4caa896b2b3b5672ab14,regimen,0.316985
uuid-0c80290cb83c4caa896b2b3b5672ab14,shared,0.404742
uuid-0c80290cb83c4caa896b2b3b5672ab14,commented,0.338337
uuid-0c80290cb83c4caa896b2b3b5672ab14,physicians,0.600163
uuid-0c80290cb83c4caa896b2b3b5672ab14,preferred,0.35679
uuid-0c80290cb83c4caa896b2b3b5672ab14,SCCHN,0.419041
uuid-0c80290cb83c4caa896b2b3b5672ab14,oncologist,0.344451
uuid-0c80290cb83c4caa896b2b3b5672ab14,indicated,0.313953
uuid-0c80290cb83c4caa896b2b3b5672ab14,LTL,0.315477
uuid-0c80290cb83c4caa896b2b3b5672ab14,TLs,0.35315
uuid-0c80290cb83c4caa896b2b3b5672ab14,Regional TL,0.469779
uuid-0c80290cb83c4caa896b2b3b5672ab14,RTL stated,0.337449
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,Nivo,0.425428
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,pembro,0.470306
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,1L,0.622267
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,RCC,0.398863
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,chemo,0.340448
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,2L,0.621728
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,agents,0.430461
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,approval,0.359413
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,atezo,0.450533
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,preferred,0.556492
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,monotherapy,0.441881
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,using nivo,0.524104
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,data,0.314033
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,combo,0.361517
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,indication,0.366681
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,approved,0.508445
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,SCCHN,0.319194
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,nivo and pembro,0.407768
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,believes,0.426912
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,impressed,0.364256
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,feels,0.500899
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,RTL stated,0.35956
uuid-4c9e10f9c91a406781e7fccd4a9ccb1d,option,0.542681
uuid-bf8b06d3184a4a79a4a303772849d994,pembro,0.364521
uuid-bf8b06d3184a4a79a4a303772849d994,RTL,0.317186
uuid-bf8b06d3184a4a79a4a303772849d994,dose,0.345697
uuid-bf8b06d3184a4a79a4a303772849d994,trial,0.479086
uuid-bf8b06d3184a4a79a4a303772849d994,NTL,0.304301
uuid-bf8b06d3184a4a79a4a303772849d994,shared,0.452281
uuid-bf8b06d3184a4a79a4a303772849d994,institution,0.354952
uuid-bf8b06d3184a4a79a4a303772849d994,Ipi,0.403405
uuid-bf8b06d3184a4a79a4a303772849d994,atezo,0.309119
uuid-bf8b06d3184a4a79a4a303772849d994,clinical trials,0.359736
uuid-bf8b06d3184a4a79a4a303772849d994,SCCHN,0.313874
uuid-bf8b06d3184a4a79a4a303772849d994,bladder,0.386569
uuid-bf8b06d3184a4a79a4a303772849d994,flat dosing,0.411158
uuid-b3706a0f89824fbf806f473bc91d7bac,Nivo,0.433012
uuid-b3706a0f89824fbf806f473bc91d7bac,patients,0.490192
uuid-b3706a0f89824fbf806f473bc91d7bac,therapy,0.441353
uuid-b3706a0f89824fbf806f473bc91d7bac,nivolumab,0.559637
uuid-b3706a0f89824fbf806f473bc91d7bac,1L,0.564245
uuid-b3706a0f89824fbf806f473bc91d7bac,regimen,0.396978
uuid-b3706a0f89824fbf806f473bc91d7bac,treated,0.384721
uuid-b3706a0f89824fbf806f473bc91d7bac,RCC,0.598325
uuid-b3706a0f89824fbf806f473bc91d7bac,TL stated,0.373568
uuid-b3706a0f89824fbf806f473bc91d7bac,combination,0.393998
uuid-b3706a0f89824fbf806f473bc91d7bac,chemo,0.441929
uuid-b3706a0f89824fbf806f473bc91d7bac,2L,0.615109
uuid-b3706a0f89824fbf806f473bc91d7bac,pts,0.492796
uuid-b3706a0f89824fbf806f473bc91d7bac,preferred,0.499573
uuid-b3706a0f89824fbf806f473bc91d7bac,monotherapy,0.607444
uuid-b3706a0f89824fbf806f473bc91d7bac,treatment,0.355176
uuid-b3706a0f89824fbf806f473bc91d7bac,using nivo,0.635178
uuid-b3706a0f89824fbf806f473bc91d7bac,response,0.309766
uuid-b3706a0f89824fbf806f473bc91d7bac,combo,0.392935
uuid-b3706a0f89824fbf806f473bc91d7bac,PD1,0.44002
uuid-b3706a0f89824fbf806f473bc91d7bac,approved,0.368089
uuid-b3706a0f89824fbf806f473bc91d7bac,SCCHN,0.363397
uuid-b3706a0f89824fbf806f473bc91d7bac,progression,0.432296
uuid-b3706a0f89824fbf806f473bc91d7bac,chemotherapy,0.338711
uuid-b3706a0f89824fbf806f473bc91d7bac,RTL stated,0.604236
uuid-b3706a0f89824fbf806f473bc91d7bac,TL shared,0.40768
uuid-b3706a0f89824fbf806f473bc91d7bac,option,0.518995
uuid-b3706a0f89824fbf806f473bc91d7bac,bladder,0.348125
uuid-749dce2a00a142b8a965dabbb719bb1f,patients,0.747009
uuid-749dce2a00a142b8a965dabbb719bb1f,Opdivo,0.307756
uuid-749dce2a00a142b8a965dabbb719bb1f,therapy,0.515408
uuid-749dce2a00a142b8a965dabbb719bb1f,toxicity,0.406357
uuid-749dce2a00a142b8a965dabbb719bb1f,regimen,0.566865
uuid-749dce2a00a142b8a965dabbb719bb1f,treated,0.512256
uuid-749dce2a00a142b8a965dabbb719bb1f,chemo,0.377299
uuid-749dce2a00a142b8a965dabbb719bb1f,pts,0.568825
uuid-749dce2a00a142b8a965dabbb719bb1f,treatment,0.795226
uuid-749dce2a00a142b8a965dabbb719bb1f,response,0.634634
uuid-749dce2a00a142b8a965dabbb719bb1f,PD1,0.3369
uuid-749dce2a00a142b8a965dabbb719bb1f,progression,0.821063
uuid-749dce2a00a142b8a965dabbb719bb1f,chemotherapy,0.390375
uuid-749dce2a00a142b8a965dabbb719bb1f,respond,0.701057
uuid-f7d920c3f5c34185b82673268a6a8d14,Nivo,0.515274
uuid-f7d920c3f5c34185b82673268a6a8d14,pembro,0.512906
uuid-f7d920c3f5c34185b82673268a6a8d14,lung,0.343817
uuid-f7d920c3f5c34185b82673268a6a8d14,1L,0.705373
uuid-f7d920c3f5c34185b82673268a6a8d14,RCC,0.665748
uuid-f7d920c3f5c34185b82673268a6a8d14,TL stated,0.335369
uuid-f7d920c3f5c34185b82673268a6a8d14,combination,0.334742
uuid-f7d920c3f5c34185b82673268a6a8d14,chemo,0.336277
uuid-f7d920c3f5c34185b82673268a6a8d14,2L,0.801377
uuid-f7d920c3f5c34185b82673268a6a8d14,agents,0.520278
uuid-f7d920c3f5c34185b82673268a6a8d14,approval,0.342276
uuid-f7d920c3f5c34185b82673268a6a8d14,atezo,0.55461
uuid-f7d920c3f5c34185b82673268a6a8d14,preferred,0.652421
uuid-f7d920c3f5c34185b82673268a6a8d14,monotherapy,0.565513
uuid-f7d920c3f5c34185b82673268a6a8d14,using nivo,0.668574
uuid-f7d920c3f5c34185b82673268a6a8d14,combo,0.449292
uuid-f7d920c3f5c34185b82673268a6a8d14,indication,0.335513
uuid-f7d920c3f5c34185b82673268a6a8d14,PD1,0.329039
uuid-f7d920c3f5c34185b82673268a6a8d14,approved,0.509029
uuid-f7d920c3f5c34185b82673268a6a8d14,SCCHN,0.400076
uuid-f7d920c3f5c34185b82673268a6a8d14,nivo and pembro,0.414834
uuid-f7d920c3f5c34185b82673268a6a8d14,believes,0.377911
uuid-f7d920c3f5c34185b82673268a6a8d14,TLs,0.328341
uuid-f7d920c3f5c34185b82673268a6a8d14,SCLC,0.326924
uuid-f7d920c3f5c34185b82673268a6a8d14,RTL stated,0.578222
uuid-f7d920c3f5c34185b82673268a6a8d14,TL shared,0.353559
uuid-f7d920c3f5c34185b82673268a6a8d14,option,0.490944
uuid-f7d920c3f5c34185b82673268a6a8d14,bladder,0.383917
uuid-017e461c3ec545618f70f4909b274c66,Nivo,0.323544
uuid-017e461c3ec545618f70f4909b274c66,patients,0.676095
uuid-017e461c3ec545618f70f4909b274c66,Opdivo,0.39766
uuid-017e461c3ec545618f70f4909b274c66,therapy,0.486495
uuid-017e461c3ec545618f70f4909b274c66,nivolumab,0.457387
uuid-017e461c3ec545618f70f4909b274c66,toxicity,0.419228
uuid-017e461c3ec545618f70f4909b274c66,regimen,0.812923
uuid-017e461c3ec545618f70f4909b274c66,treated,0.494129
uuid-017e461c3ec545618f70f4909b274c66,combination,0.37524
uuid-017e461c3ec545618f70f4909b274c66,chemo,0.421137
uuid-017e461c3ec545618f70f4909b274c66,pts,0.507615
uuid-017e461c3ec545618f70f4909b274c66,monotherapy,0.531627
uuid-017e461c3ec545618f70f4909b274c66,treatment,0.601028
uuid-017e461c3ec545618f70f4909b274c66,response,0.404324
uuid-017e461c3ec545618f70f4909b274c66,combo,0.366381
uuid-017e461c3ec545618f70f4909b274c66,PD1,0.37761
uuid-017e461c3ec545618f70f4909b274c66,progression,0.565121
uuid-017e461c3ec545618f70f4909b274c66,chemotherapy,0.461104
uuid-017e461c3ec545618f70f4909b274c66,respond,0.54522
uuid-017e461c3ec545618f70f4909b274c66,option,0.3984
uuid-3af1764ec5754b209e06f211e1fd4a89,RTL,0.398375
uuid-3af1764ec5754b209e06f211e1fd4a89,NTL,0.370126
uuid-3af1764ec5754b209e06f211e1fd4a89,shared,0.331438
uuid-3af1764ec5754b209e06f211e1fd4a89,commented,0.546911
uuid-3af1764ec5754b209e06f211e1fd4a89,stated,0.315184
uuid-3af1764ec5754b209e06f211e1fd4a89,physicians,0.336778
uuid-3af1764ec5754b209e06f211e1fd4a89,data,0.324761
uuid-3af1764ec5754b209e06f211e1fd4a89,expressed,0.505086
uuid-3af1764ec5754b209e06f211e1fd4a89,mentioned,0.354583
uuid-3af1764ec5754b209e06f211e1fd4a89,HCP,0.345327
uuid-3af1764ec5754b209e06f211e1fd4a89,lung cancer,0.300153
uuid-3af1764ec5754b209e06f211e1fd4a89,ASCO,0.511881
uuid-3af1764ec5754b209e06f211e1fd4a89,impressed,0.468069
uuid-3af1764ec5754b209e06f211e1fd4a89,Regional TL,0.519363
uuid-4638ac3e17ea49eba36fc2382c315023,Nivo,0.321941
uuid-4638ac3e17ea49eba36fc2382c315023,patients,0.606664
uuid-4638ac3e17ea49eba36fc2382c315023,therapy,0.678957
uuid-4638ac3e17ea49eba36fc2382c315023,nivolumab,0.58636
uuid-4638ac3e17ea49eba36fc2382c315023,1L,0.434552
uuid-4638ac3e17ea49eba36fc2382c315023,regimen,0.484845
uuid-4638ac3e17ea49eba36fc2382c315023,treated,0.527421
uuid-4638ac3e17ea49eba36fc2382c315023,RCC,0.391032
uuid-4638ac3e17ea49eba36fc2382c315023,combination,0.479423
uuid-4638ac3e17ea49eba36fc2382c315023,chemo,0.446319
uuid-4638ac3e17ea49eba36fc2382c315023,2L,0.491818
uuid-4638ac3e17ea49eba36fc2382c315023,pts,0.414758
uuid-4638ac3e17ea49eba36fc2382c315023,agents,0.367614
uuid-4638ac3e17ea49eba36fc2382c315023,approval,0.321016
uuid-4638ac3e17ea49eba36fc2382c315023,preferred,0.55594
uuid-4638ac3e17ea49eba36fc2382c315023,monotherapy,0.588681
uuid-4638ac3e17ea49eba36fc2382c315023,treatment,0.617732
uuid-4638ac3e17ea49eba36fc2382c315023,using nivo,0.482982
uuid-4638ac3e17ea49eba36fc2382c315023,combo,0.392585
uuid-4638ac3e17ea49eba36fc2382c315023,PD1,0.450456
uuid-4638ac3e17ea49eba36fc2382c315023,approved,0.385706
uuid-4638ac3e17ea49eba36fc2382c315023,progression,0.458844
uuid-4638ac3e17ea49eba36fc2382c315023,chemotherapy,0.565831
uuid-4638ac3e17ea49eba36fc2382c315023,RTL stated,0.493774
uuid-4638ac3e17ea49eba36fc2382c315023,option,0.63445
uuid-37f57eabb5d84cc48080fc58b60890e7,Nivo,0.366301
uuid-37f57eabb5d84cc48080fc58b60890e7,patients,0.473149
uuid-37f57eabb5d84cc48080fc58b60890e7,therapy,0.420352
uuid-37f57eabb5d84cc48080fc58b60890e7,regimen,0.328448
uuid-37f57eabb5d84cc48080fc58b60890e7,chemo,0.434128
uuid-37f57eabb5d84cc48080fc58b60890e7,pts,0.488182
uuid-37f57eabb5d84cc48080fc58b60890e7,OS,0.502064
uuid-37f57eabb5d84cc48080fc58b60890e7,treatment,0.398172
uuid-37f57eabb5d84cc48080fc58b60890e7,response,0.505207
uuid-37f57eabb5d84cc48080fc58b60890e7,PFS,0.518502
uuid-37f57eabb5d84cc48080fc58b60890e7,PD1,0.339008
uuid-37f57eabb5d84cc48080fc58b60890e7,ORR,0.419735
uuid-37f57eabb5d84cc48080fc58b60890e7,progression,0.592216
uuid-37f57eabb5d84cc48080fc58b60890e7,chemotherapy,0.419434
uuid-37f57eabb5d84cc48080fc58b60890e7,respond,0.489637
uuid-e44e6bf2cd524c898db5baf8ad9974fb,patients,0.695695
uuid-e44e6bf2cd524c898db5baf8ad9974fb,Opdivo,0.386009
uuid-e44e6bf2cd524c898db5baf8ad9974fb,therapy,0.603112
uuid-e44e6bf2cd524c898db5baf8ad9974fb,nivolumab,0.337649
uuid-e44e6bf2cd524c898db5baf8ad9974fb,regimen,0.465148
uuid-e44e6bf2cd524c898db5baf8ad9974fb,treated,0.440033
uuid-e44e6bf2cd524c898db5baf8ad9974fb,chemo,0.375768
uuid-e44e6bf2cd524c898db5baf8ad9974fb,pts,0.454637
uuid-e44e6bf2cd524c898db5baf8ad9974fb,treatment,0.82171
uuid-e44e6bf2cd524c898db5baf8ad9974fb,response,0.440983
uuid-e44e6bf2cd524c898db5baf8ad9974fb,progression,0.653003
uuid-e44e6bf2cd524c898db5baf8ad9974fb,chemotherapy,0.421542
uuid-e44e6bf2cd524c898db5baf8ad9974fb,respond,0.551304
uuid-e44e6bf2cd524c898db5baf8ad9974fb,option,0.337976
uuid-45c90aa9791c43989ea07e3fc84ab50a,Nivo,0.332469
uuid-45c90aa9791c43989ea07e3fc84ab50a,pembro,0.383088
uuid-45c90aa9791c43989ea07e3fc84ab50a,trial,0.574987
uuid-45c90aa9791c43989ea07e3fc84ab50a,combination,0.313641
uuid-45c90aa9791c43989ea07e3fc84ab50a,chemo,0.400382
uuid-45c90aa9791c43989ea07e3fc84ab50a,clinical trials,0.357744
uuid-45c90aa9791c43989ea07e3fc84ab50a,nivo and pembro,0.305571
uuid-45c90aa9791c43989ea07e3fc84ab50a,chemotherapy,0.420908
uuid-45c90aa9791c43989ea07e3fc84ab50a,feels,0.359635
uuid-2b99b19611b743feacb0095cadd66ee5,pembro,0.333587
uuid-2b99b19611b743feacb0095cadd66ee5,1L,0.414845
uuid-2b99b19611b743feacb0095cadd66ee5,PDL1,0.34714
uuid-2b99b19611b743feacb0095cadd66ee5,2L,0.398981
uuid-2b99b19611b743feacb0095cadd66ee5,agents,0.435714
uuid-2b99b19611b743feacb0095cadd66ee5,PD-L1,0.307699
uuid-2b99b19611b743feacb0095cadd66ee5,atezo,0.370291
uuid-2b99b19611b743feacb0095cadd66ee5,preferred,0.467855
uuid-2b99b19611b743feacb0095cadd66ee5,monotherapy,0.45322
uuid-2b99b19611b743feacb0095cadd66ee5,indication,0.320482
uuid-2b99b19611b743feacb0095cadd66ee5,approved,0.341136
uuid-2b99b19611b743feacb0095cadd66ee5,chemotherapy,0.343972
uuid-2b99b19611b743feacb0095cadd66ee5,feels,0.327458
uuid-2b99b19611b743feacb0095cadd66ee5,PDL1 expression,0.327868
uuid-2b99b19611b743feacb0095cadd66ee5,option,0.584917
uuid-a9f1733a293240bfbf7e9c940dccabdb,Nivo,0.325036
uuid-a9f1733a293240bfbf7e9c940dccabdb,patients,0.926965
uuid-a9f1733a293240bfbf7e9c940dccabdb,Opdivo,0.352477
uuid-a9f1733a293240bfbf7e9c940dccabdb,therapy,0.70309
uuid-a9f1733a293240bfbf7e9c940dccabdb,nivolumab,0.43381
uuid-a9f1733a293240bfbf7e9c940dccabdb,regimen,0.537849
uuid-a9f1733a293240bfbf7e9c940dccabdb,treated,0.557359
uuid-a9f1733a293240bfbf7e9c940dccabdb,chemo,0.525656
uuid-a9f1733a293240bfbf7e9c940dccabdb,pts,0.590166
uuid-a9f1733a293240bfbf7e9c940dccabdb,monotherapy,0.482437
uuid-a9f1733a293240bfbf7e9c940dccabdb,treatment,0.753812
uuid-a9f1733a293240bfbf7e9c940dccabdb,using nivo,0.316609
uuid-a9f1733a293240bfbf7e9c940dccabdb,response,0.414755
uuid-a9f1733a293240bfbf7e9c940dccabdb,PD1,0.396688
uuid-a9f1733a293240bfbf7e9c940dccabdb,progression,0.699108
uuid-a9f1733a293240bfbf7e9c940dccabdb,chemotherapy,0.575323
uuid-a9f1733a293240bfbf7e9c940dccabdb,respond,0.540776
uuid-a9f1733a293240bfbf7e9c940dccabdb,option,0.496957
uuid-73b4c2732fbf4e13a0fabec165aa73df,TL,0.34995
uuid-73b4c2732fbf4e13a0fabec165aa73df,PDL1,0.339656
uuid-73b4c2732fbf4e13a0fabec165aa73df,Merck,0.304606
uuid-73b4c2732fbf4e13a0fabec165aa73df,PD-L1,0.607152
uuid-73b4c2732fbf4e13a0fabec165aa73df,PD-L1 testing,0.639653
uuid-73b4c2732fbf4e13a0fabec165aa73df,testing,0.787582
uuid-73b4c2732fbf4e13a0fabec165aa73df,PDL1 testing,0.599543
uuid-73b4c2732fbf4e13a0fabec165aa73df,NSCLC patients,0.58869
uuid-73b4c2732fbf4e13a0fabec165aa73df,assay,0.482728
uuid-73b4c2732fbf4e13a0fabec165aa73df,biomarker,0.454954
uuid-69714962cec643c5a4f8aaa826068b8c,therapy,0.392721
uuid-69714962cec643c5a4f8aaa826068b8c,nivolumab,0.322181
uuid-69714962cec643c5a4f8aaa826068b8c,toxicity,0.371758
uuid-69714962cec643c5a4f8aaa826068b8c,regimen,0.359657
uuid-69714962cec643c5a4f8aaa826068b8c,combination,0.67884
uuid-69714962cec643c5a4f8aaa826068b8c,chemo,0.478864
uuid-69714962cec643c5a4f8aaa826068b8c,IO,0.395415
uuid-69714962cec643c5a4f8aaa826068b8c,agents,0.470721
uuid-69714962cec643c5a4f8aaa826068b8c,monotherapy,0.460814
uuid-69714962cec643c5a4f8aaa826068b8c,treatment,0.351651
uuid-69714962cec643c5a4f8aaa826068b8c,combo,0.544316
uuid-69714962cec643c5a4f8aaa826068b8c,PD1,0.464328
uuid-69714962cec643c5a4f8aaa826068b8c,progression,0.315936
uuid-69714962cec643c5a4f8aaa826068b8c,chemotherapy,0.539065
uuid-69714962cec643c5a4f8aaa826068b8c,immunotherapy,0.368213
uuid-69714962cec643c5a4f8aaa826068b8c,PD-1,0.305568
uuid-69714962cec643c5a4f8aaa826068b8c,option,0.417849
uuid-d7480c1f87684168b5765ad519e91b2d,trial,0.480349
uuid-d7480c1f87684168b5765ad519e91b2d,efficacy,0.423144
uuid-d7480c1f87684168b5765ad519e91b2d,commented,0.429754
uuid-d7480c1f87684168b5765ad519e91b2d,OS,0.685792
uuid-d7480c1f87684168b5765ad519e91b2d,data,0.746708
uuid-d7480c1f87684168b5765ad519e91b2d,PFS,0.659054
uuid-d7480c1f87684168b5765ad519e91b2d,ORR,0.75523
uuid-d7480c1f87684168b5765ad519e91b2d,nivo and pembro,0.316407
uuid-d7480c1f87684168b5765ad519e91b2d,ASCO,0.424999
uuid-d7480c1f87684168b5765ad519e91b2d,impressed,0.679903
uuid-562b724c1a9d45debdba54ecfbf148c0,patients,0.602259
uuid-562b724c1a9d45debdba54ecfbf148c0,therapy,0.448141
uuid-562b724c1a9d45debdba54ecfbf148c0,toxicity,0.322133
uuid-562b724c1a9d45debdba54ecfbf148c0,regimen,0.330366
uuid-562b724c1a9d45debdba54ecfbf148c0,treated,0.360386
uuid-562b724c1a9d45debdba54ecfbf148c0,chemo,0.382491
uuid-562b724c1a9d45debdba54ecfbf148c0,tumor,0.422265
uuid-562b724c1a9d45debdba54ecfbf148c0,pts,0.515051
uuid-562b724c1a9d45debdba54ecfbf148c0,treatment,0.498045
uuid-562b724c1a9d45debdba54ecfbf148c0,response,0.431738
uuid-562b724c1a9d45debdba54ecfbf148c0,progression,0.554375
uuid-562b724c1a9d45debdba54ecfbf148c0,chemotherapy,0.494866
uuid-562b724c1a9d45debdba54ecfbf148c0,respond,0.331578
uuid-562b724c1a9d45debdba54ecfbf148c0,immunotherapy,0.322564
uuid-234891f163284168980027a6fb03b052,NTL,0.358639
uuid-234891f163284168980027a6fb03b052,lung cancer,0.930864
uuid-30774d53b6644418bbc59ce02b1e985a,TL,0.383384
uuid-30774d53b6644418bbc59ce02b1e985a,PDL1,0.408194
uuid-30774d53b6644418bbc59ce02b1e985a,Merck,0.313757
uuid-30774d53b6644418bbc59ce02b1e985a,PD-L1,0.580713
uuid-30774d53b6644418bbc59ce02b1e985a,PD-L1 testing,0.476866
uuid-30774d53b6644418bbc59ce02b1e985a,testing,0.492381
uuid-30774d53b6644418bbc59ce02b1e985a,indicated,0.373959
uuid-30774d53b6644418bbc59ce02b1e985a,Keytruda,0.398532
uuid-30774d53b6644418bbc59ce02b1e985a,assay,0.543343
uuid-30774d53b6644418bbc59ce02b1e985a,PDL1 expression,0.333817
uuid-30774d53b6644418bbc59ce02b1e985a,biomarker,0.306677
uuid-de5796a46b0341a6b991fcb0def42e99,TL,0.769921
uuid-de5796a46b0341a6b991fcb0def42e99,TL stated,0.329823
uuid-de5796a46b0341a6b991fcb0def42e99,Merck,0.30674
uuid-de5796a46b0341a6b991fcb0def42e99,institution,0.364009
uuid-de5796a46b0341a6b991fcb0def42e99,PD-L1,0.702165
uuid-de5796a46b0341a6b991fcb0def42e99,PD-L1 testing,0.822436
uuid-de5796a46b0341a6b991fcb0def42e99,testing,0.736263
uuid-de5796a46b0341a6b991fcb0def42e99,PDL1 testing,0.496314
uuid-de5796a46b0341a6b991fcb0def42e99,NSCLC patients,0.428717
uuid-de5796a46b0341a6b991fcb0def42e99,assay,0.858134
uuid-35e7fffaac2a41bdbb2f33fac4e02516,patients,0.44021
uuid-35e7fffaac2a41bdbb2f33fac4e02516,TL,0.351617
uuid-35e7fffaac2a41bdbb2f33fac4e02516,pembro,0.476721
uuid-35e7fffaac2a41bdbb2f33fac4e02516,therapy,0.341596
uuid-35e7fffaac2a41bdbb2f33fac4e02516,nivolumab,0.315444
uuid-35e7fffaac2a41bdbb2f33fac4e02516,1L,0.548192
uuid-35e7fffaac2a41bdbb2f33fac4e02516,RCC,0.34142
uuid-35e7fffaac2a41bdbb2f33fac4e02516,2L,0.556284
uuid-35e7fffaac2a41bdbb2f33fac4e02516,approval,0.631379
uuid-35e7fffaac2a41bdbb2f33fac4e02516,atezo,0.39346
uuid-35e7fffaac2a41bdbb2f33fac4e02516,preferred,0.489865
uuid-35e7fffaac2a41bdbb2f33fac4e02516,PD-L1 testing,0.393623
uuid-35e7fffaac2a41bdbb2f33fac4e02516,testing,0.405832
uuid-35e7fffaac2a41bdbb2f33fac4e02516,monotherapy,0.338737
uuid-35e7fffaac2a41bdbb2f33fac4e02516,using nivo,0.597609
uuid-35e7fffaac2a41bdbb2f33fac4e02516,PDL1 testing,0.41184
uuid-35e7fffaac2a41bdbb2f33fac4e02516,NSCLC patients,0.490194
uuid-35e7fffaac2a41bdbb2f33fac4e02516,approved,0.508339
uuid-35e7fffaac2a41bdbb2f33fac4e02516,SCCHN,0.326712
uuid-35e7fffaac2a41bdbb2f33fac4e02516,label,0.328125
uuid-35e7fffaac2a41bdbb2f33fac4e02516,RTL stated,0.426769
uuid-35e7fffaac2a41bdbb2f33fac4e02516,option,0.44249
uuid-35e7fffaac2a41bdbb2f33fac4e02516,bladder,0.33014
uuid-c4464fb4c21544ad9191f818db3972e9,preferred,0.332598
uuid-c4464fb4c21544ad9191f818db3972e9,using nivo,0.302698
uuid-c4464fb4c21544ad9191f818db3972e9,data,0.379849
uuid-c4464fb4c21544ad9191f818db3972e9,SCCHN,0.326108
uuid-c4464fb4c21544ad9191f818db3972e9,impressed,0.350452
uuid-c4464fb4c21544ad9191f818db3972e9,LTL,0.422119
uuid-c4464fb4c21544ad9191f818db3972e9,feels,0.503908
uuid-c4464fb4c21544ad9191f818db3972e9,RTL stated,0.309984
uuid-b8e2d87ea6fb498da131ae5540d0412a,patients,0.411237
uuid-b8e2d87ea6fb498da131ae5540d0412a,therapy,0.557383
uuid-b8e2d87ea6fb498da131ae5540d0412a,treated,0.306916
uuid-b8e2d87ea6fb498da131ae5540d0412a,chemo,0.333593
uuid-b8e2d87ea6fb498da131ae5540d0412a,treatment,0.382359
uuid-b8e2d87ea6fb498da131ae5540d0412a,PD1,0.341025
uuid-b8e2d87ea6fb498da131ae5540d0412a,cHL,0.409863
uuid-b8e2d87ea6fb498da131ae5540d0412a,progression,0.394899
uuid-b8e2d87ea6fb498da131ae5540d0412a,chemotherapy,0.4258
uuid-b8e2d87ea6fb498da131ae5540d0412a,option,0.331713
uuid-d84d008d13e04c5299434f86ef85a116,TL,0.538134
uuid-d84d008d13e04c5299434f86ef85a116,PDL1,0.388236
uuid-d84d008d13e04c5299434f86ef85a116,TL stated,0.365103
uuid-d84d008d13e04c5299434f86ef85a116,PD-L1,0.808429
uuid-d84d008d13e04c5299434f86ef85a116,PD-L1 testing,0.810646
uuid-d84d008d13e04c5299434f86ef85a116,testing,0.88457
uuid-d84d008d13e04c5299434f86ef85a116,PDL1 testing,0.660461
uuid-d84d008d13e04c5299434f86ef85a116,NSCLC patients,0.714859
uuid-d84d008d13e04c5299434f86ef85a116,assay,0.701775
uuid-d84d008d13e04c5299434f86ef85a116,biomarker,0.359702
uuid-15766d606c9548dcb687a88b33cf4155,PDL1,0.364426
uuid-15766d606c9548dcb687a88b33cf4155,combination,0.377201
uuid-15766d606c9548dcb687a88b33cf4155,chemo,0.537425
uuid-15766d606c9548dcb687a88b33cf4155,pts,0.50931
uuid-15766d606c9548dcb687a88b33cf4155,monotherapy,0.365507
uuid-15766d606c9548dcb687a88b33cf4155,response,0.439656
uuid-15766d606c9548dcb687a88b33cf4155,combo,0.381378
uuid-15766d606c9548dcb687a88b33cf4155,PD1,0.369226
uuid-15766d606c9548dcb687a88b33cf4155,progression,0.316968
uuid-15766d606c9548dcb687a88b33cf4155,believes,0.453982
uuid-15766d606c9548dcb687a88b33cf4155,chemotherapy,0.414115
uuid-15766d606c9548dcb687a88b33cf4155,respond,0.405159
uuid-15766d606c9548dcb687a88b33cf4155,feels,0.368731
uuid-15766d606c9548dcb687a88b33cf4155,immunotherapy,0.35017
uuid-15766d606c9548dcb687a88b33cf4155,PDL1 expression,0.370828
uuid-15766d606c9548dcb687a88b33cf4155,option,0.332628
uuid-15766d606c9548dcb687a88b33cf4155,biomarker,0.300592
uuid-c784276ce0624206bb55b68477ed92ae,patients,0.413166
uuid-c784276ce0624206bb55b68477ed92ae,therapy,0.630129
uuid-c784276ce0624206bb55b68477ed92ae,nivolumab,0.316815
uuid-c784276ce0624206bb55b68477ed92ae,regimen,0.418769
uuid-c784276ce0624206bb55b68477ed92ae,treated,0.407082
uuid-c784276ce0624206bb55b68477ed92ae,combination,0.369272
uuid-c784276ce0624206bb55b68477ed92ae,chemo,0.544779
uuid-c784276ce0624206bb55b68477ed92ae,pts,0.475129
uuid-c784276ce0624206bb55b68477ed92ae,IO,0.370116
uuid-c784276ce0624206bb55b68477ed92ae,monotherapy,0.325076
uuid-c784276ce0624206bb55b68477ed92ae,treatment,0.589436
uuid-c784276ce0624206bb55b68477ed92ae,response,0.817651
uuid-c784276ce0624206bb55b68477ed92ae,PD1,0.543499
uuid-c784276ce0624206bb55b68477ed92ae,progression,0.743038
uuid-c784276ce0624206bb55b68477ed92ae,chemotherapy,0.555796
uuid-c784276ce0624206bb55b68477ed92ae,respond,0.543361
uuid-c784276ce0624206bb55b68477ed92ae,immunotherapy,0.501433
uuid-3c32e28d36d34dd08c25b0feb9a89343,pembro,0.450521
uuid-3c32e28d36d34dd08c25b0feb9a89343,RTL,0.392386
uuid-3c32e28d36d34dd08c25b0feb9a89343,atezo,0.356425
uuid-3c32e28d36d34dd08c25b0feb9a89343,using nivo,0.331413
uuid-3c32e28d36d34dd08c25b0feb9a89343,data,0.446608
uuid-3c32e28d36d34dd08c25b0feb9a89343,mentioned,0.316077
uuid-3c32e28d36d34dd08c25b0feb9a89343,SCCHN,0.338489
uuid-3c32e28d36d34dd08c25b0feb9a89343,HCP,0.334341
uuid-3c32e28d36d34dd08c25b0feb9a89343,nivo and pembro,0.310254
uuid-3c32e28d36d34dd08c25b0feb9a89343,impressed,0.364597
uuid-3c32e28d36d34dd08c25b0feb9a89343,LTL,0.510171
uuid-3c32e28d36d34dd08c25b0feb9a89343,feels,0.353656
uuid-814f6ed5ff61476ca11f9960237925ba,shared,0.414775
uuid-814f6ed5ff61476ca11f9960237925ba,physicians,0.711294
uuid-814f6ed5ff61476ca11f9960237925ba,oncology,0.458335
uuid-814f6ed5ff61476ca11f9960237925ba,clinical,0.472234
uuid-814f6ed5ff61476ca11f9960237925ba,academic,0.368289
uuid-5847e1d525944ca886a67972bd35aa81,TL,0.300538
uuid-5847e1d525944ca886a67972bd35aa81,pembro,0.309543
uuid-5847e1d525944ca886a67972bd35aa81,1L,0.472249
uuid-5847e1d525944ca886a67972bd35aa81,shared,0.418218
uuid-5847e1d525944ca886a67972bd35aa81,RCC,0.339256
uuid-5847e1d525944ca886a67972bd35aa81,TL stated,0.380812
uuid-5847e1d525944ca886a67972bd35aa81,2L,0.460986
uuid-5847e1d525944ca886a67972bd35aa81,institution,0.359335
uuid-5847e1d525944ca886a67972bd35aa81,PD-L1,0.4995
uuid-5847e1d525944ca886a67972bd35aa81,approval,0.430017
uuid-5847e1d525944ca886a67972bd35aa81,atezo,0.377077
uuid-5847e1d525944ca886a67972bd35aa81,preferred,0.45913
uuid-5847e1d525944ca886a67972bd35aa81,PD-L1 testing,0.516529
uuid-5847e1d525944ca886a67972bd35aa81,testing,0.586763
uuid-5847e1d525944ca886a67972bd35aa81,using nivo,0.325717
uuid-5847e1d525944ca886a67972bd35aa81,PDL1 testing,0.627419
uuid-5847e1d525944ca886a67972bd35aa81,NSCLC patients,0.506462
uuid-5847e1d525944ca886a67972bd35aa81,approved,0.45211
uuid-5847e1d525944ca886a67972bd35aa81,SCCHN,0.395184
uuid-5847e1d525944ca886a67972bd35aa81,tumor types,0.328292
uuid-5847e1d525944ca886a67972bd35aa81,academic,0.379704
uuid-5847e1d525944ca886a67972bd35aa81,assay,0.335764
uuid-5847e1d525944ca886a67972bd35aa81,RTL stated,0.469495
uuid-69133a294b00440fad1e67d0e5abe3b4,pembro,0.350331
uuid-69133a294b00440fad1e67d0e5abe3b4,RTL,0.494083
uuid-69133a294b00440fad1e67d0e5abe3b4,1L,0.330049
uuid-69133a294b00440fad1e67d0e5abe3b4,trial,0.419634
uuid-69133a294b00440fad1e67d0e5abe3b4,melanoma,0.316878
uuid-69133a294b00440fad1e67d0e5abe3b4,shared,0.638628
uuid-69133a294b00440fad1e67d0e5abe3b4,commented,0.368815
uuid-69133a294b00440fad1e67d0e5abe3b4,RCC,0.467311
uuid-69133a294b00440fad1e67d0e5abe3b4,combination,0.369507
uuid-69133a294b00440fad1e67d0e5abe3b4,2L,0.41516
uuid-69133a294b00440fad1e67d0e5abe3b4,stated,0.441732
uuid-69133a294b00440fad1e67d0e5abe3b4,approval,0.35963
uuid-69133a294b00440fad1e67d0e5abe3b4,atezo,0.32736
uuid-69133a294b00440fad1e67d0e5abe3b4,preferred,0.440213
uuid-69133a294b00440fad1e67d0e5abe3b4,monotherapy,0.303729
uuid-69133a294b00440fad1e67d0e5abe3b4,using nivo,0.458193
uuid-69133a294b00440fad1e67d0e5abe3b4,combo,0.393649
uuid-69133a294b00440fad1e67d0e5abe3b4,clinical trials,0.535802
uuid-69133a294b00440fad1e67d0e5abe3b4,approved,0.381539
uuid-69133a294b00440fad1e67d0e5abe3b4,SCCHN,0.550167
uuid-69133a294b00440fad1e67d0e5abe3b4,impressed,0.3947
uuid-69133a294b00440fad1e67d0e5abe3b4,LTL,0.451026
uuid-69133a294b00440fad1e67d0e5abe3b4,TLs,0.392681
uuid-69133a294b00440fad1e67d0e5abe3b4,academic,0.410213
uuid-69133a294b00440fad1e67d0e5abe3b4,SCLC,0.334765
uuid-69133a294b00440fad1e67d0e5abe3b4,feels,0.410783
uuid-69133a294b00440fad1e67d0e5abe3b4,Regional TL,0.483811
uuid-69133a294b00440fad1e67d0e5abe3b4,RTL stated,0.568834
uuid-69133a294b00440fad1e67d0e5abe3b4,TL shared,0.327729
uuid-69133a294b00440fad1e67d0e5abe3b4,bladder,0.414258
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,Nivo,0.309432
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,patients,0.358891
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,1L,0.301827
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,toxicity,0.311362
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,regimen,0.38641
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,chemo,0.334019
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,2L,0.392992
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,agents,0.381367
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,preferred,0.706523
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,monotherapy,0.466403
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,treatment,0.359061
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,using nivo,0.402624
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,indication,0.305827
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,SCCHN,0.306402
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,chemotherapy,0.380676
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,RTL stated,0.425845
uuid-1546b53a1a1f4a21a3e97177cd68fdf1,option,0.567618
uuid-e9a94c44aedd44d88f01cef804008846,lung,0.380495
uuid-e9a94c44aedd44d88f01cef804008846,1L,0.30523
uuid-e9a94c44aedd44d88f01cef804008846,melanoma,0.328394
uuid-e9a94c44aedd44d88f01cef804008846,RCC,0.318448
uuid-e9a94c44aedd44d88f01cef804008846,2L,0.41735
uuid-e9a94c44aedd44d88f01cef804008846,institution,0.492561
uuid-e9a94c44aedd44d88f01cef804008846,preferred,0.364538
uuid-e9a94c44aedd44d88f01cef804008846,PDL1 testing,0.300501
uuid-e9a94c44aedd44d88f01cef804008846,AI,0.520911
uuid-e9a94c44aedd44d88f01cef804008846,oncology,0.333447
uuid-17d825a080d4443caa9d7683f707b5f0,Nivo,0.452914
uuid-17d825a080d4443caa9d7683f707b5f0,pembro,0.641111
uuid-17d825a080d4443caa9d7683f707b5f0,1L,0.474232
uuid-17d825a080d4443caa9d7683f707b5f0,PDL1,0.51754
uuid-17d825a080d4443caa9d7683f707b5f0,trial,0.396017
uuid-17d825a080d4443caa9d7683f707b5f0,efficacy,0.513219
uuid-17d825a080d4443caa9d7683f707b5f0,2L,0.405606
uuid-17d825a080d4443caa9d7683f707b5f0,approval,0.340393
uuid-17d825a080d4443caa9d7683f707b5f0,OS,0.492093
uuid-17d825a080d4443caa9d7683f707b5f0,atezo,0.580782
uuid-17d825a080d4443caa9d7683f707b5f0,using nivo,0.345346
uuid-17d825a080d4443caa9d7683f707b5f0,data,0.609517
uuid-17d825a080d4443caa9d7683f707b5f0,PFS,0.464056
uuid-17d825a080d4443caa9d7683f707b5f0,ORR,0.500726
uuid-17d825a080d4443caa9d7683f707b5f0,nivo and pembro,0.550911
uuid-17d825a080d4443caa9d7683f707b5f0,believes,0.314919
uuid-17d825a080d4443caa9d7683f707b5f0,impressed,0.483621
uuid-17d825a080d4443caa9d7683f707b5f0,vs,0.35725
uuid-17d825a080d4443caa9d7683f707b5f0,feels,0.385638
uuid-17d825a080d4443caa9d7683f707b5f0,PDL1 expression,0.440148
uuid-9624f1d26f6e48daa50d48572c112fba,patients,0.325699
uuid-9624f1d26f6e48daa50d48572c112fba,therapy,0.380124
uuid-9624f1d26f6e48daa50d48572c112fba,nivolumab,0.480057
uuid-9624f1d26f6e48daa50d48572c112fba,1L,0.356242
uuid-9624f1d26f6e48daa50d48572c112fba,treated,0.400654
uuid-9624f1d26f6e48daa50d48572c112fba,RCC,0.435093
uuid-9624f1d26f6e48daa50d48572c112fba,combination,0.31157
uuid-9624f1d26f6e48daa50d48572c112fba,chemo,0.306426
uuid-9624f1d26f6e48daa50d48572c112fba,2L,0.333541
uuid-9624f1d26f6e48daa50d48572c112fba,approval,0.312638
uuid-9624f1d26f6e48daa50d48572c112fba,preferred,0.570416
uuid-9624f1d26f6e48daa50d48572c112fba,monotherapy,0.384033
uuid-9624f1d26f6e48daa50d48572c112fba,treatment,0.325262
uuid-9624f1d26f6e48daa50d48572c112fba,using nivo,0.478083
uuid-9624f1d26f6e48daa50d48572c112fba,SCCHN,0.50489
uuid-9624f1d26f6e48daa50d48572c112fba,chemotherapy,0.406701
uuid-9624f1d26f6e48daa50d48572c112fba,RTL stated,0.565472
uuid-9624f1d26f6e48daa50d48572c112fba,TL shared,0.37742
uuid-9624f1d26f6e48daa50d48572c112fba,option,0.50933
uuid-9624f1d26f6e48daa50d48572c112fba,bladder,0.376965
uuid-eb4d4863cac04eb9813706bce2eddee7,Nivo,0.739855
uuid-eb4d4863cac04eb9813706bce2eddee7,pembro,0.674834
uuid-eb4d4863cac04eb9813706bce2eddee7,1L,0.449637
uuid-eb4d4863cac04eb9813706bce2eddee7,efficacy,0.365868
uuid-eb4d4863cac04eb9813706bce2eddee7,combination,0.303001
uuid-eb4d4863cac04eb9813706bce2eddee7,2L,0.565368
uuid-eb4d4863cac04eb9813706bce2eddee7,agents,0.414378
uuid-eb4d4863cac04eb9813706bce2eddee7,Ipi,0.368155
uuid-eb4d4863cac04eb9813706bce2eddee7,atezo,0.660721
uuid-eb4d4863cac04eb9813706bce2eddee7,preferred,0.574635
uuid-eb4d4863cac04eb9813706bce2eddee7,monotherapy,0.430176
uuid-eb4d4863cac04eb9813706bce2eddee7,using nivo,0.585754
uuid-eb4d4863cac04eb9813706bce2eddee7,indication,0.334273
uuid-eb4d4863cac04eb9813706bce2eddee7,approved,0.339095
uuid-eb4d4863cac04eb9813706bce2eddee7,nivo and pembro,0.443481
uuid-eb4d4863cac04eb9813706bce2eddee7,vs,0.478032
uuid-eb4d4863cac04eb9813706bce2eddee7,feels,0.50988
uuid-eb4d4863cac04eb9813706bce2eddee7,RTL stated,0.411881
uuid-eb4d4863cac04eb9813706bce2eddee7,option,0.451846
uuid-a33b3e5fcb4d480c87d50bedb2e12274,Nivo,0.399032
uuid-a33b3e5fcb4d480c87d50bedb2e12274,pembro,0.423859
uuid-a33b3e5fcb4d480c87d50bedb2e12274,dose,0.327404
uuid-a33b3e5fcb4d480c87d50bedb2e12274,nivolumab,0.302928
uuid-a33b3e5fcb4d480c87d50bedb2e12274,1L,0.502281
uuid-a33b3e5fcb4d480c87d50bedb2e12274,regimen,0.331936
uuid-a33b3e5fcb4d480c87d50bedb2e12274,RCC,0.430016
uuid-a33b3e5fcb4d480c87d50bedb2e12274,combination,0.657265
uuid-a33b3e5fcb4d480c87d50bedb2e12274,chemo,0.439867
uuid-a33b3e5fcb4d480c87d50bedb2e12274,2L,0.605848
uuid-a33b3e5fcb4d480c87d50bedb2e12274,IO,0.401975
uuid-a33b3e5fcb4d480c87d50bedb2e12274,agents,0.636085
uuid-a33b3e5fcb4d480c87d50bedb2e12274,Ipi,0.459116
uuid-a33b3e5fcb4d480c87d50bedb2e12274,atezo,0.531485
uuid-a33b3e5fcb4d480c87d50bedb2e12274,preferred,0.560043
uuid-a33b3e5fcb4d480c87d50bedb2e12274,monotherapy,0.58544
uuid-a33b3e5fcb4d480c87d50bedb2e12274,using nivo,0.38008
uuid-a33b3e5fcb4d480c87d50bedb2e12274,combo,0.678123
uuid-a33b3e5fcb4d480c87d50bedb2e12274,PD1,0.363519
uuid-a33b3e5fcb4d480c87d50bedb2e12274,approved,0.327188
uuid-a33b3e5fcb4d480c87d50bedb2e12274,believes,0.436058
uuid-a33b3e5fcb4d480c87d50bedb2e12274,chemotherapy,0.346097
uuid-a33b3e5fcb4d480c87d50bedb2e12274,vs,0.371448
uuid-a33b3e5fcb4d480c87d50bedb2e12274,TLs,0.314173
uuid-a33b3e5fcb4d480c87d50bedb2e12274,RTL stated,0.429449
uuid-a33b3e5fcb4d480c87d50bedb2e12274,option,0.447048
uuid-a33b3e5fcb4d480c87d50bedb2e12274,bladder,0.347204
uuid-7d7fba8a766545118fcfbb5857762d2f,nivolumab,0.307633
uuid-7d7fba8a766545118fcfbb5857762d2f,trial,0.655299
uuid-7d7fba8a766545118fcfbb5857762d2f,combination,0.490434
uuid-7d7fba8a766545118fcfbb5857762d2f,combo,0.322903
uuid-7d7fba8a766545118fcfbb5857762d2f,clinical trials,0.423651
uuid-7d7fba8a766545118fcfbb5857762d2f,chemotherapy,0.322281
uuid-7d7fba8a766545118fcfbb5857762d2f,bladder,0.334274
uuid-379408da63964473825ddcfe06aa8262,NSCLC,0.435016
uuid-379408da63964473825ddcfe06aa8262,trial,0.339842
uuid-379408da63964473825ddcfe06aa8262,combination,0.400124
uuid-379408da63964473825ddcfe06aa8262,chemo,0.301056
uuid-379408da63964473825ddcfe06aa8262,IO,0.584325
uuid-379408da63964473825ddcfe06aa8262,OS,0.323182
uuid-379408da63964473825ddcfe06aa8262,combo,0.419565
uuid-379408da63964473825ddcfe06aa8262,PFS,0.330672
uuid-379408da63964473825ddcfe06aa8262,ORR,0.329151
uuid-379408da63964473825ddcfe06aa8262,believes,0.391041
uuid-566ae8db112649e69b6634b55fcc6b39,patients,0.787616
uuid-566ae8db112649e69b6634b55fcc6b39,Opdivo,0.69273
uuid-566ae8db112649e69b6634b55fcc6b39,therapy,0.402506
uuid-566ae8db112649e69b6634b55fcc6b39,nivolumab,0.554099
uuid-566ae8db112649e69b6634b55fcc6b39,regimen,0.332945
uuid-566ae8db112649e69b6634b55fcc6b39,treated,0.505203
uuid-566ae8db112649e69b6634b55fcc6b39,pts,0.470348
uuid-566ae8db112649e69b6634b55fcc6b39,approval,0.418159
uuid-566ae8db112649e69b6634b55fcc6b39,treatment,0.503843
uuid-566ae8db112649e69b6634b55fcc6b39,using nivo,0.466123
uuid-566ae8db112649e69b6634b55fcc6b39,approved,0.365355
uuid-566ae8db112649e69b6634b55fcc6b39,cHL,0.357655
uuid-566ae8db112649e69b6634b55fcc6b39,progression,0.416742
uuid-566ae8db112649e69b6634b55fcc6b39,RTL stated,0.356706
uuid-566ae8db112649e69b6634b55fcc6b39,option,0.308697
uuid-692a753127dd4ffc9bb86d69e89ceeaf,patients,0.360408
uuid-692a753127dd4ffc9bb86d69e89ceeaf,pembro,0.304729
uuid-692a753127dd4ffc9bb86d69e89ceeaf,1L,0.579777
uuid-692a753127dd4ffc9bb86d69e89ceeaf,PDL1,0.408565
uuid-692a753127dd4ffc9bb86d69e89ceeaf,regimen,0.308899
uuid-692a753127dd4ffc9bb86d69e89ceeaf,chemo,0.465752
uuid-692a753127dd4ffc9bb86d69e89ceeaf,2L,0.489202
uuid-692a753127dd4ffc9bb86d69e89ceeaf,pts,0.437532
uuid-692a753127dd4ffc9bb86d69e89ceeaf,agents,0.322366
uuid-692a753127dd4ffc9bb86d69e89ceeaf,PD-L1,0.340904
uuid-692a753127dd4ffc9bb86d69e89ceeaf,atezo,0.307445
uuid-692a753127dd4ffc9bb86d69e89ceeaf,preferred,0.376053
uuid-692a753127dd4ffc9bb86d69e89ceeaf,monotherapy,0.557971
uuid-692a753127dd4ffc9bb86d69e89ceeaf,combo,0.453445
uuid-692a753127dd4ffc9bb86d69e89ceeaf,PDL1 testing,0.310938
uuid-692a753127dd4ffc9bb86d69e89ceeaf,NSCLC patients,0.430179
uuid-692a753127dd4ffc9bb86d69e89ceeaf,PD1,0.4307
uuid-692a753127dd4ffc9bb86d69e89ceeaf,progression,0.390239
uuid-692a753127dd4ffc9bb86d69e89ceeaf,believes,0.457781
uuid-692a753127dd4ffc9bb86d69e89ceeaf,chemotherapy,0.368212
uuid-692a753127dd4ffc9bb86d69e89ceeaf,feels,0.459946
uuid-692a753127dd4ffc9bb86d69e89ceeaf,option,0.521664
uuid-692a753127dd4ffc9bb86d69e89ceeaf,biomarker,0.324117
uuid-c21f524e44a6429e92878e4fed08481d,dose,0.334889
uuid-c21f524e44a6429e92878e4fed08481d,toxicity,0.68075
uuid-c21f524e44a6429e92878e4fed08481d,efficacy,0.444713
uuid-c21f524e44a6429e92878e4fed08481d,regimen,0.653974
uuid-c21f524e44a6429e92878e4fed08481d,combination,0.308896
uuid-c21f524e44a6429e92878e4fed08481d,Ipi,0.307995
uuid-c21f524e44a6429e92878e4fed08481d,physicians,0.313973
uuid-c21f524e44a6429e92878e4fed08481d,treatment,0.324799
uuid-c21f524e44a6429e92878e4fed08481d,combo,0.333174
uuid-c21f524e44a6429e92878e4fed08481d,believes,0.300928
uuid-c21f524e44a6429e92878e4fed08481d,respond,0.328178
uuid-c21f524e44a6429e92878e4fed08481d,feels,0.346152
uuid-f9fb6cc74e034d36a997ceb8055e92ab,efficacy,0.374839
uuid-f9fb6cc74e034d36a997ceb8055e92ab,regimen,0.464952
uuid-f9fb6cc74e034d36a997ceb8055e92ab,combination,0.382141
uuid-f9fb6cc74e034d36a997ceb8055e92ab,chemo,0.342432
uuid-f9fb6cc74e034d36a997ceb8055e92ab,IO,0.340074
uuid-f9fb6cc74e034d36a997ceb8055e92ab,OS,0.357668
uuid-f9fb6cc74e034d36a997ceb8055e92ab,monotherapy,0.38431
uuid-f9fb6cc74e034d36a997ceb8055e92ab,response,0.346759
uuid-f9fb6cc74e034d36a997ceb8055e92ab,data,0.421977
uuid-f9fb6cc74e034d36a997ceb8055e92ab,combo,0.403965
uuid-f9fb6cc74e034d36a997ceb8055e92ab,PFS,0.316034
uuid-f9fb6cc74e034d36a997ceb8055e92ab,PD1,0.361811
uuid-f9fb6cc74e034d36a997ceb8055e92ab,ORR,0.354044
uuid-f9fb6cc74e034d36a997ceb8055e92ab,progression,0.387463
uuid-f9fb6cc74e034d36a997ceb8055e92ab,believes,0.36836
uuid-f9fb6cc74e034d36a997ceb8055e92ab,chemotherapy,0.325933
uuid-f9fb6cc74e034d36a997ceb8055e92ab,impressed,0.450925
uuid-f9fb6cc74e034d36a997ceb8055e92ab,respond,0.326086
uuid-f9fb6cc74e034d36a997ceb8055e92ab,feels,0.62148
uuid-656613c0caf94ef39fdc072b09fcbf5b,PDL1,0.490848
uuid-656613c0caf94ef39fdc072b09fcbf5b,Merck,0.426227
uuid-656613c0caf94ef39fdc072b09fcbf5b,PD-L1,0.503021
uuid-656613c0caf94ef39fdc072b09fcbf5b,PD-L1 testing,0.35336
uuid-656613c0caf94ef39fdc072b09fcbf5b,testing,0.49504
uuid-656613c0caf94ef39fdc072b09fcbf5b,PDL1 testing,0.368756
uuid-656613c0caf94ef39fdc072b09fcbf5b,assay,0.539604
uuid-656613c0caf94ef39fdc072b09fcbf5b,PDL1 expression,0.348888
uuid-656613c0caf94ef39fdc072b09fcbf5b,biomarker,0.413257
uuid-efa2e6edbca749ae9f6a623de42a987f,Nivo,0.319814
uuid-efa2e6edbca749ae9f6a623de42a987f,Opdivo,0.374556
uuid-efa2e6edbca749ae9f6a623de42a987f,dose,0.905338
uuid-efa2e6edbca749ae9f6a623de42a987f,toxicity,0.543299
uuid-efa2e6edbca749ae9f6a623de42a987f,regimen,0.460637
uuid-efa2e6edbca749ae9f6a623de42a987f,Ipi,0.56229
uuid-efa2e6edbca749ae9f6a623de42a987f,treatment,0.304774
uuid-efa2e6edbca749ae9f6a623de42a987f,vs,0.544424
uuid-efa2e6edbca749ae9f6a623de42a987f,flat dosing,0.574403
uuid-1bdd33e163e74eecb55f4cda7e36c934,TL,0.571924
uuid-1bdd33e163e74eecb55f4cda7e36c934,RTL,0.326456
uuid-1bdd33e163e74eecb55f4cda7e36c934,lung,0.313371
uuid-1bdd33e163e74eecb55f4cda7e36c934,commented,0.385043
uuid-1bdd33e163e74eecb55f4cda7e36c934,TL stated,0.461717
uuid-1bdd33e163e74eecb55f4cda7e36c934,PD-L1,0.333961
uuid-1bdd33e163e74eecb55f4cda7e36c934,PD-L1 testing,0.439081
uuid-1bdd33e163e74eecb55f4cda7e36c934,testing,0.381411
uuid-1bdd33e163e74eecb55f4cda7e36c934,PDL1 testing,0.319806
uuid-1bdd33e163e74eecb55f4cda7e36c934,SCCHN,0.342161
uuid-1bdd33e163e74eecb55f4cda7e36c934,assay,0.429409
uuid-1bdd33e163e74eecb55f4cda7e36c934,Regional TL,0.358259
uuid-1bdd33e163e74eecb55f4cda7e36c934,TL shared,0.383496
uuid-4637c19a74594e7bb6665970806fb506,patients,0.491879
uuid-4637c19a74594e7bb6665970806fb506,1L,0.359873
uuid-4637c19a74594e7bb6665970806fb506,treated,0.331691
uuid-4637c19a74594e7bb6665970806fb506,RCC,0.309397
uuid-4637c19a74594e7bb6665970806fb506,TL stated,0.475242
uuid-4637c19a74594e7bb6665970806fb506,2L,0.332783
uuid-4637c19a74594e7bb6665970806fb506,PD-L1,0.371822
uuid-4637c19a74594e7bb6665970806fb506,preferred,0.369258
uuid-4637c19a74594e7bb6665970806fb506,PD-L1 testing,0.462257
uuid-4637c19a74594e7bb6665970806fb506,testing,0.58754
uuid-4637c19a74594e7bb6665970806fb506,treatment,0.331364
uuid-4637c19a74594e7bb6665970806fb506,using nivo,0.353833
uuid-4637c19a74594e7bb6665970806fb506,PDL1 testing,0.667142
uuid-4637c19a74594e7bb6665970806fb506,NSCLC patients,0.725976
uuid-4637c19a74594e7bb6665970806fb506,SCCHN,0.392839
uuid-4637c19a74594e7bb6665970806fb506,tumor types,0.419427
uuid-4637c19a74594e7bb6665970806fb506,RTL stated,0.385385
uuid-eae31ebcd13b4826922937d9fed4e5ab,patients,0.541764
uuid-eae31ebcd13b4826922937d9fed4e5ab,therapy,0.395942
uuid-eae31ebcd13b4826922937d9fed4e5ab,nivolumab,0.483946
uuid-eae31ebcd13b4826922937d9fed4e5ab,toxicity,0.550399
uuid-eae31ebcd13b4826922937d9fed4e5ab,regimen,0.598137
uuid-eae31ebcd13b4826922937d9fed4e5ab,treated,0.424991
uuid-eae31ebcd13b4826922937d9fed4e5ab,combination,0.47316
uuid-eae31ebcd13b4826922937d9fed4e5ab,chemo,0.359021
uuid-eae31ebcd13b4826922937d9fed4e5ab,pts,0.380379
uuid-eae31ebcd13b4826922937d9fed4e5ab,Ipi,0.311265
uuid-eae31ebcd13b4826922937d9fed4e5ab,monotherapy,0.407013
uuid-eae31ebcd13b4826922937d9fed4e5ab,treatment,0.515073
uuid-eae31ebcd13b4826922937d9fed4e5ab,combo,0.398404
uuid-eae31ebcd13b4826922937d9fed4e5ab,PD1,0.340439
uuid-eae31ebcd13b4826922937d9fed4e5ab,progression,0.424369
uuid-eae31ebcd13b4826922937d9fed4e5ab,chemotherapy,0.440091
uuid-eae31ebcd13b4826922937d9fed4e5ab,respond,0.386294
uuid-a231f6662af64801a6b4422791dd38a9,Nivo,0.337986
uuid-a231f6662af64801a6b4422791dd38a9,pembro,0.579436
uuid-a231f6662af64801a6b4422791dd38a9,dose,0.740288
uuid-a231f6662af64801a6b4422791dd38a9,trial,0.31071
uuid-a231f6662af64801a6b4422791dd38a9,efficacy,0.581386
uuid-a231f6662af64801a6b4422791dd38a9,Ipi,0.498591
uuid-a231f6662af64801a6b4422791dd38a9,atezo,0.50811
uuid-a231f6662af64801a6b4422791dd38a9,nivo and pembro,0.336663
uuid-a231f6662af64801a6b4422791dd38a9,vs,0.806673
uuid-a231f6662af64801a6b4422791dd38a9,flat dosing,0.59593
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,patients,0.523267
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,Opdivo,0.336735
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,regimen,0.319478
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,treated,0.547656
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,shared,0.356745
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,physicians,0.462721
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,treatment,0.415903
uuid-0e98c3b46f5a48a2bd6ec791ea278f82,clinical trials,0.335936
uuid-97754c1a13974d7da42f62d070add37a,patients,0.78375
uuid-97754c1a13974d7da42f62d070add37a,therapy,0.523249
uuid-97754c1a13974d7da42f62d070add37a,nivolumab,0.519264
uuid-97754c1a13974d7da42f62d070add37a,regimen,0.564401
uuid-97754c1a13974d7da42f62d070add37a,treated,0.602767
uuid-97754c1a13974d7da42f62d070add37a,RCC,0.322215
uuid-97754c1a13974d7da42f62d070add37a,combination,0.394918
uuid-97754c1a13974d7da42f62d070add37a,chemo,0.406178
uuid-97754c1a13974d7da42f62d070add37a,pts,0.650125
uuid-97754c1a13974d7da42f62d070add37a,IO,0.356923
uuid-97754c1a13974d7da42f62d070add37a,monotherapy,0.510384
uuid-97754c1a13974d7da42f62d070add37a,treatment,0.580588
uuid-97754c1a13974d7da42f62d070add37a,using nivo,0.358773
uuid-97754c1a13974d7da42f62d070add37a,response,0.475772
uuid-97754c1a13974d7da42f62d070add37a,combo,0.410859
uuid-97754c1a13974d7da42f62d070add37a,PD1,0.426913
uuid-97754c1a13974d7da42f62d070add37a,progression,0.697287
uuid-97754c1a13974d7da42f62d070add37a,chemotherapy,0.435158
uuid-97754c1a13974d7da42f62d070add37a,respond,0.446678
uuid-97754c1a13974d7da42f62d070add37a,RTL stated,0.342699
uuid-97754c1a13974d7da42f62d070add37a,TL shared,0.333857
uuid-97754c1a13974d7da42f62d070add37a,option,0.403153
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,patients,0.474828
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,Opdivo,0.303596
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,therapy,0.443121
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,nivolumab,0.569036
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,1L,0.401916
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,treated,0.364474
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,RCC,0.354891
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,combination,0.314957
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,2L,0.447261
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,approval,0.434214
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,preferred,0.629585
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,monotherapy,0.468735
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,treatment,0.38191
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,using nivo,0.540155
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,approved,0.507603
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,SCCHN,0.371903
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,chemotherapy,0.370889
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,tumor types,0.305705
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,label,0.31827
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,RTL stated,0.526776
uuid-2cf5d3efcf4645f382ba0dd950b5d24f,option,0.5993
uuid-df357ba26d424f5784eba3d6c75c6cb2,Nivo,0.550037
uuid-df357ba26d424f5784eba3d6c75c6cb2,pembro,0.706424
uuid-df357ba26d424f5784eba3d6c75c6cb2,dose,0.715616
uuid-df357ba26d424f5784eba3d6c75c6cb2,trial,0.331169
uuid-df357ba26d424f5784eba3d6c75c6cb2,efficacy,0.483709
uuid-df357ba26d424f5784eba3d6c75c6cb2,Ipi,0.555063
uuid-df357ba26d424f5784eba3d6c75c6cb2,atezo,0.585252
uuid-df357ba26d424f5784eba3d6c75c6cb2,preferred,0.340413
uuid-df357ba26d424f5784eba3d6c75c6cb2,nivo and pembro,0.308027
uuid-df357ba26d424f5784eba3d6c75c6cb2,vs,0.802545
uuid-df357ba26d424f5784eba3d6c75c6cb2,flat dosing,0.50177
uuid-fa380ec9691d4ce1893884dff1b8f408,Nivo,0.334238
uuid-fa380ec9691d4ce1893884dff1b8f408,therapy,0.328573
uuid-fa380ec9691d4ce1893884dff1b8f408,toxicity,0.46024
uuid-fa380ec9691d4ce1893884dff1b8f408,efficacy,0.39624
uuid-fa380ec9691d4ce1893884dff1b8f408,regimen,0.590598
uuid-fa380ec9691d4ce1893884dff1b8f408,combination,0.49045
uuid-fa380ec9691d4ce1893884dff1b8f408,chemo,0.537365
uuid-fa380ec9691d4ce1893884dff1b8f408,pts,0.324656
uuid-fa380ec9691d4ce1893884dff1b8f408,IO,0.362706
uuid-fa380ec9691d4ce1893884dff1b8f408,Ipi,0.393743
uuid-fa380ec9691d4ce1893884dff1b8f408,OS,0.308531
uuid-fa380ec9691d4ce1893884dff1b8f408,monotherapy,0.547699
uuid-fa380ec9691d4ce1893884dff1b8f408,treatment,0.307047
uuid-fa380ec9691d4ce1893884dff1b8f408,response,0.425595
uuid-fa380ec9691d4ce1893884dff1b8f408,combo,0.50013
uuid-fa380ec9691d4ce1893884dff1b8f408,PD1,0.452098
uuid-fa380ec9691d4ce1893884dff1b8f408,ORR,0.302114
uuid-fa380ec9691d4ce1893884dff1b8f408,progression,0.419155
uuid-fa380ec9691d4ce1893884dff1b8f408,believes,0.446766
uuid-fa380ec9691d4ce1893884dff1b8f408,chemotherapy,0.477003
uuid-fa380ec9691d4ce1893884dff1b8f408,impressed,0.341911
uuid-fa380ec9691d4ce1893884dff1b8f408,respond,0.340792
uuid-fa380ec9691d4ce1893884dff1b8f408,feels,0.410994
uuid-fa380ec9691d4ce1893884dff1b8f408,option,0.335509
uuid-43519990e3604bda8170814a505dfae6,TL,0.368392
uuid-43519990e3604bda8170814a505dfae6,pembro,0.400661
uuid-43519990e3604bda8170814a505dfae6,1L,0.372298
uuid-43519990e3604bda8170814a505dfae6,PDL1,0.555583
uuid-43519990e3604bda8170814a505dfae6,TL stated,0.325476
uuid-43519990e3604bda8170814a505dfae6,Merck,0.338898
uuid-43519990e3604bda8170814a505dfae6,PD-L1,0.763104
uuid-43519990e3604bda8170814a505dfae6,atezo,0.406518
uuid-43519990e3604bda8170814a505dfae6,PD-L1 testing,0.711776
uuid-43519990e3604bda8170814a505dfae6,testing,0.85143
uuid-43519990e3604bda8170814a505dfae6,PDL1 testing,0.661434
uuid-43519990e3604bda8170814a505dfae6,NSCLC patients,0.674135
uuid-43519990e3604bda8170814a505dfae6,assay,0.641553
uuid-43519990e3604bda8170814a505dfae6,PDL1 expression,0.390387
uuid-43519990e3604bda8170814a505dfae6,biomarker,0.439911
uuid-ce5497633a514778922a7f3bf714c0b7,RTL,0.475153
uuid-ce5497633a514778922a7f3bf714c0b7,nivolumab,0.378857
uuid-ce5497633a514778922a7f3bf714c0b7,trial,0.406789
uuid-ce5497633a514778922a7f3bf714c0b7,NTL,0.44203
uuid-ce5497633a514778922a7f3bf714c0b7,commented,0.306977
uuid-ce5497633a514778922a7f3bf714c0b7,stated,0.347923
uuid-ce5497633a514778922a7f3bf714c0b7,approval,0.337635
uuid-ce5497633a514778922a7f3bf714c0b7,preferred,0.364322
uuid-ce5497633a514778922a7f3bf714c0b7,using nivo,0.432862
uuid-ce5497633a514778922a7f3bf714c0b7,mentioned,0.494918
uuid-ce5497633a514778922a7f3bf714c0b7,clinical trials,0.421308
uuid-ce5497633a514778922a7f3bf714c0b7,indication,0.384155
uuid-ce5497633a514778922a7f3bf714c0b7,SCCHN,0.498894
uuid-ce5497633a514778922a7f3bf714c0b7,HCP,0.309118
uuid-ce5497633a514778922a7f3bf714c0b7,LTL,0.410462
uuid-ce5497633a514778922a7f3bf714c0b7,SCLC,0.305562
uuid-ce5497633a514778922a7f3bf714c0b7,Regional TL,0.478409
uuid-ce5497633a514778922a7f3bf714c0b7,RTL stated,0.434379
uuid-ce5497633a514778922a7f3bf714c0b7,bladder,0.406469
uuid-3f5cb4b240414243859ae4d05254e1ea,patients,0.398298
uuid-3f5cb4b240414243859ae4d05254e1ea,Opdivo,0.541852
uuid-3f5cb4b240414243859ae4d05254e1ea,lung cancer,0.490813
uuid-3f5cb4b240414243859ae4d05254e1ea,flat dosing,0.377481
uuid-088322d6b0ba4287894edf1073594e68,response,0.323538
uuid-088322d6b0ba4287894edf1073594e68,progression,0.353368
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,pembro,0.434334
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,1L,0.541247
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,RCC,0.398322
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,2L,0.65265
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,agents,0.36894
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,approval,0.321054
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,atezo,0.504534
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,preferred,0.732811
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,monotherapy,0.365554
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,using nivo,0.538532
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,PDL1 testing,0.396738
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,indication,0.418252
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,approved,0.403267
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,SCCHN,0.462076
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,RTL stated,0.570387
uuid-f50edfbb2e1f4fdbb1a4db957f956e53,option,0.493402
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,patients,0.437816
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,Opdivo,0.486866
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,dose,0.703835
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,toxicity,0.369504
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,regimen,0.348067
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,treated,0.381722
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,Ipi,0.338943
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,vs,0.408265
uuid-e9ef5c94d1fe4735b2e5b82661af0be4,flat dosing,0.61531
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,pembro,0.424253
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,BMS,0.317799
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,PDL1,0.707081
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,efficacy,0.411565
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,Merck,0.436622
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,PD-L1,0.478696
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,OS,0.376849
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,atezo,0.452287
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,testing,0.315723
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,data,0.569917
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,PFS,0.381722
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,ORR,0.365186
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,nivo and pembro,0.677027
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,believes,0.399607
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,assay,0.586024
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,PDL1 expression,0.545096
uuid-482dc0c8dad445e5a2c1cf6e74debcd6,biomarker,0.401817
uuid-4c5583d78aa1484a82853763e5687387,TL,0.432166
uuid-4c5583d78aa1484a82853763e5687387,PDL1,0.55566
uuid-4c5583d78aa1484a82853763e5687387,Merck,0.526452
uuid-4c5583d78aa1484a82853763e5687387,PD-L1,0.610341
uuid-4c5583d78aa1484a82853763e5687387,PD-L1 testing,0.47106
uuid-4c5583d78aa1484a82853763e5687387,testing,0.540282
uuid-4c5583d78aa1484a82853763e5687387,data,0.40314
uuid-4c5583d78aa1484a82853763e5687387,PDL1 testing,0.312115
uuid-4c5583d78aa1484a82853763e5687387,nivo and pembro,0.349247
uuid-4c5583d78aa1484a82853763e5687387,assay,0.781608
uuid-4c5583d78aa1484a82853763e5687387,PDL1 expression,0.419048
uuid-4c5583d78aa1484a82853763e5687387,biomarker,0.44648
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,patients,0.772561
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,Opdivo,0.375276
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,therapy,0.37338
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,nivolumab,0.396716
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,1L,0.343353
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,regimen,0.483037
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,treated,0.424938
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,chemo,0.310565
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,2L,0.381348
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,pts,0.511746
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,approval,0.312804
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,preferred,0.369209
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,monotherapy,0.422686
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,treatment,0.519483
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,using nivo,0.439904
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,approved,0.358391
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,progression,0.510337
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,respond,0.342468
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,RTL stated,0.303775
uuid-c75c1190a8ba4d43ac4986fe3e0447d6,option,0.479452
uuid-b87e983beb384c0e9145abdda47cb863,TL,0.316106
uuid-b87e983beb384c0e9145abdda47cb863,RTL,0.328664
uuid-b87e983beb384c0e9145abdda47cb863,treated,0.442021
uuid-b87e983beb384c0e9145abdda47cb863,physicians,0.443914
uuid-b87e983beb384c0e9145abdda47cb863,oncologist,0.329495
uuid-b87e983beb384c0e9145abdda47cb863,academic,0.43211
uuid-b87e983beb384c0e9145abdda47cb863,Regional TL,0.374163
uuid-b87e983beb384c0e9145abdda47cb863,flat dosing,0.312557
uuid-6d24c1ad55954e4bbe572c635aff61f0,therapy,0.377207
uuid-6d24c1ad55954e4bbe572c635aff61f0,nivolumab,0.314689
uuid-6d24c1ad55954e4bbe572c635aff61f0,mentioned,0.532355
uuid-6d24c1ad55954e4bbe572c635aff61f0,cHL,0.636287
uuid-dfa9350c2907441aaeb5e2917f8f6256,Nivo,0.324895
uuid-dfa9350c2907441aaeb5e2917f8f6256,patients,0.855525
uuid-dfa9350c2907441aaeb5e2917f8f6256,Opdivo,0.338561
uuid-dfa9350c2907441aaeb5e2917f8f6256,therapy,0.651702
uuid-dfa9350c2907441aaeb5e2917f8f6256,nivolumab,0.410871
uuid-dfa9350c2907441aaeb5e2917f8f6256,toxicity,0.501974
uuid-dfa9350c2907441aaeb5e2917f8f6256,regimen,0.608109
uuid-dfa9350c2907441aaeb5e2917f8f6256,treated,0.496616
uuid-dfa9350c2907441aaeb5e2917f8f6256,combination,0.338554
uuid-dfa9350c2907441aaeb5e2917f8f6256,chemo,0.561807
uuid-dfa9350c2907441aaeb5e2917f8f6256,pts,0.540772
uuid-dfa9350c2907441aaeb5e2917f8f6256,monotherapy,0.505078
uuid-dfa9350c2907441aaeb5e2917f8f6256,treatment,0.70946
uuid-dfa9350c2907441aaeb5e2917f8f6256,response,0.428378
uuid-dfa9350c2907441aaeb5e2917f8f6256,PD1,0.407374
uuid-dfa9350c2907441aaeb5e2917f8f6256,progression,0.675946
uuid-dfa9350c2907441aaeb5e2917f8f6256,chemotherapy,0.596454
uuid-dfa9350c2907441aaeb5e2917f8f6256,respond,0.476554
uuid-dfa9350c2907441aaeb5e2917f8f6256,option,0.468064
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,Opdivo,0.511015
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,physicians,0.639626
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,oncology,0.461585
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,drug,0.488524
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,clinical,0.352177
uuid-ba8ae3a6ac2d4f4087c0c77fc056bdb9,flat dosing,0.347252
uuid-7fc382ba716f4f1ea8d6b125ab859152,TL,0.762468
uuid-7fc382ba716f4f1ea8d6b125ab859152,TL stated,0.401182
uuid-7fc382ba716f4f1ea8d6b125ab859152,institution,0.384335
uuid-7fc382ba716f4f1ea8d6b125ab859152,PD-L1,0.565943
uuid-7fc382ba716f4f1ea8d6b125ab859152,PD-L1 testing,0.889642
uuid-7fc382ba716f4f1ea8d6b125ab859152,testing,0.708356
uuid-7fc382ba716f4f1ea8d6b125ab859152,PDL1 testing,0.556448
uuid-7fc382ba716f4f1ea8d6b125ab859152,NSCLC patients,0.453233
uuid-7fc382ba716f4f1ea8d6b125ab859152,assay,0.602542
uuid-c31062c82f214902a9ac53998f59bdd8,TL,0.673455
uuid-c31062c82f214902a9ac53998f59bdd8,TL stated,0.3924
uuid-c31062c82f214902a9ac53998f59bdd8,institution,0.363925
uuid-c31062c82f214902a9ac53998f59bdd8,PD-L1,0.735108
uuid-c31062c82f214902a9ac53998f59bdd8,PD-L1 testing,0.929512
uuid-c31062c82f214902a9ac53998f59bdd8,testing,0.853244
uuid-c31062c82f214902a9ac53998f59bdd8,PDL1 testing,0.665879
uuid-c31062c82f214902a9ac53998f59bdd8,NSCLC patients,0.562739
uuid-c31062c82f214902a9ac53998f59bdd8,assay,0.688792
uuid-c31062c82f214902a9ac53998f59bdd8,biomarker,0.331069
uuid-c43e58824be945dc8d59f28994b950ab,TL,0.554587
uuid-c43e58824be945dc8d59f28994b950ab,PDL1,0.374237
uuid-c43e58824be945dc8d59f28994b950ab,TL stated,0.475931
uuid-c43e58824be945dc8d59f28994b950ab,PD-L1,0.798339
uuid-c43e58824be945dc8d59f28994b950ab,PD-L1 testing,0.783018
uuid-c43e58824be945dc8d59f28994b950ab,testing,0.91754
uuid-c43e58824be945dc8d59f28994b950ab,PDL1 testing,0.76763
uuid-c43e58824be945dc8d59f28994b950ab,NSCLC patients,0.763728
uuid-c43e58824be945dc8d59f28994b950ab,assay,0.676582
uuid-c43e58824be945dc8d59f28994b950ab,PD-1,0.340375
uuid-c43e58824be945dc8d59f28994b950ab,biomarker,0.442029
uuid-dfcd050054294585b3369e87d7bf0c68,Nivo,0.447877
uuid-dfcd050054294585b3369e87d7bf0c68,patients,0.450049
uuid-dfcd050054294585b3369e87d7bf0c68,therapy,0.317471
uuid-dfcd050054294585b3369e87d7bf0c68,nivolumab,0.378842
uuid-dfcd050054294585b3369e87d7bf0c68,trial,0.396873
uuid-dfcd050054294585b3369e87d7bf0c68,approval,0.512311
uuid-dfcd050054294585b3369e87d7bf0c68,clinical trials,0.342114
uuid-dfcd050054294585b3369e87d7bf0c68,indication,0.433996
uuid-dfcd050054294585b3369e87d7bf0c68,approved,0.485417
uuid-dfcd050054294585b3369e87d7bf0c68,chemotherapy,0.385651
uuid-dfcd050054294585b3369e87d7bf0c68,label,0.41601
uuid-dfcd050054294585b3369e87d7bf0c68,SCLC,0.378361
uuid-dfcd050054294585b3369e87d7bf0c68,option,0.354814
uuid-a1dc0f23f57647109fd108d4ef5c4f63,TL,0.634986
uuid-a1dc0f23f57647109fd108d4ef5c4f63,PDL1,0.313247
uuid-a1dc0f23f57647109fd108d4ef5c4f63,TL stated,0.313328
uuid-a1dc0f23f57647109fd108d4ef5c4f63,Merck,0.31596
uuid-a1dc0f23f57647109fd108d4ef5c4f63,institution,0.470103
uuid-a1dc0f23f57647109fd108d4ef5c4f63,PD-L1,0.750718
uuid-a1dc0f23f57647109fd108d4ef5c4f63,PD-L1 testing,0.885502
uuid-a1dc0f23f57647109fd108d4ef5c4f63,testing,0.827689
uuid-a1dc0f23f57647109fd108d4ef5c4f63,PDL1 testing,0.566848
uuid-a1dc0f23f57647109fd108d4ef5c4f63,NSCLC patients,0.513186
uuid-a1dc0f23f57647109fd108d4ef5c4f63,assay,0.859976
uuid-c4f54c346af84cf4a01c58e3ff749e84,TL,0.673176
uuid-c4f54c346af84cf4a01c58e3ff749e84,TL stated,0.40441
uuid-c4f54c346af84cf4a01c58e3ff749e84,institution,0.42118
uuid-c4f54c346af84cf4a01c58e3ff749e84,PD-L1,0.67932
uuid-c4f54c346af84cf4a01c58e3ff749e84,PD-L1 testing,0.907829
uuid-c4f54c346af84cf4a01c58e3ff749e84,testing,0.764474
uuid-c4f54c346af84cf4a01c58e3ff749e84,PDL1 testing,0.586692
uuid-c4f54c346af84cf4a01c58e3ff749e84,NSCLC patients,0.453481
uuid-c4f54c346af84cf4a01c58e3ff749e84,assay,0.689774
uuid-c4f54c346af84cf4a01c58e3ff749e84,biomarker,0.318937
uuid-3ea96ac3991f41d883969fceccfda17d,agents,0.324108
uuid-3ea96ac3991f41d883969fceccfda17d,physicians,0.514084
uuid-3ea96ac3991f41d883969fceccfda17d,preferred,0.346246
uuid-3ea96ac3991f41d883969fceccfda17d,TLs,0.314537
uuid-1e4b71dd524c4f3ebf77eb33d498760c,BMS,0.674723
uuid-1e4b71dd524c4f3ebf77eb33d498760c,shared,0.339735
uuid-1e4b71dd524c4f3ebf77eb33d498760c,Merck,0.50613
uuid-1e4b71dd524c4f3ebf77eb33d498760c,physicians,0.411773
uuid-1e4b71dd524c4f3ebf77eb33d498760c,indication,0.319077
uuid-1e4b71dd524c4f3ebf77eb33d498760c,drug,0.431107
uuid-0948551d5b874084b5246d6c20064bec,therapy,0.47771
uuid-0948551d5b874084b5246d6c20064bec,PDL1,0.379623
uuid-0948551d5b874084b5246d6c20064bec,PD-L1,0.593136
uuid-0948551d5b874084b5246d6c20064bec,PD-L1 testing,0.395898
uuid-0948551d5b874084b5246d6c20064bec,testing,0.533616
uuid-0948551d5b874084b5246d6c20064bec,treatment,0.338669
uuid-0948551d5b874084b5246d6c20064bec,PDL1 testing,0.319872
uuid-0948551d5b874084b5246d6c20064bec,NSCLC patients,0.434916
uuid-0948551d5b874084b5246d6c20064bec,progression,0.305743
uuid-0948551d5b874084b5246d6c20064bec,assay,0.402133
uuid-0948551d5b874084b5246d6c20064bec,PD-1,0.439582
uuid-0948551d5b874084b5246d6c20064bec,PDL1 expression,0.312756
uuid-0948551d5b874084b5246d6c20064bec,option,0.354177
uuid-0948551d5b874084b5246d6c20064bec,biomarker,0.545882
uuid-d201d9809b9248c4b4a567ecec4ffd75,Nivo,0.348753
uuid-d201d9809b9248c4b4a567ecec4ffd75,patients,0.712936
uuid-d201d9809b9248c4b4a567ecec4ffd75,Opdivo,0.431309
uuid-d201d9809b9248c4b4a567ecec4ffd75,therapy,0.489002
uuid-d201d9809b9248c4b4a567ecec4ffd75,nivolumab,0.642752
uuid-d201d9809b9248c4b4a567ecec4ffd75,regimen,0.355969
uuid-d201d9809b9248c4b4a567ecec4ffd75,treated,0.673202
uuid-d201d9809b9248c4b4a567ecec4ffd75,RCC,0.349066
uuid-d201d9809b9248c4b4a567ecec4ffd75,pts,0.493463
uuid-d201d9809b9248c4b4a567ecec4ffd75,approval,0.417031
uuid-d201d9809b9248c4b4a567ecec4ffd75,treatment,0.538052
uuid-d201d9809b9248c4b4a567ecec4ffd75,using nivo,0.465617
uuid-d201d9809b9248c4b4a567ecec4ffd75,SCCHN,0.337683
uuid-d201d9809b9248c4b4a567ecec4ffd75,cHL,0.498148
uuid-d201d9809b9248c4b4a567ecec4ffd75,progression,0.465734
uuid-d201d9809b9248c4b4a567ecec4ffd75,respond,0.306237
uuid-d201d9809b9248c4b4a567ecec4ffd75,RTL stated,0.433947
uuid-d201d9809b9248c4b4a567ecec4ffd75,TL shared,0.35938
uuid-9432191aa41a44a5855c453878b102a0,RTL,0.34414
uuid-9432191aa41a44a5855c453878b102a0,commented,0.364415
uuid-9432191aa41a44a5855c453878b102a0,stated,0.328802
uuid-9432191aa41a44a5855c453878b102a0,preferred,0.401376
uuid-9432191aa41a44a5855c453878b102a0,using nivo,0.414603
uuid-9432191aa41a44a5855c453878b102a0,mentioned,0.530406
uuid-9432191aa41a44a5855c453878b102a0,indication,0.42333
uuid-9432191aa41a44a5855c453878b102a0,SCCHN,0.483549
uuid-9432191aa41a44a5855c453878b102a0,HCP,0.330084
uuid-9432191aa41a44a5855c453878b102a0,oncologist,0.339823
uuid-9432191aa41a44a5855c453878b102a0,LTL,0.449576
uuid-9432191aa41a44a5855c453878b102a0,Regional TL,0.50016
uuid-9432191aa41a44a5855c453878b102a0,RTL stated,0.353156
uuid-9432191aa41a44a5855c453878b102a0,option,0.338238
uuid-2acbfbd692614ac58f33f00d3caf5eea,TL,0.340084
uuid-2acbfbd692614ac58f33f00d3caf5eea,BMS,0.324393
uuid-2acbfbd692614ac58f33f00d3caf5eea,shared,0.310519
uuid-2acbfbd692614ac58f33f00d3caf5eea,commented,0.393133
uuid-2acbfbd692614ac58f33f00d3caf5eea,Merck,0.473941
uuid-2acbfbd692614ac58f33f00d3caf5eea,stated,0.360916
uuid-2acbfbd692614ac58f33f00d3caf5eea,mentioned,0.436182
uuid-2acbfbd692614ac58f33f00d3caf5eea,LTL,0.350711
uuid-1493d33f5c074128bd1422853ca73cf9,patients,0.605422
uuid-1493d33f5c074128bd1422853ca73cf9,Opdivo,0.468642
uuid-1493d33f5c074128bd1422853ca73cf9,pts,0.314443
uuid-1493d33f5c074128bd1422853ca73cf9,approval,0.353866
uuid-1493d33f5c074128bd1422853ca73cf9,mentioned,0.331539
uuid-ef2e1d93d5414799809fa5aceb36d6a9,patients,0.642532
uuid-ef2e1d93d5414799809fa5aceb36d6a9,therapy,0.476455
uuid-ef2e1d93d5414799809fa5aceb36d6a9,nivolumab,0.319036
uuid-ef2e1d93d5414799809fa5aceb36d6a9,1L,0.324654
uuid-ef2e1d93d5414799809fa5aceb36d6a9,regimen,0.455552
uuid-ef2e1d93d5414799809fa5aceb36d6a9,treated,0.38397
uuid-ef2e1d93d5414799809fa5aceb36d6a9,chemo,0.402586
uuid-ef2e1d93d5414799809fa5aceb36d6a9,2L,0.303158
uuid-ef2e1d93d5414799809fa5aceb36d6a9,pts,0.486785
uuid-ef2e1d93d5414799809fa5aceb36d6a9,IO,0.339397
uuid-ef2e1d93d5414799809fa5aceb36d6a9,preferred,0.353902
uuid-ef2e1d93d5414799809fa5aceb36d6a9,monotherapy,0.4952
uuid-ef2e1d93d5414799809fa5aceb36d6a9,treatment,0.47948
uuid-ef2e1d93d5414799809fa5aceb36d6a9,NSCLC patients,0.347944
uuid-ef2e1d93d5414799809fa5aceb36d6a9,PD1,0.334308
uuid-ef2e1d93d5414799809fa5aceb36d6a9,progression,0.500892
uuid-ef2e1d93d5414799809fa5aceb36d6a9,chemotherapy,0.351194
uuid-ef2e1d93d5414799809fa5aceb36d6a9,respond,0.340102
uuid-ef2e1d93d5414799809fa5aceb36d6a9,option,0.511659
uuid-81ed738a22d44ada8f9696b15f6f018f,lung,0.516713
uuid-81ed738a22d44ada8f9696b15f6f018f,1L,0.335609
uuid-81ed738a22d44ada8f9696b15f6f018f,regimen,0.40285
uuid-81ed738a22d44ada8f9696b15f6f018f,melanoma,0.498067
uuid-81ed738a22d44ada8f9696b15f6f018f,RCC,0.570843
uuid-81ed738a22d44ada8f9696b15f6f018f,TL stated,0.491593
uuid-81ed738a22d44ada8f9696b15f6f018f,2L,0.402957
uuid-81ed738a22d44ada8f9696b15f6f018f,monotherapy,0.34988
uuid-81ed738a22d44ada8f9696b15f6f018f,combo,0.373064
uuid-81ed738a22d44ada8f9696b15f6f018f,AI,0.349139
uuid-81ed738a22d44ada8f9696b15f6f018f,RTL stated,0.35378
uuid-81ed738a22d44ada8f9696b15f6f018f,TL shared,0.457882
uuid-c5939d3ca4324fbb903ccb40c6076efa,patients,0.762343
uuid-c5939d3ca4324fbb903ccb40c6076efa,Opdivo,0.355
uuid-c5939d3ca4324fbb903ccb40c6076efa,therapy,0.571725
uuid-c5939d3ca4324fbb903ccb40c6076efa,nivolumab,0.513669
uuid-c5939d3ca4324fbb903ccb40c6076efa,regimen,0.4734
uuid-c5939d3ca4324fbb903ccb40c6076efa,treated,0.580992
uuid-c5939d3ca4324fbb903ccb40c6076efa,pts,0.438986
uuid-c5939d3ca4324fbb903ccb40c6076efa,treatment,0.663953
uuid-c5939d3ca4324fbb903ccb40c6076efa,response,0.428307
uuid-c5939d3ca4324fbb903ccb40c6076efa,progression,0.61273
uuid-c5939d3ca4324fbb903ccb40c6076efa,chemotherapy,0.371354
uuid-c5939d3ca4324fbb903ccb40c6076efa,respond,0.453044
uuid-b731e55d235241b2a1da0891f482c96b,patients,0.46517
uuid-b731e55d235241b2a1da0891f482c96b,pts,0.33458
uuid-b731e55d235241b2a1da0891f482c96b,stated,0.355834
uuid-b731e55d235241b2a1da0891f482c96b,treatment,0.316955
uuid-b731e55d235241b2a1da0891f482c96b,clinical trials,0.391071
uuid-b731e55d235241b2a1da0891f482c96b,approved,0.321099
uuid-b731e55d235241b2a1da0891f482c96b,progression,0.307098
uuid-b731e55d235241b2a1da0891f482c96b,option,0.333216
uuid-62e059ded5f245e587e1db7f8a4949b2,patients,0.522531
uuid-62e059ded5f245e587e1db7f8a4949b2,therapy,0.325915
uuid-62e059ded5f245e587e1db7f8a4949b2,dose,0.302065
uuid-62e059ded5f245e587e1db7f8a4949b2,nivolumab,0.319591
uuid-62e059ded5f245e587e1db7f8a4949b2,regimen,0.393332
uuid-62e059ded5f245e587e1db7f8a4949b2,treated,0.36336
uuid-62e059ded5f245e587e1db7f8a4949b2,combination,0.438562
uuid-62e059ded5f245e587e1db7f8a4949b2,chemo,0.346512
uuid-62e059ded5f245e587e1db7f8a4949b2,pts,0.327303
uuid-62e059ded5f245e587e1db7f8a4949b2,Ipi,0.332267
uuid-62e059ded5f245e587e1db7f8a4949b2,monotherapy,0.318379
uuid-62e059ded5f245e587e1db7f8a4949b2,treatment,0.398651
uuid-62e059ded5f245e587e1db7f8a4949b2,combo,0.33335
uuid-62e059ded5f245e587e1db7f8a4949b2,progression,0.362361
uuid-62e059ded5f245e587e1db7f8a4949b2,chemotherapy,0.400814
uuid-f9e08b16e90047db87a360bfebfe5f69,Nivo,0.302196
uuid-f9e08b16e90047db87a360bfebfe5f69,patients,0.637316
uuid-f9e08b16e90047db87a360bfebfe5f69,therapy,0.487906
uuid-f9e08b16e90047db87a360bfebfe5f69,regimen,0.372824
uuid-f9e08b16e90047db87a360bfebfe5f69,combination,0.33434
uuid-f9e08b16e90047db87a360bfebfe5f69,chemo,0.494346
uuid-f9e08b16e90047db87a360bfebfe5f69,2L,0.301812
uuid-f9e08b16e90047db87a360bfebfe5f69,pts,0.370319
uuid-f9e08b16e90047db87a360bfebfe5f69,agents,0.30066
uuid-f9e08b16e90047db87a360bfebfe5f69,preferred,0.455658
uuid-f9e08b16e90047db87a360bfebfe5f69,monotherapy,0.487652
uuid-f9e08b16e90047db87a360bfebfe5f69,treatment,0.538732
uuid-f9e08b16e90047db87a360bfebfe5f69,progression,0.405424
uuid-f9e08b16e90047db87a360bfebfe5f69,chemotherapy,0.542547
uuid-f9e08b16e90047db87a360bfebfe5f69,respond,0.314194
uuid-f9e08b16e90047db87a360bfebfe5f69,feels,0.367334
uuid-f9e08b16e90047db87a360bfebfe5f69,option,0.632057
uuid-5d86705b377f4ceca983bb463e83beab,tumor,0.49348
uuid-6be94825f168433c9dd7746bbd637b95,patients,0.539672
uuid-6be94825f168433c9dd7746bbd637b95,therapy,0.338312
uuid-6be94825f168433c9dd7746bbd637b95,nivolumab,0.362031
uuid-6be94825f168433c9dd7746bbd637b95,toxicity,0.606843
uuid-6be94825f168433c9dd7746bbd637b95,regimen,0.746348
uuid-6be94825f168433c9dd7746bbd637b95,treated,0.598592
uuid-6be94825f168433c9dd7746bbd637b95,combination,0.410171
uuid-6be94825f168433c9dd7746bbd637b95,chemo,0.338956
uuid-6be94825f168433c9dd7746bbd637b95,pts,0.41323
uuid-6be94825f168433c9dd7746bbd637b95,IO,0.310064
uuid-6be94825f168433c9dd7746bbd637b95,monotherapy,0.462202
uuid-6be94825f168433c9dd7746bbd637b95,treatment,0.586181
uuid-6be94825f168433c9dd7746bbd637b95,response,0.335765
uuid-6be94825f168433c9dd7746bbd637b95,combo,0.358431
uuid-6be94825f168433c9dd7746bbd637b95,PD1,0.341516
uuid-6be94825f168433c9dd7746bbd637b95,progression,0.472727
uuid-6be94825f168433c9dd7746bbd637b95,chemotherapy,0.353264
uuid-6be94825f168433c9dd7746bbd637b95,respond,0.460789
uuid-6be94825f168433c9dd7746bbd637b95,feels,0.332693
uuid-72c315d273c0491abb2cf4634edff662,Nivo,0.320612
uuid-72c315d273c0491abb2cf4634edff662,Opdivo,0.374501
uuid-72c315d273c0491abb2cf4634edff662,pembro,0.40225
uuid-72c315d273c0491abb2cf4634edff662,dose,0.459728
uuid-72c315d273c0491abb2cf4634edff662,regimen,0.311399
uuid-72c315d273c0491abb2cf4634edff662,2L,0.342091
uuid-72c315d273c0491abb2cf4634edff662,Ipi,0.304058
uuid-72c315d273c0491abb2cf4634edff662,approval,0.416848
uuid-72c315d273c0491abb2cf4634edff662,atezo,0.410642
uuid-72c315d273c0491abb2cf4634edff662,preferred,0.460972
uuid-72c315d273c0491abb2cf4634edff662,using nivo,0.319453
uuid-72c315d273c0491abb2cf4634edff662,indication,0.560926
uuid-72c315d273c0491abb2cf4634edff662,approved,0.467306
uuid-72c315d273c0491abb2cf4634edff662,label,0.364316
uuid-72c315d273c0491abb2cf4634edff662,Keytruda,0.310147
uuid-72c315d273c0491abb2cf4634edff662,option,0.342821
uuid-72c315d273c0491abb2cf4634edff662,bladder,0.325953
uuid-72c315d273c0491abb2cf4634edff662,flat dosing,0.414193
uuid-b15409a2f1304d2ebc54b814536accb6,patients,0.401582
uuid-b15409a2f1304d2ebc54b814536accb6,Opdivo,0.344442
uuid-b15409a2f1304d2ebc54b814536accb6,treated,0.331226
uuid-b15409a2f1304d2ebc54b814536accb6,treatment,0.300966
uuid-6467eda7059d41abb4b42acfa8a88eb0,patients,0.532651
uuid-6467eda7059d41abb4b42acfa8a88eb0,Opdivo,0.365517
uuid-6467eda7059d41abb4b42acfa8a88eb0,treated,0.461518
uuid-6467eda7059d41abb4b42acfa8a88eb0,physicians,0.434164
uuid-6467eda7059d41abb4b42acfa8a88eb0,treatment,0.475422
uuid-2e82240e19104acb9da5606e23df222b,physicians,0.303495
uuid-2196b98a55884caf9b1e713de9e40e67,dose,0.472868
uuid-2196b98a55884caf9b1e713de9e40e67,AI,0.499628
uuid-2196b98a55884caf9b1e713de9e40e67,drug,0.443397
uuid-2196b98a55884caf9b1e713de9e40e67,Keytruda,0.584303
uuid-2196b98a55884caf9b1e713de9e40e67,flat dosing,0.606402
uuid-e2b88290c7bc45a2b0c055ffd3e06061,pembro,0.336418
uuid-e2b88290c7bc45a2b0c055ffd3e06061,lung,0.51177
uuid-e2b88290c7bc45a2b0c055ffd3e06061,efficacy,0.337389
uuid-e2b88290c7bc45a2b0c055ffd3e06061,melanoma,0.313167
uuid-e2b88290c7bc45a2b0c055ffd3e06061,atezo,0.398318
uuid-e2b88290c7bc45a2b0c055ffd3e06061,regards,0.421127
uuid-e2b88290c7bc45a2b0c055ffd3e06061,AI,0.834767
uuid-e2b88290c7bc45a2b0c055ffd3e06061,nivo and pembro,0.568439
uuid-e2b88290c7bc45a2b0c055ffd3e06061,NCCN,0.41402
uuid-460686b11cdd4aa09fc2a88dafb8d724,RTL,0.429281
uuid-460686b11cdd4aa09fc2a88dafb8d724,BMS,0.500912
uuid-460686b11cdd4aa09fc2a88dafb8d724,trial,0.576816
uuid-460686b11cdd4aa09fc2a88dafb8d724,efficacy,0.320493
uuid-460686b11cdd4aa09fc2a88dafb8d724,commented,0.658563
uuid-460686b11cdd4aa09fc2a88dafb8d724,Merck,0.351281
uuid-460686b11cdd4aa09fc2a88dafb8d724,stated,0.407351
uuid-460686b11cdd4aa09fc2a88dafb8d724,OS,0.63672
uuid-460686b11cdd4aa09fc2a88dafb8d724,regards,0.329088
uuid-460686b11cdd4aa09fc2a88dafb8d724,data,0.843227
uuid-460686b11cdd4aa09fc2a88dafb8d724,expressed,0.386102
uuid-460686b11cdd4aa09fc2a88dafb8d724,clinical trials,0.324828
uuid-460686b11cdd4aa09fc2a88dafb8d724,PFS,0.571984
uuid-460686b11cdd4aa09fc2a88dafb8d724,ORR,0.625847
uuid-460686b11cdd4aa09fc2a88dafb8d724,ASCO,0.604467
uuid-460686b11cdd4aa09fc2a88dafb8d724,impressed,0.799014
uuid-460686b11cdd4aa09fc2a88dafb8d724,Regional TL,0.404371
uuid-897a2dc8ff694b568a8b8c37ff0243c3,Nivo,0.713931
uuid-897a2dc8ff694b568a8b8c37ff0243c3,pembro,0.506441
uuid-897a2dc8ff694b568a8b8c37ff0243c3,therapy,0.476207
uuid-897a2dc8ff694b568a8b8c37ff0243c3,nivolumab,0.340993
uuid-897a2dc8ff694b568a8b8c37ff0243c3,1L,0.410954
uuid-897a2dc8ff694b568a8b8c37ff0243c3,efficacy,0.315076
uuid-897a2dc8ff694b568a8b8c37ff0243c3,combination,0.63635
uuid-897a2dc8ff694b568a8b8c37ff0243c3,chemo,0.541048
uuid-897a2dc8ff694b568a8b8c37ff0243c3,2L,0.453744
uuid-897a2dc8ff694b568a8b8c37ff0243c3,agents,0.599868
uuid-897a2dc8ff694b568a8b8c37ff0243c3,Ipi,0.39577
uuid-897a2dc8ff694b568a8b8c37ff0243c3,atezo,0.431443
uuid-897a2dc8ff694b568a8b8c37ff0243c3,preferred,0.488306
uuid-897a2dc8ff694b568a8b8c37ff0243c3,monotherapy,0.619901
uuid-897a2dc8ff694b568a8b8c37ff0243c3,using nivo,0.363819
uuid-897a2dc8ff694b568a8b8c37ff0243c3,combo,0.491877
uuid-897a2dc8ff694b568a8b8c37ff0243c3,PD1,0.516194
uuid-897a2dc8ff694b568a8b8c37ff0243c3,nivo and pembro,0.386845
uuid-897a2dc8ff694b568a8b8c37ff0243c3,believes,0.340838
uuid-897a2dc8ff694b568a8b8c37ff0243c3,chemotherapy,0.524977
uuid-897a2dc8ff694b568a8b8c37ff0243c3,vs,0.340885
uuid-897a2dc8ff694b568a8b8c37ff0243c3,feels,0.313219
uuid-897a2dc8ff694b568a8b8c37ff0243c3,PD-1,0.34947
uuid-897a2dc8ff694b568a8b8c37ff0243c3,option,0.541857
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,Nivo,0.473942
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,patients,0.616251
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,Opdivo,0.45553
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,therapy,0.667822
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,nivolumab,0.570135
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,treated,0.39176
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,treatment,0.467191
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,using nivo,0.384363
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,cHL,0.777984
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,progression,0.389657
uuid-c4476d3c6c4e463aa0cd9d69ff3aca78,chemotherapy,0.347081
uuid-5a5bfcc52c454efa97dc816c893d5fc5,patients,0.305851
uuid-5a5bfcc52c454efa97dc816c893d5fc5,dose,0.309656
uuid-5a5bfcc52c454efa97dc816c893d5fc5,nivolumab,0.30537
uuid-5a5bfcc52c454efa97dc816c893d5fc5,regimen,0.406513
uuid-5a5bfcc52c454efa97dc816c893d5fc5,treated,0.339973
uuid-5a5bfcc52c454efa97dc816c893d5fc5,shared,0.319282
uuid-5a5bfcc52c454efa97dc816c893d5fc5,physicians,0.3719
uuid-5a5bfcc52c454efa97dc816c893d5fc5,treatment,0.308454
uuid-5a5bfcc52c454efa97dc816c893d5fc5,respond,0.31587
uuid-06e54188ef06414d998b9ada85165e91,Nivo,0.473241
uuid-06e54188ef06414d998b9ada85165e91,patients,0.443325
uuid-06e54188ef06414d998b9ada85165e91,pembro,0.381016
uuid-06e54188ef06414d998b9ada85165e91,nivolumab,0.425373
uuid-06e54188ef06414d998b9ada85165e91,1L,0.65284
uuid-06e54188ef06414d998b9ada85165e91,regimen,0.512264
uuid-06e54188ef06414d998b9ada85165e91,RCC,0.539795
uuid-06e54188ef06414d998b9ada85165e91,combination,0.499482
uuid-06e54188ef06414d998b9ada85165e91,chemo,0.481406
uuid-06e54188ef06414d998b9ada85165e91,2L,0.691613
uuid-06e54188ef06414d998b9ada85165e91,pts,0.452384
uuid-06e54188ef06414d998b9ada85165e91,IO,0.341104
uuid-06e54188ef06414d998b9ada85165e91,agents,0.36546
uuid-06e54188ef06414d998b9ada85165e91,Ipi,0.345621
uuid-06e54188ef06414d998b9ada85165e91,approval,0.334675
uuid-06e54188ef06414d998b9ada85165e91,atezo,0.349639
uuid-06e54188ef06414d998b9ada85165e91,preferred,0.596251
uuid-06e54188ef06414d998b9ada85165e91,monotherapy,0.717665
uuid-06e54188ef06414d998b9ada85165e91,treatment,0.314177
uuid-06e54188ef06414d998b9ada85165e91,using nivo,0.624087
uuid-06e54188ef06414d998b9ada85165e91,combo,0.592555
uuid-06e54188ef06414d998b9ada85165e91,clinical trials,0.301817
uuid-06e54188ef06414d998b9ada85165e91,PD1,0.399479
uuid-06e54188ef06414d998b9ada85165e91,approved,0.499242
uuid-06e54188ef06414d998b9ada85165e91,SCCHN,0.382276
uuid-06e54188ef06414d998b9ada85165e91,progression,0.318545
uuid-06e54188ef06414d998b9ada85165e91,believes,0.333421
uuid-06e54188ef06414d998b9ada85165e91,chemotherapy,0.376721
uuid-06e54188ef06414d998b9ada85165e91,feels,0.435466
uuid-06e54188ef06414d998b9ada85165e91,RTL stated,0.565083
uuid-06e54188ef06414d998b9ada85165e91,option,0.647371
uuid-06e54188ef06414d998b9ada85165e91,bladder,0.379734
uuid-928a43c93f264d68a4769703a0ba6e88,RTL,0.313959
uuid-928a43c93f264d68a4769703a0ba6e88,trial,0.575552
uuid-928a43c93f264d68a4769703a0ba6e88,stated,0.352381
uuid-928a43c93f264d68a4769703a0ba6e88,approval,0.352718
uuid-928a43c93f264d68a4769703a0ba6e88,data,0.307008
uuid-928a43c93f264d68a4769703a0ba6e88,clinical trials,0.426178
uuid-928a43c93f264d68a4769703a0ba6e88,bladder,0.362678
uuid-7f4e222302c24152b68d6f6a2d893348,Nivo,0.510117
uuid-7f4e222302c24152b68d6f6a2d893348,patients,0.519754
uuid-7f4e222302c24152b68d6f6a2d893348,pembro,0.490782
uuid-7f4e222302c24152b68d6f6a2d893348,dose,0.576279
uuid-7f4e222302c24152b68d6f6a2d893348,1L,0.3212
uuid-7f4e222302c24152b68d6f6a2d893348,toxicity,0.360933
uuid-7f4e222302c24152b68d6f6a2d893348,regimen,0.418706
uuid-7f4e222302c24152b68d6f6a2d893348,chemo,0.331216
uuid-7f4e222302c24152b68d6f6a2d893348,2L,0.473044
uuid-7f4e222302c24152b68d6f6a2d893348,pts,0.345542
uuid-7f4e222302c24152b68d6f6a2d893348,Ipi,0.41176
uuid-7f4e222302c24152b68d6f6a2d893348,atezo,0.493458
uuid-7f4e222302c24152b68d6f6a2d893348,preferred,0.527129
uuid-7f4e222302c24152b68d6f6a2d893348,monotherapy,0.468819
uuid-7f4e222302c24152b68d6f6a2d893348,using nivo,0.446538
uuid-7f4e222302c24152b68d6f6a2d893348,approved,0.30661
uuid-7f4e222302c24152b68d6f6a2d893348,vs,0.525661
uuid-7f4e222302c24152b68d6f6a2d893348,RTL stated,0.313009
uuid-7f4e222302c24152b68d6f6a2d893348,option,0.440039
uuid-7f4e222302c24152b68d6f6a2d893348,flat dosing,0.317844
uuid-022347a9dc434731ac59f2f55c4bae4e,patients,0.64177
uuid-022347a9dc434731ac59f2f55c4bae4e,therapy,0.494493
uuid-022347a9dc434731ac59f2f55c4bae4e,regimen,0.332448
uuid-022347a9dc434731ac59f2f55c4bae4e,treated,0.320136
uuid-022347a9dc434731ac59f2f55c4bae4e,chemo,0.352486
uuid-022347a9dc434731ac59f2f55c4bae4e,pts,0.46292
uuid-022347a9dc434731ac59f2f55c4bae4e,treatment,0.49152
uuid-022347a9dc434731ac59f2f55c4bae4e,progression,0.543643
uuid-022347a9dc434731ac59f2f55c4bae4e,chemotherapy,0.350953
uuid-022347a9dc434731ac59f2f55c4bae4e,respond,0.471922
uuid-022347a9dc434731ac59f2f55c4bae4e,option,0.392595
uuid-6dcbd060792144e88dbaa819692f8ca8,RTL,0.508495
uuid-6dcbd060792144e88dbaa819692f8ca8,lung,0.500912
uuid-6dcbd060792144e88dbaa819692f8ca8,1L,0.351893
uuid-6dcbd060792144e88dbaa819692f8ca8,NTL,0.310533
uuid-6dcbd060792144e88dbaa819692f8ca8,discussed,0.345954
uuid-6dcbd060792144e88dbaa819692f8ca8,melanoma,0.565759
uuid-6dcbd060792144e88dbaa819692f8ca8,shared,0.454936
uuid-6dcbd060792144e88dbaa819692f8ca8,RCC,0.712889
uuid-6dcbd060792144e88dbaa819692f8ca8,TL stated,0.463778
uuid-6dcbd060792144e88dbaa819692f8ca8,2L,0.434688
uuid-6dcbd060792144e88dbaa819692f8ca8,stated,0.381331
uuid-6dcbd060792144e88dbaa819692f8ca8,preferred,0.36391
uuid-6dcbd060792144e88dbaa819692f8ca8,using nivo,0.489778
uuid-6dcbd060792144e88dbaa819692f8ca8,clinical trials,0.359344
uuid-6dcbd060792144e88dbaa819692f8ca8,PDL1 testing,0.365119
uuid-6dcbd060792144e88dbaa819692f8ca8,SCCHN,0.687075
uuid-6dcbd060792144e88dbaa819692f8ca8,LTL,0.41811
uuid-6dcbd060792144e88dbaa819692f8ca8,TLs,0.573824
uuid-6dcbd060792144e88dbaa819692f8ca8,academic,0.78578
uuid-6dcbd060792144e88dbaa819692f8ca8,Regional TL,0.551122
uuid-6dcbd060792144e88dbaa819692f8ca8,RTL stated,0.758046
uuid-6dcbd060792144e88dbaa819692f8ca8,TL shared,0.595387
uuid-6dcbd060792144e88dbaa819692f8ca8,bladder,0.393728
uuid-6c317a74d5ed47e39b85503db6764377,Nivo,0.560157
uuid-6c317a74d5ed47e39b85503db6764377,pembro,0.585301
uuid-6c317a74d5ed47e39b85503db6764377,1L,0.490391
uuid-6c317a74d5ed47e39b85503db6764377,PDL1,0.454451
uuid-6c317a74d5ed47e39b85503db6764377,efficacy,0.508215
uuid-6c317a74d5ed47e39b85503db6764377,chemo,0.414106
uuid-6c317a74d5ed47e39b85503db6764377,2L,0.472825
uuid-6c317a74d5ed47e39b85503db6764377,agents,0.387154
uuid-6c317a74d5ed47e39b85503db6764377,OS,0.33574
uuid-6c317a74d5ed47e39b85503db6764377,atezo,0.527969
uuid-6c317a74d5ed47e39b85503db6764377,preferred,0.349113
uuid-6c317a74d5ed47e39b85503db6764377,monotherapy,0.456005
uuid-6c317a74d5ed47e39b85503db6764377,using nivo,0.335511
uuid-6c317a74d5ed47e39b85503db6764377,data,0.449439
uuid-6c317a74d5ed47e39b85503db6764377,combo,0.32767
uuid-6c317a74d5ed47e39b85503db6764377,ORR,0.364561
uuid-6c317a74d5ed47e39b85503db6764377,approved,0.361029
uuid-6c317a74d5ed47e39b85503db6764377,nivo and pembro,0.476136
uuid-6c317a74d5ed47e39b85503db6764377,believes,0.455028
uuid-6c317a74d5ed47e39b85503db6764377,impressed,0.341357
uuid-6c317a74d5ed47e39b85503db6764377,vs,0.404864
uuid-6c317a74d5ed47e39b85503db6764377,feels,0.466947
uuid-6c317a74d5ed47e39b85503db6764377,PDL1 expression,0.374189
uuid-6c317a74d5ed47e39b85503db6764377,option,0.437088
uuid-23485c2fa809404191c965fc9057a7cb,physicians,0.533862
uuid-23485c2fa809404191c965fc9057a7cb,oncology,0.434267
uuid-23485c2fa809404191c965fc9057a7cb,drug,0.458063
uuid-23485c2fa809404191c965fc9057a7cb,clinical,0.519028
uuid-9c0b143432d24655ade8a54b186775b7,Nivo,0.362482
uuid-9c0b143432d24655ade8a54b186775b7,pembro,0.577419
uuid-9c0b143432d24655ade8a54b186775b7,BMS,0.328252
uuid-9c0b143432d24655ade8a54b186775b7,1L,0.433382
uuid-9c0b143432d24655ade8a54b186775b7,trial,0.462585
uuid-9c0b143432d24655ade8a54b186775b7,efficacy,0.305082
uuid-9c0b143432d24655ade8a54b186775b7,commented,0.378415
uuid-9c0b143432d24655ade8a54b186775b7,2L,0.422699
uuid-9c0b143432d24655ade8a54b186775b7,Merck,0.348277
uuid-9c0b143432d24655ade8a54b186775b7,stated,0.33444
uuid-9c0b143432d24655ade8a54b186775b7,approval,0.423988
uuid-9c0b143432d24655ade8a54b186775b7,atezo,0.536557
uuid-9c0b143432d24655ade8a54b186775b7,preferred,0.42437
uuid-9c0b143432d24655ade8a54b186775b7,using nivo,0.385136
uuid-9c0b143432d24655ade8a54b186775b7,data,0.604517
uuid-9c0b143432d24655ade8a54b186775b7,expressed,0.332332
uuid-9c0b143432d24655ade8a54b186775b7,clinical trials,0.408827
uuid-9c0b143432d24655ade8a54b186775b7,indication,0.455699
uuid-9c0b143432d24655ade8a54b186775b7,approved,0.466513
uuid-9c0b143432d24655ade8a54b186775b7,SCCHN,0.493012
uuid-9c0b143432d24655ade8a54b186775b7,nivo and pembro,0.432058
uuid-9c0b143432d24655ade8a54b186775b7,impressed,0.51649
uuid-9c0b143432d24655ade8a54b186775b7,LTL,0.307353
uuid-9c0b143432d24655ade8a54b186775b7,TLs,0.330042
uuid-9c0b143432d24655ade8a54b186775b7,SCLC,0.362737
uuid-9c0b143432d24655ade8a54b186775b7,feels,0.423308
uuid-9c0b143432d24655ade8a54b186775b7,Regional TL,0.325545
uuid-9c0b143432d24655ade8a54b186775b7,RTL stated,0.423774
uuid-9c0b143432d24655ade8a54b186775b7,option,0.310792
uuid-9c0b143432d24655ade8a54b186775b7,bladder,0.518226
uuid-9f23973aa01c4ef6984f7d7668418e6f,Nivo,0.353785
uuid-9f23973aa01c4ef6984f7d7668418e6f,patients,0.360187
uuid-9f23973aa01c4ef6984f7d7668418e6f,Opdivo,0.31821
uuid-9f23973aa01c4ef6984f7d7668418e6f,pembro,0.349986
uuid-9f23973aa01c4ef6984f7d7668418e6f,dose,0.656181
uuid-9f23973aa01c4ef6984f7d7668418e6f,regimen,0.339446
uuid-9f23973aa01c4ef6984f7d7668418e6f,2L,0.327663
uuid-9f23973aa01c4ef6984f7d7668418e6f,Ipi,0.397925
uuid-9f23973aa01c4ef6984f7d7668418e6f,atezo,0.379444
uuid-9f23973aa01c4ef6984f7d7668418e6f,preferred,0.517769
uuid-9f23973aa01c4ef6984f7d7668418e6f,monotherapy,0.324358
uuid-9f23973aa01c4ef6984f7d7668418e6f,using nivo,0.331609
uuid-9f23973aa01c4ef6984f7d7668418e6f,indication,0.300416
uuid-9f23973aa01c4ef6984f7d7668418e6f,vs,0.479386
uuid-9f23973aa01c4ef6984f7d7668418e6f,option,0.364374
uuid-9f23973aa01c4ef6984f7d7668418e6f,flat dosing,0.550644
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,BMS,0.336965
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,discussed,0.33493
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,shared,0.320288
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,physicians,0.312343
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,regards,0.325816
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,oncology,0.455414
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,drug,0.329484
uuid-3f8d8dfa3f56439e9f73ba4ffb9fff5d,clinical,0.537856
uuid-c99a293094f74a48a6ce4f91dd5daac1,Nivo,0.533116
uuid-c99a293094f74a48a6ce4f91dd5daac1,patients,0.519125
uuid-c99a293094f74a48a6ce4f91dd5daac1,pembro,0.455959
uuid-c99a293094f74a48a6ce4f91dd5daac1,nivolumab,0.442137
uuid-c99a293094f74a48a6ce4f91dd5daac1,1L,0.373861
uuid-c99a293094f74a48a6ce4f91dd5daac1,treated,0.353168
uuid-c99a293094f74a48a6ce4f91dd5daac1,RCC,0.332882
uuid-c99a293094f74a48a6ce4f91dd5daac1,2L,0.418592
uuid-c99a293094f74a48a6ce4f91dd5daac1,pts,0.418308
uuid-c99a293094f74a48a6ce4f91dd5daac1,stated,0.386836
uuid-c99a293094f74a48a6ce4f91dd5daac1,approval,0.565365
uuid-c99a293094f74a48a6ce4f91dd5daac1,monotherapy,0.340207
uuid-c99a293094f74a48a6ce4f91dd5daac1,using nivo,0.557857
uuid-c99a293094f74a48a6ce4f91dd5daac1,approved,0.499525
uuid-c99a293094f74a48a6ce4f91dd5daac1,SCCHN,0.374164
uuid-c99a293094f74a48a6ce4f91dd5daac1,label,0.368606
uuid-c99a293094f74a48a6ce4f91dd5daac1,SCLC,0.431283
uuid-c99a293094f74a48a6ce4f91dd5daac1,RTL stated,0.439802
uuid-c99a293094f74a48a6ce4f91dd5daac1,option,0.368373
uuid-c99a293094f74a48a6ce4f91dd5daac1,bladder,0.371965
uuid-05bf6dbcb2aa4074b7555dcacbf12a5c,toxicity,0.365795
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,BMS,0.396496
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,PDL1,0.48489
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,Merck,0.47471
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,institution,0.309995
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,PD-L1,0.354036
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,testing,0.334882
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,regards,0.438539
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,PFS,0.349404
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,AI,0.585618
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,nivo and pembro,0.385587
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,assay,0.616345
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,PDL1 expression,0.420822
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,biomarker,0.441177
uuid-3057468dd96b4ab488eb78cdb2bf0c4e,NCCN,0.337022
uuid-2f53cb015aad452ca14a9e28387552c7,TL,0.336481
uuid-2f53cb015aad452ca14a9e28387552c7,lung,0.357912
uuid-2f53cb015aad452ca14a9e28387552c7,NSCLC,0.555645
uuid-2f53cb015aad452ca14a9e28387552c7,TL stated,0.410822
uuid-2f53cb015aad452ca14a9e28387552c7,institution,0.600766
uuid-2f53cb015aad452ca14a9e28387552c7,PD-L1,0.528644
uuid-2f53cb015aad452ca14a9e28387552c7,PD-L1 testing,0.650487
uuid-2f53cb015aad452ca14a9e28387552c7,testing,0.619971
uuid-2f53cb015aad452ca14a9e28387552c7,PDL1 testing,0.55666
uuid-2f53cb015aad452ca14a9e28387552c7,AI,0.365425
uuid-2f53cb015aad452ca14a9e28387552c7,NSCLC patients,0.454695
uuid-2f53cb015aad452ca14a9e28387552c7,assay,0.472079
uuid-2f53cb015aad452ca14a9e28387552c7,NCCN,0.339419
uuid-9fb964bc0cff436e934eb0e323406c1e,TL,0.622338
uuid-9fb964bc0cff436e934eb0e323406c1e,PDL1,0.456837
uuid-9fb964bc0cff436e934eb0e323406c1e,TL stated,0.301785
uuid-9fb964bc0cff436e934eb0e323406c1e,Merck,0.344192
uuid-9fb964bc0cff436e934eb0e323406c1e,institution,0.338671
uuid-9fb964bc0cff436e934eb0e323406c1e,PD-L1,0.828491
uuid-9fb964bc0cff436e934eb0e323406c1e,PD-L1 testing,0.826061
uuid-9fb964bc0cff436e934eb0e323406c1e,testing,0.865199
uuid-9fb964bc0cff436e934eb0e323406c1e,PDL1 testing,0.569872
uuid-9fb964bc0cff436e934eb0e323406c1e,NSCLC patients,0.541611
uuid-9fb964bc0cff436e934eb0e323406c1e,assay,0.929673
uuid-9fb964bc0cff436e934eb0e323406c1e,biomarker,0.428717
uuid-a02e728b80da472abefe202ecf5af6f4,patients,0.574359
uuid-a02e728b80da472abefe202ecf5af6f4,therapy,0.445695
uuid-a02e728b80da472abefe202ecf5af6f4,toxicity,0.551104
uuid-a02e728b80da472abefe202ecf5af6f4,regimen,0.5728
uuid-a02e728b80da472abefe202ecf5af6f4,treated,0.656637
uuid-a02e728b80da472abefe202ecf5af6f4,pts,0.327485
uuid-a02e728b80da472abefe202ecf5af6f4,treatment,0.73459
uuid-a02e728b80da472abefe202ecf5af6f4,response,0.397118
uuid-a02e728b80da472abefe202ecf5af6f4,progression,0.521862
uuid-a02e728b80da472abefe202ecf5af6f4,respond,0.608649
uuid-507edcea62e84c77a94a0a4f67d4b9b8,discussed,0.380531
uuid-507edcea62e84c77a94a0a4f67d4b9b8,physicians,0.48169
uuid-507edcea62e84c77a94a0a4f67d4b9b8,clinical,0.321263
uuid-507edcea62e84c77a94a0a4f67d4b9b8,academic,0.418561
uuid-44a1dc5661684fe9b0c165f07c0fb93a,patients,0.433139
uuid-44a1dc5661684fe9b0c165f07c0fb93a,therapy,0.376025
uuid-44a1dc5661684fe9b0c165f07c0fb93a,treated,0.336726
uuid-44a1dc5661684fe9b0c165f07c0fb93a,treatment,0.387955
uuid-44a1dc5661684fe9b0c165f07c0fb93a,using nivo,0.332233
uuid-44a1dc5661684fe9b0c165f07c0fb93a,progression,0.30375
uuid-44a1dc5661684fe9b0c165f07c0fb93a,RTL stated,0.339221
uuid-44a1dc5661684fe9b0c165f07c0fb93a,TL shared,0.342401
uuid-3b314675977d4d36be45cd48d0b72cb9,Opdivo,0.502892
uuid-3b314675977d4d36be45cd48d0b72cb9,physicians,0.549192
uuid-3b314675977d4d36be45cd48d0b72cb9,oncology,0.307351
uuid-3b314675977d4d36be45cd48d0b72cb9,drug,0.331771
uuid-3b314675977d4d36be45cd48d0b72cb9,flat dosing,0.481149
uuid-f15925b6080c49369dbc717dd56629a9,patients,0.858545
uuid-f15925b6080c49369dbc717dd56629a9,Opdivo,0.635197
uuid-f15925b6080c49369dbc717dd56629a9,therapy,0.567023
uuid-f15925b6080c49369dbc717dd56629a9,nivolumab,0.429307
uuid-f15925b6080c49369dbc717dd56629a9,regimen,0.457847
uuid-f15925b6080c49369dbc717dd56629a9,treated,0.585928
uuid-f15925b6080c49369dbc717dd56629a9,pts,0.560104
uuid-f15925b6080c49369dbc717dd56629a9,treatment,0.750177
uuid-f15925b6080c49369dbc717dd56629a9,response,0.385453
uuid-f15925b6080c49369dbc717dd56629a9,cHL,0.404723
uuid-f15925b6080c49369dbc717dd56629a9,progression,0.691785
uuid-f15925b6080c49369dbc717dd56629a9,respond,0.584398
uuid-11b9229a61ed4ad4aeb24e02e4d33512,RTL,0.321061
uuid-11b9229a61ed4ad4aeb24e02e4d33512,BMS,0.433384
uuid-11b9229a61ed4ad4aeb24e02e4d33512,shared,0.585866
uuid-11b9229a61ed4ad4aeb24e02e4d33512,commented,0.394277
uuid-11b9229a61ed4ad4aeb24e02e4d33512,stated,0.499719
uuid-11b9229a61ed4ad4aeb24e02e4d33512,data,0.462524
uuid-11b9229a61ed4ad4aeb24e02e4d33512,expressed,0.413472
uuid-11b9229a61ed4ad4aeb24e02e4d33512,clinical trials,0.388046
uuid-11b9229a61ed4ad4aeb24e02e4d33512,impressed,0.514733
uuid-11b9229a61ed4ad4aeb24e02e4d33512,LTL,0.386508
uuid-11b9229a61ed4ad4aeb24e02e4d33512,TLs,0.389736
uuid-11b9229a61ed4ad4aeb24e02e4d33512,feels,0.468813
uuid-11b9229a61ed4ad4aeb24e02e4d33512,Regional TL,0.325979
uuid-11b9229a61ed4ad4aeb24e02e4d33512,RTL stated,0.301947
uuid-11b9229a61ed4ad4aeb24e02e4d33512,bladder,0.313808
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,patients,0.567511
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,therapy,0.318551
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,chemo,0.341947
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,pts,0.34886
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,treatment,0.357809
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,response,0.315723
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,progression,0.336775
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,chemotherapy,0.36227
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,respond,0.335441
uuid-45b8abccc3e34e8dbdafa9ff407d0de8,option,0.319327
uuid-a86cbc442ea6438795452083c9464b3d,lung,0.386247
uuid-a86cbc442ea6438795452083c9464b3d,efficacy,0.327287
uuid-a86cbc442ea6438795452083c9464b3d,OS,0.495719
uuid-a86cbc442ea6438795452083c9464b3d,regards,0.465934
uuid-a86cbc442ea6438795452083c9464b3d,data,0.339162
uuid-a86cbc442ea6438795452083c9464b3d,expressed,0.336696
uuid-a86cbc442ea6438795452083c9464b3d,PFS,0.553474
uuid-a86cbc442ea6438795452083c9464b3d,AI,0.802905
uuid-a86cbc442ea6438795452083c9464b3d,ORR,0.471281
uuid-a86cbc442ea6438795452083c9464b3d,nivo and pembro,0.381571
uuid-a86cbc442ea6438795452083c9464b3d,NCCN,0.474859
uuid-a87e7dea9cdf4ef0b066fb6313e2249e,toxicity,0.462559
uuid-a87e7dea9cdf4ef0b066fb6313e2249e,physicians,0.472587
uuid-a87e7dea9cdf4ef0b066fb6313e2249e,drug,0.413263
uuid-c25fceab336f435c85e93626c73beca2,TL,0.361171
uuid-c25fceab336f435c85e93626c73beca2,PDL1,0.333957
uuid-c25fceab336f435c85e93626c73beca2,TL stated,0.444713
uuid-c25fceab336f435c85e93626c73beca2,PD-L1,0.685623
uuid-c25fceab336f435c85e93626c73beca2,PD-L1 testing,0.641848
uuid-c25fceab336f435c85e93626c73beca2,testing,0.841943
uuid-c25fceab336f435c85e93626c73beca2,PDL1 testing,0.716489
uuid-c25fceab336f435c85e93626c73beca2,NSCLC patients,0.76941
uuid-c25fceab336f435c85e93626c73beca2,tumor types,0.322877
uuid-c25fceab336f435c85e93626c73beca2,assay,0.443558
uuid-c25fceab336f435c85e93626c73beca2,biomarker,0.477811
uuid-0fdf23980f6947d68872d5701abe9cbd,Nivo,0.306039
uuid-0fdf23980f6947d68872d5701abe9cbd,pembro,0.413549
uuid-0fdf23980f6947d68872d5701abe9cbd,1L,0.447228
uuid-0fdf23980f6947d68872d5701abe9cbd,efficacy,0.503278
uuid-0fdf23980f6947d68872d5701abe9cbd,combination,0.374531
uuid-0fdf23980f6947d68872d5701abe9cbd,chemo,0.320055
uuid-0fdf23980f6947d68872d5701abe9cbd,2L,0.410761
uuid-0fdf23980f6947d68872d5701abe9cbd,IO,0.396486
uuid-0fdf23980f6947d68872d5701abe9cbd,agents,0.486178
uuid-0fdf23980f6947d68872d5701abe9cbd,OS,0.317603
uuid-0fdf23980f6947d68872d5701abe9cbd,atezo,0.456788
uuid-0fdf23980f6947d68872d5701abe9cbd,preferred,0.427662
uuid-0fdf23980f6947d68872d5701abe9cbd,monotherapy,0.433368
uuid-0fdf23980f6947d68872d5701abe9cbd,data,0.511737
uuid-0fdf23980f6947d68872d5701abe9cbd,combo,0.44933
uuid-0fdf23980f6947d68872d5701abe9cbd,indication,0.31336
uuid-0fdf23980f6947d68872d5701abe9cbd,nivo and pembro,0.426793
uuid-0fdf23980f6947d68872d5701abe9cbd,believes,0.510502
uuid-0fdf23980f6947d68872d5701abe9cbd,impressed,0.425547
uuid-0fdf23980f6947d68872d5701abe9cbd,TLs,0.426913
uuid-0fdf23980f6947d68872d5701abe9cbd,feels,0.515401
uuid-0fdf23980f6947d68872d5701abe9cbd,option,0.394803
uuid-3779de1d2ce64513958ac480f915c2e2,Opdivo,0.336453
uuid-3779de1d2ce64513958ac480f915c2e2,physicians,0.759797
uuid-1aed58b622ef4ce8876ea7816a5cd649,Nivo,0.341275
uuid-1aed58b622ef4ce8876ea7816a5cd649,patients,0.323366
uuid-1aed58b622ef4ce8876ea7816a5cd649,dose,0.769778
uuid-1aed58b622ef4ce8876ea7816a5cd649,toxicity,0.540302
uuid-1aed58b622ef4ce8876ea7816a5cd649,regimen,0.544723
uuid-1aed58b622ef4ce8876ea7816a5cd649,Ipi,0.522037
uuid-1aed58b622ef4ce8876ea7816a5cd649,treatment,0.372329
uuid-1aed58b622ef4ce8876ea7816a5cd649,vs,0.420207
uuid-1aed58b622ef4ce8876ea7816a5cd649,respond,0.337315
uuid-1aed58b622ef4ce8876ea7816a5cd649,flat dosing,0.389707
uuid-c0d139b012ef419281280072468a00e3,patients,0.540775
uuid-c0d139b012ef419281280072468a00e3,therapy,0.377475
uuid-c0d139b012ef419281280072468a00e3,nivolumab,0.388356
uuid-c0d139b012ef419281280072468a00e3,treated,0.453689
uuid-c0d139b012ef419281280072468a00e3,tumor,0.337356
uuid-c0d139b012ef419281280072468a00e3,pts,0.438154
uuid-c0d139b012ef419281280072468a00e3,treatment,0.479431
uuid-c0d139b012ef419281280072468a00e3,response,0.393352
uuid-c0d139b012ef419281280072468a00e3,cHL,0.416366
uuid-c0d139b012ef419281280072468a00e3,progression,0.366201
uuid-c0d139b012ef419281280072468a00e3,respond,0.371583
uuid-3e51f68bc4bf49c3a24db8022de42e54,Nivo,0.305677
uuid-3e51f68bc4bf49c3a24db8022de42e54,patients,0.489803
uuid-3e51f68bc4bf49c3a24db8022de42e54,therapy,0.562759
uuid-3e51f68bc4bf49c3a24db8022de42e54,nivolumab,0.485373
uuid-3e51f68bc4bf49c3a24db8022de42e54,toxicity,0.315929
uuid-3e51f68bc4bf49c3a24db8022de42e54,regimen,0.459607
uuid-3e51f68bc4bf49c3a24db8022de42e54,treated,0.408363
uuid-3e51f68bc4bf49c3a24db8022de42e54,combination,0.496103
uuid-3e51f68bc4bf49c3a24db8022de42e54,chemo,0.405765
uuid-3e51f68bc4bf49c3a24db8022de42e54,pts,0.453814
uuid-3e51f68bc4bf49c3a24db8022de42e54,monotherapy,0.505605
uuid-3e51f68bc4bf49c3a24db8022de42e54,treatment,0.56404
uuid-3e51f68bc4bf49c3a24db8022de42e54,response,0.437452
uuid-3e51f68bc4bf49c3a24db8022de42e54,combo,0.439452
uuid-3e51f68bc4bf49c3a24db8022de42e54,PD1,0.62094
uuid-3e51f68bc4bf49c3a24db8022de42e54,progression,0.552316
uuid-3e51f68bc4bf49c3a24db8022de42e54,chemotherapy,0.384415
uuid-3e51f68bc4bf49c3a24db8022de42e54,respond,0.44896
uuid-3e51f68bc4bf49c3a24db8022de42e54,PD-1,0.438164
uuid-3e51f68bc4bf49c3a24db8022de42e54,option,0.359905
uuid-d2d260090e434707b882a74e7c1b0ffe,Opdivo,0.407215
uuid-d2d260090e434707b882a74e7c1b0ffe,physicians,0.617288
uuid-d2d260090e434707b882a74e7c1b0ffe,oncology,0.33847
uuid-d2d260090e434707b882a74e7c1b0ffe,drug,0.487972
uuid-d2d260090e434707b882a74e7c1b0ffe,clinical,0.36228
uuid-d2d260090e434707b882a74e7c1b0ffe,flat dosing,0.377417
uuid-41a3de15d9b14e3998ec5ad111963d35,dose,0.500587
uuid-41a3de15d9b14e3998ec5ad111963d35,toxicity,0.409036
uuid-41a3de15d9b14e3998ec5ad111963d35,regimen,0.352369
uuid-41a3de15d9b14e3998ec5ad111963d35,physicians,0.557695
uuid-41a3de15d9b14e3998ec5ad111963d35,treatment,0.399903
uuid-0f91af25afb54804b911e14fceb2e7e4,therapy,0.32003
uuid-0f91af25afb54804b911e14fceb2e7e4,nivolumab,0.302569
uuid-0f91af25afb54804b911e14fceb2e7e4,regimen,0.49863
uuid-0f91af25afb54804b911e14fceb2e7e4,combination,0.620676
uuid-0f91af25afb54804b911e14fceb2e7e4,chemo,0.450582
uuid-0f91af25afb54804b911e14fceb2e7e4,IO,0.790717
uuid-0f91af25afb54804b911e14fceb2e7e4,agents,0.419807
uuid-0f91af25afb54804b911e14fceb2e7e4,preferred,0.356735
uuid-0f91af25afb54804b911e14fceb2e7e4,monotherapy,0.602227
uuid-0f91af25afb54804b911e14fceb2e7e4,combo,0.586305
uuid-0f91af25afb54804b911e14fceb2e7e4,PD1,0.392747
uuid-0f91af25afb54804b911e14fceb2e7e4,progression,0.332532
uuid-0f91af25afb54804b911e14fceb2e7e4,believes,0.337649
uuid-0f91af25afb54804b911e14fceb2e7e4,chemotherapy,0.444298
uuid-0f91af25afb54804b911e14fceb2e7e4,feels,0.366924
uuid-0f91af25afb54804b911e14fceb2e7e4,RTL stated,0.329501
uuid-0f91af25afb54804b911e14fceb2e7e4,option,0.445273
uuid-f562cbf9a31943ca9e670a092d40f7ba,BMS,0.612872
uuid-f562cbf9a31943ca9e670a092d40f7ba,PDL1,0.413458
uuid-f562cbf9a31943ca9e670a092d40f7ba,trial,0.551682
uuid-f562cbf9a31943ca9e670a092d40f7ba,efficacy,0.418544
uuid-f562cbf9a31943ca9e670a092d40f7ba,Merck,0.471989
uuid-f562cbf9a31943ca9e670a092d40f7ba,OS,0.316985
uuid-f562cbf9a31943ca9e670a092d40f7ba,regards,0.356866
uuid-f562cbf9a31943ca9e670a092d40f7ba,data,0.523164
uuid-f562cbf9a31943ca9e670a092d40f7ba,PFS,0.347324
uuid-f562cbf9a31943ca9e670a092d40f7ba,ORR,0.393
uuid-f562cbf9a31943ca9e670a092d40f7ba,nivo and pembro,0.358877
uuid-f562cbf9a31943ca9e670a092d40f7ba,believes,0.303625
uuid-f562cbf9a31943ca9e670a092d40f7ba,impressed,0.342361
uuid-f562cbf9a31943ca9e670a092d40f7ba,feels,0.529936
uuid-f562cbf9a31943ca9e670a092d40f7ba,PDL1 expression,0.411321
uuid-f562cbf9a31943ca9e670a092d40f7ba,biomarker,0.369259
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,Opdivo,0.328454
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,dose,0.597527
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,efficacy,0.367819
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,Ipi,0.328558
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,vs,0.372057
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,drug,0.380354
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,Keytruda,0.522419
uuid-c1cb9fbcc1d14435919cb586f4f46b4e,flat dosing,0.630339
uuid-430aaab3db59471f940b55902baa2832,patients,0.490499
uuid-430aaab3db59471f940b55902baa2832,pts,0.308912
uuid-430aaab3db59471f940b55902baa2832,physicians,0.321629
uuid-430aaab3db59471f940b55902baa2832,treatment,0.337391
uuid-430aaab3db59471f940b55902baa2832,clinical trials,0.371747
uuid-430aaab3db59471f940b55902baa2832,feels,0.620437
uuid-430aaab3db59471f940b55902baa2832,option,0.314712
uuid-5541439034a8426ea3c6001d15173379,trial,0.380448
uuid-5541439034a8426ea3c6001d15173379,efficacy,0.381873
uuid-5541439034a8426ea3c6001d15173379,commented,0.381005
uuid-5541439034a8426ea3c6001d15173379,OS,0.599272
uuid-5541439034a8426ea3c6001d15173379,data,0.561462
uuid-5541439034a8426ea3c6001d15173379,PFS,0.522278
uuid-5541439034a8426ea3c6001d15173379,ORR,0.58764
uuid-5541439034a8426ea3c6001d15173379,ASCO,0.319049
uuid-5541439034a8426ea3c6001d15173379,impressed,0.64132
uuid-8abb9048e0c840088a874bae76b6cf56,nivolumab,0.333279
uuid-8abb9048e0c840088a874bae76b6cf56,1L,0.407629
uuid-8abb9048e0c840088a874bae76b6cf56,trial,0.326948
uuid-8abb9048e0c840088a874bae76b6cf56,RCC,0.336057
uuid-8abb9048e0c840088a874bae76b6cf56,combination,0.34666
uuid-8abb9048e0c840088a874bae76b6cf56,chemo,0.325004
uuid-8abb9048e0c840088a874bae76b6cf56,2L,0.361813
uuid-8abb9048e0c840088a874bae76b6cf56,approval,0.352759
uuid-8abb9048e0c840088a874bae76b6cf56,preferred,0.448765
uuid-8abb9048e0c840088a874bae76b6cf56,monotherapy,0.338809
uuid-8abb9048e0c840088a874bae76b6cf56,using nivo,0.378854
uuid-8abb9048e0c840088a874bae76b6cf56,combo,0.305907
uuid-8abb9048e0c840088a874bae76b6cf56,clinical trials,0.373488
uuid-8abb9048e0c840088a874bae76b6cf56,indication,0.393474
uuid-8abb9048e0c840088a874bae76b6cf56,approved,0.353182
uuid-8abb9048e0c840088a874bae76b6cf56,SCCHN,0.424272
uuid-8abb9048e0c840088a874bae76b6cf56,chemotherapy,0.407256
uuid-8abb9048e0c840088a874bae76b6cf56,feels,0.313648
uuid-8abb9048e0c840088a874bae76b6cf56,RTL stated,0.417028
uuid-8abb9048e0c840088a874bae76b6cf56,option,0.470246
uuid-8abb9048e0c840088a874bae76b6cf56,bladder,0.474386
uuid-59c5649455814efb888b8590b88ea5b2,efficacy,0.387614
uuid-59c5649455814efb888b8590b88ea5b2,oncology,0.364203
uuid-59c5649455814efb888b8590b88ea5b2,clinical,0.359084
uuid-3e49e13430c14236bde904ca9af7088b,RTL,0.422781
uuid-3e49e13430c14236bde904ca9af7088b,lung,0.495328
uuid-3e49e13430c14236bde904ca9af7088b,1L,0.344496
uuid-3e49e13430c14236bde904ca9af7088b,treated,0.38598
uuid-3e49e13430c14236bde904ca9af7088b,discussed,0.301322
uuid-3e49e13430c14236bde904ca9af7088b,melanoma,0.468388
uuid-3e49e13430c14236bde904ca9af7088b,commented,0.415306
uuid-3e49e13430c14236bde904ca9af7088b,RCC,0.631522
uuid-3e49e13430c14236bde904ca9af7088b,TL stated,0.454956
uuid-3e49e13430c14236bde904ca9af7088b,2L,0.329334
uuid-3e49e13430c14236bde904ca9af7088b,stated,0.442451
uuid-3e49e13430c14236bde904ca9af7088b,using nivo,0.390108
uuid-3e49e13430c14236bde904ca9af7088b,clinical trials,0.320566
uuid-3e49e13430c14236bde904ca9af7088b,SCCHN,0.555673
uuid-3e49e13430c14236bde904ca9af7088b,impressed,0.384686
uuid-3e49e13430c14236bde904ca9af7088b,tumor types,0.319826
uuid-3e49e13430c14236bde904ca9af7088b,LTL,0.343462
uuid-3e49e13430c14236bde904ca9af7088b,TLs,0.492794
uuid-3e49e13430c14236bde904ca9af7088b,academic,0.429034
uuid-3e49e13430c14236bde904ca9af7088b,feels,0.309275
uuid-3e49e13430c14236bde904ca9af7088b,Regional TL,0.49738
uuid-3e49e13430c14236bde904ca9af7088b,RTL stated,0.58762
uuid-3e49e13430c14236bde904ca9af7088b,TL shared,0.567712
uuid-3e49e13430c14236bde904ca9af7088b,bladder,0.375539
uuid-895d5a35fad84063b5e3ffcb9b9a941e,TL,0.779392
uuid-895d5a35fad84063b5e3ffcb9b9a941e,TL stated,0.323249
uuid-895d5a35fad84063b5e3ffcb9b9a941e,Merck,0.385786
uuid-895d5a35fad84063b5e3ffcb9b9a941e,institution,0.388428
uuid-895d5a35fad84063b5e3ffcb9b9a941e,PD-L1,0.683694
uuid-895d5a35fad84063b5e3ffcb9b9a941e,PD-L1 testing,0.818948
uuid-895d5a35fad84063b5e3ffcb9b9a941e,testing,0.750512
uuid-895d5a35fad84063b5e3ffcb9b9a941e,PDL1 testing,0.496467
uuid-895d5a35fad84063b5e3ffcb9b9a941e,NSCLC patients,0.402209
uuid-895d5a35fad84063b5e3ffcb9b9a941e,assay,0.833028
uuid-895d5a35fad84063b5e3ffcb9b9a941e,biomarker,0.346445
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,toxicity,0.480484
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,regimen,0.363584
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,treated,0.309504
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,treatment,0.383534
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,response,0.359685
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,progression,0.342718
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,respond,0.352339
uuid-abcd29ed04c94c6f8ed78a67cf3b5a15,immunotherapy,0.336617
uuid-67ca292d7ed64015937f56596888334b,TL,0.682898
uuid-67ca292d7ed64015937f56596888334b,PDL1,0.301472
uuid-67ca292d7ed64015937f56596888334b,TL stated,0.327661
uuid-67ca292d7ed64015937f56596888334b,institution,0.410947
uuid-67ca292d7ed64015937f56596888334b,PD-L1,0.744248
uuid-67ca292d7ed64015937f56596888334b,PD-L1 testing,0.856958
uuid-67ca292d7ed64015937f56596888334b,testing,0.761222
uuid-67ca292d7ed64015937f56596888334b,PDL1 testing,0.55843
uuid-67ca292d7ed64015937f56596888334b,NSCLC patients,0.478836
uuid-67ca292d7ed64015937f56596888334b,indicated,0.373614
uuid-67ca292d7ed64015937f56596888334b,assay,0.731481
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,nivolumab,0.307722
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,regimen,0.340241
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,shared,0.498794
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,combination,0.722237
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,chemo,0.302408
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,IO,0.486134
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,agents,0.413045
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,Ipi,0.340812
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,monotherapy,0.44582
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,combo,0.661129
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,PD1,0.357072
uuid-f2d6eb6db5614fea88e7aa3a1d23f864,chemotherapy,0.363538
uuid-26b4816705614caead0a4e96c8452f7f,Nivo,0.316042
uuid-26b4816705614caead0a4e96c8452f7f,patients,0.350971
uuid-26b4816705614caead0a4e96c8452f7f,Opdivo,0.457284
uuid-26b4816705614caead0a4e96c8452f7f,pembro,0.332013
uuid-26b4816705614caead0a4e96c8452f7f,dose,0.883634
uuid-26b4816705614caead0a4e96c8452f7f,toxicity,0.41034
uuid-26b4816705614caead0a4e96c8452f7f,regimen,0.433656
uuid-26b4816705614caead0a4e96c8452f7f,Ipi,0.613308
uuid-26b4816705614caead0a4e96c8452f7f,combo,0.307898
uuid-26b4816705614caead0a4e96c8452f7f,vs,0.517938
uuid-26b4816705614caead0a4e96c8452f7f,Keytruda,0.35785
uuid-26b4816705614caead0a4e96c8452f7f,flat dosing,0.704281
uuid-60d96f153955438f8a533de9ea6ebc92,physicians,0.673106
uuid-60d96f153955438f8a533de9ea6ebc92,oncology,0.399174
uuid-60d96f153955438f8a533de9ea6ebc92,drug,0.389457
uuid-60d96f153955438f8a533de9ea6ebc92,clinical,0.462876
uuid-7758b50f921d48be8e7701a426ebd236,physicians,0.572363
uuid-7758b50f921d48be8e7701a426ebd236,oncology,0.390217
uuid-7758b50f921d48be8e7701a426ebd236,clinical,0.360644
uuid-d71add936e1f4f21b4e6444ed85ff2b6,pembro,0.327282
uuid-d71add936e1f4f21b4e6444ed85ff2b6,lung,0.464104
uuid-d71add936e1f4f21b4e6444ed85ff2b6,1L,0.398821
uuid-d71add936e1f4f21b4e6444ed85ff2b6,PDL1,0.394571
uuid-d71add936e1f4f21b4e6444ed85ff2b6,2L,0.314593
uuid-d71add936e1f4f21b4e6444ed85ff2b6,atezo,0.310832
uuid-d71add936e1f4f21b4e6444ed85ff2b6,regards,0.412339
uuid-d71add936e1f4f21b4e6444ed85ff2b6,indication,0.319964
uuid-d71add936e1f4f21b4e6444ed85ff2b6,AI,0.611894
uuid-d71add936e1f4f21b4e6444ed85ff2b6,nivo and pembro,0.514753
uuid-d71add936e1f4f21b4e6444ed85ff2b6,PDL1 expression,0.316903
uuid-d71add936e1f4f21b4e6444ed85ff2b6,NCCN,0.358342
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,patients,0.574061
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,Opdivo,0.374632
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,therapy,0.519935
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,nivolumab,0.398874
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,regimen,0.57667
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,treated,0.46143
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,pts,0.546771
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,monotherapy,0.387407
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,treatment,0.675278
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,response,0.38639
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,PD1,0.374435
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,progression,0.682858
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,chemotherapy,0.319386
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,respond,0.446292
uuid-d0054a7060f94747a0fa7fb53cb8c8c6,option,0.309882
uuid-86263dbc38864331a89b458e47f17991,pembro,0.312841
uuid-86263dbc38864331a89b458e47f17991,BMS,0.480434
uuid-86263dbc38864331a89b458e47f17991,1L,0.403226
uuid-86263dbc38864331a89b458e47f17991,PDL1,0.487257
uuid-86263dbc38864331a89b458e47f17991,trial,0.475259
uuid-86263dbc38864331a89b458e47f17991,efficacy,0.537187
uuid-86263dbc38864331a89b458e47f17991,chemo,0.312953
uuid-86263dbc38864331a89b458e47f17991,OS,0.676206
uuid-86263dbc38864331a89b458e47f17991,data,0.661078
uuid-86263dbc38864331a89b458e47f17991,combo,0.371498
uuid-86263dbc38864331a89b458e47f17991,PFS,0.665113
uuid-86263dbc38864331a89b458e47f17991,ORR,0.651562
uuid-86263dbc38864331a89b458e47f17991,nivo and pembro,0.566562
uuid-86263dbc38864331a89b458e47f17991,believes,0.495847
uuid-86263dbc38864331a89b458e47f17991,impressed,0.517763
uuid-86263dbc38864331a89b458e47f17991,TLs,0.309793
uuid-86263dbc38864331a89b458e47f17991,feels,0.534509
uuid-86263dbc38864331a89b458e47f17991,PDL1 expression,0.443827
uuid-b93a80567c89469398e2cce011202136,pembro,0.366162
uuid-b93a80567c89469398e2cce011202136,BMS,0.609284
uuid-b93a80567c89469398e2cce011202136,trial,0.593501
uuid-b93a80567c89469398e2cce011202136,shared,0.355171
uuid-b93a80567c89469398e2cce011202136,Merck,0.673743
uuid-b93a80567c89469398e2cce011202136,institution,0.344036
uuid-b93a80567c89469398e2cce011202136,stated,0.413126
uuid-b93a80567c89469398e2cce011202136,approval,0.429031
uuid-b93a80567c89469398e2cce011202136,data,0.364926
uuid-b93a80567c89469398e2cce011202136,clinical trials,0.37794
uuid-b93a80567c89469398e2cce011202136,indication,0.328026
uuid-b93a80567c89469398e2cce011202136,approved,0.398404
uuid-b93a80567c89469398e2cce011202136,label,0.365322
uuid-e94935d637d84619b235de46c35d0f07,tumor,0.389502
uuid-e94935d637d84619b235de46c35d0f07,physicians,0.426745
uuid-e94935d637d84619b235de46c35d0f07,response,0.3056
uuid-e94935d637d84619b235de46c35d0f07,progression,0.309822
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,patients,0.782463
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,Opdivo,0.364509
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,therapy,0.483147
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,nivolumab,0.38658
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,toxicity,0.358564
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,regimen,0.519819
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,treated,0.5635
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,chemo,0.307718
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,pts,0.647976
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,treatment,0.702101
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,response,0.573507
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,progression,0.769995
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,chemotherapy,0.324672
uuid-3c2bc3d9c1e04a259fdca14178f5bb4d,respond,0.621143
uuid-6d31443b93c1424db38c3641fd289e86,institution,0.38317
uuid-6d31443b93c1424db38c3641fd289e86,AI,0.627794
uuid-6d31443b93c1424db38c3641fd289e86,oncology,0.746412
uuid-6d31443b93c1424db38c3641fd289e86,drug,0.341337
uuid-6d31443b93c1424db38c3641fd289e86,clinical,0.398709
uuid-6d31443b93c1424db38c3641fd289e86,NCCN,0.36558
uuid-86c207b59bd945eb9e3081fcfdfbc704,patients,0.397889
uuid-86c207b59bd945eb9e3081fcfdfbc704,toxicity,0.387031
uuid-86c207b59bd945eb9e3081fcfdfbc704,regimen,0.315828
uuid-86c207b59bd945eb9e3081fcfdfbc704,pts,0.375826
uuid-86c207b59bd945eb9e3081fcfdfbc704,clinical trials,0.330538
uuid-86c207b59bd945eb9e3081fcfdfbc704,impressed,0.30446
uuid-86c207b59bd945eb9e3081fcfdfbc704,feels,0.376566
uuid-86c207b59bd945eb9e3081fcfdfbc704,TL shared,0.313382
uuid-a64848b55dc04ffb86437412710ec84f,patients,0.340453
uuid-a64848b55dc04ffb86437412710ec84f,pts,0.345683
uuid-a64848b55dc04ffb86437412710ec84f,OS,0.301574
uuid-a64848b55dc04ffb86437412710ec84f,data,0.403587
uuid-a64848b55dc04ffb86437412710ec84f,ORR,0.339066
uuid-a64848b55dc04ffb86437412710ec84f,impressed,0.462254
uuid-a64848b55dc04ffb86437412710ec84f,feels,0.530587
uuid-17d0751729344ffda4bfb0f0d0d2c420,Nivo,0.360885
uuid-17d0751729344ffda4bfb0f0d0d2c420,BMS,0.306866
uuid-17d0751729344ffda4bfb0f0d0d2c420,trial,0.586683
uuid-17d0751729344ffda4bfb0f0d0d2c420,efficacy,0.547583
uuid-17d0751729344ffda4bfb0f0d0d2c420,combination,0.591064
uuid-17d0751729344ffda4bfb0f0d0d2c420,chemo,0.440063
uuid-17d0751729344ffda4bfb0f0d0d2c420,agents,0.410433
uuid-17d0751729344ffda4bfb0f0d0d2c420,Ipi,0.357049
uuid-17d0751729344ffda4bfb0f0d0d2c420,OS,0.371982
uuid-17d0751729344ffda4bfb0f0d0d2c420,monotherapy,0.367042
uuid-17d0751729344ffda4bfb0f0d0d2c420,data,0.4609
uuid-17d0751729344ffda4bfb0f0d0d2c420,combo,0.560666
uuid-17d0751729344ffda4bfb0f0d0d2c420,PFS,0.376005
uuid-17d0751729344ffda4bfb0f0d0d2c420,ORR,0.449189
uuid-17d0751729344ffda4bfb0f0d0d2c420,nivo and pembro,0.388913
uuid-17d0751729344ffda4bfb0f0d0d2c420,believes,0.485258
uuid-17d0751729344ffda4bfb0f0d0d2c420,chemotherapy,0.38434
uuid-17d0751729344ffda4bfb0f0d0d2c420,impressed,0.395036
uuid-17d0751729344ffda4bfb0f0d0d2c420,feels,0.591521
uuid-7f3e5d6b871546e28cfd71539980aebf,trial,0.379207
uuid-7f3e5d6b871546e28cfd71539980aebf,efficacy,0.493787
uuid-7f3e5d6b871546e28cfd71539980aebf,combination,0.408885
uuid-7f3e5d6b871546e28cfd71539980aebf,chemo,0.334788
uuid-7f3e5d6b871546e28cfd71539980aebf,IO,0.37877
uuid-7f3e5d6b871546e28cfd71539980aebf,OS,0.573089
uuid-7f3e5d6b871546e28cfd71539980aebf,monotherapy,0.333171
uuid-7f3e5d6b871546e28cfd71539980aebf,response,0.327927
uuid-7f3e5d6b871546e28cfd71539980aebf,data,0.599486
uuid-7f3e5d6b871546e28cfd71539980aebf,combo,0.479572
uuid-7f3e5d6b871546e28cfd71539980aebf,PFS,0.518835
uuid-7f3e5d6b871546e28cfd71539980aebf,ORR,0.637456
uuid-7f3e5d6b871546e28cfd71539980aebf,nivo and pembro,0.321439
uuid-7f3e5d6b871546e28cfd71539980aebf,believes,0.434234
uuid-7f3e5d6b871546e28cfd71539980aebf,impressed,0.569582
uuid-7f3e5d6b871546e28cfd71539980aebf,feels,0.498673
uuid-53b197e90b26439c8f7c92c5769fb7a8,Nivo,0.54584
uuid-53b197e90b26439c8f7c92c5769fb7a8,pembro,0.370214
uuid-53b197e90b26439c8f7c92c5769fb7a8,trial,0.354116
uuid-53b197e90b26439c8f7c92c5769fb7a8,efficacy,0.690951
uuid-53b197e90b26439c8f7c92c5769fb7a8,chemo,0.391844
uuid-53b197e90b26439c8f7c92c5769fb7a8,Ipi,0.345048
uuid-53b197e90b26439c8f7c92c5769fb7a8,OS,0.619901
uuid-53b197e90b26439c8f7c92c5769fb7a8,data,0.52248
uuid-53b197e90b26439c8f7c92c5769fb7a8,PFS,0.608135
uuid-53b197e90b26439c8f7c92c5769fb7a8,ORR,0.641555
uuid-53b197e90b26439c8f7c92c5769fb7a8,nivo and pembro,0.400896
uuid-53b197e90b26439c8f7c92c5769fb7a8,believes,0.300273
uuid-53b197e90b26439c8f7c92c5769fb7a8,chemotherapy,0.352871
uuid-53b197e90b26439c8f7c92c5769fb7a8,impressed,0.475999
uuid-53b197e90b26439c8f7c92c5769fb7a8,vs,0.490445
uuid-53b197e90b26439c8f7c92c5769fb7a8,feels,0.560789
uuid-cf126a12f1d441eb98b8b7260588e60c,TL,0.702213
uuid-cf126a12f1d441eb98b8b7260588e60c,TL stated,0.364754
uuid-cf126a12f1d441eb98b8b7260588e60c,institution,0.370796
uuid-cf126a12f1d441eb98b8b7260588e60c,PD-L1,0.750064
uuid-cf126a12f1d441eb98b8b7260588e60c,PD-L1 testing,0.887882
uuid-cf126a12f1d441eb98b8b7260588e60c,testing,0.818189
uuid-cf126a12f1d441eb98b8b7260588e60c,PDL1 testing,0.579099
uuid-cf126a12f1d441eb98b8b7260588e60c,NSCLC patients,0.513425
uuid-cf126a12f1d441eb98b8b7260588e60c,assay,0.818659
uuid-2bdf4dc093a747aa8413cf46d1225817,RTL,0.32673
uuid-2bdf4dc093a747aa8413cf46d1225817,commented,0.432399
uuid-2bdf4dc093a747aa8413cf46d1225817,stated,0.360262
uuid-2bdf4dc093a747aa8413cf46d1225817,OS,0.306431
uuid-2bdf4dc093a747aa8413cf46d1225817,data,0.434189
uuid-2bdf4dc093a747aa8413cf46d1225817,expressed,0.355585
uuid-2bdf4dc093a747aa8413cf46d1225817,ASCO,0.380092
uuid-2bdf4dc093a747aa8413cf46d1225817,impressed,0.456161
uuid-0b1df65f46b44714aadf9630a744ece0,Opdivo,0.336697
uuid-0b1df65f46b44714aadf9630a744ece0,dose,0.605151
uuid-0b1df65f46b44714aadf9630a744ece0,toxicity,0.420416
uuid-0b1df65f46b44714aadf9630a744ece0,efficacy,0.329032
uuid-0b1df65f46b44714aadf9630a744ece0,regimen,0.334184
uuid-0b1df65f46b44714aadf9630a744ece0,agents,0.312364
uuid-0b1df65f46b44714aadf9630a744ece0,atezo,0.307236
uuid-0b1df65f46b44714aadf9630a744ece0,physicians,0.422646
uuid-0b1df65f46b44714aadf9630a744ece0,preferred,0.370652
uuid-0b1df65f46b44714aadf9630a744ece0,vs,0.313414
uuid-0b1df65f46b44714aadf9630a744ece0,drug,0.356497
uuid-0b1df65f46b44714aadf9630a744ece0,flat dosing,0.521069
uuid-77fdefaabd464fce9ce3b820a7627bf5,BMS,0.631642
uuid-77fdefaabd464fce9ce3b820a7627bf5,Merck,0.498023
uuid-77fdefaabd464fce9ce3b820a7627bf5,regards,0.353534
uuid-77fdefaabd464fce9ce3b820a7627bf5,expressed,0.618699
uuid-cb6dea038e934a8fa5ea09c9f72e28ec,dose,0.553449
uuid-cb6dea038e934a8fa5ea09c9f72e28ec,toxicity,0.505037
uuid-cb6dea038e934a8fa5ea09c9f72e28ec,regimen,0.33043
uuid-cb6dea038e934a8fa5ea09c9f72e28ec,physicians,0.476341
uuid-cb6dea038e934a8fa5ea09c9f72e28ec,treatment,0.333719
uuid-9b4f3051bc884a7284fb4f314f2d359a,Opdivo,0.543062
uuid-9b4f3051bc884a7284fb4f314f2d359a,dose,0.32981
uuid-9b4f3051bc884a7284fb4f314f2d359a,physicians,0.430673
uuid-9b4f3051bc884a7284fb4f314f2d359a,expressed,0.325315
uuid-9b4f3051bc884a7284fb4f314f2d359a,oncology,0.367316
uuid-9b4f3051bc884a7284fb4f314f2d359a,drug,0.409445
uuid-9b4f3051bc884a7284fb4f314f2d359a,Keytruda,0.412156
uuid-9b4f3051bc884a7284fb4f314f2d359a,flat dosing,0.594433
uuid-91487e900ead401ca5cb15d3dfa78b31,PDL1,0.438266
uuid-91487e900ead401ca5cb15d3dfa78b31,efficacy,0.490931
uuid-91487e900ead401ca5cb15d3dfa78b31,chemo,0.402954
uuid-91487e900ead401ca5cb15d3dfa78b31,OS,0.805488
uuid-91487e900ead401ca5cb15d3dfa78b31,response,0.330499
uuid-91487e900ead401ca5cb15d3dfa78b31,data,0.451959
uuid-91487e900ead401ca5cb15d3dfa78b31,PFS,0.801016
uuid-91487e900ead401ca5cb15d3dfa78b31,PD1,0.303287
uuid-91487e900ead401ca5cb15d3dfa78b31,ORR,0.672401
uuid-91487e900ead401ca5cb15d3dfa78b31,nivo and pembro,0.451735
uuid-91487e900ead401ca5cb15d3dfa78b31,believes,0.527681
uuid-91487e900ead401ca5cb15d3dfa78b31,chemotherapy,0.360129
uuid-91487e900ead401ca5cb15d3dfa78b31,impressed,0.352273
uuid-91487e900ead401ca5cb15d3dfa78b31,feels,0.388093
uuid-91487e900ead401ca5cb15d3dfa78b31,PDL1 expression,0.342248
uuid-91487e900ead401ca5cb15d3dfa78b31,biomarker,0.300737
uuid-f67ad261032d4561b5a7f6ea019b3e17,Opdivo,0.425846
uuid-f67ad261032d4561b5a7f6ea019b3e17,BMS,0.411082
uuid-f67ad261032d4561b5a7f6ea019b3e17,shared,0.467794
uuid-f67ad261032d4561b5a7f6ea019b3e17,Merck,0.311395
uuid-f67ad261032d4561b5a7f6ea019b3e17,physicians,0.391492
uuid-f67ad261032d4561b5a7f6ea019b3e17,clinical trials,0.305611
uuid-f67ad261032d4561b5a7f6ea019b3e17,indication,0.304148
uuid-f67ad261032d4561b5a7f6ea019b3e17,approved,0.343758
uuid-f67ad261032d4561b5a7f6ea019b3e17,label,0.305389
uuid-f67ad261032d4561b5a7f6ea019b3e17,drug,0.602138
uuid-f67ad261032d4561b5a7f6ea019b3e17,Keytruda,0.399384
uuid-f67ad261032d4561b5a7f6ea019b3e17,flat dosing,0.453012
uuid-609cd34c7811424e886a3b680eb9eb37,Nivo,0.435478
uuid-609cd34c7811424e886a3b680eb9eb37,patients,0.70288
uuid-609cd34c7811424e886a3b680eb9eb37,Opdivo,0.366342
uuid-609cd34c7811424e886a3b680eb9eb37,therapy,0.556618
uuid-609cd34c7811424e886a3b680eb9eb37,nivolumab,0.442329
uuid-609cd34c7811424e886a3b680eb9eb37,toxicity,0.425535
uuid-609cd34c7811424e886a3b680eb9eb37,regimen,0.593499
uuid-609cd34c7811424e886a3b680eb9eb37,treated,0.425208
uuid-609cd34c7811424e886a3b680eb9eb37,combination,0.379421
uuid-609cd34c7811424e886a3b680eb9eb37,chemo,0.46537
uuid-609cd34c7811424e886a3b680eb9eb37,pts,0.689896
uuid-609cd34c7811424e886a3b680eb9eb37,monotherapy,0.55017
uuid-609cd34c7811424e886a3b680eb9eb37,treatment,0.59825
uuid-609cd34c7811424e886a3b680eb9eb37,using nivo,0.306437
uuid-609cd34c7811424e886a3b680eb9eb37,response,0.490536
uuid-609cd34c7811424e886a3b680eb9eb37,combo,0.401739
uuid-609cd34c7811424e886a3b680eb9eb37,PD1,0.514559
uuid-609cd34c7811424e886a3b680eb9eb37,progression,0.727271
uuid-609cd34c7811424e886a3b680eb9eb37,chemotherapy,0.416557
uuid-609cd34c7811424e886a3b680eb9eb37,respond,0.583393
uuid-609cd34c7811424e886a3b680eb9eb37,option,0.423183
uuid-8f0e927ddc1848c68c6c7067597fd8ea,Nivo,0.387948
uuid-8f0e927ddc1848c68c6c7067597fd8ea,NSCLC,0.32819
uuid-8f0e927ddc1848c68c6c7067597fd8ea,1L,0.563024
uuid-8f0e927ddc1848c68c6c7067597fd8ea,efficacy,0.344799
uuid-8f0e927ddc1848c68c6c7067597fd8ea,regimen,0.391372
uuid-8f0e927ddc1848c68c6c7067597fd8ea,combination,0.658572
uuid-8f0e927ddc1848c68c6c7067597fd8ea,chemo,0.62722
uuid-8f0e927ddc1848c68c6c7067597fd8ea,2L,0.488904
uuid-8f0e927ddc1848c68c6c7067597fd8ea,pts,0.347143
uuid-8f0e927ddc1848c68c6c7067597fd8ea,IO,0.649153
uuid-8f0e927ddc1848c68c6c7067597fd8ea,agents,0.542489
uuid-8f0e927ddc1848c68c6c7067597fd8ea,Ipi,0.332447
uuid-8f0e927ddc1848c68c6c7067597fd8ea,preferred,0.401091
uuid-8f0e927ddc1848c68c6c7067597fd8ea,monotherapy,0.71682
uuid-8f0e927ddc1848c68c6c7067597fd8ea,response,0.353359
uuid-8f0e927ddc1848c68c6c7067597fd8ea,combo,0.727871
uuid-8f0e927ddc1848c68c6c7067597fd8ea,PD1,0.577408
uuid-8f0e927ddc1848c68c6c7067597fd8ea,nivo and pembro,0.310607
uuid-8f0e927ddc1848c68c6c7067597fd8ea,progression,0.303866
uuid-8f0e927ddc1848c68c6c7067597fd8ea,believes,0.59049
uuid-8f0e927ddc1848c68c6c7067597fd8ea,chemotherapy,0.470178
uuid-8f0e927ddc1848c68c6c7067597fd8ea,feels,0.615777
uuid-8f0e927ddc1848c68c6c7067597fd8ea,option,0.576912
uuid-ebf2d7ed58a14e12bc7f0172a610f324,tumor,0.379888
uuid-ebf2d7ed58a14e12bc7f0172a610f324,PD-L1,0.322186
uuid-ebf2d7ed58a14e12bc7f0172a610f324,testing,0.333459
uuid-ebf2d7ed58a14e12bc7f0172a610f324,ASCO,0.318479
uuid-ebf2d7ed58a14e12bc7f0172a610f324,biomarker,0.396802
uuid-fb1fd75c21b5418eb22c2590173d4871,Nivo,0.342794
uuid-fb1fd75c21b5418eb22c2590173d4871,patients,0.556395
uuid-fb1fd75c21b5418eb22c2590173d4871,therapy,0.421967
uuid-fb1fd75c21b5418eb22c2590173d4871,1L,0.508749
uuid-fb1fd75c21b5418eb22c2590173d4871,regimen,0.469693
uuid-fb1fd75c21b5418eb22c2590173d4871,combination,0.368711
uuid-fb1fd75c21b5418eb22c2590173d4871,chemo,0.588116
uuid-fb1fd75c21b5418eb22c2590173d4871,2L,0.439808
uuid-fb1fd75c21b5418eb22c2590173d4871,pts,0.522877
uuid-fb1fd75c21b5418eb22c2590173d4871,IO,0.494792
uuid-fb1fd75c21b5418eb22c2590173d4871,agents,0.324179
uuid-fb1fd75c21b5418eb22c2590173d4871,preferred,0.355148
uuid-fb1fd75c21b5418eb22c2590173d4871,monotherapy,0.671021
uuid-fb1fd75c21b5418eb22c2590173d4871,treatment,0.420066
uuid-fb1fd75c21b5418eb22c2590173d4871,using nivo,0.329509
uuid-fb1fd75c21b5418eb22c2590173d4871,response,0.409684
uuid-fb1fd75c21b5418eb22c2590173d4871,combo,0.460738
uuid-fb1fd75c21b5418eb22c2590173d4871,PD1,0.445714
uuid-fb1fd75c21b5418eb22c2590173d4871,progression,0.520857
uuid-fb1fd75c21b5418eb22c2590173d4871,believes,0.486847
uuid-fb1fd75c21b5418eb22c2590173d4871,chemotherapy,0.494411
uuid-fb1fd75c21b5418eb22c2590173d4871,respond,0.527431
uuid-fb1fd75c21b5418eb22c2590173d4871,feels,0.463099
uuid-fb1fd75c21b5418eb22c2590173d4871,option,0.62738
uuid-069a396d8dd54821bad1e4ab992b3475,pembro,0.337533
uuid-069a396d8dd54821bad1e4ab992b3475,BMS,0.467338
uuid-069a396d8dd54821bad1e4ab992b3475,trial,0.466637
uuid-069a396d8dd54821bad1e4ab992b3475,efficacy,0.538706
uuid-069a396d8dd54821bad1e4ab992b3475,commented,0.425358
uuid-069a396d8dd54821bad1e4ab992b3475,Merck,0.362554
uuid-069a396d8dd54821bad1e4ab992b3475,OS,0.42765
uuid-069a396d8dd54821bad1e4ab992b3475,regards,0.485662
uuid-069a396d8dd54821bad1e4ab992b3475,data,0.705772
uuid-069a396d8dd54821bad1e4ab992b3475,expressed,0.357411
uuid-069a396d8dd54821bad1e4ab992b3475,mentioned,0.332393
uuid-069a396d8dd54821bad1e4ab992b3475,indication,0.520105
uuid-069a396d8dd54821bad1e4ab992b3475,PFS,0.405443
uuid-069a396d8dd54821bad1e4ab992b3475,ORR,0.458093
uuid-069a396d8dd54821bad1e4ab992b3475,nivo and pembro,0.325322
uuid-069a396d8dd54821bad1e4ab992b3475,impressed,0.571655
uuid-069a396d8dd54821bad1e4ab992b3475,label,0.317212
uuid-96e5248b71314f3fbfe2752ffa413f4e,Nivo,0.499574
uuid-96e5248b71314f3fbfe2752ffa413f4e,patients,0.563114
uuid-96e5248b71314f3fbfe2752ffa413f4e,pembro,0.320008
uuid-96e5248b71314f3fbfe2752ffa413f4e,therapy,0.516078
uuid-96e5248b71314f3fbfe2752ffa413f4e,nivolumab,0.57155
uuid-96e5248b71314f3fbfe2752ffa413f4e,1L,0.383253
uuid-96e5248b71314f3fbfe2752ffa413f4e,trial,0.324282
uuid-96e5248b71314f3fbfe2752ffa413f4e,regimen,0.390787
uuid-96e5248b71314f3fbfe2752ffa413f4e,treated,0.338899
uuid-96e5248b71314f3fbfe2752ffa413f4e,combination,0.497829
uuid-96e5248b71314f3fbfe2752ffa413f4e,chemo,0.527123
uuid-96e5248b71314f3fbfe2752ffa413f4e,2L,0.375948
uuid-96e5248b71314f3fbfe2752ffa413f4e,pts,0.453855
uuid-96e5248b71314f3fbfe2752ffa413f4e,preferred,0.400525
uuid-96e5248b71314f3fbfe2752ffa413f4e,monotherapy,0.585899
uuid-96e5248b71314f3fbfe2752ffa413f4e,treatment,0.363983
uuid-96e5248b71314f3fbfe2752ffa413f4e,using nivo,0.50081
uuid-96e5248b71314f3fbfe2752ffa413f4e,combo,0.421278
uuid-96e5248b71314f3fbfe2752ffa413f4e,clinical trials,0.37068
uuid-96e5248b71314f3fbfe2752ffa413f4e,PD1,0.453817
uuid-96e5248b71314f3fbfe2752ffa413f4e,approved,0.321672
uuid-96e5248b71314f3fbfe2752ffa413f4e,progression,0.334033
uuid-96e5248b71314f3fbfe2752ffa413f4e,chemotherapy,0.631259
uuid-96e5248b71314f3fbfe2752ffa413f4e,feels,0.493802
uuid-96e5248b71314f3fbfe2752ffa413f4e,RTL stated,0.396884
uuid-96e5248b71314f3fbfe2752ffa413f4e,option,0.612351
uuid-8a04691f389e4c2d9c965968161dbf3c,patients,0.783956
uuid-8a04691f389e4c2d9c965968161dbf3c,Opdivo,0.343337
uuid-8a04691f389e4c2d9c965968161dbf3c,therapy,0.552217
uuid-8a04691f389e4c2d9c965968161dbf3c,nivolumab,0.607116
uuid-8a04691f389e4c2d9c965968161dbf3c,regimen,0.461591
uuid-8a04691f389e4c2d9c965968161dbf3c,treated,0.57
uuid-8a04691f389e4c2d9c965968161dbf3c,RCC,0.377083
uuid-8a04691f389e4c2d9c965968161dbf3c,chemo,0.342724
uuid-8a04691f389e4c2d9c965968161dbf3c,2L,0.323198
uuid-8a04691f389e4c2d9c965968161dbf3c,pts,0.469279
uuid-8a04691f389e4c2d9c965968161dbf3c,preferred,0.346582
uuid-8a04691f389e4c2d9c965968161dbf3c,monotherapy,0.440435
uuid-8a04691f389e4c2d9c965968161dbf3c,treatment,0.691958
uuid-8a04691f389e4c2d9c965968161dbf3c,using nivo,0.419359
uuid-8a04691f389e4c2d9c965968161dbf3c,PD1,0.319532
uuid-8a04691f389e4c2d9c965968161dbf3c,progression,0.549624
uuid-8a04691f389e4c2d9c965968161dbf3c,chemotherapy,0.400835
uuid-8a04691f389e4c2d9c965968161dbf3c,respond,0.361261
uuid-8a04691f389e4c2d9c965968161dbf3c,RTL stated,0.416071
uuid-8a04691f389e4c2d9c965968161dbf3c,TL shared,0.401763
uuid-8a04691f389e4c2d9c965968161dbf3c,option,0.470227
uuid-7da410b9ccd44410aa1565932ca36dc5,Opdivo,0.476933
uuid-1bd67274802e47c48a0622505d76986f,Nivo,0.352229
uuid-1bd67274802e47c48a0622505d76986f,pembro,0.379006
uuid-1bd67274802e47c48a0622505d76986f,RTL,0.442879
uuid-1bd67274802e47c48a0622505d76986f,BMS,0.347129
uuid-1bd67274802e47c48a0622505d76986f,trial,0.764877
uuid-1bd67274802e47c48a0622505d76986f,efficacy,0.427106
uuid-1bd67274802e47c48a0622505d76986f,combination,0.337219
uuid-1bd67274802e47c48a0622505d76986f,Ipi,0.396848
uuid-1bd67274802e47c48a0622505d76986f,OS,0.374478
uuid-1bd67274802e47c48a0622505d76986f,data,0.519571
uuid-1bd67274802e47c48a0622505d76986f,clinical trials,0.338967
uuid-1bd67274802e47c48a0622505d76986f,PFS,0.391976
uuid-1bd67274802e47c48a0622505d76986f,ORR,0.467366
uuid-1bd67274802e47c48a0622505d76986f,nivo and pembro,0.354223
uuid-1bd67274802e47c48a0622505d76986f,impressed,0.477344
uuid-1bd67274802e47c48a0622505d76986f,vs,0.324838
uuid-32e9eff21efa481d9367af3e91a6678a,BMS,0.339717
uuid-32e9eff21efa481d9367af3e91a6678a,combination,0.53891
uuid-32e9eff21efa481d9367af3e91a6678a,IO,0.59985
uuid-32e9eff21efa481d9367af3e91a6678a,agents,0.369276
uuid-32e9eff21efa481d9367af3e91a6678a,combo,0.47979
uuid-32e9eff21efa481d9367af3e91a6678a,believes,0.408999
uuid-32e9eff21efa481d9367af3e91a6678a,feels,0.333133
uuid-7b7e56296e3145cf9f6e47341fae4236,RTL,0.463746
uuid-7b7e56296e3145cf9f6e47341fae4236,trial,0.347707
uuid-7b7e56296e3145cf9f6e47341fae4236,NTL,0.401811
uuid-7b7e56296e3145cf9f6e47341fae4236,commented,0.530968
uuid-7b7e56296e3145cf9f6e47341fae4236,stated,0.456026
uuid-7b7e56296e3145cf9f6e47341fae4236,OS,0.402922
uuid-7b7e56296e3145cf9f6e47341fae4236,data,0.58117
uuid-7b7e56296e3145cf9f6e47341fae4236,expressed,0.385597
uuid-7b7e56296e3145cf9f6e47341fae4236,mentioned,0.357592
uuid-7b7e56296e3145cf9f6e47341fae4236,indication,0.425844
uuid-7b7e56296e3145cf9f6e47341fae4236,PFS,0.331582
uuid-7b7e56296e3145cf9f6e47341fae4236,ORR,0.38022
uuid-7b7e56296e3145cf9f6e47341fae4236,SCCHN,0.488326
uuid-7b7e56296e3145cf9f6e47341fae4236,HCP,0.337129
uuid-7b7e56296e3145cf9f6e47341fae4236,ASCO,0.428322
uuid-7b7e56296e3145cf9f6e47341fae4236,impressed,0.665217
uuid-7b7e56296e3145cf9f6e47341fae4236,LTL,0.392596
uuid-7b7e56296e3145cf9f6e47341fae4236,SCLC,0.359152
uuid-7b7e56296e3145cf9f6e47341fae4236,feels,0.338307
uuid-7b7e56296e3145cf9f6e47341fae4236,Regional TL,0.496972
uuid-7b7e56296e3145cf9f6e47341fae4236,bladder,0.322602
uuid-efef56fd8a1840aba4ba1c69e45c2a47,Opdivo,0.648502
uuid-efef56fd8a1840aba4ba1c69e45c2a47,dose,0.363786
uuid-efef56fd8a1840aba4ba1c69e45c2a47,regimen,0.362438
uuid-efef56fd8a1840aba4ba1c69e45c2a47,preferred,0.365499
uuid-efef56fd8a1840aba4ba1c69e45c2a47,indication,0.369729
uuid-efef56fd8a1840aba4ba1c69e45c2a47,approved,0.500591
uuid-efef56fd8a1840aba4ba1c69e45c2a47,label,0.337035
uuid-efef56fd8a1840aba4ba1c69e45c2a47,drug,0.497183
uuid-efef56fd8a1840aba4ba1c69e45c2a47,Keytruda,0.461702
uuid-efef56fd8a1840aba4ba1c69e45c2a47,option,0.337474
uuid-efef56fd8a1840aba4ba1c69e45c2a47,flat dosing,0.389317
uuid-1059d023585f4cb69fd0d598db49b01d,Nivo,0.496442
uuid-1059d023585f4cb69fd0d598db49b01d,toxicity,0.301024
uuid-1059d023585f4cb69fd0d598db49b01d,trial,0.431254
uuid-1059d023585f4cb69fd0d598db49b01d,efficacy,0.674803
uuid-1059d023585f4cb69fd0d598db49b01d,regimen,0.370046
uuid-1059d023585f4cb69fd0d598db49b01d,combination,0.591256
uuid-1059d023585f4cb69fd0d598db49b01d,chemo,0.498665
uuid-1059d023585f4cb69fd0d598db49b01d,IO,0.366273
uuid-1059d023585f4cb69fd0d598db49b01d,agents,0.356429
uuid-1059d023585f4cb69fd0d598db49b01d,Ipi,0.551425
uuid-1059d023585f4cb69fd0d598db49b01d,OS,0.522909
uuid-1059d023585f4cb69fd0d598db49b01d,monotherapy,0.470033
uuid-1059d023585f4cb69fd0d598db49b01d,data,0.386242
uuid-1059d023585f4cb69fd0d598db49b01d,combo,0.697521
uuid-1059d023585f4cb69fd0d598db49b01d,PFS,0.47548
uuid-1059d023585f4cb69fd0d598db49b01d,PD1,0.380422
uuid-1059d023585f4cb69fd0d598db49b01d,ORR,0.552744
uuid-1059d023585f4cb69fd0d598db49b01d,nivo and pembro,0.398382
uuid-1059d023585f4cb69fd0d598db49b01d,believes,0.491473
uuid-1059d023585f4cb69fd0d598db49b01d,chemotherapy,0.419329
uuid-1059d023585f4cb69fd0d598db49b01d,impressed,0.359515
uuid-1059d023585f4cb69fd0d598db49b01d,vs,0.332795
uuid-1059d023585f4cb69fd0d598db49b01d,feels,0.439855
uuid-1059d023585f4cb69fd0d598db49b01d,option,0.322097
uuid-24a15aa2d4f84e889816c3f3bf1261e3,Nivo,0.404268
uuid-24a15aa2d4f84e889816c3f3bf1261e3,pembro,0.353324
uuid-24a15aa2d4f84e889816c3f3bf1261e3,dose,0.324691
uuid-24a15aa2d4f84e889816c3f3bf1261e3,toxicity,0.300581
uuid-24a15aa2d4f84e889816c3f3bf1261e3,efficacy,0.66029
uuid-24a15aa2d4f84e889816c3f3bf1261e3,regimen,0.300272
uuid-24a15aa2d4f84e889816c3f3bf1261e3,combination,0.308954
uuid-24a15aa2d4f84e889816c3f3bf1261e3,chemo,0.35939
uuid-24a15aa2d4f84e889816c3f3bf1261e3,agents,0.387523
uuid-24a15aa2d4f84e889816c3f3bf1261e3,Ipi,0.398075
uuid-24a15aa2d4f84e889816c3f3bf1261e3,atezo,0.367845
uuid-24a15aa2d4f84e889816c3f3bf1261e3,monotherapy,0.319378
uuid-24a15aa2d4f84e889816c3f3bf1261e3,data,0.389363
uuid-24a15aa2d4f84e889816c3f3bf1261e3,combo,0.327426
uuid-24a15aa2d4f84e889816c3f3bf1261e3,indication,0.350516
uuid-24a15aa2d4f84e889816c3f3bf1261e3,believes,0.394158
uuid-24a15aa2d4f84e889816c3f3bf1261e3,impressed,0.350635
uuid-24a15aa2d4f84e889816c3f3bf1261e3,vs,0.384373
uuid-24a15aa2d4f84e889816c3f3bf1261e3,feels,0.454337
uuid-093d099aa4e44fe19c4f353ef5df46d0,Nivo,0.429817
uuid-093d099aa4e44fe19c4f353ef5df46d0,patients,0.369322
uuid-093d099aa4e44fe19c4f353ef5df46d0,therapy,0.576085
uuid-093d099aa4e44fe19c4f353ef5df46d0,nivolumab,0.351212
uuid-093d099aa4e44fe19c4f353ef5df46d0,toxicity,0.49909
uuid-093d099aa4e44fe19c4f353ef5df46d0,efficacy,0.334739
uuid-093d099aa4e44fe19c4f353ef5df46d0,regimen,0.48021
uuid-093d099aa4e44fe19c4f353ef5df46d0,combination,0.519417
uuid-093d099aa4e44fe19c4f353ef5df46d0,chemo,0.496564
uuid-093d099aa4e44fe19c4f353ef5df46d0,pts,0.300526
uuid-093d099aa4e44fe19c4f353ef5df46d0,Ipi,0.33072
uuid-093d099aa4e44fe19c4f353ef5df46d0,monotherapy,0.471191
uuid-093d099aa4e44fe19c4f353ef5df46d0,treatment,0.410403
uuid-093d099aa4e44fe19c4f353ef5df46d0,response,0.54126
uuid-093d099aa4e44fe19c4f353ef5df46d0,combo,0.368653
uuid-093d099aa4e44fe19c4f353ef5df46d0,PD1,0.551649
uuid-093d099aa4e44fe19c4f353ef5df46d0,cHL,0.319573
uuid-093d099aa4e44fe19c4f353ef5df46d0,progression,0.511716
uuid-093d099aa4e44fe19c4f353ef5df46d0,chemotherapy,0.545222
uuid-093d099aa4e44fe19c4f353ef5df46d0,respond,0.360383
uuid-093d099aa4e44fe19c4f353ef5df46d0,option,0.306631
uuid-059bd56f4ef74061ba3b61483749d508,patients,0.36127
uuid-059bd56f4ef74061ba3b61483749d508,Opdivo,0.568488
uuid-059bd56f4ef74061ba3b61483749d508,dose,0.800228
uuid-059bd56f4ef74061ba3b61483749d508,toxicity,0.365531
uuid-059bd56f4ef74061ba3b61483749d508,Ipi,0.315903
uuid-059bd56f4ef74061ba3b61483749d508,indication,0.311734
uuid-059bd56f4ef74061ba3b61483749d508,vs,0.376087
uuid-059bd56f4ef74061ba3b61483749d508,drug,0.361627
uuid-059bd56f4ef74061ba3b61483749d508,Keytruda,0.519433
uuid-059bd56f4ef74061ba3b61483749d508,flat dosing,0.814123
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,Nivo,0.335636
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,patients,0.75837
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,Opdivo,0.446328
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,therapy,0.400382
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,dose,0.358266
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,nivolumab,0.36686
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,regimen,0.592261
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,treated,0.397535
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,chemo,0.40273
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,pts,0.592909
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,monotherapy,0.434103
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,treatment,0.512123
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,response,0.302175
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,progression,0.573366
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,chemotherapy,0.357709
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,respond,0.46353
uuid-f0e157ceaa9a437fbc5e6f24d5c7e986,option,0.426805
uuid-276d3a0b7fda4930a3817195c9f866bc,pembro,0.401444
uuid-276d3a0b7fda4930a3817195c9f866bc,BMS,0.664736
uuid-276d3a0b7fda4930a3817195c9f866bc,PDL1,0.383424
uuid-276d3a0b7fda4930a3817195c9f866bc,trial,0.875715
uuid-276d3a0b7fda4930a3817195c9f866bc,efficacy,0.454558
uuid-276d3a0b7fda4930a3817195c9f866bc,Merck,0.537834
uuid-276d3a0b7fda4930a3817195c9f866bc,OS,0.474496
uuid-276d3a0b7fda4930a3817195c9f866bc,data,0.56622
uuid-276d3a0b7fda4930a3817195c9f866bc,clinical trials,0.36253
uuid-276d3a0b7fda4930a3817195c9f866bc,PFS,0.512808
uuid-276d3a0b7fda4930a3817195c9f866bc,ORR,0.532244
uuid-276d3a0b7fda4930a3817195c9f866bc,nivo and pembro,0.442439
uuid-276d3a0b7fda4930a3817195c9f866bc,impressed,0.399965
uuid-276d3a0b7fda4930a3817195c9f866bc,feels,0.373583
uuid-276d3a0b7fda4930a3817195c9f866bc,PDL1 expression,0.371655
uuid-b849f3e262d14005ab3d80ecc90c4f45,tumor,0.343583
uuid-b849f3e262d14005ab3d80ecc90c4f45,believes,0.348894
uuid-b849f3e262d14005ab3d80ecc90c4f45,immunotherapy,0.448639
uuid-b849f3e262d14005ab3d80ecc90c4f45,PDL1 expression,0.333344
uuid-b849f3e262d14005ab3d80ecc90c4f45,biomarker,0.423443
uuid-8968eb35de86485298dcddc05763c89d,lung,0.329322
uuid-8968eb35de86485298dcddc05763c89d,chemo,0.348034
uuid-8968eb35de86485298dcddc05763c89d,OS,0.472756
uuid-8968eb35de86485298dcddc05763c89d,response,0.397435
uuid-8968eb35de86485298dcddc05763c89d,PFS,0.531907
uuid-8968eb35de86485298dcddc05763c89d,AI,0.637109
uuid-8968eb35de86485298dcddc05763c89d,ORR,0.448157
uuid-8968eb35de86485298dcddc05763c89d,nivo and pembro,0.383596
uuid-0f0de3bcf84947de9adc86385bba06c8,patients,0.678182
uuid-0f0de3bcf84947de9adc86385bba06c8,therapy,0.581226
uuid-0f0de3bcf84947de9adc86385bba06c8,nivolumab,0.347078
uuid-0f0de3bcf84947de9adc86385bba06c8,NSCLC,0.318882
uuid-0f0de3bcf84947de9adc86385bba06c8,1L,0.484578
uuid-0f0de3bcf84947de9adc86385bba06c8,regimen,0.495944
uuid-0f0de3bcf84947de9adc86385bba06c8,treated,0.441225
uuid-0f0de3bcf84947de9adc86385bba06c8,combination,0.372497
uuid-0f0de3bcf84947de9adc86385bba06c8,chemo,0.632762
uuid-0f0de3bcf84947de9adc86385bba06c8,2L,0.398843
uuid-0f0de3bcf84947de9adc86385bba06c8,pts,0.586423
uuid-0f0de3bcf84947de9adc86385bba06c8,IO,0.480831
uuid-0f0de3bcf84947de9adc86385bba06c8,preferred,0.323514
uuid-0f0de3bcf84947de9adc86385bba06c8,monotherapy,0.600548
uuid-0f0de3bcf84947de9adc86385bba06c8,treatment,0.567848
uuid-0f0de3bcf84947de9adc86385bba06c8,using nivo,0.343989
uuid-0f0de3bcf84947de9adc86385bba06c8,response,0.507538
uuid-0f0de3bcf84947de9adc86385bba06c8,combo,0.415197
uuid-0f0de3bcf84947de9adc86385bba06c8,PD1,0.521091
uuid-0f0de3bcf84947de9adc86385bba06c8,progression,0.684505
uuid-0f0de3bcf84947de9adc86385bba06c8,chemotherapy,0.573727
uuid-0f0de3bcf84947de9adc86385bba06c8,respond,0.451388
uuid-0f0de3bcf84947de9adc86385bba06c8,RTL stated,0.312858
uuid-0f0de3bcf84947de9adc86385bba06c8,option,0.557891
uuid-be67776c15924a07a79d8ca1368b10bc,patients,0.570668
uuid-be67776c15924a07a79d8ca1368b10bc,Opdivo,0.337622
uuid-be67776c15924a07a79d8ca1368b10bc,therapy,0.348643
uuid-be67776c15924a07a79d8ca1368b10bc,nivolumab,0.367484
uuid-be67776c15924a07a79d8ca1368b10bc,regimen,0.449559
uuid-be67776c15924a07a79d8ca1368b10bc,treated,0.669292
uuid-be67776c15924a07a79d8ca1368b10bc,physicians,0.435804
uuid-be67776c15924a07a79d8ca1368b10bc,treatment,0.631399
uuid-be67776c15924a07a79d8ca1368b10bc,progression,0.446186
uuid-be67776c15924a07a79d8ca1368b10bc,oncologist,0.335882
uuid-be67776c15924a07a79d8ca1368b10bc,respond,0.334933
uuid-f8a5da661105449499b5f10e727aaed8,Nivo,0.319811
uuid-f8a5da661105449499b5f10e727aaed8,pembro,0.562145
uuid-f8a5da661105449499b5f10e727aaed8,BMS,0.347621
uuid-f8a5da661105449499b5f10e727aaed8,PDL1,0.494934
uuid-f8a5da661105449499b5f10e727aaed8,trial,0.404457
uuid-f8a5da661105449499b5f10e727aaed8,efficacy,0.658196
uuid-f8a5da661105449499b5f10e727aaed8,agents,0.337093
uuid-f8a5da661105449499b5f10e727aaed8,OS,0.338966
uuid-f8a5da661105449499b5f10e727aaed8,atezo,0.569419
uuid-f8a5da661105449499b5f10e727aaed8,data,0.522436
uuid-f8a5da661105449499b5f10e727aaed8,PFS,0.336256
uuid-f8a5da661105449499b5f10e727aaed8,ORR,0.393847
uuid-f8a5da661105449499b5f10e727aaed8,nivo and pembro,0.646972
uuid-f8a5da661105449499b5f10e727aaed8,believes,0.443424
uuid-f8a5da661105449499b5f10e727aaed8,vs,0.580775
uuid-f8a5da661105449499b5f10e727aaed8,feels,0.408672
uuid-f8a5da661105449499b5f10e727aaed8,PDL1 expression,0.504333
uuid-0d42b26133974bc88fbb35d431b13212,patients,0.612831
uuid-0d42b26133974bc88fbb35d431b13212,therapy,0.350855
uuid-0d42b26133974bc88fbb35d431b13212,regimen,0.571534
uuid-0d42b26133974bc88fbb35d431b13212,treated,0.399483
uuid-0d42b26133974bc88fbb35d431b13212,chemo,0.456386
uuid-0d42b26133974bc88fbb35d431b13212,pts,0.496019
uuid-0d42b26133974bc88fbb35d431b13212,monotherapy,0.410534
uuid-0d42b26133974bc88fbb35d431b13212,treatment,0.509625
uuid-0d42b26133974bc88fbb35d431b13212,response,0.398663
uuid-0d42b26133974bc88fbb35d431b13212,progression,0.568709
uuid-0d42b26133974bc88fbb35d431b13212,chemotherapy,0.396539
uuid-0d42b26133974bc88fbb35d431b13212,respond,0.498666
uuid-0d42b26133974bc88fbb35d431b13212,feels,0.360805
uuid-0d42b26133974bc88fbb35d431b13212,option,0.389208
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,Nivo,0.340959
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,pembro,0.538181
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,dose,0.560488
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,trial,0.611725
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,combination,0.306132
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,Ipi,0.550654
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,atezo,0.347572
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,combo,0.341729
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,clinical trials,0.347876
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,vs,0.616951
uuid-c7d851ab2e2641bfbdedbcf6f7fa0f70,flat dosing,0.439355
uuid-006d97a32aa8400ba69bfeef124a177a,Nivo,0.385597
uuid-006d97a32aa8400ba69bfeef124a177a,patients,0.837004
uuid-006d97a32aa8400ba69bfeef124a177a,Opdivo,0.315772
uuid-006d97a32aa8400ba69bfeef124a177a,therapy,0.682158
uuid-006d97a32aa8400ba69bfeef124a177a,nivolumab,0.511735
uuid-006d97a32aa8400ba69bfeef124a177a,toxicity,0.32103
uuid-006d97a32aa8400ba69bfeef124a177a,regimen,0.664158
uuid-006d97a32aa8400ba69bfeef124a177a,treated,0.545056
uuid-006d97a32aa8400ba69bfeef124a177a,combination,0.355299
uuid-006d97a32aa8400ba69bfeef124a177a,chemo,0.542848
uuid-006d97a32aa8400ba69bfeef124a177a,pts,0.694778
uuid-006d97a32aa8400ba69bfeef124a177a,monotherapy,0.535413
uuid-006d97a32aa8400ba69bfeef124a177a,treatment,0.726788
uuid-006d97a32aa8400ba69bfeef124a177a,response,0.630013
uuid-006d97a32aa8400ba69bfeef124a177a,combo,0.300469
uuid-006d97a32aa8400ba69bfeef124a177a,PD1,0.500472
uuid-006d97a32aa8400ba69bfeef124a177a,progression,0.813941
uuid-006d97a32aa8400ba69bfeef124a177a,chemotherapy,0.53489
uuid-006d97a32aa8400ba69bfeef124a177a,respond,0.611693
uuid-006d97a32aa8400ba69bfeef124a177a,option,0.424045
uuid-0b0714a1cc9f41439fac207d31d3e651,therapy,0.301198
uuid-0b0714a1cc9f41439fac207d31d3e651,toxicity,0.44872
uuid-0b0714a1cc9f41439fac207d31d3e651,efficacy,0.348326
uuid-0b0714a1cc9f41439fac207d31d3e651,regimen,0.381324
uuid-0b0714a1cc9f41439fac207d31d3e651,combination,0.643646
uuid-0b0714a1cc9f41439fac207d31d3e651,chemo,0.531491
uuid-0b0714a1cc9f41439fac207d31d3e651,IO,0.383684
uuid-0b0714a1cc9f41439fac207d31d3e651,agents,0.36089
uuid-0b0714a1cc9f41439fac207d31d3e651,Ipi,0.319917
uuid-0b0714a1cc9f41439fac207d31d3e651,monotherapy,0.510763
uuid-0b0714a1cc9f41439fac207d31d3e651,response,0.515382
uuid-0b0714a1cc9f41439fac207d31d3e651,combo,0.562966
uuid-0b0714a1cc9f41439fac207d31d3e651,PD1,0.660351
uuid-0b0714a1cc9f41439fac207d31d3e651,progression,0.451727
uuid-0b0714a1cc9f41439fac207d31d3e651,believes,0.428163
uuid-0b0714a1cc9f41439fac207d31d3e651,chemotherapy,0.48078
uuid-0b0714a1cc9f41439fac207d31d3e651,respond,0.339201
uuid-0b0714a1cc9f41439fac207d31d3e651,PD-1,0.320146
uuid-11811999ad9a48da92aa8c12e0ebf7d1,Nivo,0.430104
uuid-11811999ad9a48da92aa8c12e0ebf7d1,PDL1,0.445817
uuid-11811999ad9a48da92aa8c12e0ebf7d1,trial,0.365283
uuid-11811999ad9a48da92aa8c12e0ebf7d1,efficacy,0.644381
uuid-11811999ad9a48da92aa8c12e0ebf7d1,chemo,0.313731
uuid-11811999ad9a48da92aa8c12e0ebf7d1,OS,0.865311
uuid-11811999ad9a48da92aa8c12e0ebf7d1,data,0.594081
uuid-11811999ad9a48da92aa8c12e0ebf7d1,PFS,0.882312
uuid-11811999ad9a48da92aa8c12e0ebf7d1,ORR,0.815304
uuid-11811999ad9a48da92aa8c12e0ebf7d1,nivo and pembro,0.554568
uuid-11811999ad9a48da92aa8c12e0ebf7d1,believes,0.423018
uuid-11811999ad9a48da92aa8c12e0ebf7d1,impressed,0.493108
uuid-11811999ad9a48da92aa8c12e0ebf7d1,feels,0.410079
uuid-11811999ad9a48da92aa8c12e0ebf7d1,PDL1 expression,0.418409
uuid-4363b7b254b043f29dae3909f05638ee,PD-L1,0.362051
uuid-4363b7b254b043f29dae3909f05638ee,PD-L1 testing,0.446048
uuid-4363b7b254b043f29dae3909f05638ee,testing,0.454361
uuid-4363b7b254b043f29dae3909f05638ee,assay,0.366502
uuid-4363b7b254b043f29dae3909f05638ee,biomarker,0.36531
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,Nivo,0.38383
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,patients,0.833033
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,Opdivo,0.310416
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,therapy,0.657174
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,nivolumab,0.500993
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,toxicity,0.357145
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,regimen,0.703759
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,treated,0.52609
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,combination,0.391599
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,chemo,0.56037
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,pts,0.687372
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,monotherapy,0.567559
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,treatment,0.723554
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,response,0.609111
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,combo,0.343292
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,PD1,0.495301
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,progression,0.794776
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,chemotherapy,0.545224
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,respond,0.600573
uuid-c2bf4d4127934c3fa0b982b0f2f3df45,option,0.461321
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,RTL,0.3044
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,BMS,0.454498
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,shared,0.349995
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,commented,0.310707
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,physicians,0.503729
uuid-620fac13a5aa4e7cb0fe2912c86c5e5a,academic,0.304324
uuid-50ba60b6c7734dd19e63c4abd09582ae,Nivo,0.482788
uuid-50ba60b6c7734dd19e63c4abd09582ae,pembro,0.432915
uuid-50ba60b6c7734dd19e63c4abd09582ae,dose,0.55412
uuid-50ba60b6c7734dd19e63c4abd09582ae,trial,0.601988
uuid-50ba60b6c7734dd19e63c4abd09582ae,efficacy,0.532171
uuid-50ba60b6c7734dd19e63c4abd09582ae,combination,0.445974
uuid-50ba60b6c7734dd19e63c4abd09582ae,chemo,0.315822
uuid-50ba60b6c7734dd19e63c4abd09582ae,Ipi,0.707347
uuid-50ba60b6c7734dd19e63c4abd09582ae,atezo,0.304579
uuid-50ba60b6c7734dd19e63c4abd09582ae,combo,0.481964
uuid-50ba60b6c7734dd19e63c4abd09582ae,ORR,0.316209
uuid-50ba60b6c7734dd19e63c4abd09582ae,vs,0.553637
uuid-50ba60b6c7734dd19e63c4abd09582ae,feels,0.340391
uuid-50ba60b6c7734dd19e63c4abd09582ae,flat dosing,0.344149
uuid-55d39895e800482193d4df5dfa0e401c,Opdivo,0.337519
uuid-55d39895e800482193d4df5dfa0e401c,dose,0.567614
uuid-55d39895e800482193d4df5dfa0e401c,indication,0.372627
uuid-55d39895e800482193d4df5dfa0e401c,AI,0.488611
uuid-55d39895e800482193d4df5dfa0e401c,drug,0.460278
uuid-55d39895e800482193d4df5dfa0e401c,Keytruda,0.490228
uuid-55d39895e800482193d4df5dfa0e401c,flat dosing,0.674004
uuid-210a11a100c34e66b360b3fe51df1445,patients,0.589383
uuid-210a11a100c34e66b360b3fe51df1445,nivolumab,0.30323
uuid-210a11a100c34e66b360b3fe51df1445,lung,0.394066
uuid-210a11a100c34e66b360b3fe51df1445,regimen,0.420696
uuid-210a11a100c34e66b360b3fe51df1445,treated,0.702189
uuid-210a11a100c34e66b360b3fe51df1445,melanoma,0.468077
uuid-210a11a100c34e66b360b3fe51df1445,RCC,0.446705
uuid-210a11a100c34e66b360b3fe51df1445,TL stated,0.338489
uuid-210a11a100c34e66b360b3fe51df1445,pts,0.456592
uuid-210a11a100c34e66b360b3fe51df1445,treatment,0.541146
uuid-210a11a100c34e66b360b3fe51df1445,progression,0.48542
uuid-210a11a100c34e66b360b3fe51df1445,respond,0.389125
uuid-210a11a100c34e66b360b3fe51df1445,RTL stated,0.381422
uuid-210a11a100c34e66b360b3fe51df1445,TL shared,0.591912
uuid-29b04052a663423b92bb267a26c519f6,TL,0.51852
uuid-29b04052a663423b92bb267a26c519f6,1L,0.346161
uuid-29b04052a663423b92bb267a26c519f6,TL stated,0.589332
uuid-29b04052a663423b92bb267a26c519f6,PD-L1,0.647174
uuid-29b04052a663423b92bb267a26c519f6,PD-L1 testing,0.774834
uuid-29b04052a663423b92bb267a26c519f6,testing,0.784529
uuid-29b04052a663423b92bb267a26c519f6,PDL1 testing,0.721067
uuid-29b04052a663423b92bb267a26c519f6,NSCLC patients,0.697661
uuid-29b04052a663423b92bb267a26c519f6,assay,0.46553
uuid-29b04052a663423b92bb267a26c519f6,RTL stated,0.306714
uuid-1d23befa0a724ef3ba679451f6dca177,patients,0.364276
uuid-5e53e2f826b0472c96c468d218ee6674,patients,0.575416
uuid-5e53e2f826b0472c96c468d218ee6674,therapy,0.475814
uuid-5e53e2f826b0472c96c468d218ee6674,treated,0.392895
uuid-5e53e2f826b0472c96c468d218ee6674,tumor,0.456288
uuid-5e53e2f826b0472c96c468d218ee6674,pts,0.537474
uuid-5e53e2f826b0472c96c468d218ee6674,treatment,0.480858
uuid-5e53e2f826b0472c96c468d218ee6674,response,0.70497
uuid-5e53e2f826b0472c96c468d218ee6674,PD1,0.314219
uuid-5e53e2f826b0472c96c468d218ee6674,progression,0.702877
uuid-5e53e2f826b0472c96c468d218ee6674,respond,0.492121
uuid-b3a1084a6b3b4310a41ea490702a3130,Nivo,0.426475
uuid-b3a1084a6b3b4310a41ea490702a3130,pembro,0.437267
uuid-b3a1084a6b3b4310a41ea490702a3130,BMS,0.334893
uuid-b3a1084a6b3b4310a41ea490702a3130,1L,0.348356
uuid-b3a1084a6b3b4310a41ea490702a3130,PDL1,0.302617
uuid-b3a1084a6b3b4310a41ea490702a3130,trial,0.435907
uuid-b3a1084a6b3b4310a41ea490702a3130,efficacy,0.533708
uuid-b3a1084a6b3b4310a41ea490702a3130,combination,0.373241
uuid-b3a1084a6b3b4310a41ea490702a3130,2L,0.342666
uuid-b3a1084a6b3b4310a41ea490702a3130,agents,0.458709
uuid-b3a1084a6b3b4310a41ea490702a3130,stated,0.312204
uuid-b3a1084a6b3b4310a41ea490702a3130,OS,0.424446
uuid-b3a1084a6b3b4310a41ea490702a3130,atezo,0.407028
uuid-b3a1084a6b3b4310a41ea490702a3130,monotherapy,0.337728
uuid-b3a1084a6b3b4310a41ea490702a3130,data,0.761755
uuid-b3a1084a6b3b4310a41ea490702a3130,combo,0.381354
uuid-b3a1084a6b3b4310a41ea490702a3130,clinical trials,0.301276
uuid-b3a1084a6b3b4310a41ea490702a3130,indication,0.301178
uuid-b3a1084a6b3b4310a41ea490702a3130,PFS,0.362749
uuid-b3a1084a6b3b4310a41ea490702a3130,PD1,0.321696
uuid-b3a1084a6b3b4310a41ea490702a3130,ORR,0.476761
uuid-b3a1084a6b3b4310a41ea490702a3130,approved,0.349216
uuid-b3a1084a6b3b4310a41ea490702a3130,nivo and pembro,0.48659
uuid-b3a1084a6b3b4310a41ea490702a3130,believes,0.384553
uuid-b3a1084a6b3b4310a41ea490702a3130,impressed,0.572407
uuid-b3a1084a6b3b4310a41ea490702a3130,SCLC,0.352556
uuid-b3a1084a6b3b4310a41ea490702a3130,feels,0.505041
uuid-b3a1084a6b3b4310a41ea490702a3130,option,0.323368
uuid-3f3b718cfa0740f6886ef19903b7a642,dose,0.640818
uuid-3f3b718cfa0740f6886ef19903b7a642,Ipi,0.363757
uuid-3f3b718cfa0740f6886ef19903b7a642,vs,0.363725
uuid-3f3b718cfa0740f6886ef19903b7a642,NCCN,0.354881
uuid-3f3b718cfa0740f6886ef19903b7a642,flat dosing,0.544852
uuid-f9889f76399f4d5ba355368630533d36,Nivo,0.461874
uuid-f9889f76399f4d5ba355368630533d36,patients,0.391835
uuid-f9889f76399f4d5ba355368630533d36,therapy,0.368758
uuid-f9889f76399f4d5ba355368630533d36,toxicity,0.305475
uuid-f9889f76399f4d5ba355368630533d36,efficacy,0.380674
uuid-f9889f76399f4d5ba355368630533d36,regimen,0.416582
uuid-f9889f76399f4d5ba355368630533d36,chemo,0.633353
uuid-f9889f76399f4d5ba355368630533d36,pts,0.447185
uuid-f9889f76399f4d5ba355368630533d36,IO,0.33734
uuid-f9889f76399f4d5ba355368630533d36,OS,0.390494
uuid-f9889f76399f4d5ba355368630533d36,monotherapy,0.430877
uuid-f9889f76399f4d5ba355368630533d36,treatment,0.354431
uuid-f9889f76399f4d5ba355368630533d36,response,0.646479
uuid-f9889f76399f4d5ba355368630533d36,PFS,0.371343
uuid-f9889f76399f4d5ba355368630533d36,PD1,0.44176
uuid-f9889f76399f4d5ba355368630533d36,ORR,0.355248
uuid-f9889f76399f4d5ba355368630533d36,progression,0.572651
uuid-f9889f76399f4d5ba355368630533d36,believes,0.462648
uuid-f9889f76399f4d5ba355368630533d36,chemotherapy,0.466231
uuid-f9889f76399f4d5ba355368630533d36,respond,0.584512
uuid-f9889f76399f4d5ba355368630533d36,feels,0.482028
uuid-f9889f76399f4d5ba355368630533d36,option,0.315918
uuid-0f0dd6410e874e43a5ffd648f10100fe,Nivo,0.511469
uuid-0f0dd6410e874e43a5ffd648f10100fe,pembro,0.657339
uuid-0f0dd6410e874e43a5ffd648f10100fe,1L,0.500499
uuid-0f0dd6410e874e43a5ffd648f10100fe,PDL1,0.461384
uuid-0f0dd6410e874e43a5ffd648f10100fe,efficacy,0.708484
uuid-0f0dd6410e874e43a5ffd648f10100fe,chemo,0.327813
uuid-0f0dd6410e874e43a5ffd648f10100fe,2L,0.573976
uuid-0f0dd6410e874e43a5ffd648f10100fe,agents,0.621929
uuid-0f0dd6410e874e43a5ffd648f10100fe,atezo,0.751694
uuid-0f0dd6410e874e43a5ffd648f10100fe,preferred,0.490976
uuid-0f0dd6410e874e43a5ffd648f10100fe,monotherapy,0.412979
uuid-0f0dd6410e874e43a5ffd648f10100fe,data,0.381234
uuid-0f0dd6410e874e43a5ffd648f10100fe,combo,0.357659
uuid-0f0dd6410e874e43a5ffd648f10100fe,indication,0.445251
uuid-0f0dd6410e874e43a5ffd648f10100fe,ORR,0.307487
uuid-0f0dd6410e874e43a5ffd648f10100fe,approved,0.375551
uuid-0f0dd6410e874e43a5ffd648f10100fe,nivo and pembro,0.641829
uuid-0f0dd6410e874e43a5ffd648f10100fe,believes,0.495791
uuid-0f0dd6410e874e43a5ffd648f10100fe,vs,0.530573
uuid-0f0dd6410e874e43a5ffd648f10100fe,TLs,0.332265
uuid-0f0dd6410e874e43a5ffd648f10100fe,feels,0.492003
uuid-0f0dd6410e874e43a5ffd648f10100fe,PDL1 expression,0.455113
uuid-0f0dd6410e874e43a5ffd648f10100fe,option,0.427917
uuid-f718c68393124c29ba04ca22c6248806,Nivo,0.456907
uuid-f718c68393124c29ba04ca22c6248806,pembro,0.472577
uuid-f718c68393124c29ba04ca22c6248806,NSCLC,0.362056
uuid-f718c68393124c29ba04ca22c6248806,1L,0.514056
uuid-f718c68393124c29ba04ca22c6248806,PDL1,0.331731
uuid-f718c68393124c29ba04ca22c6248806,efficacy,0.553898
uuid-f718c68393124c29ba04ca22c6248806,combination,0.466357
uuid-f718c68393124c29ba04ca22c6248806,chemo,0.499776
uuid-f718c68393124c29ba04ca22c6248806,2L,0.426872
uuid-f718c68393124c29ba04ca22c6248806,IO,0.520013
uuid-f718c68393124c29ba04ca22c6248806,agents,0.461519
uuid-f718c68393124c29ba04ca22c6248806,Ipi,0.353253
uuid-f718c68393124c29ba04ca22c6248806,OS,0.314067
uuid-f718c68393124c29ba04ca22c6248806,atezo,0.486369
uuid-f718c68393124c29ba04ca22c6248806,preferred,0.362151
uuid-f718c68393124c29ba04ca22c6248806,monotherapy,0.566021
uuid-f718c68393124c29ba04ca22c6248806,data,0.365509
uuid-f718c68393124c29ba04ca22c6248806,combo,0.555989
uuid-f718c68393124c29ba04ca22c6248806,PD1,0.348153
uuid-f718c68393124c29ba04ca22c6248806,ORR,0.344655
uuid-f718c68393124c29ba04ca22c6248806,nivo and pembro,0.428992
uuid-f718c68393124c29ba04ca22c6248806,believes,0.478858
uuid-f718c68393124c29ba04ca22c6248806,chemotherapy,0.367571
uuid-f718c68393124c29ba04ca22c6248806,vs,0.42897
uuid-f718c68393124c29ba04ca22c6248806,feels,0.441312
uuid-f718c68393124c29ba04ca22c6248806,option,0.472483
uuid-fd87767f65a845498cb26684458650fe,pembro,0.621481
uuid-fd87767f65a845498cb26684458650fe,trial,0.375426
uuid-fd87767f65a845498cb26684458650fe,Merck,0.498957
uuid-fd87767f65a845498cb26684458650fe,approval,0.463534
uuid-fd87767f65a845498cb26684458650fe,atezo,0.563517
uuid-fd87767f65a845498cb26684458650fe,data,0.342388
uuid-fd87767f65a845498cb26684458650fe,indication,0.481899
uuid-fd87767f65a845498cb26684458650fe,approved,0.469438
uuid-fd87767f65a845498cb26684458650fe,vs,0.376165
uuid-fd87767f65a845498cb26684458650fe,label,0.374175
uuid-fd87767f65a845498cb26684458650fe,Keytruda,0.341393
uuid-fd87767f65a845498cb26684458650fe,assay,0.365734
uuid-3ebc738e81e04eeda3cdef0533cb918d,BMS,0.542243
uuid-3ebc738e81e04eeda3cdef0533cb918d,PDL1,0.37714
uuid-3ebc738e81e04eeda3cdef0533cb918d,trial,0.703488
uuid-3ebc738e81e04eeda3cdef0533cb918d,efficacy,0.410226
uuid-3ebc738e81e04eeda3cdef0533cb918d,commented,0.374026
uuid-3ebc738e81e04eeda3cdef0533cb918d,Merck,0.402342
uuid-3ebc738e81e04eeda3cdef0533cb918d,OS,0.491985
uuid-3ebc738e81e04eeda3cdef0533cb918d,regards,0.415258
uuid-3ebc738e81e04eeda3cdef0533cb918d,data,0.614245
uuid-3ebc738e81e04eeda3cdef0533cb918d,expressed,0.333308
uuid-3ebc738e81e04eeda3cdef0533cb918d,clinical trials,0.353191
uuid-3ebc738e81e04eeda3cdef0533cb918d,PFS,0.552705
uuid-3ebc738e81e04eeda3cdef0533cb918d,ORR,0.544441
uuid-3ebc738e81e04eeda3cdef0533cb918d,nivo and pembro,0.397447
uuid-3ebc738e81e04eeda3cdef0533cb918d,impressed,0.417265
uuid-3ebc738e81e04eeda3cdef0533cb918d,TLs,0.314276
uuid-3ebc738e81e04eeda3cdef0533cb918d,PDL1 expression,0.507005
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,Nivo,0.389264
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,pembro,0.498968
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,PDL1,0.305725
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,trial,0.552495
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,efficacy,0.597147
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,Ipi,0.344243
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,OS,0.415443
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,atezo,0.401954
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,regards,0.306129
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,data,0.514389
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,indication,0.335302
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,PFS,0.42136
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,ORR,0.479439
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,nivo and pembro,0.459545
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,impressed,0.425225
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,vs,0.498214
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,feels,0.413975
uuid-cfd15ddc9f0b42f2b1b77ab73e619441,PDL1 expression,0.322201
uuid-4a0fb1c5e92e4985ab15af0cc18ca05e,nivolumab,0.326464
uuid-4a0fb1c5e92e4985ab15af0cc18ca05e,PD1,0.333261
uuid-8fa454baf55547ff98728ec488838366,patients,0.496238
uuid-8fa454baf55547ff98728ec488838366,TL,0.329509
uuid-8fa454baf55547ff98728ec488838366,approval,0.366106
uuid-8fa454baf55547ff98728ec488838366,PD-L1 testing,0.425826
uuid-8fa454baf55547ff98728ec488838366,using nivo,0.380138
uuid-8fa454baf55547ff98728ec488838366,NSCLC patients,0.309556
uuid-8fa454baf55547ff98728ec488838366,SCCHN,0.348159
uuid-8fa454baf55547ff98728ec488838366,indicated,0.319774
uuid-8fa454baf55547ff98728ec488838366,Regional TL,0.347258
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,PDL1,0.497262
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,PD-L1,0.540287
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,PD-L1 testing,0.305244
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,testing,0.395546
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,NSCLC patients,0.339596
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,assay,0.419514
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,PDL1 expression,0.450546
uuid-fd10ddccef8b4653b3c4b5cf152ffebc,biomarker,0.399408
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,TL,0.722237
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,shared,0.310428
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,TL stated,0.440165
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,Merck,0.319369
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,institution,0.644274
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,PD-L1,0.673784
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,PD-L1 testing,0.842293
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,testing,0.728362
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,PDL1 testing,0.610759
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,NSCLC patients,0.445257
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,assay,0.647659
uuid-b4ee89f1d233430e981b1c0efcbf5ff9,biomarker,0.342632
uuid-e74cd8f73bcd4e22ab066fed000f1b63,patients,0.351002
uuid-e74cd8f73bcd4e22ab066fed000f1b63,Opdivo,0.341249
uuid-e74cd8f73bcd4e22ab066fed000f1b63,therapy,0.498096
uuid-e74cd8f73bcd4e22ab066fed000f1b63,nivolumab,0.38812
uuid-e74cd8f73bcd4e22ab066fed000f1b63,cHL,0.693109
uuid-858152bc42c24c3b816aa48e126aada1,patients,0.676842
uuid-858152bc42c24c3b816aa48e126aada1,Opdivo,0.663004
uuid-858152bc42c24c3b816aa48e126aada1,dose,0.588707
uuid-858152bc42c24c3b816aa48e126aada1,nivolumab,0.42267
uuid-858152bc42c24c3b816aa48e126aada1,regimen,0.424986
uuid-858152bc42c24c3b816aa48e126aada1,treated,0.425353
uuid-858152bc42c24c3b816aa48e126aada1,pts,0.353093
uuid-858152bc42c24c3b816aa48e126aada1,treatment,0.503452
uuid-858152bc42c24c3b816aa48e126aada1,progression,0.350056
uuid-858152bc42c24c3b816aa48e126aada1,flat dosing,0.565504
uuid-402eaacb9c0e4034b8fc810eb3d2370b,patients,0.342897
uuid-402eaacb9c0e4034b8fc810eb3d2370b,Opdivo,0.648393
uuid-402eaacb9c0e4034b8fc810eb3d2370b,dose,0.718736
uuid-402eaacb9c0e4034b8fc810eb3d2370b,toxicity,0.40646
uuid-402eaacb9c0e4034b8fc810eb3d2370b,regimen,0.32929
uuid-402eaacb9c0e4034b8fc810eb3d2370b,drug,0.442451
uuid-402eaacb9c0e4034b8fc810eb3d2370b,Keytruda,0.58531
uuid-402eaacb9c0e4034b8fc810eb3d2370b,flat dosing,0.70692
uuid-e984d63bd6b845c58993c52286a1cbd0,patients,0.858187
uuid-e984d63bd6b845c58993c52286a1cbd0,Opdivo,0.47635
uuid-e984d63bd6b845c58993c52286a1cbd0,therapy,0.401593
uuid-e984d63bd6b845c58993c52286a1cbd0,nivolumab,0.369042
uuid-e984d63bd6b845c58993c52286a1cbd0,regimen,0.436799
uuid-e984d63bd6b845c58993c52286a1cbd0,treated,0.524231
uuid-e984d63bd6b845c58993c52286a1cbd0,pts,0.588782
uuid-e984d63bd6b845c58993c52286a1cbd0,treatment,0.580548
uuid-e984d63bd6b845c58993c52286a1cbd0,response,0.304592
uuid-e984d63bd6b845c58993c52286a1cbd0,progression,0.605177
uuid-e984d63bd6b845c58993c52286a1cbd0,respond,0.492265
uuid-7c8ff7bedaac4bb8a2dbd727eabc538f,RTL,0.30582
uuid-7c8ff7bedaac4bb8a2dbd727eabc538f,nivolumab,0.420017
uuid-7c8ff7bedaac4bb8a2dbd727eabc538f,treated,0.326051
uuid-7c8ff7bedaac4bb8a2dbd727eabc538f,impressed,0.305894
uuid-7c8ff7bedaac4bb8a2dbd727eabc538f,Regional TL,0.328983
uuid-6ccf5750673441829abfd2bffa47f72a,oncology,0.458369
uuid-6ccf5750673441829abfd2bffa47f72a,drug,0.355493
uuid-6ccf5750673441829abfd2bffa47f72a,clinical,0.324704
uuid-6ccf5750673441829abfd2bffa47f72a,flat dosing,0.331544
uuid-7fb786f34745457abcce6931c3e43a66,Nivo,0.357723
uuid-7fb786f34745457abcce6931c3e43a66,pembro,0.363809
uuid-7fb786f34745457abcce6931c3e43a66,1L,0.350003
uuid-7fb786f34745457abcce6931c3e43a66,PDL1,0.399137
uuid-7fb786f34745457abcce6931c3e43a66,efficacy,0.33478
uuid-7fb786f34745457abcce6931c3e43a66,agents,0.364714
uuid-7fb786f34745457abcce6931c3e43a66,atezo,0.315847
uuid-7fb786f34745457abcce6931c3e43a66,monotherapy,0.331154
uuid-7fb786f34745457abcce6931c3e43a66,data,0.495623
uuid-7fb786f34745457abcce6931c3e43a66,indication,0.316834
uuid-7fb786f34745457abcce6931c3e43a66,ORR,0.331328
uuid-7fb786f34745457abcce6931c3e43a66,nivo and pembro,0.494916
uuid-7fb786f34745457abcce6931c3e43a66,feels,0.318857
uuid-7fb786f34745457abcce6931c3e43a66,PDL1 expression,0.422745
uuid-7fb786f34745457abcce6931c3e43a66,option,0.324197
uuid-05ba57cbd85f4b75916d981231d5c12f,Opdivo,0.509588
uuid-05ba57cbd85f4b75916d981231d5c12f,dose,0.564658
uuid-05ba57cbd85f4b75916d981231d5c12f,physicians,0.442378
uuid-05ba57cbd85f4b75916d981231d5c12f,indication,0.304798
uuid-05ba57cbd85f4b75916d981231d5c12f,drug,0.65619
uuid-05ba57cbd85f4b75916d981231d5c12f,Keytruda,0.537587
uuid-05ba57cbd85f4b75916d981231d5c12f,flat dosing,0.681695
uuid-312d9737c5df4e3ba783d05a4a4ef1f6,nivolumab,0.460018
uuid-312d9737c5df4e3ba783d05a4a4ef1f6,trial,0.334575
uuid-312d9737c5df4e3ba783d05a4a4ef1f6,combination,0.339848
uuid-312d9737c5df4e3ba783d05a4a4ef1f6,PD1,0.481182
uuid-312d9737c5df4e3ba783d05a4a4ef1f6,PD-1,0.338998
uuid-039b934d41254c92a52a5a4e7cd12b76,tumor,0.601628
uuid-e3532129c2bf48e0afb206648032f6f4,BMS,0.506943
uuid-e3532129c2bf48e0afb206648032f6f4,PDL1,0.352031
uuid-e3532129c2bf48e0afb206648032f6f4,trial,0.515673
uuid-e3532129c2bf48e0afb206648032f6f4,efficacy,0.560343
uuid-e3532129c2bf48e0afb206648032f6f4,commented,0.40859
uuid-e3532129c2bf48e0afb206648032f6f4,Merck,0.347407
uuid-e3532129c2bf48e0afb206648032f6f4,OS,0.615526
uuid-e3532129c2bf48e0afb206648032f6f4,regards,0.362538
uuid-e3532129c2bf48e0afb206648032f6f4,data,0.781881
uuid-e3532129c2bf48e0afb206648032f6f4,expressed,0.308843
uuid-e3532129c2bf48e0afb206648032f6f4,PFS,0.584809
uuid-e3532129c2bf48e0afb206648032f6f4,ORR,0.60292
uuid-e3532129c2bf48e0afb206648032f6f4,nivo and pembro,0.469599
uuid-e3532129c2bf48e0afb206648032f6f4,believes,0.328869
uuid-e3532129c2bf48e0afb206648032f6f4,impressed,0.596495
uuid-e3532129c2bf48e0afb206648032f6f4,feels,0.469267
uuid-e3532129c2bf48e0afb206648032f6f4,PDL1 expression,0.338561
uuid-2f0e33bf18b0422882f0529c364a3a57,Nivo,0.458399
uuid-2f0e33bf18b0422882f0529c364a3a57,pembro,0.406085
uuid-2f0e33bf18b0422882f0529c364a3a57,1L,0.399158
uuid-2f0e33bf18b0422882f0529c364a3a57,trial,0.386841
uuid-2f0e33bf18b0422882f0529c364a3a57,efficacy,0.307507
uuid-2f0e33bf18b0422882f0529c364a3a57,combination,0.363832
uuid-2f0e33bf18b0422882f0529c364a3a57,chemo,0.447405
uuid-2f0e33bf18b0422882f0529c364a3a57,OS,0.345358
uuid-2f0e33bf18b0422882f0529c364a3a57,preferred,0.343285
uuid-2f0e33bf18b0422882f0529c364a3a57,monotherapy,0.448372
uuid-2f0e33bf18b0422882f0529c364a3a57,data,0.433993
uuid-2f0e33bf18b0422882f0529c364a3a57,combo,0.331535
uuid-2f0e33bf18b0422882f0529c364a3a57,PFS,0.340041
uuid-2f0e33bf18b0422882f0529c364a3a57,ORR,0.358315
uuid-2f0e33bf18b0422882f0529c364a3a57,approved,0.310495
uuid-2f0e33bf18b0422882f0529c364a3a57,chemotherapy,0.461938
uuid-2f0e33bf18b0422882f0529c364a3a57,impressed,0.335716
uuid-2f0e33bf18b0422882f0529c364a3a57,feels,0.509535
uuid-2f0e33bf18b0422882f0529c364a3a57,option,0.528569
uuid-05887751760a4646a2dc13c67a3dddda,TL,0.538019
uuid-05887751760a4646a2dc13c67a3dddda,RTL,0.392022
uuid-05887751760a4646a2dc13c67a3dddda,nivolumab,0.306378
uuid-05887751760a4646a2dc13c67a3dddda,NTL,0.304131
uuid-05887751760a4646a2dc13c67a3dddda,PD-L1 testing,0.469912
uuid-05887751760a4646a2dc13c67a3dddda,testing,0.303093
uuid-05887751760a4646a2dc13c67a3dddda,oncology,0.348331
uuid-05887751760a4646a2dc13c67a3dddda,SCCHN,0.369318
uuid-05887751760a4646a2dc13c67a3dddda,LTL,0.361666
uuid-05887751760a4646a2dc13c67a3dddda,clinical,0.343169
uuid-05887751760a4646a2dc13c67a3dddda,academic,0.332226
uuid-05887751760a4646a2dc13c67a3dddda,Regional TL,0.476668
uuid-05887751760a4646a2dc13c67a3dddda,RTL stated,0.323878
uuid-3c06ae154c3a4117a096aa29b2b1f716,RTL,0.356717
uuid-3c06ae154c3a4117a096aa29b2b1f716,BMS,0.601784
uuid-3c06ae154c3a4117a096aa29b2b1f716,trial,0.391579
uuid-3c06ae154c3a4117a096aa29b2b1f716,NTL,0.321103
uuid-3c06ae154c3a4117a096aa29b2b1f716,shared,0.310272
uuid-3c06ae154c3a4117a096aa29b2b1f716,commented,0.55115
uuid-3c06ae154c3a4117a096aa29b2b1f716,Merck,0.541317
uuid-3c06ae154c3a4117a096aa29b2b1f716,stated,0.517806
uuid-3c06ae154c3a4117a096aa29b2b1f716,regards,0.359978
uuid-3c06ae154c3a4117a096aa29b2b1f716,data,0.575892
uuid-3c06ae154c3a4117a096aa29b2b1f716,expressed,0.422858
uuid-3c06ae154c3a4117a096aa29b2b1f716,ASCO,0.348532
uuid-3c06ae154c3a4117a096aa29b2b1f716,impressed,0.516424
uuid-3c06ae154c3a4117a096aa29b2b1f716,LTL,0.306006
uuid-3c06ae154c3a4117a096aa29b2b1f716,TLs,0.359534
uuid-3c06ae154c3a4117a096aa29b2b1f716,Regional TL,0.498215
uuid-4d9ac5e15c3e46e1afd6a9ad53128fa6,patients,0.351792
uuid-4d9ac5e15c3e46e1afd6a9ad53128fa6,tumor,0.657103
uuid-4d9ac5e15c3e46e1afd6a9ad53128fa6,progression,0.315897
uuid-59afc4bfaaee4878958b3fb72d02c5e9,Nivo,0.372137
uuid-59afc4bfaaee4878958b3fb72d02c5e9,patients,0.480754
uuid-59afc4bfaaee4878958b3fb72d02c5e9,Opdivo,0.545749
uuid-59afc4bfaaee4878958b3fb72d02c5e9,dose,0.82315
uuid-59afc4bfaaee4878958b3fb72d02c5e9,nivolumab,0.368637
uuid-59afc4bfaaee4878958b3fb72d02c5e9,toxicity,0.415225
uuid-59afc4bfaaee4878958b3fb72d02c5e9,regimen,0.48478
uuid-59afc4bfaaee4878958b3fb72d02c5e9,Ipi,0.514403
uuid-59afc4bfaaee4878958b3fb72d02c5e9,treatment,0.343734
uuid-59afc4bfaaee4878958b3fb72d02c5e9,vs,0.430983
uuid-59afc4bfaaee4878958b3fb72d02c5e9,flat dosing,0.652664
uuid-66eec0717eab48ac8fbacbbd898af604,Nivo,0.506437
uuid-66eec0717eab48ac8fbacbbd898af604,pembro,0.424183
uuid-66eec0717eab48ac8fbacbbd898af604,PDL1,0.496361
uuid-66eec0717eab48ac8fbacbbd898af604,trial,0.375816
uuid-66eec0717eab48ac8fbacbbd898af604,efficacy,0.661002
uuid-66eec0717eab48ac8fbacbbd898af604,OS,0.56862
uuid-66eec0717eab48ac8fbacbbd898af604,atezo,0.320165
uuid-66eec0717eab48ac8fbacbbd898af604,data,0.423281
uuid-66eec0717eab48ac8fbacbbd898af604,PFS,0.654229
uuid-66eec0717eab48ac8fbacbbd898af604,ORR,0.600983
uuid-66eec0717eab48ac8fbacbbd898af604,nivo and pembro,0.560159
uuid-66eec0717eab48ac8fbacbbd898af604,vs,0.527597
uuid-66eec0717eab48ac8fbacbbd898af604,PDL1 expression,0.480524
uuid-e70da8f7a43c43c9b6256143072e775f,oncology,0.58727
uuid-e70da8f7a43c43c9b6256143072e775f,clinical,0.60194
uuid-f60f516dd27c496c9ad8aa93a1e27643,Nivo,0.516707
uuid-f60f516dd27c496c9ad8aa93a1e27643,patients,0.302831
uuid-f60f516dd27c496c9ad8aa93a1e27643,therapy,0.457254
uuid-f60f516dd27c496c9ad8aa93a1e27643,1L,0.356969
uuid-f60f516dd27c496c9ad8aa93a1e27643,PDL1,0.407365
uuid-f60f516dd27c496c9ad8aa93a1e27643,efficacy,0.474708
uuid-f60f516dd27c496c9ad8aa93a1e27643,regimen,0.314869
uuid-f60f516dd27c496c9ad8aa93a1e27643,combination,0.360615
uuid-f60f516dd27c496c9ad8aa93a1e27643,chemo,0.70098
uuid-f60f516dd27c496c9ad8aa93a1e27643,pts,0.432941
uuid-f60f516dd27c496c9ad8aa93a1e27643,agents,0.315399
uuid-f60f516dd27c496c9ad8aa93a1e27643,OS,0.429522
uuid-f60f516dd27c496c9ad8aa93a1e27643,monotherapy,0.512201
uuid-f60f516dd27c496c9ad8aa93a1e27643,response,0.452993
uuid-f60f516dd27c496c9ad8aa93a1e27643,combo,0.38491
uuid-f60f516dd27c496c9ad8aa93a1e27643,PFS,0.475178
uuid-f60f516dd27c496c9ad8aa93a1e27643,PD1,0.529586
uuid-f60f516dd27c496c9ad8aa93a1e27643,ORR,0.448179
uuid-f60f516dd27c496c9ad8aa93a1e27643,nivo and pembro,0.480707
uuid-f60f516dd27c496c9ad8aa93a1e27643,progression,0.437956
uuid-f60f516dd27c496c9ad8aa93a1e27643,believes,0.568341
uuid-f60f516dd27c496c9ad8aa93a1e27643,chemotherapy,0.602135
uuid-f60f516dd27c496c9ad8aa93a1e27643,respond,0.409029
uuid-f60f516dd27c496c9ad8aa93a1e27643,feels,0.373147
uuid-f60f516dd27c496c9ad8aa93a1e27643,PDL1 expression,0.393974
uuid-f60f516dd27c496c9ad8aa93a1e27643,option,0.427806
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,Nivo,0.621581
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,pembro,0.610899
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,1L,0.49119
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,PDL1,0.453929
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,trial,0.373881
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,efficacy,0.607569
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,chemo,0.423708
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,2L,0.450987
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,agents,0.367886
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,Ipi,0.312517
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,OS,0.450473
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,atezo,0.534854
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,preferred,0.316524
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,monotherapy,0.450405
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,data,0.471233
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,combo,0.356437
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,indication,0.332282
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,PFS,0.450044
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,PD1,0.334928
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,ORR,0.495524
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,approved,0.347103
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,nivo and pembro,0.615071
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,believes,0.509849
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,chemotherapy,0.30092
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,impressed,0.375164
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,vs,0.374057
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,feels,0.547961
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,PDL1 expression,0.464692
uuid-10ee0a6a70bc4f45b7d4e9dfc843a2f5,option,0.466307
uuid-d2adf19c11d04790b5192063dcf9f441,lung,0.33389
uuid-d2adf19c11d04790b5192063dcf9f441,1L,0.365594
uuid-d2adf19c11d04790b5192063dcf9f441,PDL1,0.407756
uuid-d2adf19c11d04790b5192063dcf9f441,chemo,0.362522
uuid-d2adf19c11d04790b5192063dcf9f441,OS,0.358204
uuid-d2adf19c11d04790b5192063dcf9f441,monotherapy,0.337271
uuid-d2adf19c11d04790b5192063dcf9f441,PFS,0.372434
uuid-d2adf19c11d04790b5192063dcf9f441,ORR,0.30291
uuid-d2adf19c11d04790b5192063dcf9f441,nivo and pembro,0.338715
uuid-d2adf19c11d04790b5192063dcf9f441,progression,0.355803
uuid-d2adf19c11d04790b5192063dcf9f441,believes,0.309089
uuid-d2adf19c11d04790b5192063dcf9f441,PDL1 expression,0.333846
uuid-d2adf19c11d04790b5192063dcf9f441,option,0.344245
uuid-62746ef0712d46ccb50884153746c791,pembro,0.371439
uuid-62746ef0712d46ccb50884153746c791,1L,0.383249
uuid-62746ef0712d46ccb50884153746c791,PDL1,0.369903
uuid-62746ef0712d46ccb50884153746c791,trial,0.445272
uuid-62746ef0712d46ccb50884153746c791,efficacy,0.449024
uuid-62746ef0712d46ccb50884153746c791,OS,0.416123
uuid-62746ef0712d46ccb50884153746c791,atezo,0.344795
uuid-62746ef0712d46ccb50884153746c791,monotherapy,0.367845
uuid-62746ef0712d46ccb50884153746c791,data,0.582441
uuid-62746ef0712d46ccb50884153746c791,combo,0.375819
uuid-62746ef0712d46ccb50884153746c791,indication,0.324403
uuid-62746ef0712d46ccb50884153746c791,PFS,0.361297
uuid-62746ef0712d46ccb50884153746c791,ORR,0.446836
uuid-62746ef0712d46ccb50884153746c791,nivo and pembro,0.362773
uuid-62746ef0712d46ccb50884153746c791,believes,0.367209
uuid-62746ef0712d46ccb50884153746c791,impressed,0.397522
uuid-62746ef0712d46ccb50884153746c791,feels,0.365463
uuid-62746ef0712d46ccb50884153746c791,PDL1 expression,0.372055
uuid-62746ef0712d46ccb50884153746c791,option,0.349714
uuid-bbda9735f1844f4dba88ca98628af135,ASCO,0.361719
uuid-bbda9735f1844f4dba88ca98628af135,immunotherapy,0.306937
uuid-b5f123ad309d4af8981bd284f18e379a,dose,0.356354
uuid-b5f123ad309d4af8981bd284f18e379a,toxicity,0.551899
uuid-47651954a2f24fef8810ca1d6c0f0e3d,Opdivo,0.341953
uuid-47651954a2f24fef8810ca1d6c0f0e3d,dose,0.554173
uuid-47651954a2f24fef8810ca1d6c0f0e3d,indication,0.378261
uuid-47651954a2f24fef8810ca1d6c0f0e3d,AI,0.494313
uuid-47651954a2f24fef8810ca1d6c0f0e3d,label,0.308736
uuid-47651954a2f24fef8810ca1d6c0f0e3d,drug,0.469529
uuid-47651954a2f24fef8810ca1d6c0f0e3d,Keytruda,0.48382
uuid-47651954a2f24fef8810ca1d6c0f0e3d,flat dosing,0.682798
uuid-76365aa94b5a49d990485c80358a8af4,patients,0.544036
uuid-76365aa94b5a49d990485c80358a8af4,Opdivo,0.32491
uuid-76365aa94b5a49d990485c80358a8af4,therapy,0.396048
uuid-76365aa94b5a49d990485c80358a8af4,regimen,0.463241
uuid-76365aa94b5a49d990485c80358a8af4,treated,0.493624
uuid-76365aa94b5a49d990485c80358a8af4,chemo,0.350545
uuid-76365aa94b5a49d990485c80358a8af4,pts,0.512879
uuid-76365aa94b5a49d990485c80358a8af4,treatment,0.566894
uuid-76365aa94b5a49d990485c80358a8af4,response,0.468768
uuid-76365aa94b5a49d990485c80358a8af4,progression,0.650785
uuid-76365aa94b5a49d990485c80358a8af4,chemotherapy,0.308016
uuid-76365aa94b5a49d990485c80358a8af4,respond,0.568161
uuid-76365aa94b5a49d990485c80358a8af4,feels,0.31997
uuid-53a7a7c20471441eac1cd50426a6b171,Nivo,0.346639
uuid-53a7a7c20471441eac1cd50426a6b171,pembro,0.351863
uuid-53a7a7c20471441eac1cd50426a6b171,1L,0.410575
uuid-53a7a7c20471441eac1cd50426a6b171,efficacy,0.408093
uuid-53a7a7c20471441eac1cd50426a6b171,regimen,0.343089
uuid-53a7a7c20471441eac1cd50426a6b171,RCC,0.32413
uuid-53a7a7c20471441eac1cd50426a6b171,2L,0.39186
uuid-53a7a7c20471441eac1cd50426a6b171,OS,0.43719
uuid-53a7a7c20471441eac1cd50426a6b171,atezo,0.312134
uuid-53a7a7c20471441eac1cd50426a6b171,monotherapy,0.443695
uuid-53a7a7c20471441eac1cd50426a6b171,data,0.446856
uuid-53a7a7c20471441eac1cd50426a6b171,combo,0.328384
uuid-53a7a7c20471441eac1cd50426a6b171,PFS,0.328388
uuid-53a7a7c20471441eac1cd50426a6b171,ORR,0.389354
uuid-53a7a7c20471441eac1cd50426a6b171,approved,0.32958
uuid-53a7a7c20471441eac1cd50426a6b171,nivo and pembro,0.328935
uuid-53a7a7c20471441eac1cd50426a6b171,impressed,0.49267
uuid-53a7a7c20471441eac1cd50426a6b171,feels,0.382104
uuid-53a7a7c20471441eac1cd50426a6b171,option,0.323897
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,pembro,0.342791
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,BMS,0.312369
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,2L,0.378683
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,approval,0.530476
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,atezo,0.329814
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,preferred,0.461071
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,using nivo,0.41833
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,clinical trials,0.35318
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,indication,0.399552
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,approved,0.57095
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,SCCHN,0.343353
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,label,0.399598
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,RTL stated,0.34805
uuid-591ca183be1a49fe947f8a5ba3e1fc2d,option,0.352848
uuid-2cd22b7d33034573b6696fbc73c33b76,tumor,0.520642
uuid-2cd22b7d33034573b6696fbc73c33b76,response,0.41544
uuid-2cd22b7d33034573b6696fbc73c33b76,immunotherapy,0.324549
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,TL,0.619302
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,PDL1,0.346774
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,TL stated,0.382984
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,Merck,0.317515
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,PD-L1,0.716608
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,PD-L1 testing,0.783833
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,testing,0.755683
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,PDL1 testing,0.534134
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,NSCLC patients,0.548562
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,assay,0.663429
uuid-6fa0f68f4ee347d48809ad5d02e07b4c,biomarker,0.340807
uuid-a914516af591492e9f297ab88123b192,Nivo,0.452902
uuid-a914516af591492e9f297ab88123b192,patients,0.756662
uuid-a914516af591492e9f297ab88123b192,Opdivo,0.449112
uuid-a914516af591492e9f297ab88123b192,therapy,0.475469
uuid-a914516af591492e9f297ab88123b192,dose,0.328611
uuid-a914516af591492e9f297ab88123b192,nivolumab,0.338738
uuid-a914516af591492e9f297ab88123b192,toxicity,0.462616
uuid-a914516af591492e9f297ab88123b192,regimen,0.582715
uuid-a914516af591492e9f297ab88123b192,chemo,0.415365
uuid-a914516af591492e9f297ab88123b192,pts,0.459278
uuid-a914516af591492e9f297ab88123b192,monotherapy,0.428082
uuid-a914516af591492e9f297ab88123b192,treatment,0.540422
uuid-a914516af591492e9f297ab88123b192,response,0.363014
uuid-a914516af591492e9f297ab88123b192,progression,0.54053
uuid-a914516af591492e9f297ab88123b192,chemotherapy,0.494735
uuid-a914516af591492e9f297ab88123b192,respond,0.46242
uuid-a914516af591492e9f297ab88123b192,option,0.425164
uuid-157c719b2c0e4dba8a42feaf475767b4,Nivo,0.470386
uuid-157c719b2c0e4dba8a42feaf475767b4,pembro,0.562355
uuid-157c719b2c0e4dba8a42feaf475767b4,BMS,0.38763
uuid-157c719b2c0e4dba8a42feaf475767b4,PDL1,0.334496
uuid-157c719b2c0e4dba8a42feaf475767b4,trial,0.727876
uuid-157c719b2c0e4dba8a42feaf475767b4,efficacy,0.507198
uuid-157c719b2c0e4dba8a42feaf475767b4,stated,0.331999
uuid-157c719b2c0e4dba8a42feaf475767b4,OS,0.480096
uuid-157c719b2c0e4dba8a42feaf475767b4,atezo,0.445463
uuid-157c719b2c0e4dba8a42feaf475767b4,data,0.717639
uuid-157c719b2c0e4dba8a42feaf475767b4,clinical trials,0.386708
uuid-157c719b2c0e4dba8a42feaf475767b4,indication,0.375375
uuid-157c719b2c0e4dba8a42feaf475767b4,PFS,0.50264
uuid-157c719b2c0e4dba8a42feaf475767b4,ORR,0.56882
uuid-157c719b2c0e4dba8a42feaf475767b4,nivo and pembro,0.519647
uuid-157c719b2c0e4dba8a42feaf475767b4,impressed,0.515513
uuid-157c719b2c0e4dba8a42feaf475767b4,vs,0.330954
uuid-157c719b2c0e4dba8a42feaf475767b4,LTL,0.30058
uuid-157c719b2c0e4dba8a42feaf475767b4,feels,0.415911
uuid-157c719b2c0e4dba8a42feaf475767b4,PDL1 expression,0.432443
uuid-da372f3aae664a0abb09c91d60bc111a,Nivo,0.440096
uuid-da372f3aae664a0abb09c91d60bc111a,Opdivo,0.337811
uuid-da372f3aae664a0abb09c91d60bc111a,pembro,0.586571
uuid-da372f3aae664a0abb09c91d60bc111a,RTL,0.346709
uuid-da372f3aae664a0abb09c91d60bc111a,dose,0.48665
uuid-da372f3aae664a0abb09c91d60bc111a,2L,0.414074
uuid-da372f3aae664a0abb09c91d60bc111a,Ipi,0.40923
uuid-da372f3aae664a0abb09c91d60bc111a,stated,0.508117
uuid-da372f3aae664a0abb09c91d60bc111a,approval,0.472861
uuid-da372f3aae664a0abb09c91d60bc111a,atezo,0.527883
uuid-da372f3aae664a0abb09c91d60bc111a,preferred,0.415277
uuid-da372f3aae664a0abb09c91d60bc111a,using nivo,0.540224
uuid-da372f3aae664a0abb09c91d60bc111a,mentioned,0.318557
uuid-da372f3aae664a0abb09c91d60bc111a,indication,0.47769
uuid-da372f3aae664a0abb09c91d60bc111a,approved,0.511754
uuid-da372f3aae664a0abb09c91d60bc111a,SCCHN,0.434376
uuid-da372f3aae664a0abb09c91d60bc111a,HCP,0.385859
uuid-da372f3aae664a0abb09c91d60bc111a,vs,0.393298
uuid-da372f3aae664a0abb09c91d60bc111a,label,0.384979
uuid-da372f3aae664a0abb09c91d60bc111a,LTL,0.525123
uuid-da372f3aae664a0abb09c91d60bc111a,TLs,0.368871
uuid-da372f3aae664a0abb09c91d60bc111a,Regional TL,0.300407
uuid-da372f3aae664a0abb09c91d60bc111a,RTL stated,0.395687
uuid-da372f3aae664a0abb09c91d60bc111a,bladder,0.339489
uuid-da372f3aae664a0abb09c91d60bc111a,flat dosing,0.590045
uuid-aaf50ddea6d34273a2f8703473135e40,Nivo,0.306451
uuid-aaf50ddea6d34273a2f8703473135e40,pembro,0.65208
uuid-aaf50ddea6d34273a2f8703473135e40,NSCLC,0.430864
uuid-aaf50ddea6d34273a2f8703473135e40,1L,0.669864
uuid-aaf50ddea6d34273a2f8703473135e40,RCC,0.358697
uuid-aaf50ddea6d34273a2f8703473135e40,TL stated,0.31046
uuid-aaf50ddea6d34273a2f8703473135e40,2L,0.628002
uuid-aaf50ddea6d34273a2f8703473135e40,stated,0.459141
uuid-aaf50ddea6d34273a2f8703473135e40,approval,0.517084
uuid-aaf50ddea6d34273a2f8703473135e40,atezo,0.615666
uuid-aaf50ddea6d34273a2f8703473135e40,preferred,0.528233
uuid-aaf50ddea6d34273a2f8703473135e40,monotherapy,0.344101
uuid-aaf50ddea6d34273a2f8703473135e40,using nivo,0.558281
uuid-aaf50ddea6d34273a2f8703473135e40,data,0.386662
uuid-aaf50ddea6d34273a2f8703473135e40,PDL1 testing,0.381677
uuid-aaf50ddea6d34273a2f8703473135e40,indication,0.354469
uuid-aaf50ddea6d34273a2f8703473135e40,NSCLC patients,0.316938
uuid-aaf50ddea6d34273a2f8703473135e40,approved,0.522671
uuid-aaf50ddea6d34273a2f8703473135e40,SCCHN,0.503106
uuid-aaf50ddea6d34273a2f8703473135e40,nivo and pembro,0.301285
uuid-aaf50ddea6d34273a2f8703473135e40,impressed,0.312378
uuid-aaf50ddea6d34273a2f8703473135e40,LTL,0.406274
uuid-aaf50ddea6d34273a2f8703473135e40,TLs,0.332993
uuid-aaf50ddea6d34273a2f8703473135e40,feels,0.327898
uuid-aaf50ddea6d34273a2f8703473135e40,Regional TL,0.369521
uuid-aaf50ddea6d34273a2f8703473135e40,RTL stated,0.500494
uuid-aaf50ddea6d34273a2f8703473135e40,option,0.398374
uuid-aaf50ddea6d34273a2f8703473135e40,bladder,0.350771
uuid-24ad25375ebb4063968ffb0428ebf7be,Nivo,0.523148
uuid-24ad25375ebb4063968ffb0428ebf7be,pembro,0.315216
uuid-24ad25375ebb4063968ffb0428ebf7be,therapy,0.379588
uuid-24ad25375ebb4063968ffb0428ebf7be,nivolumab,0.308963
uuid-24ad25375ebb4063968ffb0428ebf7be,1L,0.517074
uuid-24ad25375ebb4063968ffb0428ebf7be,efficacy,0.43775
uuid-24ad25375ebb4063968ffb0428ebf7be,regimen,0.46902
uuid-24ad25375ebb4063968ffb0428ebf7be,combination,0.851519
uuid-24ad25375ebb4063968ffb0428ebf7be,chemo,0.706477
uuid-24ad25375ebb4063968ffb0428ebf7be,2L,0.475434
uuid-24ad25375ebb4063968ffb0428ebf7be,pts,0.311699
uuid-24ad25375ebb4063968ffb0428ebf7be,IO,0.524168
uuid-24ad25375ebb4063968ffb0428ebf7be,agents,0.650785
uuid-24ad25375ebb4063968ffb0428ebf7be,Ipi,0.451258
uuid-24ad25375ebb4063968ffb0428ebf7be,preferred,0.385995
uuid-24ad25375ebb4063968ffb0428ebf7be,monotherapy,0.781434
uuid-24ad25375ebb4063968ffb0428ebf7be,response,0.370397
uuid-24ad25375ebb4063968ffb0428ebf7be,combo,0.815377
uuid-24ad25375ebb4063968ffb0428ebf7be,PD1,0.631884
uuid-24ad25375ebb4063968ffb0428ebf7be,nivo and pembro,0.334544
uuid-24ad25375ebb4063968ffb0428ebf7be,progression,0.318757
uuid-24ad25375ebb4063968ffb0428ebf7be,believes,0.523141
uuid-24ad25375ebb4063968ffb0428ebf7be,chemotherapy,0.643674
uuid-24ad25375ebb4063968ffb0428ebf7be,feels,0.408004
uuid-24ad25375ebb4063968ffb0428ebf7be,PD-1,0.31698
uuid-24ad25375ebb4063968ffb0428ebf7be,option,0.605196
uuid-a4aeb6ad12854d16af26607f8e94fa04,Nivo,0.466501
uuid-a4aeb6ad12854d16af26607f8e94fa04,patients,0.480665
uuid-a4aeb6ad12854d16af26607f8e94fa04,pembro,0.361775
uuid-a4aeb6ad12854d16af26607f8e94fa04,1L,0.428501
uuid-a4aeb6ad12854d16af26607f8e94fa04,efficacy,0.347487
uuid-a4aeb6ad12854d16af26607f8e94fa04,regimen,0.443499
uuid-a4aeb6ad12854d16af26607f8e94fa04,combination,0.364326
uuid-a4aeb6ad12854d16af26607f8e94fa04,chemo,0.557581
uuid-a4aeb6ad12854d16af26607f8e94fa04,2L,0.394938
uuid-a4aeb6ad12854d16af26607f8e94fa04,pts,0.559459
uuid-a4aeb6ad12854d16af26607f8e94fa04,agents,0.313942
uuid-a4aeb6ad12854d16af26607f8e94fa04,preferred,0.386843
uuid-a4aeb6ad12854d16af26607f8e94fa04,monotherapy,0.594497
uuid-a4aeb6ad12854d16af26607f8e94fa04,response,0.374495
uuid-a4aeb6ad12854d16af26607f8e94fa04,combo,0.366749
uuid-a4aeb6ad12854d16af26607f8e94fa04,PD1,0.383133
uuid-a4aeb6ad12854d16af26607f8e94fa04,progression,0.393363
uuid-a4aeb6ad12854d16af26607f8e94fa04,believes,0.336933
uuid-a4aeb6ad12854d16af26607f8e94fa04,chemotherapy,0.436617
uuid-a4aeb6ad12854d16af26607f8e94fa04,respond,0.41586
uuid-a4aeb6ad12854d16af26607f8e94fa04,feels,0.492078
uuid-a4aeb6ad12854d16af26607f8e94fa04,option,0.554546
uuid-e3a0be0c76d641c78adc0bc55deed045,TL,0.354676
uuid-e3a0be0c76d641c78adc0bc55deed045,pembro,0.318056
uuid-e3a0be0c76d641c78adc0bc55deed045,RTL,0.383221
uuid-e3a0be0c76d641c78adc0bc55deed045,lung,0.346689
uuid-e3a0be0c76d641c78adc0bc55deed045,1L,0.558526
uuid-e3a0be0c76d641c78adc0bc55deed045,commented,0.308488
uuid-e3a0be0c76d641c78adc0bc55deed045,RCC,0.685364
uuid-e3a0be0c76d641c78adc0bc55deed045,TL stated,0.621067
uuid-e3a0be0c76d641c78adc0bc55deed045,2L,0.626248
uuid-e3a0be0c76d641c78adc0bc55deed045,stated,0.546568
uuid-e3a0be0c76d641c78adc0bc55deed045,approval,0.444731
uuid-e3a0be0c76d641c78adc0bc55deed045,atezo,0.363472
uuid-e3a0be0c76d641c78adc0bc55deed045,preferred,0.550317
uuid-e3a0be0c76d641c78adc0bc55deed045,using nivo,0.629767
uuid-e3a0be0c76d641c78adc0bc55deed045,PDL1 testing,0.507792
uuid-e3a0be0c76d641c78adc0bc55deed045,NSCLC patients,0.409135
uuid-e3a0be0c76d641c78adc0bc55deed045,approved,0.442206
uuid-e3a0be0c76d641c78adc0bc55deed045,SCCHN,0.63377
uuid-e3a0be0c76d641c78adc0bc55deed045,tumor types,0.436728
uuid-e3a0be0c76d641c78adc0bc55deed045,LTL,0.443666
uuid-e3a0be0c76d641c78adc0bc55deed045,TLs,0.479359
uuid-e3a0be0c76d641c78adc0bc55deed045,Regional TL,0.570469
uuid-e3a0be0c76d641c78adc0bc55deed045,RTL stated,0.678947
uuid-e3a0be0c76d641c78adc0bc55deed045,TL shared,0.429293
uuid-e3a0be0c76d641c78adc0bc55deed045,option,0.322786
uuid-e3a0be0c76d641c78adc0bc55deed045,bladder,0.466801
uuid-02186a80239845ddb0af372dfe2c516b,pembro,0.424915
uuid-02186a80239845ddb0af372dfe2c516b,lung,0.310762
uuid-02186a80239845ddb0af372dfe2c516b,1L,0.336462
uuid-02186a80239845ddb0af372dfe2c516b,RCC,0.359066
uuid-02186a80239845ddb0af372dfe2c516b,TL stated,0.441658
uuid-02186a80239845ddb0af372dfe2c516b,2L,0.427941
uuid-02186a80239845ddb0af372dfe2c516b,atezo,0.500548
uuid-02186a80239845ddb0af372dfe2c516b,preferred,0.363872
uuid-02186a80239845ddb0af372dfe2c516b,using nivo,0.322515
uuid-02186a80239845ddb0af372dfe2c516b,PDL1 testing,0.326094
uuid-02186a80239845ddb0af372dfe2c516b,NSCLC patients,0.358352
uuid-02186a80239845ddb0af372dfe2c516b,nivo and pembro,0.374251
uuid-02186a80239845ddb0af372dfe2c516b,tumor types,0.401383
uuid-02186a80239845ddb0af372dfe2c516b,TLs,0.418739
uuid-02186a80239845ddb0af372dfe2c516b,RTL stated,0.339198
uuid-02186a80239845ddb0af372dfe2c516b,bladder,0.303714
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,Nivo,0.4495
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,Opdivo,0.438251
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,pembro,0.627256
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,dose,0.756021
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,2L,0.363435
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,Ipi,0.49222
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,approval,0.401963
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,atezo,0.605307
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,preferred,0.418369
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,using nivo,0.35212
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,indication,0.437659
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,approved,0.453406
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,vs,0.545324
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,label,0.37187
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,Keytruda,0.497614
uuid-ad3ac93443ae4ce295ccbbf418ff37a3,flat dosing,0.784205
uuid-854d0e29c1fa4b5db2eb11acfa775fee,pembro,0.346484
uuid-854d0e29c1fa4b5db2eb11acfa775fee,BMS,0.361081
uuid-854d0e29c1fa4b5db2eb11acfa775fee,PDL1,0.564394
uuid-854d0e29c1fa4b5db2eb11acfa775fee,trial,0.319016
uuid-854d0e29c1fa4b5db2eb11acfa775fee,efficacy,0.398799
uuid-854d0e29c1fa4b5db2eb11acfa775fee,Merck,0.41411
uuid-854d0e29c1fa4b5db2eb11acfa775fee,PD-L1,0.315546
uuid-854d0e29c1fa4b5db2eb11acfa775fee,OS,0.35136
uuid-854d0e29c1fa4b5db2eb11acfa775fee,atezo,0.403781
uuid-854d0e29c1fa4b5db2eb11acfa775fee,regards,0.414645
uuid-854d0e29c1fa4b5db2eb11acfa775fee,data,0.325598
uuid-854d0e29c1fa4b5db2eb11acfa775fee,indication,0.302798
uuid-854d0e29c1fa4b5db2eb11acfa775fee,PFS,0.414555
uuid-854d0e29c1fa4b5db2eb11acfa775fee,AI,0.581994
uuid-854d0e29c1fa4b5db2eb11acfa775fee,ORR,0.336021
uuid-854d0e29c1fa4b5db2eb11acfa775fee,nivo and pembro,0.615835
uuid-854d0e29c1fa4b5db2eb11acfa775fee,assay,0.489844
uuid-854d0e29c1fa4b5db2eb11acfa775fee,PDL1 expression,0.529205
uuid-854d0e29c1fa4b5db2eb11acfa775fee,biomarker,0.389331
uuid-5fd0fedafaf744b1857395442fd16456,mentioned,0.559719
uuid-5fd0fedafaf744b1857395442fd16456,cHL,0.53639
uuid-8103669e16894cfbb970ce275965d09b,patients,0.671919
uuid-8103669e16894cfbb970ce275965d09b,Opdivo,0.392403
uuid-8103669e16894cfbb970ce275965d09b,therapy,0.615669
uuid-8103669e16894cfbb970ce275965d09b,nivolumab,0.469625
uuid-8103669e16894cfbb970ce275965d09b,treated,0.417293
uuid-8103669e16894cfbb970ce275965d09b,treatment,0.48674
uuid-8103669e16894cfbb970ce275965d09b,cHL,0.612386
uuid-8103669e16894cfbb970ce275965d09b,progression,0.43672
uuid-8103669e16894cfbb970ce275965d09b,chemotherapy,0.366089
uuid-fe66a51794484076a03eb4e01a5da474,RTL,0.45974
uuid-fe66a51794484076a03eb4e01a5da474,nivolumab,0.463895
uuid-fe66a51794484076a03eb4e01a5da474,stated,0.467338
uuid-fe66a51794484076a03eb4e01a5da474,clinical trials,0.323792
uuid-fe66a51794484076a03eb4e01a5da474,SCCHN,0.315148
uuid-fe66a51794484076a03eb4e01a5da474,cHL,0.389727
uuid-fe66a51794484076a03eb4e01a5da474,impressed,0.389277
uuid-fe66a51794484076a03eb4e01a5da474,LTL,0.41507
uuid-fe66a51794484076a03eb4e01a5da474,academic,0.355384
uuid-fe66a51794484076a03eb4e01a5da474,Regional TL,0.452926
uuid-fe66a51794484076a03eb4e01a5da474,RTL stated,0.318358
uuid-095013aaf7be47d5926c7a87368b0ca8,Opdivo,0.345306
uuid-095013aaf7be47d5926c7a87368b0ca8,pembro,0.349771
uuid-095013aaf7be47d5926c7a87368b0ca8,dose,0.371946
uuid-095013aaf7be47d5926c7a87368b0ca8,shared,0.470493
uuid-095013aaf7be47d5926c7a87368b0ca8,RCC,0.321718
uuid-095013aaf7be47d5926c7a87368b0ca8,2L,0.390058
uuid-095013aaf7be47d5926c7a87368b0ca8,institution,0.467984
uuid-095013aaf7be47d5926c7a87368b0ca8,Ipi,0.321119
uuid-095013aaf7be47d5926c7a87368b0ca8,stated,0.481906
uuid-095013aaf7be47d5926c7a87368b0ca8,approval,0.460883
uuid-095013aaf7be47d5926c7a87368b0ca8,atezo,0.369028
uuid-095013aaf7be47d5926c7a87368b0ca8,preferred,0.382048
uuid-095013aaf7be47d5926c7a87368b0ca8,using nivo,0.509643
uuid-095013aaf7be47d5926c7a87368b0ca8,indication,0.309185
uuid-095013aaf7be47d5926c7a87368b0ca8,approved,0.447371
uuid-095013aaf7be47d5926c7a87368b0ca8,SCCHN,0.404199
uuid-095013aaf7be47d5926c7a87368b0ca8,label,0.304949
uuid-095013aaf7be47d5926c7a87368b0ca8,SCLC,0.309906
uuid-095013aaf7be47d5926c7a87368b0ca8,RTL stated,0.402921
uuid-095013aaf7be47d5926c7a87368b0ca8,flat dosing,0.414144
uuid-f7435d25f9c14ba599fb387de594a77e,pembro,0.40098
uuid-f7435d25f9c14ba599fb387de594a77e,BMS,0.486678
uuid-f7435d25f9c14ba599fb387de594a77e,PDL1,0.453428
uuid-f7435d25f9c14ba599fb387de594a77e,trial,0.787919
uuid-f7435d25f9c14ba599fb387de594a77e,efficacy,0.450291
uuid-f7435d25f9c14ba599fb387de594a77e,Merck,0.512747
uuid-f7435d25f9c14ba599fb387de594a77e,OS,0.416018
uuid-f7435d25f9c14ba599fb387de594a77e,atezo,0.318184
uuid-f7435d25f9c14ba599fb387de594a77e,regards,0.325547
uuid-f7435d25f9c14ba599fb387de594a77e,data,0.598663
uuid-f7435d25f9c14ba599fb387de594a77e,expressed,0.325952
uuid-f7435d25f9c14ba599fb387de594a77e,clinical trials,0.384773
uuid-f7435d25f9c14ba599fb387de594a77e,PFS,0.460198
uuid-f7435d25f9c14ba599fb387de594a77e,ORR,0.495034
uuid-f7435d25f9c14ba599fb387de594a77e,nivo and pembro,0.45733
uuid-f7435d25f9c14ba599fb387de594a77e,impressed,0.351599
uuid-f7435d25f9c14ba599fb387de594a77e,PDL1 expression,0.493512
uuid-f7435d25f9c14ba599fb387de594a77e,biomarker,0.326875
uuid-720587888d1e49dd95d8732a4b147f22,PD-L1 testing,0.43196
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,Nivo,0.303159
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,BMS,0.530804
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,PDL1,0.314349
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,trial,0.471543
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,efficacy,0.610461
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,commented,0.337896
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,OS,0.496908
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,regards,0.338937
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,data,0.69438
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,PFS,0.49564
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,ORR,0.505435
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,nivo and pembro,0.395519
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,impressed,0.550294
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,vs,0.351007
uuid-fe95b44c0386403d9b5b0284a2b9b3fb,feels,0.577583
uuid-1f2229f9c46341c48023c7fc9fb38e78,RTL,0.459828
uuid-1f2229f9c46341c48023c7fc9fb38e78,BMS,0.447516
uuid-1f2229f9c46341c48023c7fc9fb38e78,PDL1,0.343538
uuid-1f2229f9c46341c48023c7fc9fb38e78,trial,0.664505
uuid-1f2229f9c46341c48023c7fc9fb38e78,commented,0.486853
uuid-1f2229f9c46341c48023c7fc9fb38e78,Merck,0.467443
uuid-1f2229f9c46341c48023c7fc9fb38e78,stated,0.390574
uuid-1f2229f9c46341c48023c7fc9fb38e78,OS,0.445714
uuid-1f2229f9c46341c48023c7fc9fb38e78,data,0.737036
uuid-1f2229f9c46341c48023c7fc9fb38e78,expressed,0.363421
uuid-1f2229f9c46341c48023c7fc9fb38e78,clinical trials,0.341175
uuid-1f2229f9c46341c48023c7fc9fb38e78,PFS,0.451085
uuid-1f2229f9c46341c48023c7fc9fb38e78,ORR,0.48144
uuid-1f2229f9c46341c48023c7fc9fb38e78,ASCO,0.358038
uuid-1f2229f9c46341c48023c7fc9fb38e78,impressed,0.589513
uuid-1f2229f9c46341c48023c7fc9fb38e78,Regional TL,0.388034
uuid-f728ea6643a745ca89d72d4a290525c4,patients,0.72664
uuid-f728ea6643a745ca89d72d4a290525c4,Opdivo,0.482195
uuid-f728ea6643a745ca89d72d4a290525c4,therapy,0.545631
uuid-f728ea6643a745ca89d72d4a290525c4,nivolumab,0.700697
uuid-f728ea6643a745ca89d72d4a290525c4,regimen,0.55231
uuid-f728ea6643a745ca89d72d4a290525c4,treated,0.715635
uuid-f728ea6643a745ca89d72d4a290525c4,RCC,0.335067
uuid-f728ea6643a745ca89d72d4a290525c4,combination,0.35497
uuid-f728ea6643a745ca89d72d4a290525c4,chemo,0.322055
uuid-f728ea6643a745ca89d72d4a290525c4,pts,0.577238
uuid-f728ea6643a745ca89d72d4a290525c4,monotherapy,0.446472
uuid-f728ea6643a745ca89d72d4a290525c4,treatment,0.638131
uuid-f728ea6643a745ca89d72d4a290525c4,using nivo,0.344674
uuid-f728ea6643a745ca89d72d4a290525c4,response,0.416241
uuid-f728ea6643a745ca89d72d4a290525c4,PD1,0.357899
uuid-f728ea6643a745ca89d72d4a290525c4,progression,0.591319
uuid-f728ea6643a745ca89d72d4a290525c4,chemotherapy,0.388275
uuid-f728ea6643a745ca89d72d4a290525c4,respond,0.428218
uuid-f728ea6643a745ca89d72d4a290525c4,RTL stated,0.392655
uuid-f728ea6643a745ca89d72d4a290525c4,TL shared,0.362431
uuid-f728ea6643a745ca89d72d4a290525c4,option,0.325842
uuid-1e14b266f54843abb542ea7b0b431afd,patients,0.734598
uuid-1e14b266f54843abb542ea7b0b431afd,Opdivo,0.609654
uuid-1e14b266f54843abb542ea7b0b431afd,therapy,0.492012
uuid-1e14b266f54843abb542ea7b0b431afd,dose,0.491455
uuid-1e14b266f54843abb542ea7b0b431afd,nivolumab,0.622831
uuid-1e14b266f54843abb542ea7b0b431afd,toxicity,0.453293
uuid-1e14b266f54843abb542ea7b0b431afd,regimen,0.69631
uuid-1e14b266f54843abb542ea7b0b431afd,treated,0.633136
uuid-1e14b266f54843abb542ea7b0b431afd,combination,0.459242
uuid-1e14b266f54843abb542ea7b0b431afd,chemo,0.309464
uuid-1e14b266f54843abb542ea7b0b431afd,pts,0.48733
uuid-1e14b266f54843abb542ea7b0b431afd,Ipi,0.382489
uuid-1e14b266f54843abb542ea7b0b431afd,monotherapy,0.466449
uuid-1e14b266f54843abb542ea7b0b431afd,treatment,0.677733
uuid-1e14b266f54843abb542ea7b0b431afd,using nivo,0.332873
uuid-1e14b266f54843abb542ea7b0b431afd,combo,0.40967
uuid-1e14b266f54843abb542ea7b0b431afd,PD1,0.305321
uuid-1e14b266f54843abb542ea7b0b431afd,progression,0.529073
uuid-1e14b266f54843abb542ea7b0b431afd,chemotherapy,0.395955
uuid-1e14b266f54843abb542ea7b0b431afd,respond,0.382112
uuid-1e14b266f54843abb542ea7b0b431afd,option,0.345931
uuid-23c3ca2c25214ae1a35c277a5fca0834,patients,0.792497
uuid-23c3ca2c25214ae1a35c277a5fca0834,therapy,0.414987
uuid-23c3ca2c25214ae1a35c277a5fca0834,1L,0.364379
uuid-23c3ca2c25214ae1a35c277a5fca0834,regimen,0.375659
uuid-23c3ca2c25214ae1a35c277a5fca0834,treated,0.340398
uuid-23c3ca2c25214ae1a35c277a5fca0834,chemo,0.375718
uuid-23c3ca2c25214ae1a35c277a5fca0834,pts,0.563628
uuid-23c3ca2c25214ae1a35c277a5fca0834,monotherapy,0.433356
uuid-23c3ca2c25214ae1a35c277a5fca0834,treatment,0.499025
uuid-23c3ca2c25214ae1a35c277a5fca0834,NSCLC patients,0.445409
uuid-23c3ca2c25214ae1a35c277a5fca0834,progression,0.494792
uuid-23c3ca2c25214ae1a35c277a5fca0834,chemotherapy,0.373375
uuid-23c3ca2c25214ae1a35c277a5fca0834,respond,0.389529
uuid-23c3ca2c25214ae1a35c277a5fca0834,option,0.527362
uuid-68278f690d2f42a7b2ce3ed3fb83887e,Nivo,0.335777
uuid-68278f690d2f42a7b2ce3ed3fb83887e,pembro,0.368195
uuid-68278f690d2f42a7b2ce3ed3fb83887e,dose,0.516864
uuid-68278f690d2f42a7b2ce3ed3fb83887e,regimen,0.347472
uuid-68278f690d2f42a7b2ce3ed3fb83887e,2L,0.307134
uuid-68278f690d2f42a7b2ce3ed3fb83887e,Ipi,0.341828
uuid-68278f690d2f42a7b2ce3ed3fb83887e,atezo,0.371624
uuid-68278f690d2f42a7b2ce3ed3fb83887e,preferred,0.447046
uuid-68278f690d2f42a7b2ce3ed3fb83887e,monotherapy,0.306781
uuid-68278f690d2f42a7b2ce3ed3fb83887e,vs,0.392594
uuid-68278f690d2f42a7b2ce3ed3fb83887e,feels,0.360903
uuid-30361d8453f643bf9883893efab246b5,lung,0.394765
uuid-30361d8453f643bf9883893efab246b5,efficacy,0.363646
uuid-30361d8453f643bf9883893efab246b5,discussed,0.481891
uuid-30361d8453f643bf9883893efab246b5,melanoma,0.347605
uuid-30361d8453f643bf9883893efab246b5,OS,0.331967
uuid-30361d8453f643bf9883893efab246b5,atezo,0.324156
uuid-30361d8453f643bf9883893efab246b5,regards,0.459688
uuid-30361d8453f643bf9883893efab246b5,data,0.401663
uuid-30361d8453f643bf9883893efab246b5,PFS,0.327951
uuid-30361d8453f643bf9883893efab246b5,AI,0.5469
uuid-30361d8453f643bf9883893efab246b5,nivo and pembro,0.446616
uuid-30361d8453f643bf9883893efab246b5,NCCN,0.329712
uuid-55d44d7932a249b88ae401f5b7ae91f2,regimen,0.425525
uuid-55d44d7932a249b88ae401f5b7ae91f2,melanoma,0.349991
uuid-55d44d7932a249b88ae401f5b7ae91f2,Ipi,0.350589
uuid-55d44d7932a249b88ae401f5b7ae91f2,OS,0.319002
uuid-55d44d7932a249b88ae401f5b7ae91f2,regards,0.319184
uuid-55d44d7932a249b88ae401f5b7ae91f2,response,0.356325
uuid-55d44d7932a249b88ae401f5b7ae91f2,combo,0.322379
uuid-55d44d7932a249b88ae401f5b7ae91f2,PFS,0.304097
uuid-55d44d7932a249b88ae401f5b7ae91f2,ORR,0.347182
uuid-55d44d7932a249b88ae401f5b7ae91f2,impressed,0.394426
uuid-55d44d7932a249b88ae401f5b7ae91f2,respond,0.32021
uuid-55d44d7932a249b88ae401f5b7ae91f2,SCLC,0.525696
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,patients,0.331534
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,1L,0.374561
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,PDL1,0.320942
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,PD-L1,0.592295
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,PD-L1 testing,0.628866
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,testing,0.730925
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,PDL1 testing,0.644316
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,NSCLC patients,0.619704
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,assay,0.373938
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,option,0.30662
uuid-3328ac0ef53f43948fcf41c4fa84d7b8,biomarker,0.328641
uuid-1c71dffcdb7b473db84482ca74b31f37,tumor,0.693613
uuid-1c71dffcdb7b473db84482ca74b31f37,tumor types,0.371279
uuid-3b44512696264b96820135c0ca1a47c2,RTL,0.554348
uuid-3b44512696264b96820135c0ca1a47c2,BMS,0.367364
uuid-3b44512696264b96820135c0ca1a47c2,NTL,0.344038
uuid-3b44512696264b96820135c0ca1a47c2,shared,0.767307
uuid-3b44512696264b96820135c0ca1a47c2,commented,0.588765
uuid-3b44512696264b96820135c0ca1a47c2,RCC,0.378888
uuid-3b44512696264b96820135c0ca1a47c2,stated,0.63741
uuid-3b44512696264b96820135c0ca1a47c2,data,0.550435
uuid-3b44512696264b96820135c0ca1a47c2,expressed,0.421548
uuid-3b44512696264b96820135c0ca1a47c2,clinical trials,0.421005
uuid-3b44512696264b96820135c0ca1a47c2,SCCHN,0.469452
uuid-3b44512696264b96820135c0ca1a47c2,HCP,0.350258
uuid-3b44512696264b96820135c0ca1a47c2,ASCO,0.329725
uuid-3b44512696264b96820135c0ca1a47c2,impressed,0.611931
uuid-3b44512696264b96820135c0ca1a47c2,LTL,0.618227
uuid-3b44512696264b96820135c0ca1a47c2,TLs,0.55983
uuid-3b44512696264b96820135c0ca1a47c2,academic,0.373542
uuid-3b44512696264b96820135c0ca1a47c2,SCLC,0.302737
uuid-3b44512696264b96820135c0ca1a47c2,feels,0.307363
uuid-3b44512696264b96820135c0ca1a47c2,Regional TL,0.581472
uuid-3b44512696264b96820135c0ca1a47c2,RTL stated,0.353595
uuid-3b44512696264b96820135c0ca1a47c2,bladder,0.309783
uuid-f82fac14ed994729af689a634f223ca2,BMS,0.316043
uuid-f82fac14ed994729af689a634f223ca2,PDL1,0.317057
uuid-f82fac14ed994729af689a634f223ca2,trial,0.564907
uuid-f82fac14ed994729af689a634f223ca2,efficacy,0.614525
uuid-f82fac14ed994729af689a634f223ca2,OS,0.719065
uuid-f82fac14ed994729af689a634f223ca2,data,0.696325
uuid-f82fac14ed994729af689a634f223ca2,PFS,0.697953
uuid-f82fac14ed994729af689a634f223ca2,ORR,0.826385
uuid-f82fac14ed994729af689a634f223ca2,nivo and pembro,0.452807
uuid-f82fac14ed994729af689a634f223ca2,ASCO,0.30731
uuid-f82fac14ed994729af689a634f223ca2,impressed,0.698725
uuid-f82fac14ed994729af689a634f223ca2,feels,0.366052
uuid-f82fac14ed994729af689a634f223ca2,PDL1 expression,0.372754
uuid-861b1af67ab8452d9775adeae6fbc769,BMS,0.358769
uuid-861b1af67ab8452d9775adeae6fbc769,trial,0.305492
uuid-861b1af67ab8452d9775adeae6fbc769,efficacy,0.376552
uuid-861b1af67ab8452d9775adeae6fbc769,commented,0.396634
uuid-861b1af67ab8452d9775adeae6fbc769,OS,0.777542
uuid-861b1af67ab8452d9775adeae6fbc769,data,0.664503
uuid-861b1af67ab8452d9775adeae6fbc769,PFS,0.692102
uuid-861b1af67ab8452d9775adeae6fbc769,ORR,0.65378
uuid-861b1af67ab8452d9775adeae6fbc769,ASCO,0.422642
uuid-861b1af67ab8452d9775adeae6fbc769,impressed,0.690323
uuid-861b1af67ab8452d9775adeae6fbc769,feels,0.328549
uuid-4069b825727b4e7da6f14b5da9e1ef92,trial,0.476842
uuid-4069b825727b4e7da6f14b5da9e1ef92,combination,0.516714
uuid-4069b825727b4e7da6f14b5da9e1ef92,chemo,0.473428
uuid-4069b825727b4e7da6f14b5da9e1ef92,IO,0.342965
uuid-4069b825727b4e7da6f14b5da9e1ef92,monotherapy,0.368538
uuid-4069b825727b4e7da6f14b5da9e1ef92,response,0.36538
uuid-4069b825727b4e7da6f14b5da9e1ef92,data,0.322049
uuid-4069b825727b4e7da6f14b5da9e1ef92,combo,0.457224
uuid-4069b825727b4e7da6f14b5da9e1ef92,PD1,0.422193
uuid-4069b825727b4e7da6f14b5da9e1ef92,ORR,0.366692
uuid-4069b825727b4e7da6f14b5da9e1ef92,chemotherapy,0.456382
uuid-4069b825727b4e7da6f14b5da9e1ef92,impressed,0.380582
uuid-554f6f33f59c4e18be982b3362460a12,RTL,0.309136
uuid-554f6f33f59c4e18be982b3362460a12,BMS,0.324475
uuid-554f6f33f59c4e18be982b3362460a12,trial,0.715532
uuid-554f6f33f59c4e18be982b3362460a12,data,0.445608
uuid-554f6f33f59c4e18be982b3362460a12,clinical trials,0.44222
uuid-554f6f33f59c4e18be982b3362460a12,PFS,0.309018
uuid-554f6f33f59c4e18be982b3362460a12,ORR,0.389159
uuid-554f6f33f59c4e18be982b3362460a12,impressed,0.417035
uuid-ecdd81bcced7414d865c5843363dd3a3,1L,0.4616
uuid-ecdd81bcced7414d865c5843363dd3a3,PDL1,0.401441
uuid-ecdd81bcced7414d865c5843363dd3a3,2L,0.317405
uuid-ecdd81bcced7414d865c5843363dd3a3,testing,0.376614
uuid-ecdd81bcced7414d865c5843363dd3a3,PDL1 testing,0.443163
uuid-ecdd81bcced7414d865c5843363dd3a3,NSCLC patients,0.459884
uuid-ecdd81bcced7414d865c5843363dd3a3,believes,0.302166
uuid-ecdd81bcced7414d865c5843363dd3a3,feels,0.37529
uuid-ecdd81bcced7414d865c5843363dd3a3,PDL1 expression,0.31419
uuid-ecdd81bcced7414d865c5843363dd3a3,option,0.315367
uuid-24d92638628d4dfeaf15a9bb3e414241,patients,0.454228
uuid-24d92638628d4dfeaf15a9bb3e414241,Opdivo,0.334671
uuid-24d92638628d4dfeaf15a9bb3e414241,therapy,0.381826
uuid-24d92638628d4dfeaf15a9bb3e414241,nivolumab,0.301087
uuid-24d92638628d4dfeaf15a9bb3e414241,treated,0.39969
uuid-24d92638628d4dfeaf15a9bb3e414241,treatment,0.319277
uuid-24d92638628d4dfeaf15a9bb3e414241,mentioned,0.437383
uuid-24d92638628d4dfeaf15a9bb3e414241,cHL,0.688411
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,TL,0.49124
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,RTL,0.319795
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,NTL,0.392524
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,commented,0.461653
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,TL stated,0.413468
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,Merck,0.431509
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,physicians,0.46739
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,expressed,0.337102
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,mentioned,0.427379
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,ASCO,0.405541
uuid-3a48dfc1f20b49b79c08d3e5edeb5208,Regional TL,0.439624
uuid-1059281b350f447181c120c6126b2d79,pembro,0.311874
uuid-1059281b350f447181c120c6126b2d79,RTL,0.546241
uuid-1059281b350f447181c120c6126b2d79,BMS,0.402439
uuid-1059281b350f447181c120c6126b2d79,trial,0.736751
uuid-1059281b350f447181c120c6126b2d79,NTL,0.411273
uuid-1059281b350f447181c120c6126b2d79,shared,0.306374
uuid-1059281b350f447181c120c6126b2d79,commented,0.565681
uuid-1059281b350f447181c120c6126b2d79,Merck,0.399418
uuid-1059281b350f447181c120c6126b2d79,stated,0.428348
uuid-1059281b350f447181c120c6126b2d79,approval,0.337176
uuid-1059281b350f447181c120c6126b2d79,OS,0.347448
uuid-1059281b350f447181c120c6126b2d79,data,0.620393
uuid-1059281b350f447181c120c6126b2d79,expressed,0.370018
uuid-1059281b350f447181c120c6126b2d79,clinical trials,0.387365
uuid-1059281b350f447181c120c6126b2d79,PFS,0.320656
uuid-1059281b350f447181c120c6126b2d79,ORR,0.385303
uuid-1059281b350f447181c120c6126b2d79,SCCHN,0.407385
uuid-1059281b350f447181c120c6126b2d79,ASCO,0.456539
uuid-1059281b350f447181c120c6126b2d79,impressed,0.645612
uuid-1059281b350f447181c120c6126b2d79,LTL,0.343325
uuid-1059281b350f447181c120c6126b2d79,TLs,0.332719
uuid-1059281b350f447181c120c6126b2d79,SCLC,0.376205
uuid-1059281b350f447181c120c6126b2d79,Regional TL,0.504239
uuid-1059281b350f447181c120c6126b2d79,bladder,0.334877
uuid-7ee3626ae76c4844b9b0050273e27012,patients,0.370918
uuid-7ee3626ae76c4844b9b0050273e27012,dose,0.319088
uuid-7ee3626ae76c4844b9b0050273e27012,toxicity,0.430185
uuid-7ee3626ae76c4844b9b0050273e27012,regimen,0.314279
uuid-7ee3626ae76c4844b9b0050273e27012,treated,0.325353
uuid-7ee3626ae76c4844b9b0050273e27012,physicians,0.450361
uuid-7ee3626ae76c4844b9b0050273e27012,treatment,0.558434
uuid-7ee3626ae76c4844b9b0050273e27012,progression,0.302331
uuid-7ee3626ae76c4844b9b0050273e27012,respond,0.392717
uuid-6431000de6124dbea707f789d8d7c3ff,chemo,0.366146
uuid-6431000de6124dbea707f789d8d7c3ff,pts,0.335164
uuid-6431000de6124dbea707f789d8d7c3ff,NSCLC patients,0.305703
uuid-6431000de6124dbea707f789d8d7c3ff,tumor types,0.385333
uuid-6431000de6124dbea707f789d8d7c3ff,biomarker,0.337451
uuid-c08fd8552b5148dc86cf6bac814b4edb,patients,0.374625
uuid-c08fd8552b5148dc86cf6bac814b4edb,trial,0.354286
uuid-c08fd8552b5148dc86cf6bac814b4edb,pts,0.329682
uuid-c08fd8552b5148dc86cf6bac814b4edb,clinical trials,0.389237
uuid-953a586cfa7446f8b25ac8cf20e8ee96,Nivo,0.382765
uuid-953a586cfa7446f8b25ac8cf20e8ee96,patients,0.584722
uuid-953a586cfa7446f8b25ac8cf20e8ee96,Opdivo,0.440592
uuid-953a586cfa7446f8b25ac8cf20e8ee96,therapy,0.412766
uuid-953a586cfa7446f8b25ac8cf20e8ee96,nivolumab,0.352639
uuid-953a586cfa7446f8b25ac8cf20e8ee96,1L,0.411694
uuid-953a586cfa7446f8b25ac8cf20e8ee96,regimen,0.491615
uuid-953a586cfa7446f8b25ac8cf20e8ee96,treated,0.314836
uuid-953a586cfa7446f8b25ac8cf20e8ee96,chemo,0.350435
uuid-953a586cfa7446f8b25ac8cf20e8ee96,2L,0.413235
uuid-953a586cfa7446f8b25ac8cf20e8ee96,pts,0.430078
uuid-953a586cfa7446f8b25ac8cf20e8ee96,preferred,0.424289
uuid-953a586cfa7446f8b25ac8cf20e8ee96,monotherapy,0.537958
uuid-953a586cfa7446f8b25ac8cf20e8ee96,treatment,0.503325
uuid-953a586cfa7446f8b25ac8cf20e8ee96,using nivo,0.440299
uuid-953a586cfa7446f8b25ac8cf20e8ee96,indication,0.322983
uuid-953a586cfa7446f8b25ac8cf20e8ee96,approved,0.366547
uuid-953a586cfa7446f8b25ac8cf20e8ee96,progression,0.402488
uuid-953a586cfa7446f8b25ac8cf20e8ee96,chemotherapy,0.391769
uuid-953a586cfa7446f8b25ac8cf20e8ee96,respond,0.416447
uuid-953a586cfa7446f8b25ac8cf20e8ee96,feels,0.32818
uuid-953a586cfa7446f8b25ac8cf20e8ee96,option,0.586674
uuid-d840da4fabef435d806c9f1bf26ff2c5,patients,0.851087
uuid-d840da4fabef435d806c9f1bf26ff2c5,Opdivo,0.568443
uuid-d840da4fabef435d806c9f1bf26ff2c5,therapy,0.474274
uuid-d840da4fabef435d806c9f1bf26ff2c5,dose,0.373562
uuid-d840da4fabef435d806c9f1bf26ff2c5,nivolumab,0.404932
uuid-d840da4fabef435d806c9f1bf26ff2c5,toxicity,0.526693
uuid-d840da4fabef435d806c9f1bf26ff2c5,regimen,0.661052
uuid-d840da4fabef435d806c9f1bf26ff2c5,treated,0.451905
uuid-d840da4fabef435d806c9f1bf26ff2c5,chemo,0.360009
uuid-d840da4fabef435d806c9f1bf26ff2c5,pts,0.551045
uuid-d840da4fabef435d806c9f1bf26ff2c5,monotherapy,0.4506
uuid-d840da4fabef435d806c9f1bf26ff2c5,treatment,0.650435
uuid-d840da4fabef435d806c9f1bf26ff2c5,response,0.311296
uuid-d840da4fabef435d806c9f1bf26ff2c5,progression,0.551091
uuid-d840da4fabef435d806c9f1bf26ff2c5,chemotherapy,0.389871
uuid-d840da4fabef435d806c9f1bf26ff2c5,respond,0.476534
uuid-d840da4fabef435d806c9f1bf26ff2c5,option,0.409509
uuid-2b1664e00a8d45c4a9291de249c54ff0,Nivo,0.338616
uuid-2b1664e00a8d45c4a9291de249c54ff0,patients,0.36612
uuid-2b1664e00a8d45c4a9291de249c54ff0,therapy,0.613129
uuid-2b1664e00a8d45c4a9291de249c54ff0,nivolumab,0.431597
uuid-2b1664e00a8d45c4a9291de249c54ff0,1L,0.382578
uuid-2b1664e00a8d45c4a9291de249c54ff0,toxicity,0.442989
uuid-2b1664e00a8d45c4a9291de249c54ff0,regimen,0.562318
uuid-2b1664e00a8d45c4a9291de249c54ff0,treated,0.401323
uuid-2b1664e00a8d45c4a9291de249c54ff0,combination,0.673411
uuid-2b1664e00a8d45c4a9291de249c54ff0,chemo,0.579928
uuid-2b1664e00a8d45c4a9291de249c54ff0,2L,0.380754
uuid-2b1664e00a8d45c4a9291de249c54ff0,pts,0.458627
uuid-2b1664e00a8d45c4a9291de249c54ff0,IO,0.504824
uuid-2b1664e00a8d45c4a9291de249c54ff0,agents,0.484003
uuid-2b1664e00a8d45c4a9291de249c54ff0,preferred,0.341492
uuid-2b1664e00a8d45c4a9291de249c54ff0,monotherapy,0.763076
uuid-2b1664e00a8d45c4a9291de249c54ff0,treatment,0.442541
uuid-2b1664e00a8d45c4a9291de249c54ff0,response,0.408092
uuid-2b1664e00a8d45c4a9291de249c54ff0,combo,0.617107
uuid-2b1664e00a8d45c4a9291de249c54ff0,PD1,0.692106
uuid-2b1664e00a8d45c4a9291de249c54ff0,progression,0.472117
uuid-2b1664e00a8d45c4a9291de249c54ff0,believes,0.357859
uuid-2b1664e00a8d45c4a9291de249c54ff0,chemotherapy,0.558285
uuid-2b1664e00a8d45c4a9291de249c54ff0,respond,0.344325
uuid-2b1664e00a8d45c4a9291de249c54ff0,PD-1,0.43728
uuid-2b1664e00a8d45c4a9291de249c54ff0,option,0.557788
uuid-c90f28a7d1674f478ef815a3d42b0fe5,BMS,0.426752
uuid-c90f28a7d1674f478ef815a3d42b0fe5,PDL1,0.484109
uuid-c90f28a7d1674f478ef815a3d42b0fe5,trial,0.383831
uuid-c90f28a7d1674f478ef815a3d42b0fe5,efficacy,0.550534
uuid-c90f28a7d1674f478ef815a3d42b0fe5,commented,0.434772
uuid-c90f28a7d1674f478ef815a3d42b0fe5,Merck,0.305171
uuid-c90f28a7d1674f478ef815a3d42b0fe5,OS,0.511789
uuid-c90f28a7d1674f478ef815a3d42b0fe5,regards,0.435054
uuid-c90f28a7d1674f478ef815a3d42b0fe5,data,0.740901
uuid-c90f28a7d1674f478ef815a3d42b0fe5,expressed,0.471487
uuid-c90f28a7d1674f478ef815a3d42b0fe5,PFS,0.496735
uuid-c90f28a7d1674f478ef815a3d42b0fe5,ORR,0.577289
uuid-c90f28a7d1674f478ef815a3d42b0fe5,nivo and pembro,0.381115
uuid-c90f28a7d1674f478ef815a3d42b0fe5,ASCO,0.340421
uuid-c90f28a7d1674f478ef815a3d42b0fe5,believes,0.348083
uuid-c90f28a7d1674f478ef815a3d42b0fe5,impressed,0.593087
uuid-c90f28a7d1674f478ef815a3d42b0fe5,TLs,0.364466
uuid-c90f28a7d1674f478ef815a3d42b0fe5,feels,0.336207
uuid-c90f28a7d1674f478ef815a3d42b0fe5,PDL1 expression,0.479661
uuid-c90f28a7d1674f478ef815a3d42b0fe5,biomarker,0.348216
uuid-318899ccbe3c49a59f056298dde5443b,patients,0.493939
uuid-318899ccbe3c49a59f056298dde5443b,Opdivo,0.354765
uuid-318899ccbe3c49a59f056298dde5443b,toxicity,0.516146
uuid-318899ccbe3c49a59f056298dde5443b,regimen,0.51227
uuid-318899ccbe3c49a59f056298dde5443b,treated,0.526454
uuid-318899ccbe3c49a59f056298dde5443b,shared,0.40276
uuid-318899ccbe3c49a59f056298dde5443b,physicians,0.417763
uuid-318899ccbe3c49a59f056298dde5443b,treatment,0.449901
uuid-318899ccbe3c49a59f056298dde5443b,progression,0.325951
uuid-318899ccbe3c49a59f056298dde5443b,respond,0.33249
uuid-318899ccbe3c49a59f056298dde5443b,TL shared,0.3373
uuid-3f099a92779149f68302006dfec1449e,Nivo,0.382312
uuid-3f099a92779149f68302006dfec1449e,regimen,0.400785
uuid-3f099a92779149f68302006dfec1449e,shared,0.369144
uuid-3f099a92779149f68302006dfec1449e,combination,0.527984
uuid-3f099a92779149f68302006dfec1449e,IO,0.300525
uuid-3f099a92779149f68302006dfec1449e,Ipi,0.493068
uuid-3f099a92779149f68302006dfec1449e,monotherapy,0.428828
uuid-3f099a92779149f68302006dfec1449e,combo,0.544884
uuid-3f099a92779149f68302006dfec1449e,impressed,0.323846
uuid-3f099a92779149f68302006dfec1449e,SCLC,0.313968
uuid-3f099a92779149f68302006dfec1449e,feels,0.317947
uuid-3f099a92779149f68302006dfec1449e,RTL stated,0.342276
uuid-3f099a92779149f68302006dfec1449e,option,0.30415
uuid-4011fe5977e54312a6cb07b1f8e79098,RTL,0.445716
uuid-4011fe5977e54312a6cb07b1f8e79098,lung,0.307235
uuid-4011fe5977e54312a6cb07b1f8e79098,NSCLC,0.376703
uuid-4011fe5977e54312a6cb07b1f8e79098,NTL,0.567936
uuid-4011fe5977e54312a6cb07b1f8e79098,discussed,0.377252
uuid-4011fe5977e54312a6cb07b1f8e79098,commented,0.370199
uuid-4011fe5977e54312a6cb07b1f8e79098,OS,0.323243
uuid-4011fe5977e54312a6cb07b1f8e79098,PFS,0.326932
uuid-4011fe5977e54312a6cb07b1f8e79098,ASCO,0.32588
uuid-4011fe5977e54312a6cb07b1f8e79098,impressed,0.370236
uuid-4011fe5977e54312a6cb07b1f8e79098,indicated,0.442808
uuid-4011fe5977e54312a6cb07b1f8e79098,TLs,0.399332
uuid-4011fe5977e54312a6cb07b1f8e79098,academic,0.340565
uuid-4011fe5977e54312a6cb07b1f8e79098,Regional TL,0.442218
uuid-7c840ccbd663456fb7debb4e9322456f,Nivo,0.360204
uuid-7c840ccbd663456fb7debb4e9322456f,patients,0.537859
uuid-7c840ccbd663456fb7debb4e9322456f,Opdivo,0.373301
uuid-7c840ccbd663456fb7debb4e9322456f,therapy,0.547778
uuid-7c840ccbd663456fb7debb4e9322456f,nivolumab,0.571661
uuid-7c840ccbd663456fb7debb4e9322456f,treated,0.464581
uuid-7c840ccbd663456fb7debb4e9322456f,approval,0.484929
uuid-7c840ccbd663456fb7debb4e9322456f,treatment,0.411369
uuid-7c840ccbd663456fb7debb4e9322456f,using nivo,0.449412
uuid-7c840ccbd663456fb7debb4e9322456f,cHL,0.580086
uuid-7c840ccbd663456fb7debb4e9322456f,progression,0.319569
uuid-7c840ccbd663456fb7debb4e9322456f,RTL stated,0.323994
uuid-e36d53f217e34522b6a8f8f3cceb0af3,Nivo,0.429598
uuid-e36d53f217e34522b6a8f8f3cceb0af3,pembro,0.424088
uuid-e36d53f217e34522b6a8f8f3cceb0af3,dose,0.763363
uuid-e36d53f217e34522b6a8f8f3cceb0af3,toxicity,0.522413
uuid-e36d53f217e34522b6a8f8f3cceb0af3,efficacy,0.366514
uuid-e36d53f217e34522b6a8f8f3cceb0af3,regimen,0.372084
uuid-e36d53f217e34522b6a8f8f3cceb0af3,combination,0.359435
uuid-e36d53f217e34522b6a8f8f3cceb0af3,Ipi,0.697121
uuid-e36d53f217e34522b6a8f8f3cceb0af3,atezo,0.421601
uuid-e36d53f217e34522b6a8f8f3cceb0af3,preferred,0.383403
uuid-e36d53f217e34522b6a8f8f3cceb0af3,combo,0.355441
uuid-e36d53f217e34522b6a8f8f3cceb0af3,indication,0.343977
uuid-e36d53f217e34522b6a8f8f3cceb0af3,vs,0.521746
uuid-e36d53f217e34522b6a8f8f3cceb0af3,flat dosing,0.535708
uuid-876a55f8cfd14893a25e7ec44fab05d9,combination,0.318835
uuid-876a55f8cfd14893a25e7ec44fab05d9,response,0.313699
uuid-876a55f8cfd14893a25e7ec44fab05d9,PD1,0.465041
uuid-876a55f8cfd14893a25e7ec44fab05d9,ORR,0.329938
uuid-876a55f8cfd14893a25e7ec44fab05d9,believes,0.336774
uuid-df546ba02fb94cf88c5b8295d41bfbbb,chemo,0.368634
uuid-df546ba02fb94cf88c5b8295d41bfbbb,tumor,0.459791
uuid-df546ba02fb94cf88c5b8295d41bfbbb,pts,0.362003
uuid-df546ba02fb94cf88c5b8295d41bfbbb,response,0.547387
uuid-c57cea33afff48bcb9a3e337727d5e45,patients,0.57478
uuid-c57cea33afff48bcb9a3e337727d5e45,Opdivo,0.36348
uuid-c57cea33afff48bcb9a3e337727d5e45,dose,0.465145
uuid-c57cea33afff48bcb9a3e337727d5e45,nivolumab,0.327215
uuid-c57cea33afff48bcb9a3e337727d5e45,regimen,0.361722
uuid-c57cea33afff48bcb9a3e337727d5e45,treated,0.367469
uuid-c57cea33afff48bcb9a3e337727d5e45,pts,0.343284
uuid-c57cea33afff48bcb9a3e337727d5e45,Ipi,0.344512
uuid-c57cea33afff48bcb9a3e337727d5e45,treatment,0.37335
uuid-c57cea33afff48bcb9a3e337727d5e45,clinical trials,0.352167
uuid-c57cea33afff48bcb9a3e337727d5e45,flat dosing,0.308
uuid-739f4d4a333043db8ae5b7d766616e7f,patients,0.405057
uuid-739f4d4a333043db8ae5b7d766616e7f,Opdivo,0.518167
uuid-739f4d4a333043db8ae5b7d766616e7f,2L,0.311928
uuid-739f4d4a333043db8ae5b7d766616e7f,approval,0.475979
uuid-739f4d4a333043db8ae5b7d766616e7f,physicians,0.316701
uuid-739f4d4a333043db8ae5b7d766616e7f,preferred,0.411077
uuid-739f4d4a333043db8ae5b7d766616e7f,using nivo,0.379608
uuid-739f4d4a333043db8ae5b7d766616e7f,clinical trials,0.314864
uuid-739f4d4a333043db8ae5b7d766616e7f,indication,0.360514
uuid-739f4d4a333043db8ae5b7d766616e7f,approved,0.525286
uuid-739f4d4a333043db8ae5b7d766616e7f,tumor types,0.333158
uuid-739f4d4a333043db8ae5b7d766616e7f,label,0.402655
uuid-739f4d4a333043db8ae5b7d766616e7f,Keytruda,0.312941
uuid-739f4d4a333043db8ae5b7d766616e7f,option,0.349964
uuid-e726bf0019c44af980595dcce1c08874,patients,0.784034
uuid-e726bf0019c44af980595dcce1c08874,Opdivo,0.393645
uuid-e726bf0019c44af980595dcce1c08874,therapy,0.564118
uuid-e726bf0019c44af980595dcce1c08874,nivolumab,0.526377
uuid-e726bf0019c44af980595dcce1c08874,regimen,0.458783
uuid-e726bf0019c44af980595dcce1c08874,treated,0.604395
uuid-e726bf0019c44af980595dcce1c08874,pts,0.466472
uuid-e726bf0019c44af980595dcce1c08874,monotherapy,0.366886
uuid-e726bf0019c44af980595dcce1c08874,treatment,0.621946
uuid-e726bf0019c44af980595dcce1c08874,using nivo,0.409163
uuid-e726bf0019c44af980595dcce1c08874,cHL,0.343319
uuid-e726bf0019c44af980595dcce1c08874,progression,0.561361
uuid-e726bf0019c44af980595dcce1c08874,chemotherapy,0.350697
uuid-e726bf0019c44af980595dcce1c08874,respond,0.414624
uuid-e726bf0019c44af980595dcce1c08874,option,0.363801
uuid-00b7ca2cd49c430ebf16357ce3feeb68,patients,0.509878
uuid-00b7ca2cd49c430ebf16357ce3feeb68,chemo,0.360629
uuid-00b7ca2cd49c430ebf16357ce3feeb68,pts,0.393734
uuid-00b7ca2cd49c430ebf16357ce3feeb68,response,0.330967
uuid-00b7ca2cd49c430ebf16357ce3feeb68,NSCLC patients,0.431995
uuid-00b7ca2cd49c430ebf16357ce3feeb68,progression,0.405715
uuid-00b7ca2cd49c430ebf16357ce3feeb68,tumor types,0.323528
uuid-00b7ca2cd49c430ebf16357ce3feeb68,respond,0.409132
uuid-996038189753430eacfdc2db97d21e51,patients,0.51267
uuid-996038189753430eacfdc2db97d21e51,therapy,0.36417
uuid-996038189753430eacfdc2db97d21e51,1L,0.324847
uuid-996038189753430eacfdc2db97d21e51,toxicity,0.390713
uuid-996038189753430eacfdc2db97d21e51,regimen,0.591371
uuid-996038189753430eacfdc2db97d21e51,combination,0.489078
uuid-996038189753430eacfdc2db97d21e51,chemo,0.60378
uuid-996038189753430eacfdc2db97d21e51,pts,0.618469
uuid-996038189753430eacfdc2db97d21e51,IO,0.421364
uuid-996038189753430eacfdc2db97d21e51,monotherapy,0.619941
uuid-996038189753430eacfdc2db97d21e51,treatment,0.369547
uuid-996038189753430eacfdc2db97d21e51,response,0.560019
uuid-996038189753430eacfdc2db97d21e51,combo,0.517627
uuid-996038189753430eacfdc2db97d21e51,PD1,0.515424
uuid-996038189753430eacfdc2db97d21e51,progression,0.62349
uuid-996038189753430eacfdc2db97d21e51,believes,0.3356
uuid-996038189753430eacfdc2db97d21e51,chemotherapy,0.475364
uuid-996038189753430eacfdc2db97d21e51,respond,0.458183
uuid-996038189753430eacfdc2db97d21e51,feels,0.428108
uuid-996038189753430eacfdc2db97d21e51,option,0.464937
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,patients,0.641074
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,Opdivo,0.319134
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,toxicity,0.587681
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,regimen,0.554179
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,treated,0.394474
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,chemo,0.314187
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,pts,0.413189
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,treatment,0.65855
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,response,0.375954
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,progression,0.542093
uuid-9f6db49fb2724d0dba26eb854f8ee3bb,respond,0.605399
uuid-faf93f091a344fbe945de239b8adf600,Nivo,0.500734
uuid-faf93f091a344fbe945de239b8adf600,patients,0.573705
uuid-faf93f091a344fbe945de239b8adf600,Opdivo,0.345986
uuid-faf93f091a344fbe945de239b8adf600,therapy,0.300333
uuid-faf93f091a344fbe945de239b8adf600,dose,0.328624
uuid-faf93f091a344fbe945de239b8adf600,nivolumab,0.522056
uuid-faf93f091a344fbe945de239b8adf600,trial,0.306122
uuid-faf93f091a344fbe945de239b8adf600,regimen,0.488164
uuid-faf93f091a344fbe945de239b8adf600,treated,0.349946
uuid-faf93f091a344fbe945de239b8adf600,combination,0.371833
uuid-faf93f091a344fbe945de239b8adf600,chemo,0.306155
uuid-faf93f091a344fbe945de239b8adf600,pts,0.447151
uuid-faf93f091a344fbe945de239b8adf600,Ipi,0.544815
uuid-faf93f091a344fbe945de239b8adf600,monotherapy,0.352937
uuid-faf93f091a344fbe945de239b8adf600,treatment,0.331473
uuid-faf93f091a344fbe945de239b8adf600,using nivo,0.339088
uuid-faf93f091a344fbe945de239b8adf600,combo,0.345325
uuid-faf93f091a344fbe945de239b8adf600,progression,0.392057
uuid-faf93f091a344fbe945de239b8adf600,chemotherapy,0.363582
uuid-faf93f091a344fbe945de239b8adf600,impressed,0.301945
uuid-faf93f091a344fbe945de239b8adf600,respond,0.31941
uuid-faf93f091a344fbe945de239b8adf600,SCLC,0.303307
uuid-c13beff4f8994b238d579228a854c18a,dose,0.330843
uuid-c13beff4f8994b238d579228a854c18a,toxicity,0.375006
uuid-c13beff4f8994b238d579228a854c18a,efficacy,0.387047
uuid-c13beff4f8994b238d579228a854c18a,combination,0.404987
uuid-c13beff4f8994b238d579228a854c18a,chemo,0.459418
uuid-c13beff4f8994b238d579228a854c18a,tumor,0.475381
uuid-c13beff4f8994b238d579228a854c18a,IO,0.459676
uuid-c13beff4f8994b238d579228a854c18a,Ipi,0.338117
uuid-c13beff4f8994b238d579228a854c18a,response,0.46358
uuid-c13beff4f8994b238d579228a854c18a,combo,0.408822
uuid-c13beff4f8994b238d579228a854c18a,progression,0.325267
uuid-c13beff4f8994b238d579228a854c18a,believes,0.347668
uuid-c13beff4f8994b238d579228a854c18a,chemotherapy,0.313162
uuid-c13beff4f8994b238d579228a854c18a,vs,0.362959
uuid-2e0d31b1750440cbb08d83cf4e4575f2,patients,0.620169
uuid-2e0d31b1750440cbb08d83cf4e4575f2,Opdivo,0.442243
uuid-2e0d31b1750440cbb08d83cf4e4575f2,therapy,0.317277
uuid-2e0d31b1750440cbb08d83cf4e4575f2,dose,0.323093
uuid-2e0d31b1750440cbb08d83cf4e4575f2,nivolumab,0.313232
uuid-2e0d31b1750440cbb08d83cf4e4575f2,toxicity,0.568056
uuid-2e0d31b1750440cbb08d83cf4e4575f2,regimen,0.580943
uuid-2e0d31b1750440cbb08d83cf4e4575f2,treated,0.383029
uuid-2e0d31b1750440cbb08d83cf4e4575f2,chemo,0.313848
uuid-2e0d31b1750440cbb08d83cf4e4575f2,2L,0.34538
uuid-2e0d31b1750440cbb08d83cf4e4575f2,pts,0.367661
uuid-2e0d31b1750440cbb08d83cf4e4575f2,preferred,0.539437
uuid-2e0d31b1750440cbb08d83cf4e4575f2,monotherapy,0.520037
uuid-2e0d31b1750440cbb08d83cf4e4575f2,treatment,0.557124
uuid-2e0d31b1750440cbb08d83cf4e4575f2,using nivo,0.311658
uuid-2e0d31b1750440cbb08d83cf4e4575f2,progression,0.354737
uuid-2e0d31b1750440cbb08d83cf4e4575f2,respond,0.405218
uuid-2e0d31b1750440cbb08d83cf4e4575f2,option,0.552383
uuid-875091f6ca5348428032773e3e7571f5,combination,0.516294
uuid-875091f6ca5348428032773e3e7571f5,IO,0.492478
uuid-875091f6ca5348428032773e3e7571f5,agents,0.482753
uuid-875091f6ca5348428032773e3e7571f5,preferred,0.33644
uuid-875091f6ca5348428032773e3e7571f5,combo,0.452162
uuid-875091f6ca5348428032773e3e7571f5,believes,0.322367
uuid-875091f6ca5348428032773e3e7571f5,feels,0.355644
uuid-875091f6ca5348428032773e3e7571f5,option,0.361632
uuid-22d4075dc20f4446843e5fd0eba7696f,patients,0.778834
uuid-22d4075dc20f4446843e5fd0eba7696f,Opdivo,0.469568
uuid-22d4075dc20f4446843e5fd0eba7696f,therapy,0.618598
uuid-22d4075dc20f4446843e5fd0eba7696f,nivolumab,0.477763
uuid-22d4075dc20f4446843e5fd0eba7696f,regimen,0.429737
uuid-22d4075dc20f4446843e5fd0eba7696f,treated,0.610526
uuid-22d4075dc20f4446843e5fd0eba7696f,pts,0.430932
uuid-22d4075dc20f4446843e5fd0eba7696f,treatment,0.66284
uuid-22d4075dc20f4446843e5fd0eba7696f,response,0.434381
uuid-22d4075dc20f4446843e5fd0eba7696f,cHL,0.498037
uuid-22d4075dc20f4446843e5fd0eba7696f,progression,0.652542
uuid-22d4075dc20f4446843e5fd0eba7696f,respond,0.512797
uuid-8734d180c5614376b05cba1a17fcd912,combination,0.461304
uuid-8734d180c5614376b05cba1a17fcd912,agents,0.383336
uuid-8734d180c5614376b05cba1a17fcd912,immunotherapy,0.409542
uuid-6bb0b3d20f6a48a4872946638bfb4c14,patients,0.302656
uuid-6bb0b3d20f6a48a4872946638bfb4c14,therapy,0.322874
uuid-6bb0b3d20f6a48a4872946638bfb4c14,toxicity,0.370566
uuid-6bb0b3d20f6a48a4872946638bfb4c14,combination,0.340273
uuid-6bb0b3d20f6a48a4872946638bfb4c14,chemo,0.36453
uuid-6bb0b3d20f6a48a4872946638bfb4c14,treatment,0.319198
uuid-6bb0b3d20f6a48a4872946638bfb4c14,chemotherapy,0.412432
uuid-6bb0b3d20f6a48a4872946638bfb4c14,option,0.363614
uuid-ae968e4165a840c9a9651f18d6b66535,tumor,0.596002
uuid-ae968e4165a840c9a9651f18d6b66535,response,0.345292
uuid-ae968e4165a840c9a9651f18d6b66535,immunotherapy,0.382763
uuid-1b6f554540314ce893a47edd39a3819f,OS,0.391316
uuid-1b6f554540314ce893a47edd39a3819f,PFS,0.344423
uuid-1b6f554540314ce893a47edd39a3819f,ORR,0.306612
uuid-676ec3d1185a4d52b82d50ced2788e2c,BMS,0.319321
uuid-676ec3d1185a4d52b82d50ced2788e2c,trial,0.384012
uuid-676ec3d1185a4d52b82d50ced2788e2c,efficacy,0.375589
uuid-676ec3d1185a4d52b82d50ced2788e2c,commented,0.63087
uuid-676ec3d1185a4d52b82d50ced2788e2c,stated,0.308841
uuid-676ec3d1185a4d52b82d50ced2788e2c,OS,0.630241
uuid-676ec3d1185a4d52b82d50ced2788e2c,regards,0.386302
uuid-676ec3d1185a4d52b82d50ced2788e2c,data,0.794532
uuid-676ec3d1185a4d52b82d50ced2788e2c,expressed,0.375059
uuid-676ec3d1185a4d52b82d50ced2788e2c,PFS,0.574241
uuid-676ec3d1185a4d52b82d50ced2788e2c,ORR,0.660281
uuid-676ec3d1185a4d52b82d50ced2788e2c,ASCO,0.511214
uuid-676ec3d1185a4d52b82d50ced2788e2c,impressed,0.727588
uuid-676ec3d1185a4d52b82d50ced2788e2c,TLs,0.320751
uuid-676ec3d1185a4d52b82d50ced2788e2c,SCLC,0.335385
uuid-676ec3d1185a4d52b82d50ced2788e2c,Regional TL,0.310735
uuid-676ec3d1185a4d52b82d50ced2788e2c,NCCN,0.310927
uuid-b1cf915ad1974b5998357f8be929b826,patients,0.584967
uuid-b1cf915ad1974b5998357f8be929b826,1L,0.472633
uuid-b1cf915ad1974b5998357f8be929b826,treated,0.300888
uuid-b1cf915ad1974b5998357f8be929b826,TL stated,0.338615
uuid-b1cf915ad1974b5998357f8be929b826,2L,0.411777
uuid-b1cf915ad1974b5998357f8be929b826,pts,0.399965
uuid-b1cf915ad1974b5998357f8be929b826,PD-L1,0.424197
uuid-b1cf915ad1974b5998357f8be929b826,approval,0.406705
uuid-b1cf915ad1974b5998357f8be929b826,preferred,0.442943
uuid-b1cf915ad1974b5998357f8be929b826,PD-L1 testing,0.566569
uuid-b1cf915ad1974b5998357f8be929b826,testing,0.598705
uuid-b1cf915ad1974b5998357f8be929b826,treatment,0.353682
uuid-b1cf915ad1974b5998357f8be929b826,using nivo,0.38269
uuid-b1cf915ad1974b5998357f8be929b826,PDL1 testing,0.556675
uuid-b1cf915ad1974b5998357f8be929b826,NSCLC patients,0.645472
uuid-b1cf915ad1974b5998357f8be929b826,approved,0.306151
uuid-b1cf915ad1974b5998357f8be929b826,progression,0.324291
uuid-b1cf915ad1974b5998357f8be929b826,RTL stated,0.337905
uuid-b1cf915ad1974b5998357f8be929b826,option,0.44305
uuid-c3748cd9965e43118c365954492b1fae,TL,0.427002
uuid-c3748cd9965e43118c365954492b1fae,pembro,0.404817
uuid-c3748cd9965e43118c365954492b1fae,PDL1,0.603121
uuid-c3748cd9965e43118c365954492b1fae,Merck,0.488294
uuid-c3748cd9965e43118c365954492b1fae,PD-L1,0.646454
uuid-c3748cd9965e43118c365954492b1fae,atezo,0.441976
uuid-c3748cd9965e43118c365954492b1fae,PD-L1 testing,0.521037
uuid-c3748cd9965e43118c365954492b1fae,testing,0.613234
uuid-c3748cd9965e43118c365954492b1fae,data,0.384101
uuid-c3748cd9965e43118c365954492b1fae,PDL1 testing,0.485883
uuid-c3748cd9965e43118c365954492b1fae,NSCLC patients,0.35783
uuid-c3748cd9965e43118c365954492b1fae,nivo and pembro,0.488895
uuid-c3748cd9965e43118c365954492b1fae,assay,0.692031
uuid-c3748cd9965e43118c365954492b1fae,PDL1 expression,0.43929
uuid-c3748cd9965e43118c365954492b1fae,biomarker,0.453791
uuid-39f9812974934fa688570edc582478bf,patients,0.39304
uuid-39f9812974934fa688570edc582478bf,dose,0.422506
uuid-39f9812974934fa688570edc582478bf,toxicity,0.61733
uuid-39f9812974934fa688570edc582478bf,regimen,0.464434
uuid-39f9812974934fa688570edc582478bf,physicians,0.369315
uuid-39f9812974934fa688570edc582478bf,treatment,0.442505
uuid-39f9812974934fa688570edc582478bf,progression,0.36107
uuid-39f9812974934fa688570edc582478bf,respond,0.400052
uuid-b619651210c9490fbea5bc1d05056949,patients,0.326647
uuid-b619651210c9490fbea5bc1d05056949,Opdivo,0.441087
uuid-b619651210c9490fbea5bc1d05056949,BMS,0.395183
uuid-b619651210c9490fbea5bc1d05056949,physicians,0.390714
uuid-3841ca544f3e4394a3b1bc6a1f90fabe,drug,0.365994
uuid-c59d233c8f194f6fb8a59903d1655ade,Opdivo,0.347065
uuid-c59d233c8f194f6fb8a59903d1655ade,stated,0.412922
uuid-c59d233c8f194f6fb8a59903d1655ade,approval,0.508409
uuid-c59d233c8f194f6fb8a59903d1655ade,preferred,0.302902
uuid-c59d233c8f194f6fb8a59903d1655ade,using nivo,0.423131
uuid-c59d233c8f194f6fb8a59903d1655ade,clinical trials,0.447411
uuid-c59d233c8f194f6fb8a59903d1655ade,indication,0.489564
uuid-c59d233c8f194f6fb8a59903d1655ade,approved,0.539408
uuid-c59d233c8f194f6fb8a59903d1655ade,SCCHN,0.325745
uuid-c59d233c8f194f6fb8a59903d1655ade,tumor types,0.304205
uuid-c59d233c8f194f6fb8a59903d1655ade,label,0.412039
uuid-c59d233c8f194f6fb8a59903d1655ade,bladder,0.376063
uuid-a35f3b5aa56643c693e2c2865e913abb,patients,0.679075
uuid-a35f3b5aa56643c693e2c2865e913abb,Opdivo,0.339685
uuid-a35f3b5aa56643c693e2c2865e913abb,therapy,0.352744
uuid-a35f3b5aa56643c693e2c2865e913abb,nivolumab,0.419392
uuid-a35f3b5aa56643c693e2c2865e913abb,toxicity,0.456822
uuid-a35f3b5aa56643c693e2c2865e913abb,regimen,0.648311
uuid-a35f3b5aa56643c693e2c2865e913abb,treated,0.703023
uuid-a35f3b5aa56643c693e2c2865e913abb,melanoma,0.442913
uuid-a35f3b5aa56643c693e2c2865e913abb,RCC,0.410712
uuid-a35f3b5aa56643c693e2c2865e913abb,pts,0.508462
uuid-a35f3b5aa56643c693e2c2865e913abb,monotherapy,0.375328
uuid-a35f3b5aa56643c693e2c2865e913abb,treatment,0.633269
uuid-a35f3b5aa56643c693e2c2865e913abb,progression,0.544902
uuid-a35f3b5aa56643c693e2c2865e913abb,respond,0.40338
uuid-a35f3b5aa56643c693e2c2865e913abb,RTL stated,0.414139
uuid-a35f3b5aa56643c693e2c2865e913abb,TL shared,0.510575
uuid-9e50ab946e994b4f9b4a792baf746e48,RTL,0.578701
uuid-9e50ab946e994b4f9b4a792baf746e48,lung,0.489802
uuid-9e50ab946e994b4f9b4a792baf746e48,NTL,0.514396
uuid-9e50ab946e994b4f9b4a792baf746e48,discussed,0.6637
uuid-9e50ab946e994b4f9b4a792baf746e48,melanoma,0.437318
uuid-9e50ab946e994b4f9b4a792baf746e48,shared,0.582763
uuid-9e50ab946e994b4f9b4a792baf746e48,commented,0.608134
uuid-9e50ab946e994b4f9b4a792baf746e48,RCC,0.404794
uuid-9e50ab946e994b4f9b4a792baf746e48,stated,0.504471
uuid-9e50ab946e994b4f9b4a792baf746e48,data,0.46059
uuid-9e50ab946e994b4f9b4a792baf746e48,expressed,0.386735
uuid-9e50ab946e994b4f9b4a792baf746e48,SCCHN,0.599821
uuid-9e50ab946e994b4f9b4a792baf746e48,ASCO,0.449973
uuid-9e50ab946e994b4f9b4a792baf746e48,impressed,0.489394
uuid-9e50ab946e994b4f9b4a792baf746e48,LTL,0.484011
uuid-9e50ab946e994b4f9b4a792baf746e48,TLs,0.512558
uuid-9e50ab946e994b4f9b4a792baf746e48,academic,0.664588
uuid-9e50ab946e994b4f9b4a792baf746e48,Regional TL,0.624167
uuid-9e50ab946e994b4f9b4a792baf746e48,RTL stated,0.37623
uuid-9e50ab946e994b4f9b4a792baf746e48,TL shared,0.430191
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,patients,0.504704
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,Opdivo,0.319226
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,nivolumab,0.461665
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,regimen,0.602508
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,treated,0.534798
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,melanoma,0.374418
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,RCC,0.414842
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,pts,0.407569
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,monotherapy,0.313487
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,treatment,0.403719
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,using nivo,0.385553
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,SCCHN,0.332922
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,progression,0.345188
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,Regional TL,0.355536
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,RTL stated,0.39476
uuid-5ee8cd9e17184b08b8f4f9b03e8e8fd2,TL shared,0.407299
uuid-e3871c0ca259460e8cd44db1bd362ece,therapy,0.40843
uuid-e3871c0ca259460e8cd44db1bd362ece,treatment,0.374208
uuid-e3871c0ca259460e8cd44db1bd362ece,PD1,0.485219
uuid-e3871c0ca259460e8cd44db1bd362ece,immunotherapy,0.384937
uuid-e3871c0ca259460e8cd44db1bd362ece,PD-1,0.441739
uuid-97ecff364e174ba284e4b43f698a6c3c,patients,0.854485
uuid-97ecff364e174ba284e4b43f698a6c3c,Opdivo,0.606131
uuid-97ecff364e174ba284e4b43f698a6c3c,therapy,0.618229
uuid-97ecff364e174ba284e4b43f698a6c3c,nivolumab,0.610733
uuid-97ecff364e174ba284e4b43f698a6c3c,regimen,0.549
uuid-97ecff364e174ba284e4b43f698a6c3c,treated,0.649987
uuid-97ecff364e174ba284e4b43f698a6c3c,pts,0.513981
uuid-97ecff364e174ba284e4b43f698a6c3c,monotherapy,0.355632
uuid-97ecff364e174ba284e4b43f698a6c3c,treatment,0.694985
uuid-97ecff364e174ba284e4b43f698a6c3c,using nivo,0.407718
uuid-97ecff364e174ba284e4b43f698a6c3c,PD1,0.304504
uuid-97ecff364e174ba284e4b43f698a6c3c,cHL,0.509706
uuid-97ecff364e174ba284e4b43f698a6c3c,progression,0.624868
uuid-97ecff364e174ba284e4b43f698a6c3c,chemotherapy,0.347867
uuid-97ecff364e174ba284e4b43f698a6c3c,respond,0.435821
uuid-97ecff364e174ba284e4b43f698a6c3c,RTL stated,0.301233
uuid-97ecff364e174ba284e4b43f698a6c3c,option,0.304591
uuid-e086eacfbbc74c51bf6da49fd989367c,RTL,0.375946
uuid-e086eacfbbc74c51bf6da49fd989367c,lung,0.745615
uuid-e086eacfbbc74c51bf6da49fd989367c,NTL,0.440443
uuid-e086eacfbbc74c51bf6da49fd989367c,melanoma,0.648141
uuid-e086eacfbbc74c51bf6da49fd989367c,shared,0.330629
uuid-e086eacfbbc74c51bf6da49fd989367c,commented,0.504014
uuid-e086eacfbbc74c51bf6da49fd989367c,RCC,0.611505
uuid-e086eacfbbc74c51bf6da49fd989367c,TL stated,0.611528
uuid-e086eacfbbc74c51bf6da49fd989367c,stated,0.318772
uuid-e086eacfbbc74c51bf6da49fd989367c,expressed,0.3612
uuid-e086eacfbbc74c51bf6da49fd989367c,PDL1 testing,0.425838
uuid-e086eacfbbc74c51bf6da49fd989367c,AI,0.310546
uuid-e086eacfbbc74c51bf6da49fd989367c,SCCHN,0.539957
uuid-e086eacfbbc74c51bf6da49fd989367c,ASCO,0.505445
uuid-e086eacfbbc74c51bf6da49fd989367c,tumor types,0.346344
uuid-e086eacfbbc74c51bf6da49fd989367c,TLs,0.466596
uuid-e086eacfbbc74c51bf6da49fd989367c,academic,0.322547
uuid-e086eacfbbc74c51bf6da49fd989367c,SCLC,0.318543
uuid-e086eacfbbc74c51bf6da49fd989367c,Regional TL,0.535395
uuid-e086eacfbbc74c51bf6da49fd989367c,RTL stated,0.420247
uuid-e086eacfbbc74c51bf6da49fd989367c,TL shared,0.63174
uuid-e086eacfbbc74c51bf6da49fd989367c,NCCN,0.391929
uuid-e086eacfbbc74c51bf6da49fd989367c,bladder,0.451941
uuid-aacb718c7a064e96937b18418439beab,testing,0.327065
uuid-aacb718c7a064e96937b18418439beab,PDL1 testing,0.339824
uuid-bc7354c7eb2e40f1946b25499bfa149c,patients,0.681675
uuid-bc7354c7eb2e40f1946b25499bfa149c,Opdivo,0.345814
uuid-bc7354c7eb2e40f1946b25499bfa149c,therapy,0.35849
uuid-bc7354c7eb2e40f1946b25499bfa149c,regimen,0.421345
uuid-bc7354c7eb2e40f1946b25499bfa149c,treated,0.419114
uuid-bc7354c7eb2e40f1946b25499bfa149c,chemo,0.374545
uuid-bc7354c7eb2e40f1946b25499bfa149c,pts,0.48202
uuid-bc7354c7eb2e40f1946b25499bfa149c,monotherapy,0.326714
uuid-bc7354c7eb2e40f1946b25499bfa149c,treatment,0.494144
uuid-bc7354c7eb2e40f1946b25499bfa149c,progression,0.534812
uuid-bc7354c7eb2e40f1946b25499bfa149c,chemotherapy,0.413514
uuid-bc7354c7eb2e40f1946b25499bfa149c,respond,0.354408
uuid-bc7354c7eb2e40f1946b25499bfa149c,option,0.361412
uuid-241a036811fc499691948dcbc5742f50,PDL1,0.366743
uuid-241a036811fc499691948dcbc5742f50,tumor,0.488109
uuid-241a036811fc499691948dcbc5742f50,PD-L1,0.571762
uuid-241a036811fc499691948dcbc5742f50,PD-L1 testing,0.390052
uuid-241a036811fc499691948dcbc5742f50,testing,0.529501
uuid-241a036811fc499691948dcbc5742f50,PDL1 testing,0.308389
uuid-241a036811fc499691948dcbc5742f50,NSCLC patients,0.411122
uuid-241a036811fc499691948dcbc5742f50,assay,0.427035
uuid-241a036811fc499691948dcbc5742f50,PDL1 expression,0.31167
uuid-241a036811fc499691948dcbc5742f50,biomarker,0.455894
uuid-02104fdbb77747d3b321d69a12f96687,patients,0.329085
uuid-02104fdbb77747d3b321d69a12f96687,Opdivo,0.302582
uuid-02104fdbb77747d3b321d69a12f96687,Merck,0.335003
uuid-02104fdbb77747d3b321d69a12f96687,preferred,0.497648
uuid-02104fdbb77747d3b321d69a12f96687,approved,0.369904
uuid-02104fdbb77747d3b321d69a12f96687,label,0.377137
uuid-02104fdbb77747d3b321d69a12f96687,option,0.301898
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,patients,0.400146
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,Opdivo,0.470026
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,dose,0.396213
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,toxicity,0.458743
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,regimen,0.372402
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,physicians,0.507107
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,treatment,0.394758
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,drug,0.33112
uuid-fc5b7c4b0ff54dd29396d045b12eea0c,flat dosing,0.395786
uuid-47a823d783614bc2a015a8b7306f6c30,pembro,0.546171
uuid-47a823d783614bc2a015a8b7306f6c30,dose,0.578083
uuid-47a823d783614bc2a015a8b7306f6c30,efficacy,0.311373
uuid-47a823d783614bc2a015a8b7306f6c30,shared,0.460779
uuid-47a823d783614bc2a015a8b7306f6c30,RCC,0.354398
uuid-47a823d783614bc2a015a8b7306f6c30,2L,0.475607
uuid-47a823d783614bc2a015a8b7306f6c30,Ipi,0.483431
uuid-47a823d783614bc2a015a8b7306f6c30,atezo,0.654554
uuid-47a823d783614bc2a015a8b7306f6c30,preferred,0.42077
uuid-47a823d783614bc2a015a8b7306f6c30,using nivo,0.368595
uuid-47a823d783614bc2a015a8b7306f6c30,combo,0.359233
uuid-47a823d783614bc2a015a8b7306f6c30,indication,0.361162
uuid-47a823d783614bc2a015a8b7306f6c30,approved,0.31781
uuid-47a823d783614bc2a015a8b7306f6c30,nivo and pembro,0.312764
uuid-47a823d783614bc2a015a8b7306f6c30,vs,0.507275
uuid-47a823d783614bc2a015a8b7306f6c30,TLs,0.489664
uuid-47a823d783614bc2a015a8b7306f6c30,flat dosing,0.550924
uuid-a646fe91cee74ac29c6f0f1735db4c76,patients,0.861436
uuid-a646fe91cee74ac29c6f0f1735db4c76,Opdivo,0.391169
uuid-a646fe91cee74ac29c6f0f1735db4c76,therapy,0.638302
uuid-a646fe91cee74ac29c6f0f1735db4c76,nivolumab,0.435794
uuid-a646fe91cee74ac29c6f0f1735db4c76,toxicity,0.304484
uuid-a646fe91cee74ac29c6f0f1735db4c76,regimen,0.591058
uuid-a646fe91cee74ac29c6f0f1735db4c76,treated,0.5902
uuid-a646fe91cee74ac29c6f0f1735db4c76,chemo,0.427973
uuid-a646fe91cee74ac29c6f0f1735db4c76,pts,0.645547
uuid-a646fe91cee74ac29c6f0f1735db4c76,monotherapy,0.439253
uuid-a646fe91cee74ac29c6f0f1735db4c76,treatment,0.798522
uuid-a646fe91cee74ac29c6f0f1735db4c76,response,0.53543
uuid-a646fe91cee74ac29c6f0f1735db4c76,PD1,0.408984
uuid-a646fe91cee74ac29c6f0f1735db4c76,progression,0.819807
uuid-a646fe91cee74ac29c6f0f1735db4c76,chemotherapy,0.460326
uuid-a646fe91cee74ac29c6f0f1735db4c76,respond,0.608831
uuid-a646fe91cee74ac29c6f0f1735db4c76,option,0.401101
uuid-2539fd961bd5431db12aa806a2ef20b8,patients,0.326615
uuid-2539fd961bd5431db12aa806a2ef20b8,Opdivo,0.683931
uuid-2539fd961bd5431db12aa806a2ef20b8,dose,0.822299
uuid-2539fd961bd5431db12aa806a2ef20b8,toxicity,0.367813
uuid-2539fd961bd5431db12aa806a2ef20b8,regimen,0.336157
uuid-2539fd961bd5431db12aa806a2ef20b8,Ipi,0.386354
uuid-2539fd961bd5431db12aa806a2ef20b8,vs,0.409795
uuid-2539fd961bd5431db12aa806a2ef20b8,drug,0.437041
uuid-2539fd961bd5431db12aa806a2ef20b8,Keytruda,0.537845
uuid-2539fd961bd5431db12aa806a2ef20b8,flat dosing,0.777295
uuid-6af70adea55e4a058fb5fb25c0dd5aff,Nivo,0.44413
uuid-6af70adea55e4a058fb5fb25c0dd5aff,pembro,0.522022
uuid-6af70adea55e4a058fb5fb25c0dd5aff,dose,0.473181
uuid-6af70adea55e4a058fb5fb25c0dd5aff,efficacy,0.424975
uuid-6af70adea55e4a058fb5fb25c0dd5aff,Ipi,0.324501
uuid-6af70adea55e4a058fb5fb25c0dd5aff,atezo,0.476364
uuid-6af70adea55e4a058fb5fb25c0dd5aff,preferred,0.352995
uuid-6af70adea55e4a058fb5fb25c0dd5aff,indication,0.304862
uuid-6af70adea55e4a058fb5fb25c0dd5aff,nivo and pembro,0.32214
uuid-6af70adea55e4a058fb5fb25c0dd5aff,vs,0.601965
uuid-6af70adea55e4a058fb5fb25c0dd5aff,feels,0.50832
uuid-6af70adea55e4a058fb5fb25c0dd5aff,flat dosing,0.395606
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,institution,0.444494
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,approval,0.363821
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,physicians,0.406292
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,PD-L1 testing,0.441162
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,testing,0.40446
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,PDL1 testing,0.368801
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,oncology,0.492196
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,approved,0.363818
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,label,0.351033
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,oncologist,0.310804
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,drug,0.418395
uuid-d1e58b1e91d84e2d8d6a3dd6ee760e88,clinical,0.360044
uuid-ed1c393212634f80b525dc0d8dc49c14,patients,0.530592
uuid-ed1c393212634f80b525dc0d8dc49c14,treated,0.427451
uuid-ed1c393212634f80b525dc0d8dc49c14,pts,0.305968
uuid-ed1c393212634f80b525dc0d8dc49c14,PD-L1 testing,0.408217
uuid-ed1c393212634f80b525dc0d8dc49c14,treatment,0.409707
uuid-ed1c393212634f80b525dc0d8dc49c14,NSCLC patients,0.318044
uuid-ed1c393212634f80b525dc0d8dc49c14,progression,0.344555
uuid-8464f69a44bc44ffbdc106557d881591,Nivo,0.331467
uuid-8464f69a44bc44ffbdc106557d881591,pembro,0.40153
uuid-8464f69a44bc44ffbdc106557d881591,BMS,0.357424
uuid-8464f69a44bc44ffbdc106557d881591,PDL1,0.582432
uuid-8464f69a44bc44ffbdc106557d881591,trial,0.574489
uuid-8464f69a44bc44ffbdc106557d881591,efficacy,0.609025
uuid-8464f69a44bc44ffbdc106557d881591,OS,0.595717
uuid-8464f69a44bc44ffbdc106557d881591,atezo,0.360387
uuid-8464f69a44bc44ffbdc106557d881591,regards,0.353971
uuid-8464f69a44bc44ffbdc106557d881591,data,0.673311
uuid-8464f69a44bc44ffbdc106557d881591,expressed,0.457229
uuid-8464f69a44bc44ffbdc106557d881591,PFS,0.602212
uuid-8464f69a44bc44ffbdc106557d881591,ORR,0.646758
uuid-8464f69a44bc44ffbdc106557d881591,nivo and pembro,0.602011
uuid-8464f69a44bc44ffbdc106557d881591,believes,0.38552
uuid-8464f69a44bc44ffbdc106557d881591,impressed,0.497082
uuid-8464f69a44bc44ffbdc106557d881591,feels,0.33696
uuid-8464f69a44bc44ffbdc106557d881591,PDL1 expression,0.555177
uuid-8464f69a44bc44ffbdc106557d881591,biomarker,0.320015
uuid-c87c6d39da8e4411a7f3b843230ce72d,RTL,0.484908
uuid-c87c6d39da8e4411a7f3b843230ce72d,BMS,0.40178
uuid-c87c6d39da8e4411a7f3b843230ce72d,trial,0.455681
uuid-c87c6d39da8e4411a7f3b843230ce72d,NTL,0.344646
uuid-c87c6d39da8e4411a7f3b843230ce72d,shared,0.31292
uuid-c87c6d39da8e4411a7f3b843230ce72d,commented,0.585336
uuid-c87c6d39da8e4411a7f3b843230ce72d,stated,0.510668
uuid-c87c6d39da8e4411a7f3b843230ce72d,OS,0.4097
uuid-c87c6d39da8e4411a7f3b843230ce72d,regards,0.311036
uuid-c87c6d39da8e4411a7f3b843230ce72d,data,0.826245
uuid-c87c6d39da8e4411a7f3b843230ce72d,expressed,0.456924
uuid-c87c6d39da8e4411a7f3b843230ce72d,PFS,0.342012
uuid-c87c6d39da8e4411a7f3b843230ce72d,ORR,0.436141
uuid-c87c6d39da8e4411a7f3b843230ce72d,SCCHN,0.383785
uuid-c87c6d39da8e4411a7f3b843230ce72d,ASCO,0.549361
uuid-c87c6d39da8e4411a7f3b843230ce72d,impressed,0.741584
uuid-c87c6d39da8e4411a7f3b843230ce72d,LTL,0.414616
uuid-c87c6d39da8e4411a7f3b843230ce72d,TLs,0.418696
uuid-c87c6d39da8e4411a7f3b843230ce72d,SCLC,0.420253
uuid-c87c6d39da8e4411a7f3b843230ce72d,feels,0.308433
uuid-c87c6d39da8e4411a7f3b843230ce72d,Regional TL,0.490452
uuid-c87c6d39da8e4411a7f3b843230ce72d,bladder,0.358676
uuid-e95f0ee899af414cae87d5cda08e1de6,patients,0.8906
uuid-e95f0ee899af414cae87d5cda08e1de6,Opdivo,0.535547
uuid-e95f0ee899af414cae87d5cda08e1de6,therapy,0.506256
uuid-e95f0ee899af414cae87d5cda08e1de6,nivolumab,0.505763
uuid-e95f0ee899af414cae87d5cda08e1de6,regimen,0.498997
uuid-e95f0ee899af414cae87d5cda08e1de6,treated,0.659652
uuid-e95f0ee899af414cae87d5cda08e1de6,pts,0.598227
uuid-e95f0ee899af414cae87d5cda08e1de6,monotherapy,0.307045
uuid-e95f0ee899af414cae87d5cda08e1de6,treatment,0.687231
uuid-e95f0ee899af414cae87d5cda08e1de6,using nivo,0.3805
uuid-e95f0ee899af414cae87d5cda08e1de6,response,0.334004
uuid-e95f0ee899af414cae87d5cda08e1de6,cHL,0.324559
uuid-e95f0ee899af414cae87d5cda08e1de6,progression,0.649969
uuid-e95f0ee899af414cae87d5cda08e1de6,respond,0.519751
uuid-dabad3a028604fd2ad7add8e2e2c884e,Nivo,0.364117
uuid-dabad3a028604fd2ad7add8e2e2c884e,patients,0.692704
uuid-dabad3a028604fd2ad7add8e2e2c884e,pembro,0.403727
uuid-dabad3a028604fd2ad7add8e2e2c884e,1L,0.398569
uuid-dabad3a028604fd2ad7add8e2e2c884e,chemo,0.301443
uuid-dabad3a028604fd2ad7add8e2e2c884e,2L,0.393986
uuid-dabad3a028604fd2ad7add8e2e2c884e,pts,0.477081
uuid-dabad3a028604fd2ad7add8e2e2c884e,approval,0.343947
uuid-dabad3a028604fd2ad7add8e2e2c884e,preferred,0.361336
uuid-dabad3a028604fd2ad7add8e2e2c884e,monotherapy,0.354917
uuid-dabad3a028604fd2ad7add8e2e2c884e,treatment,0.301611
uuid-dabad3a028604fd2ad7add8e2e2c884e,using nivo,0.427909
uuid-dabad3a028604fd2ad7add8e2e2c884e,NSCLC patients,0.328551
uuid-dabad3a028604fd2ad7add8e2e2c884e,approved,0.33178
uuid-dabad3a028604fd2ad7add8e2e2c884e,progression,0.329151
uuid-dabad3a028604fd2ad7add8e2e2c884e,feels,0.365074
uuid-dabad3a028604fd2ad7add8e2e2c884e,option,0.479645
uuid-0a0e753ded684592b43c3ec98ddac9be,lung,0.450047
uuid-0a0e753ded684592b43c3ec98ddac9be,1L,0.317176
uuid-0a0e753ded684592b43c3ec98ddac9be,melanoma,0.464727
uuid-0a0e753ded684592b43c3ec98ddac9be,shared,0.336905
uuid-0a0e753ded684592b43c3ec98ddac9be,RCC,0.471183
uuid-0a0e753ded684592b43c3ec98ddac9be,2L,0.400478
uuid-0a0e753ded684592b43c3ec98ddac9be,institution,0.436368
uuid-0a0e753ded684592b43c3ec98ddac9be,stated,0.329902
uuid-0a0e753ded684592b43c3ec98ddac9be,approval,0.344604
uuid-0a0e753ded684592b43c3ec98ddac9be,preferred,0.406489
uuid-0a0e753ded684592b43c3ec98ddac9be,using nivo,0.416214
uuid-0a0e753ded684592b43c3ec98ddac9be,PDL1 testing,0.331891
uuid-0a0e753ded684592b43c3ec98ddac9be,AI,0.344346
uuid-0a0e753ded684592b43c3ec98ddac9be,approved,0.344905
uuid-0a0e753ded684592b43c3ec98ddac9be,SCCHN,0.540208
uuid-0a0e753ded684592b43c3ec98ddac9be,academic,0.422945
uuid-0a0e753ded684592b43c3ec98ddac9be,Regional TL,0.322055
uuid-0a0e753ded684592b43c3ec98ddac9be,RTL stated,0.467111
uuid-0a0e753ded684592b43c3ec98ddac9be,TL shared,0.388819
uuid-0a0e753ded684592b43c3ec98ddac9be,NCCN,0.370689
uuid-d96ed31c96154d1b8036265d086ed277,therapy,0.449625
uuid-d96ed31c96154d1b8036265d086ed277,combination,0.366814
uuid-d96ed31c96154d1b8036265d086ed277,chemo,0.417143
uuid-d96ed31c96154d1b8036265d086ed277,pts,0.352438
uuid-d96ed31c96154d1b8036265d086ed277,response,0.637995
uuid-d96ed31c96154d1b8036265d086ed277,PD1,0.356725
uuid-d96ed31c96154d1b8036265d086ed277,progression,0.336752
uuid-d96ed31c96154d1b8036265d086ed277,believes,0.31141
uuid-d96ed31c96154d1b8036265d086ed277,chemotherapy,0.305925
uuid-d96ed31c96154d1b8036265d086ed277,respond,0.40806
uuid-8c47ac239ee641cd8241ac57afd66c2f,patients,0.481912
uuid-8c47ac239ee641cd8241ac57afd66c2f,therapy,0.527073
uuid-8c47ac239ee641cd8241ac57afd66c2f,nivolumab,0.606975
uuid-8c47ac239ee641cd8241ac57afd66c2f,treated,0.406928
uuid-8c47ac239ee641cd8241ac57afd66c2f,combination,0.347631
uuid-8c47ac239ee641cd8241ac57afd66c2f,chemo,0.423683
uuid-8c47ac239ee641cd8241ac57afd66c2f,pts,0.43738
uuid-8c47ac239ee641cd8241ac57afd66c2f,treatment,0.372536
uuid-8c47ac239ee641cd8241ac57afd66c2f,response,0.532689
uuid-8c47ac239ee641cd8241ac57afd66c2f,PD1,0.395575
uuid-8c47ac239ee641cd8241ac57afd66c2f,cHL,0.31791
uuid-8c47ac239ee641cd8241ac57afd66c2f,progression,0.429313
uuid-8c47ac239ee641cd8241ac57afd66c2f,chemotherapy,0.388371
uuid-ed6f2afad1344237b5c5d27cf5b97ad3,discussed,0.42176
uuid-0364cb75680f4a8dba353a52db6f6c22,TL,0.754034
uuid-0364cb75680f4a8dba353a52db6f6c22,institution,0.330044
uuid-0364cb75680f4a8dba353a52db6f6c22,PD-L1,0.66597
uuid-0364cb75680f4a8dba353a52db6f6c22,PD-L1 testing,0.753664
uuid-0364cb75680f4a8dba353a52db6f6c22,testing,0.684714
uuid-0364cb75680f4a8dba353a52db6f6c22,PDL1 testing,0.405323
uuid-0364cb75680f4a8dba353a52db6f6c22,NSCLC patients,0.385788
uuid-0364cb75680f4a8dba353a52db6f6c22,assay,0.790533
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,TL,0.59038
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,pembro,0.340018
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,1L,0.32843
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,PDL1,0.314876
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,TL stated,0.473729
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,institution,0.329794
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,PD-L1,0.725722
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,approval,0.393308
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,atezo,0.375877
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,PD-L1 testing,0.810881
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,testing,0.826192
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,PDL1 testing,0.657141
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,NSCLC patients,0.655365
uuid-70d67e7d6e8048e2bf11bc0f238a70c2,assay,0.781443
uuid-200730d4efe34fca9fffe57f9b151cf1,TL,0.517031
uuid-200730d4efe34fca9fffe57f9b151cf1,PDL1,0.379657
uuid-200730d4efe34fca9fffe57f9b151cf1,TL stated,0.385136
uuid-200730d4efe34fca9fffe57f9b151cf1,tumor,0.539752
uuid-200730d4efe34fca9fffe57f9b151cf1,PD-L1,0.622188
uuid-200730d4efe34fca9fffe57f9b151cf1,PD-L1 testing,0.607107
uuid-200730d4efe34fca9fffe57f9b151cf1,testing,0.585827
uuid-200730d4efe34fca9fffe57f9b151cf1,PDL1 testing,0.449668
uuid-200730d4efe34fca9fffe57f9b151cf1,NSCLC patients,0.362619
uuid-200730d4efe34fca9fffe57f9b151cf1,assay,0.556147
uuid-200730d4efe34fca9fffe57f9b151cf1,PDL1 expression,0.31663
uuid-200730d4efe34fca9fffe57f9b151cf1,biomarker,0.392985
uuid-3f8a02b305794e99b6de82a4d83c2166,TL,0.367531
uuid-3f8a02b305794e99b6de82a4d83c2166,TL stated,0.387548
uuid-3f8a02b305794e99b6de82a4d83c2166,tumor,0.536988
uuid-3f8a02b305794e99b6de82a4d83c2166,PD-L1,0.579213
uuid-3f8a02b305794e99b6de82a4d83c2166,PD-L1 testing,0.615098
uuid-3f8a02b305794e99b6de82a4d83c2166,testing,0.619128
uuid-3f8a02b305794e99b6de82a4d83c2166,PDL1 testing,0.479798
uuid-3f8a02b305794e99b6de82a4d83c2166,NSCLC patients,0.366937
uuid-3f8a02b305794e99b6de82a4d83c2166,assay,0.517907
uuid-3f8a02b305794e99b6de82a4d83c2166,biomarker,0.371987
uuid-b5c2a3d733304924976ff6e41a0bcf6d,TL,0.73038
uuid-b5c2a3d733304924976ff6e41a0bcf6d,TL stated,0.394915
uuid-b5c2a3d733304924976ff6e41a0bcf6d,institution,0.469561
uuid-b5c2a3d733304924976ff6e41a0bcf6d,PD-L1,0.770719
uuid-b5c2a3d733304924976ff6e41a0bcf6d,PD-L1 testing,0.884269
uuid-b5c2a3d733304924976ff6e41a0bcf6d,testing,0.849086
uuid-b5c2a3d733304924976ff6e41a0bcf6d,PDL1 testing,0.631351
uuid-b5c2a3d733304924976ff6e41a0bcf6d,NSCLC patients,0.571211
uuid-b5c2a3d733304924976ff6e41a0bcf6d,assay,0.747856
uuid-b5c2a3d733304924976ff6e41a0bcf6d,biomarker,0.358465
uuid-4bff94d448ee4544b0eea26da785f558,TL,0.672532
uuid-4bff94d448ee4544b0eea26da785f558,PDL1,0.300449
uuid-4bff94d448ee4544b0eea26da785f558,TL stated,0.322035
uuid-4bff94d448ee4544b0eea26da785f558,institution,0.367124
uuid-4bff94d448ee4544b0eea26da785f558,PD-L1,0.699722
uuid-4bff94d448ee4544b0eea26da785f558,PD-L1 testing,0.854195
uuid-4bff94d448ee4544b0eea26da785f558,testing,0.787421
uuid-4bff94d448ee4544b0eea26da785f558,PDL1 testing,0.582465
uuid-4bff94d448ee4544b0eea26da785f558,NSCLC patients,0.435757
uuid-4bff94d448ee4544b0eea26da785f558,assay,0.72671
uuid-4bff94d448ee4544b0eea26da785f558,biomarker,0.322833
uuid-020db0531a09430b9c07d9ccd374f32f,PD-L1 testing,0.31712
uuid-020db0531a09430b9c07d9ccd374f32f,assay,0.320202
uuid-ebb024713eab42b3a030d86eac7c58c2,TL,0.582465
uuid-ebb024713eab42b3a030d86eac7c58c2,PDL1,0.314805
uuid-ebb024713eab42b3a030d86eac7c58c2,TL stated,0.412607
uuid-ebb024713eab42b3a030d86eac7c58c2,institution,0.410474
uuid-ebb024713eab42b3a030d86eac7c58c2,PD-L1,0.707493
uuid-ebb024713eab42b3a030d86eac7c58c2,PD-L1 testing,0.869318
uuid-ebb024713eab42b3a030d86eac7c58c2,testing,0.830774
uuid-ebb024713eab42b3a030d86eac7c58c2,PDL1 testing,0.687036
uuid-ebb024713eab42b3a030d86eac7c58c2,NSCLC patients,0.523234
uuid-ebb024713eab42b3a030d86eac7c58c2,assay,0.669425
uuid-ebb024713eab42b3a030d86eac7c58c2,biomarker,0.337957
uuid-a786ad644b9c4963a3bd226364723d22,TL,0.396701
uuid-a786ad644b9c4963a3bd226364723d22,institution,0.636893
uuid-a786ad644b9c4963a3bd226364723d22,PD-L1,0.636096
uuid-a786ad644b9c4963a3bd226364723d22,PD-L1 testing,0.712857
uuid-a786ad644b9c4963a3bd226364723d22,testing,0.676566
uuid-a786ad644b9c4963a3bd226364723d22,PDL1 testing,0.532221
uuid-a786ad644b9c4963a3bd226364723d22,NSCLC patients,0.515775
uuid-a786ad644b9c4963a3bd226364723d22,Keytruda,0.37802
uuid-a786ad644b9c4963a3bd226364723d22,assay,0.497636
uuid-c1dbd1193cad40e6b8a1a646d11abac1,TL,0.831599
uuid-c1dbd1193cad40e6b8a1a646d11abac1,TL stated,0.440951
uuid-c1dbd1193cad40e6b8a1a646d11abac1,Merck,0.301385
uuid-c1dbd1193cad40e6b8a1a646d11abac1,institution,0.414071
uuid-c1dbd1193cad40e6b8a1a646d11abac1,PD-L1,0.612188
uuid-c1dbd1193cad40e6b8a1a646d11abac1,PD-L1 testing,0.805588
uuid-c1dbd1193cad40e6b8a1a646d11abac1,testing,0.682203
uuid-c1dbd1193cad40e6b8a1a646d11abac1,PDL1 testing,0.512613
uuid-c1dbd1193cad40e6b8a1a646d11abac1,NSCLC patients,0.400127
uuid-c1dbd1193cad40e6b8a1a646d11abac1,assay,0.72609
uuid-1b2499685c68453c83e18053b5a86d8a,lung,0.536498
uuid-1b2499685c68453c83e18053b5a86d8a,1L,0.56908
uuid-1b2499685c68453c83e18053b5a86d8a,melanoma,0.50632
uuid-1b2499685c68453c83e18053b5a86d8a,RCC,0.911228
uuid-1b2499685c68453c83e18053b5a86d8a,TL stated,0.646937
uuid-1b2499685c68453c83e18053b5a86d8a,2L,0.626249
uuid-1b2499685c68453c83e18053b5a86d8a,stated,0.326224
uuid-1b2499685c68453c83e18053b5a86d8a,approval,0.415874
uuid-1b2499685c68453c83e18053b5a86d8a,preferred,0.519736
uuid-1b2499685c68453c83e18053b5a86d8a,monotherapy,0.340256
uuid-1b2499685c68453c83e18053b5a86d8a,using nivo,0.620756
uuid-1b2499685c68453c83e18053b5a86d8a,PDL1 testing,0.533387
uuid-1b2499685c68453c83e18053b5a86d8a,NSCLC patients,0.499948
uuid-1b2499685c68453c83e18053b5a86d8a,approved,0.423946
uuid-1b2499685c68453c83e18053b5a86d8a,SCCHN,0.669019
uuid-1b2499685c68453c83e18053b5a86d8a,tumor types,0.544401
uuid-1b2499685c68453c83e18053b5a86d8a,oncologist,0.308694
uuid-1b2499685c68453c83e18053b5a86d8a,TLs,0.360205
uuid-1b2499685c68453c83e18053b5a86d8a,Regional TL,0.450876
uuid-1b2499685c68453c83e18053b5a86d8a,RTL stated,0.698565
uuid-1b2499685c68453c83e18053b5a86d8a,TL shared,0.6392
uuid-1b2499685c68453c83e18053b5a86d8a,option,0.360829
uuid-1b2499685c68453c83e18053b5a86d8a,bladder,0.563694
uuid-b887a65498a545b5bbde17c92573355c,patients,0.901557
uuid-b887a65498a545b5bbde17c92573355c,Opdivo,0.55627
uuid-b887a65498a545b5bbde17c92573355c,therapy,0.562342
uuid-b887a65498a545b5bbde17c92573355c,nivolumab,0.614125
uuid-b887a65498a545b5bbde17c92573355c,toxicity,0.305344
uuid-b887a65498a545b5bbde17c92573355c,regimen,0.549694
uuid-b887a65498a545b5bbde17c92573355c,treated,0.728319
uuid-b887a65498a545b5bbde17c92573355c,pts,0.582929
uuid-b887a65498a545b5bbde17c92573355c,monotherapy,0.340182
uuid-b887a65498a545b5bbde17c92573355c,treatment,0.686805
uuid-b887a65498a545b5bbde17c92573355c,using nivo,0.33679
uuid-b887a65498a545b5bbde17c92573355c,response,0.330001
uuid-b887a65498a545b5bbde17c92573355c,cHL,0.427913
uuid-b887a65498a545b5bbde17c92573355c,progression,0.64181
uuid-b887a65498a545b5bbde17c92573355c,chemotherapy,0.349469
uuid-b887a65498a545b5bbde17c92573355c,respond,0.454432
uuid-d7c16284b3404705b5125fccbe885540,lung,0.740347
uuid-d7c16284b3404705b5125fccbe885540,1L,0.424883
uuid-d7c16284b3404705b5125fccbe885540,melanoma,0.604709
uuid-d7c16284b3404705b5125fccbe885540,shared,0.327182
uuid-d7c16284b3404705b5125fccbe885540,RCC,0.709722
uuid-d7c16284b3404705b5125fccbe885540,TL stated,0.721012
uuid-d7c16284b3404705b5125fccbe885540,2L,0.431703
uuid-d7c16284b3404705b5125fccbe885540,institution,0.52677
uuid-d7c16284b3404705b5125fccbe885540,stated,0.303641
uuid-d7c16284b3404705b5125fccbe885540,PD-L1,0.39784
uuid-d7c16284b3404705b5125fccbe885540,approval,0.318729
uuid-d7c16284b3404705b5125fccbe885540,PD-L1 testing,0.493018
uuid-d7c16284b3404705b5125fccbe885540,testing,0.543206
uuid-d7c16284b3404705b5125fccbe885540,using nivo,0.37121
uuid-d7c16284b3404705b5125fccbe885540,PDL1 testing,0.729789
uuid-d7c16284b3404705b5125fccbe885540,AI,0.387415
uuid-d7c16284b3404705b5125fccbe885540,NSCLC patients,0.558741
uuid-d7c16284b3404705b5125fccbe885540,SCCHN,0.554251
uuid-d7c16284b3404705b5125fccbe885540,tumor types,0.454475
uuid-d7c16284b3404705b5125fccbe885540,TLs,0.329404
uuid-d7c16284b3404705b5125fccbe885540,Regional TL,0.336314
uuid-d7c16284b3404705b5125fccbe885540,RTL stated,0.52616
uuid-d7c16284b3404705b5125fccbe885540,TL shared,0.625814
uuid-d7c16284b3404705b5125fccbe885540,NCCN,0.304678
uuid-d7c16284b3404705b5125fccbe885540,bladder,0.428642
uuid-11db31c2af244c19b59d23978b580997,Nivo,0.309266
uuid-11db31c2af244c19b59d23978b580997,patients,0.914561
uuid-11db31c2af244c19b59d23978b580997,Opdivo,0.525846
uuid-11db31c2af244c19b59d23978b580997,therapy,0.621675
uuid-11db31c2af244c19b59d23978b580997,nivolumab,0.53777
uuid-11db31c2af244c19b59d23978b580997,toxicity,0.364953
uuid-11db31c2af244c19b59d23978b580997,regimen,0.588821
uuid-11db31c2af244c19b59d23978b580997,treated,0.593205
uuid-11db31c2af244c19b59d23978b580997,chemo,0.358509
uuid-11db31c2af244c19b59d23978b580997,pts,0.596338
uuid-11db31c2af244c19b59d23978b580997,monotherapy,0.347406
uuid-11db31c2af244c19b59d23978b580997,treatment,0.759241
uuid-11db31c2af244c19b59d23978b580997,response,0.441667
uuid-11db31c2af244c19b59d23978b580997,cHL,0.382953
uuid-11db31c2af244c19b59d23978b580997,progression,0.660582
uuid-11db31c2af244c19b59d23978b580997,chemotherapy,0.389591
uuid-11db31c2af244c19b59d23978b580997,respond,0.550185
uuid-11db31c2af244c19b59d23978b580997,option,0.315813
uuid-641114f9a8aa4c27bc06b2046b8be056,tumor,0.618566
uuid-641114f9a8aa4c27bc06b2046b8be056,bladder,0.343789
uuid-a28020fd65024ad580abbf44e354686a,RTL,0.433354
uuid-a28020fd65024ad580abbf44e354686a,commented,0.312112
uuid-a28020fd65024ad580abbf44e354686a,RCC,0.430565
uuid-a28020fd65024ad580abbf44e354686a,TL stated,0.500618
uuid-a28020fd65024ad580abbf44e354686a,stated,0.494503
uuid-a28020fd65024ad580abbf44e354686a,approval,0.358437
uuid-a28020fd65024ad580abbf44e354686a,preferred,0.309826
uuid-a28020fd65024ad580abbf44e354686a,PD-L1 testing,0.301838
uuid-a28020fd65024ad580abbf44e354686a,using nivo,0.464887
uuid-a28020fd65024ad580abbf44e354686a,PDL1 testing,0.442833
uuid-a28020fd65024ad580abbf44e354686a,NSCLC patients,0.368198
uuid-a28020fd65024ad580abbf44e354686a,SCCHN,0.571979
uuid-a28020fd65024ad580abbf44e354686a,tumor types,0.334047
uuid-a28020fd65024ad580abbf44e354686a,oncologist,0.416903
uuid-a28020fd65024ad580abbf44e354686a,LTL,0.415718
uuid-a28020fd65024ad580abbf44e354686a,TLs,0.331842
uuid-a28020fd65024ad580abbf44e354686a,Regional TL,0.52244
uuid-a28020fd65024ad580abbf44e354686a,RTL stated,0.488829
uuid-a28020fd65024ad580abbf44e354686a,TL shared,0.345345
uuid-a28020fd65024ad580abbf44e354686a,bladder,0.321144
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,RTL,0.649655
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,NTL,0.420619
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,shared,0.467631
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,commented,0.316039
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,stated,0.51951
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,approval,0.365787
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,using nivo,0.360517
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,mentioned,0.401757
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,clinical trials,0.527434
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,SCCHN,0.569222
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,HCP,0.316587
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,LTL,0.518568
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,TLs,0.42028
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,academic,0.521578
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,Regional TL,0.611133
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,RTL stated,0.439762
uuid-7cd2e61c1c86403abdafb9d85ea6f3f4,bladder,0.334138
uuid-36f68ff9d8bb41a5abdefd0d4b6deac5,RTL,0.347694
uuid-36f68ff9d8bb41a5abdefd0d4b6deac5,trial,0.576988
uuid-36f68ff9d8bb41a5abdefd0d4b6deac5,clinical trials,0.371187
uuid-fd2609a2fb264f37906e2b607041dc0e,patients,0.390773
uuid-fd2609a2fb264f37906e2b607041dc0e,Opdivo,0.533293
uuid-fd2609a2fb264f37906e2b607041dc0e,nivolumab,0.383557
uuid-fd2609a2fb264f37906e2b607041dc0e,treated,0.321411
uuid-fd2609a2fb264f37906e2b607041dc0e,RCC,0.342347
uuid-fd2609a2fb264f37906e2b607041dc0e,2L,0.35144
uuid-fd2609a2fb264f37906e2b607041dc0e,stated,0.304066
uuid-fd2609a2fb264f37906e2b607041dc0e,approval,0.523425
uuid-fd2609a2fb264f37906e2b607041dc0e,physicians,0.369022
uuid-fd2609a2fb264f37906e2b607041dc0e,preferred,0.522723
uuid-fd2609a2fb264f37906e2b607041dc0e,using nivo,0.46235
uuid-fd2609a2fb264f37906e2b607041dc0e,clinical trials,0.350926
uuid-fd2609a2fb264f37906e2b607041dc0e,indication,0.432096
uuid-fd2609a2fb264f37906e2b607041dc0e,approved,0.527549
uuid-fd2609a2fb264f37906e2b607041dc0e,SCCHN,0.451618
uuid-fd2609a2fb264f37906e2b607041dc0e,label,0.37641
uuid-fd2609a2fb264f37906e2b607041dc0e,Keytruda,0.306556
uuid-fd2609a2fb264f37906e2b607041dc0e,Regional TL,0.301841
uuid-fd2609a2fb264f37906e2b607041dc0e,RTL stated,0.377033
uuid-fd2609a2fb264f37906e2b607041dc0e,option,0.333411
uuid-fd2609a2fb264f37906e2b607041dc0e,bladder,0.321159
uuid-fd2609a2fb264f37906e2b607041dc0e,flat dosing,0.30938
uuid-93ba8c8ee2b2476eb1d61bb436268002,TL,0.636056
uuid-93ba8c8ee2b2476eb1d61bb436268002,PDL1,0.500717
uuid-93ba8c8ee2b2476eb1d61bb436268002,TL stated,0.393407
uuid-93ba8c8ee2b2476eb1d61bb436268002,Merck,0.457468
uuid-93ba8c8ee2b2476eb1d61bb436268002,PD-L1,0.844878
uuid-93ba8c8ee2b2476eb1d61bb436268002,approval,0.307389
uuid-93ba8c8ee2b2476eb1d61bb436268002,atezo,0.340746
uuid-93ba8c8ee2b2476eb1d61bb436268002,PD-L1 testing,0.804691
uuid-93ba8c8ee2b2476eb1d61bb436268002,testing,0.883227
uuid-93ba8c8ee2b2476eb1d61bb436268002,PDL1 testing,0.663552
uuid-93ba8c8ee2b2476eb1d61bb436268002,NSCLC patients,0.623899
uuid-93ba8c8ee2b2476eb1d61bb436268002,assay,0.854485
uuid-93ba8c8ee2b2476eb1d61bb436268002,biomarker,0.397692
uuid-10dc5443fae0485aa1b2538b86e76494,patients,0.619101
uuid-10dc5443fae0485aa1b2538b86e76494,Opdivo,0.406253
uuid-10dc5443fae0485aa1b2538b86e76494,therapy,0.348196
uuid-10dc5443fae0485aa1b2538b86e76494,nivolumab,0.341366
uuid-10dc5443fae0485aa1b2538b86e76494,toxicity,0.360988
uuid-10dc5443fae0485aa1b2538b86e76494,regimen,0.440689
uuid-10dc5443fae0485aa1b2538b86e76494,treated,0.617484
uuid-10dc5443fae0485aa1b2538b86e76494,melanoma,0.406956
uuid-10dc5443fae0485aa1b2538b86e76494,pts,0.333623
uuid-10dc5443fae0485aa1b2538b86e76494,treatment,0.643864
uuid-10dc5443fae0485aa1b2538b86e76494,progression,0.502234
uuid-10dc5443fae0485aa1b2538b86e76494,respond,0.407874
uuid-10dc5443fae0485aa1b2538b86e76494,TL shared,0.417667
uuid-43d4738fef054e1fae8286b9506edd13,TL,0.436377
uuid-43d4738fef054e1fae8286b9506edd13,PDL1,0.426022
uuid-43d4738fef054e1fae8286b9506edd13,commented,0.361533
uuid-43d4738fef054e1fae8286b9506edd13,TL stated,0.397749
uuid-43d4738fef054e1fae8286b9506edd13,Merck,0.429324
uuid-43d4738fef054e1fae8286b9506edd13,PD-L1,0.616441
uuid-43d4738fef054e1fae8286b9506edd13,approval,0.356082
uuid-43d4738fef054e1fae8286b9506edd13,PD-L1 testing,0.518154
uuid-43d4738fef054e1fae8286b9506edd13,testing,0.656362
uuid-43d4738fef054e1fae8286b9506edd13,PDL1 testing,0.568506
uuid-43d4738fef054e1fae8286b9506edd13,NSCLC patients,0.498939
uuid-43d4738fef054e1fae8286b9506edd13,tumor types,0.306185
uuid-43d4738fef054e1fae8286b9506edd13,assay,0.488261
uuid-43d4738fef054e1fae8286b9506edd13,biomarker,0.401816
uuid-a482a1a1920b4858a21ed7c9ab471e26,TL,0.357111
uuid-a482a1a1920b4858a21ed7c9ab471e26,RTL,0.341466
uuid-a482a1a1920b4858a21ed7c9ab471e26,NSCLC,0.353149
uuid-a482a1a1920b4858a21ed7c9ab471e26,physicians,0.450613
uuid-a482a1a1920b4858a21ed7c9ab471e26,PD-L1 testing,0.307496
uuid-a482a1a1920b4858a21ed7c9ab471e26,using nivo,0.338825
uuid-a482a1a1920b4858a21ed7c9ab471e26,oncology,0.305262
uuid-a482a1a1920b4858a21ed7c9ab471e26,SCCHN,0.377765
uuid-a482a1a1920b4858a21ed7c9ab471e26,oncologist,0.418073
uuid-a482a1a1920b4858a21ed7c9ab471e26,indicated,0.508387
uuid-a482a1a1920b4858a21ed7c9ab471e26,LTL,0.34981
uuid-a482a1a1920b4858a21ed7c9ab471e26,TLs,0.30823
uuid-a482a1a1920b4858a21ed7c9ab471e26,academic,0.345714
uuid-a482a1a1920b4858a21ed7c9ab471e26,Regional TL,0.499725
uuid-cfbc7e1587854ebf9984930733ba36f9,patients,0.3287
uuid-cfbc7e1587854ebf9984930733ba36f9,Opdivo,0.372316
uuid-cfbc7e1587854ebf9984930733ba36f9,dose,0.604728
uuid-cfbc7e1587854ebf9984930733ba36f9,toxicity,0.509
uuid-cfbc7e1587854ebf9984930733ba36f9,regimen,0.465493
uuid-cfbc7e1587854ebf9984930733ba36f9,treated,0.34275
uuid-cfbc7e1587854ebf9984930733ba36f9,physicians,0.421998
uuid-cfbc7e1587854ebf9984930733ba36f9,treatment,0.503293
uuid-cfbc7e1587854ebf9984930733ba36f9,respond,0.359825
uuid-3e244efd9c554b49b2d6c7ec1ff35037,patients,0.498748
uuid-3e244efd9c554b49b2d6c7ec1ff35037,Opdivo,0.616767
uuid-3e244efd9c554b49b2d6c7ec1ff35037,dose,0.599907
uuid-3e244efd9c554b49b2d6c7ec1ff35037,toxicity,0.38337
uuid-3e244efd9c554b49b2d6c7ec1ff35037,regimen,0.328463
uuid-3e244efd9c554b49b2d6c7ec1ff35037,treatment,0.344575
uuid-3e244efd9c554b49b2d6c7ec1ff35037,drug,0.410749
uuid-3e244efd9c554b49b2d6c7ec1ff35037,Keytruda,0.479748
uuid-3e244efd9c554b49b2d6c7ec1ff35037,flat dosing,0.59603
uuid-ddff954e61e648faa228165eaf49f8cb,Opdivo,0.368987
uuid-ddff954e61e648faa228165eaf49f8cb,RTL,0.301551
uuid-ddff954e61e648faa228165eaf49f8cb,BMS,0.419507
uuid-ddff954e61e648faa228165eaf49f8cb,shared,0.34167
uuid-ddff954e61e648faa228165eaf49f8cb,commented,0.30251
uuid-ddff954e61e648faa228165eaf49f8cb,stated,0.363326
uuid-ddff954e61e648faa228165eaf49f8cb,physicians,0.532825
uuid-ddff954e61e648faa228165eaf49f8cb,clinical trials,0.363094
uuid-ddff954e61e648faa228165eaf49f8cb,HCP,0.310967
uuid-ddff954e61e648faa228165eaf49f8cb,LTL,0.35996
uuid-c13323b75a4b47c5a7293e2a135c0646,patients,0.832677
uuid-c13323b75a4b47c5a7293e2a135c0646,Opdivo,0.483245
uuid-c13323b75a4b47c5a7293e2a135c0646,therapy,0.44514
uuid-c13323b75a4b47c5a7293e2a135c0646,dose,0.379363
uuid-c13323b75a4b47c5a7293e2a135c0646,nivolumab,0.610951
uuid-c13323b75a4b47c5a7293e2a135c0646,toxicity,0.379215
uuid-c13323b75a4b47c5a7293e2a135c0646,regimen,0.576524
uuid-c13323b75a4b47c5a7293e2a135c0646,treated,0.654912
uuid-c13323b75a4b47c5a7293e2a135c0646,chemo,0.350603
uuid-c13323b75a4b47c5a7293e2a135c0646,pts,0.607268
uuid-c13323b75a4b47c5a7293e2a135c0646,monotherapy,0.403692
uuid-c13323b75a4b47c5a7293e2a135c0646,treatment,0.62726
uuid-c13323b75a4b47c5a7293e2a135c0646,using nivo,0.329416
uuid-c13323b75a4b47c5a7293e2a135c0646,response,0.42471
uuid-c13323b75a4b47c5a7293e2a135c0646,progression,0.583234
uuid-c13323b75a4b47c5a7293e2a135c0646,chemotherapy,0.329829
uuid-c13323b75a4b47c5a7293e2a135c0646,respond,0.458073
uuid-c13323b75a4b47c5a7293e2a135c0646,option,0.312891
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,Nivo,0.324302
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,Opdivo,0.31508
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,pembro,0.431474
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,dose,0.91048
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,Ipi,0.615115
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,atezo,0.367009
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,vs,0.623217
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,Keytruda,0.331856
uuid-f1b834b4a4df4aa3bda67b275e0acb5f,flat dosing,0.694526
uuid-4940ca6901fe41a1813029a5633d6500,BMS,0.60218
uuid-4940ca6901fe41a1813029a5633d6500,commented,0.304562
uuid-4940ca6901fe41a1813029a5633d6500,Merck,0.341461
uuid-4940ca6901fe41a1813029a5633d6500,physicians,0.321177
uuid-4940ca6901fe41a1813029a5633d6500,clinical trials,0.387785
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,pembro,0.314913
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,RTL,0.435807
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,BMS,0.332728
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,trial,0.765373
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,efficacy,0.302398
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,commented,0.389618
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,Merck,0.320516
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,stated,0.332748
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,approval,0.355025
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,OS,0.484235
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,data,0.639979
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,expressed,0.312829
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,clinical trials,0.361851
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,PFS,0.467368
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,ORR,0.530549
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,ASCO,0.330517
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,impressed,0.677605
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,SCLC,0.367382
uuid-81fc67e5324d4dfbb4fe7384fe0b8238,Regional TL,0.32077
uuid-4431b624ee3446bca77df09f80d9acf1,patients,0.302214
uuid-4431b624ee3446bca77df09f80d9acf1,treated,0.405371
uuid-4431b624ee3446bca77df09f80d9acf1,commented,0.407033
uuid-4431b624ee3446bca77df09f80d9acf1,physicians,0.35879
uuid-4431b624ee3446bca77df09f80d9acf1,ASCO,0.384387
uuid-4431b624ee3446bca77df09f80d9acf1,impressed,0.39726
uuid-4431b624ee3446bca77df09f80d9acf1,TL shared,0.328828
uuid-bcfdf43e47a34a5c95adb472e34e634b,Nivo,0.623027
uuid-bcfdf43e47a34a5c95adb472e34e634b,patients,0.649643
uuid-bcfdf43e47a34a5c95adb472e34e634b,pembro,0.502229
uuid-bcfdf43e47a34a5c95adb472e34e634b,therapy,0.400907
uuid-bcfdf43e47a34a5c95adb472e34e634b,nivolumab,0.4267
uuid-bcfdf43e47a34a5c95adb472e34e634b,1L,0.675822
uuid-bcfdf43e47a34a5c95adb472e34e634b,regimen,0.371215
uuid-bcfdf43e47a34a5c95adb472e34e634b,RCC,0.407417
uuid-bcfdf43e47a34a5c95adb472e34e634b,combination,0.309937
uuid-bcfdf43e47a34a5c95adb472e34e634b,chemo,0.481806
uuid-bcfdf43e47a34a5c95adb472e34e634b,2L,0.701934
uuid-bcfdf43e47a34a5c95adb472e34e634b,pts,0.540962
uuid-bcfdf43e47a34a5c95adb472e34e634b,agents,0.302332
uuid-bcfdf43e47a34a5c95adb472e34e634b,approval,0.389762
uuid-bcfdf43e47a34a5c95adb472e34e634b,atezo,0.426519
uuid-bcfdf43e47a34a5c95adb472e34e634b,preferred,0.562307
uuid-bcfdf43e47a34a5c95adb472e34e634b,monotherapy,0.640582
uuid-bcfdf43e47a34a5c95adb472e34e634b,treatment,0.37053
uuid-bcfdf43e47a34a5c95adb472e34e634b,using nivo,0.638927
uuid-bcfdf43e47a34a5c95adb472e34e634b,combo,0.404827
uuid-bcfdf43e47a34a5c95adb472e34e634b,NSCLC patients,0.334889
uuid-bcfdf43e47a34a5c95adb472e34e634b,PD1,0.382004
uuid-bcfdf43e47a34a5c95adb472e34e634b,approved,0.50126
uuid-bcfdf43e47a34a5c95adb472e34e634b,progression,0.383511
uuid-bcfdf43e47a34a5c95adb472e34e634b,chemotherapy,0.37381
uuid-bcfdf43e47a34a5c95adb472e34e634b,tumor types,0.337096
uuid-bcfdf43e47a34a5c95adb472e34e634b,RTL stated,0.487778
uuid-bcfdf43e47a34a5c95adb472e34e634b,option,0.632049
uuid-bcfdf43e47a34a5c95adb472e34e634b,bladder,0.329374
uuid-4b3cfa9f1d7342af88e568e45879e496,RTL,0.45441
uuid-4b3cfa9f1d7342af88e568e45879e496,lung,0.481599
uuid-4b3cfa9f1d7342af88e568e45879e496,NTL,0.406963
uuid-4b3cfa9f1d7342af88e568e45879e496,melanoma,0.482605
uuid-4b3cfa9f1d7342af88e568e45879e496,shared,0.523976
uuid-4b3cfa9f1d7342af88e568e45879e496,commented,0.420301
uuid-4b3cfa9f1d7342af88e568e45879e496,RCC,0.575006
uuid-4b3cfa9f1d7342af88e568e45879e496,TL stated,0.510077
uuid-4b3cfa9f1d7342af88e568e45879e496,stated,0.419338
uuid-4b3cfa9f1d7342af88e568e45879e496,physicians,0.515414
uuid-4b3cfa9f1d7342af88e568e45879e496,using nivo,0.363231
uuid-4b3cfa9f1d7342af88e568e45879e496,mentioned,0.321819
uuid-4b3cfa9f1d7342af88e568e45879e496,SCCHN,0.53507
uuid-4b3cfa9f1d7342af88e568e45879e496,HCP,0.331978
uuid-4b3cfa9f1d7342af88e568e45879e496,oncologist,0.387339
uuid-4b3cfa9f1d7342af88e568e45879e496,indicated,0.312454
uuid-4b3cfa9f1d7342af88e568e45879e496,LTL,0.404818
uuid-4b3cfa9f1d7342af88e568e45879e496,TLs,0.566102
uuid-4b3cfa9f1d7342af88e568e45879e496,academic,0.391182
uuid-4b3cfa9f1d7342af88e568e45879e496,Regional TL,0.585049
uuid-4b3cfa9f1d7342af88e568e45879e496,RTL stated,0.454213
uuid-4b3cfa9f1d7342af88e568e45879e496,TL shared,0.468753
uuid-4b3cfa9f1d7342af88e568e45879e496,bladder,0.323595
uuid-9ce1842ef3dd43678a0a95b822f7cd31,patients,0.863634
uuid-9ce1842ef3dd43678a0a95b822f7cd31,Opdivo,0.395865
uuid-9ce1842ef3dd43678a0a95b822f7cd31,therapy,0.457434
uuid-9ce1842ef3dd43678a0a95b822f7cd31,nivolumab,0.40356
uuid-9ce1842ef3dd43678a0a95b822f7cd31,toxicity,0.35921
uuid-9ce1842ef3dd43678a0a95b822f7cd31,regimen,0.545568
uuid-9ce1842ef3dd43678a0a95b822f7cd31,treated,0.528546
uuid-9ce1842ef3dd43678a0a95b822f7cd31,pts,0.619278
uuid-9ce1842ef3dd43678a0a95b822f7cd31,monotherapy,0.392195
uuid-9ce1842ef3dd43678a0a95b822f7cd31,treatment,0.595874
uuid-9ce1842ef3dd43678a0a95b822f7cd31,using nivo,0.306643
uuid-9ce1842ef3dd43678a0a95b822f7cd31,response,0.311139
uuid-9ce1842ef3dd43678a0a95b822f7cd31,NSCLC patients,0.328454
uuid-9ce1842ef3dd43678a0a95b822f7cd31,progression,0.599942
uuid-9ce1842ef3dd43678a0a95b822f7cd31,chemotherapy,0.324603
uuid-9ce1842ef3dd43678a0a95b822f7cd31,respond,0.443919
uuid-9ce1842ef3dd43678a0a95b822f7cd31,TL shared,0.376261
uuid-9ce1842ef3dd43678a0a95b822f7cd31,option,0.375931
uuid-db62121e18e949998aab92326b60aabf,Nivo,0.4073
uuid-db62121e18e949998aab92326b60aabf,patients,0.710539
uuid-db62121e18e949998aab92326b60aabf,therapy,0.440892
uuid-db62121e18e949998aab92326b60aabf,nivolumab,0.439033
uuid-db62121e18e949998aab92326b60aabf,regimen,0.382043
uuid-db62121e18e949998aab92326b60aabf,treated,0.464516
uuid-db62121e18e949998aab92326b60aabf,chemo,0.316621
uuid-db62121e18e949998aab92326b60aabf,pts,0.492896
uuid-db62121e18e949998aab92326b60aabf,monotherapy,0.330639
uuid-db62121e18e949998aab92326b60aabf,treatment,0.517812
uuid-db62121e18e949998aab92326b60aabf,using nivo,0.347864
uuid-db62121e18e949998aab92326b60aabf,response,0.35963
uuid-db62121e18e949998aab92326b60aabf,cHL,0.30806
uuid-db62121e18e949998aab92326b60aabf,progression,0.521105
uuid-db62121e18e949998aab92326b60aabf,chemotherapy,0.344494
uuid-db62121e18e949998aab92326b60aabf,respond,0.399538
uuid-db62121e18e949998aab92326b60aabf,RTL stated,0.334075
uuid-89742fb21ab34669830d8a113c140eb5,RTL,0.456264
uuid-89742fb21ab34669830d8a113c140eb5,toxicity,0.365077
uuid-89742fb21ab34669830d8a113c140eb5,trial,0.350473
uuid-89742fb21ab34669830d8a113c140eb5,regimen,0.404023
uuid-89742fb21ab34669830d8a113c140eb5,mentioned,0.318236
uuid-89742fb21ab34669830d8a113c140eb5,HCP,0.359858
uuid-89742fb21ab34669830d8a113c140eb5,impressed,0.404219
uuid-89742fb21ab34669830d8a113c140eb5,LTL,0.327325
uuid-1b2296f7705c44e9ac7bedc07c5e7665,PD-L1,0.332746
uuid-1b2296f7705c44e9ac7bedc07c5e7665,assay,0.321038
uuid-1b2296f7705c44e9ac7bedc07c5e7665,PDL1 expression,0.408456
uuid-1b2296f7705c44e9ac7bedc07c5e7665,biomarker,0.451348
uuid-a6410d496b9649719728f5f93829a499,toxicity,0.492076
uuid-a6410d496b9649719728f5f93829a499,efficacy,0.538078
uuid-a6410d496b9649719728f5f93829a499,regimen,0.35664
uuid-a6410d496b9649719728f5f93829a499,OS,0.349269
uuid-a6410d496b9649719728f5f93829a499,PFS,0.316068
uuid-a6410d496b9649719728f5f93829a499,ORR,0.414747
uuid-a6410d496b9649719728f5f93829a499,impressed,0.302784
uuid-a6410d496b9649719728f5f93829a499,feels,0.382648
uuid-b8f0be5a0c064e55a77713cac7b509a8,Nivo,0.376085
uuid-b8f0be5a0c064e55a77713cac7b509a8,patients,0.713271
uuid-b8f0be5a0c064e55a77713cac7b509a8,Opdivo,0.309941
uuid-b8f0be5a0c064e55a77713cac7b509a8,therapy,0.373382
uuid-b8f0be5a0c064e55a77713cac7b509a8,dose,0.386362
uuid-b8f0be5a0c064e55a77713cac7b509a8,nivolumab,0.362513
uuid-b8f0be5a0c064e55a77713cac7b509a8,toxicity,0.559322
uuid-b8f0be5a0c064e55a77713cac7b509a8,regimen,0.698953
uuid-b8f0be5a0c064e55a77713cac7b509a8,treated,0.449736
uuid-b8f0be5a0c064e55a77713cac7b509a8,chemo,0.428356
uuid-b8f0be5a0c064e55a77713cac7b509a8,pts,0.447718
uuid-b8f0be5a0c064e55a77713cac7b509a8,Ipi,0.382447
uuid-b8f0be5a0c064e55a77713cac7b509a8,preferred,0.352513
uuid-b8f0be5a0c064e55a77713cac7b509a8,monotherapy,0.466051
uuid-b8f0be5a0c064e55a77713cac7b509a8,treatment,0.637724
uuid-b8f0be5a0c064e55a77713cac7b509a8,using nivo,0.330817
uuid-b8f0be5a0c064e55a77713cac7b509a8,progression,0.496661
uuid-b8f0be5a0c064e55a77713cac7b509a8,chemotherapy,0.368125
uuid-b8f0be5a0c064e55a77713cac7b509a8,respond,0.546528
uuid-b8f0be5a0c064e55a77713cac7b509a8,option,0.426274
uuid-fc1dab1227f540779995143783482f49,patients,0.39387
uuid-fc1dab1227f540779995143783482f49,toxicity,0.520833
uuid-fc1dab1227f540779995143783482f49,regimen,0.393038
uuid-fc1dab1227f540779995143783482f49,treated,0.393228
uuid-fc1dab1227f540779995143783482f49,treatment,0.453432
uuid-fc1dab1227f540779995143783482f49,progression,0.344104
uuid-fc1dab1227f540779995143783482f49,respond,0.409824
uuid-7e9b161a27ab4adc9debfb6fcd53148f,RTL,0.372868
uuid-7e9b161a27ab4adc9debfb6fcd53148f,trial,0.312582
uuid-7e9b161a27ab4adc9debfb6fcd53148f,NTL,0.43043
uuid-7e9b161a27ab4adc9debfb6fcd53148f,commented,0.330905
uuid-7e9b161a27ab4adc9debfb6fcd53148f,data,0.448204
uuid-7e9b161a27ab4adc9debfb6fcd53148f,mentioned,0.325365
uuid-7e9b161a27ab4adc9debfb6fcd53148f,cHL,0.42668
uuid-7e9b161a27ab4adc9debfb6fcd53148f,ASCO,0.432312
uuid-7e9b161a27ab4adc9debfb6fcd53148f,impressed,0.398682
uuid-7e9b161a27ab4adc9debfb6fcd53148f,Regional TL,0.311382
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,patients,0.63202
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,therapy,0.607083
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,nivolumab,0.43597
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,toxicity,0.497621
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,regimen,0.587495
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,treated,0.556195
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,combination,0.445589
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,chemo,0.576827
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,pts,0.492546
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,IO,0.339356
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,monotherapy,0.44975
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,treatment,0.734397
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,response,0.594719
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,combo,0.32562
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,PD1,0.49831
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,progression,0.717157
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,chemotherapy,0.59866
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,respond,0.55258
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,immunotherapy,0.3909
uuid-6886ea7746d2423fa5c5c1f2b2a79ab6,option,0.382713
uuid-f849f43d647f415aa983c1640c4d566e,TL,0.471621
uuid-f849f43d647f415aa983c1640c4d566e,PDL1,0.319986
uuid-f849f43d647f415aa983c1640c4d566e,TL stated,0.429171
uuid-f849f43d647f415aa983c1640c4d566e,PD-L1,0.660235
uuid-f849f43d647f415aa983c1640c4d566e,PD-L1 testing,0.696428
uuid-f849f43d647f415aa983c1640c4d566e,testing,0.764015
uuid-f849f43d647f415aa983c1640c4d566e,PDL1 testing,0.671853
uuid-f849f43d647f415aa983c1640c4d566e,NSCLC patients,0.678317
uuid-f849f43d647f415aa983c1640c4d566e,assay,0.485674
uuid-f849f43d647f415aa983c1640c4d566e,biomarker,0.354473
uuid-d9c2d29376f049c3b95880634cbddb54,PD-L1,0.361595
uuid-d9c2d29376f049c3b95880634cbddb54,testing,0.371467
uuid-d9c2d29376f049c3b95880634cbddb54,NSCLC patients,0.334782
uuid-d9c2d29376f049c3b95880634cbddb54,biomarker,0.397861
uuid-ca8b1e33d0b94e6ca2232fbf025d300b,trial,0.356133
uuid-ca8b1e33d0b94e6ca2232fbf025d300b,commented,0.310535
uuid-ca8b1e33d0b94e6ca2232fbf025d300b,impressed,0.35665
uuid-ca8b1e33d0b94e6ca2232fbf025d300b,respond,0.331802
uuid-094a2265d972416d8e5735660cc9c462,stated,0.40757
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,TL,0.467476
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,Merck,0.327024
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,PD-L1,0.3764
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,PD-L1 testing,0.375794
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,testing,0.335851
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,indicated,0.481169
uuid-a7fd8e6e6bf64a058199e8edf1f8953e,assay,0.461378
uuid-75e33fda2a00498d84fa4aa67e251f59,patients,0.592071
uuid-75e33fda2a00498d84fa4aa67e251f59,therapy,0.642684
uuid-75e33fda2a00498d84fa4aa67e251f59,regimen,0.390998
uuid-75e33fda2a00498d84fa4aa67e251f59,chemo,0.434312
uuid-75e33fda2a00498d84fa4aa67e251f59,pts,0.344748
uuid-75e33fda2a00498d84fa4aa67e251f59,monotherapy,0.302347
uuid-75e33fda2a00498d84fa4aa67e251f59,treatment,0.638921
uuid-75e33fda2a00498d84fa4aa67e251f59,response,0.44815
uuid-75e33fda2a00498d84fa4aa67e251f59,PD1,0.365931
uuid-75e33fda2a00498d84fa4aa67e251f59,progression,0.628006
uuid-75e33fda2a00498d84fa4aa67e251f59,chemotherapy,0.469881
uuid-75e33fda2a00498d84fa4aa67e251f59,respond,0.534492
uuid-75e33fda2a00498d84fa4aa67e251f59,drug,0.384637
uuid-75e33fda2a00498d84fa4aa67e251f59,option,0.365694
uuid-d3b6530a81504f2a920a61034abf3e84,BMS,0.455087
uuid-d3b6530a81504f2a920a61034abf3e84,PDL1,0.360661
uuid-d3b6530a81504f2a920a61034abf3e84,trial,0.379381
uuid-d3b6530a81504f2a920a61034abf3e84,efficacy,0.523408
uuid-d3b6530a81504f2a920a61034abf3e84,OS,0.839977
uuid-d3b6530a81504f2a920a61034abf3e84,data,0.534728
uuid-d3b6530a81504f2a920a61034abf3e84,PFS,0.819007
uuid-d3b6530a81504f2a920a61034abf3e84,ORR,0.705409
uuid-d3b6530a81504f2a920a61034abf3e84,nivo and pembro,0.384348
uuid-d3b6530a81504f2a920a61034abf3e84,believes,0.364546
uuid-d3b6530a81504f2a920a61034abf3e84,impressed,0.417051
uuid-d3b6530a81504f2a920a61034abf3e84,feels,0.301839
uuid-d3b6530a81504f2a920a61034abf3e84,PDL1 expression,0.336052
uuid-0ad93fdafbe24cf48b036f25afe94533,Nivo,0.359235
uuid-0ad93fdafbe24cf48b036f25afe94533,dose,0.45481
uuid-0ad93fdafbe24cf48b036f25afe94533,toxicity,0.495873
uuid-0ad93fdafbe24cf48b036f25afe94533,efficacy,0.674416
uuid-0ad93fdafbe24cf48b036f25afe94533,regimen,0.522126
uuid-0ad93fdafbe24cf48b036f25afe94533,combination,0.586959
uuid-0ad93fdafbe24cf48b036f25afe94533,chemo,0.506402
uuid-0ad93fdafbe24cf48b036f25afe94533,IO,0.408088
uuid-0ad93fdafbe24cf48b036f25afe94533,agents,0.512776
uuid-0ad93fdafbe24cf48b036f25afe94533,Ipi,0.521355
uuid-0ad93fdafbe24cf48b036f25afe94533,monotherapy,0.526944
uuid-0ad93fdafbe24cf48b036f25afe94533,combo,0.608653
uuid-0ad93fdafbe24cf48b036f25afe94533,PD1,0.40608
uuid-0ad93fdafbe24cf48b036f25afe94533,believes,0.472045
uuid-0ad93fdafbe24cf48b036f25afe94533,chemotherapy,0.427074
uuid-0ad93fdafbe24cf48b036f25afe94533,vs,0.466126
uuid-0ad93fdafbe24cf48b036f25afe94533,feels,0.361014
uuid-0ad93fdafbe24cf48b036f25afe94533,option,0.360697
uuid-096862b392954fe18d7349b331fce20c,BMS,0.53093
uuid-096862b392954fe18d7349b331fce20c,shared,0.302554
uuid-096862b392954fe18d7349b331fce20c,commented,0.383113
uuid-096862b392954fe18d7349b331fce20c,Merck,0.375828
uuid-096862b392954fe18d7349b331fce20c,stated,0.304146
uuid-096862b392954fe18d7349b331fce20c,physicians,0.31733
uuid-096862b392954fe18d7349b331fce20c,regards,0.379508
uuid-096862b392954fe18d7349b331fce20c,expressed,0.333481
uuid-096862b392954fe18d7349b331fce20c,AI,0.310424
uuid-096862b392954fe18d7349b331fce20c,drug,0.390624
uuid-c7ce426c6d41477c8fbfa1e045476954,Nivo,0.457589
uuid-c7ce426c6d41477c8fbfa1e045476954,patients,0.302918
uuid-c7ce426c6d41477c8fbfa1e045476954,Opdivo,0.473206
uuid-c7ce426c6d41477c8fbfa1e045476954,pembro,0.330843
uuid-c7ce426c6d41477c8fbfa1e045476954,dose,0.773618
uuid-c7ce426c6d41477c8fbfa1e045476954,toxicity,0.315554
uuid-c7ce426c6d41477c8fbfa1e045476954,efficacy,0.350472
uuid-c7ce426c6d41477c8fbfa1e045476954,regimen,0.300115
uuid-c7ce426c6d41477c8fbfa1e045476954,Ipi,0.529276
uuid-c7ce426c6d41477c8fbfa1e045476954,indication,0.408813
uuid-c7ce426c6d41477c8fbfa1e045476954,vs,0.451649
uuid-c7ce426c6d41477c8fbfa1e045476954,label,0.343672
uuid-c7ce426c6d41477c8fbfa1e045476954,Keytruda,0.357413
uuid-c7ce426c6d41477c8fbfa1e045476954,flat dosing,0.73802
uuid-2f53ff0cf235455f83b08ee8713d5901,TL,0.356244
uuid-2f53ff0cf235455f83b08ee8713d5901,TL stated,0.345924
uuid-2f53ff0cf235455f83b08ee8713d5901,PD-L1,0.507584
uuid-2f53ff0cf235455f83b08ee8713d5901,approval,0.32703
uuid-2f53ff0cf235455f83b08ee8713d5901,physicians,0.340507
uuid-2f53ff0cf235455f83b08ee8713d5901,preferred,0.377772
uuid-2f53ff0cf235455f83b08ee8713d5901,PD-L1 testing,0.528602
uuid-2f53ff0cf235455f83b08ee8713d5901,testing,0.621275
uuid-2f53ff0cf235455f83b08ee8713d5901,PDL1 testing,0.542976
uuid-2f53ff0cf235455f83b08ee8713d5901,NSCLC patients,0.525776
uuid-2f53ff0cf235455f83b08ee8713d5901,approved,0.325268
uuid-2f53ff0cf235455f83b08ee8713d5901,tumor types,0.317976
uuid-2f53ff0cf235455f83b08ee8713d5901,assay,0.333129
uuid-580a85a9e3bf4ac6a5d264d2d9fa12cb,oncology,0.46351
uuid-580a85a9e3bf4ac6a5d264d2d9fa12cb,drug,0.379878
uuid-580a85a9e3bf4ac6a5d264d2d9fa12cb,flat dosing,0.399045
uuid-d580520ebf5345f999f5a8e19d0f3cb6,Nivo,0.356335
uuid-d580520ebf5345f999f5a8e19d0f3cb6,toxicity,0.538279
uuid-d580520ebf5345f999f5a8e19d0f3cb6,efficacy,0.599341
uuid-d580520ebf5345f999f5a8e19d0f3cb6,regimen,0.548132
uuid-d580520ebf5345f999f5a8e19d0f3cb6,combination,0.781975
uuid-d580520ebf5345f999f5a8e19d0f3cb6,chemo,0.533366
uuid-d580520ebf5345f999f5a8e19d0f3cb6,IO,0.420138
uuid-d580520ebf5345f999f5a8e19d0f3cb6,agents,0.531255
uuid-d580520ebf5345f999f5a8e19d0f3cb6,Ipi,0.451271
uuid-d580520ebf5345f999f5a8e19d0f3cb6,monotherapy,0.562507
uuid-d580520ebf5345f999f5a8e19d0f3cb6,response,0.335612
uuid-d580520ebf5345f999f5a8e19d0f3cb6,combo,0.692309
uuid-d580520ebf5345f999f5a8e19d0f3cb6,PD1,0.530956
uuid-d580520ebf5345f999f5a8e19d0f3cb6,believes,0.514058
uuid-d580520ebf5345f999f5a8e19d0f3cb6,chemotherapy,0.520905
uuid-d580520ebf5345f999f5a8e19d0f3cb6,feels,0.429748
uuid-d580520ebf5345f999f5a8e19d0f3cb6,option,0.371643
uuid-8aae180def8d4f00a21df49247ca5d0f,Nivo,0.438083
uuid-8aae180def8d4f00a21df49247ca5d0f,Opdivo,0.333664
uuid-8aae180def8d4f00a21df49247ca5d0f,pembro,0.378151
uuid-8aae180def8d4f00a21df49247ca5d0f,dose,0.829406
uuid-8aae180def8d4f00a21df49247ca5d0f,nivolumab,0.336427
uuid-8aae180def8d4f00a21df49247ca5d0f,toxicity,0.407663
uuid-8aae180def8d4f00a21df49247ca5d0f,regimen,0.393458
uuid-8aae180def8d4f00a21df49247ca5d0f,combination,0.408313
uuid-8aae180def8d4f00a21df49247ca5d0f,Ipi,0.756639
uuid-8aae180def8d4f00a21df49247ca5d0f,atezo,0.357342
uuid-8aae180def8d4f00a21df49247ca5d0f,combo,0.406912
uuid-8aae180def8d4f00a21df49247ca5d0f,vs,0.537486
uuid-8aae180def8d4f00a21df49247ca5d0f,TLs,0.319692
uuid-8aae180def8d4f00a21df49247ca5d0f,flat dosing,0.689116
uuid-bbee8287e350454ebbe3eaa5d6ee8760,Nivo,0.604422
uuid-bbee8287e350454ebbe3eaa5d6ee8760,patients,0.434434
uuid-bbee8287e350454ebbe3eaa5d6ee8760,therapy,0.597506
uuid-bbee8287e350454ebbe3eaa5d6ee8760,nivolumab,0.42443
uuid-bbee8287e350454ebbe3eaa5d6ee8760,toxicity,0.566688
uuid-bbee8287e350454ebbe3eaa5d6ee8760,regimen,0.542748
uuid-bbee8287e350454ebbe3eaa5d6ee8760,combination,0.504414
uuid-bbee8287e350454ebbe3eaa5d6ee8760,chemo,0.545883
uuid-bbee8287e350454ebbe3eaa5d6ee8760,2L,0.319673
uuid-bbee8287e350454ebbe3eaa5d6ee8760,pts,0.321514
uuid-bbee8287e350454ebbe3eaa5d6ee8760,agents,0.340699
uuid-bbee8287e350454ebbe3eaa5d6ee8760,Ipi,0.411286
uuid-bbee8287e350454ebbe3eaa5d6ee8760,monotherapy,0.644855
uuid-bbee8287e350454ebbe3eaa5d6ee8760,treatment,0.426882
uuid-bbee8287e350454ebbe3eaa5d6ee8760,using nivo,0.30376
uuid-bbee8287e350454ebbe3eaa5d6ee8760,response,0.462493
uuid-bbee8287e350454ebbe3eaa5d6ee8760,combo,0.431462
uuid-bbee8287e350454ebbe3eaa5d6ee8760,PD1,0.624935
uuid-bbee8287e350454ebbe3eaa5d6ee8760,cHL,0.339101
uuid-bbee8287e350454ebbe3eaa5d6ee8760,progression,0.511432
uuid-bbee8287e350454ebbe3eaa5d6ee8760,believes,0.303966
uuid-bbee8287e350454ebbe3eaa5d6ee8760,chemotherapy,0.554124
uuid-bbee8287e350454ebbe3eaa5d6ee8760,respond,0.384874
uuid-bbee8287e350454ebbe3eaa5d6ee8760,option,0.447371
uuid-2fa7fabb08e64ed18c37f449ea4f2974,trial,0.353627
uuid-2fa7fabb08e64ed18c37f449ea4f2974,chemo,0.304626
uuid-2fa7fabb08e64ed18c37f449ea4f2974,tumor,0.55008
uuid-2fa7fabb08e64ed18c37f449ea4f2974,tumor types,0.324658
uuid-2fa7fabb08e64ed18c37f449ea4f2974,PDL1 expression,0.376819
uuid-071e8a19710148df8350e76197aea7f3,RTL,0.485396
uuid-071e8a19710148df8350e76197aea7f3,commented,0.385759
uuid-071e8a19710148df8350e76197aea7f3,data,0.314929
uuid-071e8a19710148df8350e76197aea7f3,mentioned,0.301392
uuid-071e8a19710148df8350e76197aea7f3,HCP,0.326119
uuid-071e8a19710148df8350e76197aea7f3,ASCO,0.41453
uuid-071e8a19710148df8350e76197aea7f3,impressed,0.552195
uuid-071e8a19710148df8350e76197aea7f3,LTL,0.316774
uuid-071e8a19710148df8350e76197aea7f3,Regional TL,0.348367
uuid-071e8a19710148df8350e76197aea7f3,flat dosing,0.325942
uuid-d2ebb03ab082448db02dd5d15d2c1d51,Nivo,0.400953
uuid-d2ebb03ab082448db02dd5d15d2c1d51,pembro,0.367659
uuid-d2ebb03ab082448db02dd5d15d2c1d51,RTL,0.393606
uuid-d2ebb03ab082448db02dd5d15d2c1d51,BMS,0.319564
uuid-d2ebb03ab082448db02dd5d15d2c1d51,trial,0.588725
uuid-d2ebb03ab082448db02dd5d15d2c1d51,efficacy,0.52544
uuid-d2ebb03ab082448db02dd5d15d2c1d51,commented,0.397007
uuid-d2ebb03ab082448db02dd5d15d2c1d51,combination,0.400943
uuid-d2ebb03ab082448db02dd5d15d2c1d51,Ipi,0.381188
uuid-d2ebb03ab082448db02dd5d15d2c1d51,stated,0.370267
uuid-d2ebb03ab082448db02dd5d15d2c1d51,OS,0.458583
uuid-d2ebb03ab082448db02dd5d15d2c1d51,atezo,0.308564
uuid-d2ebb03ab082448db02dd5d15d2c1d51,data,0.768811
uuid-d2ebb03ab082448db02dd5d15d2c1d51,combo,0.406469
uuid-d2ebb03ab082448db02dd5d15d2c1d51,expressed,0.326417
uuid-d2ebb03ab082448db02dd5d15d2c1d51,clinical trials,0.319753
uuid-d2ebb03ab082448db02dd5d15d2c1d51,PFS,0.417097
uuid-d2ebb03ab082448db02dd5d15d2c1d51,ORR,0.55179
uuid-d2ebb03ab082448db02dd5d15d2c1d51,nivo and pembro,0.40375
uuid-d2ebb03ab082448db02dd5d15d2c1d51,ASCO,0.337395
uuid-d2ebb03ab082448db02dd5d15d2c1d51,impressed,0.664138
uuid-d2ebb03ab082448db02dd5d15d2c1d51,LTL,0.342658
uuid-d2ebb03ab082448db02dd5d15d2c1d51,TLs,0.377572
uuid-d2ebb03ab082448db02dd5d15d2c1d51,SCLC,0.396294
uuid-d2ebb03ab082448db02dd5d15d2c1d51,feels,0.402123
uuid-d2ebb03ab082448db02dd5d15d2c1d51,Regional TL,0.33939
uuid-d2ebb03ab082448db02dd5d15d2c1d51,bladder,0.350943
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,TL,0.454061
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,pembro,0.355784
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,RTL,0.309468
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,lung,0.573555
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,1L,0.396611
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,melanoma,0.397554
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,shared,0.478801
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,RCC,0.555096
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,TL stated,0.671691
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,2L,0.477759
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,Merck,0.461138
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,institution,0.414252
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,stated,0.342747
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,PD-L1,0.353469
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,approval,0.38358
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,atezo,0.500547
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,preferred,0.408136
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,PD-L1 testing,0.448011
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,testing,0.437115
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,using nivo,0.376809
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,expressed,0.36355
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,PDL1 testing,0.637189
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,NSCLC patients,0.336711
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,approved,0.32837
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,SCCHN,0.541402
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,tumor types,0.339789
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,LTL,0.35877
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,TLs,0.554249
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,academic,0.327146
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,assay,0.381164
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,Regional TL,0.417334
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,RTL stated,0.459938
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,TL shared,0.443342
uuid-0e45ebf6367a4b3b9cd92a66bc614b6b,bladder,0.470084
uuid-df412aae6fc34c528d3716f0819e2f60,Nivo,0.613266
uuid-df412aae6fc34c528d3716f0819e2f60,patients,0.695921
uuid-df412aae6fc34c528d3716f0819e2f60,Opdivo,0.451659
uuid-df412aae6fc34c528d3716f0819e2f60,pembro,0.308274
uuid-df412aae6fc34c528d3716f0819e2f60,therapy,0.427096
uuid-df412aae6fc34c528d3716f0819e2f60,dose,0.362897
uuid-df412aae6fc34c528d3716f0819e2f60,nivolumab,0.576462
uuid-df412aae6fc34c528d3716f0819e2f60,toxicity,0.323065
uuid-df412aae6fc34c528d3716f0819e2f60,regimen,0.495397
uuid-df412aae6fc34c528d3716f0819e2f60,treated,0.43881
uuid-df412aae6fc34c528d3716f0819e2f60,2L,0.343909
uuid-df412aae6fc34c528d3716f0819e2f60,pts,0.40637
uuid-df412aae6fc34c528d3716f0819e2f60,Ipi,0.471832
uuid-df412aae6fc34c528d3716f0819e2f60,approval,0.337337
uuid-df412aae6fc34c528d3716f0819e2f60,preferred,0.334049
uuid-df412aae6fc34c528d3716f0819e2f60,monotherapy,0.447113
uuid-df412aae6fc34c528d3716f0819e2f60,treatment,0.418625
uuid-df412aae6fc34c528d3716f0819e2f60,using nivo,0.642264
uuid-df412aae6fc34c528d3716f0819e2f60,cHL,0.431697
uuid-df412aae6fc34c528d3716f0819e2f60,progression,0.354397
uuid-df412aae6fc34c528d3716f0819e2f60,chemotherapy,0.313752
uuid-df412aae6fc34c528d3716f0819e2f60,respond,0.34728
uuid-df412aae6fc34c528d3716f0819e2f60,RTL stated,0.414164
uuid-df412aae6fc34c528d3716f0819e2f60,option,0.330025
uuid-e2c6999b67da44aaaaf6e961c61bc274,patients,0.758891
uuid-e2c6999b67da44aaaaf6e961c61bc274,therapy,0.493522
uuid-e2c6999b67da44aaaaf6e961c61bc274,nivolumab,0.562665
uuid-e2c6999b67da44aaaaf6e961c61bc274,regimen,0.484029
uuid-e2c6999b67da44aaaaf6e961c61bc274,treated,0.646431
uuid-e2c6999b67da44aaaaf6e961c61bc274,pts,0.5513
uuid-e2c6999b67da44aaaaf6e961c61bc274,monotherapy,0.4466
uuid-e2c6999b67da44aaaaf6e961c61bc274,treatment,0.524724
uuid-e2c6999b67da44aaaaf6e961c61bc274,using nivo,0.382523
uuid-e2c6999b67da44aaaaf6e961c61bc274,NSCLC patients,0.328469
uuid-e2c6999b67da44aaaaf6e961c61bc274,progression,0.453921
uuid-e2c6999b67da44aaaaf6e961c61bc274,chemotherapy,0.330641
uuid-e2c6999b67da44aaaaf6e961c61bc274,respond,0.300118
uuid-e2c6999b67da44aaaaf6e961c61bc274,RTL stated,0.403873
uuid-e2c6999b67da44aaaaf6e961c61bc274,TL shared,0.344313
uuid-e2c6999b67da44aaaaf6e961c61bc274,option,0.329058
uuid-58e54e626efa40c7bca00a67a56abde2,1L,0.365336
uuid-58e54e626efa40c7bca00a67a56abde2,RCC,0.348858
uuid-58e54e626efa40c7bca00a67a56abde2,2L,0.355543
uuid-58e54e626efa40c7bca00a67a56abde2,agents,0.307796
uuid-58e54e626efa40c7bca00a67a56abde2,preferred,0.633468
uuid-58e54e626efa40c7bca00a67a56abde2,monotherapy,0.340191
uuid-58e54e626efa40c7bca00a67a56abde2,using nivo,0.356523
uuid-58e54e626efa40c7bca00a67a56abde2,indication,0.364502
uuid-58e54e626efa40c7bca00a67a56abde2,SCCHN,0.482324
uuid-58e54e626efa40c7bca00a67a56abde2,feels,0.321084
uuid-58e54e626efa40c7bca00a67a56abde2,RTL stated,0.465684
uuid-58e54e626efa40c7bca00a67a56abde2,TL shared,0.358554
uuid-58e54e626efa40c7bca00a67a56abde2,option,0.51479
uuid-d0cc18e054ab47af9c5c2037a44fff88,pembro,0.33047
uuid-d0cc18e054ab47af9c5c2037a44fff88,1L,0.527705
uuid-d0cc18e054ab47af9c5c2037a44fff88,PDL1,0.420624
uuid-d0cc18e054ab47af9c5c2037a44fff88,chemo,0.332324
uuid-d0cc18e054ab47af9c5c2037a44fff88,2L,0.476557
uuid-d0cc18e054ab47af9c5c2037a44fff88,agents,0.379962
uuid-d0cc18e054ab47af9c5c2037a44fff88,PD-L1,0.535031
uuid-d0cc18e054ab47af9c5c2037a44fff88,atezo,0.405429
uuid-d0cc18e054ab47af9c5c2037a44fff88,preferred,0.526014
uuid-d0cc18e054ab47af9c5c2037a44fff88,PD-L1 testing,0.39096
uuid-d0cc18e054ab47af9c5c2037a44fff88,testing,0.54559
uuid-d0cc18e054ab47af9c5c2037a44fff88,monotherapy,0.357139
uuid-d0cc18e054ab47af9c5c2037a44fff88,PDL1 testing,0.487749
uuid-d0cc18e054ab47af9c5c2037a44fff88,NSCLC patients,0.498653
uuid-d0cc18e054ab47af9c5c2037a44fff88,believes,0.364057
uuid-d0cc18e054ab47af9c5c2037a44fff88,tumor types,0.327227
uuid-d0cc18e054ab47af9c5c2037a44fff88,assay,0.326445
uuid-d0cc18e054ab47af9c5c2037a44fff88,PDL1 expression,0.339558
uuid-d0cc18e054ab47af9c5c2037a44fff88,option,0.55133
uuid-d0cc18e054ab47af9c5c2037a44fff88,biomarker,0.464674
uuid-01b73cba924b43dfb9cd4ade937d040e,dose,0.340723
uuid-01b73cba924b43dfb9cd4ade937d040e,toxicity,0.451266
uuid-01b73cba924b43dfb9cd4ade937d040e,regimen,0.359183
uuid-01b73cba924b43dfb9cd4ade937d040e,treated,0.371453
uuid-01b73cba924b43dfb9cd4ade937d040e,physicians,0.4156
uuid-01b73cba924b43dfb9cd4ade937d040e,treatment,0.433454
uuid-1d561256cc924ace9e538efb5895b3ea,Nivo,0.432586
uuid-1d561256cc924ace9e538efb5895b3ea,patients,0.644275
uuid-1d561256cc924ace9e538efb5895b3ea,Opdivo,0.500636
uuid-1d561256cc924ace9e538efb5895b3ea,pembro,0.323893
uuid-1d561256cc924ace9e538efb5895b3ea,therapy,0.416087
uuid-1d561256cc924ace9e538efb5895b3ea,nivolumab,0.555475
uuid-1d561256cc924ace9e538efb5895b3ea,1L,0.356885
uuid-1d561256cc924ace9e538efb5895b3ea,regimen,0.451568
uuid-1d561256cc924ace9e538efb5895b3ea,treated,0.453531
uuid-1d561256cc924ace9e538efb5895b3ea,RCC,0.329398
uuid-1d561256cc924ace9e538efb5895b3ea,combination,0.346887
uuid-1d561256cc924ace9e538efb5895b3ea,chemo,0.315554
uuid-1d561256cc924ace9e538efb5895b3ea,2L,0.450121
uuid-1d561256cc924ace9e538efb5895b3ea,pts,0.398918
uuid-1d561256cc924ace9e538efb5895b3ea,approval,0.434796
uuid-1d561256cc924ace9e538efb5895b3ea,preferred,0.554447
uuid-1d561256cc924ace9e538efb5895b3ea,monotherapy,0.527284
uuid-1d561256cc924ace9e538efb5895b3ea,treatment,0.447081
uuid-1d561256cc924ace9e538efb5895b3ea,using nivo,0.569368
uuid-1d561256cc924ace9e538efb5895b3ea,combo,0.318579
uuid-1d561256cc924ace9e538efb5895b3ea,clinical trials,0.337469
uuid-1d561256cc924ace9e538efb5895b3ea,indication,0.320409
uuid-1d561256cc924ace9e538efb5895b3ea,approved,0.508856
uuid-1d561256cc924ace9e538efb5895b3ea,SCCHN,0.335752
uuid-1d561256cc924ace9e538efb5895b3ea,chemotherapy,0.413957
uuid-1d561256cc924ace9e538efb5895b3ea,feels,0.303962
uuid-1d561256cc924ace9e538efb5895b3ea,RTL stated,0.459822
uuid-1d561256cc924ace9e538efb5895b3ea,option,0.561295
uuid-1d561256cc924ace9e538efb5895b3ea,bladder,0.314555
uuid-a28dbd2f60464163be2c5e52dd8418d9,Nivo,0.337698
uuid-a28dbd2f60464163be2c5e52dd8418d9,pembro,0.399771
uuid-a28dbd2f60464163be2c5e52dd8418d9,dose,0.549591
uuid-a28dbd2f60464163be2c5e52dd8418d9,efficacy,0.470099
uuid-a28dbd2f60464163be2c5e52dd8418d9,agents,0.470411
uuid-a28dbd2f60464163be2c5e52dd8418d9,atezo,0.47664
uuid-a28dbd2f60464163be2c5e52dd8418d9,preferred,0.473444
uuid-a28dbd2f60464163be2c5e52dd8418d9,indication,0.419334
uuid-a28dbd2f60464163be2c5e52dd8418d9,approved,0.334644
uuid-a28dbd2f60464163be2c5e52dd8418d9,vs,0.449241
uuid-a28dbd2f60464163be2c5e52dd8418d9,drug,0.507036
uuid-a28dbd2f60464163be2c5e52dd8418d9,Keytruda,0.464357
uuid-a28dbd2f60464163be2c5e52dd8418d9,option,0.363037
uuid-a28dbd2f60464163be2c5e52dd8418d9,flat dosing,0.477734
uuid-d9051d46ecd64d759d7c33597a4866e4,patients,0.325182
uuid-d9051d46ecd64d759d7c33597a4866e4,dose,0.337209
uuid-d9051d46ecd64d759d7c33597a4866e4,feels,0.339048
uuid-d9b793fbac024ec8a2619a85f24bc8cb,toxicity,0.349893
uuid-d9b793fbac024ec8a2619a85f24bc8cb,physicians,0.348047
uuid-d9b793fbac024ec8a2619a85f24bc8cb,treatment,0.335668
uuid-101d772712b14659a7fe2b36089cc8fb,efficacy,0.467067
uuid-101d772712b14659a7fe2b36089cc8fb,regimen,0.315901
uuid-101d772712b14659a7fe2b36089cc8fb,combination,0.327717
uuid-101d772712b14659a7fe2b36089cc8fb,chemo,0.315563
uuid-101d772712b14659a7fe2b36089cc8fb,OS,0.412757
uuid-101d772712b14659a7fe2b36089cc8fb,data,0.363252
uuid-101d772712b14659a7fe2b36089cc8fb,combo,0.331151
uuid-101d772712b14659a7fe2b36089cc8fb,PFS,0.39209
uuid-101d772712b14659a7fe2b36089cc8fb,ORR,0.368529
uuid-101d772712b14659a7fe2b36089cc8fb,believes,0.328524
uuid-101d772712b14659a7fe2b36089cc8fb,chemotherapy,0.336984
uuid-101d772712b14659a7fe2b36089cc8fb,impressed,0.314041
uuid-101d772712b14659a7fe2b36089cc8fb,feels,0.327915
uuid-c517f25cf6654316b2085ba8f9fa877b,Nivo,0.461954
uuid-c517f25cf6654316b2085ba8f9fa877b,patients,0.306119
uuid-c517f25cf6654316b2085ba8f9fa877b,pembro,0.607888
uuid-c517f25cf6654316b2085ba8f9fa877b,dose,0.464396
uuid-c517f25cf6654316b2085ba8f9fa877b,1L,0.398491
uuid-c517f25cf6654316b2085ba8f9fa877b,2L,0.556676
uuid-c517f25cf6654316b2085ba8f9fa877b,Ipi,0.389967
uuid-c517f25cf6654316b2085ba8f9fa877b,approval,0.384937
uuid-c517f25cf6654316b2085ba8f9fa877b,atezo,0.643034
uuid-c517f25cf6654316b2085ba8f9fa877b,preferred,0.582796
uuid-c517f25cf6654316b2085ba8f9fa877b,monotherapy,0.357887
uuid-c517f25cf6654316b2085ba8f9fa877b,using nivo,0.501514
uuid-c517f25cf6654316b2085ba8f9fa877b,indication,0.373381
uuid-c517f25cf6654316b2085ba8f9fa877b,approved,0.430146
uuid-c517f25cf6654316b2085ba8f9fa877b,vs,0.45809
uuid-c517f25cf6654316b2085ba8f9fa877b,RTL stated,0.336626
uuid-c517f25cf6654316b2085ba8f9fa877b,option,0.400202
uuid-c517f25cf6654316b2085ba8f9fa877b,flat dosing,0.338127
uuid-cf1be7fcb9ce413e880e489e0712ea6a,1L,0.311254
uuid-cf1be7fcb9ce413e880e489e0712ea6a,PDL1,0.589755
uuid-cf1be7fcb9ce413e880e489e0712ea6a,agents,0.325346
uuid-cf1be7fcb9ce413e880e489e0712ea6a,Merck,0.374182
uuid-cf1be7fcb9ce413e880e489e0712ea6a,PD-L1,0.58843
uuid-cf1be7fcb9ce413e880e489e0712ea6a,atezo,0.331044
uuid-cf1be7fcb9ce413e880e489e0712ea6a,PD-L1 testing,0.355558
uuid-cf1be7fcb9ce413e880e489e0712ea6a,testing,0.542797
uuid-cf1be7fcb9ce413e880e489e0712ea6a,PDL1 testing,0.414051
uuid-cf1be7fcb9ce413e880e489e0712ea6a,NSCLC patients,0.314125
uuid-cf1be7fcb9ce413e880e489e0712ea6a,nivo and pembro,0.355497
uuid-cf1be7fcb9ce413e880e489e0712ea6a,believes,0.387894
uuid-cf1be7fcb9ce413e880e489e0712ea6a,assay,0.60565
uuid-cf1be7fcb9ce413e880e489e0712ea6a,PDL1 expression,0.456801
uuid-cf1be7fcb9ce413e880e489e0712ea6a,biomarker,0.617313
uuid-d9678339d8ab42d88d09fbe2d39f7e45,PDL1,0.522763
uuid-d9678339d8ab42d88d09fbe2d39f7e45,efficacy,0.35305
uuid-d9678339d8ab42d88d09fbe2d39f7e45,chemo,0.30036
uuid-d9678339d8ab42d88d09fbe2d39f7e45,OS,0.327071
uuid-d9678339d8ab42d88d09fbe2d39f7e45,PFS,0.371873
uuid-d9678339d8ab42d88d09fbe2d39f7e45,ORR,0.322445
uuid-d9678339d8ab42d88d09fbe2d39f7e45,nivo and pembro,0.556264
uuid-d9678339d8ab42d88d09fbe2d39f7e45,believes,0.533667
uuid-d9678339d8ab42d88d09fbe2d39f7e45,feels,0.353344
uuid-d9678339d8ab42d88d09fbe2d39f7e45,PDL1 expression,0.42058
uuid-baef6624aa0e44ac932fef46f22ef358,Opdivo,0.318865
uuid-baef6624aa0e44ac932fef46f22ef358,BMS,0.421777
uuid-baef6624aa0e44ac932fef46f22ef358,Merck,0.323915
uuid-baef6624aa0e44ac932fef46f22ef358,physicians,0.358021
uuid-baef6624aa0e44ac932fef46f22ef358,approved,0.434047
uuid-baef6624aa0e44ac932fef46f22ef358,drug,0.414136
uuid-bdff05c95780498fbdef5b3b860ba714,pembro,0.334641
uuid-bdff05c95780498fbdef5b3b860ba714,1L,0.420706
uuid-bdff05c95780498fbdef5b3b860ba714,PDL1,0.520497
uuid-bdff05c95780498fbdef5b3b860ba714,chemo,0.339186
uuid-bdff05c95780498fbdef5b3b860ba714,2L,0.37949
uuid-bdff05c95780498fbdef5b3b860ba714,agents,0.545224
uuid-bdff05c95780498fbdef5b3b860ba714,PD-L1,0.49289
uuid-bdff05c95780498fbdef5b3b860ba714,atezo,0.392981
uuid-bdff05c95780498fbdef5b3b860ba714,preferred,0.38019
uuid-bdff05c95780498fbdef5b3b860ba714,testing,0.341187
uuid-bdff05c95780498fbdef5b3b860ba714,monotherapy,0.404341
uuid-bdff05c95780498fbdef5b3b860ba714,NSCLC patients,0.319977
uuid-bdff05c95780498fbdef5b3b860ba714,nivo and pembro,0.433253
uuid-bdff05c95780498fbdef5b3b860ba714,believes,0.369244
uuid-bdff05c95780498fbdef5b3b860ba714,assay,0.3204
uuid-bdff05c95780498fbdef5b3b860ba714,PD-1,0.415044
uuid-bdff05c95780498fbdef5b3b860ba714,PDL1 expression,0.476047
uuid-bdff05c95780498fbdef5b3b860ba714,option,0.424918
uuid-bdff05c95780498fbdef5b3b860ba714,biomarker,0.417924
uuid-a1c79e9154474dfa812210f9e6d9c7cd,commented,0.344904
uuid-a1c79e9154474dfa812210f9e6d9c7cd,institution,0.326909
uuid-a1c79e9154474dfa812210f9e6d9c7cd,regards,0.359195
uuid-a1c79e9154474dfa812210f9e6d9c7cd,indication,0.309647
uuid-a1c79e9154474dfa812210f9e6d9c7cd,NCCN,0.678528
uuid-d65689e537cc49288523ed883efa68d2,patients,0.852975
uuid-d65689e537cc49288523ed883efa68d2,Opdivo,0.393932
uuid-d65689e537cc49288523ed883efa68d2,therapy,0.699127
uuid-d65689e537cc49288523ed883efa68d2,nivolumab,0.414518
uuid-d65689e537cc49288523ed883efa68d2,toxicity,0.381618
uuid-d65689e537cc49288523ed883efa68d2,regimen,0.611834
uuid-d65689e537cc49288523ed883efa68d2,treated,0.553066
uuid-d65689e537cc49288523ed883efa68d2,chemo,0.427514
uuid-d65689e537cc49288523ed883efa68d2,pts,0.543617
uuid-d65689e537cc49288523ed883efa68d2,monotherapy,0.422027
uuid-d65689e537cc49288523ed883efa68d2,treatment,0.867164
uuid-d65689e537cc49288523ed883efa68d2,response,0.481866
uuid-d65689e537cc49288523ed883efa68d2,PD1,0.384467
uuid-d65689e537cc49288523ed883efa68d2,progression,0.795396
uuid-d65689e537cc49288523ed883efa68d2,chemotherapy,0.496882
uuid-d65689e537cc49288523ed883efa68d2,respond,0.592352
uuid-d65689e537cc49288523ed883efa68d2,option,0.434881
uuid-236e40c9e21e4f649e0f7e7003379e4f,Nivo,0.419837
uuid-236e40c9e21e4f649e0f7e7003379e4f,patients,0.770657
uuid-236e40c9e21e4f649e0f7e7003379e4f,Opdivo,0.610643
uuid-236e40c9e21e4f649e0f7e7003379e4f,therapy,0.43082
uuid-236e40c9e21e4f649e0f7e7003379e4f,dose,0.512605
uuid-236e40c9e21e4f649e0f7e7003379e4f,nivolumab,0.502385
uuid-236e40c9e21e4f649e0f7e7003379e4f,regimen,0.453364
uuid-236e40c9e21e4f649e0f7e7003379e4f,treated,0.367887
uuid-236e40c9e21e4f649e0f7e7003379e4f,2L,0.315082
uuid-236e40c9e21e4f649e0f7e7003379e4f,pts,0.472499
uuid-236e40c9e21e4f649e0f7e7003379e4f,approval,0.323249
uuid-236e40c9e21e4f649e0f7e7003379e4f,preferred,0.425743
uuid-236e40c9e21e4f649e0f7e7003379e4f,monotherapy,0.383086
uuid-236e40c9e21e4f649e0f7e7003379e4f,treatment,0.525597
uuid-236e40c9e21e4f649e0f7e7003379e4f,using nivo,0.437087
uuid-236e40c9e21e4f649e0f7e7003379e4f,approved,0.379875
uuid-236e40c9e21e4f649e0f7e7003379e4f,progression,0.416606
uuid-236e40c9e21e4f649e0f7e7003379e4f,respond,0.382253
uuid-236e40c9e21e4f649e0f7e7003379e4f,option,0.437895
uuid-236e40c9e21e4f649e0f7e7003379e4f,flat dosing,0.424866
uuid-7a24f2f4f01447479c997d038a4eafa2,TL,0.507279
uuid-7a24f2f4f01447479c997d038a4eafa2,PDL1,0.389989
uuid-7a24f2f4f01447479c997d038a4eafa2,TL stated,0.384102
uuid-7a24f2f4f01447479c997d038a4eafa2,Merck,0.497812
uuid-7a24f2f4f01447479c997d038a4eafa2,institution,0.329336
uuid-7a24f2f4f01447479c997d038a4eafa2,PD-L1,0.653254
uuid-7a24f2f4f01447479c997d038a4eafa2,PD-L1 testing,0.69557
uuid-7a24f2f4f01447479c997d038a4eafa2,testing,0.655771
uuid-7a24f2f4f01447479c997d038a4eafa2,PDL1 testing,0.596282
uuid-7a24f2f4f01447479c997d038a4eafa2,NSCLC patients,0.46518
uuid-7a24f2f4f01447479c997d038a4eafa2,TLs,0.303
uuid-7a24f2f4f01447479c997d038a4eafa2,assay,0.562208
uuid-7a24f2f4f01447479c997d038a4eafa2,PDL1 expression,0.339783
uuid-7a24f2f4f01447479c997d038a4eafa2,biomarker,0.315039
uuid-0f5816b8e6a24f288782912b2383788a,Nivo,0.41792
uuid-0f5816b8e6a24f288782912b2383788a,pembro,0.595064
uuid-0f5816b8e6a24f288782912b2383788a,1L,0.69878
uuid-0f5816b8e6a24f288782912b2383788a,PDL1,0.588829
uuid-0f5816b8e6a24f288782912b2383788a,efficacy,0.373253
uuid-0f5816b8e6a24f288782912b2383788a,chemo,0.349054
uuid-0f5816b8e6a24f288782912b2383788a,2L,0.642555
uuid-0f5816b8e6a24f288782912b2383788a,agents,0.538779
uuid-0f5816b8e6a24f288782912b2383788a,PD-L1,0.37187
uuid-0f5816b8e6a24f288782912b2383788a,atezo,0.634462
uuid-0f5816b8e6a24f288782912b2383788a,preferred,0.528024
uuid-0f5816b8e6a24f288782912b2383788a,monotherapy,0.481834
uuid-0f5816b8e6a24f288782912b2383788a,using nivo,0.350286
uuid-0f5816b8e6a24f288782912b2383788a,combo,0.317155
uuid-0f5816b8e6a24f288782912b2383788a,PDL1 testing,0.330489
uuid-0f5816b8e6a24f288782912b2383788a,indication,0.308768
uuid-0f5816b8e6a24f288782912b2383788a,approved,0.382549
uuid-0f5816b8e6a24f288782912b2383788a,nivo and pembro,0.581805
uuid-0f5816b8e6a24f288782912b2383788a,believes,0.481268
uuid-0f5816b8e6a24f288782912b2383788a,feels,0.459376
uuid-0f5816b8e6a24f288782912b2383788a,PDL1 expression,0.516819
uuid-0f5816b8e6a24f288782912b2383788a,option,0.542216
uuid-0f5816b8e6a24f288782912b2383788a,biomarker,0.384593
uuid-fe20c22527a1485aa48942201785c618,pembro,0.392138
uuid-fe20c22527a1485aa48942201785c618,RTL,0.300637
uuid-fe20c22527a1485aa48942201785c618,lung,0.596671
uuid-fe20c22527a1485aa48942201785c618,1L,0.353164
uuid-fe20c22527a1485aa48942201785c618,melanoma,0.619132
uuid-fe20c22527a1485aa48942201785c618,shared,0.31403
uuid-fe20c22527a1485aa48942201785c618,RCC,0.64443
uuid-fe20c22527a1485aa48942201785c618,TL stated,0.558944
uuid-fe20c22527a1485aa48942201785c618,2L,0.527654
uuid-fe20c22527a1485aa48942201785c618,atezo,0.475654
uuid-fe20c22527a1485aa48942201785c618,preferred,0.512525
uuid-fe20c22527a1485aa48942201785c618,using nivo,0.500815
uuid-fe20c22527a1485aa48942201785c618,PDL1 testing,0.380361
uuid-fe20c22527a1485aa48942201785c618,SCCHN,0.635894
uuid-fe20c22527a1485aa48942201785c618,TLs,0.487417
uuid-fe20c22527a1485aa48942201785c618,academic,0.36481
uuid-fe20c22527a1485aa48942201785c618,Regional TL,0.357363
uuid-fe20c22527a1485aa48942201785c618,RTL stated,0.666632
uuid-fe20c22527a1485aa48942201785c618,TL shared,0.566515
uuid-fe20c22527a1485aa48942201785c618,bladder,0.416448
uuid-2c20498406e544a9afc404a261f5857e,Nivo,0.327276
uuid-2c20498406e544a9afc404a261f5857e,pembro,0.428304
uuid-2c20498406e544a9afc404a261f5857e,RTL,0.393887
uuid-2c20498406e544a9afc404a261f5857e,trial,0.695949
uuid-2c20498406e544a9afc404a261f5857e,combination,0.583684
uuid-2c20498406e544a9afc404a261f5857e,agents,0.341547
uuid-2c20498406e544a9afc404a261f5857e,Ipi,0.386207
uuid-2c20498406e544a9afc404a261f5857e,atezo,0.315483
uuid-2c20498406e544a9afc404a261f5857e,preferred,0.351869
uuid-2c20498406e544a9afc404a261f5857e,monotherapy,0.366862
uuid-2c20498406e544a9afc404a261f5857e,data,0.346956
uuid-2c20498406e544a9afc404a261f5857e,combo,0.489294
uuid-2c20498406e544a9afc404a261f5857e,clinical trials,0.415316
uuid-2c20498406e544a9afc404a261f5857e,SCCHN,0.324984
uuid-2c20498406e544a9afc404a261f5857e,chemotherapy,0.316381
uuid-2c20498406e544a9afc404a261f5857e,impressed,0.333027
uuid-2c20498406e544a9afc404a261f5857e,feels,0.424682
uuid-2c20498406e544a9afc404a261f5857e,RTL stated,0.338559
uuid-2c20498406e544a9afc404a261f5857e,bladder,0.319399
uuid-6e9a447cd294476caafd917c179ce792,combination,0.709928
uuid-6e9a447cd294476caafd917c179ce792,chemo,0.435393
uuid-6e9a447cd294476caafd917c179ce792,IO,0.570114
uuid-6e9a447cd294476caafd917c179ce792,agents,0.463032
uuid-6e9a447cd294476caafd917c179ce792,monotherapy,0.552517
uuid-6e9a447cd294476caafd917c179ce792,combo,0.603937
uuid-6e9a447cd294476caafd917c179ce792,PD1,0.458578
uuid-6e9a447cd294476caafd917c179ce792,believes,0.427913
uuid-6e9a447cd294476caafd917c179ce792,chemotherapy,0.390818
uuid-6e9a447cd294476caafd917c179ce792,feels,0.423404
uuid-6e9a447cd294476caafd917c179ce792,PD-1,0.332625
uuid-6e9a447cd294476caafd917c179ce792,option,0.369085
uuid-5ed36c3963e34d2bb6b4f0e26412d080,Nivo,0.659586
uuid-5ed36c3963e34d2bb6b4f0e26412d080,pembro,0.618152
uuid-5ed36c3963e34d2bb6b4f0e26412d080,1L,0.383823
uuid-5ed36c3963e34d2bb6b4f0e26412d080,trial,0.44874
uuid-5ed36c3963e34d2bb6b4f0e26412d080,efficacy,0.417413
uuid-5ed36c3963e34d2bb6b4f0e26412d080,combination,0.33498
uuid-5ed36c3963e34d2bb6b4f0e26412d080,chemo,0.399081
uuid-5ed36c3963e34d2bb6b4f0e26412d080,2L,0.404457
uuid-5ed36c3963e34d2bb6b4f0e26412d080,agents,0.32683
uuid-5ed36c3963e34d2bb6b4f0e26412d080,Ipi,0.329494
uuid-5ed36c3963e34d2bb6b4f0e26412d080,approval,0.347167
uuid-5ed36c3963e34d2bb6b4f0e26412d080,OS,0.30036
uuid-5ed36c3963e34d2bb6b4f0e26412d080,atezo,0.479911
uuid-5ed36c3963e34d2bb6b4f0e26412d080,preferred,0.321842
uuid-5ed36c3963e34d2bb6b4f0e26412d080,monotherapy,0.393578
uuid-5ed36c3963e34d2bb6b4f0e26412d080,using nivo,0.403193
uuid-5ed36c3963e34d2bb6b4f0e26412d080,data,0.396472
uuid-5ed36c3963e34d2bb6b4f0e26412d080,combo,0.341748
uuid-5ed36c3963e34d2bb6b4f0e26412d080,indication,0.324309
uuid-5ed36c3963e34d2bb6b4f0e26412d080,PD1,0.314659
uuid-5ed36c3963e34d2bb6b4f0e26412d080,ORR,0.317302
uuid-5ed36c3963e34d2bb6b4f0e26412d080,approved,0.410196
uuid-5ed36c3963e34d2bb6b4f0e26412d080,nivo and pembro,0.438956
uuid-5ed36c3963e34d2bb6b4f0e26412d080,believes,0.351538
uuid-5ed36c3963e34d2bb6b4f0e26412d080,chemotherapy,0.313569
uuid-5ed36c3963e34d2bb6b4f0e26412d080,impressed,0.382812
uuid-5ed36c3963e34d2bb6b4f0e26412d080,vs,0.365289
uuid-5ed36c3963e34d2bb6b4f0e26412d080,feels,0.568233
uuid-5ed36c3963e34d2bb6b4f0e26412d080,option,0.396314
uuid-2208457cdb3844cf9c8fec8ddd52263d,1L,0.349828
uuid-2208457cdb3844cf9c8fec8ddd52263d,PDL1,0.496798
uuid-2208457cdb3844cf9c8fec8ddd52263d,agents,0.338069
uuid-2208457cdb3844cf9c8fec8ddd52263d,PD-L1,0.458425
uuid-2208457cdb3844cf9c8fec8ddd52263d,testing,0.449667
uuid-2208457cdb3844cf9c8fec8ddd52263d,PDL1 testing,0.400913
uuid-2208457cdb3844cf9c8fec8ddd52263d,NSCLC patients,0.313813
uuid-2208457cdb3844cf9c8fec8ddd52263d,believes,0.394418
uuid-2208457cdb3844cf9c8fec8ddd52263d,feels,0.301339
uuid-2208457cdb3844cf9c8fec8ddd52263d,assay,0.32402
uuid-2208457cdb3844cf9c8fec8ddd52263d,PDL1 expression,0.366203
uuid-2208457cdb3844cf9c8fec8ddd52263d,biomarker,0.528816
uuid-4c8fd70656784752a944bb00dd2fa0b8,patients,0.370126
uuid-4c8fd70656784752a944bb00dd2fa0b8,TL,0.563527
uuid-4c8fd70656784752a944bb00dd2fa0b8,TL stated,0.413307
uuid-4c8fd70656784752a944bb00dd2fa0b8,PD-L1,0.578617
uuid-4c8fd70656784752a944bb00dd2fa0b8,approval,0.320491
uuid-4c8fd70656784752a944bb00dd2fa0b8,PD-L1 testing,0.719006
uuid-4c8fd70656784752a944bb00dd2fa0b8,testing,0.741781
uuid-4c8fd70656784752a944bb00dd2fa0b8,PDL1 testing,0.624784
uuid-4c8fd70656784752a944bb00dd2fa0b8,NSCLC patients,0.705582
uuid-4c8fd70656784752a944bb00dd2fa0b8,assay,0.420567
uuid-47554c51c426405786c7c0ca1a511e26,TL,0.348383
uuid-47554c51c426405786c7c0ca1a511e26,RTL,0.346626
uuid-47554c51c426405786c7c0ca1a511e26,toxicity,0.352972
uuid-47554c51c426405786c7c0ca1a511e26,NTL,0.356907
uuid-47554c51c426405786c7c0ca1a511e26,TL stated,0.323346
uuid-47554c51c426405786c7c0ca1a511e26,TL shared,0.337337
uuid-09197211d94c4d4bb056bd1d63a54272,Nivo,0.564741
uuid-09197211d94c4d4bb056bd1d63a54272,patients,0.345419
uuid-09197211d94c4d4bb056bd1d63a54272,pembro,0.604139
uuid-09197211d94c4d4bb056bd1d63a54272,nivolumab,0.391606
uuid-09197211d94c4d4bb056bd1d63a54272,1L,0.599267
uuid-09197211d94c4d4bb056bd1d63a54272,RCC,0.46741
uuid-09197211d94c4d4bb056bd1d63a54272,2L,0.682019
uuid-09197211d94c4d4bb056bd1d63a54272,pts,0.321477
uuid-09197211d94c4d4bb056bd1d63a54272,stated,0.417868
uuid-09197211d94c4d4bb056bd1d63a54272,approval,0.555661
uuid-09197211d94c4d4bb056bd1d63a54272,atezo,0.531239
uuid-09197211d94c4d4bb056bd1d63a54272,preferred,0.56567
uuid-09197211d94c4d4bb056bd1d63a54272,monotherapy,0.517284
uuid-09197211d94c4d4bb056bd1d63a54272,using nivo,0.711598
uuid-09197211d94c4d4bb056bd1d63a54272,clinical trials,0.350741
uuid-09197211d94c4d4bb056bd1d63a54272,indication,0.391102
uuid-09197211d94c4d4bb056bd1d63a54272,approved,0.596029
uuid-09197211d94c4d4bb056bd1d63a54272,SCCHN,0.543981
uuid-09197211d94c4d4bb056bd1d63a54272,impressed,0.33716
uuid-09197211d94c4d4bb056bd1d63a54272,tumor types,0.329835
uuid-09197211d94c4d4bb056bd1d63a54272,label,0.348121
uuid-09197211d94c4d4bb056bd1d63a54272,LTL,0.386255
uuid-09197211d94c4d4bb056bd1d63a54272,SCLC,0.384705
uuid-09197211d94c4d4bb056bd1d63a54272,feels,0.408206
uuid-09197211d94c4d4bb056bd1d63a54272,Regional TL,0.334521
uuid-09197211d94c4d4bb056bd1d63a54272,RTL stated,0.625235
uuid-09197211d94c4d4bb056bd1d63a54272,option,0.5168
uuid-09197211d94c4d4bb056bd1d63a54272,bladder,0.512996
uuid-0bf093fbb15f45e9adc0d38089295d0d,Nivo,0.608532
uuid-0bf093fbb15f45e9adc0d38089295d0d,pembro,0.522744
uuid-0bf093fbb15f45e9adc0d38089295d0d,nivolumab,0.411559
uuid-0bf093fbb15f45e9adc0d38089295d0d,1L,0.566052
uuid-0bf093fbb15f45e9adc0d38089295d0d,RCC,0.486615
uuid-0bf093fbb15f45e9adc0d38089295d0d,combination,0.495398
uuid-0bf093fbb15f45e9adc0d38089295d0d,chemo,0.348778
uuid-0bf093fbb15f45e9adc0d38089295d0d,2L,0.667771
uuid-0bf093fbb15f45e9adc0d38089295d0d,agents,0.443981
uuid-0bf093fbb15f45e9adc0d38089295d0d,Ipi,0.366676
uuid-0bf093fbb15f45e9adc0d38089295d0d,stated,0.320139
uuid-0bf093fbb15f45e9adc0d38089295d0d,approval,0.383875
uuid-0bf093fbb15f45e9adc0d38089295d0d,atezo,0.477876
uuid-0bf093fbb15f45e9adc0d38089295d0d,preferred,0.639118
uuid-0bf093fbb15f45e9adc0d38089295d0d,monotherapy,0.607647
uuid-0bf093fbb15f45e9adc0d38089295d0d,using nivo,0.706626
uuid-0bf093fbb15f45e9adc0d38089295d0d,combo,0.476639
uuid-0bf093fbb15f45e9adc0d38089295d0d,PD1,0.328034
uuid-0bf093fbb15f45e9adc0d38089295d0d,approved,0.493011
uuid-0bf093fbb15f45e9adc0d38089295d0d,SCCHN,0.460666
uuid-0bf093fbb15f45e9adc0d38089295d0d,LTL,0.443387
uuid-0bf093fbb15f45e9adc0d38089295d0d,SCLC,0.339516
uuid-0bf093fbb15f45e9adc0d38089295d0d,feels,0.484348
uuid-0bf093fbb15f45e9adc0d38089295d0d,RTL stated,0.659486
uuid-0bf093fbb15f45e9adc0d38089295d0d,option,0.553422
uuid-0bf093fbb15f45e9adc0d38089295d0d,bladder,0.354554
uuid-b98e04abbd1f4474a739c9c8c98bdb92,RTL,0.492194
uuid-b98e04abbd1f4474a739c9c8c98bdb92,trial,0.31807
uuid-b98e04abbd1f4474a739c9c8c98bdb92,NTL,0.405809
uuid-b98e04abbd1f4474a739c9c8c98bdb92,discussed,0.347651
uuid-b98e04abbd1f4474a739c9c8c98bdb92,commented,0.58883
uuid-b98e04abbd1f4474a739c9c8c98bdb92,regards,0.460764
uuid-b98e04abbd1f4474a739c9c8c98bdb92,data,0.48304
uuid-b98e04abbd1f4474a739c9c8c98bdb92,expressed,0.511984
uuid-b98e04abbd1f4474a739c9c8c98bdb92,mentioned,0.658244
uuid-b98e04abbd1f4474a739c9c8c98bdb92,HCP,0.361382
uuid-b98e04abbd1f4474a739c9c8c98bdb92,ASCO,0.427767
uuid-b98e04abbd1f4474a739c9c8c98bdb92,impressed,0.52029
uuid-b98e04abbd1f4474a739c9c8c98bdb92,LTL,0.429286
uuid-b98e04abbd1f4474a739c9c8c98bdb92,TLs,0.317108
uuid-b98e04abbd1f4474a739c9c8c98bdb92,Regional TL,0.442365
uuid-79fc81bea3dd4feebe04c992ea5740bd,BMS,0.616578
uuid-79fc81bea3dd4feebe04c992ea5740bd,shared,0.383536
uuid-79fc81bea3dd4feebe04c992ea5740bd,Merck,0.590542
uuid-79fc81bea3dd4feebe04c992ea5740bd,physicians,0.427297
uuid-79fc81bea3dd4feebe04c992ea5740bd,drug,0.491679
uuid-79fc81bea3dd4feebe04c992ea5740bd,Keytruda,0.329667
uuid-6fd52f97f60943059f39a82774291e2a,Nivo,0.730192
uuid-6fd52f97f60943059f39a82774291e2a,patients,0.53776
uuid-6fd52f97f60943059f39a82774291e2a,pembro,0.400411
uuid-6fd52f97f60943059f39a82774291e2a,therapy,0.410239
uuid-6fd52f97f60943059f39a82774291e2a,dose,0.664244
uuid-6fd52f97f60943059f39a82774291e2a,nivolumab,0.457989
uuid-6fd52f97f60943059f39a82774291e2a,toxicity,0.3779
uuid-6fd52f97f60943059f39a82774291e2a,regimen,0.517458
uuid-6fd52f97f60943059f39a82774291e2a,combination,0.45512
uuid-6fd52f97f60943059f39a82774291e2a,chemo,0.455658
uuid-6fd52f97f60943059f39a82774291e2a,pts,0.419965
uuid-6fd52f97f60943059f39a82774291e2a,Ipi,0.73733
uuid-6fd52f97f60943059f39a82774291e2a,preferred,0.301815
uuid-6fd52f97f60943059f39a82774291e2a,monotherapy,0.459303
uuid-6fd52f97f60943059f39a82774291e2a,treatment,0.348257
uuid-6fd52f97f60943059f39a82774291e2a,using nivo,0.366718
uuid-6fd52f97f60943059f39a82774291e2a,response,0.312686
uuid-6fd52f97f60943059f39a82774291e2a,combo,0.382088
uuid-6fd52f97f60943059f39a82774291e2a,progression,0.323147
uuid-6fd52f97f60943059f39a82774291e2a,chemotherapy,0.403652
uuid-6fd52f97f60943059f39a82774291e2a,vs,0.490024
uuid-6fd52f97f60943059f39a82774291e2a,option,0.339242
uuid-6fd52f97f60943059f39a82774291e2a,flat dosing,0.355591
uuid-6680e39a0d174cdcb5e353834ad9f4b0,patients,0.604721
uuid-6680e39a0d174cdcb5e353834ad9f4b0,therapy,0.461599
uuid-6680e39a0d174cdcb5e353834ad9f4b0,nivolumab,0.312834
uuid-6680e39a0d174cdcb5e353834ad9f4b0,toxicity,0.522451
uuid-6680e39a0d174cdcb5e353834ad9f4b0,regimen,0.577583
uuid-6680e39a0d174cdcb5e353834ad9f4b0,treated,0.586602
uuid-6680e39a0d174cdcb5e353834ad9f4b0,chemo,0.343911
uuid-6680e39a0d174cdcb5e353834ad9f4b0,pts,0.348883
uuid-6680e39a0d174cdcb5e353834ad9f4b0,monotherapy,0.345295
uuid-6680e39a0d174cdcb5e353834ad9f4b0,treatment,0.686034
uuid-6680e39a0d174cdcb5e353834ad9f4b0,progression,0.465219
uuid-6680e39a0d174cdcb5e353834ad9f4b0,chemotherapy,0.383215
uuid-6680e39a0d174cdcb5e353834ad9f4b0,respond,0.491659
uuid-7f6bc2bf337f442db427e7f82d58c151,BMS,0.418679
uuid-7f6bc2bf337f442db427e7f82d58c151,PDL1,0.388321
uuid-7f6bc2bf337f442db427e7f82d58c151,trial,0.343787
uuid-7f6bc2bf337f442db427e7f82d58c151,efficacy,0.545651
uuid-7f6bc2bf337f442db427e7f82d58c151,OS,0.906269
uuid-7f6bc2bf337f442db427e7f82d58c151,data,0.536244
uuid-7f6bc2bf337f442db427e7f82d58c151,PFS,0.870192
uuid-7f6bc2bf337f442db427e7f82d58c151,ORR,0.746105
uuid-7f6bc2bf337f442db427e7f82d58c151,nivo and pembro,0.363684
uuid-7f6bc2bf337f442db427e7f82d58c151,believes,0.342519
uuid-7f6bc2bf337f442db427e7f82d58c151,impressed,0.423322
uuid-7f6bc2bf337f442db427e7f82d58c151,feels,0.343873
uuid-7f6bc2bf337f442db427e7f82d58c151,PDL1 expression,0.33934
uuid-b4cd8478cbbf455d8a2721195ae7d41d,patients,0.629782
uuid-b4cd8478cbbf455d8a2721195ae7d41d,Opdivo,0.409277
uuid-b4cd8478cbbf455d8a2721195ae7d41d,dose,0.357232
uuid-b4cd8478cbbf455d8a2721195ae7d41d,pts,0.349059
uuid-b4cd8478cbbf455d8a2721195ae7d41d,treatment,0.397357
uuid-b4cd8478cbbf455d8a2721195ae7d41d,using nivo,0.339281
uuid-b4cd8478cbbf455d8a2721195ae7d41d,progression,0.360792
uuid-b4cd8478cbbf455d8a2721195ae7d41d,respond,0.344073
uuid-90a6fcc5f04148ecaf50b920819fcda2,Nivo,0.379578
uuid-90a6fcc5f04148ecaf50b920819fcda2,pembro,0.462581
uuid-90a6fcc5f04148ecaf50b920819fcda2,trial,0.432372
uuid-90a6fcc5f04148ecaf50b920819fcda2,commented,0.347079
uuid-90a6fcc5f04148ecaf50b920819fcda2,stated,0.510057
uuid-90a6fcc5f04148ecaf50b920819fcda2,approval,0.435934
uuid-90a6fcc5f04148ecaf50b920819fcda2,OS,0.348612
uuid-90a6fcc5f04148ecaf50b920819fcda2,atezo,0.36029
uuid-90a6fcc5f04148ecaf50b920819fcda2,using nivo,0.335106
uuid-90a6fcc5f04148ecaf50b920819fcda2,data,0.612588
uuid-90a6fcc5f04148ecaf50b920819fcda2,indication,0.308359
uuid-90a6fcc5f04148ecaf50b920819fcda2,PFS,0.334554
uuid-90a6fcc5f04148ecaf50b920819fcda2,ORR,0.347834
uuid-90a6fcc5f04148ecaf50b920819fcda2,approved,0.383964
uuid-90a6fcc5f04148ecaf50b920819fcda2,SCCHN,0.367776
uuid-90a6fcc5f04148ecaf50b920819fcda2,nivo and pembro,0.368336
uuid-90a6fcc5f04148ecaf50b920819fcda2,impressed,0.514548
uuid-90a6fcc5f04148ecaf50b920819fcda2,label,0.319099
uuid-90a6fcc5f04148ecaf50b920819fcda2,SCLC,0.420423
uuid-90a6fcc5f04148ecaf50b920819fcda2,feels,0.376418
uuid-90a6fcc5f04148ecaf50b920819fcda2,Regional TL,0.301417
uuid-90a6fcc5f04148ecaf50b920819fcda2,NCCN,0.340618
uuid-0223c30b38944c63943ffa49b8f6bfed,PDL1,0.405063
uuid-0223c30b38944c63943ffa49b8f6bfed,OS,0.347481
uuid-0223c30b38944c63943ffa49b8f6bfed,PFS,0.343556
uuid-0223c30b38944c63943ffa49b8f6bfed,ORR,0.308703
uuid-0223c30b38944c63943ffa49b8f6bfed,believes,0.434438
uuid-0223c30b38944c63943ffa49b8f6bfed,feels,0.571252
uuid-0223c30b38944c63943ffa49b8f6bfed,PDL1 expression,0.309525
uuid-0223c30b38944c63943ffa49b8f6bfed,biomarker,0.30157
uuid-bf398560a3254ebfba32329889262971,Opdivo,0.426185
uuid-bf398560a3254ebfba32329889262971,dose,0.478742
uuid-bf398560a3254ebfba32329889262971,drug,0.638793
uuid-bf398560a3254ebfba32329889262971,Keytruda,0.339455
uuid-bf398560a3254ebfba32329889262971,flat dosing,0.508522
uuid-47b6d3ee35ab4d7384dbdba700507780,Opdivo,0.303705
uuid-47b6d3ee35ab4d7384dbdba700507780,dose,0.588209
uuid-47b6d3ee35ab4d7384dbdba700507780,toxicity,0.569857
uuid-47b6d3ee35ab4d7384dbdba700507780,regimen,0.444272
uuid-47b6d3ee35ab4d7384dbdba700507780,treated,0.353538
uuid-47b6d3ee35ab4d7384dbdba700507780,physicians,0.438715
uuid-47b6d3ee35ab4d7384dbdba700507780,treatment,0.421424
uuid-47b6d3ee35ab4d7384dbdba700507780,respond,0.301448
uuid-934a2e6c7ab04b6b8aac6811b614d245,RTL,0.332099
uuid-934a2e6c7ab04b6b8aac6811b614d245,BMS,0.393475
uuid-934a2e6c7ab04b6b8aac6811b614d245,shared,0.417322
uuid-934a2e6c7ab04b6b8aac6811b614d245,commented,0.368635
uuid-934a2e6c7ab04b6b8aac6811b614d245,stated,0.537582
uuid-934a2e6c7ab04b6b8aac6811b614d245,physicians,0.381212
uuid-934a2e6c7ab04b6b8aac6811b614d245,clinical trials,0.384436
uuid-934a2e6c7ab04b6b8aac6811b614d245,SCCHN,0.30204
uuid-934a2e6c7ab04b6b8aac6811b614d245,impressed,0.34764
uuid-934a2e6c7ab04b6b8aac6811b614d245,LTL,0.302835
uuid-934a2e6c7ab04b6b8aac6811b614d245,Regional TL,0.432827
uuid-934a2e6c7ab04b6b8aac6811b614d245,flat dosing,0.330353
uuid-3596d0e99b7e489b9d34d4dfff570c5b,Nivo,0.412058
uuid-3596d0e99b7e489b9d34d4dfff570c5b,patients,0.670597
uuid-3596d0e99b7e489b9d34d4dfff570c5b,therapy,0.382828
uuid-3596d0e99b7e489b9d34d4dfff570c5b,nivolumab,0.311595
uuid-3596d0e99b7e489b9d34d4dfff570c5b,1L,0.365034
uuid-3596d0e99b7e489b9d34d4dfff570c5b,regimen,0.312621
uuid-3596d0e99b7e489b9d34d4dfff570c5b,treated,0.305123
uuid-3596d0e99b7e489b9d34d4dfff570c5b,chemo,0.337517
uuid-3596d0e99b7e489b9d34d4dfff570c5b,2L,0.302152
uuid-3596d0e99b7e489b9d34d4dfff570c5b,pts,0.608821
uuid-3596d0e99b7e489b9d34d4dfff570c5b,monotherapy,0.408906
uuid-3596d0e99b7e489b9d34d4dfff570c5b,using nivo,0.369396
uuid-3596d0e99b7e489b9d34d4dfff570c5b,response,0.388
uuid-3596d0e99b7e489b9d34d4dfff570c5b,NSCLC patients,0.346775
uuid-3596d0e99b7e489b9d34d4dfff570c5b,PD1,0.316612
uuid-3596d0e99b7e489b9d34d4dfff570c5b,progression,0.513882
uuid-3596d0e99b7e489b9d34d4dfff570c5b,respond,0.387558
uuid-3596d0e99b7e489b9d34d4dfff570c5b,option,0.336576
uuid-f634d446835c48e282f21b1ea5f26dfa,patients,0.61548
uuid-f634d446835c48e282f21b1ea5f26dfa,Opdivo,0.676565
uuid-f634d446835c48e282f21b1ea5f26dfa,therapy,0.351002
uuid-f634d446835c48e282f21b1ea5f26dfa,nivolumab,0.321164
uuid-f634d446835c48e282f21b1ea5f26dfa,regimen,0.355404
uuid-f634d446835c48e282f21b1ea5f26dfa,treated,0.35695
uuid-f634d446835c48e282f21b1ea5f26dfa,pts,0.337119
uuid-f634d446835c48e282f21b1ea5f26dfa,treatment,0.421524
uuid-f634d446835c48e282f21b1ea5f26dfa,mentioned,0.310774
uuid-f634d446835c48e282f21b1ea5f26dfa,cHL,0.323061
uuid-f634d446835c48e282f21b1ea5f26dfa,progression,0.418832
uuid-f634d446835c48e282f21b1ea5f26dfa,Keytruda,0.332224
uuid-26b67e303b014a52ac0e1e09a79e0a02,Opdivo,0.423558
uuid-26b67e303b014a52ac0e1e09a79e0a02,TL,0.346513
uuid-26b67e303b014a52ac0e1e09a79e0a02,commented,0.408668
uuid-26b67e303b014a52ac0e1e09a79e0a02,TL stated,0.342719
uuid-26b67e303b014a52ac0e1e09a79e0a02,physicians,0.43688
uuid-26b67e303b014a52ac0e1e09a79e0a02,mentioned,0.498962
uuid-26b67e303b014a52ac0e1e09a79e0a02,ASCO,0.337591
uuid-26b67e303b014a52ac0e1e09a79e0a02,Keytruda,0.328248
uuid-26b67e303b014a52ac0e1e09a79e0a02,Regional TL,0.306751
uuid-359bfee95f9f4689a15f6b68675273ae,patients,0.425726
uuid-359bfee95f9f4689a15f6b68675273ae,1L,0.351572
uuid-359bfee95f9f4689a15f6b68675273ae,TL stated,0.310042
uuid-359bfee95f9f4689a15f6b68675273ae,2L,0.321836
uuid-359bfee95f9f4689a15f6b68675273ae,PD-L1,0.430136
uuid-359bfee95f9f4689a15f6b68675273ae,approval,0.312317
uuid-359bfee95f9f4689a15f6b68675273ae,preferred,0.320905
uuid-359bfee95f9f4689a15f6b68675273ae,PD-L1 testing,0.421141
uuid-359bfee95f9f4689a15f6b68675273ae,testing,0.550641
uuid-359bfee95f9f4689a15f6b68675273ae,PDL1 testing,0.519378
uuid-359bfee95f9f4689a15f6b68675273ae,NSCLC patients,0.589186
uuid-359bfee95f9f4689a15f6b68675273ae,approved,0.362368
uuid-359bfee95f9f4689a15f6b68675273ae,tumor types,0.448573
uuid-359bfee95f9f4689a15f6b68675273ae,option,0.420047
uuid-3dc50d415a9844039a151b060de9185b,nivolumab,0.501713
uuid-3dc50d415a9844039a151b060de9185b,lung,0.335564
uuid-3dc50d415a9844039a151b060de9185b,1L,0.528539
uuid-3dc50d415a9844039a151b060de9185b,RCC,0.759828
uuid-3dc50d415a9844039a151b060de9185b,TL stated,0.445641
uuid-3dc50d415a9844039a151b060de9185b,combination,0.347226
uuid-3dc50d415a9844039a151b060de9185b,2L,0.654511
uuid-3dc50d415a9844039a151b060de9185b,agents,0.40992
uuid-3dc50d415a9844039a151b060de9185b,approval,0.357187
uuid-3dc50d415a9844039a151b060de9185b,preferred,0.668905
uuid-3dc50d415a9844039a151b060de9185b,monotherapy,0.512687
uuid-3dc50d415a9844039a151b060de9185b,using nivo,0.706754
uuid-3dc50d415a9844039a151b060de9185b,combo,0.342547
uuid-3dc50d415a9844039a151b060de9185b,PDL1 testing,0.319436
uuid-3dc50d415a9844039a151b060de9185b,approved,0.45066
uuid-3dc50d415a9844039a151b060de9185b,SCCHN,0.56495
uuid-3dc50d415a9844039a151b060de9185b,tumor types,0.356017
uuid-3dc50d415a9844039a151b060de9185b,oncologist,0.317893
uuid-3dc50d415a9844039a151b060de9185b,LTL,0.324155
uuid-3dc50d415a9844039a151b060de9185b,TLs,0.312732
uuid-3dc50d415a9844039a151b060de9185b,Regional TL,0.445335
uuid-3dc50d415a9844039a151b060de9185b,RTL stated,0.72324
uuid-3dc50d415a9844039a151b060de9185b,TL shared,0.468689
uuid-3dc50d415a9844039a151b060de9185b,option,0.49884
uuid-3dc50d415a9844039a151b060de9185b,bladder,0.442945
uuid-fc6967a86f3642f3895bd579014bc79b,lung,0.526934
uuid-fc6967a86f3642f3895bd579014bc79b,melanoma,0.398749
uuid-fc6967a86f3642f3895bd579014bc79b,institution,0.480219
uuid-fc6967a86f3642f3895bd579014bc79b,AI,0.703441
uuid-fc6967a86f3642f3895bd579014bc79b,oncology,0.566534
uuid-fc6967a86f3642f3895bd579014bc79b,clinical,0.377582
uuid-fc6967a86f3642f3895bd579014bc79b,NCCN,0.359809
uuid-9fb2e603238e49388ec176682c516119,Opdivo,0.427725
uuid-9fb2e603238e49388ec176682c516119,dose,0.370674
uuid-9fb2e603238e49388ec176682c516119,approval,0.438132
uuid-9fb2e603238e49388ec176682c516119,indication,0.406192
uuid-9fb2e603238e49388ec176682c516119,approved,0.531283
uuid-9fb2e603238e49388ec176682c516119,label,0.413527
uuid-9fb2e603238e49388ec176682c516119,Keytruda,0.32453
uuid-9fb2e603238e49388ec176682c516119,flat dosing,0.608343
uuid-a2505c6397f64c2fa55e52899189fdae,Opdivo,0.436513
uuid-a2505c6397f64c2fa55e52899189fdae,nivolumab,0.349451
uuid-a2505c6397f64c2fa55e52899189fdae,regimen,0.319181
uuid-a2505c6397f64c2fa55e52899189fdae,treated,0.345683
uuid-a2505c6397f64c2fa55e52899189fdae,shared,0.370257
uuid-a2505c6397f64c2fa55e52899189fdae,RCC,0.382762
uuid-a2505c6397f64c2fa55e52899189fdae,stated,0.340254
uuid-a2505c6397f64c2fa55e52899189fdae,physicians,0.490639
uuid-a2505c6397f64c2fa55e52899189fdae,preferred,0.393662
uuid-a2505c6397f64c2fa55e52899189fdae,treatment,0.324248
uuid-a2505c6397f64c2fa55e52899189fdae,using nivo,0.358495
uuid-a2505c6397f64c2fa55e52899189fdae,approved,0.305432
uuid-a2505c6397f64c2fa55e52899189fdae,SCCHN,0.349215
uuid-a2505c6397f64c2fa55e52899189fdae,LTL,0.303075
uuid-a2505c6397f64c2fa55e52899189fdae,Regional TL,0.332393
uuid-a2505c6397f64c2fa55e52899189fdae,RTL stated,0.41983
uuid-a2505c6397f64c2fa55e52899189fdae,TL shared,0.315116
uuid-a2505c6397f64c2fa55e52899189fdae,option,0.340918
uuid-4a88326747a9401c8be97f2105470118,Nivo,0.397562
uuid-4a88326747a9401c8be97f2105470118,pembro,0.438655
uuid-4a88326747a9401c8be97f2105470118,BMS,0.488759
uuid-4a88326747a9401c8be97f2105470118,PDL1,0.452896
uuid-4a88326747a9401c8be97f2105470118,trial,0.442952
uuid-4a88326747a9401c8be97f2105470118,efficacy,0.542531
uuid-4a88326747a9401c8be97f2105470118,agents,0.355743
uuid-4a88326747a9401c8be97f2105470118,Merck,0.311971
uuid-4a88326747a9401c8be97f2105470118,OS,0.424509
uuid-4a88326747a9401c8be97f2105470118,atezo,0.391736
uuid-4a88326747a9401c8be97f2105470118,data,0.560373
uuid-4a88326747a9401c8be97f2105470118,expressed,0.326322
uuid-4a88326747a9401c8be97f2105470118,PFS,0.448544
uuid-4a88326747a9401c8be97f2105470118,ORR,0.467832
uuid-4a88326747a9401c8be97f2105470118,nivo and pembro,0.570829
uuid-4a88326747a9401c8be97f2105470118,believes,0.394817
uuid-4a88326747a9401c8be97f2105470118,impressed,0.442596
uuid-4a88326747a9401c8be97f2105470118,feels,0.706718
uuid-4a88326747a9401c8be97f2105470118,PDL1 expression,0.448912
uuid-d472776e22d743b39a9175a706b010dd,patients,0.345484
uuid-d472776e22d743b39a9175a706b010dd,therapy,0.460203
uuid-d472776e22d743b39a9175a706b010dd,nivolumab,0.419023
uuid-d472776e22d743b39a9175a706b010dd,regimen,0.35132
uuid-d472776e22d743b39a9175a706b010dd,treated,0.413541
uuid-d472776e22d743b39a9175a706b010dd,melanoma,0.406702
uuid-d472776e22d743b39a9175a706b010dd,RCC,0.449042
uuid-d472776e22d743b39a9175a706b010dd,combination,0.351788
uuid-d472776e22d743b39a9175a706b010dd,stated,0.300584
uuid-d472776e22d743b39a9175a706b010dd,monotherapy,0.312256
uuid-d472776e22d743b39a9175a706b010dd,treatment,0.438383
uuid-d472776e22d743b39a9175a706b010dd,using nivo,0.337246
uuid-d472776e22d743b39a9175a706b010dd,combo,0.314861
uuid-d472776e22d743b39a9175a706b010dd,PD1,0.373762
uuid-d472776e22d743b39a9175a706b010dd,SCCHN,0.3797
uuid-d472776e22d743b39a9175a706b010dd,progression,0.327099
uuid-d472776e22d743b39a9175a706b010dd,chemotherapy,0.380462
uuid-d472776e22d743b39a9175a706b010dd,tumor types,0.300652
uuid-d472776e22d743b39a9175a706b010dd,RTL stated,0.421206
uuid-d472776e22d743b39a9175a706b010dd,TL shared,0.31444
uuid-d472776e22d743b39a9175a706b010dd,option,0.388222
uuid-d472776e22d743b39a9175a706b010dd,bladder,0.328119
uuid-9c2a53ea88cf4dbebef6d136baee06dd,patients,0.750852
uuid-9c2a53ea88cf4dbebef6d136baee06dd,Opdivo,0.475797
uuid-9c2a53ea88cf4dbebef6d136baee06dd,therapy,0.378178
uuid-9c2a53ea88cf4dbebef6d136baee06dd,toxicity,0.349002
uuid-9c2a53ea88cf4dbebef6d136baee06dd,regimen,0.475275
uuid-9c2a53ea88cf4dbebef6d136baee06dd,treated,0.488755
uuid-9c2a53ea88cf4dbebef6d136baee06dd,pts,0.369304
uuid-9c2a53ea88cf4dbebef6d136baee06dd,physicians,0.438621
uuid-9c2a53ea88cf4dbebef6d136baee06dd,treatment,0.746883
uuid-9c2a53ea88cf4dbebef6d136baee06dd,progression,0.523895
uuid-9c2a53ea88cf4dbebef6d136baee06dd,respond,0.544234
uuid-d3713243ad3a403498ec51014fba0270,patients,0.642042
uuid-d3713243ad3a403498ec51014fba0270,therapy,0.685045
uuid-d3713243ad3a403498ec51014fba0270,nivolumab,0.479817
uuid-d3713243ad3a403498ec51014fba0270,regimen,0.317342
uuid-d3713243ad3a403498ec51014fba0270,treated,0.385099
uuid-d3713243ad3a403498ec51014fba0270,combination,0.316081
uuid-d3713243ad3a403498ec51014fba0270,chemo,0.384294
uuid-d3713243ad3a403498ec51014fba0270,pts,0.390074
uuid-d3713243ad3a403498ec51014fba0270,monotherapy,0.357963
uuid-d3713243ad3a403498ec51014fba0270,treatment,0.534304
uuid-d3713243ad3a403498ec51014fba0270,response,0.490064
uuid-d3713243ad3a403498ec51014fba0270,PD1,0.385069
uuid-d3713243ad3a403498ec51014fba0270,cHL,0.379457
uuid-d3713243ad3a403498ec51014fba0270,progression,0.559566
uuid-d3713243ad3a403498ec51014fba0270,chemotherapy,0.492354
uuid-d3713243ad3a403498ec51014fba0270,respond,0.328904
uuid-d3713243ad3a403498ec51014fba0270,option,0.353763
uuid-e28387242c5449c1abfe33bc0ed4b5b3,patients,0.952418
uuid-e28387242c5449c1abfe33bc0ed4b5b3,Opdivo,0.583903
uuid-e28387242c5449c1abfe33bc0ed4b5b3,therapy,0.56208
uuid-e28387242c5449c1abfe33bc0ed4b5b3,nivolumab,0.492398
uuid-e28387242c5449c1abfe33bc0ed4b5b3,regimen,0.538718
uuid-e28387242c5449c1abfe33bc0ed4b5b3,treated,0.595962
uuid-e28387242c5449c1abfe33bc0ed4b5b3,chemo,0.345202
uuid-e28387242c5449c1abfe33bc0ed4b5b3,pts,0.612252
uuid-e28387242c5449c1abfe33bc0ed4b5b3,monotherapy,0.377345
uuid-e28387242c5449c1abfe33bc0ed4b5b3,treatment,0.714615
uuid-e28387242c5449c1abfe33bc0ed4b5b3,using nivo,0.300019
uuid-e28387242c5449c1abfe33bc0ed4b5b3,response,0.370097
uuid-e28387242c5449c1abfe33bc0ed4b5b3,cHL,0.308994
uuid-e28387242c5449c1abfe33bc0ed4b5b3,progression,0.673926
uuid-e28387242c5449c1abfe33bc0ed4b5b3,chemotherapy,0.388081
uuid-e28387242c5449c1abfe33bc0ed4b5b3,respond,0.510353
uuid-e28387242c5449c1abfe33bc0ed4b5b3,option,0.37061
uuid-76b30ca3cd224328bfd8d001799917ca,patients,0.381337
uuid-76b30ca3cd224328bfd8d001799917ca,toxicity,0.365777
uuid-76b30ca3cd224328bfd8d001799917ca,physicians,0.338675
uuid-76b30ca3cd224328bfd8d001799917ca,treatment,0.322342
uuid-d1e0491e70194941a514b4b52f27b80c,Nivo,0.670769
uuid-d1e0491e70194941a514b4b52f27b80c,patients,0.573468
uuid-d1e0491e70194941a514b4b52f27b80c,pembro,0.40571
uuid-d1e0491e70194941a514b4b52f27b80c,therapy,0.371351
uuid-d1e0491e70194941a514b4b52f27b80c,nivolumab,0.484505
uuid-d1e0491e70194941a514b4b52f27b80c,regimen,0.425594
uuid-d1e0491e70194941a514b4b52f27b80c,combination,0.357176
uuid-d1e0491e70194941a514b4b52f27b80c,chemo,0.358647
uuid-d1e0491e70194941a514b4b52f27b80c,2L,0.327777
uuid-d1e0491e70194941a514b4b52f27b80c,pts,0.468507
uuid-d1e0491e70194941a514b4b52f27b80c,Ipi,0.611962
uuid-d1e0491e70194941a514b4b52f27b80c,approval,0.370046
uuid-d1e0491e70194941a514b4b52f27b80c,monotherapy,0.461221
uuid-d1e0491e70194941a514b4b52f27b80c,treatment,0.309603
uuid-d1e0491e70194941a514b4b52f27b80c,using nivo,0.543923
uuid-d1e0491e70194941a514b4b52f27b80c,combo,0.336486
uuid-d1e0491e70194941a514b4b52f27b80c,PD1,0.311178
uuid-d1e0491e70194941a514b4b52f27b80c,approved,0.333548
uuid-d1e0491e70194941a514b4b52f27b80c,progression,0.335425
uuid-d1e0491e70194941a514b4b52f27b80c,chemotherapy,0.347716
uuid-d1e0491e70194941a514b4b52f27b80c,SCLC,0.533714
uuid-d1e0491e70194941a514b4b52f27b80c,RTL stated,0.327635
uuid-d1e0491e70194941a514b4b52f27b80c,option,0.385941
uuid-bb52026ce6d84e0da92487afbd63e754,Nivo,0.318316
uuid-bb52026ce6d84e0da92487afbd63e754,pembro,0.43965
uuid-bb52026ce6d84e0da92487afbd63e754,trial,0.508322
uuid-bb52026ce6d84e0da92487afbd63e754,efficacy,0.494926
uuid-bb52026ce6d84e0da92487afbd63e754,Ipi,0.353316
uuid-bb52026ce6d84e0da92487afbd63e754,OS,0.370973
uuid-bb52026ce6d84e0da92487afbd63e754,atezo,0.451426
uuid-bb52026ce6d84e0da92487afbd63e754,data,0.413366
uuid-bb52026ce6d84e0da92487afbd63e754,clinical trials,0.378095
uuid-bb52026ce6d84e0da92487afbd63e754,indication,0.38652
uuid-bb52026ce6d84e0da92487afbd63e754,PFS,0.344655
uuid-bb52026ce6d84e0da92487afbd63e754,ORR,0.412801
uuid-bb52026ce6d84e0da92487afbd63e754,nivo and pembro,0.373551
uuid-bb52026ce6d84e0da92487afbd63e754,impressed,0.33433
uuid-bb52026ce6d84e0da92487afbd63e754,vs,0.374651
uuid-bb52026ce6d84e0da92487afbd63e754,TLs,0.403895
uuid-bb52026ce6d84e0da92487afbd63e754,bladder,0.358514
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,Nivo,0.382053
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,patients,0.701574
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,Opdivo,0.361385
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,therapy,0.477503
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,nivolumab,0.497679
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,toxicity,0.364373
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,regimen,0.554768
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,treated,0.497918
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,chemo,0.353271
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,pts,0.421367
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,monotherapy,0.419843
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,treatment,0.571277
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,using nivo,0.349632
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,cHL,0.426217
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,progression,0.397997
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,chemotherapy,0.450838
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,respond,0.326117
uuid-853c4214e2fb4c46a3d7f02d96b25dfc,option,0.395806
uuid-49bed9e172024d0ea77c46934d02b6b8,patients,0.685938
uuid-49bed9e172024d0ea77c46934d02b6b8,Opdivo,0.792565
uuid-49bed9e172024d0ea77c46934d02b6b8,therapy,0.362253
uuid-49bed9e172024d0ea77c46934d02b6b8,nivolumab,0.487911
uuid-49bed9e172024d0ea77c46934d02b6b8,regimen,0.309465
uuid-49bed9e172024d0ea77c46934d02b6b8,treated,0.444338
uuid-49bed9e172024d0ea77c46934d02b6b8,pts,0.399955
uuid-49bed9e172024d0ea77c46934d02b6b8,approval,0.436618
uuid-49bed9e172024d0ea77c46934d02b6b8,preferred,0.318803
uuid-49bed9e172024d0ea77c46934d02b6b8,treatment,0.47106
uuid-49bed9e172024d0ea77c46934d02b6b8,using nivo,0.424661
uuid-49bed9e172024d0ea77c46934d02b6b8,approved,0.432085
uuid-49bed9e172024d0ea77c46934d02b6b8,cHL,0.356211
uuid-49bed9e172024d0ea77c46934d02b6b8,progression,0.303762
uuid-49bed9e172024d0ea77c46934d02b6b8,label,0.38257
uuid-49bed9e172024d0ea77c46934d02b6b8,Keytruda,0.535693
uuid-49bed9e172024d0ea77c46934d02b6b8,option,0.329772
uuid-49bed9e172024d0ea77c46934d02b6b8,flat dosing,0.306224
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,patients,0.671933
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,Opdivo,0.34032
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,therapy,0.683467
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,nivolumab,0.45527
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,regimen,0.532163
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,treated,0.543984
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,melanoma,0.320619
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,chemo,0.379563
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,pts,0.590241
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,monotherapy,0.43488
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,treatment,0.729719
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,response,0.577873
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,PD1,0.534007
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,cHL,0.337949
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,progression,0.805418
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,chemotherapy,0.422551
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,respond,0.572246
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,TL shared,0.332822
uuid-fb0b5eb17fc54050acb8711b9a8f6e11,option,0.342863
uuid-feacaa5bf2874f0da225163940bda21d,BMS,0.360511
uuid-feacaa5bf2874f0da225163940bda21d,1L,0.316722
uuid-feacaa5bf2874f0da225163940bda21d,PDL1,0.638025
uuid-feacaa5bf2874f0da225163940bda21d,efficacy,0.397454
uuid-feacaa5bf2874f0da225163940bda21d,commented,0.341287
uuid-feacaa5bf2874f0da225163940bda21d,Merck,0.321645
uuid-feacaa5bf2874f0da225163940bda21d,OS,0.460006
uuid-feacaa5bf2874f0da225163940bda21d,data,0.686162
uuid-feacaa5bf2874f0da225163940bda21d,PFS,0.426359
uuid-feacaa5bf2874f0da225163940bda21d,ORR,0.422704
uuid-feacaa5bf2874f0da225163940bda21d,nivo and pembro,0.462505
uuid-feacaa5bf2874f0da225163940bda21d,believes,0.40226
uuid-feacaa5bf2874f0da225163940bda21d,impressed,0.429027
uuid-feacaa5bf2874f0da225163940bda21d,feels,0.42853
uuid-feacaa5bf2874f0da225163940bda21d,PDL1 expression,0.491466
uuid-feacaa5bf2874f0da225163940bda21d,biomarker,0.412202
uuid-338aa466aa1f4a06a2262f45f7c23140,patients,0.351721
uuid-338aa466aa1f4a06a2262f45f7c23140,therapy,0.365942
uuid-338aa466aa1f4a06a2262f45f7c23140,chemo,0.358774
uuid-338aa466aa1f4a06a2262f45f7c23140,PD1,0.33378
uuid-338aa466aa1f4a06a2262f45f7c23140,progression,0.42455
uuid-338aa466aa1f4a06a2262f45f7c23140,chemotherapy,0.364188
uuid-338aa466aa1f4a06a2262f45f7c23140,vs,0.343461
uuid-455f5813f9d54e228c1fd7f30cb6c141,1L,0.461853
uuid-455f5813f9d54e228c1fd7f30cb6c141,PDL1,0.804222
uuid-455f5813f9d54e228c1fd7f30cb6c141,TL stated,0.374474
uuid-455f5813f9d54e228c1fd7f30cb6c141,2L,0.319923
uuid-455f5813f9d54e228c1fd7f30cb6c141,PD-L1,0.611081
uuid-455f5813f9d54e228c1fd7f30cb6c141,testing,0.513805
uuid-455f5813f9d54e228c1fd7f30cb6c141,PDL1 testing,0.515289
uuid-455f5813f9d54e228c1fd7f30cb6c141,NSCLC patients,0.460995
uuid-455f5813f9d54e228c1fd7f30cb6c141,nivo and pembro,0.436689
uuid-455f5813f9d54e228c1fd7f30cb6c141,believes,0.384298
uuid-455f5813f9d54e228c1fd7f30cb6c141,tumor types,0.43628
uuid-455f5813f9d54e228c1fd7f30cb6c141,assay,0.376394
uuid-455f5813f9d54e228c1fd7f30cb6c141,PDL1 expression,0.688346
uuid-455f5813f9d54e228c1fd7f30cb6c141,biomarker,0.666615
uuid-5dcda886caea48a0a7e38685d5f59b60,lung,0.448692
uuid-5dcda886caea48a0a7e38685d5f59b60,1L,0.546109
uuid-5dcda886caea48a0a7e38685d5f59b60,regimen,0.318897
uuid-5dcda886caea48a0a7e38685d5f59b60,melanoma,0.31317
uuid-5dcda886caea48a0a7e38685d5f59b60,RCC,0.454179
uuid-5dcda886caea48a0a7e38685d5f59b60,TL stated,0.390709
uuid-5dcda886caea48a0a7e38685d5f59b60,chemo,0.35016
uuid-5dcda886caea48a0a7e38685d5f59b60,2L,0.479853
uuid-5dcda886caea48a0a7e38685d5f59b60,agents,0.346108
uuid-5dcda886caea48a0a7e38685d5f59b60,preferred,0.371621
uuid-5dcda886caea48a0a7e38685d5f59b60,monotherapy,0.484325
uuid-5dcda886caea48a0a7e38685d5f59b60,combo,0.411844
uuid-5dcda886caea48a0a7e38685d5f59b60,PDL1 testing,0.327045
uuid-5dcda886caea48a0a7e38685d5f59b60,AI,0.330796
uuid-5dcda886caea48a0a7e38685d5f59b60,believes,0.353499
uuid-5dcda886caea48a0a7e38685d5f59b60,chemotherapy,0.340371
uuid-5dcda886caea48a0a7e38685d5f59b60,tumor types,0.321979
uuid-5dcda886caea48a0a7e38685d5f59b60,TL shared,0.353801
uuid-5dcda886caea48a0a7e38685d5f59b60,option,0.552324
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,Nivo,0.413443
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,patients,0.314094
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,pembro,0.415064
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,1L,0.499892
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,chemo,0.497268
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,2L,0.520531
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,pts,0.340942
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,agents,0.384964
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,atezo,0.381489
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,preferred,0.415438
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,monotherapy,0.490189
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,using nivo,0.394282
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,combo,0.445683
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,PD1,0.430158
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,nivo and pembro,0.38744
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,believes,0.441632
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,chemotherapy,0.341664
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,vs,0.330464
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,respond,0.306815
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,feels,0.465119
uuid-b032abdeb55e4449bdeb1e8aad9cd1d2,option,0.550011
uuid-d9a84dda5db243daa54cb685253c7add,patients,0.561451
uuid-d9a84dda5db243daa54cb685253c7add,Opdivo,0.330762
uuid-d9a84dda5db243daa54cb685253c7add,therapy,0.49379
uuid-d9a84dda5db243daa54cb685253c7add,dose,0.313184
uuid-d9a84dda5db243daa54cb685253c7add,toxicity,0.569473
uuid-d9a84dda5db243daa54cb685253c7add,regimen,0.743275
uuid-d9a84dda5db243daa54cb685253c7add,treated,0.417302
uuid-d9a84dda5db243daa54cb685253c7add,combination,0.405261
uuid-d9a84dda5db243daa54cb685253c7add,chemo,0.477275
uuid-d9a84dda5db243daa54cb685253c7add,pts,0.413731
uuid-d9a84dda5db243daa54cb685253c7add,IO,0.348105
uuid-d9a84dda5db243daa54cb685253c7add,monotherapy,0.521075
uuid-d9a84dda5db243daa54cb685253c7add,treatment,0.724624
uuid-d9a84dda5db243daa54cb685253c7add,response,0.452372
uuid-d9a84dda5db243daa54cb685253c7add,combo,0.38153
uuid-d9a84dda5db243daa54cb685253c7add,PD1,0.385446
uuid-d9a84dda5db243daa54cb685253c7add,progression,0.602463
uuid-d9a84dda5db243daa54cb685253c7add,chemotherapy,0.476448
uuid-d9a84dda5db243daa54cb685253c7add,respond,0.637425
uuid-d9a84dda5db243daa54cb685253c7add,option,0.444547
uuid-e95f4be06eea4091add725761de0b1a6,Nivo,0.312504
uuid-e95f4be06eea4091add725761de0b1a6,BMS,0.302905
uuid-e95f4be06eea4091add725761de0b1a6,trial,0.784402
uuid-e95f4be06eea4091add725761de0b1a6,combination,0.431985
uuid-e95f4be06eea4091add725761de0b1a6,Ipi,0.342479
uuid-e95f4be06eea4091add725761de0b1a6,combo,0.34422
uuid-e95f4be06eea4091add725761de0b1a6,clinical trials,0.387408
uuid-e95f4be06eea4091add725761de0b1a6,chemotherapy,0.36637
uuid-e95f4be06eea4091add725761de0b1a6,feels,0.328966
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,BMS,0.763618
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,trial,0.741081
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,commented,0.305004
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,Merck,0.724356
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,data,0.495656
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,expressed,0.343183
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,clinical trials,0.438328
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,indication,0.307539
uuid-b8c42218fdbf46cb9c6ce16bfaa5cdd8,impressed,0.364285
uuid-cfb5a917ae374fcb92630b9a2d4b8404,Nivo,0.50904
uuid-cfb5a917ae374fcb92630b9a2d4b8404,pembro,0.440997
uuid-cfb5a917ae374fcb92630b9a2d4b8404,PDL1,0.472056
uuid-cfb5a917ae374fcb92630b9a2d4b8404,trial,0.451462
uuid-cfb5a917ae374fcb92630b9a2d4b8404,efficacy,0.733221
uuid-cfb5a917ae374fcb92630b9a2d4b8404,chemo,0.347741
uuid-cfb5a917ae374fcb92630b9a2d4b8404,OS,0.687559
uuid-cfb5a917ae374fcb92630b9a2d4b8404,atezo,0.377988
uuid-cfb5a917ae374fcb92630b9a2d4b8404,data,0.716614
uuid-cfb5a917ae374fcb92630b9a2d4b8404,PFS,0.641275
uuid-cfb5a917ae374fcb92630b9a2d4b8404,ORR,0.689065
uuid-cfb5a917ae374fcb92630b9a2d4b8404,nivo and pembro,0.600125
uuid-cfb5a917ae374fcb92630b9a2d4b8404,believes,0.465809
uuid-cfb5a917ae374fcb92630b9a2d4b8404,impressed,0.52727
uuid-cfb5a917ae374fcb92630b9a2d4b8404,vs,0.351644
uuid-cfb5a917ae374fcb92630b9a2d4b8404,feels,0.44474
uuid-cfb5a917ae374fcb92630b9a2d4b8404,PDL1 expression,0.400841
uuid-27aab07cbf554a229fe304732b80b96a,patients,0.845607
uuid-27aab07cbf554a229fe304732b80b96a,Opdivo,0.676077
uuid-27aab07cbf554a229fe304732b80b96a,therapy,0.430384
uuid-27aab07cbf554a229fe304732b80b96a,nivolumab,0.428134
uuid-27aab07cbf554a229fe304732b80b96a,regimen,0.378694
uuid-27aab07cbf554a229fe304732b80b96a,treated,0.526647
uuid-27aab07cbf554a229fe304732b80b96a,pts,0.515998
uuid-27aab07cbf554a229fe304732b80b96a,approval,0.309887
uuid-27aab07cbf554a229fe304732b80b96a,treatment,0.581734
uuid-27aab07cbf554a229fe304732b80b96a,cHL,0.39976
uuid-27aab07cbf554a229fe304732b80b96a,progression,0.566903
uuid-27aab07cbf554a229fe304732b80b96a,respond,0.449663
uuid-5532ddb3ed844795bdc19b62bbf3db93,Nivo,0.492303
uuid-5532ddb3ed844795bdc19b62bbf3db93,pembro,0.620625
uuid-5532ddb3ed844795bdc19b62bbf3db93,dose,0.301279
uuid-5532ddb3ed844795bdc19b62bbf3db93,trial,0.307667
uuid-5532ddb3ed844795bdc19b62bbf3db93,efficacy,0.358156
uuid-5532ddb3ed844795bdc19b62bbf3db93,2L,0.342163
uuid-5532ddb3ed844795bdc19b62bbf3db93,Ipi,0.309985
uuid-5532ddb3ed844795bdc19b62bbf3db93,atezo,0.601411
uuid-5532ddb3ed844795bdc19b62bbf3db93,preferred,0.405619
uuid-5532ddb3ed844795bdc19b62bbf3db93,nivo and pembro,0.574967
uuid-5532ddb3ed844795bdc19b62bbf3db93,vs,0.57942
uuid-5532ddb3ed844795bdc19b62bbf3db93,feels,0.364254
uuid-1b4141033764462c8b9862342508f64c,pembro,0.322235
uuid-1b4141033764462c8b9862342508f64c,PDL1,0.694934
uuid-1b4141033764462c8b9862342508f64c,Merck,0.353738
uuid-1b4141033764462c8b9862342508f64c,PD-L1,0.536397
uuid-1b4141033764462c8b9862342508f64c,atezo,0.359674
uuid-1b4141033764462c8b9862342508f64c,PD-L1 testing,0.306118
uuid-1b4141033764462c8b9862342508f64c,testing,0.43724
uuid-1b4141033764462c8b9862342508f64c,PDL1 testing,0.382656
uuid-1b4141033764462c8b9862342508f64c,nivo and pembro,0.45896
uuid-1b4141033764462c8b9862342508f64c,assay,0.462272
uuid-1b4141033764462c8b9862342508f64c,PDL1 expression,0.653277
uuid-1b4141033764462c8b9862342508f64c,biomarker,0.443635
uuid-6f0b54c71ef34d8c8ef66577fa200fda,RTL,0.431729
uuid-6f0b54c71ef34d8c8ef66577fa200fda,shared,0.348841
uuid-6f0b54c71ef34d8c8ef66577fa200fda,combination,0.328618
uuid-6f0b54c71ef34d8c8ef66577fa200fda,combo,0.358152
uuid-6f0b54c71ef34d8c8ef66577fa200fda,expressed,0.353977
uuid-6f0b54c71ef34d8c8ef66577fa200fda,LTL,0.313437
uuid-6f0b54c71ef34d8c8ef66577fa200fda,TLs,0.389642
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,TL,0.492718
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,shared,0.319609
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,TL stated,0.476593
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,institution,0.549702
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,PD-L1,0.630749
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,PD-L1 testing,0.796674
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,testing,0.716521
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,PDL1 testing,0.665596
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,NSCLC patients,0.611953
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,SCCHN,0.332453
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,academic,0.366331
uuid-49d73e89c3ed4c7d80574e6f6cb60bbe,assay,0.444541
uuid-7e7f00eea9204ca595c867647bae0ca2,BMS,0.418781
uuid-7e7f00eea9204ca595c867647bae0ca2,efficacy,0.308834
uuid-7e7f00eea9204ca595c867647bae0ca2,regards,0.356965
uuid-7e7f00eea9204ca595c867647bae0ca2,indicated,0.442098
uuid-6e2ce09869e449729b251de6a45ec2a0,patients,0.62663
uuid-6e2ce09869e449729b251de6a45ec2a0,Opdivo,0.730506
uuid-6e2ce09869e449729b251de6a45ec2a0,nivolumab,0.327937
uuid-6e2ce09869e449729b251de6a45ec2a0,regimen,0.312996
uuid-6e2ce09869e449729b251de6a45ec2a0,treated,0.39281
uuid-6e2ce09869e449729b251de6a45ec2a0,pts,0.388547
uuid-6e2ce09869e449729b251de6a45ec2a0,approval,0.313506
uuid-6e2ce09869e449729b251de6a45ec2a0,treatment,0.420806
uuid-6e2ce09869e449729b251de6a45ec2a0,progression,0.348948
uuid-6e2ce09869e449729b251de6a45ec2a0,respond,0.343134
uuid-6a3fb198a5da4a04a53c5335607403dd,TL,0.547397
uuid-6a3fb198a5da4a04a53c5335607403dd,PDL1,0.529323
uuid-6a3fb198a5da4a04a53c5335607403dd,Merck,0.46699
uuid-6a3fb198a5da4a04a53c5335607403dd,PD-L1,0.684904
uuid-6a3fb198a5da4a04a53c5335607403dd,PD-L1 testing,0.579734
uuid-6a3fb198a5da4a04a53c5335607403dd,testing,0.6131
uuid-6a3fb198a5da4a04a53c5335607403dd,data,0.314636
uuid-6a3fb198a5da4a04a53c5335607403dd,PDL1 testing,0.342974
uuid-6a3fb198a5da4a04a53c5335607403dd,assay,0.902097
uuid-6a3fb198a5da4a04a53c5335607403dd,PDL1 expression,0.355281
uuid-6a3fb198a5da4a04a53c5335607403dd,biomarker,0.491572
uuid-f3750844c38245539881dc7ae775805c,BMS,0.696634
uuid-f3750844c38245539881dc7ae775805c,Merck,0.464866
uuid-f3750844c38245539881dc7ae775805c,clinical trials,0.321198
uuid-af76353c565344f79008dfdaec031937,patients,0.363655
uuid-af76353c565344f79008dfdaec031937,trial,0.388367
uuid-af76353c565344f79008dfdaec031937,treated,0.334465
uuid-af76353c565344f79008dfdaec031937,treatment,0.326636
uuid-af76353c565344f79008dfdaec031937,chemotherapy,0.330651
uuid-c0bb4e6bb9ee4fc8943781d12db90771,Nivo,0.573725
uuid-c0bb4e6bb9ee4fc8943781d12db90771,RTL,0.303866
uuid-c0bb4e6bb9ee4fc8943781d12db90771,therapy,0.337869
uuid-c0bb4e6bb9ee4fc8943781d12db90771,nivolumab,0.466818
uuid-c0bb4e6bb9ee4fc8943781d12db90771,NTL,0.314497
uuid-c0bb4e6bb9ee4fc8943781d12db90771,approval,0.310513
uuid-c0bb4e6bb9ee4fc8943781d12db90771,using nivo,0.498086
uuid-c0bb4e6bb9ee4fc8943781d12db90771,PD1,0.369419
uuid-c0bb4e6bb9ee4fc8943781d12db90771,cHL,0.619606
uuid-c0bb4e6bb9ee4fc8943781d12db90771,RTL stated,0.434566
uuid-b5cf072efb7e42238ad6dbccf2e2c129,therapy,0.360199
uuid-b5cf072efb7e42238ad6dbccf2e2c129,nivolumab,0.371411
uuid-b5cf072efb7e42238ad6dbccf2e2c129,cHL,0.481518
uuid-3201437ff6994415a0eb3af4b0aed1bb,Opdivo,0.470214
uuid-3201437ff6994415a0eb3af4b0aed1bb,pembro,0.386469
uuid-3201437ff6994415a0eb3af4b0aed1bb,dose,0.755489
uuid-3201437ff6994415a0eb3af4b0aed1bb,shared,0.421758
uuid-3201437ff6994415a0eb3af4b0aed1bb,Ipi,0.412913
uuid-3201437ff6994415a0eb3af4b0aed1bb,atezo,0.365333
uuid-3201437ff6994415a0eb3af4b0aed1bb,preferred,0.363556
uuid-3201437ff6994415a0eb3af4b0aed1bb,indication,0.333288
uuid-3201437ff6994415a0eb3af4b0aed1bb,approved,0.306426
uuid-3201437ff6994415a0eb3af4b0aed1bb,vs,0.389524
uuid-3201437ff6994415a0eb3af4b0aed1bb,drug,0.318167
uuid-3201437ff6994415a0eb3af4b0aed1bb,Keytruda,0.491668
uuid-3201437ff6994415a0eb3af4b0aed1bb,flat dosing,0.781657
uuid-dec8cb943278475189787ce510403ce8,PDL1,0.331587
uuid-dec8cb943278475189787ce510403ce8,PD-L1,0.420214
uuid-dec8cb943278475189787ce510403ce8,testing,0.537616
uuid-dec8cb943278475189787ce510403ce8,PDL1 testing,0.501102
uuid-dec8cb943278475189787ce510403ce8,NSCLC patients,0.655711
uuid-dec8cb943278475189787ce510403ce8,tumor types,0.374637
uuid-dec8cb943278475189787ce510403ce8,PD-1,0.323956
uuid-dec8cb943278475189787ce510403ce8,biomarker,0.43245
uuid-48730d701e0b479abaa72507ffeedafb,Nivo,0.461742
uuid-48730d701e0b479abaa72507ffeedafb,patients,0.354487
uuid-48730d701e0b479abaa72507ffeedafb,RTL,0.301761
uuid-48730d701e0b479abaa72507ffeedafb,regimen,0.358511
uuid-48730d701e0b479abaa72507ffeedafb,pts,0.334726
uuid-48730d701e0b479abaa72507ffeedafb,Ipi,0.49523
uuid-48730d701e0b479abaa72507ffeedafb,monotherapy,0.314244
uuid-48730d701e0b479abaa72507ffeedafb,using nivo,0.419327
uuid-48730d701e0b479abaa72507ffeedafb,mentioned,0.386181
uuid-48730d701e0b479abaa72507ffeedafb,HCP,0.593055
uuid-48730d701e0b479abaa72507ffeedafb,impressed,0.307404
uuid-48730d701e0b479abaa72507ffeedafb,SCLC,0.357496
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,patients,0.594319
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,Opdivo,0.469938
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,therapy,0.451483
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,nivolumab,0.603936
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,toxicity,0.48111
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,regimen,0.530203
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,treated,0.620815
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,physicians,0.409312
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,treatment,0.627001
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,HCP,0.313881
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,cHL,0.355289
uuid-6153ab529e9d415bb3f6970cd2dd9ed1,progression,0.420832
uuid-7aaf6e9cef1a44168d9c2daf21201208,Nivo,0.331974
uuid-7aaf6e9cef1a44168d9c2daf21201208,pembro,0.480436
uuid-7aaf6e9cef1a44168d9c2daf21201208,dose,0.873918
uuid-7aaf6e9cef1a44168d9c2daf21201208,Ipi,0.581693
uuid-7aaf6e9cef1a44168d9c2daf21201208,atezo,0.479536
uuid-7aaf6e9cef1a44168d9c2daf21201208,vs,0.684479
uuid-7aaf6e9cef1a44168d9c2daf21201208,Keytruda,0.319424
uuid-7aaf6e9cef1a44168d9c2daf21201208,flat dosing,0.764154
uuid-92dd8d6d37f0441d9e2541cb758c9e06,Opdivo,0.509511
uuid-92dd8d6d37f0441d9e2541cb758c9e06,dose,0.617606
uuid-92dd8d6d37f0441d9e2541cb758c9e06,shared,0.411054
uuid-92dd8d6d37f0441d9e2541cb758c9e06,Ipi,0.309577
uuid-92dd8d6d37f0441d9e2541cb758c9e06,approval,0.340359
uuid-92dd8d6d37f0441d9e2541cb758c9e06,indication,0.324389
uuid-92dd8d6d37f0441d9e2541cb758c9e06,approved,0.375324
uuid-92dd8d6d37f0441d9e2541cb758c9e06,HCP,0.306947
uuid-92dd8d6d37f0441d9e2541cb758c9e06,label,0.398031
uuid-92dd8d6d37f0441d9e2541cb758c9e06,Keytruda,0.370726
uuid-92dd8d6d37f0441d9e2541cb758c9e06,flat dosing,0.776661
uuid-a5588a88be484a9ba90fff8585e21e89,Nivo,0.504791
uuid-a5588a88be484a9ba90fff8585e21e89,pembro,0.712697
uuid-a5588a88be484a9ba90fff8585e21e89,dose,0.354813
uuid-a5588a88be484a9ba90fff8585e21e89,BMS,0.305661
uuid-a5588a88be484a9ba90fff8585e21e89,1L,0.314169
uuid-a5588a88be484a9ba90fff8585e21e89,trial,0.462968
uuid-a5588a88be484a9ba90fff8585e21e89,efficacy,0.577853
uuid-a5588a88be484a9ba90fff8585e21e89,2L,0.362418
uuid-a5588a88be484a9ba90fff8585e21e89,Ipi,0.471889
uuid-a5588a88be484a9ba90fff8585e21e89,OS,0.315189
uuid-a5588a88be484a9ba90fff8585e21e89,atezo,0.628242
uuid-a5588a88be484a9ba90fff8585e21e89,data,0.602625
uuid-a5588a88be484a9ba90fff8585e21e89,combo,0.368981
uuid-a5588a88be484a9ba90fff8585e21e89,indication,0.351166
uuid-a5588a88be484a9ba90fff8585e21e89,ORR,0.349563
uuid-a5588a88be484a9ba90fff8585e21e89,approved,0.336009
uuid-a5588a88be484a9ba90fff8585e21e89,nivo and pembro,0.466659
uuid-a5588a88be484a9ba90fff8585e21e89,impressed,0.468171
uuid-a5588a88be484a9ba90fff8585e21e89,vs,0.588649
uuid-a5588a88be484a9ba90fff8585e21e89,TLs,0.331365
uuid-a5588a88be484a9ba90fff8585e21e89,feels,0.389549
uuid-a5588a88be484a9ba90fff8585e21e89,flat dosing,0.336097
uuid-c874f1d445d14b5e887138cbe7e5e366,Nivo,0.348179
uuid-c874f1d445d14b5e887138cbe7e5e366,pembro,0.360016
uuid-c874f1d445d14b5e887138cbe7e5e366,dose,0.349726
uuid-c874f1d445d14b5e887138cbe7e5e366,nivolumab,0.457305
uuid-c874f1d445d14b5e887138cbe7e5e366,1L,0.435513
uuid-c874f1d445d14b5e887138cbe7e5e366,toxicity,0.338378
uuid-c874f1d445d14b5e887138cbe7e5e366,regimen,0.519217
uuid-c874f1d445d14b5e887138cbe7e5e366,shared,0.317079
uuid-c874f1d445d14b5e887138cbe7e5e366,RCC,0.513531
uuid-c874f1d445d14b5e887138cbe7e5e366,combination,0.533814
uuid-c874f1d445d14b5e887138cbe7e5e366,chemo,0.302446
uuid-c874f1d445d14b5e887138cbe7e5e366,2L,0.586205
uuid-c874f1d445d14b5e887138cbe7e5e366,agents,0.373845
uuid-c874f1d445d14b5e887138cbe7e5e366,Ipi,0.445758
uuid-c874f1d445d14b5e887138cbe7e5e366,approval,0.368902
uuid-c874f1d445d14b5e887138cbe7e5e366,atezo,0.378749
uuid-c874f1d445d14b5e887138cbe7e5e366,preferred,0.636329
uuid-c874f1d445d14b5e887138cbe7e5e366,monotherapy,0.557403
uuid-c874f1d445d14b5e887138cbe7e5e366,using nivo,0.534924
uuid-c874f1d445d14b5e887138cbe7e5e366,combo,0.564143
uuid-c874f1d445d14b5e887138cbe7e5e366,clinical trials,0.403812
uuid-c874f1d445d14b5e887138cbe7e5e366,indication,0.354748
uuid-c874f1d445d14b5e887138cbe7e5e366,approved,0.548982
uuid-c874f1d445d14b5e887138cbe7e5e366,SCCHN,0.378725
uuid-c874f1d445d14b5e887138cbe7e5e366,chemotherapy,0.31146
uuid-c874f1d445d14b5e887138cbe7e5e366,RTL stated,0.494341
uuid-c874f1d445d14b5e887138cbe7e5e366,option,0.518401
uuid-c874f1d445d14b5e887138cbe7e5e366,bladder,0.419471
uuid-dd3439ca42f0433182665446db32dc2e,therapy,0.429456
uuid-dd3439ca42f0433182665446db32dc2e,dose,0.403185
uuid-dd3439ca42f0433182665446db32dc2e,nivolumab,0.399277
uuid-dd3439ca42f0433182665446db32dc2e,toxicity,0.310271
uuid-dd3439ca42f0433182665446db32dc2e,PD1,0.393325
uuid-dd3439ca42f0433182665446db32dc2e,cHL,0.39245
uuid-dd3439ca42f0433182665446db32dc2e,PD-1,0.379061
uuid-06febf04c2ec4c9b954a613f99a80c7a,patients,0.775145
uuid-06febf04c2ec4c9b954a613f99a80c7a,Opdivo,0.68084
uuid-06febf04c2ec4c9b954a613f99a80c7a,therapy,0.377262
uuid-06febf04c2ec4c9b954a613f99a80c7a,dose,0.321816
uuid-06febf04c2ec4c9b954a613f99a80c7a,nivolumab,0.408188
uuid-06febf04c2ec4c9b954a613f99a80c7a,toxicity,0.531408
uuid-06febf04c2ec4c9b954a613f99a80c7a,regimen,0.535876
uuid-06febf04c2ec4c9b954a613f99a80c7a,treated,0.503353
uuid-06febf04c2ec4c9b954a613f99a80c7a,pts,0.445523
uuid-06febf04c2ec4c9b954a613f99a80c7a,treatment,0.603202
uuid-06febf04c2ec4c9b954a613f99a80c7a,lung cancer,0.347467
uuid-06febf04c2ec4c9b954a613f99a80c7a,progression,0.514879
uuid-06febf04c2ec4c9b954a613f99a80c7a,respond,0.425273
uuid-63ee3b0122b44247b1a01f01e40c09f2,BMS,0.48327
uuid-63ee3b0122b44247b1a01f01e40c09f2,commented,0.409826
uuid-63ee3b0122b44247b1a01f01e40c09f2,Merck,0.374486
uuid-63ee3b0122b44247b1a01f01e40c09f2,OS,0.332835
uuid-63ee3b0122b44247b1a01f01e40c09f2,data,0.381673
uuid-63ee3b0122b44247b1a01f01e40c09f2,expressed,0.424257
uuid-63ee3b0122b44247b1a01f01e40c09f2,mentioned,0.542169
uuid-63ee3b0122b44247b1a01f01e40c09f2,PFS,0.370469
uuid-63ee3b0122b44247b1a01f01e40c09f2,impressed,0.346586
uuid-63ee3b0122b44247b1a01f01e40c09f2,LTL,0.333423
uuid-d95ef354c8504e88b782d91c2cfe3360,institution,0.499275
uuid-d95ef354c8504e88b782d91c2cfe3360,AI,0.683444
uuid-d95ef354c8504e88b782d91c2cfe3360,oncology,0.519567
uuid-d95ef354c8504e88b782d91c2cfe3360,drug,0.426594
uuid-d95ef354c8504e88b782d91c2cfe3360,NCCN,0.386288
uuid-0722bf819efa4e3b86cd665d3f09a32d,Nivo,0.390347
uuid-0722bf819efa4e3b86cd665d3f09a32d,trial,0.526494
uuid-0722bf819efa4e3b86cd665d3f09a32d,efficacy,0.514683
uuid-0722bf819efa4e3b86cd665d3f09a32d,combination,0.450945
uuid-0722bf819efa4e3b86cd665d3f09a32d,chemo,0.318591
uuid-0722bf819efa4e3b86cd665d3f09a32d,agents,0.30523
uuid-0722bf819efa4e3b86cd665d3f09a32d,Ipi,0.380516
uuid-0722bf819efa4e3b86cd665d3f09a32d,OS,0.488806
uuid-0722bf819efa4e3b86cd665d3f09a32d,regards,0.328327
uuid-0722bf819efa4e3b86cd665d3f09a32d,data,0.433052
uuid-0722bf819efa4e3b86cd665d3f09a32d,combo,0.447455
uuid-0722bf819efa4e3b86cd665d3f09a32d,PFS,0.444789
uuid-0722bf819efa4e3b86cd665d3f09a32d,ORR,0.491674
uuid-0722bf819efa4e3b86cd665d3f09a32d,nivo and pembro,0.438458
uuid-0722bf819efa4e3b86cd665d3f09a32d,believes,0.492678
uuid-0722bf819efa4e3b86cd665d3f09a32d,impressed,0.430901
uuid-0722bf819efa4e3b86cd665d3f09a32d,SCLC,0.335514
uuid-0722bf819efa4e3b86cd665d3f09a32d,feels,0.393878
uuid-869ba49c06db4b91acb3ba546383956a,patients,0.605766
uuid-869ba49c06db4b91acb3ba546383956a,Opdivo,0.33936
uuid-869ba49c06db4b91acb3ba546383956a,therapy,0.321815
uuid-869ba49c06db4b91acb3ba546383956a,toxicity,0.594313
uuid-869ba49c06db4b91acb3ba546383956a,regimen,0.436371
uuid-869ba49c06db4b91acb3ba546383956a,treated,0.43908
uuid-869ba49c06db4b91acb3ba546383956a,treatment,0.48692
uuid-869ba49c06db4b91acb3ba546383956a,progression,0.391899
uuid-869ba49c06db4b91acb3ba546383956a,respond,0.427652
uuid-52970588d20f4f3d84c089f2f116fd76,patients,0.579966
uuid-52970588d20f4f3d84c089f2f116fd76,therapy,0.718372
uuid-52970588d20f4f3d84c089f2f116fd76,nivolumab,0.459422
uuid-52970588d20f4f3d84c089f2f116fd76,treated,0.35765
uuid-52970588d20f4f3d84c089f2f116fd76,chemo,0.318057
uuid-52970588d20f4f3d84c089f2f116fd76,treatment,0.533315
uuid-52970588d20f4f3d84c089f2f116fd76,response,0.375565
uuid-52970588d20f4f3d84c089f2f116fd76,PD1,0.573309
uuid-52970588d20f4f3d84c089f2f116fd76,cHL,0.516227
uuid-52970588d20f4f3d84c089f2f116fd76,progression,0.51784
uuid-52970588d20f4f3d84c089f2f116fd76,chemotherapy,0.412464
uuid-52970588d20f4f3d84c089f2f116fd76,respond,0.382477
uuid-52970588d20f4f3d84c089f2f116fd76,immunotherapy,0.315287
uuid-52970588d20f4f3d84c089f2f116fd76,PD-1,0.470075
uuid-0c4c811c6190458eb2a567d1bb75c4c3,pembro,0.302495
uuid-0c4c811c6190458eb2a567d1bb75c4c3,BMS,0.479916
uuid-0c4c811c6190458eb2a567d1bb75c4c3,PDL1,0.750111
uuid-0c4c811c6190458eb2a567d1bb75c4c3,trial,0.458847
uuid-0c4c811c6190458eb2a567d1bb75c4c3,efficacy,0.608644
uuid-0c4c811c6190458eb2a567d1bb75c4c3,Merck,0.460606
uuid-0c4c811c6190458eb2a567d1bb75c4c3,PD-L1,0.378863
uuid-0c4c811c6190458eb2a567d1bb75c4c3,OS,0.598587
uuid-0c4c811c6190458eb2a567d1bb75c4c3,atezo,0.319446
uuid-0c4c811c6190458eb2a567d1bb75c4c3,regards,0.374082
uuid-0c4c811c6190458eb2a567d1bb75c4c3,data,0.613933
uuid-0c4c811c6190458eb2a567d1bb75c4c3,PFS,0.605251
uuid-0c4c811c6190458eb2a567d1bb75c4c3,ORR,0.599278
uuid-0c4c811c6190458eb2a567d1bb75c4c3,nivo and pembro,0.585539
uuid-0c4c811c6190458eb2a567d1bb75c4c3,believes,0.440552
uuid-0c4c811c6190458eb2a567d1bb75c4c3,impressed,0.35262
uuid-0c4c811c6190458eb2a567d1bb75c4c3,feels,0.346016
uuid-0c4c811c6190458eb2a567d1bb75c4c3,assay,0.424943
uuid-0c4c811c6190458eb2a567d1bb75c4c3,PDL1 expression,0.635006
uuid-0c4c811c6190458eb2a567d1bb75c4c3,biomarker,0.512886
uuid-2f5693433edf43deb06dc5283498c0a2,Nivo,0.565034
uuid-2f5693433edf43deb06dc5283498c0a2,patients,0.301373
uuid-2f5693433edf43deb06dc5283498c0a2,pembro,0.638644
uuid-2f5693433edf43deb06dc5283498c0a2,dose,0.483924
uuid-2f5693433edf43deb06dc5283498c0a2,1L,0.539943
uuid-2f5693433edf43deb06dc5283498c0a2,efficacy,0.306026
uuid-2f5693433edf43deb06dc5283498c0a2,regimen,0.362315
uuid-2f5693433edf43deb06dc5283498c0a2,combination,0.345066
uuid-2f5693433edf43deb06dc5283498c0a2,chemo,0.330147
uuid-2f5693433edf43deb06dc5283498c0a2,2L,0.666596
uuid-2f5693433edf43deb06dc5283498c0a2,agents,0.407353
uuid-2f5693433edf43deb06dc5283498c0a2,Ipi,0.443221
uuid-2f5693433edf43deb06dc5283498c0a2,approval,0.352737
uuid-2f5693433edf43deb06dc5283498c0a2,atezo,0.659968
uuid-2f5693433edf43deb06dc5283498c0a2,preferred,0.669545
uuid-2f5693433edf43deb06dc5283498c0a2,monotherapy,0.55078
uuid-2f5693433edf43deb06dc5283498c0a2,using nivo,0.573202
uuid-2f5693433edf43deb06dc5283498c0a2,combo,0.429106
uuid-2f5693433edf43deb06dc5283498c0a2,indication,0.359156
uuid-2f5693433edf43deb06dc5283498c0a2,approved,0.489943
uuid-2f5693433edf43deb06dc5283498c0a2,vs,0.495091
uuid-2f5693433edf43deb06dc5283498c0a2,feels,0.358933
uuid-2f5693433edf43deb06dc5283498c0a2,RTL stated,0.338697
uuid-2f5693433edf43deb06dc5283498c0a2,option,0.544439
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,patients,0.546024
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,therapy,0.336691
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,nivolumab,0.381354
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,lung,0.301436
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,1L,0.47488
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,regimen,0.514423
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,treated,0.487039
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,melanoma,0.363521
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,RCC,0.566264
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,TL stated,0.460103
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,2L,0.479748
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,pts,0.440365
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,preferred,0.519508
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,monotherapy,0.523062
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,treatment,0.446052
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,using nivo,0.459422
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,combo,0.334799
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,PDL1 testing,0.351294
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,NSCLC patients,0.34041
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,SCCHN,0.438446
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,progression,0.386632
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,RTL stated,0.562165
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,TL shared,0.538385
uuid-8e0a16bf5c5f46fc907d67c6c461dee0,option,0.490461
uuid-2c16756adfe249af8224009643dcac1f,TL,0.339196
uuid-2c16756adfe249af8224009643dcac1f,PDL1,0.331931
uuid-2c16756adfe249af8224009643dcac1f,TL stated,0.357761
uuid-2c16756adfe249af8224009643dcac1f,tumor,0.497493
uuid-2c16756adfe249af8224009643dcac1f,PD-L1,0.588648
uuid-2c16756adfe249af8224009643dcac1f,PD-L1 testing,0.471193
uuid-2c16756adfe249af8224009643dcac1f,testing,0.622581
uuid-2c16756adfe249af8224009643dcac1f,PDL1 testing,0.415256
uuid-2c16756adfe249af8224009643dcac1f,NSCLC patients,0.505163
uuid-2c16756adfe249af8224009643dcac1f,assay,0.440161
uuid-2c16756adfe249af8224009643dcac1f,biomarker,0.456909
uuid-7180bddd177c470a8e462894f46c8094,patients,0.772924
uuid-7180bddd177c470a8e462894f46c8094,therapy,0.5911
uuid-7180bddd177c470a8e462894f46c8094,nivolumab,0.304092
uuid-7180bddd177c470a8e462894f46c8094,1L,0.315374
uuid-7180bddd177c470a8e462894f46c8094,regimen,0.382842
uuid-7180bddd177c470a8e462894f46c8094,treated,0.361368
uuid-7180bddd177c470a8e462894f46c8094,chemo,0.385402
uuid-7180bddd177c470a8e462894f46c8094,pts,0.573126
uuid-7180bddd177c470a8e462894f46c8094,monotherapy,0.458941
uuid-7180bddd177c470a8e462894f46c8094,treatment,0.540143
uuid-7180bddd177c470a8e462894f46c8094,progression,0.548001
uuid-7180bddd177c470a8e462894f46c8094,chemotherapy,0.431072
uuid-7180bddd177c470a8e462894f46c8094,respond,0.323416
uuid-7180bddd177c470a8e462894f46c8094,option,0.502633
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,Nivo,0.440074
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,pembro,0.334343
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,NSCLC,0.353693
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,1L,0.610058
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,regimen,0.421501
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,RCC,0.495182
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,combination,0.485321
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,chemo,0.448035
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,2L,0.670977
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,IO,0.533551
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,agents,0.485257
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,Ipi,0.337044
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,atezo,0.429251
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,preferred,0.593859
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,monotherapy,0.667449
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,using nivo,0.432786
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,combo,0.608415
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,PD1,0.38783
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,believes,0.445228
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,TLs,0.319158
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,feels,0.349155
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,RTL stated,0.406347
uuid-84a0f55fe5c9473e8dca8d3ca3eff8e6,option,0.539272
uuid-b10a850735b44f57a2e8a8a6af1a2108,regimen,0.310309
uuid-b10a850735b44f57a2e8a8a6af1a2108,treated,0.340563
uuid-b10a850735b44f57a2e8a8a6af1a2108,treatment,0.354313
uuid-b10a850735b44f57a2e8a8a6af1a2108,respond,0.360344
uuid-794e90d63eb942c09fc9da6b67d22d58,patients,0.397333
uuid-794e90d63eb942c09fc9da6b67d22d58,therapy,0.306804
uuid-794e90d63eb942c09fc9da6b67d22d58,regimen,0.399946
uuid-794e90d63eb942c09fc9da6b67d22d58,chemo,0.468259
uuid-794e90d63eb942c09fc9da6b67d22d58,pts,0.514127
uuid-794e90d63eb942c09fc9da6b67d22d58,OS,0.303923
uuid-794e90d63eb942c09fc9da6b67d22d58,treatment,0.33795
uuid-794e90d63eb942c09fc9da6b67d22d58,response,0.70698
uuid-794e90d63eb942c09fc9da6b67d22d58,PD1,0.364255
uuid-794e90d63eb942c09fc9da6b67d22d58,progression,0.684063
uuid-794e90d63eb942c09fc9da6b67d22d58,believes,0.334728
uuid-794e90d63eb942c09fc9da6b67d22d58,chemotherapy,0.301906
uuid-794e90d63eb942c09fc9da6b67d22d58,respond,0.578053
uuid-4f1aeeca97674d0382a627ada8ea07ce,patients,0.755607
uuid-4f1aeeca97674d0382a627ada8ea07ce,Opdivo,0.485799
uuid-4f1aeeca97674d0382a627ada8ea07ce,therapy,0.314786
uuid-4f1aeeca97674d0382a627ada8ea07ce,treated,0.387343
uuid-4f1aeeca97674d0382a627ada8ea07ce,pts,0.439604
uuid-4f1aeeca97674d0382a627ada8ea07ce,PD-L1 testing,0.381938
uuid-4f1aeeca97674d0382a627ada8ea07ce,testing,0.371872
uuid-4f1aeeca97674d0382a627ada8ea07ce,treatment,0.472539
uuid-4f1aeeca97674d0382a627ada8ea07ce,NSCLC patients,0.429513
uuid-4f1aeeca97674d0382a627ada8ea07ce,progression,0.475311
uuid-4f1aeeca97674d0382a627ada8ea07ce,respond,0.410169
uuid-ec982f7251314a3680cf0b8af9851c4f,patients,0.670167
uuid-ec982f7251314a3680cf0b8af9851c4f,Opdivo,0.701635
uuid-ec982f7251314a3680cf0b8af9851c4f,therapy,0.415713
uuid-ec982f7251314a3680cf0b8af9851c4f,dose,0.375297
uuid-ec982f7251314a3680cf0b8af9851c4f,nivolumab,0.423286
uuid-ec982f7251314a3680cf0b8af9851c4f,toxicity,0.43537
uuid-ec982f7251314a3680cf0b8af9851c4f,regimen,0.435459
uuid-ec982f7251314a3680cf0b8af9851c4f,treated,0.473637
uuid-ec982f7251314a3680cf0b8af9851c4f,pts,0.316205
uuid-ec982f7251314a3680cf0b8af9851c4f,physicians,0.375487
uuid-ec982f7251314a3680cf0b8af9851c4f,treatment,0.565136
uuid-ec982f7251314a3680cf0b8af9851c4f,cHL,0.347307
uuid-ec982f7251314a3680cf0b8af9851c4f,progression,0.38512
uuid-ec982f7251314a3680cf0b8af9851c4f,respond,0.384329
uuid-ec982f7251314a3680cf0b8af9851c4f,flat dosing,0.329545
uuid-92e0ac665fc742aca2f7a9d9cce2f309,Opdivo,0.571022
uuid-92e0ac665fc742aca2f7a9d9cce2f309,TL,0.389656
uuid-92e0ac665fc742aca2f7a9d9cce2f309,TL stated,0.346386
uuid-92e0ac665fc742aca2f7a9d9cce2f309,approval,0.328717
uuid-92e0ac665fc742aca2f7a9d9cce2f309,physicians,0.475347
uuid-92e0ac665fc742aca2f7a9d9cce2f309,PD-L1 testing,0.39722
uuid-92e0ac665fc742aca2f7a9d9cce2f309,testing,0.314313
uuid-92e0ac665fc742aca2f7a9d9cce2f309,PDL1 testing,0.36024
uuid-92e0ac665fc742aca2f7a9d9cce2f309,HCP,0.321279
uuid-237cf692e7a94b3fbb2b7b0412972701,Opdivo,0.342434
uuid-237cf692e7a94b3fbb2b7b0412972701,approval,0.444876
uuid-237cf692e7a94b3fbb2b7b0412972701,preferred,0.402192
uuid-237cf692e7a94b3fbb2b7b0412972701,using nivo,0.328951
uuid-237cf692e7a94b3fbb2b7b0412972701,clinical trials,0.351029
uuid-237cf692e7a94b3fbb2b7b0412972701,PDL1 testing,0.349814
uuid-237cf692e7a94b3fbb2b7b0412972701,approved,0.453472
uuid-237cf692e7a94b3fbb2b7b0412972701,label,0.457581
uuid-237cf692e7a94b3fbb2b7b0412972701,RTL stated,0.303085
uuid-ef18477431304155a7fac88ec9df5509,Opdivo,0.527369
uuid-ef18477431304155a7fac88ec9df5509,shared,0.311837
uuid-ef18477431304155a7fac88ec9df5509,commented,0.391335
uuid-ef18477431304155a7fac88ec9df5509,TL stated,0.387767
uuid-ef18477431304155a7fac88ec9df5509,stated,0.391885
uuid-ef18477431304155a7fac88ec9df5509,approval,0.372471
uuid-ef18477431304155a7fac88ec9df5509,physicians,0.402359
uuid-ef18477431304155a7fac88ec9df5509,using nivo,0.325151
uuid-ef18477431304155a7fac88ec9df5509,mentioned,0.327718
uuid-ef18477431304155a7fac88ec9df5509,SCCHN,0.368679
uuid-ef18477431304155a7fac88ec9df5509,HCP,0.350664
uuid-ef18477431304155a7fac88ec9df5509,impressed,0.306653
uuid-ef18477431304155a7fac88ec9df5509,LTL,0.374012
uuid-ef18477431304155a7fac88ec9df5509,TLs,0.3613
uuid-ef18477431304155a7fac88ec9df5509,Regional TL,0.366028
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,Nivo,0.303902
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,patients,0.645176
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,therapy,0.38703
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,nivolumab,0.379635
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,toxicity,0.565678
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,regimen,0.722323
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,treated,0.4394
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,combination,0.371461
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,chemo,0.429989
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,pts,0.525453
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,Ipi,0.351591
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,monotherapy,0.438603
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,treatment,0.590611
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,response,0.377884
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,combo,0.393798
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,PD1,0.367693
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,progression,0.586919
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,chemotherapy,0.407934
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,respond,0.577293
uuid-972975d4b1fa4829a6cb1b5b133fd8b9,option,0.317742
uuid-817485565032442680d6d74294f3a3b7,Nivo,0.337769
uuid-817485565032442680d6d74294f3a3b7,PDL1,0.363963
uuid-817485565032442680d6d74294f3a3b7,efficacy,0.348111
uuid-817485565032442680d6d74294f3a3b7,chemo,0.420465
uuid-817485565032442680d6d74294f3a3b7,pts,0.365711
uuid-817485565032442680d6d74294f3a3b7,response,0.415862
uuid-817485565032442680d6d74294f3a3b7,PDL1 expression,0.38353
uuid-610a85028ce94f4bad534d12507dad9b,patients,0.655619
uuid-610a85028ce94f4bad534d12507dad9b,therapy,0.446274
uuid-610a85028ce94f4bad534d12507dad9b,1L,0.372422
uuid-610a85028ce94f4bad534d12507dad9b,treated,0.327239
uuid-610a85028ce94f4bad534d12507dad9b,chemo,0.397126
uuid-610a85028ce94f4bad534d12507dad9b,2L,0.304662
uuid-610a85028ce94f4bad534d12507dad9b,pts,0.606414
uuid-610a85028ce94f4bad534d12507dad9b,monotherapy,0.340751
uuid-610a85028ce94f4bad534d12507dad9b,treatment,0.439392
uuid-610a85028ce94f4bad534d12507dad9b,using nivo,0.329491
uuid-610a85028ce94f4bad534d12507dad9b,response,0.395742
uuid-610a85028ce94f4bad534d12507dad9b,NSCLC patients,0.386555
uuid-610a85028ce94f4bad534d12507dad9b,PD1,0.310262
uuid-610a85028ce94f4bad534d12507dad9b,progression,0.551099
uuid-610a85028ce94f4bad534d12507dad9b,chemotherapy,0.311006
uuid-610a85028ce94f4bad534d12507dad9b,respond,0.43342
uuid-610a85028ce94f4bad534d12507dad9b,option,0.436116
uuid-bc1d70eb3639413c8120da10bdbd7b3e,patients,0.305793
uuid-bc1d70eb3639413c8120da10bdbd7b3e,therapy,0.504628
uuid-bc1d70eb3639413c8120da10bdbd7b3e,regimen,0.442194
uuid-bc1d70eb3639413c8120da10bdbd7b3e,combination,0.343088
uuid-bc1d70eb3639413c8120da10bdbd7b3e,chemo,0.500652
uuid-bc1d70eb3639413c8120da10bdbd7b3e,pts,0.42541
uuid-bc1d70eb3639413c8120da10bdbd7b3e,IO,0.375936
uuid-bc1d70eb3639413c8120da10bdbd7b3e,monotherapy,0.424112
uuid-bc1d70eb3639413c8120da10bdbd7b3e,treatment,0.483864
uuid-bc1d70eb3639413c8120da10bdbd7b3e,response,0.667832
uuid-bc1d70eb3639413c8120da10bdbd7b3e,combo,0.340878
uuid-bc1d70eb3639413c8120da10bdbd7b3e,AI,0.304979
uuid-bc1d70eb3639413c8120da10bdbd7b3e,PD1,0.546118
uuid-bc1d70eb3639413c8120da10bdbd7b3e,progression,0.616388
uuid-bc1d70eb3639413c8120da10bdbd7b3e,believes,0.356905
uuid-bc1d70eb3639413c8120da10bdbd7b3e,chemotherapy,0.457325
uuid-bc1d70eb3639413c8120da10bdbd7b3e,respond,0.531427
uuid-bc1d70eb3639413c8120da10bdbd7b3e,immunotherapy,0.368471
uuid-bc1d70eb3639413c8120da10bdbd7b3e,PD-1,0.343471
uuid-afa4d802639540e8bd919a5059b7ecca,dose,0.341914
uuid-afa4d802639540e8bd919a5059b7ecca,BMS,0.341961
uuid-afa4d802639540e8bd919a5059b7ecca,efficacy,0.401238
uuid-afa4d802639540e8bd919a5059b7ecca,discussed,0.407695
uuid-afa4d802639540e8bd919a5059b7ecca,commented,0.344693
uuid-afa4d802639540e8bd919a5059b7ecca,regards,0.434171
uuid-afa4d802639540e8bd919a5059b7ecca,data,0.348933
uuid-afa4d802639540e8bd919a5059b7ecca,expressed,0.303775
uuid-afa4d802639540e8bd919a5059b7ecca,indication,0.305439
uuid-afa4d802639540e8bd919a5059b7ecca,impressed,0.313199
uuid-afa4d802639540e8bd919a5059b7ecca,vs,0.32677
uuid-afa4d802639540e8bd919a5059b7ecca,TLs,0.506908
uuid-afa4d802639540e8bd919a5059b7ecca,flat dosing,0.333673
uuid-b5dc0381bfb6434cb0e78f86cb36b040,PDL1,0.494323
uuid-b5dc0381bfb6434cb0e78f86cb36b040,efficacy,0.466352
uuid-b5dc0381bfb6434cb0e78f86cb36b040,chemo,0.404323
uuid-b5dc0381bfb6434cb0e78f86cb36b040,OS,0.750042
uuid-b5dc0381bfb6434cb0e78f86cb36b040,response,0.466297
uuid-b5dc0381bfb6434cb0e78f86cb36b040,data,0.351356
uuid-b5dc0381bfb6434cb0e78f86cb36b040,PFS,0.718414
uuid-b5dc0381bfb6434cb0e78f86cb36b040,ORR,0.639041
uuid-b5dc0381bfb6434cb0e78f86cb36b040,nivo and pembro,0.412278
uuid-b5dc0381bfb6434cb0e78f86cb36b040,progression,0.321543
uuid-b5dc0381bfb6434cb0e78f86cb36b040,believes,0.424609
uuid-b5dc0381bfb6434cb0e78f86cb36b040,chemotherapy,0.310964
uuid-b5dc0381bfb6434cb0e78f86cb36b040,respond,0.328642
uuid-b5dc0381bfb6434cb0e78f86cb36b040,PDL1 expression,0.419145
uuid-b5dc0381bfb6434cb0e78f86cb36b040,biomarker,0.333023
uuid-ab7666d5773b4fedbdc41758e716fbdd,Nivo,0.302963
uuid-ab7666d5773b4fedbdc41758e716fbdd,patients,0.331644
uuid-ab7666d5773b4fedbdc41758e716fbdd,1L,0.462743
uuid-ab7666d5773b4fedbdc41758e716fbdd,regimen,0.324895
uuid-ab7666d5773b4fedbdc41758e716fbdd,melanoma,0.334608
uuid-ab7666d5773b4fedbdc41758e716fbdd,RCC,0.491444
uuid-ab7666d5773b4fedbdc41758e716fbdd,TL stated,0.300474
uuid-ab7666d5773b4fedbdc41758e716fbdd,chemo,0.33011
uuid-ab7666d5773b4fedbdc41758e716fbdd,2L,0.411294
uuid-ab7666d5773b4fedbdc41758e716fbdd,pts,0.47571
uuid-ab7666d5773b4fedbdc41758e716fbdd,stated,0.321208
uuid-ab7666d5773b4fedbdc41758e716fbdd,monotherapy,0.456571
uuid-ab7666d5773b4fedbdc41758e716fbdd,using nivo,0.42758
uuid-ab7666d5773b4fedbdc41758e716fbdd,combo,0.330174
uuid-ab7666d5773b4fedbdc41758e716fbdd,PD1,0.384499
uuid-ab7666d5773b4fedbdc41758e716fbdd,SCCHN,0.391107
uuid-ab7666d5773b4fedbdc41758e716fbdd,progression,0.375834
uuid-ab7666d5773b4fedbdc41758e716fbdd,believes,0.335229
uuid-ab7666d5773b4fedbdc41758e716fbdd,impressed,0.402542
uuid-ab7666d5773b4fedbdc41758e716fbdd,respond,0.317014
uuid-ab7666d5773b4fedbdc41758e716fbdd,SCLC,0.315632
uuid-ab7666d5773b4fedbdc41758e716fbdd,feels,0.419204
uuid-ab7666d5773b4fedbdc41758e716fbdd,RTL stated,0.455874
uuid-ab7666d5773b4fedbdc41758e716fbdd,TL shared,0.388161
uuid-ab7666d5773b4fedbdc41758e716fbdd,option,0.374938
uuid-139f292f98904949a91bf2d2af613191,Nivo,0.330094
uuid-139f292f98904949a91bf2d2af613191,pembro,0.47668
uuid-139f292f98904949a91bf2d2af613191,BMS,0.348178
uuid-139f292f98904949a91bf2d2af613191,1L,0.361117
uuid-139f292f98904949a91bf2d2af613191,RCC,0.33177
uuid-139f292f98904949a91bf2d2af613191,2L,0.455691
uuid-139f292f98904949a91bf2d2af613191,Merck,0.322514
uuid-139f292f98904949a91bf2d2af613191,stated,0.497318
uuid-139f292f98904949a91bf2d2af613191,approval,0.634095
uuid-139f292f98904949a91bf2d2af613191,atezo,0.387931
uuid-139f292f98904949a91bf2d2af613191,preferred,0.42038
uuid-139f292f98904949a91bf2d2af613191,using nivo,0.563068
uuid-139f292f98904949a91bf2d2af613191,mentioned,0.309761
uuid-139f292f98904949a91bf2d2af613191,clinical trials,0.381634
uuid-139f292f98904949a91bf2d2af613191,indication,0.44769
uuid-139f292f98904949a91bf2d2af613191,approved,0.603627
uuid-139f292f98904949a91bf2d2af613191,SCCHN,0.5211
uuid-139f292f98904949a91bf2d2af613191,label,0.449292
uuid-139f292f98904949a91bf2d2af613191,LTL,0.343342
uuid-139f292f98904949a91bf2d2af613191,Regional TL,0.339853
uuid-139f292f98904949a91bf2d2af613191,RTL stated,0.456868
uuid-139f292f98904949a91bf2d2af613191,option,0.31283
uuid-139f292f98904949a91bf2d2af613191,bladder,0.377812
uuid-2f3d5cc456804ff1ac53f187e8617b79,patients,0.38142
uuid-2f3d5cc456804ff1ac53f187e8617b79,TL,0.30581
uuid-2f3d5cc456804ff1ac53f187e8617b79,1L,0.382531
uuid-2f3d5cc456804ff1ac53f187e8617b79,TL stated,0.372853
uuid-2f3d5cc456804ff1ac53f187e8617b79,PD-L1,0.609706
uuid-2f3d5cc456804ff1ac53f187e8617b79,approval,0.383683
uuid-2f3d5cc456804ff1ac53f187e8617b79,PD-L1 testing,0.714772
uuid-2f3d5cc456804ff1ac53f187e8617b79,testing,0.767688
uuid-2f3d5cc456804ff1ac53f187e8617b79,PDL1 testing,0.687436
uuid-2f3d5cc456804ff1ac53f187e8617b79,NSCLC patients,0.719804
uuid-2f3d5cc456804ff1ac53f187e8617b79,assay,0.367437
uuid-3cc83de86bec47e2974723a4993d5ec0,patients,0.416786
uuid-3cc83de86bec47e2974723a4993d5ec0,lung,0.314508
uuid-3cc83de86bec47e2974723a4993d5ec0,treated,0.415772
uuid-3cc83de86bec47e2974723a4993d5ec0,melanoma,0.342625
uuid-3cc83de86bec47e2974723a4993d5ec0,pts,0.310809
uuid-3cc83de86bec47e2974723a4993d5ec0,treatment,0.383095
uuid-3cc83de86bec47e2974723a4993d5ec0,response,0.376373
uuid-3cc83de86bec47e2974723a4993d5ec0,AI,0.311008
uuid-3cc83de86bec47e2974723a4993d5ec0,progression,0.435054
uuid-3cc83de86bec47e2974723a4993d5ec0,respond,0.358085
uuid-3cc83de86bec47e2974723a4993d5ec0,TL shared,0.366642
uuid-95030adace074e729ba693d5aba50cbb,1L,0.507
uuid-95030adace074e729ba693d5aba50cbb,PDL1,0.327735
uuid-95030adace074e729ba693d5aba50cbb,chemo,0.334519
uuid-95030adace074e729ba693d5aba50cbb,2L,0.474149
uuid-95030adace074e729ba693d5aba50cbb,agents,0.484721
uuid-95030adace074e729ba693d5aba50cbb,PD-L1,0.330106
uuid-95030adace074e729ba693d5aba50cbb,atezo,0.334754
uuid-95030adace074e729ba693d5aba50cbb,preferred,0.559941
uuid-95030adace074e729ba693d5aba50cbb,testing,0.36151
uuid-95030adace074e729ba693d5aba50cbb,monotherapy,0.436218
uuid-95030adace074e729ba693d5aba50cbb,PDL1 testing,0.347978
uuid-95030adace074e729ba693d5aba50cbb,NSCLC patients,0.33276
uuid-95030adace074e729ba693d5aba50cbb,believes,0.431981
uuid-95030adace074e729ba693d5aba50cbb,feels,0.445545
uuid-95030adace074e729ba693d5aba50cbb,option,0.586958
uuid-5b4e6734cb1941718cda208fe639d753,PDL1,0.317068
uuid-5b4e6734cb1941718cda208fe639d753,trial,0.382725
uuid-5b4e6734cb1941718cda208fe639d753,efficacy,0.468821
uuid-5b4e6734cb1941718cda208fe639d753,OS,0.88062
uuid-5b4e6734cb1941718cda208fe639d753,regards,0.333604
uuid-5b4e6734cb1941718cda208fe639d753,data,0.529439
uuid-5b4e6734cb1941718cda208fe639d753,PFS,0.881537
uuid-5b4e6734cb1941718cda208fe639d753,ORR,0.762017
uuid-5b4e6734cb1941718cda208fe639d753,nivo and pembro,0.342344
uuid-5b4e6734cb1941718cda208fe639d753,impressed,0.494129
uuid-c84a206a4de948ee98ea62a2043c5ed6,RTL,0.372783
uuid-c84a206a4de948ee98ea62a2043c5ed6,commented,0.455241
uuid-c84a206a4de948ee98ea62a2043c5ed6,stated,0.316998
uuid-c84a206a4de948ee98ea62a2043c5ed6,OS,0.614502
uuid-c84a206a4de948ee98ea62a2043c5ed6,data,0.50757
uuid-c84a206a4de948ee98ea62a2043c5ed6,PFS,0.5659
uuid-c84a206a4de948ee98ea62a2043c5ed6,ORR,0.515669
uuid-c84a206a4de948ee98ea62a2043c5ed6,ASCO,0.562334
uuid-c84a206a4de948ee98ea62a2043c5ed6,impressed,0.694949
uuid-c84a206a4de948ee98ea62a2043c5ed6,Regional TL,0.352869
uuid-39bf991a8ae1424d80f91f663113e731,TL,0.35923
uuid-39bf991a8ae1424d80f91f663113e731,RTL,0.371096
uuid-39bf991a8ae1424d80f91f663113e731,lung,0.389061
uuid-39bf991a8ae1424d80f91f663113e731,commented,0.544126
uuid-39bf991a8ae1424d80f91f663113e731,TL stated,0.595442
uuid-39bf991a8ae1424d80f91f663113e731,Merck,0.432763
uuid-39bf991a8ae1424d80f91f663113e731,stated,0.410296
uuid-39bf991a8ae1424d80f91f663113e731,PD-L1,0.300359
uuid-39bf991a8ae1424d80f91f663113e731,PD-L1 testing,0.391064
uuid-39bf991a8ae1424d80f91f663113e731,testing,0.431886
uuid-39bf991a8ae1424d80f91f663113e731,data,0.328528
uuid-39bf991a8ae1424d80f91f663113e731,expressed,0.408177
uuid-39bf991a8ae1424d80f91f663113e731,mentioned,0.437175
uuid-39bf991a8ae1424d80f91f663113e731,PDL1 testing,0.575677
uuid-39bf991a8ae1424d80f91f663113e731,NSCLC patients,0.33946
uuid-39bf991a8ae1424d80f91f663113e731,SCCHN,0.409658
uuid-39bf991a8ae1424d80f91f663113e731,ASCO,0.386392
uuid-39bf991a8ae1424d80f91f663113e731,impressed,0.36953
uuid-39bf991a8ae1424d80f91f663113e731,LTL,0.30794
uuid-39bf991a8ae1424d80f91f663113e731,TLs,0.325134
uuid-39bf991a8ae1424d80f91f663113e731,Regional TL,0.440246
uuid-39bf991a8ae1424d80f91f663113e731,bladder,0.326805
uuid-6f57467bc3b743f1a0f6b7800a12d12c,TL,0.49278
uuid-6f57467bc3b743f1a0f6b7800a12d12c,1L,0.305901
uuid-6f57467bc3b743f1a0f6b7800a12d12c,PDL1,0.461518
uuid-6f57467bc3b743f1a0f6b7800a12d12c,TL stated,0.533705
uuid-6f57467bc3b743f1a0f6b7800a12d12c,Merck,0.350797
uuid-6f57467bc3b743f1a0f6b7800a12d12c,institution,0.323195
uuid-6f57467bc3b743f1a0f6b7800a12d12c,PD-L1,0.753938
uuid-6f57467bc3b743f1a0f6b7800a12d12c,PD-L1 testing,0.765626
uuid-6f57467bc3b743f1a0f6b7800a12d12c,testing,0.869983
uuid-6f57467bc3b743f1a0f6b7800a12d12c,PDL1 testing,0.820922
uuid-6f57467bc3b743f1a0f6b7800a12d12c,NSCLC patients,0.677998
uuid-6f57467bc3b743f1a0f6b7800a12d12c,tumor types,0.316422
uuid-6f57467bc3b743f1a0f6b7800a12d12c,assay,0.601209
uuid-6f57467bc3b743f1a0f6b7800a12d12c,PDL1 expression,0.304486
uuid-6f57467bc3b743f1a0f6b7800a12d12c,biomarker,0.462734
uuid-c038e7f43ac243f3971a199ba447c28b,therapy,0.425505
uuid-c038e7f43ac243f3971a199ba447c28b,nivolumab,0.383499
uuid-c038e7f43ac243f3971a199ba447c28b,toxicity,0.507674
uuid-c038e7f43ac243f3971a199ba447c28b,regimen,0.374241
uuid-c038e7f43ac243f3971a199ba447c28b,treated,0.432181
uuid-c038e7f43ac243f3971a199ba447c28b,combination,0.368783
uuid-c038e7f43ac243f3971a199ba447c28b,treatment,0.54702
uuid-c038e7f43ac243f3971a199ba447c28b,PD1,0.421155
uuid-c038e7f43ac243f3971a199ba447c28b,progression,0.394991
uuid-c038e7f43ac243f3971a199ba447c28b,chemotherapy,0.400174
uuid-c038e7f43ac243f3971a199ba447c28b,immunotherapy,0.416054
uuid-335a11c0d20f45f6a301618424ec6984,patients,0.429845
uuid-335a11c0d20f45f6a301618424ec6984,Opdivo,0.585051
uuid-335a11c0d20f45f6a301618424ec6984,dose,0.697881
uuid-335a11c0d20f45f6a301618424ec6984,nivolumab,0.33958
uuid-335a11c0d20f45f6a301618424ec6984,toxicity,0.463993
uuid-335a11c0d20f45f6a301618424ec6984,regimen,0.477818
uuid-335a11c0d20f45f6a301618424ec6984,Ipi,0.330069
uuid-335a11c0d20f45f6a301618424ec6984,preferred,0.472869
uuid-335a11c0d20f45f6a301618424ec6984,monotherapy,0.344678
uuid-335a11c0d20f45f6a301618424ec6984,treatment,0.352551
uuid-335a11c0d20f45f6a301618424ec6984,drug,0.409854
uuid-335a11c0d20f45f6a301618424ec6984,Keytruda,0.541434
uuid-335a11c0d20f45f6a301618424ec6984,option,0.323639
uuid-335a11c0d20f45f6a301618424ec6984,flat dosing,0.586077
uuid-b614a3400e9d4746b9d37fd26564231d,patients,0.680962
uuid-b614a3400e9d4746b9d37fd26564231d,Opdivo,0.453773
uuid-b614a3400e9d4746b9d37fd26564231d,nivolumab,0.30987
uuid-b614a3400e9d4746b9d37fd26564231d,1L,0.424779
uuid-b614a3400e9d4746b9d37fd26564231d,regimen,0.355623
uuid-b614a3400e9d4746b9d37fd26564231d,2L,0.478232
uuid-b614a3400e9d4746b9d37fd26564231d,pts,0.482519
uuid-b614a3400e9d4746b9d37fd26564231d,approval,0.305367
uuid-b614a3400e9d4746b9d37fd26564231d,preferred,0.550596
uuid-b614a3400e9d4746b9d37fd26564231d,monotherapy,0.505604
uuid-b614a3400e9d4746b9d37fd26564231d,treatment,0.400625
uuid-b614a3400e9d4746b9d37fd26564231d,using nivo,0.470041
uuid-b614a3400e9d4746b9d37fd26564231d,NSCLC patients,0.36934
uuid-b614a3400e9d4746b9d37fd26564231d,approved,0.456821
uuid-b614a3400e9d4746b9d37fd26564231d,tumor types,0.352435
uuid-b614a3400e9d4746b9d37fd26564231d,feels,0.375047
uuid-b614a3400e9d4746b9d37fd26564231d,option,0.59698
uuid-abb158bea19c46349e65d726f00d0841,Opdivo,0.321288
uuid-abb158bea19c46349e65d726f00d0841,lung,0.332277
uuid-abb158bea19c46349e65d726f00d0841,stated,0.342991
uuid-abb158bea19c46349e65d726f00d0841,atezo,0.303184
uuid-abb158bea19c46349e65d726f00d0841,data,0.409213
uuid-abb158bea19c46349e65d726f00d0841,expressed,0.3027
uuid-abb158bea19c46349e65d726f00d0841,indication,0.464112
uuid-abb158bea19c46349e65d726f00d0841,AI,0.472463
uuid-abb158bea19c46349e65d726f00d0841,impressed,0.371014
uuid-abb158bea19c46349e65d726f00d0841,label,0.30887
uuid-abb158bea19c46349e65d726f00d0841,Keytruda,0.462435
uuid-abb158bea19c46349e65d726f00d0841,NCCN,0.486712
uuid-abb158bea19c46349e65d726f00d0841,flat dosing,0.365529
uuid-0f81d8c70e6244fc84e1da8401e8a891,patients,0.80261
uuid-0f81d8c70e6244fc84e1da8401e8a891,Opdivo,0.495836
uuid-0f81d8c70e6244fc84e1da8401e8a891,therapy,0.316274
uuid-0f81d8c70e6244fc84e1da8401e8a891,nivolumab,0.408558
uuid-0f81d8c70e6244fc84e1da8401e8a891,toxicity,0.522095
uuid-0f81d8c70e6244fc84e1da8401e8a891,regimen,0.551621
uuid-0f81d8c70e6244fc84e1da8401e8a891,treated,0.564468
uuid-0f81d8c70e6244fc84e1da8401e8a891,pts,0.420999
uuid-0f81d8c70e6244fc84e1da8401e8a891,treatment,0.58738
uuid-0f81d8c70e6244fc84e1da8401e8a891,progression,0.448501
uuid-0f81d8c70e6244fc84e1da8401e8a891,respond,0.410415
uuid-c97d1367291a4313b7b1a1d9199e7b4a,Nivo,0.338667
uuid-c97d1367291a4313b7b1a1d9199e7b4a,RTL,0.441483
uuid-c97d1367291a4313b7b1a1d9199e7b4a,BMS,0.378479
uuid-c97d1367291a4313b7b1a1d9199e7b4a,trial,0.594964
uuid-c97d1367291a4313b7b1a1d9199e7b4a,efficacy,0.49205
uuid-c97d1367291a4313b7b1a1d9199e7b4a,commented,0.383244
uuid-c97d1367291a4313b7b1a1d9199e7b4a,Ipi,0.30685
uuid-c97d1367291a4313b7b1a1d9199e7b4a,OS,0.567439
uuid-c97d1367291a4313b7b1a1d9199e7b4a,data,0.757433
uuid-c97d1367291a4313b7b1a1d9199e7b4a,expressed,0.350942
uuid-c97d1367291a4313b7b1a1d9199e7b4a,clinical trials,0.307432
uuid-c97d1367291a4313b7b1a1d9199e7b4a,PFS,0.53585
uuid-c97d1367291a4313b7b1a1d9199e7b4a,ORR,0.618483
uuid-c97d1367291a4313b7b1a1d9199e7b4a,nivo and pembro,0.351658
uuid-c97d1367291a4313b7b1a1d9199e7b4a,ASCO,0.387676
uuid-c97d1367291a4313b7b1a1d9199e7b4a,impressed,0.692297
uuid-c97d1367291a4313b7b1a1d9199e7b4a,LTL,0.327775
uuid-c97d1367291a4313b7b1a1d9199e7b4a,SCLC,0.316705
uuid-c97d1367291a4313b7b1a1d9199e7b4a,feels,0.452781
uuid-9d8ad83a29b54966b15724108ce46402,patients,0.346967
uuid-9d8ad83a29b54966b15724108ce46402,tumor,0.309485
uuid-9d8ad83a29b54966b15724108ce46402,bladder,0.338732
uuid-5f632cd1796f4c978e0e17937779b70e,TL,0.359666
uuid-5f632cd1796f4c978e0e17937779b70e,RTL,0.34503
uuid-5f632cd1796f4c978e0e17937779b70e,lung,0.638815
uuid-5f632cd1796f4c978e0e17937779b70e,1L,0.4253
uuid-5f632cd1796f4c978e0e17937779b70e,melanoma,0.485154
uuid-5f632cd1796f4c978e0e17937779b70e,shared,0.405673
uuid-5f632cd1796f4c978e0e17937779b70e,commented,0.365538
uuid-5f632cd1796f4c978e0e17937779b70e,RCC,0.82829
uuid-5f632cd1796f4c978e0e17937779b70e,TL stated,0.738146
uuid-5f632cd1796f4c978e0e17937779b70e,2L,0.483257
uuid-5f632cd1796f4c978e0e17937779b70e,stated,0.447637
uuid-5f632cd1796f4c978e0e17937779b70e,approval,0.373406
uuid-5f632cd1796f4c978e0e17937779b70e,preferred,0.382715
uuid-5f632cd1796f4c978e0e17937779b70e,PD-L1 testing,0.338835
uuid-5f632cd1796f4c978e0e17937779b70e,using nivo,0.438611
uuid-5f632cd1796f4c978e0e17937779b70e,clinical trials,0.301112
uuid-5f632cd1796f4c978e0e17937779b70e,PDL1 testing,0.583195
uuid-5f632cd1796f4c978e0e17937779b70e,NSCLC patients,0.340014
uuid-5f632cd1796f4c978e0e17937779b70e,approved,0.346612
uuid-5f632cd1796f4c978e0e17937779b70e,SCCHN,0.670911
uuid-5f632cd1796f4c978e0e17937779b70e,tumor types,0.479952
uuid-5f632cd1796f4c978e0e17937779b70e,oncologist,0.351664
uuid-5f632cd1796f4c978e0e17937779b70e,LTL,0.335529
uuid-5f632cd1796f4c978e0e17937779b70e,TLs,0.559061
uuid-5f632cd1796f4c978e0e17937779b70e,academic,0.321848
uuid-5f632cd1796f4c978e0e17937779b70e,Regional TL,0.571307
uuid-5f632cd1796f4c978e0e17937779b70e,RTL stated,0.590433
uuid-5f632cd1796f4c978e0e17937779b70e,TL shared,0.599158
uuid-5f632cd1796f4c978e0e17937779b70e,bladder,0.579662
uuid-5bc49b562469464b9033a20447fb7a0e,1L,0.46375
uuid-5bc49b562469464b9033a20447fb7a0e,PDL1,0.365413
uuid-5bc49b562469464b9033a20447fb7a0e,RCC,0.407545
uuid-5bc49b562469464b9033a20447fb7a0e,TL stated,0.476367
uuid-5bc49b562469464b9033a20447fb7a0e,2L,0.379331
uuid-5bc49b562469464b9033a20447fb7a0e,stated,0.447334
uuid-5bc49b562469464b9033a20447fb7a0e,PD-L1,0.438312
uuid-5bc49b562469464b9033a20447fb7a0e,approval,0.436584
uuid-5bc49b562469464b9033a20447fb7a0e,PD-L1 testing,0.410565
uuid-5bc49b562469464b9033a20447fb7a0e,testing,0.411376
uuid-5bc49b562469464b9033a20447fb7a0e,using nivo,0.343362
uuid-5bc49b562469464b9033a20447fb7a0e,data,0.35466
uuid-5bc49b562469464b9033a20447fb7a0e,PDL1 testing,0.500342
uuid-5bc49b562469464b9033a20447fb7a0e,NSCLC patients,0.416934
uuid-5bc49b562469464b9033a20447fb7a0e,approved,0.433469
uuid-5bc49b562469464b9033a20447fb7a0e,SCCHN,0.425523
uuid-5bc49b562469464b9033a20447fb7a0e,impressed,0.354052
uuid-5bc49b562469464b9033a20447fb7a0e,tumor types,0.3603
uuid-5bc49b562469464b9033a20447fb7a0e,TLs,0.321791
uuid-5bc49b562469464b9033a20447fb7a0e,Regional TL,0.385886
uuid-5bc49b562469464b9033a20447fb7a0e,RTL stated,0.363768
uuid-5bc49b562469464b9033a20447fb7a0e,bladder,0.328244
uuid-e4914b078c51436cbfafaed24858d28b,patients,0.443898
uuid-e4914b078c51436cbfafaed24858d28b,Opdivo,0.45976
uuid-e4914b078c51436cbfafaed24858d28b,regimen,0.348955
uuid-e4914b078c51436cbfafaed24858d28b,pts,0.329718
uuid-e4914b078c51436cbfafaed24858d28b,preferred,0.354047
uuid-e4914b078c51436cbfafaed24858d28b,monotherapy,0.353609
uuid-e4914b078c51436cbfafaed24858d28b,Keytruda,0.372954
uuid-e4914b078c51436cbfafaed24858d28b,feels,0.344005
uuid-e4914b078c51436cbfafaed24858d28b,option,0.419584
uuid-aac33cbf812f46c4adff8552a2dc3f8f,pembro,0.302493
uuid-aac33cbf812f46c4adff8552a2dc3f8f,PDL1,0.302069
uuid-aac33cbf812f46c4adff8552a2dc3f8f,efficacy,0.498018
uuid-aac33cbf812f46c4adff8552a2dc3f8f,OS,0.308053
uuid-aac33cbf812f46c4adff8552a2dc3f8f,atezo,0.415743
uuid-aac33cbf812f46c4adff8552a2dc3f8f,regards,0.351938
uuid-aac33cbf812f46c4adff8552a2dc3f8f,data,0.305357
uuid-aac33cbf812f46c4adff8552a2dc3f8f,PFS,0.3156
uuid-aac33cbf812f46c4adff8552a2dc3f8f,ORR,0.319744
uuid-aac33cbf812f46c4adff8552a2dc3f8f,nivo and pembro,0.453215
uuid-aac33cbf812f46c4adff8552a2dc3f8f,believes,0.377741
uuid-aac33cbf812f46c4adff8552a2dc3f8f,vs,0.319632
uuid-aac33cbf812f46c4adff8552a2dc3f8f,TLs,0.485344
uuid-aac33cbf812f46c4adff8552a2dc3f8f,PDL1 expression,0.30175
uuid-7080990326e24fa7b58b9b99f7543c35,TL,0.515807
uuid-7080990326e24fa7b58b9b99f7543c35,1L,0.313265
uuid-7080990326e24fa7b58b9b99f7543c35,TL stated,0.540259
uuid-7080990326e24fa7b58b9b99f7543c35,Merck,0.363017
uuid-7080990326e24fa7b58b9b99f7543c35,institution,0.318516
uuid-7080990326e24fa7b58b9b99f7543c35,PD-L1,0.556881
uuid-7080990326e24fa7b58b9b99f7543c35,approval,0.497453
uuid-7080990326e24fa7b58b9b99f7543c35,PD-L1 testing,0.738111
uuid-7080990326e24fa7b58b9b99f7543c35,testing,0.742989
uuid-7080990326e24fa7b58b9b99f7543c35,PDL1 testing,0.710334
uuid-7080990326e24fa7b58b9b99f7543c35,NSCLC patients,0.674452
uuid-7080990326e24fa7b58b9b99f7543c35,approved,0.319136
uuid-7080990326e24fa7b58b9b99f7543c35,SCCHN,0.368158
uuid-7080990326e24fa7b58b9b99f7543c35,assay,0.504776
uuid-7080990326e24fa7b58b9b99f7543c35,RTL stated,0.328177
uuid-6de81fa92ab846de9947147990eda832,trial,0.301487
uuid-6de81fa92ab846de9947147990eda832,Merck,0.311579
uuid-6de81fa92ab846de9947147990eda832,drug,0.539633
uuid-7c2f8492e5c94b5c8236ad535a4664cb,patients,0.861436
uuid-7c2f8492e5c94b5c8236ad535a4664cb,Opdivo,0.527748
uuid-7c2f8492e5c94b5c8236ad535a4664cb,therapy,0.529528
uuid-7c2f8492e5c94b5c8236ad535a4664cb,nivolumab,0.435525
uuid-7c2f8492e5c94b5c8236ad535a4664cb,toxicity,0.328532
uuid-7c2f8492e5c94b5c8236ad535a4664cb,regimen,0.557121
uuid-7c2f8492e5c94b5c8236ad535a4664cb,treated,0.621752
uuid-7c2f8492e5c94b5c8236ad535a4664cb,pts,0.568765
uuid-7c2f8492e5c94b5c8236ad535a4664cb,treatment,0.775295
uuid-7c2f8492e5c94b5c8236ad535a4664cb,response,0.454941
uuid-7c2f8492e5c94b5c8236ad535a4664cb,progression,0.745575
uuid-7c2f8492e5c94b5c8236ad535a4664cb,chemotherapy,0.302423
uuid-7c2f8492e5c94b5c8236ad535a4664cb,respond,0.613333
uuid-7e1d4e5f7c154a15b17c795436fc7daf,patients,0.725982
uuid-7e1d4e5f7c154a15b17c795436fc7daf,Opdivo,0.319155
uuid-7e1d4e5f7c154a15b17c795436fc7daf,therapy,0.687978
uuid-7e1d4e5f7c154a15b17c795436fc7daf,nivolumab,0.350921
uuid-7e1d4e5f7c154a15b17c795436fc7daf,regimen,0.464956
uuid-7e1d4e5f7c154a15b17c795436fc7daf,treated,0.469766
uuid-7e1d4e5f7c154a15b17c795436fc7daf,chemo,0.385207
uuid-7e1d4e5f7c154a15b17c795436fc7daf,pts,0.505589
uuid-7e1d4e5f7c154a15b17c795436fc7daf,monotherapy,0.330549
uuid-7e1d4e5f7c154a15b17c795436fc7daf,treatment,0.824118
uuid-7e1d4e5f7c154a15b17c795436fc7daf,response,0.480163
uuid-7e1d4e5f7c154a15b17c795436fc7daf,PD1,0.359611
uuid-7e1d4e5f7c154a15b17c795436fc7daf,progression,0.721915
uuid-7e1d4e5f7c154a15b17c795436fc7daf,chemotherapy,0.466605
uuid-7e1d4e5f7c154a15b17c795436fc7daf,respond,0.567434
uuid-7e1d4e5f7c154a15b17c795436fc7daf,option,0.403917
uuid-c2690e59fe7746d79884861870716609,expressed,0.341043
uuid-c2690e59fe7746d79884861870716609,bladder,0.303582
uuid-23e589bdb57a4d03a2d9dbb179c9835b,patients,0.300017
uuid-23e589bdb57a4d03a2d9dbb179c9835b,Opdivo,0.50746
uuid-23e589bdb57a4d03a2d9dbb179c9835b,dose,0.723114
uuid-23e589bdb57a4d03a2d9dbb179c9835b,toxicity,0.356317
uuid-23e589bdb57a4d03a2d9dbb179c9835b,Ipi,0.431342
uuid-23e589bdb57a4d03a2d9dbb179c9835b,mentioned,0.420629
uuid-23e589bdb57a4d03a2d9dbb179c9835b,HCP,0.498594
uuid-23e589bdb57a4d03a2d9dbb179c9835b,vs,0.430091
uuid-23e589bdb57a4d03a2d9dbb179c9835b,drug,0.326339
uuid-23e589bdb57a4d03a2d9dbb179c9835b,Keytruda,0.371319
uuid-23e589bdb57a4d03a2d9dbb179c9835b,flat dosing,0.679296
uuid-4a35bf8f6e4f49dfb4456229838a7a37,patients,0.582439
uuid-4a35bf8f6e4f49dfb4456229838a7a37,regimen,0.376604
uuid-4a35bf8f6e4f49dfb4456229838a7a37,treated,0.389773
uuid-4a35bf8f6e4f49dfb4456229838a7a37,TL stated,0.368835
uuid-4a35bf8f6e4f49dfb4456229838a7a37,pts,0.454211
uuid-4a35bf8f6e4f49dfb4456229838a7a37,testing,0.306499
uuid-4a35bf8f6e4f49dfb4456229838a7a37,PDL1 testing,0.30512
uuid-4a35bf8f6e4f49dfb4456229838a7a37,NSCLC patients,0.572137
uuid-4a35bf8f6e4f49dfb4456229838a7a37,progression,0.39812
uuid-4a35bf8f6e4f49dfb4456229838a7a37,tumor types,0.309364
uuid-4a35bf8f6e4f49dfb4456229838a7a37,respond,0.314079
uuid-4a35bf8f6e4f49dfb4456229838a7a37,RTL stated,0.323377
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,patients,0.684634
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,Opdivo,0.365274
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,therapy,0.493418
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,nivolumab,0.493172
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,toxicity,0.397908
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,regimen,0.559848
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,treated,0.635315
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,pts,0.432251
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,treatment,0.601121
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,response,0.343536
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,PD1,0.35507
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,cHL,0.350885
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,progression,0.626623
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,chemotherapy,0.382657
uuid-85ee960faf5c4250ac2252bf9cdcfcc4,respond,0.410846
uuid-555f0c3df51d4a26b4d874015dddeaa1,nivolumab,0.318068
uuid-555f0c3df51d4a26b4d874015dddeaa1,treated,0.320592
uuid-53e0b6acef324f76b6ff4cbb48f556d5,Nivo,0.356816
uuid-53e0b6acef324f76b6ff4cbb48f556d5,patients,0.451516
uuid-53e0b6acef324f76b6ff4cbb48f556d5,Opdivo,0.542063
uuid-53e0b6acef324f76b6ff4cbb48f556d5,pembro,0.336691
uuid-53e0b6acef324f76b6ff4cbb48f556d5,dose,0.866471
uuid-53e0b6acef324f76b6ff4cbb48f556d5,nivolumab,0.303202
uuid-53e0b6acef324f76b6ff4cbb48f556d5,toxicity,0.316142
uuid-53e0b6acef324f76b6ff4cbb48f556d5,regimen,0.326898
uuid-53e0b6acef324f76b6ff4cbb48f556d5,Ipi,0.467537
uuid-53e0b6acef324f76b6ff4cbb48f556d5,vs,0.45254
uuid-53e0b6acef324f76b6ff4cbb48f556d5,Keytruda,0.408563
uuid-53e0b6acef324f76b6ff4cbb48f556d5,flat dosing,0.747731
uuid-49c811ad52374624819fcc6872a40a85,TL,0.597564
uuid-49c811ad52374624819fcc6872a40a85,PD-L1,0.331867
uuid-49c811ad52374624819fcc6872a40a85,PD-L1 testing,0.596247
uuid-49c811ad52374624819fcc6872a40a85,testing,0.491833
uuid-49c811ad52374624819fcc6872a40a85,PDL1 testing,0.341626
uuid-49c811ad52374624819fcc6872a40a85,NSCLC patients,0.30379
uuid-49c811ad52374624819fcc6872a40a85,assay,0.415291
uuid-1873270823254486852e6b047f773c88,Nivo,0.340797
uuid-1873270823254486852e6b047f773c88,patients,0.718906
uuid-1873270823254486852e6b047f773c88,Opdivo,0.499143
uuid-1873270823254486852e6b047f773c88,therapy,0.640932
uuid-1873270823254486852e6b047f773c88,nivolumab,0.442122
uuid-1873270823254486852e6b047f773c88,toxicity,0.426969
uuid-1873270823254486852e6b047f773c88,regimen,0.614198
uuid-1873270823254486852e6b047f773c88,treated,0.429481
uuid-1873270823254486852e6b047f773c88,combination,0.371446
uuid-1873270823254486852e6b047f773c88,chemo,0.515679
uuid-1873270823254486852e6b047f773c88,pts,0.426841
uuid-1873270823254486852e6b047f773c88,monotherapy,0.467938
uuid-1873270823254486852e6b047f773c88,treatment,0.769958
uuid-1873270823254486852e6b047f773c88,response,0.402145
uuid-1873270823254486852e6b047f773c88,combo,0.310326
uuid-1873270823254486852e6b047f773c88,PD1,0.415401
uuid-1873270823254486852e6b047f773c88,progression,0.619722
uuid-1873270823254486852e6b047f773c88,chemotherapy,0.510937
uuid-1873270823254486852e6b047f773c88,respond,0.54047
uuid-1873270823254486852e6b047f773c88,option,0.459606
uuid-ee1d17c391ed41e28d6285f4d3f48433,lung,0.369073
uuid-ee1d17c391ed41e28d6285f4d3f48433,commented,0.361141
uuid-ee1d17c391ed41e28d6285f4d3f48433,regards,0.413251
uuid-ee1d17c391ed41e28d6285f4d3f48433,indication,0.366286
uuid-ee1d17c391ed41e28d6285f4d3f48433,AI,0.349616
uuid-ee1d17c391ed41e28d6285f4d3f48433,oncology,0.473662
uuid-ee1d17c391ed41e28d6285f4d3f48433,TLs,0.409283
uuid-ee1d17c391ed41e28d6285f4d3f48433,NCCN,0.363438
uuid-008295eb188247e698b2bb75ea8d2f31,patients,0.529772
uuid-008295eb188247e698b2bb75ea8d2f31,Opdivo,0.459064
uuid-008295eb188247e698b2bb75ea8d2f31,dose,0.503426
uuid-008295eb188247e698b2bb75ea8d2f31,nivolumab,0.362413
uuid-008295eb188247e698b2bb75ea8d2f31,toxicity,0.550997
uuid-008295eb188247e698b2bb75ea8d2f31,regimen,0.720748
uuid-008295eb188247e698b2bb75ea8d2f31,treated,0.36947
uuid-008295eb188247e698b2bb75ea8d2f31,combination,0.334585
uuid-008295eb188247e698b2bb75ea8d2f31,pts,0.372471
uuid-008295eb188247e698b2bb75ea8d2f31,Ipi,0.43802
uuid-008295eb188247e698b2bb75ea8d2f31,monotherapy,0.358949
uuid-008295eb188247e698b2bb75ea8d2f31,treatment,0.433979
uuid-008295eb188247e698b2bb75ea8d2f31,combo,0.352319
uuid-008295eb188247e698b2bb75ea8d2f31,progression,0.449406
uuid-008295eb188247e698b2bb75ea8d2f31,respond,0.370292
uuid-40bbbb4f1c97409eaac59a8d450beaaa,discussed,0.583564
uuid-40bbbb4f1c97409eaac59a8d450beaaa,regards,0.495235
uuid-40bbbb4f1c97409eaac59a8d450beaaa,AI,0.358316
uuid-40bbbb4f1c97409eaac59a8d450beaaa,oncology,0.311371
uuid-40bbbb4f1c97409eaac59a8d450beaaa,clinical,0.307451
uuid-40bbbb4f1c97409eaac59a8d450beaaa,academic,0.31609
uuid-40bbbb4f1c97409eaac59a8d450beaaa,NCCN,0.369847
uuid-151cfbbc40ad4b6184bd377b21863991,BMS,0.474526
uuid-151cfbbc40ad4b6184bd377b21863991,trial,0.410092
uuid-151cfbbc40ad4b6184bd377b21863991,commented,0.482103
uuid-151cfbbc40ad4b6184bd377b21863991,Merck,0.325838
uuid-151cfbbc40ad4b6184bd377b21863991,regards,0.37061
uuid-151cfbbc40ad4b6184bd377b21863991,data,0.327255
uuid-151cfbbc40ad4b6184bd377b21863991,expressed,0.313767
uuid-151cfbbc40ad4b6184bd377b21863991,clinical trials,0.311456
uuid-151cfbbc40ad4b6184bd377b21863991,lung cancer,0.336476
uuid-151cfbbc40ad4b6184bd377b21863991,impressed,0.334054
uuid-151cfbbc40ad4b6184bd377b21863991,feels,0.502738
uuid-a7814f4548c14c2b8c6d707ff7a915c3,TL,0.545683
uuid-a7814f4548c14c2b8c6d707ff7a915c3,PDL1,0.383429
uuid-a7814f4548c14c2b8c6d707ff7a915c3,TL stated,0.390793
uuid-a7814f4548c14c2b8c6d707ff7a915c3,Merck,0.347247
uuid-a7814f4548c14c2b8c6d707ff7a915c3,institution,0.379048
uuid-a7814f4548c14c2b8c6d707ff7a915c3,PD-L1,0.721867
uuid-a7814f4548c14c2b8c6d707ff7a915c3,PD-L1 testing,0.779559
uuid-a7814f4548c14c2b8c6d707ff7a915c3,testing,0.819418
uuid-a7814f4548c14c2b8c6d707ff7a915c3,PDL1 testing,0.677071
uuid-a7814f4548c14c2b8c6d707ff7a915c3,NSCLC patients,0.511667
uuid-a7814f4548c14c2b8c6d707ff7a915c3,assay,0.713493
uuid-a7814f4548c14c2b8c6d707ff7a915c3,biomarker,0.503733
uuid-d14f9586fd4b4956835317f008e13004,toxicity,0.325723
uuid-d14f9586fd4b4956835317f008e13004,regimen,0.315179
uuid-d14f9586fd4b4956835317f008e13004,treated,0.34617
uuid-d14f9586fd4b4956835317f008e13004,melanoma,0.334681
uuid-8b7787a7473a4481989b3354a4fc621c,patients,0.506732
uuid-8b7787a7473a4481989b3354a4fc621c,Opdivo,0.458935
uuid-8b7787a7473a4481989b3354a4fc621c,therapy,0.45053
uuid-8b7787a7473a4481989b3354a4fc621c,nivolumab,0.369293
uuid-8b7787a7473a4481989b3354a4fc621c,regimen,0.344465
uuid-8b7787a7473a4481989b3354a4fc621c,treated,0.368402
uuid-8b7787a7473a4481989b3354a4fc621c,pts,0.358372
uuid-8b7787a7473a4481989b3354a4fc621c,treatment,0.456186
uuid-8b7787a7473a4481989b3354a4fc621c,progression,0.474908
uuid-8b7787a7473a4481989b3354a4fc621c,respond,0.341682
uuid-8b7787a7473a4481989b3354a4fc621c,feels,0.322167
uuid-9d8bbfae934e42c1bbb027cec28e26a0,discussed,0.349624
uuid-9d8bbfae934e42c1bbb027cec28e26a0,shared,0.413518
uuid-9d8bbfae934e42c1bbb027cec28e26a0,atezo,0.305414
uuid-9d8bbfae934e42c1bbb027cec28e26a0,preferred,0.34676
uuid-9d8bbfae934e42c1bbb027cec28e26a0,indication,0.360059
uuid-9d8bbfae934e42c1bbb027cec28e26a0,Keytruda,0.303997
uuid-9d8bbfae934e42c1bbb027cec28e26a0,TLs,0.366093
uuid-9d8bbfae934e42c1bbb027cec28e26a0,academic,0.361908
uuid-9d8bbfae934e42c1bbb027cec28e26a0,flat dosing,0.349418
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,patients,0.460245
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,tumor,0.588088
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,pts,0.331809
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,response,0.356931
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,NSCLC patients,0.353287
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,progression,0.364992
uuid-63ee25902f5a4ab3ba1d20eae62caf2a,respond,0.304775
uuid-5f61294847684f158a0e832792bb9498,BMS,0.35255
uuid-5f61294847684f158a0e832792bb9498,commented,0.368259
uuid-5f61294847684f158a0e832792bb9498,regards,0.31994
uuid-5f61294847684f158a0e832792bb9498,data,0.457566
uuid-5f61294847684f158a0e832792bb9498,nivo and pembro,0.344314
uuid-5f61294847684f158a0e832792bb9498,believes,0.355906
uuid-5f61294847684f158a0e832792bb9498,feels,0.488735
uuid-4259f40b8ad44c6a8bd9c57240315a72,TL,0.477109
uuid-4259f40b8ad44c6a8bd9c57240315a72,Merck,0.555716
uuid-f965af82e8874046afc55253314e0229,physicians,0.446176
uuid-3115027f63ad484f8ad6f7b289e7601a,TL,0.524812
uuid-3115027f63ad484f8ad6f7b289e7601a,pembro,0.440493
uuid-3115027f63ad484f8ad6f7b289e7601a,RTL,0.310745
uuid-3115027f63ad484f8ad6f7b289e7601a,PDL1,0.310033
uuid-3115027f63ad484f8ad6f7b289e7601a,commented,0.406831
uuid-3115027f63ad484f8ad6f7b289e7601a,TL stated,0.469424
uuid-3115027f63ad484f8ad6f7b289e7601a,Merck,0.481807
uuid-3115027f63ad484f8ad6f7b289e7601a,stated,0.339323
uuid-3115027f63ad484f8ad6f7b289e7601a,PD-L1,0.484995
uuid-3115027f63ad484f8ad6f7b289e7601a,approval,0.412125
uuid-3115027f63ad484f8ad6f7b289e7601a,atezo,0.454617
uuid-3115027f63ad484f8ad6f7b289e7601a,PD-L1 testing,0.541061
uuid-3115027f63ad484f8ad6f7b289e7601a,testing,0.543794
uuid-3115027f63ad484f8ad6f7b289e7601a,data,0.33001
uuid-3115027f63ad484f8ad6f7b289e7601a,expressed,0.308224
uuid-3115027f63ad484f8ad6f7b289e7601a,mentioned,0.358568
uuid-3115027f63ad484f8ad6f7b289e7601a,PDL1 testing,0.595112
uuid-3115027f63ad484f8ad6f7b289e7601a,indication,0.32361
uuid-3115027f63ad484f8ad6f7b289e7601a,NSCLC patients,0.381361
uuid-3115027f63ad484f8ad6f7b289e7601a,SCCHN,0.365732
uuid-3115027f63ad484f8ad6f7b289e7601a,LTL,0.365541
uuid-3115027f63ad484f8ad6f7b289e7601a,TLs,0.361336
uuid-3115027f63ad484f8ad6f7b289e7601a,assay,0.437127
uuid-3115027f63ad484f8ad6f7b289e7601a,Regional TL,0.343004
uuid-3115027f63ad484f8ad6f7b289e7601a,bladder,0.330649
uuid-1999eea3da584c3585a6ecd75678683b,RTL,0.33631
uuid-1999eea3da584c3585a6ecd75678683b,nivolumab,0.376553
uuid-1999eea3da584c3585a6ecd75678683b,NTL,0.5273
uuid-1999eea3da584c3585a6ecd75678683b,mentioned,0.469824
uuid-1999eea3da584c3585a6ecd75678683b,cHL,0.635027
uuid-1999eea3da584c3585a6ecd75678683b,ASCO,0.436062
uuid-cac03a7d83fc4163a7a6202c69fe8ee9,patients,0.332806
uuid-cac03a7d83fc4163a7a6202c69fe8ee9,treated,0.332392
uuid-cac03a7d83fc4163a7a6202c69fe8ee9,treatment,0.353021
uuid-cac03a7d83fc4163a7a6202c69fe8ee9,progression,0.362476
uuid-cac03a7d83fc4163a7a6202c69fe8ee9,immunotherapy,0.513435
uuid-8693dd471db4450c912e6e86505fe863,patients,0.416018
uuid-8693dd471db4450c912e6e86505fe863,treated,0.433006
uuid-8693dd471db4450c912e6e86505fe863,RCC,0.38877
uuid-8693dd471db4450c912e6e86505fe863,TL stated,0.311302
uuid-8693dd471db4450c912e6e86505fe863,preferred,0.491367
uuid-8693dd471db4450c912e6e86505fe863,using nivo,0.391086
uuid-8693dd471db4450c912e6e86505fe863,SCCHN,0.50662
uuid-8693dd471db4450c912e6e86505fe863,Regional TL,0.430224
uuid-8693dd471db4450c912e6e86505fe863,RTL stated,0.550696
uuid-8693dd471db4450c912e6e86505fe863,TL shared,0.375492
uuid-8693dd471db4450c912e6e86505fe863,option,0.335688
uuid-8693dd471db4450c912e6e86505fe863,bladder,0.312012
uuid-581b825b74b349a09778a84b98c4f546,patients,0.735834
uuid-581b825b74b349a09778a84b98c4f546,Opdivo,0.452756
uuid-581b825b74b349a09778a84b98c4f546,therapy,0.451677
uuid-581b825b74b349a09778a84b98c4f546,nivolumab,0.56203
uuid-581b825b74b349a09778a84b98c4f546,regimen,0.400591
uuid-581b825b74b349a09778a84b98c4f546,treated,0.7073
uuid-581b825b74b349a09778a84b98c4f546,pts,0.470897
uuid-581b825b74b349a09778a84b98c4f546,physicians,0.312441
uuid-581b825b74b349a09778a84b98c4f546,treatment,0.56096
uuid-581b825b74b349a09778a84b98c4f546,using nivo,0.417637
uuid-581b825b74b349a09778a84b98c4f546,cHL,0.402081
uuid-581b825b74b349a09778a84b98c4f546,progression,0.520058
uuid-581b825b74b349a09778a84b98c4f546,respond,0.337751
uuid-581b825b74b349a09778a84b98c4f546,RTL stated,0.374395
uuid-297ba52e6acd491d87350df7c83df471,patients,0.363228
uuid-297ba52e6acd491d87350df7c83df471,therapy,0.522457
uuid-297ba52e6acd491d87350df7c83df471,nivolumab,0.360649
uuid-297ba52e6acd491d87350df7c83df471,regimen,0.335205
uuid-297ba52e6acd491d87350df7c83df471,treated,0.366491
uuid-297ba52e6acd491d87350df7c83df471,RCC,0.431634
uuid-297ba52e6acd491d87350df7c83df471,pts,0.38348
uuid-297ba52e6acd491d87350df7c83df471,monotherapy,0.308403
uuid-297ba52e6acd491d87350df7c83df471,treatment,0.509072
uuid-297ba52e6acd491d87350df7c83df471,response,0.539933
uuid-297ba52e6acd491d87350df7c83df471,PD1,0.374379
uuid-297ba52e6acd491d87350df7c83df471,progression,0.555805
uuid-297ba52e6acd491d87350df7c83df471,respond,0.310817
uuid-297ba52e6acd491d87350df7c83df471,immunotherapy,0.310243
uuid-297ba52e6acd491d87350df7c83df471,PD-1,0.328317
uuid-297ba52e6acd491d87350df7c83df471,TL shared,0.344472
uuid-1698a17714224aafacc8e221a8843e6c,Opdivo,0.370546
uuid-1698a17714224aafacc8e221a8843e6c,dose,0.707173
uuid-1698a17714224aafacc8e221a8843e6c,toxicity,0.319895
uuid-1698a17714224aafacc8e221a8843e6c,vs,0.321355
uuid-1698a17714224aafacc8e221a8843e6c,drug,0.324391
uuid-1698a17714224aafacc8e221a8843e6c,Keytruda,0.395067
uuid-1698a17714224aafacc8e221a8843e6c,TLs,0.300681
uuid-1698a17714224aafacc8e221a8843e6c,flat dosing,0.838999
uuid-da396675c50e4eeeabfe327717f32fdf,Nivo,0.45676
uuid-da396675c50e4eeeabfe327717f32fdf,nivolumab,0.334104
uuid-da396675c50e4eeeabfe327717f32fdf,trial,0.557198
uuid-da396675c50e4eeeabfe327717f32fdf,mentioned,0.300532
uuid-da396675c50e4eeeabfe327717f32fdf,cHL,0.492782
uuid-976eb999268944d78975dd682c631b76,Nivo,0.390754
uuid-976eb999268944d78975dd682c631b76,pembro,0.440463
uuid-976eb999268944d78975dd682c631b76,1L,0.385494
uuid-976eb999268944d78975dd682c631b76,RCC,0.321786
uuid-976eb999268944d78975dd682c631b76,2L,0.474436
uuid-976eb999268944d78975dd682c631b76,stated,0.411238
uuid-976eb999268944d78975dd682c631b76,approval,0.494101
uuid-976eb999268944d78975dd682c631b76,atezo,0.440733
uuid-976eb999268944d78975dd682c631b76,preferred,0.475835
uuid-976eb999268944d78975dd682c631b76,using nivo,0.524631
uuid-976eb999268944d78975dd682c631b76,clinical trials,0.366059
uuid-976eb999268944d78975dd682c631b76,indication,0.330677
uuid-976eb999268944d78975dd682c631b76,approved,0.500637
uuid-976eb999268944d78975dd682c631b76,SCCHN,0.428461
uuid-976eb999268944d78975dd682c631b76,tumor types,0.348283
uuid-976eb999268944d78975dd682c631b76,LTL,0.32591
uuid-976eb999268944d78975dd682c631b76,Regional TL,0.309833
uuid-976eb999268944d78975dd682c631b76,RTL stated,0.550147
uuid-976eb999268944d78975dd682c631b76,option,0.331941
uuid-976eb999268944d78975dd682c631b76,bladder,0.579743
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,TL,0.345202
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,pembro,0.567435
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,1L,0.670339
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,RCC,0.412081
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,TL stated,0.373513
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,2L,0.649815
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,agents,0.381885
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,PD-L1,0.326946
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,approval,0.500781
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,atezo,0.554342
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,preferred,0.537708
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,testing,0.322222
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,monotherapy,0.458616
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,using nivo,0.52107
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,combo,0.330514
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,PDL1 testing,0.403303
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,indication,0.311245
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,NSCLC patients,0.370566
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,approved,0.472505
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,SCCHN,0.400831
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,nivo and pembro,0.301105
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,believes,0.328521
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,TLs,0.322991
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,feels,0.311878
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,RTL stated,0.512249
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,option,0.428686
uuid-72b4eed2a4b347c0bdd04f320c11b2ba,bladder,0.329247
uuid-adf9570846d34698978425968ff4d51c,Nivo,0.43379
uuid-adf9570846d34698978425968ff4d51c,pembro,0.436279
uuid-adf9570846d34698978425968ff4d51c,nivolumab,0.380788
uuid-adf9570846d34698978425968ff4d51c,1L,0.54481
uuid-adf9570846d34698978425968ff4d51c,regimen,0.487793
uuid-adf9570846d34698978425968ff4d51c,RCC,0.45328
uuid-adf9570846d34698978425968ff4d51c,combination,0.44568
uuid-adf9570846d34698978425968ff4d51c,chemo,0.35328
uuid-adf9570846d34698978425968ff4d51c,2L,0.592215
uuid-adf9570846d34698978425968ff4d51c,pts,0.377292
uuid-adf9570846d34698978425968ff4d51c,agents,0.341596
uuid-adf9570846d34698978425968ff4d51c,Ipi,0.358065
uuid-adf9570846d34698978425968ff4d51c,stated,0.309348
uuid-adf9570846d34698978425968ff4d51c,approval,0.312752
uuid-adf9570846d34698978425968ff4d51c,atezo,0.423809
uuid-adf9570846d34698978425968ff4d51c,preferred,0.521839
uuid-adf9570846d34698978425968ff4d51c,monotherapy,0.61476
uuid-adf9570846d34698978425968ff4d51c,using nivo,0.501552
uuid-adf9570846d34698978425968ff4d51c,combo,0.525338
uuid-adf9570846d34698978425968ff4d51c,PD1,0.352238
uuid-adf9570846d34698978425968ff4d51c,approved,0.458898
uuid-adf9570846d34698978425968ff4d51c,SCCHN,0.36248
uuid-adf9570846d34698978425968ff4d51c,impressed,0.404842
uuid-adf9570846d34698978425968ff4d51c,TLs,0.323842
uuid-adf9570846d34698978425968ff4d51c,SCLC,0.316883
uuid-adf9570846d34698978425968ff4d51c,feels,0.470344
uuid-adf9570846d34698978425968ff4d51c,RTL stated,0.504195
uuid-adf9570846d34698978425968ff4d51c,option,0.488272
uuid-adf9570846d34698978425968ff4d51c,bladder,0.335482
uuid-ecd32c57f46747ceae95fca33b231be7,patients,0.521433
uuid-ecd32c57f46747ceae95fca33b231be7,toxicity,0.709591
uuid-ecd32c57f46747ceae95fca33b231be7,regimen,0.621583
uuid-ecd32c57f46747ceae95fca33b231be7,treated,0.518168
uuid-ecd32c57f46747ceae95fca33b231be7,pts,0.368718
uuid-ecd32c57f46747ceae95fca33b231be7,treatment,0.50988
uuid-ecd32c57f46747ceae95fca33b231be7,response,0.353374
uuid-ecd32c57f46747ceae95fca33b231be7,progression,0.461998
uuid-ecd32c57f46747ceae95fca33b231be7,respond,0.469104
uuid-2a977945ec4740eb80d82f2f8dd52639,patients,0.305296
uuid-2a977945ec4740eb80d82f2f8dd52639,Opdivo,0.626481
uuid-2a977945ec4740eb80d82f2f8dd52639,dose,0.673978
uuid-2a977945ec4740eb80d82f2f8dd52639,toxicity,0.35494
uuid-2a977945ec4740eb80d82f2f8dd52639,Ipi,0.301365
uuid-2a977945ec4740eb80d82f2f8dd52639,mentioned,0.350429
uuid-2a977945ec4740eb80d82f2f8dd52639,HCP,0.380113
uuid-2a977945ec4740eb80d82f2f8dd52639,drug,0.362746
uuid-2a977945ec4740eb80d82f2f8dd52639,Keytruda,0.611487
uuid-2a977945ec4740eb80d82f2f8dd52639,flat dosing,0.665997
uuid-b17059c4e5bc4ad78b5aa01e25e81861,patients,0.877033
uuid-b17059c4e5bc4ad78b5aa01e25e81861,Opdivo,0.426264
uuid-b17059c4e5bc4ad78b5aa01e25e81861,therapy,0.609176
uuid-b17059c4e5bc4ad78b5aa01e25e81861,nivolumab,0.483179
uuid-b17059c4e5bc4ad78b5aa01e25e81861,toxicity,0.414284
uuid-b17059c4e5bc4ad78b5aa01e25e81861,regimen,0.621713
uuid-b17059c4e5bc4ad78b5aa01e25e81861,treated,0.587391
uuid-b17059c4e5bc4ad78b5aa01e25e81861,combination,0.304201
uuid-b17059c4e5bc4ad78b5aa01e25e81861,chemo,0.45602
uuid-b17059c4e5bc4ad78b5aa01e25e81861,pts,0.637858
uuid-b17059c4e5bc4ad78b5aa01e25e81861,monotherapy,0.444744
uuid-b17059c4e5bc4ad78b5aa01e25e81861,treatment,0.696522
uuid-b17059c4e5bc4ad78b5aa01e25e81861,response,0.479976
uuid-b17059c4e5bc4ad78b5aa01e25e81861,PD1,0.391875
uuid-b17059c4e5bc4ad78b5aa01e25e81861,cHL,0.30471
uuid-b17059c4e5bc4ad78b5aa01e25e81861,progression,0.685866
uuid-b17059c4e5bc4ad78b5aa01e25e81861,chemotherapy,0.487219
uuid-b17059c4e5bc4ad78b5aa01e25e81861,respond,0.513877
uuid-b17059c4e5bc4ad78b5aa01e25e81861,option,0.392539
uuid-d7fd566509bf4525838c99f65d3258f8,PDL1,0.491413
uuid-d7fd566509bf4525838c99f65d3258f8,efficacy,0.428668
uuid-d7fd566509bf4525838c99f65d3258f8,discussed,0.357087
uuid-d7fd566509bf4525838c99f65d3258f8,chemo,0.308152
uuid-d7fd566509bf4525838c99f65d3258f8,OS,0.413768
uuid-d7fd566509bf4525838c99f65d3258f8,data,0.328721
uuid-d7fd566509bf4525838c99f65d3258f8,PFS,0.447608
uuid-d7fd566509bf4525838c99f65d3258f8,ORR,0.402039
uuid-d7fd566509bf4525838c99f65d3258f8,nivo and pembro,0.322598
uuid-d7fd566509bf4525838c99f65d3258f8,believes,0.345065
uuid-d7fd566509bf4525838c99f65d3258f8,feels,0.500774
uuid-d7fd566509bf4525838c99f65d3258f8,PDL1 expression,0.502882
uuid-d7fd566509bf4525838c99f65d3258f8,option,0.336299
uuid-d7fd566509bf4525838c99f65d3258f8,biomarker,0.368519
uuid-31615acde74947f0b3b73ae6fd10f098,pembro,0.431789
uuid-31615acde74947f0b3b73ae6fd10f098,lung,0.449524
uuid-31615acde74947f0b3b73ae6fd10f098,NSCLC,0.379141
uuid-31615acde74947f0b3b73ae6fd10f098,trial,0.384043
uuid-31615acde74947f0b3b73ae6fd10f098,melanoma,0.301236
uuid-31615acde74947f0b3b73ae6fd10f098,RCC,0.379024
uuid-31615acde74947f0b3b73ae6fd10f098,TL stated,0.311717
uuid-31615acde74947f0b3b73ae6fd10f098,Merck,0.36326
uuid-31615acde74947f0b3b73ae6fd10f098,stated,0.330418
uuid-31615acde74947f0b3b73ae6fd10f098,atezo,0.42
uuid-31615acde74947f0b3b73ae6fd10f098,preferred,0.321763
uuid-31615acde74947f0b3b73ae6fd10f098,data,0.308149
uuid-31615acde74947f0b3b73ae6fd10f098,clinical trials,0.312354
uuid-31615acde74947f0b3b73ae6fd10f098,indication,0.395349
uuid-31615acde74947f0b3b73ae6fd10f098,SCCHN,0.488833
uuid-31615acde74947f0b3b73ae6fd10f098,TLs,0.381013
uuid-31615acde74947f0b3b73ae6fd10f098,Regional TL,0.347132
uuid-31615acde74947f0b3b73ae6fd10f098,RTL stated,0.359151
uuid-31615acde74947f0b3b73ae6fd10f098,TL shared,0.336389
uuid-31615acde74947f0b3b73ae6fd10f098,bladder,0.447542
uuid-b4f2e3a6857f41039a8dde380653f5a1,patients,0.441247
uuid-b4f2e3a6857f41039a8dde380653f5a1,Opdivo,0.519589
uuid-b4f2e3a6857f41039a8dde380653f5a1,dose,0.322454
uuid-b4f2e3a6857f41039a8dde380653f5a1,regimen,0.306681
uuid-b4f2e3a6857f41039a8dde380653f5a1,pts,0.323742
uuid-b4f2e3a6857f41039a8dde380653f5a1,progression,0.305011
uuid-b4f2e3a6857f41039a8dde380653f5a1,feels,0.303764
uuid-b4f2e3a6857f41039a8dde380653f5a1,flat dosing,0.316859
uuid-5bc5b9f9c9b943f8b5a4464773b44abc,tumor,0.492822
uuid-5bc5b9f9c9b943f8b5a4464773b44abc,response,0.389533
uuid-5bc5b9f9c9b943f8b5a4464773b44abc,progression,0.342723
uuid-5bc5b9f9c9b943f8b5a4464773b44abc,respond,0.39738
uuid-5bc5b9f9c9b943f8b5a4464773b44abc,immunotherapy,0.31895
uuid-a267e1ab9f2d42acadab7eec5f5e0081,lung,0.413635
uuid-a267e1ab9f2d42acadab7eec5f5e0081,regimen,0.425226
uuid-a267e1ab9f2d42acadab7eec5f5e0081,melanoma,0.386801
uuid-a267e1ab9f2d42acadab7eec5f5e0081,RCC,0.373649
uuid-a267e1ab9f2d42acadab7eec5f5e0081,TL stated,0.428241
uuid-a267e1ab9f2d42acadab7eec5f5e0081,combo,0.309752
uuid-a267e1ab9f2d42acadab7eec5f5e0081,TL shared,0.394681
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,RTL,0.328183
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,NTL,0.315374
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,melanoma,0.354727
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,combination,0.318575
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,stated,0.349092
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,data,0.420692
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,combo,0.307191
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,PD1,0.304971
uuid-d288d84bf6dc4e11bc1eca6fce7e0465,impressed,0.352534
uuid-44986584d2874fa182339a369db2d129,therapy,0.457716
uuid-44986584d2874fa182339a369db2d129,regimen,0.410929
uuid-44986584d2874fa182339a369db2d129,treated,0.327466
uuid-44986584d2874fa182339a369db2d129,combination,0.447999
uuid-44986584d2874fa182339a369db2d129,chemo,0.444821
uuid-44986584d2874fa182339a369db2d129,IO,0.60204
uuid-44986584d2874fa182339a369db2d129,agents,0.382568
uuid-44986584d2874fa182339a369db2d129,physicians,0.343848
uuid-44986584d2874fa182339a369db2d129,preferred,0.329769
uuid-44986584d2874fa182339a369db2d129,monotherapy,0.463718
uuid-44986584d2874fa182339a369db2d129,treatment,0.573993
uuid-44986584d2874fa182339a369db2d129,response,0.336354
uuid-44986584d2874fa182339a369db2d129,combo,0.390684
uuid-44986584d2874fa182339a369db2d129,PD1,0.357961
uuid-44986584d2874fa182339a369db2d129,progression,0.4158
uuid-44986584d2874fa182339a369db2d129,chemotherapy,0.440699
uuid-44986584d2874fa182339a369db2d129,oncologist,0.368999
uuid-44986584d2874fa182339a369db2d129,respond,0.315659
uuid-44986584d2874fa182339a369db2d129,immunotherapy,0.309376
uuid-44986584d2874fa182339a369db2d129,option,0.459201
uuid-50a5bf6422234002be7b0a34871308d3,Nivo,0.380512
uuid-50a5bf6422234002be7b0a34871308d3,patients,0.577129
uuid-50a5bf6422234002be7b0a34871308d3,therapy,0.392239
uuid-50a5bf6422234002be7b0a34871308d3,nivolumab,0.344298
uuid-50a5bf6422234002be7b0a34871308d3,1L,0.533398
uuid-50a5bf6422234002be7b0a34871308d3,regimen,0.47702
uuid-50a5bf6422234002be7b0a34871308d3,combination,0.390228
uuid-50a5bf6422234002be7b0a34871308d3,chemo,0.490793
uuid-50a5bf6422234002be7b0a34871308d3,2L,0.540947
uuid-50a5bf6422234002be7b0a34871308d3,pts,0.516392
uuid-50a5bf6422234002be7b0a34871308d3,agents,0.322114
uuid-50a5bf6422234002be7b0a34871308d3,preferred,0.538867
uuid-50a5bf6422234002be7b0a34871308d3,monotherapy,0.662327
uuid-50a5bf6422234002be7b0a34871308d3,treatment,0.418664
uuid-50a5bf6422234002be7b0a34871308d3,using nivo,0.465592
uuid-50a5bf6422234002be7b0a34871308d3,combo,0.49446
uuid-50a5bf6422234002be7b0a34871308d3,PD1,0.368204
uuid-50a5bf6422234002be7b0a34871308d3,approved,0.418796
uuid-50a5bf6422234002be7b0a34871308d3,progression,0.434079
uuid-50a5bf6422234002be7b0a34871308d3,chemotherapy,0.39087
uuid-50a5bf6422234002be7b0a34871308d3,respond,0.356083
uuid-50a5bf6422234002be7b0a34871308d3,feels,0.48056
uuid-50a5bf6422234002be7b0a34871308d3,RTL stated,0.347596
uuid-50a5bf6422234002be7b0a34871308d3,option,0.765329
uuid-fbe416f2234a4c5e82218bf684354f76,patients,0.417361
uuid-fbe416f2234a4c5e82218bf684354f76,therapy,0.313351
uuid-fbe416f2234a4c5e82218bf684354f76,1L,0.553738
uuid-fbe416f2234a4c5e82218bf684354f76,PDL1,0.340852
uuid-fbe416f2234a4c5e82218bf684354f76,TL stated,0.31804
uuid-fbe416f2234a4c5e82218bf684354f76,2L,0.484508
uuid-fbe416f2234a4c5e82218bf684354f76,PD-L1,0.583101
uuid-fbe416f2234a4c5e82218bf684354f76,approval,0.311618
uuid-fbe416f2234a4c5e82218bf684354f76,preferred,0.383952
uuid-fbe416f2234a4c5e82218bf684354f76,PD-L1 testing,0.550545
uuid-fbe416f2234a4c5e82218bf684354f76,testing,0.691163
uuid-fbe416f2234a4c5e82218bf684354f76,monotherapy,0.321175
uuid-fbe416f2234a4c5e82218bf684354f76,using nivo,0.330165
uuid-fbe416f2234a4c5e82218bf684354f76,PDL1 testing,0.619531
uuid-fbe416f2234a4c5e82218bf684354f76,NSCLC patients,0.683539
uuid-fbe416f2234a4c5e82218bf684354f76,tumor types,0.304304
uuid-fbe416f2234a4c5e82218bf684354f76,assay,0.329359
uuid-fbe416f2234a4c5e82218bf684354f76,PD-1,0.307276
uuid-fbe416f2234a4c5e82218bf684354f76,RTL stated,0.329846
uuid-fbe416f2234a4c5e82218bf684354f76,option,0.435375
uuid-fbe416f2234a4c5e82218bf684354f76,biomarker,0.312151
uuid-a72e957122eb49a6aefcdfbc9d41b620,Nivo,0.311488
uuid-a72e957122eb49a6aefcdfbc9d41b620,patients,0.470056
uuid-a72e957122eb49a6aefcdfbc9d41b620,therapy,0.4089
uuid-a72e957122eb49a6aefcdfbc9d41b620,1L,0.350404
uuid-a72e957122eb49a6aefcdfbc9d41b620,toxicity,0.349313
uuid-a72e957122eb49a6aefcdfbc9d41b620,regimen,0.585412
uuid-a72e957122eb49a6aefcdfbc9d41b620,chemo,0.6718
uuid-a72e957122eb49a6aefcdfbc9d41b620,pts,0.482852
uuid-a72e957122eb49a6aefcdfbc9d41b620,IO,0.377148
uuid-a72e957122eb49a6aefcdfbc9d41b620,OS,0.389041
uuid-a72e957122eb49a6aefcdfbc9d41b620,monotherapy,0.534772
uuid-a72e957122eb49a6aefcdfbc9d41b620,treatment,0.516063
uuid-a72e957122eb49a6aefcdfbc9d41b620,response,0.513197
uuid-a72e957122eb49a6aefcdfbc9d41b620,combo,0.423419
uuid-a72e957122eb49a6aefcdfbc9d41b620,PFS,0.341551
uuid-a72e957122eb49a6aefcdfbc9d41b620,PD1,0.433443
uuid-a72e957122eb49a6aefcdfbc9d41b620,progression,0.642502
uuid-a72e957122eb49a6aefcdfbc9d41b620,believes,0.383015
uuid-a72e957122eb49a6aefcdfbc9d41b620,chemotherapy,0.555513
uuid-a72e957122eb49a6aefcdfbc9d41b620,respond,0.495719
uuid-a72e957122eb49a6aefcdfbc9d41b620,feels,0.315855
uuid-a72e957122eb49a6aefcdfbc9d41b620,option,0.443636
uuid-872fd748340047aead64f93d5a9aecd1,BMS,0.426082
uuid-872fd748340047aead64f93d5a9aecd1,efficacy,0.361986
uuid-872fd748340047aead64f93d5a9aecd1,combination,0.633461
uuid-872fd748340047aead64f93d5a9aecd1,chemo,0.358839
uuid-872fd748340047aead64f93d5a9aecd1,IO,0.502169
uuid-872fd748340047aead64f93d5a9aecd1,agents,0.516094
uuid-872fd748340047aead64f93d5a9aecd1,monotherapy,0.39335
uuid-872fd748340047aead64f93d5a9aecd1,combo,0.572534
uuid-872fd748340047aead64f93d5a9aecd1,PD1,0.365019
uuid-872fd748340047aead64f93d5a9aecd1,believes,0.438574
uuid-872fd748340047aead64f93d5a9aecd1,feels,0.45333
uuid-872fd748340047aead64f93d5a9aecd1,option,0.302427
uuid-07e18de5683c4968924d677a21531ea1,Nivo,0.304803
uuid-07e18de5683c4968924d677a21531ea1,pembro,0.518949
uuid-07e18de5683c4968924d677a21531ea1,dose,0.595947
uuid-07e18de5683c4968924d677a21531ea1,BMS,0.35119
uuid-07e18de5683c4968924d677a21531ea1,trial,0.560094
uuid-07e18de5683c4968924d677a21531ea1,Merck,0.348204
uuid-07e18de5683c4968924d677a21531ea1,Ipi,0.564877
uuid-07e18de5683c4968924d677a21531ea1,atezo,0.410553
uuid-07e18de5683c4968924d677a21531ea1,clinical trials,0.338518
uuid-07e18de5683c4968924d677a21531ea1,vs,0.557756
uuid-07e18de5683c4968924d677a21531ea1,flat dosing,0.502289
uuid-3ed543ba2b3444b5b75042588c5762b4,patients,0.678873
uuid-3ed543ba2b3444b5b75042588c5762b4,therapy,0.379211
uuid-3ed543ba2b3444b5b75042588c5762b4,nivolumab,0.345409
uuid-3ed543ba2b3444b5b75042588c5762b4,toxicity,0.37706
uuid-3ed543ba2b3444b5b75042588c5762b4,regimen,0.617407
uuid-3ed543ba2b3444b5b75042588c5762b4,treated,0.454522
uuid-3ed543ba2b3444b5b75042588c5762b4,combination,0.319497
uuid-3ed543ba2b3444b5b75042588c5762b4,chemo,0.395848
uuid-3ed543ba2b3444b5b75042588c5762b4,pts,0.504922
uuid-3ed543ba2b3444b5b75042588c5762b4,monotherapy,0.44703
uuid-3ed543ba2b3444b5b75042588c5762b4,treatment,0.49055
uuid-3ed543ba2b3444b5b75042588c5762b4,response,0.424934
uuid-3ed543ba2b3444b5b75042588c5762b4,combo,0.334337
uuid-3ed543ba2b3444b5b75042588c5762b4,progression,0.581347
uuid-3ed543ba2b3444b5b75042588c5762b4,chemotherapy,0.352937
uuid-3ed543ba2b3444b5b75042588c5762b4,respond,0.471883
uuid-3ed543ba2b3444b5b75042588c5762b4,option,0.353553
uuid-6227a7773a914f0caff50effd3e5a620,1L,0.482433
uuid-6227a7773a914f0caff50effd3e5a620,PDL1,0.34636
uuid-6227a7773a914f0caff50effd3e5a620,2L,0.451044
uuid-6227a7773a914f0caff50effd3e5a620,agents,0.325919
uuid-6227a7773a914f0caff50effd3e5a620,PD-L1,0.384839
uuid-6227a7773a914f0caff50effd3e5a620,preferred,0.475439
uuid-6227a7773a914f0caff50effd3e5a620,testing,0.374207
uuid-6227a7773a914f0caff50effd3e5a620,monotherapy,0.32724
uuid-6227a7773a914f0caff50effd3e5a620,PDL1 testing,0.473788
uuid-6227a7773a914f0caff50effd3e5a620,NSCLC patients,0.462543
uuid-6227a7773a914f0caff50effd3e5a620,tumor types,0.33316
uuid-6227a7773a914f0caff50effd3e5a620,PD-1,0.394107
uuid-6227a7773a914f0caff50effd3e5a620,RTL stated,0.363542
uuid-6227a7773a914f0caff50effd3e5a620,option,0.394485
uuid-b63ef0bdd78441a9b7093fc45c7a9495,dose,0.366371
uuid-b63ef0bdd78441a9b7093fc45c7a9495,toxicity,0.664186
uuid-b63ef0bdd78441a9b7093fc45c7a9495,regimen,0.623924
uuid-b63ef0bdd78441a9b7093fc45c7a9495,treated,0.315116
uuid-b63ef0bdd78441a9b7093fc45c7a9495,combination,0.352466
uuid-b63ef0bdd78441a9b7093fc45c7a9495,Ipi,0.335121
uuid-b63ef0bdd78441a9b7093fc45c7a9495,physicians,0.306746
uuid-b63ef0bdd78441a9b7093fc45c7a9495,monotherapy,0.34488
uuid-b63ef0bdd78441a9b7093fc45c7a9495,treatment,0.324158
uuid-b63ef0bdd78441a9b7093fc45c7a9495,combo,0.399187
uuid-b63ef0bdd78441a9b7093fc45c7a9495,feels,0.379386
uuid-cd92325bead54077859b1987f6ffc6e6,Nivo,0.555471
uuid-cd92325bead54077859b1987f6ffc6e6,pembro,0.54059
uuid-cd92325bead54077859b1987f6ffc6e6,1L,0.35291
uuid-cd92325bead54077859b1987f6ffc6e6,trial,0.51322
uuid-cd92325bead54077859b1987f6ffc6e6,efficacy,0.327067
uuid-cd92325bead54077859b1987f6ffc6e6,chemo,0.383755
uuid-cd92325bead54077859b1987f6ffc6e6,OS,0.359795
uuid-cd92325bead54077859b1987f6ffc6e6,atezo,0.375005
uuid-cd92325bead54077859b1987f6ffc6e6,data,0.30186
uuid-cd92325bead54077859b1987f6ffc6e6,PFS,0.36539
uuid-cd92325bead54077859b1987f6ffc6e6,ORR,0.330797
uuid-cd92325bead54077859b1987f6ffc6e6,approved,0.314091
uuid-cd92325bead54077859b1987f6ffc6e6,nivo and pembro,0.31247
uuid-cd92325bead54077859b1987f6ffc6e6,vs,0.369534
uuid-cd92325bead54077859b1987f6ffc6e6,feels,0.385576
uuid-cd92325bead54077859b1987f6ffc6e6,option,0.302677
uuid-dd4be59d7d9041f3942d0345966e87d4,Nivo,0.374351
uuid-dd4be59d7d9041f3942d0345966e87d4,therapy,0.469792
uuid-dd4be59d7d9041f3942d0345966e87d4,1L,0.422978
uuid-dd4be59d7d9041f3942d0345966e87d4,PDL1,0.358387
uuid-dd4be59d7d9041f3942d0345966e87d4,efficacy,0.347875
uuid-dd4be59d7d9041f3942d0345966e87d4,regimen,0.339049
uuid-dd4be59d7d9041f3942d0345966e87d4,combination,0.43593
uuid-dd4be59d7d9041f3942d0345966e87d4,chemo,0.775234
uuid-dd4be59d7d9041f3942d0345966e87d4,pts,0.42953
uuid-dd4be59d7d9041f3942d0345966e87d4,IO,0.353812
uuid-dd4be59d7d9041f3942d0345966e87d4,agents,0.473607
uuid-dd4be59d7d9041f3942d0345966e87d4,monotherapy,0.539347
uuid-dd4be59d7d9041f3942d0345966e87d4,treatment,0.332816
uuid-dd4be59d7d9041f3942d0345966e87d4,response,0.504215
uuid-dd4be59d7d9041f3942d0345966e87d4,combo,0.454756
uuid-dd4be59d7d9041f3942d0345966e87d4,PD1,0.56688
uuid-dd4be59d7d9041f3942d0345966e87d4,nivo and pembro,0.378206
uuid-dd4be59d7d9041f3942d0345966e87d4,progression,0.457059
uuid-dd4be59d7d9041f3942d0345966e87d4,believes,0.551183
uuid-dd4be59d7d9041f3942d0345966e87d4,chemotherapy,0.635686
uuid-dd4be59d7d9041f3942d0345966e87d4,respond,0.496857
uuid-dd4be59d7d9041f3942d0345966e87d4,feels,0.443998
uuid-dd4be59d7d9041f3942d0345966e87d4,PD-1,0.35579
uuid-dd4be59d7d9041f3942d0345966e87d4,option,0.505416
uuid-8f766a256a6144c8a39d85aed0f69a27,pembro,0.359468
uuid-8f766a256a6144c8a39d85aed0f69a27,trial,0.844475
uuid-8f766a256a6144c8a39d85aed0f69a27,combination,0.332218
uuid-8f766a256a6144c8a39d85aed0f69a27,clinical trials,0.420626
uuid-a821627c6d5f4b45ae690ce4752334b6,Nivo,0.439063
uuid-a821627c6d5f4b45ae690ce4752334b6,nivolumab,0.363579
uuid-a821627c6d5f4b45ae690ce4752334b6,trial,0.487248
uuid-a821627c6d5f4b45ae690ce4752334b6,efficacy,0.357066
uuid-a821627c6d5f4b45ae690ce4752334b6,chemo,0.307307
uuid-a821627c6d5f4b45ae690ce4752334b6,OS,0.408059
uuid-a821627c6d5f4b45ae690ce4752334b6,data,0.510698
uuid-a821627c6d5f4b45ae690ce4752334b6,PFS,0.420476
uuid-a821627c6d5f4b45ae690ce4752334b6,ORR,0.432568
uuid-a821627c6d5f4b45ae690ce4752334b6,chemotherapy,0.385225
uuid-a821627c6d5f4b45ae690ce4752334b6,impressed,0.452879
uuid-a821627c6d5f4b45ae690ce4752334b6,feels,0.439601
uuid-e7076ba138dd421186f7d57c18805a28,efficacy,0.524873
uuid-e7076ba138dd421186f7d57c18805a28,commented,0.418703
uuid-e7076ba138dd421186f7d57c18805a28,OS,0.36774
uuid-e7076ba138dd421186f7d57c18805a28,regards,0.393461
uuid-e7076ba138dd421186f7d57c18805a28,data,0.63049
uuid-e7076ba138dd421186f7d57c18805a28,expressed,0.362927
uuid-e7076ba138dd421186f7d57c18805a28,PFS,0.30247
uuid-e7076ba138dd421186f7d57c18805a28,ORR,0.387753
uuid-e7076ba138dd421186f7d57c18805a28,nivo and pembro,0.349795
uuid-e7076ba138dd421186f7d57c18805a28,ASCO,0.468124
uuid-e7076ba138dd421186f7d57c18805a28,impressed,0.502533
uuid-e7076ba138dd421186f7d57c18805a28,TLs,0.372814
uuid-14e554015c66429da90a31d5c160ab6f,lung,0.389881
uuid-14e554015c66429da90a31d5c160ab6f,regards,0.366257
uuid-14e554015c66429da90a31d5c160ab6f,AI,0.668663
uuid-14e554015c66429da90a31d5c160ab6f,oncology,0.316868
uuid-14e554015c66429da90a31d5c160ab6f,NCCN,0.385907
uuid-14e554015c66429da90a31d5c160ab6f,flat dosing,0.311075
uuid-6e9e8a5a44234d138aebcf7da8b496e1,Nivo,0.305303
uuid-6e9e8a5a44234d138aebcf7da8b496e1,pembro,0.448527
uuid-6e9e8a5a44234d138aebcf7da8b496e1,1L,0.429311
uuid-6e9e8a5a44234d138aebcf7da8b496e1,trial,0.304793
uuid-6e9e8a5a44234d138aebcf7da8b496e1,RCC,0.31125
uuid-6e9e8a5a44234d138aebcf7da8b496e1,TL stated,0.305453
uuid-6e9e8a5a44234d138aebcf7da8b496e1,2L,0.363289
uuid-6e9e8a5a44234d138aebcf7da8b496e1,Merck,0.301985
uuid-6e9e8a5a44234d138aebcf7da8b496e1,stated,0.303625
uuid-6e9e8a5a44234d138aebcf7da8b496e1,approval,0.449214
uuid-6e9e8a5a44234d138aebcf7da8b496e1,OS,0.427351
uuid-6e9e8a5a44234d138aebcf7da8b496e1,atezo,0.362701
uuid-6e9e8a5a44234d138aebcf7da8b496e1,using nivo,0.372343
uuid-6e9e8a5a44234d138aebcf7da8b496e1,data,0.331928
uuid-6e9e8a5a44234d138aebcf7da8b496e1,PFS,0.367414
uuid-6e9e8a5a44234d138aebcf7da8b496e1,ORR,0.327419
uuid-6e9e8a5a44234d138aebcf7da8b496e1,approved,0.318861
uuid-6e9e8a5a44234d138aebcf7da8b496e1,SCCHN,0.452606
uuid-6e9e8a5a44234d138aebcf7da8b496e1,nivo and pembro,0.318248
uuid-6e9e8a5a44234d138aebcf7da8b496e1,impressed,0.424389
uuid-6e9e8a5a44234d138aebcf7da8b496e1,RTL stated,0.319837
uuid-6e9e8a5a44234d138aebcf7da8b496e1,bladder,0.390445
uuid-2b7554f935da4e029bb4a8c9e06baa51,patients,0.412514
uuid-2b7554f935da4e029bb4a8c9e06baa51,Opdivo,0.345288
uuid-2b7554f935da4e029bb4a8c9e06baa51,dose,0.353147
uuid-2b7554f935da4e029bb4a8c9e06baa51,toxicity,0.715566
uuid-2b7554f935da4e029bb4a8c9e06baa51,regimen,0.518582
uuid-2b7554f935da4e029bb4a8c9e06baa51,treated,0.390283
uuid-2b7554f935da4e029bb4a8c9e06baa51,treatment,0.503225
uuid-2b7554f935da4e029bb4a8c9e06baa51,progression,0.322822
uuid-2b7554f935da4e029bb4a8c9e06baa51,respond,0.395085
uuid-c6b40de6ae9c43778dcc080412a11948,RTL,0.433625
uuid-c6b40de6ae9c43778dcc080412a11948,trial,0.523619
uuid-c6b40de6ae9c43778dcc080412a11948,NTL,0.569463
uuid-c6b40de6ae9c43778dcc080412a11948,Merck,0.398618
uuid-c6b40de6ae9c43778dcc080412a11948,data,0.333378
uuid-c6b40de6ae9c43778dcc080412a11948,expressed,0.302561
uuid-c6b40de6ae9c43778dcc080412a11948,ASCO,0.420434
uuid-c6b40de6ae9c43778dcc080412a11948,impressed,0.306565
uuid-c6b40de6ae9c43778dcc080412a11948,Regional TL,0.35788
uuid-1565afa1e0b84d37b67c76b761b6c79d,RTL,0.521195
uuid-1565afa1e0b84d37b67c76b761b6c79d,nivolumab,0.389471
uuid-1565afa1e0b84d37b67c76b761b6c79d,NTL,0.538901
uuid-1565afa1e0b84d37b67c76b761b6c79d,stated,0.514676
uuid-1565afa1e0b84d37b67c76b761b6c79d,approval,0.32665
uuid-1565afa1e0b84d37b67c76b761b6c79d,using nivo,0.373898
uuid-1565afa1e0b84d37b67c76b761b6c79d,mentioned,0.518834
uuid-1565afa1e0b84d37b67c76b761b6c79d,SCCHN,0.36017
uuid-1565afa1e0b84d37b67c76b761b6c79d,cHL,0.569545
uuid-1565afa1e0b84d37b67c76b761b6c79d,LTL,0.431016
uuid-1565afa1e0b84d37b67c76b761b6c79d,Regional TL,0.477543
uuid-1565afa1e0b84d37b67c76b761b6c79d,RTL stated,0.300544
uuid-68381a6e2fad4b6aa37f3afabdde3c86,Nivo,0.376226
uuid-68381a6e2fad4b6aa37f3afabdde3c86,patients,0.77881
uuid-68381a6e2fad4b6aa37f3afabdde3c86,Opdivo,0.380514
uuid-68381a6e2fad4b6aa37f3afabdde3c86,therapy,0.669308
uuid-68381a6e2fad4b6aa37f3afabdde3c86,nivolumab,0.570026
uuid-68381a6e2fad4b6aa37f3afabdde3c86,regimen,0.376328
uuid-68381a6e2fad4b6aa37f3afabdde3c86,treated,0.551515
uuid-68381a6e2fad4b6aa37f3afabdde3c86,chemo,0.327918
uuid-68381a6e2fad4b6aa37f3afabdde3c86,pts,0.453231
uuid-68381a6e2fad4b6aa37f3afabdde3c86,approval,0.325801
uuid-68381a6e2fad4b6aa37f3afabdde3c86,monotherapy,0.338872
uuid-68381a6e2fad4b6aa37f3afabdde3c86,treatment,0.648442
uuid-68381a6e2fad4b6aa37f3afabdde3c86,using nivo,0.45119
uuid-68381a6e2fad4b6aa37f3afabdde3c86,cHL,0.510828
uuid-68381a6e2fad4b6aa37f3afabdde3c86,progression,0.512225
uuid-68381a6e2fad4b6aa37f3afabdde3c86,chemotherapy,0.466132
uuid-68381a6e2fad4b6aa37f3afabdde3c86,respond,0.309893
uuid-68381a6e2fad4b6aa37f3afabdde3c86,RTL stated,0.388889
uuid-68381a6e2fad4b6aa37f3afabdde3c86,option,0.397238
uuid-366db1376d2d4305aa61fac816563703,TL,0.336261
uuid-366db1376d2d4305aa61fac816563703,lung,0.322955
uuid-366db1376d2d4305aa61fac816563703,1L,0.301123
uuid-366db1376d2d4305aa61fac816563703,shared,0.38258
uuid-366db1376d2d4305aa61fac816563703,commented,0.383509
uuid-366db1376d2d4305aa61fac816563703,RCC,0.533149
uuid-366db1376d2d4305aa61fac816563703,TL stated,0.519877
uuid-366db1376d2d4305aa61fac816563703,2L,0.33855
uuid-366db1376d2d4305aa61fac816563703,stated,0.337099
uuid-366db1376d2d4305aa61fac816563703,approval,0.399684
uuid-366db1376d2d4305aa61fac816563703,preferred,0.325791
uuid-366db1376d2d4305aa61fac816563703,PD-L1 testing,0.371959
uuid-366db1376d2d4305aa61fac816563703,testing,0.322418
uuid-366db1376d2d4305aa61fac816563703,using nivo,0.325138
uuid-366db1376d2d4305aa61fac816563703,PDL1 testing,0.49032
uuid-366db1376d2d4305aa61fac816563703,approved,0.366452
uuid-366db1376d2d4305aa61fac816563703,SCCHN,0.459524
uuid-366db1376d2d4305aa61fac816563703,TLs,0.335218
uuid-366db1376d2d4305aa61fac816563703,Regional TL,0.463643
uuid-366db1376d2d4305aa61fac816563703,RTL stated,0.384113
uuid-366db1376d2d4305aa61fac816563703,TL shared,0.357269
uuid-366db1376d2d4305aa61fac816563703,bladder,0.336691
uuid-4df41b8a59544956bc224608b731cf8d,pembro,0.312731
uuid-4df41b8a59544956bc224608b731cf8d,BMS,0.566036
uuid-4df41b8a59544956bc224608b731cf8d,commented,0.34797
uuid-4df41b8a59544956bc224608b731cf8d,Merck,0.488344
uuid-4df41b8a59544956bc224608b731cf8d,stated,0.338643
uuid-4df41b8a59544956bc224608b731cf8d,approval,0.402523
uuid-4df41b8a59544956bc224608b731cf8d,atezo,0.323208
uuid-4df41b8a59544956bc224608b731cf8d,preferred,0.324457
uuid-4df41b8a59544956bc224608b731cf8d,clinical trials,0.439755
uuid-4df41b8a59544956bc224608b731cf8d,indication,0.428085
uuid-4df41b8a59544956bc224608b731cf8d,approved,0.439973
uuid-4df41b8a59544956bc224608b731cf8d,SCCHN,0.311138
uuid-4df41b8a59544956bc224608b731cf8d,label,0.314405
uuid-4df41b8a59544956bc224608b731cf8d,feels,0.316195
uuid-4ec2e61b9b254ea6a8055d17403386d2,Nivo,0.309646
uuid-4ec2e61b9b254ea6a8055d17403386d2,pembro,0.357672
uuid-4ec2e61b9b254ea6a8055d17403386d2,trial,0.568304
uuid-4ec2e61b9b254ea6a8055d17403386d2,combination,0.318477
uuid-4ec2e61b9b254ea6a8055d17403386d2,chemotherapy,0.326283
uuid-80082046f92f46ce9fb58eea26406414,pembro,0.348016
uuid-80082046f92f46ce9fb58eea26406414,BMS,0.571639
uuid-80082046f92f46ce9fb58eea26406414,1L,0.379322
uuid-80082046f92f46ce9fb58eea26406414,PDL1,0.352774
uuid-80082046f92f46ce9fb58eea26406414,trial,0.361493
uuid-80082046f92f46ce9fb58eea26406414,agents,0.300198
uuid-80082046f92f46ce9fb58eea26406414,Merck,0.506772
uuid-80082046f92f46ce9fb58eea26406414,atezo,0.322929
uuid-80082046f92f46ce9fb58eea26406414,data,0.327373
uuid-80082046f92f46ce9fb58eea26406414,clinical trials,0.348763
uuid-80082046f92f46ce9fb58eea26406414,indication,0.305463
uuid-80082046f92f46ce9fb58eea26406414,approved,0.353704
uuid-80082046f92f46ce9fb58eea26406414,nivo and pembro,0.431135
uuid-80082046f92f46ce9fb58eea26406414,believes,0.383752
uuid-80082046f92f46ce9fb58eea26406414,feels,0.450315
uuid-a8b41abebcc74184b32e29d6ca80d8b9,Nivo,0.406609
uuid-a8b41abebcc74184b32e29d6ca80d8b9,efficacy,0.362944
uuid-a8b41abebcc74184b32e29d6ca80d8b9,OS,0.47627
uuid-a8b41abebcc74184b32e29d6ca80d8b9,data,0.578016
uuid-a8b41abebcc74184b32e29d6ca80d8b9,PFS,0.448609
uuid-a8b41abebcc74184b32e29d6ca80d8b9,ORR,0.468893
uuid-a8b41abebcc74184b32e29d6ca80d8b9,impressed,0.594616
uuid-a8b41abebcc74184b32e29d6ca80d8b9,feels,0.3348
uuid-eeed2cc0db2348259ec2337aa366a2c3,patients,0.365772
uuid-eeed2cc0db2348259ec2337aa366a2c3,Opdivo,0.348043
uuid-eeed2cc0db2348259ec2337aa366a2c3,dose,0.301966
uuid-eeed2cc0db2348259ec2337aa366a2c3,toxicity,0.453108
uuid-eeed2cc0db2348259ec2337aa366a2c3,regimen,0.458625
uuid-eeed2cc0db2348259ec2337aa366a2c3,treated,0.319403
uuid-eeed2cc0db2348259ec2337aa366a2c3,physicians,0.311813
uuid-eeed2cc0db2348259ec2337aa366a2c3,treatment,0.439135
uuid-eeed2cc0db2348259ec2337aa366a2c3,respond,0.38115
uuid-376c74f1526f4da5afd4ea72af133fa5,pembro,0.354439
uuid-376c74f1526f4da5afd4ea72af133fa5,BMS,0.501425
uuid-376c74f1526f4da5afd4ea72af133fa5,1L,0.365502
uuid-376c74f1526f4da5afd4ea72af133fa5,PDL1,0.750144
uuid-376c74f1526f4da5afd4ea72af133fa5,trial,0.474943
uuid-376c74f1526f4da5afd4ea72af133fa5,efficacy,0.486816
uuid-376c74f1526f4da5afd4ea72af133fa5,Merck,0.476025
uuid-376c74f1526f4da5afd4ea72af133fa5,PD-L1,0.353272
uuid-376c74f1526f4da5afd4ea72af133fa5,OS,0.557119
uuid-376c74f1526f4da5afd4ea72af133fa5,atezo,0.32917
uuid-376c74f1526f4da5afd4ea72af133fa5,data,0.727642
uuid-376c74f1526f4da5afd4ea72af133fa5,PFS,0.554629
uuid-376c74f1526f4da5afd4ea72af133fa5,ORR,0.576235
uuid-376c74f1526f4da5afd4ea72af133fa5,nivo and pembro,0.583655
uuid-376c74f1526f4da5afd4ea72af133fa5,believes,0.43856
uuid-376c74f1526f4da5afd4ea72af133fa5,impressed,0.436127
uuid-376c74f1526f4da5afd4ea72af133fa5,feels,0.410718
uuid-376c74f1526f4da5afd4ea72af133fa5,PDL1 expression,0.646684
uuid-376c74f1526f4da5afd4ea72af133fa5,biomarker,0.561893
uuid-369bd94e260f4f6da9ab2670ca1030a7,Nivo,0.62118
uuid-369bd94e260f4f6da9ab2670ca1030a7,patients,0.343291
uuid-369bd94e260f4f6da9ab2670ca1030a7,pembro,0.641372
uuid-369bd94e260f4f6da9ab2670ca1030a7,dose,0.520425
uuid-369bd94e260f4f6da9ab2670ca1030a7,1L,0.342015
uuid-369bd94e260f4f6da9ab2670ca1030a7,toxicity,0.320298
uuid-369bd94e260f4f6da9ab2670ca1030a7,efficacy,0.430249
uuid-369bd94e260f4f6da9ab2670ca1030a7,regimen,0.318185
uuid-369bd94e260f4f6da9ab2670ca1030a7,chemo,0.457107
uuid-369bd94e260f4f6da9ab2670ca1030a7,2L,0.445965
uuid-369bd94e260f4f6da9ab2670ca1030a7,agents,0.407953
uuid-369bd94e260f4f6da9ab2670ca1030a7,Ipi,0.420569
uuid-369bd94e260f4f6da9ab2670ca1030a7,atezo,0.57847
uuid-369bd94e260f4f6da9ab2670ca1030a7,preferred,0.494176
uuid-369bd94e260f4f6da9ab2670ca1030a7,monotherapy,0.473104
uuid-369bd94e260f4f6da9ab2670ca1030a7,using nivo,0.343071
uuid-369bd94e260f4f6da9ab2670ca1030a7,nivo and pembro,0.472552
uuid-369bd94e260f4f6da9ab2670ca1030a7,believes,0.343832
uuid-369bd94e260f4f6da9ab2670ca1030a7,chemotherapy,0.310342
uuid-369bd94e260f4f6da9ab2670ca1030a7,vs,0.642234
uuid-369bd94e260f4f6da9ab2670ca1030a7,feels,0.468913
uuid-369bd94e260f4f6da9ab2670ca1030a7,option,0.452255
uuid-18c52157e118460a956009a045060a1b,RTL,0.637087
uuid-18c52157e118460a956009a045060a1b,nivolumab,0.547343
uuid-18c52157e118460a956009a045060a1b,treated,0.31591
uuid-18c52157e118460a956009a045060a1b,NTL,0.478296
uuid-18c52157e118460a956009a045060a1b,melanoma,0.373029
uuid-18c52157e118460a956009a045060a1b,shared,0.436655
uuid-18c52157e118460a956009a045060a1b,commented,0.345536
uuid-18c52157e118460a956009a045060a1b,RCC,0.516104
uuid-18c52157e118460a956009a045060a1b,stated,0.581213
uuid-18c52157e118460a956009a045060a1b,approval,0.565311
uuid-18c52157e118460a956009a045060a1b,using nivo,0.554684
uuid-18c52157e118460a956009a045060a1b,expressed,0.318193
uuid-18c52157e118460a956009a045060a1b,mentioned,0.443073
uuid-18c52157e118460a956009a045060a1b,clinical trials,0.462823
uuid-18c52157e118460a956009a045060a1b,approved,0.509981
uuid-18c52157e118460a956009a045060a1b,SCCHN,0.700101
uuid-18c52157e118460a956009a045060a1b,HCP,0.427536
uuid-18c52157e118460a956009a045060a1b,tumor types,0.32976
uuid-18c52157e118460a956009a045060a1b,label,0.424765
uuid-18c52157e118460a956009a045060a1b,LTL,0.536833
uuid-18c52157e118460a956009a045060a1b,SCLC,0.554662
uuid-18c52157e118460a956009a045060a1b,Regional TL,0.645757
uuid-18c52157e118460a956009a045060a1b,RTL stated,0.567151
uuid-18c52157e118460a956009a045060a1b,TL shared,0.39891
uuid-18c52157e118460a956009a045060a1b,bladder,0.515627
uuid-c3b55be1e87b45798abf9c6a5deaee3e,Opdivo,0.367019
uuid-c3b55be1e87b45798abf9c6a5deaee3e,pembro,0.411681
uuid-c3b55be1e87b45798abf9c6a5deaee3e,dose,0.780682
uuid-c3b55be1e87b45798abf9c6a5deaee3e,Ipi,0.448734
uuid-c3b55be1e87b45798abf9c6a5deaee3e,approval,0.319318
uuid-c3b55be1e87b45798abf9c6a5deaee3e,atezo,0.410957
uuid-c3b55be1e87b45798abf9c6a5deaee3e,preferred,0.31792
uuid-c3b55be1e87b45798abf9c6a5deaee3e,indication,0.4061
uuid-c3b55be1e87b45798abf9c6a5deaee3e,vs,0.420105
uuid-c3b55be1e87b45798abf9c6a5deaee3e,Keytruda,0.375615
uuid-c3b55be1e87b45798abf9c6a5deaee3e,flat dosing,0.730298
uuid-fd20f77b3dbd4779899a869545dad5c0,Nivo,0.390829
uuid-fd20f77b3dbd4779899a869545dad5c0,patients,0.582081
uuid-fd20f77b3dbd4779899a869545dad5c0,Opdivo,0.509588
uuid-fd20f77b3dbd4779899a869545dad5c0,therapy,0.351794
uuid-fd20f77b3dbd4779899a869545dad5c0,dose,0.619799
uuid-fd20f77b3dbd4779899a869545dad5c0,nivolumab,0.351292
uuid-fd20f77b3dbd4779899a869545dad5c0,toxicity,0.437175
uuid-fd20f77b3dbd4779899a869545dad5c0,regimen,0.43066
uuid-fd20f77b3dbd4779899a869545dad5c0,chemo,0.311441
uuid-fd20f77b3dbd4779899a869545dad5c0,pts,0.39861
uuid-fd20f77b3dbd4779899a869545dad5c0,Ipi,0.361556
uuid-fd20f77b3dbd4779899a869545dad5c0,monotherapy,0.308728
uuid-fd20f77b3dbd4779899a869545dad5c0,treatment,0.36427
uuid-fd20f77b3dbd4779899a869545dad5c0,progression,0.384062
uuid-fd20f77b3dbd4779899a869545dad5c0,chemotherapy,0.308466
uuid-fd20f77b3dbd4779899a869545dad5c0,vs,0.368214
uuid-fd20f77b3dbd4779899a869545dad5c0,option,0.30792
uuid-fd20f77b3dbd4779899a869545dad5c0,flat dosing,0.520263
uuid-8f3779a1036147e299a7ae1173d17e20,PDL1,0.309565
uuid-8f3779a1036147e299a7ae1173d17e20,efficacy,0.430949
uuid-8f3779a1036147e299a7ae1173d17e20,regimen,0.344694
uuid-8f3779a1036147e299a7ae1173d17e20,combination,0.413968
uuid-8f3779a1036147e299a7ae1173d17e20,chemo,0.57599
uuid-8f3779a1036147e299a7ae1173d17e20,pts,0.461939
uuid-8f3779a1036147e299a7ae1173d17e20,IO,0.40888
uuid-8f3779a1036147e299a7ae1173d17e20,OS,0.534403
uuid-8f3779a1036147e299a7ae1173d17e20,monotherapy,0.362312
uuid-8f3779a1036147e299a7ae1173d17e20,response,0.708908
uuid-8f3779a1036147e299a7ae1173d17e20,combo,0.388137
uuid-8f3779a1036147e299a7ae1173d17e20,PFS,0.510628
uuid-8f3779a1036147e299a7ae1173d17e20,PD1,0.497412
uuid-8f3779a1036147e299a7ae1173d17e20,ORR,0.498403
uuid-8f3779a1036147e299a7ae1173d17e20,progression,0.454789
uuid-8f3779a1036147e299a7ae1173d17e20,believes,0.532692
uuid-8f3779a1036147e299a7ae1173d17e20,chemotherapy,0.428011
uuid-8f3779a1036147e299a7ae1173d17e20,respond,0.447406
uuid-8f3779a1036147e299a7ae1173d17e20,feels,0.380839
uuid-15133f0d3be64256a8f42ece12c9bdfc,Nivo,0.326924
uuid-15133f0d3be64256a8f42ece12c9bdfc,patients,0.343004
uuid-15133f0d3be64256a8f42ece12c9bdfc,Opdivo,0.468952
uuid-15133f0d3be64256a8f42ece12c9bdfc,pembro,0.373239
uuid-15133f0d3be64256a8f42ece12c9bdfc,dose,0.880012
uuid-15133f0d3be64256a8f42ece12c9bdfc,Ipi,0.510391
uuid-15133f0d3be64256a8f42ece12c9bdfc,atezo,0.308323
uuid-15133f0d3be64256a8f42ece12c9bdfc,vs,0.566183
uuid-15133f0d3be64256a8f42ece12c9bdfc,drug,0.300003
uuid-15133f0d3be64256a8f42ece12c9bdfc,Keytruda,0.411052
uuid-15133f0d3be64256a8f42ece12c9bdfc,flat dosing,0.789626
uuid-b414b7857e8a4c01b76b09f457384485,pembro,0.538549
uuid-b414b7857e8a4c01b76b09f457384485,RTL,0.417066
uuid-b414b7857e8a4c01b76b09f457384485,1L,0.306417
uuid-b414b7857e8a4c01b76b09f457384485,trial,0.771216
uuid-b414b7857e8a4c01b76b09f457384485,NTL,0.330797
uuid-b414b7857e8a4c01b76b09f457384485,Merck,0.336554
uuid-b414b7857e8a4c01b76b09f457384485,approval,0.38447
uuid-b414b7857e8a4c01b76b09f457384485,atezo,0.383484
uuid-b414b7857e8a4c01b76b09f457384485,combo,0.315576
uuid-b414b7857e8a4c01b76b09f457384485,clinical trials,0.560804
uuid-b414b7857e8a4c01b76b09f457384485,approved,0.350745
uuid-b414b7857e8a4c01b76b09f457384485,SCCHN,0.374279
uuid-b414b7857e8a4c01b76b09f457384485,Regional TL,0.336161
uuid-b414b7857e8a4c01b76b09f457384485,RTL stated,0.305388
uuid-b414b7857e8a4c01b76b09f457384485,bladder,0.445573
uuid-937b9bca74254176979bd531b18fc192,Nivo,0.63937
uuid-937b9bca74254176979bd531b18fc192,patients,0.51376
uuid-937b9bca74254176979bd531b18fc192,therapy,0.596574
uuid-937b9bca74254176979bd531b18fc192,nivolumab,0.470286
uuid-937b9bca74254176979bd531b18fc192,1L,0.436067
uuid-937b9bca74254176979bd531b18fc192,toxicity,0.362839
uuid-937b9bca74254176979bd531b18fc192,regimen,0.548583
uuid-937b9bca74254176979bd531b18fc192,combination,0.552036
uuid-937b9bca74254176979bd531b18fc192,chemo,0.66122
uuid-937b9bca74254176979bd531b18fc192,2L,0.436824
uuid-937b9bca74254176979bd531b18fc192,pts,0.489246
uuid-937b9bca74254176979bd531b18fc192,IO,0.316584
uuid-937b9bca74254176979bd531b18fc192,agents,0.396266
uuid-937b9bca74254176979bd531b18fc192,Ipi,0.342483
uuid-937b9bca74254176979bd531b18fc192,preferred,0.408197
uuid-937b9bca74254176979bd531b18fc192,monotherapy,0.723702
uuid-937b9bca74254176979bd531b18fc192,treatment,0.488629
uuid-937b9bca74254176979bd531b18fc192,using nivo,0.445883
uuid-937b9bca74254176979bd531b18fc192,response,0.503909
uuid-937b9bca74254176979bd531b18fc192,combo,0.477167
uuid-937b9bca74254176979bd531b18fc192,PD1,0.600913
uuid-937b9bca74254176979bd531b18fc192,progression,0.55489
uuid-937b9bca74254176979bd531b18fc192,believes,0.418729
uuid-937b9bca74254176979bd531b18fc192,chemotherapy,0.581884
uuid-937b9bca74254176979bd531b18fc192,respond,0.47864
uuid-937b9bca74254176979bd531b18fc192,feels,0.412587
uuid-937b9bca74254176979bd531b18fc192,RTL stated,0.323
uuid-937b9bca74254176979bd531b18fc192,option,0.643837
uuid-876e96ab6d9940f48694192b59641213,Nivo,0.384212
uuid-876e96ab6d9940f48694192b59641213,patients,0.670774
uuid-876e96ab6d9940f48694192b59641213,Opdivo,0.365099
uuid-876e96ab6d9940f48694192b59641213,therapy,0.652312
uuid-876e96ab6d9940f48694192b59641213,nivolumab,0.607145
uuid-876e96ab6d9940f48694192b59641213,1L,0.317187
uuid-876e96ab6d9940f48694192b59641213,toxicity,0.346633
uuid-876e96ab6d9940f48694192b59641213,regimen,0.618184
uuid-876e96ab6d9940f48694192b59641213,treated,0.519942
uuid-876e96ab6d9940f48694192b59641213,RCC,0.355149
uuid-876e96ab6d9940f48694192b59641213,combination,0.535354
uuid-876e96ab6d9940f48694192b59641213,chemo,0.483922
uuid-876e96ab6d9940f48694192b59641213,2L,0.382027
uuid-876e96ab6d9940f48694192b59641213,pts,0.6048
uuid-876e96ab6d9940f48694192b59641213,preferred,0.388126
uuid-876e96ab6d9940f48694192b59641213,monotherapy,0.618458
uuid-876e96ab6d9940f48694192b59641213,treatment,0.640664
uuid-876e96ab6d9940f48694192b59641213,using nivo,0.461347
uuid-876e96ab6d9940f48694192b59641213,response,0.422636
uuid-876e96ab6d9940f48694192b59641213,combo,0.436954
uuid-876e96ab6d9940f48694192b59641213,PD1,0.522258
uuid-876e96ab6d9940f48694192b59641213,progression,0.655024
uuid-876e96ab6d9940f48694192b59641213,chemotherapy,0.49707
uuid-876e96ab6d9940f48694192b59641213,respond,0.499039
uuid-876e96ab6d9940f48694192b59641213,RTL stated,0.435381
uuid-876e96ab6d9940f48694192b59641213,option,0.526493
uuid-5a809534ec4d47faafe899e3eb739876,RTL,0.469235
uuid-5a809534ec4d47faafe899e3eb739876,BMS,0.302605
uuid-5a809534ec4d47faafe899e3eb739876,trial,0.660023
uuid-5a809534ec4d47faafe899e3eb739876,NTL,0.416776
uuid-5a809534ec4d47faafe899e3eb739876,commented,0.320797
uuid-5a809534ec4d47faafe899e3eb739876,OS,0.362758
uuid-5a809534ec4d47faafe899e3eb739876,data,0.59551
uuid-5a809534ec4d47faafe899e3eb739876,clinical trials,0.305307
uuid-5a809534ec4d47faafe899e3eb739876,PFS,0.38663
uuid-5a809534ec4d47faafe899e3eb739876,ORR,0.454563
uuid-5a809534ec4d47faafe899e3eb739876,ASCO,0.344331
uuid-5a809534ec4d47faafe899e3eb739876,impressed,0.571555
uuid-5a809534ec4d47faafe899e3eb739876,LTL,0.310918
uuid-d5e9140d52694cd49cf09f596ecd6a12,BMS,0.769646
uuid-d5e9140d52694cd49cf09f596ecd6a12,Merck,0.545125
uuid-d5e9140d52694cd49cf09f596ecd6a12,stated,0.337638
uuid-d5e9140d52694cd49cf09f596ecd6a12,clinical trials,0.310273
uuid-d5e9140d52694cd49cf09f596ecd6a12,approved,0.439403
uuid-d5e9140d52694cd49cf09f596ecd6a12,label,0.340638
uuid-d5e9140d52694cd49cf09f596ecd6a12,feels,0.342311
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,Nivo,0.598529
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,1L,0.316984
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,efficacy,0.405332
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,chemo,0.441538
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,OS,0.480522
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,monotherapy,0.30298
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,PFS,0.417049
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,ORR,0.377371
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,nivo and pembro,0.331113
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,chemotherapy,0.357721
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,feels,0.30568
uuid-0d4c9ee2390e4fffb7a94d00f22e0786,option,0.370564
uuid-4435801d60a145edb29badd22c225429,trial,0.330098
uuid-4435801d60a145edb29badd22c225429,combination,0.44443
uuid-4435801d60a145edb29badd22c225429,combo,0.311368
uuid-4435801d60a145edb29badd22c225429,PD1,0.339579
uuid-4435801d60a145edb29badd22c225429,nivo and pembro,0.304179
uuid-4435801d60a145edb29badd22c225429,believes,0.301068
uuid-f739e9fe7a074f49aaea6cc61c06a928,patients,0.337201
uuid-d12b7b565ded44e996883190d7717940,Nivo,0.363782
uuid-d12b7b565ded44e996883190d7717940,patients,0.682947
uuid-d12b7b565ded44e996883190d7717940,Opdivo,0.32613
uuid-d12b7b565ded44e996883190d7717940,therapy,0.430403
uuid-d12b7b565ded44e996883190d7717940,dose,0.412476
uuid-d12b7b565ded44e996883190d7717940,nivolumab,0.551239
uuid-d12b7b565ded44e996883190d7717940,toxicity,0.368205
uuid-d12b7b565ded44e996883190d7717940,regimen,0.571281
uuid-d12b7b565ded44e996883190d7717940,treated,0.5272
uuid-d12b7b565ded44e996883190d7717940,melanoma,0.309671
uuid-d12b7b565ded44e996883190d7717940,RCC,0.330149
uuid-d12b7b565ded44e996883190d7717940,combination,0.402873
uuid-d12b7b565ded44e996883190d7717940,2L,0.341978
uuid-d12b7b565ded44e996883190d7717940,pts,0.502755
uuid-d12b7b565ded44e996883190d7717940,Ipi,0.454569
uuid-d12b7b565ded44e996883190d7717940,preferred,0.373133
uuid-d12b7b565ded44e996883190d7717940,monotherapy,0.499406
uuid-d12b7b565ded44e996883190d7717940,treatment,0.523902
uuid-d12b7b565ded44e996883190d7717940,using nivo,0.464481
uuid-d12b7b565ded44e996883190d7717940,combo,0.366307
uuid-d12b7b565ded44e996883190d7717940,PD1,0.315037
uuid-d12b7b565ded44e996883190d7717940,progression,0.435882
uuid-d12b7b565ded44e996883190d7717940,chemotherapy,0.314418
uuid-d12b7b565ded44e996883190d7717940,RTL stated,0.451461
uuid-d12b7b565ded44e996883190d7717940,TL shared,0.326942
uuid-d12b7b565ded44e996883190d7717940,option,0.418709
uuid-89ec6bc01d664821a148a5b7a3e95298,patients,0.371189
uuid-89ec6bc01d664821a148a5b7a3e95298,1L,0.308624
uuid-89ec6bc01d664821a148a5b7a3e95298,PDL1 testing,0.341988
uuid-89ec6bc01d664821a148a5b7a3e95298,NSCLC patients,0.573558
uuid-89ec6bc01d664821a148a5b7a3e95298,tumor types,0.340512
uuid-653ab6873698414b9a105f2ca9b49583,toxicity,0.537917
uuid-653ab6873698414b9a105f2ca9b49583,physicians,0.342318
uuid-471625efe7474bad99417545cd6aafb6,RTL,0.491524
uuid-471625efe7474bad99417545cd6aafb6,nivolumab,0.328354
uuid-471625efe7474bad99417545cd6aafb6,lung,0.452567
uuid-471625efe7474bad99417545cd6aafb6,treated,0.368569
uuid-471625efe7474bad99417545cd6aafb6,NTL,0.642914
uuid-471625efe7474bad99417545cd6aafb6,melanoma,0.462785
uuid-471625efe7474bad99417545cd6aafb6,commented,0.35578
uuid-471625efe7474bad99417545cd6aafb6,RCC,0.331919
uuid-471625efe7474bad99417545cd6aafb6,mentioned,0.469832
uuid-471625efe7474bad99417545cd6aafb6,SCCHN,0.413846
uuid-471625efe7474bad99417545cd6aafb6,HCP,0.322919
uuid-471625efe7474bad99417545cd6aafb6,LTL,0.344301
uuid-471625efe7474bad99417545cd6aafb6,Regional TL,0.438845
uuid-471625efe7474bad99417545cd6aafb6,RTL stated,0.382784
uuid-471625efe7474bad99417545cd6aafb6,TL shared,0.537957
uuid-471625efe7474bad99417545cd6aafb6,bladder,0.361698
uuid-5ea4b6a09c6b49a084337f806661860b,Nivo,0.366578
uuid-5ea4b6a09c6b49a084337f806661860b,patients,0.4384
uuid-5ea4b6a09c6b49a084337f806661860b,therapy,0.689704
uuid-5ea4b6a09c6b49a084337f806661860b,nivolumab,0.498203
uuid-5ea4b6a09c6b49a084337f806661860b,regimen,0.40289
uuid-5ea4b6a09c6b49a084337f806661860b,treated,0.433775
uuid-5ea4b6a09c6b49a084337f806661860b,combination,0.562172
uuid-5ea4b6a09c6b49a084337f806661860b,chemo,0.528036
uuid-5ea4b6a09c6b49a084337f806661860b,pts,0.374477
uuid-5ea4b6a09c6b49a084337f806661860b,monotherapy,0.437347
uuid-5ea4b6a09c6b49a084337f806661860b,treatment,0.515426
uuid-5ea4b6a09c6b49a084337f806661860b,response,0.477671
uuid-5ea4b6a09c6b49a084337f806661860b,combo,0.35026
uuid-5ea4b6a09c6b49a084337f806661860b,PD1,0.566438
uuid-5ea4b6a09c6b49a084337f806661860b,cHL,0.412137
uuid-5ea4b6a09c6b49a084337f806661860b,progression,0.528018
uuid-5ea4b6a09c6b49a084337f806661860b,chemotherapy,0.670747
uuid-5ea4b6a09c6b49a084337f806661860b,respond,0.315896
uuid-5ea4b6a09c6b49a084337f806661860b,feels,0.303719
uuid-5ea4b6a09c6b49a084337f806661860b,option,0.362519
uuid-38b78c2fb07c4291932c31208895e2fe,data,0.30108
uuid-e57614decc95484586740cd8472e1a7f,Nivo,0.436316
uuid-e57614decc95484586740cd8472e1a7f,patients,0.480634
uuid-e57614decc95484586740cd8472e1a7f,therapy,0.698462
uuid-e57614decc95484586740cd8472e1a7f,nivolumab,0.663864
uuid-e57614decc95484586740cd8472e1a7f,treated,0.426394
uuid-e57614decc95484586740cd8472e1a7f,approval,0.308586
uuid-e57614decc95484586740cd8472e1a7f,treatment,0.377656
uuid-e57614decc95484586740cd8472e1a7f,using nivo,0.406577
uuid-e57614decc95484586740cd8472e1a7f,mentioned,0.30881
uuid-e57614decc95484586740cd8472e1a7f,PD1,0.367925
uuid-e57614decc95484586740cd8472e1a7f,cHL,0.773193
uuid-e57614decc95484586740cd8472e1a7f,progression,0.314964
uuid-e57614decc95484586740cd8472e1a7f,chemotherapy,0.3734
uuid-7303ba82222a41c794f49bfcb79e08a4,Nivo,0.554895
uuid-7303ba82222a41c794f49bfcb79e08a4,pembro,0.522252
uuid-7303ba82222a41c794f49bfcb79e08a4,1L,0.596726
uuid-7303ba82222a41c794f49bfcb79e08a4,efficacy,0.325479
uuid-7303ba82222a41c794f49bfcb79e08a4,RCC,0.431167
uuid-7303ba82222a41c794f49bfcb79e08a4,chemo,0.357219
uuid-7303ba82222a41c794f49bfcb79e08a4,2L,0.630769
uuid-7303ba82222a41c794f49bfcb79e08a4,agents,0.471962
uuid-7303ba82222a41c794f49bfcb79e08a4,atezo,0.502198
uuid-7303ba82222a41c794f49bfcb79e08a4,preferred,0.583129
uuid-7303ba82222a41c794f49bfcb79e08a4,monotherapy,0.505287
uuid-7303ba82222a41c794f49bfcb79e08a4,using nivo,0.506752
uuid-7303ba82222a41c794f49bfcb79e08a4,data,0.405518
uuid-7303ba82222a41c794f49bfcb79e08a4,combo,0.376989
uuid-7303ba82222a41c794f49bfcb79e08a4,indication,0.393482
uuid-7303ba82222a41c794f49bfcb79e08a4,approved,0.457045
uuid-7303ba82222a41c794f49bfcb79e08a4,SCCHN,0.330682
uuid-7303ba82222a41c794f49bfcb79e08a4,nivo and pembro,0.465631
uuid-7303ba82222a41c794f49bfcb79e08a4,believes,0.412886
uuid-7303ba82222a41c794f49bfcb79e08a4,impressed,0.368294
uuid-7303ba82222a41c794f49bfcb79e08a4,SCLC,0.300386
uuid-7303ba82222a41c794f49bfcb79e08a4,feels,0.54752
uuid-7303ba82222a41c794f49bfcb79e08a4,RTL stated,0.423495
uuid-7303ba82222a41c794f49bfcb79e08a4,option,0.606277
uuid-59130b075140464fb1af5c5e40dbec97,Nivo,0.582162
uuid-59130b075140464fb1af5c5e40dbec97,patients,0.688025
uuid-59130b075140464fb1af5c5e40dbec97,therapy,0.592568
uuid-59130b075140464fb1af5c5e40dbec97,nivolumab,0.538966
uuid-59130b075140464fb1af5c5e40dbec97,1L,0.317987
uuid-59130b075140464fb1af5c5e40dbec97,regimen,0.51413
uuid-59130b075140464fb1af5c5e40dbec97,treated,0.420249
uuid-59130b075140464fb1af5c5e40dbec97,combination,0.424711
uuid-59130b075140464fb1af5c5e40dbec97,chemo,0.54223
uuid-59130b075140464fb1af5c5e40dbec97,2L,0.320588
uuid-59130b075140464fb1af5c5e40dbec97,pts,0.635416
uuid-59130b075140464fb1af5c5e40dbec97,monotherapy,0.58466
uuid-59130b075140464fb1af5c5e40dbec97,treatment,0.537538
uuid-59130b075140464fb1af5c5e40dbec97,using nivo,0.455163
uuid-59130b075140464fb1af5c5e40dbec97,response,0.557156
uuid-59130b075140464fb1af5c5e40dbec97,combo,0.355164
uuid-59130b075140464fb1af5c5e40dbec97,PD1,0.522442
uuid-59130b075140464fb1af5c5e40dbec97,cHL,0.315067
uuid-59130b075140464fb1af5c5e40dbec97,progression,0.684589
uuid-59130b075140464fb1af5c5e40dbec97,chemotherapy,0.4962
uuid-59130b075140464fb1af5c5e40dbec97,respond,0.495256
uuid-59130b075140464fb1af5c5e40dbec97,RTL stated,0.37165
uuid-59130b075140464fb1af5c5e40dbec97,option,0.502208
uuid-9d2146d34b8d407ab4398e1165021231,lung,0.335021
uuid-9d2146d34b8d407ab4398e1165021231,regimen,0.338118
uuid-9d2146d34b8d407ab4398e1165021231,melanoma,0.345593
uuid-9d2146d34b8d407ab4398e1165021231,AI,0.687876
uuid-b694902e4bbe435aa389e2d43773770d,dose,0.3535
uuid-b694902e4bbe435aa389e2d43773770d,nivolumab,0.358521
uuid-b694902e4bbe435aa389e2d43773770d,trial,0.322901
uuid-b694902e4bbe435aa389e2d43773770d,combination,0.343091
uuid-b694902e4bbe435aa389e2d43773770d,vs,0.371101
uuid-b694902e4bbe435aa389e2d43773770d,flat dosing,0.331788
uuid-31872c452ccf4dcdb371c0fba2a119ad,commented,0.488785
uuid-31872c452ccf4dcdb371c0fba2a119ad,stated,0.319233
uuid-31872c452ccf4dcdb371c0fba2a119ad,regards,0.42241
uuid-31872c452ccf4dcdb371c0fba2a119ad,data,0.442432
uuid-31872c452ccf4dcdb371c0fba2a119ad,AI,0.314222
uuid-31872c452ccf4dcdb371c0fba2a119ad,SCCHN,0.303079
uuid-31872c452ccf4dcdb371c0fba2a119ad,ASCO,0.369495
uuid-31872c452ccf4dcdb371c0fba2a119ad,impressed,0.32224
uuid-31872c452ccf4dcdb371c0fba2a119ad,NCCN,0.732492
uuid-654da27955c3447ca29f9c83ee04dcce,RTL,0.411213
uuid-654da27955c3447ca29f9c83ee04dcce,nivolumab,0.463842
uuid-654da27955c3447ca29f9c83ee04dcce,treated,0.334089
uuid-654da27955c3447ca29f9c83ee04dcce,NTL,0.534385
uuid-654da27955c3447ca29f9c83ee04dcce,cHL,0.35842
uuid-654da27955c3447ca29f9c83ee04dcce,Regional TL,0.355906
uuid-3754ea05eb8741e2916799c831754cb5,Nivo,0.548954
uuid-3754ea05eb8741e2916799c831754cb5,patients,0.758521
uuid-3754ea05eb8741e2916799c831754cb5,Opdivo,0.301867
uuid-3754ea05eb8741e2916799c831754cb5,therapy,0.554854
uuid-3754ea05eb8741e2916799c831754cb5,nivolumab,0.429466
uuid-3754ea05eb8741e2916799c831754cb5,toxicity,0.302379
uuid-3754ea05eb8741e2916799c831754cb5,regimen,0.550949
uuid-3754ea05eb8741e2916799c831754cb5,treated,0.389332
uuid-3754ea05eb8741e2916799c831754cb5,chemo,0.512241
uuid-3754ea05eb8741e2916799c831754cb5,pts,0.587972
uuid-3754ea05eb8741e2916799c831754cb5,Ipi,0.357332
uuid-3754ea05eb8741e2916799c831754cb5,monotherapy,0.463602
uuid-3754ea05eb8741e2916799c831754cb5,treatment,0.559774
uuid-3754ea05eb8741e2916799c831754cb5,using nivo,0.31014
uuid-3754ea05eb8741e2916799c831754cb5,response,0.462889
uuid-3754ea05eb8741e2916799c831754cb5,PD1,0.40974
uuid-3754ea05eb8741e2916799c831754cb5,progression,0.641286
uuid-3754ea05eb8741e2916799c831754cb5,chemotherapy,0.512509
uuid-3754ea05eb8741e2916799c831754cb5,respond,0.551238
uuid-3754ea05eb8741e2916799c831754cb5,option,0.397955
uuid-4b9e8ee95ba64347bde65108ddf6ea1a,patients,0.333161
uuid-6cb0dbe5f11341eb812a2d41da127ce9,patients,0.333161
uuid-b22badb288734c8c8ceea8f35294b746,Nivo,0.674055
uuid-b22badb288734c8c8ceea8f35294b746,patients,0.477209
uuid-b22badb288734c8c8ceea8f35294b746,pembro,0.50894
uuid-b22badb288734c8c8ceea8f35294b746,therapy,0.32084
uuid-b22badb288734c8c8ceea8f35294b746,dose,0.568108
uuid-b22badb288734c8c8ceea8f35294b746,nivolumab,0.349209
uuid-b22badb288734c8c8ceea8f35294b746,1L,0.403818
uuid-b22badb288734c8c8ceea8f35294b746,toxicity,0.444668
uuid-b22badb288734c8c8ceea8f35294b746,efficacy,0.404051
uuid-b22badb288734c8c8ceea8f35294b746,regimen,0.61006
uuid-b22badb288734c8c8ceea8f35294b746,combination,0.498675
uuid-b22badb288734c8c8ceea8f35294b746,chemo,0.549917
uuid-b22badb288734c8c8ceea8f35294b746,2L,0.473231
uuid-b22badb288734c8c8ceea8f35294b746,pts,0.404671
uuid-b22badb288734c8c8ceea8f35294b746,agents,0.338146
uuid-b22badb288734c8c8ceea8f35294b746,Ipi,0.655585
uuid-b22badb288734c8c8ceea8f35294b746,atezo,0.437418
uuid-b22badb288734c8c8ceea8f35294b746,preferred,0.458615
uuid-b22badb288734c8c8ceea8f35294b746,monotherapy,0.6441
uuid-b22badb288734c8c8ceea8f35294b746,treatment,0.336992
uuid-b22badb288734c8c8ceea8f35294b746,using nivo,0.405261
uuid-b22badb288734c8c8ceea8f35294b746,combo,0.550055
uuid-b22badb288734c8c8ceea8f35294b746,PD1,0.394306
uuid-b22badb288734c8c8ceea8f35294b746,approved,0.329104
uuid-b22badb288734c8c8ceea8f35294b746,progression,0.356447
uuid-b22badb288734c8c8ceea8f35294b746,chemotherapy,0.47532
uuid-b22badb288734c8c8ceea8f35294b746,vs,0.500155
uuid-b22badb288734c8c8ceea8f35294b746,respond,0.305293
uuid-b22badb288734c8c8ceea8f35294b746,feels,0.371457
uuid-b22badb288734c8c8ceea8f35294b746,option,0.5315
uuid-cee015a75d404847983d7c97f4c6b049,2L,0.3727
uuid-cee015a75d404847983d7c97f4c6b049,agents,0.308683
uuid-cee015a75d404847983d7c97f4c6b049,preferred,0.443741
uuid-cee015a75d404847983d7c97f4c6b049,monotherapy,0.317885
uuid-cee015a75d404847983d7c97f4c6b049,using nivo,0.359786
uuid-cee015a75d404847983d7c97f4c6b049,SCCHN,0.308797
uuid-cee015a75d404847983d7c97f4c6b049,academic,0.393465
uuid-cee015a75d404847983d7c97f4c6b049,feels,0.548796
uuid-cee015a75d404847983d7c97f4c6b049,RTL stated,0.487919
uuid-cee015a75d404847983d7c97f4c6b049,option,0.404502
uuid-7c5655ae5baa40bc94d722c85d409a06,patients,0.466648
uuid-7c5655ae5baa40bc94d722c85d409a06,Opdivo,0.510207
uuid-7c5655ae5baa40bc94d722c85d409a06,nivolumab,0.379048
uuid-7c5655ae5baa40bc94d722c85d409a06,treated,0.375208
uuid-7c5655ae5baa40bc94d722c85d409a06,approval,0.396711
uuid-7c5655ae5baa40bc94d722c85d409a06,treatment,0.379065
uuid-7c5655ae5baa40bc94d722c85d409a06,approved,0.303303
uuid-c83023c2bf4048048ab24a5a95ae6e04,Nivo,0.470566
uuid-c83023c2bf4048048ab24a5a95ae6e04,1L,0.362185
uuid-c83023c2bf4048048ab24a5a95ae6e04,toxicity,0.327271
uuid-c83023c2bf4048048ab24a5a95ae6e04,efficacy,0.621728
uuid-c83023c2bf4048048ab24a5a95ae6e04,regimen,0.367319
uuid-c83023c2bf4048048ab24a5a95ae6e04,combination,0.470409
uuid-c83023c2bf4048048ab24a5a95ae6e04,chemo,0.584155
uuid-c83023c2bf4048048ab24a5a95ae6e04,pts,0.345751
uuid-c83023c2bf4048048ab24a5a95ae6e04,IO,0.344292
uuid-c83023c2bf4048048ab24a5a95ae6e04,agents,0.348869
uuid-c83023c2bf4048048ab24a5a95ae6e04,Ipi,0.43688
uuid-c83023c2bf4048048ab24a5a95ae6e04,OS,0.511965
uuid-c83023c2bf4048048ab24a5a95ae6e04,monotherapy,0.565514
uuid-c83023c2bf4048048ab24a5a95ae6e04,response,0.442887
uuid-c83023c2bf4048048ab24a5a95ae6e04,combo,0.570911
uuid-c83023c2bf4048048ab24a5a95ae6e04,PFS,0.486499
uuid-c83023c2bf4048048ab24a5a95ae6e04,PD1,0.569436
uuid-c83023c2bf4048048ab24a5a95ae6e04,ORR,0.529513
uuid-c83023c2bf4048048ab24a5a95ae6e04,nivo and pembro,0.49482
uuid-c83023c2bf4048048ab24a5a95ae6e04,progression,0.349476
uuid-c83023c2bf4048048ab24a5a95ae6e04,believes,0.614179
uuid-c83023c2bf4048048ab24a5a95ae6e04,chemotherapy,0.437611
uuid-c83023c2bf4048048ab24a5a95ae6e04,vs,0.362149
uuid-c83023c2bf4048048ab24a5a95ae6e04,feels,0.338929
uuid-c83023c2bf4048048ab24a5a95ae6e04,option,0.339146
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,patients,0.515725
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,RTL,0.323553
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,nivolumab,0.47085
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,toxicity,0.33372
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,trial,0.329283
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,regimen,0.540227
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,treated,0.483258
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,combination,0.499733
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,pts,0.389338
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,Ipi,0.3289
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,monotherapy,0.432499
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,treatment,0.362974
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,using nivo,0.33005
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,combo,0.439218
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,clinical trials,0.403486
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,chemotherapy,0.34914
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,feels,0.304699
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,RTL stated,0.350506
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,TL shared,0.323907
uuid-d4fe4cfefbb045d1af0ae50f87bf399f,bladder,0.328546
uuid-d1467848daaa479b8ee4cf81d4cbc82f,patients,0.67818
uuid-d1467848daaa479b8ee4cf81d4cbc82f,Opdivo,0.498052
uuid-d1467848daaa479b8ee4cf81d4cbc82f,therapy,0.489662
uuid-d1467848daaa479b8ee4cf81d4cbc82f,nivolumab,0.356292
uuid-d1467848daaa479b8ee4cf81d4cbc82f,regimen,0.720078
uuid-d1467848daaa479b8ee4cf81d4cbc82f,treated,0.394094
uuid-d1467848daaa479b8ee4cf81d4cbc82f,chemo,0.411785
uuid-d1467848daaa479b8ee4cf81d4cbc82f,pts,0.492707
uuid-d1467848daaa479b8ee4cf81d4cbc82f,monotherapy,0.522353
uuid-d1467848daaa479b8ee4cf81d4cbc82f,treatment,0.617707
uuid-d1467848daaa479b8ee4cf81d4cbc82f,response,0.329897
uuid-d1467848daaa479b8ee4cf81d4cbc82f,combo,0.316488
uuid-d1467848daaa479b8ee4cf81d4cbc82f,PD1,0.308877
uuid-d1467848daaa479b8ee4cf81d4cbc82f,progression,0.610498
uuid-d1467848daaa479b8ee4cf81d4cbc82f,chemotherapy,0.480381
uuid-d1467848daaa479b8ee4cf81d4cbc82f,respond,0.448148
uuid-d1467848daaa479b8ee4cf81d4cbc82f,option,0.478861
uuid-7624cd5593ad4c30a6048c8509c44803,Nivo,0.503165
uuid-7624cd5593ad4c30a6048c8509c44803,patients,0.372905
uuid-7624cd5593ad4c30a6048c8509c44803,dose,0.421547
uuid-7624cd5593ad4c30a6048c8509c44803,toxicity,0.591004
uuid-7624cd5593ad4c30a6048c8509c44803,efficacy,0.363221
uuid-7624cd5593ad4c30a6048c8509c44803,regimen,0.479672
uuid-7624cd5593ad4c30a6048c8509c44803,combination,0.446223
uuid-7624cd5593ad4c30a6048c8509c44803,chemo,0.454091
uuid-7624cd5593ad4c30a6048c8509c44803,pts,0.38081
uuid-7624cd5593ad4c30a6048c8509c44803,Ipi,0.514713
uuid-7624cd5593ad4c30a6048c8509c44803,monotherapy,0.432219
uuid-7624cd5593ad4c30a6048c8509c44803,response,0.358001
uuid-7624cd5593ad4c30a6048c8509c44803,combo,0.386864
uuid-7624cd5593ad4c30a6048c8509c44803,progression,0.306514
uuid-7624cd5593ad4c30a6048c8509c44803,chemotherapy,0.397089
uuid-7624cd5593ad4c30a6048c8509c44803,vs,0.347593
uuid-7624cd5593ad4c30a6048c8509c44803,option,0.347138
uuid-f7ac69cfac2a4dcfb008b4f1642df1cf,nivolumab,0.445932
uuid-e3491be8166d49e9bf95db56c691fba3,Nivo,0.338633
uuid-e3491be8166d49e9bf95db56c691fba3,nivolumab,0.457814
uuid-e3491be8166d49e9bf95db56c691fba3,trial,0.46876
uuid-e3491be8166d49e9bf95db56c691fba3,combination,0.564322
uuid-e3491be8166d49e9bf95db56c691fba3,chemo,0.424521
uuid-e3491be8166d49e9bf95db56c691fba3,agents,0.305834
uuid-e3491be8166d49e9bf95db56c691fba3,Ipi,0.330256
uuid-e3491be8166d49e9bf95db56c691fba3,combo,0.419893
uuid-e3491be8166d49e9bf95db56c691fba3,chemotherapy,0.424222
uuid-087a14c2a5224539b8387d69d41a256f,lung,0.562491
uuid-087a14c2a5224539b8387d69d41a256f,NTL,0.430767
uuid-087a14c2a5224539b8387d69d41a256f,melanoma,0.359073
uuid-087a14c2a5224539b8387d69d41a256f,shared,0.347864
uuid-087a14c2a5224539b8387d69d41a256f,commented,0.462083
uuid-087a14c2a5224539b8387d69d41a256f,RCC,0.493915
uuid-087a14c2a5224539b8387d69d41a256f,TL stated,0.517945
uuid-087a14c2a5224539b8387d69d41a256f,stated,0.351418
uuid-087a14c2a5224539b8387d69d41a256f,physicians,0.447196
uuid-087a14c2a5224539b8387d69d41a256f,oncology,0.30006
uuid-087a14c2a5224539b8387d69d41a256f,SCCHN,0.37613
uuid-087a14c2a5224539b8387d69d41a256f,ASCO,0.349925
uuid-087a14c2a5224539b8387d69d41a256f,oncologist,0.335865
uuid-087a14c2a5224539b8387d69d41a256f,TLs,0.42275
uuid-087a14c2a5224539b8387d69d41a256f,Regional TL,0.524819
uuid-087a14c2a5224539b8387d69d41a256f,RTL stated,0.313068
uuid-087a14c2a5224539b8387d69d41a256f,TL shared,0.429159
uuid-3c86df0ec8a54bf3903b742d24e85b96,patients,0.73157
uuid-3c86df0ec8a54bf3903b742d24e85b96,therapy,0.426336
uuid-3c86df0ec8a54bf3903b742d24e85b96,nivolumab,0.332516
uuid-3c86df0ec8a54bf3903b742d24e85b96,1L,0.384298
uuid-3c86df0ec8a54bf3903b742d24e85b96,regimen,0.42731
uuid-3c86df0ec8a54bf3903b742d24e85b96,treated,0.446752
uuid-3c86df0ec8a54bf3903b742d24e85b96,chemo,0.327862
uuid-3c86df0ec8a54bf3903b742d24e85b96,2L,0.34129
uuid-3c86df0ec8a54bf3903b742d24e85b96,pts,0.529928
uuid-3c86df0ec8a54bf3903b742d24e85b96,preferred,0.364611
uuid-3c86df0ec8a54bf3903b742d24e85b96,monotherapy,0.420233
uuid-3c86df0ec8a54bf3903b742d24e85b96,treatment,0.549347
uuid-3c86df0ec8a54bf3903b742d24e85b96,using nivo,0.351069
uuid-3c86df0ec8a54bf3903b742d24e85b96,NSCLC patients,0.541981
uuid-3c86df0ec8a54bf3903b742d24e85b96,PD1,0.306345
uuid-3c86df0ec8a54bf3903b742d24e85b96,progression,0.557949
uuid-3c86df0ec8a54bf3903b742d24e85b96,tumor types,0.348819
uuid-3c86df0ec8a54bf3903b742d24e85b96,respond,0.447037
uuid-3c86df0ec8a54bf3903b742d24e85b96,RTL stated,0.350542
uuid-3c86df0ec8a54bf3903b742d24e85b96,option,0.492612
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,Nivo,0.587431
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,pembro,0.419831
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,therapy,0.322576
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,1L,0.407283
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,PDL1,0.313876
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,efficacy,0.44724
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,combination,0.492484
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,chemo,0.483285
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,2L,0.398582
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,agents,0.573603
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,atezo,0.362615
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,preferred,0.317985
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,monotherapy,0.539597
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,data,0.340377
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,combo,0.472607
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,PD1,0.482819
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,approved,0.313454
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,nivo and pembro,0.428791
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,believes,0.458942
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,chemotherapy,0.436665
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,feels,0.495351
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,PD-1,0.308887
uuid-30b90a72a2d742b4a37e4112e1c1a8e6,option,0.487334
uuid-3ef3de629ee04c6bb40884024cb2f5f9,pembro,0.338563
uuid-3ef3de629ee04c6bb40884024cb2f5f9,RTL,0.356143
uuid-3ef3de629ee04c6bb40884024cb2f5f9,BMS,0.449559
uuid-3ef3de629ee04c6bb40884024cb2f5f9,PDL1,0.369106
uuid-3ef3de629ee04c6bb40884024cb2f5f9,trial,0.672465
uuid-3ef3de629ee04c6bb40884024cb2f5f9,efficacy,0.440836
uuid-3ef3de629ee04c6bb40884024cb2f5f9,commented,0.419264
uuid-3ef3de629ee04c6bb40884024cb2f5f9,Merck,0.40819
uuid-3ef3de629ee04c6bb40884024cb2f5f9,stated,0.323958
uuid-3ef3de629ee04c6bb40884024cb2f5f9,OS,0.533141
uuid-3ef3de629ee04c6bb40884024cb2f5f9,data,0.697098
uuid-3ef3de629ee04c6bb40884024cb2f5f9,expressed,0.373529
uuid-3ef3de629ee04c6bb40884024cb2f5f9,clinical trials,0.341902
uuid-3ef3de629ee04c6bb40884024cb2f5f9,PFS,0.535793
uuid-3ef3de629ee04c6bb40884024cb2f5f9,ORR,0.544616
uuid-3ef3de629ee04c6bb40884024cb2f5f9,nivo and pembro,0.367006
uuid-3ef3de629ee04c6bb40884024cb2f5f9,impressed,0.574654
uuid-3ef3de629ee04c6bb40884024cb2f5f9,TLs,0.317121
uuid-3ef3de629ee04c6bb40884024cb2f5f9,feels,0.463883
uuid-3ef3de629ee04c6bb40884024cb2f5f9,PDL1 expression,0.326993
uuid-5fee57f03eee40c3b4def517070a49cf,RTL,0.387651
uuid-5fee57f03eee40c3b4def517070a49cf,BMS,0.450048
uuid-5fee57f03eee40c3b4def517070a49cf,PDL1,0.365696
uuid-5fee57f03eee40c3b4def517070a49cf,trial,0.622021
uuid-5fee57f03eee40c3b4def517070a49cf,efficacy,0.380113
uuid-5fee57f03eee40c3b4def517070a49cf,NTL,0.331334
uuid-5fee57f03eee40c3b4def517070a49cf,commented,0.51314
uuid-5fee57f03eee40c3b4def517070a49cf,Merck,0.376754
uuid-5fee57f03eee40c3b4def517070a49cf,stated,0.342707
uuid-5fee57f03eee40c3b4def517070a49cf,OS,0.510577
uuid-5fee57f03eee40c3b4def517070a49cf,data,0.841343
uuid-5fee57f03eee40c3b4def517070a49cf,expressed,0.360895
uuid-5fee57f03eee40c3b4def517070a49cf,clinical trials,0.301357
uuid-5fee57f03eee40c3b4def517070a49cf,PFS,0.491599
uuid-5fee57f03eee40c3b4def517070a49cf,ORR,0.560341
uuid-5fee57f03eee40c3b4def517070a49cf,nivo and pembro,0.383448
uuid-5fee57f03eee40c3b4def517070a49cf,ASCO,0.341542
uuid-5fee57f03eee40c3b4def517070a49cf,impressed,0.619368
uuid-5fee57f03eee40c3b4def517070a49cf,feels,0.388926
uuid-5fee57f03eee40c3b4def517070a49cf,PDL1 expression,0.372922
uuid-a309410b5b5e4218a6cb06d2119bc6b7,treated,0.345676
uuid-a309410b5b5e4218a6cb06d2119bc6b7,shared,0.412473
uuid-a309410b5b5e4218a6cb06d2119bc6b7,physicians,0.319486
uuid-a309410b5b5e4218a6cb06d2119bc6b7,feels,0.438011
uuid-7550330fc601437ea295f53d04e20536,Nivo,0.37262
uuid-7550330fc601437ea295f53d04e20536,patients,0.429477
uuid-7550330fc601437ea295f53d04e20536,therapy,0.444339
uuid-7550330fc601437ea295f53d04e20536,nivolumab,0.450572
uuid-7550330fc601437ea295f53d04e20536,1L,0.724982
uuid-7550330fc601437ea295f53d04e20536,regimen,0.483419
uuid-7550330fc601437ea295f53d04e20536,treated,0.326213
uuid-7550330fc601437ea295f53d04e20536,RCC,0.574781
uuid-7550330fc601437ea295f53d04e20536,TL stated,0.357596
uuid-7550330fc601437ea295f53d04e20536,combination,0.483688
uuid-7550330fc601437ea295f53d04e20536,chemo,0.515548
uuid-7550330fc601437ea295f53d04e20536,2L,0.748691
uuid-7550330fc601437ea295f53d04e20536,pts,0.516878
uuid-7550330fc601437ea295f53d04e20536,IO,0.3755
uuid-7550330fc601437ea295f53d04e20536,agents,0.48965
uuid-7550330fc601437ea295f53d04e20536,preferred,0.65694
uuid-7550330fc601437ea295f53d04e20536,monotherapy,0.765778
uuid-7550330fc601437ea295f53d04e20536,treatment,0.439505
uuid-7550330fc601437ea295f53d04e20536,using nivo,0.533003
uuid-7550330fc601437ea295f53d04e20536,response,0.322425
uuid-7550330fc601437ea295f53d04e20536,combo,0.536153
uuid-7550330fc601437ea295f53d04e20536,NSCLC patients,0.334438
uuid-7550330fc601437ea295f53d04e20536,PD1,0.558644
uuid-7550330fc601437ea295f53d04e20536,approved,0.42173
uuid-7550330fc601437ea295f53d04e20536,progression,0.484725
uuid-7550330fc601437ea295f53d04e20536,believes,0.352756
uuid-7550330fc601437ea295f53d04e20536,chemotherapy,0.394363
uuid-7550330fc601437ea295f53d04e20536,respond,0.325735
uuid-7550330fc601437ea295f53d04e20536,PD-1,0.407226
uuid-7550330fc601437ea295f53d04e20536,RTL stated,0.504169
uuid-7550330fc601437ea295f53d04e20536,TL shared,0.357767
uuid-7550330fc601437ea295f53d04e20536,option,0.675431
uuid-1b3fec2616c04bb5843d87af73448f28,lung,0.417676
uuid-1b3fec2616c04bb5843d87af73448f28,shared,0.362045
uuid-1b3fec2616c04bb5843d87af73448f28,institution,0.72573
uuid-1b3fec2616c04bb5843d87af73448f28,AI,0.567177
uuid-1b3fec2616c04bb5843d87af73448f28,oncology,0.610211
uuid-1b3fec2616c04bb5843d87af73448f28,clinical,0.371684
uuid-1b3fec2616c04bb5843d87af73448f28,NCCN,0.414684
uuid-95794bfd82654ae8b29f61eec8e75b7f,Nivo,0.385519
uuid-95794bfd82654ae8b29f61eec8e75b7f,patients,0.608722
uuid-95794bfd82654ae8b29f61eec8e75b7f,therapy,0.433086
uuid-95794bfd82654ae8b29f61eec8e75b7f,nivolumab,0.392169
uuid-95794bfd82654ae8b29f61eec8e75b7f,1L,0.465443
uuid-95794bfd82654ae8b29f61eec8e75b7f,toxicity,0.338091
uuid-95794bfd82654ae8b29f61eec8e75b7f,regimen,0.550106
uuid-95794bfd82654ae8b29f61eec8e75b7f,treated,0.332444
uuid-95794bfd82654ae8b29f61eec8e75b7f,combination,0.48349
uuid-95794bfd82654ae8b29f61eec8e75b7f,chemo,0.536706
uuid-95794bfd82654ae8b29f61eec8e75b7f,2L,0.478605
uuid-95794bfd82654ae8b29f61eec8e75b7f,pts,0.502676
uuid-95794bfd82654ae8b29f61eec8e75b7f,IO,0.313674
uuid-95794bfd82654ae8b29f61eec8e75b7f,agents,0.462407
uuid-95794bfd82654ae8b29f61eec8e75b7f,preferred,0.5462
uuid-95794bfd82654ae8b29f61eec8e75b7f,monotherapy,0.712366
uuid-95794bfd82654ae8b29f61eec8e75b7f,treatment,0.453417
uuid-95794bfd82654ae8b29f61eec8e75b7f,using nivo,0.386726
uuid-95794bfd82654ae8b29f61eec8e75b7f,combo,0.483484
uuid-95794bfd82654ae8b29f61eec8e75b7f,PD1,0.454746
uuid-95794bfd82654ae8b29f61eec8e75b7f,progression,0.438954
uuid-95794bfd82654ae8b29f61eec8e75b7f,chemotherapy,0.472148
uuid-95794bfd82654ae8b29f61eec8e75b7f,respond,0.416389
uuid-95794bfd82654ae8b29f61eec8e75b7f,feels,0.417622
uuid-95794bfd82654ae8b29f61eec8e75b7f,RTL stated,0.38551
uuid-95794bfd82654ae8b29f61eec8e75b7f,option,0.692066
uuid-90aa213ce9264bfebd14f98059210537,RTL,0.384736
uuid-90aa213ce9264bfebd14f98059210537,trial,0.385229
uuid-90aa213ce9264bfebd14f98059210537,NTL,0.513378
uuid-90aa213ce9264bfebd14f98059210537,Regional TL,0.333721
uuid-f07737d500b942f39d02002890f6e66b,dose,0.348313
uuid-f07737d500b942f39d02002890f6e66b,oncologist,0.306576
uuid-f07737d500b942f39d02002890f6e66b,indicated,0.559819
uuid-f07737d500b942f39d02002890f6e66b,flat dosing,0.438491
uuid-2818cae96c8b48e49f312a625911ef9f,Nivo,0.472216
uuid-2818cae96c8b48e49f312a625911ef9f,dose,0.563066
uuid-2818cae96c8b48e49f312a625911ef9f,toxicity,0.525
uuid-2818cae96c8b48e49f312a625911ef9f,trial,0.304692
uuid-2818cae96c8b48e49f312a625911ef9f,efficacy,0.545748
uuid-2818cae96c8b48e49f312a625911ef9f,regimen,0.521984
uuid-2818cae96c8b48e49f312a625911ef9f,combination,0.447353
uuid-2818cae96c8b48e49f312a625911ef9f,chemo,0.311638
uuid-2818cae96c8b48e49f312a625911ef9f,Ipi,0.68815
uuid-2818cae96c8b48e49f312a625911ef9f,monotherapy,0.351913
uuid-2818cae96c8b48e49f312a625911ef9f,combo,0.499673
uuid-2818cae96c8b48e49f312a625911ef9f,impressed,0.314703
uuid-2818cae96c8b48e49f312a625911ef9f,vs,0.424081
uuid-2818cae96c8b48e49f312a625911ef9f,feels,0.314737
uuid-2818cae96c8b48e49f312a625911ef9f,flat dosing,0.355386
uuid-6a90e7fbbe9a4114ab53452498b31172,patients,0.515102
uuid-6a90e7fbbe9a4114ab53452498b31172,Opdivo,0.475083
uuid-6a90e7fbbe9a4114ab53452498b31172,toxicity,0.331739
uuid-6a90e7fbbe9a4114ab53452498b31172,regimen,0.377029
uuid-6a90e7fbbe9a4114ab53452498b31172,treated,0.466714
uuid-6a90e7fbbe9a4114ab53452498b31172,shared,0.310176
uuid-6a90e7fbbe9a4114ab53452498b31172,physicians,0.354839
uuid-6a90e7fbbe9a4114ab53452498b31172,treatment,0.40576
uuid-6a90e7fbbe9a4114ab53452498b31172,progression,0.369816
uuid-6a90e7fbbe9a4114ab53452498b31172,respond,0.349511
uuid-e267e7977029433c9bc848d22d71045d,regimen,0.313506
uuid-e267e7977029433c9bc848d22d71045d,combination,0.321229
uuid-e267e7977029433c9bc848d22d71045d,NCCN,0.320254
uuid-1cefcdda0b704c779fc81402360c43a8,BMS,0.343683
uuid-1cefcdda0b704c779fc81402360c43a8,AI,0.45259
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,Nivo,0.573638
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,patients,0.37373
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,Opdivo,0.632136
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,pembro,0.460317
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,dose,0.563975
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,nivolumab,0.456557
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,Ipi,0.342088
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,approval,0.414369
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,atezo,0.342869
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,preferred,0.324234
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,using nivo,0.464591
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,indication,0.302977
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,approved,0.338398
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,cHL,0.488879
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,vs,0.422819
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,label,0.351435
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,Keytruda,0.44825
uuid-ecbe4e82efdd45aca000d9f9e44ce95f,flat dosing,0.507576
uuid-32d8e4b08b504fae98afbdd24c9a8da6,Nivo,0.536377
uuid-32d8e4b08b504fae98afbdd24c9a8da6,patients,0.837155
uuid-32d8e4b08b504fae98afbdd24c9a8da6,Opdivo,0.465625
uuid-32d8e4b08b504fae98afbdd24c9a8da6,therapy,0.705721
uuid-32d8e4b08b504fae98afbdd24c9a8da6,nivolumab,0.560172
uuid-32d8e4b08b504fae98afbdd24c9a8da6,regimen,0.357722
uuid-32d8e4b08b504fae98afbdd24c9a8da6,treated,0.456358
uuid-32d8e4b08b504fae98afbdd24c9a8da6,chemo,0.34396
uuid-32d8e4b08b504fae98afbdd24c9a8da6,pts,0.441706
uuid-32d8e4b08b504fae98afbdd24c9a8da6,monotherapy,0.31496
uuid-32d8e4b08b504fae98afbdd24c9a8da6,treatment,0.606919
uuid-32d8e4b08b504fae98afbdd24c9a8da6,using nivo,0.365067
uuid-32d8e4b08b504fae98afbdd24c9a8da6,response,0.338881
uuid-32d8e4b08b504fae98afbdd24c9a8da6,PD1,0.338136
uuid-32d8e4b08b504fae98afbdd24c9a8da6,cHL,0.625722
uuid-32d8e4b08b504fae98afbdd24c9a8da6,progression,0.544878
uuid-32d8e4b08b504fae98afbdd24c9a8da6,chemotherapy,0.426532
uuid-32d8e4b08b504fae98afbdd24c9a8da6,respond,0.409896
uuid-32d8e4b08b504fae98afbdd24c9a8da6,option,0.305328
uuid-f5abbd2b64f540d69c24174264290470,patients,0.448065
uuid-f5abbd2b64f540d69c24174264290470,treated,0.305306
uuid-f5abbd2b64f540d69c24174264290470,chemo,0.378676
uuid-f5abbd2b64f540d69c24174264290470,pts,0.420119
uuid-f5abbd2b64f540d69c24174264290470,NSCLC patients,0.321861
uuid-f5abbd2b64f540d69c24174264290470,progression,0.369736
uuid-f5abbd2b64f540d69c24174264290470,respond,0.382764
uuid-69568935ec864217844327d38b2e61e4,therapy,0.440226
uuid-69568935ec864217844327d38b2e61e4,mentioned,0.386253
uuid-69568935ec864217844327d38b2e61e4,cHL,0.690367
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,patients,0.445075
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,Opdivo,0.527948
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,nivolumab,0.398487
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,treated,0.391293
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,approval,0.374233
uuid-f7c2eec171fd4fbdb86179e1deef9cbb,treatment,0.353154
uuid-825cb678869e4e2389f52490bb4f6e81,Nivo,0.412075
uuid-825cb678869e4e2389f52490bb4f6e81,pembro,0.546529
uuid-825cb678869e4e2389f52490bb4f6e81,lung,0.4747
uuid-825cb678869e4e2389f52490bb4f6e81,1L,0.658322
uuid-825cb678869e4e2389f52490bb4f6e81,melanoma,0.500173
uuid-825cb678869e4e2389f52490bb4f6e81,RCC,0.624092
uuid-825cb678869e4e2389f52490bb4f6e81,TL stated,0.426772
uuid-825cb678869e4e2389f52490bb4f6e81,2L,0.756389
uuid-825cb678869e4e2389f52490bb4f6e81,agents,0.343534
uuid-825cb678869e4e2389f52490bb4f6e81,approval,0.355084
uuid-825cb678869e4e2389f52490bb4f6e81,atezo,0.549372
uuid-825cb678869e4e2389f52490bb4f6e81,preferred,0.664703
uuid-825cb678869e4e2389f52490bb4f6e81,monotherapy,0.512121
uuid-825cb678869e4e2389f52490bb4f6e81,using nivo,0.665037
uuid-825cb678869e4e2389f52490bb4f6e81,combo,0.399529
uuid-825cb678869e4e2389f52490bb4f6e81,PDL1 testing,0.343533
uuid-825cb678869e4e2389f52490bb4f6e81,indication,0.301491
uuid-825cb678869e4e2389f52490bb4f6e81,NSCLC patients,0.306833
uuid-825cb678869e4e2389f52490bb4f6e81,approved,0.453397
uuid-825cb678869e4e2389f52490bb4f6e81,SCCHN,0.490367
uuid-825cb678869e4e2389f52490bb4f6e81,tumor types,0.333373
uuid-825cb678869e4e2389f52490bb4f6e81,RTL stated,0.617366
uuid-825cb678869e4e2389f52490bb4f6e81,TL shared,0.483048
uuid-825cb678869e4e2389f52490bb4f6e81,option,0.506497
uuid-825cb678869e4e2389f52490bb4f6e81,bladder,0.451968
uuid-09a37fea583b46128b309dbed8fb5045,patients,0.440429
uuid-09a37fea583b46128b309dbed8fb5045,RTL,0.356327
uuid-09a37fea583b46128b309dbed8fb5045,treated,0.527615
uuid-09a37fea583b46128b309dbed8fb5045,melanoma,0.413848
uuid-09a37fea583b46128b309dbed8fb5045,RCC,0.46738
uuid-09a37fea583b46128b309dbed8fb5045,TL stated,0.425495
uuid-09a37fea583b46128b309dbed8fb5045,tumor,0.34352
uuid-09a37fea583b46128b309dbed8fb5045,pts,0.423959
uuid-09a37fea583b46128b309dbed8fb5045,treatment,0.371544
uuid-09a37fea583b46128b309dbed8fb5045,SCCHN,0.360167
uuid-09a37fea583b46128b309dbed8fb5045,progression,0.478854
uuid-09a37fea583b46128b309dbed8fb5045,Regional TL,0.340632
uuid-09a37fea583b46128b309dbed8fb5045,RTL stated,0.359055
uuid-09a37fea583b46128b309dbed8fb5045,TL shared,0.469318
uuid-9c1f9675696f4f6f9d3b8331014c9f35,Nivo,0.647906
uuid-9c1f9675696f4f6f9d3b8331014c9f35,pembro,0.522596
uuid-9c1f9675696f4f6f9d3b8331014c9f35,1L,0.41087
uuid-9c1f9675696f4f6f9d3b8331014c9f35,efficacy,0.408
uuid-9c1f9675696f4f6f9d3b8331014c9f35,chemo,0.578528
uuid-9c1f9675696f4f6f9d3b8331014c9f35,2L,0.432985
uuid-9c1f9675696f4f6f9d3b8331014c9f35,agents,0.427525
uuid-9c1f9675696f4f6f9d3b8331014c9f35,Ipi,0.367055
uuid-9c1f9675696f4f6f9d3b8331014c9f35,atezo,0.442304
uuid-9c1f9675696f4f6f9d3b8331014c9f35,preferred,0.368354
uuid-9c1f9675696f4f6f9d3b8331014c9f35,monotherapy,0.487843
uuid-9c1f9675696f4f6f9d3b8331014c9f35,using nivo,0.306173
uuid-9c1f9675696f4f6f9d3b8331014c9f35,combo,0.351232
uuid-9c1f9675696f4f6f9d3b8331014c9f35,PD1,0.349877
uuid-9c1f9675696f4f6f9d3b8331014c9f35,nivo and pembro,0.571667
uuid-9c1f9675696f4f6f9d3b8331014c9f35,believes,0.534658
uuid-9c1f9675696f4f6f9d3b8331014c9f35,chemotherapy,0.396898
uuid-9c1f9675696f4f6f9d3b8331014c9f35,vs,0.452123
uuid-9c1f9675696f4f6f9d3b8331014c9f35,respond,0.315246
uuid-9c1f9675696f4f6f9d3b8331014c9f35,feels,0.472259
uuid-9c1f9675696f4f6f9d3b8331014c9f35,option,0.457133
uuid-ee6a077681c24307a30a1b263f77be26,Opdivo,0.468244
uuid-ee6a077681c24307a30a1b263f77be26,dose,0.468949
uuid-ee6a077681c24307a30a1b263f77be26,drug,0.458388
uuid-ee6a077681c24307a30a1b263f77be26,Keytruda,0.714504
uuid-ee6a077681c24307a30a1b263f77be26,flat dosing,0.583838
uuid-c8a49de9fd6648a29f0fb021edf0f6af,patients,0.677124
uuid-c8a49de9fd6648a29f0fb021edf0f6af,Opdivo,0.348243
uuid-c8a49de9fd6648a29f0fb021edf0f6af,therapy,0.498058
uuid-c8a49de9fd6648a29f0fb021edf0f6af,nivolumab,0.323093
uuid-c8a49de9fd6648a29f0fb021edf0f6af,toxicity,0.640373
uuid-c8a49de9fd6648a29f0fb021edf0f6af,regimen,0.649729
uuid-c8a49de9fd6648a29f0fb021edf0f6af,treated,0.431668
uuid-c8a49de9fd6648a29f0fb021edf0f6af,combination,0.325436
uuid-c8a49de9fd6648a29f0fb021edf0f6af,chemo,0.41314
uuid-c8a49de9fd6648a29f0fb021edf0f6af,pts,0.416258
uuid-c8a49de9fd6648a29f0fb021edf0f6af,monotherapy,0.46738
uuid-c8a49de9fd6648a29f0fb021edf0f6af,treatment,0.69044
uuid-c8a49de9fd6648a29f0fb021edf0f6af,response,0.401896
uuid-c8a49de9fd6648a29f0fb021edf0f6af,PD1,0.366281
uuid-c8a49de9fd6648a29f0fb021edf0f6af,progression,0.573555
uuid-c8a49de9fd6648a29f0fb021edf0f6af,chemotherapy,0.460674
uuid-c8a49de9fd6648a29f0fb021edf0f6af,respond,0.527171
uuid-c8a49de9fd6648a29f0fb021edf0f6af,option,0.41266
uuid-8e1db6eb1faf47fabb17144e2edd90f2,patients,0.516256
uuid-8e1db6eb1faf47fabb17144e2edd90f2,RTL,0.446383
uuid-8e1db6eb1faf47fabb17144e2edd90f2,therapy,0.346187
uuid-8e1db6eb1faf47fabb17144e2edd90f2,nivolumab,0.592915
uuid-8e1db6eb1faf47fabb17144e2edd90f2,regimen,0.381008
uuid-8e1db6eb1faf47fabb17144e2edd90f2,treated,0.573338
uuid-8e1db6eb1faf47fabb17144e2edd90f2,melanoma,0.431881
uuid-8e1db6eb1faf47fabb17144e2edd90f2,RCC,0.647426
uuid-8e1db6eb1faf47fabb17144e2edd90f2,TL stated,0.311132
uuid-8e1db6eb1faf47fabb17144e2edd90f2,pts,0.454075
uuid-8e1db6eb1faf47fabb17144e2edd90f2,stated,0.321958
uuid-8e1db6eb1faf47fabb17144e2edd90f2,approval,0.347133
uuid-8e1db6eb1faf47fabb17144e2edd90f2,monotherapy,0.360972
uuid-8e1db6eb1faf47fabb17144e2edd90f2,treatment,0.438062
uuid-8e1db6eb1faf47fabb17144e2edd90f2,using nivo,0.507919
uuid-8e1db6eb1faf47fabb17144e2edd90f2,PD1,0.327264
uuid-8e1db6eb1faf47fabb17144e2edd90f2,SCCHN,0.516196
uuid-8e1db6eb1faf47fabb17144e2edd90f2,progression,0.437136
uuid-8e1db6eb1faf47fabb17144e2edd90f2,oncologist,0.303974
uuid-8e1db6eb1faf47fabb17144e2edd90f2,LTL,0.304867
uuid-8e1db6eb1faf47fabb17144e2edd90f2,SCLC,0.328008
uuid-8e1db6eb1faf47fabb17144e2edd90f2,Regional TL,0.424665
uuid-8e1db6eb1faf47fabb17144e2edd90f2,RTL stated,0.601903
uuid-8e1db6eb1faf47fabb17144e2edd90f2,TL shared,0.508649
uuid-8e1db6eb1faf47fabb17144e2edd90f2,bladder,0.386173
uuid-272372c80c2a4b599042dc73043234bc,BMS,0.363389
uuid-272372c80c2a4b599042dc73043234bc,PDL1,0.354946
uuid-272372c80c2a4b599042dc73043234bc,trial,0.534648
uuid-272372c80c2a4b599042dc73043234bc,efficacy,0.500684
uuid-272372c80c2a4b599042dc73043234bc,commented,0.334643
uuid-272372c80c2a4b599042dc73043234bc,stated,0.331332
uuid-272372c80c2a4b599042dc73043234bc,OS,0.751875
uuid-272372c80c2a4b599042dc73043234bc,data,0.79177
uuid-272372c80c2a4b599042dc73043234bc,PFS,0.720384
uuid-272372c80c2a4b599042dc73043234bc,ORR,0.722119
uuid-272372c80c2a4b599042dc73043234bc,nivo and pembro,0.437284
uuid-272372c80c2a4b599042dc73043234bc,ASCO,0.316537
uuid-272372c80c2a4b599042dc73043234bc,believes,0.312112
uuid-272372c80c2a4b599042dc73043234bc,impressed,0.664368
uuid-272372c80c2a4b599042dc73043234bc,feels,0.45195
uuid-272372c80c2a4b599042dc73043234bc,PDL1 expression,0.301257
uuid-dac8b9a83cbd4abd819f6a2938ccc575,PDL1,0.43858
uuid-dac8b9a83cbd4abd819f6a2938ccc575,efficacy,0.493616
uuid-dac8b9a83cbd4abd819f6a2938ccc575,OS,0.602023
uuid-dac8b9a83cbd4abd819f6a2938ccc575,regards,0.347837
uuid-dac8b9a83cbd4abd819f6a2938ccc575,data,0.581559
uuid-dac8b9a83cbd4abd819f6a2938ccc575,PFS,0.61463
uuid-dac8b9a83cbd4abd819f6a2938ccc575,ORR,0.57071
uuid-dac8b9a83cbd4abd819f6a2938ccc575,nivo and pembro,0.580395
uuid-dac8b9a83cbd4abd819f6a2938ccc575,believes,0.471467
uuid-dac8b9a83cbd4abd819f6a2938ccc575,impressed,0.328077
uuid-dac8b9a83cbd4abd819f6a2938ccc575,indicated,0.368587
uuid-dac8b9a83cbd4abd819f6a2938ccc575,feels,0.35688
uuid-dac8b9a83cbd4abd819f6a2938ccc575,PDL1 expression,0.354551
uuid-aa50928327e74d2f9d1065a3ee45a419,patients,0.772437
uuid-aa50928327e74d2f9d1065a3ee45a419,Opdivo,0.37919
uuid-aa50928327e74d2f9d1065a3ee45a419,therapy,0.520066
uuid-aa50928327e74d2f9d1065a3ee45a419,nivolumab,0.497795
uuid-aa50928327e74d2f9d1065a3ee45a419,regimen,0.574225
uuid-aa50928327e74d2f9d1065a3ee45a419,treated,0.538516
uuid-aa50928327e74d2f9d1065a3ee45a419,chemo,0.362624
uuid-aa50928327e74d2f9d1065a3ee45a419,pts,0.490162
uuid-aa50928327e74d2f9d1065a3ee45a419,physicians,0.300556
uuid-aa50928327e74d2f9d1065a3ee45a419,monotherapy,0.389088
uuid-aa50928327e74d2f9d1065a3ee45a419,treatment,0.591787
uuid-aa50928327e74d2f9d1065a3ee45a419,using nivo,0.386594
uuid-aa50928327e74d2f9d1065a3ee45a419,response,0.335869
uuid-aa50928327e74d2f9d1065a3ee45a419,progression,0.546889
uuid-aa50928327e74d2f9d1065a3ee45a419,chemotherapy,0.37204
uuid-aa50928327e74d2f9d1065a3ee45a419,respond,0.426218
uuid-aa50928327e74d2f9d1065a3ee45a419,option,0.317505
uuid-30a1a94084464e8ea0a529dbabf320b1,lung,0.600675
uuid-30a1a94084464e8ea0a529dbabf320b1,melanoma,0.460195
uuid-30a1a94084464e8ea0a529dbabf320b1,institution,0.377396
uuid-30a1a94084464e8ea0a529dbabf320b1,regards,0.434801
uuid-30a1a94084464e8ea0a529dbabf320b1,AI,0.89945
uuid-30a1a94084464e8ea0a529dbabf320b1,oncology,0.363763
uuid-30a1a94084464e8ea0a529dbabf320b1,NCCN,0.770682
uuid-f5fd6899d5db4209aa6a90a9816d03cc,physicians,0.353751
uuid-f5fd6899d5db4209aa6a90a9816d03cc,response,0.311648
uuid-f5fd6899d5db4209aa6a90a9816d03cc,progression,0.349623
uuid-f5fd6899d5db4209aa6a90a9816d03cc,indicated,0.383286
uuid-f5fd6899d5db4209aa6a90a9816d03cc,respond,0.451939
uuid-34bcde4eb999455b8cd057574e8a7217,pts,0.43979
uuid-34bcde4eb999455b8cd057574e8a7217,immunotherapy,0.448238
uuid-e8de91b97c364b4cacf1ae359b06c92c,patients,0.48633
uuid-e8de91b97c364b4cacf1ae359b06c92c,Opdivo,0.306287
uuid-e8de91b97c364b4cacf1ae359b06c92c,toxicity,0.558756
uuid-e8de91b97c364b4cacf1ae359b06c92c,regimen,0.615412
uuid-e8de91b97c364b4cacf1ae359b06c92c,treated,0.328961
uuid-e8de91b97c364b4cacf1ae359b06c92c,melanoma,0.359928
uuid-e8de91b97c364b4cacf1ae359b06c92c,pts,0.462762
uuid-e8de91b97c364b4cacf1ae359b06c92c,monotherapy,0.314052
uuid-e8de91b97c364b4cacf1ae359b06c92c,treatment,0.446735
uuid-e8de91b97c364b4cacf1ae359b06c92c,response,0.349953
uuid-e8de91b97c364b4cacf1ae359b06c92c,combo,0.368212
uuid-e8de91b97c364b4cacf1ae359b06c92c,progression,0.53086
uuid-e8de91b97c364b4cacf1ae359b06c92c,respond,0.454565
uuid-e8de91b97c364b4cacf1ae359b06c92c,TL shared,0.332486
uuid-e030c2f6408d47958ff29db978be4c6b,Opdivo,0.462629
uuid-e030c2f6408d47958ff29db978be4c6b,physicians,0.406556
uuid-e030c2f6408d47958ff29db978be4c6b,drug,0.474305
uuid-e9b5ba2e2e06419da3ac57021d54ab31,patients,0.301165
uuid-e9b5ba2e2e06419da3ac57021d54ab31,tumor,0.583014
uuid-662047634e7e46619a1081a3b6aa72b0,patients,0.639401
uuid-662047634e7e46619a1081a3b6aa72b0,therapy,0.413469
uuid-662047634e7e46619a1081a3b6aa72b0,nivolumab,0.306325
uuid-662047634e7e46619a1081a3b6aa72b0,regimen,0.532904
uuid-662047634e7e46619a1081a3b6aa72b0,treated,0.515764
uuid-662047634e7e46619a1081a3b6aa72b0,chemo,0.318549
uuid-662047634e7e46619a1081a3b6aa72b0,pts,0.533358
uuid-662047634e7e46619a1081a3b6aa72b0,IO,0.312114
uuid-662047634e7e46619a1081a3b6aa72b0,monotherapy,0.383781
uuid-662047634e7e46619a1081a3b6aa72b0,treatment,0.58878
uuid-662047634e7e46619a1081a3b6aa72b0,response,0.455747
uuid-662047634e7e46619a1081a3b6aa72b0,PD1,0.3595
uuid-662047634e7e46619a1081a3b6aa72b0,progression,0.648774
uuid-662047634e7e46619a1081a3b6aa72b0,chemotherapy,0.321715
uuid-662047634e7e46619a1081a3b6aa72b0,respond,0.475848
uuid-662047634e7e46619a1081a3b6aa72b0,PD-1,0.314674
uuid-662047634e7e46619a1081a3b6aa72b0,TL shared,0.321795
uuid-662047634e7e46619a1081a3b6aa72b0,option,0.317244
uuid-16529280b9b24987a93057376bdc18de,patients,0.550755
uuid-16529280b9b24987a93057376bdc18de,Opdivo,0.413446
uuid-16529280b9b24987a93057376bdc18de,treated,0.319776
uuid-16529280b9b24987a93057376bdc18de,pts,0.363404
uuid-16529280b9b24987a93057376bdc18de,PD-L1,0.318539
uuid-16529280b9b24987a93057376bdc18de,approval,0.335936
uuid-16529280b9b24987a93057376bdc18de,PD-L1 testing,0.406019
uuid-16529280b9b24987a93057376bdc18de,testing,0.477162
uuid-16529280b9b24987a93057376bdc18de,PDL1 testing,0.387929
uuid-16529280b9b24987a93057376bdc18de,NSCLC patients,0.484619
uuid-16529280b9b24987a93057376bdc18de,tumor types,0.378476
uuid-53d91121017546b699fa3c042df0e2e8,RTL,0.354213
uuid-53d91121017546b699fa3c042df0e2e8,BMS,0.336798
uuid-53d91121017546b699fa3c042df0e2e8,shared,0.468662
uuid-53d91121017546b699fa3c042df0e2e8,Merck,0.436677
uuid-53d91121017546b699fa3c042df0e2e8,stated,0.35983
uuid-53d91121017546b699fa3c042df0e2e8,approval,0.390685
uuid-53d91121017546b699fa3c042df0e2e8,physicians,0.324971
uuid-53d91121017546b699fa3c042df0e2e8,clinical trials,0.630093
uuid-53d91121017546b699fa3c042df0e2e8,approved,0.308983
uuid-53d91121017546b699fa3c042df0e2e8,SCCHN,0.36922
uuid-53d91121017546b699fa3c042df0e2e8,academic,0.308322
uuid-53d91121017546b699fa3c042df0e2e8,Regional TL,0.376567
uuid-3df588dabe394e6eac6c2713d2997c63,indicated,0.306644
uuid-bbeaa3e61e13465ebc232925e327c2e3,patients,0.362431
uuid-bbeaa3e61e13465ebc232925e327c2e3,therapy,0.307913
uuid-bbeaa3e61e13465ebc232925e327c2e3,NSCLC,0.316946
uuid-bbeaa3e61e13465ebc232925e327c2e3,1L,0.385348
uuid-bbeaa3e61e13465ebc232925e327c2e3,pts,0.310926
uuid-bbeaa3e61e13465ebc232925e327c2e3,IO,0.494481
uuid-bbeaa3e61e13465ebc232925e327c2e3,PD-L1,0.36603
uuid-bbeaa3e61e13465ebc232925e327c2e3,PD-L1 testing,0.376005
uuid-bbeaa3e61e13465ebc232925e327c2e3,testing,0.452782
uuid-bbeaa3e61e13465ebc232925e327c2e3,monotherapy,0.38325
uuid-bbeaa3e61e13465ebc232925e327c2e3,treatment,0.336535
uuid-bbeaa3e61e13465ebc232925e327c2e3,PDL1 testing,0.373428
uuid-bbeaa3e61e13465ebc232925e327c2e3,NSCLC patients,0.431219
uuid-bbeaa3e61e13465ebc232925e327c2e3,progression,0.30006
uuid-bbeaa3e61e13465ebc232925e327c2e3,chemotherapy,0.329508
uuid-bbeaa3e61e13465ebc232925e327c2e3,option,0.388314
uuid-578ba10703b345a9976b0dbe6ec34981,pembro,0.3027
uuid-578ba10703b345a9976b0dbe6ec34981,BMS,0.303604
uuid-578ba10703b345a9976b0dbe6ec34981,lung,0.605483
uuid-578ba10703b345a9976b0dbe6ec34981,1L,0.371389
uuid-578ba10703b345a9976b0dbe6ec34981,melanoma,0.368315
uuid-578ba10703b345a9976b0dbe6ec34981,RCC,0.388431
uuid-578ba10703b345a9976b0dbe6ec34981,2L,0.356215
uuid-578ba10703b345a9976b0dbe6ec34981,atezo,0.347593
uuid-578ba10703b345a9976b0dbe6ec34981,regards,0.376109
uuid-578ba10703b345a9976b0dbe6ec34981,expressed,0.33123
uuid-578ba10703b345a9976b0dbe6ec34981,PDL1 testing,0.332516
uuid-578ba10703b345a9976b0dbe6ec34981,indication,0.361603
uuid-578ba10703b345a9976b0dbe6ec34981,AI,0.655394
uuid-578ba10703b345a9976b0dbe6ec34981,nivo and pembro,0.432783
uuid-578ba10703b345a9976b0dbe6ec34981,tumor types,0.352378
uuid-578ba10703b345a9976b0dbe6ec34981,TL shared,0.315647
uuid-578ba10703b345a9976b0dbe6ec34981,NCCN,0.356494
uuid-5e25596172764270a96f86a989014a31,patients,0.782401
uuid-5e25596172764270a96f86a989014a31,Opdivo,0.479
uuid-5e25596172764270a96f86a989014a31,therapy,0.514407
uuid-5e25596172764270a96f86a989014a31,nivolumab,0.619469
uuid-5e25596172764270a96f86a989014a31,regimen,0.337846
uuid-5e25596172764270a96f86a989014a31,treated,0.562841
uuid-5e25596172764270a96f86a989014a31,pts,0.395234
uuid-5e25596172764270a96f86a989014a31,approval,0.403197
uuid-5e25596172764270a96f86a989014a31,preferred,0.328663
uuid-5e25596172764270a96f86a989014a31,monotherapy,0.32128
uuid-5e25596172764270a96f86a989014a31,treatment,0.590206
uuid-5e25596172764270a96f86a989014a31,using nivo,0.486955
uuid-5e25596172764270a96f86a989014a31,approved,0.342321
uuid-5e25596172764270a96f86a989014a31,SCCHN,0.31744
uuid-5e25596172764270a96f86a989014a31,cHL,0.381538
uuid-5e25596172764270a96f86a989014a31,progression,0.388663
uuid-5e25596172764270a96f86a989014a31,chemotherapy,0.315607
uuid-5e25596172764270a96f86a989014a31,RTL stated,0.424173
uuid-5e25596172764270a96f86a989014a31,option,0.390202
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,patients,0.459891
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,Opdivo,0.338693
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,dose,0.490021
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,toxicity,0.578173
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,regimen,0.529063
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,treated,0.466029
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,physicians,0.388143
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,treatment,0.560285
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,progression,0.325096
uuid-ea1992f4ab0d4c249f7a03c507fb45d3,respond,0.447339
uuid-a86cdef2751b463086bd053ffb1877c9,patients,0.856668
uuid-a86cdef2751b463086bd053ffb1877c9,Opdivo,0.339295
uuid-a86cdef2751b463086bd053ffb1877c9,therapy,0.561521
uuid-a86cdef2751b463086bd053ffb1877c9,nivolumab,0.45094
uuid-a86cdef2751b463086bd053ffb1877c9,toxicity,0.447181
uuid-a86cdef2751b463086bd053ffb1877c9,regimen,0.752201
uuid-a86cdef2751b463086bd053ffb1877c9,treated,0.569356
uuid-a86cdef2751b463086bd053ffb1877c9,combination,0.354459
uuid-a86cdef2751b463086bd053ffb1877c9,chemo,0.505768
uuid-a86cdef2751b463086bd053ffb1877c9,pts,0.621119
uuid-a86cdef2751b463086bd053ffb1877c9,monotherapy,0.580625
uuid-a86cdef2751b463086bd053ffb1877c9,treatment,0.700765
uuid-a86cdef2751b463086bd053ffb1877c9,response,0.489995
uuid-a86cdef2751b463086bd053ffb1877c9,combo,0.319141
uuid-a86cdef2751b463086bd053ffb1877c9,PD1,0.401451
uuid-a86cdef2751b463086bd053ffb1877c9,progression,0.699102
uuid-a86cdef2751b463086bd053ffb1877c9,chemotherapy,0.484338
uuid-a86cdef2751b463086bd053ffb1877c9,respond,0.572649
uuid-a86cdef2751b463086bd053ffb1877c9,option,0.473129
uuid-49c68017c3f34ad4a7d416786951c2c0,lung,0.380273
uuid-49c68017c3f34ad4a7d416786951c2c0,1L,0.475343
uuid-49c68017c3f34ad4a7d416786951c2c0,PDL1,0.466381
uuid-49c68017c3f34ad4a7d416786951c2c0,RCC,0.315657
uuid-49c68017c3f34ad4a7d416786951c2c0,TL stated,0.519483
uuid-49c68017c3f34ad4a7d416786951c2c0,2L,0.425371
uuid-49c68017c3f34ad4a7d416786951c2c0,institution,0.363091
uuid-49c68017c3f34ad4a7d416786951c2c0,PD-L1,0.599854
uuid-49c68017c3f34ad4a7d416786951c2c0,atezo,0.354012
uuid-49c68017c3f34ad4a7d416786951c2c0,preferred,0.381017
uuid-49c68017c3f34ad4a7d416786951c2c0,PD-L1 testing,0.500781
uuid-49c68017c3f34ad4a7d416786951c2c0,testing,0.679259
uuid-49c68017c3f34ad4a7d416786951c2c0,PDL1 testing,0.809247
uuid-49c68017c3f34ad4a7d416786951c2c0,indication,0.310556
uuid-49c68017c3f34ad4a7d416786951c2c0,NSCLC patients,0.613894
uuid-49c68017c3f34ad4a7d416786951c2c0,tumor types,0.487345
uuid-49c68017c3f34ad4a7d416786951c2c0,assay,0.37725
uuid-49c68017c3f34ad4a7d416786951c2c0,PDL1 expression,0.343653
uuid-49c68017c3f34ad4a7d416786951c2c0,biomarker,0.397838
uuid-bda5854ea7c240bd898b89743455a9aa,patients,0.688777
uuid-bda5854ea7c240bd898b89743455a9aa,Opdivo,0.396276
uuid-bda5854ea7c240bd898b89743455a9aa,therapy,0.61051
uuid-bda5854ea7c240bd898b89743455a9aa,nivolumab,0.557458
uuid-bda5854ea7c240bd898b89743455a9aa,toxicity,0.433138
uuid-bda5854ea7c240bd898b89743455a9aa,regimen,0.417603
uuid-bda5854ea7c240bd898b89743455a9aa,treated,0.495966
uuid-bda5854ea7c240bd898b89743455a9aa,pts,0.309948
uuid-bda5854ea7c240bd898b89743455a9aa,treatment,0.548734
uuid-bda5854ea7c240bd898b89743455a9aa,PD1,0.324353
uuid-bda5854ea7c240bd898b89743455a9aa,cHL,0.556616
uuid-bda5854ea7c240bd898b89743455a9aa,progression,0.4549
uuid-bda5854ea7c240bd898b89743455a9aa,chemotherapy,0.333297
uuid-bda5854ea7c240bd898b89743455a9aa,respond,0.388073
uuid-aec9966e01d748c2be981909c000a585,pembro,0.319821
uuid-aec9966e01d748c2be981909c000a585,PDL1,0.439379
uuid-aec9966e01d748c2be981909c000a585,trial,0.365144
uuid-aec9966e01d748c2be981909c000a585,efficacy,0.397439
uuid-aec9966e01d748c2be981909c000a585,commented,0.350244
uuid-aec9966e01d748c2be981909c000a585,OS,0.570069
uuid-aec9966e01d748c2be981909c000a585,data,0.714461
uuid-aec9966e01d748c2be981909c000a585,PFS,0.561528
uuid-aec9966e01d748c2be981909c000a585,ORR,0.560614
uuid-aec9966e01d748c2be981909c000a585,nivo and pembro,0.549282
uuid-aec9966e01d748c2be981909c000a585,impressed,0.48354
uuid-aec9966e01d748c2be981909c000a585,feels,0.317198
uuid-aec9966e01d748c2be981909c000a585,PDL1 expression,0.395003
uuid-c73420b48c974d12b73dda41cf1c2b99,indication,0.32803
uuid-c73420b48c974d12b73dda41cf1c2b99,option,0.318739
uuid-67a96e06af0a400dbedfcb3840b863c9,lung,0.55278
uuid-67a96e06af0a400dbedfcb3840b863c9,melanoma,0.413483
uuid-67a96e06af0a400dbedfcb3840b863c9,regards,0.446953
uuid-67a96e06af0a400dbedfcb3840b863c9,expressed,0.314789
uuid-67a96e06af0a400dbedfcb3840b863c9,AI,0.892713
uuid-67a96e06af0a400dbedfcb3840b863c9,oncology,0.473417
uuid-67a96e06af0a400dbedfcb3840b863c9,NCCN,0.493873
uuid-17da41bf9d1447b28160efe1c2790e2a,Nivo,0.310816
uuid-17da41bf9d1447b28160efe1c2790e2a,patients,0.826612
uuid-17da41bf9d1447b28160efe1c2790e2a,Opdivo,0.385895
uuid-17da41bf9d1447b28160efe1c2790e2a,therapy,0.60084
uuid-17da41bf9d1447b28160efe1c2790e2a,nivolumab,0.523252
uuid-17da41bf9d1447b28160efe1c2790e2a,toxicity,0.303998
uuid-17da41bf9d1447b28160efe1c2790e2a,regimen,0.416115
uuid-17da41bf9d1447b28160efe1c2790e2a,treated,0.627774
uuid-17da41bf9d1447b28160efe1c2790e2a,chemo,0.321622
uuid-17da41bf9d1447b28160efe1c2790e2a,pts,0.46238
uuid-17da41bf9d1447b28160efe1c2790e2a,preferred,0.340087
uuid-17da41bf9d1447b28160efe1c2790e2a,monotherapy,0.426541
uuid-17da41bf9d1447b28160efe1c2790e2a,treatment,0.623527
uuid-17da41bf9d1447b28160efe1c2790e2a,using nivo,0.436646
uuid-17da41bf9d1447b28160efe1c2790e2a,PD1,0.327121
uuid-17da41bf9d1447b28160efe1c2790e2a,cHL,0.393235
uuid-17da41bf9d1447b28160efe1c2790e2a,progression,0.471986
uuid-17da41bf9d1447b28160efe1c2790e2a,chemotherapy,0.436079
uuid-17da41bf9d1447b28160efe1c2790e2a,respond,0.375022
uuid-17da41bf9d1447b28160efe1c2790e2a,RTL stated,0.354447
uuid-17da41bf9d1447b28160efe1c2790e2a,option,0.434257
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,patients,0.650234
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,Opdivo,0.48405
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,therapy,0.395463
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,nivolumab,0.389393
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,regimen,0.573332
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,treated,0.40531
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,pts,0.328799
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,IO,0.487423
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,physicians,0.344462
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,preferred,0.314389
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,monotherapy,0.480057
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,treatment,0.509993
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,progression,0.473442
uuid-618d6b60ef844ea3bfe44fe88ec8a2fe,option,0.385917
uuid-d06e55f54a644615818b955e83e4c41a,patients,0.648612
uuid-d06e55f54a644615818b955e83e4c41a,therapy,0.499128
uuid-d06e55f54a644615818b955e83e4c41a,nivolumab,0.441507
uuid-d06e55f54a644615818b955e83e4c41a,regimen,0.419339
uuid-d06e55f54a644615818b955e83e4c41a,treated,0.519433
uuid-d06e55f54a644615818b955e83e4c41a,chemo,0.404418
uuid-d06e55f54a644615818b955e83e4c41a,pts,0.552448
uuid-d06e55f54a644615818b955e83e4c41a,monotherapy,0.307819
uuid-d06e55f54a644615818b955e83e4c41a,treatment,0.506193
uuid-d06e55f54a644615818b955e83e4c41a,response,0.614019
uuid-d06e55f54a644615818b955e83e4c41a,PD1,0.417576
uuid-d06e55f54a644615818b955e83e4c41a,progression,0.618419
uuid-d06e55f54a644615818b955e83e4c41a,chemotherapy,0.379404
uuid-d06e55f54a644615818b955e83e4c41a,respond,0.562397
uuid-10c24b0c83354dea8b55970a89dc38c3,Opdivo,0.361231
uuid-10c24b0c83354dea8b55970a89dc38c3,RTL,0.365792
uuid-10c24b0c83354dea8b55970a89dc38c3,NTL,0.336915
uuid-10c24b0c83354dea8b55970a89dc38c3,shared,0.599113
uuid-10c24b0c83354dea8b55970a89dc38c3,commented,0.44124
uuid-10c24b0c83354dea8b55970a89dc38c3,stated,0.329219
uuid-10c24b0c83354dea8b55970a89dc38c3,physicians,0.373178
uuid-10c24b0c83354dea8b55970a89dc38c3,mentioned,0.471171
uuid-10c24b0c83354dea8b55970a89dc38c3,ASCO,0.330187
uuid-10c24b0c83354dea8b55970a89dc38c3,LTL,0.43028
uuid-10c24b0c83354dea8b55970a89dc38c3,Regional TL,0.357092
uuid-10c24b0c83354dea8b55970a89dc38c3,flat dosing,0.433019
uuid-6141e54bc90d4ecc9527e34abc1ee259,shared,0.393138
uuid-6141e54bc90d4ecc9527e34abc1ee259,commented,0.366552
uuid-6141e54bc90d4ecc9527e34abc1ee259,RCC,0.319302
uuid-6141e54bc90d4ecc9527e34abc1ee259,stated,0.460734
uuid-6141e54bc90d4ecc9527e34abc1ee259,approval,0.317122
uuid-6141e54bc90d4ecc9527e34abc1ee259,using nivo,0.418109
uuid-6141e54bc90d4ecc9527e34abc1ee259,data,0.30306
uuid-6141e54bc90d4ecc9527e34abc1ee259,SCCHN,0.481991
uuid-6141e54bc90d4ecc9527e34abc1ee259,impressed,0.3784
uuid-6141e54bc90d4ecc9527e34abc1ee259,LTL,0.411922
uuid-6141e54bc90d4ecc9527e34abc1ee259,SCLC,0.355586
uuid-6141e54bc90d4ecc9527e34abc1ee259,feels,0.459317
uuid-6141e54bc90d4ecc9527e34abc1ee259,Regional TL,0.387661
uuid-6141e54bc90d4ecc9527e34abc1ee259,RTL stated,0.447493
uuid-872427335d24497ba8af1a6aeffebe2d,PDL1,0.457053
uuid-872427335d24497ba8af1a6aeffebe2d,efficacy,0.585582
uuid-872427335d24497ba8af1a6aeffebe2d,OS,0.587105
uuid-872427335d24497ba8af1a6aeffebe2d,atezo,0.313256
uuid-872427335d24497ba8af1a6aeffebe2d,regards,0.35706
uuid-872427335d24497ba8af1a6aeffebe2d,data,0.671572
uuid-872427335d24497ba8af1a6aeffebe2d,PFS,0.609044
uuid-872427335d24497ba8af1a6aeffebe2d,ORR,0.614406
uuid-872427335d24497ba8af1a6aeffebe2d,nivo and pembro,0.497422
uuid-872427335d24497ba8af1a6aeffebe2d,impressed,0.439518
uuid-872427335d24497ba8af1a6aeffebe2d,indicated,0.327718
uuid-872427335d24497ba8af1a6aeffebe2d,TLs,0.305533
uuid-872427335d24497ba8af1a6aeffebe2d,PDL1 expression,0.488182
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,patients,0.333955
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,Opdivo,0.44866
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,shared,0.420653
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,2L,0.305563
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,institution,0.316557
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,approval,0.361236
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,preferred,0.420449
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,using nivo,0.342211
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,indication,0.34326
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,approved,0.427997
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,drug,0.44355
uuid-b4755762288c4010b7e2b9b6f4bb4fc0,option,0.318249
uuid-612cc4c987b64c7c9e94f696e3084d53,patients,0.320145
uuid-612cc4c987b64c7c9e94f696e3084d53,regimen,0.306789
uuid-612cc4c987b64c7c9e94f696e3084d53,treatment,0.325885
uuid-612cc4c987b64c7c9e94f696e3084d53,progression,0.323361
uuid-6c258825048143eeabede2dc183d74dd,therapy,0.320165
uuid-6c258825048143eeabede2dc183d74dd,regimen,0.314448
uuid-6c258825048143eeabede2dc183d74dd,treated,0.322953
uuid-6c258825048143eeabede2dc183d74dd,chemo,0.38436
uuid-6c258825048143eeabede2dc183d74dd,pts,0.33293
uuid-6c258825048143eeabede2dc183d74dd,treatment,0.336846
uuid-6c258825048143eeabede2dc183d74dd,response,0.439445
uuid-6c258825048143eeabede2dc183d74dd,progression,0.466444
uuid-6c258825048143eeabede2dc183d74dd,respond,0.374331
uuid-d14733fbf72147e9807886e41a5d7ec0,preferred,0.451358
uuid-d14733fbf72147e9807886e41a5d7ec0,SCCHN,0.355812
uuid-d14733fbf72147e9807886e41a5d7ec0,option,0.36456
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,Nivo,0.387006
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,lung,0.47623
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,trial,0.352058
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,melanoma,0.430699
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,RCC,0.344551
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,AI,0.545403
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,SCLC,0.332518
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,RTL stated,0.32212
uuid-b4a1c6d4f5cf486fbd2e17314a0ed31d,bladder,0.305865
uuid-3e064d426f0a472c8ad2162777501807,toxicity,0.586342
uuid-3e064d426f0a472c8ad2162777501807,efficacy,0.448415
uuid-3e064d426f0a472c8ad2162777501807,ORR,0.322148
uuid-7ce789f1a81b459a8b48b0288dc4167c,patients,0.806825
uuid-7ce789f1a81b459a8b48b0288dc4167c,Opdivo,0.528868
uuid-7ce789f1a81b459a8b48b0288dc4167c,therapy,0.419256
uuid-7ce789f1a81b459a8b48b0288dc4167c,dose,0.406715
uuid-7ce789f1a81b459a8b48b0288dc4167c,nivolumab,0.372322
uuid-7ce789f1a81b459a8b48b0288dc4167c,toxicity,0.350749
uuid-7ce789f1a81b459a8b48b0288dc4167c,regimen,0.484219
uuid-7ce789f1a81b459a8b48b0288dc4167c,treated,0.470128
uuid-7ce789f1a81b459a8b48b0288dc4167c,pts,0.451044
uuid-7ce789f1a81b459a8b48b0288dc4167c,treatment,0.643425
uuid-7ce789f1a81b459a8b48b0288dc4167c,progression,0.596209
uuid-7ce789f1a81b459a8b48b0288dc4167c,respond,0.454886
uuid-356b5c8949e54c3a8a2b955b619d329b,patients,0.476876
uuid-356b5c8949e54c3a8a2b955b619d329b,Opdivo,0.325328
uuid-356b5c8949e54c3a8a2b955b619d329b,TL,0.327362
uuid-356b5c8949e54c3a8a2b955b619d329b,PD-L1,0.35344
uuid-356b5c8949e54c3a8a2b955b619d329b,physicians,0.305528
uuid-356b5c8949e54c3a8a2b955b619d329b,PD-L1 testing,0.535809
uuid-356b5c8949e54c3a8a2b955b619d329b,testing,0.544532
uuid-356b5c8949e54c3a8a2b955b619d329b,treatment,0.322721
uuid-356b5c8949e54c3a8a2b955b619d329b,PDL1 testing,0.442307
uuid-356b5c8949e54c3a8a2b955b619d329b,NSCLC patients,0.50055
uuid-e57da0babb324d4ba7705a6314d534f7,patients,0.326025
uuid-e57da0babb324d4ba7705a6314d534f7,dose,0.40473
uuid-e57da0babb324d4ba7705a6314d534f7,regimen,0.375405
uuid-64648760e99e44b5922731ca98333366,patients,0.542725
uuid-64648760e99e44b5922731ca98333366,Opdivo,0.388407
uuid-64648760e99e44b5922731ca98333366,dose,0.393049
uuid-64648760e99e44b5922731ca98333366,toxicity,0.479327
uuid-64648760e99e44b5922731ca98333366,regimen,0.466019
uuid-64648760e99e44b5922731ca98333366,treated,0.631377
uuid-64648760e99e44b5922731ca98333366,physicians,0.588529
uuid-64648760e99e44b5922731ca98333366,treatment,0.586932
uuid-64648760e99e44b5922731ca98333366,respond,0.333703
uuid-4b0ca2d44592472da60689b8c9b66282,pembro,0.411572
uuid-4b0ca2d44592472da60689b8c9b66282,1L,0.586939
uuid-4b0ca2d44592472da60689b8c9b66282,PDL1,0.389796
uuid-4b0ca2d44592472da60689b8c9b66282,chemo,0.328893
uuid-4b0ca2d44592472da60689b8c9b66282,2L,0.523962
uuid-4b0ca2d44592472da60689b8c9b66282,agents,0.390211
uuid-4b0ca2d44592472da60689b8c9b66282,PD-L1,0.322148
uuid-4b0ca2d44592472da60689b8c9b66282,atezo,0.438556
uuid-4b0ca2d44592472da60689b8c9b66282,preferred,0.442128
uuid-4b0ca2d44592472da60689b8c9b66282,testing,0.310532
uuid-4b0ca2d44592472da60689b8c9b66282,monotherapy,0.440276
uuid-4b0ca2d44592472da60689b8c9b66282,using nivo,0.305786
uuid-4b0ca2d44592472da60689b8c9b66282,combo,0.421809
uuid-4b0ca2d44592472da60689b8c9b66282,PDL1 testing,0.365772
uuid-4b0ca2d44592472da60689b8c9b66282,NSCLC patients,0.300051
uuid-4b0ca2d44592472da60689b8c9b66282,approved,0.405619
uuid-4b0ca2d44592472da60689b8c9b66282,nivo and pembro,0.34901
uuid-4b0ca2d44592472da60689b8c9b66282,believes,0.517356
uuid-4b0ca2d44592472da60689b8c9b66282,tumor types,0.338295
uuid-4b0ca2d44592472da60689b8c9b66282,feels,0.329258
uuid-4b0ca2d44592472da60689b8c9b66282,option,0.530582
uuid-4b0ca2d44592472da60689b8c9b66282,biomarker,0.311212
uuid-3f1082f8b42f4ee695047f6e4c31e5e2,dose,0.412221
uuid-3f1082f8b42f4ee695047f6e4c31e5e2,regimen,0.312086
uuid-3f1082f8b42f4ee695047f6e4c31e5e2,Ipi,0.527817
uuid-3f1082f8b42f4ee695047f6e4c31e5e2,combo,0.324878
uuid-c8469c480613425284527f82087463b7,regimen,0.304044
uuid-a4d9ff067cb44ceabda2a825f6b7b216,Nivo,0.5748
uuid-a4d9ff067cb44ceabda2a825f6b7b216,Opdivo,0.392737
uuid-a4d9ff067cb44ceabda2a825f6b7b216,pembro,0.413553
uuid-a4d9ff067cb44ceabda2a825f6b7b216,RTL,0.303049
uuid-a4d9ff067cb44ceabda2a825f6b7b216,nivolumab,0.560771
uuid-a4d9ff067cb44ceabda2a825f6b7b216,2L,0.403264
uuid-a4d9ff067cb44ceabda2a825f6b7b216,stated,0.455107
uuid-a4d9ff067cb44ceabda2a825f6b7b216,approval,0.743517
uuid-a4d9ff067cb44ceabda2a825f6b7b216,preferred,0.352619
uuid-a4d9ff067cb44ceabda2a825f6b7b216,using nivo,0.683043
uuid-a4d9ff067cb44ceabda2a825f6b7b216,mentioned,0.303237
uuid-a4d9ff067cb44ceabda2a825f6b7b216,indication,0.412738
uuid-a4d9ff067cb44ceabda2a825f6b7b216,approved,0.649005
uuid-a4d9ff067cb44ceabda2a825f6b7b216,SCCHN,0.433446
uuid-a4d9ff067cb44ceabda2a825f6b7b216,cHL,0.602154
uuid-a4d9ff067cb44ceabda2a825f6b7b216,label,0.584768
uuid-a4d9ff067cb44ceabda2a825f6b7b216,LTL,0.34424
uuid-a4d9ff067cb44ceabda2a825f6b7b216,SCLC,0.3171
uuid-a4d9ff067cb44ceabda2a825f6b7b216,Regional TL,0.300252
uuid-a4d9ff067cb44ceabda2a825f6b7b216,RTL stated,0.489876
uuid-a4d9ff067cb44ceabda2a825f6b7b216,bladder,0.320354
uuid-52e3869dad944745a04b086246fe952d,Nivo,0.355942
uuid-52e3869dad944745a04b086246fe952d,patients,0.462723
uuid-52e3869dad944745a04b086246fe952d,efficacy,0.356853
uuid-52e3869dad944745a04b086246fe952d,regimen,0.367425
uuid-52e3869dad944745a04b086246fe952d,chemo,0.449286
uuid-52e3869dad944745a04b086246fe952d,pts,0.429503
uuid-52e3869dad944745a04b086246fe952d,OS,0.411945
uuid-52e3869dad944745a04b086246fe952d,monotherapy,0.411693
uuid-52e3869dad944745a04b086246fe952d,response,0.330833
uuid-52e3869dad944745a04b086246fe952d,PFS,0.385247
uuid-52e3869dad944745a04b086246fe952d,ORR,0.348092
uuid-52e3869dad944745a04b086246fe952d,progression,0.391072
uuid-52e3869dad944745a04b086246fe952d,chemotherapy,0.429347
uuid-52e3869dad944745a04b086246fe952d,respond,0.359105
uuid-52e3869dad944745a04b086246fe952d,feels,0.381962
uuid-52e3869dad944745a04b086246fe952d,option,0.444092
uuid-4561a2bd7631403482c0bc575feb2792,Opdivo,0.473967
uuid-4561a2bd7631403482c0bc575feb2792,physicians,0.416039
uuid-4561a2bd7631403482c0bc575feb2792,treatment,0.421705
uuid-4561a2bd7631403482c0bc575feb2792,drug,0.339928
uuid-31cf2f58776f46f2ac86398841285152,regimen,0.385455
uuid-31cf2f58776f46f2ac86398841285152,treated,0.436315
uuid-31cf2f58776f46f2ac86398841285152,combination,0.37209
uuid-31cf2f58776f46f2ac86398841285152,physicians,0.376101
uuid-31cf2f58776f46f2ac86398841285152,treatment,0.405068
uuid-31cf2f58776f46f2ac86398841285152,response,0.312363
uuid-31cf2f58776f46f2ac86398841285152,progression,0.321063
uuid-31cf2f58776f46f2ac86398841285152,chemotherapy,0.316633
uuid-5c3144ae161b48f7a3e45aaceec069a6,BMS,0.570928
uuid-5c3144ae161b48f7a3e45aaceec069a6,PDL1,0.341045
uuid-5c3144ae161b48f7a3e45aaceec069a6,trial,0.321839
uuid-5c3144ae161b48f7a3e45aaceec069a6,Merck,0.581359
uuid-5c3144ae161b48f7a3e45aaceec069a6,data,0.451417
uuid-5c3144ae161b48f7a3e45aaceec069a6,expressed,0.329627
uuid-638fe7f935b44c73b2af7f22be4c84ba,patients,0.324434
uuid-638fe7f935b44c73b2af7f22be4c84ba,therapy,0.379085
uuid-638fe7f935b44c73b2af7f22be4c84ba,dose,0.30961
uuid-638fe7f935b44c73b2af7f22be4c84ba,nivolumab,0.434462
uuid-638fe7f935b44c73b2af7f22be4c84ba,regimen,0.348243
uuid-638fe7f935b44c73b2af7f22be4c84ba,combination,0.320399
uuid-638fe7f935b44c73b2af7f22be4c84ba,chemo,0.319612
uuid-638fe7f935b44c73b2af7f22be4c84ba,pts,0.37307
uuid-638fe7f935b44c73b2af7f22be4c84ba,monotherapy,0.310637
uuid-638fe7f935b44c73b2af7f22be4c84ba,treatment,0.385003
uuid-638fe7f935b44c73b2af7f22be4c84ba,response,0.375305
uuid-638fe7f935b44c73b2af7f22be4c84ba,PD1,0.550099
uuid-638fe7f935b44c73b2af7f22be4c84ba,progression,0.422383
uuid-638fe7f935b44c73b2af7f22be4c84ba,respond,0.35164
uuid-638fe7f935b44c73b2af7f22be4c84ba,PD-1,0.390829
uuid-62b28cd21efc4d3c9a8d94a26b087d14,indication,0.309317
uuid-62b28cd21efc4d3c9a8d94a26b087d14,AI,0.322606
uuid-62b28cd21efc4d3c9a8d94a26b087d14,oncology,0.426907
uuid-62b28cd21efc4d3c9a8d94a26b087d14,approved,0.319501
uuid-62b28cd21efc4d3c9a8d94a26b087d14,tumor types,0.465224
uuid-62b28cd21efc4d3c9a8d94a26b087d14,clinical,0.337155
uuid-5026f02aa02c494a89bd98732d4c81c7,patients,0.681065
uuid-5026f02aa02c494a89bd98732d4c81c7,therapy,0.498959
uuid-5026f02aa02c494a89bd98732d4c81c7,nivolumab,0.367138
uuid-5026f02aa02c494a89bd98732d4c81c7,1L,0.325309
uuid-5026f02aa02c494a89bd98732d4c81c7,regimen,0.509084
uuid-5026f02aa02c494a89bd98732d4c81c7,treated,0.330952
uuid-5026f02aa02c494a89bd98732d4c81c7,combination,0.352859
uuid-5026f02aa02c494a89bd98732d4c81c7,chemo,0.522236
uuid-5026f02aa02c494a89bd98732d4c81c7,pts,0.557414
uuid-5026f02aa02c494a89bd98732d4c81c7,IO,0.364606
uuid-5026f02aa02c494a89bd98732d4c81c7,monotherapy,0.523082
uuid-5026f02aa02c494a89bd98732d4c81c7,treatment,0.518673
uuid-5026f02aa02c494a89bd98732d4c81c7,response,0.443422
uuid-5026f02aa02c494a89bd98732d4c81c7,combo,0.404437
uuid-5026f02aa02c494a89bd98732d4c81c7,PD1,0.422319
uuid-5026f02aa02c494a89bd98732d4c81c7,progression,0.648807
uuid-5026f02aa02c494a89bd98732d4c81c7,chemotherapy,0.512784
uuid-5026f02aa02c494a89bd98732d4c81c7,respond,0.448818
uuid-5026f02aa02c494a89bd98732d4c81c7,option,0.481003
uuid-26ef091f5cc24e258f6351ef26632560,dose,0.36424
uuid-26ef091f5cc24e258f6351ef26632560,toxicity,0.475324
uuid-26ef091f5cc24e258f6351ef26632560,treated,0.354766
uuid-26ef091f5cc24e258f6351ef26632560,physicians,0.34537
uuid-26ef091f5cc24e258f6351ef26632560,treatment,0.409938
uuid-86960bf1577245a2922aef0cdc32c67d,patients,0.802107
uuid-86960bf1577245a2922aef0cdc32c67d,Opdivo,0.536665
uuid-86960bf1577245a2922aef0cdc32c67d,therapy,0.4381
uuid-86960bf1577245a2922aef0cdc32c67d,nivolumab,0.410219
uuid-86960bf1577245a2922aef0cdc32c67d,regimen,0.337281
uuid-86960bf1577245a2922aef0cdc32c67d,treated,0.52839
uuid-86960bf1577245a2922aef0cdc32c67d,pts,0.46646
uuid-86960bf1577245a2922aef0cdc32c67d,treatment,0.621634
uuid-86960bf1577245a2922aef0cdc32c67d,response,0.338713
uuid-86960bf1577245a2922aef0cdc32c67d,cHL,0.324325
uuid-86960bf1577245a2922aef0cdc32c67d,progression,0.608525
uuid-86960bf1577245a2922aef0cdc32c67d,respond,0.447204
uuid-901f03672b354db29d76811541682212,patients,0.33187
uuid-901f03672b354db29d76811541682212,TL,0.315904
uuid-901f03672b354db29d76811541682212,treated,0.648861
uuid-901f03672b354db29d76811541682212,RCC,0.303375
uuid-901f03672b354db29d76811541682212,TL stated,0.31622
uuid-901f03672b354db29d76811541682212,physicians,0.531322
uuid-901f03672b354db29d76811541682212,treatment,0.41624
uuid-901f03672b354db29d76811541682212,SCCHN,0.364791
uuid-901f03672b354db29d76811541682212,oncologist,0.535449
uuid-901f03672b354db29d76811541682212,Regional TL,0.382115
uuid-901f03672b354db29d76811541682212,TL shared,0.354332
uuid-743acae923504b14899262d314f15e31,treated,0.384095
uuid-743acae923504b14899262d314f15e31,treatment,0.314025
uuid-743acae923504b14899262d314f15e31,clinical trials,0.361348
uuid-743acae923504b14899262d314f15e31,SCCHN,0.338026
uuid-743acae923504b14899262d314f15e31,tumor types,0.312647
uuid-743acae923504b14899262d314f15e31,Regional TL,0.319235
uuid-743acae923504b14899262d314f15e31,RTL stated,0.323604
uuid-743acae923504b14899262d314f15e31,TL shared,0.325779
uuid-743acae923504b14899262d314f15e31,bladder,0.340259
uuid-26b2b5cd9b4b432493a47bd273607a19,patients,0.608727
uuid-26b2b5cd9b4b432493a47bd273607a19,Opdivo,0.516291
uuid-26b2b5cd9b4b432493a47bd273607a19,dose,0.361209
uuid-26b2b5cd9b4b432493a47bd273607a19,nivolumab,0.322943
uuid-26b2b5cd9b4b432493a47bd273607a19,toxicity,0.435069
uuid-26b2b5cd9b4b432493a47bd273607a19,regimen,0.470861
uuid-26b2b5cd9b4b432493a47bd273607a19,treated,0.505227
uuid-26b2b5cd9b4b432493a47bd273607a19,pts,0.343963
uuid-26b2b5cd9b4b432493a47bd273607a19,treatment,0.504585
uuid-26b2b5cd9b4b432493a47bd273607a19,progression,0.419766
uuid-26b2b5cd9b4b432493a47bd273607a19,respond,0.455316
uuid-bedaedddff6143eaa8a4ceeb166ea95e,Nivo,0.479318
uuid-bedaedddff6143eaa8a4ceeb166ea95e,pembro,0.478424
uuid-bedaedddff6143eaa8a4ceeb166ea95e,dose,0.396304
uuid-bedaedddff6143eaa8a4ceeb166ea95e,efficacy,0.364678
uuid-bedaedddff6143eaa8a4ceeb166ea95e,2L,0.33394
uuid-bedaedddff6143eaa8a4ceeb166ea95e,agents,0.321851
uuid-bedaedddff6143eaa8a4ceeb166ea95e,atezo,0.486383
uuid-bedaedddff6143eaa8a4ceeb166ea95e,preferred,0.40541
uuid-bedaedddff6143eaa8a4ceeb166ea95e,monotherapy,0.311117
uuid-bedaedddff6143eaa8a4ceeb166ea95e,using nivo,0.306402
uuid-bedaedddff6143eaa8a4ceeb166ea95e,indication,0.350343
uuid-bedaedddff6143eaa8a4ceeb166ea95e,approved,0.351117
uuid-bedaedddff6143eaa8a4ceeb166ea95e,vs,0.483176
uuid-bedaedddff6143eaa8a4ceeb166ea95e,feels,0.463593
uuid-bedaedddff6143eaa8a4ceeb166ea95e,option,0.360209
uuid-bedaedddff6143eaa8a4ceeb166ea95e,flat dosing,0.304104
uuid-72789ce5725c43d593df079b46dbf3b8,Nivo,0.479292
uuid-72789ce5725c43d593df079b46dbf3b8,patients,0.710884
uuid-72789ce5725c43d593df079b46dbf3b8,therapy,0.596934
uuid-72789ce5725c43d593df079b46dbf3b8,nivolumab,0.492756
uuid-72789ce5725c43d593df079b46dbf3b8,1L,0.36628
uuid-72789ce5725c43d593df079b46dbf3b8,regimen,0.467386
uuid-72789ce5725c43d593df079b46dbf3b8,treated,0.375583
uuid-72789ce5725c43d593df079b46dbf3b8,combination,0.358871
uuid-72789ce5725c43d593df079b46dbf3b8,chemo,0.587337
uuid-72789ce5725c43d593df079b46dbf3b8,2L,0.341852
uuid-72789ce5725c43d593df079b46dbf3b8,pts,0.519076
uuid-72789ce5725c43d593df079b46dbf3b8,preferred,0.373797
uuid-72789ce5725c43d593df079b46dbf3b8,monotherapy,0.583013
uuid-72789ce5725c43d593df079b46dbf3b8,treatment,0.54541
uuid-72789ce5725c43d593df079b46dbf3b8,using nivo,0.382522
uuid-72789ce5725c43d593df079b46dbf3b8,response,0.359875
uuid-72789ce5725c43d593df079b46dbf3b8,PD1,0.422215
uuid-72789ce5725c43d593df079b46dbf3b8,progression,0.531847
uuid-72789ce5725c43d593df079b46dbf3b8,chemotherapy,0.614158
uuid-72789ce5725c43d593df079b46dbf3b8,respond,0.382037
uuid-72789ce5725c43d593df079b46dbf3b8,feels,0.398655
uuid-72789ce5725c43d593df079b46dbf3b8,RTL stated,0.310144
uuid-72789ce5725c43d593df079b46dbf3b8,option,0.603614
uuid-fd2c159fe5234437823dcbfae9ab897f,Nivo,0.302561
uuid-fd2c159fe5234437823dcbfae9ab897f,patients,0.530238
uuid-fd2c159fe5234437823dcbfae9ab897f,therapy,0.519418
uuid-fd2c159fe5234437823dcbfae9ab897f,nivolumab,0.383629
uuid-fd2c159fe5234437823dcbfae9ab897f,regimen,0.337854
uuid-fd2c159fe5234437823dcbfae9ab897f,chemo,0.355832
uuid-fd2c159fe5234437823dcbfae9ab897f,pts,0.322265
uuid-fd2c159fe5234437823dcbfae9ab897f,treatment,0.499404
uuid-fd2c159fe5234437823dcbfae9ab897f,progression,0.44844
uuid-fd2c159fe5234437823dcbfae9ab897f,chemotherapy,0.461251
uuid-10253fa5ba22478eb169d25596b403f6,TL,0.659343
uuid-10253fa5ba22478eb169d25596b403f6,PDL1,0.447142
uuid-10253fa5ba22478eb169d25596b403f6,TL stated,0.352692
uuid-10253fa5ba22478eb169d25596b403f6,institution,0.312502
uuid-10253fa5ba22478eb169d25596b403f6,PD-L1,0.837586
uuid-10253fa5ba22478eb169d25596b403f6,PD-L1 testing,0.886418
uuid-10253fa5ba22478eb169d25596b403f6,testing,0.864262
uuid-10253fa5ba22478eb169d25596b403f6,PDL1 testing,0.608117
uuid-10253fa5ba22478eb169d25596b403f6,NSCLC patients,0.585561
uuid-10253fa5ba22478eb169d25596b403f6,assay,0.803352
uuid-10253fa5ba22478eb169d25596b403f6,PDL1 expression,0.323329
uuid-10253fa5ba22478eb169d25596b403f6,biomarker,0.43678
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,Nivo,0.41256
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,patients,0.538236
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,pembro,0.555012
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,1L,0.596752
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,PDL1,0.305061
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,chemo,0.541626
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,2L,0.562032
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,pts,0.458168
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,agents,0.32909
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,PD-L1,0.343821
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,approval,0.305168
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,atezo,0.463648
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,preferred,0.50905
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,testing,0.350013
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,monotherapy,0.546729
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,using nivo,0.456711
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,NSCLC patients,0.531394
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,PD1,0.318257
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,approved,0.3694
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,believes,0.313755
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,chemotherapy,0.390544
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,respond,0.30509
uuid-6a5c969c2ca743eaa4e0b9ced0ea679c,option,0.543647
uuid-492b46e7d26a4c3e90993c9e2259cf27,patients,0.463201
uuid-492b46e7d26a4c3e90993c9e2259cf27,therapy,0.409319
uuid-492b46e7d26a4c3e90993c9e2259cf27,nivolumab,0.396509
uuid-492b46e7d26a4c3e90993c9e2259cf27,treated,0.431748
uuid-492b46e7d26a4c3e90993c9e2259cf27,treatment,0.408399
uuid-492b46e7d26a4c3e90993c9e2259cf27,progression,0.310321
uuid-492b46e7d26a4c3e90993c9e2259cf27,chemotherapy,0.391242
uuid-492b46e7d26a4c3e90993c9e2259cf27,option,0.314808
uuid-54c44681e94a46b59c02865a9dc284aa,Nivo,0.46543
uuid-54c44681e94a46b59c02865a9dc284aa,pembro,0.684177
uuid-54c44681e94a46b59c02865a9dc284aa,dose,0.344112
uuid-54c44681e94a46b59c02865a9dc284aa,1L,0.379565
uuid-54c44681e94a46b59c02865a9dc284aa,PDL1,0.360024
uuid-54c44681e94a46b59c02865a9dc284aa,efficacy,0.696082
uuid-54c44681e94a46b59c02865a9dc284aa,2L,0.467504
uuid-54c44681e94a46b59c02865a9dc284aa,agents,0.603923
uuid-54c44681e94a46b59c02865a9dc284aa,Ipi,0.353932
uuid-54c44681e94a46b59c02865a9dc284aa,atezo,0.74398
uuid-54c44681e94a46b59c02865a9dc284aa,preferred,0.406103
uuid-54c44681e94a46b59c02865a9dc284aa,monotherapy,0.331222
uuid-54c44681e94a46b59c02865a9dc284aa,data,0.436918
uuid-54c44681e94a46b59c02865a9dc284aa,combo,0.325559
uuid-54c44681e94a46b59c02865a9dc284aa,indication,0.350551
uuid-54c44681e94a46b59c02865a9dc284aa,nivo and pembro,0.643847
uuid-54c44681e94a46b59c02865a9dc284aa,believes,0.412102
uuid-54c44681e94a46b59c02865a9dc284aa,vs,0.679838
uuid-54c44681e94a46b59c02865a9dc284aa,TLs,0.314801
uuid-54c44681e94a46b59c02865a9dc284aa,feels,0.41952
uuid-54c44681e94a46b59c02865a9dc284aa,PDL1 expression,0.336335
uuid-b17197c5e5604928bc6d8584408bc4e8,Nivo,0.591688
uuid-b17197c5e5604928bc6d8584408bc4e8,patients,0.583803
uuid-b17197c5e5604928bc6d8584408bc4e8,pembro,0.544458
uuid-b17197c5e5604928bc6d8584408bc4e8,therapy,0.329873
uuid-b17197c5e5604928bc6d8584408bc4e8,nivolumab,0.404673
uuid-b17197c5e5604928bc6d8584408bc4e8,1L,0.332949
uuid-b17197c5e5604928bc6d8584408bc4e8,trial,0.421355
uuid-b17197c5e5604928bc6d8584408bc4e8,treated,0.357492
uuid-b17197c5e5604928bc6d8584408bc4e8,chemo,0.339205
uuid-b17197c5e5604928bc6d8584408bc4e8,2L,0.371365
uuid-b17197c5e5604928bc6d8584408bc4e8,pts,0.451688
uuid-b17197c5e5604928bc6d8584408bc4e8,Ipi,0.337454
uuid-b17197c5e5604928bc6d8584408bc4e8,approval,0.46046
uuid-b17197c5e5604928bc6d8584408bc4e8,atezo,0.351269
uuid-b17197c5e5604928bc6d8584408bc4e8,preferred,0.358364
uuid-b17197c5e5604928bc6d8584408bc4e8,monotherapy,0.343975
uuid-b17197c5e5604928bc6d8584408bc4e8,using nivo,0.485711
uuid-b17197c5e5604928bc6d8584408bc4e8,clinical trials,0.315229
uuid-b17197c5e5604928bc6d8584408bc4e8,approved,0.385088
uuid-b17197c5e5604928bc6d8584408bc4e8,chemotherapy,0.353297
uuid-b17197c5e5604928bc6d8584408bc4e8,vs,0.341044
uuid-b17197c5e5604928bc6d8584408bc4e8,RTL stated,0.358549
uuid-b17197c5e5604928bc6d8584408bc4e8,option,0.368277
uuid-b17197c5e5604928bc6d8584408bc4e8,bladder,0.341732
uuid-ffc27f6c69f3486c8e8742a674a88539,pembro,0.394626
uuid-ffc27f6c69f3486c8e8742a674a88539,BMS,0.525637
uuid-ffc27f6c69f3486c8e8742a674a88539,trial,0.738375
uuid-ffc27f6c69f3486c8e8742a674a88539,efficacy,0.626795
uuid-ffc27f6c69f3486c8e8742a674a88539,Merck,0.430592
uuid-ffc27f6c69f3486c8e8742a674a88539,OS,0.57095
uuid-ffc27f6c69f3486c8e8742a674a88539,atezo,0.329787
uuid-ffc27f6c69f3486c8e8742a674a88539,regards,0.37312
uuid-ffc27f6c69f3486c8e8742a674a88539,data,0.657636
uuid-ffc27f6c69f3486c8e8742a674a88539,indication,0.373089
uuid-ffc27f6c69f3486c8e8742a674a88539,PFS,0.564956
uuid-ffc27f6c69f3486c8e8742a674a88539,ORR,0.58975
uuid-ffc27f6c69f3486c8e8742a674a88539,nivo and pembro,0.484184
uuid-ffc27f6c69f3486c8e8742a674a88539,believes,0.304363
uuid-ffc27f6c69f3486c8e8742a674a88539,impressed,0.454739
uuid-ffc27f6c69f3486c8e8742a674a88539,vs,0.395123
uuid-ffc27f6c69f3486c8e8742a674a88539,PDL1 expression,0.330085
uuid-46a884c16f564c48bcd003d7655d37f5,data,0.475885
uuid-46a884c16f564c48bcd003d7655d37f5,NCCN,0.696388
uuid-2ec0f4a110e240bcb5311fd136e80c1c,institution,0.306023
uuid-2ec0f4a110e240bcb5311fd136e80c1c,AI,0.343228
uuid-2ec0f4a110e240bcb5311fd136e80c1c,NCCN,0.779571
uuid-950f085693e24ce081280f9ff6ebbc63,TL,0.303584
uuid-950f085693e24ce081280f9ff6ebbc63,PDL1,0.308855
uuid-950f085693e24ce081280f9ff6ebbc63,tumor,0.599146
uuid-950f085693e24ce081280f9ff6ebbc63,PD-L1,0.40571
uuid-950f085693e24ce081280f9ff6ebbc63,PD-L1 testing,0.363258
uuid-950f085693e24ce081280f9ff6ebbc63,testing,0.341232
uuid-950f085693e24ce081280f9ff6ebbc63,assay,0.442359
uuid-950f085693e24ce081280f9ff6ebbc63,PDL1 expression,0.314764
uuid-97b049cf22cc463da4d5347c03e4e5e7,patients,0.813226
uuid-97b049cf22cc463da4d5347c03e4e5e7,Opdivo,0.496707
uuid-97b049cf22cc463da4d5347c03e4e5e7,therapy,0.710501
uuid-97b049cf22cc463da4d5347c03e4e5e7,nivolumab,0.612319
uuid-97b049cf22cc463da4d5347c03e4e5e7,regimen,0.441335
uuid-97b049cf22cc463da4d5347c03e4e5e7,treated,0.615548
uuid-97b049cf22cc463da4d5347c03e4e5e7,pts,0.495067
uuid-97b049cf22cc463da4d5347c03e4e5e7,monotherapy,0.331911
uuid-97b049cf22cc463da4d5347c03e4e5e7,treatment,0.664203
uuid-97b049cf22cc463da4d5347c03e4e5e7,using nivo,0.394097
uuid-97b049cf22cc463da4d5347c03e4e5e7,response,0.354035
uuid-97b049cf22cc463da4d5347c03e4e5e7,PD1,0.33495
uuid-97b049cf22cc463da4d5347c03e4e5e7,cHL,0.584238
uuid-97b049cf22cc463da4d5347c03e4e5e7,progression,0.623407
uuid-97b049cf22cc463da4d5347c03e4e5e7,chemotherapy,0.420317
uuid-97b049cf22cc463da4d5347c03e4e5e7,respond,0.384658
uuid-97b049cf22cc463da4d5347c03e4e5e7,RTL stated,0.303356
uuid-97b049cf22cc463da4d5347c03e4e5e7,option,0.329613
uuid-86b9b0e502b24631b47a37dd600b15a9,Opdivo,0.311102
uuid-86b9b0e502b24631b47a37dd600b15a9,toxicity,0.441676
uuid-86b9b0e502b24631b47a37dd600b15a9,regimen,0.328313
uuid-86b9b0e502b24631b47a37dd600b15a9,treated,0.337507
uuid-86b9b0e502b24631b47a37dd600b15a9,physicians,0.566939
uuid-86b9b0e502b24631b47a37dd600b15a9,treatment,0.501602
uuid-86b9b0e502b24631b47a37dd600b15a9,drug,0.338767
uuid-58cd8bdebcb945bd818f16c7d3a7e669,Nivo,0.397045
uuid-58cd8bdebcb945bd818f16c7d3a7e669,therapy,0.470293
uuid-58cd8bdebcb945bd818f16c7d3a7e669,nivolumab,0.335341
uuid-58cd8bdebcb945bd818f16c7d3a7e669,mentioned,0.378184
uuid-58cd8bdebcb945bd818f16c7d3a7e669,cHL,0.660274
uuid-f7dce826efb942c3902bfce68766219c,patients,0.465206
uuid-f7dce826efb942c3902bfce68766219c,therapy,0.359977
uuid-f7dce826efb942c3902bfce68766219c,chemo,0.423898
uuid-f7dce826efb942c3902bfce68766219c,pts,0.307772
uuid-f7dce826efb942c3902bfce68766219c,treatment,0.30615
uuid-f7dce826efb942c3902bfce68766219c,response,0.323624
uuid-f7dce826efb942c3902bfce68766219c,NSCLC patients,0.384076
uuid-f7dce826efb942c3902bfce68766219c,progression,0.354692
uuid-f7dce826efb942c3902bfce68766219c,tumor types,0.412734
uuid-f7dce826efb942c3902bfce68766219c,respond,0.482722
uuid-f7dce826efb942c3902bfce68766219c,PD-1,0.307401
uuid-f7dce826efb942c3902bfce68766219c,option,0.3168
uuid-ae353eaa3cfb44a3b991571c356008d5,patients,0.405059
uuid-ae353eaa3cfb44a3b991571c356008d5,Opdivo,0.471175
uuid-ae353eaa3cfb44a3b991571c356008d5,nivolumab,0.306847
uuid-ae353eaa3cfb44a3b991571c356008d5,regimen,0.437403
uuid-ae353eaa3cfb44a3b991571c356008d5,treated,0.387189
uuid-ae353eaa3cfb44a3b991571c356008d5,shared,0.326052
uuid-ae353eaa3cfb44a3b991571c356008d5,physicians,0.61442
uuid-ae353eaa3cfb44a3b991571c356008d5,treatment,0.457442
uuid-6ccd82599f8c498f80791fd56a4f22a0,patients,0.551768
uuid-6ccd82599f8c498f80791fd56a4f22a0,Opdivo,0.32001
uuid-6ccd82599f8c498f80791fd56a4f22a0,therapy,0.400162
uuid-6ccd82599f8c498f80791fd56a4f22a0,nivolumab,0.350994
uuid-6ccd82599f8c498f80791fd56a4f22a0,treated,0.409366
uuid-6ccd82599f8c498f80791fd56a4f22a0,treatment,0.513148
uuid-6ccd82599f8c498f80791fd56a4f22a0,cHL,0.321155
uuid-6ccd82599f8c498f80791fd56a4f22a0,progression,0.381748
uuid-204535002edb4b0fa00232a91521abb5,therapy,0.326887
uuid-204535002edb4b0fa00232a91521abb5,combination,0.396561
uuid-204535002edb4b0fa00232a91521abb5,chemo,0.360628
uuid-204535002edb4b0fa00232a91521abb5,agents,0.369018
uuid-204535002edb4b0fa00232a91521abb5,PD1,0.32231
uuid-204535002edb4b0fa00232a91521abb5,chemotherapy,0.479735
uuid-204535002edb4b0fa00232a91521abb5,clinical,0.37134
uuid-204535002edb4b0fa00232a91521abb5,immunotherapy,0.534551
uuid-baccadafc2d041338cc1042e32212417,tumor,0.47756
uuid-baccadafc2d041338cc1042e32212417,PD-L1,0.378734
uuid-baccadafc2d041338cc1042e32212417,PD-L1 testing,0.372268
uuid-baccadafc2d041338cc1042e32212417,testing,0.477536
uuid-baccadafc2d041338cc1042e32212417,PDL1 testing,0.314318
uuid-baccadafc2d041338cc1042e32212417,assay,0.33762
uuid-baccadafc2d041338cc1042e32212417,biomarker,0.373462
uuid-5c127dc3ab8741cd956de44e118293fc,nivolumab,0.395296
uuid-5c127dc3ab8741cd956de44e118293fc,combination,0.52163
uuid-5c127dc3ab8741cd956de44e118293fc,clinical trials,0.380079
uuid-5c127dc3ab8741cd956de44e118293fc,immunotherapy,0.377341
uuid-5c127dc3ab8741cd956de44e118293fc,Regional TL,0.327497
uuid-5c127dc3ab8741cd956de44e118293fc,bladder,0.309069
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,BMS,0.364338
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,efficacy,0.432667
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,discussed,0.347435
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,commented,0.527514
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,stated,0.375733
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,OS,0.501757
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,regards,0.452099
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,data,0.646131
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,expressed,0.360339
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,indication,0.308997
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,PFS,0.445987
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,ORR,0.450565
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,ASCO,0.491939
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,impressed,0.631187
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,TLs,0.346412
uuid-bd1bf8a39d7046d7bf92b4fce9ca27ce,feels,0.342967
uuid-99f5e53337d441da832b005e47a72885,Nivo,0.415113
uuid-99f5e53337d441da832b005e47a72885,pembro,0.506481
uuid-99f5e53337d441da832b005e47a72885,BMS,0.517431
uuid-99f5e53337d441da832b005e47a72885,trial,0.633938
uuid-99f5e53337d441da832b005e47a72885,efficacy,0.487131
uuid-99f5e53337d441da832b005e47a72885,commented,0.368171
uuid-99f5e53337d441da832b005e47a72885,Merck,0.38584
uuid-99f5e53337d441da832b005e47a72885,Ipi,0.309152
uuid-99f5e53337d441da832b005e47a72885,stated,0.382513
uuid-99f5e53337d441da832b005e47a72885,approval,0.397843
uuid-99f5e53337d441da832b005e47a72885,OS,0.371819
uuid-99f5e53337d441da832b005e47a72885,atezo,0.39454
uuid-99f5e53337d441da832b005e47a72885,regards,0.301082
uuid-99f5e53337d441da832b005e47a72885,data,0.737678
uuid-99f5e53337d441da832b005e47a72885,expressed,0.351737
uuid-99f5e53337d441da832b005e47a72885,clinical trials,0.371067
uuid-99f5e53337d441da832b005e47a72885,indication,0.460325
uuid-99f5e53337d441da832b005e47a72885,PFS,0.361113
uuid-99f5e53337d441da832b005e47a72885,ORR,0.432086
uuid-99f5e53337d441da832b005e47a72885,approved,0.390967
uuid-99f5e53337d441da832b005e47a72885,nivo and pembro,0.332261
uuid-99f5e53337d441da832b005e47a72885,impressed,0.617246
uuid-99f5e53337d441da832b005e47a72885,vs,0.345598
uuid-99f5e53337d441da832b005e47a72885,label,0.336832
uuid-99f5e53337d441da832b005e47a72885,LTL,0.312846
uuid-99f5e53337d441da832b005e47a72885,feels,0.374672
uuid-99f5e53337d441da832b005e47a72885,flat dosing,0.364327
uuid-41f1d9f4e4864364acbd337be779de3f,pembro,0.467695
uuid-41f1d9f4e4864364acbd337be779de3f,1L,0.496279
uuid-41f1d9f4e4864364acbd337be779de3f,PDL1,0.470025
uuid-41f1d9f4e4864364acbd337be779de3f,2L,0.353748
uuid-41f1d9f4e4864364acbd337be779de3f,PD-L1,0.310173
uuid-41f1d9f4e4864364acbd337be779de3f,approval,0.421534
uuid-41f1d9f4e4864364acbd337be779de3f,OS,0.49033
uuid-41f1d9f4e4864364acbd337be779de3f,atezo,0.352798
uuid-41f1d9f4e4864364acbd337be779de3f,using nivo,0.303385
uuid-41f1d9f4e4864364acbd337be779de3f,data,0.499182
uuid-41f1d9f4e4864364acbd337be779de3f,PFS,0.394484
uuid-41f1d9f4e4864364acbd337be779de3f,NSCLC patients,0.425889
uuid-41f1d9f4e4864364acbd337be779de3f,ORR,0.39238
uuid-41f1d9f4e4864364acbd337be779de3f,approved,0.364318
uuid-41f1d9f4e4864364acbd337be779de3f,SCCHN,0.356385
uuid-41f1d9f4e4864364acbd337be779de3f,nivo and pembro,0.336681
uuid-41f1d9f4e4864364acbd337be779de3f,impressed,0.478525
uuid-41f1d9f4e4864364acbd337be779de3f,PDL1 expression,0.393223
uuid-41f1d9f4e4864364acbd337be779de3f,bladder,0.30093
uuid-305923fdf01c48cbbf280b36b4b045cf,TL,0.484561
uuid-305923fdf01c48cbbf280b36b4b045cf,PDL1,0.325355
uuid-305923fdf01c48cbbf280b36b4b045cf,TL stated,0.460163
uuid-305923fdf01c48cbbf280b36b4b045cf,institution,0.374748
uuid-305923fdf01c48cbbf280b36b4b045cf,PD-L1,0.768139
uuid-305923fdf01c48cbbf280b36b4b045cf,PD-L1 testing,0.83314
uuid-305923fdf01c48cbbf280b36b4b045cf,testing,0.903215
uuid-305923fdf01c48cbbf280b36b4b045cf,PDL1 testing,0.797006
uuid-305923fdf01c48cbbf280b36b4b045cf,NSCLC patients,0.717569
uuid-305923fdf01c48cbbf280b36b4b045cf,assay,0.634542
uuid-305923fdf01c48cbbf280b36b4b045cf,biomarker,0.399022
uuid-72200b63430a4127a33bf672bf803afb,Nivo,0.503622
uuid-72200b63430a4127a33bf672bf803afb,patients,0.317646
uuid-72200b63430a4127a33bf672bf803afb,therapy,0.673167
uuid-72200b63430a4127a33bf672bf803afb,nivolumab,0.348736
uuid-72200b63430a4127a33bf672bf803afb,combination,0.301936
uuid-72200b63430a4127a33bf672bf803afb,chemo,0.420238
uuid-72200b63430a4127a33bf672bf803afb,agents,0.401446
uuid-72200b63430a4127a33bf672bf803afb,preferred,0.303359
uuid-72200b63430a4127a33bf672bf803afb,monotherapy,0.457612
uuid-72200b63430a4127a33bf672bf803afb,treatment,0.333189
uuid-72200b63430a4127a33bf672bf803afb,using nivo,0.333254
uuid-72200b63430a4127a33bf672bf803afb,PD1,0.463947
uuid-72200b63430a4127a33bf672bf803afb,cHL,0.450821
uuid-72200b63430a4127a33bf672bf803afb,chemotherapy,0.492214
uuid-72200b63430a4127a33bf672bf803afb,PD-1,0.307794
uuid-72200b63430a4127a33bf672bf803afb,option,0.490344
uuid-28c4e669dd69461d94daa5c47caa21b1,Nivo,0.391841
uuid-28c4e669dd69461d94daa5c47caa21b1,patients,0.598781
uuid-28c4e669dd69461d94daa5c47caa21b1,Opdivo,0.385331
uuid-28c4e669dd69461d94daa5c47caa21b1,therapy,0.751019
uuid-28c4e669dd69461d94daa5c47caa21b1,nivolumab,0.493723
uuid-28c4e669dd69461d94daa5c47caa21b1,treated,0.321018
uuid-28c4e669dd69461d94daa5c47caa21b1,chemo,0.333111
uuid-28c4e669dd69461d94daa5c47caa21b1,treatment,0.520884
uuid-28c4e669dd69461d94daa5c47caa21b1,response,0.372045
uuid-28c4e669dd69461d94daa5c47caa21b1,PD1,0.386914
uuid-28c4e669dd69461d94daa5c47caa21b1,cHL,0.564804
uuid-28c4e669dd69461d94daa5c47caa21b1,progression,0.505165
uuid-28c4e669dd69461d94daa5c47caa21b1,chemotherapy,0.45853
uuid-28c4e669dd69461d94daa5c47caa21b1,respond,0.321147
uuid-28c4e669dd69461d94daa5c47caa21b1,option,0.350852
uuid-3469892c6448430d8b14f7af59f1f8cf,patients,0.755823
uuid-3469892c6448430d8b14f7af59f1f8cf,Opdivo,0.688184
uuid-3469892c6448430d8b14f7af59f1f8cf,therapy,0.48451
uuid-3469892c6448430d8b14f7af59f1f8cf,nivolumab,0.455501
uuid-3469892c6448430d8b14f7af59f1f8cf,regimen,0.357053
uuid-3469892c6448430d8b14f7af59f1f8cf,treated,0.4535
uuid-3469892c6448430d8b14f7af59f1f8cf,physicians,0.315229
uuid-3469892c6448430d8b14f7af59f1f8cf,treatment,0.595767
uuid-3469892c6448430d8b14f7af59f1f8cf,using nivo,0.316644
uuid-3469892c6448430d8b14f7af59f1f8cf,cHL,0.447078
uuid-3469892c6448430d8b14f7af59f1f8cf,progression,0.421396
uuid-f370ca03b31e4f198b9740a26aff4236,Nivo,0.476939
uuid-f370ca03b31e4f198b9740a26aff4236,patients,0.67638
uuid-f370ca03b31e4f198b9740a26aff4236,Opdivo,0.537896
uuid-f370ca03b31e4f198b9740a26aff4236,pembro,0.320842
uuid-f370ca03b31e4f198b9740a26aff4236,therapy,0.308894
uuid-f370ca03b31e4f198b9740a26aff4236,dose,0.785934
uuid-f370ca03b31e4f198b9740a26aff4236,nivolumab,0.411646
uuid-f370ca03b31e4f198b9740a26aff4236,toxicity,0.378139
uuid-f370ca03b31e4f198b9740a26aff4236,regimen,0.505646
uuid-f370ca03b31e4f198b9740a26aff4236,treated,0.332118
uuid-f370ca03b31e4f198b9740a26aff4236,pts,0.3983
uuid-f370ca03b31e4f198b9740a26aff4236,Ipi,0.493818
uuid-f370ca03b31e4f198b9740a26aff4236,preferred,0.305701
uuid-f370ca03b31e4f198b9740a26aff4236,treatment,0.453394
uuid-f370ca03b31e4f198b9740a26aff4236,using nivo,0.304685
uuid-f370ca03b31e4f198b9740a26aff4236,progression,0.347491
uuid-f370ca03b31e4f198b9740a26aff4236,vs,0.433939
uuid-f370ca03b31e4f198b9740a26aff4236,respond,0.316583
uuid-f370ca03b31e4f198b9740a26aff4236,flat dosing,0.511357
uuid-bed1a413afdc4406941dbf48c81e7093,Nivo,0.521344
uuid-bed1a413afdc4406941dbf48c81e7093,pembro,0.569264
uuid-bed1a413afdc4406941dbf48c81e7093,1L,0.301075
uuid-bed1a413afdc4406941dbf48c81e7093,PDL1,0.363753
uuid-bed1a413afdc4406941dbf48c81e7093,trial,0.548108
uuid-bed1a413afdc4406941dbf48c81e7093,efficacy,0.595222
uuid-bed1a413afdc4406941dbf48c81e7093,chemo,0.338883
uuid-bed1a413afdc4406941dbf48c81e7093,OS,0.564039
uuid-bed1a413afdc4406941dbf48c81e7093,atezo,0.415656
uuid-bed1a413afdc4406941dbf48c81e7093,data,0.546369
uuid-bed1a413afdc4406941dbf48c81e7093,PFS,0.586164
uuid-bed1a413afdc4406941dbf48c81e7093,ORR,0.56741
uuid-bed1a413afdc4406941dbf48c81e7093,nivo and pembro,0.532282
uuid-bed1a413afdc4406941dbf48c81e7093,believes,0.37324
uuid-bed1a413afdc4406941dbf48c81e7093,impressed,0.44361
uuid-bed1a413afdc4406941dbf48c81e7093,vs,0.488417
uuid-bed1a413afdc4406941dbf48c81e7093,feels,0.549694
uuid-bed1a413afdc4406941dbf48c81e7093,PDL1 expression,0.358864
uuid-886f5656d0cd490da0f0138bc9904f8e,pembro,0.432656
uuid-886f5656d0cd490da0f0138bc9904f8e,BMS,0.382753
uuid-886f5656d0cd490da0f0138bc9904f8e,1L,0.362283
uuid-886f5656d0cd490da0f0138bc9904f8e,PDL1,0.526337
uuid-886f5656d0cd490da0f0138bc9904f8e,trial,0.664301
uuid-886f5656d0cd490da0f0138bc9904f8e,efficacy,0.401809
uuid-886f5656d0cd490da0f0138bc9904f8e,Merck,0.404161
uuid-886f5656d0cd490da0f0138bc9904f8e,OS,0.519594
uuid-886f5656d0cd490da0f0138bc9904f8e,atezo,0.366796
uuid-886f5656d0cd490da0f0138bc9904f8e,data,0.607816
uuid-886f5656d0cd490da0f0138bc9904f8e,PFS,0.514742
uuid-886f5656d0cd490da0f0138bc9904f8e,ORR,0.560255
uuid-886f5656d0cd490da0f0138bc9904f8e,nivo and pembro,0.522278
uuid-886f5656d0cd490da0f0138bc9904f8e,believes,0.351198
uuid-886f5656d0cd490da0f0138bc9904f8e,impressed,0.466669
uuid-886f5656d0cd490da0f0138bc9904f8e,TLs,0.354842
uuid-886f5656d0cd490da0f0138bc9904f8e,PDL1 expression,0.490028
uuid-886f5656d0cd490da0f0138bc9904f8e,biomarker,0.343461
uuid-886f5656d0cd490da0f0138bc9904f8e,bladder,0.319472
uuid-0d60b6429d434c739f12a37cd3793dce,patients,0.641537
uuid-0d60b6429d434c739f12a37cd3793dce,Opdivo,0.304096
uuid-0d60b6429d434c739f12a37cd3793dce,dose,0.353344
uuid-0d60b6429d434c739f12a37cd3793dce,nivolumab,0.30794
uuid-0d60b6429d434c739f12a37cd3793dce,toxicity,0.372753
uuid-0d60b6429d434c739f12a37cd3793dce,regimen,0.411877
uuid-0d60b6429d434c739f12a37cd3793dce,treated,0.498461
uuid-0d60b6429d434c739f12a37cd3793dce,melanoma,0.304826
uuid-0d60b6429d434c739f12a37cd3793dce,tumor,0.468123
uuid-0d60b6429d434c739f12a37cd3793dce,pts,0.490356
uuid-0d60b6429d434c739f12a37cd3793dce,treatment,0.515522
uuid-0d60b6429d434c739f12a37cd3793dce,response,0.329835
uuid-0d60b6429d434c739f12a37cd3793dce,progression,0.515222
uuid-0d60b6429d434c739f12a37cd3793dce,respond,0.364923
uuid-0d60b6429d434c739f12a37cd3793dce,TL shared,0.344399
uuid-4965ed126253463d81802375c6abffdb,patients,0.686969
uuid-4965ed126253463d81802375c6abffdb,Opdivo,0.360155
uuid-4965ed126253463d81802375c6abffdb,therapy,0.400178
uuid-4965ed126253463d81802375c6abffdb,nivolumab,0.340879
uuid-4965ed126253463d81802375c6abffdb,regimen,0.50555
uuid-4965ed126253463d81802375c6abffdb,treated,0.384797
uuid-4965ed126253463d81802375c6abffdb,chemo,0.462271
uuid-4965ed126253463d81802375c6abffdb,pts,0.60838
uuid-4965ed126253463d81802375c6abffdb,monotherapy,0.399531
uuid-4965ed126253463d81802375c6abffdb,treatment,0.54664
uuid-4965ed126253463d81802375c6abffdb,response,0.478183
uuid-4965ed126253463d81802375c6abffdb,PD1,0.350871
uuid-4965ed126253463d81802375c6abffdb,progression,0.662416
uuid-4965ed126253463d81802375c6abffdb,chemotherapy,0.347835
uuid-4965ed126253463d81802375c6abffdb,respond,0.532839
uuid-4965ed126253463d81802375c6abffdb,feels,0.326568
uuid-4965ed126253463d81802375c6abffdb,option,0.389086
uuid-136ad36eca4e40518d50721b009fc774,patients,0.625837
uuid-136ad36eca4e40518d50721b009fc774,therapy,0.639455
uuid-136ad36eca4e40518d50721b009fc774,nivolumab,0.351505
uuid-136ad36eca4e40518d50721b009fc774,toxicity,0.320264
uuid-136ad36eca4e40518d50721b009fc774,regimen,0.600355
uuid-136ad36eca4e40518d50721b009fc774,treated,0.458188
uuid-136ad36eca4e40518d50721b009fc774,melanoma,0.388288
uuid-136ad36eca4e40518d50721b009fc774,chemo,0.480434
uuid-136ad36eca4e40518d50721b009fc774,pts,0.543073
uuid-136ad36eca4e40518d50721b009fc774,monotherapy,0.462814
uuid-136ad36eca4e40518d50721b009fc774,treatment,0.641257
uuid-136ad36eca4e40518d50721b009fc774,response,0.610103
uuid-136ad36eca4e40518d50721b009fc774,AI,0.302451
uuid-136ad36eca4e40518d50721b009fc774,PD1,0.480456
uuid-136ad36eca4e40518d50721b009fc774,progression,0.718054
uuid-136ad36eca4e40518d50721b009fc774,chemotherapy,0.464566
uuid-136ad36eca4e40518d50721b009fc774,respond,0.57183
uuid-136ad36eca4e40518d50721b009fc774,TL shared,0.308012
uuid-136ad36eca4e40518d50721b009fc774,option,0.350467
uuid-ff0fde33393e4dd5bbee073349484d39,Nivo,0.555688
uuid-ff0fde33393e4dd5bbee073349484d39,patients,0.43225
uuid-ff0fde33393e4dd5bbee073349484d39,pembro,0.623098
uuid-ff0fde33393e4dd5bbee073349484d39,dose,0.364489
uuid-ff0fde33393e4dd5bbee073349484d39,nivolumab,0.433176
uuid-ff0fde33393e4dd5bbee073349484d39,1L,0.458933
uuid-ff0fde33393e4dd5bbee073349484d39,regimen,0.311021
uuid-ff0fde33393e4dd5bbee073349484d39,RCC,0.346706
uuid-ff0fde33393e4dd5bbee073349484d39,combination,0.33386
uuid-ff0fde33393e4dd5bbee073349484d39,2L,0.544817
uuid-ff0fde33393e4dd5bbee073349484d39,pts,0.319867
uuid-ff0fde33393e4dd5bbee073349484d39,Ipi,0.510816
uuid-ff0fde33393e4dd5bbee073349484d39,approval,0.568781
uuid-ff0fde33393e4dd5bbee073349484d39,atezo,0.45973
uuid-ff0fde33393e4dd5bbee073349484d39,preferred,0.530658
uuid-ff0fde33393e4dd5bbee073349484d39,monotherapy,0.444595
uuid-ff0fde33393e4dd5bbee073349484d39,using nivo,0.66216
uuid-ff0fde33393e4dd5bbee073349484d39,combo,0.396218
uuid-ff0fde33393e4dd5bbee073349484d39,clinical trials,0.303886
uuid-ff0fde33393e4dd5bbee073349484d39,indication,0.331604
uuid-ff0fde33393e4dd5bbee073349484d39,approved,0.588353
uuid-ff0fde33393e4dd5bbee073349484d39,SCCHN,0.355758
uuid-ff0fde33393e4dd5bbee073349484d39,vs,0.339701
uuid-ff0fde33393e4dd5bbee073349484d39,label,0.343998
uuid-ff0fde33393e4dd5bbee073349484d39,SCLC,0.322284
uuid-ff0fde33393e4dd5bbee073349484d39,RTL stated,0.455037
uuid-ff0fde33393e4dd5bbee073349484d39,option,0.449513
uuid-ff0fde33393e4dd5bbee073349484d39,bladder,0.345976
uuid-782e593019e646fa8a591d6453557fa4,pembro,0.31745
uuid-782e593019e646fa8a591d6453557fa4,RTL,0.442342
uuid-782e593019e646fa8a591d6453557fa4,BMS,0.400425
uuid-782e593019e646fa8a591d6453557fa4,PDL1,0.446215
uuid-782e593019e646fa8a591d6453557fa4,trial,0.426151
uuid-782e593019e646fa8a591d6453557fa4,efficacy,0.322616
uuid-782e593019e646fa8a591d6453557fa4,commented,0.506428
uuid-782e593019e646fa8a591d6453557fa4,Merck,0.425011
uuid-782e593019e646fa8a591d6453557fa4,stated,0.392085
uuid-782e593019e646fa8a591d6453557fa4,OS,0.536311
uuid-782e593019e646fa8a591d6453557fa4,data,0.743152
uuid-782e593019e646fa8a591d6453557fa4,expressed,0.449196
uuid-782e593019e646fa8a591d6453557fa4,PFS,0.463212
uuid-782e593019e646fa8a591d6453557fa4,ORR,0.501081
uuid-782e593019e646fa8a591d6453557fa4,SCCHN,0.372091
uuid-782e593019e646fa8a591d6453557fa4,HCP,0.324915
uuid-782e593019e646fa8a591d6453557fa4,nivo and pembro,0.338725
uuid-782e593019e646fa8a591d6453557fa4,ASCO,0.382633
uuid-782e593019e646fa8a591d6453557fa4,impressed,0.669888
uuid-782e593019e646fa8a591d6453557fa4,LTL,0.368303
uuid-782e593019e646fa8a591d6453557fa4,TLs,0.384231
uuid-782e593019e646fa8a591d6453557fa4,feels,0.343086
uuid-782e593019e646fa8a591d6453557fa4,Regional TL,0.389882
uuid-782e593019e646fa8a591d6453557fa4,PDL1 expression,0.388173
uuid-782e593019e646fa8a591d6453557fa4,bladder,0.351166
uuid-3dcdc7ba0691477788b1f132c22db3b3,efficacy,0.360685
uuid-3dcdc7ba0691477788b1f132c22db3b3,tumor,0.331605
uuid-3dcdc7ba0691477788b1f132c22db3b3,OS,0.372082
uuid-3dcdc7ba0691477788b1f132c22db3b3,response,0.330249
uuid-3dcdc7ba0691477788b1f132c22db3b3,data,0.335559
uuid-3dcdc7ba0691477788b1f132c22db3b3,PFS,0.325591
uuid-3dcdc7ba0691477788b1f132c22db3b3,ORR,0.363411
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,patients,0.575524
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,therapy,0.418204
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,treated,0.322942
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,pts,0.418365
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,PD-L1,0.369409
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,approval,0.371787
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,PD-L1 testing,0.36821
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,testing,0.497599
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,treatment,0.403966
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,PDL1 testing,0.333828
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,NSCLC patients,0.501675
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,progression,0.353778
uuid-b9d3bc53bcb94b4a8e9273f08d7e292a,option,0.382382
uuid-acf70dcbd93b4b668aea729627244cb8,agents,0.328069
uuid-acf70dcbd93b4b668aea729627244cb8,clinical,0.308822
uuid-acf70dcbd93b4b668aea729627244cb8,immunotherapy,0.533936
uuid-8318bb2c120c4cdaa89f8e80dc7d0c72,Nivo,0.413722
uuid-8318bb2c120c4cdaa89f8e80dc7d0c72,combination,0.305818
uuid-8318bb2c120c4cdaa89f8e80dc7d0c72,chemo,0.344561
uuid-8318bb2c120c4cdaa89f8e80dc7d0c72,agents,0.430995
uuid-8318bb2c120c4cdaa89f8e80dc7d0c72,believes,0.413059
uuid-d3b3a3b95d144f19851019f9edc4988c,patients,0.331257
uuid-d3b3a3b95d144f19851019f9edc4988c,tumor,0.677336
uuid-d3b3a3b95d144f19851019f9edc4988c,pts,0.309467
uuid-d3b3a3b95d144f19851019f9edc4988c,PD-L1,0.370172
uuid-d3b3a3b95d144f19851019f9edc4988c,testing,0.467369
uuid-d3b3a3b95d144f19851019f9edc4988c,PDL1 testing,0.327898
uuid-d3b3a3b95d144f19851019f9edc4988c,NSCLC patients,0.412048
uuid-d3b3a3b95d144f19851019f9edc4988c,progression,0.309133
uuid-d3b3a3b95d144f19851019f9edc4988c,biomarker,0.379826
uuid-57ad250b67b5403ba827304491123eed,patients,0.500862
uuid-57ad250b67b5403ba827304491123eed,toxicity,0.407548
uuid-57ad250b67b5403ba827304491123eed,regimen,0.339944
uuid-57ad250b67b5403ba827304491123eed,treated,0.467425
uuid-57ad250b67b5403ba827304491123eed,melanoma,0.329748
uuid-57ad250b67b5403ba827304491123eed,pts,0.39083
uuid-57ad250b67b5403ba827304491123eed,treatment,0.434346
uuid-57ad250b67b5403ba827304491123eed,progression,0.438286
uuid-57ad250b67b5403ba827304491123eed,respond,0.424532
uuid-57ad250b67b5403ba827304491123eed,TL shared,0.465256
uuid-0068515d246b448a9029190f224272b7,TL,0.376065
uuid-0068515d246b448a9029190f224272b7,pembro,0.502563
uuid-0068515d246b448a9029190f224272b7,1L,0.423519
uuid-0068515d246b448a9029190f224272b7,PDL1,0.578766
uuid-0068515d246b448a9029190f224272b7,trial,0.405159
uuid-0068515d246b448a9029190f224272b7,TL stated,0.328893
uuid-0068515d246b448a9029190f224272b7,Merck,0.475878
uuid-0068515d246b448a9029190f224272b7,PD-L1,0.649278
uuid-0068515d246b448a9029190f224272b7,approval,0.341253
uuid-0068515d246b448a9029190f224272b7,atezo,0.470471
uuid-0068515d246b448a9029190f224272b7,PD-L1 testing,0.526776
uuid-0068515d246b448a9029190f224272b7,testing,0.654165
uuid-0068515d246b448a9029190f224272b7,PDL1 testing,0.556795
uuid-0068515d246b448a9029190f224272b7,NSCLC patients,0.498329
uuid-0068515d246b448a9029190f224272b7,nivo and pembro,0.364656
uuid-0068515d246b448a9029190f224272b7,assay,0.601803
uuid-0068515d246b448a9029190f224272b7,PDL1 expression,0.462042
uuid-0068515d246b448a9029190f224272b7,biomarker,0.416438
uuid-0068515d246b448a9029190f224272b7,bladder,0.3439
uuid-680f0132379a4fc7b0ff3bd23ab9707c,institution,0.395684
uuid-680f0132379a4fc7b0ff3bd23ab9707c,oncology,0.354397
uuid-2d75afc51ff0439fb4311c8999518d6c,commented,0.331432
uuid-2d75afc51ff0439fb4311c8999518d6c,physicians,0.374204
uuid-2d75afc51ff0439fb4311c8999518d6c,regards,0.361789
uuid-2d75afc51ff0439fb4311c8999518d6c,AI,0.455032
uuid-2d75afc51ff0439fb4311c8999518d6c,oncology,0.728754
uuid-2d75afc51ff0439fb4311c8999518d6c,ASCO,0.370695
uuid-2d75afc51ff0439fb4311c8999518d6c,clinical,0.472334
uuid-3bd83f0a757741eb84b197ec058b7e73,NSCLC patients,0.302735
uuid-ff54ecbdf596465684d3c9db37ea48d1,Nivo,0.337587
uuid-ff54ecbdf596465684d3c9db37ea48d1,pembro,0.35592
uuid-ff54ecbdf596465684d3c9db37ea48d1,therapy,0.411758
uuid-ff54ecbdf596465684d3c9db37ea48d1,nivolumab,0.531317
uuid-ff54ecbdf596465684d3c9db37ea48d1,1L,0.669744
uuid-ff54ecbdf596465684d3c9db37ea48d1,regimen,0.349974
uuid-ff54ecbdf596465684d3c9db37ea48d1,RCC,0.608889
uuid-ff54ecbdf596465684d3c9db37ea48d1,combination,0.544332
uuid-ff54ecbdf596465684d3c9db37ea48d1,chemo,0.345598
uuid-ff54ecbdf596465684d3c9db37ea48d1,2L,0.746711
uuid-ff54ecbdf596465684d3c9db37ea48d1,agents,0.57812
uuid-ff54ecbdf596465684d3c9db37ea48d1,approval,0.365297
uuid-ff54ecbdf596465684d3c9db37ea48d1,atezo,0.366028
uuid-ff54ecbdf596465684d3c9db37ea48d1,preferred,0.768211
uuid-ff54ecbdf596465684d3c9db37ea48d1,monotherapy,0.723016
uuid-ff54ecbdf596465684d3c9db37ea48d1,using nivo,0.663456
uuid-ff54ecbdf596465684d3c9db37ea48d1,combo,0.516704
uuid-ff54ecbdf596465684d3c9db37ea48d1,indication,0.315583
uuid-ff54ecbdf596465684d3c9db37ea48d1,PD1,0.458185
uuid-ff54ecbdf596465684d3c9db37ea48d1,approved,0.539641
uuid-ff54ecbdf596465684d3c9db37ea48d1,SCCHN,0.422384
uuid-ff54ecbdf596465684d3c9db37ea48d1,chemotherapy,0.385302
uuid-ff54ecbdf596465684d3c9db37ea48d1,tumor types,0.336697
uuid-ff54ecbdf596465684d3c9db37ea48d1,PD-1,0.411525
uuid-ff54ecbdf596465684d3c9db37ea48d1,RTL stated,0.67314
uuid-ff54ecbdf596465684d3c9db37ea48d1,TL shared,0.376039
uuid-ff54ecbdf596465684d3c9db37ea48d1,option,0.708845
uuid-ff54ecbdf596465684d3c9db37ea48d1,bladder,0.372737
uuid-fddbe440f7e546159bf14823ea4ae6ff,patients,0.770014
uuid-fddbe440f7e546159bf14823ea4ae6ff,Opdivo,0.420567
uuid-fddbe440f7e546159bf14823ea4ae6ff,therapy,0.457288
uuid-fddbe440f7e546159bf14823ea4ae6ff,nivolumab,0.52556
uuid-fddbe440f7e546159bf14823ea4ae6ff,toxicity,0.315047
uuid-fddbe440f7e546159bf14823ea4ae6ff,regimen,0.608529
uuid-fddbe440f7e546159bf14823ea4ae6ff,treated,0.533722
uuid-fddbe440f7e546159bf14823ea4ae6ff,combination,0.344086
uuid-fddbe440f7e546159bf14823ea4ae6ff,chemo,0.383859
uuid-fddbe440f7e546159bf14823ea4ae6ff,pts,0.639069
uuid-fddbe440f7e546159bf14823ea4ae6ff,preferred,0.306102
uuid-fddbe440f7e546159bf14823ea4ae6ff,monotherapy,0.478477
uuid-fddbe440f7e546159bf14823ea4ae6ff,treatment,0.58417
uuid-fddbe440f7e546159bf14823ea4ae6ff,using nivo,0.343444
uuid-fddbe440f7e546159bf14823ea4ae6ff,response,0.379285
uuid-fddbe440f7e546159bf14823ea4ae6ff,combo,0.356818
uuid-fddbe440f7e546159bf14823ea4ae6ff,PD1,0.397175
uuid-fddbe440f7e546159bf14823ea4ae6ff,progression,0.661962
uuid-fddbe440f7e546159bf14823ea4ae6ff,chemotherapy,0.339286
uuid-fddbe440f7e546159bf14823ea4ae6ff,respond,0.50832
uuid-fddbe440f7e546159bf14823ea4ae6ff,RTL stated,0.332932
uuid-fddbe440f7e546159bf14823ea4ae6ff,option,0.386351
uuid-f57bf70cbd1740bbac5a0a670064ced6,trial,0.45249
uuid-f57bf70cbd1740bbac5a0a670064ced6,efficacy,0.428611
uuid-f57bf70cbd1740bbac5a0a670064ced6,chemo,0.314548
uuid-f57bf70cbd1740bbac5a0a670064ced6,OS,0.628099
uuid-f57bf70cbd1740bbac5a0a670064ced6,response,0.405619
uuid-f57bf70cbd1740bbac5a0a670064ced6,data,0.385757
uuid-f57bf70cbd1740bbac5a0a670064ced6,PFS,0.673329
uuid-f57bf70cbd1740bbac5a0a670064ced6,ORR,0.619529
uuid-f57bf70cbd1740bbac5a0a670064ced6,progression,0.30415
uuid-f57bf70cbd1740bbac5a0a670064ced6,believes,0.322902
uuid-f57bf70cbd1740bbac5a0a670064ced6,chemotherapy,0.337186
uuid-f57bf70cbd1740bbac5a0a670064ced6,impressed,0.397775
uuid-9a304d9e5e75435ba05a51103389de45,trial,0.339943
uuid-9a304d9e5e75435ba05a51103389de45,efficacy,0.356572
uuid-9a304d9e5e75435ba05a51103389de45,combination,0.347052
uuid-9a304d9e5e75435ba05a51103389de45,chemo,0.323337
uuid-9a304d9e5e75435ba05a51103389de45,IO,0.532276
uuid-9a304d9e5e75435ba05a51103389de45,OS,0.464982
uuid-9a304d9e5e75435ba05a51103389de45,response,0.322468
uuid-9a304d9e5e75435ba05a51103389de45,data,0.413544
uuid-9a304d9e5e75435ba05a51103389de45,combo,0.378297
uuid-9a304d9e5e75435ba05a51103389de45,PFS,0.471337
uuid-9a304d9e5e75435ba05a51103389de45,PD1,0.316188
uuid-9a304d9e5e75435ba05a51103389de45,ORR,0.470295
uuid-9a304d9e5e75435ba05a51103389de45,believes,0.388484
uuid-9a304d9e5e75435ba05a51103389de45,chemotherapy,0.343747
uuid-9a304d9e5e75435ba05a51103389de45,impressed,0.372097
uuid-9a304d9e5e75435ba05a51103389de45,feels,0.510446
uuid-c963266612f248518b4d4bb77b60f874,1L,0.490322
uuid-c963266612f248518b4d4bb77b60f874,RCC,0.300769
uuid-c963266612f248518b4d4bb77b60f874,2L,0.425189
uuid-c963266612f248518b4d4bb77b60f874,stated,0.413747
uuid-c963266612f248518b4d4bb77b60f874,approval,0.462709
uuid-c963266612f248518b4d4bb77b60f874,preferred,0.370649
uuid-c963266612f248518b4d4bb77b60f874,using nivo,0.37065
uuid-c963266612f248518b4d4bb77b60f874,clinical trials,0.344264
uuid-c963266612f248518b4d4bb77b60f874,PDL1 testing,0.302695
uuid-c963266612f248518b4d4bb77b60f874,indication,0.356502
uuid-c963266612f248518b4d4bb77b60f874,approved,0.588526
uuid-c963266612f248518b4d4bb77b60f874,SCCHN,0.405295
uuid-c963266612f248518b4d4bb77b60f874,tumor types,0.414199
uuid-c963266612f248518b4d4bb77b60f874,label,0.361676
uuid-c963266612f248518b4d4bb77b60f874,feels,0.360957
uuid-c963266612f248518b4d4bb77b60f874,RTL stated,0.344083
uuid-c963266612f248518b4d4bb77b60f874,option,0.434301
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,Nivo,0.418049
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,patients,0.642814
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,pembro,0.370354
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,therapy,0.509535
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,nivolumab,0.314777
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,1L,0.696264
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,regimen,0.446401
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,combination,0.317895
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,chemo,0.622405
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,2L,0.655643
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,pts,0.501038
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,agents,0.438554
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,atezo,0.321033
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,preferred,0.671265
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,monotherapy,0.715872
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,treatment,0.468171
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,using nivo,0.490202
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,combo,0.379982
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,NSCLC patients,0.419043
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,PD1,0.417404
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,approved,0.37311
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,progression,0.429367
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,chemotherapy,0.509312
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,respond,0.351448
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,feels,0.321395
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,PD-1,0.320892
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,RTL stated,0.393895
uuid-8bff06ec7fde4c1aa9c7dea3bf2143ed,option,0.763822
uuid-d71b0105bb7e4bfc81c40a83a270b05c,Nivo,0.483414
uuid-d71b0105bb7e4bfc81c40a83a270b05c,patients,0.302658
uuid-d71b0105bb7e4bfc81c40a83a270b05c,dose,0.614455
uuid-d71b0105bb7e4bfc81c40a83a270b05c,toxicity,0.586872
uuid-d71b0105bb7e4bfc81c40a83a270b05c,efficacy,0.412825
uuid-d71b0105bb7e4bfc81c40a83a270b05c,regimen,0.624921
uuid-d71b0105bb7e4bfc81c40a83a270b05c,combination,0.515657
uuid-d71b0105bb7e4bfc81c40a83a270b05c,chemo,0.469981
uuid-d71b0105bb7e4bfc81c40a83a270b05c,pts,0.316735
uuid-d71b0105bb7e4bfc81c40a83a270b05c,agents,0.311969
uuid-d71b0105bb7e4bfc81c40a83a270b05c,Ipi,0.669625
uuid-d71b0105bb7e4bfc81c40a83a270b05c,preferred,0.348141
uuid-d71b0105bb7e4bfc81c40a83a270b05c,monotherapy,0.545773
uuid-d71b0105bb7e4bfc81c40a83a270b05c,treatment,0.322168
uuid-d71b0105bb7e4bfc81c40a83a270b05c,combo,0.514196
uuid-d71b0105bb7e4bfc81c40a83a270b05c,PD1,0.312773
uuid-d71b0105bb7e4bfc81c40a83a270b05c,believes,0.301228
uuid-d71b0105bb7e4bfc81c40a83a270b05c,chemotherapy,0.39062
uuid-d71b0105bb7e4bfc81c40a83a270b05c,vs,0.37565
uuid-d71b0105bb7e4bfc81c40a83a270b05c,feels,0.339751
uuid-d71b0105bb7e4bfc81c40a83a270b05c,option,0.408091
uuid-3badb5f588474b4e8748e2538506f3d2,TL,0.552509
uuid-3badb5f588474b4e8748e2538506f3d2,PDL1,0.52621
uuid-3badb5f588474b4e8748e2538506f3d2,Merck,0.413819
uuid-3badb5f588474b4e8748e2538506f3d2,PD-L1,0.670705
uuid-3badb5f588474b4e8748e2538506f3d2,PD-L1 testing,0.614498
uuid-3badb5f588474b4e8748e2538506f3d2,testing,0.588383
uuid-3badb5f588474b4e8748e2538506f3d2,data,0.319503
uuid-3badb5f588474b4e8748e2538506f3d2,PDL1 testing,0.361036
uuid-3badb5f588474b4e8748e2538506f3d2,NSCLC patients,0.325359
uuid-3badb5f588474b4e8748e2538506f3d2,assay,0.746923
uuid-3badb5f588474b4e8748e2538506f3d2,PDL1 expression,0.378426
uuid-3badb5f588474b4e8748e2538506f3d2,biomarker,0.420419
uuid-0f1bd336b4514a4790033da764e0ca0c,TL,0.530153
uuid-0f1bd336b4514a4790033da764e0ca0c,PDL1,0.335768
uuid-0f1bd336b4514a4790033da764e0ca0c,TL stated,0.44587
uuid-0f1bd336b4514a4790033da764e0ca0c,PD-L1,0.650072
uuid-0f1bd336b4514a4790033da764e0ca0c,PD-L1 testing,0.685576
uuid-0f1bd336b4514a4790033da764e0ca0c,testing,0.777819
uuid-0f1bd336b4514a4790033da764e0ca0c,PDL1 testing,0.62848
uuid-0f1bd336b4514a4790033da764e0ca0c,NSCLC patients,0.565446
uuid-0f1bd336b4514a4790033da764e0ca0c,assay,0.603588
uuid-0f1bd336b4514a4790033da764e0ca0c,biomarker,0.41875
uuid-4344d02cc788474dae24ac7d9c2b9d9c,Nivo,0.337185
uuid-4344d02cc788474dae24ac7d9c2b9d9c,trial,0.343608
uuid-4344d02cc788474dae24ac7d9c2b9d9c,efficacy,0.485152
uuid-4344d02cc788474dae24ac7d9c2b9d9c,OS,0.621871
uuid-4344d02cc788474dae24ac7d9c2b9d9c,data,0.499357
uuid-4344d02cc788474dae24ac7d9c2b9d9c,PFS,0.600653
uuid-4344d02cc788474dae24ac7d9c2b9d9c,ORR,0.59938
uuid-4344d02cc788474dae24ac7d9c2b9d9c,ASCO,0.306929
uuid-4344d02cc788474dae24ac7d9c2b9d9c,impressed,0.601699
uuid-12cbcf2b941d46cda64aad2575be760b,patients,0.624234
uuid-12cbcf2b941d46cda64aad2575be760b,therapy,0.595518
uuid-12cbcf2b941d46cda64aad2575be760b,regimen,0.458697
uuid-12cbcf2b941d46cda64aad2575be760b,treated,0.305708
uuid-12cbcf2b941d46cda64aad2575be760b,chemo,0.487723
uuid-12cbcf2b941d46cda64aad2575be760b,pts,0.421259
uuid-12cbcf2b941d46cda64aad2575be760b,IO,0.315715
uuid-12cbcf2b941d46cda64aad2575be760b,monotherapy,0.398518
uuid-12cbcf2b941d46cda64aad2575be760b,treatment,0.684045
uuid-12cbcf2b941d46cda64aad2575be760b,response,0.530141
uuid-12cbcf2b941d46cda64aad2575be760b,PD1,0.398091
uuid-12cbcf2b941d46cda64aad2575be760b,progression,0.695214
uuid-12cbcf2b941d46cda64aad2575be760b,believes,0.325082
uuid-12cbcf2b941d46cda64aad2575be760b,chemotherapy,0.485635
uuid-12cbcf2b941d46cda64aad2575be760b,respond,0.595577
uuid-12cbcf2b941d46cda64aad2575be760b,option,0.47239
uuid-1528023b41a940b59dfe9099670f3303,Nivo,0.430787
uuid-1528023b41a940b59dfe9099670f3303,pembro,0.686058
uuid-1528023b41a940b59dfe9099670f3303,RTL,0.368498
uuid-1528023b41a940b59dfe9099670f3303,BMS,0.440092
uuid-1528023b41a940b59dfe9099670f3303,1L,0.349044
uuid-1528023b41a940b59dfe9099670f3303,trial,0.732604
uuid-1528023b41a940b59dfe9099670f3303,efficacy,0.333985
uuid-1528023b41a940b59dfe9099670f3303,commented,0.300123
uuid-1528023b41a940b59dfe9099670f3303,2L,0.353069
uuid-1528023b41a940b59dfe9099670f3303,Merck,0.445823
uuid-1528023b41a940b59dfe9099670f3303,stated,0.430285
uuid-1528023b41a940b59dfe9099670f3303,approval,0.499718
uuid-1528023b41a940b59dfe9099670f3303,atezo,0.560449
uuid-1528023b41a940b59dfe9099670f3303,using nivo,0.374092
uuid-1528023b41a940b59dfe9099670f3303,data,0.62813
uuid-1528023b41a940b59dfe9099670f3303,expressed,0.30175
uuid-1528023b41a940b59dfe9099670f3303,clinical trials,0.456289
uuid-1528023b41a940b59dfe9099670f3303,indication,0.424521
uuid-1528023b41a940b59dfe9099670f3303,ORR,0.342511
uuid-1528023b41a940b59dfe9099670f3303,approved,0.501058
uuid-1528023b41a940b59dfe9099670f3303,SCCHN,0.377872
uuid-1528023b41a940b59dfe9099670f3303,nivo and pembro,0.446704
uuid-1528023b41a940b59dfe9099670f3303,impressed,0.513045
uuid-1528023b41a940b59dfe9099670f3303,vs,0.322047
uuid-1528023b41a940b59dfe9099670f3303,label,0.302504
uuid-1528023b41a940b59dfe9099670f3303,LTL,0.33595
uuid-1528023b41a940b59dfe9099670f3303,TLs,0.304401
uuid-1528023b41a940b59dfe9099670f3303,SCLC,0.343698
uuid-1528023b41a940b59dfe9099670f3303,feels,0.349917
uuid-1528023b41a940b59dfe9099670f3303,Regional TL,0.356419
uuid-1528023b41a940b59dfe9099670f3303,bladder,0.43445
uuid-6a2a793fc7ef4007bbcab76295d88bf8,physicians,0.535004
uuid-aa3e0425cea84b6386582833dc254ab8,Opdivo,0.415231
uuid-aa3e0425cea84b6386582833dc254ab8,dose,0.765796
uuid-aa3e0425cea84b6386582833dc254ab8,toxicity,0.309262
uuid-aa3e0425cea84b6386582833dc254ab8,vs,0.442968
uuid-aa3e0425cea84b6386582833dc254ab8,Keytruda,0.337759
uuid-aa3e0425cea84b6386582833dc254ab8,flat dosing,0.775888
uuid-be10a4efc01b492281fb2754e1c283e4,Nivo,0.305469
uuid-be10a4efc01b492281fb2754e1c283e4,patients,0.669447
uuid-be10a4efc01b492281fb2754e1c283e4,Opdivo,0.324722
uuid-be10a4efc01b492281fb2754e1c283e4,therapy,0.435851
uuid-be10a4efc01b492281fb2754e1c283e4,nivolumab,0.525054
uuid-be10a4efc01b492281fb2754e1c283e4,1L,0.591991
uuid-be10a4efc01b492281fb2754e1c283e4,regimen,0.478304
uuid-be10a4efc01b492281fb2754e1c283e4,treated,0.470602
uuid-be10a4efc01b492281fb2754e1c283e4,RCC,0.526924
uuid-be10a4efc01b492281fb2754e1c283e4,TL stated,0.305718
uuid-be10a4efc01b492281fb2754e1c283e4,combination,0.340103
uuid-be10a4efc01b492281fb2754e1c283e4,chemo,0.363732
uuid-be10a4efc01b492281fb2754e1c283e4,2L,0.651312
uuid-be10a4efc01b492281fb2754e1c283e4,pts,0.555399
uuid-be10a4efc01b492281fb2754e1c283e4,approval,0.331148
uuid-be10a4efc01b492281fb2754e1c283e4,preferred,0.633061
uuid-be10a4efc01b492281fb2754e1c283e4,monotherapy,0.651134
uuid-be10a4efc01b492281fb2754e1c283e4,treatment,0.518374
uuid-be10a4efc01b492281fb2754e1c283e4,using nivo,0.627649
uuid-be10a4efc01b492281fb2754e1c283e4,combo,0.360372
uuid-be10a4efc01b492281fb2754e1c283e4,NSCLC patients,0.331747
uuid-be10a4efc01b492281fb2754e1c283e4,PD1,0.370018
uuid-be10a4efc01b492281fb2754e1c283e4,approved,0.431969
uuid-be10a4efc01b492281fb2754e1c283e4,SCCHN,0.397922
uuid-be10a4efc01b492281fb2754e1c283e4,progression,0.473842
uuid-be10a4efc01b492281fb2754e1c283e4,chemotherapy,0.325064
uuid-be10a4efc01b492281fb2754e1c283e4,tumor types,0.307674
uuid-be10a4efc01b492281fb2754e1c283e4,RTL stated,0.615315
uuid-be10a4efc01b492281fb2754e1c283e4,TL shared,0.376737
uuid-be10a4efc01b492281fb2754e1c283e4,option,0.637801
uuid-a61a847bf8124b4e97d2d9dafce8085f,patients,0.542637
uuid-a61a847bf8124b4e97d2d9dafce8085f,toxicity,0.592816
uuid-a61a847bf8124b4e97d2d9dafce8085f,regimen,0.622375
uuid-a61a847bf8124b4e97d2d9dafce8085f,treated,0.378852
uuid-a61a847bf8124b4e97d2d9dafce8085f,pts,0.377568
uuid-a61a847bf8124b4e97d2d9dafce8085f,monotherapy,0.32601
uuid-a61a847bf8124b4e97d2d9dafce8085f,treatment,0.44656
uuid-a61a847bf8124b4e97d2d9dafce8085f,progression,0.437872
uuid-a61a847bf8124b4e97d2d9dafce8085f,respond,0.442039
uuid-bb0560794c734d62a9f1192bbaec8259,Nivo,0.736585
uuid-bb0560794c734d62a9f1192bbaec8259,pembro,0.648689
uuid-bb0560794c734d62a9f1192bbaec8259,1L,0.549669
uuid-bb0560794c734d62a9f1192bbaec8259,trial,0.336672
uuid-bb0560794c734d62a9f1192bbaec8259,efficacy,0.450803
uuid-bb0560794c734d62a9f1192bbaec8259,regimen,0.30526
uuid-bb0560794c734d62a9f1192bbaec8259,combination,0.657638
uuid-bb0560794c734d62a9f1192bbaec8259,chemo,0.639287
uuid-bb0560794c734d62a9f1192bbaec8259,2L,0.563772
uuid-bb0560794c734d62a9f1192bbaec8259,IO,0.312828
uuid-bb0560794c734d62a9f1192bbaec8259,agents,0.570175
uuid-bb0560794c734d62a9f1192bbaec8259,Ipi,0.618861
uuid-bb0560794c734d62a9f1192bbaec8259,atezo,0.557241
uuid-bb0560794c734d62a9f1192bbaec8259,preferred,0.526252
uuid-bb0560794c734d62a9f1192bbaec8259,monotherapy,0.668381
uuid-bb0560794c734d62a9f1192bbaec8259,using nivo,0.438874
uuid-bb0560794c734d62a9f1192bbaec8259,combo,0.644566
uuid-bb0560794c734d62a9f1192bbaec8259,PD1,0.449314
uuid-bb0560794c734d62a9f1192bbaec8259,approved,0.373834
uuid-bb0560794c734d62a9f1192bbaec8259,nivo and pembro,0.458165
uuid-bb0560794c734d62a9f1192bbaec8259,believes,0.497253
uuid-bb0560794c734d62a9f1192bbaec8259,chemotherapy,0.512386
uuid-bb0560794c734d62a9f1192bbaec8259,vs,0.468222
uuid-bb0560794c734d62a9f1192bbaec8259,feels,0.421503
uuid-bb0560794c734d62a9f1192bbaec8259,option,0.57622
uuid-80d5f94419ed422e8cb3202f63d432ce,TL,0.301458
uuid-80d5f94419ed422e8cb3202f63d432ce,1L,0.467102
uuid-80d5f94419ed422e8cb3202f63d432ce,PDL1,0.636085
uuid-80d5f94419ed422e8cb3202f63d432ce,2L,0.301108
uuid-80d5f94419ed422e8cb3202f63d432ce,PD-L1,0.821961
uuid-80d5f94419ed422e8cb3202f63d432ce,PD-L1 testing,0.635604
uuid-80d5f94419ed422e8cb3202f63d432ce,testing,0.829864
uuid-80d5f94419ed422e8cb3202f63d432ce,PDL1 testing,0.644782
uuid-80d5f94419ed422e8cb3202f63d432ce,NSCLC patients,0.686688
uuid-80d5f94419ed422e8cb3202f63d432ce,tumor types,0.300703
uuid-80d5f94419ed422e8cb3202f63d432ce,assay,0.602138
uuid-80d5f94419ed422e8cb3202f63d432ce,PD-1,0.378832
uuid-80d5f94419ed422e8cb3202f63d432ce,PDL1 expression,0.518548
uuid-80d5f94419ed422e8cb3202f63d432ce,biomarker,0.655708
uuid-d8aab17f37f646079ab91d24cd8e575d,pembro,0.390327
uuid-d8aab17f37f646079ab91d24cd8e575d,BMS,0.405389
uuid-d8aab17f37f646079ab91d24cd8e575d,PDL1,0.506793
uuid-d8aab17f37f646079ab91d24cd8e575d,trial,0.478966
uuid-d8aab17f37f646079ab91d24cd8e575d,efficacy,0.595232
uuid-d8aab17f37f646079ab91d24cd8e575d,agents,0.36396
uuid-d8aab17f37f646079ab91d24cd8e575d,Merck,0.334821
uuid-d8aab17f37f646079ab91d24cd8e575d,OS,0.48047
uuid-d8aab17f37f646079ab91d24cd8e575d,atezo,0.396252
uuid-d8aab17f37f646079ab91d24cd8e575d,regards,0.338675
uuid-d8aab17f37f646079ab91d24cd8e575d,data,0.685179
uuid-d8aab17f37f646079ab91d24cd8e575d,expressed,0.312392
uuid-d8aab17f37f646079ab91d24cd8e575d,PFS,0.5096
uuid-d8aab17f37f646079ab91d24cd8e575d,ORR,0.528255
uuid-d8aab17f37f646079ab91d24cd8e575d,nivo and pembro,0.630782
uuid-d8aab17f37f646079ab91d24cd8e575d,believes,0.458136
uuid-d8aab17f37f646079ab91d24cd8e575d,impressed,0.4645
uuid-d8aab17f37f646079ab91d24cd8e575d,TLs,0.361056
uuid-d8aab17f37f646079ab91d24cd8e575d,feels,0.537262
uuid-d8aab17f37f646079ab91d24cd8e575d,PDL1 expression,0.508743
uuid-15edd38f96ce4891b8b4490c6e178d5b,patients,0.332864
uuid-15edd38f96ce4891b8b4490c6e178d5b,dose,0.499663
uuid-15edd38f96ce4891b8b4490c6e178d5b,toxicity,0.730652
uuid-15edd38f96ce4891b8b4490c6e178d5b,regimen,0.477395
uuid-15edd38f96ce4891b8b4490c6e178d5b,treatment,0.369723
uuid-15edd38f96ce4891b8b4490c6e178d5b,respond,0.42818
uuid-be6e2cc431434daf83ad735a281ff00e,Nivo,0.337677
uuid-be6e2cc431434daf83ad735a281ff00e,patients,0.675726
uuid-be6e2cc431434daf83ad735a281ff00e,Opdivo,0.316821
uuid-be6e2cc431434daf83ad735a281ff00e,therapy,0.563715
uuid-be6e2cc431434daf83ad735a281ff00e,nivolumab,0.384547
uuid-be6e2cc431434daf83ad735a281ff00e,1L,0.403296
uuid-be6e2cc431434daf83ad735a281ff00e,regimen,0.523911
uuid-be6e2cc431434daf83ad735a281ff00e,treated,0.317643
uuid-be6e2cc431434daf83ad735a281ff00e,combination,0.356827
uuid-be6e2cc431434daf83ad735a281ff00e,chemo,0.521084
uuid-be6e2cc431434daf83ad735a281ff00e,2L,0.383118
uuid-be6e2cc431434daf83ad735a281ff00e,pts,0.607942
uuid-be6e2cc431434daf83ad735a281ff00e,IO,0.362497
uuid-be6e2cc431434daf83ad735a281ff00e,preferred,0.349465
uuid-be6e2cc431434daf83ad735a281ff00e,monotherapy,0.578877
uuid-be6e2cc431434daf83ad735a281ff00e,treatment,0.572701
uuid-be6e2cc431434daf83ad735a281ff00e,using nivo,0.308687
uuid-be6e2cc431434daf83ad735a281ff00e,response,0.513713
uuid-be6e2cc431434daf83ad735a281ff00e,combo,0.373844
uuid-be6e2cc431434daf83ad735a281ff00e,PD1,0.473058
uuid-be6e2cc431434daf83ad735a281ff00e,progression,0.736859
uuid-be6e2cc431434daf83ad735a281ff00e,chemotherapy,0.425399
uuid-be6e2cc431434daf83ad735a281ff00e,respond,0.558576
uuid-be6e2cc431434daf83ad735a281ff00e,option,0.542895
uuid-50fb703311cd44089fa588beaf855eb2,Opdivo,0.469256
uuid-50fb703311cd44089fa588beaf855eb2,dose,0.747635
uuid-50fb703311cd44089fa588beaf855eb2,efficacy,0.320644
uuid-50fb703311cd44089fa588beaf855eb2,Ipi,0.386282
uuid-50fb703311cd44089fa588beaf855eb2,physicians,0.35425
uuid-50fb703311cd44089fa588beaf855eb2,indication,0.308402
uuid-50fb703311cd44089fa588beaf855eb2,vs,0.471448
uuid-50fb703311cd44089fa588beaf855eb2,Keytruda,0.425289
uuid-50fb703311cd44089fa588beaf855eb2,flat dosing,0.7731
uuid-2198d87add0b4a7bb6dc4470d63513a9,TL,0.436445
uuid-2198d87add0b4a7bb6dc4470d63513a9,RTL,0.384952
uuid-2198d87add0b4a7bb6dc4470d63513a9,lung,0.455601
uuid-2198d87add0b4a7bb6dc4470d63513a9,melanoma,0.377807
uuid-2198d87add0b4a7bb6dc4470d63513a9,RCC,0.539837
uuid-2198d87add0b4a7bb6dc4470d63513a9,TL stated,0.591499
uuid-2198d87add0b4a7bb6dc4470d63513a9,tumor,0.305937
uuid-2198d87add0b4a7bb6dc4470d63513a9,PD-L1,0.422316
uuid-2198d87add0b4a7bb6dc4470d63513a9,PD-L1 testing,0.510694
uuid-2198d87add0b4a7bb6dc4470d63513a9,testing,0.517719
uuid-2198d87add0b4a7bb6dc4470d63513a9,PDL1 testing,0.58063
uuid-2198d87add0b4a7bb6dc4470d63513a9,NSCLC patients,0.577947
uuid-2198d87add0b4a7bb6dc4470d63513a9,SCCHN,0.524341
uuid-2198d87add0b4a7bb6dc4470d63513a9,tumor types,0.383288
uuid-2198d87add0b4a7bb6dc4470d63513a9,oncologist,0.38309
uuid-2198d87add0b4a7bb6dc4470d63513a9,indicated,0.329461
uuid-2198d87add0b4a7bb6dc4470d63513a9,TLs,0.419177
uuid-2198d87add0b4a7bb6dc4470d63513a9,academic,0.470401
uuid-2198d87add0b4a7bb6dc4470d63513a9,Regional TL,0.454747
uuid-2198d87add0b4a7bb6dc4470d63513a9,RTL stated,0.408467
uuid-2198d87add0b4a7bb6dc4470d63513a9,TL shared,0.443122
uuid-2198d87add0b4a7bb6dc4470d63513a9,bladder,0.424302
uuid-444fb39d52134e49957201aca9bdc129,RTL,0.418493
uuid-444fb39d52134e49957201aca9bdc129,trial,0.460038
uuid-444fb39d52134e49957201aca9bdc129,NTL,0.587336
uuid-444fb39d52134e49957201aca9bdc129,Regional TL,0.309639
uuid-9717b166bf1f4290be189e429ee24f2c,RTL,0.602287
uuid-9717b166bf1f4290be189e429ee24f2c,BMS,0.540373
uuid-9717b166bf1f4290be189e429ee24f2c,trial,0.42943
uuid-9717b166bf1f4290be189e429ee24f2c,NTL,0.444869
uuid-9717b166bf1f4290be189e429ee24f2c,discussed,0.327618
uuid-9717b166bf1f4290be189e429ee24f2c,shared,0.384919
uuid-9717b166bf1f4290be189e429ee24f2c,commented,0.551341
uuid-9717b166bf1f4290be189e429ee24f2c,Merck,0.387108
uuid-9717b166bf1f4290be189e429ee24f2c,stated,0.55276
uuid-9717b166bf1f4290be189e429ee24f2c,regards,0.315686
uuid-9717b166bf1f4290be189e429ee24f2c,data,0.59926
uuid-9717b166bf1f4290be189e429ee24f2c,expressed,0.42298
uuid-9717b166bf1f4290be189e429ee24f2c,mentioned,0.406946
uuid-9717b166bf1f4290be189e429ee24f2c,clinical trials,0.362231
uuid-9717b166bf1f4290be189e429ee24f2c,indication,0.307518
uuid-9717b166bf1f4290be189e429ee24f2c,SCCHN,0.356171
uuid-9717b166bf1f4290be189e429ee24f2c,HCP,0.312563
uuid-9717b166bf1f4290be189e429ee24f2c,ASCO,0.379524
uuid-9717b166bf1f4290be189e429ee24f2c,impressed,0.588887
uuid-9717b166bf1f4290be189e429ee24f2c,LTL,0.499098
uuid-9717b166bf1f4290be189e429ee24f2c,TLs,0.352319
uuid-9717b166bf1f4290be189e429ee24f2c,Regional TL,0.548789
uuid-5b4d0511ef874cb981281083c79c88cd,Nivo,0.547876
uuid-5b4d0511ef874cb981281083c79c88cd,1L,0.406783
uuid-5b4d0511ef874cb981281083c79c88cd,efficacy,0.369571
uuid-5b4d0511ef874cb981281083c79c88cd,regimen,0.329689
uuid-5b4d0511ef874cb981281083c79c88cd,RCC,0.376766
uuid-5b4d0511ef874cb981281083c79c88cd,combination,0.358065
uuid-5b4d0511ef874cb981281083c79c88cd,chemo,0.334595
uuid-5b4d0511ef874cb981281083c79c88cd,2L,0.479866
uuid-5b4d0511ef874cb981281083c79c88cd,agents,0.408081
uuid-5b4d0511ef874cb981281083c79c88cd,atezo,0.316877
uuid-5b4d0511ef874cb981281083c79c88cd,preferred,0.385061
uuid-5b4d0511ef874cb981281083c79c88cd,monotherapy,0.472037
uuid-5b4d0511ef874cb981281083c79c88cd,using nivo,0.385647
uuid-5b4d0511ef874cb981281083c79c88cd,combo,0.396539
uuid-5b4d0511ef874cb981281083c79c88cd,indication,0.403618
uuid-5b4d0511ef874cb981281083c79c88cd,PD1,0.31694
uuid-5b4d0511ef874cb981281083c79c88cd,approved,0.455183
uuid-5b4d0511ef874cb981281083c79c88cd,nivo and pembro,0.310516
uuid-5b4d0511ef874cb981281083c79c88cd,believes,0.348923
uuid-5b4d0511ef874cb981281083c79c88cd,chemotherapy,0.300988
uuid-5b4d0511ef874cb981281083c79c88cd,impressed,0.316595
uuid-5b4d0511ef874cb981281083c79c88cd,SCLC,0.348244
uuid-5b4d0511ef874cb981281083c79c88cd,feels,0.353823
uuid-5b4d0511ef874cb981281083c79c88cd,option,0.491723
uuid-0b19fdbeea4e46dca6ba8020681e81a8,oncology,0.384314
uuid-0b19fdbeea4e46dca6ba8020681e81a8,drug,0.602775
uuid-db130fdbfdf445dc9fd8847df32b77c3,TL,0.6075
uuid-db130fdbfdf445dc9fd8847df32b77c3,TL stated,0.40973
uuid-db130fdbfdf445dc9fd8847df32b77c3,institution,0.366352
uuid-db130fdbfdf445dc9fd8847df32b77c3,PD-L1,0.601056
uuid-db130fdbfdf445dc9fd8847df32b77c3,PD-L1 testing,0.808023
uuid-db130fdbfdf445dc9fd8847df32b77c3,testing,0.790837
uuid-db130fdbfdf445dc9fd8847df32b77c3,PDL1 testing,0.635778
uuid-db130fdbfdf445dc9fd8847df32b77c3,NSCLC patients,0.639857
uuid-db130fdbfdf445dc9fd8847df32b77c3,assay,0.535738
uuid-fe436ae37e954ae0a066dc547ba24b5f,RTL,0.376892
uuid-fe436ae37e954ae0a066dc547ba24b5f,NTL,0.373255
uuid-fe436ae37e954ae0a066dc547ba24b5f,shared,0.433548
uuid-fe436ae37e954ae0a066dc547ba24b5f,commented,0.506569
uuid-fe436ae37e954ae0a066dc547ba24b5f,stated,0.378156
uuid-fe436ae37e954ae0a066dc547ba24b5f,physicians,0.363418
uuid-fe436ae37e954ae0a066dc547ba24b5f,mentioned,0.34354
uuid-fe436ae37e954ae0a066dc547ba24b5f,clinical trials,0.353759
uuid-fe436ae37e954ae0a066dc547ba24b5f,oncology,0.544256
uuid-fe436ae37e954ae0a066dc547ba24b5f,SCCHN,0.430044
uuid-fe436ae37e954ae0a066dc547ba24b5f,ASCO,0.303741
uuid-fe436ae37e954ae0a066dc547ba24b5f,tumor types,0.36672
uuid-fe436ae37e954ae0a066dc547ba24b5f,LTL,0.373503
uuid-fe436ae37e954ae0a066dc547ba24b5f,Regional TL,0.646402
uuid-0a7954965f81423b80c6573643ade2a7,patients,0.310505
uuid-0a7954965f81423b80c6573643ade2a7,1L,0.60504
uuid-0a7954965f81423b80c6573643ade2a7,PDL1,0.304788
uuid-0a7954965f81423b80c6573643ade2a7,RCC,0.344195
uuid-0a7954965f81423b80c6573643ade2a7,TL stated,0.320711
uuid-0a7954965f81423b80c6573643ade2a7,2L,0.495084
uuid-0a7954965f81423b80c6573643ade2a7,pts,0.357032
uuid-0a7954965f81423b80c6573643ade2a7,PD-L1,0.519173
uuid-0a7954965f81423b80c6573643ade2a7,approval,0.365155
uuid-0a7954965f81423b80c6573643ade2a7,preferred,0.515522
uuid-0a7954965f81423b80c6573643ade2a7,PD-L1 testing,0.426433
uuid-0a7954965f81423b80c6573643ade2a7,testing,0.522587
uuid-0a7954965f81423b80c6573643ade2a7,monotherapy,0.4241
uuid-0a7954965f81423b80c6573643ade2a7,using nivo,0.418736
uuid-0a7954965f81423b80c6573643ade2a7,PDL1 testing,0.532308
uuid-0a7954965f81423b80c6573643ade2a7,NSCLC patients,0.622578
uuid-0a7954965f81423b80c6573643ade2a7,approved,0.39359
uuid-0a7954965f81423b80c6573643ade2a7,SCCHN,0.347771
uuid-0a7954965f81423b80c6573643ade2a7,tumor types,0.483217
uuid-0a7954965f81423b80c6573643ade2a7,RTL stated,0.440697
uuid-0a7954965f81423b80c6573643ade2a7,option,0.585602
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,TL stated,0.339663
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,PD-L1,0.541812
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,PD-L1 testing,0.504758
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,testing,0.730847
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,PDL1 testing,0.67099
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,NSCLC patients,0.717338
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,tumor types,0.35803
uuid-6f31a0bfc67e48ddb0d6fb6f5a6e94c8,biomarker,0.356513
uuid-60f33425011b42cc8cf95ba7439a06fd,Nivo,0.37473
uuid-60f33425011b42cc8cf95ba7439a06fd,therapy,0.464195
uuid-60f33425011b42cc8cf95ba7439a06fd,nivolumab,0.327994
uuid-60f33425011b42cc8cf95ba7439a06fd,1L,0.320674
uuid-60f33425011b42cc8cf95ba7439a06fd,combination,0.433703
uuid-60f33425011b42cc8cf95ba7439a06fd,chemo,0.404575
uuid-60f33425011b42cc8cf95ba7439a06fd,2L,0.313008
uuid-60f33425011b42cc8cf95ba7439a06fd,agents,0.436818
uuid-60f33425011b42cc8cf95ba7439a06fd,preferred,0.311284
uuid-60f33425011b42cc8cf95ba7439a06fd,monotherapy,0.43411
uuid-60f33425011b42cc8cf95ba7439a06fd,using nivo,0.418937
uuid-60f33425011b42cc8cf95ba7439a06fd,combo,0.350762
uuid-60f33425011b42cc8cf95ba7439a06fd,PD1,0.457949
uuid-60f33425011b42cc8cf95ba7439a06fd,chemotherapy,0.493076
uuid-60f33425011b42cc8cf95ba7439a06fd,oncologist,0.35857
uuid-60f33425011b42cc8cf95ba7439a06fd,indicated,0.394529
uuid-60f33425011b42cc8cf95ba7439a06fd,option,0.46955
uuid-2d279c5126d4471988de685d275395fe,pembro,0.515354
uuid-2d279c5126d4471988de685d275395fe,BMS,0.376184
uuid-2d279c5126d4471988de685d275395fe,1L,0.407878
uuid-2d279c5126d4471988de685d275395fe,PDL1,0.346091
uuid-2d279c5126d4471988de685d275395fe,2L,0.388538
uuid-2d279c5126d4471988de685d275395fe,Merck,0.481669
uuid-2d279c5126d4471988de685d275395fe,approval,0.49134
uuid-2d279c5126d4471988de685d275395fe,atezo,0.44517
uuid-2d279c5126d4471988de685d275395fe,preferred,0.331734
uuid-2d279c5126d4471988de685d275395fe,data,0.424572
uuid-2d279c5126d4471988de685d275395fe,indication,0.568224
uuid-2d279c5126d4471988de685d275395fe,approved,0.563369
uuid-2d279c5126d4471988de685d275395fe,SCCHN,0.317023
uuid-2d279c5126d4471988de685d275395fe,nivo and pembro,0.335808
uuid-2d279c5126d4471988de685d275395fe,tumor types,0.317843
uuid-2d279c5126d4471988de685d275395fe,label,0.462087
uuid-2d279c5126d4471988de685d275395fe,Keytruda,0.345315
uuid-2d279c5126d4471988de685d275395fe,PDL1 expression,0.341531
uuid-2d279c5126d4471988de685d275395fe,option,0.334398
uuid-6393d1ff0ee54dd2a4ff13e08949a272,Opdivo,0.384132
uuid-6393d1ff0ee54dd2a4ff13e08949a272,treated,0.37017
uuid-6393d1ff0ee54dd2a4ff13e08949a272,physicians,0.569883
uuid-59075a212bf34d9db205e17977d83288,toxicity,0.319793
uuid-59075a212bf34d9db205e17977d83288,regimen,0.38276
uuid-59075a212bf34d9db205e17977d83288,physicians,0.422687
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,Opdivo,0.307094
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,dose,0.426387
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,physicians,0.456888
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,regards,0.31775
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,indication,0.318273
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,drug,0.427016
uuid-26b2cd6f9ecb4c9ab3ec1cae6e8530d0,flat dosing,0.49545
uuid-52c2e7c4b1f9460aa87bbb67a6344290,combination,0.314919
uuid-52c2e7c4b1f9460aa87bbb67a6344290,chemo,0.349944
uuid-52c2e7c4b1f9460aa87bbb67a6344290,tumor,0.569317
uuid-52c2e7c4b1f9460aa87bbb67a6344290,response,0.495339
uuid-52c2e7c4b1f9460aa87bbb67a6344290,immunotherapy,0.645788
uuid-6387293898d94edcae7f4806ae64e13e,treated,0.301013
uuid-e8b0616abf534b4db4281b39e94447f3,Nivo,0.354938
uuid-e8b0616abf534b4db4281b39e94447f3,trial,0.445484
uuid-e8b0616abf534b4db4281b39e94447f3,combination,0.421871
uuid-e8b0616abf534b4db4281b39e94447f3,chemo,0.324364
uuid-e8b0616abf534b4db4281b39e94447f3,tumor,0.34322
uuid-e8b0616abf534b4db4281b39e94447f3,pts,0.538928
uuid-e8b0616abf534b4db4281b39e94447f3,Ipi,0.374521
uuid-e8b0616abf534b4db4281b39e94447f3,response,0.342971
uuid-e8b0616abf534b4db4281b39e94447f3,combo,0.316134
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,patients,0.314394
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,lung,0.394512
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,regimen,0.385291
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,treated,0.372631
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,melanoma,0.546663
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,RCC,0.44125
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,pts,0.401146
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,combo,0.322494
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,progression,0.360003
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,impressed,0.328713
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,respond,0.312135
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,SCLC,0.363952
uuid-acaf7dbaf97240a5a23fc39cb898f5f9,TL shared,0.458072
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,Opdivo,0.605814
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,dose,0.582467
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,shared,0.303829
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,drug,0.423038
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,Keytruda,0.563399
uuid-a453967b8651414aa8dfdcb0a1ebe9ef,flat dosing,0.756039
uuid-abafa56055a14197a90905f3211dc554,nivolumab,0.362325
uuid-abafa56055a14197a90905f3211dc554,lung,0.450396
uuid-abafa56055a14197a90905f3211dc554,regimen,0.534091
uuid-abafa56055a14197a90905f3211dc554,treated,0.458852
uuid-abafa56055a14197a90905f3211dc554,melanoma,0.759664
uuid-abafa56055a14197a90905f3211dc554,shared,0.410143
uuid-abafa56055a14197a90905f3211dc554,RCC,0.589982
uuid-abafa56055a14197a90905f3211dc554,TL stated,0.31698
uuid-abafa56055a14197a90905f3211dc554,combination,0.468384
uuid-abafa56055a14197a90905f3211dc554,pts,0.473713
uuid-abafa56055a14197a90905f3211dc554,monotherapy,0.435725
uuid-abafa56055a14197a90905f3211dc554,treatment,0.37256
uuid-abafa56055a14197a90905f3211dc554,combo,0.515018
uuid-abafa56055a14197a90905f3211dc554,PD1,0.362573
uuid-abafa56055a14197a90905f3211dc554,SCCHN,0.338684
uuid-abafa56055a14197a90905f3211dc554,progression,0.421306
uuid-abafa56055a14197a90905f3211dc554,SCLC,0.350439
uuid-abafa56055a14197a90905f3211dc554,RTL stated,0.462291
uuid-abafa56055a14197a90905f3211dc554,TL shared,0.590639
uuid-50fd426e71aa4126904d905d8ad30395,Nivo,0.338452
uuid-50fd426e71aa4126904d905d8ad30395,patients,0.53552
uuid-50fd426e71aa4126904d905d8ad30395,Opdivo,0.653057
uuid-50fd426e71aa4126904d905d8ad30395,therapy,0.393739
uuid-50fd426e71aa4126904d905d8ad30395,dose,0.356235
uuid-50fd426e71aa4126904d905d8ad30395,nivolumab,0.512624
uuid-50fd426e71aa4126904d905d8ad30395,toxicity,0.456698
uuid-50fd426e71aa4126904d905d8ad30395,regimen,0.578636
uuid-50fd426e71aa4126904d905d8ad30395,treated,0.427122
uuid-50fd426e71aa4126904d905d8ad30395,combination,0.361394
uuid-50fd426e71aa4126904d905d8ad30395,pts,0.316063
uuid-50fd426e71aa4126904d905d8ad30395,agents,0.303278
uuid-50fd426e71aa4126904d905d8ad30395,physicians,0.344302
uuid-50fd426e71aa4126904d905d8ad30395,preferred,0.427798
uuid-50fd426e71aa4126904d905d8ad30395,monotherapy,0.477126
uuid-50fd426e71aa4126904d905d8ad30395,treatment,0.509152
uuid-50fd426e71aa4126904d905d8ad30395,using nivo,0.36103
uuid-50fd426e71aa4126904d905d8ad30395,combo,0.300527
uuid-50fd426e71aa4126904d905d8ad30395,approved,0.332272
uuid-50fd426e71aa4126904d905d8ad30395,progression,0.389629
uuid-50fd426e71aa4126904d905d8ad30395,chemotherapy,0.331074
uuid-50fd426e71aa4126904d905d8ad30395,respond,0.333281
uuid-50fd426e71aa4126904d905d8ad30395,option,0.392645
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,patients,0.784829
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,Opdivo,0.409156
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,therapy,0.548239
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,nivolumab,0.496897
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,regimen,0.508362
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,treated,0.694938
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,chemo,0.318073
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,pts,0.615119
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,treatment,0.677156
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,response,0.552749
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,PD1,0.314563
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,progression,0.722743
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,chemotherapy,0.382222
uuid-b1b898a1fc6f4737b1e03d7d5f36eb73,respond,0.532392
uuid-8019810e5cc84f89bb6f554faad620b1,Opdivo,0.454179
uuid-8019810e5cc84f89bb6f554faad620b1,physicians,0.334389
uuid-8019810e5cc84f89bb6f554faad620b1,treatment,0.326577
uuid-8019810e5cc84f89bb6f554faad620b1,option,0.362303
uuid-5a9a895d3a2546199470ad5865160c68,Nivo,0.424949
uuid-5a9a895d3a2546199470ad5865160c68,patients,0.476773
uuid-5a9a895d3a2546199470ad5865160c68,Opdivo,0.494041
uuid-5a9a895d3a2546199470ad5865160c68,pembro,0.374288
uuid-5a9a895d3a2546199470ad5865160c68,dose,0.719678
uuid-5a9a895d3a2546199470ad5865160c68,toxicity,0.357835
uuid-5a9a895d3a2546199470ad5865160c68,regimen,0.420537
uuid-5a9a895d3a2546199470ad5865160c68,Ipi,0.443842
uuid-5a9a895d3a2546199470ad5865160c68,atezo,0.37366
uuid-5a9a895d3a2546199470ad5865160c68,preferred,0.312112
uuid-5a9a895d3a2546199470ad5865160c68,vs,0.469863
uuid-5a9a895d3a2546199470ad5865160c68,Keytruda,0.308909
uuid-5a9a895d3a2546199470ad5865160c68,flat dosing,0.521525
uuid-fe6e19f11a5747c6a957006b5d41d759,patients,0.360032
uuid-fe6e19f11a5747c6a957006b5d41d759,therapy,0.353326
uuid-fe6e19f11a5747c6a957006b5d41d759,1L,0.347295
uuid-fe6e19f11a5747c6a957006b5d41d759,regimen,0.318414
uuid-fe6e19f11a5747c6a957006b5d41d759,chemo,0.314689
uuid-fe6e19f11a5747c6a957006b5d41d759,2L,0.353246
uuid-fe6e19f11a5747c6a957006b5d41d759,agents,0.313165
uuid-fe6e19f11a5747c6a957006b5d41d759,preferred,0.373444
uuid-fe6e19f11a5747c6a957006b5d41d759,testing,0.300013
uuid-fe6e19f11a5747c6a957006b5d41d759,monotherapy,0.372867
uuid-fe6e19f11a5747c6a957006b5d41d759,treatment,0.482372
uuid-fe6e19f11a5747c6a957006b5d41d759,NSCLC patients,0.310445
uuid-fe6e19f11a5747c6a957006b5d41d759,respond,0.363124
uuid-fe6e19f11a5747c6a957006b5d41d759,option,0.486388
uuid-494bae76f440474085ed36c2ab29d6eb,pembro,0.391944
uuid-494bae76f440474085ed36c2ab29d6eb,1L,0.347636
uuid-494bae76f440474085ed36c2ab29d6eb,PDL1,0.673336
uuid-494bae76f440474085ed36c2ab29d6eb,trial,0.348828
uuid-494bae76f440474085ed36c2ab29d6eb,efficacy,0.477289
uuid-494bae76f440474085ed36c2ab29d6eb,PD-L1,0.318424
uuid-494bae76f440474085ed36c2ab29d6eb,OS,0.531019
uuid-494bae76f440474085ed36c2ab29d6eb,atezo,0.329074
uuid-494bae76f440474085ed36c2ab29d6eb,data,0.615248
uuid-494bae76f440474085ed36c2ab29d6eb,PFS,0.5336
uuid-494bae76f440474085ed36c2ab29d6eb,ORR,0.520512
uuid-494bae76f440474085ed36c2ab29d6eb,nivo and pembro,0.564843
uuid-494bae76f440474085ed36c2ab29d6eb,believes,0.503282
uuid-494bae76f440474085ed36c2ab29d6eb,impressed,0.405683
uuid-494bae76f440474085ed36c2ab29d6eb,feels,0.511826
uuid-494bae76f440474085ed36c2ab29d6eb,PDL1 expression,0.559464
uuid-494bae76f440474085ed36c2ab29d6eb,biomarker,0.335084
uuid-18c4f1abf73d45dc97c7d661e6d5e3a0,physicians,0.716295
uuid-18c4f1abf73d45dc97c7d661e6d5e3a0,treatment,0.348353
uuid-36ed73960ccc41f89826f9b9553f83a3,patients,0.381248
uuid-36ed73960ccc41f89826f9b9553f83a3,therapy,0.34836
uuid-36ed73960ccc41f89826f9b9553f83a3,toxicity,0.325893
uuid-36ed73960ccc41f89826f9b9553f83a3,treatment,0.33687
uuid-36ed73960ccc41f89826f9b9553f83a3,progression,0.36172
uuid-4a52b499ae0a4082a239f3393e3d3c0e,Nivo,0.432316
uuid-4a52b499ae0a4082a239f3393e3d3c0e,pembro,0.454436
uuid-4a52b499ae0a4082a239f3393e3d3c0e,RTL,0.396045
uuid-4a52b499ae0a4082a239f3393e3d3c0e,dose,0.394019
uuid-4a52b499ae0a4082a239f3393e3d3c0e,trial,0.465662
uuid-4a52b499ae0a4082a239f3393e3d3c0e,efficacy,0.437008
uuid-4a52b499ae0a4082a239f3393e3d3c0e,combination,0.451205
uuid-4a52b499ae0a4082a239f3393e3d3c0e,Ipi,0.657441
uuid-4a52b499ae0a4082a239f3393e3d3c0e,atezo,0.366628
uuid-4a52b499ae0a4082a239f3393e3d3c0e,data,0.448204
uuid-4a52b499ae0a4082a239f3393e3d3c0e,combo,0.468962
uuid-4a52b499ae0a4082a239f3393e3d3c0e,ORR,0.301133
uuid-4a52b499ae0a4082a239f3393e3d3c0e,impressed,0.550129
uuid-4a52b499ae0a4082a239f3393e3d3c0e,vs,0.433895
uuid-4a52b499ae0a4082a239f3393e3d3c0e,LTL,0.347024
uuid-4a52b499ae0a4082a239f3393e3d3c0e,TLs,0.377145
uuid-4a52b499ae0a4082a239f3393e3d3c0e,SCLC,0.37346
uuid-4a52b499ae0a4082a239f3393e3d3c0e,feels,0.419225
uuid-4a52b499ae0a4082a239f3393e3d3c0e,flat dosing,0.320021
uuid-11a2cfb711a34a64834be5bd007f6dcd,patients,0.501381
uuid-11a2cfb711a34a64834be5bd007f6dcd,Opdivo,0.527066
uuid-11a2cfb711a34a64834be5bd007f6dcd,regimen,0.372529
uuid-11a2cfb711a34a64834be5bd007f6dcd,treated,0.418969
uuid-11a2cfb711a34a64834be5bd007f6dcd,stated,0.37294
uuid-11a2cfb711a34a64834be5bd007f6dcd,physicians,0.509191
uuid-11a2cfb711a34a64834be5bd007f6dcd,treatment,0.413029
uuid-11a2cfb711a34a64834be5bd007f6dcd,HCP,0.305413
uuid-11a2cfb711a34a64834be5bd007f6dcd,progression,0.436189
uuid-11a2cfb711a34a64834be5bd007f6dcd,respond,0.326898
uuid-c9389a37b9f9448db9c7b3e401db4346,physicians,0.52716
uuid-c9389a37b9f9448db9c7b3e401db4346,oncology,0.368305
uuid-c9389a37b9f9448db9c7b3e401db4346,drug,0.395951
uuid-c9389a37b9f9448db9c7b3e401db4346,clinical,0.415349
uuid-242f8d920adf4ba19effd6767074f314,toxicity,0.337673
uuid-242f8d920adf4ba19effd6767074f314,physicians,0.338188
uuid-242f8d920adf4ba19effd6767074f314,treatment,0.367651
uuid-242f8d920adf4ba19effd6767074f314,lung cancer,0.377426
uuid-242f8d920adf4ba19effd6767074f314,respond,0.35428
uuid-d1ea9a19c1d240fbbb9e31e0c6f79ba0,Opdivo,0.364405
uuid-d1ea9a19c1d240fbbb9e31e0c6f79ba0,toxicity,0.365865
uuid-d1ea9a19c1d240fbbb9e31e0c6f79ba0,physicians,0.590972
uuid-d1ea9a19c1d240fbbb9e31e0c6f79ba0,treatment,0.317959
uuid-c90eac93c569403280959af584580bde,Nivo,0.480502
uuid-c90eac93c569403280959af584580bde,pembro,0.790313
uuid-c90eac93c569403280959af584580bde,1L,0.586378
uuid-c90eac93c569403280959af584580bde,PDL1,0.36169
uuid-c90eac93c569403280959af584580bde,efficacy,0.310375
uuid-c90eac93c569403280959af584580bde,2L,0.652586
uuid-c90eac93c569403280959af584580bde,agents,0.460526
uuid-c90eac93c569403280959af584580bde,Merck,0.328214
uuid-c90eac93c569403280959af584580bde,approval,0.493069
uuid-c90eac93c569403280959af584580bde,atezo,0.798021
uuid-c90eac93c569403280959af584580bde,preferred,0.593837
uuid-c90eac93c569403280959af584580bde,monotherapy,0.341181
uuid-c90eac93c569403280959af584580bde,using nivo,0.518145
uuid-c90eac93c569403280959af584580bde,data,0.424843
uuid-c90eac93c569403280959af584580bde,indication,0.528974
uuid-c90eac93c569403280959af584580bde,approved,0.588966
uuid-c90eac93c569403280959af584580bde,SCCHN,0.369917
uuid-c90eac93c569403280959af584580bde,nivo and pembro,0.55099
uuid-c90eac93c569403280959af584580bde,vs,0.315871
uuid-c90eac93c569403280959af584580bde,label,0.352877
uuid-c90eac93c569403280959af584580bde,feels,0.463146
uuid-c90eac93c569403280959af584580bde,RTL stated,0.373354
uuid-c90eac93c569403280959af584580bde,option,0.456596
uuid-c90eac93c569403280959af584580bde,bladder,0.422399
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,Nivo,0.430651
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,pembro,0.477461
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,dose,0.476153
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,efficacy,0.732424
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,Ipi,0.454646
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,OS,0.508225
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,atezo,0.488561
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,data,0.440044
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,PFS,0.443029
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,ORR,0.556849
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,nivo and pembro,0.405976
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,impressed,0.41999
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,vs,0.6214
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,TLs,0.347774
uuid-d4cc8084e4df4b8aac4b00cfe62ca9cd,flat dosing,0.369941
uuid-406e224d391e4c09b0497a0c59237b72,patients,0.754683
uuid-406e224d391e4c09b0497a0c59237b72,Opdivo,0.391817
uuid-406e224d391e4c09b0497a0c59237b72,therapy,0.743276
uuid-406e224d391e4c09b0497a0c59237b72,nivolumab,0.447305
uuid-406e224d391e4c09b0497a0c59237b72,regimen,0.534046
uuid-406e224d391e4c09b0497a0c59237b72,treated,0.483287
uuid-406e224d391e4c09b0497a0c59237b72,chemo,0.455626
uuid-406e224d391e4c09b0497a0c59237b72,pts,0.662071
uuid-406e224d391e4c09b0497a0c59237b72,monotherapy,0.444118
uuid-406e224d391e4c09b0497a0c59237b72,treatment,0.729847
uuid-406e224d391e4c09b0497a0c59237b72,response,0.78627
uuid-406e224d391e4c09b0497a0c59237b72,PD1,0.502196
uuid-406e224d391e4c09b0497a0c59237b72,cHL,0.333843
uuid-406e224d391e4c09b0497a0c59237b72,progression,0.827387
uuid-406e224d391e4c09b0497a0c59237b72,chemotherapy,0.486038
uuid-406e224d391e4c09b0497a0c59237b72,respond,0.647357
uuid-406e224d391e4c09b0497a0c59237b72,option,0.365161
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,Nivo,0.445043
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,pembro,0.667009
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,dose,0.733052
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,1L,0.351077
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,2L,0.551908
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,agents,0.38923
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,Ipi,0.41333
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,atezo,0.735848
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,preferred,0.681725
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,monotherapy,0.364309
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,using nivo,0.418523
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,indication,0.41135
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,approved,0.409574
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,vs,0.579574
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,Keytruda,0.466836
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,option,0.403393
uuid-ba74e16d3ae949ecbccacf612a3c0c4f,flat dosing,0.562652
uuid-c78824b64d9a4633a2676e22b7baada6,patients,0.341267
uuid-c78824b64d9a4633a2676e22b7baada6,toxicity,0.388836
uuid-c78824b64d9a4633a2676e22b7baada6,regimen,0.37324
uuid-c78824b64d9a4633a2676e22b7baada6,treated,0.329116
uuid-c78824b64d9a4633a2676e22b7baada6,melanoma,0.369659
uuid-c78824b64d9a4633a2676e22b7baada6,treatment,0.336033
uuid-c78824b64d9a4633a2676e22b7baada6,respond,0.34623
uuid-c78824b64d9a4633a2676e22b7baada6,SCLC,0.315288
uuid-c78824b64d9a4633a2676e22b7baada6,NCCN,0.485449
uuid-47a4c952751c4b6d8d19c040633648ca,patients,0.341267
uuid-47a4c952751c4b6d8d19c040633648ca,toxicity,0.388836
uuid-47a4c952751c4b6d8d19c040633648ca,regimen,0.37324
uuid-47a4c952751c4b6d8d19c040633648ca,treated,0.329116
uuid-47a4c952751c4b6d8d19c040633648ca,melanoma,0.369659
uuid-47a4c952751c4b6d8d19c040633648ca,treatment,0.336033
uuid-47a4c952751c4b6d8d19c040633648ca,respond,0.34623
uuid-47a4c952751c4b6d8d19c040633648ca,SCLC,0.315288
uuid-47a4c952751c4b6d8d19c040633648ca,NCCN,0.485449
uuid-f4108e6a9e4e44c6b6f014cf6cd76fe5,NCCN,0.611832
uuid-d9e192bd174f47b4be7fd148fea893dc,patients,0.681688
uuid-d9e192bd174f47b4be7fd148fea893dc,Opdivo,0.305201
uuid-d9e192bd174f47b4be7fd148fea893dc,therapy,0.370438
uuid-d9e192bd174f47b4be7fd148fea893dc,toxicity,0.43926
uuid-d9e192bd174f47b4be7fd148fea893dc,regimen,0.488618
uuid-d9e192bd174f47b4be7fd148fea893dc,treated,0.499935
uuid-d9e192bd174f47b4be7fd148fea893dc,pts,0.343346
uuid-d9e192bd174f47b4be7fd148fea893dc,physicians,0.41209
uuid-d9e192bd174f47b4be7fd148fea893dc,treatment,0.718306
uuid-d9e192bd174f47b4be7fd148fea893dc,response,0.365549
uuid-d9e192bd174f47b4be7fd148fea893dc,progression,0.59565
uuid-d9e192bd174f47b4be7fd148fea893dc,respond,0.536058
uuid-ea2b6a056625463bb6f83880861d5ff0,treated,0.342716
uuid-ea2b6a056625463bb6f83880861d5ff0,physicians,0.355306
uuid-ea2b6a056625463bb6f83880861d5ff0,oncology,0.449795
uuid-ea2b6a056625463bb6f83880861d5ff0,ASCO,0.316236
uuid-ea2b6a056625463bb6f83880861d5ff0,oncologist,0.383624
uuid-ea2b6a056625463bb6f83880861d5ff0,immunotherapy,0.433725
uuid-1d616141cf5c4b9082ece334e0517329,tumor,0.484174
uuid-1d616141cf5c4b9082ece334e0517329,response,0.472989
uuid-1d616141cf5c4b9082ece334e0517329,progression,0.438249
uuid-1d616141cf5c4b9082ece334e0517329,respond,0.336562
uuid-37b5159df4054958abefc478d0af2464,AI,0.362586
uuid-37b5159df4054958abefc478d0af2464,oncology,0.492967
uuid-37b5159df4054958abefc478d0af2464,oncologist,0.338241
uuid-37b5159df4054958abefc478d0af2464,clinical,0.55566
uuid-37b5159df4054958abefc478d0af2464,immunotherapy,0.358647
uuid-57e54d6e98f440888d61bfa96903cb4c,BMS,0.520987
uuid-57e54d6e98f440888d61bfa96903cb4c,trial,0.382568
uuid-57e54d6e98f440888d61bfa96903cb4c,efficacy,0.477846
uuid-57e54d6e98f440888d61bfa96903cb4c,commented,0.477881
uuid-57e54d6e98f440888d61bfa96903cb4c,Merck,0.308121
uuid-57e54d6e98f440888d61bfa96903cb4c,stated,0.383963
uuid-57e54d6e98f440888d61bfa96903cb4c,OS,0.517212
uuid-57e54d6e98f440888d61bfa96903cb4c,regards,0.312863
uuid-57e54d6e98f440888d61bfa96903cb4c,data,0.76828
uuid-57e54d6e98f440888d61bfa96903cb4c,expressed,0.400174
uuid-57e54d6e98f440888d61bfa96903cb4c,PFS,0.442427
uuid-57e54d6e98f440888d61bfa96903cb4c,ORR,0.500298
uuid-57e54d6e98f440888d61bfa96903cb4c,ASCO,0.360621
uuid-57e54d6e98f440888d61bfa96903cb4c,impressed,0.717795
uuid-57e54d6e98f440888d61bfa96903cb4c,feels,0.485164
uuid-df741f46acd44d239d055d95c20ec9cb,RTL,0.382407
uuid-df741f46acd44d239d055d95c20ec9cb,lung,0.390923
uuid-df741f46acd44d239d055d95c20ec9cb,melanoma,0.33728
uuid-df741f46acd44d239d055d95c20ec9cb,RCC,0.389952
uuid-df741f46acd44d239d055d95c20ec9cb,stated,0.308325
uuid-df741f46acd44d239d055d95c20ec9cb,approval,0.415018
uuid-df741f46acd44d239d055d95c20ec9cb,clinical trials,0.347598
uuid-df741f46acd44d239d055d95c20ec9cb,indication,0.396825
uuid-df741f46acd44d239d055d95c20ec9cb,SCCHN,0.500956
uuid-df741f46acd44d239d055d95c20ec9cb,label,0.351779
uuid-df741f46acd44d239d055d95c20ec9cb,RTL stated,0.338428
uuid-df741f46acd44d239d055d95c20ec9cb,TL shared,0.385266
uuid-df741f46acd44d239d055d95c20ec9cb,bladder,0.462246
uuid-12b4b2e6299542bc9485114dac82381f,Nivo,0.528362
uuid-12b4b2e6299542bc9485114dac82381f,pembro,0.425828
uuid-12b4b2e6299542bc9485114dac82381f,1L,0.389849
uuid-12b4b2e6299542bc9485114dac82381f,toxicity,0.400749
uuid-12b4b2e6299542bc9485114dac82381f,efficacy,0.37355
uuid-12b4b2e6299542bc9485114dac82381f,regimen,0.400909
uuid-12b4b2e6299542bc9485114dac82381f,combination,0.403273
uuid-12b4b2e6299542bc9485114dac82381f,chemo,0.376323
uuid-12b4b2e6299542bc9485114dac82381f,2L,0.438159
uuid-12b4b2e6299542bc9485114dac82381f,agents,0.348672
uuid-12b4b2e6299542bc9485114dac82381f,Ipi,0.360707
uuid-12b4b2e6299542bc9485114dac82381f,atezo,0.399407
uuid-12b4b2e6299542bc9485114dac82381f,preferred,0.482212
uuid-12b4b2e6299542bc9485114dac82381f,monotherapy,0.560512
uuid-12b4b2e6299542bc9485114dac82381f,using nivo,0.432195
uuid-12b4b2e6299542bc9485114dac82381f,combo,0.389458
uuid-12b4b2e6299542bc9485114dac82381f,PD1,0.308129
uuid-12b4b2e6299542bc9485114dac82381f,impressed,0.305352
uuid-12b4b2e6299542bc9485114dac82381f,feels,0.523762
uuid-12b4b2e6299542bc9485114dac82381f,RTL stated,0.416176
uuid-12b4b2e6299542bc9485114dac82381f,option,0.430597
uuid-74430d004e614eec81a2f6e5407b91df,patients,0.514689
uuid-74430d004e614eec81a2f6e5407b91df,Opdivo,0.503546
uuid-74430d004e614eec81a2f6e5407b91df,treated,0.32183
uuid-74430d004e614eec81a2f6e5407b91df,physicians,0.411423
uuid-74430d004e614eec81a2f6e5407b91df,treatment,0.416824
uuid-2528f2f07f204a64843246e96387fe35,Nivo,0.588221
uuid-2528f2f07f204a64843246e96387fe35,patients,0.434356
uuid-2528f2f07f204a64843246e96387fe35,pembro,0.390284
uuid-2528f2f07f204a64843246e96387fe35,therapy,0.306907
uuid-2528f2f07f204a64843246e96387fe35,nivolumab,0.352026
uuid-2528f2f07f204a64843246e96387fe35,1L,0.523397
uuid-2528f2f07f204a64843246e96387fe35,regimen,0.387878
uuid-2528f2f07f204a64843246e96387fe35,RCC,0.330564
uuid-2528f2f07f204a64843246e96387fe35,combination,0.342691
uuid-2528f2f07f204a64843246e96387fe35,chemo,0.496422
uuid-2528f2f07f204a64843246e96387fe35,2L,0.458653
uuid-2528f2f07f204a64843246e96387fe35,pts,0.4416
uuid-2528f2f07f204a64843246e96387fe35,OS,0.339658
uuid-2528f2f07f204a64843246e96387fe35,preferred,0.361491
uuid-2528f2f07f204a64843246e96387fe35,monotherapy,0.566894
uuid-2528f2f07f204a64843246e96387fe35,using nivo,0.513022
uuid-2528f2f07f204a64843246e96387fe35,combo,0.398439
uuid-2528f2f07f204a64843246e96387fe35,PD1,0.393909
uuid-2528f2f07f204a64843246e96387fe35,ORR,0.328432
uuid-2528f2f07f204a64843246e96387fe35,approved,0.31557
uuid-2528f2f07f204a64843246e96387fe35,SCCHN,0.347629
uuid-2528f2f07f204a64843246e96387fe35,progression,0.332012
uuid-2528f2f07f204a64843246e96387fe35,chemotherapy,0.469638
uuid-2528f2f07f204a64843246e96387fe35,impressed,0.37065
uuid-2528f2f07f204a64843246e96387fe35,SCLC,0.3611
uuid-2528f2f07f204a64843246e96387fe35,feels,0.40311
uuid-2528f2f07f204a64843246e96387fe35,RTL stated,0.387042
uuid-2528f2f07f204a64843246e96387fe35,option,0.516111
uuid-2528f2f07f204a64843246e96387fe35,bladder,0.33868
uuid-3047af30115b4e26a57ff2d1d02e0df2,patients,0.310434
uuid-3047af30115b4e26a57ff2d1d02e0df2,Opdivo,0.623541
uuid-3047af30115b4e26a57ff2d1d02e0df2,physicians,0.427976
uuid-7e8e56a316e743f78c9a98ff39a96ce7,pembro,0.33124
uuid-7e8e56a316e743f78c9a98ff39a96ce7,1L,0.324964
uuid-7e8e56a316e743f78c9a98ff39a96ce7,PDL1,0.530268
uuid-7e8e56a316e743f78c9a98ff39a96ce7,efficacy,0.522577
uuid-7e8e56a316e743f78c9a98ff39a96ce7,chemo,0.361957
uuid-7e8e56a316e743f78c9a98ff39a96ce7,agents,0.359107
uuid-7e8e56a316e743f78c9a98ff39a96ce7,OS,0.305857
uuid-7e8e56a316e743f78c9a98ff39a96ce7,atezo,0.415152
uuid-7e8e56a316e743f78c9a98ff39a96ce7,PFS,0.31468
uuid-7e8e56a316e743f78c9a98ff39a96ce7,nivo and pembro,0.581077
uuid-7e8e56a316e743f78c9a98ff39a96ce7,believes,0.594973
uuid-7e8e56a316e743f78c9a98ff39a96ce7,vs,0.306104
uuid-7e8e56a316e743f78c9a98ff39a96ce7,PDL1 expression,0.445748
uuid-7e8e56a316e743f78c9a98ff39a96ce7,option,0.308801
uuid-7e8e56a316e743f78c9a98ff39a96ce7,biomarker,0.356167
uuid-c143ffd6ad5b40fcb504ecae4a43c471,patients,0.80374
uuid-c143ffd6ad5b40fcb504ecae4a43c471,Opdivo,0.543486
uuid-c143ffd6ad5b40fcb504ecae4a43c471,therapy,0.610083
uuid-c143ffd6ad5b40fcb504ecae4a43c471,nivolumab,0.549923
uuid-c143ffd6ad5b40fcb504ecae4a43c471,regimen,0.457496
uuid-c143ffd6ad5b40fcb504ecae4a43c471,treated,0.572531
uuid-c143ffd6ad5b40fcb504ecae4a43c471,RCC,0.316625
uuid-c143ffd6ad5b40fcb504ecae4a43c471,pts,0.537058
uuid-c143ffd6ad5b40fcb504ecae4a43c471,treatment,0.694597
uuid-c143ffd6ad5b40fcb504ecae4a43c471,using nivo,0.317601
uuid-c143ffd6ad5b40fcb504ecae4a43c471,response,0.420689
uuid-c143ffd6ad5b40fcb504ecae4a43c471,cHL,0.362661
uuid-c143ffd6ad5b40fcb504ecae4a43c471,progression,0.688866
uuid-c143ffd6ad5b40fcb504ecae4a43c471,chemotherapy,0.32683
uuid-c143ffd6ad5b40fcb504ecae4a43c471,respond,0.427938
uuid-c143ffd6ad5b40fcb504ecae4a43c471,TL shared,0.35759
uuid-118af457e38a4c22898675d5c37b1169,pembro,0.416729
uuid-118af457e38a4c22898675d5c37b1169,BMS,0.418654
uuid-118af457e38a4c22898675d5c37b1169,1L,0.366514
uuid-118af457e38a4c22898675d5c37b1169,PDL1,0.606747
uuid-118af457e38a4c22898675d5c37b1169,trial,0.579765
uuid-118af457e38a4c22898675d5c37b1169,efficacy,0.504428
uuid-118af457e38a4c22898675d5c37b1169,Merck,0.345013
uuid-118af457e38a4c22898675d5c37b1169,stated,0.305074
uuid-118af457e38a4c22898675d5c37b1169,OS,0.58874
uuid-118af457e38a4c22898675d5c37b1169,atezo,0.329186
uuid-118af457e38a4c22898675d5c37b1169,data,0.739194
uuid-118af457e38a4c22898675d5c37b1169,expressed,0.312588
uuid-118af457e38a4c22898675d5c37b1169,PFS,0.58163
uuid-118af457e38a4c22898675d5c37b1169,ORR,0.625462
uuid-118af457e38a4c22898675d5c37b1169,nivo and pembro,0.644875
uuid-118af457e38a4c22898675d5c37b1169,believes,0.477106
uuid-118af457e38a4c22898675d5c37b1169,impressed,0.526665
uuid-118af457e38a4c22898675d5c37b1169,feels,0.484927
uuid-118af457e38a4c22898675d5c37b1169,PDL1 expression,0.531437
uuid-118af457e38a4c22898675d5c37b1169,biomarker,0.30806
uuid-e1af2fba34d143f7bde0136b28870620,BMS,0.412231
uuid-e1af2fba34d143f7bde0136b28870620,PDL1,0.488839
uuid-e1af2fba34d143f7bde0136b28870620,trial,0.338901
uuid-e1af2fba34d143f7bde0136b28870620,efficacy,0.536434
uuid-e1af2fba34d143f7bde0136b28870620,Merck,0.349955
uuid-e1af2fba34d143f7bde0136b28870620,PD-L1,0.300748
uuid-e1af2fba34d143f7bde0136b28870620,regards,0.321368
uuid-e1af2fba34d143f7bde0136b28870620,nivo and pembro,0.409274
uuid-e1af2fba34d143f7bde0136b28870620,believes,0.35753
uuid-e1af2fba34d143f7bde0136b28870620,PDL1 expression,0.469737
uuid-e1af2fba34d143f7bde0136b28870620,biomarker,0.508898
uuid-8ccfffa43ab04d8c8be535c862569a6b,AI,0.362875
uuid-8ccfffa43ab04d8c8be535c862569a6b,oncology,0.37864
uuid-8ccfffa43ab04d8c8be535c862569a6b,indicated,0.362744
uuid-8ccfffa43ab04d8c8be535c862569a6b,drug,0.475343
uuid-8ccfffa43ab04d8c8be535c862569a6b,Keytruda,0.333638
uuid-8ccfffa43ab04d8c8be535c862569a6b,clinical,0.333618
uuid-8ccfffa43ab04d8c8be535c862569a6b,NCCN,0.308344
uuid-8ccfffa43ab04d8c8be535c862569a6b,flat dosing,0.366329
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,patients,0.475961
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,chemo,0.335616
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,tumor,0.673781
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,pts,0.473889
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,treatment,0.305009
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,response,0.325467
uuid-64f05e8ffd2c4ec990fbe2690e07f0d7,progression,0.383822
uuid-ab412d0535c041149efe73d676bd0e09,RTL,0.465073
uuid-ab412d0535c041149efe73d676bd0e09,commented,0.497776
uuid-ab412d0535c041149efe73d676bd0e09,stated,0.364746
uuid-ab412d0535c041149efe73d676bd0e09,OS,0.354583
uuid-ab412d0535c041149efe73d676bd0e09,data,0.684082
uuid-ab412d0535c041149efe73d676bd0e09,expressed,0.330789
uuid-ab412d0535c041149efe73d676bd0e09,ORR,0.392575
uuid-ab412d0535c041149efe73d676bd0e09,SCCHN,0.395209
uuid-ab412d0535c041149efe73d676bd0e09,HCP,0.348261
uuid-ab412d0535c041149efe73d676bd0e09,ASCO,0.46938
uuid-ab412d0535c041149efe73d676bd0e09,impressed,0.710706
uuid-ab412d0535c041149efe73d676bd0e09,LTL,0.381535
uuid-ab412d0535c041149efe73d676bd0e09,Regional TL,0.411673
